<SEC-DOCUMENT>0001125345-25-000042.txt : 20250320
<SEC-HEADER>0001125345-25-000042.hdr.sgml : 20250320
<ACCEPTANCE-DATETIME>20250320160504
ACCESSION NUMBER:		0001125345-25-000042
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		93
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250320
DATE AS OF CHANGE:		20250320

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MACROGENICS INC
		CENTRAL INDEX KEY:			0001125345
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36112
		FILM NUMBER:		25756439

	BUSINESS ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			Rockville
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-251-5172

	MAIL ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>mgnx-20241231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:976c6134-a70d-4bed-9067-acb735c066ae,g:6888b12e-4125-48cc-8fc7-0d9038c82cb8,d:b90895a7822448df9e5a179143ce4792-->
<html xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:mgnx="http://macrogenics.com/20241231" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mgnx-20241231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-33">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-34">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-35">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-36">0001125345</ix:nonNumeric><ix:nonNumeric contextRef="c-6" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-69">364</ix:nonNumeric><ix:nonNumeric contextRef="c-8" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-70">364</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mgnx-20241231.xsd"/></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="productcandidate"><xbrli:measure>mgnx:productCandidate</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>mgnx:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="performanceobligation"><xbrli:measure>mgnx:performanceObligation</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">mgnx:JamesKarrelsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">mgnx:JamesKarrelsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">mgnx:JamesKarrelsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">mgnx:JeffreyPetersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">mgnx:JeffreyPetersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">mgnx:JeffreyPetersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:ContractManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:ContractManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:ContractManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-14</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ASDHealthcareAndOncologySupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ZaiLabLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ASDHealthcareAndOncologySupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ASDHealthcareAndOncologySupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:CardinalHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:CardinalHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:LaboratoryAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:SynaffixBVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:SynaffixBVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:SynaffixBVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:SynaffixBVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:UndesignatedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:UndesignatedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-01</xbrli:startDate><xbrli:endDate>2024-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteClinicalSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteClinicalSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteClinicalSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteCommercialSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteCommercialSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteCommercialSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-14</xbrli:startDate><xbrli:endDate>2022-10-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:GileadFirstResearchProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:GileadFirstResearchProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:GileadFirstResearchProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:GileadFirstResearchProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:GileadFirstResearchProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:GileadFirstResearchProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:DRIHealthcareAcquisitionsLPDRIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:DRIHealthcareAcquisitionsLPDRIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-08</xbrli:startDate><xbrli:endDate>2023-03-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:DRIHealthcareAcquisitionsLPDRIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:DRIHealthcareAcquisitionsLPDRIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:SideLetterAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionAPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAmendmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAmendmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAmendmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:TerSeraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2023MemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2023MemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-01</xbrli:startDate><xbrli:endDate>2024-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2023MemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2023MemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-25</xbrli:startDate><xbrli:endDate>2024-10-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:DrScottKoenigMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:DrScottKoenigMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:DrScottKoenigMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:TerSeraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:TerSeraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:CombinedServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mgnx:TaxYear2027To2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mgnx:IndefiniteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mgnx:TaxYear2027To2044Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:VobramitanmabDuocarmazineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:VobramitanmabDuocarmazineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:VobramitanmabDuocarmazineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:LorigerlimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:LorigerlimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:LorigerlimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:MGC028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:MGC028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:MGC028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:ADCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:ADCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:ADCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:MGC026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:MGC026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:MGC026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:MargetuximabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:MargetuximabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:MargetuximabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:MGD024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:MGD024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:MGD024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:NextGenerationTCellEngagersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:NextGenerationTCellEngagersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:NextGenerationTCellEngagersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:RetifanlimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:RetifanlimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:RetifanlimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:EnoblituzumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:EnoblituzumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:EnoblituzumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:OtherProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:OtherProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:OtherProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ib90895a7822448df9e5a179143ce4792_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C.&#160;&#160;20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-4"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-3">December 31</ix:nonNumeric>, 2024</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to &#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-36112</ix:nonNumeric></span></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">MACROGENICS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Exact name of registrant)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:46.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.142%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">06-1591613</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(State of organization)&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(I.R.S. Employer Identification Number)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">9704 Medical Center Drive</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Rockville</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-12">Maryland</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">20850</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Address of principal executive offices and zip code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">301</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">251-5172</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant's telephone number)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"/><td style="width:37.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.193%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.262%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, par value $0.01 per share</ix:nonNumeric></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">MGNX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: None</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-19">No</ix:nonNumeric>&#160;&#160;&#160;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-20">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric>&#160;&#160;&#160;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric>&#160;&#160;&#160;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer a smaller reporting company, or an emerging growth company.&#160;See the definitions of "large accelerated filer," "accelerated filer", "smaller reporting company", and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:22.294%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.447%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.113%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-23">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-24">&#9746;</ix:nonNumeric></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-25">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-26">&#9745;</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-27">&#9744;</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-28">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No&#160;&#160;&#160;</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value of the registrant's common stock, par value $0.01 per share, held by non-affiliates of the registrant on June&#160;28, <ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-29">2024</ix:nonNumeric>, the last business day of the registrant's most recently completed second fiscal quarter, was approximately $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="dei:EntityPublicFloat" scale="6" id="f-30">259.4</ix:nonFraction> million based on the closing price of the registrant's common stock on the Nasdaq Global Select Market on that date.&#160;Exclusion of shares held by any person should not be construed to indicate that such person possesses the power, direct or indirect, to direct or cause the direction of management or policies of the registrant, or that such person is controlled by or under common control with the registrant.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of the registrant's common stock outstanding on March&#160;14, 2025 was <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-31">63,090,323</ix:nonFraction>.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-32" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portions of MacroGenics, Inc.'s definitive proxy statement for the 2025 annual meeting of stockholders are incorporated by reference into Part III of this Annual Report.</span></div></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ib90895a7822448df9e5a179143ce4792_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNUAL REPORT ON FORM 10-K</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.170%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_13">PART I</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_16">Business</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_19">Risk Factors</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1B</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_22">Unresolved Staff Comments</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1C</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_25">Cybersecurity</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_28">Properties</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_31">Legal Proceedings</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_34">Mine Safety Disclosures</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_37">PART II</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_40">Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_43">Reserved</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_46">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_67">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_70">Financial Statements and Supplementary Data</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_73">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_76">Controls and Procedures</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9B</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_79">Other Information</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9C</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_85">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_91">PART III</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 10</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_94">Directors, Executive Officers and Corporate Governance</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 11</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_97">Executive Compensation</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 12</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_100">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 13</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_103">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 14</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_106">Principal Accountant Fees and Services</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_109">PART IV</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 15</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_112">Exhibits and Financial Statement Schedules</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 16</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_115">Form 10-K Summary</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_118">Signatures</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ib90895a7822448df9e5a179143ce4792_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs and other information that is not historical information. Many of these statements appear, in particular, under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in this Annual Report on Form 10-K. Forward-looking statements can often be identified by the use of terminology such as "subject to", "believe", "anticipate", "plan", "expect", "intend", "estimate", "project", "may", "will", "should", "would", "could", "can", the negatives thereof, variations thereon and similar expressions, or by discussions of strategy.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All forward-looking statements, including, without limitation, our examination of historical operating trends, are based upon our current expectations and various assumptions. We believe there is a reasonable basis for our expectations and beliefs, but they are inherently uncertain. We may not realize our expectations, and our beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements. The following uncertainties and factors, among others (including those set forth under "Risk Factors"), could affect future performance and cause actual results to differ materially from those matters expressed in or implied by forward-looking statements:</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to develop and commercialize our product candidates;</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcomes of our ongoing and planned clinical trials and the timing of those outcomes, including when clinical trials will be initiated or completed, enrollment of trials, and when data will be reported or regulatory filings will be made;</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of and our ability to obtain and maintain regulatory approvals for our product candidates and the labeling for any approved products;</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to raise additional capital through the capital markets or through one or more corporate partnerships, equity offerings, debt financings, collaborations, licensing arrangements or asset sales;</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding product candidates currently being developed by our collaborators;</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the anticipated receipt of sales milestone payments in connection with the sale of MARGENZA to TerSera Therapeutics, LLC, or TerSera;</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the compromise of our or our third parties&#8217; information technology systems and resultant costs, disruptions in our operations or related impact on our reputation;</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enter into new collaborations or to identify additional products or product candidates with significant commercial potential that are consistent with our commercial objectives;</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential benefits and future operation of our existing collaborations; </span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to recover the investment in our manufacturing capabilities;</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility of our products;</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our commercialization, marketing and manufacturing capabilities and strategy;</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant competition in our industry;</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of litigation and the failure to successfully defend lawsuits and other claims against us and our expectations regarding the outcome of any regulatory or legal proceedings;</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic, political and other risks associated with our international operations;</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to receive research funding and achieve anticipated milestones under our collaborations;</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to protect and enforce patents and other intellectual property;</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of compliance and our failure to comply with new and existing governmental regulations including, but not limited to, tax regulations;</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss or retirement of key members of management;</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to successfully execute our growth strategy, including any delays in our planned future growth;</span></div><div style="margin-bottom:3pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure to maintain effective internal controls; and</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of legislative and regulatory developments, public health crises, geopolitical tensions or other macroeconomic factors on our business, operations, clinical programs, manufacturing, financial results and other aspects of our business.</span></div><div style="margin-bottom:4pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consequently, forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates and beliefs. You should not place undue reliance on forward-looking statements. We cannot guarantee future results, events, levels of activity, performance or achievements. Except as required by law, we do not </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ib90895a7822448df9e5a179143ce4792_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="ib90895a7822448df9e5a179143ce4792_16"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;BUSINESS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Except as otherwise indicated herein or as the context otherwise requires, references in this annual report on Form 10-K to "MacroGenics," the "company," "we," "us" and "our" refer to MacroGenics, Inc. and its consolidated subsidiaries. &#8220;MacroGenics</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, the MacroGenics logo, DART</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, TRIDENT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> and the phrases Breakthrough Biologics, Life-Changing Medicines</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> and Developing Breakthrough Biologics, Life-Changing Medicines</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> are our trademarks. The other trademarks, trade names and service marks appearing in this report are the property of their respective owners.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Overview</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer. We generate our pipeline of product candidates from our proprietary suite of antibody technology platforms. We are currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which we refer to as DART and TRIDENT molecules). The combination of our technology platforms and antibody engineering expertise has allowed us to generate promising product candidates &#8211; three of which have received marketing approval by the U.S. Food and Drug Administration (FDA) &#8211; and to enter into several strategic collaborations with global biopharmaceutical companies. These collaborations have provided us with over $1.4 billion of non-dilutive funding since our inception in 2000, and have enabled us to leverage the additional expertise of our collaborators to advance the development of multiple partnered product candidates. In addition, we operate a 5 &#215; 2,000 liter commercial-scale cGMP antibody manufacturing facility in our Maryland headquarters to support our clinical programs. We also provide outsourced contract development and manufacturing services to our collaborators and other third parties for commercial and clinical products to offset a portion of the operating costs of this facility. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. We are also actively developing multiple preclinical-stage ADC and next generation T-cell engager programs. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our partners are developing or commercializing product candidates for which we retain certain economic rights. These include three products approved by the FDA: MARGENZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (margetuximab-cmkb), an anti-HER2 monoclonal antibody (mAb) that we recently sold to a partner, ZYNYZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (retifanlimab-dlwr), an anti-PD-1 mAb that we out-licensed; and TZIELD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (teplizumab-mzwv), an anti-CD3 mAb that we sold to a partner. We are also collaborating with Gilead Sciences, Inc. (Gilead) on the development of MGD024, a bispecific DART antibody targeting CD123 and CD3 that utilizes our next-generation T-cell engager technology, as well as two additional undisclosed pre-clinical DART development programs.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Wholly Owned Pipeline in Active Development </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below depicts the status of our diverse portfolio of investigational oncology product candidates for which we retain commercialization or other important rights in the U.S. or more broadly: </span></div><div><span><br/></span></div><div><img src="mgnx-20241231_g1.jpg" alt="Pipeline 1.jpg" style="height:174px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lorigerlimab  </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lorigerlimab (previously known as MGD019) is an investigational, bispecific tetravalent DART molecule designed to enable simultaneous and/or independent blockade of PD-1 and CTLA-4, with potentially enhanced CTLA-4 blockade on T cells co-expressing these immune checkpoint molecules. Approved mAbs that target the immune checkpoints PD-1 and CTLA-4 have shown enhanced clinical antitumor activity when given in combination in various cancers, including renal cell carcinoma, melanoma, non-small cell lung cancer (NSCLC), esophageal cancer and microsatellite instability-high (MSI-H) colorectal cancer. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We initiated the randomized Phase 2 LORIKEET study in the second half of 2023. This trial is evaluating lorigerlimab combined with docetaxel versus docetaxel alone in second-line, chemotherapy-na&#239;ve, metastatic castration-resistant prostate cancer (mCRPC) patients. The study&#8217;s primary endpoint is radiographic progression-free survival (rPFS). In late 2024, we completed enrollment of the 150 patient, 2:1 randomized study. In February 2025, the LORIKEET Independent Data Monitoring Committee (IDMC) recommended that the study may continue as planned. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond the evaluation of lorigerlimab in patients with mCRPC, we intend to commence the LINNET study in patients with platinum-resistant ovarian cancer (PROC). This study will evaluate lorigerlimab as monotherapy in a Simon two-stage trial in eligible patients who have previously received up to three prior lines of therapy. If a certain predefined threshold of activity is achieved in part 1 of the two-stage design, the study will be expanded with a total of up to 40 patients evaluated. In addition, the LINNET study will evaluate up to 20 patients with clear cell gynecologic cancer (CCGC)&#8239;who have received at least one prior line of therapy. Any patients with PROC or CCGC who have primary platinum-refractory disease are excluded from study participation. The study&#8217;s primary endpoint is ORR, with multiple secondary endpoints. We expect to commence the LINNET study by mid-2025. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MGC026 </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MGC026 is an investigational ADC incorporating a B7-H3-targeting antibody and a novel TOP1i-based linker-payload, SYNtecan E&#8482;. This cleavable linker-payload is based on exatecan, a clinically validated and potent camptothecin, and is site-specifically conjugated using the GlycoConnect&#174; technology developed by our collaboration partner, Synaffix (a Lonza company).  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase 1 dose escalation study of MGC026 in patients with advanced solid tumors is ongoing. We expect to initiate dose expansion in selected indications in 2025.   </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preclinical studies, MGC026 exhibited a favorable profile, with potent in vivo activity toward B7-H3-expressing tumor xenografts representing a range of cancer indications. MGC026 was tolerated in cynomolgus monkeys, a relevant toxicology model, at exposure levels exceeding those likely required for antitumor activity in patients. MGC026 preclinical data was presented at the American Association for Cancer Research (AACR) Annual Meeting in April 2024. In preclinical studies, MGC026 was shown to have greater potency than B7-H3-directed antibodies conjugated to deruxtecan, or DXd, a topoisomerase-based payload utilized in other ADCs. In addition, the MGC026 payload has been shown to be less susceptible to multi-drug resistance (MDR) mechanisms than DXd and SN-38. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MGC028</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MGC028 is the second of our ADC molecules incorporating Synaffix&#8217;s novel glycan-linked TOP1i-based linker payload, and the second ADAM9-targeted ADC that we have pursued. ADAM9 is a member of the ADAM family of multifunctional type 1 transmembrane proteins that play a role in tumorigenesis and cancer progression and is overexpressed in multiple cancers, making it an attractive target for cancer treatment. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preclinical studies, MGC028 exhibited specific, dose-dependent in vivo antitumor activity toward ADAM9-positive cell-derived and patient-derived xenograft models, including in gastric, lung, pancreatic, colorectal, and head and neck cancers as well as in cholangiocarcinoma. In addition, MGC028 was well tolerated in a repeat-dose non-human primate toxicology study at high dose levels.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase 1 dose escalation study of MGC028 was recently initiated. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MGC030 </span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MGC030 is a preclinical ADC molecule incorporating Synaffix&#8217;s novel glycan-linked TOP1i-based linker payload, which targets a non-disclosed antigen expressed across several solid tumor types. In early preclinical studies, MGC030 was well tolerated in a pilot toxicology study, with a planned GLP toxicology study to be initiated. In addition, MGC030 showed encouraging anti-tumor activity across multiple cell-derived xenograft models, with patient-derived xenograft models initiated.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An Investigational New Drug (IND) application submission to the FDA is targeted for 2026. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional Wholly Owned Programs  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vobramitamab Duocarmazine </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vobra duo is an investigational ADC with a cleavable peptide linker designed to deliver a DNA-alkylating duocarmycin payload to dividing and non-dividing cells on solid tumors that express B7-H3. The underlying ADC technology was licensed from Byondis B.V. (Byondis). We conducted a Phase 2 study, which we refer to as the TAMARACK study, of vobra duo in a total of 177 mCRPC patients and four patients with other cancer types. On July 30, 2024, we reported that after a review of accumulated study data though a July 9, 2024 data cut-off, at which time there had been an aggregate of eight investigator-reported, treatment-related deaths on the TAMARACK study, we agreed with the study&#8217;s IDMC recommendation that study treatment be discontinued for the remaining mCRPC study participants who potentially could have received additional doses. At that point in time, there were a limited number of mCRPC patients still potentially eligible to receive additional doses of vobra duo and the study had reached its primary endpoint. Although treatment was discontinued for mCRPC patients as of such time, those patients remaining on the study continued to be monitored through study completion per study protocol. Investigators for the study reported an aggregate of eleven treatment-related deaths (11 of 180 patients who received treatment, or 6.1%) for all indications. These eleven patient deaths occurred between 87 days and 339 days after commencing treatment with vobra duo. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of a February 21, 2025 data cut-off, with 95 PFS events (52.5%), the median rPFS was approximately 9.5 months for the 2.0 mg/kg cohort (95% CI, 8.5-11.2) and 10.0 months for the 2.7 mg/kg cohort (95% CI, 7.4-11.4).</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The TAMARACK study has been completed, and no patients are currently being treated with vobra duo in a Company-sponsored trial, although an investigator-sponsored study in small cell lung cancer is ongoing.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our assessment of the safety and efficacy profile from the TAMARACK study and a review of our portfolio and internal resources, vobra duo does not meet our threshold for further financial investment and we have decided not to pursue further internal development. We believe additional studies to mitigate certain adverse events potentially linked to prolonged exposure might improve the safety of vobra duo in mCRPC patients. However, any further development would require external partnering, which may or may not materialize. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Partnered Programs</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the molecules identified above, we have out-licensed various product candidates for which we retain certain economic rights. These molecules provide potential sources of future cash flow and platform validation and are identified below: </span></div><div style="margin-bottom:9pt"><img src="mgnx-20241231_g2.jpg" alt="Pipeline.jpg" style="height:237px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Partnered Marketed Products </span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MARGENZA </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2024, we announced that we had entered into an agreement in which TerSera Therapeutics LLC (TerSera), a privately-held biopharmaceutical company with a focus in oncology and non-opioid pain management, would acquire global rights to MARGENZA&#174; (margetuximab-cmkb). Pursuant to the terms of the agreement, TerSera paid MacroGenics $40.0 million at the closing in November 2024; in addition, we are eligible to receive sales milestone payments from TerSera of up to an aggregate of $35.0 million. In November 2024, we paid an $8.0 million amendment fee to Eversana Life Sciences Services, LLC (Eversana), our former partner that had previously commercialized MARGENZA. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MARGENZA was approved by the FDA in December 2020 in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. The approval was based on results from the pivotal SOPHIA Phase 3 head-to-head clinical trial evaluating the safety and efficacy of MARGENZA vs. Herceptin&#174; (trastuzumab), both combined with chemotherapy. Margetuximab is a mAb developed using our Fc Optimization platform and targets the HER2 oncoprotein, a protein found on the surface of some cancer cells that promotes growth and is associated with aggressive disease and poor prognosis.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our November 2018 license and collaboration agreement, Zai Lab received the rights to develop margetuximab in mainland China, Hong Kong, Macau and Taiwan. In August 2023, the China National Medical Products Administration approved the New Drug Application (NDA) for margetuximab for patients with pretreated metastatic HER2-positive breast cancer. Zai Lab terminated this agreement, effective May 2024. In November 2024, we received $7.0 million in fulfillment of an approval milestone from Zai Lab. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ZYNYZ </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we licensed retifanlimab (previously known as MGA012), a mAb targeting PD-1, to Incyte Corporation (Incyte) under a global collaboration and license agreement (Incyte Agreement); we retain the right to develop the molecule in combination with product candidates from our pipeline. In March 2023, the FDA approved ZYNYZ (retifanlimab-dlwr) for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma. ZYNYZ is marketed by Incyte.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2024, Incyte announced positive Phase 3 top-line results for its registrational studies of retifanlimab in squamous cell carcinoma of the anal canal and non-small cell lung cancer. In February 2025, Incyte disclosed that its supplemental Biologics License Application (sBLA) for retifanlimab in advanced/metastatic squamous cell anal cancer was filed with the FDA in December 2024, with approval anticipated in the second half of 2025. Incyte continues to conduct global studies of retifanlimab across multiple indications. Also, in July 2024, we announced the achievement of $100.0 million in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">milestones from Incyte related to development progress of retifanlimab, following an agreement, pursuant to which certain milestones were deemed to have been met. We remain eligible to receive up to a total of $210.0 million in potential development and regulatory milestones and up to $330.0 million in potential commercial milestones. We receive tiered royalties, which range from 15 to 24 percent, on worldwide net sales of ZYNYZ. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TZIELD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we entered into an asset purchase agreement (Provention APA) with Provention Bio, Inc., subsequently acquired by Sanofi S.A. (Sanofi), pursuant to which they acquired our interest in teplizumab, a mAb we had been developing for the treatment of type 1 diabetes. Teplizumab was granted Breakthrough Therapy Designation by the FDA and PRIority MEdicines (PRIME) designation by the European Medicines Agency (EMA). </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, the U.S. FDA approved TZIELD (teplizumab-mzwv) to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients aged 8 years and older with Stage 2 T1D, which triggered a $60.0 million milestone payment to us. Under the Provention APA, Sanofi has a remaining obligation to pay us contingent milestone payments totaling $105.0 million upon the achievement of certain regulatory approval milestones, in addition to contingent milestone payments totaling $225.0 million upon the achievement of certain sales milestones.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, we sold our royalty interest in TZIELD to a wholly-owned subsidiary of DRI Healthcare Trust for $100.0 million. Such royalty interest was subsequently acquired by Sanofi. In July 2023, Sanofi reported that the PROTECT placebo-controlled study investigating TZIELD in patients with newly-diagnosed stage 3 T1D met its primary endpoint, having demonstrated preservation of beta cell function. This positive study outcome triggered payment of a $50.0 million milestone to us by Sanofi. We retain the right to receive a 50% share of the royalty on global net sales above a certain annual threshold. In addition, we are eligible to receive $50.0 million if TZIELD achieves a certain level of net sales. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Candidates in Development under Collaborations </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MGD024 </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MGD024 is an investigational, next-generation, bispecific CD123 &#215; CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells, to kill CD123-expressing cancer cells for the potential treatment of certain hematologic malignancies, including AML. MGD024 was designed to minimize cytokine-release syndrome, while maintaining anti-tumor cytolytic activity, and permitting intermittent dosing through a longer half-life. CD123, the interleukin-3 receptor alpha chain, is widely overexpressed in various hematologic malignancies, including AML and myelodysplastic syndrome (MDS), making it an attractive therapeutic target.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to enroll patients in a Phase 1 dose-escalation study of MGD024 in patients with CD123-positive neoplasms, including acute myeloid leukemia and myelodysplastic syndromes. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, we and Gilead entered into an exclusive option and collaboration agreement (Gilead Agreement) to develop and commercialize MGD024 and create up to two separate bispecific cancer target research programs using our DART platform and undertake their early development. Under the Gilead Agreement, we will continue the ongoing phase 1 trial for MGD024 according to a development plan, during which Gilead will have the right to exercise an option granted to them to obtain an exclusive license to develop and commercialize MGD024 and other bispecific antibodies of ours that bind CD123 and CD3 (CD123 Option). The agreement also grants Gilead the right, within the first two years, to nominate a bispecific cancer target set for up to two research programs conducted by us and to exercise separate options to obtain an exclusive license for the development, commercialization and exploitation of molecules created under each research program (Research Program Option). Gilead nominated the first of the two research programs in September 2023. In January 2024, the parties amended the Gilead Agreement to revise certain matters related to intellectual property in the performance of the research plans under the agreement. On August 30, 2024, the parties amended the agreement by entering into a second letter agreement under which Gilead will pay us to conduct certain research and which extends the period for Gilead to select its second research target combination. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Gilead Agreement, Gilead paid us a non-refundable upfront payment of $60.0 million, and we are eligible to receive up to $1.7 billion in target nomination fees and option fees, as well as development, regulatory and commercial milestones, assuming Gilead exercises the CD123 Option and Research Program Option, successfully develops and commercializes MGD024 or other CD123 products developed under the agreement, and assuming products result from the two additional research programs. Assuming exercise of the CD123 Option, we will also be eligible to receive tiered, low double-digit royalties on worldwide net sales of MGD024 (or other CD123 products developed under the agreement) and assuming </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exercise of the Research Program Option, a flat royalty on worldwide net sales of any products resulting from the two research programs. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Early Bispecific Research Program </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, Gilead nominated the first of two potential research programs under the Research Program Option as part of the Gilead Agreement, leveraging our DART and TRIDENT platforms for generating bispecific antibodies. This nomination granted Gilead an exclusive option to license worldwide rights to the research program, upon achievement of a pre-defined preclinical milestone. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HIV DART Molecules </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted clinical studies of MGD014 and MGD020 under a contract awarded to us in September 2015 by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). These bispecific DART molecules are designed to target the viral envelope (Env) protein of human immunodeficiency virus (HIV) infected cells and CD3 on T cells to redirect the immune system's T cells to kill HIV-infected cells. Both the Phase 1 study of MGD014 in persons with HIV maintained on antiretroviral therapy and the Phase 1 study of MGD020 alone and combined with MGD014 have been completed and we are in the process of closing out the contract. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ancillary Contract Development and Manufacturing Services</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to manufacturing antibody-based products and product candidates in our commercial-scale facility for our own needs, we provide outsourced contract development and manufacturing services to a small number of clients, including collaboration partners. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incyte</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we entered into an agreement with Incyte to provide manufacturing services to produce certain Incyte bulk drug substance over a three-year period. Under the terms of this agreement, we received an upfront payment of $10.0 million and are eligible to receive annual fixed payments paid quarterly over the term of the contract totaling $14.4 million. We will also be reimbursed for materials used to manufacture product as well as other costs incurred to provide manufacturing services. In July 2022, we and Incyte executed an amendment to the agreement which extended the term for one year and provided for an additional annual fixed payment of $5.1 million. In December 2024, we and Incyte entered into a letter agreement whereby Incyte reserved additional manufacturing services with a fixed cost of $9.1 million. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Emergent BioSolutions </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023 and December 2023, we entered into agreements with Emergent BioSolutions (Emergent) to provide manufacturing services to produce certain Emergent bulk drug substances. Under the terms of the agreements, we receive payments in accordance with the manufacturing schedule and are reimbursed for materials used to manufacture product, as well as other costs incurred to provide manufacturing services. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TerSera </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, we sold global rights to MARGENZA to TerSera. In connection with the sale, we entered into an agreement with TerSera to provide manufacturing services to produce MARGENZA. Under the terms of the agreement, we receive payments in accordance with the manufacturing schedule and are reimbursed for materials used to manufacture product, as well as other costs incurred to provide manufacturing services.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Therapeutic Area Focus: Cancer </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cancer is a broad group of diseases in which cells divide and grow in an uncontrolled manner, forming malignancies that can invade other parts of the body. In normal tissues, the rates of new cell growth and cell death are tightly regulated and kept in balance. In cancerous tissues, this balance is disrupted as a result of mutations, causing unregulated cell division or proliferation that leads to tumor formation and growth. While tumors can grow slowly or rapidly, the dividing cells will nevertheless accumulate, and the normal organization of the tissue will become disrupted. Cancers subsequently can spread throughout the body by processes known as invasion and metastasis. Once cancer spreads to sites beyond the primary tumor, it generally becomes more difficult to treat and may be incurable. Cancer cells that arise in the lymphatic system and bone marrow are referred to as hematological malignancies. Cancer cells that arise in other tissues or organs are referred to as solid </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tumors. Cancer can arise in virtually any part of the body, with the most common types arising in the prostate gland, breast, lung, colon and skin. Cancer is the second leading cause of death in the United States, exceeded only by heart disease. An increasing number of people are also living longer with cancer. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our platforms position us very well strategically to actively develop approaches for the treatment of both solid tumors and hematologic malignancies. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Platforms and Technology Expertise </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply our understanding of disease biology, immune-mediated mechanisms and next-generation antibody technologies to design specifically targeted antibody-based product candidates based on our DART and licensed ADC platforms. Through these platforms, we have designed antibody-based product candidates that have the potential to improve on standard treatments by having one or more of the following attributes: (1) multiple specificities; (2) increased abilities to interact with the body's immune system to fight tumors; (3) capacity to bind more avidly to antigen targets; (4) increased potency; (5) reduced immunogenicity or (6) the ability to target and kill cancer cells that are resistant to standard treatments. Moreover, these technology platforms are complementary in certain cases and can be combined to address the complex biology of cancer. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DART and TRIDENT Platforms: Our Proprietary Approach to Engineer Multi-Specific Antibodies </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use our DART platform to create derivatives of antibodies with the ability to bind to two distinct targets instead of a single target as with traditional mAbs. DART product candidates are therefore bispecific.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because cancer cells have developed ways to escape the immune system, we have created DART molecules, which are alternative antibody-like structures with more potent immune properties than the parent antibody molecules from which they are derived. The two variable regions of an antibody are mono-specific and are able to target only a single type structural component of an antigen. For many years, researchers have sought to create recombinant molecules that are capable of targeting two antigens or epitopes (i.e., specific part of an antigen bound by the antibody) within the same molecule. The challenges in creating such molecules have been the instability of the resulting bispecific molecules and their inherently short half-lives, as well as the inefficiencies in manufacturing these compounds. We believe our DART platform has overcome these engineering challenges by incorporating proprietary covalent di-sulfide linkages and particular amino acid sequences that efficiently pair the chains of the DART molecule. This is designed to provide a structure with enhanced manufacturability, long-term structural stability and the ability to tailor the half-lives of the DART molecules to their clinical needs. This engineered antibody-like protein has a compact and stable structure and enables the targeting of two different antigens with a single recombinant molecule. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The DART platform has been specifically engineered to accommodate virtually any variable region sequence with predictable expression, folding and antigen recognition. We believe our multi-specific platforms may provide a significant advantage over current biological interventions in cancer, autoimmune disorders and infectious disease by enabling a range of modalities. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the ability to tailor a DART molecule's valency, we have the capacity to modify the strength by which the binding sites attach to their targets and the molecule's half-life in the blood circulation after delivery to a patient. Furthermore, when an Fc domain is coupled with a DART molecule, additional changes can be included that can modulate the DART molecule's engagement with different immune cells. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently developing product candidates using our DART technology, including lorigerlimab and MGD024, in clinical trials, as well as others in preclinical development. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also advanced beyond our DART platform to establish a TRIDENT platform, which reflects the continuing evolution of our multi-specific antibody-based targeting expertise. Built on the DART module, the trivalent TRIDENT platform incorporates in an Ig-like format an additional domain capable of engaging an independent antigen. With the inclusion of a third targeting arm, TRIDENT molecules enable a broader range of mechanisms of action than bispecific targeting, allowing, for instance, the engagement of multiple antigens on a single or on different cells or enabling enhanced target selectivity by modulating the avidity of one of two antigens. Product candidates using this technology are currently in preclinical development. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensed ADC Platforms</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have licensed ADC platforms from collaboration partners to leverage their past investment in proprietary linker-toxin technology and know-how. While we don&#8217;t necessarily believe there is a single best linker-toxin technology capable of addressing all targets and indications, we have selected what we believe are best-in-class technologies for construction of each of our ADC product candidates. For example, to date we have utilized linker-toxin payloads developed by Byondis for vobra duo and by Synaffix B.V. (Synaffix) for multiple molecules, including MGC026 and MGC028. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Collaborations </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout our company's history, we have entered into collaborations with other biopharmaceutical companies and plan to continue to do so. We enter into collaborations when there is a strategic advantage to us and when we believe the financial terms of the collaboration are favorable for meeting our short-term and long-term strategic objectives. We are not dependent upon any one of these collaborations, but in many cases, we have rights to receive sales royalties and other significant financial payments if the partnered product candidates achieve certain development and sales milestones. We endeavor to establish collaborations that preserve our right to participate in future commercialization, for example by securing co-promotion or profit-sharing rights under certain circumstances. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We pursue a balanced approach between product candidates that we develop ourselves and those that we develop with our collaborators. Under our strategic collaborations to date, we have received significant non-dilutive funding and continue to have rights to additional funding upon completion of certain research, achievement of key product development milestones and royalties and other payments upon the commercial sale of products. Each of our collaborations has a unique set of terms and conditions. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to protect the proprietary technologies that we believe are important to our business, including seeking and maintaining patents intended to protect, for example, the composition of matter of our product candidates, their methods of use, their formulation, the technology platforms used to generate them, related technologies and/or other aspects of the inventions that are important to our business. We also rely on trade secrets, confidentiality and invention assignment agreements and careful monitoring of our proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend significantly on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business. In addition, there is cost and risk to our business in defending and enforcing our patents, maintaining our licenses to use intellectual property owned by third parties and preserving the confidentiality of our trade secrets and operating without infringing the valid and enforceable patents and other proprietary rights of third parties. We also rely on know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary positions. We currently use multiple industry-standard patent monitoring systems to monitor new United States Patent and Trademark Office (USPTO) filings for any applications by third parties that may infringe on our patents. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of biopharmaceutical companies like us are generally uncertain and involve complex legal, scientific and factual questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted by the courts after issuance. Consequently, we do not know whether any of our product candidates will be protectable or remain protected by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, narrowed, circumvented or invalidated by third parties. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A third party may hold patents or other intellectual property rights that are important to or necessary for the development of our product candidates or use of our technology platforms. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our product candidates, in which case we would be required to obtain a license from these third parties on commercially reasonable terms, or our business could be harmed, possibly materially. Because patent applications in the United States and certain other jurisdictions can be maintained in secrecy for 18 months or potentially even longer, and because publication of discoveries in the scientific or patent literature often lags behind actual discoveries, we cannot be certain of the priority of inventions covered by pending patent applications. Moreover, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention. In the ordinary course of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business we participate in post-grant challenge proceedings, such as oppositions, that challenge the patentability of third party patents. Such proceedings could result in substantial cost, even if the eventual outcome is favorable to us. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pipeline Patent Protection</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we held 73 patents in the United States with 35 patent applications pending and 891 patents in other countries of the world with 410 patent applications pending. In addition to patents and patent applications generally providing protection for various aspects of our Fc Optimization, DART, and TRIDENT platforms, we have patent and patent applications for the composition of matter of each of our clinical pipeline product candidates and, in some cases, we also have other patents and patent application related to various aspects of the technology underlying these product candidates or their methods of use.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent terms may be adjusted or extended, as described in greater detail below, in certain circumstances. However, assuming no adjustments or extensions, the primary composition of matter patent for each of our clinical pipeline product candidates is expected to expire in the following timeframes:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:51.093%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#d9d9d9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product or Product Candidate</span></td><td colspan="3" style="background-color:#d9d9d9;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">retifanlimab</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">lorigerlimab</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">vobramitamab duocarmazine</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2037</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGD024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2039</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGC026</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2044*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGC028</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2045*</span></div></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">* pending</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Term Extension and Reference Product Exclusivity </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Hatch-Waxman Act permits a patent term extension for FDA-approved drugs, including biological products, of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended. Similar provisions are available in Europe and other jurisdictions to extend the term of a patent that covers an approved drug. If and when our pharmaceutical product candidates receive FDA approval, we expect to apply, or have applied, for patent term extensions on patents covering those products. We intend to seek, and are seeking, patent term extensions to our issued patents in any jurisdiction where these are available. For example, we have submitted a request to obtain patent term extension of U.S. Patent No. 10,577,422, the primary composition of matter of retifanlimab. However, there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Affordability Reconciliation Act (collectively the ACA) created a regulatory scheme authorizing the FDA to approve biosimilars via an abbreviated licensure pathway. In many cases, this allows biosimilars to be brought to market without conducting the full suite of clinical trials typically required of originators. Under the ACA, a manufacturer may submit an application for licensure of a biologic product that is "biosimilar to" or "interchangeable with" a previously approved biological product or "reference product." The "biosimilar" application must include specific information demonstrating biosimilarity based on data derived from: (1) analytical studies, (2) animal studies, and (3) a clinical study or studies that are sufficient to demonstrate safety, purity, and potency in one or more appropriate conditions of use for which the reference product is licensed, except that FDA may waive some of these requirements for a given application. Under this new statutory scheme, an application for a biosimilar product may not be submitted to the FDA until four years after the date of first licensure. The FDA may not approve a biosimilar product until 12 years from the date on which the reference product was first licensed. The law does not change the duration of patents granted on biological products. Even if a product is considered to be a reference product eligible for exclusivity, another company could market a competing version of that product if the FDA approves a full biologics license application (BLA) for such product containing the sponsor's own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. There have been persistent proposals to repeal or modify the ACA and it is uncertain how any of those proposals, if in the future approved, would affect these provisions. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Secrets </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on trade secret protection for our confidential and proprietary information. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to enter into agreements with confidentiality terms prior to sharing any of our proprietary and confidential information with them. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual during the course of the individual's relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions made, conceived, created or reduced to practice by the individual, and which are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property. In many cases our agreements with consultants, outside scientific collaborators, sponsored researchers and other advisors require them to assign or grant us licenses to inventions they invent as a result the work or services they render under such agreements or grant us an option to negotiate a license to use such inventions. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-Licensed Intellectual Property </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into patent and know-how license agreements that grant us the rights to use certain technologies related to biological manufacturing for our commercial and clinical product candidates such as, but not limited to, technology related to the conjugation of cytotoxic payloads to our antibody molecules. We anticipate using these technologies for future product candidates. These licensors have businesses dedicated to licensing this type of technology and we anticipate that licenses to use these technologies for our future products will be available. The licenses typically include yearly maintenance payments and sales royalties, and may also include upfront payments or milestone payments. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently manufacture drug substance for most of our clinical trials at our manufacturing facility located in Rockville, Maryland. We also rely on our licensees and contract manufacturers, including Byondis, Synaffix and Millipore Sigma, for producing components of our ADC candidates. We have an FDA-approved commercial manufacturing site at 9704 Medical Center Drive in Rockville, Maryland for the manufacture of MARGENZA and ZYNYZ drug substance. We commercially produce MARGENZA and ZYNYZ for TerSera and Incyte, respectively, and intend to commercially produce any of our product candidates when, and if approved, by the FDA. In addition, we currently rely on and will continue to rely on contract fill-finish service providers, primarily Ajinomoto Bio-Pharma Services, BSP Pharmaceuticals, and Simtra BioPharma Solutions, to fulfill our fill-finish needs for our current and future product candidates. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of the principal materials we use in our manufacturing operations are available from more than one source. However, we obtain certain raw materials principally from only one source. In the event one of these suppliers was unable to provide the materials or product, we generally seek to maintain sufficient inventory to supply the market until an alternative source of supply can be implemented. However, in the event of an extended failure of a supplier or general national supply chain disruption, it is possible that we could experience an interruption in supply until we established new sources or, in some cases, implemented alternative processes. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Production processes for biological therapeutic products are complex, highly regulated, and vary widely from product to product. Shifting or adding manufacturing capacity can be a very lengthy process requiring significant capital expenditures, process modifications, and regulatory approvals. Accordingly, if we were to experience extended plant shutdowns at our own facility, extended failure of a contract supplier or contract manufacturing organization, or extraordinary unplanned increases in demand, we could experience an interruption in supply of certain products or product shortages until production could be resumed or expanded. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercialization </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the three products that originated from our pipeline and for which U.S. approval for commercialization has been received, MARGENZA was the only product for which we retained the majority of commercial rights, until we sold global rights to MARGENZA to TerSera in November 2024. In November 2020, we partnered with Eversana, a pioneer of next-generation commercial services to the global life sciences industry, to commercialize margetuximab in the U.S. by leveraging their integrated commercial services. Under the terms of the Eversana agreement, we maintained ownership of margetuximab, including all manufacturing, regulatory and development responsibilities for the product. Eversana received a co-exclusive right </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to conduct approved commercialization activities. Eversana utilized its internal capabilities to support marketing, channel management services, medical affairs and other commercial and patient access related services; we booked MARGENZA sales. We and Eversana equally shared in funding Eversana&#8217;s commercialization expenses. In exchange for co-funding these expenses, Eversana was eligible to earn future revenue share payments which were capped at 125% of Eversana&#8217;s cumulative service fees. The term of the agreement was five years following the date of FDA approval, subject to predefined termination provisions. Pursuant to the sale of MARGENZA to TerSera, we paid Eversana an amendment fee.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our product candidates, we cannot market or promote a new product in a country until a marketing application has been approved by the appropriate regulatory authority for that jurisdiction. Subject to receiving marketing authorization in a jurisdiction, we believe we will be able to commercialize in that market through arrangements with third-party commercial partners. If we are unable to enter into third-party commercial arrangements for our product candidates that may be approved in the future, with respect to the United States we believe that we could potentially build the capabilities to commercialize our approved product or products. Outside the United States, our strategy is to enter into arrangements with third-party commercial partners for any of our product candidates that obtain marketing approval.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a large number of companies developing or marketing treatments for cancer, including many major pharmaceutical and biotechnology companies. These treatments consist both of small molecule drug products, as well as biologic therapeutics that work by using next-generation antibody technology platforms to address specific cancer targets.  </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, we are developing a PD-1 and CTLA-4 directed DART molecule, which if successful, will likely face significant competition both by therapeutics that are already being marketed as well as those that will be approved for marketing before our program. The bispecific immuno-oncology field targeting PD-1 and CTLA-4 has several competitors, with treatments currently approved in China or in development for various tumor types and patient populations. Akeso, Inc., AstraZeneca plc (AstraZeneca), Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Xencor, Inc. (Xencor) have anti-PD-1 or anti-PD-L1 and CTLA-4 bispecific antibodies in clinical development, all of which would compete with our PD-1 and CTLA-4 DART program and have significantly greater resources than we do.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, several of our product candidates in clinical development are ADCs and many companies have ADC therapeutics in development. Such companies include Abbvie Inc. (Abbvie), AstraZeneca, in collaboration with its partner, Daiichi Sankyo Company, Ltd (Daiichi), BeOne Medicines, BioNTech SE (BioNTech), in collaboration with its partner, Duality Biologics Co. Ltd., Genmab A/S (Genmab), GSK plc, in collaboration with its partner, Hansoh Pharmaceutical Group Company Ltd, Innovent Biologics Co., Ltd., Merck &amp; Co., Inc., in collaboration with its partner, Daiichi and Pfizer Inc. These companies have significantly greater resources than we do. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, several companies are also developing therapeutics that work by targeting multiple specificities using a single recombinant molecule. Amgen Inc. has obtained marketing approval for one product that works by targeting antigens both on immune effector cell populations and those expressed on certain cancer cells, and has other product candidates in development that use this mechanism. In addition, other companies are developing new treatments for cancer that utilize multi-specific approaches, including Abbvie, Affimed N.V., AstraZeneca, BioNTech, Eli Lilly and Company, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., particularly through its affiliate, Genentech, Inc., Genmab A/S, Johnson &amp; Johnson Services, Inc., Merus B.V., Regeneron Pharmaceuticals, Inc., Xencor and Zymeworks, Inc.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, our competition in the contract development and manufacturing organization (CDMO) service market includes a number of full-service contract manufacturers and large pharmaceutical companies offering third-party development and manufacturing services to fill their excess capacity. Large pharmaceutical companies have been seeking to divest portions of their manufacturing capacity, and any such divested businesses may compete with us in the future. In addition, most of our competitors have substantially greater financial, marketing, technical or other resources than we do. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining top qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key competitive factors affecting the success of all our therapeutic product candidates, if approved, are likely to be their efficacy, safety, dosing convenience, price, the effectiveness of companion diagnostics in guiding the use of related therapeutics, the level of generic or biosimilar competition and the availability of reimbursement from government and other third-party payors. In addition, the standard of medical care provided to cancer patients continues to evolve as more scientific and medical information becomes available. These changes in medical care relate to pharmaceutical products, but are also affected by other factors, and such changes can positively or negatively affect the prospects of our product candidates as well as those of our competitors. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial opportunity for our product candidates could be reduced or eliminated if our competitors develop and commercialize products that are more effective, have fewer or less severe effects, are more convenient or are less expensive than any products that we may develop, or the standards of care for cancer patients change while our clinical trials are ongoing. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of biosimilar products. Biosimilar products are expected to become available over the coming years. For example, trastuzumab biosimilars have been approved in the U.S. by the FDA. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most common methods of treating patients with cancer are surgery, radiation and drug therapy. There are a variety of available drug therapies marketed for cancer. Many of these approved drugs are well established therapies and are widely accepted by physicians, patients and third-party payors. In many cases, these drugs are administered in combination to enhance efficacy. The treatment landscape for cancer is complex due to the sequential order in which oncology drugs are administered. Initially, first-line treatments are prescribed, followed by second-line treatments when the first no longer yields results, and so on with third-line treatments and beyond. While our product candidates may compete with many existing drug and other therapies, to the extent an approved drug is ultimately used in combination with or as an adjunct to these therapies, our product candidates will not be competitive with the approved drug. </span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation and Product Approval</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities in the United States, at the federal, state and local level, and in other countries extensively regulate, among other things, the research, development, testing, manufacture, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, pricing, reimbursement, marketing, import and export of pharmaceutical products such as those we are developing. The processes for obtaining regulatory approvals in the United States and in foreign countries, along with subsequent compliance with applicable statutes and regulations, require the expenditure of substantial time and financial resources.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FDA Regulation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our current product candidates are subject to regulation in the United States by the FDA as biological products (biologics). The FDA subjects biologics to extensive pre- and post-market regulation. The Public Health Service Act, the Federal Food, Drug, and Cosmetic Act (FDCA) and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of biologics. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending BLAs, withdrawal of approvals, clinical holds, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, or criminal penalties.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preclinical Studies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Preclinical studies include laboratory evaluation of product chemistry, formulation and toxicity, pharmacology, as well as animal trials to assess the characteristics and potential safety and efficacy of the product. The conduct of the preclinical tests must comply with federal regulations and requirements including the FDA's good laboratory practice (GLP) regulations and the U.S. Department of Agriculture's regulations implementing the Animal Welfare Act. After laboratory analysis and preclinical testing in animals, we file an IND application with the FDA to begin human testing. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature, and a proposed clinical trial protocol, among other things, to the FDA as part of an IND application. Certain preclinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue even after the IND application is submitted. An IND application automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold or agrees on an alternate approach with us. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the IND application is cleared and the clinical trial can begin. As a result, submission of an IND application may not result in the FDA allowing clinical trials to commence.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Clinical trials involve the administration of the investigational drug to human subjects (healthy volunteers or patients) under the supervision of a qualified investigator. Clinical trials must be conducted: (i) in compliance with all applicable federal regulations and guidance, including those pertaining to good clinical practice (GCP) standards that are meant to protect the rights, safety, and welfare of human subjects and to define the roles of clinical trial sponsors, investigators, and monitors; as well as (ii) under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. Each protocol involving testing of a new drug in the United States (whether in patients or healthy volunteers) must be included in the IND application submission, and the FDA must be notified of subsequent protocol amendments. In addition, the protocol must be reviewed and approved by an institutional review board (IRB) and all study subjects must provide informed consent prior to participating in the study. Typically, each institution participating in the clinical trial will require review of the protocol before any clinical trial commences at that institution. Information about certain clinical trials must be submitted within specific timeframes to NIH for public dissemination on their ClinicalTrials.gov website. Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and there are additional, more frequent reporting requirements for suspected unexpected serious adverse events.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A study sponsor might choose to discontinue a clinical trial or a clinical development program for a variety of reasons. In addition, the FDA may impose a temporary or permanent clinical hold, or other sanctions, if it believes that the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial subjects. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB's requirements, or may impose other conditions.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials to support BLAs for marketing approval are typically conducted in three pre-approval phases, but the phases may overlap or be combined, particularly in testing for oncology indications. In Phase 1, testing is conducted in a small group of subjects who may be patients with the target disease or condition or healthy volunteers, to evaluate its safety, determine a safe dosage range, and identify side effects. In Phase 2, the drug is given to a larger group of subjects with the target condition to further evaluate its safety and gather preliminary evidence of efficacy. Phase 3 studies typically last multiple years for oncology indications. In Phase 3, the drug is given to a large group of subjects with the target disease or condition (several hundred to several thousand), often at multiple geographical sites, to confirm its effectiveness, monitor side effects, and collect data to support drug approval. In some cases, the FDA may require post-market studies, known as Phase 4 studies, to be conducted as a condition of approval in order to gather additional information on the drug's effect in various populations and any side effects associated with long-term use. Depending on the risks posed by the drugs, other post-market requirements may be imposed. Only a small percentage of investigational drugs complete all three phases and obtain marketing approval.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. After completion of the required clinical testing, a BLA can be prepared and submitted to the FDA. FDA approval of the BLA is required before marketing of the product may begin in the United States. The BLA must include the results of preclinical, clinical and other testing and a compilation of data relating to the product's chemistry, manufacture and controls. The cost of preparing and submitting a BLA is substantial. Under federal law, the submission of most BLAs is additionally subject to a substantial application user fee, and annual program user fees also apply. These fees are typically increased annually.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has 60 days from its receipt of a BLA to determine whether the application will be accepted for filing based on the FDA's threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins a substantive review, and the review period under the Prescription Drug User Fee Act begins. The standard for reviewing a BLA is whether the product is safe, pure and potent, which has been interpreted to include that the product is safe and effective and has a favorable benefit-risk profile. The FDA's current performance goals call for the FDA to complete review of 90 percent of standard (non-priority) BLAs within 10 months of filing and within six months for priority BLAs, which is 12 months and eight months, respectively, if the 60-day review of the initial application is included in the timeline. In addition, the FDA has developed approaches intended to make certain qualifying products available to patients rapidly - Priority Review, Breakthrough Therapy, Accelerated Approval, and Fast Track. While the timelines for approval under these pathways may be shorter, there are requirements and conditions associated with each pathway, and there can be no assurance that any of our investigational products will be able to meet the conditions or requirements necessary to receive any such designation or be able to receive the review or approval benefits associated with such designations.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes outside clinicians and other experts, for review, evaluation and a recommendation as to whether sufficient data exist in the application to support product approval. The FDA is not bound by the recommendation of an advisory committee, but it generally gives significant deference to such recommendations.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving a BLA, the FDA will typically inspect one or more clinical sites and possibly the sponsor itself to assure compliance with GCP. Additionally, the FDA will typically inspect the facility or the facilities at which the drug is </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufactured. The FDA will not approve the product unless compliance with current Good Manufacturing Practices (cGMPs) is satisfactory. The FDA also reviews the proposed labeling submitted with the BLA and typically requires changes in the labeling text.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the FDA evaluates the BLA and the manufacturing and testing facilities, it issues either an approval letter or a complete response letter. Complete response letters generally outline the deficiencies in the submission and delineate the additional testing or information needed in order for the FDA to reconsider the application. If and when deficiencies outlined in a complete response letter have been addressed to the FDA's satisfaction in a resubmission of the BLA, the FDA will issue an approval letter. The FDA has committed to reviewing 90 percent of resubmissions within two or six months from receipt depending on the type of information included.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An approval letter authorizes commercial marketing of the drug for the approved indication or indications and the other conditions of use set out in the approved prescribing information. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a condition of BLA approval, the FDA may require substantial post-approval testing and surveillance to monitor the drug's safety or efficacy and may impose other conditions, including labeling restrictions that can materially affect the potential market and profitability of the product. As a condition of approval, or after approval, the FDA also may require submission of a risk evaluation and mitigation strategy (REMS) to mitigate any identified or suspected serious risks. The REMS may include medication guides, physician communication plans, assessment plans, and elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other U.S. Post-Marketing Regulatory Requirements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Once a BLA is approved, a product will be subject to certain post-approval requirements, including those relating to advertising, promotion, adverse event reporting, recordkeeping, and cGMPs, as well as registration, listing, and inspection. There also are continuing, annual program user fee requirements for marketed products, as well as new application fees for supplemental applications with clinical data.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA regulates the content and format of prescription drug labeling, advertising, and promotion, including direct-to-consumer advertising and promotional Internet communications. The FDA also establishes parameters for permissible non-promotional communications between industry and the medical community, including industry-supported scientific and educational activities. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion for uses not consistent with the approved labeling, and a company that is found to have improperly promoted off-label uses or otherwise not to have met applicable promotion rules may be subject to significant liability under both the FDCA and other statutes, including the False Claims Act. See "Other Healthcare Laws and Compliance Requirements" below for more information.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All aspects of pharmaceutical manufacture must conform to cGMPs after approval. Drug manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA during which the FDA inspects manufacturing facilities to assess compliance with cGMPs. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMPs and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMPs.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Changes to some of the conditions established in an approved application, including changes in indications, labeling, product formulation or manufacturing processes or facilities, require submission and FDA approval of a new BLA or BLA supplement, in some cases before the change may be implemented. A BLA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing BLA supplements as it does in reviewing BLAs.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers are subject to requirements for adverse event reporting and submission of periodic reports following FDA approval of a BLA. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, or failure of Phase 4 studies to meet their specified endpoints, may result in revisions to the approved labeling to add new safety information, the need to conduct additional post-market studies or clinical trials to assess new safety risks, imposition of distribution or other restrictions under a REMS program, or recall of the product and withdrawal of the BLA.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncompliance with post-marketing requirements can result in one or more of the following consequences:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Warning letters;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Holds on post-approval clinical trials;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Refusal of the FDA to approve pending BLAs or supplements to approved BLAs, or suspension or revocation of product license approvals;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product seizure or detention, or refusal to permit the import or export of products; or</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the distribution of prescription pharmaceutical products is subject to the Drug Supply Chain Security Act which sets minimum standards for the registration and regulation of drug distributors by the states. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Approval of Biosimilars. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ACA authorized the FDA to approve biosimilars via a separate, abbreviated pathway. In many cases, this allows biosimilars to be brought to market without conducting the full suite of clinical trials typically required of originators. The law establishes a period of 12 years of exclusivity for reference products in order to preserve incentives for future innovation, and outlines statutory criteria for science-based biosimilar approval standards that take into account patient safety considerations. Under this framework, exclusivity protects innovator products by prohibiting others, for a period of 12 years, from being granted FDA approval based in part on reliance on or reference to the innovator's data in their application to the FDA. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Healthcare Laws and Compliance Requirements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to various federal and state laws pertaining to health care &#8220;fraud and abuse,&#8221; including anti-kickback and false claims laws, as well as laws related to health care transparency and data protection. Anti-kickback laws generally prohibit a prescription drug manufacturer from soliciting, offering, receiving, or paying any remuneration to generate business, including the purchase or prescription of a particular drug. Although the specific provisions of these laws vary, their scope is generally broad and there may not be regulations, guidance or court decisions that apply the laws to particular industry practices. There is therefore a possibility that such laws may apply and our practices might be challenged under such anti-kickback laws. False claims laws prohibit anyone from knowingly and willingly presenting, or causing to be presented, any claims for payment for reimbursed drugs or services to third-party payors (including Medicare and Medicaid) that are false or fraudulent. Violations of fraud and abuse laws may be punishable by criminal or civil sanctions, including fines and civil monetary penalties, and/or exclusion from federal health care programs (including Medicare and Medicaid).</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laws and regulations enacted by the federal government and various states to regulate the sales and marketing practices of pharmaceutical manufacturers with marketed products generally limit financial interactions between manufacturers and health care providers and/or require disclosure to the government and public of such interactions. State laws may also require disclosure of pharmaceutical pricing information and marketing expenditures. Many of these laws and regulations contain ambiguous requirements or require administrative guidance for implementation. We are subject to federal, state and foreign laws that govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways, thus complicating compliance efforts. Given the lack of clarity in laws and their implementation, our activities could be subject to the penalty provisions of the pertinent laws and regulations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International Regulation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the United States, we and our collaborators, may be subject to a variety of foreign regulations governing clinical trials, drug registration, commercial sales and distribution of our product candidates outside the United States. These regulations can vary between jurisdictions and can be more onerous than regulations in the United States. Whether or not we obtain FDA approval for a product candidate, we must obtain approval from the comparable regulatory authorities of foreign countries or economic areas, such as the European Union (EU) before we may commence clinical trials or market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from place to place, and the time to approval may be longer or shorter than that required for FDA approval.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain countries outside of the United States have a process that requires the submission of a clinical trial application (CTA) much like an IND prior to the commencement of human clinical trials. In Europe, for example, a CTA must be submitted to the competent national health authority and to independent ethics committees in each country in which a company intends to conduct clinical trials. Once the CTA is approved in accordance with a country&#8217;s requirements, clinical trial </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development may proceed in that country. In all cases, the clinical trials must be conducted in accordance with GCP, and other applicable regulatory requirements. A separate CTA must be submitted for each clinical trial to be conducted.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, for example, to obtain regulatory approval of an investigational medicinal product, a company must submit a marketing authorization application (MAA). The content of the MAA is similar to that of a BLA filed in the United States, with the exception of, among other things, EU-specific document requirements. Under the EU regulatory system, a company may submit marketing authorization applications either under a centralized or decentralized procedure. Under the centralized procedure in the EU, a MAA is submitted to the European Medicines Agency (EMA) where it will be evaluated by the Committee for Medicinal Products for Human Use (CHMP). The maximum timeframe for a CHMP evaluation of an MAA that has been validated is 210 days, excluding time taken by an applicant to respond to questions. A favorable opinion on the application by the CHMP will typically result in the granting of the marketing authorization by the European Commission within 67 days of receipt of the opinion. Generally, the entire review process takes approximately 13-14 months. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. In this circumstance, the EMA ensures that the opinion of the CHMP is given within 150 days, excluding time taken by an applicant to respond to questions.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As in the United States, we or our collaborators may apply for designation of a product as an orphan drug for the treatment of a specific indication in the EU before the MAA is made. Orphan drugs in Europe enjoy certain benefits, including up to 10 years of exclusivity for the approved indication unless another applicant can show that its product is safer, more effective or otherwise clinically superior to the orphan designated product. The PRIME initiative was established by the EMA to help promote and foster the development of new medicines in the EU that demonstrate potential for a major therapeutic advantage in areas of unmet medical need. Benefits from the PRIME designation include early confirmation of potential for accelerated assessment, early dialogue and increased interaction with relevant regulatory committees to discuss development options, scientific advice at key development milestones, and proactive regulatory support from the EMA.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we, or our collaborators, fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biopharmaceutical Coverage, Pricing, Reimbursement, and Health Care Reform</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and other countries, sales of any product candidates for which we receive regulatory approval for commercial sale will depend in part on the availability of adequate reimbursement from third-party payors, including government health administrative authorities, managed care providers, private health insurers, and other organizations. Third-party payors are increasingly examining the medical necessity and cost effectiveness of medical products and services in addition to safety and efficacy and, accordingly, significant uncertainty exists as to the reimbursement status of newly approved therapeutics. Third-party reimbursement adequate to enable us to realize an appropriate return on our investment in research and product development may not be available or optimal for our products. Further, coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug prices have become a subject of increased focus in recent years. Although there are currently no direct government price controls over private sector purchases in the U.S., federal law requires pharmaceutical manufacturers to pay prescribed rebates on certain government or Medicaid-reimbursed drugs to enable them to be eligible for reimbursement under certain public healthcare programs such as Medicaid and Medicare Part B. Various states have adopted further mechanisms that seek to control drug prices, including by disfavoring certain higher priced drugs or by seeking supplemental rebates from manufacturers. Managed care has also become a potent force in the marketplace that increases downward pressure on the prices of pharmaceutical products.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public and private healthcare payors control costs and influence drug pricing through a variety of mechanisms, including through negotiating discounts with the manufacturers and through the use of tiered formularies and other mechanisms that provide preferential access to certain drugs over others within a therapeutic class. Payors also set other criteria to govern the uses of a drug that will be deemed medically appropriate and therefore reimbursed or otherwise covered.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, in the U.S., there have been several presidential executive orders, congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. For example, on August 16, 2022, the Inflation Reduction Act of 2022 (IRA) was signed into law, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which among other things, (i) extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025, (ii) authorizes HHS to negotiate the price of certain high-expenditure, single-source drugs covered under Medicare that have been on the market for at least 7 years, and (iii) imposes rebates with respect to certain drugs and biologics covered under Medicare Part B or Medicare Part D to penalize price increases that outpace inflation. These provisions began to take effect progressively starting in fiscal year 2023. Additional state and federal health reform measures may be adopted in the future, particularly in light of the recent U.S. Presidential and Congressional elections, any of which could limit the amounts that federal and state governments will pay for healthcare products and services. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Management</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we had 341 full-time employees, 273 of whom were primarily engaged in research, development and manufacturing activities, and 71 of whom had an M.D. and/or Ph.D. Our employees are critically important to the achievement of our company&#8217;s mission and goals. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our senior leadership oversees all human capital management matters and is committed to attracting, developing, engaging and retaining the best people. We strive to offer our employees an intellectually challenging and diverse work environment, opportunities to expand their knowledge and skills, feedback on performance, and paths for career advancement. We believe management&#8217;s relationships with our employees is very positive and they are not subject to a collective bargaining agreement or represented by a trade or labor union.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation and Benefits</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compensation programs are designed to align our employees' interests with our business goals and stockholder returns. We provide employee wages that are competitive within our industry, and we engage an outside compensation and benefits consulting firm to independently evaluate the effectiveness of our compensation and benefit programs and to provide benchmarking against our peers within the industry. We link annual changes in compensation to overall Company performance, as well as each individual&#8217;s contribution to the results achieved. The emphasis on overall Company performance is intended to align the employee&#8217;s financial interests with the interests of stockholders. We are committed to providing our employees with a benefits program that is both comprehensive and competitive. Our benefits program offers health care, dental and vision coverage, along with benefits designed to provide increased financial security to our employees and their families.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain an Employee Stock Purchase Plan under which employees may purchase Company common stock through payroll deductions at a price equal to 85% of the fair market value of the stock as of the end of the offering periods.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Culture</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Living Values are the backbone of our culture: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patients First, Do It Right, Innovate, Pitch In, Take Action </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Be Inclusive. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with our Living Value of &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Be Inclusive</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; we have a number of initiatives to reinforce the importance of an inclusive workforce and culture of belonging to our Company&#8217;s success. To further champion our inclusion efforts, we formed an employee-led team with sponsorship from our senior leadership team. The team focused on raising awareness and promoting a sense of commitment in 2024, and held a number of focus groups and company-wide events.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All employees are required to observe high standards of business and personal ethics and must adhere to our Code of Business Conduct and Ethics, for which they receive training annually. The Code requires reporting any actual or suspected misconduct, illegal activities or fraud. To that end, we maintain a Speak Up Culture where all employees are encouraged to raise issues, report concerns, and ask questions. We also maintain an anonymous hotline that is available to all of our employees, contractors and vendors to report any matter of concern. Communications to the hotline (which is facilitated by an independent third party) are routed to our General Counsel (or, if the General Counsel is the subject of the communication, to the Chair of our Audit Committee) for investigation and resolution. We also maintain a policy of no retaliation, where employees who report any misconduct are to be free of any harassment, retaliation or adverse employment consequence.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically conduct employee engagement surveys to understand our employees&#8217; perspectives and endeavor to listen, change and improve on how we work together in response to these perspectives. In 2024, 95% of our workforce participated in our engagement survey. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Learning and Development</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to invest in our employees to achieve their goals and to lead our company through learning and development. We conduct regular performance reviews. We encourage all employees to take advantage of our leadership, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">management and technical skill trainings and resources. In addition, we provide focused development for managers and emerging leaders who are designated as &#8220;key talent&#8221; based on performance and leadership potential.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Community</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe in giving back and supporting the local communities where we work as well as initiatives consistent with our areas of focus. Employees are encouraged to participate in charitable causes and receive eight hours of voluntary paid time off annually to participate in local opportunities to give back to the community.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Securities and Exchange Commission Filing Information</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our main company website address is www.macrogenics.com. We post links to http://ir.macrogenics.com/financial-information/sec-filings for the following filings as soon as reasonably practicable after they are electronically filed with or furnished to the Securities and Exchange Commission (SEC): annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements, and any amendments to those reports filed or furnished pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. All such filings are available through our website free of charge. In addition, the SEC makes available at its website (www.sec.gov), free of charge, reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="ib90895a7822448df9e5a179143ce4792_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. &#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The discussion below addresses material factors, of which we are currently aware, that could have a material and adverse effect on our business, results of operations and financial condition. These risk factors and other forward-looking statements that relate to future events, expectations, trends and operating periods involve certain factors that are subject to change, and important risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties should not be considered a complete discussion of all the risks and uncertainties we may face and although the risks are organized by headings and each risk is discussed separately, many are interrelated.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Risk Factors Affecting Our Business  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to numerous risks. The following summary highlights some of the risks you should consider with respect to our business and prospects. This summary is not complete and the risks summarized below are not the only risks we face. You should review and consider carefully the risks and uncertainties described in the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K, which includes a more complete discussion of the risks summarized below as well as a discussion of other risks related to our business and an investment in our common stock, as well as our other SEC filings.  </span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will require substantial additional funding, which may not be available to us on acceptable terms, or at all, and, if not available, may require us to delay, scale back, or cease our product development programs or operations.  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant losses since inception and anticipate that we will continue to incur losses for the foreseeable future. Accordingly, we may never achieve or sustain profitability. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend substantially on the success of the clinical development of our product candidates, through our own efforts or those of our collaborators. If we are unable to successfully complete clinical development, obtain additional regulatory approvals and commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed and we may not be able to generate sufficient revenues and cash flows to continue our operations.  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical drug development involves a lengthy and expensive process, with a highly uncertain outcome. We expect to incur significant additional costs related to the development of our product candidates and may experience delays in completing, or ultimately be unable to complete, the development and commercialization of our other product candidates. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our product candidates may have undesirable side effects which may delay or prevent further clinical development or marketing approval, or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales.  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our existing therapeutic collaborations are important to our business, and future collaborations may also be important to us. If we are unable to maintain any of these collaborations, or if these collaborations are not successful, our business could be adversely affected. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If clinical trials for our product candidates are prolonged, delayed or stopped for any reason, including for safety reasons or lack of efficacy, we may be unable to obtain regulatory approval and commercialize our product candidates on a timely basis, which would require us to incur additional costs and delay our receipt of any product revenue.  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The results of previous clinical trials may not be predictive of future results, and interim, immature, or top line data may be subject to change or qualification based the complete analysis of data. In addition, the results of our current or planned clinical trials may not satisfy the requirements of the FDA or non-U.S. regulatory authorities for product approval.  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face significant competition and if our competitors continue to develop and market products that are more effective, safer or less expensive than our product candidates, our current or future commercial opportunities may be negatively impacted.  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We use novel technologies in the development of our product candidates and the FDA and other regulatory authorities have not approved or may not approve products that utilize these technologies.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be successful in our efforts to use and expand our technology platforms to build a pipeline of product candidates. We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our product candidates, if approved, may fail to achieve or maintain market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The manufacture of our product candidates, for ourselves and our collaborators, is complex, and we may encounter difficulties in production. There can be no assurance that we will be able to effectively manufacture clinical quantities of our product candidates in the future. Further, we have limited experience in large-scale commercial manufacturing, and there can be no assurance that we will be able to effectively manufacture commercial quantities of our products or product candidates for ourselves or our collaborators, if and when approved.  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our manufacturing facility is subject to significant government regulations and approvals, which are often costly and could result in adverse consequences to our business if we fail to comply with the regulations or maintain the approvals.   </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have limited experience in launching and marketing biopharmaceutical products. If our product candidates achieve regulatory approval and we are unable to develop marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate substantial product sales revenue.  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our future success depends on our ability to attract or retain key executives and to attract, retain and motivate qualified personnel.  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Actual or anticipated changes to the laws, regulations, policies and governmental priorities, governing the health care system may have a negative impact on cost and access to health insurance coverage and reimbursement of health care items and services.  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reimbursement decisions by third-party payors, including government payors, may have an adverse effect on pricing and market acceptance.  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish substantial rights.  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We contract with, and may in the future contract with, third parties for components of the manufacturing of our product candidates, including our antibody drug conjugate candidates. Failure of third-party contractors to successfully perform their obligations could harm our ability to develop or commercialize our product or product candidates.  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our information technology systems or those third parties upon which we rely for our data, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our success depends significantly on our ability to operate without infringing the valid patents and other proprietary rights of third parties.  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to obtain and enforce patent protection for our products and our product candidates and related technology, our business could be materially harmed.  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have been and may in the future be subject to securities litigation, which is expensive and could divert management attention and adversely impact our business. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to successfully develop and commercialize companion diagnostics with third party contractors for use with our product candidates could harm our ability to commercialize our product candidates. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If any product liability lawsuits are successfully brought against us or any of our collaborators, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require substantial additional funding, which may not be available to us on acceptable terms, or at all, and, if not available, may require us to delay, scale back, or cease our product development programs or operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discovering, developing and commercializing pharmaceutical products, including conducting nonclinical studies and clinical trials, is expensive. In order to obtain regulatory approval of product candidates, we will be required to conduct clinical trials for each indication for each of our product candidates. We will continue to require additional funding beyond what was raised in our public offerings and through our collaborations and license agreements to complete the development and commercialization of our product candidates and to continue to advance the development of our other product candidates. Due to worsening and highly uncertain global economic conditions, including high rates of inflation, fluctuating interest rates and concerns of a recession or economic volatility in the United States or other major markets, the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide, and geopolitical instability, including but not limited to resulting from the ongoing conflicts between Russia and Ukraine, the regional conflict in the Middle East and increasing tensions between China and Taiwan, such funding may not be available on acceptable terms or at all. Although it is difficult to predict our funding requirements, we anticipate that our cash, cash equivalents and marketable securities as of December&#160;31, 2024, combined with anticipated and potential collaboration payments, contract manufacturing revenue, and royalties, should enable us to fund our operations into the second half of 2026. Such guidance does not reflect or further expansion of studies currently ongoing. Because development of our product candidates is uncertain, we are unable to estimate accurately the actual funds we will require to complete research, development and clinical testing to commercialize our product candidates. Our future funding requirements will depend on many factors, including but not limited to: </span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and characteristics of other product candidates and indications that we pursue;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, timing, cost and results of research, nonclinical development, and clinical trials;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing and outcome of seeking and obtaining FDA and non-U.S. regulatory approvals;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with manufacturing our product candidates as well as the costs of operation of our manufacturing facility;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the economic and other terms, timing of and success of our existing collaborations, and any collaboration, licensing, or other arrangements into which we may enter in the future, including the timing of receipt of any milestone or royalty payments under these agreements;</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of establishing sales, marketing, and distribution capabilities;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain, expand, and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make in connection with the licensing, filing, defense and enforcement of any patents or other intellectual property rights;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our need and ability to hire additional management, scientific, and medical personnel;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing products that may limit market potential of our product candidates;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our need to implement additional internal systems and infrastructure, including financial and reporting systems;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the economic and other terms, timing of and success of our existing collaborations, and any collaboration, licensing, or other arrangements into which we may enter in the future, including the timing of receipt of any milestone or royalty payments under these agreements; and </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of establishing sales, marketing, and distribution capabilities.  </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until we can generate a sufficient amount of product revenue to finance our cash requirements, which we may never do, we expect to finance future cash needs primarily through a combination of public or private equity offerings, debt financings, strategic collaborations, and grant funding. If sufficient funds on acceptable terms are not available when needed, or at all, we could be forced to significantly reduce operating expenses and delay, scale back or eliminate one or more of our development programs or our business operations.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses since inception and anticipate that we will continue to incur losses for the foreseeable future. We may never achieve or sustain profitability.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant losses since our inception. As of December&#160;31, 2024, our accumulated deficit was approximately $1.2 billion. We expect to continue to incur losses for the foreseeable future, and we expect our accumulated deficit to increase as we continue our research and development of, and seek regulatory approvals for, our product candidates, manufacture product and product candidate inventory, prepare for and begin to commercialize any future approved products, and add infrastructure and personnel if needed to support our product development efforts and operations as a public company. The net losses and negative cash flows incurred to date, together with expected future losses, have had, and likely will continue to have, an adverse effect on our stockholders' deficit and working capital. The amount of future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with pharmaceutical product development and commercialization, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. For example, our expenses could increase if we are required by the FDA to perform trials in addition to those that we currently expect to perform, or if there are any delays in completing our currently planned clinical trials or in the development of any of our product candidates. Our expenses would significantly increase to the extent we build out a sales force and other commercially relevant functions to support the commercialization of any of our product candidates. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To become and remain profitable, we must succeed in developing and commercializing products with significant market potential. In order to commercialize any additional product candidates, we will need to be successful in a range of challenging activities for which we are only in the preliminary stages, including developing product candidates, obtaining regulatory approval for them, and manufacturing, marketing and selling approved products and product candidates for which we may obtain regulatory approval. We may never succeed in these activities and may never generate revenue from product sales that is significant enough to achieve profitability. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our failure to become or remain profitable would depress our market value and could impair our ability to raise capital, expand our business, develop other product candidates, or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely affected by economic downturns, inflation, increases in interest rates, disruption in global supply chains, natural disasters, political crises, geopolitical events, such as the ongoing military conflict in Ukraine, or other macroeconomic conditions, which have in the past and may in the future negatively impact our business and financial performance.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including, among other things, severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, supply chain shortages, increases in inflation rates, higher interest rates and uncertainty about economic stability. Over the past several years, the Federal Reserve has raised interest rates multiple times in response to concerns about inflation and it may raise them again. Higher interest rates, coupled with reduced government spending and volatility in financial markets, may increase economic uncertainty and affect consumer spending. Similarly, the ongoing military conflicts between Russia and Ukraine, the regional conflict in the Middle East and increasing tensions between China and Taiwan have created extreme volatility in the global capital markets and is expected to have further global economic consequences, including disruptions of the global supply chain and energy markets. Further, tariffs imposed by either the U.S. government or foreign governments could increase the cost of manufacturing our product candidates, although we are seeking alternative sources for certain components to mitigate supply risk. Any such or other volatility or global market disruptions may adversely affect our business or the third parties on whom we rely. If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing more costly or more dilutive or more difficult to obtain in a timely manner or on favorable terms, if at all. Increased inflation rates can adversely affect us by increasing our costs, including labor and employee benefit costs. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish substantial rights.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available at all, may involve agreements that include covenants limiting or restricting our ability to take specific actions such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, product candidates, or future revenue streams, or grant licenses on terms that are not favorable to us. We cannot assure you that we will be able to obtain additional funding if and when necessary. If we are unable to obtain adequate financing on a timely basis, we could be required to delay, scale back or eliminate one or more of our development programs or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards and other tax attributes may be limited.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. federal net operating loss (NOL) carryforwards generated in taxable periods beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility of such NOL carryforwards in a taxable year is limited to 80% of taxable income in such year. In addition, our ability to utilize portions of our federal NOL carryforwards and federal tax credits is currently limited, and may be limited further, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended. The limitations apply if an ownership change, as defined by Section&#8239;382, occurs. Generally, an ownership change occurs when certain shareholders increase their aggregate ownership by more than 50 percentage points over their lowest ownership percentage in a testing period, which is typically three years or since the last ownership change. We are already subject to Section&#8239;382 limitations due to acquisitions we made in 2002 and 2008.&#8239;As of December&#160;31, 2024, we had federal and state NOL carryforwards of approximately $554.0 million and federal research and development tax credits of approximately $109.0 million available. Future changes in stock ownership may also trigger an ownership change and, consequently, another Section&#8239;382 limitation. Similar rules may apply under state tax laws. In addition, there may be other limitations under state law on our ability to utilize NOL carryforwards, including temporary suspensions or other limitations on the use of NOL carryforwards s to offset taxable income. Any limitation may result in expiration of a portion of the net operating loss or tax credit carryforwards before utilization which would reduce our gross deferred income tax assets and corresponding valuation allowance. As a result, if we earn net taxable income, our ability to use our pre-change NOL carryforwards and tax credit carryforwards to reduce United States federal income tax may be subject to limitations, which could potentially result in increased future cash tax liability to us.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and the Development and Commercialization of Our Product Candidates  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend substantially on the success of the clinical development of our product candidates, through our own efforts or those of our collaborators. If we or our collaborators are unable to successfully complete clinical development, obtain additional regulatory approvals and commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed and we may not be able to generate sufficient revenues and cash flows to continue our operations.   </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business depends on the successful development, regulatory approval and commercialization of our product candidates. We have invested and will continue to invest a significant portion of our efforts and financial resources in the development of our product candidates. The success of our product candidates depends on many factors, including but not limited to:  </span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful and timely patient enrollment in, and completion of, clinical trials, as well as completion of nonclinical studies;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the acceptability and adequacy of safety, tolerability and efficacy data from our clinical trials and other studies; </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sufficiency of our financial resources and ability to obtain additional funding for the development of our product candidates;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receipt of regulatory approvals;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the performance by clinical research organizations (CROs) or other third parties we may retain of their duties to us in a manner that complies with our protocols and applicable laws and that protects the integrity of the resulting data;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining patent, trade secret and other intellectual property protection and regulatory exclusivity;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ensuring we do not infringe, misappropriate or otherwise violate the valid patent, trade secret or other intellectual property rights of third parties;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully launching our product candidates if and when approved;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining commercial manufacturing capabilities, either by utilizing our current manufacturing facilities or making arrangements with third-party manufacturers;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing or obtaining sufficient supplies of our product candidates that may be necessary for use in clinical trials for evaluation of our product candidates and commercialization of our products;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining favorable reimbursement from third-party payors for product candidates;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition with other products;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">post-marketing commitments to regulatory agencies following regulatory approval; and </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued acceptable safety profile following regulatory approval. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical drug development involves a lengthy and expensive process, with a highly uncertain outcome. We expect to incur significant additional costs related to the development of our product candidates and may experience delays in completing, or ultimately be unable to complete, the development and commercialization of our other product candidates.   </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research, testing, manufacturing, labeling, approval, selling, marketing and distribution of drug products are subject to extensive regulation by the FDA and non-U.S. regulatory authorities, which regulations differ from country to country. We are not permitted to market our product candidates in the United States or in other countries until we receive approval of a BLA from the FDA or marketing approval from applicable regulatory authorities outside the United States. Our product candidates are in various stages of development and are subject to the risks of failure inherent in drug development.  The approval of a BLA can be a lengthy, expensive and uncertain process. In addition, failure to comply with FDA and non-U.S. regulatory requirements may, either before or after product approval, subject our company or our collaborators to administrative or judicially imposed sanctions, including:  </span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials;  </span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the products, manufacturers, manufacturing facilities or manufacturing process;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning letters or untitled letters;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">civil and criminal penalties;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or withdrawal of regulatory approvals;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizures, detentions or import bans;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">voluntary or mandatory product recalls; </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">total or partial suspension of production;  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs; </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposition of restrictions on marketing or operations, including costly new manufacturing requirements; and  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to approve pending BLAs or supplements to approved BLAs or analogous marketing approvals outside the United States.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and foreign regulatory authorities also have substantial discretion in the drug approval process. The number of nonclinical studies and clinical trials that will be required for regulatory approval varies depending on the product candidate, the disease or condition that the product candidate is designed to address, and the regulations applicable to any particular drug candidate. Regulatory agencies can delay, limit or deny approval of a product candidate for many reasons, including:  </span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a product candidate may not be deemed safe or effective;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results may not confirm the positive results from earlier nonclinical studies or clinical trials;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory agencies may not find the data from nonclinical studies and clinical trials sufficient or meaningful;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory agencies might not approve or might require changes to our manufacturing processes or facilities; or  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory agencies may change their approval policies or adopt new regulations.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay in obtaining or failure to obtain required approvals could materially adversely affect our ability to generate revenue from the particular product candidate, which likely would result in significant harm to our financial position and adversely impact our stock price. Furthermore, any regulatory approval to market a product may be subject to limitations on the indicated uses for which we may market the product. These limitations may limit the size of the potential market for a product candidate, if approved. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If clinical trials for our product candidates are prolonged, delayed or stopped, for any reason, we may be unable to obtain regulatory approval and commercialize our product candidates on a timely basis, which would require us to incur additional costs and delay our receipt of any product revenue. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, or our collaborators or investigators, are either currently enrolling patients in clinical trials or anticipate initiating, continuing, designing, or supporting clinical trials for molecules that include lorigerlimab, retifanlimab, vobra duo, MGD024, MGC026, MGC028, or other molecules, as monotherapies or in combination with other product candidates. We anticipate in the future collaborators will initiate or continue clinical trials of one or more our product candidates. The continuation, modification, or commencement of existing or new clinical trials could be substantially delayed or prevented by several factors, including:  </span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further discussions with the FDA or other regulatory agencies regarding the scope or design of our clinical trials;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the limited number of, and competition for, suitable sites to conduct our clinical trials, many of which may already be engaged in other clinical trial programs, including some that may be for the same indication as our product candidates;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any delay or failure in patient recruitment or enrollment in our or our collaborators&#8217; trials for any reason;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any delay or failure to obtain regulatory approval or agreement to commence a clinical trial in any of the countries where enrollment is planned;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to obtain sufficient funds required for a clinical trial;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical holds on, or other regulatory objections to, a new or ongoing clinical trial;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay or failure to manufacture sufficient supplies of the product candidate for our clinical trials;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay or failure to reach agreement on acceptable clinical trial terms or clinical trial protocols with prospective sites or CROs the terms of which can be subject to extensive negotiation and may vary significantly among different sites or CROs;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay or failure to obtain IRB approval to conduct a clinical trial at a prospective site;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant competition of product candidates that are expected to be more effective or have a more favorable safety profile; and</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval of potential therapies by competitors. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The progress or completion of our, or our collaborators', clinical trials have been and could also be substantially delayed or prevented by many factors, including:  </span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen safety issues, including severe or unexpected drug-related adverse effects experienced by patients, including actual and possible deaths;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in expected site initiation, patient recruitment and enrollment, for any reason;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of patients to complete the clinical trial;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of efficacy during clinical trials;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">termination of our clinical trials by one or more clinical trial sites;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability or unwillingness of patients or clinical investigators to follow our clinical trial protocols;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic and political instability in countries where our trial sites are located, including terrorist attacks, civil unrest and actual or threatened armed conflict; </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to monitor patients adequately during or after treatment by us, our collaboration partners and/or our CROs; and  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the need to repeat or terminate clinical trials as a result of inconclusive or negative results or unforeseen complications in testing.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in regulatory requirements and guidance may also occur and we may need to significantly amend clinical trial protocols to reflect these changes with appropriate regulatory authorities. Amendments may require us to renegotiate terms with CROs or resubmit clinical trial protocols to IRBs for re-examination, which may impact the costs, timing or successful completion of a clinical trial. Our clinical trials may be suspended or terminated at any time by the FDA, other regulatory authorities, the IRB overseeing the clinical trial at issue, any of our clinical trial sites with respect to that site, or us, due to a number of factors, including:  </span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen safety issues or any determination that a clinical trial presents unacceptable health risks;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of adequate funding to continue the clinical trial due to unforeseen costs or other business decisions; and  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">upon a breach or pursuant to the terms of any agreement with, or for any other reason by, current or future collaborators that have responsibility for the clinical development of any of our product candidates.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials of our product candidates are subject to partial or full clinical holds from time to time. A clinical hold received in the midst of conducting a trial may delay the progress of a clinical trial, or may require us to modify or discontinue such trial. Any failure or significant delay in completing clinical trials for our product candidates would adversely affect our ability to obtain regulatory approval and our commercial prospects and ability to generate product revenue will be diminished. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The results of previous clinical trials may not be predictive of future results, and interim or top line data may be subject to change or qualification, based on several factors, including a complete analysis of data, or in the case of interim analysis, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">the continued or ongoing accrual of data. In addition, the results of our current and planned clinical trials may not satisfy the requirements of the FDA or non-U.S. regulatory authorities for product approval.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical failure can occur at any stage of clinical development. Clinical trials may produce negative or inconclusive results, and we or any of our current and future collaborators may decide, or regulators may require us, to conduct additional clinical or nonclinical testing. Success in early clinical trials does not mean that future larger registration clinical trials will be successful because product candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA and non-U.S. regulatory authorities despite having progressed through initial clinical trials. A number of companies in the pharmaceutical industry, including those with greater resources and experience than us, have suffered significant setbacks in advanced clinical trials, even after obtaining promising results in earlier clinical trials.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may publicly disclose top line or interim data from time to time, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial or continued progress of the study or trial. The top line or interim results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top line and interim data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. In addition, the achievement of one primary endpoint for a trial does not guarantee that additional co-primary endpoints or secondary endpoints will be achieved, which may have an adverse effect on our ability to obtain or retain additional regulatory approval of products or product candidates in the U.S. or in other jurisdictions.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain of our antibody-drug conjugate, or ADC, product candidates incorporate technology developed by our collaboration partners. To date, no ADC product candidates incorporating any such technology have been approved by the FDA. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our ADC products in development incorporate technology developed by our collaboration partners, including: vobra duo (incorporates seco-DUBA developed by our collaboration partner, Byondis B.V.) and MGC026 and MGC028 (incorporate Hydraspace</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, GlycoConnect&#8482; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and toxSYN&#174; technology developed by our collaboration partner, Synaffix (a Lonza company)). To date, no ADC product candidates incorporating any of the seco-DUBA, Hydraspace GlycoConnect&#8482; or toxSYN technologies have been approved by the FDA. There is no assurance that the FDA will approve future product candidates using such technologies. The validation process takes time and resources, may require independent third-party analyses, and may not be accepted by the FDA and other regulatory authorities. For some of our product candidates that are based on these technology platforms, the regulatory approval path and requirements may not be clear or evolve as more data becomes available for this product candidates, which could add significant delay and expense. Delays or failure to obtain regulatory approval of any of the product candidates that we develop would adversely affect our business.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in our efforts to use and expand our technology platforms to build a pipeline of product candidates. We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.   </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A key element of our strategy is to use and expand our technology platforms to continue to build a pipeline of product candidates and progress several of these product candidates through clinical development for the treatment of a variety of different types of diseases. Although our research and development efforts to date have resulted in a pipeline of product candidates directed at various cancers, as well as autoimmune disorders and infectious diseases, we may not be able to develop product candidates that are safe and effective. Even if we are successful in continuing to build our pipeline, the potential product candidates that we identify may not be suitable for initial or continued clinical development, including as a result of being shown to have harmful side effects or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance. If we do not continue to successfully develop and begin to commercialize product candidates, we will face difficulty in obtaining product revenues in future periods, which could result in significant harm to our financial position and adversely affect our stock price.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates, if approved, may fail to achieve or maintain market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates, if approved, may fail to achieve or maintain market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If product candidates that we develop do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of any product candidates that we develop will depend on a number of factors, including but not limited to:  </span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efficacy and potential advantages compared to alternative treatments;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any side effects;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any safety events that may have occurred in connection with the development of the product candidate;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to offer our products for sale at competitive prices;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the convenience and ease of administration compared to alternative treatments;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of physicians to prescribe the product or other new therapies, and of the patient population to try the product or these therapies;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the strength of marketing, sales, and distribution support;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of third-party coverage and adequate reimbursement; and  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any restrictions on the use of our products together with other medications.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potential market opportunities for our product candidates are difficult to precisely estimate. A product&#8217;s market acceptance depends significantly on the medical community&#8217;s determination of clinical benefit and safety compared to alternative therapies available both now and in the future. Our internal estimates of the potential market opportunities our product candidates include several key assumptions based on a variety of factors, which may include our industry knowledge, industry publications, third-party research reports, assessment of competition, and other surveys. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions. If any of these assumptions proves to be inaccurate, then the actual market for our product candidates could be smaller than our estimates of our potential market opportunity. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates may have undesirable side effects, including fatalities. These side effects may delay or prevent further clinical development or marketing approval, or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although all of our product candidates have undergone or will undergo safety testing, not all adverse effects of drugs can be predicted or anticipated. Unforeseen side effects from any of our product candidates have arisen, either during clinical development or after the approved product has been marketed, and may arise in the future. Ongoing or future trials of our product candidates may not support the conclusion that one or more of these product candidates have acceptable safety profiles.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of future clinical or nonclinical trials may show undesirable or unacceptable side effects, which could interrupt, delay or halt clinical trials, and result in delay of, or failure to obtain, marketing approval from the FDA and other regulatory authorities, or result in marketing approval from the FDA and other regulatory authorities with restrictive label warnings, risk management measures, or potential product liability claims. These risks have affected our business and may continue to do so. For example, in July 2022 we announced the discontinuation of our Phase 2 trial of enoblituzumab in combination with either retifanlimab or tebotelimab in the treatment of patients with recurrent or metastatic SCCHN, based on an internal review of safety data. In addition, in July 2024, we announced the discontinuation of vobra duo treatment of mCRPC patients in our TAMARACK study based on the recommendation of the study&#8217;s Independent Data Monitoring Committee (IDMC). The investigators for the TAMARACK study have reported a total of 11 treatment-related deaths across all patient types (6.1% of the 180 patients who received treatment). These patient deaths occurred between 87 days and 339 days after commencing treatment with vobra duo. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if our product candidates are approved for marketing, and we or others later identify undesirable or unacceptable side effects potentially caused by such products:  </span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require us to take our approved product off the market;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies; </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to change the way the product is administered, impose other risk-management measures, conduct additional clinical trials or change the labeling of the product;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be subject to limitations on how we may promote the product;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of the product may decrease significantly;  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be subject to litigation or product liability claims; and  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us, our collaborators or our potential future partners from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from the sale of our products.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our manufacturing facilities are subject to significant government regulations and approvals, which are often costly and could result in adverse consequences to our business if we fail to comply with the regulations or maintain the approvals.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must comply with the FDA&#8217;s cGMP requirements, as set out in statute, regulations and interpreted through guidance. We may encounter difficulties in achieving quality control and quality assurance and may experience shortages in qualified personnel. We are subject to inspections by the FDA and comparable agencies in other jurisdictions to confirm compliance with applicable regulatory requirements. See &#8220;Other U.S. Post-Marketing Regulatory Requirements&#8221; above for additional information. Any failure to follow cGMP or other regulatory requirements or delay, interruption or other issues that arise in the manufacture, fill-finish, packaging, or storage of our product or product candidates as a result of a failure of our facilities or the facilities or operations of third parties to comply with regulatory requirements or pass any regulatory authority inspection could significantly impair our ability to develop and commercialize our product candidates, including leading to significant delays in the availability of drug product for sale and our clinical trials or the termination or hold on a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our product candidates. Significant noncompliance could also result in the imposition of sanctions, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approvals for our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could damage our reputation or negatively impact a product&#8217;s commercial success. If we are not able to maintain regulatory compliance, we may not be permitted to market our product candidates and/or may be subject to product recalls, seizures, injunctions, or criminal prosecution. Additionally, if the FDA or a comparable foreign regulatory authority does not approve of our facilities for the manufacture of a customer product or if it withdraws such approval in the future, our customers may choose to identify alternative manufacturing facilities and/or relationships, which could significantly impact our ability to expand our CDMO capacity and capabilities and achieve profitability. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face significant competition and if our competitors continue to develop and market products that are more effective, safer or less expensive than our product candidates, our current or future commercial opportunities may be negatively impacted. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The life sciences industry is highly competitive and subject to rapid and significant technological change. We are currently developing therapeutics that will compete with other drugs and therapies that currently exist or are being developed. Products we may develop in the future are also likely to face competition from other drugs and therapies, some of which we may not currently be aware. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, universities and other research institutions. Many of our competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources than we do. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients and manufacturing pharmaceutical products. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These companies also have significantly greater research and marketing capabilities than we do and may also have products that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. As a result of all of these factors, our competitors may succeed, or may have succeeded, in obtaining patent protection and/or FDA approval or discovering, developing and commercializing products in our field before we do.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, there are a large number of companies developing or marketing potential treatments for cancer, including many major pharmaceutical and biotechnology companies. These treatments consist both of small molecule drug products, as well as biologic therapeutics that work by using next-generation antibody technology platforms to address specific cancer targets. In addition, several companies are developing therapeutics that work by targeting multiple specificities using a single recombinant molecule. See &#8220;Competition&#8221; above for additional information.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial opportunity for future product candidates may be reduced or limited if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of biosimilar products.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. In addition, the biopharmaceutical industry is characterized by rapid technological change. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our technologies, products or product candidates obsolete, less competitive or not profitable.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The manufacture of products or product candidates, for ourselves and our collaborators, is complex, and we may encounter difficulties in production. There can be no assurance that we will be able to effectively manufacture clinical quantities of our product candidates in the future. Further, we have limited experience in large-scale commercial manufacturing, and there can be no assurance that we will be able to effectively manufacture commercial quantities of products or product candidates for ourselves or our collaborators, if and when approved.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently manufacture product and product candidates for ourselves and our collaborators in our in-house manufacturing facility, and we anticipate manufacturing both commercial product as well as product candidates in the future. We have limited experience in manufacturing at commercial scale. The process of commercial or clinical biotechnology manufacturing for ourselves and our collaborators is highly susceptible to delays or product loss due to a variety of factors, including but not limited to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics, difficulties in scaling the production process, and vendor supply chain disruptions or fluctuations. Even minor deviations from manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our products or product candidates or in the manufacturing facilities in which our products and our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. Any adverse developments affecting manufacturing operations for our products and our product candidates, if any are approved, may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. In addition, if we fail to supply required quantities of a product or a product candidate for one of our collaborators, our collaborator may terminate our agreement. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we currently maintain insurance coverage against damage to our property and to cover business interruption and research and development restoration expenses, our insurance coverage may not reimburse us, or may not be sufficient to reimburse us, for any expenses or losses we may suffer. If there were to be a catastrophic event or failure of our manufacturing facilities or processes, we may be unable to meet our requirements for supply of our products or product candidates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public health crises such as pandemics or similar outbreaks may have a significant negative impact on our clinical trials, nonclinical studies, development, manufacturing and commercialization of our product candidates and other aspects of our business, staff, and operations. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public health crises such as pandemics or similar outbreaks may have a material impact our business. For instance, the COVID-19 pandemic impaired, and future public health crises may in the future impair, our ability to enroll patients in clinical trials, continue ongoing clinical trials and activate clinical trial sites. Further, patients may be unable or unwilling to enroll in our clinical trials or be unable to comply with clinical trial protocols if public health restrictions impede patient movement or interrupt healthcare services. Public health crises may also negatively affect the operations of third-party CROs that we rely upon to carry out our clinical trials, or the operations of other service providers, which could result in delays or disruptions in the supply of our product candidates or other aspects of our business or that of our collaborators. Any negative impact public health crises could adversely affect our ability to seek and obtain regulatory approval for and to commercialize any approved product candidates, increase our operating expenses and have a material adverse effect on our business and financial results.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited experience in launching and marketing approved products. If our products achieve regulatory approval and we are unable to further develop marketing and sales capabilities or enter into agreements with third parties to market and sell our products we may not be able to generate substantial product sales revenue.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited experience in commercializing products. In March 2021, following FDA approval, we launched MARGENZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. In November 2024, we completed the sale of the global rights to MARGENZA to TerSera Therapeutics LLC. We continue to have limited internal commercialization capabilities, and the commercialization of any future l products or product candidates that we may develop or in-license, will require building, or contracting for, capabilities, which will require significant capital expenditures, management resources and time. For example, we have limited experience in building and managing a commercial team, conducting a comprehensive market analysis or managing distributors and a field force for our products. We will compete with many companies that currently have extensive and well-funded sales and marketing operations with respect to any approved products.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For commercialization of any or all of our product candidates, we will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. If we are unable to, or decide not to, further develop internal sales, marketing, and commercial distribution capabilities for any or all of our products, we will likely pursue additional collaborative arrangements regarding the sales and marketing of our products. However, there can be no assurance that we will be able to establish or maintain such collaborative arrangements, or if we are able to do so, that they will be effective. There can be no assurance that we will be able to develop or successfully maintain internal sales and commercial capabilities or establish or maintain relationships with third-party collaborators to successfully commercialize any product, and as a result, we may not be able to generate substantial product sales revenue. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Actual or anticipated changes to the laws and regulations governing the health care system may have a negative impact on cost and access to health insurance coverage and reimbursement of healthcare items and services.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States and several foreign jurisdictions are considering, or have already enacted, a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell any of our future approved products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs through lowering prescription drug prices, improving quality and/or expanding access to healthcare. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives, including the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, which became law in 2010. While it is difficult to assess the impact of the ACA in isolation, either in general or on our business specifically, it is widely thought that the ACA increases the likelihood of downward pressure on pharmaceutical reimbursement, which could negatively affect market acceptance of, and the price we may charge for, any products we develop that receive regulatory approval. Further, the United State and foreign governments regularly consider additional reform measures that affect healthcare coverage and costs. Such reforms may include changes to the coverage and reimbursement of healthcare services and products. In particular, there have been executive, judicial and Congressional challenges and amendments to the ACA. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (IRA) into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how such challenges and any healthcare reform measures of the second Trump administration will impact the ACA and our business.  </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. For example, the IRA, among other things, (i) directs the U.S. Department of Health and Human Services (HHS) to negotiate the price of certain high-expenditure, single-source drugs covered under Medicare that have been on the market for at least 7 years, and subject drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; for such drugs under the law (the Medicare Drug Price Negotiation Program), and (ii) imposes rebates with respect to certain drugs and biologics covered under Medicare Part B or Medicare Part D to penalize price increases that outpace inflation. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. These provisions began to take effect progressively starting in fiscal year 2023. On August 15, 2024, HHS announced the agreed-upon prices of the first ten drugs that were subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. On January 17, 2025, HHS selected fifteen additional drugs covered under Part D for price negotiation in 2025. Each year thereafter more Part B and Part D products will become subject to the Medicare drug price negotiation program. Further, on December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework. We cannot predict what healthcare initiatives, if any, will be implemented at the federal or state level, however, government and other regulatory oversight and future regulatory and government interference with the healthcare systems could adversely impact our business and results of operations.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additional health reform measures may continue and affect our business in unknown ways, particularly given the recent change in administration. The current Trump administration is pursuing policies to reduce regulations and expenditures across government including at HHS, the FDA, CMS and related agencies. These actions, presently directed by executive orders or memoranda from the Office of Management and Budget, may propose policy changes that create additional uncertainty for our business. These actions may include, for example, directives to reduce agency workforce, rescinding a Biden administration executive order tasking the Center for Medicare and Medicaid Innovation to consider new payment and healthcare models to limit drug spending and eliminating the Biden administration&#8217;s executive order that directed HHS to establishing an AI task force and developing a strategic plan, and directing certain federal agencies to enforce existing law regarding hospital and price plan transparency and by standardizing prices across hospitals and health plans. Additionally, in its June 2024 decision in Loper Bright Enterprises v. Raimondo, the U.S. Supreme Court overturned the longstanding Chevron doctrine, under which courts were required to give deference to regulatory agencies&#8217; reasonable interpretations of ambiguous federal statutes. The Loper Bright decision could result in additional legal challenges to current regulations and guidance issued by federal agencies applicable to our operations, including those issued by the FDA. Congress may introduce and ultimately pass health care related legislation that could impact the drug approval process and make changes to the Medicare Drug Price Negotiation Program created under the IRA. We expect to experience pricing pressures in connection with the sale of any products that we develop, due to the trend toward managed healthcare, the increasing influence of various and evolving payor models and additional legislative proposals. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reimbursement decisions by third-party payors may have an adverse effect on pricing and market acceptance. If there is not sufficient reimbursement for our products, it is less likely that our products will be widely used. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market acceptance and sales of our product candidates, if approved for sale by the appropriate regulatory authorities, may depend on reimbursement policies and may be affected by future healthcare reform measures. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drugs they will reimburse and establish payment levels and, in some cases, utilization management strategies, such as tiered formularies and prior authorization. We cannot be certain that reimbursement will be available for our products or any products that we develop. Also, we cannot be certain that reimbursement policies will not reduce the demand for, or the price paid for, our products. Our ability to commercialize our products may depend, in part, on the extent to which reimbursement for the products will be available from government authorities and third-party payors. If reimbursement for our products is not available or is available on a limited basis, or if the reimbursement amount for our products is inadequate to support a product&#8217;s price, we may not be able to successfully commercialize any of our approved products.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the United States, for example, principal decisions about reimbursement for new products are typically made by CMS, an agency within HHS. CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare, and private third-party payors often follow CMS&#8217;s decisions regarding coverage and reimbursement to a substantial degree. However, one third-party payor&#8217;s determination to provide coverage for a product candidate does not assure that other payors </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will also provide coverage for the product candidate. Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. As a result, the coverage and reimbursement determination process is often time-consuming and costly. This process may require us to provide scientific and clinical information to support the coverage or reimbursement of our products to each third-party payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As federal and state governments implement additional health care cost containment measures, including measures to lower prescription drug pricing, we cannot be sure that our products and our product candidates, if approved, will be covered, or remain covered, by private or public payors, and if covered, whether the reimbursement will be perceived by product purchasers as adequate. Health reform actions by federal and state governments and health plans may put additional downward pressure on pharmaceutical pricing and health care costs, which could negatively impact coverage and reimbursement for our product or our product candidates, if approved, our revenue, and our ability to compete with other marketed products and to recoup the costs of our research and development.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increasingly, third-party payors are requiring that biopharmaceutical manufacturers provide them with discounts from list prices and are challenging the prices charged for medical products. Further, such payors are increasingly challenging the price, examining the medical necessity and reviewing the cost effectiveness of medical products. There may be especially significant delays in obtaining coverage and reimbursement for newly approved drugs. Third-party payors may limit coverage to specific product candidates on an approved list, known as a formulary, which might not include all FDA-approved drugs for a particular indication. We may need to conduct expensive pharmaco-economic studies to demonstrate the medical necessity and cost effectiveness of our products. Nonetheless, our products may not be considered medically necessary or cost effective. We cannot be sure that coverage and reimbursement will be available for any approved product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Further, coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained, less favorable coverage policies and reimbursement rates may be implemented in the future. Additionally, we or our collaborators may develop companion diagnostic tests for use with our product candidates where appropriate. We or our collaborators will be required to obtain coverage and reimbursement for these tests separate and apart from the coverage and reimbursement we may seek for our product candidates. While we have not yet developed any companion diagnostic tests for our product candidates, if we do, there is significant uncertainty regarding our ability to obtain coverage and adequate reimbursement for the same reasons applicable to our product candidates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If any product liability lawsuits are successfully brought against us or any of our collaborators, we may incur substantial liabilities and may be required to limit commercialization of our products or product candidates.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability lawsuits related to the sale of our products to, use of our products by, and testing of our product candidates in, seriously ill patients. Product liability claims may be brought against us or our collaborators by participants enrolled in our clinical trials, patients, health care providers or others using, administering or selling any of our approved products. If we cannot successfully defend ourselves against any such claims, we may incur substantial liabilities. Regardless of their merit or eventual outcome, liability claims may result in: </span></div><div><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our future approved products;  </span></div><div style="padding-left:13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injury to our reputation;  </span></div><div style="padding-left:13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants;  </span></div><div style="padding-left:13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">termination of clinical trial sites or entire trial programs;  </span></div><div style="padding-left:13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased regulatory scrutiny;  </span></div><div style="padding-left:13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant litigation costs;  </span></div><div style="padding-left:13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to or costly settlement with patients or other claimants;  </span></div><div style="padding-left:13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recalls or a change in the indications for which they may be used;  </span></div><div style="padding-left:13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue;  </span></div><div style="padding-left:13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of management and scientific resources from our business operations; and  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize our product candidates.   </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our product candidates that may receive approval for commercial sale or our partners&#8217; products, we are, and will be, highly dependent upon physician and patient perceptions of us and the safety and quality of our products. We could be adversely affected if we are subject to negative publicity. We could also be adversely affected if any of our products or any similar products distributed by other companies prove to be, or are asserted to be, harmful to patients. Because of our dependence upon consumer perceptions, any adverse publicity associated with illness or other adverse effects resulting from patients&#8217; use or misuse of our products or any similar products distributed by other companies could have a material adverse impact on our financial condition or results of operations.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we hold $20.0 million in product liability insurance coverage in the aggregate, with a per incident limit of $20.0 million, which may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage when we begin the commercialization of product candidates. Insurance coverage is becoming increasingly expensive. As a result, we may be unable to maintain or obtain sufficient insurance at a reasonable cost to protect us against losses that could have a material adverse effect on our business. A successful product liability claim or series of claims brought against us, particularly if judgments exceed any insurance coverage we may have, could decrease our cash resources and adversely affect our business, financial condition and results of operation.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we and our collaborators obtain regulatory approvals to market our current and any future approved products, we and our collaborators will remain subject to extensive ongoing regulatory obligations and oversight, including post-approval requirements, that could result in significant additional expense and could negatively impact our and our collaborators' ability to commercialize our current and any future approved products.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators are subject to extensive ongoing obligations and continued regulatory review from applicable regulatory agencies with respect to any product obtaining regulatory approval, , such as continued adverse event reporting requirements and post-marketing commitments, all of which may result in significant expense and limit our and our collaborators' ability to commercialize our current and any future approved products.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and the manufacturers of our current and any future approved products are also required, or will be required, to comply with cGMP regulations, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation. Further, regulatory agencies must approve these manufacturing facilities before they can be used to manufacture our product candidates, and these facilities are subject to ongoing regulatory inspections. In addition, regulatory agencies subject an approved product, its manufacturer and the manufacturer&#8217;s facilities to continual review and inspections, including periodic unannounced inspections. The subsequent discovery of previously unknown problems with our current or any future approved products, including adverse events of unanticipated severity or frequency, or problems with the facilities where our current or any future approved products are manufactured, may result in restrictions on the marketing of our current or any such future approved products, up to and including withdrawal of the affected product from the market. If our manufacturing facilities, our collaborators' manufacturing facilities, or those of our respective suppliers, fail to comply with applicable regulatory requirements, such noncompliance could result in regulatory action and additional costs to us.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with applicable FDA and other regulatory requirements may subject us to administrative or judicially imposed sanctions, including:  </span></div><div><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issuance of Form FDA 483 notices or Warning Letters by the FDA or other regulatory agencies;  </span></div><div style="padding-left:13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposition of fines and other civil penalties;  </span></div><div style="padding-left:13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">criminal prosecutions;  </span></div><div style="padding-left:13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions, suspensions or revocations of regulatory approvals;  </span></div><div style="padding-left:13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension of any ongoing clinical trials;  </span></div><div style="padding-left:13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">total or partial suspension of manufacturing;  </span></div><div style="padding-left:13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in commercialization;  </span></div><div style="padding-left:13.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal by the FDA to approve pending applications or supplements to approved applications submitted by us;  </span></div><div style="padding-left:13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusals to permit drugs to be imported into or exported from the United States;  </span></div><div style="padding-left:13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on operations, including costly new manufacturing requirements; and  </span></div><div style="padding-left:13.5pt"><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recalls or seizures.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The policies of the FDA and other regulatory agencies may change and additional government regulations may be enacted that could prevent or delay regulatory approval of our product candidates, or further restrict or regulate post-approval activities. We cannot predict the likelihood, nature or extent of adverse government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are not able to maintain regulatory compliance, we or our collaborators might not be permitted to market our current or any future approved products and our business would suffer.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and/or our collaboration partners may never obtain approval or commercialize our products outside of the United States, which would limit our ability to realize their full market potential. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any products outside of the United States, we and our current and potential collaboration partners must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and may require additional nonclinical studies or clinical trials or additional administrative review periods, which could result in significant delays, difficulties and costs for us. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. Further, even if a product candidate receives regulatory approval outside of the United States, the collaborator may not commercialize the product or may not commercialize the product effectively. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our target market will be reduced and our ability to realize the full market potential of our products will be harmed.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inadequate funding or government efficiency initiatives for the FDA and other government agencies could reduce agency staffing or hinder agency ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget, funding and staffing levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result and may fluctuate significantly in the future. In addition, government funding and staffing levels of other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the past decade, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA, and other government employees and pause or stop critical activities. If a prolonged government shutdown occurs, or if FDA or other government employees&#8217; positions are eliminated or become vacant, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. tax law may have a material adverse effect on our business, financial condition and results of operations, and changes in international trade relations may have a material adverse effect on the commercialization of some or all of our product candidates. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in laws and policy relating to taxes may have an adverse effect on our business, financial condition and results of operations. Recent tax reforms in the United States have resulted in significant changes to preexisting U.S. tax rules and regulations. These changes may trigger an adverse effect on our business, financial conditions and results of operations.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, there is inherent risk, based on the complex relationships among the United States and the countries in which we plan to conduct business in, that political, diplomatic, and national security factors can lead to global trade restrictions </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and changes in trade policies and export regulations that may adversely affect our business and operations. The United States and other countries have imposed and may continue to impose new trade restrictions and export regulations, have levied tariffs and taxes on certain goods, and could significantly increase tariffs on a broad array of goods. Overall, changes in international trade relations, such as the imposition of or increase in tariffs or other trade barriers, could materially and adversely impact our costs, the ability to make sales of our product candidates to any of our significant customers in other countries, and reduce the competitiveness of our product candidates.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties </span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our existing therapeutic collaborations are important to our business, and future collaborations may also be important to us. If we are unable to maintain any of these collaborations, or if these collaborations are not successful, our business could be adversely affected.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited capabilities for drug development and have little to no internal capability for sales, marketing or distribution. We have entered into collaborations with other companies that we believe can provide such capabilities, including our agreements with, for example, Gilead Sciences, Inc, and Incyte Corporation. These current collaborations also have provided us with important funding for our development programs and technology platforms and we expect to receive additional funding under these collaborations in the future. Our existing therapeutic collaborations, and any future collaborations we enter into, may pose a number of risks, including the following:   </span></div><div><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not perform their obligations as expected;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators' strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays in payment, or non-payment, of royalties, milestones or other monies owed, delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates. For example, each of our collaboration and license agreements may be terminated for convenience upon the completion of a specified notice period.   </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our collaborations do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. All of the risks relating to product development, regulatory approval and commercialization described in this Annual Report on Form 10-K also apply to the activities of our program collaborators.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, subject to its contractual obligations to us, if one of our collaborators is involved in a business combination, the collaborator might de-emphasize or terminate the development or commercialization of any product candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future decide to collaborate with additional pharmaceutical and biotechnology companies for development and potential commercialization, if approved, our product candidates. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. These factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative products, product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborations are complex and time-consuming to negotiate and document. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of our product candidates, reduce or delay one or more of our other development programs, delay the commercialization of a product candidate or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our technology platforms and our business may be materially and adversely affected.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also be restricted under collaboration agreements from entering into additional agreements on certain terms with potential collaborators. Most of our existing therapeutic collaborations contain a restriction on our engaging in activities that are the subject of the collaboration with third parties for specified periods of time.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We contract with, and may in the future contract with, third parties for components of the manufacturing of our product candidates, including our antibody drug conjugate candidates. Failure of third-party contractors to successfully perform their obligations could harm our ability to develop or commercialize our product or product candidates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have one cGMP manufacturing facility located in Rockville, Maryland in compliance with cGMP to support future clinical and commercial production of our and our collaborators&#8217; product candidates. We manufacture drug substance lots at this facility that we use for clinical trials of our and our collaborators&#8217; product candidates. We will continue to rely on third parties for bioconjugation to produce ADCs and for fill finish activities, neither of which our cGMP manufacturing facility can currently accommodate. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into agreements with contract manufacturing organizations in the past to supplement our clinical supply and internal capacity as we advance product candidates in our pipeline. In addition, in the future, we may use third parties for the manufacture of some or all components of our product candidates for clinical testing, including antibody drug conjugates, as well as for commercial manufacture of some of our product candidates that receive marketing approval and that are not manufactured by us or one of our third-party collaborators. We may be unable to reach agreement with any of these contract manufacturers, or to identify and reach arrangements on satisfactory terms with other contract manufacturers, to manufacture any of our product candidates. Additionally, the facilities used by any contract manufacturer to manufacture any of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our product candidates must be the subject of a satisfactory inspection before the FDA and other regulatory authorities approve a BLA or marketing authorization for the product candidate manufactured at that facility. We will depend on these third-party manufacturing partners for compliance with the FDA&#8217;s requirements for the manufacture of our finished products. If our manufacturers cannot successfully manufacture material that conforms to our specifications and the FDA and other regulatory authorities&#8217; cGMP requirements, our product candidates will not be approved or, if already approved, may be subject to recalls.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured products or product candidates ourselves, including:  </span></div><div><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the possibility of a breach of the manufacturing agreements by the third parties because of factors beyond our control;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the possibility of termination or nonrenewal of the agreements by the third parties before we are able to arrange for a qualified replacement third-party manufacturer; and  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the possibility that we may not be able to secure a manufacturer or manufacturing capacity in a timely manner and on satisfactory terms in order to meet our manufacturing needs.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these factors could adversely impact the development of our product candidates, delay approval of our product candidates, or cause us to incur higher costs or prevent us from commercializing our products or product candidates successfully. Furthermore, if contract manufacturers fail to deliver the required quantities of finished product on a timely basis and at commercially reasonable prices, and we are unable to find one or more replacement manufacturers capable of production at a substantially equivalent cost, in substantially equivalent volumes and quality and on a timely basis, we would likely be unable to meet expectations for our clinical development needs, which would delay our ability to execute and complete clinical trials It may take several years to establish an alternative source of supply for our product candidates and to have any such new source approved by the FDA or any other relevant regulatory authorities.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to successfully develop and commercialize companion diagnostics with third party contractors for use with our product candidates could harm our ability to commercialize our product candidates.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to develop, or engage third parties to develop, companion diagnostics for our product candidates where appropriate. At least in some cases, the FDA and similar regulatory authorities outside the United States may request or require the development and regulatory approval of a companion diagnostic as a condition to approving one or more of our product candidates. We do not have experience or capabilities in developing or commercializing diagnostics and are relying, and in the future plan to continue to rely, in large part on third parties to perform these functions.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In most cases, we will likely outsource the development, production and commercialization of companion diagnostics to third parties. By outsourcing these companion diagnostics to third parties, we become dependent on the efforts of our third party contractors to successfully develop and commercialize these companion diagnostics. Our contractors:  </span></div><div><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">may not perform their obligations as expected;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">may encounter production difficulties that could constrain the supply of the companion diagnostic;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">may have difficulties gaining acceptance of the use of the companion diagnostic in the clinical community;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">may not commit sufficient resources to the marketing and distribution of such product; and  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">may terminate their relationship with us.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any companion diagnostic for use with one of our product candidates fails to gain market acceptance, our ability to derive revenues from sales of such product candidate could be harmed. If our third-party contractors fail to commercialize such companion diagnostic, we may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with such product candidate or do so on commercially reasonable terms, which could adversely affect and delay the development or commercialization of such product candidate. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Independent clinical investigators and CROs that we engage to conduct our clinical trials may not devote sufficient time or attention to our clinical trials or be able to repeat their past success.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to depend on independent clinical investigators and CROs to conduct our clinical trials. CROs may also assist us in the collection and analysis of data. There is a limited number of third-party service providers that specialize or have the expertise required to achieve our business objectives. Identifying, qualifying and managing performance of third-party service providers can be difficult, time consuming and cause delays in our development programs. These investigators and CROs are not and will not be our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our product candidates and clinical trials. If independent investigators or CROs fail to devote sufficient resources to the development of our product candidates, or if their performance is substandard, it may delay or compromise the prospects for approval and commercialization of any product candidates that we develop. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated. Further, the FDA requires that we comply with standards, commonly referred to as current Good Clinical Practice (GCP) for conducting, recording and reporting clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial subjects are protected. Failure of clinical investigators or CROs to meet their obligations to us or comply with GCP procedures could adversely affect the clinical development of our product candidates and harm our business.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercialization collaborations will be important to our business. If we are unable to maintain commercialization collaborations, or if commercialization collaborations are not successful, our business could be adversely affected</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited capabilities for drug commercialization, with little to no internal capability for sales, marketing or distribution. We may enter into commercial collaborations in the future for any approved products or our product candidates. Any future commercialization collaborations we enter into may pose a number of risks, including the following:  </span></div><div><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may have significant discretion in determining the efforts and resources that they will apply to these collaborations;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not perform their obligations as expected;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not pursue commercialization our products or any product candidates that achieve regulatory approval or may elect not to continue commercialization based on clinical trial results, changes in the collaborators' strategic focus or other factors that divert resources or create competing priorities;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators could independently commercialize products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully commercialized under terms that are more economically attractive than ours;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators with marketing and distribution rights to our products or our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disagreements with collaborators, including disagreements on contract interpretation, commercialization strategy or tactics, might cause delays or termination of the commercialization of products or product candidates, might lead to additional responsibilities for us with respect to our products or product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not properly utilize our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may violate, or be investigated for potentially violating, health care compliance and related laws and regulations, which may expose us to litigation, enforcement actions or inquiries, or other potential liability; and  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further commercialization of our products or applicable product candidates.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the risks relating to commercialization, and health care legal compliance described in this Annual Report on Form 10-K also apply to the commercialization activities of our collaborators.   </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, subject to its contractual obligations to us, if one of our collaborators is involved in a business combination, the collaborator might de-emphasize or terminate the development or commercialization of a product candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators for the products in the covered territory or elsewhere. We may also be restricted under commercialization collaboration agreements from entering into future agreements on certain terms with potential collaborators.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercialization collaborations are complex and time-consuming to negotiate and document. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the commercialization of a product or product candidate, reduce the scope of any sales or marketing activities, or increase our expenditures and undertake or commercialization activities at our own expense. If in the future we elect to fund and undertake commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations to commercialize our product candidates and do not have sufficient funds or expertise to undertake the necessary commercialization activities, we may not be able to commercialize our product candidates or bring them to market or continue and our business may be materially and adversely affected.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our information technology systems, or those third parties with whom we work, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we and the third parties with whom we work, process, collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, process) proprietary, confidential, and sensitive data, including personal data (such as health-related data), intellectual property, trade secrets and any other sensitive data the we may process, e.g., business plans, transactions, financial information, etc. (collectively, sensitive information).  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cyber-attacks, malicious internet-based activity, online and offline fraud, and other similar activities threaten the confidentiality, integrity, and availability of our sensitive information and information technology systems, and those of the third parties upon which we rely. Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors.   </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we, the third parties upon which we rely, and our customers may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our goods and services.   </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and the third parties upon which we rely are subject to a variety of evolving threats, including but not limited to social-engineering attacks (including through deep fakes and the use of Artificial Intelligence (AI)), which may be increasingly more difficult to identify as fake, and phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks, credential stuffing attacks, credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures, earthquakes, fires, floods, attacks enhanced or facilitated by AI, and other similar threats.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations, ability to provide our products or services, loss of sensitive data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments. Remote work has become more common and has increased risks to our information technology systems and data, as more of our employees utilize network connections, computers and devices outside our premises or network, including working at home, while in transit and in public locations. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies. Furthermore, we may discover security issues that were not found during due diligence of such </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-parties to operate critical business systems to process sensitive information in a variety of contexts, including, without limitation, encryption and authentication technology, employee email, content delivery to customers, and other functions. Our ability to monitor these third parties&#8217; information security practices is limited, as is our ability to determine whether these third parties may not have adequate information security measures in place. If the third-parties with whom we work experience a security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. Any of the previously identified or similar threats could cause a security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive information or our information technology systems, or those of the third parties upon whom we rely. A security incident or other interruption could disrupt our ability (and that of third parties upon whom we rely) to provide our products. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against security incidents. Certain data privacy and security obligations may require us to implement and maintain specific security measures or industry-standard or reasonable security measures to protect our information technology systems and sensitive information. Applicable data privacy and security obligations may require us to notify relevant stakeholders, including affected individuals, customers, regulators, and investors, of security incidents. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; diversion of management attention; interruptions in our operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may prevent or cause customers to stop using our products, deter new customers from using our products, and negatively impact our ability to grow and operate our business.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.  </span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to experiencing a security incident, third parties may gather, collect, or infer sensitive information about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position. Additionally, sensitive information of the Company could be leaked, disclosed, or revealed as a result of or in connection with our employees&#8217;, personnel&#8217;s, or vendors&#8217; use of generative AI technologies. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends significantly on our ability to operate without infringing the valid patents and other proprietary rights of third parties. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend in part on our ability to operate without infringing the proprietary rights of third parties. Third parties may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our future approved products or impair our competitive position.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties could possess patents that we may ultimately be found to infringe, or such third-party patents could issue in the future. Third parties may have or may obtain valid and enforceable patents or proprietary rights that could block us from </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">developing product candidates using our technology. Our failure to obtain a license to any technology that we require may materially harm our business, financial condition and results of operations. Moreover, our failure to maintain a license to any technology that we require may also materially harm our business, financial condition, and results of operations. Furthermore, we would be exposed to a threat of litigation.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the biopharmaceutical industry, significant litigation and other proceedings regarding patents, patent applications, trademarks and other intellectual property rights have become commonplace. The types of situations in which we may become a party to such litigation or proceedings include:  </span></div><div><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our collaborators may initiate litigation or other proceedings against third parties seeking to invalidate the patents held by those third parties or to obtain a judgment that our products or processes do not infringe those third parties' patents;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if our competitors file patent applications that claim technology also claimed by us or our licensors, we or our licensors may be required to participate in interference, opposition or other proceedings to determine the priority of invention, which could jeopardize our patent rights and potentially provide a third party with a dominant patent position;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if third parties initiate litigation claiming that our processes or products infringe their patent or other intellectual property rights, we and our collaborators will need to defend against such proceedings; and  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if a license to necessary technology is terminated, the licensor may initiate litigation claiming that our processes or products infringe or misappropriate their patent or other intellectual property rights and/or that we breached our obligations under the license agreement, and we and our collaborators would need to defend against such proceedings.   </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These lawsuits would be costly and could affect our results of operations and divert the attention of our management and scientific personnel. There is a risk that a court would decide that we or our collaborators are infringing the third party&#8217;s patents and would order us or our collaborators to stop the activities covered by the patents. In that event, we or our collaborators may not have a viable alternative to the technology protected by the patent and may need to halt work on the affected product candidate or cease commercialization of an approved product. In addition, there is a risk that a court will order us or our collaborators to pay the other party damages. An adverse outcome in any litigation or other proceeding could subject us to significant liabilities to third parties and require us to cease using the technology that is at issue or to license the technology from third parties. We may not be able to obtain any required licenses on commercially acceptable terms or at all. Any of these outcomes could have a material adverse effect on our business. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical and biotechnology industries have produced a significant number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products, methods of use, or processes. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform or predictable. If we are sued for patent infringement, we would need to demonstrate that our products, methods, or processes either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be able to do so. Proving invalidity is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and divert management&#8217;s time and attention in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, defend an infringement action or challenge the validity of the patents in court. Patent litigation is costly and time consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, if we do not obtain a license, develop or obtain non-infringing technology, fail to defend an infringement action successfully or have infringed patents declared invalid, we may incur substantial monetary damages, encounter significant delays in bringing our product candidates to market and be precluded from manufacturing or selling our product candidates.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of any patent litigation or other proceeding, even if resolved in our favor, could be substantial. Some of our competitors may be able to sustain the cost of such litigation and proceedings more effectively than we can because of their substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Patent litigation and other proceedings may also absorb significant management time.  </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and enforce patent protection for our products and our product candidates and related technology, our business could be materially harmed.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Issued patents may be challenged, narrowed, invalidated or circumvented. In addition, court decisions may introduce uncertainty in the enforceability or scope of patents owned by biotechnology companies. The legal systems of certain countries do not favor the aggressive enforcement of patents, and the laws of foreign countries may not allow us to protect our inventions with patents to the same extent as the laws of the United States. Patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Publications of discoveries in scientific literature lag behind actual discoveries, thus we cannot be certain that we were the first to make the inventions claimed in our issued patents or pending patent applications, or that we were the first to file for protection of the inventions set forth in our patents or patent applications. As a result, we may not be able to obtain or maintain protection for certain inventions. Therefore, the enforceability and scope of our patents in the United States and in foreign countries cannot be predicted with certainty and, as a result, any patents that we own or license may not provide sufficient protection against competitors. We may not be able to obtain or maintain patent protection from our pending patent applications, from those we may file in the future, or from those we may license from third parties. Moreover, even if we can obtain patent protection, it may be of insufficient scope to achieve our business objectives.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy depends on our ability to identify and seek patent protection for our discoveries. This process is expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost, in a timely manner, or in all jurisdictions where protection may be commercially advantageous. Despite our efforts to protect our proprietary rights, unauthorized parties may be able to obtain and use information that we regard as proprietary.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent does not ensure that a court or agency finds or will find the patent valid or enforceable, so even if we obtain patents, they may not be valid or enforceable against third parties. In addition, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from marketing our own patented product and practicing our own patented technology. Third parties may also seek to market biosimilar versions of any approved products. Alternatively, third parties may seek approval to market their own products, which are similar to or otherwise competitive with our products. In these circumstances, we may need to defend and/or assert our patents, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or agency with jurisdiction may find our patents invalid and/or unenforceable. Even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of pharmaceutical or biotechnology companies, including ours, is generally uncertain and involves complex legal and factual considerations. The standards which the USPTO and its foreign counterparts use to grant patents are not always applied predictably or uniformly and can change. There is also no uniform, worldwide policy regarding the subject matter and scope of claims granted or allowable in pharmaceutical or biotechnology patents. The laws of some foreign countries do not protect proprietary information to the same extent as the laws of the United States, and many companies have encountered significant problems and costs in protecting their proprietary information in these foreign countries. Outside the United States, patent protection must be sought in individual jurisdictions, further adding to the cost and uncertainty of obtaining adequate patent protection outside of the United States. Accordingly, we cannot predict whether additional patents protecting our technology will issue in the United States or in foreign jurisdictions, or whether any patents that do issue will have claims of adequate scope to provide competitive advantage. Moreover, we cannot predict whether third parties will be able to successfully obtain claims or the breadth of such claims. The allowance of broader claims may increase the incidence and cost of patent interference proceedings, opposition proceedings, and/or reexamination proceedings, the risk of infringement litigation, and the vulnerability of the claims to challenge. On the other hand, the allowance of narrower claims does not eliminate the potential for adversarial proceedings and may fail to provide a competitive advantage. Our issued patents may not contain claims sufficiently broad to protect us against third parties with similar technologies or products or provide us with any competitive advantage.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits to protect or enforce our patents, which could be expensive, time consuming and unsuccessful. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even after they have been issued, our patents and any patents which we license may be challenged, narrowed, invalidated or circumvented. If our patents are invalidated or otherwise limited or will expire prior to the commercialization of any approved product candidates, other companies may be better able to develop products that compete with ours, which could adversely affect our competitive business position, business prospects and financial condition.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are examples of litigation and other adversarial proceedings or disputes that we could become a party to involving our patents or patents licensed to us:  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our collaborators may initiate litigation or other proceedings against third parties to enforce our patent rights;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third parties may initiate litigation or other proceedings seeking to invalidate patents owned by or licensed to us or to obtain a declaratory judgment that their product or technology does not infringe our patents or patents licensed to us;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third parties may initiate opposition, reexamination or inter partes review proceedings challenging the validity or scope of our patent rights, requiring us or our collaborators and/or licensors to participate in such proceedings to defend the validity and scope of our patents;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">there may be a challenge or dispute regarding inventorship or ownership of patents currently identified as being owned by or licensed to us;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the USPTO may initiate an interference between patents or patent applications owned by or licensed to us and those of our competitors, requiring us or our collaborators and/or licensors to participate in an interference proceeding to determine the priority of invention, which could jeopardize our patent rights; or  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third parties may seek approval to market biosimilar versions of our future approved products prior to expiration of relevant patents owned by or licensed to us, requiring us to defend our patents, including by filing lawsuits alleging patent infringement.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These lawsuits and proceedings would be costly and could affect our results of operations and divert the attention of our managerial and scientific personnel. There is a risk that a court or administrative body would decide that our patents are invalid or not infringed by a third party&#8217;s activities, or that the scope of certain issued claims must be further limited. An adverse outcome in a litigation or proceeding involving our own patents could limit our ability to assert our patents against these or other competitors, affect our ability to receive royalties or other licensing consideration from our licensees, and may curtail or preclude our ability to exclude third parties from making, using and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example: </span></div><div><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to develop a platform that is similar to, or better than, ours in a way that is not covered by the claims of our patents;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to make compounds that are similar to our product candidates but that are not covered by the claims of our patents;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we might not have been the first to make the inventions covered by patents or pending patent applications;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we might not have been the first to file patent applications for these inventions;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any patents that we obtain may not provide us with any competitive advantages or may ultimately be found invalid or unenforceable; or  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop additional proprietary technologies that are patentable.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations under our intellectual property licenses with third parties, we could lose license rights that are important to our business. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently party to various intellectual property license agreements. These license agreements impose, and we expect that future license agreements may impose, various diligence, milestone payment, royalty, insurance and other obligations on us. For example, we entered into patent and know-how license agreements that grant us the right to use certain technologies related to biological manufacturing to manufacture our clinical product candidates. These licenses typically include an obligation to pay yearly maintenance payments and royalties on sales and may also include upfront and milestone payments. If we fail to comply with our obligations under the licenses, the licensors may have the right to terminate their respective license agreements, in which event we might not be able to market any product that is covered by the agreements. Termination of the license agreements or reduction or elimination of our licensed rights may result in our having to negotiate </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">new or reinstated licenses with less favorable terms, which could adversely affect our competitive business position and harm our business.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our proprietary information, the value of our technology and products could be adversely affected.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patent protection, we also rely on other proprietary rights, including protection of trade secrets, and other proprietary information. To maintain the confidentiality of trade secrets and proprietary information, we enter into confidentiality agreements with our employees, consultants, collaborators and others upon the commencement of their relationships with us. These agreements require that all confidential information developed by the individual or made known to the individual by us during the course of the individual&#8217;s relationship with us be kept confidential and not disclosed to third parties. Our agreements with employees and our personnel policies also provide that any inventions conceived by the individual while rendering services to us shall be our exclusive property. However, we may not obtain these agreements in all circumstances, and individuals with whom we have these agreements may not comply with their terms. Thus, despite such agreement, such inventions may become assigned to third parties. In the event of unauthorized use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained, may not provide meaningful protection, particularly for our trade secrets or other confidential information. To the extent that our employees, consultants or contractors use technology or know-how owned by third parties in their work for us, disputes may arise between us and those third parties as to the rights in related inventions. To the extent that an individual who is not obligated to assign rights in intellectual property to us is rightfully an inventor of intellectual property, we may need to obtain an assignment or a license to that intellectual property from that individual, or a third party or from that individual&#8217;s assignee. Such assignment or license may not be available on commercially reasonable terms or at all.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adequate remedies may not exist in the event of unauthorized use or disclosure of our proprietary information. The disclosure of our trade secrets would impair our competitive position and may materially harm our business, financial condition and results of operations. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to maintain trade secret protection could adversely affect our competitive business position. In addition, others may independently discover or develop our trade secrets and proprietary information, and the existence of our own trade secrets affords no protection against such independent discovery.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously or concurrently employed at research institutions and/or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that these employees, or we, have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers, or that patents and applications we have filed to protect inventions of these employees, even those related to one or more of our product candidates, are rightfully owned by their former or concurrent employer. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the USPTO and various foreign patent offices at various points over the lifetime of our patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on our outside counsel or our agents to pay these fees when due. Additionally, the USPTO and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business. In addition, we may be responsible for the payment of patent fees for patent rights that we license from other parties. If any licensor of these patents does not itself elect to make these payments, and we fail to do so, we may be liable to the licensor for any costs and consequences of any resulting loss of patent rights.  </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain protection under the Hatch-Waxman Amendments and similar foreign legislation for extending the term of patents covering each of our product candidates, our business may be materially harmed. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced, possibly materially.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Legal Compliance Matters  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures, and legal expenses, which could adversely affect our business, results of operations and financial condition. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Our operations are subject to anti-corruption laws, including the U.S. Foreign Corrupt Practices Act (FCPA), and other anti-corruption laws that apply in countries where we do business. The FCPA and these other laws generally prohibit us and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. We and our commercial partners operate in a number of jurisdictions that pose a risk of potential FCPA violations, and we participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the FCPA or other anti-corruption laws. There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws. If we violate provisions of the FCPA or other anti-corruption laws or are subject to an investigation or audit pursuant to these laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures and legal expenses, which could have an adverse impact on our business, financial condition and results of operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development involves, and may in the future involve, the use of potentially hazardous materials and chemicals. Our operations may produce hazardous waste products. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards mandated by local, state and federal laws and regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and regulations and fire and building codes, including those governing laboratory procedures, exposure to blood-borne pathogens, use and storage of flammable agents and the handling of biohazardous materials. Although we maintain workers&#8217; compensation insurance as prescribed by the States of Maryland and California to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our collaborators are subject to various healthcare laws, and our failure, or the failure of our collaborators, to comply with those laws could result in significant penalties and adversely affect our business, operations and financial condition. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, our operations, and those of our collaborators, are subject to regulation by various local, state, federal authorities in addition to the FDA, including but not limited to, CMS, other divisions of HHS (such as the Office of Inspector General, Office for Civil Rights and the Health Resources and Service Administration), the U.S. Department of Justice (DOJ) and individual U.S. Attorney offices within the DOJ, and state and local governments. We and our collaborators are or may be subject to broadly applicable &#8220;fraud and abuse&#8221; laws, such as false claims, anti-kickback laws, transparency laws, and privacy and security laws. Federal false claims laws, including the federal civil False Claims Act, prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, or causing to be made, a false statement to get a claim paid.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal healthcare program anti-kickback statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid or other federally financed healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. Although there are several statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exemption or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the federal anti-kickback statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Our practices, or those of our collaborators, may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the intent standard under the federal anti-kickback statute and the criminal healthcare fraud statutes (discussed below) was amended by the ACA to a stricter standard such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the ACA codified case law that a claim including items or services resulting from a violation of the federal anti-kickback statute constitutes a false or fraudulent claim for purposes of the federal civil false claims act.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) which prohibits, among other things, knowingly and willfully executing, or attempting to execute, a scheme or artifice to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private), willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false, fictitious or fraudulent statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal anti-kickback statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the federal Physician Payment Sunshine Act provisions of the ACA, covered manufacturers of drugs, devices, biological and medical supplies for which payment is available under a federal health care program (with certain exceptions) are subject to annual federal reporting and disclosure requirements with regard to payments or other transfers of value made to physicians defined to include doctors, dentists, optometrists, podiatrists and chiropractors, other healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals as well as information regarding certain ownership and investment interests held by physicians and their immediate family members.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most states also have statutes or regulations similar to the federal anti-kickback law and federal false claims laws, which may apply to items such as pharmaceutical products and services reimbursed by private insurers. Some state laws also prohibit certain gifts to healthcare providers, require pharmaceutical companies to report payments to healthcare professionals, and/or require companies to adopt compliance programs or codes of conduct.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2019, or HITECH, and their respective implementing regulations, impose obligations on &#8220;covered entities,&#8221; including certain healthcare providers, health plans, and healthcare clearinghouses, as well as their respective &#8220;business associates&#8221; that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity and their subcontractors that use, disclose, access, or otherwise process individually identifiable health information, with respect to safeguarding the privacy, security and transmission of individually identifiable health information. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, in order to distribute products commercially in the United States, we or our collaborators must also comply with state laws that require the registration of manufacturers and wholesale distributors of pharmaceutical products in a state, including, in certain states, manufacturers, and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain. Several states have enacted legislation requiring pharmaceutical companies to establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, track, and report gifts, compensation and other remuneration made to physicians and other healthcare providers, clinical trials and other activities, and/or register their sales </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical companies for use in sales and marketing, and to prohibit certain other sales and marketing practices.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our operations, or those of our collaborators marketing, distributing or commercializing any of our products on our behalf, are found to be in violation of any of the federal and state healthcare laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including without limitation, significant civil, criminal and/or administrative penalties, damages, fines, disgorgement, exclusion from participation in government programs, such as Medicare and Medicaid, injunctions, private &#8220;qui tam&#8221; actions brought by individual whistleblowers in the name of the government, or refusal to allow us to enter into government contracts, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our operations and those of our collaborators may be subject to analogous foreign health care laws in the jurisdictions in which we operate.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and the third parties with whom we work are subject to stringent and evolving U.S. and foreign laws, regulations, and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation (including class claims) and mass arbitration demands; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers; and other adverse business consequences. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we and the third parties with whom we work process personal data and other sensitive information, including proprietary and confidential business data, trade secrets, intellectual property, data we collect about trial participants in connection with clinical trials, sensitive third-party data, business plans, transactions, and financial information, which we collectively refer to as &#8220;sensitive data.&#8221;. Our data processing activities subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to data privacy and security. Data privacy and security have become significant issues in the United States, Europe, and in many other jurisdictions where we or our partners may in the future conduct our operations.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;In the United States, federal, state, and local governments have enacted numerous data privacy and security laws and regulations, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws). Furthermore, numerous U.S. states have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal data. For example, the California Consumer Privacy Act of 2018 (the &#8220;CCPA&#8221;) applies to personal data of consumers, business representatives, and employees who are California residents, and requires businesses to provide specific disclosures in privacy notices and honor requests of such individuals to exercise certain privacy rights. The CCPA provides for fines for violations and allows private litigants affected by certain data breaches to recover significant statutory damages. Although the CCPA exempts some data processed in the context of clinical trials, the CCPA increases compliance costs and potential liability with respect to other personal data we maintain about California residents. Similar laws are being considered in several other states, as well as at the federal and local levels, and we expect more states to pass similar laws in the future. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, an increasing number of laws, regulations, and industry standards govern data privacy and security. For example, the European Union&#8217;s General Data Protection Regulation (EU GDPR), companies may face temporary or definitive bans on data processing and other corrective actions; fines of up to 20 million Euros under the EU GDPR, 17.5 million pounds sterling under the UK GDPR or, in each case, 4% of annual global revenue, whichever is greater; or private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests. In Canada, the Personal Information Protection and Electronic Documents Act (PIPEDA) and various related provincial laws, may apply to our operations. As another example, Australia&#8217;s Privacy Act of 1998 may apply to our operations.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compliance with these legal requirements and obligations, together with any policies or practices that we have or may implement to further secure and protect sensitive data, could limit our ability to utilize data that may be valuable to our business.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our employees and personnel may integrate generative AI technologies to perform their work, and the disclosure and use of personal data in generative AI technologies is subject to various privacy laws and other privacy obligations. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Governments have passed and are likely to pass additional laws regulating generative AI. Any use of this technology could result in additional compliance costs, regulatory investigations and actions, and lawsuits. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obligations related to data privacy and security (and consumers&#8217; data privacy expectations) are quickly changing, becoming increasingly stringent, and creating uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Failure to comply with these current and future laws, policies, industry standards or legal obligations or any security incident resulting in the unauthorized access to, or acquisition, release or transfer of personal information may result in governmental enforcement actions, litigation, fines and penalties or adverse publicity and could cause our customers to lose trust in us, which could have a material adverse effect on our business and results of operations. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may at times fail (or be perceived to have failed) in our efforts to comply with our data privacy and security obligations. Moreover, despite our efforts, our personnel or third parties with whom we work may fail to comply with such obligations, which could negatively impact our business operations. If we or the third parties with whom we work fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face significant consequences, including but not limited to: government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-action claims) and mass arbitration demands; additional reporting requirements and/or oversight; bans on processing personal data; orders to destroy or not use personal data; and imprisonment of company officials. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, plaintiffs have become increasingly more active in bringing privacy-related claims against companies, including class claims and mass arbitration demands. Some of these claims allow for the recovery of statutory damages on a per violation basis, and, if viable, carry the potential for significant statutory damages, depending on the volume of data and the number of violations. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: loss of customers; interruptions or stoppages in our business operations (including, clinical trials); inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with FDA regulations, to provide accurate information to the FDA or other agencies, to comply with federal and state health care fraud and abuse laws and regulations, to report financial information or data accurately or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a code of conduct, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Employee Matters and Human Capital Management  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to attract or retain key executives and to attract, retain and motivate qualified personnel.  </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on the research and development, clinical and business development expertise of certain of our executive officers and other key employees. Although we have entered into employment agreements with our executive officers, each of them may terminate their employment with us at any time. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development, manufacturing and commercialization objectives and seriously harm our ability to successfully implement our business strategy.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2024, we announced the separation of our President and Chief Executive Officer, Dr. Scott Koenig and the appointment of a special executive search committee of the Board to identify a new Chief Executive Officer for our company. Although we intend to navigate this transition effectively and the identification of a new Chief Executive Officer is intended to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be in the best interest of our company and our stockholders, as we navigate Dr. Koenig&#8217;s separation and the hiring of a new Chief Executive Officer, the uncertainty during the transition period may increase the risks of employee departures, which may also result in the loss of institutional or technical knowledge, which may adversely affect our business. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recruiting and retaining qualified scientific, clinical, manufacturing and other personnel will also be critical to our success. For example, we have experienced employee turnover, consistent with the broader American economy, and we may continue to experience employee turnover in the future that may have an adverse effect on our business strategy. New hires require significant training and, in most cases, take significant time before they achieve full productivity. New employees may not become as productive as we expect, and we may be unable to hire or retain sufficient numbers of qualified individuals. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, motivate existing employees, or maintain our corporate culture in a hybrid or remote work environment and in the midst of higher turnover, our ability to pursue our growth strategy will be limited.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in January 2023, the U.S. Federal Trade Commission (FTC) published a proposed rule that would generally prohibit post-employment non-compete clauses (or other clauses with comparable effect) in agreements between employers and their employees. As of August 20, 2024, the FTC cannot enforce this rule as a result of a court order, which remains subject to appeal. If this rule goes into effect, or if we fail to adequately address any of the issues referred to above, it could adversely impact our ability to attract or retain key executives, which may result in a material adverse effect on our business, operating results and financial condition. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may undertake internal restructuring activities, including associated workforce reductions, that could result in disruptions to our business or otherwise materially harm our results of operations or financial condition.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may undertake internal restricting activities, including associated workforce reductions, as we continue to evaluate and attempt to optimize our cost and operating structure in light of developments in our business strategy and long-term operating plans. For example, in August 2022, we announced a reduction in workforce by approximately 15% in connection with the restructuring of our business to prioritize and focus on our lead assets, and, as a result, we incurred certain restructuring charges, including employee termination-related charges. Any restructuring activities that we may undertake in the future may result in write-offs or other restructuring charges, including employee termination-related charges in connection with any associated workforce reductions. We may not realize, in full or in part, the anticipated benefits, savings and improvements in our operating structure from any restructuring efforts due to unforeseen difficulties, delays or unexpected costs. If we are unable to realize the expected operational efficiencies and cost savings from any restructuring, our results of operation and financial condition could be adversely affected. Furthermore, any strategic restructuring plan may be disruptive to our operations. For example, any workforce reductions could yield unanticipated consequences, such as attrition beyond planned staff reductions, increased difficulties in our day-to-day operations and reduced employee morale. Any employees not affected by any reduction in force may seek alternate employment, which could result in us seeking contract support which may result in unplanned additional expense or harm our productivity. Any workforce reductions could also harm our ability to attract and retain qualified management, scientific, clinical, and manufacturing personnel who are critical to our business. Any failure to attract or retain qualified personnel could prevent us from successfully developing our product candidates in the future. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to grow or contract our organization, and we may experience difficulties in managing this growth or contraction, which could disrupt our operations. </span></div><div><span><br/></span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we had 341 full-time employees. In addition to the risks associated with a reduction in force, as our finances, development and commercialization plans and strategies evolve, we may choose to expand or contract our employee base for managerial, operational, manufacturing, financial and other resources. Future growth or additional contraction would impose significant costs as well as added responsibilities on members of management, including the potential need to identify, recruit, maintain, motivate and integrate additional employees. Also, our management may need to divert a disproportionate amount of their attention away from our day-to-day activities and devote a substantial amount of time to managing either growth or contraction activities. We may not be able to effectively manage our operations which may result in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">weaknesses in our infrastructure, give rise to operational errors, loss of business opportunities, loss of employees and reduced productivity among remaining employees.  </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of existing and additional product candidates. If our management is unable to effectively manage such growth, our expenses may increase more than expected, our ability to generate and/or grow revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to develop and commercialize our product candidates and compete effectively with others in our industry will depend, in part, on our ability to effectively manage any such growth. </span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have been and may in the future be subject to securities litigation, which is expensive and could divert management attention and adversely impact our business.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;The market price of our common stock has been and may continue to be volatile. Companies that have experienced volatility in the market price of their common stock are often subject to securities class action litigation. For example, in July 2024, a putative securities class action suit, entitled Crain v. MacroGenics, Inc. (Case No. 24-cv-02184), was filed in the U.S. District Court for the District of Maryland against our company and Scott Koenig, M.D., Ph.D., our President, Chief Executive Officer and a member of our Board of Directors, alleging violations of securities laws during 2024. On December 20, 2024, the District Court issued an Order dismissing the case, without prejudice. Previously, on September 13, 2019, a securities class action complaint was filed against us, and certain of our officers and/or directors in the U.S. District Court for the District of Maryland. On September 29, 2021, the District Court issued an Order dismissing the case, with prejudice, and on March 2, 2023 the Fourth Circuit affirmed the District Court&#8217;s dismissal.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the inherent uncertainties in legal proceedings, we cannot accurately predict the ultimate outcome of any such proceedings. Any securities litigation brought by private parties or government enforcement agencies could result in substantial costs and diversion of management&#8217;s attention and resources, which could adversely impact our business. Any adverse determination in litigation could also subject us to significant liabilities.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our stock may fluctuate unpredictably in response to factors unrelated to our operating performance. The stock market has recently experienced significant volatility, particularly with respect to pharmaceutical, biotechnology, and other life sciences company stocks. The volatility of pharmaceutical, biotechnology, and other life sciences company stocks often does not relate to the operating performance of the companies represented by the stock. Some of the factors that may cause the market price of our common stock to fluctuate include:  </span></div><div><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results and timing of our clinical trials and clinical trials of our competitors&#8217; products;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure or discontinuation of any of our development programs;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issues in manufacturing our product candidates or future approved products;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments or enforcement in the United States and foreign countries with respect to our product candidates or our competitors&#8217; products;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition from existing products or new products that may emerge;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments or disputes concerning patents or other proprietary rights;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">introduction of technological innovations or new commercial products by us or our competitors;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us, our collaborators or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in estimates or recommendations by securities analysts, if any cover our common stock;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in the valuation of companies perceived by investors to be comparable to us;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public concern over our product candidates or any future approved products;  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">threatened or actual litigation;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future or anticipated sales of our common stock;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of health care payment systems in the United States or overseas;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of any of our product candidates, if approved, to achieve commercial success;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic and other external factors or other disasters or crises;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">period-to-period fluctuations in our financial condition and results of operations, including the timing of receipt of any milestone or other payments under commercialization or licensing agreements;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general market conditions and market conditions for biopharmaceutical stocks; and </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">overall fluctuations in U.S. equity markets. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the past, when the market price of a stock has been volatile, holders of that stock have sometimes instituted securities class action litigation against the company that issued the stock. For example, we recently had one such securities class action lawsuit brought against us that was later voluntarily dismissed by the plaintiffs, as discussed above, and two related state derivative lawsuits that are pending. We could incur substantial costs defending these similar lawsuits, as well as diversion of the time and attention of our management, any or all of which could seriously harm our business.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions of our charter, bylaws, third-party agreements and Delaware law may make an acquisition of us or a change in our management more difficult. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain provisions of our restated certificate of incorporation and amended and restated bylaws could discourage, delay, or prevent a merger, acquisition, or other change in control that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. Stockholders who wish to participate in these transactions may not have the opportunity to do so. Furthermore, since our board of directors is responsible for appointing the members of our management team, these provisions could prevent or frustrate attempts by our stockholders to replace or remove our management by making it more difficult for stockholders to replace members of our board of directors. These provisions:  </span></div><div><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">allow the authorized number of directors to be changed only by resolution of our board of directors;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a classified board of directors, providing that not all members of the board of directors be elected at one time;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorize our board of directors to issue without stockholder approval blank check preferred stock that, if issued, could operate as a "poison pill" to dilute the stock ownership of a potential hostile acquirer to prevent an acquisition that is not approved by our board of directors;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit stockholder action by written consent;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish advance notice requirements for stockholder nominations to our board of directors or for stockholder proposals that can be acted on at stockholder meetings;  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit who may call stockholder meetings; and  </span></div><div style="padding-left:9pt"><span><br/></span></div><div style="padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require the approval of the holders of 75% of the outstanding shares of our capital stock entitled to vote in order to amend certain provisions of our restated certificate of incorporation and restated bylaws.   </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, in the ordinary course of our business, from time to time we discuss and enter into collaborations, licenses and other transactions with various third parties, including other pharmaceutical companies and biotechnology companies. When we deem it appropriate, our agreements with such third parties may include standstill provisions. These standstill provisions, several of which may be in force from time-to-time, typically prohibit such parties from acquiring our securities for a period of time, which may discourage such parties from acquiring MacroGenics even if doing so would be beneficial to our stockholders.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#8239;203 of the Delaware General Corporation Law, which may, unless certain criteria are met, prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a prescribed period of time. This provision could have the effect of delaying or preventing a change of control, whether or not it is desired by or beneficial to our stockholders.   </span></div><div id="ib90895a7822448df9e5a179143ce4792_22"></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B.&#160;&#160;&#160;&#160;UNRESOLVED STAFF COMMENTS</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="ib90895a7822448df9e5a179143ce4792_25"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1C. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false" id="f-37">CYBERSECURITY</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="f-38" continuedAt="f-38-1" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Management and Strategy</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have implemented and maintain various information security processes designed to identify, assess, and manage material risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and clinical trial data (Information Systems and Data).  </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our information security function is led by our Executive Director of Information Technology and supported by the Senior Information Security Manager, our legal team, a management-level Technology Steering Committee, and the Audit Committee of the Board of Directors. This function is responsible for identifying, assessing, and managing the Company&#8217;s cybersecurity threats and risks. We employ various methods to monitor and evaluate the threat environment, including automated tools, subscriptions to cybersecurity threat reports and services, analysis of threats reported to us, evaluations of our and our industry&#8217;s risk profile, threat actor analyses, audits, vulnerability assessments, and tabletop incident response exercises.  </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the environment and system, we implement and maintain various technical, physical, and organizational measures, processes, and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data. These include: an incident response plan and procedures, incident detection and response playbook, business continuity plans, encryption of certain data, network security controls, identity management and access controls, physical security controls, 24/7 systems monitoring, vendor risk management processes, employee cybersecurity and privacy training, penetration testing, cybersecurity insurance, and dedicated cybersecurity staff. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="f-40" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true" id="f-39">Our assessment and management of material risks from cybersecurity threats are integrated into our overall risk management processes.</ix:nonNumeric> Specifically, (1) cybersecurity risk is addressed as a component of our enterprise risk management program and identified in our risk register; (2) the information security function works with management to prioritize our risk management processes and mitigate cybersecurity threats that are more likely to lead to a material impact to our business; (3) our Technology Steering Committee evaluates material risks from cybersecurity threats against our overall business objectives and reports to the Audit Committee of the board of directors, which evaluates our overall enterprise risk.</ix:nonNumeric>  </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true" id="f-41">We engage third-party service providers, including professional services firms, cybersecurity consultants, cybersecurity software providers, managed cybersecurity service providers, penetration testing firms, and dark web monitoring services, to assist in identifying, assessing, and managing material risks from cybersecurity threats.</ix:nonNumeric>   </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we use third-party service providers to perform a variety of functions throughout our business, such as application providers, hosting companies, CROs, distributors, and supply chain management resources. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true" id="f-42" continuedAt="f-42-1">We have vendor management processes to manage cybersecurity risks associated with our use of certain of these providers, such as reviewing security questionnaires, reviewing the vendor&#8217;s written security program, conducting risk assessments for certain vendors, arranging security assessment calls with the vendor&#8217;s security personnel, reviewing security assessments, or imposing contractual obligations on the vendor. Depending on the nature of the services provided, the sensitivity of the Information </ix:nonNumeric></span></div></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-38-1"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-42-1">Systems and Data at issue, and the identity of the provider, our vendor management process may involve different levels of assessment designed to help identify and mitigate cybersecurity risks associated with a provider.</ix:continuation> </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of the risks from cybersecurity threats that may materially affect the Company and how they may do so, see our risk factors under Part 1. Item 1A. Risk Factors in this Annual Report on Form 10-K.</span></div></ix:continuation><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governance</span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="f-43" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors addresses the Company&#8217;s cybersecurity risk management as part of its general oversight function. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-44" escape="true">The board of directors&#8217; Audit Committee and management&#8217;s Technology Steering Committee are responsible for overseeing the Company&#8217;s cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.</ix:nonNumeric></span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="f-45" continuedAt="f-45-1" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="f-47" continuedAt="f-47-1" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="f-46" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity risk assessment and management processes are implemented and maintained by <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true" id="f-48">certain Company management</ix:nonNumeric>, including our Executive Director, Information Technology, who has fourteen years of information security experience and holds a Certified Information Systems Security Professional (CISSP) certification. Our Senior Information Security Manager holds CISSP certification, an MSc. in Information Security, and has over 20 years government and industry cybersecurity experience.</span></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-47-1">Company management is responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company&#8217;s overall risk management strategy, and communicating key priorities to relevant personnel. Company management is also responsible for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.</ix:continuation> </span></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="f-49" escape="true"><ix:continuation id="f-45-1">Our cybersecurity incident response processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances and incident severity, including our Executive Director Information Technology who works with the Company&#8217;s incident response team to help the Company mitigate and remediate cybersecurity incidents. In addition, the Company&#8217;s incident response process includes reporting to the audit and technology steering committees of the board of directors for certain cybersecurity incidents.</ix:continuation></ix:nonNumeric> </span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-50" escape="true">The <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true" id="f-51">board</ix:nonNumeric> of directors&#8217; Audit Committee receives periodic reports from our Vice President Information Technology concerning the Company&#8217;s significant cybersecurity threats and risk and the processes the Company has implemented to address them. The board of directors also receives regular reports, summaries or presentations related to cybersecurity threats, risk, and mitigation.</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:36pt"><span><br/></span></div><div id="ib90895a7822448df9e5a179143ce4792_28"></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;PROPERTIES</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease a total of approximately 190,000 square feet of manufacturing, office, laboratory and warehouse space in Maryland. Our headquarters building in Rockville, Maryland currently houses laboratory, office and manufacturing operations to support clinical and commercial quantities and scale. This location is occupied under a lease that expires in 2035. Our leases each have one or more five-year options to renew. We believe that our properties are generally in good condition, well maintained, suitable and adequate to carry on our business. We believe our capital resources are sufficient to lease any additional facilities required to meet our expected growth needs.</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span><br/></span></div><div id="ib90895a7822448df9e5a179143ce4792_31"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Litigation</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2024, a putative securities class action suit, entitled Crain v. MacroGenics, Inc. (Case No. 24-cv-02184), was filed in the U.S. District Court for the District of Maryland against the Company and Scott Koenig, M.D., Ph.D., the Company&#8217;s President, Chief Executive Officer and a member of the Company&#8217;s Board of Directors, alleging violations of securities laws during 2024. The suit asserted certain claims under Section 10 and Rule 10b-5 of the Securities and Exchange Act of 1934 based on alleged misstatements or omissions concerning the Company's TAMARACK Phase 2 study of vobramitamab duocarmazine in patients with metastatic castration-resistant prostate cancer. On December 20, 2024, the District Court issued an Order dismissing the case, without prejudice. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 9, 2024, a shareholder derivative suit, entitled Gregora v. Heiden et al. (Case No. 24-cv-03546), was filed in the U.S. District Court for the District of Maryland against certain of the Company&#8217;s officers and directors and naming </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company as a nominal defendant. The suit asserts certain claims under Section 10(b) and Rule 10b-5 of the Securities and Exchange Act of 1934 and for breach of fiduciary duty, aiding and abetting breach of fiduciary duty, unjust enrichment, and waste of corporate assets based on the same facts as the Securities Class Action. On March 10, 2025, the plaintiff filed a notice of voluntary dismissal. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 11, 2024, a shareholder derivative suit, entitled Cottle v. MacroGenics, Inc., et al. (Case No. 8:24-cv-03578), was filed in the U.S. District Court for the District of Maryland against the same defendants and alleging similar claims as the Gregora derivative action.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 20, 2025, the parties filed a stipulation of dismissal without prejudice.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we are or may be involved in various legal or regulatory proceedings, claims or class actions related to alleged patent infringements and other intellectual property rights, or alleged violation of commercial, corporate, securities, labor and employment, and other matters incidental to our business. We do not, however, expect such legal proceedings to have a material adverse effect on our business, financial condition or results of operations. However, depending on the nature and timing of a given dispute, an eventual unfavorable resolution could materially affect our current or future results of operations or cash flows.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ib90895a7822448df9e5a179143ce4792_34"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160; MINE SAFETY DISCLOSURES</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="ib90895a7822448df9e5a179143ce4792_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="ib90895a7822448df9e5a179143ce4792_40"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. &#160;&#160;&#160;&#160;MARKET FOR REGISTRANT'S COMMON EQUITY,&#160;RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on the Nasdaq Global Select Market under the symbol "MGNX".&#160;As of March&#160;14, 2025, we had 63,090,323 shares of common stock outstanding held by approximately 52 holders of record, which include shares held by a broker, bank or other nominee.&#160;We have never declared or paid any cash dividends.&#160;We do not anticipate declaring or paying cash dividends for the foreseeable future.&#160;Instead, we will retain our earnings, if any, for the future operation and expansion of our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph compares the five-year cumulative total return of our common stock with the Nasdaq Composite Index (U.S.) and the Nasdaq Biotechnology Index.&#160;The comparison assumes a $100 investment on December 31, 2019 in our common stock, the stocks comprising the Nasdaq Composite Index, and the stocks comprising the Nasdaq Biotechnology Index, and assumes reinvestment of the full amount of all dividends, if any.&#160;Historical stockholder return is not necessarily indicative of the performance to be expected for any future periods.</span></div><div style="margin-bottom:9pt;text-align:center"><img src="mgnx-20241231_g3.jpg" alt="1186" style="height:380px;margin-bottom:5pt;vertical-align:text-bottom;width:650px"/></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information set forth under the heading "Performance Graph" shall not be deemed to be "soliciting material" or to be "filed" with the SEC or subject to liabilities of Section 18 of the Exchange Act, except to the extent that we specifically request that such information be treated as soliciting material or specifically be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span><br/></span></div><div id="ib90895a7822448df9e5a179143ce4792_43"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;&#160;&#160;[RESERVED]</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="ib90895a7822448df9e5a179143ce4792_46"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:72pt;text-indent:-72pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7.&#160;&#160;&#160;&#160;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion of our financial condition and results of operations should be read together with our selected consolidated financial data and the consolidated financial statements and related notes included elsewhere herein. This discussion contains forward-looking statements that involve risks and uncertainties. As a result of many factors including, but not limited to, those set forth under the sections entitled "Risk Factors" and "Forward-Looking Statements", our actual results may differ materially from those anticipated in such forward-looking statements.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the discussion of our financial condition and results of operations for the year ended December&#160;31, 2023 compared to the year ended December&#160;31, 2022, please refer to Part II, Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the year ended December&#160;31, 2023 filed with the SEC on March&#160;7, 2024.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ib90895a7822448df9e5a179143ce4792_49"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer. We generate our pipeline of product candidates from our proprietary suite of antibody technology platforms. We are currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which we refer to as DART and TRIDENT molecules). The combination of our technology platforms and antibody engineering expertise has allowed us to generate promising product candidates &#8211; three of which have received marketing approval by the U.S. Food and Drug Administration (FDA) &#8211; and to enter into several strategic collaborations with global biopharmaceutical companies. These collaborations have provided us with over $1.4 billion of non-dilutive funding since our inception in 2000, and have enabled us to leverage the additional expertise of our collaborators to advance the development of multiple partnered product candidates. In addition, we operate a 5 &#215; 2,000 liter commercial-scale cGMP antibody manufacturing facility in our Maryland headquarters to support our clinical programs. We also provide outsourced contract development and manufacturing services to our collaborators and other third parties for commercial and clinical products to offset a portion of the operating costs of this facility. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. We are also actively developing multiple preclinical-stage ADC and next generation T-cell engager programs. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our partners are developing or commercializing product candidates for which we retain certain economic rights. These include three products approved by the FDA: MARGENZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (margetuximab-cmkb), an anti-HER2 monoclonal antibody (mAb) that we recently sold to a partner, ZYNYZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (retifanlimab-dlwr), an anti-PD-1 mAb that we out-licensed; and TZIELD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (teplizumab-mzwv), an anti-CD3 mAb that we sold to a partner. We are also collaborating with Gilead Sciences, Inc. (Gilead) on the development of MGD024, a bispecific DART antibody targeting CD123 and CD3 that utilizes our next-generation T-cell engager technology, as well as two additional undisclosed pre-clinical DART development programs.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations to date have concentrated on developing our technology platforms, identifying potential product candidates, undertaking preclinical studies, conducting clinical trials, developing collaborations, operating manufacturing facilities, business planning and raising capital. We only began generating revenues from the sale of products in 2021. We have financed our operations primarily through the public and private offerings of our securities, and collaborations with other biopharmaceutical companies.&#160;Although it is difficult to predict our funding requirements, we anticipate that our cash, cash equivalents and marketable securities as of December&#160;31, 2024, combined with anticipated and potential collaboration payments, contract manufacturing revenue, and royalties, should enable us to fund our operations into the second half of 2026. Our expected funding requirements reflect anticipated expenditures related to the ongoing Phase 2 LORIKEET study of lorigerlimab in mCRPC as well as our other clinical and preclinical studies currently ongoing. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through December&#160;31, 2024, we had an accumulated deficit of $1.2 billion.&#160;We expect that over the next several years this deficit will increase as we continue to incur research and development expense in connection with our ongoing activities and several clinical trials.&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Macroeconomic Conditions </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global economy, credit markets and financial markets have and may continue to experience significant volatility as a result of significant worldwide events, including, fluctuating interest rates, and geopolitical upheaval (collectively, the Macroeconomic Conditions). These Macroeconomic Conditions have and may continue to create supply chain disruptions, inventory disruptions, and fluctuations in economic growth, including fluctuations in employment rates, inflation, energy prices and consumer sentiment. It remains difficult to assess or predict the ultimate duration and economic impact of the Macroeconomic Conditions. Prolonged uncertainty with respect to Macroeconomic Conditions could cause further economic slowdown or cause other unpredictable events, each of which could adversely affect our business, results of operations or financial condition. </span></div><div style="margin-bottom:9pt"><span><br/></span></div><div id="ib90895a7822448df9e5a179143ce4792_52"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborations</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We pursue a balanced approach between product candidates that we develop ourselves and those that we develop with our collaborators. Under our strategic collaborations to date, we have received significant non-dilutive funding and continue to have rights to additional funding upon completion of certain research, achievement of key product development milestones and royalties and other payments upon the commercial sale of products. Our current collaborations include the following:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.53pt">Incyte Corporation (Incyte). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an exclusive global collaboration and license agreement with Incyte for retifanlimab, an investigational monoclonal antibody that inhibits PD-1 (Incyte License Agreement). Under this agreement, as amended, Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while we retain the right to develop our pipeline assets in combination with retifanlimab. We received an upfront payment of $150.0 million and milestone payments totaling $215.0 million from Incyte through December&#160;31, 2024, including $100.0 million received in August 2024</span><span style="color:#008080;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are eligible to receive up to an additional $210.0 million in development and regulatory milestones and $330.0 million in commercial milestones. We receive tiered royalties of 15% to 24% on any global net sales and we have the option to co-promote retifanlimab with Incyte. We retain the right to develop our pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and us commercializing our asset(s), if any such potential combinations are approved. We also have an agreement with Incyte under which we performed development and manufacturing services for Incyte's clinical needs of retifanlimab (Incyte Clinical Supply Agreement) and another agreement under which we are entitled to manufacture a portion of Incyte&#8217;s global commercial supply of retifanlimab (Incyte Commercial Supply Agreement).</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.53pt">Gilead</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In October 2022, we and Gilead entered into an exclusive option and collaboration agreement (Gilead Agreement) to develop and commercialize MGD024 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and create bispecific cancer antibodies using our DART platform and undertake their early development under a maximum of two separate bispecific cancer target research programs. Under t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Gilead Agreement, we </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will continue the ongoing phase 1 trial for MGD024 accordi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ng to a development plan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, during which Gilead will have the right to exercise an option granted to Gilead to obtain an exclusive license to develop and commercialize MGD024 and other bispecific antibodies of ours that bind CD123 and CD3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CD123 Option). The agreement also granted Gilead the right, within its first two years, to nominate a bispecific cancer target set for up to two research programs conducted by us and to exercise separate options to obtain an exclusive license for the development, commercialization and exploitation of molecules created under each research program (Research Program Option). As part of the Gilead Agreement, Gilead paid us a non-refundable upfront payment of $60.0&#160;million and we will be eligible to receive up to $1.7&#160;billion in target nomination, option fees, and development, regulatory and commercial milestones, assuming Gilead exercises the CD123 Option and Research Program Option, successfully develops and commercializes MGD024 or other CD123 products developed under the agreement, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and products result from the two additional research programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming exercise of the CD123 Option, w</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e will also be eligible to receive tiered, low double-digit royalties on worldwide net sales of MGD024 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(or other CD123 products developed under the agreement) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assuming exercise of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research Program Option, a flat royalty on worldwide net sales of any products resulting from the two research programs.</span><span style="color:#008080;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, Gilead nominated the first of the two research programs contemplated in the Gilead Agreement (First Research Program) and paid us a $15.7 million nomination fee. We granted Gilead a research license, and the parties agreed on a research plan for the First Research Program under which we will provide research and development services. In January 2024, the parties amended the Gilead Agreement to revise certain matters related to intellectual property in the performance of the research plans under the agreement. In </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 2024, Gilead paid us variable consideration totaling $3.3 million upon achievement of a research plan milestone. On August 30, 2024, the parties entered into a second letter agreement under which Gilead will pay us to conduct certain research and which extends the period for Gilead to select its second research target combination.</span></div><div style="padding-left:18pt"><span><br/></span></div><div id="ib90895a7822448df9e5a179143ce4792_55"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue consists of the following:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">revenue from collaborative and other agreements which includes amounts recognized relating to upfront nonrefundable payments for licenses or options to obtain future licenses, amounts earned by performing development and manufacturing services, research and development funding and milestone payments earned under our collaboration and license agreements with our strategic collaborators;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product sales, net which reflects sales of MARGENZA which was launched in 2021. Product revenue is recorded net of applicable reserves for variable consideration, including discounts and other allowances. In November 2024, we sold global rights to MARGENZA to TerSera Therapeutics, LLC (TerSera) for an upfront payment of $40.0 million;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contract manufacturing revenue which is earned from providing development and manufacturing services to third parties and manufacturing their drug substance; and </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">government agreements revenue which reflects amounts earned through grants and/or contracts with the U.S. government and other research institutions on behalf of the U.S. government, primarily with respect to research and development activities related to infectious disease product candidates. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Product Sales</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales relates to sales of MARGENZA. These costs include materials and manufacturing costs, as well as royalties payable on net sales of MARGENZA and inventory reserves. All product costs incurred prior to FDA approval of MARGENZA in December 2020 were expensed as research and development expense. As a result, cost of product sales was positively impacted as we sold through inventory that was expensed prior to FDA approval of MARGENZA. In November 2024, we sold global rights to MARGENZA to TerSera.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Manufacturing Services</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of manufacturing services consists of the costs to provide manufacturing services to produce certain bulk drug substance under manufacturing and clinical supply agreements with third parties, including salaries and benefits and related stock-based compensation, materials, overhead and other related costs.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense consists of expenses incurred in performing research and development activities. These expenses include conducting preclinical experiments and studies, clinical trials, manufacturing efforts and regulatory filings for all product candidates, and other indirect expenses in support of our research and development activities. We capture research and development expense on a program-by-program basis for our product candidates and recognize these expenses as they are incurred. The following are items we include in research and development expense:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, such as salaries and benefits;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related overhead expenses, such as facilities and other allocated items;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">stock-based compensation expense to employees engaged in research and development activities;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">depreciation of laboratory and manufacturing equipment, computers and leasehold improvements;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fees paid to consultants, subcontractors, clinical research organizations (CROs) and other third party vendors for work performed under our preclinical and clinical trials including, but not limited to, investigator grants, laboratory work and analysis, database management, statistical analysis, and other items;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">amounts paid to vendors and suppliers for laboratory supplies;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">internal and third party costs related to manufacturing clinical trial materials, including vialing, packaging and testing;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">license fees and other third party vendor payments related to in-licensed product candidates and technology; and</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs related to compliance with regulatory requirements.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is difficult to determine with certainty the duration and completion costs of our current or future preclinical programs and clinical trials of our product candidates, or if, when or to what extent we will generate revenues from the commercialization and sale of any of our product candidates that obtain regulatory approval. The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors, including the uncertainties of future clinical trials and preclinical studies, uncertainties in clinical trial enrollment rates and significant and changing government regulation. In addition, the probability of success for each product candidate will depend on numerous factors, including competition, manufacturing capability and commercial viability. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical success of each product candidate, as well as an assessment of each product candidate's commercial potential.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expense</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expense consists of salaries and related benefit costs for employees in our executive, finance, legal and intellectual property, business development, human resources, information technology and other support functions. Selling, general and administrative expense also includes costs incurred under the arrangement with our commercialization partner, Eversana Life Science Services, LLC, and other legal and professional fees. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gain on Sale of MARGENZA</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 17, 2024, we entered into an Asset Purchase and Sale Agreement (ASA) with TerSera, which closed in November 2024. Under the terms of the ASA, we sold the global rights to MARGENZA, inclusive of our business of researching, developing, commercializing, manufacturing, packaging, distributing, promoting, marketing and selling the MARGENZA product, as well as using and licensing the intellectual property relating to MARGENZA. In addition to MARGENZA&#8217;s intellectual property, TerSera also acquired all existing MARGENZA inventory. We recognized a gain of $36.3 million related to the ASA with TerSera during the year ended December 31, 2024.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ib90895a7822448df9e5a179143ce4792_58"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management's discussion and analysis of financial conditions and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of these consolidated financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the balance sheets and the reported amount of the revenue and expenses recorded during the reporting period. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable. We review and evaluate these estimates on an on-going basis. These assumptions and estimates form the basis for making judgments about the carrying values of assets and liabilities and amounts that have been recorded as revenues and expenses. Actual results and experiences may differ from these estimates. We did not make any material changes to these assumptions during the year ended December&#160;31, 2024, and do not expect any material changes in the near term to the underlying assumptions. If we were to adjust our assumptions, the results of any material revisions would be reflected in the consolidated financial statements prospectively from the date of the change in estimate. Management considers an accounting estimate to be critical if:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it requires a significant level of estimation uncertainty; and </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the estimate are reasonably likely to have a material effect on our financial condition or results of operations.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While a summary of significant accounting policies is described fully in Note 2 in our consolidated financial statements, we believe that the following accounting policies are the most critical to assist you in fully understanding and evaluating our financial results and the effect of the estimates and judgments we used in preparing our consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Revenue Recognition</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue under Accounting Standards Codification (ASC) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s, (ASC 606) when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, management performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Agreements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into licensing agreements that are within the scope of ASC 606, under which we may license rights to research, develop, manufacture and commercialize our product candidates to third parties. The terms of these arrangements typically include payment to us of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products. We may also enter into development and manufacturing service agreements with our collaborators.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each arrangement that results in revenues, we identify all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, management estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. We constrain (reduce) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside our control that could result in a significant reversal of revenue. In making these assessments, management considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. We must develop assumptions that require judgment to determine the standalone selling price in order to account for these agreements. To determine the standalone selling price, management&#8217;s assumptions may include (i) the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. We do not include a financing component to its estimated transaction price at contract inception unless we estimate that certain performance obligations will not be satisfied within one year.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we grant a license to our intellectual property, we </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determine whether the </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nature of the intellectual property to which the customer will have rights is functional intellectual property (functional IP), which has significant standalone functionality, or symbolic intellectual property (symbolic IP) which does not have significant standalone functionality. Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to our intellectual property. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to our intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, we recognize revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, we consider factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, we consider whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, management utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue we record in future periods. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research, Development and/or Manufacturing Services. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promises under our agreements may include research and development or manufacturing services to be performed by us on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, we recognize the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by us does not create an asset with an alternative use and we have an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, we recognize the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Options. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an arrangement contains customer options, we evaluate whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. We allocate the transaction price to material rights based on the relative standalone selling price, which is determined using assumptions regarding estimated costs, discount rates, post-option development timeline, the probability of technical and regulatory success and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires. If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, management evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or the licensee's control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. We evaluate factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, management reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We analyze our collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by management. We account for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on ASC 606. We account for other components based on a reasonable, rational and consistently applied accounting policy election.&#160;Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Sales, Net</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the sale of MARGENZA to TerSera in November 2024, we entered into a limited number of arrangements with specialty distributors in the United States to distribute MARGENZA. The delivery of our product represents a single performance obligation for these transactions and we record net product revenue when control is transferred to the customer, generally upon receipt by the customer. The transaction price for net product revenue represents the amount we expect to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">receive, which is net of estimated government-mandated rebates and chargebacks, distribution fees, estimated product returns, and other deductions. Accruals are established for these deductions, and actual amounts incurred are offset against applicable accruals. Customer discounts are recorded as reductions of accounts receivable on the consolidated balance sheets. Allowance for product returns, provider chargebacks, government and other rebates and service fees are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets. Sales deductions are based on management's estimates that consider payor mix in target markets and experience to-date. These estimates involve a substantial degree of judgment, in particular, for government-mandated rebates and chargebacks, such as for the Medicaid and 340B programs.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Manufacturing Revenue</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into agreements with third parties to manufacture their drug substance at our Good Manufacturing Practice (GMP) facility. The terms of these arrangements can include an upfront payment to us to reserve manufacturing capacity, scheduled payments during the manufacturing process and reimbursement for materials used to manufacture product.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue over time on a straight-line basis as the manufacturing services are performed, as we believe that our efforts in providing the manufacturing services are incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product are allocated to the related manufacturing activities and are recognized as revenue as those activities occur.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense, Including Clinical Trial Accruals/Expenses</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense consists of costs we incur for our own research and development activities and costs incurred by our collaborators under cost sharing arrangements. Research and development costs consist of salaries and benefits, including related stock-based compensation, laboratory supplies and facility costs, as well as fees paid to other entities that conduct certain research and development activities on our behalf, such as </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CROs, and the cost of acquiring and manufacturing clinical trial materials, including costs incurred under agreements with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contract manufacturing organizations (CMOs). Research and development costs are expensed as incurred. We receive estimates from our collaborators when we are sharing development expenses, and use these estimates to record an increase or decrease in research and development expense, depending on how much we have each spent during the period. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expenses are a significant component of research and development expense, and we outsource a significant portion of these costs to third parties. Third party clinical trial expenses include investigator fees, site and patient costs, CRO costs, costs for central laboratory testing, data management and CMO costs. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as a prepaid asset or accrued expenses. These third-party agreements are generally cancelable, and related costs are recorded as research and development expense as incurred. Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> performed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> When evaluating the adequacy of the accrued expenses, we analyze progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs.</span></div><div style="margin-bottom:9pt;text-indent:-0.01pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Accounting Pronouncements</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2, Summary of Significant Accounting Policies, to the consolidated financial statements for information under the caption "Recent Accounting Pronouncements."</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="ib90895a7822448df9e5a179143ce4792_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a comparison of our revenue for the years ended December&#160;31, 2024 and 2023 (dollars in millions):<br/><br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:43.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.154%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.154%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.154%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.159%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative and other agreements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract manufacturing </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $89.5 million in revenue from collaborative and other agreements for the year ended December&#160;31, 2024 compared to the year ended December&#160;31, 2023 was primarily due to a net increase of $85.0 million in revenue recognized from milestones achieved under the Incyte License Agreement.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from collaborative and other agreements may vary substantially from period to period depending on the progress made by our collaborators with their product candidates and the timing of milestones achieved under current agreements, and whether we enter into additional collaboration agreements. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in product sales, net is due to the fact that we sold the global rights to MARGENZA to TerSera in November 2024. Revenue from product sales is recorded net of applicable provisions for rebates, chargebacks and discounts, distribution-related fees and other sales-related deductions. The table below includes a reconciliation of the accounts associated with these deductions (in millions):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.981%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Rebates and chargebacks </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Distribution fees, product returns and other </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Total </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments related to prior year sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments related to prior year sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/credits </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract manufacturing revenue increased by $3.3 million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the year ended December&#160;31, 2024 compared to the year ended December 31, 2023 due to increased manufacturing under the Incyte Manufacturing and Clinical Supply Agreement and the revenue recognized under the Emergent BioSolutions Manufacturing and Clinical Supply Agreements executed in the second half of 2023.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Product Sales</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales was $0.8&#160;million and $0.6&#160;million for the years ended December&#160;31, 2024 and 2023, respectively. Cost of product sales includes product royalties and fill finish costs for both years, and cost of product sales for 2023 also includes reserves for unsaleable inventory. Product sold during both periods consisted of drug product that was previously charged to research and development expense prior to FDA approval of MARGENZA, which favorably impacted our gross margin.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Manufacturing Services</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of manufacturing services was $11.5&#160;million and $7.6&#160;million for the years ended December&#160;31, 2024 and 2023, respectively. Cost of manufacturing services includes the costs to provide manufacturing services to produce certain Incyte bulk drug substance under the Incyte Manufacturing and Clinical Supply Agreement for both years. Cost of manufacturing services for the year ended December&#160;31, 2024 also includes costs to provide manufacturing services under the Emergent BioSolutions Manufacturing and Clinical Supply Agreement. We expect cost of manufacturing services to vary from period to period based on the agreed-upon manufacturing schedule. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a comparison of our research and development expense for the years ended December&#160;31, 2024 and 2023 (dollars in millions):<br/><br/></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:43.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.131%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.131%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.131%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.998%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vobramitamab duocarmazine</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lorigerlimab</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGC028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical antibody-drug conjugates (ADCs)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGC026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Margetuximab</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGD024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Next-generation T-cell engagers (a)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retifanlimab</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enoblituzumab</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other programs (a) (b)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Includes research and discovery projects, as well as early preclinical molecules and molecules not advanced to clinical development.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Includes discontinued projects.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense for the year ended December&#160;31, 2024 increased by $10.6 million compared to the year ended December&#160;31, 2023. This increase was primarily attributable to:</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased development, manufacturing and IND-enabling costs related to MGC028;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased clinical trial costs related to lorigerlimab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased development costs for preclinical ADCs; and</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased clinical costs related to MGD024.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These increases were partially offset by:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased development, manufacturing and clinical trial costs related to discontinued projects;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased development and clinical trial costs related to margetuximab;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased development and clinical trial costs related to enoblituzumab;</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased development costs related to t-cell engagers; and</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased manufacturing costs related to retifanlimab.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are uncertainties associated with our research and development expenses for future periods which are impacted by multiple variables, including timing of wind down activities for recently closed studies and current and expected expenditures associated with our ongoing clinical studies.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses were $71.0 million and $52.2 million for the years ended December&#160;31, 2024 and 2023, respectively. The increase is primarily due to an amendment fee paid to Eversana pursuant to the sale of MARGENZA in November 2024 and increased stock-based compensation expense and accrued severance related to the separation agreement with our Chief Executive Officer.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gain on Sale of MARGENZA</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2024, we entered into an ASA with TerSera which closed in November 2024. Under the terms of the ASA, we sold the global rights to MARGENZA, inclusive of our business of researching, developing, commercializing, manufacturing, packaging, distributing, promoting, marketing and selling the MARGENZA product, as well as using and licensing the intellectual property relating to MARGENZA. In addition to MARGENZA&#8217;s intellectual property, TerSera also acquired all existing MARGENZA inventory. We recognized a gain of $36.3 million related to the ASA with TerSera during the year ended December 31, 2024.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gain on Royalty Monetization Arrangement</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, we entered into the Tripartite Agreement with DRI Healthcare Acquisitions LP (DRI) and Sanofi S.A (Sanofi), whereby we consented to the sale of DRI&#8217;s royalty interest in TZIELD and the related milestone payment obligations to Sanofi. The execution of the Tripartite Agreement resulted in a modification to the liability related to future royalties, and we recognized a $100.9 million gain on royalty monetization arrangement. In July 2023, Sanofi reported achievement of the primary endpoint milestone event related to a $50.0 million milestone, which resulted in an additional $50.0 million gain on royalty monetization arrangement. In September 2023, we amended the Provention asset purchase agreement and terminated the Royalty Purchase Agreement with DRI.</span></div><div><span><br/></span></div><div id="ib90895a7822448df9e5a179143ce4792_64"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents a summary of our cash flows for the years ended December&#160;31, 2024 and 2023 (dollars in millions):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NM: Not Meaningful</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities consists of our net loss adjusted for non-cash items such as depreciation and amortization expense and stock-based compensation, gain on royalty monetization arrangement which is classified as a financing activity, gain on sale of MARGENZA which is classified as an investing activity, and changes in working capital. Net cash used in operating activities for the year ended December&#160;31, 2024 benefited from a $100.0 million milestone payment received from Incyte under the Incyte License Agreement. Net cash used in operating activities for the year ended December&#160;31, 2023 benefited from $45.0 million in milestone payments received from Provention and a $15.0 million milestone payment received from Incyte under the Incyte License Agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities during the year ended December&#160;31, 2024 is primarily due to proceeds from the sale of MARGENZA to TerSera and maturities of marketable securities, partially offset by purchases of marketable </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">securities. Net cash used in investing activities during the year ended December&#160;31, 2023 is primarily due to purchases of marketable securities, partially offset by maturities of marketable securities.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the year ended December&#160;31, 2024 includes proceeds from stock option exercises and ESPP purchases, offset by taxes paid related to net share settlement of equity awards. Net cash provided by financing activities for the year ended December&#160;31, 2023 includes net cash proceeds from our Royalty Purchase Agreement with DRI of $149.7 million.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our multiple product candidates currently under development will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use. Our future success is dependent on our ability to identify and develop our product candidates, and ultimately upon our ability to attain profitable operations. We have devoted substantially all of our financial resources and efforts to research and development and general and administrative expenses to support such research and development. Net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#8217; equity and working capital, and accordingly, our ability to execute our future operating plans.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a biotechnology company, we have primarily funded our operations with proceeds from the sale of our common stock in equity offerings and revenue from our multiple collaboration agreements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management regularly reviews our available liquidity relative to our operating budget and forecast to monitor the sufficiency of our working capital and anticipates continuing to draw upon available sources of capital, including equity and debt instruments, to support our product development activities. There can be no assurances that new sources of capital will be available to us on commercially acceptable terms, if at all. Also, any future collaborations, strategic alliances and marketing, distribution or licensing arrangements may require us to give up some or all rights to a product or technology at less than its full potential value. If we are unable to enter into new arrangements or to perform under current or future agreements or obtain additional capital, we will assess our capital resources and may be required to delay, reduce the scope of, or eliminate one or more of our product research and development programs or clinical studies, and/or downsize our organization</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although it is difficult to predict our funding requirements, we anticipate that our cash, cash equivalents and marketable securities as of December&#160;31, 2024, combined with anticipated and potential collaboration payments, contract manufacturing revenue, and royalties, should enable us to fund our operations into the second half of 2026. Our expected funding requirements reflect anticipated expenditures related to the ongoing Phase 2 LORIKEET study of lorigerlimab in mCRPC as well as our other clinical and preclinical studies currently ongoing. </span></div><div style="margin-bottom:9pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Material Cash Requirements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our short-term and long-term material cash requirements consist of operational and capital expenditures, some of which contain contractual obligations. Our primary uses of cash relate to paying salaries and benefits, administering clinical trials and providing the technology and facilities necessary to support our operations. The most significant contractual obligations are the operating leases at our facilities in Maryland. Our future minimum lease payments as of December&#160;31, 2024 totaled $5.2&#160;million related to short-term lease liabilities, and $65.3&#160;million related to long-term lease liabilities. See Note 6, Commitments and Contingencies, in the Notes to the Financial Statements in this Annual Report on Form 10-K for additional information about our contractual obligations. We expect to fund these requirements with current cash, cash equivalents and marketable securities as well as anticipated and potential collaboration payments. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements, as defined under the rules and regulations of the Securities and Exchange Commission.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div id="ib90895a7822448df9e5a179143ce4792_67"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary objective when considering our investment activities is to preserve capital in order to fund our operations.&#160;We also seek to maximize income from our investments without assuming significant risk.&#160;Our current investment policy is to invest principally in deposits and securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations, corporate debt obligations and money market instruments.&#160;As of December&#160;31, 2024, we had cash, cash equivalents and marketable securities of $201.7 million.&#160;Our primary exposure to market risk is related to changes in interest rates.&#160;</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the short-term maturities of our cash equivalents and marketable securities and the low risk profile of our marketable securities, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents and marketable securities. We have the ability to hold our marketable securities </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">until maturity, and we therefore do not expect a change in market interest rates to affect our operating results or cash flows to any significant degree.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ib90895a7822448df9e5a179143ce4792_70"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is set forth beginning on page F-1 in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="ib90895a7822448df9e5a179143ce4792_73"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9.&#160;&#160;&#160;&#160;CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL DISCLOSURE</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ib90895a7822448df9e5a179143ce4792_76"></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our principal executive and principal financial officers, has evaluated the effectiveness of our disclosure controls and procedures as of December&#160;31, 2024. Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed in this Annual Report on Form 10-K has been appropriately recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, to allow timely decisions regarding required disclosure.&#160;Based on that evaluation, our principal executive and principal financial officers have concluded that our disclosure controls and procedures are effective at the reasonable assurance level.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control</span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our principal executive and principal financial officers, has evaluated any changes in our internal control over financial reporting that occurred during the quarterly period ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and has concluded that there was no change that occurred during the quarterly period ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> December&#160;31, 2024 that have materially affected, or are reasonably likely to materially effect, the Company's internal control over financial reporting.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management's Report on Internal Control over Financial Reporting</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting.&#160;Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Securities Exchange Act of 1934, as amended, as a process designed by, or under the supervision of, the Company's principal executive and principal financial officers and effected by the Company's board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pertain to the management of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company's assets that could have a material effect on the financial statements.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.&#160;Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.&#160;All internal control systems, no matter how well designed, have inherent limitations.&#160;Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's management assessed the effectiveness of the Company's internal control over financial reporting as of December&#160;31, 2024.&#160;In making this assessment, the Company's management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (COSO) in Internal Control-Integrated </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Framework.&#160;Based on our assessment, management believes that, as of December&#160;31, 2024, the Company's internal control over financial reporting is effective based on those criteria.</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of our internal control over financial reporting as of December&#160;31, 2024 has been audited by Ernst &amp; Young, LLP, an independent registered public accounting firm, as stated in their report which is included herein on page 70.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="ib90895a7822448df9e5a179143ce4792_79"></div><div style="margin-bottom:3pt;margin-top:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9B.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10b5-1 Trading Plans</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December&#160;31, 2024 the following Section 16 officer and directors <ix:nonNumeric contextRef="c-4" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-52">adopted</ix:nonNumeric>, modified or <ix:nonNumeric contextRef="c-4" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-53"><ix:nonNumeric contextRef="c-4" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-54">terminated</ix:nonNumeric></ix:nonNumeric> a &#8220;Rule 10b5-1 trading arrangement&#8221; (as defined in Item 408 of Regulation S-K of the Exchange Act):</span></div><div style="text-indent:13.5pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><ix:nonNumeric contextRef="c-5" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-55" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"><ix:nonNumeric contextRef="c-6" name="ecd:TrdArrIndName" id="f-56">James Karrels</ix:nonNumeric>, <ix:nonNumeric contextRef="c-6" name="ecd:TrdArrIndTitle" id="f-57">Senior Vice President and Chief Financial Officer</ix:nonNumeric>, <ix:nonNumeric contextRef="c-6" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-58">adopted</ix:nonNumeric> a new trading plan on <ix:nonNumeric contextRef="c-6" name="ecd:TrdArrAdoptionDate" id="f-59">November 21, 2024</ix:nonNumeric> (with the first trade possible under the new plan no sooner than April 16, 2025). The trading plan will be effective until <ix:nonNumeric contextRef="c-6" name="ecd:TrdArrExpirationDate" id="f-60">April 15, 2026</ix:nonNumeric> and covers the potential sale of up to <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-61">410,000</ix:nonFraction> shares of common stock.</span></ix:nonNumeric></div><div style="margin-bottom:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><ix:nonNumeric contextRef="c-9" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-63" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"><ix:nonNumeric contextRef="c-8" name="ecd:TrdArrIndName" id="f-62">Jeffrey Peters</ix:nonNumeric>, <ix:nonNumeric contextRef="c-8" name="ecd:TrdArrIndTitle" id="f-64">Senior Vice President and General Counsel</ix:nonNumeric>, <ix:nonNumeric contextRef="c-8" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-65">adopted</ix:nonNumeric> a new trading plan on <ix:nonNumeric contextRef="c-8" name="ecd:TrdArrAdoptionDate" id="f-66">November 15, 2024</ix:nonNumeric> (with the first trade possible under the new plan no sooner than March 21, 2025). The trading plan will be effective until <ix:nonNumeric contextRef="c-8" name="ecd:TrdArrExpirationDate" id="f-67">March 20, 2026</ix:nonNumeric> and covers the potential sale of up to <ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-68">448,881</ix:nonFraction> shares of common stock.</span></ix:nonNumeric></div><div><span><br/></span></div><div id="ib90895a7822448df9e5a179143ce4792_85"></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9C.&#160;&#160;&#160;&#160;DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="ib90895a7822448df9e5a179143ce4792_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">To the Shareholders and the Board of Directors of MacroGenics, Inc. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited MacroGenics, Inc.&#8217;s internal control over financial reporting as of December&#160;31, 2024, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, MacroGenics, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December&#160;31, 2024, based on the COSO criteria.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December&#160;31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for each of the three years in the period ended December&#160;31, 2024, and the related notes and our report dated March&#160;20, 2025, expressed an unqualified opinion thereon. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tysons, Virginia</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;20, 2025 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="ib90895a7822448df9e5a179143ce4792_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="ib90895a7822448df9e5a179143ce4792_94"></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10.&#160;&#160;&#160;&#160;DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incorporate herein by reference the relevant information concerning directors, executive officers and corporate governance to be included in our definitive proxy statement for the 2025 annual meeting of stockholders (the 2025 Proxy Statement) under the captions &#8220;Directors and Nominees,&#8221; &#8220;Corporate Governance,&#8221; &#8220;Executive Officers,&#8221; and &#8220;Delinquent Section 16(a) Reports&#8221;.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a Code of Business Conduct and Ethics (the &#8220;Code&#8221;) that applies to all of our employees, officers and directors. The Code is available under the Corporate Governance section of our website at http://ir.macrogenics.com/governance. We expect that any amendments to the Code, or any waivers of its requirements, will be disclosed on our website.</span></div><div style="text-indent:36pt"><span style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have&#160;an <ix:nonNumeric contextRef="c-1" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true" id="f-71">insider trading policy</ix:nonNumeric> governing the purchase, sale and other dispositions of our securities that applies to all of our personnel, including directors, officers, employees, and other covered persons. We believe that our insider trading policy is reasonably designed to promote compliance with insider trading laws, rules and regulations, and listing standards applicable to us. A copy of our insider trading policy is filed as Exhibit 19.1 to this Annual Report on Form 10-K.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ib90895a7822448df9e5a179143ce4792_97"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11.&#160;&#160;&#160;&#160;EXECUTIVE COMPENSATION</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incorporate herein by reference the relevant information concerning executive compensation to be included in the 2025 Proxy Statement under the captions &#8220;Executive Compensation Information&#8221; and &#8220;Director Compensation&#8221;.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="ib90895a7822448df9e5a179143ce4792_100"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12.&#160;&#160;&#160;&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incorporate herein by reference the relevant information concerning security ownership of certain beneficial owners and management to be included in the 2025 Proxy Statement under the captions &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Information About Equity Compensation Plans&#8221;.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="ib90895a7822448df9e5a179143ce4792_103"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13. &#160;&#160;&#160;&#160;CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incorporate herein by reference the relevant information concerning certain other relationships and related transactions to be included in the 2025 Proxy Statement under the captions &#8220;Corporate Governance&#8221; and &#8220;Certain Relationships and Related Party Transactions&#8221;.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="ib90895a7822448df9e5a179143ce4792_106"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14.&#160;&#160;&#160;&#160;PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incorporate herein by reference the relevant information concerning principal accountant fees and services to be included in the 2025 Proxy Statement under the caption &#8220;Principal Accountant Fees and Services&#8221;.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><div id="ib90895a7822448df9e5a179143ce4792_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="ib90895a7822448df9e5a179143ce4792_112"></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15. &#160;&#160;&#160;&#160;EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The following documents are filed as part of this Annual Report on Form 10-K:</span></div><div style="margin-bottom:9pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Consolidated Financial Statements:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.912%"><tr><td style="width:1.0%"/><td style="width:71.745%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Report of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib90895a7822448df9e5a179143ce4792_124">F - </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib90895a7822448df9e5a179143ce4792_124">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Balance Sheets</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib90895a7822448df9e5a179143ce4792_127">F - </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib90895a7822448df9e5a179143ce4792_127">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Operations and Comprehensive Loss</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib90895a7822448df9e5a179143ce4792_130">F - </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib90895a7822448df9e5a179143ce4792_130">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Stockholders' Equity</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib90895a7822448df9e5a179143ce4792_133">F - </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib90895a7822448df9e5a179143ce4792_133">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Cash Flows</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib90895a7822448df9e5a179143ce4792_136">F - </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib90895a7822448df9e5a179143ce4792_136">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib90895a7822448df9e5a179143ce4792_139">F - </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib90895a7822448df9e5a179143ce4792_139">7</a></span></div></td></tr></table></div><div style="margin-bottom:9pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Financial Statement Schedules:</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the financial statements or the notes thereto.&#160;</span></div><div style="margin-bottom:9pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Exhibits:</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits filed as part of this Annual Report on Form 10-K are set forth on the Exhibit Index immediately following our consolidated financial statements. The Exhibit Index is incorporated herein by reference.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="ib90895a7822448df9e5a179143ce4792_115"></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16.&#160;&#160;&#160;&#160;FORM 10-K SUMMARY</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><div id="ib90895a7822448df9e5a179143ce4792_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:47.713%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.615%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.372%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MacroGenics, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Scott Koenig</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Koenig, M.D., Ph.D.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and CEO and Director</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Act of 1934, as amended, this Report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:38.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.318%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.429%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.384%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Scott Koenig</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and CEO and Director<br/>(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;20, 2025</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Koenig, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ James Karrels</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Chief <br/>Financial Officer and Secretary <br/>(Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;20, 2025</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Karrels</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Beth Smith</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President, Controller and Treasurer<br/>(Principal Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;20, 2025</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beth Smith</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Karen Ferrante, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;20, 2025</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Karen Ferrante, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ William Heiden</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;20, 2025</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William Heiden</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Edward Hurwitz</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;20, 2025</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Edward Hurwitz</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Scott Jackson</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;20, 2025</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Jackson</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Meenu Chhabra Karson</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;20, 2025</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Meenu Chhabra Karson</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Margaret A. Liu, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;20, 2025</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Margaret A. Liu, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Federica O&#8217;Brien</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;20, 2025</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federica O&#8217;Brien</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jay Siegel, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;20, 2025</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jay Siegel, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David Stump, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;20, 2025</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Stump, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="ib90895a7822448df9e5a179143ce4792_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_124">Report of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm (PCAOB ID: </a></span><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-72">42</ix:nonNumeric></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_124">)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_124">F - </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_124">1</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_127">Consolidated Balance Sheets at December 31, 2024 and December 31, 2023</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_127">F - </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_127">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_130">Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2024, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_130">F - </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_130">4</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_133">Consolidated Statements of Stockholders' Equity for the years ended December 31, 2024, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_133">F - </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_133">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_136">Consolidated Statements of Cash Flows for the years ended December 31, 2024, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_136">F - </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_136">6</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_139">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_139">F - </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib90895a7822448df9e5a179143ce4792_139">7</a></span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ib90895a7822448df9e5a179143ce4792_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and the Board of Directors of MacroGenics, Inc. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of MacroGenics, Inc. (the Company) as of December&#160;31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for each of the three years in the period ended December&#160;31, 2024, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2024, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December&#160;31, 2024, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated March&#160;20, 2025 expressed an unqualified opinion thereon. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting for the Sale of MARGENZA</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"><tr><td style="width:1.0%"/><td style="width:21.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:73.244%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description of the Matter</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 10 of the consolidated financial statements, in October 2024, the Company entered into an Asset Purchase and Sale Agreement (&#8220;ASA&#8221;) with TerSera Therapeutics, LLC (&#8220;TerSera&#8221;) in which TerSera acquired global rights to MARGENZA along with a Master Manufacturing and Supply Agreement (&#8220;MSA&#8221;) under which the Company will manufacture MARGENZA for TerSera, and a Transition Services Agreement to provide certain services to TerSera (&#8220;Sale of MARGENZA&#8221;). As part of the ASA, the Company received $40.0 million and is eligible to receive sales milestone payments of up to an aggregate of $35.0 million. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting for the Sale of MARGENZA required the Company to make significant judgments. Specifically, there was significant judgment involved with the evaluation of the key terms of the agreements to determine the appropriate and applicable authoritative guidance to apply to each of the elements of the single combined contract. As a result, auditing the Sale of MARGENZA and related agreements required especially subjective and complex auditor judgment.</span></div><div><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding, evaluated the design, and tested the operating effectiveness of the Company&#8217;s control over the evaluation of the technical accounting for the Sale of MARGENZA, which included management&#8217;s review over the application and evaluation of the applicable authoritative guidance.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To audit the Company&#8217;s accounting for the Sale of MARGENZA, we performed audit procedures that included inspecting the executed agreements and related accounting analyses performed by management and evaluating the conclusions. We also involved our subject matter resources to assist with auditing the significant and judgmental conclusions reached by management including the evaluation of the terms of the agreements and the application of the related accounting guidance.</span></div><div><span><br/></span></div></td></tr></table></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-73">Ernst &amp; Young LLP</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have served as the Company's auditor since 2006.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-74">Tysons, Virginia</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 20, 2025</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 2</span></div></div></div><div id="ib90895a7822448df9e5a179143ce4792_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-75">182,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-76">100,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="3" id="f-77">18,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="3" id="f-78">128,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-79">4,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-80">10,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:InventoryNet" format="ixt:fixed-zero" scale="3" id="f-81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-82">1,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-83">11,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-84">9,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-85">217,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-86">251,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-87">18,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-88">21,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-89">24,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-90">23,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-91">1,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-92">1,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-93">261,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-94">298,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-95">5,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-96">6,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-97">29,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-98">24,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredRevenueCurrent" format="ixt:num-dot-decimal" scale="3" id="f-99">16,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredRevenueCurrent" format="ixt:num-dot-decimal" scale="3" id="f-100">21,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-101">4,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-102">3,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-103">55,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-104">56,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredRevenueNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-105">55,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredRevenueNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-106">59,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-107">32,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-108">30,196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-109">1,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-110">258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-111">145,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-112">145,805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, <ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-113"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-114">0.01</ix:nonFraction></ix:nonFraction> par value -- <ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-115"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-116">125,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-117">62,819,857</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-118">62,070,627</ix:nonFraction> shares outstanding at December&#160;31, 2024 and December&#160;31, 2023, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-119">628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-120">621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-121">1,285,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-122">1,254,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive gain (loss)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-123">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-124">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-125">1,169,718</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-126">1,102,752</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-127">116,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-128">152,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-129">261,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-130">298,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 3</span></div></div></div><div id="ib90895a7822448df9e5a179143ce4792_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative and other agreements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-131">118,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-132">29,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-133">119,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-134">16,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-135">17,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-136">16,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract manufacturing </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-137">13,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-138">9,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-139">13,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government agreements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-140">1,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-141">1,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-142">1,923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-143">149,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-144">58,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-145">151,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="f-146">847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="f-147">619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-148">3,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of manufacturing services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="mgnx:CostOfManufacturingServices" format="ixt:num-dot-decimal" scale="3" id="f-149">11,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="mgnx:CostOfManufacturingServices" format="ixt:num-dot-decimal" scale="3" id="f-150">7,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="mgnx:CostOfManufacturingServices" format="ixt:num-dot-decimal" scale="3" id="f-151">4,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-152">177,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-153">166,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-154">207,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-155">71,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-156">52,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-157">58,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-158">260,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-159">226,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-160">273,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-161">110,578</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-162">168,244</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-163">121,418</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on royalty monetization arrangement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="mgnx:GainOnRoyaltyMonetizationArrangement" format="ixt:fixed-zero" scale="3" id="f-164">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="mgnx:GainOnRoyaltyMonetizationArrangement" format="ixt:num-dot-decimal" scale="3" id="f-165">150,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="mgnx:GainOnRoyaltyMonetizationArrangement" format="ixt:fixed-zero" scale="3" id="f-166">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of MARGENZA</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="mgnx:GainOnSaleOfMARGENZA" format="ixt:num-dot-decimal" scale="3" id="f-167">36,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="mgnx:GainOnSaleOfMARGENZA" format="ixt:fixed-zero" scale="3" id="f-168">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="mgnx:GainOnSaleOfMARGENZA" format="ixt:fixed-zero" scale="3" id="f-169">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-170">9,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-171">9,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-172">1,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other expense</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-173">1,115</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-174">1,430</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="f-175">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes </span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-176">66,022</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-177">9,058</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-178">119,758</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-179">944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-180">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-181">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-182">66,966</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-183">9,058</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-184">119,758</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-185">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-186">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-187">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-188">66,956</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-189">9,059</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-190">119,702</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-191"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-192">1.07</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-25" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-193"><ix:nonFraction unitRef="usdPerShare" contextRef="c-25" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-194">0.15</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-26" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-195"><ix:nonFraction unitRef="usdPerShare" contextRef="c-26" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-196">1.95</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-197"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-198">62,621,185</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-199"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-200">61,929,198</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-201"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-202">61,433,124</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 4</span></div></div></div><div id="ib90895a7822448df9e5a179143ce4792_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share amounts)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.482%"/><td style="width:0.1%"/></tr><tr style="height:25pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Paid-In</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deficit</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Comprehensive Income (Loss)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stockholders'</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-203">61,307,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-204">613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-205">1,213,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-206">973,936</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-207">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-208">239,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-209">20,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-210">20,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-211">160,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-212">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-213">1,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-214">1,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock plan related activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="INF" name="mgnx:StockIssuedDuringPeriodSharesStockPlanActivity" format="ixt:num-dot-decimal" scale="0" id="f-215">233,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="f-216">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="f-217">572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="f-218">574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="f-219">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="f-220">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-221">119,758</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-222">119,758</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-36" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-223">61,701,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-224">617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-225">1,235,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-226">1,093,694</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-227">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-228">142,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-229">18,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-230">18,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-231">167,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-232">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-233">1,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-234">1,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock plan related activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="INF" name="mgnx:StockIssuedDuringPeriodSharesStockPlanActivity" format="ixt:num-dot-decimal" scale="0" id="f-235">201,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="f-236">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="f-237">245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="f-238">247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="f-239">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="f-240">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-241">9,058</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-242">9,058</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-45" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-243">62,070,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-244">621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-245">1,254,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-246">1,102,752</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-247">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-248">152,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-249">29,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-250">29,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock plan related activity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-50" decimals="INF" name="mgnx:StockIssuedDuringPeriodSharesStockPlanActivity" format="ixt:num-dot-decimal" scale="0" id="f-251">749,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="f-252">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="f-253">954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="mgnx:StockIssuedDuringPeriodValueStockPlanActivity" scale="3" id="f-254">961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="f-255">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="f-256">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-257">66,966</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-258">66,966</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-53" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-259">62,819,857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-260">628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-261">1,285,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-262">1,169,718</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-263">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-264">116,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 5</span></div></div></div><div id="ib90895a7822448df9e5a179143ce4792_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">                                                                                          (In thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-265">66,966</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-266">9,058</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-267">119,758</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-268">7,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-269">9,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-270">11,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premiums and discounts on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-271">2,810</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-272">5,004</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="f-273">403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-274">29,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-275">18,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-276">20,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on royalty monetization arrangement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="mgnx:GainOnRoyaltyMonetizationArrangement" format="ixt:fixed-zero" scale="3" id="f-277">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="mgnx:GainOnRoyaltyMonetizationArrangement" format="ixt:num-dot-decimal" scale="3" id="f-278">150,930</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="mgnx:GainOnRoyaltyMonetizationArrangement" format="ixt:fixed-zero" scale="3" id="f-279">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of MARGENZA</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="mgnx:GainOnSaleOfMARGENZA" format="ixt:num-dot-decimal" scale="3" id="f-280">36,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="mgnx:GainOnSaleOfMARGENZA" format="ixt:fixed-zero" scale="3" id="f-281">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="mgnx:GainOnSaleOfMARGENZA" format="ixt:fixed-zero" scale="3" id="f-282">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="mgnx:NonCashInterestExpenseRecognized" format="ixt:fixed-zero" scale="3" id="f-283">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="mgnx:NonCashInterestExpenseRecognized" format="ixt:num-dot-decimal" scale="3" id="f-284">1,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="mgnx:NonCashInterestExpenseRecognized" format="ixt:fixed-zero" scale="3" id="f-285">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="mgnx:OperatingLeaseNoncashExpense" scale="3" id="f-286">663</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="mgnx:OperatingLeaseNoncashExpense" format="ixt:num-dot-decimal" scale="3" id="f-287">3,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="mgnx:OperatingLeaseNoncashExpense" format="ixt:num-dot-decimal" scale="3" id="f-288">3,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-cash items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="f-289">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="f-290">423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-291">2,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gain) loss on disposal of assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" id="f-292">57</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" id="f-293">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets" format="ixt:fixed-zero" scale="3" id="f-294">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-295">6,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-296">45,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-297">45,836</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-298">2,188</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="f-299">230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="f-300">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="f-301">1,567</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="f-302">215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="f-303">11,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="f-304">170</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="f-305">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="f-306">14,045</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-307">1,530</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-308">1,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-309">10,860</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-310">5,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-311">4,823</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-312">4,638</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="mgnx:IncreaseDecreaseInLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-313">3,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="mgnx:IncreaseDecreaseInLeaseLiabilities" scale="3" id="f-314">861</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="mgnx:IncreaseDecreaseInLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-315">9,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-316">9,414</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-317">11,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-318">48,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-319">1,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" format="ixt:fixed-zero" scale="3" id="f-320">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" format="ixt:fixed-zero" scale="3" id="f-321">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-322">68,373</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-323">78,205</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-324">86,959</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-325">77,182</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-326">239,683</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-327">120,602</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-328">190,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-329">161,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-330">194,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-331">3,706</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-332">1,764</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-333">3,623</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of MARGENZA</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfOtherProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="f-334">40,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:ProceedsFromSaleOfOtherProductiveAssets" format="ixt:fixed-zero" scale="3" id="f-335">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:ProceedsFromSaleOfOtherProductiveAssets" format="ixt:fixed-zero" scale="3" id="f-336">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales of equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" scale="3" id="f-337">160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" scale="3" id="f-338">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" format="ixt:fixed-zero" scale="3" id="f-339">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-340">149,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-341">80,084</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-342">70,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-343">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="f-344">616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-345">1,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from stock option exercises and ESPP purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases" format="ixt:num-dot-decimal" scale="3" id="f-346">3,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases" scale="3" id="f-347">553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases" scale="3" id="f-348">574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-349">2,475</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-350">306</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="f-351">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal payments on royalty monetization arrangement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="mgnx:PrincipalPaymentsOnRoyaltyMonetizationArrangement" format="ixt:fixed-zero" scale="3" id="f-352">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="mgnx:PrincipalPaymentsOnRoyaltyMonetizationArrangement" scale="3" id="f-353">157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="mgnx:PrincipalPaymentsOnRoyaltyMonetizationArrangement" format="ixt:fixed-zero" scale="3" id="f-354">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net proceeds from sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="mgnx:NetProceedsFromSaleOfFutureRoyalties" format="ixt:fixed-zero" scale="3" id="f-355">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="mgnx:NetProceedsFromSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="f-356">149,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="mgnx:NetProceedsFromSaleOfFutureRoyalties" format="ixt:fixed-zero" scale="3" id="f-357">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-358">960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-359">150,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-360">1,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-361">81,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-362">7,928</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-363">14,585</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-364">100,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-365">108,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-366">123,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-367">182,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-368">100,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-369">108,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental cash flow disclosures</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="f-370">944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:IncomeTaxesPaid" format="ixt:fixed-zero" scale="3" id="f-371">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:IncomeTaxesPaid" format="ixt:fixed-zero" scale="3" id="f-372">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-cash operating and investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment included in accounts payable or accruals</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-373">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-374">505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-375">118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 6</span></div></div></div><div id="ib90895a7822448df9e5a179143ce4792_139"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div id="ib90895a7822448df9e5a179143ce4792_142"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-376" continuedAt="f-376-1" escape="true">Organization and Nature of Operations</ix:nonNumeric></span></div><ix:continuation id="f-376-1" continuedAt="f-376-2"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MacroGenics, Inc. (the Company) is incorporated in the state of Delaware. The Company is a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates from its proprietary suite of antibody technology platforms. The Company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which is referred to as DART and TRIDENT molecules). The combination of the Company&#8217;s technology platforms and antibody engineering expertise has allowed the Company to generate promising product candidates &#8211; <ix:nonFraction unitRef="productcandidate" contextRef="c-1" decimals="INF" name="mgnx:NumberOfProductCandidatesApprovedByTheFoodAndDrugAdministration" format="ixt-sec:numwordsen" id="f-377">three</ix:nonFraction> of which have received marketing approval by the U.S. Food and Drug Administration (FDA) &#8211; and to enter into several strategic collaborations with global biopharmaceutical companies. These collaborations have provided the Company with over $<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="mgnx:NonDilutiveFunding" format="ixt:num-dot-decimal" scale="9" id="f-378">1.4</ix:nonFraction>&#160;billion of non-dilutive funding since its inception in 2000, and have enabled the Company to leverage the additional expertise of its collaborators to advance the development of multiple partnered product candidates. In addition, the Company operates a 5 &#215; 2,000 liter commercial-scale cGMP antibody manufacturing facility in its Maryland headquarters to support its clinical programs. The Company also provides outsourced contract development and manufacturing services to its collaborators and other third parties for commercial and clinical products to offset a portion of the operating costs of this facility. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is currently advancing <ix:nonFraction unitRef="productcandidate" contextRef="c-1" decimals="INF" name="mgnx:NumberOfProprietaryProductCandidatesAdvancingInClinicalDevelopment" format="ixt-sec:numwordsen" id="f-379">three</ix:nonFraction> proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. The Company is also actively developing multiple preclinical-stage ADC and next generation T-cell engager programs. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its partners are developing or commercializing product candidates for which the Company retain certain economic rights. These include <ix:nonFraction unitRef="productcandidate" contextRef="c-1" decimals="INF" name="mgnx:NumberOfProductCandidatesApprovedByTheFoodAndDrugAdministration" format="ixt-sec:numwordsen" id="f-380">three</ix:nonFraction> products approved by the FDA: MARGENZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (margetuximab-cmkb), an anti-HER2 monoclonal antibody (mAb) that the Company recently sold to a partner, ZYNYZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (retifanlimab-dlwr), an anti-PD-1 mAb that the Company out-licensed; and TZIELD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (teplizumab-mzwv), an anti-CD3 mAb that the Company sold to a partner. The Company is also collaborating with </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead Sciences, Inc. (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead) on the development of MGD024, a bispecific DART antibody targeting CD123 and CD3 that utilizes its next-generation T-cell engager technology, as well as two additional undisclosed pre-clinical DART development programs. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s multiple product candidates currently under development will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future success of the Company is dependent on its ability to identify and develop its product candidates, and ultimately upon its ability to attain profitable operations. The Company has devoted substantially all of its financial resources and efforts to research and development and general and administrative expense to support such research and development. Net losses and negative cash flows have had, and will continue to have, an adverse effect on the Company&#8217;s stockholders&#8217; equity and working capital, and accordingly, its ability to execute its future operating plans.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a biotechnology company, the Company has primarily funded its operations with proceeds from the sale of its common stock in equity offerings and revenue from its multiple collaboration agreements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management regularly reviews the Company&#8217;s available liquidity relative to its operating budget and forecast to monitor the sufficiency of the Company&#8217;s working capital. The Company plans to meet its future operating requirements by generating revenue from current and future strategic collaborations or other arrangements and royalties.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company anticipates continuing to draw upon available sources of capital, including equity and debt instruments, to support its product development activities. If the Company is unable to enter into new arrangements or to perform under current or future agreements or obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of, or eliminate one or more of its product research and development programs or clinical studies, reduce other operating expenses, and/or downsize its organization. Based on the Company&#8217;s most recent cash flow forecast, the Company believes its current resources are sufficient to fund its operating plans for a minimum of twelve months from the date that this Annual Report on Form 10-K was filed.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-376-2"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the other risk factors pertinent to the Company's business, including significant equity market volatility and availability of funding in the biotechnology sector, as well as potential issues in the global economy, credit markets and financial markets as a result of significant worldwide events, including inflation, fluctuating interest rates and geopolitical upheaval, might unfavorably impact the Company's ability to generate such additional funding. Given the uncertainty in the rapidly changing market and economic conditions related to these uncertainties, the Company will continue to evaluate the nature and extent of the impact of these uncertainties on its business and financial position.</span></div></ix:continuation><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="ib90895a7822448df9e5a179143ce4792_145"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-381" continuedAt="f-381-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-381-1" continuedAt="f-381-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-382" continuedAt="f-382-1" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-382-1">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited.&#160;All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-383">one</ix:nonFraction> operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-384">one</ix:nonFraction> segment, which is developing and commercializing monoclonal antibody-based therapeutics. See Note 13, Segment Reporting, for the Company&#8217;s evaluation of its reportable segment and additional disclosures.</ix:continuation>  </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-385" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, inventory, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Although actual results could differ from these estimates, management does not believe that such differences would be material.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-386" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Marketable Securities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Classification of marketable securities between current and non-current is dependent upon the maturity date at the balance sheet date taking into consideration the Company&#8217;s ability and intent to hold the investment to maturity. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income, along with interest income and amortization of premiums and discounts.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="f-387" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable arise from product sales, amounts due from the Company&#8217;s collaborative partners and contract manufacturing work performed by the Company. The amount from product sales represents amounts due from specialty distributors. Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. <ix:nonFraction unitRef="usd" contextRef="c-12" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt-sec:numwordsen" id="f-388"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt-sec:numwordsen" id="f-389">No</ix:nonFraction></ix:nonFraction> allowance was recorded as of December&#160;31, 2024 or 2023, as the Company has a history of collecting on all outstanding accounts.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-381-2" continuedAt="f-381-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-390" continuedAt="f-390-1" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8211; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8211; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8211; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#8211; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</span></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:36pt"><ix:continuation id="f-390-1" continuedAt="f-390-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy. </span></ix:continuation><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-390-2">There were no transfers between levels during the periods presented.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="f-391" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:51.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.612%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.852%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at December&#160;31, 2024</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-392">67,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-393">67,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-394">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-395">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-396">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-397">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-398">3,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-399">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-400">3,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-401">25,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-402">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-403">25,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-404">102,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-405">67,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-406">34,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.108%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at December&#160;31, 2023</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-407">91,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-408">91,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-409">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-410">31,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-411">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-412">31,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprise</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-413">45,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-414">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-415">45,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-416">52,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-417">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-418">52,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-419">220,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-420">91,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-421">128,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:15pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Total assets measured at fair value at December&#160;31, 2024 includes approximately $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="f-422">83.6</ix:nonFraction> million reported as cash and cash equivalents and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="f-423">18.8</ix:nonFraction>&#160;million reported as marketable securities on the balance sheet.</span></div><div style="margin-bottom:9pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Total assets measured at fair value at December&#160;31, 2023 includes approximately $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="f-424">91.7</ix:nonFraction> million reported as cash and cash equivalents and $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="f-425">128.8</ix:nonFraction>&#160;million reported as marketable securities on the balance sheet.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-381-3" continuedAt="f-381-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-426" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, the Company has not experienced any losses on related accounts to date.&#160;The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The counterparties are various corporations, financial institutions and government agencies of high credit standing.</span></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's revenue relates to agreements with various collaborators, MARGENZA net product sales (prior to the sale to TerSera Therapeutics LLC (TerSera) in November 2024) and&#160;contracts and research grants received from U.S. government agencies.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="f-427" continuedAt="f-427-1" escape="true">The following table includes those counterparties that represent more than 10% of total revenue earned in the periods indicated:</ix:nonNumeric></span><ix:continuation id="f-427-1" continuedAt="f-427-2"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:68.119%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.620%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.620%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incyte Corporation (Incyte)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-88" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-428">76</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-89" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-429">53</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-90" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-430">26</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC (McKesson)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-91" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-431">12</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASD Healthcare and Oncology Supply (ASD)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-92" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-432">10</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provention Bio, Inc. (Provention)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-93" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-433">10</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-94" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-434">43</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zai Lab Limited (Zai Lab)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-95" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-435">15</ix:nonFraction>%</span></td></tr></table></ix:continuation></div><ix:continuation id="f-427-2"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Amount is less than 10% for the period indicated.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes those counterparties that represent more than 10% of accounts receivable at the date indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:72.946%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incyte</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-96" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-436">39</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-97" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-437">25</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASD</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-98" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-438">18</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-99" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-439">15</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-100" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-440">13</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-441">16</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-102" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-442">12</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-103" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-443">18</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zai Lab</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-104" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-444">12</ix:nonFraction>%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Balance is less than 10% as of the date indicated.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryPolicyTextBlock" id="f-445" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company believes regulatory approval is probable and expects future economic benefit from the sales of a product candidate to be realized, the Company capitalizes manufacturing costs (whether internally produced or through third-party contract manufacturing organizations) as inventory. Prior to receiving its first approval from the FDA in December 2020, the Company expensed all costs incurred related to the manufacture of MARGENZA as research and development expense because of the inherent risks associated with the development of a product candidate, the uncertainty about the regulatory approval process and the lack of history for the Company of regulatory approval of drug candidates. Subsequent to FDA approval in December 2020, the Company began capitalizing its MARGENZA third-party contract manufacturing inventory costs. In November 2024, the Company sold global rights to MARGENZA to TerSera. As part of this transaction, the Company transferred all of its inventory to TerSera.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is composed of raw materials, work-in-process, and finished goods, which are goods that are available for sale. The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and third-party contract manufacturing costs, on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess, obsolete or unsaleable inventories to their estimated realizable value in the period in which the impairment is first identified. Such write downs, should they occur, are recorded within the cost of product sales in the statement of operations.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-381-4" continuedAt="f-381-5"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-446" continuedAt="f-446-1" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Equipment and Software</span></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-446-1">Property, equipment and software are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred.</ix:continuation> <ix:nonNumeric contextRef="c-1" name="mgnx:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" id="f-447" continuedAt="f-447-1" escape="true">Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:</ix:nonNumeric></span></div><ix:continuation id="f-447-1"><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.754%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-105" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-448">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-106" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-449">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-107" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-450">10</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and office equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-108" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-451">5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of lease term or useful life</span></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="f-452" continuedAt="f-452-1" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:36pt"><ix:continuation id="f-452-1" continuedAt="f-452-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-452-2">(ASC 360). ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.</ix:continuation> For the years ended December&#160;31, 2024, and 2023, the Company determined that there were <ix:nonFraction unitRef="usd" contextRef="c-25" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt-sec:numwordsen" id="f-453"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt-sec:numwordsen" id="f-454">no</ix:nonFraction></ix:nonFraction> impaired assets.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="f-455" continuedAt="f-455-1" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue under ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s (ASC 606) when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Agreements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into licensing agreements that are within the scope of ASC 606, under which it may license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products. The Company may also enter into development and manufacturing service agreements with its collaborators.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each arrangement that results in revenues, the Company identifies all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#8217;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. The Company must develop assumptions that require judgment to determine the standalone selling price in </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-455-1" continuedAt="f-455-2"><ix:continuation id="f-381-5" continuedAt="f-381-6"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">order to account for these agreements. To determine the standalone selling price, the Company&#8217;s assumptions may include (i) the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company grants a license to its intellectual property, it </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determines whether the </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nature of the intellectual property to which the customer will have rights is functional intellectual property (functional IP), which has significant standalone functionality, or symbolic intellectual property (symbolic IP) which does not have significant standalone functionality. Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to the Company&#8217;s intellectual property</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research, Development and/or Manufacturing Services. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promises under the Company&#8217;s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Options. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an arrangement contains customer options, the Company evaluates whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined using assumptions regarding estimated costs, discount rates, post-option development timeline, the probability of technical and regulatory success and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-455-2" continuedAt="f-455-3"><ix:continuation id="f-381-6" continuedAt="f-381-7"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by the Company. The Company accounts for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on ASC 606. The Company accounts for other components based on a reasonable, rational and consistently applied accounting policy election.&#160;Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a complete discussion of accounting for revenue from collaborative and other agreements, see Note 8, Revenue.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product sales, net</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the sale to TerSera, the Company entered into a limited number of arrangements with specialty distributors in the United States to distribute MARGENZA. These arrangements are considered to be contracts with customers and are in the scope of ASC 606. The Company has written contracts with each of its customers that have a single performance obligation - to deliver products upon receipt of a customer order - and these obligations are satisfied when delivery occurs and the customer receives the product. The specialty distributors subsequently resell the Company&#8217;s product to healthcare providers. Product revenue is recorded net of applicable reserves for variable consideration, including discounts and other allowances. Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Variable Consideration. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration. Components of variable consideration typically include discounts, product returns, provider chargebacks and discounts and government rebates. Variable consideration is estimated following the expected value method in accordance with ASC 606 and includes such factors as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Discounts and Service Fees. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may provide customers with discounts which are explicitly stated in the contracts. These discounts are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, these contracts may include written service arrangements whereby the Company pays fees to customers who provide services such as sales order management, data, contract administration and distribution services, at rates which the Company believes to be consistent with fair market value. The Company has determined such services received to date are not distinct from the Company&#8217;s sale of products to its customers and, therefore, these payments have been recorded as a reduction of revenue within the statement of operations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, the Company offers the specialty distributors product return rights pursuant to written contracts and/or Company returned goods policies. The Company estimates the amount of its product sales that may be returned by its customers and records an estimated liability and a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product returns using industry benchmarking as well as other information available, such as visibility into the inventory remaining in the distribution channel, since the Company does not have its own returns experience. The Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-381-7" continuedAt="f-381-8"><ix:continuation id="f-455-3" continuedAt="f-455-4"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provider Chargebacks and Discounts. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks for fees and discounts to healthcare providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. In such cases, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. The reserve for chargebacks is established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer&#8217;s notification to the Company of the resale. Chargebacks consist of credits the Company expects to issue for units that remain in the distribution channel at each reporting period end that the Company expects will be sold to qualified healthcare providers and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to discount and/or rebate obligations under state Medicaid programs, Medicare and contractual agreements with and statutory obligations to certain Federal and State entities. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. The Company&#8217;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer discounts are recorded as a reduction of accounts receivable on the consolidated balance sheets. Allowance for product returns, provider chargebacks, government and other rebates and service fees are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract manufacturing revenue</span></div></ix:continuation><div style="text-indent:36pt"><ix:continuation id="f-455-4"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements with third parties to manufacture their drug substance at its Good Manufacturing Practice (GMP) facility. The terms of these arrangements can include an upfront payment to the Company to reserve manufacturing capacity, scheduled payments during the manufacturing process and reimbursement for materials used to manufacture product.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue over time on a straight-line basis as the manufacturing services are performed, as the Company believes that its efforts in providing the manufacturing services are incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product are allocated to the related manufacturing activities and are recognized as revenue as those activities occur.</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CostOfSalesPolicyTextBlock" id="f-456" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cost of Product Sales</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the sale to TerSera, cost of product sales related to sales of MARGENZA. These costs include material, manufacturing and shipping costs, as well as royalties payable on net sales of MARGENZA and inventory reserves. All product costs incurred prior to FDA approval of MARGENZA in December 2020 were expensed as research and development expense. As a result, cost of product sales was positively impacted as the Company sold through inventory that was expensed prior to FDA approval of MARGENZA. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Manufacturing Services</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of manufacturing services consists of the costs to provide manufacturing services to produce certain bulk drug substance under manufacturing and clinical supply agreements with third parties, including salaries and benefits and related stock-based compensation, materials, overhead and other related costs.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-457" continuedAt="f-457-1" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense, Including Clinical Trial Accruals/Expenses</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations (CROs), investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials, including costs incurred under agreements with contract manufacturing organizations (CMOs), and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities. Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-381-8" continuedAt="f-381-9"><ix:continuation id="f-457-1"><div style="margin-bottom:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expenses are a significant component of research and development expense, and the Company outsources a significant portion of these costs to third parties. Third party clinical trial expenses include investigator fees, site and patient costs, CRO costs, costs for central laboratory testing, data management and CMO costs. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as a prepaid asset or accrued expenses. These third party agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> When evaluating the adequacy of the accrued expenses, management analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-458" continuedAt="f-458-1" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:36pt"><ix:continuation id="f-458-1" continuedAt="f-458-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement is or contains a lease at the inception of an arrangement under ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-458-2">. For leases where the Company is the lessee, right-of-use (ROU) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term of the lease for which the rate is estimated. Certain adjustments to the ROU asset may be required for items such as initial direct costs paid or incentives received. The lease terms used to calculate the ROU asset and related lease liabilities include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while the expense for finance leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-459" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale debt securities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-460" continuedAt="f-460-1" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-460-1">Basic and diluted loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. All stock options and restricted stock units (RSUs) are excluded from the per share calculations as such securities were anti-dilutive for all periods presented.</ix:continuation> <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-461" continuedAt="f-461-1" escape="true">The following table presents the number of stock options and RSUs that were excluded from the calculation of net loss per share:</ix:nonNumeric></span><ix:continuation id="f-461-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:44.036%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.380%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and RSUs</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-109" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-462">14,008,511</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-110" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-463">13,129,251</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-111" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-464">10,514,013</ix:nonFraction></span></td></tr></table></ix:continuation></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-465" continuedAt="f-465-1" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued Accounting Standards Update (ASU) No. 2024-03, Disaggregation of Income Statement Expense. The standard requires further disaggregation of relevant expense captions in a separate note to the financial statements. The standard is effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is currently assessing the impact of adopting this guidance on its consolidated financial statements.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740). The standard requires disaggregation of the effective rate reconciliation into standard categories, enhances disclosure of income taxes paid, and modifies other income tax-related disclosures. The standard is effective for fiscal years beginning after December 15, 2024. The Company is currently assessing the impact of adopting this guidance on its consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="f-465-1"><ix:continuation id="f-381-9"><div><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which is intended to improve reportable segment disclosures, primarily through enhanced disclosures about significant segment expenses, as well as how the chief operating decision maker (CODM) uses the reported measure(s) of segment profit or loss in assessing performance. The ASU also requires all annual disclosures currently required by Topic 280 to be included in interim periods. The Company adopted the standard in the fourth quarter of 2024. The adoption did not have a material impact on its consolidated financial statements. See Note 13, Segment Reporting, for additional information.</span></div></ix:continuation></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="ib90895a7822448df9e5a179143ce4792_148"></div><div style="margin-bottom:9pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="f-466" continuedAt="f-466-1" escape="true">Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="f-466-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="f-467" escape="true"><div style="margin-bottom:9pt;text-indent:31.5pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities as of December&#160;31, 2024 and 2023 were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:49.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-468">1,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-469">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-470">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-471">1,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-472">16,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-473">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-474">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-475">16,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-476">18,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-477">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-478">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-479">18,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:49.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-480">31,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-481">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-482">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-483">31,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-484">45,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-485">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-486">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-487">45,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-488">52,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-489">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-490">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-491">52,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-492">128,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-493">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-494">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-495">128,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's available-for-sale securities held at December&#160;31, 2024 and 2023 had contractual maturities of less than one year. All of the Company&#8217;s available-for-sale marketable debt securities in an unrealized loss position as of December&#160;31, 2023 were in a loss position for less than twelve months.&#160;Unrealized losses on available-for-sale debt securities as of December&#160;31, 2023 </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were not </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities. Accordingly, <ix:nonFraction unitRef="usd" contextRef="c-12" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt-sec:numwordsen" scale="0" id="f-496"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt-sec:numwordsen" scale="0" id="f-497">no</ix:nonFraction></ix:nonFraction> allowance for credit losses related to the Company's available-for-sale debt securities was recorded for the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded interest income of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InterestIncomeOther" scale="6" id="f-498">5.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:InterestIncomeOther" scale="6" id="f-499">4.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:InterestIncomeOther" scale="6" id="f-500">1.7</ix:nonFraction> million during the years ended December&#160;31, 2024, 2023 and 2022, respectively, which is included in interest and other income on the consolidated statements of operations and comprehensive loss.</span></div></ix:continuation><div id="ib90895a7822448df9e5a179143ce4792_151"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryDisclosureTextBlock" id="f-501" continuedAt="f-501-1" escape="true">Inventory, Net</ix:nonNumeric></span></div><ix:continuation id="f-501-1" continuedAt="f-501-2"><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's inventory relates to the manufacturing of MARGENZA. In November 2024, the Company sold global rights to MARGENZA to TerSera. As part of this transaction, the Company transferred all its inventory to TerSera, resulting in <ix:nonFraction unitRef="usd" contextRef="c-11" decimals="INF" name="us-gaap:InventoryNet" format="ixt-sec:numwordsen" id="f-502">no</ix:nonFraction> inventory balance on the Company&#8217;s consolidated balance sheet as of December 31, 2024. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-503" continuedAt="f-503-1" escape="true">The following table sets forth the Company's inventory as of December 31, 2023, net of reserves (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-503-1"><div style="margin-top:9pt;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"><tr><td style="width:1.0%"/><td style="width:76.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.487%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.066%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:InventoryWorkInProcess" scale="3" id="f-504">261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:InventoryFinishedGoods" scale="3" id="f-505">960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-506">1,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:31.5pt"><span><br/></span></div><ix:continuation id="f-501-2"><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to FDA approval of MARGENZA in December 2020, the cost of materials and expenses associated with the manufacturing of MARGENZA were recorded as research and development expense. Subsequent to FDA approval, the Company began capitalizing inventory costs related to the manufacture of MARGENZA. The inventory balance as of December&#160;31, 2023 is net of a reserve of $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:InventoryValuationReserves" scale="6" id="f-507">3.1</ix:nonFraction> million, for unsaleable inventory. These reserves are reflected in cost of product sales during the period they are recorded.   </span></div><div style="margin-top:3pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="mgnx:ScheduleOfInventoryReservesTableTextBlock" id="f-508" escape="true"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.952%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inventory Reserves (in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at Beginning of Year</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions Charged to Expenses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at End of Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December&#160;31, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-509">3,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:fixed-zero" scale="3" id="f-510">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="f-511">3,119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:fixed-zero" scale="3" id="f-512">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-513">4,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:fixed-zero" scale="3" id="f-514">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="f-515">1,798</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-516">3,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-517">2,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="f-518">2,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:fixed-zero" scale="3" id="f-519">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-520">4,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:3pt"><span><br/></span></div><div id="ib90895a7822448df9e5a179143ce4792_154"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-521" continuedAt="f-521-1" escape="true">Property, Equipment and Software</ix:nonNumeric></span></div><ix:continuation id="f-521-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-522" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment and software consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-523">3,661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-524">3,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-525">10,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-526">9,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-527">697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-528">706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Motor vehicles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-529">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-530">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-531">46,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-532">46,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-533">44,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-534">48,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="3" id="f-535">1,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="3" id="f-536">1,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-537">106,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-538">110,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-539">88,687</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-540">88,394</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-541">18,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-542">21,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense related to property, equipment and software for the years ended December&#160;31, 2024, 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-543">7.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-544">9.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-545">11.9</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="ib90895a7822448df9e5a179143ce4792_157"></div><div style="margin-bottom:9pt;margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-546" continuedAt="f-546-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span><ix:continuation id="f-546-1" continuedAt="f-546-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></ix:continuation></div><ix:continuation id="f-546-2" continuedAt="f-546-3"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has non-cancelable operating leases for manufacturing, laboratory, office and warehouse space in Maryland. The Company&#8217;s leases each have one or more <ix:nonNumeric contextRef="c-134" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-547">five-year</ix:nonNumeric> options to renew</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In October 2024, the Company amended the existing lease for one of its laboratory spaces to extend the lease term through 2029 in exchange for certain concessions from the lessor. This amendment was accounted for as a lease modification, and the right-of-use asset and lease liability were remeasured at the modification date, resulting in an increase to both balances of approximately $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="mgnx:RightOfUseAssetAndLeaseLiabilityIncrease" scale="6" id="f-548">3.0</ix:nonFraction> million.</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="c-1" name="mgnx:ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock" id="f-549" continuedAt="f-549-1" escape="true"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents supplemental balance sheet information related to operating leases:</span></div></ix:nonNumeric><div><ix:continuation id="f-549-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.013%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-11" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-550">10.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-12" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-551">11.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-11" decimals="3" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="f-552">12.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="f-553">12.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-546-3" continuedAt="f-546-4"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2024 and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2023, t</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company made cash payments for operating leases of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="f-554">3.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="f-555">5.9</ix:nonFraction> million, respectively. As of December&#160;31, 2024 and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2023,</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company&#8217;s ROU assets were valued at $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="f-556">24.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="f-557">23.8</ix:nonFraction> million, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-558" escape="true"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost for the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2023 were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.225%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.946%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.948%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease cost</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-559">6,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-560">7,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-561">1,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-562">1,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sublease income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="3" id="f-563">1,145</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="3" id="f-564">1,109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-565">6,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-566">7,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-567" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the maturities of the Company&#8217;s operating lease liabilities were as follows (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.327%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-568">5,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-569">5,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-570">6,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-571">7,413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="f-572">6,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-573">39,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-574">70,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-575">33,021</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-576">37,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-licensing arrangement</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company entered into a non-exclusive license agreement with Synaffix B.V., a Lonza company, (Synaffix) to develop, manufacture and commercialize up to three antibody-drug conjugate targets using Synaffix&#8217;s proprietary technology. The Company made an upfront payment to Synaffix upon contract execution. In March 2023, the Company and Synaffix amended the agreement, adding four additional targets. Assuming all seven targets are successfully developed and commercialized, the Company would be obligated to pay up to $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" format="ixt:num-dot-decimal" scale="9" id="f-577">2.8</ix:nonFraction>&#160;billion for development, regulatory and sales milestones. Finally, pursuant to the terms of this license agreement, as amended, upon commencement of commercial sales of any products developed from these targets, the Company would be required to pay Synaffix tiered royalties in the low&#8209;single digit percentages on net sales of the respective products. The Company may terminate this agreement at any time with 30 days&#8217; notice to Synaffix. Amounts paid to Synaffix under this agreement are recorded as research and development expense in the consolidated statement of operations. The Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-578">4.7</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-579">2.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-580">1.0</ix:nonFraction> million in expense under this agreement during the years ended December&#160;31, 2024, 2023 and 2022, respectively. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Litigation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2024, a putative securities class action suit, entitled Crain v. MacroGenics, Inc. (Case No. 24-cv-02184), was filed in the U.S. District Court for the District of Maryland against the Company and Scott Koenig, M.D., Ph.D., the Company&#8217;s President, Chief Executive Officer and a member of the Company&#8217;s Board of Directors, alleging violations of securities laws during 2024. The suit asserted certain claims under Section 10 and Rule 10b-5 of the Securities and Exchange Act of 1934 based on alleged misstatements or omissions concerning the Company's TAMARACK Phase 2 study of vobramitamab duocarmazine in patients with metastatic castration-resistant prostate cancer. On December 20, 2024, the District Court issued an Order dismissing the case, without prejudice.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 9, 2024, a shareholder derivative suit, entitled Gregora v. Heiden et al. (Case No. 24-cv-03546), was filed in the U.S. District Court for the District of Maryland against certain of the Company&#8217;s officers and directors and naming the Company as a nominal defendant. The suit asserts certain claims under Section 10(b) and Rule 10b-5 of the Securities and Exchange Act of 1934 and for breach of fiduciary duty, aiding and abetting breach of fiduciary duty, unjust enrichment, and waste of corporate assets based on the same facts as the Securities Class Action. On March 10, 2025, the plaintiff filed a notice of voluntary dismissal. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="f-546-4"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 11, 2024, a shareholder derivative suit, entitled Cottle v. MacroGenics, Inc., et al. (Case No. 8:24-cv-03578), was filed in the U.S. District Court for the District of Maryland against the same defendants and alleging similar claims as the Gregora derivative action. On March 20, 2025, the parties filed a stipulation of dismissal without prejudice.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="ib90895a7822448df9e5a179143ce4792_163"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-581" continuedAt="f-581-1" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><ix:continuation id="f-581-1" continuedAt="f-581-2"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's amended and restated certificate of incorporation authorizes <ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-582">125,000,000</ix:nonFraction> shares of common stock, and <ix:nonFraction unitRef="shares" contextRef="c-139" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-583">5,000,000</ix:nonFraction> shares of undesignated preferred stock, both with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-139" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-584"><ix:nonFraction unitRef="usdPerShare" contextRef="c-140" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-585">0.01</ix:nonFraction></ix:nonFraction> per share.&#160;There were <ix:nonFraction unitRef="shares" contextRef="c-139" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-586"><ix:nonFraction unitRef="shares" contextRef="c-139" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-587"><ix:nonFraction unitRef="shares" contextRef="c-140" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-588"><ix:nonFraction unitRef="shares" contextRef="c-140" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-589">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares of undesignated preferred stock issued or outstanding as of December&#160;31, 2024 or 2023. </span></div></ix:continuation><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-581-2">In March 2023, the Company entered into a sales agreement with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-5" name="mgnx:CommonStockMaximumAmountAvailableForIssuance" format="ixt:num-dot-decimal" scale="6" id="f-590">100.0</ix:nonFraction>&#160;million through an &#8220;at the market offering&#8221; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended. During the year ended December 31, 2023, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-142" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-591">95,000</ix:nonFraction> shares of common stock at a weighted average price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-143" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-592">6.60</ix:nonFraction>, resulting in net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-593">0.6</ix:nonFraction>&#160;million, net of offering expenses. <ix:nonFraction unitRef="shares" contextRef="c-144" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt-sec:numwordsen" id="f-594">No</ix:nonFraction> shares were sold under the ATM offering during the year ended December 31, 2024.</ix:continuation> </span></div><div id="ib90895a7822448df9e5a179143ce4792_166"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock" id="f-595" continuedAt="f-595-1" escape="true">Revenue</ix:nonNumeric></span></div><ix:continuation id="f-595-1" continuedAt="f-595-2"><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborative and Other Agreements </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incyte Corporation</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incyte License Agreement</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte, which was amended in March 2018, April 2022, July 2022, and July 2024, for retifanlimab, an investigational monoclonal antibody that inhibits PD-1 (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while the Company retains the right to develop its pipeline assets in combination with retifanlimab. Under the terms of the Incyte License Agreement, Incyte paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="mgnx:NonRefundableUpfrontFees" scale="6" id="f-596">150.0</ix:nonFraction> million in 2017. The Company manufactures a portion of Incyte&#8217;s global commercial supply of retifanlimab. In March 2023, the FDA approved Incyte's Biologics License Application (BLA) for ZYNYZ (retifanlimab-dlwr) for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma. Incyte has stated it is pursuing development of retifanlimab in potentially registration-enabling studies, including in patients with squamous cell carcinoma of the anal canal, MSI-high endometrial cancer and non-small cell lung cancer. Incyte is also pursuing development of retifanlimab in combination with multiple product candidates from its pipeline.  </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Incyte License Agreement, as amended, Incyte will lead global development of retifanlimab. From the inception of the Incyte License Agreement through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has recognized $<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="f-597">215.0</ix:nonFraction> million for certain development and regulatory milestones under the Incyte License Agreement, including $<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-598">15.0</ix:nonFraction> million received following the FDA approval of ZYNYZ and $<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-599">100.0</ix:nonFraction>&#160;million received in August 2024 upon entering into an amendment to the Incyte License Agreement pursuant to which certain development milestones were deemed to have been met. Assuming successful development and commercialization by Incyte in multiple indications, the Company is eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" scale="6" id="f-600">210.0</ix:nonFraction> million in development and regulatory milestones, and up to $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" scale="6" id="f-601">330.0</ix:nonFraction> million in commercial milestones. The Company is also eligible to receive tiered royalties of <ix:nonFraction unitRef="number" contextRef="c-150" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="f-602">15</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-151" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="f-603">24</ix:nonFraction>% on global net sales. The Company retains the right to develop its pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of retifanlimab, subject to the separate commercial supply agreement.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="margin-bottom:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Incyte License Agreement under the provisions of ASC 606 at inception and identified the following <ix:nonFraction unitRef="performanceobligation" contextRef="c-152" decimals="INF" name="mgnx:NumberOfPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="f-604">two</ix:nonFraction> performance obligations under the agreement: (i) the license of retifanlimab and (ii) the performance of certain clinical activities through a brief technology transfer period. The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company performed the activities during the transfer period as a matter of convenience. The Company determined that the transaction price of the Incyte License Agreement at inception was $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="mgnx:CollaborativeAgreementTransactionPrice" scale="6" id="f-605">154.0</ix:nonFraction> million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-595-2" continuedAt="f-595-3"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The standalone selling price for the agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. The potential development and regulatory milestone payments are </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. In July 2024, the Company and Incyte executed Amendment No. 4 to the Incyte License Agreement pursuant to which certain development milestones were deemed to have been met. The Company evaluated the amendment as a contract modification under the provisions of ASC 606 which resulted in $<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-606">100.0</ix:nonFraction>&#160;million of revenue being recognized during the year ended December&#160;31, 2024. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From 2018 through December&#160;31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">it became probable that a significant reversal of cumulative revenue would not occur for development milestones totaling </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="f-607">215.0</ix:nonFraction> million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to clinical and regulatory activities related to the further advancement of retifanlimab. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therefore</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the associated consideration was added to the estimated transaction price and was recognized as revenue. </span></div><div style="text-indent:42pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-608">150.0</ix:nonFraction> million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> allocated to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license when it satisfied its performance obligation and transferred the license to Incyte in 2017. The $<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" scale="6" id="f-609">4.0</ix:nonFraction> million allocated to the clinical activities was recognized ratably as services were performed during 2017 and 2018. The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-610">100.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-611">15.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-612">30.0</ix:nonFraction> million under the Incyte License Agreement during the years ended December&#160;31, 2024, 2023 and 2022, respectively. The revenue is primarily related to development milestones and includes royalties on ZYNYZ sales beginning in late 2023.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incyte Clinical Supply Agreement</span></div><div style="text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into an agreement with Incyte, under which the Company is to perform development and manufacturing services for Incyte&#8217;s clinical needs of retifanlimab (Incyte Clinical Supply Agreement). The Company evaluated the Incyte Clinical Supply Agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of retifanlimab. The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services. During the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 2023 and 2022, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-613">0.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-614">1.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-615">0.7</ix:nonFraction> million, respectively, for services performed under the Incyte Clinical Supply Agreement. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incyte Commercial Supply Agreement</span></div><div style="text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company entered into an agreement with Incyte pursuant to which the Company is entitled to manufacture a portion of the global commercial supply needs for retifanlimab (Incyte Commercial Supply Agreement). Unless terminated earlier, the term of the Incyte Commercial Supply Agreement will expire upon the expiration of Incyte&#8217;s obligation to pay royalties under the Incyte License Agreement. The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to manufacturing the commercial supply of retifanlimab. The transaction price is based on a fixed price per batch of bulk drug substance to be manufactured and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor costs incurred) related to the manufacturing services. During the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023, and 2022, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-616">1.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-617">4.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-618">0.3</ix:nonFraction>&#160;million, respectively, for services performed under the Incyte Commercial Supply Agreement. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Gilead Sciences, Inc. </span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the Company and Gilead entered into an exclusive option and collaboration agreement (Gilead Agreement) to develop and commercialize MGD024, an investigational, bispecific antibody that binds CD123 and CD3, and create bispecific cancer antibodies using the Company&#8217;s DART platform and undertake their early development under a maximum of two separate bispecific cancer target research programs. Under the agreement, the Company will continue the ongoing phase 1 trial for MGD024 accordi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ng to a development plan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, during which Gilead will have the right to exercise an option granted to Gilead to obtain an exclusive license under the Company&#8217;s intellectual property to develop and commercialize MGD024 and other </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-595-3" continuedAt="f-595-4"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bispecific antibodies of MacroGenics that bind CD123 and CD3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CD123 Option). The agreement also granted Gilead the right, within its first two years, to nominate a bispecific cancer target set for up to two research programs conducted by the Company and to exercise separate options to obtain an exclusive license for the development, commercialization and exploitation of molecules created under each research program (Research Program Option). Gilead nominated the first of the two research programs in September 2023. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2024, the parties amended the Gilead Agreement to revise certain matters related to intellectual property in the performance of the research plans under the agreement. On August 30, 2024, the parties amended the agreement by entering into a second letter agreement under which Gilead will pay the Company to conduct certain research and which extends the period for Gilead to select its second research target combination.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Gilead Agreement, as amended, in October 2022 Gilead paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="f-619">60.0</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming Gilead exercises the CD123 Option and Research Program Option and successfully develops and commercializes MGD024, or other CD123 products developed under the agreement, and products result from the two additional research programs, the Company would be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-5" name="mgnx:PotentialTargetNominationOptionFeesAndMilestonePayments" scale="9" id="f-620">1.7</ix:nonFraction> billion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in target nomination, option fees, and development, regulatory and commercial milestones. Assuming exercise of the CD123 Option, the Company will also be eligible to receive tiered, low double-digit royalties on worldwide net sales of MGD024 (or other CD123 products developed under the agreement) and assuming exercise of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research Program Option,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a flat royalty on worldwide net sales of any products resulting from the two research programs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Gilead Agreement under the provisions of ASC 606 and identified the following material promises under the agreement: (i) a license to perform any activities allocated to Gilead under the MGD024 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development plan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; (ii) development activities regarding MGD024, including manufacturing, research and early clinical development activities, necessary to deliver an informational package of development and clinical data, information and materials specified in the Gilead Agreement during the period </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which Gilead can exercise the CD123 Option; (iii) the CD123 Option and (iv) the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research Program Option</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the license under the MGD024 developme</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nt plan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and development activities are not distinct from one another, as the license has limited value without the Company&#8217;s performance of the development activities. Therefore, the Company determined that the development term license and development activities should be combined into a single performance obligation (Development Activities). The CD123 Option is considered a material right as the value of the exclusive license exceeds the payment to be made by Gilead if they exercise their option to obtain an exclusive license to develop and commercialize MGD024 or an alternative CD123 product, and is therefore a distinct performance obligation. The Company determined that the Research Program Option does not provide a material right, as there is no discount on its standalone selling price.</span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, the Company determined that the initial transaction price under the Gilead Agreement was $<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="f-621">60.0</ix:nonFraction>&#160;million, consisting of the upfront, non-refundable payment paid by Gilead. The CD123 Option and Research Program Option payments are excluded from the initial transaction price at contract inception along with any future development, regulatory, and commercial milestone payments (including royalties) following the CD123 Option and Research Program Option exercise.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company reassesses the amount of variable consideration included in the transaction price every reporting period.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:13.5pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated the $<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="f-622">60.0</ix:nonFraction>&#160;million upfront payment in the transaction price to the Development Activities and the CD123 Option based on each performance obligation&#8217;s relative standalone selling price. The standalone selling price for the Development Activities was calculated using an expected cost-plus margin approach </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the pre-option development timeline.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the standalone selling price of the CD123 Option, the Company utilized an income-based approach which included the following key assumptions:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">post-option development timeline and costs, forecasted revenues, discount rates and probabilities of technical and regulatory success. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is recognizing revenue related to the Development Activities performance obligation over the estimated period to complete the Development Activities using an input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the Development Activities. The Company has deferred revenue recognition related to the CD123 Option. If Gilead exercises the CD123 Option and obtains an exclusive license, the Company will recognize revenue as it fulfills its obligations under the Gilead Agreement. If the CD123 Option is not exercised, the Company will recognize the entirety of the revenue in the period when the CD123 Option expires.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 2023, and 2022, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company recorded revenue of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-623">1.5</ix:nonFraction>&#160;million,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-624">1.5</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-625">0.2</ix:nonFraction>&#160;million, respectively, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to the Gilead Agreement. As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-626">56.8</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in revenue was deferred under this agreement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-627">1.3</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was current and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-628">55.5</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was non-current. As of December&#160;31, 2023, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-629">58.3</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in revenue was deferred under this agreement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-630">2.2</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was current and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-631">56.1</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was non-current.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-595-4" continuedAt="f-595-5"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company and Gilead executed a Letter Agreement through which Gilead nominated the first of the two research programs contemplated in the Gilead Agreement (First Research Program), the Company granted Gilead a research license, and the parties agreed on a research plan for the First Research Program under which the Company will provide research and development services. Gilead paid the Company a $<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="f-632">15.7</ix:nonFraction>&#160;million nomination fee. The Company evaluated the Letter Agreement under the terms of ASC 606, and concluded that it is a modification to the Gilead Agreement that results in a separate contract since the modification is for additional goods and services that are distinct and at standalone selling price. The Company determined that the license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that these should be combined into a single performance obligation. Gilead also has the exclusive option to pay the Company $<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="mgnx:OptionToBuy" format="ixt:num-dot-decimal" scale="6" id="f-633">10.0</ix:nonFraction>&#160;million to obtain a license to exploit the research molecule and research product with respect to the First Research Program. The Company determined that this exclusive option does not provide a material right, as there is no discount on its standalone selling price.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, the Company determined that the initial transaction price for the First Research Program agreement was $<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="f-634">15.7</ix:nonFraction>&#160;million, consisting of the non-refundable payment paid by Gilead. The Company is recognizing revenue over the estimated period to complete the services using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the research and development services. In June 2024, the Company received variable consideration totaling $<ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="f-635">3.3</ix:nonFraction>&#160;million from Gilead upon achievement of a research plan milestone. The variable consideration was added to the transaction price and allocated to the performance obligation to determine the amount of related revenue to be recognized. A proportional amount was recognized based on the input cost to cost measurement of work completed to date.   </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023, the Company recorded revenue of $<ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-636">7.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-637">0.8</ix:nonFraction>&#160;million, respectively, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to the First Research Program. As of December&#160;31, 2024, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-638">11.0</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in revenue was deferred under this agreement, all of which was current</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of December&#160;31, 2023, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-639">14.9</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in revenue was deferred under this agreement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-640">11.8</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was current and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-641">3.1</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was non-current.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zai Lab US LLC</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the Company entered into a collaboration and license agreement with Zai Lab US LLC (Zai Lab Limited and Zai Lab US LLC, either singularly or collectively are referred to herein as Zai Lab) involving collaboration programs and license-only programs (collectively, the Programs) encompassing four separate immuno-oncology molecules (2021 Zai Lab Agreement). During 2022, the Company and Zai Lab agreed to discontinue research and development of the lead program, and in August 2023, the parties mutually agreed to terminate the 2021 Zai Lab Agreement. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the Company received $<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-642">7.0</ix:nonFraction>&#160;million from Zai Lab in fulfillment of a milestone. This was recognized as revenue for the year ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, <ix:nonFraction unitRef="usd" contextRef="c-178" decimals="INF" name="us-gaap:Revenues" format="ixt-sec:numwordsen" id="f-643">no</ix:nonFraction> revenue was recognized under the 2021 Zai Lab Agreement and during the year ended December 31, 2022, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-644">16.8</ix:nonFraction> million under the 2021 Zai Lab Agreement. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provention Bio, Inc.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into a license agreement with Provention pursuant to which the Company granted Provention exclusive global rights for the purpose of developing and commercializing MGD010 (renamed PRV-3279), a CD32B x CD79B DART molecule being developed for the treatment of autoimmune indications (Provention License Agreement). As partial consideration for the Provention License Agreement, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-180" decimals="INF" name="mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" scale="0" id="f-645">2.50</ix:nonFraction> per share. If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-3279, the Company will be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" scale="6" id="f-646">65.0</ix:nonFraction> million in development and regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" scale="6" id="f-647">225.0</ix:nonFraction> million in commercial milestones. As of December&#160;31, 2024, the Company has not recognized any milestone revenue under this agreement. If commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product. The license agreement may be terminated by either party upon a material breach or bankruptcy of the other party, by Provention without cause upon prior notice to the Company, and by the Company in the event that Provention challenges the validity of any licensed patent under the agreement, but only with respect to the challenged patent.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, in 2018, the Company entered into the Provention Asset Purchase Agreement (Provention APA) pursuant to which Provention acquired the Company&#8217;s interest in teplizumab (renamed PRV-031), a monoclonal antibody being developed for the treatment of type 1 diabetes. As partial consideration for the Provention APA, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-182" decimals="INF" name="mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" scale="0" id="f-648">2.50</ix:nonFraction> per share. Under the Provention APA, Provention is obligated to pay the Company contingent milestone payments totaling $<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" scale="6" id="f-649">170.0</ix:nonFraction> million upon the achievement of certain regulatory milestones. In addition, Provention is obligated to make contingent milestone payments to the Company </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-595-5" continuedAt="f-595-6"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">totaling $<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" scale="6" id="f-650">225.0</ix:nonFraction> million upon the achievement of certain commercial milestones as well as single-digit royalties on net sales of the product. The FDA approved the BLA for TZIELD in November 2022, and the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="f-651">60.0</ix:nonFraction> million in revenue related to this regulatory milestone during the year ended December 31, 2022. In November 2022, the Company and Provention amended the Provention APA. Under this amendment, the milestone for first approval was split into four equal payments, all of which were received prior to June 30, 2023. Provention has also agreed to pay third-party obligations, including low single-digit royalties, of which a portion is creditable against royalties payable to the Company, aggregate milestone payments of up to approximately $<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="mgnx:PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" scale="6" id="f-652">1.3</ix:nonFraction> million and other consideration, for certain third-party intellectual property under agreements Provention assumed pursuant to the Provention APA. Further, Provention is required to pay the Company a low double-digit percentage of certain consideration to the extent it is received in connection with a future grant of rights to PRV-031 by Provention to a third party.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Provention License Agreement and Provention APA under the provisions of ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: (i) the license of MGD010 and (ii) the title to teplizumab. The Company determined that the transaction price of the Provention agreements was $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" name="mgnx:CollaborativeAgreementTransactionPrice" scale="6" id="f-653">6.1</ix:nonFraction> million, based on the Black-Scholes valuation of the warrants to purchase a total of <ix:nonFraction unitRef="shares" contextRef="c-185" decimals="INF" name="mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="f-654">2,432,688</ix:nonFraction> shares of Provention's common stock. The transaction price was allocated to each performance obligation based on the number of shares of common stock the Company is entitled to purchase under each warrant. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such were excluded from the initial transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, therefore they have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-655">6.1</ix:nonFraction> million when it satisfied its performance obligations under the agreements and transferred the MGD010 license and teplizumab assets to Provention in 2018. In 2019, the Company exercised the warrants on a cashless basis, and subsequently sold all the shares of Provention common stock acquired through the exercise. No shares of Provention stock were held subsequent to the sale of stock in 2019. During the year ended December 31, 2022, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">it became probable that a significant reversal of cumulative revenue would not occur for a regulatory milestone of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="f-656">60.0</ix:nonFraction> million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">herefore</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the associated consideration was added to the estimated transaction price and was recognized as revenue. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2024, <ix:nonFraction unitRef="usd" contextRef="c-187" decimals="INF" name="us-gaap:Revenues" format="ixt-sec:numwordsen" id="f-657">no</ix:nonFraction> revenue was recognized under these agreements. During the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-658">5.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-659">60.0</ix:nonFraction> million, respectively, under these agreements.   </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the Company sold its single-digit royalty interest in TZIELD to a wholly-owned subsidiary of DRI Healthcare Trust (DRI) and received a $<ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-5" name="mgnx:UpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="f-660">100.0</ix:nonFraction>&#160;million payment from DRI under a Royalty Purchase Agreement. The Company retains its other economic interests related to TZIELD, including future potential regulatory and commercial milestones, as well as the right to receive a <ix:nonFraction unitRef="number" contextRef="c-191" decimals="3" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="f-661">50</ix:nonFraction>% share of the royalty on global net sales above a certain annual threshold. In addition, the Company received $<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-5" name="mgnx:GainOnRoyaltyMonetizationArrangement" format="ixt:num-dot-decimal" scale="6" id="f-662">50.0</ix:nonFraction>&#160;million upon the occurrence of the primary endpoint milestone event in September 2023, and remains eligible to receive an additional $<ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-5" name="mgnx:AdditionalTZIELDMilestones" format="ixt:num-dot-decimal" scale="6" id="f-663">50.0</ix:nonFraction>&#160;million if TZIELD achieves a certain level of net sales.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 27, 2023, Sanofi S.A. (Sanofi) completed its acquisition of Provention and the Company entered into a Tripartite Agreement. Also on April 27, 2023, the Company and a subsidiary of Sanofi entered into a Side Letter Agreement which specified certain post-closing covenants and also accelerated certain payments due to the Company under the Provention APA upon the closing of the merger between Sanofi and Provention. The Company evaluated the Side Letter Agreement as a contract modification under the provisions of ASC 606. As a result, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December 31, 2023</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-664">5.5</ix:nonFraction>&#160;million related to other consideration under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provention APA</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Side Letter Agreement. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-665">0.3</ix:nonFraction>&#160;million in royalty revenue under the Provention APA based on sales of TZIELD. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, the Company and Sanofi executed Amendment No. 2 to the Provention APA and terminated the Royalty Purchase Agreement with DRI. As a result, the remaining $<ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-5" name="mgnx:AdditionalTZIELDMilestones" format="ixt:num-dot-decimal" scale="6" id="f-666">50.0</ix:nonFraction>&#160;million milestone under the Royalty Purchase Agreement was incorporated into the Provention APA. The Company evaluated the amendment as a contract modification under the provisions of ASC 606 which did not result in any additional revenue being recognized during the year ended December 31, 2023. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing Services Agreements</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incyte </span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company entered into a Manufacturing and Clinical Supply Agreement with Incyte (Incyte Manufacturing and Clinical Supply Agreement) to provide manufacturing services to produce certain Incyte bulk drug </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-595-6"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">substance over a <ix:nonNumeric contextRef="c-196" name="mgnx:CollaborativeArrangementTerm" format="ixt-sec:durwordsen" id="f-667">three years</ix:nonNumeric> period. Under the terms of the Incyte Manufacturing and Clinical Supply Agreement, the Company received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="f-668">10.0</ix:nonFraction>&#160;million and was eligible to receive annual fixed payments paid quarterly over the term of the contract totaling $<ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-5" name="mgnx:TotalFixedPayments" format="ixt:num-dot-decimal" scale="6" id="f-669">14.4</ix:nonFraction>&#160;million. The Company will also be reimbursed for materials used to manufacture product as well as other costs incurred to provide manufacturing services. In July 2022, the Company and Incyte executed an amendment to the Incyte Manufacturing and Clinical Supply Agreement which extended the term for <ix:nonNumeric contextRef="c-196" name="mgnx:CollaborativeArrangementExtensionTerm" format="ixt-sec:durwordsen" id="f-670">one year</ix:nonNumeric> and provided for an additional annual fixed payment of $<ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-5" name="mgnx:AdditionalAnnualFixedPayments" format="ixt:num-dot-decimal" scale="6" id="f-671">5.1</ix:nonFraction>&#160;million (July 2022 Incyte Amendment). In December 2024, the Company and Incyte entered into a letter agreement whereby Incyte reserved additional manufacturing services with a fixed cost of $<ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-5" name="mgnx:FutureManufacturingRevenue" format="ixt:num-dot-decimal" scale="6" id="f-672">9.1</ix:nonFraction>&#160;million (December 2024 Letter Agreement). </span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Incyte Manufacturing and Clinical Supply Agreement, the July 2022 Incyte Amendment and the December 2024 Letter Agreement under the provisions of ASC 606 and identified one performance obligation to provide manufacturing runs to Incyte, as and when requested by Incyte, over the term of the contract that is part of a series of goods and services. The Company determined that the transaction price consisted of the upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-5" name="mgnx:NonRefundableUpfrontFees" format="ixt:num-dot-decimal" scale="6" id="f-673">10.0</ix:nonFraction>&#160;million and the fixed payments totaling $<ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-5" name="mgnx:TotalFixedPayments" format="ixt:num-dot-decimal" scale="6" id="f-674">28.6</ix:nonFraction>&#160;million. The Company is recognizing revenue over time on a straight-line basis as the manufacturing services are provided to Incyte, as the Company determined that its efforts in providing the manufacturing services will be incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product for Incyte will be allocated to the related manufacturing activities and will be recognized as revenue as those activities occur. Materials purchased by the Company to manufacture the product for Incyte are considered costs to fulfill a contract and will be capitalized and expensed as the materials are used to provide the manufacturing services.  </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2024, 2023, and 2022, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-675">11.0</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-676">9.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-677">8.7</ix:nonFraction>&#160;million, respectively, under the Incyte Manufacturing and Clinical Supply Agreement. As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-678">3.4</ix:nonFraction>&#160;million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in revenue was deferred under this agreement, all of which was current. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-679">7.0</ix:nonFraction>&#160;million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in revenue was deferred under this agreement, all of which was current.</span></div><div style="margin-bottom:9pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales, Net</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales, net reflected sales of MARGENZA until the Company sold global rights to MARGENZA to TerSera in November 2024. Prior to the sale to TerSera, product revenue was recorded net of applicable reserves for variable consideration, including discounts and other allowances. The Company entered into a limited number of arrangements with specialty distributors in the United States to distribute MARGENZA. The delivery of the product represented a single performance obligation for these transactions and the Company recorded net product revenue when control was transferred to the customer, generally upon receipt by the customer. The transaction price for net product revenue represented the amount the Company expected to receive, which was net of estimated government-mandated rebates and chargebacks, distribution fees, estimated product returns, and other deductions. Accruals were established for these deductions, and actual amounts incurred were offset against applicable accruals. The Company recognized net product sales revenue of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-680">16.4</ix:nonFraction>&#160;million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-681">17.9</ix:nonFraction>&#160;million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-682">16.7</ix:nonFraction>&#160;million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the years ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024, 2023 and 2022, respectively.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the sale of MARGENZA, the Company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">paid an $<ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-5" name="mgnx:AmendmentFeeToCommercializationPartner" format="ixt:num-dot-decimal" scale="6" id="f-683">8.0</ix:nonFraction>&#160;million amendment fee to Eversana Life Sciences Services, LLC (Eversana), a former partner that had previously commercialized MARGENZA, which was recorded as selling, general and administrative expense in the consolidated statement of operations. </span></div><div style="margin-bottom:6pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NIAID Contract</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a contract with the National Institute of Allergy and Infectious Diseases (NIAID), effective as of September 15, 2015,&#160;to perform product development and to advance up to <ix:nonFraction unitRef="usd" contextRef="c-207" decimals="INF" name="mgnx:NumberOfProductCandidates" format="ixt-sec:numwordsen" scale="0" id="f-684">two</ix:nonFraction> DART molecules, MGD014 and MGD020 (NIAID Contract). Under the NIAID Contract, the Company developed these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID did not receive goods or services from the Company under this contract, therefore the Company did not consider NIAID to be a customer and concluded this contract was outside the scope of ASC 606.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both the Phase 1 study of MGD014 in persons with HIV maintained on antiretroviral therapy and the Phase 1 study of MGD020 alone and combined with MGD014 have been completed and the Company is in the process of closing out the contract. The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-685">1.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-686">1.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-687">1.9</ix:nonFraction> million under the NIAID contract during the years ended December&#160;31, 2024, 2023 and 2022, respectively.</span></div></ix:continuation><div id="ib90895a7822448df9e5a179143ce4792_169"></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-688" continuedAt="f-688-1" escape="true">Stock-based Compensation</ix:nonNumeric></span></div><ix:continuation id="f-688-1" continuedAt="f-688-2"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company&#8217;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended, and is not subject to the provisions of the Employee Retirement Income Security Act of 1974. The Company reserved <ix:nonFraction unitRef="shares" contextRef="c-211" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-689">800,000</ix:nonFraction> shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to <ix:nonFraction unitRef="number" contextRef="c-212" decimals="INF" name="mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="f-690">10</ix:nonFraction>% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for <ix:nonNumeric contextRef="c-213" name="mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" format="ixt-sec:durwordsen" id="f-691">six months</ix:nonNumeric> offering periods ending on May 31 and November 30 of each year. At the end of each offering period, employees are able to purchase shares at <ix:nonFraction unitRef="number" contextRef="c-212" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-692">85</ix:nonFraction>% of the fair market value of the Company&#8217;s common stock on the last day of the offering period. During the year ended December&#160;31, 2024, employees purchased <ix:nonFraction unitRef="shares" contextRef="c-214" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-693">94,619</ix:nonFraction> shares of common stock under the 2016 ESPP for net proceeds to the Company of approximately $<ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-694">0.3</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Incentive Plans</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2013, the Company implemented the 2013 Equity Incentive Plan (2013 Plan).&#160;In May 2023, the 2013 Plan was terminated, and no further awards may be issued under the plan. If an option granted under the 2013 Plan expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares will become available for issuance under the 2023 Equity Incentive Plan (2023 Plan). As of December&#160;31, 2024, under the 2013 Plan, there were options to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-215" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-695">10,613,229</ix:nonFraction> shares of common stock outstanding at a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-215" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-696">14.96</ix:nonFraction> per share. As of December&#160;31, 2024, there were <ix:nonFraction unitRef="shares" contextRef="c-215" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-697">404,449</ix:nonFraction> unvested RSUs outstanding under the 2013 Plan.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Plan was effective as of stockholder approval in May 2023. The 2023 Plan provides for grants of stock options and other stock-based awards, as well as cash-based performance awards. The 2023 Plan authorized the issuance of up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-216" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-698">4,850,000</ix:nonFraction> shares of common stock. In May 2024, the board and stockholders of the Company approved an amendment to the 2023 Plan to increase the number of shares of common stock available for issuance thereunder by <ix:nonFraction unitRef="shares" contextRef="c-217" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" id="f-699">2,000,000</ix:nonFraction> shares. Accordingly, the maximum number of shares of common stock authorized for issuance under the 2023 Plan is <ix:nonFraction unitRef="shares" contextRef="c-218" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-700">6,850,000</ix:nonFraction> shares. If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards. As of December&#160;31, 2024, under the 2023 Plan, there were options to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-219" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-701">2,326,288</ix:nonFraction> shares of common stock outstanding at a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-219" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-702">14.06</ix:nonFraction> per share. As of December&#160;31, 2024, there were <ix:nonFraction unitRef="shares" contextRef="c-219" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-703">664,545</ix:nonFraction> unvested RSUs outstanding under the 2023 Plan.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-704" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following stock-based compensation amounts were recognized for the periods indicated (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-705">11,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-706">9,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-707">10,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-708">17,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-709">9,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-710">10,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-711">29,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-712">18,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-713">20,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 25, 2024, Dr. Scott Koenig, the President and Chief Executive Officer of the Company and the Company entered into a separation and consulting agreement (the Separation Agreement), which provides for the terms of Dr. Koenig&#8217;s separation from employment, effective February 28, 2025 (the Separation Date). Under the Separation Agreement and in accordance with the terms of his employment agreement, the Company accelerated vesting of <ix:nonFraction unitRef="number" contextRef="c-226" decimals="INF" name="mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingPercentageOfUnvestedAwards" scale="-2" id="f-714">50</ix:nonFraction>% of the unvested stock option awards and RSU awards granted to Dr. Koenig during his employment outstanding as of the Separation Date. Additionally, pursuant to the Separation Agreement, following Dr. Koenig&#8217;s Separation Date, Dr. Koenig will serve as an advisor to the Company. As compensation for the advisory services, all remaining unvested option awards and RSU awards as of the Separation Date will continue to vest during the advisory services period. Lastly, all outstanding, accelerated and continued vesting options during the advisory services were amended to extend the exercisability period. The Company evaluated the impacts of the Separation Agreement and the related modifications to Dr. Koenig&#8217;s option awards and RSU awards.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, the Company recognized all additional stock-based compensation expense in 2024 in accordance with ASC Topic 718, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation &#8211; Stock Compensation </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 718) in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" format="ixt:num-dot-decimal" scale="6" id="f-715">6.1</ix:nonFraction>&#160;million. On February 25, 2025, Dr. Koenig and the Company amended the Separation Agreement to extend Dr. Koenig&#8217;s Separation Date to a date to be determined by the Board </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-688-2" continuedAt="f-688-3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of Directors of the Company as the special executive search committee of the Board of Directors continues its process to identify the next Chief Executive Officer of the Company.</span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="mgnx:ScheduleOfShareBasedPaymentAwardModifiedAwardsValuationAssumptionsTableTextBlock" id="f-716" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used to estimate the fair value of Dr. Koenig&#8217;s modified awards in 2024 were as follows:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.625%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.175%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-227" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:num-dot-decimal" id="f-717">0</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-228" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-718">108</ix:nonFraction>% -<ix:nonFraction unitRef="number" contextRef="c-229" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-719">174</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-228" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-720">4.2</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-229" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-721">4.3</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-228" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-722">1.00</ix:nonNumeric> year - <ix:nonNumeric contextRef="c-229" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-723">5.50</ix:nonNumeric> years</span></div></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Options</span></div><div style="text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation to employees and non-employee directors in accordance with ASC 718. The Company estimates the fair value of stock option awards using the Black-Scholes option pricing model on the date of grant using the assumptions in the table below. Stock options granted to employees generally vest over <ix:nonNumeric contextRef="c-230" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-724">four years</ix:nonNumeric> and have a term of <ix:nonNumeric contextRef="c-230" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-725">ten years</ix:nonNumeric>. Stock-based compensation expense for stock options is recognized as expense over the requisite service period, which is the vesting period. As the Company has not paid dividends since inception, nor does it expect to pay any dividends for the foreseeable future, the expected dividend yield assumption is <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt-sec:numwordsen" id="f-726">zero</ix:nonFraction>. The expected volatility is based on the historical stock volatility of the Company&#8217;s own common stock over a period equal to the expected term of the options. The risk-free rate of the stock options is based on the U.S. Treasury rate in effect at the time of grant for the expected term of the stock options. The Company calculates expected term based on the historical experience with similar awards, giving consideration to the contractual terms of the share-based awards, vesting schedules and expectations of future employee behavior. In addition, the Company estimates the expected forfeiture rate and only recognizes expense for those shares expected to vest. The Company estimates the forfeiture rate based on historical experience and its expectations regarding future pre-vesting termination behavior of employees. The Company reviews its estimate of the expected forfeiture rate annually, and stock-based compensation expense is adjusted accordingly.</span></div><div style="text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-727" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:56.211%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-728">0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-25" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-729">0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-26" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-730">0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-731">95</ix:nonFraction>% -<ix:nonFraction unitRef="number" contextRef="c-232" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-732">116</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-233" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-733">76</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-234" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-734">96</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-235" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-735">88</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-236" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-736">92</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-737">3.5</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-232" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-738">4.7</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-233" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-739">3.5</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-234" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-740">4.8</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-235" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-741">1.4</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-236" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-742">4.0</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-743">6.06</ix:nonNumeric> years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-25" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-744">5.88</ix:nonNumeric> years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-26" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-745">5.95</ix:nonNumeric> years</span></td></tr></table></ix:nonNumeric></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-746" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for 2024:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contractual Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-747">12,223,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-748">15.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-25" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-749">6.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-750">1,986,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-751">15.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-752">333,522</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-753">9.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-754">165,111</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-755">11.44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-756">771,669</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-757">25.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-758">12,939,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-759">14.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-760">6.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="f-761">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December&#160;31, 2024:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-762">9,004,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-763">16.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-764">5.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="f-765">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-766">12,456,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-767">14.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-768">6.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="f-769">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the total unrecognized compensation expense related to unvested stock options, net of related forfeiture estimates, was approximately $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-770">20.1</ix:nonFraction> million, which the Company expects to recognize over a weighted-</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-688-3"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">average period of approximately <ix:nonNumeric contextRef="c-1" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-771">1.4</ix:nonNumeric> years. The following table summarizes additional information on stock options (in thousands, except per share amounts):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.080%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.452%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.452%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.454%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock issued with stock options exercises</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-772">333,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-773">34,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-774">120,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value per share of stock options granted</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-775">12.61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-25" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-776">3.83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-26" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-777">6.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intrinsic value of stock options exercised</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-778">2,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="f-779">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="f-780">634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash received for stock options exercised</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-781">3,128</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-782">129</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-783">172</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant date fair value of stock options vested</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="3" id="f-784">17,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="3" id="f-785">16,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="3" id="f-786">19,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs are valued based on the closing price of the Company&#8217;s common stock on the date of the grant. The fair value of RSUs is recognized and amortized on a straight-line basis over the requisite service period of the award</span><span style="color:#252525;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="f-787" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity for 2024:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.268%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.954%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-237" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-788">905,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-237" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-789">5.97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-238" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-790">679,715</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-238" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-791">16.43</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-238" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" format="ixt:num-dot-decimal" scale="0" id="f-792">483,181</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-238" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-793">6.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-238" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-794">33,154</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-238" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-795">13.27</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-239" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-796">1,068,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-239" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-797">11.97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2024, there was $<ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="f-798">6.4</ix:nonFraction> million of total unrecognized compensation cost related to unvested RSUs, which the Company expects to recognize over a remaining weighted-average period of <ix:nonNumeric contextRef="c-238" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-799">1.4</ix:nonNumeric> years.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="ib90895a7822448df9e5a179143ce4792_894"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="f-800" continuedAt="f-800-1" escape="true">TerSera Transaction</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-800-1"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2024, the Company entered into an Asset Purchase and Sale Agreement (ASA) with TerSera in which TerSera acquired global rights to MARGENZA. Pursuant to the ASA, the Company received $<ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-5" name="us-gaap:OtherIncome" scale="6" id="f-801">40.0</ix:nonFraction> million and may also receive up to $<ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-5" name="mgnx:FutureMilestone" scale="6" id="f-802">35.0</ix:nonFraction> million in future sales milestone payments. The transaction closed in November 2024. In connection with the ASA, the Company also entered into a Master Manufacturing &amp; Supply Agreement (MSA) with TerSera under which it will manufacture MARGENZA product for TerSera, and a Transition Services Agreement under which it will provide certain services to ensure a smooth business transition to TerSera.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the sale of MARGENZA does not qualify for reporting as a discontinued operation since it does not represent a strategic shift that has or will have a major effect on its operations and financial results. The Company determined that the agreements should be accounted for as one single combined contract with multiple elements under which the Company allocated the total consideration of $<ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-5" name="us-gaap:OtherIncome" scale="6" id="f-803">44.5</ix:nonFraction> million on a relative standalone selling price basis in accordance with the applicable authoritative guidance. The Company recorded a $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="mgnx:GainOnSaleOfMARGENZA" scale="6" id="f-804">36.3</ix:nonFraction> million gain on the sale of MARGENZA and related inventory in the &#8220;Gain on Sale of MARGENZA&#8221; line on its consolidated statements of operations and comprehensive loss for the year ended December&#160;31, 2024.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="ib90895a7822448df9e5a179143ce4792_172"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-805" continuedAt="f-805-1" escape="true">Income Tax</ix:nonNumeric></span></div><ix:continuation id="f-805-1" continuedAt="f-805-2"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024, the Company is in a taxable income position due to the Tax Cuts and Jobs Act of 2017 (the Tax Act) limitation on utilization of Net Operating Losses to 80% of taxable income as well as the limitation on utilization of income tax credits, while the company remains in a full valuation allowance position. For the years ended December&#160;31, 2023, and 2022 there was <ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-806"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-807">no</ix:nonFraction></ix:nonFraction> provision for income taxes due to taxable losses generated, fully offset by a valuation allowance.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-805-2" continuedAt="f-805-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-808" escape="true"><div style="text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense consists of the following f</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or the year ended</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.747%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="f-809">707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-810">237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-811">944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-812" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the reported estimated income tax expense to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States federal tax at statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-813">13,866</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-814">1,902</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-815">25,149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes (net of federal benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-816">4,183</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="f-817">163</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-818">7,385</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" format="ixt:num-dot-decimal" scale="3" id="f-819">7,299</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" format="ixt:num-dot-decimal" scale="3" id="f-820">5,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" scale="3" id="f-821">308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred state blended rate adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="mgnx:EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount" format="ixt:num-dot-decimal" scale="3" id="f-822">2,663</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="mgnx:EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount" format="ixt:num-dot-decimal" scale="3" id="f-823">1,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="mgnx:EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount" format="ixt:fixed-zero" scale="3" id="f-824">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credit, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="f-825">12,082</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="f-826">3,168</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="f-827">4,569</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan drug credit, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="mgnx:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" format="ixt:num-dot-decimal" scale="3" id="f-828">1,308</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="mgnx:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" format="ixt:num-dot-decimal" scale="3" id="f-829">2,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="mgnx:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" format="ixt:num-dot-decimal" scale="3" id="f-830">10,846</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="3" id="f-831">388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" format="ixt:num-dot-decimal" scale="3" id="f-832">1,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" format="ixt:num-dot-decimal" scale="3" id="f-833">1,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-834">5,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-835">1,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-836">1,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-837">36,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-838">7,257</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-839">44,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" scale="3" id="f-840">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" format="ixt:fixed-zero" scale="3" id="f-841">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" format="ixt:fixed-zero" scale="3" id="f-842">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense/(benefit)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-843">944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-844">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-845">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-846" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal U.S. net operating loss carryforward</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" format="ixt:num-dot-decimal" scale="3" id="f-847">116,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" format="ixt:num-dot-decimal" scale="3" id="f-848">140,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State net operating loss carryforward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" format="ixt:num-dot-decimal" scale="3" id="f-849">31,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" format="ixt:num-dot-decimal" scale="3" id="f-850">33,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credit, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-851">79,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-852">68,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan drug credit, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther" format="ixt:num-dot-decimal" scale="3" id="f-853">33,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther" format="ixt:num-dot-decimal" scale="3" id="f-854">33,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="mgnx:DeferredTaxAssetsOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-855">10,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="mgnx:DeferredTaxAssetsOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-856">9,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="f-857">18,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="f-858">17,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 174 deferred tax asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="mgnx:Section174DeferredTaxAsset" format="ixt:num-dot-decimal" scale="3" id="f-859">98,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="mgnx:Section174DeferredTaxAsset" format="ixt:num-dot-decimal" scale="3" id="f-860">48,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity based compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-861">16,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-862">16,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-863">4,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-864">6,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-865">410,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-866">373,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-867">401,297</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-868">365,010</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-869">8,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-870">8,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="mgnx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="f-871">6,745</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="mgnx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="f-872">6,372</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="f-873">2,155</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="f-874">2,030</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-875">8,900</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-876">8,402</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax asset/(liability)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-877">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-878">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes valuation allowances to reduce deferred tax assets to the amount that is more likely than not to be realized. In assessing the likelihood of realization, management considers (i) future reversals of existing taxable temporary </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-805-3"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">differences; (ii) future taxable income exclusive of reversing temporary difference and carryforwards; (iii) taxable income in prior carryback years if carryback is permitted under applicable tax law; and (iv) tax planning strategies. The Company's net deferred income tax asset is not more likely than not to be utilized due to the lack of sufficient sources of future taxable income and cumulative book losses which have resulted over the years.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="f-879" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activity in the valuation allowance on deferred tax assets was as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.309%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.862%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at Beginning of Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at End of Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-880">365,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="mgnx:ValuationAllowanceDeferredTaxAssetIncreaseAmount" format="ixt:num-dot-decimal" scale="3" id="f-881">36,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="mgnx:ValuationAllowanceDeferredTaxAssetDecreaseAmount" format="ixt:fixed-zero" scale="3" id="f-882">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-883">401,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-884">372,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="mgnx:ValuationAllowanceDeferredTaxAssetIncreaseAmount" format="ixt:fixed-zero" scale="3" id="f-885">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="mgnx:ValuationAllowanceDeferredTaxAssetDecreaseAmount" format="ixt:num-dot-decimal" scale="3" id="f-886">7,257</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-887">365,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-888">327,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="mgnx:ValuationAllowanceDeferredTaxAssetIncreaseAmount" format="ixt:num-dot-decimal" scale="3" id="f-889">44,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="mgnx:ValuationAllowanceDeferredTaxAssetDecreaseAmount" format="ixt:fixed-zero" scale="3" id="f-890">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-891">372,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company has U.S. federal and state net operating loss (NOL) carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="6" id="f-892">554.0</ix:nonFraction> million. Of these NOLs, $<ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="6" id="f-893">2.1</ix:nonFraction> million will expire beginning in 2027 through 2028. $<ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="6" id="f-894">551.9</ix:nonFraction> million of NOLs were generated post December 31, 2017 and carryforward indefinitely. In addition, the Company has U.S. federal tax credits of $<ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="f-895">109.0</ix:nonFraction> million, which will expire in various years beginning in 2027 through 2044.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of the Company's U.S. federal NOL and tax credit carryforwards in future years are restricted due to changes in the Company's ownership and tax attributes acquired through the Company's acquisitions. As of December&#160;31, 2024, $<ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="6" id="f-896">2.1</ix:nonFraction> million of the Company's U.S. Federal NOLs are limited for use over 2027 through 2028, in which a range of such amounts could be utilized on an annual basis of $<ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-5" name="mgnx:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationAmountUtilizableOnAnnualBasis" scale="6" id="f-897">0.2</ix:nonFraction> million. The remaining $<ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="6" id="f-898">551.9</ix:nonFraction> million of NOLs is not limited and can be offset against future taxable income, subject to certain limitations for newly enacted tax legislation. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning January 1, 2022, the Tax Act eliminated the option to deduct research and development expenditures in the current year and requires taxpayers to capitalize such expenses pursuant to Internal Revenue Code (IRC) Section 174. The capitalized expenses are amortized over a 5-year period for domestic expenses and a 15-year period for foreign expenses.</span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="f-899" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-900">7,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-901">7,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-902">7,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases for current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-903">1,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="f-904">449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="f-905">548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases/(decreases) for prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="mgnx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" scale="3" id="f-906">512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="mgnx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" scale="3" id="f-907">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="mgnx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" scale="3" id="f-908">369</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-909">9,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-910">7,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-911">7,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, of the total gross unrecognized tax benefits, approximately $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="f-912">9.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="f-913">7.8</ix:nonFraction> million would favorably impact the Company's effective income tax rate, respectively. Although, due to the Company's determination that the deferred income tax asset would not more likely than not be realized, a valuation allowance would be recorded, therefore, zero net impact would result within the Company's effective income tax rate. The Company's uncertain income tax position liability has been recorded to deferred income taxes to offset the tax attribute carryforward amounts.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2024, 2023 and 2022, the Company has <ix:nonFraction unitRef="usd" contextRef="c-25" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="f-914"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="f-915"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="f-916">not</ix:nonFraction></ix:nonFraction></ix:nonFraction> recognized any interest or penalties related to the uncertain income tax positions due to the fact such position is related to tax attribute carryforwards which have not yet been utilized. The Company does not expect its unrecognized income tax position to significantly decrease within the next twelve months.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's U.S. Federal and state income tax returns from 2007 </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forward remain open to examination due to the carryover of unused income tax credits, and from 2007 forward due to the carryover of unused net operating losses.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="ib90895a7822448df9e5a179143ce4792_175"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="c-1" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="f-917" continuedAt="f-917-1" escape="true">Employee Benefit Plan</ix:nonNumeric></span></div><ix:continuation id="f-917-1" continuedAt="f-917-2"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2002, the Company established the MacroGenics 401(k) Plan (the Plan) for its employees under Section 401(k) of the IRC. Under this Plan, all employees at least <ix:nonNumeric contextRef="c-1" name="mgnx:EmployeesEligibleAgeToParticipateInBenefitPlan" format="ixt-sec:duryear" id="f-918">21</ix:nonNumeric> years of age are eligible to participate in the Plan, starting on the first day of employment. Employees may contribute up to <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="f-919">100</ix:nonFraction>% of their salary, subject to government maximums.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-917-2">Employees are <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="mgnx:DefinedContributionPlanEmployeesContributionVestedPercentage" scale="-2" id="f-920">100</ix:nonFraction>% vested in their contributions to the Plan. The Company's contribution to the Plan, as determined by the Board of Directors, is discretionary. For the years ended December&#160;31, 2024, 2023 and 2022, the Company's contributions to the Plan totaled $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="f-921">2.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="f-922">2.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="f-923">2.3</ix:nonFraction> million, respectively.</ix:continuation> </span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ib90895a7822448df9e5a179143ce4792_178"></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-924" continuedAt="f-924-1" escape="true">Segment Reporting</ix:nonNumeric></span></div><ix:continuation id="f-924-1"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identifies its reportable segments based on information reviewed by the Company&#8217;s CODM. The Company operates as <ix:nonFraction unitRef="performanceobligation" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-925">one</ix:nonFraction> operating and reportable segment, which is discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer. The Company has determined its reportable operating segment based on the management approach, which considers the internal organization and reporting used by the Company&#8217;s CODM to make decisions about allocating resources and assessing the Company&#8217;s performance. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance and allocating resources. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CODM uses consolidated net loss, consistent with the amounts reported in the Company&#8217;s consolidated statements of operations to evaluate performance, forecast future period financial results and allocate resources. Total consolidated assets presented in the accompanying consolidated balance sheets also represent the segment&#8217;s total assets.</span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-926" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the significant expenses regularly reviewed by the CODM (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue (a)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-927">149,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-928">58,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-929">151,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="f-930">847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="f-931">619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-932">3,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of manufacturing sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="mgnx:CostOfManufacturingServices" format="ixt:num-dot-decimal" scale="3" id="f-933">11,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="mgnx:CostOfManufacturingServices" format="ixt:num-dot-decimal" scale="3" id="f-934">7,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="mgnx:CostOfManufacturingServices" format="ixt:num-dot-decimal" scale="3" id="f-935">4,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vobramitamab duocarmazine</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-936">39,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-937">39,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-938">55,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lorigerlimab</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-939">36,805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-940">27,716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-941">21,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGC028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-942">24,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-943">14,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:fixed-zero" scale="3" id="f-944">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical antibody-drug conjugates (ADCs)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-945">18,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-946">11,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-947">12,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGC026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-948">14,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-949">13,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-950">5,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Margetuximab</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-951">10,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-952">16,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-953">26,869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGD024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-954">9,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-955">6,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-956">7,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Next-generation T-cell engagers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-957">8,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-958">10,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-959">13,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retifanlimab</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-960">2,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-961">3,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-962">2,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enoblituzumab</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-963">1,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-964">5,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-965">14,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other programs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-966">11,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-967">18,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-968">46,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-969">177,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-970">166,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-971">207,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-972">71,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-973">52,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-974">58,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segment income, net (b)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:SegmentReportingOtherItemAmount" format="ixt:num-dot-decimal" scale="3" id="f-975">43,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="us-gaap:SegmentReportingOtherItemAmount" format="ixt:num-dot-decimal" scale="3" id="f-976">159,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:SegmentReportingOtherItemAmount" format="ixt:num-dot-decimal" scale="3" id="f-977">1,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-978">66,966</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-979">9,058</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-980">119,758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Total revenue includes collaborative and other agreements, product sales, net, contract manufacturing, and government agreements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Other segment income, net includes the gain on sale of MARGENZA, interest and other income and expense, and income tax expense.</span></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company operates in the United States and all material long-lived assets of the Company reside in the United States For information about the Company&#8217;s revenues, see Note 8, Revenue.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 30</span></div></div></div><div id="ib90895a7822448df9e5a179143ce4792_181"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:8.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.704%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">No.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restated Certificate of Incorporation of the Company and Certificate of Correction to the Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibits </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513402831/d613759dex31.htm">3.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513402831/d613759dex33.htm">3.3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, respectively, to the Company's Current Report on Form 8-K filed on October 18, 2013)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001125345/000112534521000052/a8-k_bylawxamendmentxexx3x1.htm">Amended and Restated By-Laws of the Company (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-36112) filed on April 2, 2021)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513394786/d575431dex42.htm">Specimen Stock Certificate (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 9, 2013)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534521000035/mgnxexhibit4-2202010xk.htm">Description of Common Stock (incorporated by reference to Exhibit 4.2 to the Company&#8217;s Annual Report on Form 10-K filed on February 25, 2021)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513386872/d575431dex1014.htm">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.14 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534518000022/exhibit10-3201710xkfinal.htm">Global Collaboration and License Agreement by and between the Company and Incyte Corporation, dated October 24, 2017 (incorporated by reference to Exhibit 10.3 to the Company's Annual Report on Form 10-K filed on February 27, 2018)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513386872/d575431dex105.htm">Company 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513386872/d575431dex106.htm">Form of Incentive Stock Option Agreement under 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.6 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513386872/d575431dex107.htm">Form of Nonstatutory Stock Option Agreement under 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.7 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534515000013/exhibit10-2.htm">Form of Restricted Stock Units Grant Notice under 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q filed on May 6, 2015)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534523000102/form_s-8x2023eipxex991.htm">Company 2023 Equity Incentive Plan (incorporated by reference to Exhibit 99.1 to the Registration Statement on Form S-8 (File No. 333-272451) filed by the Company on June 6, 2023)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000060/exhibit108employeestockopt.htm">Form of Employee Stock Option Grant Notice and Stock Option Agreement under 2023 Equity Incentive Plan </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000060/exhibit108employeestockopt.htm">(incorporated by reference to Exhibit 10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000060/exhibit108employeestockopt.htm">8</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000060/exhibit108employeestockopt.htm"> to the Company's Annual Report on Form 10-K filed </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000060/exhibit108employeestockopt.htm">on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000060/exhibit108employeestockopt.htm">March</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000060/exhibit108employeestockopt.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000060/exhibit108employeestockopt.htm">7</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000060/exhibit108employeestockopt.htm">, 20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000060/exhibit108employeestockopt.htm">24</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000060/exhibit108employeestockopt.htm">)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000060/exhibit109employeersuaward.htm">Form of Employee Restricted Stock Unit Award Grant Notice and Award Agreement under 2023 Equity Incentive Plan </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534516000046/exhibit1014.htm">(incorporated by reference to Exhibit 10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534516000046/exhibit1014.htm">9</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534516000046/exhibit1014.htm"> to the Company's Annual Report on Form 10-K filed </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534516000046/exhibit1014.htm">on March 7, 2024)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000060/exhibit1010bodoptiongrantn.htm">Form of Director Stock Option Grant Notice and Stock Option Agreement under 2023 Equity Incentive Plan </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534516000046/exhibit1014.htm">(incorporated by reference to Exhibit 10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534516000046/exhibit1014.htm">10</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534516000046/exhibit1014.htm"> to the Company's Annual Report on Form 10-K filed </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534516000046/exhibit1014.htm">on March 7, 2024)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000060/exhibit1011bodrsuawardgran.htm">Form of Director Restricted Stock Unit Award Grant Notice and Award Agreement under 2023 Equity Incentive Plan </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000060/exhibit1011bodrsuawardgran.htm">(incorporated by reference to Exhibit 10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000060/exhibit1011bodrsuawardgran.htm">11</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000060/exhibit1011bodrsuawardgran.htm"> to the Company's Annual Report on Form 10-K filed </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000060/exhibit1011bodrsuawardgran.htm">on March 7, 2024)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000155278116002035/e00576_ex4-1.htm">2016 Employee Stock Purchase Plan (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-8 (File No. 333-214386) filed by the Company on November 2, 2016)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534516000046/exhibit1014.htm">Employment Agreement between the Company and Scott Koenig, M.D., Ph.D. (incorporated by reference to Exhibit 10.14 to the Company's Annual Report on Form 10-K filed by the Company on February 29, 2016)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534516000046/exhibit1015.htm">Employment Agreement between the Company and James Karrels (incorporated by reference to Exhibit 10.15 to the Company's Annual Report on Form 10-K filed by the Company on February 29, 2016)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001125345/000112534521000060/exhibit101stepheneckemploy.htm">Employment Agreement between the Company and Stephen Eck, M.D. (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed on April 29, 2021)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534518000058/exhibit101incyteamendment.htm">Amendment No, 1 to the Global Collaboration and License Agreement by and between the Company and Incyte Corporation, dated March 15, 2018 (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed on May 7, 2018)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:8.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.704%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534522000090/exhibit101-incyte2ndamend.htm">Amendment No. 2 to the Global Collaboration and License Agreement by and between the Company and Incyte Corporation, dated April 7, 2022 (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed on August 8, 2022)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534522000104/exhibit101-incyte3rdamend.htm">Amendment No. 3 to the Global Collaboration and License Agreement by and between the Company and Incyte Corporation, dated April 7, 2022 (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed on November 3, 2022)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000160/exhibit101fourthamendmentt.htm">Amendment No. </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000160/exhibit101fourthamendmentt.htm">4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000160/exhibit101fourthamendmentt.htm"> to the Global Collaboration and License Agreement by and between the Company and Incyte Corporation, dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000160/exhibit101fourthamendmentt.htm">July</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000160/exhibit101fourthamendmentt.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000160/exhibit101fourthamendmentt.htm">24</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000160/exhibit101fourthamendmentt.htm">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000160/exhibit101fourthamendmentt.htm">4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000160/exhibit101fourthamendmentt.htm"> (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed on November </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000160/exhibit101fourthamendmentt.htm">5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000160/exhibit101fourthamendmentt.htm">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000160/exhibit101fourthamendmentt.htm">4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000160/exhibit101fourthamendmentt.htm">)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001125345/000112534521000035/exhibit1016incytecommercia.htm">Commercial Supply Agreement by and between Incyte Corporation and the Company, dated October 13, 2020 (incorporated by reference to Exhibit 10.16 to the Company&#8217;s Annual Report on Form 10-K filed on February 25, 2021)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534523000059/a1022_gileadcollab.htm">Collaboration and License Agreement by and between the Company and Gilead Sciences, Inc., dated October 14, 2022 (incorporated by reference to Exhibit 10.22 to the Company's Annual Report on Form 10-K filed by the Company on March 15, 2023)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000088/mgnxexhibit10-1.htm">Amendment No. 1 to the Collaboration and License Agreement by and between the Company and Gilead Sciences, Inc., dated January 11, 2024 </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000088/mgnxexhibit10-1.htm">(incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed on May 9, 2024)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000160/exhibit102secondletteragre.htm">Second Letter</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000160/exhibit102secondletteragre.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000160/exhibit102secondletteragre.htm">Agreement by and between the Company and Gilead Sciences, Inc., dated August 30, 2024 (incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q filed on November 5, 2024)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534523000059/a1023_proventionapa.htm">Asset Purchase Agreement by and between the Company and Provention Bio, Inc., dated May 7, 2018 (incorporated by reference to Exhibit 10.23 to the Company's Annual Report on Form 10-K filed by the Company on March 15, 2023)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534523000059/a1024_proventionapaamendme.htm">Amendment No. 1 to the Asset Purchase Agreement by and between the Company and Provention Bio, Inc., dated November 30, 2022 (incorporated by reference to Exhibit 10.24 to the Company's Annual Report on Form 10-K filed by the Company on March 15, 2023)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534523000124/exhibit101q32023.htm">Amendment No. 2 to the Asset Purchase Agreement by and between the Company and Provention Bio, Inc., dated September 19, 2023 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed on November 6, 2023</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534523000059/a1025_hqlease.htm">Lease by and between BMR-Medical Center Drive LLC and J. Craig Venter Institute, Inc., dated May 3, 2010 (incorporated by reference to Exhibit 10.25 to the Company's Annual Report on Form 10-K filed by the Company on March 15, 2023)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534523000059/a1026_firstamendmenttohqle.htm">First Amendment to Lease by and between BMR-Medical Center Drive LLC and J. Craig Venter Institute, Inc. dated March 26, 2014 (incorporated by reference to Exhibit 10.26 to the Company's Annual Report on Form 10-K filed by the Company on March 15, 2023)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534523000059/a1027_secondamendmenttohql.htm">Second Amendment to Lease by and between the Company and BMR-Medical Center Drive LLC, dated July 31, 2015 (incorporated by reference to Exhibit 10.27 to the Company's Annual Report on Form 10-K filed by the Company on March 15, 2023)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534523000059/a1028_thirdamendmenttohqle.htm">Third Amendment to Lease by and between the Company and BMR-Medical Center Drive LLC, dated November 5, 2015 (incorporated by reference to Exhibit 10.28 to the Company's Annual Report on Form 10-K filed by the Company on March 15, 2023)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534523000059/a1029_fourthamendmenttolea.htm">Fourth Amendment to Lease by and between the Company and BMR-Medical Center Drive LLC, dated July 21, 2017 (incorporated by reference to Exhibit 10.29 to the Company's Annual Report on Form 10-K filed by the Company on March 15, 2023)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534523000059/a1030_fifthamendmenttohqle.htm">Fifth Amendment to Lease by and between the Company and ARE-Maryland No. 45, LLC, dated December 14, 2022 (incorporated by reference to Exhibit 10.30 to the Company's Annual Report on Form 10-K filed by the Company on March 15, 2023)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.33+*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxex1033separationandcon.htm">S</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxex1033separationandcon.htm">eparation </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxex1033separationandcon.htm">and Consulting </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxex1033separationandcon.htm">A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxex1033separationandcon.htm">greement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxex1033separationandcon.htm"> between the Company and Scott Koe</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxex1033separationandcon.htm">nig, M.D., Ph.D.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.34+*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxex1034amendment1jkempl.htm">A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxex1034amendment1jkempl.htm">mend</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxex1034amendment1jkempl.htm">ment No.1 to the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxex1034amendment1jkempl.htm">E</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxex1034amendment1jkempl.htm">mploy</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxex1034amendment1jkempl.htm">ment </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxex1034amendment1jkempl.htm">A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxex1034amendment1jkempl.htm">greement between </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxex1034amendment1jkempl.htm">the Company and James Karrels</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.35+*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxex1035amendment1seckem.htm">A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxex1035amendment1seckem.htm">m</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxex1035amendment1seckem.htm">endment No.1 to the Employ</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxex1035amendment1seckem.htm">ment Agreement between the Company and Stephen Eck, M.D.,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxex1035amendment1seckem.htm">Ph.D.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.36+*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxex1036amendment_toxkoe.htm">A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxex1036amendment_toxkoe.htm">mendment to Sep</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxex1036amendment_toxkoe.htm">aration and Consulting Agreement between the Company and Scott Koenig, M.D., Ph.D.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="mgnxex19insidertradingpoli.htm">19</a>.1*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxex19insidertradingpoli.htm">MacroGenics Inc</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxex19insidertradingpoli.htm">.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxex19insidertradingpoli.htm"> Insider Trading</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxex19insidertradingpoli.htm"> Policy </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:8.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:85.704%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1* </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxexhibit23-1202410xk.htm">Consent of Ernst &amp; Young, LLP, Independent Registered Public Accounting Firm</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxexhibit31-1202410xk.htm">Rule 13a-14(a) Certification of Principal Executive Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxexhibit31-2202410xk.htm">Rule 13a-14(a) Certification of Principal Financial Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxexhibit32-1202410xk.htm">Section 1350 Certification of Principal Executive Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mgnxexhibit32-2202410xk.htm">Section 1350 Certification of Principal Financial Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000060/mgnxex97-1clawbackpolicy.htm">MacroGenics.Inc. Incentive Compensation Recoupment Policy </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000060/mgnxex97-1clawbackpolicy.htm">(incorporated by reference to Exhibit </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000060/mgnxex97-1clawbackpolicy.htm">97</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000060/mgnxex97-1clawbackpolicy.htm">.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1125345/000112534524000060/mgnxex97-1clawbackpolicy.htm"> to the Company's Annual Report on Form 10-K filed by the Company on March 7, 2024)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Schema Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Calculation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Definition Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Labels Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Presentation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data (formatted as Inline XBRL and contained in Exhibit 101 filed herewith)</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment granted by the SEC.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">#&#160;&#160;&#160;&#160;Portions of this document (indicated by &#8220;[***]&#8221; have been omitted because they are not material and are the type that MacroGenics, Inc. treats as private and confidential.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">            </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Indicates management contract or compensatory plan.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Furnished herewith.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.33
<SEQUENCE>2
<FILENAME>mgnxex1033separationandcon.htm
<DESCRIPTION>EX-10.33
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i0153beca16bb4a9099d88198c6028ef0_36"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Exhibit.10.33</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:313%">October 25, 2024 Scott Koenig</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">7109 Malibu Cove</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:186%">Austin, TX 78730 Dear Scott&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">This letter sets forth the substance of the separation agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) that MacroGenics, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) is offering to you to aid in your employment transition.</font></div><div style="text-indent:9pt"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:9.75pt">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:112%">EPARATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. Your last day of work with the Company and your employment termination date will be February 28, 2025 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Separation Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;). Either you or the Company may elect, upon seven (7) days&#8217; notice to the other party, to change the Separation Date to a date that is earlier than February 28, 2025. In addition, the Separation Date may be extended past February 28, 2025 with the mutual consent of both you and the Company&#8217;s Board of Directors. You will remain eligible for your full normal 2024 annual bonus regardless of whether your Separation Date occurs before or after February 28, 2025, and regardless of whether your Separation Date occurs before the date on which the 2024 annual bonus is paid. Effective as of the Separation Date, you hereby voluntarily resign your position on the Company&#8217;s Board of Directors, and resign from any and all other officer or other positions you may hold with the Company, its Board of Directors, and any affiliated or related companies&#59; provided that, upon the written request of the incoming Chief Executive Officer of the Company, which request shall be made prior to the Separation Date, you may revoke your resignation from the Board of Directors. (For the avoidance of doubt, such resignations are effective upon your execution of this Agreement, and regardless of whether or not you revoke this Agreement as set forth below.) You understand and agree that you are not authorized to hold yourself out as being employed or affiliated with the Company in any way following the Separation Date, including as a member of the Board of Directors.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:9.75pt">F</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:112%">INAL </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:112%">AY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. On the next regularly scheduled pay date following the Separation Date, the Company will pay you all accrued salary and all accrued and unused vacation time earned through the Separation Date, subject to standard payroll deductions and withholdings. You are entitled to this payment by law.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:9.75pt">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:112%">EVERANCE </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:112%">AYMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">If you timely sign this Agreement, allow the release(s) contained herein to become effective, and comply with your obligations under it (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Severance Preconditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;), then the Company will provide you (or your heirs, in the event of your death during the time that such benefits would otherwise be paid out under this Agreement) the severance benefits as if your employment termination was a termination by the Employer without Cause (each as defined and set forth in that certain Employment Agreement between you</font></div><div><font><br></font></div><div style="text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">and the Company, dated October 9, 2013, a copy of which is attached hereto as Exhibit A (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Employment Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;))&#58;</font></div><div style="text-indent:9pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:23.8pt">C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:112%">ASH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:112%">EVERANCE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The Company will pay you, the product of (i) two and (ii) the sum of your base salary and target bonus in effect immediately prior to the Separation Date (for an aggregate severance amount of $2,362,880), subject to standard payroll deductions and withholdings. This amount will be paid over the two (2) year period running from the Separation Date, paid on the same payroll schedule on which current employees are paid (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Severance </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;)&#59; provided, however, that no Severance Payment will be made prior to the first regular Company payday no earlier than one week after the Effective Date (as defined below), with such first amount totaling the amounts that would have been paid on the regular payroll paydays but for the delay for effectiveness of the release.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:23.18pt">H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:112%">EALTH </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:112%">NSURANCE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">As an additional severance benefit under this Agreement, provided that you satisfy the Severance Preconditions set forth above and timely elect continued coverage under COBRA, you and your eligible dependents will continue to participate in the Company&#8217;s medical, dental, and vision benefit plans at the same premium cost to you as charged to you immediately prior to the Separation Date for a period of twenty-four (24) months immediately following the Separation Date, or if earlier, until you obtain other employment which provides the same type of benefit&#59; provided, however, that (a) it is understood and agreed that such continued medical, dental, and vision benefits may at the election of the Company be provided by you electing the discontinuation of coverage pursuant to COBRA with the Company reimbursing you for COBRA premiums to the extent required so that your premium cost for the coverage in effect for you and your eligible dependents prior to the Separation Date is substantially the same as immediately prior to the Separation Date, and (b) if the Company determines, in its reasonable judgment, that providing medical, dental, and&#47;or vision benefits in accordance with the preceding provisions of this Section 3(b) would result in a violation of applicable law, the imposition of any penalties under applicable law, or adverse tax consequences for participants covered by the Company&#8217;s medical, dental, and&#47;or vision plans, the Company may terminate such coverage (or reimbursement) with respect to you and your eligible dependents and instead pay you taxable cash payments at the same time and in the same amounts as the Company would have been paid as premiums (or as COBRA premium reimbursements) to provide such coverage.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:23.8pt">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:112%">TOCK </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">O</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:112%">PTIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Notwithstanding Section 5.05(c) of the Employment Agreement or in any applicable equity incentive award plan or agreement, effective as of the Effective Date each stock option and restricted stock unit granted to you by the Company that is outstanding and not yet vested as of the Separation Date shall become vested with respect to 50% of the shares with respect to which the stock option or restricted stock unit is not vested as of the Separation Date (such vested and unvested stock options and restricted stock units after giving effect to such vesting, including stock options or restricted stock units that become vested during the Advisory Period (defined in Section 4(a) below), the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Separation Date Equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; and such vested and unvested stock options after giving effect to such vesting, including stock options that become vested during the Advisory Period (defined in Section 4(a) below), the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Separation Date Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;).</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:9.75pt">Advisory Relationship. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Although the Company has no obligation to do so, if you satisfy the Severance Preconditions, then the Company will engage you as an advisor under the terms and conditions set forth in this Section.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:23.8pt">Advisory Period. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Your advisory engagement will begin on the Separation Date. If you do not timely (i.e., within 21 days after you receive this Agreement) execute and return this Agreement to the Company, or you revoke it after you sign it, then your advisory engagement will end immediately upon the 30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> day after you receive this Agreement. However, if you timely sign and return this Agreement to the Company, and allow it to become effective, then the Company will continue your advisory engagement until February 28, 2030, unless </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">earlier terminated pursuant to Paragraph 4(i) below or extended by the parties in writing. Your full advisory engagement will be referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Advisory Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:23.18pt">Advisory Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. You agree to provide advisory services to the Company in any area of your expertise or relevant to your skills, knowledge and experience with the Company, and&#47;or as requested by the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Advisory Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;). You agree to make yourself available to provide the Advisory Services for up to four (4) hours per week on an as- needed basis during the Advisory Period. During the Advisory Period, you will report directly to the Company&#8217;s Board of Directors or their designee. You agree to exercise the highest degree of professionalism and utilize your expertise and creative talents in performing these services. You will not be required to report to the Company&#8217;s offices during the Advisory Period, except as specifically requested by the Company upon reasonable notice. When providing such services, you shall abide by the Company&#8217;s policies and procedures.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:22.7pt">Advisory Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. Notwithstanding Section 5.05(c) of the Employment Agreement or in any applicable equity incentive award plan or agreement but subject to Paragraph 3(c), provided you shall not have revoked this Agreement, as sole compensation for the Advisory Services, you shall continue to vest during the Advisory Period in the portion the Separation Date Equity that is not vested as of the Separation Date ratably over the period remaining in the original vesting schedule of the Separation Date Equity, and your period of service during the Advisory Period shall be deemed to be continued employment with the Company for purposes of determining the period during which, after the end of the Advisory Period, you may exercise the Separation Date Options, meaning that your Separation Date Options will remain exercisable until the earlier of (i) ninety (90) days or three (3) months, as applicable, after the end of the Advisory Period (or twelve (12) months after the end of the Advisory Period if the Advisory Period ends due to your death or Disability), or (ii) the expiration of the original term of such Separation Date Options. You acknowledge and agree that the compensation set forth in this paragraph is sufficient consideration for the Advisory Services.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:22.02pt">Independent Contractor Status. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Your relationship with the Company during the Advisory Period will be that of an independent contractor, and nothing in this Agreement is intended to, or should be construed to, create a partnership, agency, joint venture or employment relationship after the Separation Date. You will not be entitled to any of the benefits which the Company may make available to its employees, including but not limited to, group health or life insurance, profit-sharing or retirement benefits, and you acknowledge and agree that your relationship with the Company during the Advisory Period will not be subject to the Fair Labor Standards Act or other laws or regulations governing employment relationships.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:22.7pt">Limitations on Authority. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">You will have no responsibilities or authority as an advisor to the Company other than as provided above. You will have no authority to bind the Company to any contractual obligations, whether written, oral or implied, except with the Company&#8217;s express written authorization. You agree not to represent or purport to represent the Company in any manner whatsoever to any third party unless authorized by the Company, in writing, to do so.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:24.03pt">Proprietary Information and Inventions. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">You agree that, during the Advisory Period and thereafter, you will not use or disclose any confidential or proprietary information or materials of the Company, including any confidential or proprietary information that you obtain </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">or develop in the course of performing the Advisory Services. Notwithstanding the foregoing, pursuant to 18 U.S.C. Section 1833(b), you shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that&#58; (1) is made in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law&#59; or (2) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. Any and all work product you create in the course of performing the Advisory Services will be the sole and exclusive property of the Company. You hereby assign to the Company all right, title, and interest in all inventions, techniques, processes, materials, and other intellectual property developed in the course of performing the Advisory Services.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:22.02pt">Termination of Advisory Period. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Without waiving any other rights or remedies, you and the Company may mutually agree to terminate the advisory relationship at any time and for any reason. Upon termination of the Advisory Period, all equity will cease vesting.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:22.02pt">Other Work Activities &#47; Non-Competition. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Throughout the Advisory Period, you retain the right to engage in employment, consulting, or other work relationships in addition to your work for the Company. In order to protect the trade secrets and confidential and proprietary information of the Company, you agree that, during the Advisory Period, you will not perform services for, or in any way manage, operate, join, control or be connected to as an employee, shareholder (other than as a shareholder of a publicly traded company), director, manager, member, consultant, adviser, volunteer, or partner to, any company that engages in a business that is researching or developing pharmaceutical products addressing any biological target that is the subject of the Company&#8217;s drug development efforts during the period of employment prior to the Separation Date (and in which your duties and authorities for such company involve work on any molecules that are structurally or functionally identical or similar to proprietary molecules developed by or under development by the Company during the period of employment prior to the Separation Date). You agree that ten (10) days prior to beginning any director, employment, consulting, or other work relationships with another company, you will notify the General Counsel of the Company in writing (which may be via email).</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:24.69pt">Representations. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">You represent and warrant that you are self-employed in an independently established trade, occupation, or business, maintain and operate a business that is separate and independent from the Company&#8217;s business, hold yourself out to the public as independently competent and available to provide applicable services similar to the Advisory Services, have obtained and&#47;or expect to obtain clients or customers other than the Company for whom you will perform services, and will perform work for the Company that you understand is</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">outside the usual course of the Company&#8217;s business. The Company will make reasonable arrangements to enable you to perform your work for the Company at such times and in such a manner so that it will not interfere with other activities in which you may engage.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:9pt">Other Compensation or Benefits. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">You acknowledge and agree that the benefits offered to you herein satisfy fully and exceed any and all of the obligations the Company would have had to pay you severance benefits in connection with your employment termination, whether pursuant to the Employment Agreement between you and the Company or any other agreement, plan or policy. By executing this Agreement, you agree and acknowledge that the Company&#8217;s obligations to provide you any and all severance benefits (including without limitation under the Employment Agreement), compensation or other benefits, other than as set forth in this </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Agreement, are hereby extinguished. You further acknowledge that, except as expressly provided in this Agreement, you have not earned and will not receive from the Company any additional compensation (including base salary, bonus, incentive compensation, or equity), severance, or benefits before or after the Separation Date, with the exception of any vested right you may have under the express terms of a written ERISA-qualified benefit plan (e.g., 401(k) account) or any vested stock options.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:9pt">Expense Reimbursements. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">You agree that, within thirty (30) days after the Separation Date, you will submit your final documented expense reimbursement statement reflecting all business expenses you incurred through the Separation Date, if any, for which you seek reimbursement. The Company also agrees to reimburse you for up to $10,000 of your reasonable and documented legal fees incurred in connection with negotiating and documenting this Agreement and any related agreements. The Company will reimburse you for these expenses pursuant to its regular business practice.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:9pt">Release of Claims.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:22.7pt">General Release of Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. In exchange for the consideration provided to you under this Agreement to which you would not otherwise be entitled, you hereby generally and completely release the Company, and its affiliated, related, parent and subsidiary entities, and its and their current and former directors, officers, employees, shareholders, partners, agents, attorneys, predecessors, successors, insurers, affiliates, and assigns from any and all claims, liabilities, demands, causes of action, and obligations, both known and unknown, arising from or in any way related to events, acts, conduct, or omissions occurring at any time prior to and including the date you sign this Agreement.</font></div><div style="text-align:justify;text-indent:54pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:22.02pt">Scope of Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. This general release includes, but is not limited to&#58; (i) all claims arising from or in any way related to your employment with the Company or the termination of that employment&#59; (ii) all claims related to your compensation or benefits from the Company, including salary, bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership, equity, or profits interests in the Company&#59; (iii) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing&#59; (iv) all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy&#59; and (v) all federal, state, and local statutory claims, including claims for discrimination, harassment, retaliation, attorneys&#8217; fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the Age Discrimination in Employment Act (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">ADEA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;), the Fair Employment Practice Act of Maryland, the Maryland False Claims Act, the Maryland Parental Leave Act, and the Maryland Healthy Working Families Act.</font></div><div style="text-align:justify;text-indent:54pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:22.7pt">ADEA Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. You acknowledge that you are knowingly and voluntarily waiving and releasing any rights you may have under the ADEA, and that the consideration given for the waiver and releases you have given in this Agreement is in addition to anything of value to which you were already entitled. You further acknowledge that you have been advised, as required by the ADEA, that&#58; (i) your waiver and release does not apply to any rights or claims arising after the date you sign this Agreement&#59; (ii) you should consult with an attorney prior to signing this Agreement (although you may choose voluntarily not to do so)&#59; (iii) you have </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">twenty-one (21) days to consider this Agreement (although you may choose voluntarily to sign it sooner)&#59; (iv) you have seven (7) days following the date you sign this Agreement to revoke this Agreement (in a written revocation sent to the Company)&#59; and (v) this Agreement will not be effective until the date upon which the revocation period has expired, which will be the eighth day after you sign this Agreement provided that you do not revoke it (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;).</font></div><div style="text-align:justify;text-indent:54pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:22.02pt">Waiver of Unknown Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. YOU UNDERSTAND THAT THIS AGREEMENT INCLUDES A RELEASE OF ALL KNOWN AND UNKNOWN CLAIMS, EVEN THOSE UNKNOWN CLAIMS THAT, IF KNOWN BY YOU, WOULD AFFECT YOUR DECISION TO ACCEPT THIS AGREEMENT. In giving the releases set forth in this Agreement, which include claims which may be unknown to you at present, you hereby expressly waive and relinquish all rights and benefits under any law of any jurisdiction with respect to your release of any unknown or unsuspected claims herein.</font></div><div style="text-align:justify;text-indent:54pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:22.7pt">Exceptions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. Notwithstanding the foregoing, you are not releasing the Company hereby from&#58; (i) any obligation to indemnify you pursuant to the Articles and Bylaws of the Company, any valid fully executed indemnification agreement with the Company, applicable law, or applicable directors and officers liability insurance, including but not limited to any tail coverage that is applicable to active directors and officers of the Company&#59; (ii) any claims that cannot be waived by law&#59; (iii) any rights you have to file or pursue a claim for workers&#8217; compensation or unemployment insurance&#59; or (iv) any claims for breach of this Agreement.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:24.03pt">Protected Rights. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">You understand that nothing in this Agreement limits your ability to file a charge or complaint with the Equal Employment Opportunity Commission, the Department of Labor, the National Labor Relations Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission or any other federal, state or local governmental agency or commission (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Government Agencies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;). You further understand this Agreement does not limit your ability to communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company. While this Agreement does not limit your right to receive an award for information provided to the Securities and Exchange Commission, you understand and agree that, to maximum extent permitted by law, you are otherwise waiving any and all rights you may have to individual relief based on any claims that you have released and any rights you have waived by signing this Agreement. Furthermore, nothing in this Agreement waives any rights you may have under Section 7 of the National Labor Relations Act (subject to the release of claims set forth herein).</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:9pt">RETURN OF COMPANY PROPERTY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. You agree that within ten (10) business days after the Separation Date, you will return to the Company all Company documents (and all copies thereof) and other Company property in your possession or control, including, but not limited to, Company files, notes, drawings, records, plans, forecasts, reports, studies, analyses, proposals, agreements, drafts, financial and operational information, research and development information, Company account and device login and password information, sales and marketing information, customer lists, prospect information, pipeline reports, sales reports, personnel information, specifications, code, software, databases, computer-recorded information, tangible property and equipment (including, but not limited to, computing and electronic devices, mobile telephones, servers), credit cards, entry cards, identification badges and keys&#59; and any materials </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">of any kind which contain or embody any proprietary or confidential information of the Company (and all reproductions or embodiments thereof in whole or in part). You agree that you will make a diligent search to locate any such documents, property and information by the close of business on the Separation Date or as soon as possible thereafter. It is agreed that you may retain your laptop, iPad, phones (including phone numbers), printer, and any related peripherals&#59; provided that the Company shall remove any confidential information that is not being utilized for your Advisory Services. If you have used any personally owned computer or other electronic device, server, or e-mail system to receive, store, review, prepare or transmit any Company confidential or proprietary data, materials or information, within ten (10) business days after the Separation Date, you shall provide the Company with a computer-useable copy of such information and then permanently delete and expunge such Company confidential or proprietary information from those systems&#59; and you agree to provide the Company access to your system as requested to verify that the necessary copying and&#47;or deletion is completed. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Your timely compliance with this paragraph is a condition to your receipt of the severance benefits provided under this Agreement. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Following your return of Company property pursuant to this section, the Company may permit you to receive and&#47;or use certain documents and&#47;or information reasonably necessary to perform the Advisory Services, all of which you shall return to the Company by the last day of the Advisory Period, or earlier upon the Company&#8217;s request, without retaining any copies or embodiments (in whole or in part).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:9pt">Confidential Information Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. You acknowledge and reaffirm your continuing obligations under the Employment Agreement, including without limitation Section 6 (Promises and Covenants Regarding Confidential Information and Goodwill&#59; Inventions and Assignment&#59; Restrictive Covenants).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt">Mutual Non-disparagement. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Except to the extent permitted by the Protected Rights Section above, you agree not to disparage the Company, its officers, directors, employees, shareholders, parents, subsidiaries, affiliates, and agents, in any manner likely to be harmful to its or their business, business reputation, or personal reputation&#59; provided that you may respond accurately and fully to any request for information if required by legal process or in connection with a government investigation. In addition, nothing in this provision or this Agreement prohibits or restrains you from making disclosures protected under the whistleblower provisions of federal or state law or from exercising your rights to engage in protected speech under Section 7 of the National Labor Relations Act, if applicable. The Company will instruct members of the Board and executive officers of the Company not to disparage you in any manner that is likely to be harmful to your business reputation or personal reputation&#59; provided that the Company will instruct such individuals that they may respond accurately and fully to any request for information if required by legal process or in connection with a government investigation.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt">No Voluntary Adverse Action. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">You agree that you will not voluntarily (except in response to legal compulsion or as permitted under the section of this Agreement entitled &#8220;Protected Rights&#8221;) assist any person in bringing or pursuing any proposed or pending litigation, arbitration, administrative claim or other formal proceeding against the Company, its parent or subsidiary entities, affiliates, officers, directors, employees or agents.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt">COOPERATION. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">You agree to cooperate fully with the Company in connection with its actual or contemplated defense, prosecution, or investigation of any claims or demands by or against third parties, or other matters arising from events, acts, or failures to act that occurred </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">during the period of your employment by the Company. Such cooperation includes, without limitation, making yourself available to the Company upon reasonable notice, without subpoena, to provide complete, truthful and accurate information in witness interviews, depositions, and trial testimony. The Company will reimburse you for reasonable out-of-pocket expenses you incur in connection with any such cooperation (excluding foregone wages) and will make reasonable efforts to accommodate your scheduling needs. For requests requiring significant investment of time, as determined in good faith by the parties, the Company agrees to negotiate a reasonable hourly rate with you for your time spent on such significant requests.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt">NO ADMISSIONS. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">You understand and agree that the promises and payments in consideration of this Agreement shall not be construed to be an admission of any liability or obligation by the Company to you or to any other person, and that the Company makes no such admission.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt">REPRESENTATIONS. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">You hereby represent that you have&#58; been paid all compensation owed and for all hours worked&#59; received all leave and leave benefits and protections for which you are eligible pursuant to the Family and Medical Leave Act, or otherwise&#59; and not suffered any on-the-job injury for which you have not already filed a workers&#8217; compensation claim.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:3pt">MISCELLANEOUS. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">This Agreement, including Exhibit A, constitutes the complete, final and exclusive embodiment of the entire agreement between you and the Company with regard to its subject matter. It is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any other such promises, warranties or representations. This Agreement may not be modified or amended except in a writing signed by both you and a duly authorized officer of the Company. This Agreement will bind the heirs, personal representatives, successors and assigns of both you and the Company, and inure to the benefit of both you and the Company, their heirs, successors and assigns. If any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination will not affect any other provision of this Agreement and the provision in question will be modified by the court so as to be rendered enforceable to the fullest extent permitted by law, consistent with the intent of the parties. You have the right to consult with an attorney before signing this Agreement. This Agreement will be deemed to have been entered into and will be construed and enforced in accordance with the laws of the state of Maryland without regard to conflict of laws principles. Any ambiguity in this Agreement shall not be construed against either party as the drafter. Any waiver of a breach of this Agreement shall be in writing and shall not be deemed to be a waiver of any successive breach. This Agreement may be delivered and executed via facsimile, electronic mail (including PDF or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, or other applicable law) or other transmission method and shall be deemed to have been duly and validly delivered and executed and be valid and effective for all purposes.</font></div><div style="text-align:justify;text-indent:9pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">If this Agreement is acceptable to you, please sign below and return the original to me. You have twenty-one (21) calendar days to decide whether to accept this Agreement, and the Company&#8217;s offer contained herein will automatically expire if you do not sign and return the Agreement within that timeframe.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:186%">We wish you the best in your future endeavors. Sincerely,</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div style="text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">                                                                    </font></div><div style="text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">William Heiden</font></div><div style="text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Chairman of the Board of Directors</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">I  have  read,  understand  and  agree  fully  to  the  foregoing  Agreement.   I understand that this Agreement includes a release of all known and unknown claims, even those unknown claims that, if known by me, would affect my decision to accept this Agreement.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:9pt"><font><br></font></div><div style="text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">                                                                    </font></div><div style="text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Scott Koenig</font></div><div style="text-indent:27pt"><font><br></font></div><div style="text-indent:27pt"><font><br></font></div><div style="text-indent:27pt"><font><br></font></div><div style="text-indent:27pt"><font><br></font></div><div style="text-indent:27pt"><font><br></font></div><div style="text-indent:27pt"><font><br></font></div><div style="text-indent:27pt"><font><br></font></div><div style="text-indent:27pt"><font><br></font></div><div style="text-indent:27pt"><font><br></font></div><div style="text-indent:27pt"><font><br></font></div><div style="text-indent:27pt"><font><br></font></div><div style="text-indent:27pt"><font><br></font></div><div style="text-indent:27pt"><font><br></font></div><div style="text-indent:27pt"><font><br></font></div><div style="text-indent:27pt"><font><br></font></div><div style="text-indent:27pt"><font><br></font></div><div style="text-indent:27pt"><font><br></font></div><div style="text-indent:27pt"><font><br></font></div><div style="text-indent:27pt"><font><br></font></div><div style="text-indent:27pt"><font><br></font></div><div style="text-indent:27pt"><font><br></font></div><div style="text-indent:27pt"><font><br></font></div><div style="text-indent:27pt"><font><br></font></div><div style="text-indent:27pt"><font><br></font></div><div style="text-indent:27pt"><font><br></font></div><div style="text-indent:27pt"><font><br></font></div><div style="text-indent:27pt"><font><br></font></div><div style="text-indent:27pt"><font><br></font></div><div style="text-indent:27pt"><font><br></font></div><div style="text-indent:27pt"><font><br></font></div><div style="text-indent:27pt"><font><br></font></div><div style="text-indent:27pt"><font><br></font></div><div style="text-indent:27pt"><font><br></font></div><div style="text-indent:27pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-indent:27pt"><font><br></font></div><div style="text-align:center;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">EXHIBIT A</font></div><div style="text-align:center;text-indent:27pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EMPLOYMENT AGREEMENT</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.34
<SEQUENCE>3
<FILENAME>mgnxex1034amendment1jkempl.htm
<DESCRIPTION>EX-10.34
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i37c0a91752ab413989d58a4cfdb5e85b_36"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Exhibit.10.34</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Amendment #1 Employment Agreement</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">THIS AMENDMENT #1 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#8220;Amendment&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">), effective as of January</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">1, 2025 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#8220;Amendment Effective Date&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">), is by and between MacroGenics, Inc. (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#8220;Company&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">) and James Karrels (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#8220;Executive&#8221;) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">(each a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#8220;Party&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">and collectively the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#8220;Parties&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">Company and Executive executed an Employment Agreement effective on October 9, 2013 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#8220;Agreement&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">)&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">wish</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">amend</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">as</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">set</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">forth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> below&#59;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">NOW, THEREFORE, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree to the following terms and conditions&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%;padding-left:9.75pt">All capitalized terms used in this Amendment but not otherwise defined herein, shall have the meanings ascribed to such terms in the Agreement.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%;padding-left:9.75pt">References to the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">stock option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">&#8221; in the Agreement are hereby replaced with term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">equity grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">&#8221;. With</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">respect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">references</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">related</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">accelerated</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">options,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">grants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">shall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">only include stock options and restricted stock units.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%;padding-left:9.75pt">This</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">constitute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">entire</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">supersede</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">any</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">and all</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">prior</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">agreements,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">written</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">oral,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">between</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">relating</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">subject</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">matter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">this</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">Amendment and the Agreement and may not be amended unless agreed to in writing by both Parties.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%;padding-left:9.75pt">This Amendment may be executed in counterparts each of which will be deemed an original, but all of which</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">together</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">constitute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">one</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">same</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">instrument.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">Signatures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">transmitted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">email</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">after</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">having been scanned will be accepted as originals for the purposes of this Amendment.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:112%">IN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:112%">WITNESS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:112%">WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">hereto</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">have</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">executed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">this</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">as</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">Effective</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> Date.</font></div><div style="text-align:justify;text-indent:5.6pt"><font><br></font></div><div style="text-align:justify;text-indent:5.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:112%">MacroGenics,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> Inc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                                                                    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Executive</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">                                         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                                                    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">                                         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                                    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">     Scott Koenig, M.D., Ph.D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                                                             James Karrels</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">President</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> CEO                                                                                          </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.35
<SEQUENCE>4
<FILENAME>mgnxex1035amendment1seckem.htm
<DESCRIPTION>EX-10.35
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="id98f5c8efa114208810cf04e34d40e80_36"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Exhibit.10.35</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Amendment #1 Employment Agreement</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">THIS AMENDMENT #1 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#8220;Amendment&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">), effective as of January</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">1, 2025 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#8220;Amendment Effective Date&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">), is by and between MacroGenics, Inc. (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#8220;Company&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">) and Stephen L. Eck, M.D., Ph.D. (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#8220;Executive&#8221;) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">(each a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#8220;Party&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">and collectively the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#8220;Parties&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">Company and Executive executed an Employment Agreement effective on July 1, 2020 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#8220;Agreement&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">)&#59; and</font></div><div style="text-align:justify;text-indent:5.6pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">wish</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">amend</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">as</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">set</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">forth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> below&#59;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">NOW, THEREFORE, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree to the following terms and conditions&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%;padding-left:9.75pt">All capitalized terms used in this Amendment but not otherwise defined herein, shall have the meanings ascribed to such terms in the Agreement.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%;padding-left:9.75pt">References to the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">stock option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">&#8221; in the Agreement are hereby replaced with term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">equity grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">&#8221;. With</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">respect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">references</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">related</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">accelerated</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">options,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">grants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">shall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">only include stock options and restricted stock units.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%;padding-left:9.75pt">This</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">constitute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">entire</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">supersede</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">any</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">and all</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">prior</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">agreements,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">written</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">oral,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">between</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">relating</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">subject</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">matter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">this</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">Amendment and the Agreement and may not be amended unless agreed to in writing by both Parties.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%;padding-left:9.75pt">This Amendment may be executed in counterparts each of which will be deemed an original, but all of which</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">together</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">constitute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">one</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">same</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">instrument.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">Signatures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">transmitted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">email</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">after</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">having been scanned will be accepted as originals for the purposes of this Amendment.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:112%">IN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:112%">WITNESS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:112%">WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">hereto</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">have</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">executed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">this</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">as</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">Effective</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> Date.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:112%">MacroGenics,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> Inc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                                                                    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Executive</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">                                         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                                                    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">                                         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                                    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">     Scott Koenig, M.D., Ph.D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                                                              </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">Stephen Eck, M.D.,Ph.D.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">President</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> CEO                                                              </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.36
<SEQUENCE>5
<FILENAME>mgnxex1036amendment_toxkoe.htm
<DESCRIPTION>EX-10.36
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="if15813531ad24417b19dfc1f0f337a66_1"></div><div style="min-height:77.04pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.36</font></div></div><div style="margin-top:3.75pt;padding-left:36.65pt;padding-right:36.65pt;text-align:center"><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;text-decoration:underline">AMENDMENT TO SEPARATION AND CONSULTING AGREEMENT</font></div><div style="margin-top:12.7pt;padding-left:5.65pt;padding-right:5.6pt;text-align:justify;text-indent:35.75pt"><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">This Amendment to Separation and Consulting Agreement (this </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:122%">&#34;Amendment&#34;) </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">is entered into on February 25, 2025, by and between MacroGenics, Inc. (the </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:122%">&#34;Company&#34;), </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">and Dr. Scott Koenig </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:122%">(&#34;you&#34;).</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:20.2pt;padding-right:20.2pt;text-align:center"><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-top:1.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.8pt;padding-right:5.65pt;text-align:justify;text-indent:35.85pt"><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:124%">WHEREAS, </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:124%">you and the Company previously entered into that certain Separation and Consulting Agreement dated October 25, 2024 (the </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:124%">&#34;Agreement&#34;)&#59;</font></div><div><font><br></font></div><div style="padding-left:5.6pt;padding-right:5.8pt;text-align:justify;text-indent:36.05pt"><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:122%">WHEREAS</font><font style="color:#545454;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:122%">, </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">the Company's Board of Directors (the </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:122%">&#34;Board&#34;) </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">has established a special committee to oversee a search process to identify the Company's next Chief </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">Executive </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">Officer, and such committee expects to conclude such process within the coming weeks&#59;</font></div><div style="margin-top:0.85pt"><font><br></font></div><div style="padding-left:5.9pt;padding-right:5.15pt;text-align:justify;text-indent:35.75pt"><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">WHEREAS, </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">your Separation Date under the Agreement is February 28, 2025</font><font style="color:#545454;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">, </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">which date may be extended with the mutual consent of the Company's Board of Directors and you&#59; and</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:41.9pt"><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">WHEREAS, </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">the parties now desire to amend the Agreement as set forth herein.</font></div><div style="margin-top:1.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:35.4pt;padding-right:35.4pt;text-align:center"><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">AGREEMENT</font></div><div style="margin-top:1.15pt"><font><br></font></div><div style="padding-left:6.05pt;padding-right:5.25pt;text-align:justify;text-indent:35.8pt"><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:122%">NOW, THEREFORE, </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">in consideration of the foregoing and the mutual covenants and promises set forth herein, the parties agree as follows&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5.85pt;padding-right:18.75pt;text-indent:36.05pt"><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">1.</font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:21.48pt;text-decoration:underline">Amendment of Section 1</font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;Section 1 of the Agreement is hereby amended and restated to modify the timing of the Separation Date and provide you with the eligibility to receive a prorated 2025 annual bonus, as follows&#58;</font></div><div style="margin-top:0.75pt"><font><br></font></div><div style="padding-left:41.9pt;padding-right:37.1pt;text-align:justify;text-indent:0.05pt"><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">1.</font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;padding-left:21.43pt">SEPARATION. </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Your last day of work with the Company and your employment termination date will be a date to be determined by the Board of Directors of the Company (or committee thereof) (the </font><font style="color:#383838;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">&#34;Separation </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">Date&#34;) </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">upon fourteen (14) days' notice to you. You may elect, upon seven (7) days' notice to the Company</font><font style="color:#545454;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">, </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">to change the Separation Date to a date that is earlier than the date determined by the Board of Directors (or committee thereof). You will receive </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">your </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">full normal 2024 annual bonus regardless of whether </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">your </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Separation Date occurs before the date on which the 2024 annual bonus is paid. In addition, you will receive a prorated target 2025 annual bonus, to be paid at the next regular payroll payment date after the Separation Date. Effective as of the Separation Date, you hereby voluntarily resign your position on the Company</font><font style="color:#545454;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">'</font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">s Board of Directors, and </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">resign </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">from any and all other officer or other positions you may hold with the Company, its Board of Directors, and any affiliated or related companies&#59; provided that, upon the written request of the incoming Chief Executive Officer of the Company, which request shall be made prior to the Separation Date, you may revoke your resignation from the Board of Directors. (For the avoidance of doubt, such resignations are effective upon your execution of this Agreement, and regardless of whether or not </font><font style="color:#262626;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">you </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">revoke this</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="if15813531ad24417b19dfc1f0f337a66_4"></div><hr style="page-break-after:always"><div style="min-height:71.28pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.36</font></div></div><div style="margin-top:3.75pt;padding-left:42.3pt;padding-right:37.5pt;text-align:justify;text-indent:0.3pt"><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Agreement as set forth below.) You understand and agree that you are not authorized to hold yourself out as being employed or affiliated with the Company in any way following the Separation Date, including as a member of the Board of Directors.</font></div><div style="margin-top:0.95pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6.35pt;padding-right:11.3pt;text-align:justify;text-indent:36.15pt"><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">2.</font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%;padding-left:20.88pt;text-decoration:underline">Effect on Severance Payments.</font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%"> For the avoidance of doubt, (i) commencement of Severance Payments pursuant to Section 3(a) of the Agreement and (ii) the vesting of equity awards pursuant to Section 3(c) of the Agreement shall not occur until the Separation Date, as determined pursuant to Section 1 of the Agreement, as amended.</font></div><div style="margin-top:0.85pt"><font><br></font></div><div style="padding-left:6.3pt;padding-right:11.3pt;text-align:justify;text-indent:36.2pt"><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">3.</font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%;padding-left:20.88pt;text-decoration:underline">Release.</font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%"> As part of this Amendment and in exchange for the benefits provided to you pursuant to this Amendment, you hereby acknowledge and agree that the releases provided by you in Paragraph 7 of the Agreement shall apply fully and completely to waive and release any claims that you may have that arise out of or are in any way related to events, acts, conduct, or omissions occurring during the period of time from the date you first signed this Agreement to the date of your signature below.</font></div><div style="margin-top:0.95pt"><font><br></font></div><div style="padding-left:6.3pt;padding-right:12.4pt;text-align:justify;text-indent:36pt"><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">4.</font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%;padding-left:21.08pt;text-decoration:underline">Advisory Period.</font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%"> The third sentence of Section 4(a) of the Agreement is hereby amended and restated as follows&#58;</font></div><div style="margin-top:0.8pt"><font><br></font></div><div style="padding-left:42.15pt;padding-right:32.45pt;text-align:justify;text-indent:0.4pt"><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">However</font><font style="color:#4b4b4b;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">, </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">if you timely sign and return this Agreement to the Company, and allow it to become effective, then the Company will continue your advisory engagement until the fifth anniversary of the Separation Date, unless earlier terminated pursuant to Paragraph 4(i) below or extended by the parties in writing.</font></div><div style="margin-top:0.9pt"><font><br></font></div><div style="padding-left:6.35pt;padding-right:8.75pt;text-align:justify;text-indent:36.05pt"><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">5.</font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%;padding-left:20.98pt;text-decoration:underline">Remaining Terms Ratified.</font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%"> Except as expressly amended herein, all terms and provisions of the Agreement are and shall remain in full force and effect and all references therein to such Agreement shall henceforth refer to the Agreement as amended by the Amendment.</font></div><div style="margin-top:0.6pt"><font><br></font></div><div style="padding-left:6.3pt;padding-right:8.4pt;text-align:justify;text-indent:36.15pt"><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">6.</font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:20.93pt;text-decoration:underline">Entire Agreement.</font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">The </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Agreement, as amended by the Amendment, constitutes the full and complete agreement between the parties hereto regarding the subject matter of the Agreement and shall supersede all prior understandings or agreements, if any, whether written or oral, concerning the subject matter of the Agreement, as amended.</font></div><div style="margin-top:0.65pt"><font><br></font></div><div style="padding-left:6.3pt;padding-right:8.45pt;text-align:justify;text-indent:36pt"><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">7.</font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:21.08pt;text-decoration:underline">Counterparts.</font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> This Amendment may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together </font><font style="color:#2f2f2f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">shall </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:400;line-height:120%">DocuSign) </font><font style="color:#161616;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.</font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="if15813531ad24417b19dfc1f0f337a66_7"></div><hr style="page-break-after:always"><div style="min-height:84.24pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit 10.36</font></div></div><div style="margin-top:3.3pt;padding-left:6.2pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#3f3f3f;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">, </font><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">the undersigned have executed this Amendment as of the date first written above.</font></div><div style="margin-top:0.6pt"><font><br></font></div><div style="padding-left:6.3pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">MACROGENICS, INC.</font></div><div style="margin-top:0.05pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">  By&#58; __________________________</font></div><div style="margin-top:0.4pt;padding-left:6.2pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Name&#58; William Heiden</font></div><div style="margin-top:0.7pt;padding-left:6.2pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Title&#58; Chairman of the Board of Directors</font></div><div><font><br></font></div><div style="margin-top:8.65pt"><font><br></font></div><div style="padding-left:6.05pt"><font style="color:#111111;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Scott Koenig, M.D., Ph.D.</font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>6
<FILENAME>mgnxex19insidertradingpoli.htm
<DESCRIPTION>EX-19.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="id631440d965d4897b602e133cb79549c_1"></div><div style="min-height:69.12pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Exhibit 19.1</font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MACROGENICS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> INSIDER TRADING POLICY</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:12pt;padding-right:6.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">This Insider Trading Policy (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221;) provides the standards of MacroGenics, Inc. and its affiliates (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">&#34;Company&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">) for trading and causing the trading of the Company's securities or securities of other publicly-traded companies while in possession of confidential information. </font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:12pt;padding-right:9.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">One of the purposes of the federal securities laws is to prohibit so-called &#34;insider trading.&#34; Simply stated, insider trading occurs when a person uses material non-public information to make decisions to purchase, sell, give away or otherwise trade a company's securities or to provide that information to others outside the company. The prohibitions against insider trading apply to trades, tips and recommendations by virtually any person, including all persons associated with the company, if the information involved is &#34;material&#34; and &#34;non-public.&#34; These terms are defined in this Policy under Part I, Section 3 below. </font></div><div style="margin-top:0.05pt;padding-left:12pt;padding-right:9.4pt;text-indent:36pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:12pt;padding-right:9.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Any person who has a question about this Policy or its application to any proposed transaction may obtain additional guidance from the General Counsel (or their designee).  </font></div><div style="margin-top:0.05pt;padding-left:12pt;padding-right:9.4pt;text-indent:36pt"><font><br></font></div><div style="margin-top:0.55pt;text-align:center;text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">Scope of Policy</font></div><div style="margin-top:4.5pt;padding-left:12pt;padding-right:6.8pt;text-indent:36pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:12pt;padding-right:6.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">This Policy applies to all transactions in the Company's securities, including common stock, options and any other securities that the Company may issue, such as preferred stock, notes, bonds and convertible securities, as well as to derivative securities relating to any of the Company's securities, whether or not issued by the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Accordingly, for purposes of this Policy, the terms &#8220;trade,&#8221; &#8220;trading&#8221; and &#8220;transactions&#8221; include not only purchases and sales of the Company&#8217;s securities in the public market but also any other purchases, sales, transfers, gifts or other acquisitions and dispositions of common or preferred equity, options, warrants and other securities (including debt securities) and other arrangements or transactions that affect economic exposure to changes in the prices of these securities.</font></div><div style="margin-top:4.5pt;padding-left:12pt;padding-right:6.8pt;text-indent:36pt"><font><br></font></div><div style="padding-left:12pt;padding-right:6.8pt;text-indent:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">This Policy applies to all directors, officers and employees of the Company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">MacroGenics Personnel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#8221;).  It also applies to MacroGenics Personnel family members, others living in the household, and any entities over which any MacroGenics Personnel exercises control.  MacroGenics Personnel are responsible for such individuals and entities&#8217; compliance with the provisions of this Policy. </font></div><div style="padding-left:24pt;padding-right:6.8pt;text-indent:24pt"><font><br></font></div><div style="padding-left:12pt;padding-right:6.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">The Policy is divided into two parts&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">Part I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> applies to all MacroGenics Personnel.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">Part II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> imposes special additional trading restrictions and applies to (i) all directors of the Company&#59; (ii) all executive officers of the Company&#59; and (iii) the employees so designated from time to time by an Authorized Company Official (collectively, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">&#34;Covered Persons&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">).</font></div><div style="padding-right:6.8pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:216pt;padding-right:216pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:13.75pt">Part I</font></div><div style="margin-top:4.5pt;padding-right:-0.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:13.75pt">MacroGenics Personnel Trading Restrictions</font></div><div style="padding-right:6.8pt"><font><br></font></div><div style="padding-left:30pt;padding-right:16.15pt;text-indent:-15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;padding-left:6pt">General Policy&#58; No Trading or Causing Trading While in Possession of Material Non- public Information</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:3.8pt;padding-left:18pt;padding-right:5.8pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:22.58pt">MacroGenics Personnel may not purchase or sell any Company security, whether or not issued by the Company, while in possession of material non-public information about the Company. The terms &#34;material&#34; and &#34;non-public&#34; are defined in Part I, Section 3(a) and (b) below. MacroGenics Personnel who may be in possession of material non-public information are bound by confidentiality obligations regarding the Company&#8217;s business in all cases, and in particular should not share material non-public information about the Company with any other person, unless authorized.  Sharing material non-public information without authorization to any person, including to family and friends, puts the employee and the other person or persons at risk of violation of the insider trading laws </font></div><div style="margin-top:3.8pt;padding-left:18pt;padding-right:5.8pt;text-indent:22.5pt"><font><br></font></div><div style="padding-left:18pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.34pt">MacroGenics Personnel may not purchase or sell any security of any other company, whether or not issued by the Company, while in possession of material non- public information about that company that was obtained in the course of their involvement with the Company. MacroGenics Personnel who know of any such material non-public information may not communicate that information to any other person, including family and friends.</font></div><div style="padding-left:18pt;text-indent:22.5pt"><font><br></font></div><div style="padding-left:18pt;padding-right:22.5pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:22.58pt">MacroGenics Personnel should never trade, tip or recommend securities (or otherwise cause the purchase or sale of securities) while in possession of information that individual has reason to believe is material and non-public unless such MacroGenics Personnel obtains the advance approval of the Compliance Officer.</font></div><div style="padding-left:18pt;text-indent:22.5pt"><font><br></font></div><div style="padding-left:18pt;padding-right:12.05pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:21.93pt">Covered Persons must &#34;pre-clear&#34; all trading in securities of the Company in accordance with the procedures set forth in Part II, Section 3 below.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:30pt;text-indent:-15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;padding-left:6pt">Other Prohibited Transactions</font></div><div style="margin-top:0.05pt;padding-left:30pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company considers it improper and inappropriate for MacroGenics Personnel to engage in short-term or speculative transactions in the Company&#8217;s securities or in other transactions that may lead to inadvertent violations of the insider trading laws or the appearance of profiting off of insider information, potentially triggering a government investigation.  Accordingly, trading in the Company&#8217;s securities by MacroGenics Personnel is subject to the following additional restrictions&#58;</font></div><div style="margin-top:0.05pt;padding-left:30pt"><font><br></font></div><div style="padding-left:12pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:32.69pt;text-decoration:underline">Short sales.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> MacroGenics Personnel may not sell the Company's securities short&#59;</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:12pt;padding-right:20.75pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:32.01pt;text-decoration:underline">Options trading.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> MacroGenics Personnel may not buy or sell puts or calls or other derivative securities on the Company's securities&#59;</font></div><div><font><br></font></div><div style="padding-left:12pt;padding-right:38.1pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:32.69pt;text-decoration:underline">Trading on margin or pledging.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> MacroGenics Personnel may not hold Company securities in a margin account or pledge Company securities as collateral for a loan&#59; and</font></div><div><font><br></font></div><div style="padding-left:12pt;padding-right:21.3pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:32.01pt;text-decoration:underline"> Hedging.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> MacroGenics Personnel may not enter into hedging or monetization transactions or similar arrangements with respect to Company securities.</font></div><div style="margin-top:0.05pt;padding-left:30pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:30pt;text-indent:-15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;padding-left:6pt">No Trading in Securities of Other Companies While Aware of Material Non-public Information</font></div><div style="margin-top:0.05pt;padding-left:30pt"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">MacroGenics, Inc. &#8211; Insider Trading Policy</font></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="margin-top:0.05pt;padding-left:15pt;text-indent:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company may engage in business transactions with companies whose securities are publicly traded. These transactions may include, among other things, mergers, acquisitions, divestitures or renewal or termination of significant contracts, collaborations and license agreements or other arrangements. Information learned in connection with these transactions or relationships may constitute material non-public information about the other company. MacroGenics Personnel are prohibited from trading in the securities of these companies while aware of material non-public information about the companies and from communicating that information to any other person for such use.</font></div><div style="margin-top:0.05pt;padding-left:30pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:30pt;text-indent:-15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;padding-left:6pt">Definitions</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:13.5pt;padding-right:5.65pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:31.58pt;text-decoration:underline">Materiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> -- Insider trading restrictions come into play only if the information is &#34;material.&#34; Information is generally regarded as &#34;material&#34; if it has market significance, that is, if its public dissemination is likely to affect the market price of securities, or if it otherwise is information that a reasonable investor would want to know before making an investment decision.</font></div><div style="margin-top:0.5pt;padding-left:13.5pt;text-indent:18pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:12pt;padding-right:10.75pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Information dealing with the certain subjects is reasonably likely to be found material in particular situations.  These subjects include but are not limited to&#58;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.8pt">financial results or forecasts&#59;</font></div><div style="margin-top:0.05pt;padding-left:48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.8pt">significant changes in the Company's prospects&#59;</font></div><div style="padding-left:48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:14.65pt">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:14.65pt;padding-left:13.8pt">developments in connection with pre-clinical and clinical trials&#59;</font></div><div style="padding-left:48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:14.65pt">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:14.65pt;padding-left:13.8pt">significant litigation or government agency inquiries or investigations&#59;</font></div><div style="padding-left:48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:14.65pt">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:14.65pt;padding-left:13.8pt">liquidity problems&#59;</font></div><div style="padding-left:48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:14.65pt">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:14.65pt;padding-left:13.8pt">major changes in management, departure in key personnel or large volume employee layoffs&#59;</font></div><div style="padding-left:48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:14.65pt">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:14.65pt;padding-left:13.8pt">entering into major contracts or major contract cancellations&#59;</font></div><div style="padding-left:48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:14.65pt">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:14.65pt;padding-left:13.8pt">a disruption in the Company&#8217;s operations or breach or unauthorized access of its property or assets, including its facilities or information technology infrastructure&#59; </font></div><div style="padding-left:48pt;padding-right:9.25pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.8pt">proposals, plans or agreements, even if preliminary in nature, involving mergers, acquisitions, divestitures, recapitalizations, strategic alliances, licensing arrangements, or purchases or sales of substantial assets&#59; and</font></div><div style="padding-left:48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:14.65pt">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:14.65pt;padding-left:13.8pt">capital raising plans.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:12pt;padding-right:5.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Material information is not limited to historical facts but may also include projections and forecasts.  With respect to a future event, such as a collaboration or introduction of a new product candidate, for example, the point at which negotiations or product development are determined to be material is determined by balancing the probability that the event will occur against the magnitude of the effect the event would have on a company's operations or stock price should it occur. Thus, information concerning an event that would have a large effect on stock price, such as a new collaboration, may be material even if the possibility that the event will occur is relatively small. </font></div><div style="margin-top:0.05pt;padding-left:12pt;padding-right:5.4pt;text-indent:36pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:12pt;padding-right:5.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">When in doubt about whether particular non-public information is material, presume it is material unless instructed otherwise.  Any person with questions about the potential materiality of particular non-public Company information in their possession should contact the department head or the General Counsel.   </font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:12pt;padding-right:5.3pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Non-public Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> -- Insider trading prohibitions come into play only when you possess information that is material </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> &#34;non-public.&#34; The fact that information has been disclosed to a few members of </font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">MacroGenics, Inc. &#8211; Insider Trading Policy</font></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:12pt;padding-right:5.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">the public does not make it public for insider trading purposes. To be &#34;public&#34; the information must have been disseminated in a manner designed to reach investors generally, and the investors must be given the opportunity to absorb the information.  As a rule of thumb, there should a referenceable source reflecting the widespread distribution of the information. In addition, under this Policy, Covered Persons must wait until the close of business on the second trading day after the information was publicly disclosed before the information will be considered public. </font></div><div style="padding-left:30pt;padding-right:5.3pt"><font><br></font></div><div style="padding-left:12pt;padding-right:5.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Examples of non-public information may include&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:14.65pt">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:14.65pt;padding-left:13.8pt">information available to a select group of analysts or brokers or institutional investors&#59;</font></div><div style="padding-left:48pt;padding-right:10.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.8pt">undisclosed facts that are the subject of rumors, even if the rumors are widely circulated&#59; and</font></div><div style="padding-left:48pt;padding-right:11pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:13.8pt">information that has been entrusted to the Company on a confidential basis until a public announcement of the information has been made and enough time has elapsed for the market to respond to a public announcement of the information.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:18pt;padding-right:25.15pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:26.43pt;text-decoration:underline">Authorized Company Official</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> &#8211; With respect to this Policy, an Authorized Company Official includes the General Counsel, Compliance Officer, Chief Financial Officer, or their designees.  The duties of the Authorized Company Official include&#58;</font></div><div style="padding-left:36pt;padding-right:25.15pt;text-align:justify"><font><br></font></div><div style="padding-left:45pt;padding-right:25.15pt;text-align:justify;text-indent:-15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:10.8pt">identifying and notifying employees of their status as a Covered Person, and any other duties delegated by the General Counsel&#59;</font></div><div style="padding-left:45pt;padding-right:17.7pt;text-indent:-15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:10.8pt">pre-clearing all trading in securities of the Company by Covered Persons in accordance with the procedures set forth in Part II, Section 3 below&#59; and</font></div><div style="padding-left:45pt;text-indent:-15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:14.65pt">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:14.65pt;padding-left:10.8pt">providing approval of any transactions under Part II, Section 3 below.</font></div><div style="padding-left:30pt;padding-right:25.15pt;text-align:justify"><font><br></font></div><div style="padding-left:11.95pt;text-indent:28.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:22.58pt;text-decoration:underline">General Counsel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> &#8211; With respect to this Policy, the duties of the General Counsel, which duties the General Counsel may delegate an Authorized Company Official, include, but are not limited to, circulating this Policy to all MacroGenics Personnel and ensuring that this Policy is amended as necessary to remain up-to-date with insider trading laws .</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:30pt;text-indent:-15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;padding-left:6pt">Violations of Insider Trading Laws</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:12pt;padding-right:8.75pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Penalties for trading on or communicating material non-public information can be severe, both for individuals involved in such unlawful conduct and their employers and supervisors, and may include jail terms, criminal fines, civil penalties and civil enforcement injunctions. Given the severity of the potential penalties, compliance with this Policy is absolutely mandatory.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:11.95pt;padding-right:5.2pt;text-indent:15.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:0.08pt;text-decoration:underline">Legal Penalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">. A person who violates insider trading laws by engaging in transactions in a company's securities when they have material non-public information can be sentenced to a substantial jail term and required to pay a penalty of several times the amount of profits gained or losses avoided.</font></div><div style="margin-top:0.05pt;text-indent:15.05pt"><font><br></font></div><div style="padding-left:12pt;padding-right:10.1pt;text-indent:15.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">In addition, a person who tips others may also be liable for transactions by the tippees to whom he or she has disclosed material non-public information. Tippers can be subject to the same penalties and sanctions as the tippees, and the SEC has imposed large penalties even when the tipper did not profit from the transaction.</font></div><div style="text-indent:15.05pt"><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">MacroGenics, Inc. &#8211; Insider Trading Policy</font></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="padding-left:12pt;padding-right:5.5pt;text-indent:15.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">The SEC can also seek substantial penalties from any person who, at the time of an insider trading violation, &#34;directly or indirectly controlled the person who committed such violation,&#34; which would apply to the Company and&#47;or management and supervisory personnel. These control persons may be held liable for up to the greater of $1 million or three times the amount of the profits gained or losses avoided. Even for violations that result in a small or no profit, the SEC can seek a minimum of $1 million from a company and&#47;or management and supervisory personnel as control persons.</font></div><div style="text-indent:15.05pt"><font><br></font></div><div style="padding-left:11.95pt;padding-right:8.45pt;text-indent:15.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:35.43pt;text-decoration:underline">Company-imposed Penalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">. MacroGenics Personnel who violate this Policy may be subject to disciplinary action by the Company, including dismissal for cause. Any exceptions to the Policy, if permitted, may only be granted by the General Counsel and must be provided before any activity contrary to the above requirements takes place.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:224pt;padding-right:224pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">Part II</font></div><div style="padding-left:1.75pt;padding-right:1.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">Additional Trading Restrictions for Covered Persons</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;padding-left:9.38pt">Blackout Periods</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:12pt;padding-right:34.25pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">All Covered Persons are prohibited from trading in the Company's securities during blackout periods.</font></div><div style="padding-left:12pt"><font><br></font></div><div style="padding-left:18pt;padding-right:8.5pt;text-indent:7.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:1.53pt;text-decoration:underline">Quarterly Blackout Periods</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">. Trading in the Company's securities is prohibited during the period beginning on the closing of each fiscal quarter and ending at the close of business on the second business day following the date the Company's financial results are publicly disclosed. During these periods, Covered Persons generally possess or are presumed to possess material non-public information about the Company's financial results.</font></div><div style="padding-left:18pt;text-indent:7.55pt"><font><br></font></div><div style="padding-left:18pt;padding-right:19pt;text-indent:7.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:0.88pt;text-decoration:underline"> Other Blackout Periods</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">. From time to time, other types of material non-public information regarding the Company (such as negotiation of new collaborations or clinical developments) may be pending and not be publicly disclosed. While such material non-public information is pending, the Company may impose special blackout periods during which Covered Persons are prohibited from trading in the Company's securities. If the Company imposes a special blackout period, it will notify the Covered Persons affected.</font></div><div style="padding-left:18pt;padding-right:19pt;text-indent:7.55pt"><font><br></font></div><div style="margin-top:3.8pt;padding-left:18pt;padding-right:22.6pt;text-align:justify;text-indent:7.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:1.53pt;text-decoration:underline"> Exception</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">. These trading restrictions do not apply to transactions under a pre-existing written plan, contract, instruction, or arrangement under Rule 10b5-1 of the Securities Exchange Act (an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">&#34;Approved 10b5-1 Plan&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">) pursuant to Legal Department guidelines as may be adopted from time to time. </font></div><div><font><br></font></div><div style="padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;padding-left:9.38pt">Trading Window</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:12pt;padding-right:6.8pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Covered Persons are permitted to trade in the Company's securities when no blackout period is in effect, assuming they are not in possession of material non-public information.  Generally, this means that Covered Persons can trade during the period beginning on the day that the blackout period under Part II, Section 1(a) ends. However, even during this trading window, a Covered Person who is in possession of any material non-public information is prohibited from trading in the Company's securities. In addition, the Company may close this trading window if a special blackout period under Part II, Section 1(b) above is imposed and will re-open the trading window once the special blackout period has ended.</font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">MacroGenics, Inc. &#8211; Insider Trading Policy</font></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:33pt;text-indent:-21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;padding-left:12.38pt">Pre-clearance of Securities Transactions</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:13.5pt;padding-right:19.6pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:0.08pt">Because Covered Persons are likely to obtain material non-public information on a regular basis, the Company requires all such persons to refrain from trading, even during a trading window under Part II, Section 2 above, without first pre-clearing all transactions in the Company's securities.</font></div><div style="margin-top:0.55pt;padding-left:13.5pt;text-indent:13.5pt"><font><br></font></div><div style="padding-left:13.5pt;padding-right:5.85pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:35.43pt">Subject to the exemption in subsection (d) below, no Covered Person may, directly or indirectly, purchase or sell (or otherwise make any transfer, gift, pledge or loan of) any Company security at any time without first obtaining prior approval from the Authorized Company Official. These procedures also apply to transactions by such person's spouse, other persons living in such person&#8217;s household and minor children and to transactions by entities over which such person exercises control.</font></div><div style="padding-left:13.5pt;text-indent:13.5pt"><font><br></font></div><div style="padding-left:13.5pt;padding-right:11.75pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:0.08pt">The Authorized Company Official shall record the date each request is received and the date and time each request is approved or disapproved. Unless revoked, a grant of permission will normally remain valid until the close of trading two business days following the day on which it was granted. If the transaction does not occur during the two-day period, pre-clearance of the transaction must be re-requested.</font></div><div style="margin-top:0.35pt;padding-left:13.5pt;text-indent:13.5pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:13.5pt;padding-right:28.45pt;text-indent:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:35.43pt">Pre-clearance is not required for purchases and sales of securities under an Approved 10b5-1 Plan. With respect to any purchase or sale under an Approved 10b5-1 Plan, the third party effecting transactions on behalf of the Covered Person should be instructed to send duplicate confirmations of all such transactions to the Compliance Officer.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.55pt;padding-left:30pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;padding-left:9.38pt">Short Term Trading by Covered Persons</font></div><div><font><br></font></div><div style="text-indent:30pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Certain Covered Persons (officers and directors) who purchase Company securities may not sell any Company securities of the same class for at least six months after the purchase. This prohibition does not apply to stock option exercises (whether regular or cashless) and Employee Stock Purchase Plan purchases. </font></div><div><font><br></font></div><div style="height:48.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">MacroGenics, Inc. &#8211; Insider Trading Policy</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>7
<FILENAME>mgnxexhibit23-1202410xk.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="iad7a383c62e7474da8c9117197bb86cc_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 23.1</font></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:3pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Registration Statement (Form S-8 No. 333-192277) pertaining to the 2000 Stock Option and Incentive Plan, the 2003 Equity Incentive Plan, and 2013 Equity Incentive Plan of MacroGenics, Inc.,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Registration Statements (Form S-8 No. 333-202470) pertaining to the 2013 Equity Incentive Plan of MacroGenics, Inc.,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Registration Statements (Form S-8 No. 333-209812) pertaining to the 2013 Equity Incentive Plan of MacroGenics, Inc.,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Registration Statements (Form S-8 No. 333-217620) pertaining to the 2013 Equity Incentive Plan of MacroGenics, Inc.,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Registration Statements (Form S-8 No. 333-223682) pertaining to the 2013 Equity Incentive Plan of MacroGenics, Inc.,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Registration Statements (Form S-8 No. 333-230292) pertaining to the 2013 Equity Incentive Plan of MacroGenics, Inc.,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Registration Statements (Form S-8 No. 333-237127) pertaining to the 2013 Equity Incentive Plan of MacroGenics, Inc.,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Registration Statements (Form S-8 No. 333-253502) pertaining to the 2013 Equity Incentive Plan of MacroGenics, Inc.,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Registration Statements (Form S-8 No. 333-262967) pertaining to the 2013 Equity Incentive Plan of MacroGenics, Inc.,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:5.5pt">Registration Statement (Form S-8 No. 333-270562) pertaining to the 2013 Equity Incentive Plan of MacroGenics, Inc., </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:5.5pt">Registration Statement (Form S-8 No. 333-214386) pertaining to the 2016 Employee Stock Purchase Plan of MacroGenics, Inc.,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:5.5pt">Registration Statement (Form S-8 No. 333-272451) pertaining to the 2023 Equity Incentive Plan of MacroGenics, Inc.,</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:5.5pt">Registration Statement (Form S-3 No. 333-275343) of MacroGenics, Inc., and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:5.5pt">Registration Statement (Form S-8 No. 333-279674) pertaining to the 2023 Equity Incentive Plan of MacroGenics, Inc.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our reports dated March&#160;20, 2025, with respect to the consolidated financial statements of MacroGenics, Inc. and the effectiveness of internal control over financial reporting of MacroGenics, Inc. included in this Annual Report (Form 10-K) of MacroGenics, Inc. for the year ended December&#160;31, 2024.</font></div><div style="margin-bottom:3pt;margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Ernst&#160;&#38; Young LLP</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tysons, Virginia</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;20, 2025</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>8
<FILENAME>mgnxexhibit31-1202410xk.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="if29f7f2b2b2c428188811b59628c0329_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 31.1</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Scott Koenig, certify that&#58;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Annual Report on Form 10-K for the period ended December&#160;31, 2024 of MacroGenics, Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:126pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:126pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.538%"><tr><td style="width:1.0%"></td><td style="width:40.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.229%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Scott&#160;Koenig</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Koenig, M.D., Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58;&#160;March&#160;20, 2025&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>9
<FILENAME>mgnxexhibit31-2202410xk.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i0e8e862f7a1144a6ab0de8ce21bd42bc_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 31.2</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, James Karrels, certify that&#58;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Annual Report on Form 10-K for the period ended December&#160;31, 2024 of MacroGenics, Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)</font></div><div style="margin-bottom:9pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.339%"><tr><td style="width:1.0%"></td><td style="width:22.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.179%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; James Karrels</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Karrels</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58;&#160;March&#160;20, 2025&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>10
<FILENAME>mgnxexhibit32-1202410xk.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i603dbe8975fc4b4d85b48a0193b25ed7_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Executive Officer Pursuant to 18 U.S.C. 1350 (Section 906 of the Sarbanes-Oxley Act of 2002)</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Scott Koenig, President and Chief Executive Officer (principal executive officer) of MacroGenics, Inc. (the &#8220;Registrant&#8221;), certify, to the best of my knowledge, based upon a review of the Annual Report on Form 10-K for the period ended December&#160;31, 2024 of the Registrant (the &#8220;Report&#8221;), that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:20.23pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section&#160;13(a) or 15(d)&#160;of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:20.23pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Scott Koenig </font></div><div style="text-indent:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; Scott Koenig, M.D., Ph.D.</font></div><div style="text-indent:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;  March&#160;20, 2025 </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>11
<FILENAME>mgnxexhibit32-2202410xk.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ib962200567e24bbd90f247383e987c20_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 32.2</font></div><div style="text-align:right"><font><br></font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Financial Officer Pursuant to 18 U.S.C. 1350 (Section 906 of the Sarbanes-Oxley Act of 2002)</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, James Karrels, Senior Vice President and Chief Financial Officer (principal financial officer) of MacroGenics, Inc. (the &#8220;Registrant&#8221;), certify, to the best of my knowledge, based upon a review of the Annual Report on Form 10-K for the period ended December&#160;31, 2024 of the Registrant (the &#8220;Report&#8221;), that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:20.23pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section&#160;13(a) or 15(d)&#160;of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:20.23pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div><div><font><br></font></div><div style="text-indent:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; James Karrels&#160;&#160;&#160;&#160;</font></div><div style="text-indent:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; James Karrels</font></div><div style="text-indent:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March&#160;20, 2025</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>mgnx-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:976c6134-a70d-4bed-9067-acb735c066ae,g:6888b12e-4125-48cc-8fc7-0d9038c82cb8-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mgnx="http://macrogenics.com/20241231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://macrogenics.com/20241231">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af-sub/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://macrogenics.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://macrogenics.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>9952151 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>9952152 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>9952153 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>9952154 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>9952155 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandNatureofOperations" roleURI="http://macrogenics.com/role/OrganizationandNatureofOperations">
        <link:definition>9952156 - Disclosure - Organization and Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>9952157 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://macrogenics.com/role/MarketableSecurities">
        <link:definition>9952158 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://macrogenics.com/role/Inventory">
        <link:definition>9952159 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandSoftware" roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftware">
        <link:definition>9952160 - Disclosure - Property, Equipment and Software</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://macrogenics.com/role/CommitmentsandContingencies">
        <link:definition>9952161 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://macrogenics.com/role/StockholdersEquity">
        <link:definition>9952162 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://macrogenics.com/role/Revenue">
        <link:definition>9952163 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensation" roleURI="http://macrogenics.com/role/StockbasedCompensation">
        <link:definition>9952164 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TeSeraTransaction" roleURI="http://macrogenics.com/role/TeSeraTransaction">
        <link:definition>9952165 - Disclosure - TeSera Transaction</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://macrogenics.com/role/IncomeTaxes">
        <link:definition>9952166 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlan" roleURI="http://macrogenics.com/role/EmployeeBenefitPlan">
        <link:definition>9952167 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://macrogenics.com/role/SegmentReporting">
        <link:definition>9952168 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://macrogenics.com/role/MarketableSecuritiesTables">
        <link:definition>9955513 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryNetTables" roleURI="http://macrogenics.com/role/InventoryNetTables">
        <link:definition>9955514 - Disclosure - Inventory, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandSoftwareTables" roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareTables">
        <link:definition>9955515 - Disclosure - Property, Equipment and Software (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://macrogenics.com/role/CommitmentsandContingenciesTables">
        <link:definition>9955516 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationTables" roleURI="http://macrogenics.com/role/StockbasedCompensationTables">
        <link:definition>9955517 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://macrogenics.com/role/IncomeTaxesTables">
        <link:definition>9955518 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://macrogenics.com/role/SegmentReportingTables">
        <link:definition>9955519 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandNatureofOperationsDetails" roleURI="http://macrogenics.com/role/OrganizationandNatureofOperationsDetails">
        <link:definition>9955520 - Disclosure - Organization and Nature of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>9955521 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails">
        <link:definition>9955522 - Disclosure - Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails">
        <link:definition>9955523 - Disclosure - Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned and Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails">
        <link:definition>9955524 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails">
        <link:definition>9955525 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesDetails" roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails">
        <link:definition>9955526 - Disclosure - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesAvailableForSaleSecuritiesDetails" roleURI="http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails">
        <link:definition>9955527 - Disclosure - Marketable Securities - Available-For-Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryNetScheduleofInventoryDetails" roleURI="http://macrogenics.com/role/InventoryNetScheduleofInventoryDetails">
        <link:definition>9955528 - Disclosure - Inventory, Net - Schedule of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryNetDetails" roleURI="http://macrogenics.com/role/InventoryNetDetails">
        <link:definition>9955529 - Disclosure - Inventory, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandSoftwareDetails" roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails">
        <link:definition>9955530 - Disclosure - Property, Equipment and Software (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://macrogenics.com/role/CommitmentsandContingenciesDetails">
        <link:definition>9955531 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://macrogenics.com/role/StockholdersEquityDetails">
        <link:definition>9955532 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueIncyteCorporationDetails" roleURI="http://macrogenics.com/role/RevenueIncyteCorporationDetails">
        <link:definition>9955533 - Disclosure - Revenue - Incyte Corporation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueGileadSciencesIncDetails" roleURI="http://macrogenics.com/role/RevenueGileadSciencesIncDetails">
        <link:definition>9955534 - Disclosure - Revenue - Gilead Sciences Inc (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueZaiLabDetails" roleURI="http://macrogenics.com/role/RevenueZaiLabDetails">
        <link:definition>9955535 - Disclosure - Revenue - Zai Lab (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueProventionDetails" roleURI="http://macrogenics.com/role/RevenueProventionDetails">
        <link:definition>9955536 - Disclosure - Revenue - Provention (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueManufacturingServiceAgreementsDetails" roleURI="http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails">
        <link:definition>9955537 - Disclosure - Revenue - Manufacturing Service Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueNIAIDContractDetails" roleURI="http://macrogenics.com/role/RevenueNIAIDContractDetails">
        <link:definition>9955538 - Disclosure - Revenue - NIAID Contract (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueProductSalesDetails" roleURI="http://macrogenics.com/role/RevenueProductSalesDetails">
        <link:definition>9955539 - Disclosure - Revenue - Product Sales (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationNarrativeDetails" roleURI="http://macrogenics.com/role/StockbasedCompensationNarrativeDetails">
        <link:definition>9955540 - Disclosure - Stock-based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>9955541 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationOptionPricingAssumptionsDetails" roleURI="http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails">
        <link:definition>9955542 - Disclosure - Stock-based Compensation - Option Pricing Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails" roleURI="http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails">
        <link:definition>9955543 - Disclosure - Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TeSeraTransactionDetails" roleURI="http://macrogenics.com/role/TeSeraTransactionDetails">
        <link:definition>9955544 - Disclosure - TeSera Transaction (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>9955545 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails" roleURI="http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails">
        <link:definition>9955546 - Disclosure - Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesValuationAllowanceActivityDetails" roleURI="http://macrogenics.com/role/IncomeTaxesValuationAllowanceActivityDetails">
        <link:definition>9955547 - Disclosure - Income Taxes - Valuation Allowance Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails" roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails">
        <link:definition>9955548 - Disclosure - Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails" roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails">
        <link:definition>9955549 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeTaxPaidTableDetails" roleURI="http://macrogenics.com/role/IncomeTaxesIncomeTaxPaidTableDetails">
        <link:definition>9955550 - Disclosure - Income Taxes - Income Tax Paid Table (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlanDetails" roleURI="http://macrogenics.com/role/EmployeeBenefitPlanDetails">
        <link:definition>9955551 - Disclosure - Employee Benefit Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingDetails" roleURI="http://macrogenics.com/role/SegmentReportingDetails">
        <link:definition>9955552 - Disclosure - Segment Reporting (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="mgnx_AuditorInformationAbstract" abstract="true" name="AuditorInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mgnx_RevenueFromCollaborativeAgreementsMember" abstract="true" name="RevenueFromCollaborativeAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_RevenueFromGovernmentAgreementsMember" abstract="true" name="RevenueFromGovernmentAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_ContractManufacturingMember" abstract="true" name="ContractManufacturingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_CostOfManufacturingServices" abstract="false" name="CostOfManufacturingServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_GainOnRoyaltyMonetizationArrangement" abstract="false" name="GainOnRoyaltyMonetizationArrangement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_GainOnSaleOfMARGENZA" abstract="false" name="GainOnSaleOfMARGENZA" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" abstract="false" name="StockIssuedDuringPeriodSharesStockPlanActivity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mgnx_StockIssuedDuringPeriodValueStockPlanActivity" abstract="false" name="StockIssuedDuringPeriodValueStockPlanActivity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_NonCashInterestExpenseRecognized" abstract="false" name="NonCashInterestExpenseRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_OperatingLeaseNoncashExpense" abstract="false" name="OperatingLeaseNoncashExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_IncreaseDecreaseInLeaseLiabilities" abstract="false" name="IncreaseDecreaseInLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" abstract="false" name="ProceedsfromStockOptionsExercisedAndESPPPurchases" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement" abstract="false" name="PrincipalPaymentsOnRoyaltyMonetizationArrangement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_NetProceedsFromSaleOfFutureRoyalties" abstract="false" name="NetProceedsFromSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_CollaborationAndLicenseAgreementsAbstract" abstract="true" name="CollaborationAndLicenseAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" abstract="false" name="CollaborationAndLicenseAgreementsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" abstract="false" name="PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="mgnx_ScheduleOfInventoryReservesTableTextBlock" abstract="false" name="ScheduleOfInventoryReservesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock" abstract="false" name="ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="mgnx_ScheduleOfShareBasedPaymentAwardModifiedAwardsValuationAssumptionsTableTextBlock" abstract="false" name="ScheduleOfShareBasedPaymentAwardModifiedAwardsValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mgnx_NumberOfProductCandidatesApprovedByTheFoodAndDrugAdministration" abstract="false" name="NumberOfProductCandidatesApprovedByTheFoodAndDrugAdministration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_NonDilutiveFunding" abstract="false" name="NonDilutiveFunding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_NumberOfProprietaryProductCandidatesAdvancingInClinicalDevelopment" abstract="false" name="NumberOfProprietaryProductCandidatesAdvancingInClinicalDevelopment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_IncyteCorporationMember" abstract="true" name="IncyteCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember" abstract="true" name="McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_CardinalHealthIncMember" abstract="true" name="CardinalHealthIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_ASDHealthcareAndOncologySupplyMember" abstract="true" name="ASDHealthcareAndOncologySupplyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_ProventionBioMember" abstract="true" name="ProventionBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_ZaiLabLimitedMember" abstract="true" name="ZaiLabLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_ZaiLabMember" abstract="true" name="ZaiLabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_LaboratoryAndOfficeEquipmentMember" abstract="true" name="LaboratoryAndOfficeEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_StockOptionsAndRestrictedStockUnitsMember" abstract="true" name="StockOptionsAndRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_FurnitureAndOfficeEquipmentMember" abstract="true" name="FurnitureAndOfficeEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_SynaffixBVMember" abstract="true" name="SynaffixBVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_RightOfUseAssetAndLeaseLiabilityIncrease" abstract="false" name="RightOfUseAssetAndLeaseLiabilityIncrease" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" abstract="false" name="PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_UndesignatedPreferredStockMember" abstract="true" name="UndesignatedPreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_CommonStockMaximumAmountAvailableForIssuance" abstract="false" name="CommonStockMaximumAmountAvailableForIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RevenuesFromLicenseAgreementsMember" abstract="true" name="RevenuesFromLicenseAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_IncyteMGA012AgreementMember" abstract="true" name="IncyteMGA012AgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_IncyteClinicalSupplyAgreementMember" abstract="true" name="IncyteClinicalSupplyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_IncyteCommercialSupplyAgreementMember" abstract="true" name="IncyteCommercialSupplyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_NonRefundableUpfrontFees" abstract="false" name="NonRefundableUpfrontFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" abstract="false" name="PotentialCommercialMilestonePaymentsUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" abstract="false" name="DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ProceedsfromRoyaltiesPercent" abstract="false" name="ProceedsfromRoyaltiesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="mgnx_NumberOfPerformanceObligations" abstract="false" name="NumberOfPerformanceObligations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_CollaborativeAgreementTransactionPrice" abstract="false" name="CollaborativeAgreementTransactionPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" abstract="false" name="RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_GileadMember" abstract="true" name="GileadMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_A2022GileadCollaborationAndLicenseAgreementMember" abstract="true" name="A2022GileadCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_GileadFirstResearchProgramMember" abstract="true" name="GileadFirstResearchProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments" abstract="false" name="PotentialTargetNominationOptionFeesAndMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_OptionToBuy" abstract="false" name="OptionToBuy" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_A2021ZaiLabAgreementsMember" abstract="true" name="A2021ZaiLabAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_DRIHealthcareAcquisitionsLPDRIMember" abstract="true" name="DRIHealthcareAcquisitionsLPDRIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_ProventionPRV3279Member" abstract="true" name="ProventionPRV3279Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_ProventionPRV031Member" abstract="true" name="ProventionPRV031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_ProventionLicenseAgreementMember" abstract="true" name="ProventionLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_AssetPurchaseAgreementMember" abstract="true" name="AssetPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_SideLetterAgreementMember" abstract="true" name="SideLetterAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_ProventionAPAMember" abstract="true" name="ProventionAPAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" abstract="false" name="CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" abstract="false" name="CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" abstract="false" name="PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_UpfrontPayment" abstract="false" name="UpfrontPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_AdditionalTZIELDMilestones" abstract="false" name="AdditionalTZIELDMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RevenuesFromCMOAgreementsMemberMember" abstract="true" name="RevenuesFromCMOAgreementsMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_RevenuesFromCMOAmendmentAgreementMember" abstract="true" name="RevenuesFromCMOAmendmentAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_CollaborativeArrangementTerm" abstract="false" name="CollaborativeArrangementTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mgnx_TotalFixedPayments" abstract="false" name="TotalFixedPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_CollaborativeArrangementExtensionTerm" abstract="false" name="CollaborativeArrangementExtensionTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mgnx_AdditionalAnnualFixedPayments" abstract="false" name="AdditionalAnnualFixedPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_FutureManufacturingRevenue" abstract="false" name="FutureManufacturingRevenue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RevenuesFromGrantsMember" abstract="true" name="RevenuesFromGrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" abstract="true" name="NationalInstituteOfAllergyAndInfectiousDiseasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_NumberOfProductCandidates" abstract="false" name="NumberOfProductCandidates" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_TerSeraMember" abstract="true" name="TerSeraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_AmendmentFeeToCommercializationPartner" abstract="false" name="AmendmentFeeToCommercializationPartner" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandSixteenEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_StockIncentivePlan2023MemberMember" abstract="true" name="StockIncentivePlan2023MemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_StockIncentivePlan2013Member" abstract="true" name="StockIncentivePlan2013Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_DrScottKoenigMember" abstract="true" name="DrScottKoenigMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" abstract="false" name="EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingPercentageOfUnvestedAwards" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingPercentageOfUnvestedAwards" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mgnx_CombinedServicesAgreementMember" abstract="true" name="CombinedServicesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_FutureMilestone" abstract="false" name="FutureMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" abstract="true" name="DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_TaxYear2027To2028Member" abstract="true" name="TaxYear2027To2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_IndefiniteMember" abstract="true" name="IndefiniteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mgnx_TaxYear2027To2044Member" abstract="true" name="TaxYear2027To2044Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationAmountUtilizableOnAnnualBasis" abstract="false" name="DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationAmountUtilizableOnAnnualBasis" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_DeferredTaxAssetsOperatingLeaseLiabilities" abstract="false" name="DeferredTaxAssetsOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_Section174DeferredTaxAsset" abstract="false" name="Section174DeferredTaxAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" abstract="false" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ValuationAllowanceRollForward" abstract="true" name="ValuationAllowanceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mgnx_ValuationAllowanceDeferredTaxAssetIncreaseAmount" abstract="false" name="ValuationAllowanceDeferredTaxAssetIncreaseAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ValuationAllowanceDeferredTaxAssetDecreaseAmount" abstract="false" name="ValuationAllowanceDeferredTaxAssetDecreaseAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" abstract="false" name="UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" abstract="false" name="EmployeesEligibleAgeToParticipateInBenefitPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" abstract="false" name="DefinedContributionPlanEmployeesContributionVestedPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="mgnx_MainSegmentMember" abstract="true" name="MainSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_VobramitanmabDuocarmazineMember" abstract="true" name="VobramitanmabDuocarmazineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_LorigerlimabMember" abstract="true" name="LorigerlimabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_MGC028Member" abstract="true" name="MGC028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_ADCMember" abstract="true" name="ADCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_MGC026Member" abstract="true" name="MGC026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_MargetuximabMember" abstract="true" name="MargetuximabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_MGD024Member" abstract="true" name="MGD024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_NextGenerationTCellEngagersMember" abstract="true" name="NextGenerationTCellEngagersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_RetifanlimabMember" abstract="true" name="RetifanlimabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_EnoblituzumabMember" abstract="true" name="EnoblituzumabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_OtherProgramsMember" abstract="true" name="OtherProgramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_JamesKarrelsMember" abstract="true" name="JamesKarrelsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mgnx_JeffreyPetersMember" abstract="true" name="JeffreyPetersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>mgnx-20241231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:976c6134-a70d-4bed-9067-acb735c066ae,g:6888b12e-4125-48cc-8fc7-0d9038c82cb8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mgnx-20241231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_fa3e6033-c6e4-4382-9639-d7ed5ac197fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d1d9b9f1-4159-46c5-a216-fdfb844767a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_fa3e6033-c6e4-4382-9639-d7ed5ac197fc" xlink:to="loc_us-gaap_Liabilities_d1d9b9f1-4159-46c5-a216-fdfb844767a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e76935d9-052f-4ba8-b8f8-6c9f630c588c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_fa3e6033-c6e4-4382-9639-d7ed5ac197fc" xlink:to="loc_us-gaap_StockholdersEquity_e76935d9-052f-4ba8-b8f8-6c9f630c588c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_91047795-308e-4424-8ab3-114e0169ec23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_51babd09-51cf-47dd-815a-19791a3bf07c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_91047795-308e-4424-8ab3-114e0169ec23" xlink:to="loc_us-gaap_AccountsPayableCurrent_51babd09-51cf-47dd-815a-19791a3bf07c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7faffaa4-492e-4698-bcac-e3ea23bd75c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_91047795-308e-4424-8ab3-114e0169ec23" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7faffaa4-492e-4698-bcac-e3ea23bd75c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_bb0c48a4-34aa-47aa-844d-329c65426d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_91047795-308e-4424-8ab3-114e0169ec23" xlink:to="loc_us-gaap_DeferredRevenueCurrent_bb0c48a4-34aa-47aa-844d-329c65426d2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_072e8c15-d529-4c62-8000-85c3a1357e06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_91047795-308e-4424-8ab3-114e0169ec23" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_072e8c15-d529-4c62-8000-85c3a1357e06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_fbfbe243-5ebe-4d5a-a680-ab879aa11a63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_35b4d893-4088-4302-b27f-cda7f154d4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fbfbe243-5ebe-4d5a-a680-ab879aa11a63" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_35b4d893-4088-4302-b27f-cda7f154d4ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_6040cae1-a2c7-4687-8667-d7edc11c0bff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fbfbe243-5ebe-4d5a-a680-ab879aa11a63" xlink:to="loc_us-gaap_InventoryNet_6040cae1-a2c7-4687-8667-d7edc11c0bff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_860f4d9b-9fb1-42e0-97e9-79b0f506c6e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Investments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fbfbe243-5ebe-4d5a-a680-ab879aa11a63" xlink:to="loc_us-gaap_Investments_860f4d9b-9fb1-42e0-97e9-79b0f506c6e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_cc392426-1de8-4be5-9539-4da1b6a9cf98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fbfbe243-5ebe-4d5a-a680-ab879aa11a63" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_cc392426-1de8-4be5-9539-4da1b6a9cf98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_41d1f1f4-55df-403f-813e-f373aa50fece" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fbfbe243-5ebe-4d5a-a680-ab879aa11a63" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_41d1f1f4-55df-403f-813e-f373aa50fece" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_02bc47b8-1d3f-491f-b425-df3bb3426930" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_296d95e7-395c-49a8-ad5f-9e98d1abcfc7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_02bc47b8-1d3f-491f-b425-df3bb3426930" xlink:to="loc_us-gaap_CommonStockValue_296d95e7-395c-49a8-ad5f-9e98d1abcfc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_c1f83e45-d01d-475c-9640-cb75fd3bcd4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_02bc47b8-1d3f-491f-b425-df3bb3426930" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_c1f83e45-d01d-475c-9640-cb75fd3bcd4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_39ca10cc-1b0b-472e-84a4-8504fce8f1b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_02bc47b8-1d3f-491f-b425-df3bb3426930" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_39ca10cc-1b0b-472e-84a4-8504fce8f1b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bd2cc200-d5a7-45cd-b3b3-14bccd0fafa2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_02bc47b8-1d3f-491f-b425-df3bb3426930" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bd2cc200-d5a7-45cd-b3b3-14bccd0fafa2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e66d46bc-36b7-445d-bce2-e53bf900d078" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_587833c9-e65d-4f2c-8ea0-fa979e782ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e66d46bc-36b7-445d-bce2-e53bf900d078" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_587833c9-e65d-4f2c-8ea0-fa979e782ca3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_55df9af9-2fe6-4ba7-977a-e3010a1add1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e66d46bc-36b7-445d-bce2-e53bf900d078" xlink:to="loc_us-gaap_AssetsCurrent_55df9af9-2fe6-4ba7-977a-e3010a1add1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_56a3f5ab-e2b9-4bd4-af5e-d489ced87d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e66d46bc-36b7-445d-bce2-e53bf900d078" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_56a3f5ab-e2b9-4bd4-af5e-d489ced87d8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_47151255-d6cc-412b-8a57-8cf4cc203100" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e66d46bc-36b7-445d-bce2-e53bf900d078" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_47151255-d6cc-412b-8a57-8cf4cc203100" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c2d250f4-be80-4778-922a-ff4b6dca90ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7eb060a3-401b-4983-a9b1-923d17117cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c2d250f4-be80-4778-922a-ff4b6dca90ef" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7eb060a3-401b-4983-a9b1-923d17117cdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_32a5ca53-4b86-4dc0-b33a-9075ebc7288b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c2d250f4-be80-4778-922a-ff4b6dca90ef" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_32a5ca53-4b86-4dc0-b33a-9075ebc7288b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ebf3bbca-4de6-421d-a10e-17daa5cd4d50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c2d250f4-be80-4778-922a-ff4b6dca90ef" xlink:to="loc_us-gaap_LiabilitiesCurrent_ebf3bbca-4de6-421d-a10e-17daa5cd4d50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_28be959a-9ee5-4271-9116-784b43a49d68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c2d250f4-be80-4778-922a-ff4b6dca90ef" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_28be959a-9ee5-4271-9116-784b43a49d68" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20241231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_533f2936-46e7-4c99-864a-c8e7f81931b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_25c606c8-fd2b-435a-93c4-fe8610882004" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_533f2936-46e7-4c99-864a-c8e7f81931b2" xlink:to="loc_us-gaap_NetIncomeLoss_25c606c8-fd2b-435a-93c4-fe8610882004" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_066f0eb8-7324-4d05-90d6-c1751bcb723e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_533f2936-46e7-4c99-864a-c8e7f81931b2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_066f0eb8-7324-4d05-90d6-c1751bcb723e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_fcdeec66-6d8b-47e2-a7c8-827da0423f17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CostOfManufacturingServices_d1194dd8-f25b-4a80-b5f4-273850c21e47" xlink:href="mgnx-20241231.xsd#mgnx_CostOfManufacturingServices"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_fcdeec66-6d8b-47e2-a7c8-827da0423f17" xlink:to="loc_mgnx_CostOfManufacturingServices_d1194dd8-f25b-4a80-b5f4-273850c21e47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9f2faa77-b934-43d9-ad8d-003ce2f79e22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_fcdeec66-6d8b-47e2-a7c8-827da0423f17" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9f2faa77-b934-43d9-ad8d-003ce2f79e22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_53f20fa7-5b6a-45de-aebe-54d4502ca882" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_fcdeec66-6d8b-47e2-a7c8-827da0423f17" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_53f20fa7-5b6a-45de-aebe-54d4502ca882" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3e8265be-c946-446c-bf7f-5b472491334c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_fcdeec66-6d8b-47e2-a7c8-827da0423f17" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3e8265be-c946-446c-bf7f-5b472491334c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_afb4af54-4f88-4637-bbb8-77c7579abc6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1368c37e-d668-47f3-8726-40fb3a103a88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_afb4af54-4f88-4637-bbb8-77c7579abc6b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1368c37e-d668-47f3-8726-40fb3a103a88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a6450162-42d2-4c4b-811d-72e4c685501b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_afb4af54-4f88-4637-bbb8-77c7579abc6b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a6450162-42d2-4c4b-811d-72e4c685501b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a00f4983-dd20-4914-8316-ff2a68f36f71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_70e4638b-a885-4df5-be77-d2df65bf9328" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a00f4983-dd20-4914-8316-ff2a68f36f71" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_70e4638b-a885-4df5-be77-d2df65bf9328" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GainOnRoyaltyMonetizationArrangement_707825ee-12aa-449e-a9c0-52311ef5f0b0" xlink:href="mgnx-20241231.xsd#mgnx_GainOnRoyaltyMonetizationArrangement"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a00f4983-dd20-4914-8316-ff2a68f36f71" xlink:to="loc_mgnx_GainOnRoyaltyMonetizationArrangement_707825ee-12aa-449e-a9c0-52311ef5f0b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_60b40ab7-be65-4699-9765-138d22fb3349" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a00f4983-dd20-4914-8316-ff2a68f36f71" xlink:to="loc_us-gaap_OperatingIncomeLoss_60b40ab7-be65-4699-9765-138d22fb3349" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GainOnSaleOfMARGENZA_d0dab3dd-91c7-4efd-9c65-f171360daf2e" xlink:href="mgnx-20241231.xsd#mgnx_GainOnSaleOfMARGENZA"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a00f4983-dd20-4914-8316-ff2a68f36f71" xlink:to="loc_mgnx_GainOnSaleOfMARGENZA_d0dab3dd-91c7-4efd-9c65-f171360daf2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_2c3f48c1-efcf-4878-82ee-8956089368e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a00f4983-dd20-4914-8316-ff2a68f36f71" xlink:to="loc_us-gaap_InterestExpense_2c3f48c1-efcf-4878-82ee-8956089368e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5e3411fb-74ee-43b5-ab50-baa9029a6b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_abe17d51-341c-4329-b0fa-de6b9017997f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5e3411fb-74ee-43b5-ab50-baa9029a6b2e" xlink:to="loc_us-gaap_Revenues_abe17d51-341c-4329-b0fa-de6b9017997f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_9c24a41b-61e6-4e17-a886-41b4b121b713" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5e3411fb-74ee-43b5-ab50-baa9029a6b2e" xlink:to="loc_us-gaap_CostsAndExpenses_9c24a41b-61e6-4e17-a886-41b4b121b713" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mgnx-20241231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9feef190-13c1-4469-85a3-3e925c410e00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement_2da42a17-9fd9-42d9-850a-2d7dfea26e09" xlink:href="mgnx-20241231.xsd#mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9feef190-13c1-4469-85a3-3e925c410e00" xlink:to="loc_mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement_2da42a17-9fd9-42d9-850a-2d7dfea26e09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1d762826-e981-47ea-84dd-4fe49feefaad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9feef190-13c1-4469-85a3-3e925c410e00" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1d762826-e981-47ea-84dd-4fe49feefaad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NetProceedsFromSaleOfFutureRoyalties_3e86c00f-717e-4d26-9175-0a51bdf223c9" xlink:href="mgnx-20241231.xsd#mgnx_NetProceedsFromSaleOfFutureRoyalties"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9feef190-13c1-4469-85a3-3e925c410e00" xlink:to="loc_mgnx_NetProceedsFromSaleOfFutureRoyalties_3e86c00f-717e-4d26-9175-0a51bdf223c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_8509d901-0b27-4c5c-926a-bafbc7955ca0" xlink:href="mgnx-20241231.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9feef190-13c1-4469-85a3-3e925c410e00" xlink:to="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_8509d901-0b27-4c5c-926a-bafbc7955ca0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_18332e35-907d-4e26-9876-15921eaf9462" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9feef190-13c1-4469-85a3-3e925c410e00" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_18332e35-907d-4e26-9876-15921eaf9462" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1d3b18cc-27e0-4403-8f5e-918767f0a1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_75707b7b-767a-4d64-8ebe-61c055db86d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1d3b18cc-27e0-4403-8f5e-918767f0a1e9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_75707b7b-767a-4d64-8ebe-61c055db86d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_c0ea8a97-b35b-446e-ab68-86615416000f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1d3b18cc-27e0-4403-8f5e-918767f0a1e9" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_c0ea8a97-b35b-446e-ab68-86615416000f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_7fc14d0d-c928-4f98-bec8-a271e6365ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1d3b18cc-27e0-4403-8f5e-918767f0a1e9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_7fc14d0d-c928-4f98-bec8-a271e6365ca5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_8dcb022f-b4b4-4ed6-9c9b-fa895ffefccb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1d3b18cc-27e0-4403-8f5e-918767f0a1e9" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_8dcb022f-b4b4-4ed6-9c9b-fa895ffefccb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ae89bfbb-8042-4679-9c9d-553a38dc7938" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1d3b18cc-27e0-4403-8f5e-918767f0a1e9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ae89bfbb-8042-4679-9c9d-553a38dc7938" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_e30bdc11-762b-4464-8540-fce75f323729" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1d3b18cc-27e0-4403-8f5e-918767f0a1e9" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_e30bdc11-762b-4464-8540-fce75f323729" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_f8c37c0f-a5c3-46f9-9833-8511d078adec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1d3b18cc-27e0-4403-8f5e-918767f0a1e9" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_f8c37c0f-a5c3-46f9-9833-8511d078adec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonCashInterestExpenseRecognized_8b1a464d-6700-4578-8ee6-05706d36ea25" xlink:href="mgnx-20241231.xsd#mgnx_NonCashInterestExpenseRecognized"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1d3b18cc-27e0-4403-8f5e-918767f0a1e9" xlink:to="loc_mgnx_NonCashInterestExpenseRecognized_8b1a464d-6700-4578-8ee6-05706d36ea25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_f26b6d8c-ca9d-420e-bf3c-c67c26bc5a56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1d3b18cc-27e0-4403-8f5e-918767f0a1e9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_f26b6d8c-ca9d-420e-bf3c-c67c26bc5a56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInLeaseLiabilities_56845bfc-1a9b-4f4c-b018-3aa696387306" xlink:href="mgnx-20241231.xsd#mgnx_IncreaseDecreaseInLeaseLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1d3b18cc-27e0-4403-8f5e-918767f0a1e9" xlink:to="loc_mgnx_IncreaseDecreaseInLeaseLiabilities_56845bfc-1a9b-4f4c-b018-3aa696387306" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1d3677de-dba7-4067-b8df-565282131b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1d3b18cc-27e0-4403-8f5e-918767f0a1e9" xlink:to="loc_us-gaap_NetIncomeLoss_1d3677de-dba7-4067-b8df-565282131b0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ebaad0f8-abbb-44f4-bf1c-d151b9e77c95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1d3b18cc-27e0-4403-8f5e-918767f0a1e9" xlink:to="loc_us-gaap_ShareBasedCompensation_ebaad0f8-abbb-44f4-bf1c-d151b9e77c95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GainOnRoyaltyMonetizationArrangement_c746563f-9dbb-4856-87b3-05b5276c8e85" xlink:href="mgnx-20241231.xsd#mgnx_GainOnRoyaltyMonetizationArrangement"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1d3b18cc-27e0-4403-8f5e-918767f0a1e9" xlink:to="loc_mgnx_GainOnRoyaltyMonetizationArrangement_c746563f-9dbb-4856-87b3-05b5276c8e85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_51780f6a-e59a-4bf7-aa7a-5e241b516b72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1d3b18cc-27e0-4403-8f5e-918767f0a1e9" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_51780f6a-e59a-4bf7-aa7a-5e241b516b72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_309af575-0ad2-4d2c-815c-1391f285ffdd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1d3b18cc-27e0-4403-8f5e-918767f0a1e9" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_309af575-0ad2-4d2c-815c-1391f285ffdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GainOnSaleOfMARGENZA_abdbb2a9-8e00-45a7-8f2a-d11636d72282" xlink:href="mgnx-20241231.xsd#mgnx_GainOnSaleOfMARGENZA"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1d3b18cc-27e0-4403-8f5e-918767f0a1e9" xlink:to="loc_mgnx_GainOnSaleOfMARGENZA_abdbb2a9-8e00-45a7-8f2a-d11636d72282" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLeaseNoncashExpense_0f83bd62-2608-4b80-910b-62007ba1eb40" xlink:href="mgnx-20241231.xsd#mgnx_OperatingLeaseNoncashExpense"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1d3b18cc-27e0-4403-8f5e-918767f0a1e9" xlink:to="loc_mgnx_OperatingLeaseNoncashExpense_0f83bd62-2608-4b80-910b-62007ba1eb40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_32d7e97d-facd-447c-aed9-d5bae02c2645" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1d3b18cc-27e0-4403-8f5e-918767f0a1e9" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_32d7e97d-facd-447c-aed9-d5bae02c2645" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_32ab1e38-5e02-48de-b4ac-b2d01934ccfb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1d3b18cc-27e0-4403-8f5e-918767f0a1e9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_32ab1e38-5e02-48de-b4ac-b2d01934ccfb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3aba5fa9-a6f7-458b-9924-06c2ed39ea80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherProductiveAssets_20f57809-07b1-4c23-a1fb-803b4e044c87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfOtherProductiveAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3aba5fa9-a6f7-458b-9924-06c2ed39ea80" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherProductiveAssets_20f57809-07b1-4c23-a1fb-803b4e044c87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_23f856a0-6933-4706-8482-9ea65fbc613d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3aba5fa9-a6f7-458b-9924-06c2ed39ea80" xlink:to="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_23f856a0-6933-4706-8482-9ea65fbc613d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_062f40a7-6258-4a3a-934b-99ba934ce02e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3aba5fa9-a6f7-458b-9924-06c2ed39ea80" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_062f40a7-6258-4a3a-934b-99ba934ce02e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f04d1a00-ddfc-4fc9-a75d-3b096180e966" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3aba5fa9-a6f7-458b-9924-06c2ed39ea80" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f04d1a00-ddfc-4fc9-a75d-3b096180e966" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_59966d1b-5ae5-43d9-a59c-5af61ec0740d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3aba5fa9-a6f7-458b-9924-06c2ed39ea80" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_59966d1b-5ae5-43d9-a59c-5af61ec0740d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_68c2566d-4131-4dc4-9858-ef73e7d5e014" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_babca817-dad4-4a75-ab38-0ac2bb41ee56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_68c2566d-4131-4dc4-9858-ef73e7d5e014" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_babca817-dad4-4a75-ab38-0ac2bb41ee56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c0e66293-06b1-4f49-ac3b-71d5b59b710b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_68c2566d-4131-4dc4-9858-ef73e7d5e014" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c0e66293-06b1-4f49-ac3b-71d5b59b710b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2ba473a4-ee30-4d1e-8c0d-a52a6f2ffb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_68c2566d-4131-4dc4-9858-ef73e7d5e014" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2ba473a4-ee30-4d1e-8c0d-a52a6f2ffb8d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_be6f8a8e-caec-41cf-9262-f97524b8108b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1cfdecdc-bd80-45ad-93f5-0996be06aee7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_be6f8a8e-caec-41cf-9262-f97524b8108b" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1cfdecdc-bd80-45ad-93f5-0996be06aee7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b7b428f5-d62f-4c22-b823-bad9e284f51c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_be6f8a8e-caec-41cf-9262-f97524b8108b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b7b428f5-d62f-4c22-b823-bad9e284f51c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#MarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8880a64b-5a6b-439f-a7e0-7f114bd1ad31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9e0f5201-8bdc-4d3d-8d6d-6ec3ee45c702" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8880a64b-5a6b-439f-a7e0-7f114bd1ad31" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9e0f5201-8bdc-4d3d-8d6d-6ec3ee45c702" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b979ede0-f77e-4ec4-8524-54715768eb87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8880a64b-5a6b-439f-a7e0-7f114bd1ad31" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b979ede0-f77e-4ec4-8524-54715768eb87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2916775b-34fa-4418-acb6-55bb43faae27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8880a64b-5a6b-439f-a7e0-7f114bd1ad31" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2916775b-34fa-4418-acb6-55bb43faae27" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#PropertyEquipmentandSoftwareDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ed75e7a8-f24a-4cb7-95e6-c3c8c6a93ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1af0224c-9977-4c49-b0e9-cf813543b5fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_ed75e7a8-f24a-4cb7-95e6-c3c8c6a93ae5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1af0224c-9977-4c49-b0e9-cf813543b5fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6897c4ba-9171-4877-9ed6-92d03d429084" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_ed75e7a8-f24a-4cb7-95e6-c3c8c6a93ae5" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6897c4ba-9171-4877-9ed6-92d03d429084" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_b2b6332a-cc20-4785-a7ed-a55eba43518b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_ec7a182f-12ef-4dc9-9835-a92c442c9e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_b2b6332a-cc20-4785-a7ed-a55eba43518b" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_ec7a182f-12ef-4dc9-9835-a92c442c9e4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_5f11f0a8-5724-4a8c-bf9a-c8bcae74a47e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_b2b6332a-cc20-4785-a7ed-a55eba43518b" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_5f11f0a8-5724-4a8c-bf9a-c8bcae74a47e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_1722c17c-1ed6-424d-a7c8-c7347b1cface" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_b2b6332a-cc20-4785-a7ed-a55eba43518b" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_1722c17c-1ed6-424d-a7c8-c7347b1cface" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_Section174DeferredTaxAsset_347461a4-19ac-4879-ae09-338f5bc135ba" xlink:href="mgnx-20241231.xsd#mgnx_Section174DeferredTaxAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_b2b6332a-cc20-4785-a7ed-a55eba43518b" xlink:to="loc_mgnx_Section174DeferredTaxAsset_347461a4-19ac-4879-ae09-338f5bc135ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_d3332b23-e3a4-41f7-893a-e3b8a24101d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_b2b6332a-cc20-4785-a7ed-a55eba43518b" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_d3332b23-e3a4-41f7-893a-e3b8a24101d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_6f9e8964-2324-4961-9592-833da231994d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_b2b6332a-cc20-4785-a7ed-a55eba43518b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_6f9e8964-2324-4961-9592-833da231994d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_744214ab-951a-4c95-9355-0ec9087dd872" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_b2b6332a-cc20-4785-a7ed-a55eba43518b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_744214ab-951a-4c95-9355-0ec9087dd872" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities_69aa0bc1-05c5-44ab-b4dc-04f82cde60e4" xlink:href="mgnx-20241231.xsd#mgnx_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_b2b6332a-cc20-4785-a7ed-a55eba43518b" xlink:to="loc_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities_69aa0bc1-05c5-44ab-b4dc-04f82cde60e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_3b94f99e-3a92-43d4-b5fa-532eb3e8791c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_b2b6332a-cc20-4785-a7ed-a55eba43518b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_3b94f99e-3a92-43d4-b5fa-532eb3e8791c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_3a54e9b9-99f8-4d9b-a383-224f68c9e952" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_a3693af9-2236-4463-9021-78cb94422610" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_3a54e9b9-99f8-4d9b-a383-224f68c9e952" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_a3693af9-2236-4463-9021-78cb94422610" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_eb4e2174-be2c-407e-b2bb-aeed83ab2663" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_3a54e9b9-99f8-4d9b-a383-224f68c9e952" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_eb4e2174-be2c-407e-b2bb-aeed83ab2663" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_79ccb9b3-4dba-4d8d-9672-d40f5080cb58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_61220c3e-6721-4a7e-89a7-d198ce2bc746" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_79ccb9b3-4dba-4d8d-9672-d40f5080cb58" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_61220c3e-6721-4a7e-89a7-d198ce2bc746" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_45dd43d7-0c7d-4025-bf1d-35b42479b402" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_79ccb9b3-4dba-4d8d-9672-d40f5080cb58" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_45dd43d7-0c7d-4025-bf1d-35b42479b402" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_523572c9-3e35-4ab3-9ce4-a269e0b74755" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_944bfe4b-6a53-4575-ac20-3d8b2d485bb2" xlink:href="mgnx-20241231.xsd#mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_523572c9-3e35-4ab3-9ce4-a269e0b74755" xlink:to="loc_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_944bfe4b-6a53-4575-ac20-3d8b2d485bb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_2e5f2dce-a086-4ef5-85bc-c6fed6ca85d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_523572c9-3e35-4ab3-9ce4-a269e0b74755" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_2e5f2dce-a086-4ef5-85bc-c6fed6ca85d3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_688534df-75c0-4d5a-8f86-3a6d1add55af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_147f5e9f-1ff4-416c-a01b-8eb2d8f86c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_688534df-75c0-4d5a-8f86-3a6d1add55af" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_147f5e9f-1ff4-416c-a01b-8eb2d8f86c1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_97ac96d1-1396-4669-b0c5-60d9579f5a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_688534df-75c0-4d5a-8f86-3a6d1add55af" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_97ac96d1-1396-4669-b0c5-60d9579f5a0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_60e760d9-2046-4d5e-b9c8-a6262155d12c" xlink:href="mgnx-20241231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_688534df-75c0-4d5a-8f86-3a6d1add55af" xlink:to="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_60e760d9-2046-4d5e-b9c8-a6262155d12c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_423a839b-1b99-4393-8c12-9453b039a745" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_688534df-75c0-4d5a-8f86-3a6d1add55af" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_423a839b-1b99-4393-8c12-9453b039a745" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount_f21e7347-8744-4d98-bf05-f287753baeb5" xlink:href="mgnx-20241231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_688534df-75c0-4d5a-8f86-3a6d1add55af" xlink:to="loc_mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount_f21e7347-8744-4d98-bf05-f287753baeb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_d51a231a-7bb7-4999-942c-6153c2f7fb94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_688534df-75c0-4d5a-8f86-3a6d1add55af" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_d51a231a-7bb7-4999-942c-6153c2f7fb94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_aa1768b4-73ba-46f8-b556-f98846a1afd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_688534df-75c0-4d5a-8f86-3a6d1add55af" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_aa1768b4-73ba-46f8-b556-f98846a1afd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_8bd90d12-4dc8-40c2-adf2-1f7f76de475e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_688534df-75c0-4d5a-8f86-3a6d1add55af" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_8bd90d12-4dc8-40c2-adf2-1f7f76de475e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount_2af79b6f-fb5e-4092-aba0-ec9e4d82f7fe" xlink:href="mgnx-20241231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_688534df-75c0-4d5a-8f86-3a6d1add55af" xlink:to="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount_2af79b6f-fb5e-4092-aba0-ec9e4d82f7fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_0248db00-e224-4550-9dbf-a3e407f1ceea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_688534df-75c0-4d5a-8f86-3a6d1add55af" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_0248db00-e224-4550-9dbf-a3e407f1ceea" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesIncomeTaxPaidTableDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#IncomeTaxesIncomeTaxPaidTableDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/IncomeTaxesIncomeTaxPaidTableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d08f22fa-b93c-484e-a41d-8b606ea240bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_f12d407c-5093-44ec-a660-b61624fdb7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d08f22fa-b93c-484e-a41d-8b606ea240bb" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_f12d407c-5093-44ec-a660-b61624fdb7e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_06152d3b-0851-4b70-bfdd-95f73e33bb6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d08f22fa-b93c-484e-a41d-8b606ea240bb" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_06152d3b-0851-4b70-bfdd-95f73e33bb6e" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>mgnx-20241231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:976c6134-a70d-4bed-9067-acb735c066ae,g:6888b12e-4125-48cc-8fc7-0d9038c82cb8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20241231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_198fbd01-06ea-4805-ba45-a4f816e04806" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f6d45a5e-c68e-494b-b7c2-1f28985c3d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_198fbd01-06ea-4805-ba45-a4f816e04806" xlink:to="loc_us-gaap_StatementTable_f6d45a5e-c68e-494b-b7c2-1f28985c3d4b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_20f4d9c7-4b19-4c9b-941e-e1cd4277c9ac" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f6d45a5e-c68e-494b-b7c2-1f28985c3d4b" xlink:to="loc_srt_ProductOrServiceAxis_20f4d9c7-4b19-4c9b-941e-e1cd4277c9ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_20f4d9c7-4b19-4c9b-941e-e1cd4277c9ac_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_20f4d9c7-4b19-4c9b-941e-e1cd4277c9ac" xlink:to="loc_srt_ProductsAndServicesDomain_20f4d9c7-4b19-4c9b-941e-e1cd4277c9ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f0b4c5f2-ac85-4b6d-8d61-7c3d351bd654" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_20f4d9c7-4b19-4c9b-941e-e1cd4277c9ac" xlink:to="loc_srt_ProductsAndServicesDomain_f0b4c5f2-ac85-4b6d-8d61-7c3d351bd654" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember_a96ed35b-4f6d-4706-aca4-060b317850cc" xlink:href="mgnx-20241231.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f0b4c5f2-ac85-4b6d-8d61-7c3d351bd654" xlink:to="loc_mgnx_RevenueFromCollaborativeAgreementsMember_a96ed35b-4f6d-4706-aca4-060b317850cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember_6ff070f3-d31f-4def-a02e-6e24e07b5062" xlink:href="mgnx-20241231.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f0b4c5f2-ac85-4b6d-8d61-7c3d351bd654" xlink:to="loc_mgnx_RevenueFromGovernmentAgreementsMember_6ff070f3-d31f-4def-a02e-6e24e07b5062" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_6fa9040f-d15e-46a0-8a33-8b9838a15ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f0b4c5f2-ac85-4b6d-8d61-7c3d351bd654" xlink:to="loc_us-gaap_ProductMember_6fa9040f-d15e-46a0-8a33-8b9838a15ca1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ContractManufacturingMember_5de51570-2bc5-4092-b732-73192609ea6e" xlink:href="mgnx-20241231.xsd#mgnx_ContractManufacturingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f0b4c5f2-ac85-4b6d-8d61-7c3d351bd654" xlink:to="loc_mgnx_ContractManufacturingMember_5de51570-2bc5-4092-b732-73192609ea6e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_9061f692-99db-4bca-9495-ef54fb7790fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_198fbd01-06ea-4805-ba45-a4f816e04806" xlink:to="loc_us-gaap_RevenuesAbstract_9061f692-99db-4bca-9495-ef54fb7790fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b91e4c55-027c-4e1c-9beb-b2af7a72c555" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_9061f692-99db-4bca-9495-ef54fb7790fa" xlink:to="loc_us-gaap_Revenues_b91e4c55-027c-4e1c-9beb-b2af7a72c555" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_a5a8c571-17f1-4746-b25c-fd15d1b809f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_198fbd01-06ea-4805-ba45-a4f816e04806" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_a5a8c571-17f1-4746-b25c-fd15d1b809f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_eda2782d-6578-46c4-9027-73682e3628e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_a5a8c571-17f1-4746-b25c-fd15d1b809f4" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_eda2782d-6578-46c4-9027-73682e3628e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CostOfManufacturingServices_c1d14688-e318-418b-a9cf-eaf9f6591ebb" xlink:href="mgnx-20241231.xsd#mgnx_CostOfManufacturingServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_a5a8c571-17f1-4746-b25c-fd15d1b809f4" xlink:to="loc_mgnx_CostOfManufacturingServices_c1d14688-e318-418b-a9cf-eaf9f6591ebb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9f563bf1-c2e2-4d83-85f6-e4fa80855c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_a5a8c571-17f1-4746-b25c-fd15d1b809f4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9f563bf1-c2e2-4d83-85f6-e4fa80855c4f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_277998ae-4045-413e-8ea2-d3db2acab2af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_a5a8c571-17f1-4746-b25c-fd15d1b809f4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_277998ae-4045-413e-8ea2-d3db2acab2af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b74826a5-8141-4bf1-b13a-6ab283fcd574" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_a5a8c571-17f1-4746-b25c-fd15d1b809f4" xlink:to="loc_us-gaap_CostsAndExpenses_b74826a5-8141-4bf1-b13a-6ab283fcd574" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8e69913b-6d7b-4360-9ad4-f5ee3f295acb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_198fbd01-06ea-4805-ba45-a4f816e04806" xlink:to="loc_us-gaap_OperatingIncomeLoss_8e69913b-6d7b-4360-9ad4-f5ee3f295acb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GainOnRoyaltyMonetizationArrangement_cf3402e3-a621-433c-a115-0c8320b39af6" xlink:href="mgnx-20241231.xsd#mgnx_GainOnRoyaltyMonetizationArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_198fbd01-06ea-4805-ba45-a4f816e04806" xlink:to="loc_mgnx_GainOnRoyaltyMonetizationArrangement_cf3402e3-a621-433c-a115-0c8320b39af6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GainOnSaleOfMARGENZA_76954844-ad65-4a69-b662-7593abbef382" xlink:href="mgnx-20241231.xsd#mgnx_GainOnSaleOfMARGENZA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_198fbd01-06ea-4805-ba45-a4f816e04806" xlink:to="loc_mgnx_GainOnSaleOfMARGENZA_76954844-ad65-4a69-b662-7593abbef382" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e3a1364e-51a9-49eb-b619-ee6dada235ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_198fbd01-06ea-4805-ba45-a4f816e04806" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e3a1364e-51a9-49eb-b619-ee6dada235ba" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_963e435b-62fe-4104-8c44-8d14dca81746" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_198fbd01-06ea-4805-ba45-a4f816e04806" xlink:to="loc_us-gaap_InterestExpense_963e435b-62fe-4104-8c44-8d14dca81746" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_713cc54f-041e-409a-8f7c-034937bbc504" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_198fbd01-06ea-4805-ba45-a4f816e04806" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_713cc54f-041e-409a-8f7c-034937bbc504" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3678dcf4-a35a-42f1-bcf4-1ba4bc3f85c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_198fbd01-06ea-4805-ba45-a4f816e04806" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3678dcf4-a35a-42f1-bcf4-1ba4bc3f85c5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fc6d7cca-b8b8-4106-b06e-c2ece304f8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_198fbd01-06ea-4805-ba45-a4f816e04806" xlink:to="loc_us-gaap_NetIncomeLoss_fc6d7cca-b8b8-4106-b06e-c2ece304f8e5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_36c24167-8e55-47aa-a747-5622a233770f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_198fbd01-06ea-4805-ba45-a4f816e04806" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_36c24167-8e55-47aa-a747-5622a233770f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_b74cc2a6-e3ef-4dac-9f9c-0139271cdcfb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_36c24167-8e55-47aa-a747-5622a233770f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_b74cc2a6-e3ef-4dac-9f9c-0139271cdcfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d07338dd-c3ab-42cb-a717-09e77b6793e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_36c24167-8e55-47aa-a747-5622a233770f" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_d07338dd-c3ab-42cb-a717-09e77b6793e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ffb4c861-4e35-464d-852b-883f4b3a4ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_198fbd01-06ea-4805-ba45-a4f816e04806" xlink:to="loc_us-gaap_EarningsPerShareBasic_ffb4c861-4e35-464d-852b-883f4b3a4ba0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_71e4f92c-f787-42c5-8947-a7321923b7d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_198fbd01-06ea-4805-ba45-a4f816e04806" xlink:to="loc_us-gaap_EarningsPerShareDiluted_71e4f92c-f787-42c5-8947-a7321923b7d1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c9ccad57-c8e3-454d-9d9e-39e8412b4120" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_198fbd01-06ea-4805-ba45-a4f816e04806" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c9ccad57-c8e3-454d-9d9e-39e8412b4120" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bf9476e7-dfdc-4add-9812-75a2c6b79471" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_198fbd01-06ea-4805-ba45-a4f816e04806" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bf9476e7-dfdc-4add-9812-75a2c6b79471" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mgnx-20241231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_91baef23-66c4-441e-bd5f-60549d896e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ccba9b86-5ba8-4db1-b779-1f925e581057" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_91baef23-66c4-441e-bd5f-60549d896e8f" xlink:to="loc_us-gaap_StatementTable_ccba9b86-5ba8-4db1-b779-1f925e581057" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7a8a5434-3a57-46ac-9c83-0a0b931135d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ccba9b86-5ba8-4db1-b779-1f925e581057" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7a8a5434-3a57-46ac-9c83-0a0b931135d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7a8a5434-3a57-46ac-9c83-0a0b931135d7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7a8a5434-3a57-46ac-9c83-0a0b931135d7" xlink:to="loc_us-gaap_EquityComponentDomain_7a8a5434-3a57-46ac-9c83-0a0b931135d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_27887d15-8854-4f15-a940-1aa4531f2185" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7a8a5434-3a57-46ac-9c83-0a0b931135d7" xlink:to="loc_us-gaap_EquityComponentDomain_27887d15-8854-4f15-a940-1aa4531f2185" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7208b069-048c-41e1-ba31-edc2cc285bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_27887d15-8854-4f15-a940-1aa4531f2185" xlink:to="loc_us-gaap_CommonStockMember_7208b069-048c-41e1-ba31-edc2cc285bf9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8f402286-3bc5-45fa-95fb-91e0d2e5f1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_27887d15-8854-4f15-a940-1aa4531f2185" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8f402286-3bc5-45fa-95fb-91e0d2e5f1e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a236c77b-24e6-40aa-b166-a4668b548244" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_27887d15-8854-4f15-a940-1aa4531f2185" xlink:to="loc_us-gaap_RetainedEarningsMember_a236c77b-24e6-40aa-b166-a4668b548244" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_50d0f9aa-b4c0-4fc8-88fe-282f93c2c188" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_27887d15-8854-4f15-a940-1aa4531f2185" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_50d0f9aa-b4c0-4fc8-88fe-282f93c2c188" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_c59046cf-19e2-4a22-a4d6-1ec735aec63c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91baef23-66c4-441e-bd5f-60549d896e8f" xlink:to="loc_us-gaap_SharesIssued_c59046cf-19e2-4a22-a4d6-1ec735aec63c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fa7c2bad-f143-4c45-9805-f98adb1df631" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91baef23-66c4-441e-bd5f-60549d896e8f" xlink:to="loc_us-gaap_StockholdersEquity_fa7c2bad-f143-4c45-9805-f98adb1df631" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7403f740-8423-4ee0-b45b-9d3449d09231" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91baef23-66c4-441e-bd5f-60549d896e8f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7403f740-8423-4ee0-b45b-9d3449d09231" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6c89a973-ff04-4b25-afee-29dc4a1c1739" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91baef23-66c4-441e-bd5f-60549d896e8f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6c89a973-ff04-4b25-afee-29dc4a1c1739" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9153ad17-7bbe-4a4b-b36c-8720975fddd1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91baef23-66c4-441e-bd5f-60549d896e8f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9153ad17-7bbe-4a4b-b36c-8720975fddd1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_8833bccd-2582-46ce-9ccb-ead0d182d683" xlink:href="mgnx-20241231.xsd#mgnx_StockIssuedDuringPeriodSharesStockPlanActivity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91baef23-66c4-441e-bd5f-60549d896e8f" xlink:to="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_8833bccd-2582-46ce-9ccb-ead0d182d683" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_749a50b6-29a6-44c1-ac30-13d140af2b41" xlink:href="mgnx-20241231.xsd#mgnx_StockIssuedDuringPeriodValueStockPlanActivity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91baef23-66c4-441e-bd5f-60549d896e8f" xlink:to="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_749a50b6-29a6-44c1-ac30-13d140af2b41" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_99062cb7-5620-4b35-81ae-48699490e508" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91baef23-66c4-441e-bd5f-60549d896e8f" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_99062cb7-5620-4b35-81ae-48699490e508" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1b9a33ed-31b4-4949-8712-d96650018131" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_91baef23-66c4-441e-bd5f-60549d896e8f" xlink:to="loc_us-gaap_NetIncomeLoss_1b9a33ed-31b4-4949-8712-d96650018131" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_c76bad9a-97ef-4070-8417-70034f85a883" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_89e7c5ee-2964-49a0-bf6b-bf73d15b30a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_de292b17-f61e-4146-9744-3adf245d4c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4fbd5b8f-0722-40fb-8d5a-f965ce9c85d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_de292b17-f61e-4146-9744-3adf245d4c7c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4fbd5b8f-0722-40fb-8d5a-f965ce9c85d2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c3a2a2ed-701a-40e5-96ff-04b993b179d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4fbd5b8f-0722-40fb-8d5a-f965ce9c85d2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c3a2a2ed-701a-40e5-96ff-04b993b179d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c3a2a2ed-701a-40e5-96ff-04b993b179d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c3a2a2ed-701a-40e5-96ff-04b993b179d1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c3a2a2ed-701a-40e5-96ff-04b993b179d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9f8a9d64-f39f-418a-bc82-bad4c53c11e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c3a2a2ed-701a-40e5-96ff-04b993b179d1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9f8a9d64-f39f-418a-bc82-bad4c53c11e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c21e43c7-30ee-48a8-9abf-b74b73e3fc43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9f8a9d64-f39f-418a-bc82-bad4c53c11e1" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c21e43c7-30ee-48a8-9abf-b74b73e3fc43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_99b4de25-a0c0-413c-9152-e8ab93895af3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9f8a9d64-f39f-418a-bc82-bad4c53c11e1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_99b4de25-a0c0-413c-9152-e8ab93895af3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_ede60c66-6154-4251-bd51-bca1795d1b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4fbd5b8f-0722-40fb-8d5a-f965ce9c85d2" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_ede60c66-6154-4251-bd51-bca1795d1b4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ede60c66-6154-4251-bd51-bca1795d1b4c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_ede60c66-6154-4251-bd51-bca1795d1b4c" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ede60c66-6154-4251-bd51-bca1795d1b4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_937aaa3d-4cf4-4d64-9de2-398282c378e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_ede60c66-6154-4251-bd51-bca1795d1b4c" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_937aaa3d-4cf4-4d64-9de2-398282c378e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_b9318745-0fa7-4028-83ee-b6f6eb3724e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_937aaa3d-4cf4-4d64-9de2-398282c378e6" xlink:to="loc_us-gaap_MoneyMarketFundsMember_b9318745-0fa7-4028-83ee-b6f6eb3724e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_e0883b5c-5c06-49ae-9847-c9b716b2eafc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_937aaa3d-4cf4-4d64-9de2-398282c378e6" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_e0883b5c-5c06-49ae-9847-c9b716b2eafc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_437e1310-605e-47f9-b529-a97cc9d70ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_937aaa3d-4cf4-4d64-9de2-398282c378e6" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_437e1310-605e-47f9-b529-a97cc9d70ad8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_4659f07a-2f03-4a6c-b5c2-e802ace83632" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_937aaa3d-4cf4-4d64-9de2-398282c378e6" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_4659f07a-2f03-4a6c-b5c2-e802ace83632" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ba88a8a3-930d-48ea-a3b3-0d2a457654ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4fbd5b8f-0722-40fb-8d5a-f965ce9c85d2" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ba88a8a3-930d-48ea-a3b3-0d2a457654ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_ba88a8a3-930d-48ea-a3b3-0d2a457654ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ba88a8a3-930d-48ea-a3b3-0d2a457654ba" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_ba88a8a3-930d-48ea-a3b3-0d2a457654ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_ef1cd986-312d-4e39-ab45-c5287972dc5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ba88a8a3-930d-48ea-a3b3-0d2a457654ba" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_ef1cd986-312d-4e39-ab45-c5287972dc5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_7be6fe0f-066f-403d-8562-fef9c0c87d77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_ef1cd986-312d-4e39-ab45-c5287972dc5c" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_7be6fe0f-066f-403d-8562-fef9c0c87d77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_b70cd1e1-20b4-49d1-892d-1fb807430bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_de292b17-f61e-4146-9744-3adf245d4c7c" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_b70cd1e1-20b4-49d1-892d-1fb807430bb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f685bbe5-cc4f-46d9-acf6-592be9924e70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b70cd1e1-20b4-49d1-892d-1fb807430bb5" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f685bbe5-cc4f-46d9-acf6-592be9924e70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_436237e1-603d-4bf7-936f-838ca3999a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b70cd1e1-20b4-49d1-892d-1fb807430bb5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_436237e1-603d-4bf7-936f-838ca3999a8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_5b4d9190-c8c2-41c8-be45-d898364d03fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b70cd1e1-20b4-49d1-892d-1fb807430bb5" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_5b4d9190-c8c2-41c8-be45-d898364d03fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_1a9cd4fc-fd0f-49d5-9511-fd1d8a896214" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Investments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_de292b17-f61e-4146-9744-3adf245d4c7c" xlink:to="loc_us-gaap_Investments_1a9cd4fc-fd0f-49d5-9511-fd1d8a896214" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_bb821f02-4e82-440f-8b9e-64b47ee4154b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_ea254e3d-9ab1-473d-9d72-b1b2d07ec00f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_bb821f02-4e82-440f-8b9e-64b47ee4154b" xlink:to="loc_us-gaap_ConcentrationRiskTable_ea254e3d-9ab1-473d-9d72-b1b2d07ec00f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_a5ba0103-7921-4d1f-8d30-96453ce58f85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_ea254e3d-9ab1-473d-9d72-b1b2d07ec00f" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_a5ba0103-7921-4d1f-8d30-96453ce58f85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a5ba0103-7921-4d1f-8d30-96453ce58f85_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_a5ba0103-7921-4d1f-8d30-96453ce58f85" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a5ba0103-7921-4d1f-8d30-96453ce58f85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_27d08896-3f43-46b2-b8ee-56026cdaa1cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_a5ba0103-7921-4d1f-8d30-96453ce58f85" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_27d08896-3f43-46b2-b8ee-56026cdaa1cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_c10d5a9d-a86b-401c-8a53-58ff13d443b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_27d08896-3f43-46b2-b8ee-56026cdaa1cb" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_c10d5a9d-a86b-401c-8a53-58ff13d443b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_39664bae-fc65-4726-a637-e50c65812f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_ea254e3d-9ab1-473d-9d72-b1b2d07ec00f" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_39664bae-fc65-4726-a637-e50c65812f1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_39664bae-fc65-4726-a637-e50c65812f1a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_39664bae-fc65-4726-a637-e50c65812f1a" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_39664bae-fc65-4726-a637-e50c65812f1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_65816e54-a1cc-490a-ad9c-d013c60455ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_39664bae-fc65-4726-a637-e50c65812f1a" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_65816e54-a1cc-490a-ad9c-d013c60455ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_aac303ac-a7fb-409d-8b51-e8f67f96e4ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_65816e54-a1cc-490a-ad9c-d013c60455ee" xlink:to="loc_us-gaap_SalesRevenueNetMember_aac303ac-a7fb-409d-8b51-e8f67f96e4ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_87c545d4-d01c-4615-a993-955cf3b172d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_65816e54-a1cc-490a-ad9c-d013c60455ee" xlink:to="loc_us-gaap_AccountsReceivableMember_87c545d4-d01c-4615-a993-955cf3b172d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_55511bd0-7a55-43d5-8374-5d9713779ae8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_ea254e3d-9ab1-473d-9d72-b1b2d07ec00f" xlink:to="loc_srt_MajorCustomersAxis_55511bd0-7a55-43d5-8374-5d9713779ae8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_55511bd0-7a55-43d5-8374-5d9713779ae8_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_55511bd0-7a55-43d5-8374-5d9713779ae8" xlink:to="loc_srt_NameOfMajorCustomerDomain_55511bd0-7a55-43d5-8374-5d9713779ae8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b71801c4-da26-45aa-b35e-d9b751418189" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_55511bd0-7a55-43d5-8374-5d9713779ae8" xlink:to="loc_srt_NameOfMajorCustomerDomain_b71801c4-da26-45aa-b35e-d9b751418189" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_875f4025-8b53-41b3-9acf-926fada731f8" xlink:href="mgnx-20241231.xsd#mgnx_IncyteCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b71801c4-da26-45aa-b35e-d9b751418189" xlink:to="loc_mgnx_IncyteCorporationMember_875f4025-8b53-41b3-9acf-926fada731f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember_c1209834-9d1b-40cc-abab-48c921ec4a04" xlink:href="mgnx-20241231.xsd#mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b71801c4-da26-45aa-b35e-d9b751418189" xlink:to="loc_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember_c1209834-9d1b-40cc-abab-48c921ec4a04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CardinalHealthIncMember_219da165-4380-4ab8-a4ca-31eb871600ee" xlink:href="mgnx-20241231.xsd#mgnx_CardinalHealthIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b71801c4-da26-45aa-b35e-d9b751418189" xlink:to="loc_mgnx_CardinalHealthIncMember_219da165-4380-4ab8-a4ca-31eb871600ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ASDHealthcareAndOncologySupplyMember_7bf5b138-f170-4989-8faf-5f0063159ead" xlink:href="mgnx-20241231.xsd#mgnx_ASDHealthcareAndOncologySupplyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b71801c4-da26-45aa-b35e-d9b751418189" xlink:to="loc_mgnx_ASDHealthcareAndOncologySupplyMember_7bf5b138-f170-4989-8faf-5f0063159ead" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioMember_7e50554c-87ba-4d2d-a3cf-ffa17b4b6b43" xlink:href="mgnx-20241231.xsd#mgnx_ProventionBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b71801c4-da26-45aa-b35e-d9b751418189" xlink:to="loc_mgnx_ProventionBioMember_7e50554c-87ba-4d2d-a3cf-ffa17b4b6b43" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabLimitedMember_7839cecf-b61e-4fea-a5db-8ee7492312bb" xlink:href="mgnx-20241231.xsd#mgnx_ZaiLabLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b71801c4-da26-45aa-b35e-d9b751418189" xlink:to="loc_mgnx_ZaiLabLimitedMember_7839cecf-b61e-4fea-a5db-8ee7492312bb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember_6b435fd2-7934-44a5-9fd6-bcb01077e1c5" xlink:href="mgnx-20241231.xsd#mgnx_ZaiLabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b71801c4-da26-45aa-b35e-d9b751418189" xlink:to="loc_mgnx_ZaiLabMember_6b435fd2-7934-44a5-9fd6-bcb01077e1c5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_030cfbee-4636-406b-a258-f5d66d70e8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_bb821f02-4e82-440f-8b9e-64b47ee4154b" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_030cfbee-4636-406b-a258-f5d66d70e8ea" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0af6c762-78c7-49b6-8004-07b00549c9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1429303d-62df-4413-a9ba-525e03fb82f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0af6c762-78c7-49b6-8004-07b00549c9a6" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1429303d-62df-4413-a9ba-525e03fb82f2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_82a9fba2-5b25-4db9-8743-41e879d8a493" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1429303d-62df-4413-a9ba-525e03fb82f2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_82a9fba2-5b25-4db9-8743-41e879d8a493" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_82a9fba2-5b25-4db9-8743-41e879d8a493_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_82a9fba2-5b25-4db9-8743-41e879d8a493" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_82a9fba2-5b25-4db9-8743-41e879d8a493_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_375f7542-5a8f-4b9c-92ab-ef6308b6ff3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_82a9fba2-5b25-4db9-8743-41e879d8a493" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_375f7542-5a8f-4b9c-92ab-ef6308b6ff3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_26bae746-6b50-4e62-b4b0-191e31633176" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_375f7542-5a8f-4b9c-92ab-ef6308b6ff3c" xlink:to="loc_us-gaap_ComputerEquipmentMember_26bae746-6b50-4e62-b4b0-191e31633176" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_8ddd4972-dbc8-4658-be94-78317bc8f8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_375f7542-5a8f-4b9c-92ab-ef6308b6ff3c" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_8ddd4972-dbc8-4658-be94-78317bc8f8a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_cd9d5a50-45c4-40fe-94f5-792b56ce3359" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_375f7542-5a8f-4b9c-92ab-ef6308b6ff3c" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_cd9d5a50-45c4-40fe-94f5-792b56ce3359" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LaboratoryAndOfficeEquipmentMember_09d2bc44-ed49-49d5-a894-48528c772f02" xlink:href="mgnx-20241231.xsd#mgnx_LaboratoryAndOfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_375f7542-5a8f-4b9c-92ab-ef6308b6ff3c" xlink:to="loc_mgnx_LaboratoryAndOfficeEquipmentMember_09d2bc44-ed49-49d5-a894-48528c772f02" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_16db5f2a-9da5-4c88-bf1a-e6aea4bfba37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0af6c762-78c7-49b6-8004-07b00549c9a6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_16db5f2a-9da5-4c88-bf1a-e6aea4bfba37" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5d37bb63-2f26-41df-93dd-0ccf60484d09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_aa32a7b8-7bb0-4e0d-bb24-f408ff4cf5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5d37bb63-2f26-41df-93dd-0ccf60484d09" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_aa32a7b8-7bb0-4e0d-bb24-f408ff4cf5c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_114ac939-2747-49dc-99a7-e71d003e8ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_aa32a7b8-7bb0-4e0d-bb24-f408ff4cf5c9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_114ac939-2747-49dc-99a7-e71d003e8ab3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_114ac939-2747-49dc-99a7-e71d003e8ab3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_114ac939-2747-49dc-99a7-e71d003e8ab3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_114ac939-2747-49dc-99a7-e71d003e8ab3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2750f527-5bb3-4a9d-a37c-88b594e48059" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_114ac939-2747-49dc-99a7-e71d003e8ab3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2750f527-5bb3-4a9d-a37c-88b594e48059" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockOptionsAndRestrictedStockUnitsMember_df2c5963-2d6a-4b09-a6e4-3b0f107ba843" xlink:href="mgnx-20241231.xsd#mgnx_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2750f527-5bb3-4a9d-a37c-88b594e48059" xlink:to="loc_mgnx_StockOptionsAndRestrictedStockUnitsMember_df2c5963-2d6a-4b09-a6e4-3b0f107ba843" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6b8a9e98-5a9d-4640-b861-c7567568f3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5d37bb63-2f26-41df-93dd-0ccf60484d09" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6b8a9e98-5a9d-4640-b861-c7567568f3b8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#MarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_16b8caf4-38cf-41a6-b574-fe9e2a5c2758" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_bcaf0018-1680-4748-b48f-a32cb73d9b01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_16b8caf4-38cf-41a6-b574-fe9e2a5c2758" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_bcaf0018-1680-4748-b48f-a32cb73d9b01" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ae8131cc-0c2f-401a-ae12-c436d7520ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_bcaf0018-1680-4748-b48f-a32cb73d9b01" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ae8131cc-0c2f-401a-ae12-c436d7520ba6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae8131cc-0c2f-401a-ae12-c436d7520ba6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ae8131cc-0c2f-401a-ae12-c436d7520ba6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ae8131cc-0c2f-401a-ae12-c436d7520ba6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e93f35d8-8d26-4408-bfb3-4885e4dfe95b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ae8131cc-0c2f-401a-ae12-c436d7520ba6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e93f35d8-8d26-4408-bfb3-4885e4dfe95b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_fb192c6d-ae22-4fab-8d06-1869c094f60f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e93f35d8-8d26-4408-bfb3-4885e4dfe95b" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_fb192c6d-ae22-4fab-8d06-1869c094f60f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_63f31aa6-c118-4ae1-a438-20fb5ecaf921" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e93f35d8-8d26-4408-bfb3-4885e4dfe95b" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_63f31aa6-c118-4ae1-a438-20fb5ecaf921" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_402d0747-25b8-4676-957e-3cae58c75f55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e93f35d8-8d26-4408-bfb3-4885e4dfe95b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_402d0747-25b8-4676-957e-3cae58c75f55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4c4bbcc7-e74e-4310-b99a-050ac70df5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_16b8caf4-38cf-41a6-b574-fe9e2a5c2758" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4c4bbcc7-e74e-4310-b99a-050ac70df5d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a093c0ca-d9a4-434e-aaf6-d590004d9f65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_16b8caf4-38cf-41a6-b574-fe9e2a5c2758" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a093c0ca-d9a4-434e-aaf6-d590004d9f65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_80057ec9-fa97-431a-bb88-b0e7424eb9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_16b8caf4-38cf-41a6-b574-fe9e2a5c2758" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_80057ec9-fa97-431a-bb88-b0e7424eb9a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b285dd65-f14b-4fbc-bde3-f61f57bf8154" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_16b8caf4-38cf-41a6-b574-fe9e2a5c2758" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b285dd65-f14b-4fbc-bde3-f61f57bf8154" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/InventoryNetDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#InventoryNetDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/InventoryNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_502237b8-d53a-4e68-934a-4a4aa38ad974" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_b1314382-4d66-4e77-bddd-e995d9d7ae2d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_502237b8-d53a-4e68-934a-4a4aa38ad974" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_b1314382-4d66-4e77-bddd-e995d9d7ae2d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_f3f1b8ee-0340-461f-9e96-eef35667adcd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_b1314382-4d66-4e77-bddd-e995d9d7ae2d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_f3f1b8ee-0340-461f-9e96-eef35667adcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_f3f1b8ee-0340-461f-9e96-eef35667adcd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_f3f1b8ee-0340-461f-9e96-eef35667adcd" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_f3f1b8ee-0340-461f-9e96-eef35667adcd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_8dbd4700-49b2-4ab7-bd63-350d8bcd9811" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_f3f1b8ee-0340-461f-9e96-eef35667adcd" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_8dbd4700-49b2-4ab7-bd63-350d8bcd9811" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserveMember_e81d8320-a13f-464a-b592-083566207ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8dbd4700-49b2-4ab7-bd63-350d8bcd9811" xlink:to="loc_us-gaap_InventoryValuationReserveMember_e81d8320-a13f-464a-b592-083566207ab7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_f182d386-5723-46e7-9231-cdf12d34d3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_502237b8-d53a-4e68-934a-4a4aa38ad974" xlink:to="loc_us-gaap_InventoryValuationReserves_f182d386-5723-46e7-9231-cdf12d34d3fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_8021c491-2b85-4b8b-88b4-5dd727bf0bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_502237b8-d53a-4e68-934a-4a4aa38ad974" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_8021c491-2b85-4b8b-88b4-5dd727bf0bf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_ec4d2cbc-da69-4686-907a-dbfd70758720" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_502237b8-d53a-4e68-934a-4a4aa38ad974" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_ec4d2cbc-da69-4686-907a-dbfd70758720" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_54b782a8-2382-4d1f-aa94-86c983ee5cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_502237b8-d53a-4e68-934a-4a4aa38ad974" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_54b782a8-2382-4d1f-aa94-86c983ee5cb1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_b17b8d2e-15fa-4d53-8f6e-1e59274af5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#PropertyEquipmentandSoftwareDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_138a4265-ce8b-462c-90fa-def77b357ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_52d72099-9170-4d43-a612-9f89a5d1fe70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_138a4265-ce8b-462c-90fa-def77b357ac0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_52d72099-9170-4d43-a612-9f89a5d1fe70" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9fcd8f1a-47a5-4319-b996-898304d7365c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_52d72099-9170-4d43-a612-9f89a5d1fe70" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9fcd8f1a-47a5-4319-b996-898304d7365c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9fcd8f1a-47a5-4319-b996-898304d7365c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9fcd8f1a-47a5-4319-b996-898304d7365c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9fcd8f1a-47a5-4319-b996-898304d7365c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a7a55828-d2af-45c4-aa01-00690512c349" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9fcd8f1a-47a5-4319-b996-898304d7365c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a7a55828-d2af-45c4-aa01-00690512c349" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_162463dc-8adb-415e-959f-b0e3505f9e73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a7a55828-d2af-45c4-aa01-00690512c349" xlink:to="loc_us-gaap_ComputerEquipmentMember_162463dc-8adb-415e-959f-b0e3505f9e73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_703b7295-7a4d-4492-bf30-e8d95d597804" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a7a55828-d2af-45c4-aa01-00690512c349" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_703b7295-7a4d-4492-bf30-e8d95d597804" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FurnitureAndOfficeEquipmentMember_135de547-77f4-4fd2-ad75-b59c8d09a166" xlink:href="mgnx-20241231.xsd#mgnx_FurnitureAndOfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a7a55828-d2af-45c4-aa01-00690512c349" xlink:to="loc_mgnx_FurnitureAndOfficeEquipmentMember_135de547-77f4-4fd2-ad75-b59c8d09a166" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_25c943b2-a4bb-42ff-879f-dd293bfeab12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VehiclesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a7a55828-d2af-45c4-aa01-00690512c349" xlink:to="loc_us-gaap_VehiclesMember_25c943b2-a4bb-42ff-879f-dd293bfeab12" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_d073a4fe-b910-4231-a3cd-6a6e477a2dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a7a55828-d2af-45c4-aa01-00690512c349" xlink:to="loc_us-gaap_EquipmentMember_d073a4fe-b910-4231-a3cd-6a6e477a2dd6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_0d6d6b07-f36f-4345-a2ee-70bf8a9b7824" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a7a55828-d2af-45c4-aa01-00690512c349" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_0d6d6b07-f36f-4345-a2ee-70bf8a9b7824" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1b7c2ff5-9ea5-4a19-b1f9-2d222556a6df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_138a4265-ce8b-462c-90fa-def77b357ac0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1b7c2ff5-9ea5-4a19-b1f9-2d222556a6df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_080d764a-51a0-4b67-983c-ac184a68236b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_138a4265-ce8b-462c-90fa-def77b357ac0" xlink:to="loc_us-gaap_ConstructionInProgressGross_080d764a-51a0-4b67-983c-ac184a68236b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_46b4b37b-4898-4f1f-ab8c-38f587506f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_138a4265-ce8b-462c-90fa-def77b357ac0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_46b4b37b-4898-4f1f-ab8c-38f587506f4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_cefa415d-fb3d-480b-a35a-91b25d1f1783" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_138a4265-ce8b-462c-90fa-def77b357ac0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_cefa415d-fb3d-480b-a35a-91b25d1f1783" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_8125bd67-a674-4ed3-8134-4b80b2b2f18b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_138a4265-ce8b-462c-90fa-def77b357ac0" xlink:to="loc_us-gaap_Depreciation_8125bd67-a674-4ed3-8134-4b80b2b2f18b" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_d059f017-346e-49b4-a0a6-2dc63fc73767" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_d059f017-346e-49b4-a0a6-2dc63fc73767" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1a282ac9-3faf-4188-9a0f-6ecc1325103b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d059f017-346e-49b4-a0a6-2dc63fc73767" xlink:to="loc_srt_CounterpartyNameAxis_1a282ac9-3faf-4188-9a0f-6ecc1325103b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1a282ac9-3faf-4188-9a0f-6ecc1325103b_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_1a282ac9-3faf-4188-9a0f-6ecc1325103b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1a282ac9-3faf-4188-9a0f-6ecc1325103b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3de72423-653f-4f46-848c-a79f5598bdde" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_1a282ac9-3faf-4188-9a0f-6ecc1325103b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3de72423-653f-4f46-848c-a79f5598bdde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_SynaffixBVMember_4f95fafe-be7e-4724-8446-57ffb0e959af" xlink:href="mgnx-20241231.xsd#mgnx_SynaffixBVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3de72423-653f-4f46-848c-a79f5598bdde" xlink:to="loc_mgnx_SynaffixBVMember_4f95fafe-be7e-4724-8446-57ffb0e959af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_50405ae2-81ff-4cd2-8e15-9cf80335b0b4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d059f017-346e-49b4-a0a6-2dc63fc73767" xlink:to="loc_srt_RangeAxis_50405ae2-81ff-4cd2-8e15-9cf80335b0b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_50405ae2-81ff-4cd2-8e15-9cf80335b0b4_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_50405ae2-81ff-4cd2-8e15-9cf80335b0b4" xlink:to="loc_srt_RangeMember_50405ae2-81ff-4cd2-8e15-9cf80335b0b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_deb59f45-e9d2-44df-afcc-fc96310114ad" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_50405ae2-81ff-4cd2-8e15-9cf80335b0b4" xlink:to="loc_srt_RangeMember_deb59f45-e9d2-44df-afcc-fc96310114ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_684e95a2-c281-4528-829e-70decb28a079" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_deb59f45-e9d2-44df-afcc-fc96310114ad" xlink:to="loc_srt_MinimumMember_684e95a2-c281-4528-829e-70decb28a079" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_702a16f3-ef53-460c-a67e-86bfbdd7c2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_702a16f3-ef53-460c-a67e-86bfbdd7c2d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease_24d0f703-bdbd-416e-b8ed-8eccf2434cac" xlink:href="mgnx-20241231.xsd#mgnx_RightOfUseAssetAndLeaseLiabilityIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease_24d0f703-bdbd-416e-b8ed-8eccf2434cac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a79f4c58-3305-4282-b124-cfc054118576" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a79f4c58-3305-4282-b124-cfc054118576" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_19b7e954-7bd0-47f3-ad89-a4de94729c29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_19b7e954-7bd0-47f3-ad89-a4de94729c29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_fec9939e-e850-4ce5-ab4b-b13a23431f31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_us-gaap_OperatingLeasePayments_fec9939e-e850-4ce5-ab4b-b13a23431f31" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b577a97f-a245-4cd8-a583-417fc9124a63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b577a97f-a245-4cd8-a583-417fc9124a63" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_01e37b46-2015-4292-bdfe-06236fd9712d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_us-gaap_OperatingLeaseCost_01e37b46-2015-4292-bdfe-06236fd9712d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_56eb37f0-3182-402d-abe4-0656dfcff81a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_us-gaap_VariableLeaseCost_56eb37f0-3182-402d-abe4-0656dfcff81a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_45292909-87b1-4d6a-befb-69ef27d86e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_us-gaap_SubleaseIncome_45292909-87b1-4d6a-befb-69ef27d86e6f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_f0859c3c-e20a-4eb2-ba96-82bd22948b80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_us-gaap_LeaseCost_f0859c3c-e20a-4eb2-ba96-82bd22948b80" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e20a47f6-00cb-4249-ab74-c4323225c1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e20a47f6-00cb-4249-ab74-c4323225c1f4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1a916eef-f536-4191-9cb0-1f13d3e85c04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1a916eef-f536-4191-9cb0-1f13d3e85c04" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_098bbd29-55f8-4f56-aa9e-8a0179200925" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_098bbd29-55f8-4f56-aa9e-8a0179200925" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_bfd4b828-2ee8-4f60-9b7b-f4f66acce420" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_bfd4b828-2ee8-4f60-9b7b-f4f66acce420" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_4d5f9e04-590f-473f-97ea-e1e8ebfb25a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_4d5f9e04-590f-473f-97ea-e1e8ebfb25a3" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_3950bc63-96af-4a22-b86a-53d9a211703d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_3950bc63-96af-4a22-b86a-53d9a211703d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3ceee702-0c0d-4e10-b08c-53353bca5302" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3ceee702-0c0d-4e10-b08c-53353bca5302" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5185274d-8239-49b2-8fc6-d5c489fdbf7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5185274d-8239-49b2-8fc6-d5c489fdbf7f" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_df442935-8fe1-4246-ac74-fa8fbca7ab93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_us-gaap_OperatingLeaseLiability_df442935-8fe1-4246-ac74-fa8fbca7ab93" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_06afe125-ecff-434f-b5b8-32fcfd809399" xlink:href="mgnx-20241231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_06afe125-ecff-434f-b5b8-32fcfd809399" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_cf8eb0a2-98fb-46b8-b104-741a602f30ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_cf8eb0a2-98fb-46b8-b104-741a602f30ab" xlink:type="arc" order="20"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_a9c1618e-21ae-431d-8903-db96a75e62de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_bb925335-13ca-48c0-948a-a3b68684758a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_a9c1618e-21ae-431d-8903-db96a75e62de" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_bb925335-13ca-48c0-948a-a3b68684758a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5fa683ca-2198-4284-b83a-14d0edc33ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bb925335-13ca-48c0-948a-a3b68684758a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5fa683ca-2198-4284-b83a-14d0edc33ab8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5fa683ca-2198-4284-b83a-14d0edc33ab8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5fa683ca-2198-4284-b83a-14d0edc33ab8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5fa683ca-2198-4284-b83a-14d0edc33ab8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b324c825-f1ee-4527-8821-4a9d6ccc26a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5fa683ca-2198-4284-b83a-14d0edc33ab8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b324c825-f1ee-4527-8821-4a9d6ccc26a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AtTheMarketOfferingMember_f14d4a75-d51f-4bea-add1-570efcf8b6f2" xlink:href="mgnx-20241231.xsd#mgnx_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b324c825-f1ee-4527-8821-4a9d6ccc26a1" xlink:to="loc_mgnx_AtTheMarketOfferingMember_f14d4a75-d51f-4bea-add1-570efcf8b6f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0b0ab59e-f53a-433b-a6db-d3aba3cfbae1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bb925335-13ca-48c0-948a-a3b68684758a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0b0ab59e-f53a-433b-a6db-d3aba3cfbae1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0b0ab59e-f53a-433b-a6db-d3aba3cfbae1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0b0ab59e-f53a-433b-a6db-d3aba3cfbae1" xlink:to="loc_us-gaap_ClassOfStockDomain_0b0ab59e-f53a-433b-a6db-d3aba3cfbae1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8aa007f0-2dc8-4bec-aaf1-5745d565c66c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0b0ab59e-f53a-433b-a6db-d3aba3cfbae1" xlink:to="loc_us-gaap_ClassOfStockDomain_8aa007f0-2dc8-4bec-aaf1-5745d565c66c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UndesignatedPreferredStockMember_0f775ddc-4fb7-4f9e-88bb-c9b94f15fc3d" xlink:href="mgnx-20241231.xsd#mgnx_UndesignatedPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8aa007f0-2dc8-4bec-aaf1-5745d565c66c" xlink:to="loc_mgnx_UndesignatedPreferredStockMember_0f775ddc-4fb7-4f9e-88bb-c9b94f15fc3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0244b42b-1db7-421d-a8e6-74d200dddc14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a9c1618e-21ae-431d-8903-db96a75e62de" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0244b42b-1db7-421d-a8e6-74d200dddc14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_286e6597-c907-460c-829c-4c0d9897ca7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a9c1618e-21ae-431d-8903-db96a75e62de" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_286e6597-c907-460c-829c-4c0d9897ca7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_904d8989-123e-496f-9d8a-9564b94b185b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a9c1618e-21ae-431d-8903-db96a75e62de" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_904d8989-123e-496f-9d8a-9564b94b185b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_5b760911-9986-4be6-834e-6d285e1a5508" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a9c1618e-21ae-431d-8903-db96a75e62de" xlink:to="loc_us-gaap_PreferredStockSharesIssued_5b760911-9986-4be6-834e-6d285e1a5508" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_684c6ee5-f97d-468c-892c-fe846b9e8202" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a9c1618e-21ae-431d-8903-db96a75e62de" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_684c6ee5-f97d-468c-892c-fe846b9e8202" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_a64c05ad-23e5-4522-b008-26c7de0d3627" xlink:href="mgnx-20241231.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a9c1618e-21ae-431d-8903-db96a75e62de" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_a64c05ad-23e5-4522-b008-26c7de0d3627" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6962ca1f-0140-439e-9f9c-85e23d1bce97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a9c1618e-21ae-431d-8903-db96a75e62de" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6962ca1f-0140-439e-9f9c-85e23d1bce97" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_72e10c11-a3a8-437d-9645-53df630e5a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a9c1618e-21ae-431d-8903-db96a75e62de" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_72e10c11-a3a8-437d-9645-53df630e5a3d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_87c897be-dab4-49b3-a293-ea7ae8426bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a9c1618e-21ae-431d-8903-db96a75e62de" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_87c897be-dab4-49b3-a293-ea7ae8426bc3" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueIncyteCorporationDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#RevenueIncyteCorporationDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/RevenueIncyteCorporationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8f235664-ce9a-4568-865f-2ce079922805" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10c1ea30-ff98-41bc-b446-2d5ea50c6989" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8f235664-ce9a-4568-865f-2ce079922805" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10c1ea30-ff98-41bc-b446-2d5ea50c6989" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_887edc4e-b945-402a-92f1-30332aaf3a9b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10c1ea30-ff98-41bc-b446-2d5ea50c6989" xlink:to="loc_srt_ProductOrServiceAxis_887edc4e-b945-402a-92f1-30332aaf3a9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_887edc4e-b945-402a-92f1-30332aaf3a9b_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_887edc4e-b945-402a-92f1-30332aaf3a9b" xlink:to="loc_srt_ProductsAndServicesDomain_887edc4e-b945-402a-92f1-30332aaf3a9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5b526a28-69f6-45b0-b406-ff4d04356c16" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_887edc4e-b945-402a-92f1-30332aaf3a9b" xlink:to="loc_srt_ProductsAndServicesDomain_5b526a28-69f6-45b0-b406-ff4d04356c16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_426e20fc-c334-4561-999c-af1e18a229d9" xlink:href="mgnx-20241231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5b526a28-69f6-45b0-b406-ff4d04356c16" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_426e20fc-c334-4561-999c-af1e18a229d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3a7c8065-695b-4a43-95aa-1c7db1ef6221" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10c1ea30-ff98-41bc-b446-2d5ea50c6989" xlink:to="loc_srt_RangeAxis_3a7c8065-695b-4a43-95aa-1c7db1ef6221" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3a7c8065-695b-4a43-95aa-1c7db1ef6221_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3a7c8065-695b-4a43-95aa-1c7db1ef6221" xlink:to="loc_srt_RangeMember_3a7c8065-695b-4a43-95aa-1c7db1ef6221_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a25b7d53-99d5-47c4-8900-96518a96f5a7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3a7c8065-695b-4a43-95aa-1c7db1ef6221" xlink:to="loc_srt_RangeMember_a25b7d53-99d5-47c4-8900-96518a96f5a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_305b4cf7-31ab-437b-b05c-c334a7e1b6db" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a25b7d53-99d5-47c4-8900-96518a96f5a7" xlink:to="loc_srt_MinimumMember_305b4cf7-31ab-437b-b05c-c334a7e1b6db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d669da55-9c07-43eb-829c-d716b9b17246" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a25b7d53-99d5-47c4-8900-96518a96f5a7" xlink:to="loc_srt_MaximumMember_d669da55-9c07-43eb-829c-d716b9b17246" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2214f871-0efb-4f1f-ac61-40d7e7ed48db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10c1ea30-ff98-41bc-b446-2d5ea50c6989" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2214f871-0efb-4f1f-ac61-40d7e7ed48db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2214f871-0efb-4f1f-ac61-40d7e7ed48db_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2214f871-0efb-4f1f-ac61-40d7e7ed48db" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2214f871-0efb-4f1f-ac61-40d7e7ed48db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3041e403-7f8c-491c-b6de-8a112ecb1c30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2214f871-0efb-4f1f-ac61-40d7e7ed48db" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3041e403-7f8c-491c-b6de-8a112ecb1c30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_778f6df3-7de8-49bc-9964-488ffdb71938" xlink:href="mgnx-20241231.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3041e403-7f8c-491c-b6de-8a112ecb1c30" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_778f6df3-7de8-49bc-9964-488ffdb71938" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteClinicalSupplyAgreementMember_22a797e7-4da5-4a26-9db5-d8d0142e2ce3" xlink:href="mgnx-20241231.xsd#mgnx_IncyteClinicalSupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3041e403-7f8c-491c-b6de-8a112ecb1c30" xlink:to="loc_mgnx_IncyteClinicalSupplyAgreementMember_22a797e7-4da5-4a26-9db5-d8d0142e2ce3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCommercialSupplyAgreementMember_fdedd95f-1042-4706-95db-0d72912cd50e" xlink:href="mgnx-20241231.xsd#mgnx_IncyteCommercialSupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3041e403-7f8c-491c-b6de-8a112ecb1c30" xlink:to="loc_mgnx_IncyteCommercialSupplyAgreementMember_fdedd95f-1042-4706-95db-0d72912cd50e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_93ab9400-9e97-438f-a24d-78a43fa7b053" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10c1ea30-ff98-41bc-b446-2d5ea50c6989" xlink:to="loc_srt_CounterpartyNameAxis_93ab9400-9e97-438f-a24d-78a43fa7b053" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93ab9400-9e97-438f-a24d-78a43fa7b053_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_93ab9400-9e97-438f-a24d-78a43fa7b053" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93ab9400-9e97-438f-a24d-78a43fa7b053_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d020a08b-f6ce-497a-a9ee-6d5b916f880b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_93ab9400-9e97-438f-a24d-78a43fa7b053" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d020a08b-f6ce-497a-a9ee-6d5b916f880b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_73005160-35c9-48c9-9ae8-c8e384420c90" xlink:href="mgnx-20241231.xsd#mgnx_IncyteCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d020a08b-f6ce-497a-a9ee-6d5b916f880b" xlink:to="loc_mgnx_IncyteCorporationMember_73005160-35c9-48c9-9ae8-c8e384420c90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_81f39da6-8cb9-4bd3-bc6e-035148847df7" xlink:href="mgnx-20241231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8f235664-ce9a-4568-865f-2ce079922805" xlink:to="loc_mgnx_NonRefundableUpfrontFees_81f39da6-8cb9-4bd3-bc6e-035148847df7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_da55511e-3259-417b-9271-6ada783de306" xlink:href="mgnx-20241231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8f235664-ce9a-4568-865f-2ce079922805" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_da55511e-3259-417b-9271-6ada783de306" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_676f8b5b-6a7f-4345-bdc1-2e8e3eb6bf5a" xlink:href="mgnx-20241231.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8f235664-ce9a-4568-865f-2ce079922805" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_676f8b5b-6a7f-4345-bdc1-2e8e3eb6bf5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_22f63feb-f655-481c-8aae-4358622531f0" xlink:href="mgnx-20241231.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8f235664-ce9a-4568-865f-2ce079922805" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_22f63feb-f655-481c-8aae-4358622531f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_ffa1a6eb-fbbe-40bd-a46e-6176cc4aaa24" xlink:href="mgnx-20241231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8f235664-ce9a-4568-865f-2ce079922805" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_ffa1a6eb-fbbe-40bd-a46e-6176cc4aaa24" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_c2024d7b-00a6-4bbc-bfbe-d688f818aa9a" xlink:href="mgnx-20241231.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8f235664-ce9a-4568-865f-2ce079922805" xlink:to="loc_mgnx_NumberOfPerformanceObligations_c2024d7b-00a6-4bbc-bfbe-d688f818aa9a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_60ecdcfe-87e1-419c-a99c-5cb2beba5070" xlink:href="mgnx-20241231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8f235664-ce9a-4568-865f-2ce079922805" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_60ecdcfe-87e1-419c-a99c-5cb2beba5070" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f10978c7-03ed-4f0c-9675-0d46824823c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8f235664-ce9a-4568-865f-2ce079922805" xlink:to="loc_us-gaap_Revenues_f10978c7-03ed-4f0c-9675-0d46824823c9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_26c9d52e-2745-42cd-b802-f74895f72a8c" xlink:href="mgnx-20241231.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8f235664-ce9a-4568-865f-2ce079922805" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_26c9d52e-2745-42cd-b802-f74895f72a8c" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueGileadSciencesIncDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#RevenueGileadSciencesIncDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/RevenueGileadSciencesIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b3c5fa3-f557-4d76-b0c7-2933bcab4d81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_743dd0d3-8065-4d06-b93d-309dd57bd0b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b3c5fa3-f557-4d76-b0c7-2933bcab4d81" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_743dd0d3-8065-4d06-b93d-309dd57bd0b4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_93820b6a-7427-4bd3-9e92-b0a15a94c3d3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_743dd0d3-8065-4d06-b93d-309dd57bd0b4" xlink:to="loc_srt_CounterpartyNameAxis_93820b6a-7427-4bd3-9e92-b0a15a94c3d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93820b6a-7427-4bd3-9e92-b0a15a94c3d3_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_93820b6a-7427-4bd3-9e92-b0a15a94c3d3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93820b6a-7427-4bd3-9e92-b0a15a94c3d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_583ff3db-6fdc-4c3d-a8d0-0f79790a8991" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_93820b6a-7427-4bd3-9e92-b0a15a94c3d3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_583ff3db-6fdc-4c3d-a8d0-0f79790a8991" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GileadMember_c3509c5d-72b3-40e4-abc8-041454d96945" xlink:href="mgnx-20241231.xsd#mgnx_GileadMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_583ff3db-6fdc-4c3d-a8d0-0f79790a8991" xlink:to="loc_mgnx_GileadMember_c3509c5d-72b3-40e4-abc8-041454d96945" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_6199287b-64ed-4584-aa04-442a3d5873ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_743dd0d3-8065-4d06-b93d-309dd57bd0b4" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_6199287b-64ed-4584-aa04-442a3d5873ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6199287b-64ed-4584-aa04-442a3d5873ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_6199287b-64ed-4584-aa04-442a3d5873ab" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6199287b-64ed-4584-aa04-442a3d5873ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_83a6648f-bf75-46a7-b1e5-cc99dfec8034" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_6199287b-64ed-4584-aa04-442a3d5873ab" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_83a6648f-bf75-46a7-b1e5-cc99dfec8034" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2022GileadCollaborationAndLicenseAgreementMember_99ae50e9-4403-4cca-9fc0-2b583b95b27a" xlink:href="mgnx-20241231.xsd#mgnx_A2022GileadCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_83a6648f-bf75-46a7-b1e5-cc99dfec8034" xlink:to="loc_mgnx_A2022GileadCollaborationAndLicenseAgreementMember_99ae50e9-4403-4cca-9fc0-2b583b95b27a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GileadFirstResearchProgramMember_50307ecf-22ec-40b8-9b2f-ba7e5b18274a" xlink:href="mgnx-20241231.xsd#mgnx_GileadFirstResearchProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_83a6648f-bf75-46a7-b1e5-cc99dfec8034" xlink:to="loc_mgnx_GileadFirstResearchProgramMember_50307ecf-22ec-40b8-9b2f-ba7e5b18274a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_20eb8cd8-af15-446d-92ba-a892a66c9689" xlink:href="mgnx-20241231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b3c5fa3-f557-4d76-b0c7-2933bcab4d81" xlink:to="loc_mgnx_NonRefundableUpfrontFees_20eb8cd8-af15-446d-92ba-a892a66c9689" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments_5a748fda-e5d3-4e20-bfb9-5fc3df3484b5" xlink:href="mgnx-20241231.xsd#mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b3c5fa3-f557-4d76-b0c7-2933bcab4d81" xlink:to="loc_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments_5a748fda-e5d3-4e20-bfb9-5fc3df3484b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_05a6e475-302a-4fbc-bfb0-acde160b5887" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b3c5fa3-f557-4d76-b0c7-2933bcab4d81" xlink:to="loc_us-gaap_Revenues_05a6e475-302a-4fbc-bfb0-acde160b5887" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_086ef239-67e2-4002-81de-a1accab2eebf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b3c5fa3-f557-4d76-b0c7-2933bcab4d81" xlink:to="loc_us-gaap_ContractWithCustomerLiability_086ef239-67e2-4002-81de-a1accab2eebf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9210e553-2174-4d50-9efe-ceff38bec12f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b3c5fa3-f557-4d76-b0c7-2933bcab4d81" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9210e553-2174-4d50-9efe-ceff38bec12f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_742836aa-461e-4a8d-9a21-5d417f5b92ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b3c5fa3-f557-4d76-b0c7-2933bcab4d81" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_742836aa-461e-4a8d-9a21-5d417f5b92ff" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_a0cb2ddd-a985-49ac-ab25-85304887b924" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b3c5fa3-f557-4d76-b0c7-2933bcab4d81" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_a0cb2ddd-a985-49ac-ab25-85304887b924" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OptionToBuy_ecadf5cb-014e-4364-8630-ad5b5e747b20" xlink:href="mgnx-20241231.xsd#mgnx_OptionToBuy"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b3c5fa3-f557-4d76-b0c7-2933bcab4d81" xlink:to="loc_mgnx_OptionToBuy_ecadf5cb-014e-4364-8630-ad5b5e747b20" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_df69ce77-1d76-4774-91cc-02e5852e8e76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b3c5fa3-f557-4d76-b0c7-2933bcab4d81" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_df69ce77-1d76-4774-91cc-02e5852e8e76" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueZaiLabDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#RevenueZaiLabDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/RevenueZaiLabDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa50a7d4-1245-47ce-afb6-160c1216cdf4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4d7959e1-efd4-4df6-8cfd-7d4533566ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa50a7d4-1245-47ce-afb6-160c1216cdf4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4d7959e1-efd4-4df6-8cfd-7d4533566ea0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_59fee0d0-b571-498b-a308-082c351a955e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4d7959e1-efd4-4df6-8cfd-7d4533566ea0" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_59fee0d0-b571-498b-a308-082c351a955e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_59fee0d0-b571-498b-a308-082c351a955e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_59fee0d0-b571-498b-a308-082c351a955e" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_59fee0d0-b571-498b-a308-082c351a955e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d877f959-e556-4797-ad8e-f7c00ab7a991" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_59fee0d0-b571-498b-a308-082c351a955e" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d877f959-e556-4797-ad8e-f7c00ab7a991" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2021ZaiLabAgreementsMember_4108a414-e458-42fb-8183-481372fc4974" xlink:href="mgnx-20241231.xsd#mgnx_A2021ZaiLabAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d877f959-e556-4797-ad8e-f7c00ab7a991" xlink:to="loc_mgnx_A2021ZaiLabAgreementsMember_4108a414-e458-42fb-8183-481372fc4974" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_08be42cc-a5c7-4055-a3e5-ff02ae738857" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4d7959e1-efd4-4df6-8cfd-7d4533566ea0" xlink:to="loc_srt_CounterpartyNameAxis_08be42cc-a5c7-4055-a3e5-ff02ae738857" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_08be42cc-a5c7-4055-a3e5-ff02ae738857_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_08be42cc-a5c7-4055-a3e5-ff02ae738857" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_08be42cc-a5c7-4055-a3e5-ff02ae738857_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3708216b-703c-4dc4-86ba-de157f81b658" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_08be42cc-a5c7-4055-a3e5-ff02ae738857" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3708216b-703c-4dc4-86ba-de157f81b658" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember_808a8768-8886-466a-a0b1-554ad33060ce" xlink:href="mgnx-20241231.xsd#mgnx_ZaiLabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3708216b-703c-4dc4-86ba-de157f81b658" xlink:to="loc_mgnx_ZaiLabMember_808a8768-8886-466a-a0b1-554ad33060ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_dbbb5045-4afb-42fa-817e-dfcb0b74dd8d" xlink:href="mgnx-20241231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa50a7d4-1245-47ce-afb6-160c1216cdf4" xlink:to="loc_mgnx_NonRefundableUpfrontFees_dbbb5045-4afb-42fa-817e-dfcb0b74dd8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_2457d06a-426f-4019-a26e-a62ee49af7b7" xlink:href="mgnx-20241231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa50a7d4-1245-47ce-afb6-160c1216cdf4" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_2457d06a-426f-4019-a26e-a62ee49af7b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_026423d1-e572-4dc9-a022-f169342c621f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa50a7d4-1245-47ce-afb6-160c1216cdf4" xlink:to="loc_us-gaap_Revenues_026423d1-e572-4dc9-a022-f169342c621f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueProventionDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#RevenueProventionDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/RevenueProventionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb37ab7d-dc0b-4762-8185-da6114a5d4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7ef551da-15ea-4a00-b63c-39611f35b926" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb37ab7d-dc0b-4762-8185-da6114a5d4a6" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7ef551da-15ea-4a00-b63c-39611f35b926" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f576fafe-784d-4a6b-bb8a-af1f5297e449" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7ef551da-15ea-4a00-b63c-39611f35b926" xlink:to="loc_srt_CounterpartyNameAxis_f576fafe-784d-4a6b-bb8a-af1f5297e449" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f576fafe-784d-4a6b-bb8a-af1f5297e449_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_f576fafe-784d-4a6b-bb8a-af1f5297e449" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f576fafe-784d-4a6b-bb8a-af1f5297e449_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_199bb825-a84b-4d31-a131-a22d831972b6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_f576fafe-784d-4a6b-bb8a-af1f5297e449" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_199bb825-a84b-4d31-a131-a22d831972b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioMember_538cbbc9-92fc-4b50-8ad4-a191026213c9" xlink:href="mgnx-20241231.xsd#mgnx_ProventionBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_199bb825-a84b-4d31-a131-a22d831972b6" xlink:to="loc_mgnx_ProventionBioMember_538cbbc9-92fc-4b50-8ad4-a191026213c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DRIHealthcareAcquisitionsLPDRIMember_e2fedaba-7421-4434-b82b-168b801f0dd5" xlink:href="mgnx-20241231.xsd#mgnx_DRIHealthcareAcquisitionsLPDRIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_199bb825-a84b-4d31-a131-a22d831972b6" xlink:to="loc_mgnx_DRIHealthcareAcquisitionsLPDRIMember_e2fedaba-7421-4434-b82b-168b801f0dd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ebc3a9be-6f3a-458f-b69b-495e3c7caa33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7ef551da-15ea-4a00-b63c-39611f35b926" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ebc3a9be-6f3a-458f-b69b-495e3c7caa33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ebc3a9be-6f3a-458f-b69b-495e3c7caa33_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ebc3a9be-6f3a-458f-b69b-495e3c7caa33" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ebc3a9be-6f3a-458f-b69b-495e3c7caa33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f70d1965-ee1d-40d0-80f2-dfb39f5eefdb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ebc3a9be-6f3a-458f-b69b-495e3c7caa33" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f70d1965-ee1d-40d0-80f2-dfb39f5eefdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV3279Member_82536552-7f13-4e81-ae7b-5855c652ce8d" xlink:href="mgnx-20241231.xsd#mgnx_ProventionPRV3279Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f70d1965-ee1d-40d0-80f2-dfb39f5eefdb" xlink:to="loc_mgnx_ProventionPRV3279Member_82536552-7f13-4e81-ae7b-5855c652ce8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV031Member_021801ea-d467-4416-acad-4663689ee61a" xlink:href="mgnx-20241231.xsd#mgnx_ProventionPRV031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f70d1965-ee1d-40d0-80f2-dfb39f5eefdb" xlink:to="loc_mgnx_ProventionPRV031Member_021801ea-d467-4416-acad-4663689ee61a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c42c8580-226e-432e-ac5d-f142343aa96e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7ef551da-15ea-4a00-b63c-39611f35b926" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c42c8580-226e-432e-ac5d-f142343aa96e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c42c8580-226e-432e-ac5d-f142343aa96e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c42c8580-226e-432e-ac5d-f142343aa96e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c42c8580-226e-432e-ac5d-f142343aa96e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_66cee575-df34-4f15-af25-3e05b33c4215" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c42c8580-226e-432e-ac5d-f142343aa96e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_66cee575-df34-4f15-af25-3e05b33c4215" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionLicenseAgreementMember_ab42cddd-fcce-4d08-8c3d-900ce27cef79" xlink:href="mgnx-20241231.xsd#mgnx_ProventionLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_66cee575-df34-4f15-af25-3e05b33c4215" xlink:to="loc_mgnx_ProventionLicenseAgreementMember_ab42cddd-fcce-4d08-8c3d-900ce27cef79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AssetPurchaseAgreementMember_cd298071-9291-4724-a201-fbe88f987174" xlink:href="mgnx-20241231.xsd#mgnx_AssetPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_66cee575-df34-4f15-af25-3e05b33c4215" xlink:to="loc_mgnx_AssetPurchaseAgreementMember_cd298071-9291-4724-a201-fbe88f987174" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_SideLetterAgreementMember_68edb148-bbc9-4dfe-88e4-93fd1018c2bc" xlink:href="mgnx-20241231.xsd#mgnx_SideLetterAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_66cee575-df34-4f15-af25-3e05b33c4215" xlink:to="loc_mgnx_SideLetterAgreementMember_68edb148-bbc9-4dfe-88e4-93fd1018c2bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionAPAMember_6edebc68-0d68-4eeb-a896-cf68376484e8" xlink:href="mgnx-20241231.xsd#mgnx_ProventionAPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_66cee575-df34-4f15-af25-3e05b33c4215" xlink:to="loc_mgnx_ProventionAPAMember_6edebc68-0d68-4eeb-a896-cf68376484e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a2d79287-4c5b-48aa-bd12-f6678ed6eea9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7ef551da-15ea-4a00-b63c-39611f35b926" xlink:to="loc_srt_ProductOrServiceAxis_a2d79287-4c5b-48aa-bd12-f6678ed6eea9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a2d79287-4c5b-48aa-bd12-f6678ed6eea9_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a2d79287-4c5b-48aa-bd12-f6678ed6eea9" xlink:to="loc_srt_ProductsAndServicesDomain_a2d79287-4c5b-48aa-bd12-f6678ed6eea9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ab5eaed5-5eeb-4536-94e8-5a310ec4e650" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a2d79287-4c5b-48aa-bd12-f6678ed6eea9" xlink:to="loc_srt_ProductsAndServicesDomain_ab5eaed5-5eeb-4536-94e8-5a310ec4e650" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_5ad94b51-979b-4f56-95e3-35e172bd9e17" xlink:href="mgnx-20241231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ab5eaed5-5eeb-4536-94e8-5a310ec4e650" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_5ad94b51-979b-4f56-95e3-35e172bd9e17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AssetPurchaseAgreementMember_ad5f715a-01ce-4084-8803-39f72b23e44e" xlink:href="mgnx-20241231.xsd#mgnx_AssetPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ab5eaed5-5eeb-4536-94e8-5a310ec4e650" xlink:to="loc_mgnx_AssetPurchaseAgreementMember_ad5f715a-01ce-4084-8803-39f72b23e44e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_9225d98e-0845-4b21-8a8e-62011347269e" xlink:href="mgnx-20241231.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb37ab7d-dc0b-4762-8185-da6114a5d4a6" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_9225d98e-0845-4b21-8a8e-62011347269e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_29682d82-95e7-4a5d-b0bc-a798885813c0" xlink:href="mgnx-20241231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb37ab7d-dc0b-4762-8185-da6114a5d4a6" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_29682d82-95e7-4a5d-b0bc-a798885813c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_64011f76-c764-4741-adb3-9f2574bf0a38" xlink:href="mgnx-20241231.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb37ab7d-dc0b-4762-8185-da6114a5d4a6" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_64011f76-c764-4741-adb3-9f2574bf0a38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_533fa91e-3e9d-45fd-a0a2-1f8fb98fe09b" xlink:href="mgnx-20241231.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb37ab7d-dc0b-4762-8185-da6114a5d4a6" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_533fa91e-3e9d-45fd-a0a2-1f8fb98fe09b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GainOnRoyaltyMonetizationArrangement_b2eda23c-3749-43a2-846f-7d05088d951f" xlink:href="mgnx-20241231.xsd#mgnx_GainOnRoyaltyMonetizationArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb37ab7d-dc0b-4762-8185-da6114a5d4a6" xlink:to="loc_mgnx_GainOnRoyaltyMonetizationArrangement_b2eda23c-3749-43a2-846f-7d05088d951f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_4f5013d8-e7a6-4dd4-b3f6-a079b3a5988b" xlink:href="mgnx-20241231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb37ab7d-dc0b-4762-8185-da6114a5d4a6" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_4f5013d8-e7a6-4dd4-b3f6-a079b3a5988b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_46cd3442-bdc2-426d-ade0-94a5afde0893" xlink:href="mgnx-20241231.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb37ab7d-dc0b-4762-8185-da6114a5d4a6" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_46cd3442-bdc2-426d-ade0-94a5afde0893" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_21590ac4-5652-4606-b4d9-588e83a1fdba" xlink:href="mgnx-20241231.xsd#mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb37ab7d-dc0b-4762-8185-da6114a5d4a6" xlink:to="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_21590ac4-5652-4606-b4d9-588e83a1fdba" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_99771b0e-e5a3-4ec1-9295-f6b82c7f3ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb37ab7d-dc0b-4762-8185-da6114a5d4a6" xlink:to="loc_us-gaap_Revenues_99771b0e-e5a3-4ec1-9295-f6b82c7f3ba4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UpfrontPayment_f3f9a5f3-4135-4f26-b089-68c30f6dd352" xlink:href="mgnx-20241231.xsd#mgnx_UpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb37ab7d-dc0b-4762-8185-da6114a5d4a6" xlink:to="loc_mgnx_UpfrontPayment_f3f9a5f3-4135-4f26-b089-68c30f6dd352" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_cd076e05-5e39-41bc-a52b-de8a586edb8a" xlink:href="mgnx-20241231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb37ab7d-dc0b-4762-8185-da6114a5d4a6" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_cd076e05-5e39-41bc-a52b-de8a586edb8a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AdditionalTZIELDMilestones_c62aeb8f-c812-470b-82cb-e1a8506f647f" xlink:href="mgnx-20241231.xsd#mgnx_AdditionalTZIELDMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb37ab7d-dc0b-4762-8185-da6114a5d4a6" xlink:to="loc_mgnx_AdditionalTZIELDMilestones_c62aeb8f-c812-470b-82cb-e1a8506f647f" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#RevenueManufacturingServiceAgreementsDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e2195ca0-4f30-4ad6-b35c-50f5d297644f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ebffb734-5220-48f3-96b0-1a973bc278e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e2195ca0-4f30-4ad6-b35c-50f5d297644f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ebffb734-5220-48f3-96b0-1a973bc278e7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d706fa90-fd62-4860-affc-686872d64f5d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ebffb734-5220-48f3-96b0-1a973bc278e7" xlink:to="loc_srt_CounterpartyNameAxis_d706fa90-fd62-4860-affc-686872d64f5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d706fa90-fd62-4860-affc-686872d64f5d_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d706fa90-fd62-4860-affc-686872d64f5d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d706fa90-fd62-4860-affc-686872d64f5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bef09629-6c40-4310-b750-cd218112641c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d706fa90-fd62-4860-affc-686872d64f5d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bef09629-6c40-4310-b750-cd218112641c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_8b548c66-c183-4deb-9118-fe869913ead4" xlink:href="mgnx-20241231.xsd#mgnx_IncyteCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bef09629-6c40-4310-b750-cd218112641c" xlink:to="loc_mgnx_IncyteCorporationMember_8b548c66-c183-4deb-9118-fe869913ead4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioMember_d234b70d-fb94-46cc-91e2-f073df8d529b" xlink:href="mgnx-20241231.xsd#mgnx_ProventionBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bef09629-6c40-4310-b750-cd218112641c" xlink:to="loc_mgnx_ProventionBioMember_d234b70d-fb94-46cc-91e2-f073df8d529b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_89c73e6f-fb48-4e04-a945-c491f639722b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ebffb734-5220-48f3-96b0-1a973bc278e7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_89c73e6f-fb48-4e04-a945-c491f639722b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_89c73e6f-fb48-4e04-a945-c491f639722b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_89c73e6f-fb48-4e04-a945-c491f639722b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_89c73e6f-fb48-4e04-a945-c491f639722b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76d08406-50d0-4f80-b619-1a0a6fd4c9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_89c73e6f-fb48-4e04-a945-c491f639722b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76d08406-50d0-4f80-b619-1a0a6fd4c9bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_5f366049-e512-4bc0-bc6c-2469922b9cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76d08406-50d0-4f80-b619-1a0a6fd4c9bf" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_5f366049-e512-4bc0-bc6c-2469922b9cdc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b18f0633-9418-49af-83cd-bd7e43d94777" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ebffb734-5220-48f3-96b0-1a973bc278e7" xlink:to="loc_srt_ProductOrServiceAxis_b18f0633-9418-49af-83cd-bd7e43d94777" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b18f0633-9418-49af-83cd-bd7e43d94777_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b18f0633-9418-49af-83cd-bd7e43d94777" xlink:to="loc_srt_ProductsAndServicesDomain_b18f0633-9418-49af-83cd-bd7e43d94777_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6e29c94b-815d-4daf-ba3c-8739c0b6792b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b18f0633-9418-49af-83cd-bd7e43d94777" xlink:to="loc_srt_ProductsAndServicesDomain_6e29c94b-815d-4daf-ba3c-8739c0b6792b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromCMOAgreementsMemberMember_ca819dd1-4823-45b4-a48b-a2c6857d0e47" xlink:href="mgnx-20241231.xsd#mgnx_RevenuesFromCMOAgreementsMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6e29c94b-815d-4daf-ba3c-8739c0b6792b" xlink:to="loc_mgnx_RevenuesFromCMOAgreementsMemberMember_ca819dd1-4823-45b4-a48b-a2c6857d0e47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromCMOAmendmentAgreementMember_20efa24f-c8a6-498a-be8b-0383fb3d4731" xlink:href="mgnx-20241231.xsd#mgnx_RevenuesFromCMOAmendmentAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6e29c94b-815d-4daf-ba3c-8739c0b6792b" xlink:to="loc_mgnx_RevenuesFromCMOAmendmentAgreementMember_20efa24f-c8a6-498a-be8b-0383fb3d4731" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_8cf134b2-4323-455f-9367-c20c5c6a73d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6e29c94b-815d-4daf-ba3c-8739c0b6792b" xlink:to="loc_us-gaap_ProductMember_8cf134b2-4323-455f-9367-c20c5c6a73d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeArrangementTerm_67895889-a10d-4181-8f41-fd93b252ffe9" xlink:href="mgnx-20241231.xsd#mgnx_CollaborativeArrangementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e2195ca0-4f30-4ad6-b35c-50f5d297644f" xlink:to="loc_mgnx_CollaborativeArrangementTerm_67895889-a10d-4181-8f41-fd93b252ffe9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_5c2a1020-545a-4634-8a91-32eb73477287" xlink:href="mgnx-20241231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e2195ca0-4f30-4ad6-b35c-50f5d297644f" xlink:to="loc_mgnx_NonRefundableUpfrontFees_5c2a1020-545a-4634-8a91-32eb73477287" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalFixedPayments_4906e857-c761-4b3a-ae65-ea1238ed9d09" xlink:href="mgnx-20241231.xsd#mgnx_TotalFixedPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e2195ca0-4f30-4ad6-b35c-50f5d297644f" xlink:to="loc_mgnx_TotalFixedPayments_4906e857-c761-4b3a-ae65-ea1238ed9d09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeArrangementExtensionTerm_828a81a3-9d9b-4b9a-9e8d-9b0539f7e68d" xlink:href="mgnx-20241231.xsd#mgnx_CollaborativeArrangementExtensionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e2195ca0-4f30-4ad6-b35c-50f5d297644f" xlink:to="loc_mgnx_CollaborativeArrangementExtensionTerm_828a81a3-9d9b-4b9a-9e8d-9b0539f7e68d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AdditionalAnnualFixedPayments_3d256548-e0e3-4b42-bf55-f1ed51d6277c" xlink:href="mgnx-20241231.xsd#mgnx_AdditionalAnnualFixedPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e2195ca0-4f30-4ad6-b35c-50f5d297644f" xlink:to="loc_mgnx_AdditionalAnnualFixedPayments_3d256548-e0e3-4b42-bf55-f1ed51d6277c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_859e90c8-4d17-4a3c-bc65-ca6374593de4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e2195ca0-4f30-4ad6-b35c-50f5d297644f" xlink:to="loc_us-gaap_Revenues_859e90c8-4d17-4a3c-bc65-ca6374593de4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_cd5e6cce-8c48-4f76-aebe-98293128d99a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e2195ca0-4f30-4ad6-b35c-50f5d297644f" xlink:to="loc_us-gaap_ContractWithCustomerLiability_cd5e6cce-8c48-4f76-aebe-98293128d99a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9e80bebe-79a4-4e06-8fb8-f8cdda35afd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e2195ca0-4f30-4ad6-b35c-50f5d297644f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9e80bebe-79a4-4e06-8fb8-f8cdda35afd5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6e7e1b18-d4b2-4c76-b6a8-9448059b3aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e2195ca0-4f30-4ad6-b35c-50f5d297644f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6e7e1b18-d4b2-4c76-b6a8-9448059b3aaa" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FutureManufacturingRevenue_873f30ac-0f6b-4f50-bd44-12da7a8d22e9" xlink:href="mgnx-20241231.xsd#mgnx_FutureManufacturingRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e2195ca0-4f30-4ad6-b35c-50f5d297644f" xlink:to="loc_mgnx_FutureManufacturingRevenue_873f30ac-0f6b-4f50-bd44-12da7a8d22e9" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueNIAIDContractDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#RevenueNIAIDContractDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/RevenueNIAIDContractDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8e26451c-d92c-4ad7-8ffc-42068686c3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6209e1b5-66a0-4890-a734-928464529cff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8e26451c-d92c-4ad7-8ffc-42068686c3b4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6209e1b5-66a0-4890-a734-928464529cff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_71fd606a-4aea-4a00-84b7-c59befafd4df" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6209e1b5-66a0-4890-a734-928464529cff" xlink:to="loc_srt_ProductOrServiceAxis_71fd606a-4aea-4a00-84b7-c59befafd4df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_71fd606a-4aea-4a00-84b7-c59befafd4df_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_71fd606a-4aea-4a00-84b7-c59befafd4df" xlink:to="loc_srt_ProductsAndServicesDomain_71fd606a-4aea-4a00-84b7-c59befafd4df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_489da8aa-0db4-4b49-ad8d-244f13b354b0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_71fd606a-4aea-4a00-84b7-c59befafd4df" xlink:to="loc_srt_ProductsAndServicesDomain_489da8aa-0db4-4b49-ad8d-244f13b354b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromGrantsMember_5fd1443a-09cb-4a1b-ba55-519211b4a02e" xlink:href="mgnx-20241231.xsd#mgnx_RevenuesFromGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_489da8aa-0db4-4b49-ad8d-244f13b354b0" xlink:to="loc_mgnx_RevenuesFromGrantsMember_5fd1443a-09cb-4a1b-ba55-519211b4a02e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3105bccb-0557-4c2a-a8e5-827c00f16ef7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6209e1b5-66a0-4890-a734-928464529cff" xlink:to="loc_srt_CounterpartyNameAxis_3105bccb-0557-4c2a-a8e5-827c00f16ef7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3105bccb-0557-4c2a-a8e5-827c00f16ef7_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_3105bccb-0557-4c2a-a8e5-827c00f16ef7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3105bccb-0557-4c2a-a8e5-827c00f16ef7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_21bb9b89-637c-44b4-9a59-0a1cf3786c77" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_3105bccb-0557-4c2a-a8e5-827c00f16ef7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_21bb9b89-637c-44b4-9a59-0a1cf3786c77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_b4a53d3a-3e3c-4b23-aa17-1401b4fe7bb8" xlink:href="mgnx-20241231.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_21bb9b89-637c-44b4-9a59-0a1cf3786c77" xlink:to="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_b4a53d3a-3e3c-4b23-aa17-1401b4fe7bb8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfProductCandidates_5a1d8d15-9467-4847-8e91-ae57def29875" xlink:href="mgnx-20241231.xsd#mgnx_NumberOfProductCandidates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8e26451c-d92c-4ad7-8ffc-42068686c3b4" xlink:to="loc_mgnx_NumberOfProductCandidates_5a1d8d15-9467-4847-8e91-ae57def29875" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_8f6dd371-15c3-4f4a-8a79-5c9fd23883c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8e26451c-d92c-4ad7-8ffc-42068686c3b4" xlink:to="loc_us-gaap_Revenues_8f6dd371-15c3-4f4a-8a79-5c9fd23883c6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueProductSalesDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#RevenueProductSalesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/RevenueProductSalesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a97f3312-6163-4c16-b052-a1e0f9143e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c56bf0f1-7c82-4d9e-90c3-db226ba2274a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a97f3312-6163-4c16-b052-a1e0f9143e6c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c56bf0f1-7c82-4d9e-90c3-db226ba2274a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2787c0a0-edc3-4049-8c97-cc53d54bd173" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c56bf0f1-7c82-4d9e-90c3-db226ba2274a" xlink:to="loc_srt_CounterpartyNameAxis_2787c0a0-edc3-4049-8c97-cc53d54bd173" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2787c0a0-edc3-4049-8c97-cc53d54bd173_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2787c0a0-edc3-4049-8c97-cc53d54bd173" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2787c0a0-edc3-4049-8c97-cc53d54bd173_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ff047f36-4ae9-4200-8437-5b8f7f506936" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2787c0a0-edc3-4049-8c97-cc53d54bd173" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ff047f36-4ae9-4200-8437-5b8f7f506936" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TerSeraMember_463410c1-0ef9-40c9-815c-e2c48d4e699c" xlink:href="mgnx-20241231.xsd#mgnx_TerSeraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ff047f36-4ae9-4200-8437-5b8f7f506936" xlink:to="loc_mgnx_TerSeraMember_463410c1-0ef9-40c9-815c-e2c48d4e699c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AmendmentFeeToCommercializationPartner_378412c3-2871-4b2f-be36-694ebb50fa9c" xlink:href="mgnx-20241231.xsd#mgnx_AmendmentFeeToCommercializationPartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a97f3312-6163-4c16-b052-a1e0f9143e6c" xlink:to="loc_mgnx_AmendmentFeeToCommercializationPartner_378412c3-2871-4b2f-be36-694ebb50fa9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_7b05ac49-ea15-4ead-a335-af2b86e355a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a97f3312-6163-4c16-b052-a1e0f9143e6c" xlink:to="loc_us-gaap_Revenues_7b05ac49-ea15-4ead-a335-af2b86e355a2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#StockbasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockbasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_368dbc3e-76d3-4ca2-80d5-8e52098d7819" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_368dbc3e-76d3-4ca2-80d5-8e52098d7819" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f26497e8-882f-4918-a2b5-04c617eb25c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_368dbc3e-76d3-4ca2-80d5-8e52098d7819" xlink:to="loc_us-gaap_PlanNameAxis_f26497e8-882f-4918-a2b5-04c617eb25c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f26497e8-882f-4918-a2b5-04c617eb25c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_f26497e8-882f-4918-a2b5-04c617eb25c3" xlink:to="loc_us-gaap_PlanNameDomain_f26497e8-882f-4918-a2b5-04c617eb25c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_dcfccf8f-de49-4021-8c81-cd34f53e88f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_f26497e8-882f-4918-a2b5-04c617eb25c3" xlink:to="loc_us-gaap_PlanNameDomain_dcfccf8f-de49-4021-8c81-cd34f53e88f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_10651e58-f1c8-46ee-adce-5b0a35457887" xlink:href="mgnx-20241231.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_dcfccf8f-de49-4021-8c81-cd34f53e88f1" xlink:to="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_10651e58-f1c8-46ee-adce-5b0a35457887" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2023MemberMember_5c0d4302-0e8f-4f66-a87c-2a50a836cc62" xlink:href="mgnx-20241231.xsd#mgnx_StockIncentivePlan2023MemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_dcfccf8f-de49-4021-8c81-cd34f53e88f1" xlink:to="loc_mgnx_StockIncentivePlan2023MemberMember_5c0d4302-0e8f-4f66-a87c-2a50a836cc62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_53014f25-7178-4606-86b9-250441a3a499" xlink:href="mgnx-20241231.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_dcfccf8f-de49-4021-8c81-cd34f53e88f1" xlink:to="loc_mgnx_StockIncentivePlan2013Member_53014f25-7178-4606-86b9-250441a3a499" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_85656bae-ace6-4d7b-86f1-db6c5a6d696b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_368dbc3e-76d3-4ca2-80d5-8e52098d7819" xlink:to="loc_us-gaap_AwardTypeAxis_85656bae-ace6-4d7b-86f1-db6c5a6d696b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_85656bae-ace6-4d7b-86f1-db6c5a6d696b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_85656bae-ace6-4d7b-86f1-db6c5a6d696b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_85656bae-ace6-4d7b-86f1-db6c5a6d696b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5612eea-1b77-49aa-9e9c-c54455255986" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_85656bae-ace6-4d7b-86f1-db6c5a6d696b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5612eea-1b77-49aa-9e9c-c54455255986" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_70afff00-ddbf-4dc6-81f5-d5f744d61c78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5612eea-1b77-49aa-9e9c-c54455255986" xlink:to="loc_us-gaap_EmployeeStockMember_70afff00-ddbf-4dc6-81f5-d5f744d61c78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f78bf1a6-0929-47fd-b46e-b7d3068de6dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5612eea-1b77-49aa-9e9c-c54455255986" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f78bf1a6-0929-47fd-b46e-b7d3068de6dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6bdc62b1-d1a6-45a9-a133-c0319df5d7ab" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_368dbc3e-76d3-4ca2-80d5-8e52098d7819" xlink:to="loc_srt_CounterpartyNameAxis_6bdc62b1-d1a6-45a9-a133-c0319df5d7ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6bdc62b1-d1a6-45a9-a133-c0319df5d7ab_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_6bdc62b1-d1a6-45a9-a133-c0319df5d7ab" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6bdc62b1-d1a6-45a9-a133-c0319df5d7ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_17969b20-ece0-420a-9d95-570a894e402d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_6bdc62b1-d1a6-45a9-a133-c0319df5d7ab" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_17969b20-ece0-420a-9d95-570a894e402d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DrScottKoenigMember_1f146c26-5fc9-4aec-ab37-2f19d035038d" xlink:href="mgnx-20241231.xsd#mgnx_DrScottKoenigMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_17969b20-ece0-420a-9d95-570a894e402d" xlink:to="loc_mgnx_DrScottKoenigMember_1f146c26-5fc9-4aec-ab37-2f19d035038d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a61fde32-91bc-4f4f-9040-0cb7760e1e90" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_368dbc3e-76d3-4ca2-80d5-8e52098d7819" xlink:to="loc_srt_RangeAxis_a61fde32-91bc-4f4f-9040-0cb7760e1e90" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a61fde32-91bc-4f4f-9040-0cb7760e1e90_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a61fde32-91bc-4f4f-9040-0cb7760e1e90" xlink:to="loc_srt_RangeMember_a61fde32-91bc-4f4f-9040-0cb7760e1e90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cbf8ad1e-606e-4d50-8853-3472c8492993" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a61fde32-91bc-4f4f-9040-0cb7760e1e90" xlink:to="loc_srt_RangeMember_cbf8ad1e-606e-4d50-8853-3472c8492993" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fbba69ce-ee17-4a68-ba55-e3c7018540e6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cbf8ad1e-606e-4d50-8853-3472c8492993" xlink:to="loc_srt_MinimumMember_fbba69ce-ee17-4a68-ba55-e3c7018540e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fa161e9d-2618-4ae8-97e8-a8d050a3e5ac" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cbf8ad1e-606e-4d50-8853-3472c8492993" xlink:to="loc_srt_MaximumMember_fa161e9d-2618-4ae8-97e8-a8d050a3e5ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_40604179-5d99-4bb8-a6eb-efa23666d04c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_40604179-5d99-4bb8-a6eb-efa23666d04c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_7d41f0a7-547e-439e-9823-ad649242fbcf" xlink:href="mgnx-20241231.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:to="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_7d41f0a7-547e-439e-9823-ad649242fbcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_42351400-200a-4d6a-9e43-134267e0c6b4" xlink:href="mgnx-20241231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:to="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_42351400-200a-4d6a-9e43-134267e0c6b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_7604ea24-4221-493c-b741-ab89c1cdf96b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_7604ea24-4221-493c-b741-ab89c1cdf96b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_f0a9cbd8-2c74-4ef7-9533-3b6bfc45ba60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_f0a9cbd8-2c74-4ef7-9533-3b6bfc45ba60" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_340fda05-5578-42e6-9f95-7dec68bfbb83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_340fda05-5578-42e6-9f95-7dec68bfbb83" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_258fbf4b-59d4-41fb-8ba5-f2e045f802a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_258fbf4b-59d4-41fb-8ba5-f2e045f802a7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_981aba34-d526-48d7-9da5-04dcf8055fea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_981aba34-d526-48d7-9da5-04dcf8055fea" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0e6aaec9-63ab-4460-992d-cc0ba024d1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0e6aaec9-63ab-4460-992d-cc0ba024d1f2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingPercentageOfUnvestedAwards_0ebeee0f-efb8-40f5-88d9-e1375a7bc47b" xlink:href="mgnx-20241231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingPercentageOfUnvestedAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:to="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingPercentageOfUnvestedAwards_0ebeee0f-efb8-40f5-88d9-e1375a7bc47b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3baaf129-5f9a-4e86-9333-745b7ad6e5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3baaf129-5f9a-4e86-9333-745b7ad6e5fc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b4aebd52-2c19-40d4-8a4c-11c3b256ae49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b4aebd52-2c19-40d4-8a4c-11c3b256ae49" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_12d0aa3f-ac52-4b62-88c5-fb819fcfca1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_12d0aa3f-ac52-4b62-88c5-fb819fcfca1b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_65eca4e7-ade0-4739-94a5-b792f1ce809c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_65eca4e7-ade0-4739-94a5-b792f1ce809c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9b199557-e5e2-42bb-a4da-f737147aee03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9b199557-e5e2-42bb-a4da-f737147aee03" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2388fbbe-0e47-43f3-b86c-c1092694a76a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2388fbbe-0e47-43f3-b86c-c1092694a76a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_370dd3e3-303f-4c4c-a3b5-69c05cc9e328" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_370dd3e3-303f-4c4c-a3b5-69c05cc9e328" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_aa2b63a8-99e4-487e-abec-37783fc9d4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_aa2b63a8-99e4-487e-abec-37783fc9d4bf" xlink:type="arc" order="17"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#StockbasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0af94b9b-0e56-467e-b7f8-abc228566c72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4c43c919-d02d-40bf-929f-852f145d2e89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0af94b9b-0e56-467e-b7f8-abc228566c72" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4c43c919-d02d-40bf-929f-852f145d2e89" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8f4193f4-6e11-4ec3-af43-9142535fce51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4c43c919-d02d-40bf-929f-852f145d2e89" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8f4193f4-6e11-4ec3-af43-9142535fce51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8f4193f4-6e11-4ec3-af43-9142535fce51_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8f4193f4-6e11-4ec3-af43-9142535fce51" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8f4193f4-6e11-4ec3-af43-9142535fce51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1b477358-46f4-4c4d-94d6-5d49f985a28f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8f4193f4-6e11-4ec3-af43-9142535fce51" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1b477358-46f4-4c4d-94d6-5d49f985a28f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2b6b7d8a-93b7-4eec-a6fc-8684b389439e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1b477358-46f4-4c4d-94d6-5d49f985a28f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2b6b7d8a-93b7-4eec-a6fc-8684b389439e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7d0a2b1a-47b8-47f2-80aa-9b5fac136f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1b477358-46f4-4c4d-94d6-5d49f985a28f" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7d0a2b1a-47b8-47f2-80aa-9b5fac136f8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9d1a674c-5dc4-448a-b8a4-c3572db330c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0af94b9b-0e56-467e-b7f8-abc228566c72" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_9d1a674c-5dc4-448a-b8a4-c3572db330c5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#StockbasedCompensationOptionPricingAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3459533-42dc-475e-8190-06ed05aab690" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_773ae598-de77-499e-8450-310a592473c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3459533-42dc-475e-8190-06ed05aab690" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_773ae598-de77-499e-8450-310a592473c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b3b6f335-97c5-484a-9e91-657cbf2db3c1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_773ae598-de77-499e-8450-310a592473c9" xlink:to="loc_srt_RangeAxis_b3b6f335-97c5-484a-9e91-657cbf2db3c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b3b6f335-97c5-484a-9e91-657cbf2db3c1_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b3b6f335-97c5-484a-9e91-657cbf2db3c1" xlink:to="loc_srt_RangeMember_b3b6f335-97c5-484a-9e91-657cbf2db3c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5f5a6d40-bb6d-4e0f-9bb3-7a963cf27e08" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b3b6f335-97c5-484a-9e91-657cbf2db3c1" xlink:to="loc_srt_RangeMember_5f5a6d40-bb6d-4e0f-9bb3-7a963cf27e08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1b465e99-dced-4f01-8195-6d479d68a7ba" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5f5a6d40-bb6d-4e0f-9bb3-7a963cf27e08" xlink:to="loc_srt_MinimumMember_1b465e99-dced-4f01-8195-6d479d68a7ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5616a535-41c3-4e37-bc6b-a5c76be47e14" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5f5a6d40-bb6d-4e0f-9bb3-7a963cf27e08" xlink:to="loc_srt_MaximumMember_5616a535-41c3-4e37-bc6b-a5c76be47e14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5fc15c95-251d-427a-876a-f39a56131bba" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_773ae598-de77-499e-8450-310a592473c9" xlink:to="loc_srt_CounterpartyNameAxis_5fc15c95-251d-427a-876a-f39a56131bba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5fc15c95-251d-427a-876a-f39a56131bba_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5fc15c95-251d-427a-876a-f39a56131bba" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5fc15c95-251d-427a-876a-f39a56131bba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_03ef617e-1862-4670-bbb7-4848e77dcec8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5fc15c95-251d-427a-876a-f39a56131bba" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_03ef617e-1862-4670-bbb7-4848e77dcec8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DrScottKoenigMember_a07d62de-7e6d-4153-9c38-085d659d7b0b" xlink:href="mgnx-20241231.xsd#mgnx_DrScottKoenigMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_03ef617e-1862-4670-bbb7-4848e77dcec8" xlink:to="loc_mgnx_DrScottKoenigMember_a07d62de-7e6d-4153-9c38-085d659d7b0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_115a19a2-c68d-4adc-b508-e50189d992cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3459533-42dc-475e-8190-06ed05aab690" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_115a19a2-c68d-4adc-b508-e50189d992cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_71d37c32-9cdf-41b5-9b9a-0ac778b3c1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3459533-42dc-475e-8190-06ed05aab690" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_71d37c32-9cdf-41b5-9b9a-0ac778b3c1e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1f46a521-ba9a-4550-b05c-46ec57b4a610" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3459533-42dc-475e-8190-06ed05aab690" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1f46a521-ba9a-4550-b05c-46ec57b4a610" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_34ce1b8d-2d10-42d3-be96-ec269a43d04e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3459533-42dc-475e-8190-06ed05aab690" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_34ce1b8d-2d10-42d3-be96-ec269a43d04e" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b8017a9-b2e9-4294-bb19-2cd6d87d98e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_64c6bda1-5937-4de3-a9d8-69a77d19f324" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b8017a9-b2e9-4294-bb19-2cd6d87d98e7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_64c6bda1-5937-4de3-a9d8-69a77d19f324" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_99ab7907-96ad-40c7-9b75-dda5253838cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_64c6bda1-5937-4de3-a9d8-69a77d19f324" xlink:to="loc_us-gaap_AwardTypeAxis_99ab7907-96ad-40c7-9b75-dda5253838cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99ab7907-96ad-40c7-9b75-dda5253838cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_99ab7907-96ad-40c7-9b75-dda5253838cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99ab7907-96ad-40c7-9b75-dda5253838cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62a234ce-130a-48cf-b33f-9969aae3b024" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_99ab7907-96ad-40c7-9b75-dda5253838cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62a234ce-130a-48cf-b33f-9969aae3b024" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e37fd862-a8c1-4825-aa3f-0675309d07d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62a234ce-130a-48cf-b33f-9969aae3b024" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e37fd862-a8c1-4825-aa3f-0675309d07d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_59a06072-7e0e-4c46-99f2-d2b61bdd0e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_64c6bda1-5937-4de3-a9d8-69a77d19f324" xlink:to="loc_us-gaap_PlanNameAxis_59a06072-7e0e-4c46-99f2-d2b61bdd0e0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_59a06072-7e0e-4c46-99f2-d2b61bdd0e0b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_59a06072-7e0e-4c46-99f2-d2b61bdd0e0b" xlink:to="loc_us-gaap_PlanNameDomain_59a06072-7e0e-4c46-99f2-d2b61bdd0e0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_78b901ad-2ba6-4165-8300-af018f5393eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_59a06072-7e0e-4c46-99f2-d2b61bdd0e0b" xlink:to="loc_us-gaap_PlanNameDomain_78b901ad-2ba6-4165-8300-af018f5393eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_58b9ae23-60ee-46c0-b26f-4ba26b1e6534" xlink:href="mgnx-20241231.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_78b901ad-2ba6-4165-8300-af018f5393eb" xlink:to="loc_mgnx_StockIncentivePlan2013Member_58b9ae23-60ee-46c0-b26f-4ba26b1e6534" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c992ac47-4107-490f-b55b-74097a0dcd9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b8017a9-b2e9-4294-bb19-2cd6d87d98e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c992ac47-4107-490f-b55b-74097a0dcd9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5bfcd05c-8608-47a7-9604-5d6450bad523" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c992ac47-4107-490f-b55b-74097a0dcd9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5bfcd05c-8608-47a7-9604-5d6450bad523" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_9a70be08-d7f7-44f3-9256-9c75ed153d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c992ac47-4107-490f-b55b-74097a0dcd9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_9a70be08-d7f7-44f3-9256-9c75ed153d1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0a630fc5-55a7-47e1-8d79-3938117ac160" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c992ac47-4107-490f-b55b-74097a0dcd9f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0a630fc5-55a7-47e1-8d79-3938117ac160" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_f1c7d445-2bbf-4237-8fbb-89511e99a15e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c992ac47-4107-490f-b55b-74097a0dcd9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_f1c7d445-2bbf-4237-8fbb-89511e99a15e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c5d53821-0f29-49f0-99c8-8d57661b33a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c992ac47-4107-490f-b55b-74097a0dcd9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c5d53821-0f29-49f0-99c8-8d57661b33a1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bd354314-fcf4-4614-b7bd-d2420da6e7ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e0505577-88cb-4930-a273-0a61d9d906a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c992ac47-4107-490f-b55b-74097a0dcd9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e0505577-88cb-4930-a273-0a61d9d906a5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_a35aa685-2715-4903-8fdd-6706fd2e9573" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c992ac47-4107-490f-b55b-74097a0dcd9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_a35aa685-2715-4903-8fdd-6706fd2e9573" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_783c2b20-1ed8-404f-9c67-df11ccc10011" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b8017a9-b2e9-4294-bb19-2cd6d87d98e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_783c2b20-1ed8-404f-9c67-df11ccc10011" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d6935e00-2be8-4e9a-908e-e05005a42136" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_783c2b20-1ed8-404f-9c67-df11ccc10011" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d6935e00-2be8-4e9a-908e-e05005a42136" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5fc6e6fe-c475-4b61-a23c-1c59894970a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_783c2b20-1ed8-404f-9c67-df11ccc10011" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5fc6e6fe-c475-4b61-a23c-1c59894970a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4a748452-8993-4c63-bac9-bd56311c60ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_783c2b20-1ed8-404f-9c67-df11ccc10011" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4a748452-8993-4c63-bac9-bd56311c60ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e67e35cb-4233-4e78-9e32-b7e0758d1d27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_783c2b20-1ed8-404f-9c67-df11ccc10011" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e67e35cb-4233-4e78-9e32-b7e0758d1d27" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_34583f42-3677-44da-a939-b4a453ea669d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_783c2b20-1ed8-404f-9c67-df11ccc10011" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_34583f42-3677-44da-a939-b4a453ea669d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_77d6afc0-1663-4e31-8f58-46bbec54bedc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7888e591-0727-464e-8ef6-e2e1768cbf18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_783c2b20-1ed8-404f-9c67-df11ccc10011" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7888e591-0727-464e-8ef6-e2e1768cbf18" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_b301a827-db8d-4025-96fe-16637f3983fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_783c2b20-1ed8-404f-9c67-df11ccc10011" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_b301a827-db8d-4025-96fe-16637f3983fc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e554ea25-26aa-464d-8458-3f3d06f32012" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b8017a9-b2e9-4294-bb19-2cd6d87d98e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e554ea25-26aa-464d-8458-3f3d06f32012" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b83e8cc9-fa69-4d2b-93a6-cdae7ba309d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e554ea25-26aa-464d-8458-3f3d06f32012" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b83e8cc9-fa69-4d2b-93a6-cdae7ba309d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0c9b483b-ca87-4379-ad7b-c4c669fb4f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e554ea25-26aa-464d-8458-3f3d06f32012" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0c9b483b-ca87-4379-ad7b-c4c669fb4f8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_883c34ad-fd36-4d53-a8b5-aaca30704794" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e554ea25-26aa-464d-8458-3f3d06f32012" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_883c34ad-fd36-4d53-a8b5-aaca30704794" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9d2ce74f-76b4-496a-9ae1-2c9d9162bc66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e554ea25-26aa-464d-8458-3f3d06f32012" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9d2ce74f-76b4-496a-9ae1-2c9d9162bc66" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6502a5af-6229-4b04-91f9-1d0ef1f21bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e554ea25-26aa-464d-8458-3f3d06f32012" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6502a5af-6229-4b04-91f9-1d0ef1f21bb0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_25b931e9-4131-4516-b952-3b33f1436358" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e554ea25-26aa-464d-8458-3f3d06f32012" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_25b931e9-4131-4516-b952-3b33f1436358" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6c89ed74-666e-430d-8366-8773aeeae054" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b8017a9-b2e9-4294-bb19-2cd6d87d98e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6c89ed74-666e-430d-8366-8773aeeae054" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_20f568be-d2d9-459b-bae5-bcdc4de84e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6c89ed74-666e-430d-8366-8773aeeae054" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_20f568be-d2d9-459b-bae5-bcdc4de84e9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f084592c-3410-48b4-9330-6ec8825ca7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6c89ed74-666e-430d-8366-8773aeeae054" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f084592c-3410-48b4-9330-6ec8825ca7d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_06328951-a0b3-4357-8b8b-d6ec17297ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6c89ed74-666e-430d-8366-8773aeeae054" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_06328951-a0b3-4357-8b8b-d6ec17297ff6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5f93b7a8-728f-4851-8f0d-372919aa2aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6c89ed74-666e-430d-8366-8773aeeae054" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5f93b7a8-728f-4851-8f0d-372919aa2aa9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_837a519f-aeba-412b-9ae6-d3e820b90aee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_092a2773-6f8e-40d8-9906-1ad09518ee03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b8017a9-b2e9-4294-bb19-2cd6d87d98e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_092a2773-6f8e-40d8-9906-1ad09518ee03" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_966dd30b-22bd-4917-9d81-8ae4a9b798aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_092a2773-6f8e-40d8-9906-1ad09518ee03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_966dd30b-22bd-4917-9d81-8ae4a9b798aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_519ca6fa-8771-4ef1-8b72-2f88ce18c44d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_092a2773-6f8e-40d8-9906-1ad09518ee03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_519ca6fa-8771-4ef1-8b72-2f88ce18c44d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3f64d5eb-129d-459e-a630-a76cc50e44fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_092a2773-6f8e-40d8-9906-1ad09518ee03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3f64d5eb-129d-459e-a630-a76cc50e44fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e8242184-091e-41ef-be18-e43db986cabe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_092a2773-6f8e-40d8-9906-1ad09518ee03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e8242184-091e-41ef-be18-e43db986cabe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7eb7e388-8b8f-42f1-a5bc-25e86e9478c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_02aaf8f9-987b-4be7-bc20-f08098e6c08d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b8017a9-b2e9-4294-bb19-2cd6d87d98e7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_02aaf8f9-987b-4be7-bc20-f08098e6c08d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_2b5512b0-e9e1-4576-a9af-38f9c0d2efaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b8017a9-b2e9-4294-bb19-2cd6d87d98e7" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_2b5512b0-e9e1-4576-a9af-38f9c0d2efaf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_886d2f88-0b4d-44a6-8a27-9eb575170990" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b8017a9-b2e9-4294-bb19-2cd6d87d98e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_886d2f88-0b4d-44a6-8a27-9eb575170990" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_a6965913-f522-4aa0-ae02-e78ea70a38c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b8017a9-b2e9-4294-bb19-2cd6d87d98e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_a6965913-f522-4aa0-ae02-e78ea70a38c7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_86aaf143-7a37-4a6c-a44f-144af2eb8499" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b8017a9-b2e9-4294-bb19-2cd6d87d98e7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_86aaf143-7a37-4a6c-a44f-144af2eb8499" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ceb956e9-ee76-4fc5-a92f-2e490f99ab49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b8017a9-b2e9-4294-bb19-2cd6d87d98e7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ceb956e9-ee76-4fc5-a92f-2e490f99ab49" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3f858d4a-bc9a-4426-a06a-e2d3c8b0c77f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b8017a9-b2e9-4294-bb19-2cd6d87d98e7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3f858d4a-bc9a-4426-a06a-e2d3c8b0c77f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1188f353-0cb7-4758-bfd2-87ffd3166724" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_2b78f4d0-3f61-4409-a8ce-446f94cdb20d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b8017a9-b2e9-4294-bb19-2cd6d87d98e7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_2b78f4d0-3f61-4409-a8ce-446f94cdb20d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5e27ecf0-e4b0-478d-b763-7ed2c9e8d544" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/TeSeraTransactionDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#TeSeraTransactionDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/TeSeraTransactionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b540ce34-823c-44b7-bb57-c8ef287c3060" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_074ea90b-ad3a-4b0e-9c63-a4648d673f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b540ce34-823c-44b7-bb57-c8ef287c3060" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_074ea90b-ad3a-4b0e-9c63-a4648d673f9a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_97fcb069-d6d9-4e76-96c8-653e308f6427" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_074ea90b-ad3a-4b0e-9c63-a4648d673f9a" xlink:to="loc_srt_CounterpartyNameAxis_97fcb069-d6d9-4e76-96c8-653e308f6427" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_97fcb069-d6d9-4e76-96c8-653e308f6427_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_97fcb069-d6d9-4e76-96c8-653e308f6427" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_97fcb069-d6d9-4e76-96c8-653e308f6427_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1f3a4bd8-9b30-405f-b010-864c5a935d24" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_97fcb069-d6d9-4e76-96c8-653e308f6427" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1f3a4bd8-9b30-405f-b010-864c5a935d24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TerSeraMember_72cba8c8-3ca9-414a-a764-c83dbf71152e" xlink:href="mgnx-20241231.xsd#mgnx_TerSeraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1f3a4bd8-9b30-405f-b010-864c5a935d24" xlink:to="loc_mgnx_TerSeraMember_72cba8c8-3ca9-414a-a764-c83dbf71152e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0a859e9f-f649-49cb-a1a2-d9a807963247" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_074ea90b-ad3a-4b0e-9c63-a4648d673f9a" xlink:to="loc_srt_ProductOrServiceAxis_0a859e9f-f649-49cb-a1a2-d9a807963247" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0a859e9f-f649-49cb-a1a2-d9a807963247_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0a859e9f-f649-49cb-a1a2-d9a807963247" xlink:to="loc_srt_ProductsAndServicesDomain_0a859e9f-f649-49cb-a1a2-d9a807963247_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3d0aa242-1fec-4984-9baf-f52c25f1b733" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0a859e9f-f649-49cb-a1a2-d9a807963247" xlink:to="loc_srt_ProductsAndServicesDomain_3d0aa242-1fec-4984-9baf-f52c25f1b733" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CombinedServicesAgreementMember_7f5c012f-003d-4b02-a809-a29ca58c8106" xlink:href="mgnx-20241231.xsd#mgnx_CombinedServicesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3d0aa242-1fec-4984-9baf-f52c25f1b733" xlink:to="loc_mgnx_CombinedServicesAgreementMember_7f5c012f-003d-4b02-a809-a29ca58c8106" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6d953add-c564-444a-87c1-5ea785cf3ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b540ce34-823c-44b7-bb57-c8ef287c3060" xlink:to="loc_us-gaap_Revenues_6d953add-c564-444a-87c1-5ea785cf3ef7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FutureMilestone_40c5ba25-5835-4d9b-af55-7c84749c9f1a" xlink:href="mgnx-20241231.xsd#mgnx_FutureMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b540ce34-823c-44b7-bb57-c8ef287c3060" xlink:to="loc_mgnx_FutureMilestone_40c5ba25-5835-4d9b-af55-7c84749c9f1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_016b4249-46e3-420a-b257-51a7f0d5a7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b540ce34-823c-44b7-bb57-c8ef287c3060" xlink:to="loc_us-gaap_OtherIncome_016b4249-46e3-420a-b257-51a7f0d5a7a9" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_e8c02945-1463-416e-8cbe-598f23e564c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_7ab495da-d7a1-4788-9597-02d7a0a30a29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_e8c02945-1463-416e-8cbe-598f23e564c5" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_7ab495da-d7a1-4788-9597-02d7a0a30a29" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1a900f95-f132-4f95-b300-494cc0ffb270" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_7ab495da-d7a1-4788-9597-02d7a0a30a29" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1a900f95-f132-4f95-b300-494cc0ffb270" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1a900f95-f132-4f95-b300-494cc0ffb270_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1a900f95-f132-4f95-b300-494cc0ffb270" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1a900f95-f132-4f95-b300-494cc0ffb270_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_30f0761f-aead-4630-804f-99af897863c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1a900f95-f132-4f95-b300-494cc0ffb270" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_30f0761f-aead-4630-804f-99af897863c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_7ed8ef48-69c1-449a-9da3-75016e00a500" xlink:href="mgnx-20241231.xsd#mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_30f0761f-aead-4630-804f-99af897863c9" xlink:to="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_7ed8ef48-69c1-449a-9da3-75016e00a500" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_a6a59a83-e525-4591-8724-3075c837e81b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_30f0761f-aead-4630-804f-99af897863c9" xlink:to="loc_us-gaap_DomesticCountryMember_a6a59a83-e525-4591-8724-3075c837e81b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_7ab017ec-a269-496a-9e8b-551178edba1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_7ab495da-d7a1-4788-9597-02d7a0a30a29" xlink:to="loc_us-gaap_TaxPeriodAxis_7ab017ec-a269-496a-9e8b-551178edba1c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_7ab017ec-a269-496a-9e8b-551178edba1c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_7ab017ec-a269-496a-9e8b-551178edba1c" xlink:to="loc_us-gaap_TaxPeriodDomain_7ab017ec-a269-496a-9e8b-551178edba1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_7e4b169a-40e5-451a-b7ca-0585ecc2099e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_7ab017ec-a269-496a-9e8b-551178edba1c" xlink:to="loc_us-gaap_TaxPeriodDomain_7e4b169a-40e5-451a-b7ca-0585ecc2099e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TaxYear2027To2028Member_a6a017fa-3d9a-40ee-85a3-0dbe36720409" xlink:href="mgnx-20241231.xsd#mgnx_TaxYear2027To2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_7e4b169a-40e5-451a-b7ca-0585ecc2099e" xlink:to="loc_mgnx_TaxYear2027To2028Member_a6a017fa-3d9a-40ee-85a3-0dbe36720409" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IndefiniteMember_c582439f-ad9c-4265-8b0f-9b549aa740db" xlink:href="mgnx-20241231.xsd#mgnx_IndefiniteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_7e4b169a-40e5-451a-b7ca-0585ecc2099e" xlink:to="loc_mgnx_IndefiniteMember_c582439f-ad9c-4265-8b0f-9b549aa740db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TaxYear2027To2044Member_656cd285-b998-444a-8488-c39ddee6ba5d" xlink:href="mgnx-20241231.xsd#mgnx_TaxYear2027To2044Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_7e4b169a-40e5-451a-b7ca-0585ecc2099e" xlink:to="loc_mgnx_TaxYear2027To2044Member_656cd285-b998-444a-8488-c39ddee6ba5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_58f69a76-6c4f-48ff-a5f5-58e6c4104b7c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_7ab495da-d7a1-4788-9597-02d7a0a30a29" xlink:to="loc_srt_RangeAxis_58f69a76-6c4f-48ff-a5f5-58e6c4104b7c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_58f69a76-6c4f-48ff-a5f5-58e6c4104b7c_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_58f69a76-6c4f-48ff-a5f5-58e6c4104b7c" xlink:to="loc_srt_RangeMember_58f69a76-6c4f-48ff-a5f5-58e6c4104b7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_41c48ebd-0e06-419f-89d8-b1807e45c8ee" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_58f69a76-6c4f-48ff-a5f5-58e6c4104b7c" xlink:to="loc_srt_RangeMember_41c48ebd-0e06-419f-89d8-b1807e45c8ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7afa7ab4-1b89-419a-bb18-f136a9914eb5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_41c48ebd-0e06-419f-89d8-b1807e45c8ee" xlink:to="loc_srt_MinimumMember_7afa7ab4-1b89-419a-bb18-f136a9914eb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_324dfd85-8e85-4ba3-a0eb-3a9d2c8c6ddf" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_41c48ebd-0e06-419f-89d8-b1807e45c8ee" xlink:to="loc_srt_MaximumMember_324dfd85-8e85-4ba3-a0eb-3a9d2c8c6ddf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_05d618de-c6a0-4bbf-9826-f7666543c34d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_e8c02945-1463-416e-8cbe-598f23e564c5" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_05d618de-c6a0-4bbf-9826-f7666543c34d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_065cdd17-50c3-45a9-bde8-c0b398d4021e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_e8c02945-1463-416e-8cbe-598f23e564c5" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_065cdd17-50c3-45a9-bde8-c0b398d4021e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationAmountUtilizableOnAnnualBasis_e9976798-7556-4431-8544-6a9510d81f02" xlink:href="mgnx-20241231.xsd#mgnx_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationAmountUtilizableOnAnnualBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_e8c02945-1463-416e-8cbe-598f23e564c5" xlink:to="loc_mgnx_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationAmountUtilizableOnAnnualBasis_e9976798-7556-4431-8544-6a9510d81f02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_4aa4b2b0-fac9-4954-8512-6dec89814805" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_e8c02945-1463-416e-8cbe-598f23e564c5" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_4aa4b2b0-fac9-4954-8512-6dec89814805" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_d4f5f913-4f49-4f33-944e-42f9c522d46d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_e8c02945-1463-416e-8cbe-598f23e564c5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_d4f5f913-4f49-4f33-944e-42f9c522d46d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_44ff7043-2cb1-400b-8d55-7dd1c509a317" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_e8c02945-1463-416e-8cbe-598f23e564c5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_44ff7043-2cb1-400b-8d55-7dd1c509a317" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SegmentReportingDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#SegmentReportingDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SegmentReportingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_db705aec-fbeb-4e70-afc0-fc1c1119da18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_38ed2d22-95ea-4304-8835-d25d7a2c9373" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_db705aec-fbeb-4e70-afc0-fc1c1119da18" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_38ed2d22-95ea-4304-8835-d25d7a2c9373" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_4797469a-ae4d-4c24-9b83-6f6ab89ed314" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_38ed2d22-95ea-4304-8835-d25d7a2c9373" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_4797469a-ae4d-4c24-9b83-6f6ab89ed314" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4797469a-ae4d-4c24-9b83-6f6ab89ed314_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4797469a-ae4d-4c24-9b83-6f6ab89ed314" xlink:to="loc_us-gaap_SegmentDomain_4797469a-ae4d-4c24-9b83-6f6ab89ed314_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_80d47961-490c-459f-94b2-c85b25ba4c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4797469a-ae4d-4c24-9b83-6f6ab89ed314" xlink:to="loc_us-gaap_SegmentDomain_80d47961-490c-459f-94b2-c85b25ba4c8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_MainSegmentMember_bc82b62c-3d1f-463f-85ee-4be1ab58a52f" xlink:href="mgnx-20241231.xsd#mgnx_MainSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_80d47961-490c-459f-94b2-c85b25ba4c8d" xlink:to="loc_mgnx_MainSegmentMember_bc82b62c-3d1f-463f-85ee-4be1ab58a52f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_eac1a42d-f253-4f63-a78a-511803dc4151" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_38ed2d22-95ea-4304-8835-d25d7a2c9373" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_eac1a42d-f253-4f63-a78a-511803dc4151" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_eac1a42d-f253-4f63-a78a-511803dc4151_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_eac1a42d-f253-4f63-a78a-511803dc4151" xlink:to="loc_us-gaap_ProjectMember_eac1a42d-f253-4f63-a78a-511803dc4151_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_0fce8dde-ea10-4664-bb9f-2ce7b8fe8a41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_eac1a42d-f253-4f63-a78a-511803dc4151" xlink:to="loc_us-gaap_ProjectMember_0fce8dde-ea10-4664-bb9f-2ce7b8fe8a41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_VobramitanmabDuocarmazineMember_4204f521-cac5-4976-ba6a-b6a26f9ae3b9" xlink:href="mgnx-20241231.xsd#mgnx_VobramitanmabDuocarmazineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_0fce8dde-ea10-4664-bb9f-2ce7b8fe8a41" xlink:to="loc_mgnx_VobramitanmabDuocarmazineMember_4204f521-cac5-4976-ba6a-b6a26f9ae3b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LorigerlimabMember_61083ba0-8f23-4f69-88c4-ec5ff7e1b576" xlink:href="mgnx-20241231.xsd#mgnx_LorigerlimabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_0fce8dde-ea10-4664-bb9f-2ce7b8fe8a41" xlink:to="loc_mgnx_LorigerlimabMember_61083ba0-8f23-4f69-88c4-ec5ff7e1b576" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_MGC028Member_bcff699a-4358-45bf-b7a6-b62bdc449af9" xlink:href="mgnx-20241231.xsd#mgnx_MGC028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_0fce8dde-ea10-4664-bb9f-2ce7b8fe8a41" xlink:to="loc_mgnx_MGC028Member_bcff699a-4358-45bf-b7a6-b62bdc449af9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ADCMember_a281080e-2d86-458e-95a6-25c67e72a899" xlink:href="mgnx-20241231.xsd#mgnx_ADCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_0fce8dde-ea10-4664-bb9f-2ce7b8fe8a41" xlink:to="loc_mgnx_ADCMember_a281080e-2d86-458e-95a6-25c67e72a899" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_MGC026Member_983530bd-142f-40ec-b070-5de81c9083d9" xlink:href="mgnx-20241231.xsd#mgnx_MGC026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_0fce8dde-ea10-4664-bb9f-2ce7b8fe8a41" xlink:to="loc_mgnx_MGC026Member_983530bd-142f-40ec-b070-5de81c9083d9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_MargetuximabMember_a937e1ca-40ad-463b-b6e4-a75f76c10213" xlink:href="mgnx-20241231.xsd#mgnx_MargetuximabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_0fce8dde-ea10-4664-bb9f-2ce7b8fe8a41" xlink:to="loc_mgnx_MargetuximabMember_a937e1ca-40ad-463b-b6e4-a75f76c10213" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_MGD024Member_c1d44536-67ef-4a7b-ac06-92be5970417f" xlink:href="mgnx-20241231.xsd#mgnx_MGD024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_0fce8dde-ea10-4664-bb9f-2ce7b8fe8a41" xlink:to="loc_mgnx_MGD024Member_c1d44536-67ef-4a7b-ac06-92be5970417f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NextGenerationTCellEngagersMember_fb44c155-4635-4da8-8923-88f96c3b68a3" xlink:href="mgnx-20241231.xsd#mgnx_NextGenerationTCellEngagersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_0fce8dde-ea10-4664-bb9f-2ce7b8fe8a41" xlink:to="loc_mgnx_NextGenerationTCellEngagersMember_fb44c155-4635-4da8-8923-88f96c3b68a3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RetifanlimabMember_a6c56347-3456-4627-99a1-e45f5d89b3ec" xlink:href="mgnx-20241231.xsd#mgnx_RetifanlimabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_0fce8dde-ea10-4664-bb9f-2ce7b8fe8a41" xlink:to="loc_mgnx_RetifanlimabMember_a6c56347-3456-4627-99a1-e45f5d89b3ec" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EnoblituzumabMember_e42643e9-55b6-44b1-be4f-2905a3ba792c" xlink:href="mgnx-20241231.xsd#mgnx_EnoblituzumabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_0fce8dde-ea10-4664-bb9f-2ce7b8fe8a41" xlink:to="loc_mgnx_EnoblituzumabMember_e42643e9-55b6-44b1-be4f-2905a3ba792c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OtherProgramsMember_7da8cfc7-320e-471a-86c2-e001465da1f3" xlink:href="mgnx-20241231.xsd#mgnx_OtherProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_0fce8dde-ea10-4664-bb9f-2ce7b8fe8a41" xlink:to="loc_mgnx_OtherProgramsMember_7da8cfc7-320e-471a-86c2-e001465da1f3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_ecf53b99-7452-4cb9-9ea6-7e8d62752f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_db705aec-fbeb-4e70-afc0-fc1c1119da18" xlink:to="loc_us-gaap_NumberOfReportableSegments_ecf53b99-7452-4cb9-9ea6-7e8d62752f2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_1d354e81-e651-4680-bc54-de8078efb9e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_db705aec-fbeb-4e70-afc0-fc1c1119da18" xlink:to="loc_us-gaap_Revenues_1d354e81-e651-4680-bc54-de8078efb9e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_79c21a7e-85a0-416b-addf-6b60b5988f48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_db705aec-fbeb-4e70-afc0-fc1c1119da18" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_79c21a7e-85a0-416b-addf-6b60b5988f48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CostOfManufacturingServices_e64eafec-27d9-471d-a24a-411c805e641d" xlink:href="mgnx-20241231.xsd#mgnx_CostOfManufacturingServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_db705aec-fbeb-4e70-afc0-fc1c1119da18" xlink:to="loc_mgnx_CostOfManufacturingServices_e64eafec-27d9-471d-a24a-411c805e641d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e4dc5130-b4dc-4d96-9ac6-3f79c9042703" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_db705aec-fbeb-4e70-afc0-fc1c1119da18" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e4dc5130-b4dc-4d96-9ac6-3f79c9042703" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_d63e5d1d-2739-4c16-9f95-69d2ee9f17ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_db705aec-fbeb-4e70-afc0-fc1c1119da18" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_d63e5d1d-2739-4c16-9f95-69d2ee9f17ca" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_14d9e7b7-50f3-4701-9725-f5b007575534" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_db705aec-fbeb-4e70-afc0-fc1c1119da18" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_14d9e7b7-50f3-4701-9725-f5b007575534" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2c914ab1-3e8b-4631-8649-7ff239c0a627" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_db705aec-fbeb-4e70-afc0-fc1c1119da18" xlink:to="loc_us-gaap_NetIncomeLoss_2c914ab1-3e8b-4631-8649-7ff239c0a627" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract_33f59aef-0836-49d6-9617-b5e49f2181de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_db705aec-fbeb-4e70-afc0-fc1c1119da18" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract_33f59aef-0836-49d6-9617-b5e49f2181de" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JamesKarrelsMember_e791cc93-c90d-4d31-b375-022b0a828487" xlink:href="mgnx-20241231.xsd#mgnx_JamesKarrelsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_mgnx_JamesKarrelsMember_e791cc93-c90d-4d31-b375-022b0a828487" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JeffreyPetersMember_56b4a0c1-0bf9-4938-ba34-7130318a454e" xlink:href="mgnx-20241231.xsd#mgnx_JeffreyPetersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_mgnx_JeffreyPetersMember_56b4a0c1-0bf9-4938-ba34-7130318a454e" xlink:type="arc" order="3"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>mgnx-20241231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:976c6134-a70d-4bed-9067-acb735c066ae,g:6888b12e-4125-48cc-8fc7-0d9038c82cb8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_5320bc60-55d0-4680-9fcb-46a9b460bada_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining contractual term, Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9acb318c-1297-40cf-8b2c-49a784f34b36_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_186a4728-50c4-435d-8bd6-6fc3990d722e_terseLabel_en-US" xlink:label="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of employee vested contribution</link:label>
    <link:label id="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_label_en-US" xlink:label="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employees Contribution, Vested Percentage</link:label>
    <link:label id="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_documentation_en-US" xlink:label="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage vested of employee's contributions to defined contribution plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:href="mgnx-20241231.xsd#mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:to="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_76ef135f-56c9-474a-9d18-8d278c1425f8_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_d057e73e-b529-4936-8649-94c72fa6a489_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_47d4af58-7852-4e5e-a2d9-a93822fca623_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_b474fd73-f052-43a6-bc64-4b39bcda9014_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_20b2a2f7-b4b2-4372-afa9-1d8344b73c09_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_ae75a786-ac95-4d66-ac2c-765442907c62_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States federal tax at statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DRIHealthcareAcquisitionsLPDRIMember_f052ff31-772d-4298-8db1-c16cb0488fcc_terseLabel_en-US" xlink:label="lab_mgnx_DRIHealthcareAcquisitionsLPDRIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DRI Healthcare Acquisitions LP (DRI)</link:label>
    <link:label id="lab_mgnx_DRIHealthcareAcquisitionsLPDRIMember_label_en-US" xlink:label="lab_mgnx_DRIHealthcareAcquisitionsLPDRIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">DRI Healthcare Acquisitions LP (DRI) [Member]</link:label>
    <link:label id="lab_mgnx_DRIHealthcareAcquisitionsLPDRIMember_documentation_en-US" xlink:label="lab_mgnx_DRIHealthcareAcquisitionsLPDRIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">DRI Healthcare Acquisitions LP (DRI)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DRIHealthcareAcquisitionsLPDRIMember" xlink:href="mgnx-20241231.xsd#mgnx_DRIHealthcareAcquisitionsLPDRIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DRIHealthcareAcquisitionsLPDRIMember" xlink:to="lab_mgnx_DRIHealthcareAcquisitionsLPDRIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_9eab4809-00e5-4b3d-b13b-1a3e11e436dd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7b7dba39-294d-4a67-b0c4-23dc6eb72c2c_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_43eb8ec1-15b8-4e43-8180-df1bfdff645a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_6f4d031a-60a1-4943-9d8d-af14a36e2e6e_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_87611abb-1744-4ca0-9823-b13ce34f92a8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_aa39ada1-3708-436d-ac29-b604b1c5f1d7_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncreaseDecreaseInLeaseLiabilities_1323c64d-2606-4b25-860e-6703bca0180c_terseLabel_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_mgnx_IncreaseDecreaseInLeaseLiabilities_label_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in lease liabilities</link:label>
    <link:label id="lab_mgnx_IncreaseDecreaseInLeaseLiabilities_documentation_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (decrease) in lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:href="mgnx-20241231.xsd#mgnx_IncreaseDecreaseInLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:to="lab_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4846cc04-2ccf-4429-93e8-6f52a22a1eb8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_2d2e9dad-bf41-401d-8cc8-001edaca4515_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US Federal tax credits carry forward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NetProceedsFromSaleOfFutureRoyalties_5229e5df-679f-415c-b92f-9be5c25cba78_terseLabel_en-US" xlink:label="lab_mgnx_NetProceedsFromSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from sale of future royalties</link:label>
    <link:label id="lab_mgnx_NetProceedsFromSaleOfFutureRoyalties_label_en-US" xlink:label="lab_mgnx_NetProceedsFromSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net proceeds from sale of future royalties</link:label>
    <link:label id="lab_mgnx_NetProceedsFromSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_mgnx_NetProceedsFromSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net proceeds from sale of future royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NetProceedsFromSaleOfFutureRoyalties" xlink:href="mgnx-20241231.xsd#mgnx_NetProceedsFromSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NetProceedsFromSaleOfFutureRoyalties" xlink:to="lab_mgnx_NetProceedsFromSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_a70e6403-48d5-4f64-aecf-5eeb52e61f2c_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities_8df715b5-4896-470f-b8fb-b77c4a2ea729_terseLabel_en-US" xlink:label="lab_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities_label_en-US" xlink:label="lab_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liabilities</link:label>
    <link:label id="lab_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:href="mgnx-20241231.xsd#mgnx_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="lab_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_68cc115b-2ab1-4378-a45e-b56efe2188f8_terseLabel_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NIAID</link:label>
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_label_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">National Institute of Allergy and Infectious Diseases [Member]</link:label>
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_documentation_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents a collaborators with which entity has an agreement related to contracts and research grants received from U.S. government agencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:href="mgnx-20241231.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:to="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_f3e43e0b-a139-46b5-9a36-8f38a9cf6520_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:to="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_85f1ec33-dc43-4eee-a978-b209379bc3e0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationAmountUtilizableOnAnnualBasis_a191b5da-da1e-4073-82fe-058b1024401d_terseLabel_en-US" xlink:label="lab_mgnx_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationAmountUtilizableOnAnnualBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards, amount utilizable on annual basis</link:label>
    <link:label id="lab_mgnx_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationAmountUtilizableOnAnnualBasis_label_en-US" xlink:label="lab_mgnx_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationAmountUtilizableOnAnnualBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject To Expiration, Amount Utilizable On Annual Basis</link:label>
    <link:label id="lab_mgnx_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationAmountUtilizableOnAnnualBasis_documentation_en-US" xlink:label="lab_mgnx_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationAmountUtilizableOnAnnualBasis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject To Expiration, Amount Utilizable On Annual Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationAmountUtilizableOnAnnualBasis" xlink:href="mgnx-20241231.xsd#mgnx_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationAmountUtilizableOnAnnualBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationAmountUtilizableOnAnnualBasis" xlink:to="lab_mgnx_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationAmountUtilizableOnAnnualBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_3c9e1353-fcee-4b64-aeb2-817407b62822_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_2969daec-7057-4eae-9f6e-dddf17c1add1_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization and Nature of Operations</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_ed9f938f-3390-4c5b-ba21-b5fef70cf272_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_9c65ceea-dd68-4093-a838-6c27e2b47d28_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock_1b476ba1-3ef9-4e52-b606-d34abb2d06ec_terseLabel_en-US" xlink:label="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Useful Lives</link:label>
    <link:label id="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock_label_en-US" xlink:label="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property Plant And Equipment Estimated Useful Life Table [Table Text Block]</link:label>
    <link:label id="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock_documentation_en-US" xlink:label="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Property plant and equipment estimated useful life.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" xlink:href="mgnx-20241231.xsd#mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" xlink:to="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NonDilutiveFunding_08191891-7b1e-4274-ae0b-6821921ca624_terseLabel_en-US" xlink:label="lab_mgnx_NonDilutiveFunding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-dilutive funding</link:label>
    <link:label id="lab_mgnx_NonDilutiveFunding_label_en-US" xlink:label="lab_mgnx_NonDilutiveFunding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-dilutive funding</link:label>
    <link:label id="lab_mgnx_NonDilutiveFunding_documentation_en-US" xlink:label="lab_mgnx_NonDilutiveFunding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-dilutive funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonDilutiveFunding" xlink:href="mgnx-20241231.xsd#mgnx_NonDilutiveFunding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonDilutiveFunding" xlink:to="lab_mgnx_NonDilutiveFunding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_07957526-3250-41e7-83d5-43b2b30dec53_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_0d458758-a1fa-4b2f-b5df-89a09d1f6aff_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_dc408646-3d68-4174-9b56-dd41fec408bc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember_37e4df95-801b-4f7f-9ece-c11d6788d708_terseLabel_en-US" xlink:label="lab_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC</link:label>
    <link:label id="lab_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember_label_en-US" xlink:label="lab_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC [Member]</link:label>
    <link:label id="lab_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember_documentation_en-US" xlink:label="lab_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember" xlink:href="mgnx-20241231.xsd#mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember" xlink:to="lab_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_cfab3725-1c48-4523-a59b-a14bb5f04624_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_287d6f5b-f6db-41ab-b319-88e56edb8ec5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">(Gain) loss on disposal of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ce3d18ff-fba0-4cf5-b74f-2daa2a55a519_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_14e1f5f4-1039-404d-9616-2d29e7837c48_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration and Other Agreements [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_ba2b5ac5-bd74-4568-9b45-c06f0c9f610c_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_a7f2b3a8-b3a9-4737-824f-d7d05a44484b_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_eb3ab258-3337-4297-80c8-990cc07ac794_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_ef722800-4fa9-4d57-88a5-06c79a992b40_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of common stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_ac0fb91f-97e2-4610-a1a9-b459476ae075_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_f925884c-d992-4878-b111-4d11e4d034eb_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeArrangementTerm_26b79326-bf54-4020-8616-0019c2e42497_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement, term</link:label>
    <link:label id="lab_mgnx_CollaborativeArrangementTerm_label_en-US" xlink:label="lab_mgnx_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:label id="lab_mgnx_CollaborativeArrangementTerm_documentation_en-US" xlink:label="lab_mgnx_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeArrangementTerm" xlink:href="mgnx-20241231.xsd#mgnx_CollaborativeArrangementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeArrangementTerm" xlink:to="lab_mgnx_CollaborativeArrangementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_fdd91993-435e-4f8d-997f-f9df4537af8b_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_AmendmentFeeToCommercializationPartner_fc91dffa-2ad7-4a39-bf2b-c96b8a63287e_terseLabel_en-US" xlink:label="lab_mgnx_AmendmentFeeToCommercializationPartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercialization partner payments</link:label>
    <link:label id="lab_mgnx_AmendmentFeeToCommercializationPartner_label_en-US" xlink:label="lab_mgnx_AmendmentFeeToCommercializationPartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Fee to Commercialization Partner</link:label>
    <link:label id="lab_mgnx_AmendmentFeeToCommercializationPartner_documentation_en-US" xlink:label="lab_mgnx_AmendmentFeeToCommercializationPartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amendment Fee to Commercialization Partner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AmendmentFeeToCommercializationPartner" xlink:href="mgnx-20241231.xsd#mgnx_AmendmentFeeToCommercializationPartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AmendmentFeeToCommercializationPartner" xlink:to="lab_mgnx_AmendmentFeeToCommercializationPartner" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_96ec2874-6cf6-48eb-b743-0b26b810c8ad_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_label_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration And License Agreements Disclosure [Text Block]</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_documentation_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for collaboration and license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:href="mgnx-20241231.xsd#mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:to="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_a2c62744-03a0-4396-9145-50723cf95a37_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development credit, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_3812fa6e-6f55-4cfd-a3c2-68b244c50d56_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_69b516d0-e764-46e3-b6cd-4c0c32467925_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesFromCMOAgreementsMemberMember_76b0347f-9b13-4bd7-b045-5f4b4cfbac5b_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesFromCMOAgreementsMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RevenuesFromCMOAgreementsMember</link:label>
    <link:label id="lab_mgnx_RevenuesFromCMOAgreementsMemberMember_label_en-US" xlink:label="lab_mgnx_RevenuesFromCMOAgreementsMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RevenuesFromCMOAgreementsMember [Member]</link:label>
    <link:label id="lab_mgnx_RevenuesFromCMOAgreementsMemberMember_documentation_en-US" xlink:label="lab_mgnx_RevenuesFromCMOAgreementsMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">RevenuesFromCMOAgreementsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromCMOAgreementsMemberMember" xlink:href="mgnx-20241231.xsd#mgnx_RevenuesFromCMOAgreementsMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesFromCMOAgreementsMemberMember" xlink:to="lab_mgnx_RevenuesFromCMOAgreementsMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_fd967a48-a425-4c8c-b79a-17e220c6a7ed_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds of stock sale</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TotalFixedPayments_f2cb47d4-293c-4352-963e-0dcb3fb45b17_terseLabel_en-US" xlink:label="lab_mgnx_TotalFixedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total annual fixed payments</link:label>
    <link:label id="lab_mgnx_TotalFixedPayments_label_en-US" xlink:label="lab_mgnx_TotalFixedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Fixed Payments</link:label>
    <link:label id="lab_mgnx_TotalFixedPayments_documentation_en-US" xlink:label="lab_mgnx_TotalFixedPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Fixed Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalFixedPayments" xlink:href="mgnx-20241231.xsd#mgnx_TotalFixedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TotalFixedPayments" xlink:to="lab_mgnx_TotalFixedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_4305b9ca-7b5a-4822-8571-ea07ac1527a7_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">U.S Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_32a98372-12e4-4963-b5e3-aebd16f61b83_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProjectMember_87e52abd-95dc-4d26-a8a6-2227ac914ffc_terseLabel_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Project [Domain]</link:label>
    <link:label id="lab_us-gaap_ProjectMember_label_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Project [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProjectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProjectMember" xlink:to="lab_us-gaap_ProjectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_c5bb4765-9042-421b-83f5-d563f2acefbc_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State net operating loss carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_49ebd1de-77fd-4b56-9a47-b3fabe341341_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_096626c9-dbed-4538-b5a9-7be918c82686_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease_6a3347af-6b4e-4ff6-a3c6-b77d0178074e_terseLabel_en-US" xlink:label="lab_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right of use asset and lease liability increase</link:label>
    <link:label id="lab_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease_label_en-US" xlink:label="lab_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right of Use asset and Lease Liability Increase</link:label>
    <link:label id="lab_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease_documentation_en-US" xlink:label="lab_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Right of Use asset and Lease Liability Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease" xlink:href="mgnx-20241231.xsd#mgnx_RightOfUseAssetAndLeaseLiabilityIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease" xlink:to="lab_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_5ebb03f5-0789-4e01-ae52-06f667dea6f0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeArrangementExtensionTerm_41940873-0fc7-4667-8eb6-d4bba2ad04c1_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeArrangementExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement, extension term</link:label>
    <link:label id="lab_mgnx_CollaborativeArrangementExtensionTerm_label_en-US" xlink:label="lab_mgnx_CollaborativeArrangementExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Extension Term</link:label>
    <link:label id="lab_mgnx_CollaborativeArrangementExtensionTerm_documentation_en-US" xlink:label="lab_mgnx_CollaborativeArrangementExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Extension Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeArrangementExtensionTerm" xlink:href="mgnx-20241231.xsd#mgnx_CollaborativeArrangementExtensionTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeArrangementExtensionTerm" xlink:to="lab_mgnx_CollaborativeArrangementExtensionTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_0d0bee74-f157-499f-a526-ef578947ef84_terseLabel_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-refundable upfront payment</link:label>
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_label_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-refundable upfront payment</link:label>
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_documentation_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Initial fee received from collaboration or license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees" xlink:href="mgnx-20241231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonRefundableUpfrontFees" xlink:to="lab_mgnx_NonRefundableUpfrontFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_b45fe582-1b20-4926-9b9c-4d77c9cbc37b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expenses, Including Clinical Trial Accruals/Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d0d2b44e-d804-4cb1-bca5-a101bd1a9ad3_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7102a1fc-865d-4c2b-92b5-b8c3e81ca235_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_8c387f9c-a726-4bc0-9b9b-d5feb3f2ef8b_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_f0c120ed-9745-4a95-b4c9-603c3105c7e6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_bc8a8886-f6c8-4ff7-979f-9682081ae35f_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_a9f6f49d-d000-4307-a601-86c75d1a12a4_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_8e07c927-2320-43da-8f28-dd2c2c756d6e_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_abc444f3-45be-4489-aa52-f169282e03df_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_5f4dff9a-973b-4405-8c69-f9da1836dbfb_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingPercentageOfUnvestedAwards_dd0e98dc-e11b-4756-b1e7-006545ecfb21_terseLabel_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingPercentageOfUnvestedAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accelerated vesting, percentage of unvested awards</link:label>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingPercentageOfUnvestedAwards_label_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingPercentageOfUnvestedAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Accelerated Vesting, Percentage Of Unvested Awards</link:label>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingPercentageOfUnvestedAwards_documentation_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingPercentageOfUnvestedAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Accelerated Vesting, Percentage Of Unvested Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingPercentageOfUnvestedAwards" xlink:href="mgnx-20241231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingPercentageOfUnvestedAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingPercentageOfUnvestedAwards" xlink:to="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingPercentageOfUnvestedAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_5c1e49ca-e95a-45d5-87e9-544a16e8eaa0_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_FutureMilestone_fffb8fbc-0fc7-4141-9c02-01492219ba74_terseLabel_en-US" xlink:label="lab_mgnx_FutureMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone from DRI</link:label>
    <link:label id="lab_mgnx_FutureMilestone_label_en-US" xlink:label="lab_mgnx_FutureMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Milestone</link:label>
    <link:label id="lab_mgnx_FutureMilestone_documentation_en-US" xlink:label="lab_mgnx_FutureMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FutureMilestone" xlink:href="mgnx-20241231.xsd#mgnx_FutureMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_FutureMilestone" xlink:to="lab_mgnx_FutureMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_e7f540c4-b905-4a84-8314-8d1a063cb34d_terseLabel_en-US" xlink:label="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from stock option exercises and ESPP purchases</link:label>
    <link:label id="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_label_en-US" xlink:label="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised And ESPP Purchases</link:label>
    <link:label id="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_documentation_en-US" xlink:label="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised And ESPP Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:href="mgnx-20241231.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:to="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_db887f07-b76f-4059-86a9-09cb0f97d028_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred income tax asset/(liability)</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_59ded90a-7569-4ad0-a8c7-6f2a113f9c89_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1dcf4aee-6250-4220-b448-77ed6fc886ad_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_ef16ef8a-278b-4b10-b00c-a7f0e954c083_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_4a38196e-deb3-4fb1-a2b9-91981b5fd109_terseLabel_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock maximum amount available for issuance</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_label_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_documentation_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:href="mgnx-20241231.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:to="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_31bab0b5-eaf9-477b-9ed7-992ed2649918_terseLabel_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax adjustments</link:label>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_label_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deferred Tax Adjustments, Amount</link:label>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_documentation_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred tax adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:href="mgnx-20241231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:to="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_0833fd35-79c0-42c1-96a4-149bc31e723e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-based compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_414d0955-a79d-4b0d-872e-697ba737f032_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_19f6f67f-a138-4276-8b33-cdce5a01cb60_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_6d303b06-a57d-45dd-b824-d2a71babd488_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_990df275-0be7-4899-9d4b-a440d78e7192_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-dilutive stock options</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IndefiniteMember_34a00694-daaf-4014-a8ca-637c9b682e8b_terseLabel_en-US" xlink:label="lab_mgnx_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite</link:label>
    <link:label id="lab_mgnx_IndefiniteMember_label_en-US" xlink:label="lab_mgnx_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite [Member]</link:label>
    <link:label id="lab_mgnx_IndefiniteMember_documentation_en-US" xlink:label="lab_mgnx_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Indefinite</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IndefiniteMember" xlink:href="mgnx-20241231.xsd#mgnx_IndefiniteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IndefiniteMember" xlink:to="lab_mgnx_IndefiniteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_7da49f48-436c-4b83-ad23-dc0af28c1c25_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_c46ad0a8-82b0-42b0-9024-d1fe4ed642bf_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of Product Sales and Cost of Manufacturing Services</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_49a106fe-94bc-4e2a-8fef-0b3e944c4dcd_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4a07ee92-ba16-47c8-b652-cd7f3c43f188_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_78b6d485-6bbe-4e11-8b74-2a5c333cd6a8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales of equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Machinery and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_d8c52e5c-9ce2-41af-b2ea-7b329e4d50d2_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amortization of premiums and discounts on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f4814280-c041-4bd4-a6dd-7a8140d03a4f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost related to non-vested stock-based compensation arrangements</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_4443917f-535a-4484-8ef2-12a116a6af08_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NumberOfProductCandidates_f928774e-1204-445f-96dd-913a159a5f07_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of product candidates to develop</link:label>
    <link:label id="lab_mgnx_NumberOfProductCandidates_label_en-US" xlink:label="lab_mgnx_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Product Candidates</link:label>
    <link:label id="lab_mgnx_NumberOfProductCandidates_documentation_en-US" xlink:label="lab_mgnx_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Product Candidates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfProductCandidates" xlink:href="mgnx-20241231.xsd#mgnx_NumberOfProductCandidates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfProductCandidates" xlink:to="lab_mgnx_NumberOfProductCandidates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_bc940d11-6897-40ae-b5da-7c0d5d367fd8_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, allowance for credit loss</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_509e1bc7-5c0c-4ed1-965a-298c779548eb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_177c4be1-3ec1-4027-acf5-f0c07fc17830_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_e52a4ba8-db9d-4a46-a6d3-093315023e9b_terseLabel_en-US" xlink:label="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential development and regulatory milestone payments</link:label>
    <link:label id="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Development and Regulatory Milestone Payments Under Agreement</link:label>
    <link:label id="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_documentation_en-US" xlink:label="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential Development and Regulatory Milestone Payments Under Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:href="mgnx-20241231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:to="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_858817bd-6e47-404e-aba0-80f7446e04e5_terseLabel_en-US" xlink:label="lab_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases/(decreases) for prior year tax positions</link:label>
    <link:label id="lab_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase (Decrease) Resulting From Prior Period Tax Positions</link:label>
    <link:label id="lab_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_documentation_en-US" xlink:label="lab_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase (Decrease) Resulting From Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:href="mgnx-20241231.xsd#mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:to="lab_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_f457f243-8f02-4185-b9d0-6dde7ee69882_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ContractManufacturingMember_3801f79c-f9bd-4a8b-9947-bc95f1d3b55c_terseLabel_en-US" xlink:label="lab_mgnx_ContractManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Manufacturing</link:label>
    <link:label id="lab_mgnx_ContractManufacturingMember_label_en-US" xlink:label="lab_mgnx_ContractManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Manufacturing [Member]</link:label>
    <link:label id="lab_mgnx_ContractManufacturingMember_documentation_en-US" xlink:label="lab_mgnx_ContractManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ContractManufacturingMember" xlink:href="mgnx-20241231.xsd#mgnx_ContractManufacturingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ContractManufacturingMember" xlink:to="lab_mgnx_ContractManufacturingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_ddd5659d-7ab6-4dbb-b9b4-7b77d29b08da_terseLabel_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At The Market Offering</link:label>
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AtTheMarketOfferingMember" xlink:href="mgnx-20241231.xsd#mgnx_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AtTheMarketOfferingMember" xlink:to="lab_mgnx_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_A2022GileadCollaborationAndLicenseAgreementMember_5b0448a8-6be8-4778-a2b2-3fdb5011744b_terseLabel_en-US" xlink:label="lab_mgnx_A2022GileadCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022 Gilead Collaboration And License Agreement</link:label>
    <link:label id="lab_mgnx_A2022GileadCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_A2022GileadCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2022 Gilead Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_A2022GileadCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_A2022GileadCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2022 Gilead Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2022GileadCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20241231.xsd#mgnx_A2022GileadCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_A2022GileadCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_A2022GileadCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_c8700134-948e-4e41-a5f1-0398a7f5dde7_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_351725a8-93c5-4ceb-99cc-f0602ab8b75b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_a4a626bb-a0ed-4de4-b09d-45642d2e4c59_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_25b3deab-f619-4ff2-9465-b474276d8e72_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2e0ba99a-966f-4b7a-88e7-02a7e9082f11_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_2856d7e8-d7fd-4ee3-98e5-4ffdca88885c_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_179a75c2-d74a-4987-bc43-e8e8127630f8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Undesignated preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_40f0eb20-c645-4a42-8c35-b91b84f026f9_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_a9d4231e-b3f9-48b7-a124-7447c9469f9b_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_77eb2881-7fdc-4ea6-8337-ad42697af637_terseLabel_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering period</link:label>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_label_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period</link:label>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_documentation_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:href="mgnx-20241231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:to="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionAPAMember_3a0ec7a7-4f13-4326-b8ff-8d4bcc852adf_terseLabel_en-US" xlink:label="lab_mgnx_ProventionAPAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provention APA</link:label>
    <link:label id="lab_mgnx_ProventionAPAMember_label_en-US" xlink:label="lab_mgnx_ProventionAPAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provention APA [Member]</link:label>
    <link:label id="lab_mgnx_ProventionAPAMember_documentation_en-US" xlink:label="lab_mgnx_ProventionAPAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Provention APA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionAPAMember" xlink:href="mgnx-20241231.xsd#mgnx_ProventionAPAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionAPAMember" xlink:to="lab_mgnx_ProventionAPAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_b93fc009-0896-4823-b9bb-ee5914d854c6_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_5884282e-139a-494c-8e9e-39bdcf7c62bf_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_caa9ebb2-598e-4b07-9bc6-3f0a6ef99694_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_645989c0-7be2-441f-8a93-2540961e4338_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_627a8225-362c-4806-bbac-0b45515df17d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, equipment and software, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_5e47f83e-6676-4b95-a226-ea97fec3ce13_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property, equipment and software, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_3c891200-8db6-43fb-8050-ecca6686da8f_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_b6a48aef-f2d0-44bb-bf08-46f68f8af1c2_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_62e0e76b-9495-4b68-993b-ed31114fbd03_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueFromCollaborativeAgreementsMember_3c7f970e-1d58-4dff-9332-9808c5bd7825_terseLabel_en-US" xlink:label="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from collaborative agreements</link:label>
    <link:label id="lab_mgnx_RevenueFromCollaborativeAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Collaborative Agreements [Member]</link:label>
    <link:label id="lab_mgnx_RevenueFromCollaborativeAgreementsMember_documentation_en-US" xlink:label="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Collaborative Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:href="mgnx-20241231.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:to="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7cfcf39c-acfa-44ee-b0b0-c4752eeea5a0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_99f47c14-b8cb-4041-9cc5-8cb0532ee121_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_2fddbbdd-db5e-4119-835a-22fc2beca945_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_30b4c4a5-39ab-498c-9560-3deb681d2df7_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81cc489d-4ae5-4a0c-ae0d-03161125dc31_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_4d53f487-6e1e-429b-8431-f73819bea46a_terseLabel_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential milestone payment to third parties for intellectual property under agreement</link:label>
    <link:label id="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement</link:label>
    <link:label id="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_documentation_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:href="mgnx-20241231.xsd#mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:to="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CostOfManufacturingServices_36288957-3591-4308-a7fc-18ec91230caf_terseLabel_en-US" xlink:label="lab_mgnx_CostOfManufacturingServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of manufacturing services</link:label>
    <link:label id="lab_mgnx_CostOfManufacturingServices_label_en-US" xlink:label="lab_mgnx_CostOfManufacturingServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of manufacturing services</link:label>
    <link:label id="lab_mgnx_CostOfManufacturingServices_documentation_en-US" xlink:label="lab_mgnx_CostOfManufacturingServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cost of manufacturing services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CostOfManufacturingServices" xlink:href="mgnx-20241231.xsd#mgnx_CostOfManufacturingServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CostOfManufacturingServices" xlink:to="lab_mgnx_CostOfManufacturingServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_34ee19df-2d36-4d14-9904-f93be8e1e8b9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_0eaad4bb-d699-40a1-aecd-fa3a7fedccfd_negatedLabel_en-US" xlink:label="lab_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Operating lease ROU assets</link:label>
    <link:label id="lab_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_label_en-US" xlink:label="lab_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease Right Of Use Assets</link:label>
    <link:label id="lab_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease Right Of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:href="mgnx-20241231.xsd#mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:to="lab_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteCommercialSupplyAgreementMember_33eb6e36-366e-4bd1-bb06-60d7dbbc915a_terseLabel_en-US" xlink:label="lab_mgnx_IncyteCommercialSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incyte MGA012 Clinical Services</link:label>
    <link:label id="lab_mgnx_IncyteCommercialSupplyAgreementMember_label_en-US" xlink:label="lab_mgnx_IncyteCommercialSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incyte Commercial Supply Agreement [Member]</link:label>
    <link:label id="lab_mgnx_IncyteCommercialSupplyAgreementMember_documentation_en-US" xlink:label="lab_mgnx_IncyteCommercialSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Incyte Commercial Supply Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCommercialSupplyAgreementMember" xlink:href="mgnx-20241231.xsd#mgnx_IncyteCommercialSupplyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteCommercialSupplyAgreementMember" xlink:to="lab_mgnx_IncyteCommercialSupplyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_38844e65-e141-49a0-a5ae-8c406d9588ad_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of significant accounts receivable</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_fc973677-64b4-498b-b073-2b4135cd4f5c_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_148b4716-f57f-4976-9e51-f904d57ccdff_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other permanent items</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_bf082b35-2986-4df3-a24b-9bc121601b10_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0273924a-4a58-46da-932a-b0d90c9151c8_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ASDHealthcareAndOncologySupplyMember_a3a98295-5edf-433f-994e-fcc450320ae0_terseLabel_en-US" xlink:label="lab_mgnx_ASDHealthcareAndOncologySupplyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASD Healthcare and Oncology Supply</link:label>
    <link:label id="lab_mgnx_ASDHealthcareAndOncologySupplyMember_label_en-US" xlink:label="lab_mgnx_ASDHealthcareAndOncologySupplyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ASD Healthcare and Oncology Supply [Member]</link:label>
    <link:label id="lab_mgnx_ASDHealthcareAndOncologySupplyMember_documentation_en-US" xlink:label="lab_mgnx_ASDHealthcareAndOncologySupplyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ASD Healthcare and Oncology Supply</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ASDHealthcareAndOncologySupplyMember" xlink:href="mgnx-20241231.xsd#mgnx_ASDHealthcareAndOncologySupplyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ASDHealthcareAndOncologySupplyMember" xlink:to="lab_mgnx_ASDHealthcareAndOncologySupplyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_AuditorInformationAbstract_label_en-US" xlink:label="lab_mgnx_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:label id="lab_mgnx_AuditorInformationAbstract_documentation_en-US" xlink:label="lab_mgnx_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Auditor Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AuditorInformationAbstract" xlink:href="mgnx-20241231.xsd#mgnx_AuditorInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AuditorInformationAbstract" xlink:to="lab_mgnx_AuditorInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_2feba111-3e65-425f-b6ba-53a9c3aebf29_terseLabel_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts recognized</link:label>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_label_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development And Regulatory Milestone Payments Under Agreement, Recognized</link:label>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_documentation_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development And Regulatory Milestone Payments Under Agreement, Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:href="mgnx-20241231.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:to="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_cb83970a-47d5-4056-975c-7c49e3f3748d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, equipment and software</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d7702952-5fd7-48ab-ba23-bae8947fcc2f_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_b688a9e4-c9e4-433d-9254-4c613f6ec62e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_b32bfb02-641a-46a4-8fc4-5c46bf04bec8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteClinicalSupplyAgreementMember_0e5d60fb-7d04-4dc4-a8ef-d1930721b751_terseLabel_en-US" xlink:label="lab_mgnx_IncyteClinicalSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incyte MGA012 Supply Agreement</link:label>
    <link:label id="lab_mgnx_IncyteClinicalSupplyAgreementMember_label_en-US" xlink:label="lab_mgnx_IncyteClinicalSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incyte Clinical Supply Agreement [Member]</link:label>
    <link:label id="lab_mgnx_IncyteClinicalSupplyAgreementMember_documentation_en-US" xlink:label="lab_mgnx_IncyteClinicalSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Incyte Clinical Supply Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteClinicalSupplyAgreementMember" xlink:href="mgnx-20241231.xsd#mgnx_IncyteClinicalSupplyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteClinicalSupplyAgreementMember" xlink:to="lab_mgnx_IncyteClinicalSupplyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RetifanlimabMember_d35d0515-883a-4b65-81df-69ce1c3e9dbc_terseLabel_en-US" xlink:label="lab_mgnx_RetifanlimabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retifanlimab</link:label>
    <link:label id="lab_mgnx_RetifanlimabMember_label_en-US" xlink:label="lab_mgnx_RetifanlimabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retifanlimab [Member]</link:label>
    <link:label id="lab_mgnx_RetifanlimabMember_documentation_en-US" xlink:label="lab_mgnx_RetifanlimabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Retifanlimab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RetifanlimabMember" xlink:href="mgnx-20241231.xsd#mgnx_RetifanlimabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RetifanlimabMember" xlink:to="lab_mgnx_RetifanlimabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9d45403b-6624-4b0f-adbf-af9d41204a1e_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5851ec75-1346-4087-913c-4b6a80ecc58a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted weighted average number of common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7ddd3cff-d040-4eaf-a978-7c0462645323_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_SynaffixBVMember_f725a68f-5c1e-4684-bf34-c937cf09c71e_terseLabel_en-US" xlink:label="lab_mgnx_SynaffixBVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Synaffix B.V.</link:label>
    <link:label id="lab_mgnx_SynaffixBVMember_label_en-US" xlink:label="lab_mgnx_SynaffixBVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Synaffix B.V. [Member]</link:label>
    <link:label id="lab_mgnx_SynaffixBVMember_documentation_en-US" xlink:label="lab_mgnx_SynaffixBVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Synaffix B.V.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_SynaffixBVMember" xlink:href="mgnx-20241231.xsd#mgnx_SynaffixBVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_SynaffixBVMember" xlink:to="lab_mgnx_SynaffixBVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_895087d7-6f98-4cf9-a74f-d194b724e49c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TerSeraMember_22094fcd-48b3-4d55-9eb7-5dd29d3e7de5_terseLabel_en-US" xlink:label="lab_mgnx_TerSeraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TerSera</link:label>
    <link:label id="lab_mgnx_TerSeraMember_label_en-US" xlink:label="lab_mgnx_TerSeraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TerSera [Member]</link:label>
    <link:label id="lab_mgnx_TerSeraMember_documentation_en-US" xlink:label="lab_mgnx_TerSeraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TerSera</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TerSeraMember" xlink:href="mgnx-20241231.xsd#mgnx_TerSeraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TerSeraMember" xlink:to="lab_mgnx_TerSeraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_a92e5aa0-90c9-4cc4-b246-478989a26154_terseLabel_en-US" xlink:label="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Sixteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand Sixteen Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:href="mgnx-20241231.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:to="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_169a2d45-2dcc-4b0d-b67a-7ee9f5e5fe71_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_f8518eba-7792-4f61-a5cd-5e952e5f4e7d_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_d4346106-d755-4c39-acc2-9fc2bfcdcd67_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EnoblituzumabMember_9fd675dc-bb72-4f49-bbea-4aebe6c0c5c5_terseLabel_en-US" xlink:label="lab_mgnx_EnoblituzumabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Enoblituzumab</link:label>
    <link:label id="lab_mgnx_EnoblituzumabMember_label_en-US" xlink:label="lab_mgnx_EnoblituzumabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Enoblituzumab [Member]</link:label>
    <link:label id="lab_mgnx_EnoblituzumabMember_documentation_en-US" xlink:label="lab_mgnx_EnoblituzumabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Enoblituzumab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EnoblituzumabMember" xlink:href="mgnx-20241231.xsd#mgnx_EnoblituzumabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EnoblituzumabMember" xlink:to="lab_mgnx_EnoblituzumabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_4fbeb2b3-3f36-4da7-a5db-5564894fbbc5_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_UndesignatedPreferredStockMember_51e993a9-b47e-4079-a805-90469f943ebd_terseLabel_en-US" xlink:label="lab_mgnx_UndesignatedPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Undesignated Preferred Stock</link:label>
    <link:label id="lab_mgnx_UndesignatedPreferredStockMember_label_en-US" xlink:label="lab_mgnx_UndesignatedPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undesignated Preferred Stock [Member]</link:label>
    <link:label id="lab_mgnx_UndesignatedPreferredStockMember_documentation_en-US" xlink:label="lab_mgnx_UndesignatedPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Undesignated Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UndesignatedPreferredStockMember" xlink:href="mgnx-20241231.xsd#mgnx_UndesignatedPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_UndesignatedPreferredStockMember" xlink:to="lab_mgnx_UndesignatedPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_806beb27-8ac6-4c08-90e8-9a3ca7caeb79_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_28d99a24-895b-40ac-98f8-41657e12b8af_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease renewal term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_3db5dbb0-31db-4eca-b4ad-8b678bea1ac4_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_4ef31369-b2c6-425c-b507-9cd5de38e5cc_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_5c50a370-68b2-4087-b3f5-750117a110ea_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Equipment and Software</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_237f6ee7-73f2-4225-b7dc-11264cf77625_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_9b444b02-9ba3-42bf-9120-7518b6c8e3a7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TaxYear2027To2044Member_3089beac-449c-4171-b993-d7558a59c253_terseLabel_en-US" xlink:label="lab_mgnx_TaxYear2027To2044Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Year 2027 To 2044</link:label>
    <link:label id="lab_mgnx_TaxYear2027To2044Member_label_en-US" xlink:label="lab_mgnx_TaxYear2027To2044Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Year 2027 To 2044 [Member]</link:label>
    <link:label id="lab_mgnx_TaxYear2027To2044Member_documentation_en-US" xlink:label="lab_mgnx_TaxYear2027To2044Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Year 2027 To 2044</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TaxYear2027To2044Member" xlink:href="mgnx-20241231.xsd#mgnx_TaxYear2027To2044Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TaxYear2027To2044Member" xlink:to="lab_mgnx_TaxYear2027To2044Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteCorporationMember_c022bc24-c8ea-4b14-ad26-bb10b2708470_terseLabel_en-US" xlink:label="lab_mgnx_IncyteCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incyte Corporation (Incyte)</link:label>
    <link:label id="lab_mgnx_IncyteCorporationMember_label_en-US" xlink:label="lab_mgnx_IncyteCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incyte Corporation [Member]</link:label>
    <link:label id="lab_mgnx_IncyteCorporationMember_documentation_en-US" xlink:label="lab_mgnx_IncyteCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Incyte Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember" xlink:href="mgnx-20241231.xsd#mgnx_IncyteCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteCorporationMember" xlink:to="lab_mgnx_IncyteCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_4df6ad5b-b32c-44bc-8466-6cc5b820055f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_OperatingLeaseNoncashExpense_b2ef99d7-9b3d-4fd4-9581-fd420d299eeb_terseLabel_en-US" xlink:label="lab_mgnx_OperatingLeaseNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_mgnx_OperatingLeaseNoncashExpense_label_en-US" xlink:label="lab_mgnx_OperatingLeaseNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Noncash Expense</link:label>
    <link:label id="lab_mgnx_OperatingLeaseNoncashExpense_documentation_en-US" xlink:label="lab_mgnx_OperatingLeaseNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLeaseNoncashExpense" xlink:href="mgnx-20241231.xsd#mgnx_OperatingLeaseNoncashExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OperatingLeaseNoncashExpense" xlink:to="lab_mgnx_OperatingLeaseNoncashExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_355ae146-a83a-4f3a-8c17-2edcaeeef225_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_9706a3b1-354f-4924-b3fb-9b51df806262_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4c06c21f-92ee-47e9-a305-5df7d9c90e05_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation, number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_88bef98d-2d33-426e-80da-837a85aa8195_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7ee0f20a-1e30-4d8f-a01e-a91cb2d88923_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_249f47dc-5b1b-4f58-b109-b9674439b0b5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Fair Value Measurement Financial Assets</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_0f4b4b68-7825-4f2c-899f-db9af5aaef34_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesFromGrantsMember_1a4fe15e-8791-418a-ae52-38f1a12ec8e6_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesFromGrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RevenuesFromGrantsMember</link:label>
    <link:label id="lab_mgnx_RevenuesFromGrantsMember_label_en-US" xlink:label="lab_mgnx_RevenuesFromGrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RevenuesFromGrantsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromGrantsMember" xlink:href="mgnx-20241231.xsd#mgnx_RevenuesFromGrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesFromGrantsMember" xlink:to="lab_mgnx_RevenuesFromGrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3b119d2b-8840-42af-aa84-e301cb9f3a43_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining contractual term, Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_e0fb637a-9501-4565-86a5-6079902b9e5c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2568d102-613d-4c23-b4ec-7cf47018efa8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_b9304bc2-a63b-45d5-a0f7-b1300e809cb9_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_0170cc83-ed75-4374-a4b9-eeb787307949_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_GileadFirstResearchProgramMember_685c227d-fe14-4ef4-86ec-26cf6d186365_terseLabel_en-US" xlink:label="lab_mgnx_GileadFirstResearchProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gilead First Research Program</link:label>
    <link:label id="lab_mgnx_GileadFirstResearchProgramMember_label_en-US" xlink:label="lab_mgnx_GileadFirstResearchProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gilead First Research Program [Member]</link:label>
    <link:label id="lab_mgnx_GileadFirstResearchProgramMember_documentation_en-US" xlink:label="lab_mgnx_GileadFirstResearchProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gilead First Research Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GileadFirstResearchProgramMember" xlink:href="mgnx-20241231.xsd#mgnx_GileadFirstResearchProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_GileadFirstResearchProgramMember" xlink:to="lab_mgnx_GileadFirstResearchProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_ba00a11c-3b69-457d-8e21-cf465e119d25_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of employee contribution to salary</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_3b1c3658-8f77-4208-8ed1-597e5646ef26_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_553e9206-f879-4ab0-bb63-aa1d2154fda0_terseLabel_en-US" xlink:label="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eligible age to participate in plan</link:label>
    <link:label id="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_label_en-US" xlink:label="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employees Eligible Age To Participate In Benefit Plan</link:label>
    <link:label id="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_documentation_en-US" xlink:label="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to minimum eligible age of employee to participate in benefit plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:href="mgnx-20241231.xsd#mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:to="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_91c1945a-0c90-448a-9b21-cf8e321c6718_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f5ae9f28-5cd0-4537-9ea6-6468643c9e97_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining contractual term, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6f4f6302-043e-43c2-b6e2-f804237b5c7b_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_011736fa-970c-47f1-bff5-b7332f232314_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a5f3d300-5d1b-4dc9-a36c-a074761ec2f8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_f4f5f768-7ecc-42aa-bb89-38f8a42bb89a_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NonCashInterestExpenseRecognized_b4c2b89c-4c63-482a-9c64-ba08e09b61e5_terseLabel_en-US" xlink:label="lab_mgnx_NonCashInterestExpenseRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_mgnx_NonCashInterestExpenseRecognized_label_en-US" xlink:label="lab_mgnx_NonCashInterestExpenseRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-cash interest expense recognized</link:label>
    <link:label id="lab_mgnx_NonCashInterestExpenseRecognized_documentation_en-US" xlink:label="lab_mgnx_NonCashInterestExpenseRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-cash interest expense recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonCashInterestExpenseRecognized" xlink:href="mgnx-20241231.xsd#mgnx_NonCashInterestExpenseRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonCashInterestExpenseRecognized" xlink:to="lab_mgnx_NonCashInterestExpenseRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_acc17981-1bd7-42ed-95b6-179bc3b32911_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_74830817-606d-4fc3-87f1-dcc9b1ea4989_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Project [Axis]</link:label>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_label_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Project [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_f326a8ee-390b-447d-9708-99da1a49f316_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6e6143c4-e431-472a-b242-d7a72809c4c6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_e0c93085-79c8-432a-81b7-bb1c83807aa2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_64229562-7546-48e2-a67f-f1ae748a0265_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_25424334-8691-4920-acf0-7532a89165d2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_MargetuximabMember_e023ee6d-00ce-499d-93f2-f4b3e4ef01e8_terseLabel_en-US" xlink:label="lab_mgnx_MargetuximabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Margetuximab</link:label>
    <link:label id="lab_mgnx_MargetuximabMember_label_en-US" xlink:label="lab_mgnx_MargetuximabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Margetuximab [Member]</link:label>
    <link:label id="lab_mgnx_MargetuximabMember_documentation_en-US" xlink:label="lab_mgnx_MargetuximabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Margetuximab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_MargetuximabMember" xlink:href="mgnx-20241231.xsd#mgnx_MargetuximabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_MargetuximabMember" xlink:to="lab_mgnx_MargetuximabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_940464e9-76b8-4267-9b2c-ec2f520136d6_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_3557fecd-0826-47eb-978b-44cf0b6a3131_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_b1b025b9-14df-442a-8a45-4eaef0978657_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Stock Options Award Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_97646e28-5ce6-48ed-bbfb-b9342cea6eeb_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_17d19ae6-28f5-4eaa-bd7d-af284ac4a471_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_00bfb9a2-7992-452c-a259-0b4a74194e8b_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance at Beginning of Year</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_7b7530f3-47d1-4770-9410-9552b0af0076_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at End of Year</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_b2de3ffd-e5cf-4671-9fec-ef40fc828398_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease, cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_37610a99-5003-4c59-8f73-0455f0f075e5_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_24e1897f-5132-4d2d-963f-074161bdc688_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabLimitedMember_399a5c59-d462-44cb-b9b7-8d599eb84759_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Zai Lab Limited (Zai Lab)</link:label>
    <link:label id="lab_mgnx_ZaiLabLimitedMember_label_en-US" xlink:label="lab_mgnx_ZaiLabLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Zai Lab Limited [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabLimitedMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Zai Lab Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabLimitedMember" xlink:href="mgnx-20241231.xsd#mgnx_ZaiLabLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabLimitedMember" xlink:to="lab_mgnx_ZaiLabLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CardinalHealthIncMember_a7714496-697e-4ba4-956f-a3358e31ecc1_terseLabel_en-US" xlink:label="lab_mgnx_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cardinal Health</link:label>
    <link:label id="lab_mgnx_CardinalHealthIncMember_label_en-US" xlink:label="lab_mgnx_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cardinal Health, Inc [Member]</link:label>
    <link:label id="lab_mgnx_CardinalHealthIncMember_documentation_en-US" xlink:label="lab_mgnx_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cardinal Health, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CardinalHealthIncMember" xlink:href="mgnx-20241231.xsd#mgnx_CardinalHealthIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CardinalHealthIncMember" xlink:to="lab_mgnx_CardinalHealthIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bda93e39-7033-4a3a-86af-5dae38120516_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_18042c3b-cf5b-4f6f-a745-e5ac13bc24d7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock purchased by employees (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f4a26f41-1b9c-47c9-bfd8-ec62a80d5b1a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_GainOnRoyaltyMonetizationArrangement_2094931a-ef43-42eb-bc68-568bb5fa9dcc_terseLabel_en-US" xlink:label="lab_mgnx_GainOnRoyaltyMonetizationArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on royalty monetization arrangement</link:label>
    <link:label id="lab_mgnx_GainOnRoyaltyMonetizationArrangement_74a18a89-0987-41c8-888f-a0c82a199341_negatedTerseLabel_en-US" xlink:label="lab_mgnx_GainOnRoyaltyMonetizationArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain on royalty monetization arrangement</link:label>
    <link:label id="lab_mgnx_GainOnRoyaltyMonetizationArrangement_label_en-US" xlink:label="lab_mgnx_GainOnRoyaltyMonetizationArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain on royalty monetization arrangement</link:label>
    <link:label id="lab_mgnx_GainOnRoyaltyMonetizationArrangement_documentation_en-US" xlink:label="lab_mgnx_GainOnRoyaltyMonetizationArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain on royalty monetization arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GainOnRoyaltyMonetizationArrangement" xlink:href="mgnx-20241231.xsd#mgnx_GainOnRoyaltyMonetizationArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_GainOnRoyaltyMonetizationArrangement" xlink:to="lab_mgnx_GainOnRoyaltyMonetizationArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_AdditionalAnnualFixedPayments_fd4c8788-067f-4c9a-ac48-18e4ec13f588_terseLabel_en-US" xlink:label="lab_mgnx_AdditionalAnnualFixedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional annual fixed payments</link:label>
    <link:label id="lab_mgnx_AdditionalAnnualFixedPayments_label_en-US" xlink:label="lab_mgnx_AdditionalAnnualFixedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Annual Fixed Payments</link:label>
    <link:label id="lab_mgnx_AdditionalAnnualFixedPayments_documentation_en-US" xlink:label="lab_mgnx_AdditionalAnnualFixedPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Annual Fixed Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AdditionalAnnualFixedPayments" xlink:href="mgnx-20241231.xsd#mgnx_AdditionalAnnualFixedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AdditionalAnnualFixedPayments" xlink:to="lab_mgnx_AdditionalAnnualFixedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_d0667a91-593b-4f09-b671-d623e7ea583e_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_aef3752f-ad5c-43c0-87d6-5724080df295_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_6cfe35b0-bcb9-4226-9dba-b12287252025_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_b6b94085-9781-475c-a623-0687e0992fa3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_229aef7e-d447-4a53-8db1-b5c32a3fc017_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_17554f2f-9d87-472f-a088-6920d6974d90_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Options and RSUs Excluded from the Calculation of Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_1368af46-6a66-4365-a4a3-1f0f29867239_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ADCMember_2879e526-c93b-4c05-836e-75ee3b710934_terseLabel_en-US" xlink:label="lab_mgnx_ADCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ADC</link:label>
    <link:label id="lab_mgnx_ADCMember_label_en-US" xlink:label="lab_mgnx_ADCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ADC [Member]</link:label>
    <link:label id="lab_mgnx_ADCMember_documentation_en-US" xlink:label="lab_mgnx_ADCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preclinical antibody-drug conjugates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ADCMember" xlink:href="mgnx-20241231.xsd#mgnx_ADCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ADCMember" xlink:to="lab_mgnx_ADCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_39151df9-673a-4a4d-b604-323849488109_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_b38cada9-75d9-4c18-87b2-51173e1f7584_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_VobramitanmabDuocarmazineMember_e8f651e9-b01a-4b00-a660-f1c12e6c30eb_terseLabel_en-US" xlink:label="lab_mgnx_VobramitanmabDuocarmazineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vobramitanmab duocarmazine [Member]</link:label>
    <link:label id="lab_mgnx_VobramitanmabDuocarmazineMember_label_en-US" xlink:label="lab_mgnx_VobramitanmabDuocarmazineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vobramitanmab duocarmazine [Member]</link:label>
    <link:label id="lab_mgnx_VobramitanmabDuocarmazineMember_documentation_en-US" xlink:label="lab_mgnx_VobramitanmabDuocarmazineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vobramitanmab duocarmazine</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_VobramitanmabDuocarmazineMember" xlink:href="mgnx-20241231.xsd#mgnx_VobramitanmabDuocarmazineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_VobramitanmabDuocarmazineMember" xlink:to="lab_mgnx_VobramitanmabDuocarmazineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_30d3fd30-5269-4b67-b251-2dc4e649ebeb_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_e2f76495-4f34-41af-898f-c5cd798fd42b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_980f97bb-6b35-459d-b4c5-919f079c0666_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per common share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_4463e521-7cbd-4fe9-b23f-fc7103f5f4ca_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount_3c1b1ec7-27b0-405a-ba12-f6ea1c7e8722_negatedLabel_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Orphan drug credit, net</link:label>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount_label_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Orphan Drug, Amount</link:label>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount_documentation_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Orphan Drug, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:href="mgnx-20241231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:to="lab_mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_3963d81f-78c1-42d4-bddf-59522df4f95c_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement_aa424c4a-96c3-4d96-bc96-4378437f5f10_negatedTerseLabel_en-US" xlink:label="lab_mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal payments on royalty monetization arrangement</link:label>
    <link:label id="lab_mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement_label_en-US" xlink:label="lab_mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Principal payments on royalty monetization arrangement</link:label>
    <link:label id="lab_mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement_documentation_en-US" xlink:label="lab_mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Principal payments on royalty monetization arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement" xlink:href="mgnx-20241231.xsd#mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement" xlink:to="lab_mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_486435c7-bdb2-41e9-a614-fa5784fa3ba7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_5d5a1dd8-873a-468e-ade0-5eb4f366a908_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for federal or state income taxes</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_ce9f7a2e-cd55-47d3-a03c-21450eea8c77_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Provision for federal or state income taxes</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_f08f36f9-4e79-41fe-bbce-50b55312ab01_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_b792838f-fe90-4ee0-8ed9-434a98901b34_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_54080170-b662-4d37-bc11-f2a86f3af596_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock warrants (in shares)</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_label_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_documentation_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:href="mgnx-20241231.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:to="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_b57a74a5-84d6-48cd-86b0-4600d9364566_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Undesignated preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_d8ed7659-a8e0-442d-aada-be4ad9e604c7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_2027885e-26e7-49cc-bab0-536c99182562_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_d7d8017f-131c-4afd-a49d-13456787e3f3_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_afd4aebc-402d-4b40-a478-711e2af30d90_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_e3e2b834-b860-4c54-818a-94108e341a7c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Research credit, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_2132c639-3488-404b-a219-62cfe7f7b3b2_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeAgreementTransactionPrice_5ae4cbdc-f527-4fb4-b764-39d5ab5f459f_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction price</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementTransactionPrice_label_en-US" xlink:label="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement Transaction Price</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementTransactionPrice_documentation_en-US" xlink:label="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement Transaction Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice" xlink:href="mgnx-20241231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeAgreementTransactionPrice" xlink:to="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_b557c888-30b4-4193-947e-c28d6d51865a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_7d67c65b-4d74-42e2-82be-f79c53ca3cd4_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income tax expense/(benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_21c81dc8-b978-48aa-b55a-8eb8eb219c85_terseLabel_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock plan related activity</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_label_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Value Stock Plan Activity</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_documentation_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of shares issued due to stock plan related activity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:href="mgnx-20241231.xsd#mgnx_StockIssuedDuringPeriodValueStockPlanActivity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:to="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_GainOnSaleOfMARGENZA_2f3c22db-c2f3-4723-a385-d8aee5120944_terseLabel_en-US" xlink:label="lab_mgnx_GainOnSaleOfMARGENZA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of MARGENZA</link:label>
    <link:label id="lab_mgnx_GainOnSaleOfMARGENZA_aed0c99f-6be4-4438-8354-9eb2c248f7f7_negatedTerseLabel_en-US" xlink:label="lab_mgnx_GainOnSaleOfMARGENZA" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of MARGENZA</link:label>
    <link:label id="lab_mgnx_GainOnSaleOfMARGENZA_label_en-US" xlink:label="lab_mgnx_GainOnSaleOfMARGENZA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain on sale of MARGENZA</link:label>
    <link:label id="lab_mgnx_GainOnSaleOfMARGENZA_documentation_en-US" xlink:label="lab_mgnx_GainOnSaleOfMARGENZA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain on sale of MARGENZA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GainOnSaleOfMARGENZA" xlink:href="mgnx-20241231.xsd#mgnx_GainOnSaleOfMARGENZA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_GainOnSaleOfMARGENZA" xlink:to="lab_mgnx_GainOnSaleOfMARGENZA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2df4549e-ce14-4bf2-800d-d526183a6507_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueFromGovernmentAgreementsMember_67ad83ab-b51c-4370-a13e-52d26323ae82_terseLabel_en-US" xlink:label="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from government agreements</link:label>
    <link:label id="lab_mgnx_RevenueFromGovernmentAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Government Agreements [Member]</link:label>
    <link:label id="lab_mgnx_RevenueFromGovernmentAgreementsMember_documentation_en-US" xlink:label="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Government Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember" xlink:href="mgnx-20241231.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueFromGovernmentAgreementsMember" xlink:to="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_56d6d7f8-e896-4449-b38f-a0ccc3d5b7f9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_1a9938c3-99ef-4821-ad4e-58fb3fc53781_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration received common stock warrant exercise price (in usd per share)</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_label_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_documentation_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:href="mgnx-20241231.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:to="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_245a666c-880d-4543-98f2-cc565c3e2263_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CombinedServicesAgreementMember_9e0b0d66-061d-4ceb-811d-b1c637e404c9_terseLabel_en-US" xlink:label="lab_mgnx_CombinedServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Combined Services Agreement</link:label>
    <link:label id="lab_mgnx_CombinedServicesAgreementMember_label_en-US" xlink:label="lab_mgnx_CombinedServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Combined Services Agreement [Member]</link:label>
    <link:label id="lab_mgnx_CombinedServicesAgreementMember_documentation_en-US" xlink:label="lab_mgnx_CombinedServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Combined Services Agreement - Asset Purchase Agreement + Master Manufacturing &amp; Supply Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CombinedServicesAgreementMember" xlink:href="mgnx-20241231.xsd#mgnx_CombinedServicesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CombinedServicesAgreementMember" xlink:to="lab_mgnx_CombinedServicesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_2ba819d9-e3fb-433c-8dcb-b0cee7cd6f4c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_7d257112-dfb3-4dec-a186-c5d46e432c2e_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_e4c72f89-7d0c-4497-92d2-e286c6c31ceb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest and other expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Operating and Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_587963a4-7404-4c3f-8f48-6e858eac0d81_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_0592f1f0-569e-4fd3-99f3-375c3d60c7a0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_04b46e1f-1a5d-4d25-bf22-84847cb3e33b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_e290b202-aca2-4786-8488-904602fbb159_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_5f6859c8-be14-489d-8d52-4ab297ea6f2d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_9827fe7e-7965-48d8-827c-b1a104dbf840_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83c0b4fd-1928-4e31-bc4e-fc928b552ae5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_8bc76314-7aba-4787-a4dd-c79d045d27aa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of RSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_A2021ZaiLabAgreementsMember_b4bb7d52-11eb-44b9-8b48-4eb5c1cf41f3_terseLabel_en-US" xlink:label="lab_mgnx_A2021ZaiLabAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021 Zai Lab Agreements</link:label>
    <link:label id="lab_mgnx_A2021ZaiLabAgreementsMember_label_en-US" xlink:label="lab_mgnx_A2021ZaiLabAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2021 Zai Lab Agreements [Member]</link:label>
    <link:label id="lab_mgnx_A2021ZaiLabAgreementsMember_documentation_en-US" xlink:label="lab_mgnx_A2021ZaiLabAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2021 Zai Lab Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2021ZaiLabAgreementsMember" xlink:href="mgnx-20241231.xsd#mgnx_A2021ZaiLabAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_A2021ZaiLabAgreementsMember" xlink:to="lab_mgnx_A2021ZaiLabAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f23bf747-812d-4a86-90c6-19d7f71f97dc_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_eddefb38-125c-47e4-9ef7-6e17b81ece78_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited or expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b1763565-fbb3-41f0-bb36-12ef6cf6bac7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4c04bb50-5652-410a-8c39-5fb168663ef6_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_114314dd-b8c1-4feb-b251-9175e21a5199_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_6b582cb3-ce31-4518-ae17-152334497cd5_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_898bae92-82ba-455d-aff9-7015e5043c43_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_d1cd73f7-16d6-43dc-bb2c-eeb4d191028e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_09de38a8-4c96-4e23-a6a0-1267cc651995_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock_5c9d2b90-c4be-484f-91d1-a68a7a539e60_terseLabel_en-US" xlink:label="lab_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Supplemental Balance Sheet Information, Operating Leases</link:label>
    <link:label id="lab_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock_label_en-US" xlink:label="lab_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Supplemental Balance Sheet Information, Operating Leases [Table Text Block]</link:label>
    <link:label id="lab_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock_documentation_en-US" xlink:label="lab_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Supplemental Balance Sheet Information, Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock" xlink:href="mgnx-20241231.xsd#mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock" xlink:to="lab_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_ac1b0876-496e-4e88-93db-c0edcc3c740e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_49975602-c532-459f-8a44-8e2d62b0cf89_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_label_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_documentation_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:href="mgnx-20241231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:to="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_623791b6-729e-4e34-84b8-7eb695ac7ee4_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_3bb38e3e-35b6-4f9c-9391-43c86444d388_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Sublease Income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_d911f587-c179-46fb-91f7-5fec9bf73d66_terseLabel_en-US" xlink:label="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Federal and State</link:label>
    <link:label id="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_label_en-US" xlink:label="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority and State and Local Jurisdiction [Member] [Member]</link:label>
    <link:label id="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_documentation_en-US" xlink:label="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority and State and Local Jurisdiction [Member] [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:href="mgnx-20241231.xsd#mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:to="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c9f4c665-aedb-4c8e-b72e-566c129dafc7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_418b9b13-f313-4ec2-8b65-eefce1f8ca7a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9c0f1b42-f1be-458f-8c40-c6211ec87cef_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_3b040f0a-3a6b-414c-b647-c4d99cf3a2d0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_MGD024Member_01c7c838-8943-4e27-ae0f-add130f2e95d_terseLabel_en-US" xlink:label="lab_mgnx_MGD024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MGD024</link:label>
    <link:label id="lab_mgnx_MGD024Member_label_en-US" xlink:label="lab_mgnx_MGD024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MGD024 [Member]</link:label>
    <link:label id="lab_mgnx_MGD024Member_documentation_en-US" xlink:label="lab_mgnx_MGD024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MGD024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_MGD024Member" xlink:href="mgnx-20241231.xsd#mgnx_MGD024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_MGD024Member" xlink:to="lab_mgnx_MGD024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_31308975-c831-4c4f-bb59-5fb8f64323d7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Orphan drug credit, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_84facbb3-085e-4466-bd96-31bc4dae1e96_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1860fa1e-3c0d-4f86-a76e-be4cfad5c9ae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_97995fca-181b-43c8-b49e-d60b0fb54543_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions Charged to Expenses</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_9fd3adb5-5fab-4730-8d1b-8a45fc9f7f2b_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, noncurrent</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount_4be5e3ec-a3d2-4c46-a9d4-b615a3000b7f_terseLabel_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred state blended rate adjustments</link:label>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount_label_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deferred State Blended Rate Adjustments, Amount</link:label>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount_documentation_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deferred State Blended Rate Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount" xlink:href="mgnx-20241231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount" xlink:to="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_7ceb0ee4-5f05-4627-9692-a9be26f06a9e_terseLabel_en-US" xlink:label="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential commercial milestone payments</link:label>
    <link:label id="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Commercial Milestone Payments Under Agreement</link:label>
    <link:label id="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_documentation_en-US" xlink:label="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential Commercial Milestone Payments Under Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:href="mgnx-20241231.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:to="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4f4f8c04-7a14-4377-b8b1-4b4cfdf19dfd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_762f947f-7042-49c0-936c-06fed188781f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_06232afb-65e2-4c16-85ba-911f624cb0b0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ce1bb27a-4d25-4179-9f82-e633ae308929_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfOtherProductiveAssets_8a2f21d1-ff4d-4c73-9d87-3077d69681c4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfOtherProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of MARGENZA</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfOtherProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfOtherProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Other Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfOtherProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfOtherProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfOtherProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_edb28a30-836e-4c30-872b-b0d7a7a916c1_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_153fa2f8-be28-4d0a-a14d-b8b826f38483_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, ROU Assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_22fac6ed-44f1-49d4-bf98-342752928975_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c91a32af-e8ff-43ba-957a-834ec40acfdb_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1b1be673-9c2a-4ced-920c-9fbf56d6c790_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_e388536a-e455-44d8-98ae-3e29ff16cf1f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_ad87da80-092c-4a03-a7fb-72ffbda17c26_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_d92c1708-c324-410c-949a-c973a3002fa9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of the Company's Deferred Income Tax Assets (Liabilities)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProceedsfromRoyaltiesPercent_9d03caa3-ec16-48f4-9331-ab156dbf67b6_terseLabel_en-US" xlink:label="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential proceeds from royalties percent</link:label>
    <link:label id="lab_mgnx_ProceedsfromRoyaltiesPercent_label_en-US" xlink:label="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Royalties, Percent</link:label>
    <link:label id="lab_mgnx_ProceedsfromRoyaltiesPercent_documentation_en-US" xlink:label="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Royalties, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent" xlink:href="mgnx-20241231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProceedsfromRoyaltiesPercent" xlink:to="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_de0d3e72-d669-49fa-b87b-0f8b3f37a0e9_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_6e965885-3b0d-43dd-a448-a8f534ee29de_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_3a3fb0ca-858b-40a7-b26a-5f9d095841b7_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a66a7f0d-c7ca-4208-8b61-d3fb1a029723_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_8781aac7-c48a-43be-a3b0-bee757c92a30_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Federal Government</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Investments_8c5f517a-4db8-48bc-8b92-180642d817d3_terseLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_Investments_827b9f2b-0461-4d83-82fe-abdb523a3c50_verboseLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_Investments_label_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Investments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Investments" xlink:to="lab_us-gaap_Investments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncome_08cdd23c-bb3d-4249-a242-70c5a9de149d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Income</link:label>
    <link:label id="lab_us-gaap_OtherIncome_label_en-US" xlink:label="lab_us-gaap_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncome" xlink:to="lab_us-gaap_OtherIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_0d9170aa-c6d7-48bf-bba2-906326b5abce_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_078f7fdc-2857-454c-92ea-1cfbff923d7c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a4133bd2-bd6e-48d4-9991-a3822313995f_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_77212dd4-ec92-4132-a3f9-591e71affd49_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest and other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteMGA012AgreementMember_4c7fb832-8e55-44d6-97e6-9489d0697676_terseLabel_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incyte MGA012 Agreement</link:label>
    <link:label id="lab_mgnx_IncyteMGA012AgreementMember_label_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incyte MGA012 Agreement [Member]</link:label>
    <link:label id="lab_mgnx_IncyteMGA012AgreementMember_documentation_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Incyte MGA012 Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember" xlink:href="mgnx-20241231.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteMGA012AgreementMember" xlink:to="lab_mgnx_IncyteMGA012AgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3c1bceb1-c088-4a18-b66a-0d1bfb8584c8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_42e6ea6e-67ce-483d-82fe-0f0bfef004f7_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_812e71e0-ee49-471f-8c14-1e0e35bad8e3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ValuationAllowanceDeferredTaxAssetDecreaseAmount_bb00ef3b-c0fd-43cc-8104-966744cfd4d9_negatedTerseLabel_en-US" xlink:label="lab_mgnx_ValuationAllowanceDeferredTaxAssetDecreaseAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_mgnx_ValuationAllowanceDeferredTaxAssetDecreaseAmount_label_en-US" xlink:label="lab_mgnx_ValuationAllowanceDeferredTaxAssetDecreaseAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Decrease, Amount</link:label>
    <link:label id="lab_mgnx_ValuationAllowanceDeferredTaxAssetDecreaseAmount_documentation_en-US" xlink:label="lab_mgnx_ValuationAllowanceDeferredTaxAssetDecreaseAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Decrease, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ValuationAllowanceDeferredTaxAssetDecreaseAmount" xlink:href="mgnx-20241231.xsd#mgnx_ValuationAllowanceDeferredTaxAssetDecreaseAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ValuationAllowanceDeferredTaxAssetDecreaseAmount" xlink:to="lab_mgnx_ValuationAllowanceDeferredTaxAssetDecreaseAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_6998009a-ec62-42fa-9b95-83e8396b56a5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_9a82d196-24fb-4a6e-8610-af693bcbac2b_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Percentage of Customer Concentration</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_MainSegmentMember_e96b15a9-b711-4c9e-b7c6-d10b223b7ffc_terseLabel_en-US" xlink:label="lab_mgnx_MainSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Main Segment</link:label>
    <link:label id="lab_mgnx_MainSegmentMember_label_en-US" xlink:label="lab_mgnx_MainSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Main Segment [Member]</link:label>
    <link:label id="lab_mgnx_MainSegmentMember_documentation_en-US" xlink:label="lab_mgnx_MainSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reportable segment, which is discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_MainSegmentMember" xlink:href="mgnx-20241231.xsd#mgnx_MainSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_MainSegmentMember" xlink:to="lab_mgnx_MainSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_ccc3370c-30c0-4c19-ae55-a72c027b5a41_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_OtherProgramsMember_35a06cfd-2328-42b3-917d-96dd59a2e413_terseLabel_en-US" xlink:label="lab_mgnx_OtherProgramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other programs</link:label>
    <link:label id="lab_mgnx_OtherProgramsMember_label_en-US" xlink:label="lab_mgnx_OtherProgramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other programs [Member]</link:label>
    <link:label id="lab_mgnx_OtherProgramsMember_documentation_en-US" xlink:label="lab_mgnx_OtherProgramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OtherProgramsMember" xlink:href="mgnx-20241231.xsd#mgnx_OtherProgramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OtherProgramsMember" xlink:to="lab_mgnx_OtherProgramsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_887f5776-f816-4e69-bb79-7b03f5060dc8_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_53caf65e-5041-4746-9da0-f05140053921_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_LaboratoryAndOfficeEquipmentMember_e0b1e434-58de-4028-82f3-cf5f788fead1_terseLabel_en-US" xlink:label="lab_mgnx_LaboratoryAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory and office equipment</link:label>
    <link:label id="lab_mgnx_LaboratoryAndOfficeEquipmentMember_label_en-US" xlink:label="lab_mgnx_LaboratoryAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory and Office Equipment [Member]</link:label>
    <link:label id="lab_mgnx_LaboratoryAndOfficeEquipmentMember_documentation_en-US" xlink:label="lab_mgnx_LaboratoryAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">A facility that provides controlled conditions in which scientific or technological research, experiments, and measurement may be performed. and tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LaboratoryAndOfficeEquipmentMember" xlink:href="mgnx-20241231.xsd#mgnx_LaboratoryAndOfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_LaboratoryAndOfficeEquipmentMember" xlink:to="lab_mgnx_LaboratoryAndOfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_568ac3c1-84d7-47f9-ac82-cf7f9803a1ae_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_8480c8ec-db1d-48f1-9b26-672f4577b657_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_db098126-aded-417b-adaa-45c9bebd097d_periodStartLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at Beginning of Year</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_69b0aacb-af5e-47b8-891a-2fe486e9dbeb_periodEndLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at End of Year</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_1aa68c16-8ad1-4cfa-9adf-e337398e11ea_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_45f5fdc8-7561-468e-8b4f-2e18a5335661_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_affc43e4-11d9-4839-963e-d16b2314cbc6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_e683e8e2-71c1-4b2f-8d73-8b4824392942_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other non current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_933176a7-b942-4b5c-9e16-569ee2d0bfd0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_8c07f83e-df9e-481b-8755-7d42a38054e8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionPRV3279Member_d3978638-331e-4e45-900c-9ccbf67883b0_terseLabel_en-US" xlink:label="lab_mgnx_ProventionPRV3279Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provention PRV3279</link:label>
    <link:label id="lab_mgnx_ProventionPRV3279Member_label_en-US" xlink:label="lab_mgnx_ProventionPRV3279Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provention PRV3279 [Member]</link:label>
    <link:label id="lab_mgnx_ProventionPRV3279Member_documentation_en-US" xlink:label="lab_mgnx_ProventionPRV3279Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Provention PRV3279</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV3279Member" xlink:href="mgnx-20241231.xsd#mgnx_ProventionPRV3279Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionPRV3279Member" xlink:to="lab_mgnx_ProventionPRV3279Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_2d69daaa-f30e-499d-a29b-6594ca65b186_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of fair market value to purchase shares</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DrScottKoenigMember_6e0ed126-f882-46a5-9c13-156db3a540e8_terseLabel_en-US" xlink:label="lab_mgnx_DrScottKoenigMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dr Scott Koenig</link:label>
    <link:label id="lab_mgnx_DrScottKoenigMember_label_en-US" xlink:label="lab_mgnx_DrScottKoenigMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dr Scott Koenig [Member]</link:label>
    <link:label id="lab_mgnx_DrScottKoenigMember_documentation_en-US" xlink:label="lab_mgnx_DrScottKoenigMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Dr Scott Koenig</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DrScottKoenigMember" xlink:href="mgnx-20241231.xsd#mgnx_DrScottKoenigMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DrScottKoenigMember" xlink:to="lab_mgnx_DrScottKoenigMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_StockOptionsAndRestrictedStockUnitsMember_e8a09556-292b-4812-915e-a8c0b56decf3_terseLabel_en-US" xlink:label="lab_mgnx_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options and RSUs</link:label>
    <link:label id="lab_mgnx_StockOptionsAndRestrictedStockUnitsMember_label_en-US" xlink:label="lab_mgnx_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Options And Restricted Stock Units [Member]</link:label>
    <link:label id="lab_mgnx_StockOptionsAndRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_mgnx_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Options And Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockOptionsAndRestrictedStockUnitsMember" xlink:href="mgnx-20241231.xsd#mgnx_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockOptionsAndRestrictedStockUnitsMember" xlink:to="lab_mgnx_StockOptionsAndRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_bd1180d2-72ec-47b8-8dc3-07a960bce8a7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_89eb8cce-6b9e-4e5d-8cb7-1535c5ee9147_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_ad635248-6a2b-40ed-9662-c1684669a985_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_32953b51-f9d3-469d-a04c-f6dd2d5f9d5f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_OptionToBuy_0a891e3f-e5d0-439a-b3d1-a7162d43404d_terseLabel_en-US" xlink:label="lab_mgnx_OptionToBuy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option to buy</link:label>
    <link:label id="lab_mgnx_OptionToBuy_label_en-US" xlink:label="lab_mgnx_OptionToBuy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option to buy</link:label>
    <link:label id="lab_mgnx_OptionToBuy_documentation_en-US" xlink:label="lab_mgnx_OptionToBuy" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option to buy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OptionToBuy" xlink:href="mgnx-20241231.xsd#mgnx_OptionToBuy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OptionToBuy" xlink:to="lab_mgnx_OptionToBuy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_ff0660c5-e0c0-4a3b-a7c2-628fb537ccb8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_77ca61a1-a4dc-4bb5-8f40-4fd423bcdead_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_2a176929-7458-4734-abb4-cd758d8ad425_verboseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_3a23d60a-a7dd-4096-b48c-05d45577cc20_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_77e719a5-f788-4222-b506-4bda31fad9f2_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenditures</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Prepaid Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_da3b3b37-27e0-44ab-9edc-cd43dda567a6_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_2d230eba-99d8-4945-921a-8da45739d8fa_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_ebc5e154-9cb2-4c01-8c52-a7bc77ebca5f_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases for current year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_09ea493b-70e0-4d07-ae92-0a4f245d81bc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_907087a3-edf7-4d54-910f-2d0cf1b11d4d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_c525dc81-618b-409b-b7d6-583ef1ad3e49_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Undesignated preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_cb89f1f2-5ce9-46f9-902b-5cfa583ef9ba_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net of offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_116dfb20-2bec-4442-8b03-704366ac04a8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_cf25dbfe-9ec3-4602-8721-566e5e0a0710_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_adffaa73-a878-488a-9c7c-2c3ddc14002b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Accelerated Cost</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Accelerated Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_5cab08ef-b4ff-43c6-990e-a7da0500c55a_terseLabel_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock plan related activity (in shares)</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_label_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Shares Stock Plan Activity</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_documentation_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares issued due to stock plan related activity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:href="mgnx-20241231.xsd#mgnx_StockIssuedDuringPeriodSharesStockPlanActivity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:to="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_af81a641-3fab-40d9-8092-5f8ba70a02a3_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_cfb1cf45-ed1a-4c84-8830-fb0fe90a86a5_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting, Other Segment Item, Amount</link:label>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_label_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Other Segment Item, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:to="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_ad4deebd-d489-4f6e-9c7c-0bf680824f17_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ea9805d9-76a0-424a-af8c-b94ac181d917_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_d619ad93-4460-40a0-9f09-7a2aa4f54765_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_c77d8164-523b-4faa-b0d4-5bef178bc135_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ScheduleOfShareBasedPaymentAwardModifiedAwardsValuationAssumptionsTableTextBlock_6f686618-04d0-475b-8704-bf872787fe0b_terseLabel_en-US" xlink:label="lab_mgnx_ScheduleOfShareBasedPaymentAwardModifiedAwardsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Modified Awards, Valuation Assumptions</link:label>
    <link:label id="lab_mgnx_ScheduleOfShareBasedPaymentAwardModifiedAwardsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_mgnx_ScheduleOfShareBasedPaymentAwardModifiedAwardsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Modified Awards, Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_mgnx_ScheduleOfShareBasedPaymentAwardModifiedAwardsValuationAssumptionsTableTextBlock_documentation_en-US" xlink:label="lab_mgnx_ScheduleOfShareBasedPaymentAwardModifiedAwardsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions for Dr. Scott Koening</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ScheduleOfShareBasedPaymentAwardModifiedAwardsValuationAssumptionsTableTextBlock" xlink:href="mgnx-20241231.xsd#mgnx_ScheduleOfShareBasedPaymentAwardModifiedAwardsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ScheduleOfShareBasedPaymentAwardModifiedAwardsValuationAssumptionsTableTextBlock" xlink:to="lab_mgnx_ScheduleOfShareBasedPaymentAwardModifiedAwardsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_d71620b2-b18f-46ef-90e3-01338af8ff88_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Undesignated preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_2ecc6ae5-6fbe-42a2-97b8-6fe306d59b31_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_AssetPurchaseAgreementMember_e857258a-449c-42a8-931d-3139b2fef954_terseLabel_en-US" xlink:label="lab_mgnx_AssetPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Purchase Agreement</link:label>
    <link:label id="lab_mgnx_AssetPurchaseAgreementMember_label_en-US" xlink:label="lab_mgnx_AssetPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Purchase Agreement [Member]</link:label>
    <link:label id="lab_mgnx_AssetPurchaseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_AssetPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset Acquisition Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AssetPurchaseAgreementMember" xlink:href="mgnx-20241231.xsd#mgnx_AssetPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AssetPurchaseAgreementMember" xlink:to="lab_mgnx_AssetPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_231459b9-6c3d-4438-8ee0-a2d8e9266da6_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_4754dc5a-df57-4e9b-b19d-b032a7b53afb_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_JamesKarrelsMember_label_en-US" xlink:label="lab_mgnx_JamesKarrelsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">James Karrels [Member]</link:label>
    <link:label id="lab_mgnx_JamesKarrelsMember_documentation_en-US" xlink:label="lab_mgnx_JamesKarrelsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">James Karrels</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JamesKarrelsMember" xlink:href="mgnx-20241231.xsd#mgnx_JamesKarrelsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_JamesKarrelsMember" xlink:to="lab_mgnx_JamesKarrelsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TextBlockAbstract_abecd209-0c5a-4a48-bf0a-ec028fe173f6_terseLabel_en-US" xlink:label="lab_us-gaap_TextBlockAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Text Block [Abstract]</link:label>
    <link:label id="lab_us-gaap_TextBlockAbstract_label_en-US" xlink:label="lab_us-gaap_TextBlockAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Text Block [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TextBlockAbstract" xlink:to="lab_us-gaap_TextBlockAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c563ee2a-ad2e-4f0b-a298-b63e52896068_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_e01689cd-38b5-4975-bf80-0aca59324ec2_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_c746e4eb-2547-44c5-804b-0c44471beb1e_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_63701070-c658-4195-96f2-3635da20337a_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NextGenerationTCellEngagersMember_284c537d-e93c-48f5-b5bd-63ec0cce1e9e_terseLabel_en-US" xlink:label="lab_mgnx_NextGenerationTCellEngagersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Next-generation T-cell engagers</link:label>
    <link:label id="lab_mgnx_NextGenerationTCellEngagersMember_label_en-US" xlink:label="lab_mgnx_NextGenerationTCellEngagersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Next-generation T-cell engagers [Member]</link:label>
    <link:label id="lab_mgnx_NextGenerationTCellEngagersMember_documentation_en-US" xlink:label="lab_mgnx_NextGenerationTCellEngagersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Next-generation T-cell engagers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NextGenerationTCellEngagersMember" xlink:href="mgnx-20241231.xsd#mgnx_NextGenerationTCellEngagersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NextGenerationTCellEngagersMember" xlink:to="lab_mgnx_NextGenerationTCellEngagersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_Section174DeferredTaxAsset_75efb7bd-579c-4fec-ae8a-2e29d613eac8_terseLabel_en-US" xlink:label="lab_mgnx_Section174DeferredTaxAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Section 174 deferred tax asset</link:label>
    <link:label id="lab_mgnx_Section174DeferredTaxAsset_label_en-US" xlink:label="lab_mgnx_Section174DeferredTaxAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Section 174 deferred tax asset</link:label>
    <link:label id="lab_mgnx_Section174DeferredTaxAsset_documentation_en-US" xlink:label="lab_mgnx_Section174DeferredTaxAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Section 174 deferred tax asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_Section174DeferredTaxAsset" xlink:href="mgnx-20241231.xsd#mgnx_Section174DeferredTaxAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_Section174DeferredTaxAsset" xlink:to="lab_mgnx_Section174DeferredTaxAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_207d4ac5-ac08-4054-a4c7-4c532f2d13e7_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_GileadMember_bcc4a72e-11cc-4045-bc2b-eee76e9e4420_terseLabel_en-US" xlink:label="lab_mgnx_GileadMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gilead</link:label>
    <link:label id="lab_mgnx_GileadMember_label_en-US" xlink:label="lab_mgnx_GileadMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gilead [Member]</link:label>
    <link:label id="lab_mgnx_GileadMember_documentation_en-US" xlink:label="lab_mgnx_GileadMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gilead</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GileadMember" xlink:href="mgnx-20241231.xsd#mgnx_GileadMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_GileadMember" xlink:to="lab_mgnx_GileadMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesFromCMOAmendmentAgreementMember_fed9cbd5-afe8-4ef8-a0ee-7dcca59887a0_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesFromCMOAmendmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RevenuesFromCMOAmendmentAgreement</link:label>
    <link:label id="lab_mgnx_RevenuesFromCMOAmendmentAgreementMember_label_en-US" xlink:label="lab_mgnx_RevenuesFromCMOAmendmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RevenuesFromCMOAmendmentAgreement [Member]</link:label>
    <link:label id="lab_mgnx_RevenuesFromCMOAmendmentAgreementMember_documentation_en-US" xlink:label="lab_mgnx_RevenuesFromCMOAmendmentAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">RevenuesFromCMOAmendmentAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromCMOAmendmentAgreementMember" xlink:href="mgnx-20241231.xsd#mgnx_RevenuesFromCMOAmendmentAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesFromCMOAmendmentAgreementMember" xlink:to="lab_mgnx_RevenuesFromCMOAmendmentAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_76de89e6-d45e-4e84-8ee7-5868cd4d1261_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_3eda496a-fdf1-4315-9b84-7795b89174dc_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_55fad17a-b49f-4e2b-a247-780393490ae1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_11b8f510-dec8-4642-8835-0d0f8a77a954_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_98ecf75e-acb6-404d-a8e7-dbb04414c681_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_7fa8eb2a-fb0d-4195-9a14-be351422de66_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_b4811dc7-d24e-4aca-970e-6444822d14a8_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_a50c2cdf-d48e-4738-8027-12eeef0eb73d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_476b755e-9780-4c34-8576-ebf4faf8ef65_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_50a4965c-d000-4706-a073-865ffa133d64_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_ce99898f-53c9-4cc4-8942-9b92aef26ab9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_bb89df64-e6db-41a7-be5c-5d6dcaa58c2d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets for Identical Assets, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_c037df71-62b5-4360-b6b2-ccaaccfde650_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_43f45d5f-4479-40d0-95ff-acc97169df4d_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash operating and investing activities</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_c6dcbc81-9fb8-4544-a102-7658604eee71_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_709e387f-1b0f-47ca-84c2-06aebdc1b8ec_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_f714104c-75a5-4b46-9c3e-dfa4777891e0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_da7de9c8-8fde-4e41-ab3a-b75bcb1d8e92_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_56764922-32b1-4213-b266-341275b4ae98_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average grant-date fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_37d3a3b5-be48-4771-bccd-d0786e8a23f8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_LorigerlimabMember_2cd1f0d0-e879-4eb3-b533-76394a2d6ae2_terseLabel_en-US" xlink:label="lab_mgnx_LorigerlimabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lorigerlimab</link:label>
    <link:label id="lab_mgnx_LorigerlimabMember_label_en-US" xlink:label="lab_mgnx_LorigerlimabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lorigerlimab [Member]</link:label>
    <link:label id="lab_mgnx_LorigerlimabMember_documentation_en-US" xlink:label="lab_mgnx_LorigerlimabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lorigerlimab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LorigerlimabMember" xlink:href="mgnx-20241231.xsd#mgnx_LorigerlimabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_LorigerlimabMember" xlink:to="lab_mgnx_LorigerlimabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_StockIncentivePlan2023MemberMember_0f4e2430-8e55-4e7d-b9e5-021c9871283d_terseLabel_en-US" xlink:label="lab_mgnx_StockIncentivePlan2023MemberMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">StockIncentivePlan2023Member</link:label>
    <link:label id="lab_mgnx_StockIncentivePlan2023MemberMember_label_en-US" xlink:label="lab_mgnx_StockIncentivePlan2023MemberMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">StockIncentivePlan2023Member [Member]</link:label>
    <link:label id="lab_mgnx_StockIncentivePlan2023MemberMember_documentation_en-US" xlink:label="lab_mgnx_StockIncentivePlan2023MemberMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">StockIncentivePlan2023Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2023MemberMember" xlink:href="mgnx-20241231.xsd#mgnx_StockIncentivePlan2023MemberMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIncentivePlan2023MemberMember" xlink:to="lab_mgnx_StockIncentivePlan2023MemberMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_4c51e0bb-ab69-4943-aa16-21e09b18bd9c_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_3515dbe9-2ad6-4f25-928e-f030bbd4534e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_AdditionalTZIELDMilestones_ec34f80e-87e2-40fd-adef-3fe4c0561f0a_terseLabel_en-US" xlink:label="lab_mgnx_AdditionalTZIELDMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional TZIELD Milestones</link:label>
    <link:label id="lab_mgnx_AdditionalTZIELDMilestones_label_en-US" xlink:label="lab_mgnx_AdditionalTZIELDMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional TZIELD Milestones</link:label>
    <link:label id="lab_mgnx_AdditionalTZIELDMilestones_documentation_en-US" xlink:label="lab_mgnx_AdditionalTZIELDMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional TZIELD Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AdditionalTZIELDMilestones" xlink:href="mgnx-20241231.xsd#mgnx_AdditionalTZIELDMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AdditionalTZIELDMilestones" xlink:to="lab_mgnx_AdditionalTZIELDMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_998b39cd-1f22-45b2-9dde-51143673659d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ValuationAllowanceDeferredTaxAssetIncreaseAmount_05217f7a-20c2-4e7e-bd04-61bf2639d0d0_terseLabel_en-US" xlink:label="lab_mgnx_ValuationAllowanceDeferredTaxAssetIncreaseAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_mgnx_ValuationAllowanceDeferredTaxAssetIncreaseAmount_label_en-US" xlink:label="lab_mgnx_ValuationAllowanceDeferredTaxAssetIncreaseAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase, Amount</link:label>
    <link:label id="lab_mgnx_ValuationAllowanceDeferredTaxAssetIncreaseAmount_documentation_en-US" xlink:label="lab_mgnx_ValuationAllowanceDeferredTaxAssetIncreaseAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ValuationAllowanceDeferredTaxAssetIncreaseAmount" xlink:href="mgnx-20241231.xsd#mgnx_ValuationAllowanceDeferredTaxAssetIncreaseAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ValuationAllowanceDeferredTaxAssetIncreaseAmount" xlink:to="lab_mgnx_ValuationAllowanceDeferredTaxAssetIncreaseAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_e9668b6a-71eb-4c36-8f64-8eee492555ce_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_68271fc6-5aab-4906-a226-afd01ae93c8f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_82a71426-a686-4956-a94f-72e6766bd66d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_04ba69be-e9f9-4236-845e-7b8136b95921_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_2d79df9e-e753-42c8-9187-c2d5728e5c43_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_b7cb1438-cd9f-4741-9c83-b8efa25f3177_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_d3143c06-f436-4b77-a833-ed705932e756_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_41768c29-8def-4e10-b86c-c819093ce17f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_JeffreyPetersMember_label_en-US" xlink:label="lab_mgnx_JeffreyPetersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Jeffrey Peters [Member]</link:label>
    <link:label id="lab_mgnx_JeffreyPetersMember_documentation_en-US" xlink:label="lab_mgnx_JeffreyPetersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Jeffrey Peters</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JeffreyPetersMember" xlink:href="mgnx-20241231.xsd#mgnx_JeffreyPetersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_JeffreyPetersMember" xlink:to="lab_mgnx_JeffreyPetersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_a089c09e-2447-437e-92c7-a8ef6f63696c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent" xlink:to="lab_us-gaap_DeferredRevenueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_5586d86c-d681-4a73-9352-b60649463b1e_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOther_da3fa1c3-3612-41f4-9d72-1f8637727190_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Income, Other</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOther_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther" xlink:to="lab_us-gaap_InterestIncomeOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_9fa55165-aad9-46b7-8550-a17e088e9c4a_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NumberOfProductCandidatesApprovedByTheFoodAndDrugAdministration_c991f70f-d5cb-4788-8e5b-ec260603c4d6_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfProductCandidatesApprovedByTheFoodAndDrugAdministration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of product candidates approved by the FDA</link:label>
    <link:label id="lab_mgnx_NumberOfProductCandidatesApprovedByTheFoodAndDrugAdministration_label_en-US" xlink:label="lab_mgnx_NumberOfProductCandidatesApprovedByTheFoodAndDrugAdministration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Product Candidates Approved By The Food And Drug Administration</link:label>
    <link:label id="lab_mgnx_NumberOfProductCandidatesApprovedByTheFoodAndDrugAdministration_documentation_en-US" xlink:label="lab_mgnx_NumberOfProductCandidatesApprovedByTheFoodAndDrugAdministration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Product Candidates Approved By The Food And Drug Administration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfProductCandidatesApprovedByTheFoodAndDrugAdministration" xlink:href="mgnx-20241231.xsd#mgnx_NumberOfProductCandidatesApprovedByTheFoodAndDrugAdministration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfProductCandidatesApprovedByTheFoodAndDrugAdministration" xlink:to="lab_mgnx_NumberOfProductCandidatesApprovedByTheFoodAndDrugAdministration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_171cc379-33ae-4913-86ec-8b294243ca5e_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_9eb89850-5390-4801-b238-691d3968546d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_0403de1c-8b02-48ee-8624-6059b5f2d50f_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_3a63378c-cfa6-481d-814d-243fe54c9692_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:to="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_0ea6d420-0433-46c3-952f-0bdec3119d01_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_UpfrontPayment_9768974b-e884-4607-ba4d-626e4aea9856_terseLabel_en-US" xlink:label="lab_mgnx_UpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment from DRI Health Trust</link:label>
    <link:label id="lab_mgnx_UpfrontPayment_label_en-US" xlink:label="lab_mgnx_UpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront Payment</link:label>
    <link:label id="lab_mgnx_UpfrontPayment_documentation_en-US" xlink:label="lab_mgnx_UpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UpfrontPayment" xlink:href="mgnx-20241231.xsd#mgnx_UpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_UpfrontPayment" xlink:to="lab_mgnx_UpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_3314c4d4-4dde-4848-9ce9-d707dc0a351c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TeSera Transaction</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_4f6e0a8a-aea5-480c-95e4-e42a29c462c1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f2fd56b1-1475-43cf-94ff-f1a3d499d586_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VehiclesMember_9055a29e-62f7-42fb-823c-2673e43e8cd4_terseLabel_en-US" xlink:label="lab_us-gaap_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Motor vehicles</link:label>
    <link:label id="lab_us-gaap_VehiclesMember_label_en-US" xlink:label="lab_us-gaap_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vehicles [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VehiclesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VehiclesMember" xlink:to="lab_us-gaap_VehiclesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_45e86239-abb6-4038-8896-d4f9190ef4bb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs, Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fca06fbb-6e0e-499f-af9c-bd0c9d0d4623_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0417ca47-1df2-4910-a37e-95e6bb2efcc4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_23790dab-377c-4fc3-b6da-f23de50bd6e0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_963df960-f142-434d-84e1-5378655c6cbe_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_e2f08cf6-7f5e-4a6c-9a10-66f43299e719_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b2470c1e-1d41-4a0c-8004-311cb2bd7b6a_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_32883682-f40b-4231-b4a8-bb2369f76d1c_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_9ad03512-8b3f-4c23-af57-d62a5d6eb163_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_8fa7bc78-b219-4fbf-a09f-62a9dc162f85_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, 0.01 par value -- 125,000,000 shares authorized, 62,819,857 and 62,070,627 shares outstanding at December&#160;31, 2024 and December&#160;31, 2023, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_914c4ab7-f5c1-4e05-8198-dcc03ed282c4_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c215877a-9b54-4458-831a-24fb3d47cddd_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_fc2d9f01-b3c0-4376-8a3e-fa5439773a15_terseLabel_en-US" xlink:label="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum employee contribution percent</link:label>
    <link:label id="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:label id="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_documentation_en-US" xlink:label="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="mgnx-20241231.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_a025eedb-2134-4819-847a-8ef67a7a77f4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2f180500-d8f7-4859-95aa-7b5e058fdc22_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_66e06324-140e-4228-9555-62a71ca6a69d_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_4177782d-33f0-444f-95ec-ef8b6084abfa_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_87772324-75a8-4baf-b21a-18c834a4c077_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited or expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_8be85b18-dff1-4667-b33e-86a4a33d2118_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_ce198cfc-1f07-4717-b0c1-bade68f9b6a8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State taxes (net of federal benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_93c81864-47d2-4199-a441-85a79c15b6bb_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_ff6d01b3-7828-4593-8726-2f1c0f8fc9d9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d9752383-561b-4bc5-a54a-504ea649a975_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_d169741f-e2f6-45db-831d-7576c9059385_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Gross deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_55d1bb61-c13c-4ffc-a555-f1486d39bc9d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_1bfa846c-cb78-47c0-921c-8c3efddd25e2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per common share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_a22c3d28-c32a-4c2d-ab83-5e6bb831e979_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_f73b42fe-aaee-4902-bfac-30a950f73a08_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_ecdba5db-bdbe-4719-a044-6e9efa5478f2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b18489be-8c08-4a0e-91d5-da77cb31e7f3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options granted, maximum term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_38caa885-dac1-4bff-bccf-80dcf1b73e9f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_6c22d86b-319d-411c-93a5-c937a5fd546a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal U.S. net operating loss carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_bff701e9-8ea6-4f07-adf5-b22554d068ff_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_94563bdd-ba10-41b2-8efb-36ebba0fed51_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Equipment and Software</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_e6c8aca7-04df-49c7-a841-26636898bddb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_c0e73646-093b-4c6b-9886-57fb578ec381_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_923ccfc6-6b98-451b-814d-09e20c8534f8_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_237b9867-ab83-4cd4-accf-8510a59fb755_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_1f65ad72-45c2-439c-b975-912124af6735_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of product sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_84b0bd17-76f9-4975-86cb-0ff39eccf479_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6d44cba1-8e15-4df5-8a0b-a0ab6b39a17b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards granted in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a2aebdb4-d1e4-4e48-b9bd-b970cd76f9ce_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, equipment and software</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_0bca464f-a733-458d-8874-98331842c1d7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract_fc33c528-c2ca-4286-b466-11b862afd04b_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionPRV031Member_8f1955b8-e84a-4cea-8478-771ca8e335cd_terseLabel_en-US" xlink:label="lab_mgnx_ProventionPRV031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provention PRV031</link:label>
    <link:label id="lab_mgnx_ProventionPRV031Member_label_en-US" xlink:label="lab_mgnx_ProventionPRV031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provention PRV031 [Member]</link:label>
    <link:label id="lab_mgnx_ProventionPRV031Member_documentation_en-US" xlink:label="lab_mgnx_ProventionPRV031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Provention PRV031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV031Member" xlink:href="mgnx-20241231.xsd#mgnx_ProventionPRV031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionPRV031Member" xlink:to="lab_mgnx_ProventionPRV031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_SideLetterAgreementMember_30a76a2a-293e-4530-b699-3e3b2b4cc17c_terseLabel_en-US" xlink:label="lab_mgnx_SideLetterAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Side Letter Agreement</link:label>
    <link:label id="lab_mgnx_SideLetterAgreementMember_label_en-US" xlink:label="lab_mgnx_SideLetterAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Side Letter Agreement [Member]</link:label>
    <link:label id="lab_mgnx_SideLetterAgreementMember_documentation_en-US" xlink:label="lab_mgnx_SideLetterAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Side Letter Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_SideLetterAgreementMember" xlink:href="mgnx-20241231.xsd#mgnx_SideLetterAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_SideLetterAgreementMember" xlink:to="lab_mgnx_SideLetterAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_8aba2618-066a-4861-9435-34bca8ec1c8d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Reported Estimated Income Tax Benefit</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3ff98528-96e4-484f-92d7-d6bf0ab2449b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive gain (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_FutureManufacturingRevenue_9f52cf6f-1427-4028-ac8a-8895bc545b55_terseLabel_en-US" xlink:label="lab_mgnx_FutureManufacturingRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future Manufacturing Revenue</link:label>
    <link:label id="lab_mgnx_FutureManufacturingRevenue_label_en-US" xlink:label="lab_mgnx_FutureManufacturingRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Manufacturing Revenue</link:label>
    <link:label id="lab_mgnx_FutureManufacturingRevenue_documentation_en-US" xlink:label="lab_mgnx_FutureManufacturingRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future Manufacturing Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FutureManufacturingRevenue" xlink:href="mgnx-20241231.xsd#mgnx_FutureManufacturingRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_FutureManufacturingRevenue" xlink:to="lab_mgnx_FutureManufacturingRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a78873ed-2957-4d1d-8a5d-6f99eaa6cf96_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_636f2fa1-979d-48ed-b6f8-e7575c613c3d_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_580f3a68-46ab-4cc5-9dfd-1fe7970ab499_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_95a2f5dc-3a23-4308-8b9c-0f75f197bd88_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TaxYear2027To2028Member_80bf0290-48a0-43b2-9291-807bcb81f67d_terseLabel_en-US" xlink:label="lab_mgnx_TaxYear2027To2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Year 2025 To 2037</link:label>
    <link:label id="lab_mgnx_TaxYear2027To2028Member_label_en-US" xlink:label="lab_mgnx_TaxYear2027To2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Year 2027 To 2028 [Member]</link:label>
    <link:label id="lab_mgnx_TaxYear2027To2028Member_documentation_en-US" xlink:label="lab_mgnx_TaxYear2027To2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Year 2027 To 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TaxYear2027To2028Member" xlink:href="mgnx-20241231.xsd#mgnx_TaxYear2027To2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TaxYear2027To2028Member" xlink:to="lab_mgnx_TaxYear2027To2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_0025bf7d-c3d5-45de-856d-7f2e50c1f870_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_4e852ed3-fd41-431f-a03e-f54abc57580a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_44aafe1e-791d-42e8-ac8a-e6f0e31d16a6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserveMember_6c1b58dc-4137-49d2-b539-f5bdf405f7d1_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Reserve, Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserveMember_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Reserve, Inventory [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserveMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserveMember" xlink:to="lab_us-gaap_InventoryValuationReserveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1ed993d8-ccca-4f2e-b8ac-02557d4e3356_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_c564d0a7-c8aa-477d-ba78-d105b7c08850_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_951ad64e-4569-412f-901a-2619fe9dfdaa_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_57176877-26ed-4759-bcaa-0ba6850b8d21_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_744abd69-d053-41a3-b0a5-354956976d1f_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_FurnitureAndOfficeEquipmentMember_5c68846b-16ca-4fc8-8058-11b3a4ba714e_terseLabel_en-US" xlink:label="lab_mgnx_FurnitureAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and office equipment</link:label>
    <link:label id="lab_mgnx_FurnitureAndOfficeEquipmentMember_label_en-US" xlink:label="lab_mgnx_FurnitureAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture And Office Equipment [Member]</link:label>
    <link:label id="lab_mgnx_FurnitureAndOfficeEquipmentMember_documentation_en-US" xlink:label="lab_mgnx_FurnitureAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Furniture and office equipment are movable furniture, fixtures, or other equipment that have no permanent connection to the structure of a building or utilities. These items depreciate substantially but definitely are important costs to consider when valuing a company, especially in liquidation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FurnitureAndOfficeEquipmentMember" xlink:href="mgnx-20241231.xsd#mgnx_FurnitureAndOfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_FurnitureAndOfficeEquipmentMember" xlink:to="lab_mgnx_FurnitureAndOfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_ace941dc-b2ea-43ab-8e82-2eba7ae131cc_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized interest or penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a60e322c-4841-48a8-87d6-543b9b8b9719_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_b058484d-8f29-44b8-9fff-6cd6c6b219c5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined contribution plan, employer discretionary contribution amount</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_02e35dd4-fe0e-4ca8-b346-b3950e0106ba_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_d7ce94be-64be-4caf-8ca3-2a06b5de1818_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_e3442244-8e21-4c98-977c-b39552f8b517_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_MGC028Member_b735bc27-ce29-46bc-ab87-7ee23fcdb292_terseLabel_en-US" xlink:label="lab_mgnx_MGC028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MGC028</link:label>
    <link:label id="lab_mgnx_MGC028Member_label_en-US" xlink:label="lab_mgnx_MGC028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MGC028 [Member]</link:label>
    <link:label id="lab_mgnx_MGC028Member_documentation_en-US" xlink:label="lab_mgnx_MGC028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MGC028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_MGC028Member" xlink:href="mgnx-20241231.xsd#mgnx_MGC028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_MGC028Member" xlink:to="lab_mgnx_MGC028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_403983ac-40a6-42fc-a55a-e3c9fc6574e2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_1a99c365-b81c-447b-a447-aacd047dd856_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabMember_413d0987-056c-4db5-b92c-93efd478bbc2_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Zai Lab</link:label>
    <link:label id="lab_mgnx_ZaiLabMember_label_en-US" xlink:label="lab_mgnx_ZaiLabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Zai Lab [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Zai Lab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember" xlink:href="mgnx-20241231.xsd#mgnx_ZaiLabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabMember" xlink:to="lab_mgnx_ZaiLabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_b4c459d5-c0ba-497e-8027-34dece8a5ff5_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_61e4a225-cb4b-4a6a-82e8-4475add2ed24_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_64d33c94-e094-4c46-9ba5-fd98920db3aa_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_083a3b0d-1cd3-4b3f-9677-ace53fb7bb10_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_e84febca-f711-4a85-94bc-79a725ed4b24_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_c6d95044-fa8e-48ee-b933-4a90e8982f80_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_319fefb1-64da-497f-ae46-9a07350c725d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory valuation reserves</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesFromLicenseAgreementsMember_9eaaa791-c3f1-4241-8c30-37b44dfab7df_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues From License Agreements</link:label>
    <link:label id="lab_mgnx_RevenuesFromLicenseAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues From License Agreements [Member]</link:label>
    <link:label id="lab_mgnx_RevenuesFromLicenseAgreementsMember_documentation_en-US" xlink:label="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues From License Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember" xlink:href="mgnx-20241231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesFromLicenseAgreementsMember" xlink:to="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_681ee3b0-666b-4a7d-a3b3-60260975472a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other non-cash items</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ca2b30c5-4698-4e16-bd16-3cae2cbab75e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_ddda083a-f7dd-4e5f-8cf1-8fb989f283c6_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5b4d4a95-fdec-400d-84c0-dfe01fca3e71_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding nonvested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_006e6926-25a9-4849-8ed9-ffc2797c7eb8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4ae5a832-c0c8-4ee6-840a-42ae47ae1708_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_983446cc-f65d-4ba7-beff-189279eac66b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_16e2b596-e36c-4792-9dd9-77220be81689_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionLicenseAgreementMember_8b1b73f6-6322-48df-8788-8dc7af0f479f_terseLabel_en-US" xlink:label="lab_mgnx_ProventionLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provention License Agreement</link:label>
    <link:label id="lab_mgnx_ProventionLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_ProventionLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provention License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_ProventionLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_ProventionLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Provention License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionLicenseAgreementMember" xlink:href="mgnx-20241231.xsd#mgnx_ProventionLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionLicenseAgreementMember" xlink:to="lab_mgnx_ProventionLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NumberOfPerformanceObligations_81704681-2559-4433-95c5-0b7ef4662fa5_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of performance obligations</link:label>
    <link:label id="lab_mgnx_NumberOfPerformanceObligations_label_en-US" xlink:label="lab_mgnx_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Performance Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations" xlink:href="mgnx-20241231.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfPerformanceObligations" xlink:to="lab_mgnx_NumberOfPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_da834f04-4855-452c-99b5-f3835e858291_terseLabel_en-US" xlink:label="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical trial activities selling price amount</link:label>
    <link:label id="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_label_en-US" xlink:label="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</link:label>
    <link:label id="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_documentation_en-US" xlink:label="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:href="mgnx-20241231.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:to="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_85616fe7-2419-45d6-a1a7-c5e6a2915fb2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NumberOfProprietaryProductCandidatesAdvancingInClinicalDevelopment_51d013fe-b93e-4640-9cf2-d7c41747f815_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfProprietaryProductCandidatesAdvancingInClinicalDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of proprietary product candidates advancing in clinical development</link:label>
    <link:label id="lab_mgnx_NumberOfProprietaryProductCandidatesAdvancingInClinicalDevelopment_label_en-US" xlink:label="lab_mgnx_NumberOfProprietaryProductCandidatesAdvancingInClinicalDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Proprietary Product Candidates Advancing In Clinical Development</link:label>
    <link:label id="lab_mgnx_NumberOfProprietaryProductCandidatesAdvancingInClinicalDevelopment_documentation_en-US" xlink:label="lab_mgnx_NumberOfProprietaryProductCandidatesAdvancingInClinicalDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Proprietary Product Candidates Advancing In Clinical Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfProprietaryProductCandidatesAdvancingInClinicalDevelopment" xlink:href="mgnx-20241231.xsd#mgnx_NumberOfProprietaryProductCandidatesAdvancingInClinicalDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfProprietaryProductCandidatesAdvancingInClinicalDevelopment" xlink:to="lab_mgnx_NumberOfProprietaryProductCandidatesAdvancingInClinicalDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_3b2c472c-5c5b-4005-82da-153f4ed3a9fb_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_c7d2ec62-77a6-4e88-9aaf-ef2243d7cfdf_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_301c93ec-ed72-4b3d-9300-f42781316d2b_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ScheduleOfInventoryReservesTableTextBlock_f5987dbb-c057-4eb0-b051-52e5aebaa0f3_terseLabel_en-US" xlink:label="lab_mgnx_ScheduleOfInventoryReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Inventory Reserves</link:label>
    <link:label id="lab_mgnx_ScheduleOfInventoryReservesTableTextBlock_label_en-US" xlink:label="lab_mgnx_ScheduleOfInventoryReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory Reserves [Table Text Block]</link:label>
    <link:label id="lab_mgnx_ScheduleOfInventoryReservesTableTextBlock_documentation_en-US" xlink:label="lab_mgnx_ScheduleOfInventoryReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Inventory Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ScheduleOfInventoryReservesTableTextBlock" xlink:href="mgnx-20241231.xsd#mgnx_ScheduleOfInventoryReservesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ScheduleOfInventoryReservesTableTextBlock" xlink:to="lab_mgnx_ScheduleOfInventoryReservesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_4dc02cb1-a67c-4340-b834-9a56c4efc40d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ValuationAllowanceRollForward_3951dea2-b78b-44a1-a079-b625e4739046_terseLabel_en-US" xlink:label="lab_mgnx_ValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowance [Roll Forward]</link:label>
    <link:label id="lab_mgnx_ValuationAllowanceRollForward_label_en-US" xlink:label="lab_mgnx_ValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance [Roll Forward]</link:label>
    <link:label id="lab_mgnx_ValuationAllowanceRollForward_documentation_en-US" xlink:label="lab_mgnx_ValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ValuationAllowanceRollForward" xlink:href="mgnx-20241231.xsd#mgnx_ValuationAllowanceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ValuationAllowanceRollForward" xlink:to="lab_mgnx_ValuationAllowanceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_471068fa-3fc9-4943-8f3c-e4f993bfda75_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f86af5d5-4a1a-4bc7-bd51-241ba04bfee6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_483c8884-b47d-467d-b75c-69957cb97e36_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_5cb732d4-899e-4f7f-b34f-cb765353e561_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_MGC026Member_891f395c-4e38-4707-946b-667e92973856_terseLabel_en-US" xlink:label="lab_mgnx_MGC026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MGC026</link:label>
    <link:label id="lab_mgnx_MGC026Member_label_en-US" xlink:label="lab_mgnx_MGC026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MGC026 [Member]</link:label>
    <link:label id="lab_mgnx_MGC026Member_documentation_en-US" xlink:label="lab_mgnx_MGC026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MGC026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_MGC026Member" xlink:href="mgnx-20241231.xsd#mgnx_MGC026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_MGC026Member" xlink:to="lab_mgnx_MGC026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1324433d-38c8-49f5-b0af-569d9faa43d6_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic weighted average number of common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionBioMember_6fa87eef-199a-4d31-9bf6-3fc97389e2f5_terseLabel_en-US" xlink:label="lab_mgnx_ProventionBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provention Bio, Inc. (Provention)</link:label>
    <link:label id="lab_mgnx_ProventionBioMember_label_en-US" xlink:label="lab_mgnx_ProventionBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provention Bio [Member]</link:label>
    <link:label id="lab_mgnx_ProventionBioMember_documentation_en-US" xlink:label="lab_mgnx_ProventionBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Provention Bio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioMember" xlink:href="mgnx-20241231.xsd#mgnx_ProventionBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionBioMember" xlink:to="lab_mgnx_ProventionBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_f227362f-ec44-4656-91af-6421b3636013_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_399da9c8-986b-4197-a8b8-a56ff39ce933_terseLabel_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Incentive Plan 2013</link:label>
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_label_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Incentive Plan 2013 [Member]</link:label>
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_documentation_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Incentive Plan 2013 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member" xlink:href="mgnx-20241231.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIncentivePlan2013Member" xlink:to="lab_mgnx_StockIncentivePlan2013Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_16ca5845-0653-4647-94da-90a9f8f6d2de_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales revenue, net</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_88939756-6dc5-4fa3-8c06-333efded04c0_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_2c16300d-642e-484f-8284-dede733d6af3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_8de4a256-0854-4e01-ad48-778cb1a7245f_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_ad0d1e8d-c9e9-4278-8fa8-a40702e9d550_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_c5424061-26eb-4fc7-9cba-cfbe45a599a5_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_9dd22933-0ba8-4e5f-b2ee-98f6e03cfbbd_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of shares vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_7ce5be64-a6e5-48d7-ba27-c08c21346a18_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, remaining performance obligation, amount</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_91bbdac5-0607-4568-8535-b34138af4e28_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_b7edf661-cafb-42d2-a372-ab4a6f479120_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_fea018a3-3274-4439-8673-ee65ef9b5233_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments_4fa9789d-85af-49e0-9f9f-62e2b7116ee7_terseLabel_en-US" xlink:label="lab_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Target nomination, option fees and milestone</link:label>
    <link:label id="lab_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments_label_en-US" xlink:label="lab_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential target nomination, option fees and milestone payments</link:label>
    <link:label id="lab_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments_documentation_en-US" xlink:label="lab_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential target, nomination, option fees and milestone payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments" xlink:href="mgnx-20241231.xsd#mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments" xlink:to="lab_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>mgnx-20241231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:976c6134-a70d-4bed-9067-acb735c066ae,g:6888b12e-4125-48cc-8fc7-0d9038c82cb8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://macrogenics.com/role/CoverPage" xlink:type="simple" xlink:href="mgnx-20241231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_aed85933-4088-4c9f-8bad-7ef5016d79de" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_eff23255-4014-4c54-aabd-4c5056875c58" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aed85933-4088-4c9f-8bad-7ef5016d79de" xlink:to="loc_dei_DocumentType_eff23255-4014-4c54-aabd-4c5056875c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_6302f974-c341-41e1-8c5e-8622a73abb3d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aed85933-4088-4c9f-8bad-7ef5016d79de" xlink:to="loc_dei_DocumentAnnualReport_6302f974-c341-41e1-8c5e-8622a73abb3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_aca7b419-f011-44f6-b873-3e6de93053fa" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aed85933-4088-4c9f-8bad-7ef5016d79de" xlink:to="loc_dei_DocumentPeriodEndDate_aca7b419-f011-44f6-b873-3e6de93053fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_695bad2d-60c7-4fd5-96fc-c1aab15606a4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aed85933-4088-4c9f-8bad-7ef5016d79de" xlink:to="loc_dei_CurrentFiscalYearEndDate_695bad2d-60c7-4fd5-96fc-c1aab15606a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_945ad6e4-a729-4b9a-b09c-802db3b188ab" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aed85933-4088-4c9f-8bad-7ef5016d79de" xlink:to="loc_dei_DocumentTransitionReport_945ad6e4-a729-4b9a-b09c-802db3b188ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_cecd9cdb-ebc6-439a-8845-6f6b0fd9c423" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aed85933-4088-4c9f-8bad-7ef5016d79de" xlink:to="loc_dei_EntityFileNumber_cecd9cdb-ebc6-439a-8845-6f6b0fd9c423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_0b134454-0f0f-4eef-a04a-723bb2b642b2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aed85933-4088-4c9f-8bad-7ef5016d79de" xlink:to="loc_dei_EntityRegistrantName_0b134454-0f0f-4eef-a04a-723bb2b642b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_d4fb0cbb-9ca2-40a1-8382-4178ace4f99a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aed85933-4088-4c9f-8bad-7ef5016d79de" xlink:to="loc_dei_EntityIncorporationStateCountryCode_d4fb0cbb-9ca2-40a1-8382-4178ace4f99a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_0a2f3b2f-9439-469e-a3a9-dfebfe6617bf" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aed85933-4088-4c9f-8bad-7ef5016d79de" xlink:to="loc_dei_EntityTaxIdentificationNumber_0a2f3b2f-9439-469e-a3a9-dfebfe6617bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c29a67d5-41fa-4950-85b6-f7491b6249ec" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aed85933-4088-4c9f-8bad-7ef5016d79de" xlink:to="loc_dei_EntityAddressAddressLine1_c29a67d5-41fa-4950-85b6-f7491b6249ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_a214e7e8-205c-4847-b5a2-c374d11b8f58" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aed85933-4088-4c9f-8bad-7ef5016d79de" xlink:to="loc_dei_EntityAddressCityOrTown_a214e7e8-205c-4847-b5a2-c374d11b8f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_3464ce9d-b268-42f4-8036-18ccbb25c87b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aed85933-4088-4c9f-8bad-7ef5016d79de" xlink:to="loc_dei_EntityAddressStateOrProvince_3464ce9d-b268-42f4-8036-18ccbb25c87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_79ef62de-5159-4f0a-bc22-e442043ed75d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aed85933-4088-4c9f-8bad-7ef5016d79de" xlink:to="loc_dei_EntityAddressPostalZipCode_79ef62de-5159-4f0a-bc22-e442043ed75d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_be6e08b7-b4f9-48c9-b090-f3ef14bc5769" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aed85933-4088-4c9f-8bad-7ef5016d79de" xlink:to="loc_dei_CityAreaCode_be6e08b7-b4f9-48c9-b090-f3ef14bc5769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_9983801f-eb0b-41f8-a41f-4c88b688bb71" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aed85933-4088-4c9f-8bad-7ef5016d79de" xlink:to="loc_dei_LocalPhoneNumber_9983801f-eb0b-41f8-a41f-4c88b688bb71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_b6377814-4d40-4fe2-97ba-a3ec80c66f79" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aed85933-4088-4c9f-8bad-7ef5016d79de" xlink:to="loc_dei_Security12bTitle_b6377814-4d40-4fe2-97ba-a3ec80c66f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ff2a735c-aeab-40ed-af6f-b65c0b9ddc8a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aed85933-4088-4c9f-8bad-7ef5016d79de" xlink:to="loc_dei_TradingSymbol_ff2a735c-aeab-40ed-af6f-b65c0b9ddc8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_d5933acc-cdc9-40ec-a12f-05f28183ffcd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aed85933-4088-4c9f-8bad-7ef5016d79de" xlink:to="loc_dei_SecurityExchangeName_d5933acc-cdc9-40ec-a12f-05f28183ffcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_448e1335-826d-43b2-865d-62cc6dcc5e31" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aed85933-4088-4c9f-8bad-7ef5016d79de" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_448e1335-826d-43b2-865d-62cc6dcc5e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_d3e85387-3e53-4a47-b2f4-cdc5bd5f966d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aed85933-4088-4c9f-8bad-7ef5016d79de" xlink:to="loc_dei_EntityVoluntaryFilers_d3e85387-3e53-4a47-b2f4-cdc5bd5f966d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_0e9b6a57-61c9-4a0d-8812-68b842a5a72d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aed85933-4088-4c9f-8bad-7ef5016d79de" xlink:to="loc_dei_EntityCurrentReportingStatus_0e9b6a57-61c9-4a0d-8812-68b842a5a72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_2a91b661-a19f-437c-9f2a-39fb912b1603" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aed85933-4088-4c9f-8bad-7ef5016d79de" xlink:to="loc_dei_EntityInteractiveDataCurrent_2a91b661-a19f-437c-9f2a-39fb912b1603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_3ca38858-1910-4fab-b711-2322e3cfdbce" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aed85933-4088-4c9f-8bad-7ef5016d79de" xlink:to="loc_dei_EntityFilerCategory_3ca38858-1910-4fab-b711-2322e3cfdbce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_89cdd7e4-8203-4c92-94b9-6b315d736a3b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aed85933-4088-4c9f-8bad-7ef5016d79de" xlink:to="loc_dei_EntitySmallBusiness_89cdd7e4-8203-4c92-94b9-6b315d736a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_0a3a25be-6888-4dd5-a5cf-5be28811b987" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aed85933-4088-4c9f-8bad-7ef5016d79de" xlink:to="loc_dei_EntityEmergingGrowthCompany_0a3a25be-6888-4dd5-a5cf-5be28811b987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_c8d25fb3-837a-4f4f-bd1a-4daec5d409b4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aed85933-4088-4c9f-8bad-7ef5016d79de" xlink:to="loc_dei_IcfrAuditorAttestationFlag_c8d25fb3-837a-4f4f-bd1a-4daec5d409b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_7a32f6d6-c15c-4792-b49f-61ad26e723d2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aed85933-4088-4c9f-8bad-7ef5016d79de" xlink:to="loc_dei_EntityShellCompany_7a32f6d6-c15c-4792-b49f-61ad26e723d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_f8a8bf46-d670-4074-8247-d15e7dbf8d76" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aed85933-4088-4c9f-8bad-7ef5016d79de" xlink:to="loc_dei_EntityPublicFloat_f8a8bf46-d670-4074-8247-d15e7dbf8d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_499f450e-ce8d-4343-9f1d-0c6151876655" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aed85933-4088-4c9f-8bad-7ef5016d79de" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_499f450e-ce8d-4343-9f1d-0c6151876655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_3f854974-f7b4-48f1-943f-ec3f2aca23aa" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aed85933-4088-4c9f-8bad-7ef5016d79de" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_3f854974-f7b4-48f1-943f-ec3f2aca23aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_5308eb04-9fc5-4bc3-8e6f-940085af1dc3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aed85933-4088-4c9f-8bad-7ef5016d79de" xlink:to="loc_dei_AmendmentFlag_5308eb04-9fc5-4bc3-8e6f-940085af1dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_7b666101-4db7-41da-a1f3-04948b826aec" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aed85933-4088-4c9f-8bad-7ef5016d79de" xlink:to="loc_dei_DocumentFiscalYearFocus_7b666101-4db7-41da-a1f3-04948b826aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_423331b5-feed-495f-afa2-35ea62deacd0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aed85933-4088-4c9f-8bad-7ef5016d79de" xlink:to="loc_dei_DocumentFiscalPeriodFocus_423331b5-feed-495f-afa2-35ea62deacd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_612b0e60-36e3-4082-8186-09e6eaa71c4f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aed85933-4088-4c9f-8bad-7ef5016d79de" xlink:to="loc_dei_EntityCentralIndexKey_612b0e60-36e3-4082-8186-09e6eaa71c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_4d9d4143-562a-465c-a0e0-6939ab7b5ffe" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aed85933-4088-4c9f-8bad-7ef5016d79de" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_4d9d4143-562a-465c-a0e0-6939ab7b5ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/AuditInformation" xlink:type="simple" xlink:href="mgnx-20241231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AuditorInformationAbstract_763272bf-6902-4934-b08c-835231ebb6d8" xlink:href="mgnx-20241231.xsd#mgnx_AuditorInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_6d8fcf1d-8587-4588-a741-215f91f06b79" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_AuditorInformationAbstract_763272bf-6902-4934-b08c-835231ebb6d8" xlink:to="loc_dei_AuditorFirmId_6d8fcf1d-8587-4588-a741-215f91f06b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_c7c0c7a7-1594-403d-9091-6e16767098ba" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_AuditorInformationAbstract_763272bf-6902-4934-b08c-835231ebb6d8" xlink:to="loc_dei_AuditorName_c7c0c7a7-1594-403d-9091-6e16767098ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_005a7b20-02ca-443d-99b9-f1822aee08b7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_AuditorInformationAbstract_763272bf-6902-4934-b08c-835231ebb6d8" xlink:to="loc_dei_AuditorLocation_005a7b20-02ca-443d-99b9-f1822aee08b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mgnx-20241231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_07ec769d-0745-4be5-b192-1a56c800261f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_60f9b5c7-bd80-400a-81ad-1c25b2954f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_07ec769d-0745-4be5-b192-1a56c800261f" xlink:to="loc_us-gaap_AssetsAbstract_60f9b5c7-bd80-400a-81ad-1c25b2954f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_dcf165f3-74fc-4893-8cd9-81a4f631dbe8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_60f9b5c7-bd80-400a-81ad-1c25b2954f7c" xlink:to="loc_us-gaap_AssetsCurrentAbstract_dcf165f3-74fc-4893-8cd9-81a4f631dbe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_84a7d6c2-a6a4-41e0-bd48-6950d202e5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_dcf165f3-74fc-4893-8cd9-81a4f631dbe8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_84a7d6c2-a6a4-41e0-bd48-6950d202e5a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_f0932dc8-4244-4f6f-bb19-d388b7a91d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Investments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_dcf165f3-74fc-4893-8cd9-81a4f631dbe8" xlink:to="loc_us-gaap_Investments_f0932dc8-4244-4f6f-bb19-d388b7a91d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_504e9b77-5a01-4dc1-b6a2-1128644ea328" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_dcf165f3-74fc-4893-8cd9-81a4f631dbe8" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_504e9b77-5a01-4dc1-b6a2-1128644ea328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_bdccea94-9525-4e9b-9b07-979be9e1ad0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_dcf165f3-74fc-4893-8cd9-81a4f631dbe8" xlink:to="loc_us-gaap_InventoryNet_bdccea94-9525-4e9b-9b07-979be9e1ad0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_5ff067b9-e695-4759-9a8b-23889b202228" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_dcf165f3-74fc-4893-8cd9-81a4f631dbe8" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_5ff067b9-e695-4759-9a8b-23889b202228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8c38a003-d1db-4268-b890-5e2c36ca71fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_dcf165f3-74fc-4893-8cd9-81a4f631dbe8" xlink:to="loc_us-gaap_AssetsCurrent_8c38a003-d1db-4268-b890-5e2c36ca71fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0fa06bd3-11cf-453b-a9a6-90aa3eb1ef9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_60f9b5c7-bd80-400a-81ad-1c25b2954f7c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0fa06bd3-11cf-453b-a9a6-90aa3eb1ef9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d4c45bc4-2a76-43bb-b8a3-6c3dcb86faf3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_60f9b5c7-bd80-400a-81ad-1c25b2954f7c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d4c45bc4-2a76-43bb-b8a3-6c3dcb86faf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_23a34432-eb9f-4f0c-9a38-22ee706b344e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_60f9b5c7-bd80-400a-81ad-1c25b2954f7c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_23a34432-eb9f-4f0c-9a38-22ee706b344e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b9a8a307-d274-44b2-9415-dcaca450e649" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_60f9b5c7-bd80-400a-81ad-1c25b2954f7c" xlink:to="loc_us-gaap_Assets_b9a8a307-d274-44b2-9415-dcaca450e649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b76ef7d1-53fc-4299-936b-6ab4fa26ab7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_07ec769d-0745-4be5-b192-1a56c800261f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b76ef7d1-53fc-4299-936b-6ab4fa26ab7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_e79f4323-0cce-4d05-a86d-9c65753d9973" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b76ef7d1-53fc-4299-936b-6ab4fa26ab7e" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_e79f4323-0cce-4d05-a86d-9c65753d9973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_4776f9df-9274-4f6f-9c3a-208f2d826ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e79f4323-0cce-4d05-a86d-9c65753d9973" xlink:to="loc_us-gaap_AccountsPayableCurrent_4776f9df-9274-4f6f-9c3a-208f2d826ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_600cc554-7c18-4b9b-9182-3a435fd87559" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e79f4323-0cce-4d05-a86d-9c65753d9973" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_600cc554-7c18-4b9b-9182-3a435fd87559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_d09811e8-b1d9-4f91-89db-a8dd52a19140" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e79f4323-0cce-4d05-a86d-9c65753d9973" xlink:to="loc_us-gaap_DeferredRevenueCurrent_d09811e8-b1d9-4f91-89db-a8dd52a19140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1461d17a-ae91-4829-8ee8-bc62233b6c16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e79f4323-0cce-4d05-a86d-9c65753d9973" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_1461d17a-ae91-4829-8ee8-bc62233b6c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6f74fc5f-a4d8-4cdd-9fc3-9c0bb33c4c77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e79f4323-0cce-4d05-a86d-9c65753d9973" xlink:to="loc_us-gaap_LiabilitiesCurrent_6f74fc5f-a4d8-4cdd-9fc3-9c0bb33c4c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_7382b89c-d771-4e97-b6d2-b244cee33fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b76ef7d1-53fc-4299-936b-6ab4fa26ab7e" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_7382b89c-d771-4e97-b6d2-b244cee33fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b249182b-10b0-4d14-a0d8-dae83ecedd49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b76ef7d1-53fc-4299-936b-6ab4fa26ab7e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b249182b-10b0-4d14-a0d8-dae83ecedd49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_6c25bf69-73c1-4a11-85d0-4441e90ec1fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b76ef7d1-53fc-4299-936b-6ab4fa26ab7e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_6c25bf69-73c1-4a11-85d0-4441e90ec1fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_02c0fa04-67c6-4a29-b3b1-5487038a697b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b76ef7d1-53fc-4299-936b-6ab4fa26ab7e" xlink:to="loc_us-gaap_Liabilities_02c0fa04-67c6-4a29-b3b1-5487038a697b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_05129086-2c60-40fd-81c8-9fca63c367be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b76ef7d1-53fc-4299-936b-6ab4fa26ab7e" xlink:to="loc_us-gaap_StockholdersEquityAbstract_05129086-2c60-40fd-81c8-9fca63c367be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_add6f898-668d-4a6c-98dd-5ac9a1d3dbca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_05129086-2c60-40fd-81c8-9fca63c367be" xlink:to="loc_us-gaap_CommonStockValue_add6f898-668d-4a6c-98dd-5ac9a1d3dbca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_cd8fa862-30c7-4ac9-bc20-60d0f5667198" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_05129086-2c60-40fd-81c8-9fca63c367be" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_cd8fa862-30c7-4ac9-bc20-60d0f5667198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0dc4486f-d3da-4895-a191-dfab2f6be87a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_05129086-2c60-40fd-81c8-9fca63c367be" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0dc4486f-d3da-4895-a191-dfab2f6be87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_16cf5781-34d6-48a7-b73f-3c5a3b82ade3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_05129086-2c60-40fd-81c8-9fca63c367be" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_16cf5781-34d6-48a7-b73f-3c5a3b82ade3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4977fbf0-528e-4590-a4a0-7c5de3a52f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_05129086-2c60-40fd-81c8-9fca63c367be" xlink:to="loc_us-gaap_StockholdersEquity_4977fbf0-528e-4590-a4a0-7c5de3a52f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_5ca97691-a4ff-4c6f-8820-afbfea928ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b76ef7d1-53fc-4299-936b-6ab4fa26ab7e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_5ca97691-a4ff-4c6f-8820-afbfea928ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="mgnx-20241231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f9f745cb-0400-4642-b5bd-58883a0197ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_75b14fd0-4fa7-4c94-b785-65867c59f007" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f9f745cb-0400-4642-b5bd-58883a0197ce" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_75b14fd0-4fa7-4c94-b785-65867c59f007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_86835b0a-cf19-4091-8ba6-fe12cf40b130" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f9f745cb-0400-4642-b5bd-58883a0197ce" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_86835b0a-cf19-4091-8ba6-fe12cf40b130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6296f8f5-0bd2-4a5e-9604-353467cafb75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f9f745cb-0400-4642-b5bd-58883a0197ce" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6296f8f5-0bd2-4a5e-9604-353467cafb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20241231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_b96544af-b304-4387-b35e-a3eb1a732bac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f6d45a5e-c68e-494b-b7c2-1f28985c3d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b96544af-b304-4387-b35e-a3eb1a732bac" xlink:to="loc_us-gaap_StatementTable_f6d45a5e-c68e-494b-b7c2-1f28985c3d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_20f4d9c7-4b19-4c9b-941e-e1cd4277c9ac" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f6d45a5e-c68e-494b-b7c2-1f28985c3d4b" xlink:to="loc_srt_ProductOrServiceAxis_20f4d9c7-4b19-4c9b-941e-e1cd4277c9ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f0b4c5f2-ac85-4b6d-8d61-7c3d351bd654" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_20f4d9c7-4b19-4c9b-941e-e1cd4277c9ac" xlink:to="loc_srt_ProductsAndServicesDomain_f0b4c5f2-ac85-4b6d-8d61-7c3d351bd654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember_a96ed35b-4f6d-4706-aca4-060b317850cc" xlink:href="mgnx-20241231.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f0b4c5f2-ac85-4b6d-8d61-7c3d351bd654" xlink:to="loc_mgnx_RevenueFromCollaborativeAgreementsMember_a96ed35b-4f6d-4706-aca4-060b317850cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember_6ff070f3-d31f-4def-a02e-6e24e07b5062" xlink:href="mgnx-20241231.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f0b4c5f2-ac85-4b6d-8d61-7c3d351bd654" xlink:to="loc_mgnx_RevenueFromGovernmentAgreementsMember_6ff070f3-d31f-4def-a02e-6e24e07b5062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_6fa9040f-d15e-46a0-8a33-8b9838a15ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f0b4c5f2-ac85-4b6d-8d61-7c3d351bd654" xlink:to="loc_us-gaap_ProductMember_6fa9040f-d15e-46a0-8a33-8b9838a15ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ContractManufacturingMember_5de51570-2bc5-4092-b732-73192609ea6e" xlink:href="mgnx-20241231.xsd#mgnx_ContractManufacturingMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f0b4c5f2-ac85-4b6d-8d61-7c3d351bd654" xlink:to="loc_mgnx_ContractManufacturingMember_5de51570-2bc5-4092-b732-73192609ea6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_198fbd01-06ea-4805-ba45-a4f816e04806" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f6d45a5e-c68e-494b-b7c2-1f28985c3d4b" xlink:to="loc_us-gaap_StatementLineItems_198fbd01-06ea-4805-ba45-a4f816e04806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_9061f692-99db-4bca-9495-ef54fb7790fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_198fbd01-06ea-4805-ba45-a4f816e04806" xlink:to="loc_us-gaap_RevenuesAbstract_9061f692-99db-4bca-9495-ef54fb7790fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b91e4c55-027c-4e1c-9beb-b2af7a72c555" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_9061f692-99db-4bca-9495-ef54fb7790fa" xlink:to="loc_us-gaap_Revenues_b91e4c55-027c-4e1c-9beb-b2af7a72c555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_a5a8c571-17f1-4746-b25c-fd15d1b809f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_198fbd01-06ea-4805-ba45-a4f816e04806" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_a5a8c571-17f1-4746-b25c-fd15d1b809f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_eda2782d-6578-46c4-9027-73682e3628e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_a5a8c571-17f1-4746-b25c-fd15d1b809f4" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_eda2782d-6578-46c4-9027-73682e3628e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CostOfManufacturingServices_c1d14688-e318-418b-a9cf-eaf9f6591ebb" xlink:href="mgnx-20241231.xsd#mgnx_CostOfManufacturingServices"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_a5a8c571-17f1-4746-b25c-fd15d1b809f4" xlink:to="loc_mgnx_CostOfManufacturingServices_c1d14688-e318-418b-a9cf-eaf9f6591ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9f563bf1-c2e2-4d83-85f6-e4fa80855c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_a5a8c571-17f1-4746-b25c-fd15d1b809f4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9f563bf1-c2e2-4d83-85f6-e4fa80855c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_277998ae-4045-413e-8ea2-d3db2acab2af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_a5a8c571-17f1-4746-b25c-fd15d1b809f4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_277998ae-4045-413e-8ea2-d3db2acab2af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b74826a5-8141-4bf1-b13a-6ab283fcd574" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_a5a8c571-17f1-4746-b25c-fd15d1b809f4" xlink:to="loc_us-gaap_CostsAndExpenses_b74826a5-8141-4bf1-b13a-6ab283fcd574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8e69913b-6d7b-4360-9ad4-f5ee3f295acb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_198fbd01-06ea-4805-ba45-a4f816e04806" xlink:to="loc_us-gaap_OperatingIncomeLoss_8e69913b-6d7b-4360-9ad4-f5ee3f295acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GainOnRoyaltyMonetizationArrangement_cf3402e3-a621-433c-a115-0c8320b39af6" xlink:href="mgnx-20241231.xsd#mgnx_GainOnRoyaltyMonetizationArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_198fbd01-06ea-4805-ba45-a4f816e04806" xlink:to="loc_mgnx_GainOnRoyaltyMonetizationArrangement_cf3402e3-a621-433c-a115-0c8320b39af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GainOnSaleOfMARGENZA_76954844-ad65-4a69-b662-7593abbef382" xlink:href="mgnx-20241231.xsd#mgnx_GainOnSaleOfMARGENZA"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_198fbd01-06ea-4805-ba45-a4f816e04806" xlink:to="loc_mgnx_GainOnSaleOfMARGENZA_76954844-ad65-4a69-b662-7593abbef382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e3a1364e-51a9-49eb-b619-ee6dada235ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_198fbd01-06ea-4805-ba45-a4f816e04806" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e3a1364e-51a9-49eb-b619-ee6dada235ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_963e435b-62fe-4104-8c44-8d14dca81746" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_198fbd01-06ea-4805-ba45-a4f816e04806" xlink:to="loc_us-gaap_InterestExpense_963e435b-62fe-4104-8c44-8d14dca81746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_713cc54f-041e-409a-8f7c-034937bbc504" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_198fbd01-06ea-4805-ba45-a4f816e04806" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_713cc54f-041e-409a-8f7c-034937bbc504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3678dcf4-a35a-42f1-bcf4-1ba4bc3f85c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_198fbd01-06ea-4805-ba45-a4f816e04806" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3678dcf4-a35a-42f1-bcf4-1ba4bc3f85c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fc6d7cca-b8b8-4106-b06e-c2ece304f8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_198fbd01-06ea-4805-ba45-a4f816e04806" xlink:to="loc_us-gaap_NetIncomeLoss_fc6d7cca-b8b8-4106-b06e-c2ece304f8e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_36c24167-8e55-47aa-a747-5622a233770f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_198fbd01-06ea-4805-ba45-a4f816e04806" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_36c24167-8e55-47aa-a747-5622a233770f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_b74cc2a6-e3ef-4dac-9f9c-0139271cdcfb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_36c24167-8e55-47aa-a747-5622a233770f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_b74cc2a6-e3ef-4dac-9f9c-0139271cdcfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d07338dd-c3ab-42cb-a717-09e77b6793e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_36c24167-8e55-47aa-a747-5622a233770f" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_d07338dd-c3ab-42cb-a717-09e77b6793e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ffb4c861-4e35-464d-852b-883f4b3a4ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_198fbd01-06ea-4805-ba45-a4f816e04806" xlink:to="loc_us-gaap_EarningsPerShareBasic_ffb4c861-4e35-464d-852b-883f4b3a4ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_71e4f92c-f787-42c5-8947-a7321923b7d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_198fbd01-06ea-4805-ba45-a4f816e04806" xlink:to="loc_us-gaap_EarningsPerShareDiluted_71e4f92c-f787-42c5-8947-a7321923b7d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c9ccad57-c8e3-454d-9d9e-39e8412b4120" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_198fbd01-06ea-4805-ba45-a4f816e04806" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c9ccad57-c8e3-454d-9d9e-39e8412b4120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bf9476e7-dfdc-4add-9812-75a2c6b79471" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_198fbd01-06ea-4805-ba45-a4f816e04806" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bf9476e7-dfdc-4add-9812-75a2c6b79471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mgnx-20241231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_a96048af-ffbf-46d6-b96d-26ab14ca68fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ccba9b86-5ba8-4db1-b779-1f925e581057" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_a96048af-ffbf-46d6-b96d-26ab14ca68fe" xlink:to="loc_us-gaap_StatementTable_ccba9b86-5ba8-4db1-b779-1f925e581057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7a8a5434-3a57-46ac-9c83-0a0b931135d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ccba9b86-5ba8-4db1-b779-1f925e581057" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7a8a5434-3a57-46ac-9c83-0a0b931135d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_27887d15-8854-4f15-a940-1aa4531f2185" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7a8a5434-3a57-46ac-9c83-0a0b931135d7" xlink:to="loc_us-gaap_EquityComponentDomain_27887d15-8854-4f15-a940-1aa4531f2185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7208b069-048c-41e1-ba31-edc2cc285bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_27887d15-8854-4f15-a940-1aa4531f2185" xlink:to="loc_us-gaap_CommonStockMember_7208b069-048c-41e1-ba31-edc2cc285bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8f402286-3bc5-45fa-95fb-91e0d2e5f1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_27887d15-8854-4f15-a940-1aa4531f2185" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8f402286-3bc5-45fa-95fb-91e0d2e5f1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a236c77b-24e6-40aa-b166-a4668b548244" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_27887d15-8854-4f15-a940-1aa4531f2185" xlink:to="loc_us-gaap_RetainedEarningsMember_a236c77b-24e6-40aa-b166-a4668b548244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_50d0f9aa-b4c0-4fc8-88fe-282f93c2c188" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_27887d15-8854-4f15-a940-1aa4531f2185" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_50d0f9aa-b4c0-4fc8-88fe-282f93c2c188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_91baef23-66c4-441e-bd5f-60549d896e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ccba9b86-5ba8-4db1-b779-1f925e581057" xlink:to="loc_us-gaap_StatementLineItems_91baef23-66c4-441e-bd5f-60549d896e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_c59046cf-19e2-4a22-a4d6-1ec735aec63c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91baef23-66c4-441e-bd5f-60549d896e8f" xlink:to="loc_us-gaap_SharesIssued_c59046cf-19e2-4a22-a4d6-1ec735aec63c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fa7c2bad-f143-4c45-9805-f98adb1df631" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91baef23-66c4-441e-bd5f-60549d896e8f" xlink:to="loc_us-gaap_StockholdersEquity_fa7c2bad-f143-4c45-9805-f98adb1df631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7403f740-8423-4ee0-b45b-9d3449d09231" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91baef23-66c4-441e-bd5f-60549d896e8f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7403f740-8423-4ee0-b45b-9d3449d09231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6c89a973-ff04-4b25-afee-29dc4a1c1739" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91baef23-66c4-441e-bd5f-60549d896e8f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6c89a973-ff04-4b25-afee-29dc4a1c1739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9153ad17-7bbe-4a4b-b36c-8720975fddd1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91baef23-66c4-441e-bd5f-60549d896e8f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9153ad17-7bbe-4a4b-b36c-8720975fddd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_8833bccd-2582-46ce-9ccb-ead0d182d683" xlink:href="mgnx-20241231.xsd#mgnx_StockIssuedDuringPeriodSharesStockPlanActivity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91baef23-66c4-441e-bd5f-60549d896e8f" xlink:to="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_8833bccd-2582-46ce-9ccb-ead0d182d683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_749a50b6-29a6-44c1-ac30-13d140af2b41" xlink:href="mgnx-20241231.xsd#mgnx_StockIssuedDuringPeriodValueStockPlanActivity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91baef23-66c4-441e-bd5f-60549d896e8f" xlink:to="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_749a50b6-29a6-44c1-ac30-13d140af2b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_99062cb7-5620-4b35-81ae-48699490e508" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91baef23-66c4-441e-bd5f-60549d896e8f" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_99062cb7-5620-4b35-81ae-48699490e508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1b9a33ed-31b4-4949-8712-d96650018131" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91baef23-66c4-441e-bd5f-60549d896e8f" xlink:to="loc_us-gaap_NetIncomeLoss_1b9a33ed-31b4-4949-8712-d96650018131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_c76bad9a-97ef-4070-8417-70034f85a883" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91baef23-66c4-441e-bd5f-60549d896e8f" xlink:to="loc_us-gaap_SharesIssued_c76bad9a-97ef-4070-8417-70034f85a883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_89e7c5ee-2964-49a0-bf6b-bf73d15b30a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_91baef23-66c4-441e-bd5f-60549d896e8f" xlink:to="loc_us-gaap_StockholdersEquity_89e7c5ee-2964-49a0-bf6b-bf73d15b30a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mgnx-20241231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_b42a062e-73e0-4d49-a4c2-7c34de4e00dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7d81ccad-4790-4463-8668-8fd93241420e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b42a062e-73e0-4d49-a4c2-7c34de4e00dc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7d81ccad-4790-4463-8668-8fd93241420e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_21332b17-a45a-433b-bb14-bf1cf8d90886" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7d81ccad-4790-4463-8668-8fd93241420e" xlink:to="loc_us-gaap_NetIncomeLoss_21332b17-a45a-433b-bb14-bf1cf8d90886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5582e1be-3323-4ede-a326-786508627795" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7d81ccad-4790-4463-8668-8fd93241420e" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5582e1be-3323-4ede-a326-786508627795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_35912d56-7c5c-4bab-9529-cb3133d21914" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5582e1be-3323-4ede-a326-786508627795" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_35912d56-7c5c-4bab-9529-cb3133d21914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_b94d2e7d-cc7e-4391-8ea9-acac8776adca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5582e1be-3323-4ede-a326-786508627795" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_b94d2e7d-cc7e-4391-8ea9-acac8776adca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4aeaf6fc-bb8a-4b29-b96f-28459eb7442d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5582e1be-3323-4ede-a326-786508627795" xlink:to="loc_us-gaap_ShareBasedCompensation_4aeaf6fc-bb8a-4b29-b96f-28459eb7442d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GainOnRoyaltyMonetizationArrangement_ae67ed07-5a2c-494a-89b7-55c011a9451f" xlink:href="mgnx-20241231.xsd#mgnx_GainOnRoyaltyMonetizationArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5582e1be-3323-4ede-a326-786508627795" xlink:to="loc_mgnx_GainOnRoyaltyMonetizationArrangement_ae67ed07-5a2c-494a-89b7-55c011a9451f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GainOnSaleOfMARGENZA_3ee195ea-1cea-46fd-962a-8a714cb23835" xlink:href="mgnx-20241231.xsd#mgnx_GainOnSaleOfMARGENZA"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5582e1be-3323-4ede-a326-786508627795" xlink:to="loc_mgnx_GainOnSaleOfMARGENZA_3ee195ea-1cea-46fd-962a-8a714cb23835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonCashInterestExpenseRecognized_d2d60d56-531d-4d15-bb76-061127a94ee7" xlink:href="mgnx-20241231.xsd#mgnx_NonCashInterestExpenseRecognized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5582e1be-3323-4ede-a326-786508627795" xlink:to="loc_mgnx_NonCashInterestExpenseRecognized_d2d60d56-531d-4d15-bb76-061127a94ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OperatingLeaseNoncashExpense_90f6920a-df85-4a13-a1b9-5df98914944c" xlink:href="mgnx-20241231.xsd#mgnx_OperatingLeaseNoncashExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5582e1be-3323-4ede-a326-786508627795" xlink:to="loc_mgnx_OperatingLeaseNoncashExpense_90f6920a-df85-4a13-a1b9-5df98914944c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_d5dde3df-9103-4e10-a780-c3a7a6f2eb28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5582e1be-3323-4ede-a326-786508627795" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_d5dde3df-9103-4e10-a780-c3a7a6f2eb28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_b92513db-aab0-417a-bf6b-5d4b6bbb0715" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5582e1be-3323-4ede-a326-786508627795" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_b92513db-aab0-417a-bf6b-5d4b6bbb0715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e13428ee-b89b-43b2-8c64-7098bec82d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5582e1be-3323-4ede-a326-786508627795" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e13428ee-b89b-43b2-8c64-7098bec82d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_249af01e-d15a-46ed-9cc6-5db17fe1f594" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e13428ee-b89b-43b2-8c64-7098bec82d9a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_249af01e-d15a-46ed-9cc6-5db17fe1f594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_24e85b19-d13f-4d5a-9dc0-cc86c2e0d130" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e13428ee-b89b-43b2-8c64-7098bec82d9a" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_24e85b19-d13f-4d5a-9dc0-cc86c2e0d130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_e9bde38c-b6b5-4701-90d4-c115079fc439" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e13428ee-b89b-43b2-8c64-7098bec82d9a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_e9bde38c-b6b5-4701-90d4-c115079fc439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9868114b-78da-4309-b46c-966c8371a704" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e13428ee-b89b-43b2-8c64-7098bec82d9a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9868114b-78da-4309-b46c-966c8371a704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8a3f1b56-55fe-4ae8-a79c-f4e9609f136c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e13428ee-b89b-43b2-8c64-7098bec82d9a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8a3f1b56-55fe-4ae8-a79c-f4e9609f136c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_87f43a34-d931-4405-a050-071418c55c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e13428ee-b89b-43b2-8c64-7098bec82d9a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_87f43a34-d931-4405-a050-071418c55c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInLeaseLiabilities_7d62a680-3b66-44e3-bbee-be220463bca6" xlink:href="mgnx-20241231.xsd#mgnx_IncreaseDecreaseInLeaseLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e13428ee-b89b-43b2-8c64-7098bec82d9a" xlink:to="loc_mgnx_IncreaseDecreaseInLeaseLiabilities_7d62a680-3b66-44e3-bbee-be220463bca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_f80401b3-c0e0-49b5-9af5-abfb359f0089" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e13428ee-b89b-43b2-8c64-7098bec82d9a" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_f80401b3-c0e0-49b5-9af5-abfb359f0089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_f6373b5a-fd3f-4cd7-97dc-395b23856e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e13428ee-b89b-43b2-8c64-7098bec82d9a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_f6373b5a-fd3f-4cd7-97dc-395b23856e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3bb424a7-b0b0-4bee-9d60-37d01878a671" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7d81ccad-4790-4463-8668-8fd93241420e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3bb424a7-b0b0-4bee-9d60-37d01878a671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_6cd7ac28-4b0c-4e30-90b9-ace78bac8be9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b42a062e-73e0-4d49-a4c2-7c34de4e00dc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_6cd7ac28-4b0c-4e30-90b9-ace78bac8be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_efcb1df6-a63c-41a4-97dd-30ba241eef15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_6cd7ac28-4b0c-4e30-90b9-ace78bac8be9" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_efcb1df6-a63c-41a4-97dd-30ba241eef15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_bfb191f4-5e6b-4851-b51f-9c309a9c3667" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_6cd7ac28-4b0c-4e30-90b9-ace78bac8be9" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_bfb191f4-5e6b-4851-b51f-9c309a9c3667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5e85b37a-0cf3-4ea8-87c1-fc8a41e89959" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_6cd7ac28-4b0c-4e30-90b9-ace78bac8be9" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5e85b37a-0cf3-4ea8-87c1-fc8a41e89959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherProductiveAssets_4ebc199f-8d52-4248-b15b-bb18e55a4360" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfOtherProductiveAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_6cd7ac28-4b0c-4e30-90b9-ace78bac8be9" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherProductiveAssets_4ebc199f-8d52-4248-b15b-bb18e55a4360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_1911ec25-22a4-4aea-aa1f-3dfb4b6544e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_6cd7ac28-4b0c-4e30-90b9-ace78bac8be9" xlink:to="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_1911ec25-22a4-4aea-aa1f-3dfb4b6544e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a43c36ea-46eb-496b-9995-6d767ad6f6b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_6cd7ac28-4b0c-4e30-90b9-ace78bac8be9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a43c36ea-46eb-496b-9995-6d767ad6f6b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_30d55367-2b8a-4e18-9de5-b10ab1164368" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b42a062e-73e0-4d49-a4c2-7c34de4e00dc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_30d55367-2b8a-4e18-9de5-b10ab1164368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0e560c4e-abcf-43f6-a05c-58b718eba38d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_30d55367-2b8a-4e18-9de5-b10ab1164368" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0e560c4e-abcf-43f6-a05c-58b718eba38d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_ad03d60c-11b6-46d9-8040-3769a987967e" xlink:href="mgnx-20241231.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_30d55367-2b8a-4e18-9de5-b10ab1164368" xlink:to="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_ad03d60c-11b6-46d9-8040-3769a987967e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d868cb23-6311-43cd-bb68-e73a523c467b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_30d55367-2b8a-4e18-9de5-b10ab1164368" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d868cb23-6311-43cd-bb68-e73a523c467b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement_13aeadbd-9ee6-445a-a649-0d956a929e8f" xlink:href="mgnx-20241231.xsd#mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_30d55367-2b8a-4e18-9de5-b10ab1164368" xlink:to="loc_mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement_13aeadbd-9ee6-445a-a649-0d956a929e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NetProceedsFromSaleOfFutureRoyalties_17a431ab-ada6-4247-a421-94ac3db26e11" xlink:href="mgnx-20241231.xsd#mgnx_NetProceedsFromSaleOfFutureRoyalties"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_30d55367-2b8a-4e18-9de5-b10ab1164368" xlink:to="loc_mgnx_NetProceedsFromSaleOfFutureRoyalties_17a431ab-ada6-4247-a421-94ac3db26e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_064b68ba-ee54-4058-98cd-7ba8f7ab9c80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_30d55367-2b8a-4e18-9de5-b10ab1164368" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_064b68ba-ee54-4058-98cd-7ba8f7ab9c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c1d74713-d214-4478-99cb-a0816257e6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b42a062e-73e0-4d49-a4c2-7c34de4e00dc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c1d74713-d214-4478-99cb-a0816257e6b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b81d22be-6a52-43ae-8a3c-8c3a0d79bf55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b42a062e-73e0-4d49-a4c2-7c34de4e00dc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b81d22be-6a52-43ae-8a3c-8c3a0d79bf55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ced11674-edea-4f4f-abfd-2d1a55ed5d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b42a062e-73e0-4d49-a4c2-7c34de4e00dc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ced11674-edea-4f4f-abfd-2d1a55ed5d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_6aa1970d-8e09-411e-ab46-5a68a281376f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b42a062e-73e0-4d49-a4c2-7c34de4e00dc" xlink:to="loc_us-gaap_IncomeTaxesPaid_6aa1970d-8e09-411e-ab46-5a68a281376f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_9ddf0118-9d7b-4f56-b7ee-9cc00f012817" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b42a062e-73e0-4d49-a4c2-7c34de4e00dc" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_9ddf0118-9d7b-4f56-b7ee-9cc00f012817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2108acc7-4987-4379-81bf-14bc7d452c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_9ddf0118-9d7b-4f56-b7ee-9cc00f012817" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2108acc7-4987-4379-81bf-14bc7d452c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/OrganizationandNatureofOperations" xlink:type="simple" xlink:href="mgnx-20241231.xsd#OrganizationandNatureofOperations"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/OrganizationandNatureofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_69d5e7ea-d104-4726-9a11-125753572cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_13daa085-a440-488f-84d2-6511ed7f7c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_69d5e7ea-d104-4726-9a11-125753572cb9" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_13daa085-a440-488f-84d2-6511ed7f7c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="mgnx-20241231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f24aef61-67fa-4162-b5c2-43d90fe4b0b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_9219e57f-255a-450f-8eb6-cf02fac7d36a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f24aef61-67fa-4162-b5c2-43d90fe4b0b5" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_9219e57f-255a-450f-8eb6-cf02fac7d36a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecurities" xlink:type="simple" xlink:href="mgnx-20241231.xsd#MarketableSecurities"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a7e12594-e3d3-4563-a7bc-128b6beb580a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_b86ac03c-756c-4d55-9497-bbf13a23afa7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a7e12594-e3d3-4563-a7bc-128b6beb580a" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_b86ac03c-756c-4d55-9497-bbf13a23afa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/Inventory" xlink:type="simple" xlink:href="mgnx-20241231.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_104d8e4c-3f58-4a0d-b11f-d7c9084a353c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_75741772-a75b-462b-aef5-7a7074fed74d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_104d8e4c-3f58-4a0d-b11f-d7c9084a353c" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_75741772-a75b-462b-aef5-7a7074fed74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftware" xlink:type="simple" xlink:href="mgnx-20241231.xsd#PropertyEquipmentandSoftware"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/PropertyEquipmentandSoftware" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d1e10f75-1f1e-4629-bb9b-b39074dd13b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_70ac7d9a-5cb3-4157-b200-f388dc014b14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d1e10f75-1f1e-4629-bb9b-b39074dd13b6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_70ac7d9a-5cb3-4157-b200-f388dc014b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="mgnx-20241231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6442d0ca-f3af-41db-a044-bb6fdea1c432" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6be2ce6a-8275-47b3-828d-8aecde2eea3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6442d0ca-f3af-41db-a044-bb6fdea1c432" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6be2ce6a-8275-47b3-828d-8aecde2eea3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="mgnx-20241231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_61e63c98-2870-4c7e-9f1b-8f0ee70d5560" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_cb696e93-5c01-4f0f-9a0d-dc2b03e372b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_61e63c98-2870-4c7e-9f1b-8f0ee70d5560" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_cb696e93-5c01-4f0f-9a0d-dc2b03e372b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/Revenue" xlink:type="simple" xlink:href="mgnx-20241231.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_b1b39e63-d188-472b-bd1e-235db7fb8185" xlink:href="mgnx-20241231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_acb07101-95c1-4ca0-a228-5b5e7d05848b" xlink:href="mgnx-20241231.xsd#mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_b1b39e63-d188-472b-bd1e-235db7fb8185" xlink:to="loc_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_acb07101-95c1-4ca0-a228-5b5e7d05848b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="mgnx-20241231.xsd#StockbasedCompensation"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2dbcc651-b507-4412-98b0-ce6feb80b41f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f469fb6d-871b-40ee-b5f4-57f0b2ae05fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2dbcc651-b507-4412-98b0-ce6feb80b41f" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f469fb6d-871b-40ee-b5f4-57f0b2ae05fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/TeSeraTransaction" xlink:type="simple" xlink:href="mgnx-20241231.xsd#TeSeraTransaction"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/TeSeraTransaction" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_e68ac24f-35c8-4c3e-9718-55bce73acb17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_01a6b6bd-d27f-4533-a028-472a7c246b67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e68ac24f-35c8-4c3e-9718-55bce73acb17" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_01a6b6bd-d27f-4533-a028-472a7c246b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxes" xlink:type="simple" xlink:href="mgnx-20241231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_dff29ee8-f8ff-4726-95bf-11e07bebd918" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_c6fab4b0-d6ea-48c7-b459-0133e5ce4c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_dff29ee8-f8ff-4726-95bf-11e07bebd918" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_c6fab4b0-d6ea-48c7-b459-0133e5ce4c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="mgnx-20241231.xsd#EmployeeBenefitPlan"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/EmployeeBenefitPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_05f9e00b-8ac1-4951-abb0-e4d8d35e7bff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_ee482149-5295-4e2c-8f84-44a135877d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_05f9e00b-8ac1-4951-abb0-e4d8d35e7bff" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_ee482149-5295-4e2c-8f84-44a135877d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SegmentReporting" xlink:type="simple" xlink:href="mgnx-20241231.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_f418e87f-2620-426f-b50e-b86ac3a8c80b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_421ae5f4-c797-4aba-8e76-4a0f3726f7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f418e87f-2620-426f-b50e-b86ac3a8c80b" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_421ae5f4-c797-4aba-8e76-4a0f3726f7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mgnx-20241231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_565e1ade-6f87-42a9-a221-a1564eaa3db8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a4ae5478-f741-4c23-90a5-dd6d845afe5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_565e1ade-6f87-42a9-a221-a1564eaa3db8" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a4ae5478-f741-4c23-90a5-dd6d845afe5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_5a235805-ef65-40e1-925b-0fca55674e73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_565e1ade-6f87-42a9-a221-a1564eaa3db8" xlink:to="loc_us-gaap_UseOfEstimates_5a235805-ef65-40e1-925b-0fca55674e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_8a63b57c-0798-4bdb-9d7e-8b14a5f746e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_565e1ade-6f87-42a9-a221-a1564eaa3db8" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_8a63b57c-0798-4bdb-9d7e-8b14a5f746e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_e89aafdd-45eb-4774-9cba-eb129f47e775" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_565e1ade-6f87-42a9-a221-a1564eaa3db8" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_e89aafdd-45eb-4774-9cba-eb129f47e775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_9efe6c67-47e7-4b24-8a45-48db2249d7da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_565e1ade-6f87-42a9-a221-a1564eaa3db8" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_9efe6c67-47e7-4b24-8a45-48db2249d7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_f97a70a4-7f08-4363-9790-6f28998839a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_565e1ade-6f87-42a9-a221-a1564eaa3db8" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_f97a70a4-7f08-4363-9790-6f28998839a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_71d9fd57-7b77-4c33-9660-17b52903b90c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_565e1ade-6f87-42a9-a221-a1564eaa3db8" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_71d9fd57-7b77-4c33-9660-17b52903b90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_aeaa4063-7fca-4a91-a631-2e69ca26484d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_565e1ade-6f87-42a9-a221-a1564eaa3db8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_aeaa4063-7fca-4a91-a631-2e69ca26484d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_479fc1ff-da3f-44f2-a51d-265dcc8b7aca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_565e1ade-6f87-42a9-a221-a1564eaa3db8" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_479fc1ff-da3f-44f2-a51d-265dcc8b7aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_1d66eeb7-8c77-4188-bcbd-5b5c9d8a34a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_565e1ade-6f87-42a9-a221-a1564eaa3db8" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_1d66eeb7-8c77-4188-bcbd-5b5c9d8a34a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_adeb55e9-9488-4c31-b4c7-40b984b4cbd9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_565e1ade-6f87-42a9-a221-a1564eaa3db8" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_adeb55e9-9488-4c31-b4c7-40b984b4cbd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_aee23bab-9ff9-4591-a675-6271c7346a86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_565e1ade-6f87-42a9-a221-a1564eaa3db8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_aee23bab-9ff9-4591-a675-6271c7346a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_13f81170-a307-48a4-89e9-6725d845c297" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_565e1ade-6f87-42a9-a221-a1564eaa3db8" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_13f81170-a307-48a4-89e9-6725d845c297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_8b382fbc-dbba-4e1e-9919-238af282b948" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_565e1ade-6f87-42a9-a221-a1564eaa3db8" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_8b382fbc-dbba-4e1e-9919-238af282b948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_3dc008a6-65fa-4ab7-a4f9-84ebf238cdb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_565e1ade-6f87-42a9-a221-a1564eaa3db8" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_3dc008a6-65fa-4ab7-a4f9-84ebf238cdb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fc8f7b18-03d3-4ae5-a5d1-726cbe7b6fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_565e1ade-6f87-42a9-a221-a1564eaa3db8" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fc8f7b18-03d3-4ae5-a5d1-726cbe7b6fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="mgnx-20241231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_57a85d47-07e4-4e33-b3a6-873e60c146b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_7ecb8b7a-e187-4443-90d0-2f200ca9b476" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_57a85d47-07e4-4e33-b3a6-873e60c146b3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_7ecb8b7a-e187-4443-90d0-2f200ca9b476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_6f1b34e9-3ef3-4480-af4d-cd2920e24be9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_57a85d47-07e4-4e33-b3a6-873e60c146b3" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_6f1b34e9-3ef3-4480-af4d-cd2920e24be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock_674b64e5-3fc4-4134-a972-6ab4e6e37375" xlink:href="mgnx-20241231.xsd#mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_57a85d47-07e4-4e33-b3a6-873e60c146b3" xlink:to="loc_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock_674b64e5-3fc4-4134-a972-6ab4e6e37375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8f9ab3fb-9082-4f13-a4b1-099158875f51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_57a85d47-07e4-4e33-b3a6-873e60c146b3" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8f9ab3fb-9082-4f13-a4b1-099158875f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="mgnx-20241231.xsd#MarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3e5471d0-974d-496f-a119-4c6507f4b1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_ef8a2095-a32e-4f07-8ff4-93251bbb77d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3e5471d0-974d-496f-a119-4c6507f4b1ca" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_ef8a2095-a32e-4f07-8ff4-93251bbb77d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/InventoryNetTables" xlink:type="simple" xlink:href="mgnx-20241231.xsd#InventoryNetTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/InventoryNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_db51e056-9a2f-44e9-89f2-28086d9e1d79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_affc0acf-32bc-4a0e-b4ca-604f26ff8a52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_db51e056-9a2f-44e9-89f2-28086d9e1d79" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_affc0acf-32bc-4a0e-b4ca-604f26ff8a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ScheduleOfInventoryReservesTableTextBlock_65c7e420-1ad3-41b2-824a-2529d7028c66" xlink:href="mgnx-20241231.xsd#mgnx_ScheduleOfInventoryReservesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_db51e056-9a2f-44e9-89f2-28086d9e1d79" xlink:to="loc_mgnx_ScheduleOfInventoryReservesTableTextBlock_65c7e420-1ad3-41b2-824a-2529d7028c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareTables" xlink:type="simple" xlink:href="mgnx-20241231.xsd#PropertyEquipmentandSoftwareTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/PropertyEquipmentandSoftwareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5ac1cb30-17d5-4fa4-ada9-7e55e3f3d191" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_6b72b237-c3cc-4aa2-b628-f1c75ee22180" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5ac1cb30-17d5-4fa4-ada9-7e55e3f3d191" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_6b72b237-c3cc-4aa2-b628-f1c75ee22180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="mgnx-20241231.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fae75440-5bfa-42ec-95d5-0ef338d8395c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock_23fc70bb-b671-43c7-8456-79ccaf88b80b" xlink:href="mgnx-20241231.xsd#mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fae75440-5bfa-42ec-95d5-0ef338d8395c" xlink:to="loc_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock_23fc70bb-b671-43c7-8456-79ccaf88b80b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_8c668018-43b3-431c-bcb0-79ac735b0c72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fae75440-5bfa-42ec-95d5-0ef338d8395c" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_8c668018-43b3-431c-bcb0-79ac735b0c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1c87217f-d7d1-479e-a89d-b457db0938c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fae75440-5bfa-42ec-95d5-0ef338d8395c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1c87217f-d7d1-479e-a89d-b457db0938c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="mgnx-20241231.xsd#StockbasedCompensationTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_40bbd17b-a5b8-49a4-931c-32d185a1f990" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_f9e74177-8ee8-491e-b592-f0bb1f4a4249" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_40bbd17b-a5b8-49a4-931c-32d185a1f990" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_f9e74177-8ee8-491e-b592-f0bb1f4a4249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ScheduleOfShareBasedPaymentAwardModifiedAwardsValuationAssumptionsTableTextBlock_910ecf1b-fd16-4eb3-a249-d28d4d3b955d" xlink:href="mgnx-20241231.xsd#mgnx_ScheduleOfShareBasedPaymentAwardModifiedAwardsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_40bbd17b-a5b8-49a4-931c-32d185a1f990" xlink:to="loc_mgnx_ScheduleOfShareBasedPaymentAwardModifiedAwardsValuationAssumptionsTableTextBlock_910ecf1b-fd16-4eb3-a249-d28d4d3b955d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_86e0fad5-94b0-416d-9c97-0734cd436a93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_40bbd17b-a5b8-49a4-931c-32d185a1f990" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_86e0fad5-94b0-416d-9c97-0734cd436a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1806156c-fe91-44e2-8491-3c44cd837c74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_40bbd17b-a5b8-49a4-931c-32d185a1f990" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1806156c-fe91-44e2-8491-3c44cd837c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_ed1d822f-bed7-4077-9ef6-ddc1e088adae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_40bbd17b-a5b8-49a4-931c-32d185a1f990" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_ed1d822f-bed7-4077-9ef6-ddc1e088adae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="mgnx-20241231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f6c3284a-f9ea-489d-a740-61f9642259f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_6afe5b94-9bed-4a81-9516-e7179b40d628" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f6c3284a-f9ea-489d-a740-61f9642259f5" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_6afe5b94-9bed-4a81-9516-e7179b40d628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_949b2c84-cdb9-41ce-b512-cca88e201c89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f6c3284a-f9ea-489d-a740-61f9642259f5" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_949b2c84-cdb9-41ce-b512-cca88e201c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_c273e5c3-d6e4-453c-8f04-462341982eab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f6c3284a-f9ea-489d-a740-61f9642259f5" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_c273e5c3-d6e4-453c-8f04-462341982eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_cd117270-1015-4a31-b516-37cc75dceb9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f6c3284a-f9ea-489d-a740-61f9642259f5" xlink:to="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_cd117270-1015-4a31-b516-37cc75dceb9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_a6536705-80c1-46ac-af2d-7f9e98e544f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f6c3284a-f9ea-489d-a740-61f9642259f5" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_a6536705-80c1-46ac-af2d-7f9e98e544f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="mgnx-20241231.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_4a47a69b-8d23-4589-b4db-721b5370e33a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_d7c7c2cb-95d3-4fc8-bf4f-f0295daef2da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4a47a69b-8d23-4589-b4db-721b5370e33a" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_d7c7c2cb-95d3-4fc8-bf4f-f0295daef2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/OrganizationandNatureofOperationsDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#OrganizationandNatureofOperationsDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/OrganizationandNatureofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_42f008ec-2417-46ac-b73c-b345bd3de3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfProductCandidatesApprovedByTheFoodAndDrugAdministration_83e48829-0e84-4a4c-b0a3-a76b9e00fd42" xlink:href="mgnx-20241231.xsd#mgnx_NumberOfProductCandidatesApprovedByTheFoodAndDrugAdministration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_42f008ec-2417-46ac-b73c-b345bd3de3a9" xlink:to="loc_mgnx_NumberOfProductCandidatesApprovedByTheFoodAndDrugAdministration_83e48829-0e84-4a4c-b0a3-a76b9e00fd42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonDilutiveFunding_521cb5e8-0d2f-416f-841e-b800e0c30cfb" xlink:href="mgnx-20241231.xsd#mgnx_NonDilutiveFunding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_42f008ec-2417-46ac-b73c-b345bd3de3a9" xlink:to="loc_mgnx_NonDilutiveFunding_521cb5e8-0d2f-416f-841e-b800e0c30cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfProprietaryProductCandidatesAdvancingInClinicalDevelopment_3a66dc27-4652-4ea5-9b2d-c39daf377ba2" xlink:href="mgnx-20241231.xsd#mgnx_NumberOfProprietaryProductCandidatesAdvancingInClinicalDevelopment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_42f008ec-2417-46ac-b73c-b345bd3de3a9" xlink:to="loc_mgnx_NumberOfProprietaryProductCandidatesAdvancingInClinicalDevelopment_3a66dc27-4652-4ea5-9b2d-c39daf377ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_aeb1510f-2092-4cba-a626-91c06be87e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_dbe1bcb3-f388-4b0f-b9de-98ec163ef505" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aeb1510f-2092-4cba-a626-91c06be87e4e" xlink:to="loc_us-gaap_NumberOfOperatingSegments_dbe1bcb3-f388-4b0f-b9de-98ec163ef505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_19ec78ae-4b92-45c5-913c-50569acdc454" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aeb1510f-2092-4cba-a626-91c06be87e4e" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_19ec78ae-4b92-45c5-913c-50569acdc454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_efd07c79-dcb7-48f7-b053-835b98b54f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aeb1510f-2092-4cba-a626-91c06be87e4e" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_efd07c79-dcb7-48f7-b053-835b98b54f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e09d0299-ee24-4102-8eb2-0bdffe5b5a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4fbd5b8f-0722-40fb-8d5a-f965ce9c85d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e09d0299-ee24-4102-8eb2-0bdffe5b5a2b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4fbd5b8f-0722-40fb-8d5a-f965ce9c85d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c3a2a2ed-701a-40e5-96ff-04b993b179d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4fbd5b8f-0722-40fb-8d5a-f965ce9c85d2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c3a2a2ed-701a-40e5-96ff-04b993b179d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9f8a9d64-f39f-418a-bc82-bad4c53c11e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c3a2a2ed-701a-40e5-96ff-04b993b179d1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9f8a9d64-f39f-418a-bc82-bad4c53c11e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c21e43c7-30ee-48a8-9abf-b74b73e3fc43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9f8a9d64-f39f-418a-bc82-bad4c53c11e1" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c21e43c7-30ee-48a8-9abf-b74b73e3fc43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_99b4de25-a0c0-413c-9152-e8ab93895af3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9f8a9d64-f39f-418a-bc82-bad4c53c11e1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_99b4de25-a0c0-413c-9152-e8ab93895af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_ede60c66-6154-4251-bd51-bca1795d1b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4fbd5b8f-0722-40fb-8d5a-f965ce9c85d2" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_ede60c66-6154-4251-bd51-bca1795d1b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_937aaa3d-4cf4-4d64-9de2-398282c378e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_ede60c66-6154-4251-bd51-bca1795d1b4c" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_937aaa3d-4cf4-4d64-9de2-398282c378e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_b9318745-0fa7-4028-83ee-b6f6eb3724e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_937aaa3d-4cf4-4d64-9de2-398282c378e6" xlink:to="loc_us-gaap_MoneyMarketFundsMember_b9318745-0fa7-4028-83ee-b6f6eb3724e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_e0883b5c-5c06-49ae-9847-c9b716b2eafc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_937aaa3d-4cf4-4d64-9de2-398282c378e6" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_e0883b5c-5c06-49ae-9847-c9b716b2eafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_437e1310-605e-47f9-b529-a97cc9d70ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_937aaa3d-4cf4-4d64-9de2-398282c378e6" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_437e1310-605e-47f9-b529-a97cc9d70ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_4659f07a-2f03-4a6c-b5c2-e802ace83632" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_937aaa3d-4cf4-4d64-9de2-398282c378e6" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_4659f07a-2f03-4a6c-b5c2-e802ace83632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ba88a8a3-930d-48ea-a3b3-0d2a457654ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4fbd5b8f-0722-40fb-8d5a-f965ce9c85d2" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ba88a8a3-930d-48ea-a3b3-0d2a457654ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_ef1cd986-312d-4e39-ab45-c5287972dc5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ba88a8a3-930d-48ea-a3b3-0d2a457654ba" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_ef1cd986-312d-4e39-ab45-c5287972dc5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_7be6fe0f-066f-403d-8562-fef9c0c87d77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_ef1cd986-312d-4e39-ab45-c5287972dc5c" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_7be6fe0f-066f-403d-8562-fef9c0c87d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_de292b17-f61e-4146-9744-3adf245d4c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4fbd5b8f-0722-40fb-8d5a-f965ce9c85d2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_de292b17-f61e-4146-9744-3adf245d4c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_b70cd1e1-20b4-49d1-892d-1fb807430bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_de292b17-f61e-4146-9744-3adf245d4c7c" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_b70cd1e1-20b4-49d1-892d-1fb807430bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f685bbe5-cc4f-46d9-acf6-592be9924e70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b70cd1e1-20b4-49d1-892d-1fb807430bb5" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f685bbe5-cc4f-46d9-acf6-592be9924e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_436237e1-603d-4bf7-936f-838ca3999a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b70cd1e1-20b4-49d1-892d-1fb807430bb5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_436237e1-603d-4bf7-936f-838ca3999a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_5b4d9190-c8c2-41c8-be45-d898364d03fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b70cd1e1-20b4-49d1-892d-1fb807430bb5" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_5b4d9190-c8c2-41c8-be45-d898364d03fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_1a9cd4fc-fd0f-49d5-9511-fd1d8a896214" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Investments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_de292b17-f61e-4146-9744-3adf245d4c7c" xlink:to="loc_us-gaap_Investments_1a9cd4fc-fd0f-49d5-9511-fd1d8a896214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_339cd207-d8d2-4b32-97b6-80bc527b6563" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_ea254e3d-9ab1-473d-9d72-b1b2d07ec00f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_339cd207-d8d2-4b32-97b6-80bc527b6563" xlink:to="loc_us-gaap_ConcentrationRiskTable_ea254e3d-9ab1-473d-9d72-b1b2d07ec00f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_a5ba0103-7921-4d1f-8d30-96453ce58f85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_ea254e3d-9ab1-473d-9d72-b1b2d07ec00f" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_a5ba0103-7921-4d1f-8d30-96453ce58f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_27d08896-3f43-46b2-b8ee-56026cdaa1cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_a5ba0103-7921-4d1f-8d30-96453ce58f85" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_27d08896-3f43-46b2-b8ee-56026cdaa1cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_c10d5a9d-a86b-401c-8a53-58ff13d443b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_27d08896-3f43-46b2-b8ee-56026cdaa1cb" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_c10d5a9d-a86b-401c-8a53-58ff13d443b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_39664bae-fc65-4726-a637-e50c65812f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_ea254e3d-9ab1-473d-9d72-b1b2d07ec00f" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_39664bae-fc65-4726-a637-e50c65812f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_65816e54-a1cc-490a-ad9c-d013c60455ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_39664bae-fc65-4726-a637-e50c65812f1a" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_65816e54-a1cc-490a-ad9c-d013c60455ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_aac303ac-a7fb-409d-8b51-e8f67f96e4ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_65816e54-a1cc-490a-ad9c-d013c60455ee" xlink:to="loc_us-gaap_SalesRevenueNetMember_aac303ac-a7fb-409d-8b51-e8f67f96e4ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_87c545d4-d01c-4615-a993-955cf3b172d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_65816e54-a1cc-490a-ad9c-d013c60455ee" xlink:to="loc_us-gaap_AccountsReceivableMember_87c545d4-d01c-4615-a993-955cf3b172d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_55511bd0-7a55-43d5-8374-5d9713779ae8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_ea254e3d-9ab1-473d-9d72-b1b2d07ec00f" xlink:to="loc_srt_MajorCustomersAxis_55511bd0-7a55-43d5-8374-5d9713779ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b71801c4-da26-45aa-b35e-d9b751418189" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_55511bd0-7a55-43d5-8374-5d9713779ae8" xlink:to="loc_srt_NameOfMajorCustomerDomain_b71801c4-da26-45aa-b35e-d9b751418189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_875f4025-8b53-41b3-9acf-926fada731f8" xlink:href="mgnx-20241231.xsd#mgnx_IncyteCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b71801c4-da26-45aa-b35e-d9b751418189" xlink:to="loc_mgnx_IncyteCorporationMember_875f4025-8b53-41b3-9acf-926fada731f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember_c1209834-9d1b-40cc-abab-48c921ec4a04" xlink:href="mgnx-20241231.xsd#mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b71801c4-da26-45aa-b35e-d9b751418189" xlink:to="loc_mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember_c1209834-9d1b-40cc-abab-48c921ec4a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CardinalHealthIncMember_219da165-4380-4ab8-a4ca-31eb871600ee" xlink:href="mgnx-20241231.xsd#mgnx_CardinalHealthIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b71801c4-da26-45aa-b35e-d9b751418189" xlink:to="loc_mgnx_CardinalHealthIncMember_219da165-4380-4ab8-a4ca-31eb871600ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ASDHealthcareAndOncologySupplyMember_7bf5b138-f170-4989-8faf-5f0063159ead" xlink:href="mgnx-20241231.xsd#mgnx_ASDHealthcareAndOncologySupplyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b71801c4-da26-45aa-b35e-d9b751418189" xlink:to="loc_mgnx_ASDHealthcareAndOncologySupplyMember_7bf5b138-f170-4989-8faf-5f0063159ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioMember_7e50554c-87ba-4d2d-a3cf-ffa17b4b6b43" xlink:href="mgnx-20241231.xsd#mgnx_ProventionBioMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b71801c4-da26-45aa-b35e-d9b751418189" xlink:to="loc_mgnx_ProventionBioMember_7e50554c-87ba-4d2d-a3cf-ffa17b4b6b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabLimitedMember_7839cecf-b61e-4fea-a5db-8ee7492312bb" xlink:href="mgnx-20241231.xsd#mgnx_ZaiLabLimitedMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b71801c4-da26-45aa-b35e-d9b751418189" xlink:to="loc_mgnx_ZaiLabLimitedMember_7839cecf-b61e-4fea-a5db-8ee7492312bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember_6b435fd2-7934-44a5-9fd6-bcb01077e1c5" xlink:href="mgnx-20241231.xsd#mgnx_ZaiLabMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b71801c4-da26-45aa-b35e-d9b751418189" xlink:to="loc_mgnx_ZaiLabMember_6b435fd2-7934-44a5-9fd6-bcb01077e1c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_bb821f02-4e82-440f-8b9e-64b47ee4154b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_ea254e3d-9ab1-473d-9d72-b1b2d07ec00f" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_bb821f02-4e82-440f-8b9e-64b47ee4154b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_030cfbee-4636-406b-a258-f5d66d70e8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_bb821f02-4e82-440f-8b9e-64b47ee4154b" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_030cfbee-4636-406b-a258-f5d66d70e8ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_84fe715c-41fb-41b5-b8cb-2a1fa0defc23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1429303d-62df-4413-a9ba-525e03fb82f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_84fe715c-41fb-41b5-b8cb-2a1fa0defc23" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1429303d-62df-4413-a9ba-525e03fb82f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_82a9fba2-5b25-4db9-8743-41e879d8a493" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1429303d-62df-4413-a9ba-525e03fb82f2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_82a9fba2-5b25-4db9-8743-41e879d8a493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_375f7542-5a8f-4b9c-92ab-ef6308b6ff3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_82a9fba2-5b25-4db9-8743-41e879d8a493" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_375f7542-5a8f-4b9c-92ab-ef6308b6ff3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_26bae746-6b50-4e62-b4b0-191e31633176" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_375f7542-5a8f-4b9c-92ab-ef6308b6ff3c" xlink:to="loc_us-gaap_ComputerEquipmentMember_26bae746-6b50-4e62-b4b0-191e31633176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_8ddd4972-dbc8-4658-be94-78317bc8f8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_375f7542-5a8f-4b9c-92ab-ef6308b6ff3c" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_8ddd4972-dbc8-4658-be94-78317bc8f8a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_cd9d5a50-45c4-40fe-94f5-792b56ce3359" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_375f7542-5a8f-4b9c-92ab-ef6308b6ff3c" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_cd9d5a50-45c4-40fe-94f5-792b56ce3359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LaboratoryAndOfficeEquipmentMember_09d2bc44-ed49-49d5-a894-48528c772f02" xlink:href="mgnx-20241231.xsd#mgnx_LaboratoryAndOfficeEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_375f7542-5a8f-4b9c-92ab-ef6308b6ff3c" xlink:to="loc_mgnx_LaboratoryAndOfficeEquipmentMember_09d2bc44-ed49-49d5-a894-48528c772f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0af6c762-78c7-49b6-8004-07b00549c9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1429303d-62df-4413-a9ba-525e03fb82f2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0af6c762-78c7-49b6-8004-07b00549c9a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_16db5f2a-9da5-4c88-bf1a-e6aea4bfba37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0af6c762-78c7-49b6-8004-07b00549c9a6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_16db5f2a-9da5-4c88-bf1a-e6aea4bfba37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6e55dfe6-ffb4-4a6c-b1f2-b6cf983768bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_aa32a7b8-7bb0-4e0d-bb24-f408ff4cf5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6e55dfe6-ffb4-4a6c-b1f2-b6cf983768bc" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_aa32a7b8-7bb0-4e0d-bb24-f408ff4cf5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_114ac939-2747-49dc-99a7-e71d003e8ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_aa32a7b8-7bb0-4e0d-bb24-f408ff4cf5c9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_114ac939-2747-49dc-99a7-e71d003e8ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2750f527-5bb3-4a9d-a37c-88b594e48059" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_114ac939-2747-49dc-99a7-e71d003e8ab3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2750f527-5bb3-4a9d-a37c-88b594e48059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockOptionsAndRestrictedStockUnitsMember_df2c5963-2d6a-4b09-a6e4-3b0f107ba843" xlink:href="mgnx-20241231.xsd#mgnx_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2750f527-5bb3-4a9d-a37c-88b594e48059" xlink:to="loc_mgnx_StockOptionsAndRestrictedStockUnitsMember_df2c5963-2d6a-4b09-a6e4-3b0f107ba843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5d37bb63-2f26-41df-93dd-0ccf60484d09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_aa32a7b8-7bb0-4e0d-bb24-f408ff4cf5c9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5d37bb63-2f26-41df-93dd-0ccf60484d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6b8a9e98-5a9d-4640-b861-c7567568f3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5d37bb63-2f26-41df-93dd-0ccf60484d09" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6b8a9e98-5a9d-4640-b861-c7567568f3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#MarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_301f6823-e4a8-49c0-87b7-2fdf302ad64b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_bcaf0018-1680-4748-b48f-a32cb73d9b01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_301f6823-e4a8-49c0-87b7-2fdf302ad64b" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_bcaf0018-1680-4748-b48f-a32cb73d9b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ae8131cc-0c2f-401a-ae12-c436d7520ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_bcaf0018-1680-4748-b48f-a32cb73d9b01" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ae8131cc-0c2f-401a-ae12-c436d7520ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e93f35d8-8d26-4408-bfb3-4885e4dfe95b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ae8131cc-0c2f-401a-ae12-c436d7520ba6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e93f35d8-8d26-4408-bfb3-4885e4dfe95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_fb192c6d-ae22-4fab-8d06-1869c094f60f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e93f35d8-8d26-4408-bfb3-4885e4dfe95b" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_fb192c6d-ae22-4fab-8d06-1869c094f60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_63f31aa6-c118-4ae1-a438-20fb5ecaf921" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e93f35d8-8d26-4408-bfb3-4885e4dfe95b" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_63f31aa6-c118-4ae1-a438-20fb5ecaf921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_402d0747-25b8-4676-957e-3cae58c75f55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e93f35d8-8d26-4408-bfb3-4885e4dfe95b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_402d0747-25b8-4676-957e-3cae58c75f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_16b8caf4-38cf-41a6-b574-fe9e2a5c2758" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_bcaf0018-1680-4748-b48f-a32cb73d9b01" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_16b8caf4-38cf-41a6-b574-fe9e2a5c2758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4c4bbcc7-e74e-4310-b99a-050ac70df5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_16b8caf4-38cf-41a6-b574-fe9e2a5c2758" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4c4bbcc7-e74e-4310-b99a-050ac70df5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a093c0ca-d9a4-434e-aaf6-d590004d9f65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_16b8caf4-38cf-41a6-b574-fe9e2a5c2758" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a093c0ca-d9a4-434e-aaf6-d590004d9f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_80057ec9-fa97-431a-bb88-b0e7424eb9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_16b8caf4-38cf-41a6-b574-fe9e2a5c2758" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_80057ec9-fa97-431a-bb88-b0e7424eb9a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b285dd65-f14b-4fbc-bde3-f61f57bf8154" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_16b8caf4-38cf-41a6-b574-fe9e2a5c2758" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b285dd65-f14b-4fbc-bde3-f61f57bf8154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#MarketableSecuritiesAvailableForSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_283fc7a9-5a5f-42a2-becc-0da85754de5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_4c24f5c0-a6e8-4b39-be46-c18fef74ff4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_283fc7a9-5a5f-42a2-becc-0da85754de5e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_4c24f5c0-a6e8-4b39-be46-c18fef74ff4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_23ef11b5-d876-403a-ae04-0bac5119a298" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_283fc7a9-5a5f-42a2-becc-0da85754de5e" xlink:to="loc_us-gaap_InterestIncomeOther_23ef11b5-d876-403a-ae04-0bac5119a298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/InventoryNetScheduleofInventoryDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#InventoryNetScheduleofInventoryDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/InventoryNetScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_3a1c5627-e343-4a5a-a655-01b31fa2ec84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_50594201-ad8e-4d8e-9ae4-32ce131b04a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3a1c5627-e343-4a5a-a655-01b31fa2ec84" xlink:to="loc_us-gaap_InventoryWorkInProcess_50594201-ad8e-4d8e-9ae4-32ce131b04a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_4312f257-59dd-4941-ba58-0e48d4bccc7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3a1c5627-e343-4a5a-a655-01b31fa2ec84" xlink:to="loc_us-gaap_InventoryFinishedGoods_4312f257-59dd-4941-ba58-0e48d4bccc7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_8fa9774c-7b51-487b-bef9-9c1f95c0f6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3a1c5627-e343-4a5a-a655-01b31fa2ec84" xlink:to="loc_us-gaap_InventoryNet_8fa9774c-7b51-487b-bef9-9c1f95c0f6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/InventoryNetDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#InventoryNetDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/InventoryNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_029c48ab-e691-4962-b787-fa817407e11f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_b1314382-4d66-4e77-bddd-e995d9d7ae2d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_029c48ab-e691-4962-b787-fa817407e11f" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_b1314382-4d66-4e77-bddd-e995d9d7ae2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_f3f1b8ee-0340-461f-9e96-eef35667adcd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_b1314382-4d66-4e77-bddd-e995d9d7ae2d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_f3f1b8ee-0340-461f-9e96-eef35667adcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_8dbd4700-49b2-4ab7-bd63-350d8bcd9811" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_f3f1b8ee-0340-461f-9e96-eef35667adcd" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_8dbd4700-49b2-4ab7-bd63-350d8bcd9811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserveMember_e81d8320-a13f-464a-b592-083566207ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserveMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8dbd4700-49b2-4ab7-bd63-350d8bcd9811" xlink:to="loc_us-gaap_InventoryValuationReserveMember_e81d8320-a13f-464a-b592-083566207ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_502237b8-d53a-4e68-934a-4a4aa38ad974" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_b1314382-4d66-4e77-bddd-e995d9d7ae2d" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_502237b8-d53a-4e68-934a-4a4aa38ad974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_f182d386-5723-46e7-9231-cdf12d34d3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_502237b8-d53a-4e68-934a-4a4aa38ad974" xlink:to="loc_us-gaap_InventoryValuationReserves_f182d386-5723-46e7-9231-cdf12d34d3fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_8021c491-2b85-4b8b-88b4-5dd727bf0bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_502237b8-d53a-4e68-934a-4a4aa38ad974" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_8021c491-2b85-4b8b-88b4-5dd727bf0bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_ec4d2cbc-da69-4686-907a-dbfd70758720" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_502237b8-d53a-4e68-934a-4a4aa38ad974" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_ec4d2cbc-da69-4686-907a-dbfd70758720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_54b782a8-2382-4d1f-aa94-86c983ee5cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_502237b8-d53a-4e68-934a-4a4aa38ad974" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_54b782a8-2382-4d1f-aa94-86c983ee5cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_b17b8d2e-15fa-4d53-8f6e-1e59274af5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_502237b8-d53a-4e68-934a-4a4aa38ad974" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_b17b8d2e-15fa-4d53-8f6e-1e59274af5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#PropertyEquipmentandSoftwareDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_457d3aca-402f-40f1-be25-4a2784962429" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_52d72099-9170-4d43-a612-9f89a5d1fe70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_457d3aca-402f-40f1-be25-4a2784962429" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_52d72099-9170-4d43-a612-9f89a5d1fe70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9fcd8f1a-47a5-4319-b996-898304d7365c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_52d72099-9170-4d43-a612-9f89a5d1fe70" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9fcd8f1a-47a5-4319-b996-898304d7365c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a7a55828-d2af-45c4-aa01-00690512c349" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9fcd8f1a-47a5-4319-b996-898304d7365c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a7a55828-d2af-45c4-aa01-00690512c349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_162463dc-8adb-415e-959f-b0e3505f9e73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a7a55828-d2af-45c4-aa01-00690512c349" xlink:to="loc_us-gaap_ComputerEquipmentMember_162463dc-8adb-415e-959f-b0e3505f9e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_703b7295-7a4d-4492-bf30-e8d95d597804" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a7a55828-d2af-45c4-aa01-00690512c349" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_703b7295-7a4d-4492-bf30-e8d95d597804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FurnitureAndOfficeEquipmentMember_135de547-77f4-4fd2-ad75-b59c8d09a166" xlink:href="mgnx-20241231.xsd#mgnx_FurnitureAndOfficeEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a7a55828-d2af-45c4-aa01-00690512c349" xlink:to="loc_mgnx_FurnitureAndOfficeEquipmentMember_135de547-77f4-4fd2-ad75-b59c8d09a166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_25c943b2-a4bb-42ff-879f-dd293bfeab12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VehiclesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a7a55828-d2af-45c4-aa01-00690512c349" xlink:to="loc_us-gaap_VehiclesMember_25c943b2-a4bb-42ff-879f-dd293bfeab12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_d073a4fe-b910-4231-a3cd-6a6e477a2dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a7a55828-d2af-45c4-aa01-00690512c349" xlink:to="loc_us-gaap_EquipmentMember_d073a4fe-b910-4231-a3cd-6a6e477a2dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_0d6d6b07-f36f-4345-a2ee-70bf8a9b7824" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a7a55828-d2af-45c4-aa01-00690512c349" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_0d6d6b07-f36f-4345-a2ee-70bf8a9b7824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_138a4265-ce8b-462c-90fa-def77b357ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_52d72099-9170-4d43-a612-9f89a5d1fe70" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_138a4265-ce8b-462c-90fa-def77b357ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1b7c2ff5-9ea5-4a19-b1f9-2d222556a6df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_138a4265-ce8b-462c-90fa-def77b357ac0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1b7c2ff5-9ea5-4a19-b1f9-2d222556a6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_080d764a-51a0-4b67-983c-ac184a68236b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_138a4265-ce8b-462c-90fa-def77b357ac0" xlink:to="loc_us-gaap_ConstructionInProgressGross_080d764a-51a0-4b67-983c-ac184a68236b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_46b4b37b-4898-4f1f-ab8c-38f587506f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_138a4265-ce8b-462c-90fa-def77b357ac0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_46b4b37b-4898-4f1f-ab8c-38f587506f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_cefa415d-fb3d-480b-a35a-91b25d1f1783" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_138a4265-ce8b-462c-90fa-def77b357ac0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_cefa415d-fb3d-480b-a35a-91b25d1f1783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_8125bd67-a674-4ed3-8134-4b80b2b2f18b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_138a4265-ce8b-462c-90fa-def77b357ac0" xlink:to="loc_us-gaap_Depreciation_8125bd67-a674-4ed3-8134-4b80b2b2f18b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3002dd89-9115-4743-8dfb-d769bffa56d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_d059f017-346e-49b4-a0a6-2dc63fc73767" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3002dd89-9115-4743-8dfb-d769bffa56d6" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_d059f017-346e-49b4-a0a6-2dc63fc73767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1a282ac9-3faf-4188-9a0f-6ecc1325103b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d059f017-346e-49b4-a0a6-2dc63fc73767" xlink:to="loc_srt_CounterpartyNameAxis_1a282ac9-3faf-4188-9a0f-6ecc1325103b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3de72423-653f-4f46-848c-a79f5598bdde" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_1a282ac9-3faf-4188-9a0f-6ecc1325103b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3de72423-653f-4f46-848c-a79f5598bdde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_SynaffixBVMember_4f95fafe-be7e-4724-8446-57ffb0e959af" xlink:href="mgnx-20241231.xsd#mgnx_SynaffixBVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3de72423-653f-4f46-848c-a79f5598bdde" xlink:to="loc_mgnx_SynaffixBVMember_4f95fafe-be7e-4724-8446-57ffb0e959af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_50405ae2-81ff-4cd2-8e15-9cf80335b0b4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d059f017-346e-49b4-a0a6-2dc63fc73767" xlink:to="loc_srt_RangeAxis_50405ae2-81ff-4cd2-8e15-9cf80335b0b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_deb59f45-e9d2-44df-afcc-fc96310114ad" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_50405ae2-81ff-4cd2-8e15-9cf80335b0b4" xlink:to="loc_srt_RangeMember_deb59f45-e9d2-44df-afcc-fc96310114ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_684e95a2-c281-4528-829e-70decb28a079" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_deb59f45-e9d2-44df-afcc-fc96310114ad" xlink:to="loc_srt_MinimumMember_684e95a2-c281-4528-829e-70decb28a079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d059f017-346e-49b4-a0a6-2dc63fc73767" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_702a16f3-ef53-460c-a67e-86bfbdd7c2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_702a16f3-ef53-460c-a67e-86bfbdd7c2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease_24d0f703-bdbd-416e-b8ed-8eccf2434cac" xlink:href="mgnx-20241231.xsd#mgnx_RightOfUseAssetAndLeaseLiabilityIncrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease_24d0f703-bdbd-416e-b8ed-8eccf2434cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a79f4c58-3305-4282-b124-cfc054118576" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a79f4c58-3305-4282-b124-cfc054118576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_19b7e954-7bd0-47f3-ad89-a4de94729c29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_19b7e954-7bd0-47f3-ad89-a4de94729c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_fec9939e-e850-4ce5-ab4b-b13a23431f31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_us-gaap_OperatingLeasePayments_fec9939e-e850-4ce5-ab4b-b13a23431f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b577a97f-a245-4cd8-a583-417fc9124a63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b577a97f-a245-4cd8-a583-417fc9124a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_01e37b46-2015-4292-bdfe-06236fd9712d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_us-gaap_OperatingLeaseCost_01e37b46-2015-4292-bdfe-06236fd9712d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_56eb37f0-3182-402d-abe4-0656dfcff81a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_us-gaap_VariableLeaseCost_56eb37f0-3182-402d-abe4-0656dfcff81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_45292909-87b1-4d6a-befb-69ef27d86e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_us-gaap_SubleaseIncome_45292909-87b1-4d6a-befb-69ef27d86e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_f0859c3c-e20a-4eb2-ba96-82bd22948b80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_us-gaap_LeaseCost_f0859c3c-e20a-4eb2-ba96-82bd22948b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e20a47f6-00cb-4249-ab74-c4323225c1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e20a47f6-00cb-4249-ab74-c4323225c1f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1a916eef-f536-4191-9cb0-1f13d3e85c04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1a916eef-f536-4191-9cb0-1f13d3e85c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_098bbd29-55f8-4f56-aa9e-8a0179200925" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_098bbd29-55f8-4f56-aa9e-8a0179200925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_bfd4b828-2ee8-4f60-9b7b-f4f66acce420" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_bfd4b828-2ee8-4f60-9b7b-f4f66acce420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_4d5f9e04-590f-473f-97ea-e1e8ebfb25a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_4d5f9e04-590f-473f-97ea-e1e8ebfb25a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_3950bc63-96af-4a22-b86a-53d9a211703d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_3950bc63-96af-4a22-b86a-53d9a211703d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3ceee702-0c0d-4e10-b08c-53353bca5302" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3ceee702-0c0d-4e10-b08c-53353bca5302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5185274d-8239-49b2-8fc6-d5c489fdbf7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5185274d-8239-49b2-8fc6-d5c489fdbf7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_df442935-8fe1-4246-ac74-fa8fbca7ab93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_us-gaap_OperatingLeaseLiability_df442935-8fe1-4246-ac74-fa8fbca7ab93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_06afe125-ecff-434f-b5b8-32fcfd809399" xlink:href="mgnx-20241231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_06afe125-ecff-434f-b5b8-32fcfd809399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_cf8eb0a2-98fb-46b8-b104-741a602f30ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_734e2554-640e-435a-91a7-302e5e89222c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_cf8eb0a2-98fb-46b8-b104-741a602f30ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f3117cf9-b9a8-4804-9892-9498be732091" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_bb925335-13ca-48c0-948a-a3b68684758a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f3117cf9-b9a8-4804-9892-9498be732091" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_bb925335-13ca-48c0-948a-a3b68684758a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5fa683ca-2198-4284-b83a-14d0edc33ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bb925335-13ca-48c0-948a-a3b68684758a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5fa683ca-2198-4284-b83a-14d0edc33ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b324c825-f1ee-4527-8821-4a9d6ccc26a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5fa683ca-2198-4284-b83a-14d0edc33ab8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b324c825-f1ee-4527-8821-4a9d6ccc26a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AtTheMarketOfferingMember_f14d4a75-d51f-4bea-add1-570efcf8b6f2" xlink:href="mgnx-20241231.xsd#mgnx_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b324c825-f1ee-4527-8821-4a9d6ccc26a1" xlink:to="loc_mgnx_AtTheMarketOfferingMember_f14d4a75-d51f-4bea-add1-570efcf8b6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0b0ab59e-f53a-433b-a6db-d3aba3cfbae1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bb925335-13ca-48c0-948a-a3b68684758a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0b0ab59e-f53a-433b-a6db-d3aba3cfbae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8aa007f0-2dc8-4bec-aaf1-5745d565c66c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0b0ab59e-f53a-433b-a6db-d3aba3cfbae1" xlink:to="loc_us-gaap_ClassOfStockDomain_8aa007f0-2dc8-4bec-aaf1-5745d565c66c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UndesignatedPreferredStockMember_0f775ddc-4fb7-4f9e-88bb-c9b94f15fc3d" xlink:href="mgnx-20241231.xsd#mgnx_UndesignatedPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8aa007f0-2dc8-4bec-aaf1-5745d565c66c" xlink:to="loc_mgnx_UndesignatedPreferredStockMember_0f775ddc-4fb7-4f9e-88bb-c9b94f15fc3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_a9c1618e-21ae-431d-8903-db96a75e62de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bb925335-13ca-48c0-948a-a3b68684758a" xlink:to="loc_us-gaap_ClassOfStockLineItems_a9c1618e-21ae-431d-8903-db96a75e62de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0244b42b-1db7-421d-a8e6-74d200dddc14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a9c1618e-21ae-431d-8903-db96a75e62de" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0244b42b-1db7-421d-a8e6-74d200dddc14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_286e6597-c907-460c-829c-4c0d9897ca7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a9c1618e-21ae-431d-8903-db96a75e62de" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_286e6597-c907-460c-829c-4c0d9897ca7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_904d8989-123e-496f-9d8a-9564b94b185b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a9c1618e-21ae-431d-8903-db96a75e62de" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_904d8989-123e-496f-9d8a-9564b94b185b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_5b760911-9986-4be6-834e-6d285e1a5508" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a9c1618e-21ae-431d-8903-db96a75e62de" xlink:to="loc_us-gaap_PreferredStockSharesIssued_5b760911-9986-4be6-834e-6d285e1a5508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_684c6ee5-f97d-468c-892c-fe846b9e8202" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a9c1618e-21ae-431d-8903-db96a75e62de" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_684c6ee5-f97d-468c-892c-fe846b9e8202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_a64c05ad-23e5-4522-b008-26c7de0d3627" xlink:href="mgnx-20241231.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a9c1618e-21ae-431d-8903-db96a75e62de" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_a64c05ad-23e5-4522-b008-26c7de0d3627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6962ca1f-0140-439e-9f9c-85e23d1bce97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a9c1618e-21ae-431d-8903-db96a75e62de" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6962ca1f-0140-439e-9f9c-85e23d1bce97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_72e10c11-a3a8-437d-9645-53df630e5a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a9c1618e-21ae-431d-8903-db96a75e62de" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_72e10c11-a3a8-437d-9645-53df630e5a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_87c897be-dab4-49b3-a293-ea7ae8426bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a9c1618e-21ae-431d-8903-db96a75e62de" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_87c897be-dab4-49b3-a293-ea7ae8426bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueIncyteCorporationDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#RevenueIncyteCorporationDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/RevenueIncyteCorporationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_86b22bc4-33fa-41ee-976f-fb749f012bd8" xlink:href="mgnx-20241231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10c1ea30-ff98-41bc-b446-2d5ea50c6989" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_86b22bc4-33fa-41ee-976f-fb749f012bd8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10c1ea30-ff98-41bc-b446-2d5ea50c6989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_887edc4e-b945-402a-92f1-30332aaf3a9b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10c1ea30-ff98-41bc-b446-2d5ea50c6989" xlink:to="loc_srt_ProductOrServiceAxis_887edc4e-b945-402a-92f1-30332aaf3a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5b526a28-69f6-45b0-b406-ff4d04356c16" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_887edc4e-b945-402a-92f1-30332aaf3a9b" xlink:to="loc_srt_ProductsAndServicesDomain_5b526a28-69f6-45b0-b406-ff4d04356c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_426e20fc-c334-4561-999c-af1e18a229d9" xlink:href="mgnx-20241231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5b526a28-69f6-45b0-b406-ff4d04356c16" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_426e20fc-c334-4561-999c-af1e18a229d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3a7c8065-695b-4a43-95aa-1c7db1ef6221" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10c1ea30-ff98-41bc-b446-2d5ea50c6989" xlink:to="loc_srt_RangeAxis_3a7c8065-695b-4a43-95aa-1c7db1ef6221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a25b7d53-99d5-47c4-8900-96518a96f5a7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3a7c8065-695b-4a43-95aa-1c7db1ef6221" xlink:to="loc_srt_RangeMember_a25b7d53-99d5-47c4-8900-96518a96f5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_305b4cf7-31ab-437b-b05c-c334a7e1b6db" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a25b7d53-99d5-47c4-8900-96518a96f5a7" xlink:to="loc_srt_MinimumMember_305b4cf7-31ab-437b-b05c-c334a7e1b6db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d669da55-9c07-43eb-829c-d716b9b17246" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a25b7d53-99d5-47c4-8900-96518a96f5a7" xlink:to="loc_srt_MaximumMember_d669da55-9c07-43eb-829c-d716b9b17246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2214f871-0efb-4f1f-ac61-40d7e7ed48db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10c1ea30-ff98-41bc-b446-2d5ea50c6989" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2214f871-0efb-4f1f-ac61-40d7e7ed48db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3041e403-7f8c-491c-b6de-8a112ecb1c30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_2214f871-0efb-4f1f-ac61-40d7e7ed48db" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3041e403-7f8c-491c-b6de-8a112ecb1c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_778f6df3-7de8-49bc-9964-488ffdb71938" xlink:href="mgnx-20241231.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3041e403-7f8c-491c-b6de-8a112ecb1c30" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_778f6df3-7de8-49bc-9964-488ffdb71938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteClinicalSupplyAgreementMember_22a797e7-4da5-4a26-9db5-d8d0142e2ce3" xlink:href="mgnx-20241231.xsd#mgnx_IncyteClinicalSupplyAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3041e403-7f8c-491c-b6de-8a112ecb1c30" xlink:to="loc_mgnx_IncyteClinicalSupplyAgreementMember_22a797e7-4da5-4a26-9db5-d8d0142e2ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCommercialSupplyAgreementMember_fdedd95f-1042-4706-95db-0d72912cd50e" xlink:href="mgnx-20241231.xsd#mgnx_IncyteCommercialSupplyAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3041e403-7f8c-491c-b6de-8a112ecb1c30" xlink:to="loc_mgnx_IncyteCommercialSupplyAgreementMember_fdedd95f-1042-4706-95db-0d72912cd50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_93ab9400-9e97-438f-a24d-78a43fa7b053" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10c1ea30-ff98-41bc-b446-2d5ea50c6989" xlink:to="loc_srt_CounterpartyNameAxis_93ab9400-9e97-438f-a24d-78a43fa7b053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d020a08b-f6ce-497a-a9ee-6d5b916f880b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_93ab9400-9e97-438f-a24d-78a43fa7b053" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d020a08b-f6ce-497a-a9ee-6d5b916f880b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_73005160-35c9-48c9-9ae8-c8e384420c90" xlink:href="mgnx-20241231.xsd#mgnx_IncyteCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d020a08b-f6ce-497a-a9ee-6d5b916f880b" xlink:to="loc_mgnx_IncyteCorporationMember_73005160-35c9-48c9-9ae8-c8e384420c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8f235664-ce9a-4568-865f-2ce079922805" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10c1ea30-ff98-41bc-b446-2d5ea50c6989" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8f235664-ce9a-4568-865f-2ce079922805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_81f39da6-8cb9-4bd3-bc6e-035148847df7" xlink:href="mgnx-20241231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8f235664-ce9a-4568-865f-2ce079922805" xlink:to="loc_mgnx_NonRefundableUpfrontFees_81f39da6-8cb9-4bd3-bc6e-035148847df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_da55511e-3259-417b-9271-6ada783de306" xlink:href="mgnx-20241231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8f235664-ce9a-4568-865f-2ce079922805" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_da55511e-3259-417b-9271-6ada783de306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_676f8b5b-6a7f-4345-bdc1-2e8e3eb6bf5a" xlink:href="mgnx-20241231.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8f235664-ce9a-4568-865f-2ce079922805" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_676f8b5b-6a7f-4345-bdc1-2e8e3eb6bf5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_22f63feb-f655-481c-8aae-4358622531f0" xlink:href="mgnx-20241231.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8f235664-ce9a-4568-865f-2ce079922805" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_22f63feb-f655-481c-8aae-4358622531f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_ffa1a6eb-fbbe-40bd-a46e-6176cc4aaa24" xlink:href="mgnx-20241231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8f235664-ce9a-4568-865f-2ce079922805" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_ffa1a6eb-fbbe-40bd-a46e-6176cc4aaa24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_c2024d7b-00a6-4bbc-bfbe-d688f818aa9a" xlink:href="mgnx-20241231.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8f235664-ce9a-4568-865f-2ce079922805" xlink:to="loc_mgnx_NumberOfPerformanceObligations_c2024d7b-00a6-4bbc-bfbe-d688f818aa9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_60ecdcfe-87e1-419c-a99c-5cb2beba5070" xlink:href="mgnx-20241231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8f235664-ce9a-4568-865f-2ce079922805" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_60ecdcfe-87e1-419c-a99c-5cb2beba5070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f10978c7-03ed-4f0c-9675-0d46824823c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8f235664-ce9a-4568-865f-2ce079922805" xlink:to="loc_us-gaap_Revenues_f10978c7-03ed-4f0c-9675-0d46824823c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_26c9d52e-2745-42cd-b802-f74895f72a8c" xlink:href="mgnx-20241231.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8f235664-ce9a-4568-865f-2ce079922805" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_26c9d52e-2745-42cd-b802-f74895f72a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueGileadSciencesIncDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#RevenueGileadSciencesIncDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/RevenueGileadSciencesIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_8c25f18f-01a4-44a7-a1fd-615b90d3c2fb" xlink:href="mgnx-20241231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_743dd0d3-8065-4d06-b93d-309dd57bd0b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_8c25f18f-01a4-44a7-a1fd-615b90d3c2fb" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_743dd0d3-8065-4d06-b93d-309dd57bd0b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_93820b6a-7427-4bd3-9e92-b0a15a94c3d3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_743dd0d3-8065-4d06-b93d-309dd57bd0b4" xlink:to="loc_srt_CounterpartyNameAxis_93820b6a-7427-4bd3-9e92-b0a15a94c3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_583ff3db-6fdc-4c3d-a8d0-0f79790a8991" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_93820b6a-7427-4bd3-9e92-b0a15a94c3d3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_583ff3db-6fdc-4c3d-a8d0-0f79790a8991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GileadMember_c3509c5d-72b3-40e4-abc8-041454d96945" xlink:href="mgnx-20241231.xsd#mgnx_GileadMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_583ff3db-6fdc-4c3d-a8d0-0f79790a8991" xlink:to="loc_mgnx_GileadMember_c3509c5d-72b3-40e4-abc8-041454d96945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_6199287b-64ed-4584-aa04-442a3d5873ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_743dd0d3-8065-4d06-b93d-309dd57bd0b4" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_6199287b-64ed-4584-aa04-442a3d5873ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_83a6648f-bf75-46a7-b1e5-cc99dfec8034" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_6199287b-64ed-4584-aa04-442a3d5873ab" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_83a6648f-bf75-46a7-b1e5-cc99dfec8034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2022GileadCollaborationAndLicenseAgreementMember_99ae50e9-4403-4cca-9fc0-2b583b95b27a" xlink:href="mgnx-20241231.xsd#mgnx_A2022GileadCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_83a6648f-bf75-46a7-b1e5-cc99dfec8034" xlink:to="loc_mgnx_A2022GileadCollaborationAndLicenseAgreementMember_99ae50e9-4403-4cca-9fc0-2b583b95b27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GileadFirstResearchProgramMember_50307ecf-22ec-40b8-9b2f-ba7e5b18274a" xlink:href="mgnx-20241231.xsd#mgnx_GileadFirstResearchProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_83a6648f-bf75-46a7-b1e5-cc99dfec8034" xlink:to="loc_mgnx_GileadFirstResearchProgramMember_50307ecf-22ec-40b8-9b2f-ba7e5b18274a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b3c5fa3-f557-4d76-b0c7-2933bcab4d81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_743dd0d3-8065-4d06-b93d-309dd57bd0b4" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b3c5fa3-f557-4d76-b0c7-2933bcab4d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_20eb8cd8-af15-446d-92ba-a892a66c9689" xlink:href="mgnx-20241231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b3c5fa3-f557-4d76-b0c7-2933bcab4d81" xlink:to="loc_mgnx_NonRefundableUpfrontFees_20eb8cd8-af15-446d-92ba-a892a66c9689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments_5a748fda-e5d3-4e20-bfb9-5fc3df3484b5" xlink:href="mgnx-20241231.xsd#mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b3c5fa3-f557-4d76-b0c7-2933bcab4d81" xlink:to="loc_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments_5a748fda-e5d3-4e20-bfb9-5fc3df3484b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_05a6e475-302a-4fbc-bfb0-acde160b5887" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b3c5fa3-f557-4d76-b0c7-2933bcab4d81" xlink:to="loc_us-gaap_Revenues_05a6e475-302a-4fbc-bfb0-acde160b5887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_086ef239-67e2-4002-81de-a1accab2eebf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b3c5fa3-f557-4d76-b0c7-2933bcab4d81" xlink:to="loc_us-gaap_ContractWithCustomerLiability_086ef239-67e2-4002-81de-a1accab2eebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9210e553-2174-4d50-9efe-ceff38bec12f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b3c5fa3-f557-4d76-b0c7-2933bcab4d81" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9210e553-2174-4d50-9efe-ceff38bec12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_742836aa-461e-4a8d-9a21-5d417f5b92ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b3c5fa3-f557-4d76-b0c7-2933bcab4d81" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_742836aa-461e-4a8d-9a21-5d417f5b92ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_a0cb2ddd-a985-49ac-ab25-85304887b924" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b3c5fa3-f557-4d76-b0c7-2933bcab4d81" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_a0cb2ddd-a985-49ac-ab25-85304887b924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OptionToBuy_ecadf5cb-014e-4364-8630-ad5b5e747b20" xlink:href="mgnx-20241231.xsd#mgnx_OptionToBuy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b3c5fa3-f557-4d76-b0c7-2933bcab4d81" xlink:to="loc_mgnx_OptionToBuy_ecadf5cb-014e-4364-8630-ad5b5e747b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_df69ce77-1d76-4774-91cc-02e5852e8e76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b3c5fa3-f557-4d76-b0c7-2933bcab4d81" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_df69ce77-1d76-4774-91cc-02e5852e8e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueZaiLabDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#RevenueZaiLabDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/RevenueZaiLabDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_b75cc1c7-8b49-4df0-b59b-533cd6565b60" xlink:href="mgnx-20241231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4d7959e1-efd4-4df6-8cfd-7d4533566ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_b75cc1c7-8b49-4df0-b59b-533cd6565b60" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4d7959e1-efd4-4df6-8cfd-7d4533566ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_59fee0d0-b571-498b-a308-082c351a955e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4d7959e1-efd4-4df6-8cfd-7d4533566ea0" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_59fee0d0-b571-498b-a308-082c351a955e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d877f959-e556-4797-ad8e-f7c00ab7a991" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_59fee0d0-b571-498b-a308-082c351a955e" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d877f959-e556-4797-ad8e-f7c00ab7a991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2021ZaiLabAgreementsMember_4108a414-e458-42fb-8183-481372fc4974" xlink:href="mgnx-20241231.xsd#mgnx_A2021ZaiLabAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d877f959-e556-4797-ad8e-f7c00ab7a991" xlink:to="loc_mgnx_A2021ZaiLabAgreementsMember_4108a414-e458-42fb-8183-481372fc4974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_08be42cc-a5c7-4055-a3e5-ff02ae738857" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4d7959e1-efd4-4df6-8cfd-7d4533566ea0" xlink:to="loc_srt_CounterpartyNameAxis_08be42cc-a5c7-4055-a3e5-ff02ae738857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3708216b-703c-4dc4-86ba-de157f81b658" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_08be42cc-a5c7-4055-a3e5-ff02ae738857" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3708216b-703c-4dc4-86ba-de157f81b658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember_808a8768-8886-466a-a0b1-554ad33060ce" xlink:href="mgnx-20241231.xsd#mgnx_ZaiLabMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3708216b-703c-4dc4-86ba-de157f81b658" xlink:to="loc_mgnx_ZaiLabMember_808a8768-8886-466a-a0b1-554ad33060ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa50a7d4-1245-47ce-afb6-160c1216cdf4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4d7959e1-efd4-4df6-8cfd-7d4533566ea0" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa50a7d4-1245-47ce-afb6-160c1216cdf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_dbbb5045-4afb-42fa-817e-dfcb0b74dd8d" xlink:href="mgnx-20241231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa50a7d4-1245-47ce-afb6-160c1216cdf4" xlink:to="loc_mgnx_NonRefundableUpfrontFees_dbbb5045-4afb-42fa-817e-dfcb0b74dd8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_2457d06a-426f-4019-a26e-a62ee49af7b7" xlink:href="mgnx-20241231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa50a7d4-1245-47ce-afb6-160c1216cdf4" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_2457d06a-426f-4019-a26e-a62ee49af7b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_026423d1-e572-4dc9-a022-f169342c621f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aa50a7d4-1245-47ce-afb6-160c1216cdf4" xlink:to="loc_us-gaap_Revenues_026423d1-e572-4dc9-a022-f169342c621f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueProventionDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#RevenueProventionDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/RevenueProventionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_4d8d98ad-6b05-4cef-bc6c-0d0b5d32a04e" xlink:href="mgnx-20241231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7ef551da-15ea-4a00-b63c-39611f35b926" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_4d8d98ad-6b05-4cef-bc6c-0d0b5d32a04e" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7ef551da-15ea-4a00-b63c-39611f35b926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f576fafe-784d-4a6b-bb8a-af1f5297e449" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7ef551da-15ea-4a00-b63c-39611f35b926" xlink:to="loc_srt_CounterpartyNameAxis_f576fafe-784d-4a6b-bb8a-af1f5297e449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_199bb825-a84b-4d31-a131-a22d831972b6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_f576fafe-784d-4a6b-bb8a-af1f5297e449" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_199bb825-a84b-4d31-a131-a22d831972b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioMember_538cbbc9-92fc-4b50-8ad4-a191026213c9" xlink:href="mgnx-20241231.xsd#mgnx_ProventionBioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_199bb825-a84b-4d31-a131-a22d831972b6" xlink:to="loc_mgnx_ProventionBioMember_538cbbc9-92fc-4b50-8ad4-a191026213c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DRIHealthcareAcquisitionsLPDRIMember_e2fedaba-7421-4434-b82b-168b801f0dd5" xlink:href="mgnx-20241231.xsd#mgnx_DRIHealthcareAcquisitionsLPDRIMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_199bb825-a84b-4d31-a131-a22d831972b6" xlink:to="loc_mgnx_DRIHealthcareAcquisitionsLPDRIMember_e2fedaba-7421-4434-b82b-168b801f0dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ebc3a9be-6f3a-458f-b69b-495e3c7caa33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7ef551da-15ea-4a00-b63c-39611f35b926" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ebc3a9be-6f3a-458f-b69b-495e3c7caa33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f70d1965-ee1d-40d0-80f2-dfb39f5eefdb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ebc3a9be-6f3a-458f-b69b-495e3c7caa33" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f70d1965-ee1d-40d0-80f2-dfb39f5eefdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV3279Member_82536552-7f13-4e81-ae7b-5855c652ce8d" xlink:href="mgnx-20241231.xsd#mgnx_ProventionPRV3279Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f70d1965-ee1d-40d0-80f2-dfb39f5eefdb" xlink:to="loc_mgnx_ProventionPRV3279Member_82536552-7f13-4e81-ae7b-5855c652ce8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV031Member_021801ea-d467-4416-acad-4663689ee61a" xlink:href="mgnx-20241231.xsd#mgnx_ProventionPRV031Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f70d1965-ee1d-40d0-80f2-dfb39f5eefdb" xlink:to="loc_mgnx_ProventionPRV031Member_021801ea-d467-4416-acad-4663689ee61a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c42c8580-226e-432e-ac5d-f142343aa96e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7ef551da-15ea-4a00-b63c-39611f35b926" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c42c8580-226e-432e-ac5d-f142343aa96e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_66cee575-df34-4f15-af25-3e05b33c4215" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c42c8580-226e-432e-ac5d-f142343aa96e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_66cee575-df34-4f15-af25-3e05b33c4215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionLicenseAgreementMember_ab42cddd-fcce-4d08-8c3d-900ce27cef79" xlink:href="mgnx-20241231.xsd#mgnx_ProventionLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_66cee575-df34-4f15-af25-3e05b33c4215" xlink:to="loc_mgnx_ProventionLicenseAgreementMember_ab42cddd-fcce-4d08-8c3d-900ce27cef79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AssetPurchaseAgreementMember_cd298071-9291-4724-a201-fbe88f987174" xlink:href="mgnx-20241231.xsd#mgnx_AssetPurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_66cee575-df34-4f15-af25-3e05b33c4215" xlink:to="loc_mgnx_AssetPurchaseAgreementMember_cd298071-9291-4724-a201-fbe88f987174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_SideLetterAgreementMember_68edb148-bbc9-4dfe-88e4-93fd1018c2bc" xlink:href="mgnx-20241231.xsd#mgnx_SideLetterAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_66cee575-df34-4f15-af25-3e05b33c4215" xlink:to="loc_mgnx_SideLetterAgreementMember_68edb148-bbc9-4dfe-88e4-93fd1018c2bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionAPAMember_6edebc68-0d68-4eeb-a896-cf68376484e8" xlink:href="mgnx-20241231.xsd#mgnx_ProventionAPAMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_66cee575-df34-4f15-af25-3e05b33c4215" xlink:to="loc_mgnx_ProventionAPAMember_6edebc68-0d68-4eeb-a896-cf68376484e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a2d79287-4c5b-48aa-bd12-f6678ed6eea9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7ef551da-15ea-4a00-b63c-39611f35b926" xlink:to="loc_srt_ProductOrServiceAxis_a2d79287-4c5b-48aa-bd12-f6678ed6eea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ab5eaed5-5eeb-4536-94e8-5a310ec4e650" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a2d79287-4c5b-48aa-bd12-f6678ed6eea9" xlink:to="loc_srt_ProductsAndServicesDomain_ab5eaed5-5eeb-4536-94e8-5a310ec4e650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_5ad94b51-979b-4f56-95e3-35e172bd9e17" xlink:href="mgnx-20241231.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ab5eaed5-5eeb-4536-94e8-5a310ec4e650" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_5ad94b51-979b-4f56-95e3-35e172bd9e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AssetPurchaseAgreementMember_ad5f715a-01ce-4084-8803-39f72b23e44e" xlink:href="mgnx-20241231.xsd#mgnx_AssetPurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ab5eaed5-5eeb-4536-94e8-5a310ec4e650" xlink:to="loc_mgnx_AssetPurchaseAgreementMember_ad5f715a-01ce-4084-8803-39f72b23e44e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb37ab7d-dc0b-4762-8185-da6114a5d4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7ef551da-15ea-4a00-b63c-39611f35b926" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb37ab7d-dc0b-4762-8185-da6114a5d4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_9225d98e-0845-4b21-8a8e-62011347269e" xlink:href="mgnx-20241231.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb37ab7d-dc0b-4762-8185-da6114a5d4a6" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_9225d98e-0845-4b21-8a8e-62011347269e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_29682d82-95e7-4a5d-b0bc-a798885813c0" xlink:href="mgnx-20241231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb37ab7d-dc0b-4762-8185-da6114a5d4a6" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_29682d82-95e7-4a5d-b0bc-a798885813c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_64011f76-c764-4741-adb3-9f2574bf0a38" xlink:href="mgnx-20241231.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb37ab7d-dc0b-4762-8185-da6114a5d4a6" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_64011f76-c764-4741-adb3-9f2574bf0a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_533fa91e-3e9d-45fd-a0a2-1f8fb98fe09b" xlink:href="mgnx-20241231.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb37ab7d-dc0b-4762-8185-da6114a5d4a6" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_533fa91e-3e9d-45fd-a0a2-1f8fb98fe09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_GainOnRoyaltyMonetizationArrangement_b2eda23c-3749-43a2-846f-7d05088d951f" xlink:href="mgnx-20241231.xsd#mgnx_GainOnRoyaltyMonetizationArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb37ab7d-dc0b-4762-8185-da6114a5d4a6" xlink:to="loc_mgnx_GainOnRoyaltyMonetizationArrangement_b2eda23c-3749-43a2-846f-7d05088d951f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_4f5013d8-e7a6-4dd4-b3f6-a079b3a5988b" xlink:href="mgnx-20241231.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb37ab7d-dc0b-4762-8185-da6114a5d4a6" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_4f5013d8-e7a6-4dd4-b3f6-a079b3a5988b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_46cd3442-bdc2-426d-ade0-94a5afde0893" xlink:href="mgnx-20241231.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb37ab7d-dc0b-4762-8185-da6114a5d4a6" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_46cd3442-bdc2-426d-ade0-94a5afde0893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_21590ac4-5652-4606-b4d9-588e83a1fdba" xlink:href="mgnx-20241231.xsd#mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb37ab7d-dc0b-4762-8185-da6114a5d4a6" xlink:to="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_21590ac4-5652-4606-b4d9-588e83a1fdba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_99771b0e-e5a3-4ec1-9295-f6b82c7f3ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb37ab7d-dc0b-4762-8185-da6114a5d4a6" xlink:to="loc_us-gaap_Revenues_99771b0e-e5a3-4ec1-9295-f6b82c7f3ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UpfrontPayment_f3f9a5f3-4135-4f26-b089-68c30f6dd352" xlink:href="mgnx-20241231.xsd#mgnx_UpfrontPayment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb37ab7d-dc0b-4762-8185-da6114a5d4a6" xlink:to="loc_mgnx_UpfrontPayment_f3f9a5f3-4135-4f26-b089-68c30f6dd352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_cd076e05-5e39-41bc-a52b-de8a586edb8a" xlink:href="mgnx-20241231.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb37ab7d-dc0b-4762-8185-da6114a5d4a6" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_cd076e05-5e39-41bc-a52b-de8a586edb8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AdditionalTZIELDMilestones_c62aeb8f-c812-470b-82cb-e1a8506f647f" xlink:href="mgnx-20241231.xsd#mgnx_AdditionalTZIELDMilestones"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eb37ab7d-dc0b-4762-8185-da6114a5d4a6" xlink:to="loc_mgnx_AdditionalTZIELDMilestones_c62aeb8f-c812-470b-82cb-e1a8506f647f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#RevenueManufacturingServiceAgreementsDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract_4a98c842-e385-4a27-b610-6d4bf610da20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ebffb734-5220-48f3-96b0-1a973bc278e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_4a98c842-e385-4a27-b610-6d4bf610da20" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ebffb734-5220-48f3-96b0-1a973bc278e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d706fa90-fd62-4860-affc-686872d64f5d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ebffb734-5220-48f3-96b0-1a973bc278e7" xlink:to="loc_srt_CounterpartyNameAxis_d706fa90-fd62-4860-affc-686872d64f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bef09629-6c40-4310-b750-cd218112641c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d706fa90-fd62-4860-affc-686872d64f5d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bef09629-6c40-4310-b750-cd218112641c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_8b548c66-c183-4deb-9118-fe869913ead4" xlink:href="mgnx-20241231.xsd#mgnx_IncyteCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bef09629-6c40-4310-b750-cd218112641c" xlink:to="loc_mgnx_IncyteCorporationMember_8b548c66-c183-4deb-9118-fe869913ead4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioMember_d234b70d-fb94-46cc-91e2-f073df8d529b" xlink:href="mgnx-20241231.xsd#mgnx_ProventionBioMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bef09629-6c40-4310-b750-cd218112641c" xlink:to="loc_mgnx_ProventionBioMember_d234b70d-fb94-46cc-91e2-f073df8d529b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_89c73e6f-fb48-4e04-a945-c491f639722b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ebffb734-5220-48f3-96b0-1a973bc278e7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_89c73e6f-fb48-4e04-a945-c491f639722b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76d08406-50d0-4f80-b619-1a0a6fd4c9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_89c73e6f-fb48-4e04-a945-c491f639722b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76d08406-50d0-4f80-b619-1a0a6fd4c9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_5f366049-e512-4bc0-bc6c-2469922b9cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76d08406-50d0-4f80-b619-1a0a6fd4c9bf" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_5f366049-e512-4bc0-bc6c-2469922b9cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b18f0633-9418-49af-83cd-bd7e43d94777" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ebffb734-5220-48f3-96b0-1a973bc278e7" xlink:to="loc_srt_ProductOrServiceAxis_b18f0633-9418-49af-83cd-bd7e43d94777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6e29c94b-815d-4daf-ba3c-8739c0b6792b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b18f0633-9418-49af-83cd-bd7e43d94777" xlink:to="loc_srt_ProductsAndServicesDomain_6e29c94b-815d-4daf-ba3c-8739c0b6792b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromCMOAgreementsMemberMember_ca819dd1-4823-45b4-a48b-a2c6857d0e47" xlink:href="mgnx-20241231.xsd#mgnx_RevenuesFromCMOAgreementsMemberMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6e29c94b-815d-4daf-ba3c-8739c0b6792b" xlink:to="loc_mgnx_RevenuesFromCMOAgreementsMemberMember_ca819dd1-4823-45b4-a48b-a2c6857d0e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromCMOAmendmentAgreementMember_20efa24f-c8a6-498a-be8b-0383fb3d4731" xlink:href="mgnx-20241231.xsd#mgnx_RevenuesFromCMOAmendmentAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6e29c94b-815d-4daf-ba3c-8739c0b6792b" xlink:to="loc_mgnx_RevenuesFromCMOAmendmentAgreementMember_20efa24f-c8a6-498a-be8b-0383fb3d4731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_8cf134b2-4323-455f-9367-c20c5c6a73d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6e29c94b-815d-4daf-ba3c-8739c0b6792b" xlink:to="loc_us-gaap_ProductMember_8cf134b2-4323-455f-9367-c20c5c6a73d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e2195ca0-4f30-4ad6-b35c-50f5d297644f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ebffb734-5220-48f3-96b0-1a973bc278e7" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e2195ca0-4f30-4ad6-b35c-50f5d297644f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeArrangementTerm_67895889-a10d-4181-8f41-fd93b252ffe9" xlink:href="mgnx-20241231.xsd#mgnx_CollaborativeArrangementTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e2195ca0-4f30-4ad6-b35c-50f5d297644f" xlink:to="loc_mgnx_CollaborativeArrangementTerm_67895889-a10d-4181-8f41-fd93b252ffe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_5c2a1020-545a-4634-8a91-32eb73477287" xlink:href="mgnx-20241231.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e2195ca0-4f30-4ad6-b35c-50f5d297644f" xlink:to="loc_mgnx_NonRefundableUpfrontFees_5c2a1020-545a-4634-8a91-32eb73477287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalFixedPayments_4906e857-c761-4b3a-ae65-ea1238ed9d09" xlink:href="mgnx-20241231.xsd#mgnx_TotalFixedPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e2195ca0-4f30-4ad6-b35c-50f5d297644f" xlink:to="loc_mgnx_TotalFixedPayments_4906e857-c761-4b3a-ae65-ea1238ed9d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeArrangementExtensionTerm_828a81a3-9d9b-4b9a-9e8d-9b0539f7e68d" xlink:href="mgnx-20241231.xsd#mgnx_CollaborativeArrangementExtensionTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e2195ca0-4f30-4ad6-b35c-50f5d297644f" xlink:to="loc_mgnx_CollaborativeArrangementExtensionTerm_828a81a3-9d9b-4b9a-9e8d-9b0539f7e68d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AdditionalAnnualFixedPayments_3d256548-e0e3-4b42-bf55-f1ed51d6277c" xlink:href="mgnx-20241231.xsd#mgnx_AdditionalAnnualFixedPayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e2195ca0-4f30-4ad6-b35c-50f5d297644f" xlink:to="loc_mgnx_AdditionalAnnualFixedPayments_3d256548-e0e3-4b42-bf55-f1ed51d6277c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_859e90c8-4d17-4a3c-bc65-ca6374593de4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e2195ca0-4f30-4ad6-b35c-50f5d297644f" xlink:to="loc_us-gaap_Revenues_859e90c8-4d17-4a3c-bc65-ca6374593de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_cd5e6cce-8c48-4f76-aebe-98293128d99a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e2195ca0-4f30-4ad6-b35c-50f5d297644f" xlink:to="loc_us-gaap_ContractWithCustomerLiability_cd5e6cce-8c48-4f76-aebe-98293128d99a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9e80bebe-79a4-4e06-8fb8-f8cdda35afd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e2195ca0-4f30-4ad6-b35c-50f5d297644f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9e80bebe-79a4-4e06-8fb8-f8cdda35afd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6e7e1b18-d4b2-4c76-b6a8-9448059b3aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e2195ca0-4f30-4ad6-b35c-50f5d297644f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6e7e1b18-d4b2-4c76-b6a8-9448059b3aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FutureManufacturingRevenue_873f30ac-0f6b-4f50-bd44-12da7a8d22e9" xlink:href="mgnx-20241231.xsd#mgnx_FutureManufacturingRevenue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e2195ca0-4f30-4ad6-b35c-50f5d297644f" xlink:to="loc_mgnx_FutureManufacturingRevenue_873f30ac-0f6b-4f50-bd44-12da7a8d22e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueNIAIDContractDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#RevenueNIAIDContractDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/RevenueNIAIDContractDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_5e90f17f-40bf-40c6-8de0-5b8c4068e1d7" xlink:href="mgnx-20241231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6209e1b5-66a0-4890-a734-928464529cff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_5e90f17f-40bf-40c6-8de0-5b8c4068e1d7" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6209e1b5-66a0-4890-a734-928464529cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_71fd606a-4aea-4a00-84b7-c59befafd4df" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6209e1b5-66a0-4890-a734-928464529cff" xlink:to="loc_srt_ProductOrServiceAxis_71fd606a-4aea-4a00-84b7-c59befafd4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_489da8aa-0db4-4b49-ad8d-244f13b354b0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_71fd606a-4aea-4a00-84b7-c59befafd4df" xlink:to="loc_srt_ProductsAndServicesDomain_489da8aa-0db4-4b49-ad8d-244f13b354b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromGrantsMember_5fd1443a-09cb-4a1b-ba55-519211b4a02e" xlink:href="mgnx-20241231.xsd#mgnx_RevenuesFromGrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_489da8aa-0db4-4b49-ad8d-244f13b354b0" xlink:to="loc_mgnx_RevenuesFromGrantsMember_5fd1443a-09cb-4a1b-ba55-519211b4a02e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3105bccb-0557-4c2a-a8e5-827c00f16ef7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6209e1b5-66a0-4890-a734-928464529cff" xlink:to="loc_srt_CounterpartyNameAxis_3105bccb-0557-4c2a-a8e5-827c00f16ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_21bb9b89-637c-44b4-9a59-0a1cf3786c77" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_3105bccb-0557-4c2a-a8e5-827c00f16ef7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_21bb9b89-637c-44b4-9a59-0a1cf3786c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_b4a53d3a-3e3c-4b23-aa17-1401b4fe7bb8" xlink:href="mgnx-20241231.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_21bb9b89-637c-44b4-9a59-0a1cf3786c77" xlink:to="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_b4a53d3a-3e3c-4b23-aa17-1401b4fe7bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8e26451c-d92c-4ad7-8ffc-42068686c3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6209e1b5-66a0-4890-a734-928464529cff" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8e26451c-d92c-4ad7-8ffc-42068686c3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfProductCandidates_5a1d8d15-9467-4847-8e91-ae57def29875" xlink:href="mgnx-20241231.xsd#mgnx_NumberOfProductCandidates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8e26451c-d92c-4ad7-8ffc-42068686c3b4" xlink:to="loc_mgnx_NumberOfProductCandidates_5a1d8d15-9467-4847-8e91-ae57def29875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_8f6dd371-15c3-4f4a-8a79-5c9fd23883c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8e26451c-d92c-4ad7-8ffc-42068686c3b4" xlink:to="loc_us-gaap_Revenues_8f6dd371-15c3-4f4a-8a79-5c9fd23883c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/RevenueProductSalesDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#RevenueProductSalesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/RevenueProductSalesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract_e4b961c7-9b5d-444f-a87e-7af3aef42371" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c56bf0f1-7c82-4d9e-90c3-db226ba2274a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_e4b961c7-9b5d-444f-a87e-7af3aef42371" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c56bf0f1-7c82-4d9e-90c3-db226ba2274a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2787c0a0-edc3-4049-8c97-cc53d54bd173" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c56bf0f1-7c82-4d9e-90c3-db226ba2274a" xlink:to="loc_srt_CounterpartyNameAxis_2787c0a0-edc3-4049-8c97-cc53d54bd173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ff047f36-4ae9-4200-8437-5b8f7f506936" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2787c0a0-edc3-4049-8c97-cc53d54bd173" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ff047f36-4ae9-4200-8437-5b8f7f506936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TerSeraMember_463410c1-0ef9-40c9-815c-e2c48d4e699c" xlink:href="mgnx-20241231.xsd#mgnx_TerSeraMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ff047f36-4ae9-4200-8437-5b8f7f506936" xlink:to="loc_mgnx_TerSeraMember_463410c1-0ef9-40c9-815c-e2c48d4e699c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a97f3312-6163-4c16-b052-a1e0f9143e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c56bf0f1-7c82-4d9e-90c3-db226ba2274a" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a97f3312-6163-4c16-b052-a1e0f9143e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AmendmentFeeToCommercializationPartner_378412c3-2871-4b2f-be36-694ebb50fa9c" xlink:href="mgnx-20241231.xsd#mgnx_AmendmentFeeToCommercializationPartner"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a97f3312-6163-4c16-b052-a1e0f9143e6c" xlink:to="loc_mgnx_AmendmentFeeToCommercializationPartner_378412c3-2871-4b2f-be36-694ebb50fa9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_7b05ac49-ea15-4ead-a335-af2b86e355a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a97f3312-6163-4c16-b052-a1e0f9143e6c" xlink:to="loc_us-gaap_Revenues_7b05ac49-ea15-4ead-a335-af2b86e355a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#StockbasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_15eff2cd-54ab-43f7-a8b8-50f449b5a4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_368dbc3e-76d3-4ca2-80d5-8e52098d7819" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_15eff2cd-54ab-43f7-a8b8-50f449b5a4d9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_368dbc3e-76d3-4ca2-80d5-8e52098d7819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f26497e8-882f-4918-a2b5-04c617eb25c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_368dbc3e-76d3-4ca2-80d5-8e52098d7819" xlink:to="loc_us-gaap_PlanNameAxis_f26497e8-882f-4918-a2b5-04c617eb25c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_dcfccf8f-de49-4021-8c81-cd34f53e88f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_f26497e8-882f-4918-a2b5-04c617eb25c3" xlink:to="loc_us-gaap_PlanNameDomain_dcfccf8f-de49-4021-8c81-cd34f53e88f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_10651e58-f1c8-46ee-adce-5b0a35457887" xlink:href="mgnx-20241231.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_dcfccf8f-de49-4021-8c81-cd34f53e88f1" xlink:to="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_10651e58-f1c8-46ee-adce-5b0a35457887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2023MemberMember_5c0d4302-0e8f-4f66-a87c-2a50a836cc62" xlink:href="mgnx-20241231.xsd#mgnx_StockIncentivePlan2023MemberMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_dcfccf8f-de49-4021-8c81-cd34f53e88f1" xlink:to="loc_mgnx_StockIncentivePlan2023MemberMember_5c0d4302-0e8f-4f66-a87c-2a50a836cc62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_53014f25-7178-4606-86b9-250441a3a499" xlink:href="mgnx-20241231.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_dcfccf8f-de49-4021-8c81-cd34f53e88f1" xlink:to="loc_mgnx_StockIncentivePlan2013Member_53014f25-7178-4606-86b9-250441a3a499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_85656bae-ace6-4d7b-86f1-db6c5a6d696b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_368dbc3e-76d3-4ca2-80d5-8e52098d7819" xlink:to="loc_us-gaap_AwardTypeAxis_85656bae-ace6-4d7b-86f1-db6c5a6d696b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5612eea-1b77-49aa-9e9c-c54455255986" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_85656bae-ace6-4d7b-86f1-db6c5a6d696b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5612eea-1b77-49aa-9e9c-c54455255986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_70afff00-ddbf-4dc6-81f5-d5f744d61c78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5612eea-1b77-49aa-9e9c-c54455255986" xlink:to="loc_us-gaap_EmployeeStockMember_70afff00-ddbf-4dc6-81f5-d5f744d61c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f78bf1a6-0929-47fd-b46e-b7d3068de6dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5612eea-1b77-49aa-9e9c-c54455255986" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f78bf1a6-0929-47fd-b46e-b7d3068de6dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6bdc62b1-d1a6-45a9-a133-c0319df5d7ab" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_368dbc3e-76d3-4ca2-80d5-8e52098d7819" xlink:to="loc_srt_CounterpartyNameAxis_6bdc62b1-d1a6-45a9-a133-c0319df5d7ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_17969b20-ece0-420a-9d95-570a894e402d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_6bdc62b1-d1a6-45a9-a133-c0319df5d7ab" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_17969b20-ece0-420a-9d95-570a894e402d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DrScottKoenigMember_1f146c26-5fc9-4aec-ab37-2f19d035038d" xlink:href="mgnx-20241231.xsd#mgnx_DrScottKoenigMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_17969b20-ece0-420a-9d95-570a894e402d" xlink:to="loc_mgnx_DrScottKoenigMember_1f146c26-5fc9-4aec-ab37-2f19d035038d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a61fde32-91bc-4f4f-9040-0cb7760e1e90" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_368dbc3e-76d3-4ca2-80d5-8e52098d7819" xlink:to="loc_srt_RangeAxis_a61fde32-91bc-4f4f-9040-0cb7760e1e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cbf8ad1e-606e-4d50-8853-3472c8492993" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a61fde32-91bc-4f4f-9040-0cb7760e1e90" xlink:to="loc_srt_RangeMember_cbf8ad1e-606e-4d50-8853-3472c8492993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fbba69ce-ee17-4a68-ba55-e3c7018540e6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cbf8ad1e-606e-4d50-8853-3472c8492993" xlink:to="loc_srt_MinimumMember_fbba69ce-ee17-4a68-ba55-e3c7018540e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fa161e9d-2618-4ae8-97e8-a8d050a3e5ac" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cbf8ad1e-606e-4d50-8853-3472c8492993" xlink:to="loc_srt_MaximumMember_fa161e9d-2618-4ae8-97e8-a8d050a3e5ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_368dbc3e-76d3-4ca2-80d5-8e52098d7819" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_40604179-5d99-4bb8-a6eb-efa23666d04c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_40604179-5d99-4bb8-a6eb-efa23666d04c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_7d41f0a7-547e-439e-9823-ad649242fbcf" xlink:href="mgnx-20241231.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:to="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_7d41f0a7-547e-439e-9823-ad649242fbcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_42351400-200a-4d6a-9e43-134267e0c6b4" xlink:href="mgnx-20241231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:to="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_42351400-200a-4d6a-9e43-134267e0c6b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_7604ea24-4221-493c-b741-ab89c1cdf96b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_7604ea24-4221-493c-b741-ab89c1cdf96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_f0a9cbd8-2c74-4ef7-9533-3b6bfc45ba60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_f0a9cbd8-2c74-4ef7-9533-3b6bfc45ba60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_340fda05-5578-42e6-9f95-7dec68bfbb83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_340fda05-5578-42e6-9f95-7dec68bfbb83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_258fbf4b-59d4-41fb-8ba5-f2e045f802a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_258fbf4b-59d4-41fb-8ba5-f2e045f802a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_981aba34-d526-48d7-9da5-04dcf8055fea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_981aba34-d526-48d7-9da5-04dcf8055fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0e6aaec9-63ab-4460-992d-cc0ba024d1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0e6aaec9-63ab-4460-992d-cc0ba024d1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingPercentageOfUnvestedAwards_0ebeee0f-efb8-40f5-88d9-e1375a7bc47b" xlink:href="mgnx-20241231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingPercentageOfUnvestedAwards"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:to="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingPercentageOfUnvestedAwards_0ebeee0f-efb8-40f5-88d9-e1375a7bc47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3baaf129-5f9a-4e86-9333-745b7ad6e5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3baaf129-5f9a-4e86-9333-745b7ad6e5fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b4aebd52-2c19-40d4-8a4c-11c3b256ae49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b4aebd52-2c19-40d4-8a4c-11c3b256ae49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_12d0aa3f-ac52-4b62-88c5-fb819fcfca1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_12d0aa3f-ac52-4b62-88c5-fb819fcfca1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_65eca4e7-ade0-4739-94a5-b792f1ce809c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_65eca4e7-ade0-4739-94a5-b792f1ce809c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9b199557-e5e2-42bb-a4da-f737147aee03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9b199557-e5e2-42bb-a4da-f737147aee03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2388fbbe-0e47-43f3-b86c-c1092694a76a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2388fbbe-0e47-43f3-b86c-c1092694a76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_370dd3e3-303f-4c4c-a3b5-69c05cc9e328" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_370dd3e3-303f-4c4c-a3b5-69c05cc9e328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_aa2b63a8-99e4-487e-abec-37783fc9d4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_57dbf32f-485e-446b-b2bf-1cc0b8f3a0ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_aa2b63a8-99e4-487e-abec-37783fc9d4bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#StockbasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_87d939a9-2a63-4bb7-8126-36559514ad35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4c43c919-d02d-40bf-929f-852f145d2e89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_87d939a9-2a63-4bb7-8126-36559514ad35" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4c43c919-d02d-40bf-929f-852f145d2e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8f4193f4-6e11-4ec3-af43-9142535fce51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4c43c919-d02d-40bf-929f-852f145d2e89" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8f4193f4-6e11-4ec3-af43-9142535fce51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1b477358-46f4-4c4d-94d6-5d49f985a28f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8f4193f4-6e11-4ec3-af43-9142535fce51" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1b477358-46f4-4c4d-94d6-5d49f985a28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2b6b7d8a-93b7-4eec-a6fc-8684b389439e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1b477358-46f4-4c4d-94d6-5d49f985a28f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2b6b7d8a-93b7-4eec-a6fc-8684b389439e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7d0a2b1a-47b8-47f2-80aa-9b5fac136f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1b477358-46f4-4c4d-94d6-5d49f985a28f" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7d0a2b1a-47b8-47f2-80aa-9b5fac136f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0af94b9b-0e56-467e-b7f8-abc228566c72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4c43c919-d02d-40bf-929f-852f145d2e89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0af94b9b-0e56-467e-b7f8-abc228566c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9d1a674c-5dc4-448a-b8a4-c3572db330c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0af94b9b-0e56-467e-b7f8-abc228566c72" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_9d1a674c-5dc4-448a-b8a4-c3572db330c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#StockbasedCompensationOptionPricingAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fe054d6b-e6df-40b2-8f96-5d2736c71092" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_773ae598-de77-499e-8450-310a592473c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fe054d6b-e6df-40b2-8f96-5d2736c71092" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_773ae598-de77-499e-8450-310a592473c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b3b6f335-97c5-484a-9e91-657cbf2db3c1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_773ae598-de77-499e-8450-310a592473c9" xlink:to="loc_srt_RangeAxis_b3b6f335-97c5-484a-9e91-657cbf2db3c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5f5a6d40-bb6d-4e0f-9bb3-7a963cf27e08" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b3b6f335-97c5-484a-9e91-657cbf2db3c1" xlink:to="loc_srt_RangeMember_5f5a6d40-bb6d-4e0f-9bb3-7a963cf27e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1b465e99-dced-4f01-8195-6d479d68a7ba" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5f5a6d40-bb6d-4e0f-9bb3-7a963cf27e08" xlink:to="loc_srt_MinimumMember_1b465e99-dced-4f01-8195-6d479d68a7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5616a535-41c3-4e37-bc6b-a5c76be47e14" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5f5a6d40-bb6d-4e0f-9bb3-7a963cf27e08" xlink:to="loc_srt_MaximumMember_5616a535-41c3-4e37-bc6b-a5c76be47e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5fc15c95-251d-427a-876a-f39a56131bba" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_773ae598-de77-499e-8450-310a592473c9" xlink:to="loc_srt_CounterpartyNameAxis_5fc15c95-251d-427a-876a-f39a56131bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_03ef617e-1862-4670-bbb7-4848e77dcec8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5fc15c95-251d-427a-876a-f39a56131bba" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_03ef617e-1862-4670-bbb7-4848e77dcec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DrScottKoenigMember_a07d62de-7e6d-4153-9c38-085d659d7b0b" xlink:href="mgnx-20241231.xsd#mgnx_DrScottKoenigMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_03ef617e-1862-4670-bbb7-4848e77dcec8" xlink:to="loc_mgnx_DrScottKoenigMember_a07d62de-7e6d-4153-9c38-085d659d7b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3459533-42dc-475e-8190-06ed05aab690" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_773ae598-de77-499e-8450-310a592473c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3459533-42dc-475e-8190-06ed05aab690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_115a19a2-c68d-4adc-b508-e50189d992cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3459533-42dc-475e-8190-06ed05aab690" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_115a19a2-c68d-4adc-b508-e50189d992cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_71d37c32-9cdf-41b5-9b9a-0ac778b3c1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3459533-42dc-475e-8190-06ed05aab690" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_71d37c32-9cdf-41b5-9b9a-0ac778b3c1e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1f46a521-ba9a-4550-b05c-46ec57b4a610" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3459533-42dc-475e-8190-06ed05aab690" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1f46a521-ba9a-4550-b05c-46ec57b4a610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_34ce1b8d-2d10-42d3-be96-ec269a43d04e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3459533-42dc-475e-8190-06ed05aab690" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_34ce1b8d-2d10-42d3-be96-ec269a43d04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32988ba3-1679-4e95-8e18-a20e5de0c130" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_64c6bda1-5937-4de3-a9d8-69a77d19f324" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32988ba3-1679-4e95-8e18-a20e5de0c130" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_64c6bda1-5937-4de3-a9d8-69a77d19f324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_99ab7907-96ad-40c7-9b75-dda5253838cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_64c6bda1-5937-4de3-a9d8-69a77d19f324" xlink:to="loc_us-gaap_AwardTypeAxis_99ab7907-96ad-40c7-9b75-dda5253838cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62a234ce-130a-48cf-b33f-9969aae3b024" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_99ab7907-96ad-40c7-9b75-dda5253838cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62a234ce-130a-48cf-b33f-9969aae3b024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e37fd862-a8c1-4825-aa3f-0675309d07d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62a234ce-130a-48cf-b33f-9969aae3b024" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e37fd862-a8c1-4825-aa3f-0675309d07d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_59a06072-7e0e-4c46-99f2-d2b61bdd0e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_64c6bda1-5937-4de3-a9d8-69a77d19f324" xlink:to="loc_us-gaap_PlanNameAxis_59a06072-7e0e-4c46-99f2-d2b61bdd0e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_78b901ad-2ba6-4165-8300-af018f5393eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_59a06072-7e0e-4c46-99f2-d2b61bdd0e0b" xlink:to="loc_us-gaap_PlanNameDomain_78b901ad-2ba6-4165-8300-af018f5393eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_58b9ae23-60ee-46c0-b26f-4ba26b1e6534" xlink:href="mgnx-20241231.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_78b901ad-2ba6-4165-8300-af018f5393eb" xlink:to="loc_mgnx_StockIncentivePlan2013Member_58b9ae23-60ee-46c0-b26f-4ba26b1e6534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b8017a9-b2e9-4294-bb19-2cd6d87d98e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_64c6bda1-5937-4de3-a9d8-69a77d19f324" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b8017a9-b2e9-4294-bb19-2cd6d87d98e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c992ac47-4107-490f-b55b-74097a0dcd9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b8017a9-b2e9-4294-bb19-2cd6d87d98e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c992ac47-4107-490f-b55b-74097a0dcd9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5bfcd05c-8608-47a7-9604-5d6450bad523" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c992ac47-4107-490f-b55b-74097a0dcd9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5bfcd05c-8608-47a7-9604-5d6450bad523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_9a70be08-d7f7-44f3-9256-9c75ed153d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c992ac47-4107-490f-b55b-74097a0dcd9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_9a70be08-d7f7-44f3-9256-9c75ed153d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0a630fc5-55a7-47e1-8d79-3938117ac160" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c992ac47-4107-490f-b55b-74097a0dcd9f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0a630fc5-55a7-47e1-8d79-3938117ac160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_f1c7d445-2bbf-4237-8fbb-89511e99a15e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c992ac47-4107-490f-b55b-74097a0dcd9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_f1c7d445-2bbf-4237-8fbb-89511e99a15e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c5d53821-0f29-49f0-99c8-8d57661b33a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c992ac47-4107-490f-b55b-74097a0dcd9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c5d53821-0f29-49f0-99c8-8d57661b33a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bd354314-fcf4-4614-b7bd-d2420da6e7ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c992ac47-4107-490f-b55b-74097a0dcd9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bd354314-fcf4-4614-b7bd-d2420da6e7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e0505577-88cb-4930-a273-0a61d9d906a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c992ac47-4107-490f-b55b-74097a0dcd9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e0505577-88cb-4930-a273-0a61d9d906a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_a35aa685-2715-4903-8fdd-6706fd2e9573" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c992ac47-4107-490f-b55b-74097a0dcd9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_a35aa685-2715-4903-8fdd-6706fd2e9573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_783c2b20-1ed8-404f-9c67-df11ccc10011" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b8017a9-b2e9-4294-bb19-2cd6d87d98e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_783c2b20-1ed8-404f-9c67-df11ccc10011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d6935e00-2be8-4e9a-908e-e05005a42136" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_783c2b20-1ed8-404f-9c67-df11ccc10011" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d6935e00-2be8-4e9a-908e-e05005a42136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5fc6e6fe-c475-4b61-a23c-1c59894970a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_783c2b20-1ed8-404f-9c67-df11ccc10011" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5fc6e6fe-c475-4b61-a23c-1c59894970a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4a748452-8993-4c63-bac9-bd56311c60ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_783c2b20-1ed8-404f-9c67-df11ccc10011" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4a748452-8993-4c63-bac9-bd56311c60ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e67e35cb-4233-4e78-9e32-b7e0758d1d27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_783c2b20-1ed8-404f-9c67-df11ccc10011" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e67e35cb-4233-4e78-9e32-b7e0758d1d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_34583f42-3677-44da-a939-b4a453ea669d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_783c2b20-1ed8-404f-9c67-df11ccc10011" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_34583f42-3677-44da-a939-b4a453ea669d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_77d6afc0-1663-4e31-8f58-46bbec54bedc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_783c2b20-1ed8-404f-9c67-df11ccc10011" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_77d6afc0-1663-4e31-8f58-46bbec54bedc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7888e591-0727-464e-8ef6-e2e1768cbf18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_783c2b20-1ed8-404f-9c67-df11ccc10011" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7888e591-0727-464e-8ef6-e2e1768cbf18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_b301a827-db8d-4025-96fe-16637f3983fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_783c2b20-1ed8-404f-9c67-df11ccc10011" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_b301a827-db8d-4025-96fe-16637f3983fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e554ea25-26aa-464d-8458-3f3d06f32012" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b8017a9-b2e9-4294-bb19-2cd6d87d98e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e554ea25-26aa-464d-8458-3f3d06f32012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b83e8cc9-fa69-4d2b-93a6-cdae7ba309d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e554ea25-26aa-464d-8458-3f3d06f32012" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b83e8cc9-fa69-4d2b-93a6-cdae7ba309d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0c9b483b-ca87-4379-ad7b-c4c669fb4f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e554ea25-26aa-464d-8458-3f3d06f32012" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0c9b483b-ca87-4379-ad7b-c4c669fb4f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_883c34ad-fd36-4d53-a8b5-aaca30704794" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e554ea25-26aa-464d-8458-3f3d06f32012" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_883c34ad-fd36-4d53-a8b5-aaca30704794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9d2ce74f-76b4-496a-9ae1-2c9d9162bc66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e554ea25-26aa-464d-8458-3f3d06f32012" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9d2ce74f-76b4-496a-9ae1-2c9d9162bc66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6502a5af-6229-4b04-91f9-1d0ef1f21bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e554ea25-26aa-464d-8458-3f3d06f32012" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6502a5af-6229-4b04-91f9-1d0ef1f21bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_25b931e9-4131-4516-b952-3b33f1436358" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e554ea25-26aa-464d-8458-3f3d06f32012" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_25b931e9-4131-4516-b952-3b33f1436358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6c89ed74-666e-430d-8366-8773aeeae054" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b8017a9-b2e9-4294-bb19-2cd6d87d98e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6c89ed74-666e-430d-8366-8773aeeae054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_20f568be-d2d9-459b-bae5-bcdc4de84e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6c89ed74-666e-430d-8366-8773aeeae054" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_20f568be-d2d9-459b-bae5-bcdc4de84e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f084592c-3410-48b4-9330-6ec8825ca7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6c89ed74-666e-430d-8366-8773aeeae054" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f084592c-3410-48b4-9330-6ec8825ca7d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_06328951-a0b3-4357-8b8b-d6ec17297ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6c89ed74-666e-430d-8366-8773aeeae054" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_06328951-a0b3-4357-8b8b-d6ec17297ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5f93b7a8-728f-4851-8f0d-372919aa2aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6c89ed74-666e-430d-8366-8773aeeae054" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5f93b7a8-728f-4851-8f0d-372919aa2aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_837a519f-aeba-412b-9ae6-d3e820b90aee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6c89ed74-666e-430d-8366-8773aeeae054" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_837a519f-aeba-412b-9ae6-d3e820b90aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_092a2773-6f8e-40d8-9906-1ad09518ee03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b8017a9-b2e9-4294-bb19-2cd6d87d98e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_092a2773-6f8e-40d8-9906-1ad09518ee03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_966dd30b-22bd-4917-9d81-8ae4a9b798aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_092a2773-6f8e-40d8-9906-1ad09518ee03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_966dd30b-22bd-4917-9d81-8ae4a9b798aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_519ca6fa-8771-4ef1-8b72-2f88ce18c44d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_092a2773-6f8e-40d8-9906-1ad09518ee03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_519ca6fa-8771-4ef1-8b72-2f88ce18c44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3f64d5eb-129d-459e-a630-a76cc50e44fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_092a2773-6f8e-40d8-9906-1ad09518ee03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3f64d5eb-129d-459e-a630-a76cc50e44fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e8242184-091e-41ef-be18-e43db986cabe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_092a2773-6f8e-40d8-9906-1ad09518ee03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e8242184-091e-41ef-be18-e43db986cabe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7eb7e388-8b8f-42f1-a5bc-25e86e9478c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_092a2773-6f8e-40d8-9906-1ad09518ee03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7eb7e388-8b8f-42f1-a5bc-25e86e9478c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_02aaf8f9-987b-4be7-bc20-f08098e6c08d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b8017a9-b2e9-4294-bb19-2cd6d87d98e7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_02aaf8f9-987b-4be7-bc20-f08098e6c08d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_2b5512b0-e9e1-4576-a9af-38f9c0d2efaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b8017a9-b2e9-4294-bb19-2cd6d87d98e7" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_2b5512b0-e9e1-4576-a9af-38f9c0d2efaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_886d2f88-0b4d-44a6-8a27-9eb575170990" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b8017a9-b2e9-4294-bb19-2cd6d87d98e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_886d2f88-0b4d-44a6-8a27-9eb575170990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_a6965913-f522-4aa0-ae02-e78ea70a38c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b8017a9-b2e9-4294-bb19-2cd6d87d98e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_a6965913-f522-4aa0-ae02-e78ea70a38c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_86aaf143-7a37-4a6c-a44f-144af2eb8499" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b8017a9-b2e9-4294-bb19-2cd6d87d98e7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_86aaf143-7a37-4a6c-a44f-144af2eb8499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ceb956e9-ee76-4fc5-a92f-2e490f99ab49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b8017a9-b2e9-4294-bb19-2cd6d87d98e7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ceb956e9-ee76-4fc5-a92f-2e490f99ab49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3f858d4a-bc9a-4426-a06a-e2d3c8b0c77f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b8017a9-b2e9-4294-bb19-2cd6d87d98e7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3f858d4a-bc9a-4426-a06a-e2d3c8b0c77f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1188f353-0cb7-4758-bfd2-87ffd3166724" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b8017a9-b2e9-4294-bb19-2cd6d87d98e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1188f353-0cb7-4758-bfd2-87ffd3166724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_2b78f4d0-3f61-4409-a8ce-446f94cdb20d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b8017a9-b2e9-4294-bb19-2cd6d87d98e7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_2b78f4d0-3f61-4409-a8ce-446f94cdb20d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5e27ecf0-e4b0-478d-b763-7ed2c9e8d544" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/TeSeraTransactionDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#TeSeraTransactionDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/TeSeraTransactionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_1e911280-b489-4cb4-80d4-e37464668bac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_074ea90b-ad3a-4b0e-9c63-a4648d673f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_1e911280-b489-4cb4-80d4-e37464668bac" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_074ea90b-ad3a-4b0e-9c63-a4648d673f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_97fcb069-d6d9-4e76-96c8-653e308f6427" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_074ea90b-ad3a-4b0e-9c63-a4648d673f9a" xlink:to="loc_srt_CounterpartyNameAxis_97fcb069-d6d9-4e76-96c8-653e308f6427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1f3a4bd8-9b30-405f-b010-864c5a935d24" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_97fcb069-d6d9-4e76-96c8-653e308f6427" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1f3a4bd8-9b30-405f-b010-864c5a935d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TerSeraMember_72cba8c8-3ca9-414a-a764-c83dbf71152e" xlink:href="mgnx-20241231.xsd#mgnx_TerSeraMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1f3a4bd8-9b30-405f-b010-864c5a935d24" xlink:to="loc_mgnx_TerSeraMember_72cba8c8-3ca9-414a-a764-c83dbf71152e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0a859e9f-f649-49cb-a1a2-d9a807963247" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_074ea90b-ad3a-4b0e-9c63-a4648d673f9a" xlink:to="loc_srt_ProductOrServiceAxis_0a859e9f-f649-49cb-a1a2-d9a807963247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3d0aa242-1fec-4984-9baf-f52c25f1b733" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0a859e9f-f649-49cb-a1a2-d9a807963247" xlink:to="loc_srt_ProductsAndServicesDomain_3d0aa242-1fec-4984-9baf-f52c25f1b733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CombinedServicesAgreementMember_7f5c012f-003d-4b02-a809-a29ca58c8106" xlink:href="mgnx-20241231.xsd#mgnx_CombinedServicesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3d0aa242-1fec-4984-9baf-f52c25f1b733" xlink:to="loc_mgnx_CombinedServicesAgreementMember_7f5c012f-003d-4b02-a809-a29ca58c8106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b540ce34-823c-44b7-bb57-c8ef287c3060" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_074ea90b-ad3a-4b0e-9c63-a4648d673f9a" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_b540ce34-823c-44b7-bb57-c8ef287c3060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6d953add-c564-444a-87c1-5ea785cf3ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b540ce34-823c-44b7-bb57-c8ef287c3060" xlink:to="loc_us-gaap_Revenues_6d953add-c564-444a-87c1-5ea785cf3ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FutureMilestone_40c5ba25-5835-4d9b-af55-7c84749c9f1a" xlink:href="mgnx-20241231.xsd#mgnx_FutureMilestone"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b540ce34-823c-44b7-bb57-c8ef287c3060" xlink:to="loc_mgnx_FutureMilestone_40c5ba25-5835-4d9b-af55-7c84749c9f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_016b4249-46e3-420a-b257-51a7f0d5a7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b540ce34-823c-44b7-bb57-c8ef287c3060" xlink:to="loc_us-gaap_OtherIncome_016b4249-46e3-420a-b257-51a7f0d5a7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b2cd35dc-d122-4e28-9c79-346d4d647849" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_7ab495da-d7a1-4788-9597-02d7a0a30a29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b2cd35dc-d122-4e28-9c79-346d4d647849" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_7ab495da-d7a1-4788-9597-02d7a0a30a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1a900f95-f132-4f95-b300-494cc0ffb270" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_7ab495da-d7a1-4788-9597-02d7a0a30a29" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1a900f95-f132-4f95-b300-494cc0ffb270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_30f0761f-aead-4630-804f-99af897863c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1a900f95-f132-4f95-b300-494cc0ffb270" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_30f0761f-aead-4630-804f-99af897863c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_7ed8ef48-69c1-449a-9da3-75016e00a500" xlink:href="mgnx-20241231.xsd#mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_30f0761f-aead-4630-804f-99af897863c9" xlink:to="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_7ed8ef48-69c1-449a-9da3-75016e00a500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_a6a59a83-e525-4591-8724-3075c837e81b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_30f0761f-aead-4630-804f-99af897863c9" xlink:to="loc_us-gaap_DomesticCountryMember_a6a59a83-e525-4591-8724-3075c837e81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_7ab017ec-a269-496a-9e8b-551178edba1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_7ab495da-d7a1-4788-9597-02d7a0a30a29" xlink:to="loc_us-gaap_TaxPeriodAxis_7ab017ec-a269-496a-9e8b-551178edba1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_7e4b169a-40e5-451a-b7ca-0585ecc2099e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_7ab017ec-a269-496a-9e8b-551178edba1c" xlink:to="loc_us-gaap_TaxPeriodDomain_7e4b169a-40e5-451a-b7ca-0585ecc2099e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TaxYear2027To2028Member_a6a017fa-3d9a-40ee-85a3-0dbe36720409" xlink:href="mgnx-20241231.xsd#mgnx_TaxYear2027To2028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_7e4b169a-40e5-451a-b7ca-0585ecc2099e" xlink:to="loc_mgnx_TaxYear2027To2028Member_a6a017fa-3d9a-40ee-85a3-0dbe36720409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IndefiniteMember_c582439f-ad9c-4265-8b0f-9b549aa740db" xlink:href="mgnx-20241231.xsd#mgnx_IndefiniteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_7e4b169a-40e5-451a-b7ca-0585ecc2099e" xlink:to="loc_mgnx_IndefiniteMember_c582439f-ad9c-4265-8b0f-9b549aa740db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TaxYear2027To2044Member_656cd285-b998-444a-8488-c39ddee6ba5d" xlink:href="mgnx-20241231.xsd#mgnx_TaxYear2027To2044Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_7e4b169a-40e5-451a-b7ca-0585ecc2099e" xlink:to="loc_mgnx_TaxYear2027To2044Member_656cd285-b998-444a-8488-c39ddee6ba5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_58f69a76-6c4f-48ff-a5f5-58e6c4104b7c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_7ab495da-d7a1-4788-9597-02d7a0a30a29" xlink:to="loc_srt_RangeAxis_58f69a76-6c4f-48ff-a5f5-58e6c4104b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_41c48ebd-0e06-419f-89d8-b1807e45c8ee" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_58f69a76-6c4f-48ff-a5f5-58e6c4104b7c" xlink:to="loc_srt_RangeMember_41c48ebd-0e06-419f-89d8-b1807e45c8ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7afa7ab4-1b89-419a-bb18-f136a9914eb5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_41c48ebd-0e06-419f-89d8-b1807e45c8ee" xlink:to="loc_srt_MinimumMember_7afa7ab4-1b89-419a-bb18-f136a9914eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_324dfd85-8e85-4ba3-a0eb-3a9d2c8c6ddf" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_41c48ebd-0e06-419f-89d8-b1807e45c8ee" xlink:to="loc_srt_MaximumMember_324dfd85-8e85-4ba3-a0eb-3a9d2c8c6ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_e8c02945-1463-416e-8cbe-598f23e564c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_7ab495da-d7a1-4788-9597-02d7a0a30a29" xlink:to="loc_us-gaap_IncomeTaxExaminationLineItems_e8c02945-1463-416e-8cbe-598f23e564c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_05d618de-c6a0-4bbf-9826-f7666543c34d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_e8c02945-1463-416e-8cbe-598f23e564c5" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_05d618de-c6a0-4bbf-9826-f7666543c34d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_065cdd17-50c3-45a9-bde8-c0b398d4021e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_e8c02945-1463-416e-8cbe-598f23e564c5" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_065cdd17-50c3-45a9-bde8-c0b398d4021e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationAmountUtilizableOnAnnualBasis_e9976798-7556-4431-8544-6a9510d81f02" xlink:href="mgnx-20241231.xsd#mgnx_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationAmountUtilizableOnAnnualBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_e8c02945-1463-416e-8cbe-598f23e564c5" xlink:to="loc_mgnx_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationAmountUtilizableOnAnnualBasis_e9976798-7556-4431-8544-6a9510d81f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_4aa4b2b0-fac9-4954-8512-6dec89814805" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_e8c02945-1463-416e-8cbe-598f23e564c5" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_4aa4b2b0-fac9-4954-8512-6dec89814805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_d4f5f913-4f49-4f33-944e-42f9c522d46d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_e8c02945-1463-416e-8cbe-598f23e564c5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_d4f5f913-4f49-4f33-944e-42f9c522d46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_44ff7043-2cb1-400b-8d55-7dd1c509a317" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_e8c02945-1463-416e-8cbe-598f23e564c5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_44ff7043-2cb1-400b-8d55-7dd1c509a317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2ebcd7dc-2ecb-49b1-a13b-d0281ad73606" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_75567506-7285-43de-9402-3780a18c5eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2ebcd7dc-2ecb-49b1-a13b-d0281ad73606" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_75567506-7285-43de-9402-3780a18c5eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_73416f82-1557-4d8c-8da8-7909ade460b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_75567506-7285-43de-9402-3780a18c5eb5" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_73416f82-1557-4d8c-8da8-7909ade460b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_19a9d02e-6c8b-4ea4-b2a9-1109bf4adb1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_75567506-7285-43de-9402-3780a18c5eb5" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_19a9d02e-6c8b-4ea4-b2a9-1109bf4adb1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_23831200-455d-4c7f-a53c-54c415c37f89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_75567506-7285-43de-9402-3780a18c5eb5" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_23831200-455d-4c7f-a53c-54c415c37f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_5e25380d-64bd-493f-9e99-f2b1ddaa16b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_75567506-7285-43de-9402-3780a18c5eb5" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_5e25380d-64bd-493f-9e99-f2b1ddaa16b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities_3a4455d0-2cf5-44dc-9268-ebeaf68a0f91" xlink:href="mgnx-20241231.xsd#mgnx_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_75567506-7285-43de-9402-3780a18c5eb5" xlink:to="loc_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities_3a4455d0-2cf5-44dc-9268-ebeaf68a0f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_b786b321-f4bc-448f-b144-1b37b25e568b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_75567506-7285-43de-9402-3780a18c5eb5" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_b786b321-f4bc-448f-b144-1b37b25e568b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_Section174DeferredTaxAsset_ed58b883-5581-4e08-b7d2-579b2a319aa2" xlink:href="mgnx-20241231.xsd#mgnx_Section174DeferredTaxAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_75567506-7285-43de-9402-3780a18c5eb5" xlink:to="loc_mgnx_Section174DeferredTaxAsset_ed58b883-5581-4e08-b7d2-579b2a319aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_cecb349f-695e-4937-9ae8-027b33bd4a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_75567506-7285-43de-9402-3780a18c5eb5" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_cecb349f-695e-4937-9ae8-027b33bd4a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_ead5303e-e388-4f1f-af98-a6ace9836145" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_75567506-7285-43de-9402-3780a18c5eb5" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_ead5303e-e388-4f1f-af98-a6ace9836145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_fcfc57a0-240a-4465-881c-e533d3e11199" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_75567506-7285-43de-9402-3780a18c5eb5" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_fcfc57a0-240a-4465-881c-e533d3e11199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1b6d83c2-5570-46b3-93bc-cb9d72465fac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_75567506-7285-43de-9402-3780a18c5eb5" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1b6d83c2-5570-46b3-93bc-cb9d72465fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_174860ea-e26c-409b-848e-d8473cc6733f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_75567506-7285-43de-9402-3780a18c5eb5" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_174860ea-e26c-409b-848e-d8473cc6733f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_fbe76a25-0f18-454d-b6d2-280508100475" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2ebcd7dc-2ecb-49b1-a13b-d0281ad73606" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_fbe76a25-0f18-454d-b6d2-280508100475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_1d7652fb-d221-4ae5-abd7-5641ff7feef6" xlink:href="mgnx-20241231.xsd#mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_fbe76a25-0f18-454d-b6d2-280508100475" xlink:to="loc_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_1d7652fb-d221-4ae5-abd7-5641ff7feef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_62145347-f00d-4a5d-ac9a-5c03317e9a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_fbe76a25-0f18-454d-b6d2-280508100475" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_62145347-f00d-4a5d-ac9a-5c03317e9a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_4bcaeb23-c76b-4dda-b9ee-22eff3cc39e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_fbe76a25-0f18-454d-b6d2-280508100475" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_4bcaeb23-c76b-4dda-b9ee-22eff3cc39e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_2de6e7cd-85b1-4526-9ea5-f3e751fa820c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_fbe76a25-0f18-454d-b6d2-280508100475" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_2de6e7cd-85b1-4526-9ea5-f3e751fa820c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesValuationAllowanceActivityDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#IncomeTaxesValuationAllowanceActivityDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxesValuationAllowanceActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e12d1957-d027-4822-a5c7-2ec751f8e0d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ValuationAllowanceRollForward_ff91d341-69f6-47d1-84c7-f648fd2b60ee" xlink:href="mgnx-20241231.xsd#mgnx_ValuationAllowanceRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e12d1957-d027-4822-a5c7-2ec751f8e0d7" xlink:to="loc_mgnx_ValuationAllowanceRollForward_ff91d341-69f6-47d1-84c7-f648fd2b60ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_98ded5b2-b25b-430e-a12c-ddc49b85e234" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_ValuationAllowanceRollForward_ff91d341-69f6-47d1-84c7-f648fd2b60ee" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_98ded5b2-b25b-430e-a12c-ddc49b85e234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ValuationAllowanceDeferredTaxAssetIncreaseAmount_142ccd8d-27a8-4f15-ac1e-b8c8ec169051" xlink:href="mgnx-20241231.xsd#mgnx_ValuationAllowanceDeferredTaxAssetIncreaseAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_ValuationAllowanceRollForward_ff91d341-69f6-47d1-84c7-f648fd2b60ee" xlink:to="loc_mgnx_ValuationAllowanceDeferredTaxAssetIncreaseAmount_142ccd8d-27a8-4f15-ac1e-b8c8ec169051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ValuationAllowanceDeferredTaxAssetDecreaseAmount_cbbc86d9-45bc-4cef-94b2-db8dc49d3167" xlink:href="mgnx-20241231.xsd#mgnx_ValuationAllowanceDeferredTaxAssetDecreaseAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_ValuationAllowanceRollForward_ff91d341-69f6-47d1-84c7-f648fd2b60ee" xlink:to="loc_mgnx_ValuationAllowanceDeferredTaxAssetDecreaseAmount_cbbc86d9-45bc-4cef-94b2-db8dc49d3167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_573c98dc-15c5-47b1-b59f-c73b58f37856" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_ValuationAllowanceRollForward_ff91d341-69f6-47d1-84c7-f648fd2b60ee" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_573c98dc-15c5-47b1-b59f-c73b58f37856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_fd6f0ac1-0521-4b53-bcaf-8f3041946947" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_112a205e-dc49-4221-8cad-e5c7cf8f08f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fd6f0ac1-0521-4b53-bcaf-8f3041946947" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_112a205e-dc49-4221-8cad-e5c7cf8f08f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_463f42fb-8a7f-4463-b72e-1cd425b6fb00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fd6f0ac1-0521-4b53-bcaf-8f3041946947" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_463f42fb-8a7f-4463-b72e-1cd425b6fb00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_e3d27b88-84ba-415a-a8a1-4211a045b764" xlink:href="mgnx-20241231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fd6f0ac1-0521-4b53-bcaf-8f3041946947" xlink:to="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_e3d27b88-84ba-415a-a8a1-4211a045b764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount_02ccab42-a598-48e5-bfe2-b11a9181c1b2" xlink:href="mgnx-20241231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fd6f0ac1-0521-4b53-bcaf-8f3041946947" xlink:to="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount_02ccab42-a598-48e5-bfe2-b11a9181c1b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_dee8d5a9-09a9-4e80-aef8-75070f3ae4d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fd6f0ac1-0521-4b53-bcaf-8f3041946947" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_dee8d5a9-09a9-4e80-aef8-75070f3ae4d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount_813b76d1-ca2d-4a39-b1ef-7449a0faccfd" xlink:href="mgnx-20241231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fd6f0ac1-0521-4b53-bcaf-8f3041946947" xlink:to="loc_mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount_813b76d1-ca2d-4a39-b1ef-7449a0faccfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_6c33746e-0d35-4608-b4d2-083e5dadaaa0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fd6f0ac1-0521-4b53-bcaf-8f3041946947" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_6c33746e-0d35-4608-b4d2-083e5dadaaa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_7253de02-c785-4923-b314-80cac1fcad11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fd6f0ac1-0521-4b53-bcaf-8f3041946947" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_7253de02-c785-4923-b314-80cac1fcad11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c0b63698-43bc-4910-814e-466619371f04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fd6f0ac1-0521-4b53-bcaf-8f3041946947" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c0b63698-43bc-4910-814e-466619371f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_e8e24cc5-5cbb-4c4b-8eec-466488ab46ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fd6f0ac1-0521-4b53-bcaf-8f3041946947" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_e8e24cc5-5cbb-4c4b-8eec-466488ab46ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c3221669-b620-4d32-936a-3c90d207c706" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fd6f0ac1-0521-4b53-bcaf-8f3041946947" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c3221669-b620-4d32-936a-3c90d207c706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f028a262-eaa0-4f5a-931f-030f1764a3eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_fdb7f9ad-8a1b-46a5-8bbe-883784b3f7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f028a262-eaa0-4f5a-931f-030f1764a3eb" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_fdb7f9ad-8a1b-46a5-8bbe-883784b3f7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_9e973660-d395-47d7-ae7a-03960203af23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_fdb7f9ad-8a1b-46a5-8bbe-883784b3f7a9" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_9e973660-d395-47d7-ae7a-03960203af23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_b4c838f4-4996-4f23-a132-76336b0680b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_fdb7f9ad-8a1b-46a5-8bbe-883784b3f7a9" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_b4c838f4-4996-4f23-a132-76336b0680b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_fe2edebf-471d-4d38-9b8f-faf2648ce4e1" xlink:href="mgnx-20241231.xsd#mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_fdb7f9ad-8a1b-46a5-8bbe-883784b3f7a9" xlink:to="loc_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_fe2edebf-471d-4d38-9b8f-faf2648ce4e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_3d617373-e349-4db4-808a-d8c4fca02eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_fdb7f9ad-8a1b-46a5-8bbe-883784b3f7a9" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_3d617373-e349-4db4-808a-d8c4fca02eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesIncomeTaxPaidTableDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#IncomeTaxesIncomeTaxPaidTableDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxesIncomeTaxPaidTableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c6047225-1f20-487e-bec2-c883e2b59fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_63fceb3a-42e2-43d5-ab76-4f76f5f5e0e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c6047225-1f20-487e-bec2-c883e2b59fa7" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_63fceb3a-42e2-43d5-ab76-4f76f5f5e0e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_38397c56-227e-4f90-82f0-34670b69c49d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c6047225-1f20-487e-bec2-c883e2b59fa7" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_38397c56-227e-4f90-82f0-34670b69c49d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_174abcfa-848b-43c6-b953-0f5ea39beea1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c6047225-1f20-487e-bec2-c883e2b59fa7" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_174abcfa-848b-43c6-b953-0f5ea39beea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/EmployeeBenefitPlanDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#EmployeeBenefitPlanDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/EmployeeBenefitPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e63d7d4f-c024-45bb-ae87-66d4b4a59eca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_bbb9b91d-09ff-494b-8397-7cff574a2ebf" xlink:href="mgnx-20241231.xsd#mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e63d7d4f-c024-45bb-ae87-66d4b4a59eca" xlink:to="loc_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_bbb9b91d-09ff-494b-8397-7cff574a2ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_b1af8ab9-953d-4b91-93e4-5e10eb8696e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e63d7d4f-c024-45bb-ae87-66d4b4a59eca" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_b1af8ab9-953d-4b91-93e4-5e10eb8696e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_7e25b1ed-c665-46cd-8383-fb2ad3fe78bd" xlink:href="mgnx-20241231.xsd#mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e63d7d4f-c024-45bb-ae87-66d4b4a59eca" xlink:to="loc_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_7e25b1ed-c665-46cd-8383-fb2ad3fe78bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_396ed90d-8906-4559-9b08-94a5397426ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e63d7d4f-c024-45bb-ae87-66d4b4a59eca" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_396ed90d-8906-4559-9b08-94a5397426ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SegmentReportingDetails" xlink:type="simple" xlink:href="mgnx-20241231.xsd#SegmentReportingDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SegmentReportingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_1ca86a8c-24c3-4eb0-bd44-b1c31edf5012" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_38ed2d22-95ea-4304-8835-d25d7a2c9373" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1ca86a8c-24c3-4eb0-bd44-b1c31edf5012" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_38ed2d22-95ea-4304-8835-d25d7a2c9373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_4797469a-ae4d-4c24-9b83-6f6ab89ed314" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_38ed2d22-95ea-4304-8835-d25d7a2c9373" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_4797469a-ae4d-4c24-9b83-6f6ab89ed314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_80d47961-490c-459f-94b2-c85b25ba4c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4797469a-ae4d-4c24-9b83-6f6ab89ed314" xlink:to="loc_us-gaap_SegmentDomain_80d47961-490c-459f-94b2-c85b25ba4c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_MainSegmentMember_bc82b62c-3d1f-463f-85ee-4be1ab58a52f" xlink:href="mgnx-20241231.xsd#mgnx_MainSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_80d47961-490c-459f-94b2-c85b25ba4c8d" xlink:to="loc_mgnx_MainSegmentMember_bc82b62c-3d1f-463f-85ee-4be1ab58a52f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_eac1a42d-f253-4f63-a78a-511803dc4151" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_38ed2d22-95ea-4304-8835-d25d7a2c9373" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_eac1a42d-f253-4f63-a78a-511803dc4151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_0fce8dde-ea10-4664-bb9f-2ce7b8fe8a41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_eac1a42d-f253-4f63-a78a-511803dc4151" xlink:to="loc_us-gaap_ProjectMember_0fce8dde-ea10-4664-bb9f-2ce7b8fe8a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_VobramitanmabDuocarmazineMember_4204f521-cac5-4976-ba6a-b6a26f9ae3b9" xlink:href="mgnx-20241231.xsd#mgnx_VobramitanmabDuocarmazineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_0fce8dde-ea10-4664-bb9f-2ce7b8fe8a41" xlink:to="loc_mgnx_VobramitanmabDuocarmazineMember_4204f521-cac5-4976-ba6a-b6a26f9ae3b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_LorigerlimabMember_61083ba0-8f23-4f69-88c4-ec5ff7e1b576" xlink:href="mgnx-20241231.xsd#mgnx_LorigerlimabMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_0fce8dde-ea10-4664-bb9f-2ce7b8fe8a41" xlink:to="loc_mgnx_LorigerlimabMember_61083ba0-8f23-4f69-88c4-ec5ff7e1b576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_MGC028Member_bcff699a-4358-45bf-b7a6-b62bdc449af9" xlink:href="mgnx-20241231.xsd#mgnx_MGC028Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_0fce8dde-ea10-4664-bb9f-2ce7b8fe8a41" xlink:to="loc_mgnx_MGC028Member_bcff699a-4358-45bf-b7a6-b62bdc449af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ADCMember_a281080e-2d86-458e-95a6-25c67e72a899" xlink:href="mgnx-20241231.xsd#mgnx_ADCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_0fce8dde-ea10-4664-bb9f-2ce7b8fe8a41" xlink:to="loc_mgnx_ADCMember_a281080e-2d86-458e-95a6-25c67e72a899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_MGC026Member_983530bd-142f-40ec-b070-5de81c9083d9" xlink:href="mgnx-20241231.xsd#mgnx_MGC026Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_0fce8dde-ea10-4664-bb9f-2ce7b8fe8a41" xlink:to="loc_mgnx_MGC026Member_983530bd-142f-40ec-b070-5de81c9083d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_MargetuximabMember_a937e1ca-40ad-463b-b6e4-a75f76c10213" xlink:href="mgnx-20241231.xsd#mgnx_MargetuximabMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_0fce8dde-ea10-4664-bb9f-2ce7b8fe8a41" xlink:to="loc_mgnx_MargetuximabMember_a937e1ca-40ad-463b-b6e4-a75f76c10213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_MGD024Member_c1d44536-67ef-4a7b-ac06-92be5970417f" xlink:href="mgnx-20241231.xsd#mgnx_MGD024Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_0fce8dde-ea10-4664-bb9f-2ce7b8fe8a41" xlink:to="loc_mgnx_MGD024Member_c1d44536-67ef-4a7b-ac06-92be5970417f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NextGenerationTCellEngagersMember_fb44c155-4635-4da8-8923-88f96c3b68a3" xlink:href="mgnx-20241231.xsd#mgnx_NextGenerationTCellEngagersMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_0fce8dde-ea10-4664-bb9f-2ce7b8fe8a41" xlink:to="loc_mgnx_NextGenerationTCellEngagersMember_fb44c155-4635-4da8-8923-88f96c3b68a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RetifanlimabMember_a6c56347-3456-4627-99a1-e45f5d89b3ec" xlink:href="mgnx-20241231.xsd#mgnx_RetifanlimabMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_0fce8dde-ea10-4664-bb9f-2ce7b8fe8a41" xlink:to="loc_mgnx_RetifanlimabMember_a6c56347-3456-4627-99a1-e45f5d89b3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EnoblituzumabMember_e42643e9-55b6-44b1-be4f-2905a3ba792c" xlink:href="mgnx-20241231.xsd#mgnx_EnoblituzumabMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_0fce8dde-ea10-4664-bb9f-2ce7b8fe8a41" xlink:to="loc_mgnx_EnoblituzumabMember_e42643e9-55b6-44b1-be4f-2905a3ba792c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_OtherProgramsMember_7da8cfc7-320e-471a-86c2-e001465da1f3" xlink:href="mgnx-20241231.xsd#mgnx_OtherProgramsMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_0fce8dde-ea10-4664-bb9f-2ce7b8fe8a41" xlink:to="loc_mgnx_OtherProgramsMember_7da8cfc7-320e-471a-86c2-e001465da1f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_db705aec-fbeb-4e70-afc0-fc1c1119da18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_38ed2d22-95ea-4304-8835-d25d7a2c9373" xlink:to="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_db705aec-fbeb-4e70-afc0-fc1c1119da18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_ecf53b99-7452-4cb9-9ea6-7e8d62752f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_db705aec-fbeb-4e70-afc0-fc1c1119da18" xlink:to="loc_us-gaap_NumberOfReportableSegments_ecf53b99-7452-4cb9-9ea6-7e8d62752f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_1d354e81-e651-4680-bc54-de8078efb9e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_db705aec-fbeb-4e70-afc0-fc1c1119da18" xlink:to="loc_us-gaap_Revenues_1d354e81-e651-4680-bc54-de8078efb9e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_79c21a7e-85a0-416b-addf-6b60b5988f48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_db705aec-fbeb-4e70-afc0-fc1c1119da18" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_79c21a7e-85a0-416b-addf-6b60b5988f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CostOfManufacturingServices_e64eafec-27d9-471d-a24a-411c805e641d" xlink:href="mgnx-20241231.xsd#mgnx_CostOfManufacturingServices"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_db705aec-fbeb-4e70-afc0-fc1c1119da18" xlink:to="loc_mgnx_CostOfManufacturingServices_e64eafec-27d9-471d-a24a-411c805e641d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e4dc5130-b4dc-4d96-9ac6-3f79c9042703" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_db705aec-fbeb-4e70-afc0-fc1c1119da18" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e4dc5130-b4dc-4d96-9ac6-3f79c9042703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_d63e5d1d-2739-4c16-9f95-69d2ee9f17ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_db705aec-fbeb-4e70-afc0-fc1c1119da18" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_d63e5d1d-2739-4c16-9f95-69d2ee9f17ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_14d9e7b7-50f3-4701-9725-f5b007575534" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_db705aec-fbeb-4e70-afc0-fc1c1119da18" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_14d9e7b7-50f3-4701-9725-f5b007575534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2c914ab1-3e8b-4631-8649-7ff239c0a627" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_db705aec-fbeb-4e70-afc0-fc1c1119da18" xlink:to="loc_us-gaap_NetIncomeLoss_2c914ab1-3e8b-4631-8649-7ff239c0a627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract_33f59aef-0836-49d6-9617-b5e49f2181de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_db705aec-fbeb-4e70-afc0-fc1c1119da18" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract_33f59aef-0836-49d6-9617-b5e49f2181de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JamesKarrelsMember" xlink:href="mgnx-20241231.xsd#mgnx_JamesKarrelsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_mgnx_JamesKarrelsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_JeffreyPetersMember" xlink:href="mgnx-20241231.xsd#mgnx_JeffreyPetersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_mgnx_JeffreyPetersMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>mgnx-20241231_g1.jpg
<TEXT>
begin 644 mgnx-20241231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0+Z17AI9@  34T *@    @ ! $[  (
M   0   !2H=I  0    !   !6IR=  $    @   "TNH<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M5&AO;6%S+"!+:7EO=6YG   %D ,  @   !0   *HD 0  @   !0   *\DI$
M @    ,X,@  DI(  @    ,X,@  ZAP !P   0P   &<     !SJ     0
M
M
M
M
M
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M^/GZ_]H # ,!  (1 Q$ /P#RCQ?=W2^.M>"W=P -3N0 )F '[UO>L;[;=_\
M/Y<_]_F_QK3\8_\ (]Z__P!A.Y_]&M6-7JK8@F^VW?\ S^7/_?YO\:/MMW_S
M^7/_ '^;_&H:*H";[;=_\_ES_P!_F_QH^VW?_/Y<_P#?YO\ &H:* )OMMW_S
M^7/_ '^;_&C[;=_\_ES_ -_F_P :AHH F^VW?_/Y<_\ ?YO\:/MMW_S^7/\
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M;;O_ )_+G_O\W^-'VV[_ .?RY_[_ #?XU#10!-]MN_\ G\N?^_S?XT?;;O\
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M^VW?_/Y<_P#?YO\ &H:* )OMMW_S^7/_ '^;_&C[;=_\_ES_ -_F_P :AHH
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MH:* )OMMW_S^7/\ W^;_ !H^VW?_ #^7/_?YO\:AHH F^VW?_/Y<_P#?YO\
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MH!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110![-X?_ .32?$G_ &$O
M_:D->,U[-X?_ .32?$G_ &$O_:D->,UE3W?J#"BBBM0"GQPRS,5ABDE8#)$:
M%B/RIE>N?L[WG]G^*O$-X 6^SZ+)+M'?:ZG'Z5,I<L;@>2B.0R>6(W,F<; I
MW9],=:)(Y(FVS1O&W]UU*G\C7T<N@66D?%C4OB0$W:.^E1ZG:-@8:XN/W8'U
MSD_\"%5?B'X&@\9?&C5Y]6OI+'2M'T:&ZO)84W2%?G.U0?8$]^E9JJKCL?/-
M7]*T/5==EGCT;3Y[Y[>(S3+"N2B#JQ]J]"NOA?HNO:#H^M_#[5;V6SU#4UTR
M2+5(U62)V/W_ )>"!Z?K7?\ @/PYX0\+^*/%ND^'M5U*]U:QTB6&^6ZB41'H
M24(]#@$'U]J<JJ2T%8^;P00".0>E:,.@:O<:0NJV^FW$M@TXMEN43*&4D (/
M]HDCCWKU#X>_!W2/%?AG3IK\Z_:75["76[V0I:J>=H4.=\G !R!CGK5G3],D
MM/@(^E2S-'+#XR2V::$X92)%7<I['N*'46R"QY!JNE7^A:@]AK5G-8W<8!:&
M==K $9!_$54KZ;\.^'M"M/BCXUM=<O-2UK4;/3XV%U?K'*RP-$I)4[1AP20,
M #&/>O,%^'.A>(O!5OK7@.YU*>4ZRFG2P7I0LD;MM20A0,'#(3R1R?2DJJ>X
M6/,Z=)')$VV6-XVZ[74J?R->KZ7\/]#3XZRZ-8W$UQH?AY?M>I7%VRGF,;F7
M@ 8W87\&K@?&7B6;Q?XQU+7)RV+N8F)6/W(APB_@H'ZU:E=Z 8E%%%6 5)!_
MQ\P_]=%_F*CJ2#_CYA_ZZ+_,4 >O_M,?\E#TS_L&+_Z,>O'*]C_:8_Y*'IG_
M &#%_P#1CUXY6=+X$#W"BBBM "BBB@ HHHH **** "BBB@ HHHH Z;X;_P#)
M4?#/_83A_P#0JV_CG_R6;6_I#_Z*6L3X;_\ )4?#/_83A_\ 0JV_CG_R6;6_
MI#_Z*6L_^7GR#H>?4445H 4444 %%%% !1110 4444 %%%% !7I/P _Y+-IG
M_7"X_P#19KS:O2?@!_R6;3/^N%Q_Z+-14^!@<IXY_P"2B>(_^PI<_P#HQJP:
MWO'/_)1/$?\ V%+G_P!&-6#3CL@"BBBJ **** "BBB@ HHHH **** "BBB@#
MV7]FS_D:_$/_ &"?_9Q7C9^\?J:]D_9L_P"1K\0_]@G_ -G%>-G[Q^IK*/QR
M^0=!****U **** "BBB@ HHHH **** "BBB@ KV7X3_\D4^(_P#UP_\ :35X
MU7LOPG_Y(I\1_P#KA_[2:LZGP@CQH=!10.@HK0 HHHH ?'%)*VV&-Y&Z[44L
M?R%$D,L+ 3Q21$]!(A7/YUZE^SGG_A;!P<'^S9__ $)*[+Q/<G5/A_;>&O'V
MMV6M>([_ %9!9_V0BW$]O"7&2 @&2%#]AG('-92J6E8+'SQ17K_C+X/Z;H_@
M:;Q!I,FK6TEG<1QW%IJC0EV1V"[@(R=I^8<-[T>+_ /P[\#^*;+2[[6-;N;F
M62&5H(XXVV1,2.6V@$D@<>F::J1>P6/( 0>AS17T/XU\#>$_%/QWL?#D37MC
M,]B6NH[5(XXHT1,Q^7\IY/.<CTQ7':C\+O#U]X'N]7\%ZMJ%Y=Z?J:Z=.E[&
MJ1RNTBIE !D#+@Y).<'@4E53L%CRFBO==5_9_LK/2=1AM;K5SJ=A9?:?ML\4
M8LKEP,F-,'>#[FN8\4>!/!_AGP'H^JW.K:G_ &OK&EK<VMH$5H_-*JQW$+PF
M6QZ^]-5(O8+'F-/>.2(@2QO&2,@.I4D>O-=3\,_#"^+/'UA976!86Y-W?.WW
M5ACY.3VR<#\:K>/O%#^,O'.I:R2?(ED\NU4_P0KP@_+GZDU5_>L!SE%%%4 5
M8T__ )"MG_U\1_\ H8JO5C3_ /D*V?\ U\1_^AB@#[_HHHKR"SX1\8_\CWK_
M /V$[G_T:U9LU[=W,$,%S=3S0P#$,<DK,L0]%!.%Z#I6EXQ_Y'O7_P#L)W/_
M *-:NQDTW0?!7P[\+ZIK&A6^M:CKD[W<B7$C*$ME&%0$=,DJ<X]17J7LD0>>
M1WMU%:2VL5U.EM,098%E8)(1T++G!Z=Z?9ZGJ&G!QIU_=V@D^^+>=X]WUVD9
MKV?7I? VE?#?PUXEB^'.FRS:Z[Q_9S=2*(2,@'=WZ>U<1JOPFUG3/#=]K,&J
M:-JL6G*&O8M/N_-D@'?/ !Q['L:2FGN!C^#]8T;2-6N+KQ%:ZE=))%B*33KL
MP31/N!+;LC((R"/>MGQO\1U\0V6D:7X=LKC2-,TAFE@:2Y+W$DK=9&DSG/)[
M]SS4E]\'/$-AX=M=8DN],>.\MHY[6W6<^=<%\8C1"!N?YAGM[UI1_ 'Q/)/)
M;?VIH0NH8?.N+87A:2 8R RA<\]CT]Z3<+W;#4\W34;Z.^-]'>W*7C$DW*S,
M)"3U^?.?UJ1M8U1S$7U.]8PN9(BURY\MSU9>>#R>1S76:!\)==U[1[/4!>Z5
MIPU%F73K?4+KRI;TC_GFN#G\:Z;P]\&[6^^&>MZEJ^HV5EK=O/Y,?VB\*1V)
M5PK+, .'.&QU!#+3<XH#RHZG?E;E3?W16[.;@&=L3G_;Y^;\<TR:]NKF&&&Y
MNIYHH%VPQR2LRQ#T4$X4?2NW\2Z!IEY\*="\7Z-91V4J3MIFIQ0YV22KG;*
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M^(MW0[L)'Q]X?*6]-K4W[,-3,TGXW7NF1Z)YWAW2+Z_T6V^RV][*6$OE;=N
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MN>V_\+:\,#XY6OBT&]_LR+2?L;'[/^\\S)_ASTYZUS=CXS\,7?PJU[PGKO\
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M/]V45E/WO7CI7<>*=9T_1_BJGC@ZOJFG:=X@TN*:PO\ 3(EF_>*%5XI$888
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MZW_?)HVM_=;_ +Y-$HJ2LP.\^'OC_P#L?XHVOB?QC?WU\L<,L;S,3-)\RD
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M_P!\FC:W]UO^^335-)60'I7Q-\2^$_%_G:G9:[K][J@8"UM;NW6.V@CW<JH
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M_OD5)10!']GA_P">,?\ WR*/L\/_ #QC_P"^14E% $?V>'_GC'_WR*/L\/\
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M+=:G96-S:V]W<QQ37DACMXV/S2L!DA1WP!D^E $WV>'_ )XQ_P#?(H^SP_\
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MD5\\?\))KG_09O\ _P "7_QH_P"$DUS_ *#-_P#^!+_XT?V=/^8/K*['T/\
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M_P#P)?\ QH_X237/^@S?_P#@2_\ C1_9T_Y@^LKL?0_V>'_GC'_WR*/L\/\
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M\BC[/#_SQC_[Y%244 1_9X?^>,?_ 'R*/L\/_/&/_OD5)10!']GA_P">,?\
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M .RL;R/4-.MKR$,([B)94##D!@",_G4],@@CMK>."W01Q1($1%Z*H& /RI]
M!1110 4444 %%%% !1110 4444 ?/WC?_D>=7_Z[_P#LHK"K=\;_ /(\ZO\
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M5J2Y@BB666:-(V^Z[. #^-"7,$D)F2:-HESEPX*C\: )$18XU2-0J*,*JC
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MN)XX@WW=[A<_G0!+147VF#[/Y_G1^3_STWC;^?2B&Y@N%8P31RA?O%'!Q^5
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M?5EW/GC^P=8_Z!-]_P" S_X4?V#K'_0)OO\ P&?_  KZ(FO+:W8+<7$43$9
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M0OWBCAL?E38KVUGDV0W,,C_W4D!/Y4?VC+^4/JR[GSQ_8.L?] F^_P# 9_\
M"C^P=8_Z!-]_X#/_ (5]#O?6D<OE/=0K)G&PR '/TITUW;VQ N)XHBW0.X7/
MYT?VC+^4/JR[GSM_8.L?] F^_P# 9_\ "C^P=8_Z!-]_X#/_ (5]$M<P)")G
MGC6)NCEP%/XT1W,$T;2131R(OWF5P0/QH_M&7\H?5EW/G;^P=8_Z!-]_X#/_
M (4?V#K'_0)OO_ 9_P#"OHB&\MKABMO<12L!DA'#''X4GVZT\[R?M4/FYV[/
M,&[/IBC^T9?RA]67<^>/[!UC_H$WW_@,_P#A1_8.L?\ 0)OO_ 9_\*^B)KRU
MMWVW%S#$V,X>0*<?C2RW,$,:O--'&C?=9W !_&C^T9?RA]67<^=O[!UC_H$W
MW_@,_P#A7LWPZMY[7P1:174,D$H>3*2(58?.>QKHUN8'@,RS1M$.L@<;1^-$
M-U;W)(MYXI2O78X;'Y5A7Q;K0Y6K&E.BH.]R6BH$OK267RH[J%Y,XV+("?RH
MDOK6&3RYKF&-_P"ZT@!_*N(W)Z*BFNH+?;]HGCBW=-[A<_G0;F 6_GF:/R?^
M>F\;?SZ4 2T5%%<P7"LT$T<H7[Q1P<?E38KVUGDV07,,CXSM20$_I0!/14#7
MUHLWE-=0K)G&PR#.?3%+-=VUNP6XN(HB1D!W"Y_.@":BHGN8(X1-)-&D38P[
M. IS[T1W,$L+2Q31O&N<NK@@?C0!+14,-Y;7#%;>XBE8#)".&P/PI!?6C3>4
M+J$R9V[!(-V?3% $]%0S7MK;OLGN88FQG:\@!Q^-++<P0(K3S1QJWW2[@ _G
M0!+140N8#;F<3QF$=9 XV_G1#=6]SG[//'+MZ['#8_*@"6BH([ZTFD\N*YA=
M_P"ZL@)_*B2^M(I?+ENH4?\ NM( ?RH GHJ*:ZM[;'VB>.+=TWN%S^=!N8%@
M$[31B(])"XVG\: ):*BBN8)T9X)HY%7[Q1P0/RI(;VUN'V07,,K8SM20$X_"
M@":BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KA?$
M'Q)_L?2_$^HVFE&]M?#\D5L7,^S[1<.RAXU^4X""1,MZDC'&:[JO&=4T:_U7
MP'\0?"-A 9=9;6FNTMPX1I(9IDE20$D#&T,,^J$4 =#<_%"^TB/7+;Q'X:-C
MJFEZ4VJQP17JS17,(;:<2!05.[C!6IK?XC:I8W6E#Q?X7.DV.K2QP6U_;WRW
M,:R.,HL@VJ4STS@C-0^(/AK:VG@3Q/'H,=[J6MZIISVPN+Z\:>:08.V/?(>%
MSVX%4YM-\4>-;;0='U#P])H&E:;<V]U>7%W<Q22SF'!6.-(RV 6 RQ(X[4 >
MC:K<)::3<3R64U\L:$FV@C$CR_[(4\$_6L+P!K]MXF\/2ZC:Z.-'VW<UL]L=
MNX-&Y4[MHQG(Z<_4UHZ=H4UAK5U?R:YJ=XEQNVV=R\9AARV?D 0$8Z#)/%8_
MPTT74-"\-WMMJUN;>:35;RX12P;,;S,RMP3U!!IW>P'0RZWI<"WS3ZC:QC3P
M#=EYE'V?(W#?S\N0<\U/=WUM8Z?-?7<RQ6L$3322L?E5 ,EOI@5PGBWX>W_B
M3Q1_;L<UA#+8B+[%;/&6CO=I#$77]X _< SL/S<DXKKO$>C#Q'X3U/1II/)_
MM"TDMS(O.PNI&??&:0'-:)XX\1^(GMKW3/!4RZ%=<P7US?QQRNA'RR>3@D*>
M.^<'.*K:7X\\67_C*?P]-X.M()K-(9KN0:P'$<4I(#*/*&X@*W''3WJ3PEJG
MC33K?2_#^M>#_P#CT1+:;58+^+[.T:#'F!?OY( ^7'6KVDZ+J%M\7?$6L36Q
M6PO-/M(8)MP^=T,FX8SD8W#J.] &EX/\3CQ9I5U>BU-J+>^N+/89-^[RI"F[
M.!C.,X[5CZ=\2K74/B==^$5L9(XX1)'!J!DREQ/&J-+$!CJHD'?L:PO!L_BK
MPGIVJ:6_@O4+AGU"^NH+I+FW\IP[N\8QYFX9X'3C-847PR\9Z/X7T75[?53J
M&LZ;?+JKZ2+>%-TTK9N$\_.3E7<<G!P/:@#W"N,7XAPW7Q,G\':99?:)8;*2
M=[PR[8Q,A7,/0Y(WKD]LXQ6A<^&]2>XU&]L/$VJ0SW<$B6\$_EO;VKL/E8(%
M!.T\X+&N!\/^ ?%OA?Q_H5S-J6GSZ1I^G3QW%X+3RR=\BNX?=*29'(+&3H,'
M(YH ])\*^(8O%'A^+48X'M9=[PW%LYRUO-&Q22,GOA@>>XP>];%<7\+PT^@Z
MIJRJ5MM8UB[O[3(P6A9\(V/]H+N'LPKM* *]WI]E?[?MUI!<;,[?-C#;?IF@
MZ?9M9"S:TA-J.D)C&P<Y^[TZU8HH KVNGV=E&Z6=I# DG+K%&%#?7%1VVD:=
M93>;9V%M!)C&^*)5./3(%7** *;Z/ILEU]IDT^U:?<&\TPJ6R.^<9S3KO3+"
M_=7O;*WN&484RQ!B!Z<U:HH KRZ?9SVJ6T]K#) F-L3Q@JN.F!THAT^SM[5[
M:WM88H'SNB2,!6SUR.E6** *MII=A8.SV5E;V[,,%HH@I(].*:NCZ:EU]I33
M[59]V_S1"N[=ZYQG-7** *EUI.G7LWFWEA;3R8QOEB5CCTR13[G3[.]C2.\M
M(9TC^XLD88+] :L44 5UT^S6R-FMI"+8\&$1C8>_3I26FG65AN^PVD%OOQN\
MJ,+N^N*LT4 4X-'TVUN!/;:?:PS#.)(X55AGKR!1/H^FW-P;BXT^UEF."9'A
M4MQTY(JY10!6N].LK\J;ZT@N"F=OFQAMN?3-*VGV;V0LWM(6MEP!"8P4&.G'
M2K%% %>VT^SLX7BM+2&".3[Z1QA0W;D#K52.VTC2E:ZM;.VA()C+P0J&Z\C@
M>WZ58U.R@O;&5)US^[;!#$$<=B*YSPM=1:KI>GS&)G4Q>7*223N&1D^O(QFF
MU[O,C-5/WOLWVO\ =O\ F;-MIEG<7DUY/I]H)1+E7\E=X([ENYS_ "JW=Z78
M7\@>]LK>X=1M#2Q*Q ].13K0XCD4]5E?.?KG^1%6 0PR#D>HJ5L:O<KSZ?9W
M-LEO<VL,L*8V1O&"JXX& :(M/LX+1K6&TACMWSNB6,!6SUR.E6**8BK::98V
M#LUE96]NS##&*(*2/PIL>CZ;%=?:8M/M4G#%O-6%0V3U.<9S5RB@"G<Z1IMY
M-YUW86T\F -\D*L<?4BI+K3[.^1%O;2&X5.4$L88+],U8HH KC3[,67V,6D/
MV7IY/EC9US]WIUHM-/L[%7%E:0VX?[PBC"[OKBK%% %.WTC3;2<36MA;0RC.
M'CA56YZ\@42Z/IL]R;B?3[62<D$R/"I;(Z'.*N44 5KO3;&_93?6<%P4&%,L
M8;'TS2R:?9RV:VDMI"]LN-L+1@H,=..E6** *]OI]G:0/#:VL,,4F=Z1QA5;
M(QR!3+72M/L9#)96-O;N1M+11*I(],@5;HH I_V/IOVO[5]@M?M&_?YODKNW
M>N<9S2W6E:??2"2]L;>X<#:&EB5B!Z9(JW10!7N-/L[J!(+JUAFBCQLCDC#*
MN!C@'I1'I]G%9M:16D*6S9W0K& ASUXZ58HH K6FFV-@S-8V<%N7&&,487/U
MQ3(M'TV"Y%Q!I]K'."2)$A4-D]3G%7** *=QI&FW<YFNK"VFE( +R0JS<=.2
M*DNM/L[Y4%[:07 3[@EC#;?IFK%% %?^S[,V/V,VL/V7&/(\L;.N?N].M%KI
M]G8HZV5I#;J_WQ%&%#?7%6** *=MI&FV<WG6EA;02X(WQPJIQ]0*)-'TV6Z-
MS+I]J\Y8-YK0J6R.ASC-7** *MWIEC?NK7ME;W#*,*98@Q _&G2Z?9S6BVLU
MI#);IC;$T8*KCI@=*L44 5X-/L[:V>WMK6&*&3.^-(P%;(P<@4VTTNPL)"]E
M96]N[#:6BB521Z<"K5% %,:/IJW?VI=/M1<;M_FB%=V[USC.:6ZTG3KZ7S;V
MQMKB3&W=+$K''IDBK=% %>YT^SO(4BN[6&>./[B21A@O;@&A=/LTLC9I:0K;
M-G,(C 0YZ\=*L44 5K33K*P+&QM(+<OC=Y487=CUQ3(='TVVN!<6^GVL4P)(
MD2%0W/7D"KE% %.?2--NK@SW-A;33'&9)(59CCIR13[O3K*_V?;K2"XV9V^;
M&&VY],U9HH KMI]FUD+-K2$VPZ0F,;!SG[O2BVT^SLHWCL[2&!).76*,*&^H
M%6** *EKI.G64WFV=A;028QOBB53CTR!2-H^FO=?:7T^U:?=O\TPKNW>N<9S
M7C?B_P 0ZS:^,M4@MM6O888YL)&D[!5&T< 5C?\ "4:__P!!O4/_  (;_&O2
MCE\Y14N;<YGB$G:Q[_=Z787[J][96]PRC"M+$&('IS3IM/L[BU2VGM898$QM
MB>,%5QTP.E?/W_"4:_\ ]!O4/_ AO\:/^$HU_P#Z#>H?^!#?XT_[.G_,A?68
M]CZ!AT^SM[5[:"UAC@?.Z)(P%;/7(Z4VTTNPL'9[*RM[=F&&,404D>G%> ?\
M)1K_ /T&]0_\"&_QH_X2C7_^@WJ'_@0W^-']G3_F0?68]CWU-'TV.Z^TQZ?:
MK/N+>:(5#9/?.,YHN=)TZ]F\V\L+:>3&-\L2L<>F2*\"_P"$HU__ *#>H?\
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M<.HVAI8E8@>G(I\^GV=U;I;W-K#+"F-D;QAE7' P#7S]_P )1K__ $&]0_\
M AO\:/\ A*-?_P"@WJ'_ ($-_C1_9T_YD'UF/8^@8]/LX;1K6*TA2W?.Z)8P
M%;/7(Z4VTTRQL&9K&SM[=F&&,407(]\5X!_PE&O_ /0;U#_P(;_&C_A*-?\
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ML)XBFE>YK45' TKQYGC6)\GY5?=Q]<"I*@V3NKA1110,**** "BBB@ HHHH
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M?]]&C_A-/#G_ $%[;_OHT ;E%8?_  FGAS_H+VW_ 'T:/^$T\.?]!>V_[Z-
M&Y16'_PFGAS_ *"]M_WT:/\ A-/#G_07MO\ OHT ;E%8?_":>'/^@O;?]]&C
M_A-/#G_07MO^^C0!N45A_P#":>'/^@O;?]]&C_A-/#G_ $%[;_OHT ;E%8?_
M  FGAS_H+VW_ 'T:/^$T\.?]!>V_[Z- &Y16'_PFGAS_ *"]M_WT:/\ A-/#
MG_07MO\ OHT ;E%8?_":>'/^@O;?]]&C_A-/#G_07MO^^C0!N45A_P#":>'/
M^@O;?]]&C_A-/#G_ $%[;_OHT ;E%8?_  FGAS_H+VW_ 'T:/^$T\.?]!>V_
M[Z- &Y16'_PFGAS_ *"]M_WT:/\ A-/#G_07MO\ OHT ;E%8?_":>'/^@O;?
M]]&C_A-/#G_07MO^^C0!N45A_P#":>'/^@O;?]]&C_A-/#G_ $%[;_OHT >2
M^,M*U&;QIJLD.GW<D;3Y5T@8@_*.A K$_L;5?^@9>_\ @,_^%>Z_\)IX<_Z"
M]M_WT:/^$T\.?]!>V_[Z->G',)1BH\NQRO#IN]SPK^QM5_Z!E[_X#/\ X4?V
M-JO_ $#+W_P&?_"O=?\ A-/#G_07MO\ OHT?\)IX<_Z"]M_WT:K^T9?RB^K+
MN>%?V-JO_0,O?_ 9_P#"C^QM5_Z!E[_X#/\ X5[K_P )IX<_Z"]M_P!]&C_A
M-/#G_07MO^^C1_:,OY0^K+N>%?V-JO\ T#+W_P !G_PH_L;5?^@9>_\ @,_^
M%>Z_\)IX<_Z"]M_WT:/^$T\.?]!>V_[Z-']HR_E#ZLNYX5_8VJ_] R]_\!G_
M ,*/[&U7_H&7O_@,_P#A7NO_  FGAS_H+VW_ 'T:/^$T\.?]!>V_[Z-']HR_
ME#ZLNYX5_8VJ_P#0,O?_  &?_"C^QM5_Z!E[_P" S_X5[K_PFGAS_H+VW_?1
MH_X33PY_T%[;_OHT?VC+^4/JR[GA7]C:K_T#+W_P&?\ PH_L;5?^@9>_^ S_
M .%>Z_\ ":>'/^@O;?\ ?1H_X33PY_T%[;_OHT?VC+^4/JR[GA7]C:K_ - R
M]_\  9_\*/[&U7_H&7O_ (#/_A7NO_":>'/^@O;?]]&C_A-/#G_07MO^^C1_
M:,OY0^K+N>%?V-JO_0,O?_ 9_P#"C^QM5_Z!E[_X#/\ X5[K_P )IX<_Z"]M
M_P!]&C_A-/#G_07MO^^C1_:,OY0^K+N>%?V-JO\ T#+W_P !G_PH_L;5?^@9
M>_\ @,_^%>Z_\)IX<_Z"]M_WT:/^$T\.?]!>V_[Z-']HR_E#ZLNYX5_8VJ_]
M R]_\!G_ ,*/[&U7_H&7O_@,_P#A7NO_  FGAS_H+VW_ 'T:/^$T\.?]!>V_
M[Z-']HR_E#ZLNYX5_8VJ_P#0,O?_  &?_"C^QM5_Z!E[_P" S_X5[K_PFGAS
M_H+VW_?1H_X33PY_T%[;_OHT?VC+^4/JR[GA7]C:K_T#+W_P&?\ PH_L;5?^
M@9>_^ S_ .%>Z_\ ":>'/^@O;?\ ?1H_X33PY_T%[;_OHT?VC+^4/JR[GA7]
MC:K_ - R]_\  9_\*/[&U7_H&7O_ (#/_A7NO_":>'/^@O;?]]&C_A-/#G_0
M7MO^^C1_:,OY0^K+N>%?V-JO_0,O?_ 9_P#"D?1=5V-_Q*[WI_S[/_A7NW_"
M:>'/^@O;?]]&C_A-/#G_ $%[;_OHT?VC+^4/JR[FM9@BQ@!!!$:Y![<5Y_I.
MBZM8?$KQ%/J'A_[<NK3QR6NLEXF2V@2,!8RK'>"K@G &#G-=5_PFGAS_ *"]
MM_WT:/\ A-/#G_07MO\ OHUY1UGEOA[P7XDAM/#MA=^&A:3^'KV;4[[5#<1.
M^I3XDVB,@[CO+#<7VX  J?0OAE=);> ;/5=&B9;66XU36YGV$_:64E$;G+?,
MYX&1\E>E_P#":>'/^@O;?]]&C_A-/#G_ $%[;_OHT >:Z1X U>\O= CUG1Q%
M8R^(=0UW487*%(FY6V0@'!R"#@9''--MOAYJ4ND6YFT)(+S5?%W]HZA_J\VU
MHDK.HR#T(1.%_OGWKTS_ (33PY_T%[;_ +Z-'_":>'/^@O;?]]&@#S'0/ VN
M6VN73^(=-U"]EM-3N-8@EC>V6VN)_F,+%@?.8X(4*V OT%3:%\.-4L+/P%;#
M3D@N+/[3J.K7AV%DNVB(16(.6^>0],CY*](_X33PY_T%[;_OHT?\)IX<_P"@
MO;?]]&@#S&#P=XCN/@G?^%8/#9TS68H0DMX\\3'47,H:8JX)/SJ#R^/O8/%=
MC\._#C:?)?:Q?V.H6NH7:16Y^W?9T(BC'RJD=O\ (B@L1W)K=_X33PY_T%[;
M_OHT?\)IX<_Z"]M_WT: /+7\#>(-8N==TR]\."VFUG7Q>W.MRS1,L5I'(K1I
M%@ERV$ P0 -QR:O:'X?EUWXL>(K(F.7PWIFM+JLFTY$]ZT$8$1[$1D%R/[Q7
M->@7'BWPO=VLMO<:I;/%,AC=2Q^92,$?E571]:\%>'],CT_1;JQLK2/)6*$8
M&3R3[D^IYH I^*O#ESXB^(OA=[FQ%QHNE)<W<[.5*M.558EVDY.,L>F.*XW1
MOAWJ::5X6%UHD=O>3^)9-:U9U*9M@K2/&F0>F?+&%R.M>F?\)IX<_P"@O;?]
M]&C_ (33PY_T%[;_ +Z- 'EUIX2\31V>DRZGX:DOE@\2WNH:E8?:(<732;O)
MG7+8**2O#8/&<<5T?@WP7K<GAS4)-7O;[PWJFHZS<W\ZZ=)$3M)VHFYE8%=J
MJ1T-==_PFGAS_H+VW_?1H_X33PY_T%[;_OHT <'>6_B/7_&K6WBKPOK%[H%I
M=I'8P1W%N+:55('VFX&\-(<_,$Q@ =":K7G@_P 3W:^)?":Z64L?$.MM?7&M
M_:$V"T<H60+G?YF$V8QC!SFO1?\ A-/#G_07MO\ OHT?\)IX<_Z"]M_WT: .
M#TNWU_7?&<5QXQ\):J;2TNB=+MQ/ +*S1/\ 5RNHDW22\=2"%SP!UJ31_#-[
M?_$O3O$%CX2E\)I;F>35)Y;B,OJ+2*0$VQLP8;CNW-CIQ7<?\)IX<_Z"]M_W
MT:/^$T\.?]!>V_[Z- &Y16'_ ,)IX<_Z"]M_WT:/^$T\.?\ 07MO^^C0!N45
MA_\ ":>'/^@O;?\ ?1H_X33PY_T%[;_OHT ;E%8?_":>'/\ H+VW_?1H_P"$
MT\.?]!>V_P"^C0!N45A_\)IX<_Z"]M_WT:/^$T\.?]!>V_[Z- &Y16'_ ,)I
MX<_Z"]M_WT:/^$T\.?\ 07MO^^C0!N45A_\ ":>'/^@O;?\ ?1H_X33PY_T%
M[;_OHT ;E%8?_":>'/\ H+VW_?1H_P"$T\.?]!>V_P"^C0!N45A_\)IX<_Z"
M]M_WT:/^$T\.?]!>V_[Z- &Y16'_ ,)IX<_Z"]M_WT:/^$T\.?\ 07MO^^C0
M!N45A_\ ":>'/^@O;?\ ?1H_X33PY_T%[;_OHT ;E%8?_":>'/\ H+VW_?1H
M_P"$T\.?]!>V_P"^C0!N45A_\)IX<_Z"]M_WT:/^$T\.?]!>V_[Z- &Y16'_
M ,)IX<_Z"]M_WT:/^$T\.?\ 07MO^^C0!N45A_\ ":>'/^@O;?\ ?1H_X33P
MY_T%[;_OHT ;E%5HM1M)X4FAN$>.10R,#P01D&B@"S117$Z3XIU!_'U[IFH.
MC6+3R6]J0@!21 &VD]\J3^5:0IN:;70F4E&USMJ*XN?Q1?R?$>UTNT9!IHD:
M"4[ 2\HC+D ]L945):ZIKOB>>YN-'O+;2],@F:&.62'S7G9>"V"0 ,U?L))7
M>FER?:)Z(["BN7U/6M5TG3=-L1]FO=;OY3#&Z@K$,<ER.N ,<>M.>;7/#VG7
MFIZWJEO?V]O;,YACMO+.\=,')X[4O9.V_IYCYT=-17&VFL:]I^H:*VM7-O<6
M^L'88HH=AMG*[E .?F';FG:EJ'B'1-0TZ6\U"TN8[Z]6W-E';[2JL>JMG)('
M)I^Q=[70O:*USL**XS4_$T\^O75A:ZS8Z+;V;")IKE0[SRD9PJD@ #C)]:Z^
M#=]FC\QUD?8-SJ,!CCJ/:HE3<$F^I2DF]"2BBBLR@HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKRSQ'\2=;TGQ+?V%K%9F&W
MEV(7C8MC //S>]9G_"V?$/\ SQL/^_3?_%5VQP-6235C!UX)V/9J*\9_X6SX
MA_YXV'_?IO\ XJC_ (6SXA_YXV'_ 'Z;_P"*JOJ%;R%]8@>S45XS_P +9\0_
M\\;#_OTW_P 51_PMGQ#_ ,\;#_OTW_Q5'U"MY!]8@>S45XS_ ,+9\0_\\;#_
M +]-_P#%4?\ "V?$/_/&P_[]-_\ %4?4*WD'UB![-17C/_"V?$/_ #QL/^_3
M?_%4?\+9\0_\\;#_ +]-_P#%4?4*WD'UB![-17C/_"V?$/\ SQL/^_3?_%4?
M\+9\0_\ /&P_[]-_\51]0K>0?6('LU%>,_\ "V?$/_/&P_[]-_\ %4?\+9\0
M_P#/&P_[]-_\51]0K>0?6('LU%>,_P#"V?$/_/&P_P"_3?\ Q5'_  MGQ#_S
MQL/^_3?_ !5'U"MY!]8@>S45XS_PMGQ#_P \;#_OTW_Q5'_"V?$/_/&P_P"_
M3?\ Q5'U"MY!]8@>S45XS_PMGQ#_ ,\;#_OTW_Q5'_"V?$/_ #QL/^_3?_%4
M?4*WD'UB![-17C/_  MGQ#_SQL/^_3?_ !5'_"V?$/\ SQL/^_3?_%4?4*WD
M'UB![-17$?#_ ,8:CXHN+Y-22W46ZH4\E".I;.<D^E=O7)4IRIRY9;FT9*2N
M@HHHK,H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&R#R/F7D>M2:CINL_P!D_$;0UT:\D?55N;JQN4VF&8/;(BQ@[LA]RD8(]\T
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MXBU2TU)BP,+VUF;?:,<@@NV>>]<9!X8U/X>ZGI6H:!82ZY80:-#I-];PLJW
M\IBR3(&(#9+N"N0>1C.*[30=9NM:BFFN-$OM)C5@(A?;!)+QR=JLVT#ISUH
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M-=G-"EQ;R0R@F.12C $C((P>1R*BT^PM-*TZ"PTZWCMK6WC$<4,8PJ*!@ 4
M6**** "BBB@ HHHH **** "BBB@ HHHH **** **:-9Q^()M:56^VS6R6KMO
M.#&K,P&.F<L>:O444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?/WC?_ )'G5_\ KO\
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M@?\ 0%L/_ =?\*/^$6T#_H"V'_@.O^%']HP_E8?5I=SYVS1FOHG_ (1;0/\
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M&,56TSQ9I.KSO%:32AEC,I,L#QJ4'4@L "*/9SLW;8.9=Q/[&U?_ *&>\_\
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M;5_^AGO/_ 6W_P#B*VZ* ,3^QM7_ .AGO/\ P%M__B*/[&U?_H9[S_P%M_\
MXBMNB@#$_L;5_P#H9[S_ ,!;?_XBC^QM7_Z&>\_\!;?_ .(K;HH Q/[&U?\
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M=S2_L;5_^AGO/_ 6W_\ B*/[&U?_ *&>\_\  6W_ /B*S?\ A9OA?_G]E_\
M =_\*/\ A9OA?_G]E_\  =_\*/J];^5_<'M(=S2_L;5_^AGO/_ 6W_\ B*/[
M&U?_ *&>\_\  6W_ /B*S?\ A9OA?_G]E_\  =_\*/\ A9OA?_G]E_\  =_\
M*/J];^5_<'M(=S2_L;5_^AGO/_ 6W_\ B*/[&U?_ *&>\_\  6W_ /B*S?\
MA9OA?_G]E_\  =_\*/\ A9OA?_G]E_\  =_\*/J];^5_<'M(=S2_L;5_^AGO
M/_ 6W_\ B*/[&U?_ *&>\_\  6W_ /B*S?\ A9OA?_G]E_\  =_\*/\ A9OA
M?_G]E_\  =_\*/J];^5_<'M(=S2_L;5_^AGO/_ 6W_\ B*/[&U?_ *&>\_\
M 6W_ /B*S?\ A9OA?_G]E_\  =_\*/\ A9OA?_G]E_\  =_\*/J];^5_<'M(
M=S2_L;5_^AGO/_ 6W_\ B*/[&U?_ *&>\_\  6W_ /B*S?\ A9OA?_G]E_\
M =_\*/\ A9OA?_G]E_\  =_\*/J];^5_<'M(=S2_L;5_^AGO/_ 6W_\ B*/[
M&U?_ *&>\_\  6W_ /B*S?\ A9OA?_G]E_\  =_\*/\ A9OA?_G]E_\  =_\
M*/J];^5_<'M(=S2_L;5_^AGO/_ 6W_\ B*/[&U?_ *&>\_\  6W_ /B*S?\
MA9OA?_G]E_\  =_\*/\ A9OA?_G]E_\  =_\*/J];^5_<'M(=S2_L;5_^AGO
M/_ 6W_\ B*/[&U?_ *&>\_\  6W_ /B*S?\ A9OA?_G]E_\  =_\*/\ A9OA
M?_G]E_\  =_\*/J];^5_<'M(=S2_L;5_^AGO/_ 6W_\ B*/[&U?_ *&>\_\
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MO_T,]Y_X"V__ ,11_8VK_P#0SWG_ ("V_P#\16W10!B?V-J__0SWG_@+;_\
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MO_T,]Y_X"V__ ,11_8VK_P#0SWG_ ("V_P#\16W10!B?V-J__0SWG_@+;_\
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MO_T,]Y_X"V__ ,11_8VK_P#0SWG_ ("V_P#\16W10!B?V-J__0SWG_@+;_\
MQ%']C:O_ -#/>?\ @+;_ /Q%;=% %:*WN$A1)+V25U4!G*("Q]< 8_*BK-%
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M_P#R/.K_ /7?_P!E%85?44OX<?1'DS^)A1116I(4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!Z5\'/^/S5O^N<7\VKU2O*_@Y_Q^:M_P!<
MXOYM7JE?/8W^._E^1Z5#^&@HHHKC-@HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFCT>V:'SV#2O),\KR$# R[DL<#WK5HH **** "BBB@ HHHH **** /G[QO\
M\CSJ_P#UW_\ 916%7KVM_"[^V==N]1_M<P_:9-_E_9]VW@#&=W/2J'_"F_\
MJ.'_ ,!?_LJ]ZGBZ*@DY=/,\^5&HY-V/,**]/_X4W_U'#_X"_P#V5'_"F_\
MJ.'_ ,!?_LJOZY0_F_!D^PJ=CS"BO3_^%-_]1P_^ O\ ]E1_PIO_ *CA_P#
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M1P_^ O\ ]E1_PIO_ *CA_P# 7_[*CZY0_F_!A["IV/,**]/_ .%-_P#4</\
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MUG_P7R?X5NT4 87_  E47_0)UG_P7R?X4?\ "51?] G6?_!?)_A6[10!A?\
M"51?] G6?_!?)_A1_P )5%_T"=9_\%\G^%;M% &%_P )5%_T"=9_\%\G^%'_
M  E47_0)UG_P7R?X5NT4 87_  E47_0)UG_P7R?X4?\ "51?] G6?_!?)_A6
M[10!A?\ "51?] G6?_!?)_A1_P )5%_T"=9_\%\G^%;M% &%_P )5%_T"=9_
M\%\G^%'_  E47_0)UG_P7R?X5NT4 87_  E47_0)UG_P7R?X4?\ "51?] G6
M?_!?)_A6[10!A?\ "51?] G6?_!?)_A1_P )5%_T"=9_\%\G^%;M% &%_P )
M5%_T"=9_\%\G^%'_  E47_0)UG_P7R?X5NT4 87_  E47_0)UG_P7R?X4?\
M"51?] G6?_!?)_A6[10!A?\ "51?] G6?_!?)_A1_P )5%_T"=9_\%\G^%;M
M% &%_P )5%_T"=9_\%\G^%'_  E47_0)UG_P7R?X5NT4 87_  E47_0)UG_P
M7R?X4?\ "51?] G6?_!?)_A6[10!A?\ "51?] G6?_!?)_A1_P )5%_T"=9_
M\%\G^%;M% &%_P )5%_T"=9_\%\G^%'_  E47_0)UG_P7R?X5NT4 87_  E4
M7_0)UG_P7R?X4?\ "51?] G6?_!?)_A6[10!A?\ "51?] G6?_!?)_A1_P )
M5%_T"=9_\%\G^%;M% &%_P )5%_T"=9_\%\G^%'_  E47_0)UG_P7R?X5NT4
M 87_  E47_0)UG_P7R?X4?\ "51?] G6?_!?)_A6[10!A?\ "51?] G6?_!?
M)_A1_P )5%_T"=9_\%\G^%;M% &%_P )5%_T"=9_\%\G^%'_  E47_0)UG_P
M7R?X5NT4 87_  E47_0)UG_P7R?X4?\ "51?] G6?_!?)_A6[10!A?\ "51?
M] G6?_!?)_A1_P )5%_T"=9_\%\G^%;M% &%_P )5%_T"=9_\%\G^%'_  E4
M7_0)UG_P7R?X5NT4 87_  E47_0)UG_P7R?X4?\ "51?] G6?_!?)_A6[10!
MA?\ "51?] G6?_!?)_A1_P )5%_T"=9_\%\G^%;M% &%_P )5%_T"=9_\%\G
M^%'_  E47_0)UG_P7R?X5NT4 87_  E47_0)UG_P7R?X4?\ "51?] G6?_!?
M)_A6[10!A?\ "51?] G6?_!?)_A1_P )5%_T"=9_\%\G^%;M% &%_P )5%_T
M"=9_\%\G^%'_  E47_0)UG_P7R?X5NT4 87_  E47_0)UG_P7R?X4?\ "51?
M] G6?_!?)_A6[10!A?\ "51?] G6?_!?)_A1_P )5%_T"=9_\%\G^%;M% &%
M_P )5%_T"=9_\%\G^%'_  E47_0)UG_P7R?X5NT4 87_  E47_0)UG_P7R?X
M4?\ "51?] G6?_!?)_A6[10!A?\ "51?] G6?_!?)_A1_P )5%_T"=9_\%\G
M^%;M% &%_P )5%_T"=9_\%\G^%'_  E47_0)UG_P7R?X5NT4 87_  E47_0)
MUG_P7R?X4?\ "51?] G6?_!?)_A6[10!A?\ "51?] G6?_!?)_A1_P )5%_T
M"=9_\%\G^%;M% &%_P )5%_T"=9_\%\G^%'_  E47_0)UG_P7R?X5NT4 87_
M  E47_0)UG_P7R?X4?\ "51?] G6?_!?)_A6[10!A?\ "51?] G6?_!?)_A1
M_P )5%_T"=9_\%\G^%;M% &%_P )5%_T"=9_\%\G^%'_  E47_0)UG_P7R?X
M5NT4 87_  E47_0)UG_P7R?X4?\ "51?] G6?_!?)_A6[10!A?\ "51?] G6
M?_!?)_A1_P )5%_T"=9_\%\G^%;M% &%_P )5%_T"=9_\%\G^%'_  E47_0)
MUG_P7R?X5NT4 87_  E47_0)UG_P7R?X4?\ "51?] G6?_!?)_A6[10!A?\
M"51?] G6?_!?)_A1_P )5%_T"=9_\%\G^%;M% &%_P )5%_T"=9_\%\G^%'_
M  E47_0)UG_P7R?X5NT4 87_  E47_0)UG_P7R?X4?\ "51?] G6?_!?)_A6
M[10!A?\ "51?] G6?_!?)_A1_P )5%_T"=9_\%\G^%;M% &%_P )5%_T"=9_
M\%\G^%'_  E47_0)UG_P7R?X5NT4 87_  E47_0)UG_P7R?X4?\ "51?] G6
M?_!?)_A6[10!A?\ "51?] G6?_!?)_A1_P )5%_T"=9_\%\G^%;M% &%_P )
M5%_T"=9_\%\G^%'_  E47_0)UG_P7R?X5NT4 87_  E47_0)UG_P7R?X4?\
M"51?] G6?_!?)_A6[10!A?\ "51?] G6?_!?)_A1_P )5%_T"=9_\%\G^%;M
M% &%_P )5%_T"=9_\%\G^%'_  E47_0)UG_P7R?X5NT4 87_  E47_0)UG_P
M7R?X4?\ "51?] G6?_!?)_A6[10!A?\ "51?] G6?_!?)_A1_P )5%_T"=9_
M\%\G^%;M% &%_P )5%_T"=9_\%\G^%'_  E47_0)UG_P7R?X5NT4 87_  E4
M7_0)UG_P7R?X4?\ "51?] G6?_!?)_A6[10!A?\ "51?] G6?_!?)_A1_P )
M5%_T"=9_\%\G^%;M% &%_P )5%_T"=9_\%\G^%'_  E47_0)UG_P7R?X5NT4
M 87_  E47_0)UG_P7R?X4?\ "51?] G6?_!?)_A6[10!A?\ "51?] G6?_!?
M)_A1_P )5%_T"=9_\%\G^%;M% &%_P )5%_T"=9_\%\G^%'_  E47_0)UG_P
M7R?X5NT4 87_  E47_0)UG_P7R?X4?\ "51?] G6?_!?)_A6[10!A?\ "51?
M] G6?_!?)_A1_P )5%_T"=9_\%\G^%;M% &%_P )5%_T"=9_\%\G^%'_  E4
M7_0)UG_P7R?X5NT4 87_  E47_0)UG_P7R?X4?\ "51?] G6?_!?)_A6[10!
MA?\ "51?] G6?_!?)_A1_P )5%_T"=9_\%\G^%;M% &%_P )5%_T"=9_\%\G
M^%'_  E47_0)UG_P7R?X5NT4 87_  E47_0)UG_P7R?X4?\ "51?] G6?_!?
M)_A6[10!A?\ "51?] G6?_!?)_A1_P )5%_T"=9_\%\G^%;M% %6*_6:%)!!
M<H'4-M>$AAD=".QHJU10 5Y]I.N:A;_$*]CO;N673KB]DLHT=LK#(%#*!Z9&
M17H-<=<>#KN>SUU1/"EQ>7PO;*0$_NG4#:3QQR.V>#711<%S*74SFGI8I2ZW
MJ%Y\3+)+>YD32UGDM!$K865TC+.2.^"0/PI;:]G\0V]WK6I^()M%TJ.X:"WC
MMY%BX4XW.Y'))[5I6WA*>TF\.-%+$PTPRO=,Q.Z5Y%Y8<<_,3UJ-/#>LZ/+=
M0Z')IUSIMS*9A:Z@C?N7)R=I&<C/8UOS4]HVV_5_BS.TNI%>ZO=1:;HVDZ'K
M"WMSJ4SQ#4VVN51>6/'!8# JU=V=UX4T>_U8ZQJ&HM!:L1#=.&0OV;  Q52'
MP-=0>'+""&_CBU73[A[F"X1#Y8+')4C^Z>E:1TW7M8L;NP\1-IR6MQ;M$39[
MRY8]&^;@8]*EN"V:M?7SU_R&E+JC)@DU30]1\/3W&K7-\NJMY5U%.055V3<"
M@ ^4 \8J*>]>V\86-GI.OWMY>-=E;RVN"!"L?); ( !'& ,UI6/AW69KW2VU
MVYM'@TD$P"W#;IGV[0SYZ8'8=Z+W0M?URYLH]9DTV*VM+E;CS+4.97*G@#/W
M<]^35<T+ZM;?YVZ"M*Q0NI=5UJ3Q%>V^JW-BNDNT5I%"0$9D7<Q<8^;)XKJ]
M!U!M5\/V%_( KW$"2,!ZD<U@7GAG68KO5X]&N[1+/6&W3&<-YD#$;6* <'(]
M<5TVG64>FZ;;64&?+MXEC7/4@#%8U90<5;^M/\RX)WU+-%%%<QJ%%%% !111
M0 445YY\6-;\0:+_ ,(Z?"TK"XDOG>6W !^U1Q0O*T7/]X(0,=\4 >AT5P/C
MWQG*OP^M[CPE<@7^MP%["<8_=QB(RO+C_913_P "*BM/PGXK34(M%TFZ\^74
MKC08-3DG91M8-M4Y/][<<],4 =717 :]XACUF;PY+IYN($A\4FRE#';O,:S*
MW0\J2N>?;BJL/CN[U;1O&(UW1M6TJRTK[0IN[62))8T2)&*@B0GS?F)! V].
M<T >DT5R=SXXM=.U2+0[33=5U74/[/CO$B@1&9XF)7+,S* 05YR1DD8R:R=0
M\3V_B+4?!-[I;W,,;ZY-;W%O*ICDC=+:<-'(OJ&'3D=#0!Z%17('XCZ9]J##
M3]2;2C="S_MD0K]E\TOY>,[MVW?\N_;MSQFKGC[4=8TKP7>7?AV)WO(S'EHX
M?->*,N!)(L?\;*A9@O?'?I0!T=%<5X6OM.M-'O?$">.KC7=&2 O,]XT3"W*\
MLV4167CJA%6;#X@6MUJ%A;WNCZMI46IMLL;J^@5([AMI8+PQ*,0"0'"DX]:
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MO1110 4444 %%%% !1110!XEXN\2ZY:>,-3M[75KN&&.;"1I*0%&T< 5C?\
M"6^(O^@W??\ ?XU+XW_Y'G5_^N__ +**PJ^EI4X>SCHMD>7*4N9ZFQ_PEOB+
M_H-WW_?XT?\ "6^(O^@W??\ ?XUCT5I[.'9$\TNYL?\ "6^(O^@W??\ ?XT?
M\);XB_Z#=]_W^-8]%'LX=D'-+N;'_"6^(O\ H-WW_?XTJ>+?$1D4'6[[[P_Y
M;'UK&IR?ZQ/]X?SH]G#L@YI=SZ<'2B@=!17RQZP4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *C$$(N#<")!,R!#+M&XJ#D#/7&2>/>LN;PU;SSR2M?ZJI=BQ5-1F51GT
M; 'M3/\ A%K;_H(:Q_X,Y_\ XJ@#;HK$_P"$6MO^@AK'_@SG_P#BJ/\ A%K;
M_H(:Q_X,Y_\ XJ@#;HK$_P"$6MO^@AK'_@SG_P#BJ/\ A%K;_H(:Q_X,Y_\
MXJ@#;HK$_P"$6MO^@AK'_@SG_P#BJ/\ A%K;_H(:Q_X,Y_\ XJ@#;HK$_P"$
M6MO^@AK'_@SG_P#BJ/\ A%K;_H(:Q_X,Y_\ XJ@#;J.>WAN8O+N8DFCR#LD4
M,,@Y!P?0C-9'_"+6W_00UC_P9S__ !5'_"+6W_00UC_P9S__ !5 &W16)_PB
MUM_T$-8_\&<__P 51_PBUM_T$-8_\&<__P 50!MT5B?\(M;?]!#6/_!G/_\
M%4?\(M;?]!#6/_!G/_\ %4 ;=%8G_"+6W_00UC_P9S__ !5'_"+6W_00UC_P
M9S__ !5 &W16)_PBUM_T$-8_\&<__P 51_PBUM_T$-8_\&<__P 50!MT5B?\
M(M;?]!#6/_!G/_\ %4?\(M;?]!#6/_!G/_\ %4 ;=%8G_"+6W_00UC_P9S__
M !5'_"+6W_00UC_P9S__ !5 &W16)_PBUM_T$-8_\&<__P 51_PBUM_T$-8_
M\&<__P 50!MT5B?\(M;?]!#6/_!G/_\ %4?\(M;?]!#6/_!G/_\ %4 ;=%8G
M_"+6W_00UC_P9S__ !5'_"+6W_00UC_P9S__ !5 &W16)_PBUM_T$-8_\&<_
M_P 51_PBUM_T$-8_\&<__P 50!MT5B?\(M;?]!#6/_!G/_\ %4?\(M;?]!#6
M/_!G/_\ %4 ;=%8G_"+6W_00UC_P9S__ !5'_"+6W_00UC_P9S__ !5 &W16
M)_PBUM_T$-8_\&<__P 51_PBUM_T$-8_\&<__P 50!MT5B?\(M;?]!#6/_!G
M/_\ %4?\(M;?]!#6/_!G/_\ %4 ;=%8G_"+6W_00UC_P9S__ !5'_"+6W_00
MUC_P9S__ !5 &W16)_PBUM_T$-8_\&<__P 51_PBUM_T$-8_\&<__P 50!MT
M5B?\(M;?]!#6/_!G/_\ %4?\(M;?]!#6/_!G/_\ %4 ;=%8G_"+6W_00UC_P
M9S__ !5'_"+6W_00UC_P9S__ !5 &W16)_PBUM_T$-8_\&<__P 51_PBUM_T
M$-8_\&<__P 50!MT5B?\(M;?]!#6/_!G/_\ %4?\(M;?]!#6/_!G/_\ %4 ;
M=%8G_"+6W_00UC_P9S__ !5'_"+6W_00UC_P9S__ !5 &W16)_PBUM_T$-8_
M\&<__P 51_PBUM_T$-8_\&<__P 50!MT5B?\(M;?]!#6/_!G/_\ %4?\(M;?
M]!#6/_!G/_\ %4 ;=%8G_"+6W_00UC_P9S__ !5'_"+6W_00UC_P9S__ !5
M&W16)_PBUM_T$-8_\&<__P 51_PBUM_T$-8_\&<__P 50!MT5B?\(M;?]!#6
M/_!G/_\ %4?\(M;?]!#6/_!G/_\ %4 ;=%8G_"+6W_00UC_P9S__ !5'_"+6
MW_00UC_P9S__ !5 &W16)_PBUM_T$-8_\&<__P 51_PBUM_T$-8_\&<__P 5
M0!MT5B?\(M;?]!#6/_!G/_\ %4?\(M;?]!#6/_!G/_\ %4 ;=%8G_"+6W_00
MUC_P9S__ !5'_"+6W_00UC_P9S__ !5 &W16)_PBUM_T$-8_\&<__P 51_PB
MUM_T$-8_\&<__P 50!MT5B?\(M;?]!#6/_!G/_\ %4?\(M;?]!#6/_!G/_\
M%4 ;=%8G_"+6W_00UC_P9S__ !5'_"+6W_00UC_P9S__ !5 &W16)_PBUM_T
M$-8_\&<__P 51_PBUM_T$-8_\&<__P 50!MT5B?\(M;?]!#6/_!G/_\ %4?\
M(M;?]!#6/_!G/_\ %4 ;=%8G_"+6W_00UC_P9S__ !5'_"+6W_00UC_P9S__
M !5 &W16)_PBUM_T$-8_\&<__P 51_PBUM_T$-8_\&<__P 50!MT5B?\(M;?
M]!#6/_!G/_\ %4?\(M;?]!#6/_!G/_\ %4 ;=%8G_"+6W_00UC_P9S__ !5'
M_"+6W_00UC_P9S__ !5 &W16)_PBUM_T$-8_\&<__P 51_PBUM_T$-8_\&<_
M_P 50!MT5B?\(M;?]!#6/_!G/_\ %4?\(M;?]!#6/_!G/_\ %4 ;=%8G_"+6
MW_00UC_P9S__ !5'_"+6W_00UC_P9S__ !5 &W16)_PBUM_T$-8_\&<__P 5
M1_PBUM_T$-8_\&<__P 50!MT5B?\(M;?]!#6/_!G/_\ %4?\(M;?]!#6/_!G
M/_\ %4 ;=%8G_"+6W_00UC_P9S__ !5'_"+6W_00UC_P9S__ !5 &W16)_PB
MUM_T$-8_\&<__P 51_PBUM_T$-8_\&<__P 50!MT5B?\(M;?]!#6/_!G/_\
M%4?\(M;?]!#6/_!G/_\ %4 ;=%8G_"+6W_00UC_P9S__ !5'_"+6W_00UC_P
M9S__ !5 &W16)_PBUM_T$-8_\&<__P 51_PBUM_T$-8_\&<__P 50!MT5B?\
M(M;?]!#6/_!G/_\ %4?\(M;?]!#6/_!G/_\ %4 ;=%8G_"+6W_00UC_P9S__
M !5'_"+6W_00UC_P9S__ !5 &W16)_PBUM_T$-8_\&<__P 51_PBUM_T$-8_
M\&<__P 50!MT5B?\(M;?]!#6/_!G/_\ %4?\(M;?]!#6/_!G/_\ %4 ;=%8G
M_"+6W_00UC_P9S__ !5'_"+6W_00UC_P9S__ !5 &W16)_PBUM_T$-8_\&<_
M_P 51_PBUM_T$-8_\&<__P 50!MT5B?\(M;?]!#6/_!G/_\ %4?\(M;?]!#6
M/_!G/_\ %4 ;=%8G_"+6W_00UC_P9S__ !5'_"+6W_00UC_P9S__ !5 &W16
M)_PBUM_T$-8_\&<__P 51_PBUM_T$-8_\&<__P 50!MT5B?\(M;?]!#6/_!G
M/_\ %4?\(M;?]!#6/_!G/_\ %4 ;=%8G_"+6W_00UC_P9S__ !5'_"+6W_00
MUC_P9S__ !5 &W16)_PBUM_T$-8_\&<__P 51_PBUM_T$-8_\&<__P 50!MT
M5B?\(M;?]!#6/_!G/_\ %4?\(M;?]!#6/_!G/_\ %4 ;=%8G_"+6W_00UC_P
M9S__ !5'_"+6W_00UC_P9S__ !5 &W16)_PBUM_T$-8_\&<__P 51_PBUM_T
M$-8_\&<__P 50!MT5B?\(M;?]!#6/_!G/_\ %4?\(M;?]!#6/_!G/_\ %4 ;
M=%8G_"+6W_00UC_P9S__ !5'_"+6W_00UC_P9S__ !5 &W16)_PBUM_T$-8_
M\&<__P 51_PBUM_T$-8_\&<__P 50!MT5B?\(M;?]!#6/_!G/_\ %4?\(M;?
M]!#6/_!G/_\ %4 ;=%8G_"+6W_00UC_P9S__ !5'_"+6W_00UC_P9S__ !5
M&W16)_PBUM_T$-8_\&<__P 51_PBUM_T$-8_\&<__P 50!MT5B?\(M;?]!#6
M/_!G/_\ %4?\(M;?]!#6/_!G/_\ %4 ;=%8G_"+6W_00UC_P9S__ !5'_"+6
GW_00UC_P9S__ !5 &W156*P2*%(UFN6"*%!>=F8X]23DGWHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>mgnx-20241231_g2.jpg
<TEXT>
begin 644 mgnx-20241231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0*B17AI9@  34T *@    @ ! $[  (
M   0   !2H=I  0    !   !6IR=  $    @   ">NH<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M5&AO;6%S+"!+:7EO=6YG   !ZAP !P   0P   %L     !SJ     0
M
M
M
M
M
M                                             %0 : !O &T 80!S
M "P ( !+ &D >0!O '4 ;@!G    _^$#:&AT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2?ON[\G(&ED/2=7-4TP37!#96AI
M2'IR95-Z3E1C>FMC.60G/SX-"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z
M;G,Z;65T82\B/CQR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO
M<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D,S$M9#,S
M9#<U,3@R9C%B(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE
M;G1S+S$N,2\B+SX\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB=75I9#IF
M868U8F1D-2UB83-D+3$Q9&$M860S,2UD,S-D-S4Q.#)F,6(B('AM;&YS.F1C
M/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^/&1C.F-R96%T
M;W(^/')D9CI397$@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY
M+S R+S(R+7)D9BUS>6YT87@M;G,C(CX\<F1F.FQI/E1H;VUA<RP@2VEY;W5N
M9SPO<F1F.FQI/CPO<F1F.E-E<3X-"@D)"3PO9&,Z8W)E871O<CX\+W)D9CI$
M97-C<FEP=&EO;CX\+W)D9CI21$8^/"]X.GAM<&UE=&$^#0H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/#]X<&%C:V5T(&5N9#TG=R<_/O_; $,
M!P4%!@4$!P8%!@@'!P@*$0L*"0D*%0\0#!$8%1H9&!48%QL>)R$;'24=%Q@B
M+B(E*"DK+"L:("\S+RHR)RHK*O_; $,!!P@("@D*% L+%"H<&!PJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*O_
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MH?\ 01O/_ E_\:].^(WPY33X_!FG>%]!F36-2L&>[MX]S222JJ%B0QXQEL]
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M_@2_^-5J* +/]IZA_P!!&\_\"7_QH_M/4/\ H(WG_@2_^-5J* /:O -Y=/\
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MH_M/4/\ H(WG_@2_^-5J*T L_P!IZA_T$;S_ ,"7_P :/[3U#_H(WG_@2_\
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M'A#27SIOABV%HN.CSD RM]<X'U!KD_$?C#5_%6O'6=8OBUWM"1M"?+6%1T5
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MK%/+M897++ O'"CL.!^54ZVBN56$>R?#_P#Y-M\?_P#70_\ HM*\;KV3X?\
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MLZZ<\=Q.]J'(C:3R\;BO<XKS35O^0[J/_7Y-_P"C&HTS5=0T6_6]T>]GL;M
M56>!RK@'@C(]:K.[2R/)(Q9W8LS$\L2<DFK4;2;$-HHHJP/9?A=_R0?XC?\
M7$_^BC7C5>R_"[_D@_Q&_P"N)_\ 11KQJLH?%( KN?@O_P ED\._]=I/_1+U
MPU6;#4+S2K^*]TRZEM+N$DQSPMM="1@X/T)%7)730'KOC+QUX9\+6GC?0O"E
MIJ<^J:Y=S1ZC/?%1%$=S!O+ ZCYFQGUY/%>CW=UINH_%O1?"VI^'M+OK>_T$
M2375S#OF&T-M52?NCKTYR>O%?*US<37MU-<WDKSSSN7EDD.6=B<DD]R:U/\
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MQQN( QSWYKQ'4=:U36$MDU74+F]6UC\JW$\A81)Q\J^@X'Y4W^U]1_L4Z/\
M;KC^S#+YQL]Y\HO_ 'MOK[U@J6B'<^AM3\%62_%B[U+2-*TJ"TCT".]N(9K
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M9=TC_H9=0_[\1T?\,NZ1_P!#+J'_ 'XCKW6BG[:?<+(\*_X9=TC_ *&74/\
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MD?\ 0RZA_P!^(Z]UHH]M/N%D>%?\,NZ1_P!#+J'_ 'XCH_X9=TC_ *&74/\
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M 7;@?450_P"$)M&T6SL);RZ:2P8M:7:N%FA'8 @<CMS1[>#LNW^5K_(/9O\
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M?\)=XB_Z#=]_W^-'_"7>(O\ H-WW_?XUCT4>SAV0<TNYL?\ "7>(O^@W??\
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M-'_"7>(O^@W??]_C6/11[.'9!S2[FQ_PEWB+_H-WW_?XT?\ "7>(O^@W??\
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MBG5=0_L2^N)IKNS"0AG$LA=HUESE$.[!X)QN((SBO2+3BUC'D?9PJ[1$2#M
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MM'_"G+/_ *#%S_WZ6CZ[0[_@'L*G8\IHKU;_ (4Y9_\ 08N?^_2T?\*<L_\
MH,7/_?I:/KM#O^ >PJ=CRFBO5O\ A3EG_P!!BY_[]+1_PIRS_P"@Q<_]^EH^
MNT._X!["IV/*:*]6_P"%.6?_ $&+G_OTM'_"G+/_ *#%S_WZ6CZ[0[_@'L*G
M8\IHKU;_ (4Y9_\ 08N?^_2T?\*<L_\ H,7/_?I:/KM#O^ >PJ=CRFBO5O\
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M_P# =/\ "@!W]L:9_P!!&T_[_K_C1_;&F?\ 01M/^_Z_XTW^P])_Z!=G_P"
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M_P# =/\ "@!W]L:9_P!!&T_[_K_C1_;&F?\ 01M/^_Z_XTW^P])_Z!=G_P"
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M_P# =/\ "@!W]L:9_P!!&T_[_K_C1_;&F?\ 01M/^_Z_XTW^P])_Z!=G_P"
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M_P# =/\ "@!W]L:9_P!!&T_[_K_C1_;&F?\ 01M/^_Z_XTW^P])_Z!=G_P"
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M_P# =/\ "@!W]L:9_P!!&T_[_K_C1_;&F?\ 01M/^_Z_XTW^P])_Z!=G_P"
MZ?X4?V'I/_0+L_\ P'3_  H =_;&F?\ 01M/^_Z_XT?VQIG_ $$;3_O^O^--
M_L/2?^@79_\ @.G^%']AZ3_T"[/_ ,!T_P * '?VQIG_ $$;3_O^O^-']L:9
M_P!!&T_[_K_C3?[#TG_H%V?_ (#I_A1_8>D_] NS_P# =/\ "@!W]L:9_P!!
M&T_[_K_C1_;&F?\ 01M/^_Z_XTW^P])_Z!=G_P" Z?X4?V'I/_0+L_\ P'3_
M  H =_;&F?\ 01M/^_Z_XT?VQIG_ $$;3_O^O^--_L/2?^@79_\ @.G^%']A
MZ3_T"[/_ ,!T_P * '?VQIG_ $$;3_O^O^-']L:9_P!!&T_[_K_C3?[#TG_H
M%V?_ (#I_A1_8>D_] NS_P# =/\ "@!W]L:9_P!!&T_[_K_C1_;&F?\ 01M/
M^_Z_XTW^P])_Z!=G_P" Z?X4?V'I/_0+L_\ P'3_  H =_;&F?\ 01M/^_Z_
MXT?VQIG_ $$;3_O^O^--_L/2?^@79_\ @.G^%']AZ3_T"[/_ ,!T_P * '?V
MQIG_ $$;3_O^O^-']L:9_P!!&T_[_K_C3?[#TG_H%V?_ (#I_A1_8>D_] NS
M_P# =/\ "@!W]L:9_P!!&T_[_K_C1_;&F?\ 01M/^_Z_XTW^P])_Z!=G_P"
MZ?X4?V'I/_0+L_\ P'3_  H =_;&F?\ 01M/^_Z_XT?VQIG_ $$;3_O^O^--
M_L/2?^@79_\ @.G^%']AZ3_T"[/_ ,!T_P * '?VQIG_ $$;3_O^O^-']L:9
M_P!!&T_[_K_C3?[#TG_H%V?_ (#I_A1_8>D_] NS_P# =/\ "@!W]L:9_P!!
M&T_[_K_C1_;&F?\ 01M/^_Z_XTW^P])_Z!=G_P" Z?X4?V'I/_0+L_\ P'3_
M  H =_;&F?\ 01M/^_Z_XT?VQIG_ $$;3_O^O^--_L/2?^@79_\ @.G^%']A
MZ3_T"[/_ ,!T_P * '?VQIG_ $$;3_O^O^-']L:9_P!!&T_[_K_C3?[#TG_H
M%V?_ (#I_A1_8>D_] NS_P# =/\ "@!W]L:9_P!!&T_[_K_C1_;&F?\ 01M/
M^_Z_XTW^P])_Z!=G_P" Z?X4?V'I/_0+L_\ P'3_  H =_;&F?\ 01M/^_Z_
MXT?VQIG_ $$;3_O^O^--_L/2?^@79_\ @.G^%']AZ3_T"[/_ ,!T_P * '?V
MQIG_ $$;3_O^O^-']L:9_P!!&T_[_K_C3?[#TG_H%V?_ (#I_A1_8>D_] NS
M_P# =/\ "@!W]L:9_P!!&T_[_K_C1_;&F?\ 01M/^_Z_XTW^P])_Z!=G_P"
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M_P# =/\ "@!W]L:9_P!!&T_[_K_C1_;&F?\ 01M/^_Z_XTW^P])_Z!=G_P"
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MC^XUCQE-X=U"71;J7[&;R*XT>[,R* X5HWR.&^8$$<$9Z5WE !1110 4444
M%%%% !1110 4444 %%>>ZOXY\1V]SXJ?2](L)K+PS(K3//<,CW$?D),RH "
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MUC_H+7W_ ($O_C6?11R1[!S,T/[>UC_H+7W_ ($O_C1_;VL?]!:^_P# E_\
M&L^BCDCV#F9H?V]K'_06OO\ P)?_ !H_M[6/^@M??^!+_P"-9]%')'L',S0_
MM[6/^@M??^!+_P"-']O:Q_T%K[_P)?\ QK/HHY(]@YF:']O:Q_T%K[_P)?\
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M'_06OO\ P)?_ !K/HHY(]@YF:']O:Q_T%K[_ ,"7_P :/[>UC_H+7W_@2_\
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MW=MT@CD)^568DX*MC)QBM>Q\.BQUK7M0%R7.L/&QCV8\K9$(^N><XSVK:HH
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M_P#^^D_^)H_X5#HO_/\ 7_\ WTG_ ,31]>H]P^KS/'Z*]@_X5#HO_/\ 7_\
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M]?\ _?2?_$T?7J/</J\SQ^BO8/\ A4.B_P#/]?\ _?2?_$T?\*AT7_G^O_\
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M9S17NJ01QP0W \NVM5;=D=AP!G]:IWOB?^T+76'GU%52XU6".U0. 88D?)E
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M  '054I-1:D]7^0DDVK;(=1117.:A1110 4444 %%%% !1110 4444 %%%%
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M>Q@NA<10E902=WF,>3UXSBO)_P#A;7B#_GA8?]^F_P#BJ/\ A;7B#_GA8?\
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M #PL/^_3?_%4?4*WD'UB!ZPFCV,=W]I2$B7<6W>8W4^V<476D65[-YMS$7?
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M9,155$"HH55&  , "EHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110
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ML20PSU((-4-=\)^(/&'AE[7Q')HJ7D%W#=V<,4+S6^Z/JLP?!=6R0< 8![T
M87C3QC_;GP\\5:3?Z>VF:G:V*7!@^T).LD328#JZ'!Y4@@X(./6NFT'_ )*U
MXO\ ^O33OY35DR_#V^O/!^N::NE>%]%N]0@6&(Z5;%%X;),C[02#@8 7CU-=
M3INA7%EXVUW6I)8V@U*"UCB1<[E,0DW9[<[QC'H: ,_[==_\+J^P?:9?L?\
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M)'8$2,Y4%^G<9'3GK0!LZ7\17OKO0_MOAZ]T_3]>118WDLJ,&D,9D".@.5R
MV#WQVJWIOC*[US4O^)+X?N+K1EN6MVU5KB.-258J[(A.YT# C/&<'&:BN/!]
M[-I/@NU6X@#^'[F":X)W8D$<#QD)QURP/..*9X<\/>)?"[)H]E-I=UX?2XDD
MBDF\Q;J*)W+F/ &UB"Q ;(XQD4 5HOBG:2W%O<KIDW]@W-TMI%JGVB+EV?RU
M;R<[Q&7X#>X.,<UJZ#XOG\0:[?V5IHLZ6FG7LUE<WLDRA0\>,;5ZMG(^GO7,
M>'OAA-H%W;V@TCPI>6%M<&2/4KBQS?&/?N"GY<%QT\S=V!VYKL/"N@W&@KK
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#_X[0!MT5B?V]>_]"UJG_?4'_P =H_MZ]_Z%K5/^^H/_ ([0!MT5B?V]>_\
M0M:I_P!]0?\ QVC^WKW_ *%K5/\ OJ#_ ..T ;=%8G]O7O\ T+6J?]]0?_':
M/[>O?^A:U3_OJ#_X[0!MT5B?V]>_]"UJG_?4'_QVC^WKW_H6M4_[Z@_^.T ;
M=%8G]O7O_0M:I_WU!_\ ':/[>O?^A:U3_OJ#_P".T ;=%8G]O7O_ $+6J?\
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MV]>_]"UJG_?4'_QV@ \8:1<Z[X7NM/L3&)Y2FTR-A>&!/.#V%>9?\*H\1?\
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M\31_PL?PK_T$_P#R!)_\37A-%=7]GTN[_KY&/UF9[M_PL?PK_P!!/_R!)_\
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M $$__($G_P 37A-%']GTN[_KY!]9F>[?\+'\*_\ 03_\@2?_ !-'_"Q_"O\
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M@2?_ !->$T4?V?2[O^OD'UF9[M_PL?PK_P!!/_R!)_\ $T?\+'\*_P#03_\
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M_$UX311_9]+N_P"OD'UF9[M_PL?PK_T$_P#R!)_\31_PL?PK_P!!/_R!)_\
M$UX311_9]+N_Z^0?69GNW_"Q_"O_ $$__($G_P 31_PL?PK_ -!/_P @2?\
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MT+3;J]4@BYFM$>3CI\Q&>*MW6CZ;?7MK>7NGVMQ=6;;K>:6%6>$^JL1E?PH
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M/W4#S$&*)&Y7Y  #N7)(//:NG^'VM>-]3U_5(?%VG&VLXA^Y8P^7AMWW5/\
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M[ W<BN+RZ@P,;89-H/OTIT]F9[9(?M-Q%LQ^\C?#-@=SB@"S15:*S,=FUO\
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M%<V\D%Q&LD4JE'1AD,I&""/3%4=)T.ST?0+?1H?,GL[>/RHUN6\PA!]U23U
M& ,]@* /.?'/BSP[?W?@K6;'5[*338/$>V>]60")6%O)G+].XYI;;6='UCXP
M3^*=#GB;1--T26'5=50?Z/*Y<,B;NCE5#$D9P#C->G/I]E);K!)9P-"ARL;1
M*57Z#&*E2&*.$0QQHD0& BJ H'IB@#RGP)J/]J?%[5I+G4[#Q+*^D1H-4TQ-
MEO;QB4_Z.R@L"[%BV=Q.!C KI/A&3_PK6R123;Q7%U%;'U@6XD6/'MM Q[5T
M]SI-M-I-SI\ -E%<1LC-:8B9=PP2I X/O4NFZ=::1I=MIVG0K!:6L2PPQ+T5
M5& * +-%%% !1110 4444 %%%% !1110 444URRQL47<P!(7.,GTH =17F?@
MK6M<\2HNJW7BKR[ZV=CJ/AJ.QB!M@"?W6#^]#=,.3@^F#6KX6^(C:YINK7FH
MZ)J=DFGW,\8/V1FWJDI15 !),G'*@<'- ';T5S>F>.M(OTU+[4MWI,NEPBXN
MX=2@,#QPD$B3G@K\K<@]B*J67Q*TB\U/3;%['5K23593'8O=V+Q)< (7W GH
M,#O@\CB@#KZ*Y6;XBZ)#J36[)?-:QW(M)-32U8VD<Q8+L,O3.XA2>@/!(-;N
ML^=_8UT;;4(],=8RWVR1 ZP*.68AB!P >O H NT5PW@76[_4M>U>TCUQ/$FB
MVT<1M]5$<:GSB6\R'=& C[0$.0.-V#FM'Q4_BMKM(_#$:K%]E<-*QC_US21J
MIPW/R(9']#@#GI0!U%%>6ZOXBN'^(VN:5?\ Q!C\,6ME':FT@9;4&8NA+G,J
MDGD#IZUU^N>,+7PRJQWEGJM^(H!-<7%G9-*D2<Y=R.!T)P,G':@#HZ*YF^\>
MZ1::A964$=YJ%Q?V8O;5+*W,GG0E@-P/_ @><<?E6/X1\41VU]=Z?JUQ<R3:
MAXBU&VLY'RZ)Y;%A'N)^7Y0=H]C0!WU%9VGZ[9ZGJVIZ?:>8TNER)%<.4PF]
MD#[0>Y (SZ9%<JE[XB\9>(=8AT;6/["TC2+DV/FPVT<L]U.JAG/[P%51=P4<
M$DYY% '=T5P%IXVNO#$VOZ=XXN%NFT6WBO4U"W@V&YMI&*@M&#@.K*0<<$8/
M%;-AX^T>]U66PE2]L)%MFNXGOK5H4N(%QND0GJ!D9S@X(.* .FHKG-(\;Z=J
M]I<7HM=0LM/AM_M(OKZV,,,L6,[U8]L<\X..:K6GQ#TR]E,4>GZO'+) ]Q9Q
MS6+1M?(H!/D[L;C@@[3@X.<8H ZRBN \/^,->\:>$M/O],TJYTZX:[C-TTL:
MJC0!F+^66)W9"!,]07SVKJ=#AU<^%+6+6[G&K/;_ .D2QJO[N1ADX &T[2<#
MUQ0!K45YK9V'BN3Q_>Z))X[U%K>TL;>[#?8;0,Y=Y%*G]WTP@Z<\FM+4];\3
MVGQ0T#3IC8V^B:A-<QK''EYIPENSAG8@!!N'1<GCD]J .XHKS^4^(M?^(_B#
M3+#Q1<Z1::9!:-#%!:02!FE5RQ8NA/\ ".,UI^#M=U6XU;6O#OB1X+C4M'>(
M_:[>/RUNH95+(Y3)VM\K @'&1QUH ZVBBB@ HHHH **** "BBD=@D;.W11DX
MH 6BN&@^+GAN:WL;DQZE%9Z@N+2[>Q?RIY.?W*D9S)P0!CD@@$UNZ!XMT_Q
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M/^Y8_P#?EO\ XJC_ (6OXC_N6/\ WY;_ .*KB:*/JU'^5![6?<[;_A:_B/\
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M_P"1^L_^N<O_ * :]SKQ\;",*B45;0[:$G*-V%%%%<1N%%%% !1110 4444
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M /S\V'_?Q_\ XFC_ (5)K_\ S\V'_?Q__B:/K-'^8/93['"T5W7_  J37_\
MGYL/^_C_ /Q-'_"I-?\ ^?FP_P"_C_\ Q-'UFC_,'LI]CA:*[K_A4FO_ //S
M8?\ ?Q__ (FC_A4FO_\ /S8?]_'_ /B:/K-'^8/93['"T5W7_"I-?_Y^;#_O
MX_\ \31_PJ37_P#GYL/^_C__ !-'UFC_ #![*?8X6BNZ_P"%2:__ ,_-A_W\
M?_XFC_A4FO\ _/S8?]_'_P#B:/K-'^8/93['"T5W7_"I-?\ ^?FP_P"_C_\
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M .)H^LT?Y@]E/L<+17=?\*DU_P#Y^;#_ +^/_P#$T?\ "I-?_P"?FP_[^/\
M_$T?6:/\P>RGV.%HKNO^%2:__P _-A_W\?\ ^)H_X5)K_P#S\V'_ '\?_P")
MH^LT?Y@]E/L4/AI_R/UG_P!<Y?\ T U[G7FW@_X>ZMH'BBWU&]FM'AC1U(B=
MBW*X'517I->/C9QG43B[Z';0BXQLPHHHKB-PHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,3_A+--_YY
MZC_X+;C_ .(H_P"$LTW_ )YZC_X+;C_XBMNB@#$_X2S3?^>>H_\ @MN/_B*/
M^$LTW_GGJ/\ X+;C_P"(K;HH Q/^$LTW_GGJ/_@MN/\ XBC_ (2S3?\ GGJ/
M_@MN/_B*VZ* ,3_A+--_YYZC_P""VX_^(H_X2S3?^>>H_P#@MN/_ (BMNB@#
M$_X2S3?^>>H_^"VX_P#B*/\ A+--_P">>H_^"VX_^(K;HH Q/^$LTW_GGJ/_
M (+;C_XBC_A+--_YYZC_ ."VX_\ B*VZ* ,3_A+--_YYZC_X+;C_ .(H_P"$
MLTW_ )YZC_X+;C_XBMNB@#$_X2S3?^>>H_\ @MN/_B*/^$LTW_GGJ/\ X+;C
M_P"(K;HH Q/^$LTW_GGJ/_@MN/\ XBC_ (2S3?\ GGJ/_@MN/_B*VZ* ,3_A
M+--_YYZC_P""VX_^(H_X2S3?^>>H_P#@MN/_ (BMNB@#$_X2S3?^>>H_^"VX
M_P#B*/\ A+--_P">>H_^"VX_^(K;HH Q/^$LTW_GGJ/_ (+;C_XBC_A+--_Y
MYZC_ ."VX_\ B*VZ* ,3_A+--_YYZC_X+;C_ .(H_P"$LTW_ )YZC_X+;C_X
MBMNB@#$_X2S3?^>>H_\ @MN/_B*/^$LTW_GGJ/\ X+;C_P"(K;HH Q/^$LTW
M_GGJ/_@MN/\ XBC_ (2S3?\ GGJ/_@MN/_B*VZ* ,3_A+--_YYZC_P""VX_^
M(H_X2S3?^>>H_P#@MN/_ (BMNB@#$_X2S3?^>>H_^"VX_P#B*/\ A+--_P">
M>H_^"VX_^(K;HH Q/^$LTW_GGJ/_ (+;C_XBC_A+--_YYZC_ ."VX_\ B*VZ
M* ,3_A+--_YYZC_X+;C_ .(H_P"$LTW_ )YZC_X+;C_XBMNB@#$_X2S3?^>>
MH_\ @MN/_B*/^$LTW_GGJ/\ X+;C_P"(K;HH Q/^$LTW_GGJ/_@MN/\ XBC_
M (2S3?\ GGJ/_@MN/_B*VZ* ,3_A+--_YYZC_P""VX_^(H_X2S3?^>>H_P#@
MMN/_ (BMNB@#$_X2S3?^>>H_^"VX_P#B*/\ A+--_P">>H_^"VX_^(K;HH Q
M/^$LTW_GGJ/_ (+;C_XBC_A+--_YYZC_ ."VX_\ B*VZ* ,3_A+--_YYZC_X
M+;C_ .(H_P"$LTW_ )YZC_X+;C_XBMNB@#$_X2S3?^>>H_\ @MN/_B*/^$LT
MW_GGJ/\ X+;C_P"(K;HH Q/^$LTW_GGJ/_@MN/\ XBC_ (2S3?\ GGJ/_@MN
M/_B*VZ* ,3_A+--_YYZC_P""VX_^(H_X2S3?^>>H_P#@MN/_ (BMNB@#$_X2
MS3?^>>H_^"VX_P#B*/\ A+--_P">>H_^"VX_^(K;HH Q/^$LTW_GGJ/_ (+;
MC_XBC_A+--_YYZC_ ."VX_\ B*VZ* ,3_A+--_YYZC_X+;C_ .(H_P"$LTW_
M )YZC_X+;C_XBMNB@#$_X2S3?^>>H_\ @MN/_B*/^$LTW_GGJ/\ X+;C_P"(
MK;HH Q/^$LTW_GGJ/_@MN/\ XBC_ (2S3?\ GGJ/_@MN/_B*VZ* ,3_A+--_
MYYZC_P""VX_^(H_X2S3?^>>H_P#@MN/_ (BMNB@#$_X2S3?^>>H_^"VX_P#B
M*/\ A+--_P">>H_^"VX_^(K;HH Q/^$LTW_GGJ/_ (+;C_XBC_A+--_YYZC_
M ."VX_\ B*VZ* ,3_A+--_YYZC_X+;C_ .(H_P"$LTW_ )YZC_X+;C_XBMNB
M@#$_X2S3?^>>H_\ @MN/_B*/^$LTW_GGJ/\ X+;C_P"(K;HH Q/^$LTW_GGJ
M/_@MN/\ XBC_ (2S3?\ GGJ/_@MN/_B*VZ* ,3_A+--_YYZC_P""VX_^(H_X
M2S3?^>>H_P#@MN/_ (BMNB@#$_X2S3?^>>H_^"VX_P#B*/\ A+--_P">>H_^
M"VX_^(K;HH Q/^$LTW_GGJ/_ (+;C_XBC_A+--_YYZC_ ."VX_\ B*VZ* ,3
M_A+--_YYZC_X+;C_ .(H_P"$LTW_ )YZC_X+;C_XBMNB@#$_X2S3?^>>H_\
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M_P""VX_^(H_X2S3?^>>H_P#@MN/_ (BMNB@#$_X2S3?^>>H_^"VX_P#B*/\
MA+--_P">>H_^"VX_^(K;HH Q/^$LTW_GGJ/_ (+;C_XBC_A+--_YYZC_ ."V
MX_\ B*VZ* ,3_A+--_YYZC_X+;C_ .(H_P"$LTW_ )YZC_X+;C_XBMNB@#$_
MX2S3?^>>H_\ @MN/_B*/^$LTW_GGJ/\ X+;C_P"(K;HH Q/^$LTW_GGJ/_@M
MN/\ XBC_ (2S3?\ GGJ/_@MN/_B*VZ* ,3_A+--_YYZC_P""VX_^(H_X2S3?
M^>>H_P#@MN/_ (BMNB@#$_X2S3?^>>H_^"VX_P#B*/\ A+--_P">>H_^"VX_
M^(K;HH Q/^$LTW_GGJ/_ (+;C_XBC_A+--_YYZC_ ."VX_\ B*VZ* ,3_A+-
M-_YYZC_X+;C_ .(H_P"$LTW_ )YZC_X+;C_XBMNB@#$_X2S3?^>>H_\ @MN/
M_B*/^$LTW_GGJ/\ X+;C_P"(K;HH Q/^$LTW_GGJ/_@MN/\ XBC_ (2S3?\
MGGJ/_@MN/_B*VZ* ,3_A+--_YYZC_P""VX_^(H_X2S3?^>>H_P#@MN/_ (BM
MNB@#$_X2S3?^>>H_^"VX_P#B*/\ A+--_P">>H_^"VX_^(K;HH Q/^$LTW_G
MGJ/_ (+;C_XBC_A+--_YYZC_ ."VX_\ B*VZ* ,3_A+--_YYZC_X+;C_ .(H
M_P"$LTW_ )YZC_X+;C_XBMNB@#$_X2S3?^>>H_\ @MN/_B*/^$LTW_GGJ/\
MX+;C_P"(K;HH Q/^$LTW_GGJ/_@MN/\ XBC_ (2S3?\ GGJ/_@MN/_B*VZ*
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M&!ZUXE7>?"+_ )&J[_Z\S_Z&M85\+1A2E**U^9=.M-S2;/8J***\0[PHHHH
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M^*H_X0/Q/_T!YO\ OM/_ (JCVU/^9?>')+L<]170_P#"!^)_^@/-_P!]I_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "JNJ2/#H]Y)$Q1T@=E8=00IP:M53U<%M$O@HR3;
MR  ?[IH*C\2.%\=^,'\'Z?;6VG3S3:E=1;P\\A<0I_>QT)ST%4=!T6;2_"UW
MXU\5R27VIBW:>V2Z.X0#'RG!XW$X^@JUXJ\''7O&7A[4BZ2:?)&J7 +=%0%P
M?H1Q6=\4O'&GWVC+H.A7*733NOGR0G*JH.0H/<DXZ>E8/1MOY'NT8J<:=*BM
M9:R?E?;R/5;-VDL8'D.7:-2Q]3BN=G\=VAO)[?2=-U+6/L[E)I;&#=&C#JNX
MD D>U;@AE?1/(0^7*UOL!_NMMQ_.N*\#^)='T/PI#HNKW4.EZEIX:.X@NCY9
M9LD[QG[P/7(K<\%[G3WOB>UL-%LM2NK:ZCCO)HX4B>/;(C.<#<I/'O5@ZY;#
MQ,-#V2?:3:_:MV!LV;MN,^N:X'4M8NM=^&6@:CJ+(T\VKV^XHNT'$Q X^@%:
MNJ:MI^C_ !>CGU2\AM(FT8J'F<*"?-Z?I0(Z+Q%XEM_#D=H9[6ZNI+R;R(8K
M5 S,V"<8)'I4VBZR^L1S,^EW^G^6P 6]B"%\]Q@G-<;X_P!4L-1M_#5Y9:O'
M!:MJ>!?PNI$6$8%@3QQ[UKZ3K>GZ9X>U2^/B?^WDLT,TDCLA,8V\+\H'4B@#
M3L_%FFWWBN\\/P&3[9:('=BOR-TR >Y&1FEUCQ!/I5XL,6A:GJ"LFXRVD:LH
MYZ<L.:\XBL_$'A_3=)\4:C;V:PV]TUY=21NQG9+@@.'!&, %>_&VNPN_%$6G
M?$@6VH:K#;:8^E"9%E=51I#)C()[XH V-#\46&O33V\"SVUY;8\ZTNHC'*@/
M0X/4>XK9KA=-NHO$OQ.76-&S)IUA8-;2W84A)Y&;(53_ !!>N:[J@ HHHH *
MCA@AMHA';Q)%&"2%C4*,DY)P/<YK&_X1@_\ 0=UG_P "A_\ $T?\(P?^@[K/
M_@4/_B: -VBL+_A&#_T'=9_\"A_\31_PC!_Z#NL_^!0_^)H W:*PO^$8/_0=
MUG_P*'_Q-'_",'_H.ZS_ .!0_P#B: -VBL+_ (1@_P#0=UG_ ,"A_P#$T?\
M",'_ *#NL_\ @4/_ (F@#=HK"_X1@_\ 0=UG_P "A_\ $T?\(P?^@[K/_@4/
M_B: -VBL+_A&#_T'=9_\"A_\31_PC!_Z#NL_^!0_^)H V1!$+AIQ$@F90C2!
M1N*CD#/7')J2L+_A&#_T'=9_\"A_\31_PC!_Z#NL_P#@4/\ XF@#=HK"_P"$
M8/\ T'=9_P# H?\ Q-'_  C!_P"@[K/_ (%#_P")H W:*PO^$8/_ $'=9_\
M H?_ !-'_",'_H.ZS_X%#_XF@#=HK"_X1@_]!W6?_ H?_$T?\(P?^@[K/_@4
M/_B: -VBL+_A&#_T'=9_\"A_\31_PC!_Z#NL_P#@4/\ XF@#=HK"_P"$8/\
MT'=9_P# H?\ Q-'_  C!_P"@[K/_ (%#_P")H W:*PO^$8/_ $'=9_\  H?_
M !-'_",'_H.ZS_X%#_XF@#=HK"_X1@_]!W6?_ H?_$T?\(P?^@[K/_@4/_B:
M -VBL+_A&#_T'=9_\"A_\31_PC!_Z#NL_P#@4/\ XF@#=HK"_P"$8/\ T'=9
M_P# H?\ Q-'_  C!_P"@[K/_ (%#_P")H W:*PO^$8/_ $'=9_\  H?_ !-'
M_",'_H.ZS_X%#_XF@#=HK"_X1@_]!W6?_ H?_$T?\(P?^@[K/_@4/_B: -VB
ML+_A&#_T'=9_\"A_\31_PC!_Z#NL_P#@4/\ XF@#=HK"_P"$8/\ T'=9_P#
MH?\ Q-'_  C!_P"@[K/_ (%#_P")H W:*PO^$8/_ $'=9_\  H?_ !-'_",'
M_H.ZS_X%#_XF@#=HK"_X1@_]!W6?_ H?_$T?\(P?^@[K/_@4/_B: -VBL+_A
M&#_T'=9_\"A_\31_PC!_Z#NL_P#@4/\ XF@#=HK"_P"$8/\ T'=9_P# H?\
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M_$T?\(P?^@[K/_@4/_B: -VBL+_A&#_T'=9_\"A_\31_PC!_Z#NL_P#@4/\
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M8/\ T'=9_P# H?\ Q-'_  C!_P"@[K/_ (%#_P")H W:*PO^$8/_ $'=9_\
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M_ H?_$T ;4D4<L)BEC5XV&"C+D$>F*@GTRPN64W-E;S%!M4R1*VT>@R*S/\
MA&#_ -!W6?\ P*'_ ,31_P (P?\ H.ZS_P"!0_\ B: -M(TBC"1(J(O 51@"
MG5A?\(P?^@[K/_@4/_B:/^$8/_0=UG_P*'_Q- &[16%_PC!_Z#NL_P#@4/\
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M VZ*P?#/BZS\5Q-+I]EJ<$/EI*DMY920)*K<@H6&&XYX]16]0 4444 %%%%
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M^F]P]1^=&X>H_.OF3<W]YO\ OHTC,VT_,W_?1H_LW^]^'_!#ZUY'T[14=O\
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M5Y-G-YD7EP2;6S(FT'#'N1ZUFZQH!U+4='N(I4ACTZ<RM&4SO!7&!Z5Y7?\
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MQ%_WTE 'IM%>9?\ "T_$W_1+/$7_ 'TE'_"T_$W_ $2SQ%_WTE 'IM%>9?\
M"T_$W_1+/$7_ 'TE'_"T_$W_ $2SQ%_WTE 'IM%>9?\ "T_$W_1+/$7_ 'TE
M'_"T_$W_ $2SQ%_WTE 'IM%>9?\ "T_$W_1+/$7_ 'TE'_"T_$W_ $2SQ%_W
MTE 'IM%>9?\ "T_$W_1+/$7_ 'TE'_"T_$W_ $2SQ%_WTE 'IM%>9?\ "T_$
MW_1+/$7_ 'TE'_"T_$W_ $2SQ%_WTE 'IM%>9?\ "T_$W_1+/$7_ 'TE'_"T
M_$W_ $2SQ%_WTE 'IM%>9?\ "T_$W_1+/$7_ 'TE'_"T_$W_ $2SQ%_WTE '
MIM%>9?\ "T_$W_1+/$7_ 'TE'_"T_$W_ $2SQ%_WTE 'IM%>9?\ "T_$W_1+
M/$7_ 'TE'_"T_$W_ $2SQ%_WTE 'IM%>9?\ "T_$W_1+/$7_ 'TE'_"T_$W_
M $2SQ%_WTE 'IM%>9?\ "T_$W_1+/$7_ 'TE'_"T_$W_ $2SQ%_WTE 'IM%>
M9?\ "T_$W_1+/$7_ 'TE'_"T_$W_ $2SQ%_WTE 'IM%>9?\ "T_$W_1+/$7_
M 'TE'_"T_$W_ $2SQ%_WTE 'IM%>9?\ "T_$W_1+/$7_ 'TE'_"T_$W_ $2S
MQ%_WTE 'IM%>9?\ "T_$W_1+/$7_ 'TE'_"T_$W_ $2SQ%_WTE 'IM%>9?\
M"T_$W_1+/$7_ 'TE'_"T_$W_ $2SQ%_WTE 'IM%>9?\ "T_$W_1+/$7_ 'TE
M'_"T_$W_ $2SQ%_WTE 'IM%>9?\ "T_$W_1+/$7_ 'TE'_"T_$W_ $2SQ%_W
MTE 'IM%>9?\ "T_$W_1+/$7_ 'TE'_"T_$W_ $2SQ%_WTE 'IM%>9?\ "T_$
MW_1+/$7_ 'TE'_"T_$W_ $2SQ%_WTE 'IM%>9?\ "T_$W_1+/$7_ 'TE'_"T
M_$W_ $2SQ%_WTE 'IM%>9?\ "T_$W_1+/$7_ 'TE'_"T_$W_ $2SQ%_WTE '
MIM%>9?\ "T_$W_1+/$7_ 'TE'_"T_$W_ $2SQ%_WTE 'IM%>9?\ "T_$W_1+
M/$7_ 'TE'_"T_$W_ $2SQ%_WTE 'IM%>9?\ "T_$W_1+/$7_ 'TE'_"T_$W_
M $2SQ%_WTE 'IM%>9?\ "T_$W_1+/$7_ 'TE'_"T_$W_ $2SQ%_WTE 'IM%>
M9?\ "T_$W_1+/$7_ 'TE'_"T_$W_ $2SQ%_WTE 'IM%>9?\ "T_$W_1+/$7_
M 'TE'_"T_$W_ $2SQ%_WTE 'IM%>9?\ "T_$W_1+/$7_ 'TE'_"T_$W_ $2S
MQ%_WTE 'IM%>9?\ "T_$W_1+/$7_ 'TE'_"T_$W_ $2SQ%_WTE 'IC*KJ5=0
MRL,$$9!I0 H  P!P .U>9?\ "T_$W_1+/$7_ 'TE'_"T_$W_ $2SQ%_WTE '
MIM%>9?\ "T_$W_1+/$7_ 'TE'_"T_$W_ $2SQ%_WTE 'IM%>9?\ "T_$W_1+
M/$7_ 'TE'_"T_$W_ $2SQ%_WTE 'IM%>9?\ "T_$W_1+/$7_ 'TE'_"T_$W_
M $2SQ%_WTE 'IM%>9?\ "T_$W_1+/$7_ 'TE'_"T_$W_ $2SQ%_WTE 'IM%>
M9?\ "T_$W_1+/$7_ 'TE'_"T_$W_ $2SQ%_WTE 'IM%>9?\ "T_$W_1+/$7_
M 'TE'_"T_$W_ $2SQ%_WTE 'IM%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
24444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>mgnx-20241231_g3.jpg
<TEXT>
begin 644 mgnx-20241231_g3.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@"
M^ 44 P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BN=^*_P 7
M?A9\"? .H?%3XT_$71/"GAK28O,U+7?$.IQ6EI;+G WRRL%!)( &<DD 9) K
MY\\$_P#!:3_@FQ\0=*;Q3X;_ &@;T>&TE,<GC;4OA_KUCX=0AMI)UBYL8[ *
M#P6,^T>M 'U+17)_!OXZ_!W]H;PG-X\^!GQ(TGQ9H<.IW&GG6M"NUN+22X@;
M9*D<R924*V5+(67((SD&NLH **** "BBB@ HHHH **** "BO&_A1_P %!/V-
MOCC^TYXS_8V^%'QYTG6OB9\/H&F\7>%;:&=9;%%D2.0B1XQ%,8Y)(TD$3N8W
M<*X4G%>R4 %%%% !1110 4444 %%<!^T?^U-^SY^R+X!C^)O[1WQ2T[PMH]Q
MJ$6GV,U[ODFOKR4D1VMM!$KS7,[8)$42.Y"D@8!(P?V5_P!N_P#91_;5NO%V
ME_LV?%A->U'P#K;:/XUT6[T:]TW4-$O0\B&&YM+Z&&>([X9E!9 "T4@!)1@
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M:%Y8;9I0))(T*!W5>I53)&"1P"ZYZBIJ "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7P3KG_!&WX$Q^#O$&FWD>F>#$M=4%A=I(+2\661YHI=I/ER!GW,K8(W D<T
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M(TXLY=*T^)9FB)W>4SQR(&(VDHP[4 ?4/[!O_!;;7_VX_P#@E]\3O^"B&D?
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M.GX3IX@\0#PT\7B?XIII^IH=-CD$(CTN>XO\-+<NHSY";S$EN2YC#0B3[LH
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M9E\9Z9\4_#]UI'@VT\#P^*]3MM7ADM](D@\5W]S,EQ(K%86CAD21@Q!56!.
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4=4'A;5H[U+.WNI+B.#S7B)6-V>UG'E,1(OEG<JY&0#TZBBB@ HHKQOXM_\
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M%&OV,OVX+B]A_9.^,R>.8M-D$>I:AHN@Z@;.TD*EQ'+<O;K#&Y49",X9NP-
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M+";-XD%UIU\+:-]FR::2*TF*1(S.7$8*C>N?JW_@WR_X+:_LL:I^P?\ #O\
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M>7[7W[+GAW0O@K\<]82RLY_"WBNXOM:\)QSI+-:7%W'):QQ7B26\,DKK"49
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MW#I=K8>./ 6GZII4FIPV8\W5-+O;9XS:RN""1'-LEC+;MF95 'FDCY.\/_\
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M:?\  ?3[O7=4^$7C:37_ !CH.G0.]W#:1W6LQ2$P@;VV1ZC!<D@$>4&?H,@
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M0-&-E)I@T=+P:G%Y+:@/!\<!M ^[:9O.!A\O.[S 4QNXJ#]A?Q[X/_X)+_\
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M#+DCV3_@R._Y,S^,O_93K?\ ]-T5 'ZC?\%)U5O^"=7Q]5E!!^"OBH$$=?\
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M_P"";7_!670OVV_C;\6OV//B?\.(?!/QB^"FOW&G>*]#L=6-]I^J6T5PUO\
MVC8SM'&[1%U7*2(K()HN6W''YJ_\&>_Q*\#_  7^$W[8OQ=^)6O0Z3X<\+:G
MI.K:[J4X.RTL[>'5Y9I2 "2%1&. "3CBNU_X(F?#35_''_!<3]L?_@J;%J]M
M9?!."\\1:#I7CNZNEATO6))-6MI6F@N7(CEMXHK!G>524'FQ'/-?+G_!O'\+
MI_VMOV OV_OV2OACXLTY?&WCSP[9'PII4M^D4M^RQ:H4VAB#Y32&*)WQM3SE
MW8R,@'Z(67_!P9\<?$'["OB/_@K-X8_8[T63X >&_'B:%+I-WXPEC\576GM=
MP67]J(@MS:H1<7$:_92Y)PW[X !CZC_P4)_X+[_ +]D+]EGX/_'CX*^";CXE
M:W^T"L3?"CPZ+X:?'<1LL'F3W<Q20P")KF"-HPK.9'V?*%=U_+3P9\6O!OA7
M_@TO\??L-:YJ"67QE3XIQ^%S\+KD%-??4W\365\(!8'_ $@M]G60C"<F-AU!
M%>F?MW_L8_ +]EK_ ((S?L2_ _\ ;?\ B%?_  ]^-GAWQ.(_ OB9XUELO#-S
M?WHU"_&K#!W6=JK6PD$>9/-@C"'89#0!]K_&3_@L]^V)^S3_ ,%&_ ?_  3!
M^(_[&'P]\3^-OB)H-KK/A[Q+HOQ:N=)TV6"0W*/#Y=SI<S><CV5TJAI%$NV/
M&QG"T]?^"Y'QL\'_ /!9;2?^"1OQT_9#\-^$Y-=O2VB?$!OB+//;:E8O:RW-
MO+! =.3=++Y30"-G $X:/>V 6\\^ 6G?\$]_VY_^"M7@G]OSXX_\%/O@OX]^
M)WA'PS;^'OA?\,?A[?K86BSH;E_M)^UW,D]].9+VY=(45=GR9,FS-<S_ ,';
MO[(OC4?"/X:?\%3_ -G])K+QY\"?%%FE_J=C'F9-.ENTDM+@XR3]FOQ%M7IB
M\E)X% 'Z/_!_]H3XW_$C]K?XH?!#5OA'X=L_!/P[&G00^-++Q3-/=7]_=VRW
M8LVLVM$2%XK:2"60^<W%U!MW;FV2_P#!1H!O^">WQW5@"#\&?%&0?^P3<T_]
MA'X??$#P3^SAI/B'XT:;#:?$#QO/-XL^(-O"&VVVK:@WGR6:EOF:.TC:*RC)
MY\JSCSR*PO\ @J?\1_A_\-?^"=/QNU+XA>-])T."\^$WB2SLI-6U".W%S<R:
M7<K'!'O(\R1V("HN68D  F@#\P?^#);[6O['WQQDTZ*)[G_A8-GY"S.51G&G
MC:&(!(&>I ./0UZY\ /^#AK]KO\ :D^*/Q[_ &>_@M_P3:T>^\9_!"'46O;I
M_BL%TF46-S/;SO)+)8QR LT/[F)$8R%CN:%59QX5_P &3WQ3^&FA?L\?&CX>
MZY\0=%LM=E\:6FH0Z/=ZG%%<R6BV#;IUC9@S1KY<FY@,+M.2*\P_X(4_&SX.
MZ%_P4%_X*(^*M:^*7A^TTS5M+\3:EI6H7.KPI#>6:ZK?NT\3LP$D826-MRDC
M#J>XH _3S_@E5_P6[^&7_!0#_@GCXS_;I^+/@R/X>Q_#"ZU&'X@V4=ZUW;P1
MVEG'>-<P.55G1X9!A"-X=60;OE9OC;]L#_@J;^UG_P %,/\ @B7^T%^TWX3_
M &-= T/X':C97F@:/=W'CIY/$RI#<0*=3DM/LHMGMQ*0CQK.)(R)"OG!!O\
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M HHHH *RG\">!Y+Z^U.3P;I37.IJBZE<-IT1DNPA!02MMS(%(&-V<8XK5HH
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M8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\
M@,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_
M (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_
M .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-
M_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -B
MBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P"
MQ_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\
M@,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\
MZ#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_
M .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**
MQ_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'
M_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P"
MQ_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H
M-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\
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M8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\
M@,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_
M (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_
M .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-
M_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -B
MBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P"
MQ_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\
M@,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\
MZ#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_
M .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**
MQ_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'
M_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P"
MQ_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H
M-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "O*/VY_P#DT?Q[_P!@%_\ T-:]7KRC]N?_ )-'\>_]@%__ $-: .Z^%W_)
M,_#O_8"M/_1*5NUA?"[_ ))GX=_[ 5I_Z)2MV@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O*/VY_^31_'O\
MV 7_ /0UKU>O*/VY_P#DT?Q[_P!@%_\ T-: .Z^%W_),_#O_ & K3_T2E;M8
M7PN_Y)GX=_[ 5I_Z)2MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEJBOAC]@/_@O[^Q%^VU]B\%^)]?'PS\=7.V/_A&O%EXBVUW*?X;2]PL4V20
MCB*5B<",]:^YZ_E+.\@SKAS&O"9G0E2J+I);^<7M)><6UYGL4ZE.K'F@[H**
M**\<L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCX8_Z#4'_?5?CF-S+,,QJ<^*JRJ.[?O2;UD[R>KW;U?=G;&,8[*Q\-_M^_\
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M$#6S:M'LN-F^.W\T%H(G9@L<LCX_8RB@#\^/V&/@!_P4_P#VS?V4?CQ\.?\
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M_P!WF.X+R6Z!%=&9E_3RB@ HHHH I:SX<\/>(XD@\0Z#97Z1MNC2]M4E"'U
M8'!KQW]MCX?> =+_ &4O'.H:9X(T>WN(M#=HIX-,B1T.Y>0P7(->WUY1^W/_
M ,FC^/?^P"__ *&M ':?"[3=.'PR\. 6$( T*SP/*'_/%/:MW^SM/_Y\8?\
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MABS/,/VX\,>&/#G@KP[8^$/!^@V>EZ5I=I':Z;INGVRPP6L"*%2.-% 5%50
M !@ 5^NXO,<K\*,)/ 95.-;-9KEJUUK&@GO3H]Y])3Z;;Z1XE">,?-/2'1=_
M-F9\-_A-\,_@_P"!-*^&/PP\"Z9H>@:)9K:Z5I6G6BQPV\2] !W).26.2Q))
M)))K;_L[3_\ GQA_[]"IJ*_%:E2I6J.I4;<F[MO5MO=M]6SO225D0_V=I_\
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MFHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\
M^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]
M"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_
M /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FH
MH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?
M&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C
M^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\
MGQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH
MA_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'
M_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^S
MM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQ
MA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_
ML[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_O
MT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/
M_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_
M[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[
M3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*
MFHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\
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M.4GH=;_P5D_X*^?!O_@F?\.3IT?V7Q'\3M:M&;POX-6?B-3E1>7A4YBMU8'
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M%% !1110 4444 %%%% !1110 4444 %%%?EI_P %C/\ @N+JWPT\2S?L)_\
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M*]<HKJP>-QF78F.(PM25.I'52BW&2?DUJA2C&2LU='XE_&/_ ((>_P#!1?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M445V'U84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7E'[<__)H_CW_L O\ ^AK7
MJ]>4?MS_ /)H_CW_ + +_P#H:T =U\+O^29^'?\ L!6G_HE*W:POA=_R3/P[
M_P!@*T_]$I6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %!( R34=W
M=VFGVDM_?W4<$$$;2333.%2- ,EF)X  !))Z5^,/_!3G_@KM\;/^"@7Q</\
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M*<85U)KW?M15K2=FU=N^UE:VBV"BHKV]L]-M)+_4;N*""%"\TTT@1$4=22>
M!ZFI001D'(/0UV'U5U>P4444#"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** /./VM_V@O\ AEG]GOQ!\>/^$1_M
MW^POLG_$J^W_ &7S_/NX;?\ UOER;=OG;ONG.W'&<CXH_P"(@;_JTG_R_?\
M[@KZ/_X*W_\ */?X@?\ <)_].UG7XI5\QG68XS"8J,*4K+E3V3ZONC^=/%WC
MOBOA?B2EA<LQ'LZ<J,9-<E.7O.=1-WE&3VBM+VT/T_\ A5_P7D\ ^+/'=GH/
MQ/\ @<WA/0YHYVO=>C\2O?M;E(7>-1!'9JTA>14C'S #S-QX!KE/V@_^"[VJ
MW7GZ'^S-\+DM4.537_%1#R$=-R6T3;5/<%Y&]T[5\6_LK? &_P#VHOCYX?\
M@3IOB2'1Y==DN!_:4]N9E@6&VEN&.P$%B5B( R.2,D#FOU4_9\_X)"_LC_!/
MR-6\3^'9O'&L188WGB;:]LK=]EJO[O'M)YA'K6.#KYWF-)J$TE?66B?333_+
MYGF<*9UXO<=Y=..&Q,(4E-QE6<81DM(MP2A&^B:::BG>5G.VB_.>TT'_ (*
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M1110 4444 %%%% !1110 4444 %>4?MS_P#)H_CW_L O_P"AK7J]>4?MS_\
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MT''%8-[5Z+YX6_O6U@UUYE9/2[/4I8JG4?*])=F?3E%%%?GYTA1110 4444
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M]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E7)?'/XZ_";]FKX5ZO\
M&KXW^-K/P]X:T.V,VH:E>O@#LJ(HRTDC-A5C4%G8@*"3BN:_::_;,_9T_9$^
M#^I_&[XY?$.VTS1=-3"HGSW%[.02EM;Q]99GP0%'H68JJLP_%MKO]L/_ (.4
M/VHUO_$NIW/P[_9^\'ZF?+CWEH;1<?=3@+>:E(AY8C9 K]@0LOWW!O!$N((5
M,RS"K]7R^C_%JOK_ '*:^U4>R23M=73;49<U?$>S:C%7D]E_F7OBA\7OVU/^
M#E+]IP_!7X'65]X'^ ?A74$FO[J\0F&WCR0MY>[#BYO77=Y-JK;8\GD 23']
MD/V,OV+/@)^P?\$[#X&? #PJMCI]OB74M1GP]YJUT5 >ZN9 !YDC8] J@!5"
MJ HL?LT?!;]F[]D/X.Z5\"O@%HEAH?A[28\1PQ'=+<RD#?<3R$;I9G(RSMR>
M!P  .^_X3'PQ_P!!J#_OJM.,>-XYU0AE.54_J^74?@I+>3_Y^57]J;WU;MYN
M[90H>S?/-WD^OZ(TJ*S?^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJOSTZ32HK-_
MX3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^J -*BLW_A,?#'_0:@_[ZH_X3'PQ_P!!
MJ#_OJ@#2HK-_X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^J -*BLW_A,?#'_0:@_[
MZH_X3'PQ_P!!J#_OJ@#2HK-_X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^J -*BLW
M_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJ@#2HK-_X3'PQ_T&H/\ OJC_ (3'PQ_T
M&H/^^J -*BL+6OB?\//#>GOJWB+QGIUA:Q_ZRYO;I8HU^K-@"O%/B?\ \%4_
MV'?A>LD,_P 9(==NH\XL_#-I)>E_I*H$/YR"LJM>A05ZDDO5GF9CG6491#GQ
MV(A27]^2C]UWK\CZ(HK\Y_BG_P %\M.C\RT^"GP#FEZ^3J'BG4@F/3-O!NS_
M -_17SOX]_X*H?M\?&Z_.A^'O'LNCK<DB/2_!>DB&0G_ &),/<?E)7E5L^P%
M-VBW)^2_SL?G&:>-'!6!ER8>4Z\NU.+M?UERK[KG[,7VJZ7IC0IJ6I6]NUS,
M(K<3S*AED/1%R?F8]@.:L5^,/P/_ &5?V_/'_P 7?#WQHU/PUK/VW1]:M=1C
MU?QSK1@DW12K*-PN',Y!*]D-?L9_PF/AC_H-0?\ ?5=>!QE3&1E*5-P2VOU_
M!'TW!G%6/XJHUJV(P,\-&+7+SW]]-/57C':VMKK5:FE7X]?M"_MX?\%%_&/Q
MA\1_!'3?'^K6MUH^MW>G'2O ^D^1*S0S-&2KQ*UP0=N1\YZC%?KG_P )CX8_
MZ#4'_?55-/U7X>Z1/<7.E-IUK)>3&6[DMX51IY#U=R -S>YYHQV$JXR,8PJ.
M%M[=?Q0<9<+YCQ10I4<+CIX91;YN2_OII:.TH[-:7NM7H?CQX._X)H?\%!OV
M@M4'B/Q/X U.S:YQYNK^.M5\B7G^\DK-<'_O@U]!_"S_ ((&SGR[OXV_'U%Z
M>=I_A732?KBXN,?K#7Z'_P#"8^&/^@U!_P!]4?\ "8^&/^@U!_WU7)2R' 4W
M>=Y/S?\ E8^7RSP6X,P4O:8I3Q$]VYR=K^D.7\6SP+X6?\$G_P!A[X7>7<?\
M*G_X2*[CQ_I?BF]>\W?6'Y8#_P!^Z]^\,>$/"?@G2UT/P9X7T[2+)/N6>EV4
M=O$OT2, #\J3_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJO4I8>A05J<4O1'Z/EN1
MY-D\.7 X>%)?W8J+?JTKOYFE16;_ ,)CX8_Z#4'_ 'U1_P )CX8_Z#4'_?5;
M'JFE16;_ ,)CX8_Z#4'_ 'U1_P )CX8_Z#4'_?5 &E16;_PF/AC_ *#4'_?5
M'_"8^&/^@U!_WU0!I45F_P#"8^&/^@U!_P!]4?\ "8^&/^@U!_WU0!-XA\.^
M'_%VAW?ACQ7H5GJ>FW\#0WVGZA:I-!<1,,,DD;@JZD=000:_,O\ ;M_X-F?V
M?/B_?S_%3]B#Q4?A/XPCE^TP:/ND?1)IP=RE F9K!MV#NBWHN!MB'6OTN_X3
M'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZKZ+ASBSB'A/%>WRO$2IM[K>,O*47>,OFKK
MI8RJT:=96FKGXF^ /^"K7_!6G_@CYXNL?@M_P4N^#.J^/?!GF_9]-\27UP'N
MY(Q_%:ZJH:*]POSF*XS-T#/%TK]2OV*O^"EW['/[?GAY=3_9X^+-K=:K'!YN
MH>$M5Q:ZO8COYELQRZC(!DC+QYX#FO3_ !_IGP;^*WA&]\ ?$[1=$\0Z'J4)
MBU#2-:LDN;:X3T>.12K>O(X/-?EI^VK_ ,&XOPJN?$+?''_@FM\;YOAOXKL9
M_M=EX:OM5N!9+..0;2\3-Q9/G.,^8N2 #&HK] _M3P\XZTS.DLMQC_Y>TE?#
MS?\ ?I[PN^L7;=RET.?DQ.'^!\T>SW^\_7:BOQ%^!O\ P76_X*#?\$Y/&]K^
MSY_P5:^!6K^)-,B/EVWBB.**/53"IP98IU/V75$ P,AE?)):5CQ7UW\9?^#D
MC_@F[\-O#/@KQ/X)\9ZCXT7Q5J21ZI8Z-8O%=>'K0$":XNHIE4AD) 6)<F3#
M%25 )\3,?"GC3!XJG3PV'^LTZE^2I1?M*<TDW=26VB>DK7Z7+CC*$HW;LUT>
MY]_T5RO@#XX?"3XJ>"M,^(WPZ^(&FZSH>LV:76EZG8S[XKB)AD,I_0@\@@@@
M$$5L?\)CX8_Z#4'_ 'U7YW4IU*51PFFI)V:>C36Z:Z-'4FFC2HK-_P"$Q\,?
M]!J#_OJC_A,?#'_0:@_[ZJ -*BLW_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJ@#2
MKEOBU\$OA-\=O#+^#_B]X TW7]/;.R*_MPS0L1@M'(,/$W^TA!]ZU_\ A,?#
M'_0:@_[ZH_X3'PQ_T&H/^^JF48SCRR5T95Z%#%494JT5*,M&FDTUV:>C/SP_
M:>_X(7S1_:/%'[*7C;>.7_X1;Q)-@^NV&Z P?0+*![R5\T> /VA/VZ/^"<_C
M$>"KI]8T***0O)X4\36S3:?<KGEHU)V[2?\ EI PS_>-?M-_PF/AC_H-0?\
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MO_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\
MH-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'
M_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;
M_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-
M0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_
MWU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9
MO_"8^&/^@U!_WU1_PF/AC_H-0?\ ?5 &E16;_P )CX8_Z#4'_?5'_"8^&/\
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M29^'?^P%:?\ HE*W: (?[.T__GQA_P"_0H_L[3_^?&'_ +]"IJ* (?[.T_\
MY\8?^_0H_L[3_P#GQA_[]"IJ* (?[.T__GQA_P"_0H_L[3_^?&'_ +]"IJ*
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MU-]8[37K%Z_/9]&S3_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHKJ/I"'^SM/\
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MJ* (?[.T_P#Y\8?^_0H_L[3_ /GQA_[]"IJ* (?[.T__ )\8?^_0H_L[3_\
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MM*F(DOLP6C4/YIZ:;-:R7)6KR<_94M9=>R.;_P"">'_!+_\ :*_X*W_&T?\
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MX"C&<6FFJ5---.Z::C=-/5-:IA11172?0!1110 4444 %%%% !1110 4444
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M/"?@S^S_ /A*_$%KI_\ :VJ1:=IOVJ4+]INY<^7"F>KMM.!WQ6I7X4?MS?\
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M7N3E&$7*6R/R^A0JXFO&C35Y2:27=MV2^\Z"BOS/_P"(C31?^C1[K_PMU_\
MD.IK?_@XQ\+,I-W^RAJ"-G@1^,$88_&U%?/_ .M?#[_Y??\ DLO_ )$_6WX"
M>+27_(M?_@VA_P#+#]*J*_/CX4?\%\_"7Q2^*7AKX8VW[,^HV<GB/7[/2X[M
M_$\;B!KB=(@Y46XW!=^<9&<=:_0>O3P.9X',XREAI\R6^C7YI'Q/%/!/%'!5
M>G1SK#NC*HFXIRA*Z3LW[DI6U[A117Y8_P#!2/\ X*[>-M/^,=G\'_@KX?O=
M#G^&WQ#DFUR]N+P%-8DLI3&D&U.1 Y\PNK')RO3'.>:9KA<HP_M:SWT2ZO\
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M'?\ L!6G_HE*W:POA=_R3/P[_P!@*T_]$I6[0 444CND2&21PJJ,LS'  ]:
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M_,<1&<L6H033Y(14(NSO9RC:I9[.U1.VS3U/PH_X<V_\%(O^C<O_ "[]'_\
MDNOL[_@CS^S5^WA^R%X^U_P+\;O@Q+IW@?Q):BY-X/$FFW L=0B&$?RX;EWQ
M)'E&*J>5BS@ D?H3166 X2R_+L7'$4:D^:/=QL_)^[LSMXJ^D#Q;QCD-?*,P
MPF&=*JK-J%523334HMUFE)-)JZ:[IJZ(K^PL=5L9M+U2RBN;:YB:*XMYXP\<
ML; AD93PRD$@@\$&N0N/V;OV=KN/RKKX">"Y5SG;)X6M&&?QCKM**^FG2IU/
MBBGZH_$\/C<9A4_85)0O_*VOR9PG_#+?[,O_ $;IX$_\)&R_^-4ZS_9B_9KT
M[5+77-/_ &>O T%[8SI/97D/A.S66WE5@RNCB/*,& (((((!KN:*CZMA_P"1
M?<CI><YPU9XFI_X'+_,****V/-//->_9$_9/\5:W=^)O$_[,'P\U+4M0N7N+
M_4+_ ,%6$T]S,Y+/))(\19V8DDL222<FLI_V$/V*'<N?V2_AUDG)QX.LP/R$
M?%>L45S/!X23NZ<?N1[-/B+B"E%1AC*J2TLJDU^IY,_[!G[$SJ4/[)GP[P1@
MX\(6@/YB.O2_#/AKP_X,\.V/A+PIHUOIVF:9:1VNGV%I$$BMX44*D:*.%4*
M !T J]15T\/0HN]."7HDCFQF;YKF,%#%XB=1+5*4Y22?=7;"O/?BW^RC^S?\
M>=?M_%/QD^#&@^)-1M;,6MM>:K9"5XX0[.(P3T7<[''JQKT*BJJ4J5:/+4BF
MNS5S'!X_'9=75;"594YK3FC)Q>N^J:9X?<_\$UOV#;L 2_LL^$AMZ>78%/\
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M>:**SIT:5)MPBE?>W4\_!Y5EF75:E3"T8TY5&G)Q27,ULW;=A7"?"?\ :<^
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M?W*^EVW;JPHHHKH/<"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**CN;NTLT$EW<QQ*3@-(X4$_C67=_$/P!I__ !_^.='@Z_Z[4XEZ=>K5+E&.
M[-:=&M5^"+?HKFQ16=X=\8>$O%\,EQX2\4:=JD<+!9I-.OHYU1B,@$H3@_6M
M&FFI*Z)J4ZE*;A---='HPHK ^)/Q4^&_P=\,MXS^*GC?3/#^DI.D+:CJUVL,
M(D;.U=S$#)P<"ODO]L/_ (+&_ CX,3^#;;X'^.M'\9M?>)XO^$K.DS"X6TTF
M,XGVL./.?</+Y(^1L]JXL9F."P$'*O-*W2^NNFVY])PYP;Q-Q7BH4,LPLZG-
M=<RB^2\5S-.=N5:=WNTNJ/M.BO#K/_@I7^P9?1>=!^U-X34$#B:^,9_)U!KI
M_AA^V-^RW\:?%:>!OA3\=O#FO:Q)"\T>G:=J"R2LB#+,%[@#DUI#'8&I)1A5
MBV^TE_F<V(X6XGP=*56O@:T(Q5VY4II)+=MN-DO4]*HHJ*]O;33;.74=0N8X
M(((FDGFE<*L:*,EB3P  "2:ZMCPDFW9$M%>8#]MO]C$@$?M<?#'GU\>Z=_\
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MMIV6W^7X,_$/^(9<7\33Y^*LRER]:5/1+R>BBFMO@EZGYR_ ?_@@W$ODZO\
MM(_%TL>&DT3PE'@>N&N9E_ A8O7#=Z^S_@C^Q]^S-^S;:K+\*/A-I&F7,4?S
MZQ/'Y]X1CDFXF+2 'J0&"^PKX1_X*U?M\?MN?L]?M.S_  3^$WC^/1-"O]$L
M[[2!IVB027<R2*T;@RRH[9\Z*7!3:0,#MD_+4?P'_P""IW[8DBS:WX2^*/B:
MVN2#%+XGN[BWLB/]AKQTA"_[O KQZF=9?EV*EA\)A95*D79Z=?)^\_P1_8GA
M]]$KA[+LBPV=5L9A<)1JQ4XU)MSJ6:OJZC@HONHSLF?L3\3?VZ/V/?@[YD?Q
M"_:.\)V<\.?-LH-62ZN5^L$&^3_QVNT^$GQ9\!?'/X=:7\5_AAKG]I:#K,+2
MZ=?>0\7FJKLA.R0*RX9&&& /'2OR7^&7_! 7]KCQ5Y=U\1O&?A+PI V/,A:\
MDOKI/^ 0IY9_[^U^F7[$_P"S'=?L??L]Z5\!9_B%)XF32KFYE@U%].^RA5FE
M:5HQ'YDF '=S]X_>KV,IS#.\;B7]:P_LZ=M.][K>[OM?H>AQ_P )^&7#>3P6
M29N\9C.=*22_=\EI7:<8N-U+E_Y>.Z;TZGK-?GS_ ,%I_&'[:_A/QQX&TC]F
M3QAXVATOQ%I5W!=:3X*AF,[74$J$N7ME\X%DG10-V/W9P,YK]!J*]/,L$\PP
M<J"FX7MJM]'\M]CXG@OB6GPCQ#2S.IA88A04E[.HDXN\6D]5*SBVI)VOI:ZO
M<_"_PM_P2V_X*3?M ZFOB'Q1\+]8@:?_ %FJ^.=:2"49_O)-(9__ !PU[S\,
M?^#=WXEW_EW'QC_:'T32QP9+7PYI4MZQ']WS)C"%/OM8?6OU7HKP:'!F3TG>
MKS3?F_\ *WYGZMFOTD_$7&P]G@O986"T7LZ:;2]:CFONBCQ7]B3]AWX=_L,>
M!M3\$?#OQAK^KQ:S?I>WTFMS0D+,J!,Q+%&FP%0N02Q^4<U[5117T^'P]'"T
M52I*T5LC\0S;-LQSW,:F/Q]1U*U1WE)VNW:W2RV2"BBBMCS@HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *" 1@BBB@#\QO\
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MX\_X$W%SA<'SO%NJ#/O\ERM?)?5>-Y?\OZ:^2_\ D&?T!_;WT8:/_,JQ4_\
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M 2,X!K6HKZ^45*+3ZG\]4JDJ-6-2.Z::^1^.Y_X-\?VS,\?$WX8X[9UG4?\
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M=_P,/XFRZO!\-_$,_A_[1]O30[MK'[(&,OG"%]FS;SNW8QCG.,5^(G_"??\
M!8BR_P!*DU;]H553DM+!K)4?7<N*_=>BN7-\FEFLH-5I4^6_P];V\_(]OP\\
M2*7 ='$4YY=2Q7M7%_O%\/+?1>Z][Z^B/PH_X7)_P5\_Z&/X[?\ @'JG_P 1
M6Y\,?VB_^"K-_P#$GP]8Z[XR^+IL9M<M([P7&G7@C,1F0/N)CP%VYSGM7[=U
MS'QI\%>+/B1\)_$'@#P/X[_X1C5-9TN6SM?$ L#=-8^8-K2K&)(\N%+;3O&U
MB&YQ@^,^%,337-'%U&UK;OY?%U/TF/CWD^-DJ%;(,+",O=<VD^1/1RLJ3;Y=
M[)7TT39^)_\ P5F_:S_X:H_:OU/_ (1[4_/\+>$-^C>'?+?,<VQO](N1V/F2
M@X8=8TC]*_3K_@DS^UG_ ,-4?LH:9_PD.I^?XI\(;-&\1>8^9)MB_P"CW)[G
MS(@,L>LB2>E?,7_$.-_U>1_YCS_[X5[M^P%_P2N\6?L(?%B]\?Z1^T__ ,)!
MI>K:6UGK'A]_!QM%N<'=%*)/MDFUXVS@[#\KNO&[(Y<FP?$F&SJ6*Q%+W:E^
M;WHZ=G\73;T/=\2.(_!G.O#.CDF48Y.M@TG0O2K)R:5IQ;=)).HKR;;2Y[-M
M(^Q****^_/Y*"BBB@ HHHH *Y[XI?%SX6? [P7=?$?XS?$?0_"F@61476L^(
MM4BL[:)F.U5,DK*NYF("KG+$@ $FNAK\D?\ @Z&L_P!M+X/^(/V<_P#@H-^S
MSX#;QGX,^ OC*ZU_QCX7>W>>VAN<VK6U]<PI\QB5([F+SP,VYD# KYA- 'W]
M^SU_P4E_88_:G\32>!?@A^TQX8U7Q$EY>VZ^&;F\^Q:I,;2YFMIWCL[D1S2Q
MK+!*/,1"A"Y!P17:?M#_ +4'[.W[)?P^G^*G[2_QH\.>"/#\&1_:/B+5([=9
M7 SY<2L=TTA[1QAG/8&OS%_X(N_M*?\ !/S_ (*Q_"OP19ZAK6GZ%\<?A3\<
M/%?Q+TOPO>;3J6G0:IXCU346AMYF5/MEJUMJ"13&/[LD<;NBE8\^=_\ !Z?\
M!?@YIG['?P__ &A['X=Z9'XXO/BU:Z3=>*1!F]EL&TG4)#:F0\^5OMXF"?=#
M*2 "S$@'[2^ _&_A?XF^!]&^)'@?5/MVB^(-)M]2T>]$+Q_:+6>)98I-DBJZ
M[D=3M8!AG! /%>*G_@J3^P0/B(/AH?VB;#[2?%G_  BPUO\ LF^_L+^WMN[^
MR?[9\C^SOMV/^77[1YV>-F>*\0_:=^/GBK]F+_@W3N_C9X$U*6RUO2OV9])A
MT>_MW*R6=U=:7;6D4Z$='C>=74^J"OR:NM#L%_X,L;;53:IY[?%<W8EV_-YO
M_"1/#OS_ 'MGRY].* /Z*OC3\;?A'^SG\,=6^,_QU^(FD^%/"NA6_G:MKNMW
MBP6]NI(506;JS,554&69F"J"2 >1^ /[;O[,G[37BS6/A[\)/B+/+XFT&SAO
M-7\*>(/#VH:)J]M:3 &&Z-CJ4$%P;=P5VSB,QMN&&.17X!?\%:_VY_B=^T]_
MP3^_X)Q?#?QAKUS=IXWAAU?QRUQ*6_M>^T^XM-+BGES]]F+7LC9R"TH/:OI#
M_@K)\;O$7[-O_!V5^R;XP\&7DEJ?%/@;PWX:UN.%B%O+;5->UC3764#AP!+&
MPSG#0HW500 ?N)1110 5Y1^W/_R:/X]_[ +_ /H:UZO7\VOB#4/L&GML;$DG
MRI[>IKQLXS>.44XSE'F3OUMM;R>]SP,3F6<5>,<GX;RK"?6*^8U'3C[_ "*%
MG"\Y>Y.\8QDYR>G+&+>I_07<?%GX;? O]FZT^+?Q>\96/A_PYH7A:UN=5U;4
M9MD4$8A3\68DA51069F"J"2 ?Q%_:^_;=_:-_P""\GQVE_9[^!>OP_#?]G[P
MW>QS:[XA\2W:VEJT08[+W47+ 22-M8V]BK$EADY*M)'XU'XLNXK9(5MT+JN"
M[DG/X5'X*T#Q)J$<'@;X:>%KB158M;:3H6G,QW-@%ECC4DDX&3U.!FO6X0\9
M<EX2I5L93R]UL?HJ$Y23ITKWYI<G*FYK3E=VM>EO>_<,%]'/QVS:O7I8O!X7
M!TH2:4ZN*YU.*;7.HTJ4FDTE)1DX.SM)P:L?I5\"OVP?^"<O_!*WX))\!OV,
M/!6I>-]1^637?$TD8LQK5X!@S7%S(F]L$D(D<9C520I&23Y#\7_^"J?[;W[1
MVJ?\(EX(UN7PY;WKF.VT7P/:2+=39Z#SANG9L==C*#_=KR;X:?\ !+O]O[XL
MR176D_L\ZY80L03=>)WCTT(/[Q6Y9)"/]U2:_;3X$_L^?"#X$^%K73_AM\)=
M#\,W$EI&+_\ LVW#2L^T;E>=LR3 '@%V/2OF5F_$O&..K8O,)SBY.[DT[R;W
MU=K_ 'V2M;0_(/%_P/XHR*I@\-2XJHUX5%/VU/#0Y/9./+RQTJSG-33EK.4+
M<OP.Y^5OP8_X)&_MG_'B^'B;Q_IJ>$;2[?S;C4?%MRQO)<]6^SKNE+^TOEY]
M:\;\<^,/'G_!/K]JK7?"G@.TLI?$O@K5YK;3?$NH1R%P"A5;B.!7$:B2&0$Q
MR"4 /C)ZG]\:XB^_9J_9[U7X@WOQ8UCX)>%K[Q-J#1F[UZ^T.">Z<QQK&F))
M%++A$1>".%%+&\-RG2BL)5<)IW<GKIY6ZWM;\R_!O@SPG\.<XGF&>95_:4U&
M]/VK3Y:JDFI<K]Q*U]7"4D[6[GXK3?M%?\%3?VP96M]!\9_$_P 2P3L1+!X3
MLI[>T(]'6R1(@O\ O<"NE^'G_!%?_@H%\4KD:GXE\&Z9X:6Y;>]YXJU^/>V>
MK,D'G2@_[R@U^W,444$2PP1JB(H5$08"@= !VIU<L.#,/5ES8RO.H_6WY\S_
M !/Z>Q'TD<VP-)T.'LJPV#@^BCS->G*J<?OBSBOV;_A]XM^$OP"\'?"WQUK=
MKJ6J^'/#MIIEW?66[RIS!&L2LN\!C\JKDD9)S7:T45]C3IQI4U".R5ON/YUQ
MF*JX[%U,35MS3DY.RLKR=W9+97>Q5;0M$?6%\1/H]J=06#R5OC;KYPCR3L#X
MW;<L3C..3ZU:HHJDDC"4I2M=WL%%%%,D**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M ,KQQX&\&?$SPCJ'@#XB>%=/US0]6M6MM3TC5;1)[>ZB;JDD;@JP]B*_';]M
M_P#X(8?M(?L,_$]OVWO^".OC/7;6;2V>YN_ EE<F74+./.YTM-^1J%L0,-:R
MAG(  \[.U?V>HKZWA3C3.N$,1*6$DI4IZ5*4US4ZBZJ47IMI=6:VO:Z>-:A3
MK+WM^CZH_.+_ ()8?\' _P (OVNKNR^ /[5MM9?#OXK+(+2,W#&#2]<N =NR
M%I#FUN"W'V>0\M@([$[%_1VOA3_@J?\ \$*OV>/^"@]I>_$_P&+7P)\5O++Q
M^)K.V_T76' ^5-0B3[Y/3SU_>KQGS%4)7Q9^RG_P5M_;=_X)#?%6U_8J_P""
MK?@+7=9\)VV(M#\5,3<WUE: [5GM[C.W4K,<?*3YL8RN<H(:^WQ7".0<=8:>
M8<(^YB$N:I@Y/WEWE0D_CC_=W7E=1,%6J8=\M;;I+_,_;ZBN8^#GQH^%/[0?
MPZTWXM?!3Q]IOB7PYJ\/F6&K:5<"2*0=U/='4\,C ,K A@""*Z>OQ^M1JX>K
M*E5BXRB[--6::W33U378[$TU=!11168PHHHH **** "BBB@ K"^)WPU\&?&+
MP#JGPP^(>F2WNAZU:FVU.SAOIK8SQ$@E/,@=)%!Q@@,,@D'()!W:*F48SBXR
M5T]T:T*];#5HUJ,G&<6FFFTTT[IIK5-/5-:IGS%_PYM_X)N_]&Y?^7?K'_R7
M78_ O_@G7^QW^S3X^C^)_P $?A++H6N16LML+R/Q-J4X:*0 .C1S7+QN#@'#
M*<%01@@$>V45Q4\KRRE-3A0@FMFHQ37SL?2XOCOC?'X:>'Q.:8BI3FFI1E7J
MRC)/=-.333ZIJP4445WGRH4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %?._[7/\ P4*^"W[&G[1GPH^#W[1WB#2_#7A#XK:5XBAC\9:])Y-A
M9:K9-IAMK2XG<B&!+B&ZO,-(0"]NB@_,:^B*KZMI&DZ]ITNCZYI=O>VDZ[9[
M6[@62.0>C*P((^M '\W/PT_8B^''B7_@K-^SG\;?^":?B:*Z\:W?[1?CS5OB
M_I?@^\2;3?#?AC3?'%]%:7DGD$QV4%UI0DMDARJ3I'$(US*2_P!1?\'J_P 5
MOAE=?L._#KX.VOQ T:7Q7#\8+;4)_#<6I1-?0VJ:1J"M,\ ;>B9N(!N( _>K
MZBOV ^#7P,^$G[/7A&;P'\%_ MEX>TBXUK4-6FL;'=L:\OKN:\NI?F)(WSSR
ML%SM0,$0*BJHZR@#X>T_X8>"/^"DG_!!*W_9X^#7Q T/6KGQ5^SSIND:?<V&
MJ1316NL)I,#P13LC'RF2Y2(.C89<$$ BOR-N;V]G_P"#8.#_ ()K?V=,/CU#
M\?CX8_X5"%SXA-__ &NU_P"7]ASYVWR6W>9MV8'WJ_I3JA_PBOA?_A(O^$O_
M .$;L/[6\CR/[4^QI]H\K^YYF-VWVSB@#\'_ /@M9_P2?^*'[./_  34_8W^
M)GAGPW<:S/\ LPV]K9_%2/1XFN&@M[EK2ZN[X*F2UO#>6\H+#)"W(<_*K,OH
MO[3_ ,$=*_X*??\ !T'\#OB[^SOXBT_QA\//@I\-= USQQXS\/7L=YINGW=K
MJ6J:E96AN(B8VGEDFLR(PV[8[OC"-C]J6574HZ@@C!!'6J7A[POX9\(V!TKP
MIX=L=,M3*TAMM.M$@C+M]YMJ #)[GJ: +U%%% '&?&;X&>$/CGIEEI/B_5-:
MM8[&=IH6T75I+1F8KM(8I]X8[&OYS/$&H?;]0;8V8X_E3W]37],U>4?MS_\
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MYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\
MGYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ M
MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P#
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M^/O@I=70EUVUFC=XHX<X":I;1$>4X'RK>PX'3)CW^4?TG_X)M?\ !3O]D?\
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MIHUJ=:-XLS/^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VK8HKYHU,?_ (0?2/\
MGYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ M
MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P#
MMJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@
M#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\ GYO?_ MJ/^$'
MTC_GYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?
M2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO
M?_ MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]
M_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:
MMBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\ GYO?_ MJ
M/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_
M (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC
M_GYO?_ MJV*XKXQ_M&_ K]GO^P?^%W?%;1?"_P#PE&M1:1H']L7JP_;;R3[L
M29_5CA5R,D9&=J&'KXJJJ5&#E)[))MOKLM=M1-I*[-W_ (0?2/\ GYO?_ MJ
M/^$'TC_GYO?_  +:MBBL1F/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U;%% &
M/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M6Q10!C_P#"#Z1_S\WO_@6U'_"#
MZ1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;5L44 8_\
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MXK _:T_>T?[M6"UT_G2LUKHK-JEB7S>SJJTOP?H?>5%%%?F!UA1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_.C_@JC_P &
M_OP<_;'N;WX\?LPW%E\//BL'-U));H8=+UV<'=NN$C&;><MS]IC&222Z.2&7
M]%Z*]WA[B7.N%<QCC<LK.G-;]I+^64=I)]GZJSLS.K2IUH\LU<_%S]B;_@N)
M^TW^P+\4$_8@_P""Q'@K7H1IC);V7CJ\MFFU"RBSM22Y*9&HVIQQ<Q%I, D^
M<3\O[&> _'W@CXI>#M.^(7PW\6Z=KNA:O;+<:9J^DW:3V]U$W1T="0P[<=""
M.U>8?ML?L#?LS?M__"]_AC^T5X$COA"KMHVO6>(M2TB5A_K;:?!*= 2C!HWV
MC>K "OQ_UWP+_P %._\ @VY^)TWB[P%?R?$OX!:IJ0:[C=)/[/DW$*!<1C<V
MEWA& )ES'(=@)EP8U_399;PMXGQ=3*U'!9H]70;M1KOJZ3?P3?\ (]'_ .!3
M.3GK832?O0[]5ZG[S45\]_\ !/\ _P""F?[+O_!1OX>_\)7\#O%GD:W90*WB
M'P9JKK'J6E,<#+Q@GS(B3A9DRAS@E6R@^A*_(\QRW'Y1C9X3&TG3JP=G&2LU
M_71[-:K0[8SC./-%W04445PE!1110 4444 %%%% !1110 4444 %%%% !111
M0 45A>/_ (H?#/X4:*?$GQ2^(FA>&M.7.Z_U_5X;.$8Z_/,RK^M?*OQL_P""
M^7_!*WX(^=:WG[3MGXGOHL[;'P3IT^I^;C^[/$GV?\Y17KY7P_GN=RY<OPM2
MM_@A*7WM)I?,B=2G3^)I'V/17Y!?%K_@[,^'4]__ ,(_^R]^QQXF\17=P_EV
M4_BG5XK)F?MBVM5N&DS_ '1(I_E7%_\ #>'_  <S?MI_NO@#^RS+\/-,N^(+
MZ#P9'IRM$?XA<Z[(RMQ_'&!_L@&OO:'@[QA&FJN9>RP=-_:KU807W)RE]Z1S
M/&T&[0O)^2/VP9E12[L  ,DD\ 5XA\;/^"E7[ G[.WG1?%_]KGP+I=U!GSM,
MAUZ.[O4QZVML9)O_ !ROR_7_ ((+_P#!8G]KYOM?[<7_  4%6RT^Z/[[2;CQ
M)J&N-"#U M%,-JH]DDP?:O;_ ()_\&J'["_@@Q7WQF^*GCKQS=)CS+>.ZATN
MRD]<QPHTP_"?_&M?]5/#3*=<SSMUI+>&&I-_=4G[C^X/;8J?P4[>K_0U/C9_
MP=,_\$]/A_YUE\)O"_CGQ_<KGR+BQT=-/LW^LEVZ3+G_ *XFOG^Z_P"#B;_@
MIW^U7<R:5^P?_P $[@897,:WJZ3J/B.6'MN,D"00QGU+JRCOZU^E/P3_ ."4
M?_!./]GKR9?A=^QUX(@N;?'D:CJ^E#5+N,CNMQ>F653[AA7T!:VMM96T=G96
M\<,,2!(HHD"JBC@  < >U'^L_AAE&F6Y-/$26T\35?XTZ?N/[P]EBY_%4MZ+
M]6?BG_PR[_P=%_MK?-\5/CQ/\,=)N_NQR>*;;1%6(]5,6C(]P>,C;*,GOQ72
M_#/_ (-05\3:M_PEO[7'[;^MZ[?7+!K^#PSI&)G/?_3;V25G/N81^-?L716=
M7QBXLI4W2RN%'!0?2A1A'3UDI/YIH%@J+=YWEZL^)/@G_P &\O\ P2M^#'DW
M5Q\ [CQC?0XQ?>-M<GO-V/[T"-';MGWBKZR^&'P.^"WP1TO^P_@S\(?#'A*S
M*A3:^&M!M[&,@=BL**#74T5\+FO$G$.>.^88NI5\ISE)?)-V7R1T0I4J?PQ2
M"BBBO$- HHHH *RO&_@7P3\2_"UYX'^(WA#2]>T748C%?Z1K-A'<VURG]UXI
M 5<>Q%:M%5"<Z<U.#LUJFMTPW/RT_;9_X-A_@%\2-0E^)_[#'CVY^%?BJ*7[
M3;:+<SS3Z.\X.Y3&X)N+([N=R&15P L2UX'X8_X*;?\ !9C_ ((Z>(+3X:_\
M%#/@YJ'Q&\"I,+>Q\1ZG<F621.WV;6(E=9FQEO*N@TN, ^77[CU0\3^%O#/C
M;P_=^$O&?ARPU?2M0A,-_IFJ6:7%O<QGJDD<@*NI]""*_4,N\4<=6PD<OXCH
M1S##+;VFE6'^"LO>3];OI=(Y)82*ES4GRORV^X^<?V'?^"OG[#7[?5M;Z7\(
M?BK%IGBF5 9? _BD+9:HK8R1&A8I<@=<P/( .N.E?3M?F/\ MP_\&R/[+?QL
MN;CXA_L@>)9OA-XJWF>+380]QHDTP.X8BSYMH<X^:)BB=HJ^:]&_;S_X+;_\
M$5=6MO!/[;7PRN_BC\-8)E@M->U*\>[C,><*+;6$5GC8_P ,5XK-@8"*.:[G
MP)PSQ:O:\(XW]Z_^8;$-0J^D)_!4\E=66\KD_6*M'2M'3NMOGV/W,HKY._88
M_P""T?["?[>:VGA[P!\2U\-^,+@!3X(\7E+.^>0_PV[%C%=\YP(G9\#+(O2O
MK&OS'-<FS7(L8\+F%&5*HNDDT_57W79JZ?1G7"<*D;Q=T%%%%>:4%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %>4?MS_\FC^/?^P"_P#Z&M>KUY1^W/\
M\FC^/?\ L O_ .AK0!W7PN_Y)GX=_P"P%:?^B4K=K"^%W_),_#O_ & K3_T2
ME;M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB+@*!P  .@K*\/> / GA&]N=2\*>"M(TRYO#F[N-/TV*%YSG/SLB@MSSSWH
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MZ1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;5L44 8_\
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M^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\WO\
MX%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U;
M%% &/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M6Q10!C_P#"#Z1_S\WO_@6U
M'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;5L44
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M &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U;%% &/_P@^D?\_-[_ .!;4?\
M"#Z1_P _-[_X%M6Q10!C_P#"#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M6Q10!C_\
M(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?
M\_-[_P"!;5L44 8__"#Z1_S\WO\ X%M1_P (/I'_ #\WO_@6U;%% 'R=^VE_
MP1:_81_;CANM8^)7PZFT?Q5<*=GC7PS,MKJ._'#2G:8[GM_KD<@< KUK\WO&
M7_!,S_@LM_P1ZUFZ^('["/Q6O_B7\/XIFN+S0=(@>5V3J?M.CNS;F(X\RU9Y
M,9.8Q7[I45^@</>)/$6187ZC5<<3A'HZ-9<\+?W;ZQMTY79/6S.:KA:51\RT
M?='Y1_L1_P#!Q[^RW\5[V#X:_MK^%-4^%/BI)?L]QJ\=Q/<:-),#M8/D&>R.
M[C;(KHN"6E%?ICX/B^'/Q#\,V?C3P#XTBUS1]1A$VGZMI&LK<VUS&>CQRQL5
M=?<$BO&/VW/^"37[#_[?5E/>?&[X2P6WB1XML'C;PX5LM6B(&%+3*I6X ' 6
M=9%'8 \U^9WC#_@E'_P6"_X)$^)KSXK?\$V?CAJ7C[P<)C<7_AO3H0;F5!U%
MSI,I>*[;;A!);EINI58Z^A_L;PYXUURFO_9V*?\ RYK/FHR?:%7>/_;ZUV43
M/GQ5#XUS+NM_N/VK_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VK\POV+?^#GO
MX.>,=6C^%'[?OPSN_A?XIMYOLMYKUA:3S:69P=K":!@;FR;=QM(E48)9T%?I
MY\/OB-\/_BSX1L_'_P +_&^D^(M#U"/S+'5]$U".ZMIU]4DC)5OP/%?"<2<'
M\2<)U_99GAY03VEO"7^&:O%][7NNJ1T4J]*LKP8O_"#Z1_S\WO\ X%M1_P (
M/I'_ #\WO_@6U;%%?,FIC_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M6Q10!EV
M?A+3;&Z2[AN+HM&V5#W+$?B*U*** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *\H_;G_Y-'\>_P#8!?\ ]#6O5Z\H_;G_ .31_'O_ & 7_P#0
MUH [KX7?\DS\._\ 8"M/_1*5NUA?"[_DF?AW_L!6G_HE*W: "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^?_VTO^"8
M'[%G[>^DR1?M!?!ZSFUKR?+M/%^CXL]7M<#"[;A!F15[1RB2,?W:_,/X@?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFO G_!1GP)'\,?B=/9:'\7]#L@VK:2A$<.N0H #?68/YR0CF,G(RA!'Y4?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5Y1^W/_R:/X]_[ +_ /H:
MUZO7E'[<_P#R:/X]_P"P"_\ Z&M '=?"[_DF?AW_ + 5I_Z)2MVL+X7?\DS\
M._\ 8"M/_1*5NT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .3^.GQ@^'_P
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M4/\ ^C@O G_A+O7O5% '@O\ PK[_ (*'_P#1P7@3_P )=Z/^%??\%#_^C@O
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M%??\%#_^C@O G_A+O7O5% '@O_"OO^"A_P#T<%X$_P#"7>C_ (5]_P %#_\
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M%??\%#_^C@O G_A+O1_PK[_@H?\ ]'!>!/\ PEWKWJB@#P7_ (5]_P %#_\
MHX+P)_X2[T?\*^_X*'_]'!>!/_"7>O>J* /!?^%??\%#_P#HX+P)_P"$N]'_
M  K[_@H?_P!'!>!/_"7>O>J* /!?^%??\%#_ /HX+P)_X2[T?\*^_P""A_\
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MHZ_^W]\-O&7@SPG>_'/PA-)XNUMM/MY+;PR D3",ONDW DKQ_#@UVW_"OO\
M@H?_ -'!>!/_  EWK;_:/\"^+O%GQ8^$FM^'-!GN[30_&$EUJT\(!6UA,#*'
M;GIGBO7Z /!?^%??\%#_ /HX+P)_X2[T?\*^_P""A_\ T<%X$_\ "7>O>J*
M/!?^%??\%#_^C@O G_A+O1_PK[_@H?\ ]'!>!/\ PEWKWJB@#P7_ (5]_P %
M#_\ HX+P)_X2[T?\*^_X*'_]'!>!/_"7>O>J* /!?^%??\%#_P#HX+P)_P"$
MN]'_  K[_@H?_P!'!>!/_"7>O>J* /!?^%??\%#_ /HX+P)_X2[T?\*^_P""
MA_\ T<%X$_\ "7>O>J* /!?^%??\%#_^C@O G_A+O1_PK[_@H?\ ]'!>!/\
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M_"7>O>J* /!?^%??\%#_ /HX+P)_X2[T?\*^_P""A_\ T<%X$_\ "7>O>J*
M/!?^%??\%#_^C@O G_A+O7$_%'7_ -O[X;>,O!GA.]^.?A":3Q=K;:?;R6WA
MD!(F$9?=)N!)7C^'!KZPKR#]H_P+XN\6?%CX2:WX<T&>[M-#\8276K3P@%;6
M$P,H=N>F>* ,3_A7W_!0_P#Z."\"?^$N]'_"OO\ @H?_ -'!>!/_  EWKWJB
M@#P7_A7W_!0__HX+P)_X2[T?\*^_X*'_ /1P7@3_ ,)=Z]ZHH \%_P"%??\
M!0__ *."\"?^$N]'_"OO^"A__1P7@3_PEWKWJB@#P7_A7W_!0_\ Z."\"?\
MA+O1_P *^_X*'_\ 1P7@3_PEWKWJB@#P7_A7W_!0_P#Z."\"?^$N]'_"OO\
M@H?_ -'!>!/_  EWKWJB@#P7_A7W_!0__HX+P)_X2[T?\*^_X*'_ /1P7@3_
M ,)=Z]ZHH \%_P"%??\ !0__ *."\"?^$N]'_"OO^"A__1P7@3_PEWKWJB@#
MP7_A7W_!0_\ Z."\"?\ A+O1_P *^_X*'_\ 1P7@3_PEWKWJB@#P7_A7W_!0
M_P#Z."\"?^$N]'_"OO\ @H?_ -'!>!/_  EWKWJB@#P7_A7W_!0__HX+P)_X
M2[T?\*^_X*'_ /1P7@3_ ,)=Z]ZHH \%_P"%??\ !0__ *."\"?^$N]'_"OO
M^"A__1P7@3_PEWKWJB@#P7_A7W_!0_\ Z."\"?\ A+O1_P *^_X*'_\ 1P7@
M3_PEWKWJB@#P7_A7W_!0_P#Z."\"?^$N]'_"OO\ @H?_ -'!>!/_  EWKWJB
M@#P7_A7W_!0__HX+P)_X2[T?\*^_X*'_ /1P7@3_ ,)=Z]ZHH ^8OBW>_M\?
M!CX::W\4M>^-G@R_M-$T][B6TM?#3*\F!A0">/O$'Z U]$^"-5N]>\%Z1KFH
M,IN+W2[>><HN 7>-6; [#)-<9^UWX4\1^.?V:?&/A'PCI$M_J5_H[16=G  7
ME?<IVC/?BNO^'UC=Z7X!T/3-0MVBGM]'MHIXGZHZQ*&4^X((H V**** "BBB
M@ HHHH **** "BH;S4+#3EC?4+V&!99DBB,TH4/(QPJ#/5B> .I-<KK/[0OP
M"\.?%"Q^"/B'XX^#[#QIJ:!]-\(7OB:UBU2[4C(:*U:02R @$Y53TH ["BN"
M_:0_:A_9[_9!^%M[\:OVF?B[HG@SPQ8#$VJ:W=B,2/@D11(,O/*V#MBC5G;'
M"FNN\+>)M$\:^&--\9>&;X7.FZM80WNGW*J5$L$J!XWP0",JP.",\T 7Z*^%
M_P!HC_@N;\/OA3^SCX5^.OP5_9"^+7Q8U+Q?I^H:O8^$?!GAXW$^G:':7DMJ
M=8OY8/.2TM)3$7A8[C(IZ+LDV3?!3_@O1^RA\=?^"67CG_@J3X6\-:Y:Z+\/
M(;FW\3>#]0,:7T&JQK#Y5B)%+1L)FN;8),/EQ,"P5E=% /N*BOS[^"7_  6+
M^(&G_M3?L]_L]_M5^#O"UKIW[4'PGM/%WPZ\2>%%N((])U&:'[0=$NEN)9?M
M/[MHE2\0Q;Y'53;H'RO.?MD_\%,?VX/V?/\ @MI^SA^Q/K&A^"]!^$OQ-O;M
MI+G2IY;_ %+6AY=U;Q17$D\$:VFV<VTOEP!CD@&=E)2@#])Z*_-G]O7]L3X@
MZQ_P76_9]_X)=Z]X\\1>%OAAXU^'&J:]K=QX4\1W>BWFLZH\&JQVD!O[.2*X
MB2%K .J12('DG4.' 45G_P#!O/\ MQ?M*?%OQ[^T?_P3\_:O^(FH>-?$?[.?
MQ%ET;1O&VLL'O]4TTW=[:JMS(!F9T>Q+"5LLRW !)V9H _3:BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBH;[4M.TQ(Y-2OX+=99TAB:
M>4('D=@J(,GEF)  ZDG H FHKC=:_:,_9[\-_%*R^!OB+X[^#+#QMJ2JVG>#
M[WQ1:1:K=!@2ICM&D$S@@$C:IR!5+]I7]J?]G?\ 8[^%E[\:OVG/B_HG@OPS
M8C$NI:U=A/-?!(BAC&9)Y2 =L4:L[8X4T =_15#PKXFT3QKX8TWQEX:O1<Z;
MJUA#>Z?<A2HE@E0/&^" 1E6!P1GFOB3]HC_@N5X.^%_[-WA?XZ? C]C?XK_%
MS5O%VFZCK-AX0\'Z&TTNG:':7DUM_:^H3P+.EI:S&$O"Q#-(">!L?: ?=5%?
M#/P3_P""]G[*WQU_X)6^.?\ @J5X8\*:W::1\.X;FV\3>#=0>-;V#5HUA\JR
M65<HRS-<VP28#&)@6565D'/?!+_@L5\1]+_:H_9[_9\_:N\)>$X-,_:A^%%G
MXM^'7B3PE#<VZ:1J4T'V@Z+=K<32_:OW;1*EY&8=\DBJ;=0VY0#]!Z*_&[_@
MKU^VW_P7Z_8 MK;_ (*(Z=XL^&&F_!.'QC%I_P#PIG^R8[G48]/ED9;674KF
M2#S!-,J#S!:W $+S*H60*SCVO]O']N/Q_P")/^"L?['W_!/AM:\0^$_!/Q0T
M'4_$_P 0['1=;N=+U&];^SKS^S[!KRT>*>&..ZMV:1(W7S#M5OE&" ?I-17Y
MN?\ ! /]NSXT?&OQO^TA^P5^T;X\U'Q1XE_9V^*M[HNB>)M<N#-?ZCHAO;RV
M@6XF;YKB6)[)P9G)9UFCR6(+'](Z "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BF&YMQ<"T,Z"5D+K%N&XJ" 3CKC) S[BN<\%?&KX-_
M$K7]5\*?#GXM>&=?U30I?+UO3=$UZWNKC3WR1MGCB=FB.01AP#D&@#IJ*\\^
M*'[6?[-GP7^*7@_X(?$_XS:%I'C'Q_J LO!_A>>[W7^IR[6.8X$!<1C8P,K
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M>T,V,\D5OJ.FJZ7MZ9Y'NHY(KN7]TBP1XBPZ29##]5Z "BBB@ HHHH ****
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MKVYT*?P#H0M4T7R89Y7,+>3%.1"T(#K/YH,+A@^X,!Z5_P '-/[8WQX^!O\
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M";8OM;36LSND0,A5$*#=)N;<50KC?\$X?^"-7[$/_!*^\\2ZM^RGX9UZ&_\
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MX-OI_#D=H-6U;Q3?SO+IT=U>0V:RVUE'%LNG5YT8F6:-$ )*2X*5]E5\F?\
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M63BZ^W>'/%DIU%;PSSF>1I&EY+"0AE88*%5*[2H( /@W]DGX7^)O"7_!W/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** *^K:3I6O:9<:+KNF6][9W43175I=PK)%,C#!1U8$,I'!!&#5'P
MGX!\"> K/^SO O@K2=%M\8\C2=-BMDQZ;8U K6HH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L7QU\-OAU
M\4=(30/B9X!T7Q%8),)4LM=TJ&[A60='"2JRAAZXS6U10!F>%O!7@WP/8?V7
MX*\):9H]K_S[:781V\?_ 'S&H%:=%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!C>-_AS\/?B;I::'\2/
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVY^ROXB_:WUC]A+1OC%83_%G0/#L>NZOX.6VG$UO8/Y160RF,0LV)HF,:N9
MLBL5"D&O3+36-)U"\N].L-4MI[BPE6.^@AG5GMW9%=5D4'*$HRL <$JP/0B@
M"S117&?'W]H#X4_LP_"_4OC1\;=>N])\,:-"T^KZO;Z)>7R6,*J6::9;2*5H
MXE ):1@$7N10!V=%>6?LH_MI_LU_MP> Y?BC^RU\0IO%?AN.Y:W778O#]_:6
MDTJG#I%+=01K,5(PWEEMIX.#7J= !169XR\7:+X"\*:AXT\1F[%AI=J]S>&P
MTV>\F$:C+%8;='ED('.U%8^U<+^R=^V3^S1^W+\+Y?C/^RE\5K3QCX8AU:73
M)=6LK2XA1;N)(WDBVSQQMD++&<XQ\W7K0!Z;1110 4444 %%%% !1110 444
M4 %%%% !117@G[5?_!3W]A?]A[QEI'@3]K/X[1>!+[7AG19M<\/ZBMG>X*!_
M+NUMVMVV;TWXD_=[AOVYH ][HKS[X[?M2?!+]FSP/8_$KXN^);^TT'4;RVM;
M35=*\-W^J0M-<2QQ6Z$V,$VSS998HX]V!(\BJN20*[G2M2M]9TNVU>TCN$BN
MK=)HDN[22"5590P#Q2JKQM@\HZAE.00""* +%%%% !17C_Q*_;V_9.^#W[2'
MA;]D?XG?%;^Q?B#XW95\(Z!>Z%?@:N6_YX7 @,$F",-B3Y3PV#Q7L% !1110
M 45Y_P#M*?M1?!#]D+X8W?QG_:&\676@>%=/V_VEKB:#>WL%DI94#SM:0R^2
MA9U4.^U<L!G->/>'_P#@M#_P3'\06?AC5C^U;IFE:9XTG,7A+7/$^AZEH^G:
MPX<HWV>\OK:&"4!P5)5R >"0: /J&BO*OC=^V]^RM^SC\7_AW\!/C7\8[#0?
M%WQ8U.33_A]HUQ;3R/JURAC4H'BC9(<M+&BM*R*[.%4ECBO5: "BJ^K:QI.@
M:;-K.NZI;65G;ION+N[G6..)?5F8@*/<U8H ***X[X^_'[X3?LO_  FU?XY_
M'+Q.^B>%- A$VLZPNF7-TMG$6"^8Z6T<CA 2,OMVJ.20.: .QHKE/@;\</A5
M^TG\)="^.GP0\80Z_P"$_$MG]KT/6;>&2-+N'<5WA955P,J1\R@\5U= !113
M+B9+:![B17*QH681QEV( SPJ@DGV )- #Z*\D_9=_;K_ &4_VT+[Q;I7[-/Q
M9B\2W?@35%TWQA9_V3>6<VE7C&0""6.ZAB8/F&4$ $J4(.#7K= !1110 445
MXI^U]_P41_8\_8(L=,U?]KKXN/X*T_69O(TS5;[PYJ,]G/-M9O)%Q;V\D0EV
MHS>66#[5+8QS0![716)\.?B%X8^*W@K3OB%X+DOGTK5;9;BPEU'1[FPEDB89
M5S#=1QRJ",$;E&001P:VZ "BO-/VJ/VOOV>/V)_AFWQE_:>\?/X7\*QW4=M<
M:[)HM[=V]M)(P6,3-:PR>2&9E56?:&9@H)) KM? ?CCPK\3O ^C?$GP)K":C
MH?B'2;?4]&U"-&5;FTGB66&4!P& 9'5L$ C/(% &M1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!YU^T5^UM^S=^R5HNG>(OVD
M?C!I'@^QU>Z>VTVYU>1E6XE5=S(NU3R%YKR;_A]!_P $LO\ H]OP5_X%2_\
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M\=V'AV>/2[R&W%L(XIH6EEDW*;2W?S?F5F$H\E5EVI[9^V!^P/\ MR?MW?\
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M,?VL?"B1'PWX*^"UKJ.I6D+;HK;QOJ%Q#;7-J#U$FGV@ND.?O)K4;=1QX/\
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M^+MQ^S_H%UK_ ,)M<TC1#I]UXLA^SW,EO9S0Q820R-% L<L*)O$A(#!DI/\
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MU>WM9I-@F=(88D29_)$]TN3MPE=S\=_^"XGB7]G#_@DGX\_X*"^ /B_X+^-
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M3%\2_P#! S]HS6_AC^Q;X M_V@?!22_LA^(VUC[4^E797Q1(-3L[R.+:#FT
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M;R^N=8U.TM8G8<K&9YXMY'(0,1R*^GO!_P#P5S_:M^ 'Q/\ V'3^U#XC\/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ I&564JP!!&"#WI:* "BBB@ HHHH **** *^K:1I.
MOZ;/HVNZ9;WMG<QF.YM+N!9(I4/565@0P]B*L444 %%%% !1110 4444 %5W
MTC2I-5CUU],MVOHK=H(KPPJ94B9E9HP^,A254E<X)4'L*L44 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %>=?%S]D#]DO]H#Q/IWC?X\
M?LN_#KQMK6C@#2-7\7>";#4KJQ 8,!#+<1.\7S*&^4CD ]J]%HH ;%%%!$L,
M,:HB*%1%& H'0 =A3J** "BBB@ HHHH \Y\>?L>_LD_%3XFV7QK^)_[+?PY\
M1^,M-6(:=XMU[P187FIVHC),8CNI86E3:22NUAC)QBO1J** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "O.- _8[_9&\*_%^?]H3PO\ LL_#C3?'UT[O=>.+#P/80ZQ,SJ%<
MM>)")F+* "2_(&#7H]% !1110 4444 %%%% !1110 4444 %%%% !1110!YI
MXJ_8O_8[\=>+;OQ_XW_9/^&FLZ]J$GF7^MZKX$T^XN[E^FZ2:2$NY]R36YK_
M .SW\ _%?C3PY\2?%/P/\(:EXB\'1F/PCK^H>&K6:]T-",%;.=XS); @8Q&5
MKKZ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 14, 2025</div></th>
<th class="th"><div>Jun. 28, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MACROGENICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1591613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9704 Medical Center Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">251-5172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MGNX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 259.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,090,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portions of MacroGenics, Inc.'s definitive proxy statement for the 2025 annual meeting of stockholders are incorporated by reference into Part III of this Annual Report.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001125345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_AuditorInformationAbstract', window );"><strong>Auditor Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tysons, Virginia<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AuditorInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Auditor Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_AuditorInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 182,840,000<span></span>
</td>
<td class="nump">$ 100,956,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Marketable securities</a></td>
<td class="nump">18,827,000<span></span>
</td>
<td class="nump">128,849,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">4,309,000<span></span>
</td>
<td class="nump">10,367,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,221,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">11,514,000<span></span>
</td>
<td class="nump">9,946,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">217,490,000<span></span>
</td>
<td class="nump">251,339,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment and software, net</a></td>
<td class="nump">18,100,000<span></span>
</td>
<td class="nump">21,847,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, ROU Assets</a></td>
<td class="nump">24,509,000<span></span>
</td>
<td class="nump">23,846,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non current assets</a></td>
<td class="nump">1,556,000<span></span>
</td>
<td class="nump">1,386,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">261,655,000<span></span>
</td>
<td class="nump">298,418,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,013,000<span></span>
</td>
<td class="nump">6,443,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">29,334,000<span></span>
</td>
<td class="nump">24,239,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">16,319,000<span></span>
</td>
<td class="nump">21,651,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">4,864,000<span></span>
</td>
<td class="nump">3,775,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">55,530,000<span></span>
</td>
<td class="nump">56,108,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">55,503,000<span></span>
</td>
<td class="nump">59,243,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">32,597,000<span></span>
</td>
<td class="nump">30,196,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non current liabilities</a></td>
<td class="nump">1,968,000<span></span>
</td>
<td class="nump">258,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">145,598,000<span></span>
</td>
<td class="nump">145,805,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, 0.01 par value -- 125,000,000 shares authorized, 62,819,857 and 62,070,627 shares outstanding at December&#160;31, 2024 and December&#160;31, 2023, respectively</a></td>
<td class="nump">628,000<span></span>
</td>
<td class="nump">621,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,285,143,000<span></span>
</td>
<td class="nump">1,254,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Accumulated other comprehensive gain (loss)</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="num">(6,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,169,718,000)<span></span>
</td>
<td class="num">(1,102,752,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">116,057,000<span></span>
</td>
<td class="nump">152,613,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 261,655,000<span></span>
</td>
<td class="nump">$ 298,418,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(h))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">62,819,857<span></span>
</td>
<td class="nump">62,070,627<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 149,962<span></span>
</td>
<td class="nump">$ 58,749<span></span>
</td>
<td class="nump">$ 151,941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product sales</a></td>
<td class="nump">847<span></span>
</td>
<td class="nump">619<span></span>
</td>
<td class="nump">3,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CostOfManufacturingServices', window );">Cost of manufacturing services</a></td>
<td class="nump">11,452<span></span>
</td>
<td class="nump">7,603<span></span>
</td>
<td class="nump">4,033<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">177,194<span></span>
</td>
<td class="nump">166,583<span></span>
</td>
<td class="nump">207,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">71,047<span></span>
</td>
<td class="nump">52,188<span></span>
</td>
<td class="nump">58,949<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">260,540<span></span>
</td>
<td class="nump">226,993<span></span>
</td>
<td class="nump">273,359<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(110,578)<span></span>
</td>
<td class="num">(168,244)<span></span>
</td>
<td class="num">(121,418)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_GainOnRoyaltyMonetizationArrangement', window );">Gain on royalty monetization arrangement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">150,930<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_GainOnSaleOfMARGENZA', window );">Gain on sale of MARGENZA</a></td>
<td class="nump">36,250<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest and other income</a></td>
<td class="nump">9,421<span></span>
</td>
<td class="nump">9,686<span></span>
</td>
<td class="nump">1,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest and other expense</a></td>
<td class="num">(1,115)<span></span>
</td>
<td class="num">(1,430)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</a></td>
<td class="num">(66,022)<span></span>
</td>
<td class="num">(9,058)<span></span>
</td>
<td class="num">(119,758)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">944<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(66,966)<span></span>
</td>
<td class="num">(9,058)<span></span>
</td>
<td class="num">(119,758)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">10<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (66,956)<span></span>
</td>
<td class="num">$ (9,059)<span></span>
</td>
<td class="num">$ (119,702)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted net loss per common share, basic (in dollars per share)</a></td>
<td class="num">$ (1.07)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (1.95)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Basic and diluted net loss per common share, diluted (in dollars per share)</a></td>
<td class="num">$ (1.07)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (1.95)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average number of common shares outstanding (in shares)</a></td>
<td class="nump">62,621,185<span></span>
</td>
<td class="nump">61,929,198<span></span>
</td>
<td class="nump">61,433,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average number of common shares outstanding (in shares)</a></td>
<td class="nump">62,621,185<span></span>
</td>
<td class="nump">61,929,198<span></span>
</td>
<td class="nump">61,433,124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember', window );">Revenue from collaborative agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 118,856<span></span>
</td>
<td class="nump">$ 29,421<span></span>
</td>
<td class="nump">$ 119,303<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember', window );">Revenue from government agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,623<span></span>
</td>
<td class="nump">1,556<span></span>
</td>
<td class="nump">1,923<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">16,426<span></span>
</td>
<td class="nump">17,939<span></span>
</td>
<td class="nump">16,727<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_ContractManufacturingMember', window );">Contract Manufacturing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 13,057<span></span>
</td>
<td class="nump">$ 9,833<span></span>
</td>
<td class="nump">$ 13,988<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CostOfManufacturingServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of manufacturing services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CostOfManufacturingServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_GainOnRoyaltyMonetizationArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on royalty monetization arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_GainOnRoyaltyMonetizationArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_GainOnSaleOfMARGENZA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on sale of MARGENZA</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_GainOnSaleOfMARGENZA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_ContractManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_ContractManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,307,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 239,618<span></span>
</td>
<td class="nump">$ 613<span></span>
</td>
<td class="nump">$ 1,213,002<span></span>
</td>
<td class="num">$ (973,936)<span></span>
</td>
<td class="num">$ (61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">20,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">1,085<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity', window );">Stock plan related activity</a></td>
<td class="nump">574<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized Gain (Loss) on Investments</a></td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(119,758)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(119,758)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,701,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">142,013<span></span>
</td>
<td class="nump">$ 617<span></span>
</td>
<td class="nump">1,235,095<span></span>
</td>
<td class="num">(1,093,694)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">18,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">1,039<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity', window );">Stock plan related activity</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized Gain (Loss) on Investments</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(9,058)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,058)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,070,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">152,613<span></span>
</td>
<td class="nump">$ 621<span></span>
</td>
<td class="nump">1,254,750<span></span>
</td>
<td class="num">(1,102,752)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">29,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">749,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity', window );">Stock plan related activity</a></td>
<td class="nump">961<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized Gain (Loss) on Investments</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(66,966)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66,966)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,819,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 116,057<span></span>
</td>
<td class="nump">$ 628<span></span>
</td>
<td class="nump">$ 1,285,143<span></span>
</td>
<td class="num">$ (1,169,718)<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued due to stock plan related activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_StockIssuedDuringPeriodSharesStockPlanActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued due to stock plan related activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_StockIssuedDuringPeriodValueStockPlanActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (66,966)<span></span>
</td>
<td class="num">$ (9,058)<span></span>
</td>
<td class="num">$ (119,758)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">7,540<span></span>
</td>
<td class="nump">9,645<span></span>
</td>
<td class="nump">11,865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums and discounts on marketable securities</a></td>
<td class="num">(2,810)<span></span>
</td>
<td class="num">(5,004)<span></span>
</td>
<td class="nump">403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">29,439<span></span>
</td>
<td class="nump">18,373<span></span>
</td>
<td class="nump">20,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_GainOnRoyaltyMonetizationArrangement', window );">Gain on royalty monetization arrangement</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(150,930)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_GainOnSaleOfMARGENZA', window );">Gain on sale of MARGENZA</a></td>
<td class="num">(36,250)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NonCashInterestExpenseRecognized', window );">Non-cash interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,430<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_OperatingLeaseNoncashExpense', window );">Non-cash lease expense</a></td>
<td class="num">(663)<span></span>
</td>
<td class="nump">3,489<span></span>
</td>
<td class="nump">3,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash items</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">423<span></span>
</td>
<td class="nump">2,882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">(Gain) loss on disposal of assets</a></td>
<td class="num">(57)<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">6,058<span></span>
</td>
<td class="nump">45,855<span></span>
</td>
<td class="num">(45,836)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(2,188)<span></span>
</td>
<td class="nump">230<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,567)<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="nump">11,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other non current assets</a></td>
<td class="num">(170)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(14,045)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,530)<span></span>
</td>
<td class="nump">1,281<span></span>
</td>
<td class="num">(10,860)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">5,003<span></span>
</td>
<td class="num">(4,823)<span></span>
</td>
<td class="num">(4,638)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_IncreaseDecreaseInLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">3,490<span></span>
</td>
<td class="num">(861)<span></span>
</td>
<td class="nump">9,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(9,414)<span></span>
</td>
<td class="nump">11,426<span></span>
</td>
<td class="nump">48,821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other non current liabilities</a></td>
<td class="nump">1,710<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(68,373)<span></span>
</td>
<td class="num">(78,205)<span></span>
</td>
<td class="num">(86,959)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(77,182)<span></span>
</td>
<td class="num">(239,683)<span></span>
</td>
<td class="num">(120,602)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">190,025<span></span>
</td>
<td class="nump">161,299<span></span>
</td>
<td class="nump">194,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, equipment and software</a></td>
<td class="num">(3,706)<span></span>
</td>
<td class="num">(1,764)<span></span>
</td>
<td class="num">(3,623)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfOtherProductiveAssets', window );">Proceeds from sale of MARGENZA</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment', window );">Proceeds from sales of equipment</a></td>
<td class="nump">160<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">149,297<span></span>
</td>
<td class="num">(80,084)<span></span>
</td>
<td class="nump">70,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">616<span></span>
</td>
<td class="nump">1,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases', window );">Proceeds from stock option exercises and ESPP purchases</a></td>
<td class="nump">3,435<span></span>
</td>
<td class="nump">553<span></span>
</td>
<td class="nump">574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(2,475)<span></span>
</td>
<td class="num">(306)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement', window );">Principal payments on royalty monetization arrangement</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(157)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NetProceedsFromSaleOfFutureRoyalties', window );">Net proceeds from sale of future royalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">149,655<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">960<span></span>
</td>
<td class="nump">150,361<span></span>
</td>
<td class="nump">1,659<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">81,884<span></span>
</td>
<td class="num">(7,928)<span></span>
</td>
<td class="num">(14,585)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">100,956<span></span>
</td>
<td class="nump">108,884<span></span>
</td>
<td class="nump">123,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">182,840<span></span>
</td>
<td class="nump">100,956<span></span>
</td>
<td class="nump">108,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income Taxes Paid</a></td>
<td class="nump">944<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash operating and investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital Expenditures Incurred but Not yet Paid</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 505<span></span>
</td>
<td class="nump">$ 118<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_GainOnRoyaltyMonetizationArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on royalty monetization arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_GainOnRoyaltyMonetizationArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_GainOnSaleOfMARGENZA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on sale of MARGENZA</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_GainOnSaleOfMARGENZA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_IncreaseDecreaseInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in lease liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_IncreaseDecreaseInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NetProceedsFromSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from sale of future royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NetProceedsFromSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonCashInterestExpenseRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonCashInterestExpenseRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OperatingLeaseNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Noncash Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OperatingLeaseNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Principal payments on royalty monetization arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Stock Options Exercised And ESPP Purchases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sale of machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the sale of tangible or intangible assets used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Nature of Operations</a></td>
<td class="text">Organization and Nature of Operations<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MacroGenics, Inc. (the Company) is incorporated in the state of Delaware. The Company is a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates from its proprietary suite of antibody technology platforms. The Company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which is referred to as DART and TRIDENT molecules). The combination of the Company&#8217;s technology platforms and antibody engineering expertise has allowed the Company to generate promising product candidates &#8211; three of which have received marketing approval by the U.S. Food and Drug Administration (FDA) &#8211; and to enter into several strategic collaborations with global biopharmaceutical companies. These collaborations have provided the Company with over $1.4&#160;billion of non-dilutive funding since its inception in 2000, and have enabled the Company to leverage the additional expertise of its collaborators to advance the development of multiple partnered product candidates. In addition, the Company operates a 5 &#215; 2,000 liter commercial-scale cGMP antibody manufacturing facility in its Maryland headquarters to support its clinical programs. The Company also provides outsourced contract development and manufacturing services to its collaborators and other third parties for commercial and clinical products to offset a portion of the operating costs of this facility. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is currently advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. The Company is also actively developing multiple preclinical-stage ADC and next generation T-cell engager programs. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its partners are developing or commercializing product candidates for which the Company retain certain economic rights. These include three products approved by the FDA: MARGENZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (margetuximab-cmkb), an anti-HER2 monoclonal antibody (mAb) that the Company recently sold to a partner, ZYNYZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (retifanlimab-dlwr), an anti-PD-1 mAb that the Company out-licensed; and TZIELD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (teplizumab-mzwv), an anti-CD3 mAb that the Company sold to a partner. The Company is also collaborating with </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead Sciences, Inc. (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead) on the development of MGD024, a bispecific DART antibody targeting CD123 and CD3 that utilizes its next-generation T-cell engager technology, as well as two additional undisclosed pre-clinical DART development programs. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s multiple product candidates currently under development will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future success of the Company is dependent on its ability to identify and develop its product candidates, and ultimately upon its ability to attain profitable operations. The Company has devoted substantially all of its financial resources and efforts to research and development and general and administrative expense to support such research and development. Net losses and negative cash flows have had, and will continue to have, an adverse effect on the Company&#8217;s stockholders&#8217; equity and working capital, and accordingly, its ability to execute its future operating plans.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a biotechnology company, the Company has primarily funded its operations with proceeds from the sale of its common stock in equity offerings and revenue from its multiple collaboration agreements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management regularly reviews the Company&#8217;s available liquidity relative to its operating budget and forecast to monitor the sufficiency of the Company&#8217;s working capital. The Company plans to meet its future operating requirements by generating revenue from current and future strategic collaborations or other arrangements and royalties.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company anticipates continuing to draw upon available sources of capital, including equity and debt instruments, to support its product development activities. If the Company is unable to enter into new arrangements or to perform under current or future agreements or obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of, or eliminate one or more of its product research and development programs or clinical studies, reduce other operating expenses, and/or downsize its organization. Based on the Company&#8217;s most recent cash flow forecast, the Company believes its current resources are sufficient to fund its operating plans for a minimum of twelve months from the date that this Annual Report on Form 10-K was filed.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the other risk factors pertinent to the Company's business, including significant equity market volatility and availability of funding in the biotechnology sector, as well as potential issues in the global economy, credit markets and financial markets as a result of significant worldwide events, including inflation, fluctuating interest rates and geopolitical upheaval, might unfavorably impact the Company's ability to generate such additional funding. Given the uncertainty in the rapidly changing market and economic conditions related to these uncertainties, the Company will continue to evaluate the nature and extent of the impact of these uncertainties on its business and financial position.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited.&#160;All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is developing and commercializing monoclonal antibody-based therapeutics. See Note 13, Segment Reporting, for the Company&#8217;s evaluation of its reportable segment and additional disclosures.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, inventory, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Although actual results could differ from these estimates, management does not believe that such differences would be material.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Marketable Securities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Classification of marketable securities between current and non-current is dependent upon the maturity date at the balance sheet date taking into consideration the Company&#8217;s ability and intent to hold the investment to maturity. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income, along with interest income and amortization of premiums and discounts.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable arise from product sales, amounts due from the Company&#8217;s collaborative partners and contract manufacturing work performed by the Company. The amount from product sales represents amounts due from specialty distributors. Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. No allowance was recorded as of December&#160;31, 2024 or 2023, as the Company has a history of collecting on all outstanding accounts.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8211; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8211; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8211; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#8211; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between levels during the periods presented. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:51.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.612%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.852%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at December&#160;31, 2024</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,428&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,886&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,542&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.108%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at December&#160;31, 2023</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprise</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,043&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,043&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,514&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,665&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,849&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:15pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Total assets measured at fair value at December&#160;31, 2024 includes approximately $83.6 million reported as cash and cash equivalents and $18.8&#160;million reported as marketable securities on the balance sheet.</span></div><div style="margin-bottom:9pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Total assets measured at fair value at December&#160;31, 2023 includes approximately $91.7 million reported as cash and cash equivalents and $128.8&#160;million reported as marketable securities on the balance sheet.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, the Company has not experienced any losses on related accounts to date.&#160;The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The counterparties are various corporations, financial institutions and government agencies of high credit standing.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's revenue relates to agreements with various collaborators, MARGENZA net product sales (prior to the sale to TerSera Therapeutics LLC (TerSera) in November 2024) and&#160;contracts and research grants received from U.S. government agencies.&#160;The following table includes those counterparties that represent more than 10% of total revenue earned in the periods indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:68.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.620%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.620%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incyte Corporation (Incyte)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC (McKesson)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASD Healthcare and Oncology Supply (ASD)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provention Bio, Inc. (Provention)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zai Lab Limited (Zai Lab)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Amount is less than 10% for the period indicated.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes those counterparties that represent more than 10% of accounts receivable at the date indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:72.946%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incyte</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASD</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zai Lab</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Balance is less than 10% as of the date indicated.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company believes regulatory approval is probable and expects future economic benefit from the sales of a product candidate to be realized, the Company capitalizes manufacturing costs (whether internally produced or through third-party contract manufacturing organizations) as inventory. Prior to receiving its first approval from the FDA in December 2020, the Company expensed all costs incurred related to the manufacture of MARGENZA as research and development expense because of the inherent risks associated with the development of a product candidate, the uncertainty about the regulatory approval process and the lack of history for the Company of regulatory approval of drug candidates. Subsequent to FDA approval in December 2020, the Company began capitalizing its MARGENZA third-party contract manufacturing inventory costs. In November 2024, the Company sold global rights to MARGENZA to TerSera. As part of this transaction, the Company transferred all of its inventory to TerSera.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is composed of raw materials, work-in-process, and finished goods, which are goods that are available for sale. The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and third-party contract manufacturing costs, on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess, obsolete or unsaleable inventories to their estimated realizable value in the period in which the impairment is first identified. Such write downs, should they occur, are recorded within the cost of product sales in the statement of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Equipment and Software</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment and software are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred. Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and office equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of lease term or useful life</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 360). ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. For the years ended December&#160;31, 2024, and 2023, the Company determined that there were no impaired assets.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue under ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s (ASC 606) when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Agreements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into licensing agreements that are within the scope of ASC 606, under which it may license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products. The Company may also enter into development and manufacturing service agreements with its collaborators.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each arrangement that results in revenues, the Company identifies all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#8217;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. The Company must develop assumptions that require judgment to determine the standalone selling price in </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">order to account for these agreements. To determine the standalone selling price, the Company&#8217;s assumptions may include (i) the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company grants a license to its intellectual property, it </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determines whether the </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nature of the intellectual property to which the customer will have rights is functional intellectual property (functional IP), which has significant standalone functionality, or symbolic intellectual property (symbolic IP) which does not have significant standalone functionality. Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to the Company&#8217;s intellectual property</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research, Development and/or Manufacturing Services. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promises under the Company&#8217;s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Options. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an arrangement contains customer options, the Company evaluates whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined using assumptions regarding estimated costs, discount rates, post-option development timeline, the probability of technical and regulatory success and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by the Company. The Company accounts for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on ASC 606. The Company accounts for other components based on a reasonable, rational and consistently applied accounting policy election.&#160;Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a complete discussion of accounting for revenue from collaborative and other agreements, see Note 8, Revenue.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product sales, net</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the sale to TerSera, the Company entered into a limited number of arrangements with specialty distributors in the United States to distribute MARGENZA. These arrangements are considered to be contracts with customers and are in the scope of ASC 606. The Company has written contracts with each of its customers that have a single performance obligation - to deliver products upon receipt of a customer order - and these obligations are satisfied when delivery occurs and the customer receives the product. The specialty distributors subsequently resell the Company&#8217;s product to healthcare providers. Product revenue is recorded net of applicable reserves for variable consideration, including discounts and other allowances. Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Variable Consideration. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration. Components of variable consideration typically include discounts, product returns, provider chargebacks and discounts and government rebates. Variable consideration is estimated following the expected value method in accordance with ASC 606 and includes such factors as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Discounts and Service Fees. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may provide customers with discounts which are explicitly stated in the contracts. These discounts are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, these contracts may include written service arrangements whereby the Company pays fees to customers who provide services such as sales order management, data, contract administration and distribution services, at rates which the Company believes to be consistent with fair market value. The Company has determined such services received to date are not distinct from the Company&#8217;s sale of products to its customers and, therefore, these payments have been recorded as a reduction of revenue within the statement of operations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, the Company offers the specialty distributors product return rights pursuant to written contracts and/or Company returned goods policies. The Company estimates the amount of its product sales that may be returned by its customers and records an estimated liability and a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product returns using industry benchmarking as well as other information available, such as visibility into the inventory remaining in the distribution channel, since the Company does not have its own returns experience. The Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provider Chargebacks and Discounts. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks for fees and discounts to healthcare providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. In such cases, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. The reserve for chargebacks is established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer&#8217;s notification to the Company of the resale. Chargebacks consist of credits the Company expects to issue for units that remain in the distribution channel at each reporting period end that the Company expects will be sold to qualified healthcare providers and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to discount and/or rebate obligations under state Medicaid programs, Medicare and contractual agreements with and statutory obligations to certain Federal and State entities. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. The Company&#8217;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer discounts are recorded as a reduction of accounts receivable on the consolidated balance sheets. Allowance for product returns, provider chargebacks, government and other rebates and service fees are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract manufacturing revenue</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements with third parties to manufacture their drug substance at its Good Manufacturing Practice (GMP) facility. The terms of these arrangements can include an upfront payment to the Company to reserve manufacturing capacity, scheduled payments during the manufacturing process and reimbursement for materials used to manufacture product.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue over time on a straight-line basis as the manufacturing services are performed, as the Company believes that its efforts in providing the manufacturing services are incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product are allocated to the related manufacturing activities and are recognized as revenue as those activities occur.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cost of Product Sales</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the sale to TerSera, cost of product sales related to sales of MARGENZA. These costs include material, manufacturing and shipping costs, as well as royalties payable on net sales of MARGENZA and inventory reserves. All product costs incurred prior to FDA approval of MARGENZA in December 2020 were expensed as research and development expense. As a result, cost of product sales was positively impacted as the Company sold through inventory that was expensed prior to FDA approval of MARGENZA. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Manufacturing Services</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of manufacturing services consists of the costs to provide manufacturing services to produce certain bulk drug substance under manufacturing and clinical supply agreements with third parties, including salaries and benefits and related stock-based compensation, materials, overhead and other related costs.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense, Including Clinical Trial Accruals/Expenses</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations (CROs), investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials, including costs incurred under agreements with contract manufacturing organizations (CMOs), and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities. Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expenses are a significant component of research and development expense, and the Company outsources a significant portion of these costs to third parties. Third party clinical trial expenses include investigator fees, site and patient costs, CRO costs, costs for central laboratory testing, data management and CMO costs. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as a prepaid asset or accrued expenses. These third party agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> When evaluating the adequacy of the accrued expenses, management analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement is or contains a lease at the inception of an arrangement under ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For leases where the Company is the lessee, right-of-use (ROU) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term of the lease for which the rate is estimated. Certain adjustments to the ROU asset may be required for items such as initial direct costs paid or incentives received. The lease terms used to calculate the ROU asset and related lease liabilities include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while the expense for finance leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale debt securities.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. All stock options and restricted stock units (RSUs) are excluded from the per share calculations as such securities were anti-dilutive for all periods presented. The following table presents the number of stock options and RSUs that were excluded from the calculation of net loss per share:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:44.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.380%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and RSUs</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,008,511</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,129,251</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,514,013</span></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued Accounting Standards Update (ASU) No. 2024-03, Disaggregation of Income Statement Expense. The standard requires further disaggregation of relevant expense captions in a separate note to the financial statements. The standard is effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is currently assessing the impact of adopting this guidance on its consolidated financial statements.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740). The standard requires disaggregation of the effective rate reconciliation into standard categories, enhances disclosure of income taxes paid, and modifies other income tax-related disclosures. The standard is effective for fiscal years beginning after December 15, 2024. The Company is currently assessing the impact of adopting this guidance on its consolidated financial statements.</span></div><div><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which is intended to improve reportable segment disclosures, primarily through enhanced disclosures about significant segment expenses, as well as how the chief operating decision maker (CODM) uses the reported measure(s) of segment profit or loss in assessing performance. The ASU also requires all annual disclosures currently required by Topic 280 to be included in interim periods. The Company adopted the standard in the fourth quarter of 2024. The adoption did not have a material impact on its consolidated financial statements. See Note 13, Segment Reporting, for additional information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text">Marketable Securities<div style="margin-bottom:9pt;text-indent:31.5pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities as of December&#160;31, 2024 and 2023 were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:49.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,995&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,995&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,823&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,827&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:49.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,043&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,855&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,849&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's available-for-sale securities held at December&#160;31, 2024 and 2023 had contractual maturities of less than one year. All of the Company&#8217;s available-for-sale marketable debt securities in an unrealized loss position as of December&#160;31, 2023 were in a loss position for less than twelve months.&#160;Unrealized losses on available-for-sale debt securities as of December&#160;31, 2023 </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were not </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities. Accordingly, no allowance for credit losses related to the Company's available-for-sale debt securities was recorded for the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded interest income of $5.6 million, $4.0 million and $1.7 million during the years ended December&#160;31, 2024, 2023 and 2022, respectively, which is included in interest and other income on the consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/940-320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph b<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory, Net</a></td>
<td class="text">Inventory, Net<div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company's inventory relates to the manufacturing of MARGENZA. In November 2024, the Company sold global rights to MARGENZA to TerSera. As part of this transaction, the Company transferred all its inventory to TerSera, resulting in no inventory balance on the Company&#8217;s consolidated balance sheet as of December 31, 2024. The following table sets forth the Company's inventory as of December 31, 2023, net of reserves (in thousands):</span></div><div style="margin-top:9pt;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"><tr><td style="width:1.0%"></td><td style="width:76.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.487%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.066%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,221&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to FDA approval of MARGENZA in December 2020, the cost of materials and expenses associated with the manufacturing of MARGENZA were recorded as research and development expense. Subsequent to FDA approval, the Company began capitalizing inventory costs related to the manufacture of MARGENZA. The inventory balance as of December&#160;31, 2023 is net of a reserve of $3.1 million, for unsaleable inventory. These reserves are reflected in cost of product sales during the period they are recorded.   </span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inventory Reserves (in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at Beginning of Year</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions Charged to Expenses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at End of Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December&#160;31, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,119)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,798)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Software<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Equipment and Software</a></td>
<td class="text">Property, Equipment and Software<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment and software consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,661&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,542&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Motor vehicles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,787&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,241&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,687)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,394)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,847&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense related to property, equipment and software for the years ended December&#160;31, 2024, 2023 and 2022 was $7.5 million, $9.6 million and $11.9 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has non-cancelable operating leases for manufacturing, laboratory, office and warehouse space in Maryland. The Company&#8217;s leases each have one or more five-year options to renew</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In October 2024, the Company amended the existing lease for one of its laboratory spaces to extend the lease term through 2029 in exchange for certain concessions from the lessor. This amendment was accounted for as a lease modification, and the right-of-use asset and lease liability were remeasured at the modification date, resulting in an increase to both balances of approximately $3.0 million.</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents supplemental balance sheet information related to operating leases:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2024 and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2023, t</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company made cash payments for operating leases of $3.8 million and $5.9 million, respectively. As of December&#160;31, 2024 and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2023,</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company&#8217;s ROU assets were valued at $24.5 million and $23.8 million, respectively.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost for the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2023 were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.948%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease cost</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,610&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,459&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sublease income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,145)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,109)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,579&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,666&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the maturities of the Company&#8217;s operating lease liabilities were as follows (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.327%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,021)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,461&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-licensing arrangement</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company entered into a non-exclusive license agreement with Synaffix B.V., a Lonza company, (Synaffix) to develop, manufacture and commercialize up to three antibody-drug conjugate targets using Synaffix&#8217;s proprietary technology. The Company made an upfront payment to Synaffix upon contract execution. In March 2023, the Company and Synaffix amended the agreement, adding four additional targets. Assuming all seven targets are successfully developed and commercialized, the Company would be obligated to pay up to $2.8&#160;billion for development, regulatory and sales milestones. Finally, pursuant to the terms of this license agreement, as amended, upon commencement of commercial sales of any products developed from these targets, the Company would be required to pay Synaffix tiered royalties in the low&#8209;single digit percentages on net sales of the respective products. The Company may terminate this agreement at any time with 30 days&#8217; notice to Synaffix. Amounts paid to Synaffix under this agreement are recorded as research and development expense in the consolidated statement of operations. The Company incurred $4.7&#160;million, $2.8&#160;million and $1.0 million in expense under this agreement during the years ended December&#160;31, 2024, 2023 and 2022, respectively. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Litigation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2024, a putative securities class action suit, entitled Crain v. MacroGenics, Inc. (Case No. 24-cv-02184), was filed in the U.S. District Court for the District of Maryland against the Company and Scott Koenig, M.D., Ph.D., the Company&#8217;s President, Chief Executive Officer and a member of the Company&#8217;s Board of Directors, alleging violations of securities laws during 2024. The suit asserted certain claims under Section 10 and Rule 10b-5 of the Securities and Exchange Act of 1934 based on alleged misstatements or omissions concerning the Company's TAMARACK Phase 2 study of vobramitamab duocarmazine in patients with metastatic castration-resistant prostate cancer. On December 20, 2024, the District Court issued an Order dismissing the case, without prejudice.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 9, 2024, a shareholder derivative suit, entitled Gregora v. Heiden et al. (Case No. 24-cv-03546), was filed in the U.S. District Court for the District of Maryland against certain of the Company&#8217;s officers and directors and naming the Company as a nominal defendant. The suit asserts certain claims under Section 10(b) and Rule 10b-5 of the Securities and Exchange Act of 1934 and for breach of fiduciary duty, aiding and abetting breach of fiduciary duty, unjust enrichment, and waste of corporate assets based on the same facts as the Securities Class Action. On March 10, 2025, the plaintiff filed a notice of voluntary dismissal. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 11, 2024, a shareholder derivative suit, entitled Cottle v. MacroGenics, Inc., et al. (Case No. 8:24-cv-03578), was filed in the U.S. District Court for the District of Maryland against the same defendants and alleging similar claims as the Gregora derivative action. On March 20, 2025, the parties filed a stipulation of dismissal without prejudice.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's amended and restated certificate of incorporation authorizes 125,000,000 shares of common stock, and 5,000,000 shares of undesignated preferred stock, both with a par value of $0.01 per share.&#160;There were no shares of undesignated preferred stock issued or outstanding as of December&#160;31, 2024 or 2023. </span></div>In March 2023, the Company entered into a sales agreement with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to $100.0&#160;million through an &#8220;at the market offering&#8221; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended. During the year ended December 31, 2023, the Company sold 95,000 shares of common stock at a weighted average price per share of $6.60, resulting in net proceeds of approximately $0.6&#160;million, net of offering expenses. No shares were sold under the ATM offering during the year ended December 31, 2024.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration and License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock', window );">Revenue</a></td>
<td class="text">Revenue<div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborative and Other Agreements </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incyte Corporation</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incyte License Agreement</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte, which was amended in March 2018, April 2022, July 2022, and July 2024, for retifanlimab, an investigational monoclonal antibody that inhibits PD-1 (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while the Company retains the right to develop its pipeline assets in combination with retifanlimab. Under the terms of the Incyte License Agreement, Incyte paid the Company an upfront payment of $150.0 million in 2017. The Company manufactures a portion of Incyte&#8217;s global commercial supply of retifanlimab. In March 2023, the FDA approved Incyte's Biologics License Application (BLA) for ZYNYZ (retifanlimab-dlwr) for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma. Incyte has stated it is pursuing development of retifanlimab in potentially registration-enabling studies, including in patients with squamous cell carcinoma of the anal canal, MSI-high endometrial cancer and non-small cell lung cancer. Incyte is also pursuing development of retifanlimab in combination with multiple product candidates from its pipeline.  </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Incyte License Agreement, as amended, Incyte will lead global development of retifanlimab. From the inception of the Incyte License Agreement through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has recognized $215.0 million for certain development and regulatory milestones under the Incyte License Agreement, including $15.0 million received following the FDA approval of ZYNYZ and $100.0&#160;million received in August 2024 upon entering into an amendment to the Incyte License Agreement pursuant to which certain development milestones were deemed to have been met. Assuming successful development and commercialization by Incyte in multiple indications, the Company is eligible to receive up to an additional $210.0 million in development and regulatory milestones, and up to $330.0 million in commercial milestones. The Company is also eligible to receive tiered royalties of 15% to 24% on global net sales. The Company retains the right to develop its pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of retifanlimab, subject to the separate commercial supply agreement.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="margin-bottom:9pt;text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Incyte License Agreement under the provisions of ASC 606 at inception and identified the following two performance obligations under the agreement: (i) the license of retifanlimab and (ii) the performance of certain clinical activities through a brief technology transfer period. The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company performed the activities during the transfer period as a matter of convenience. The Company determined that the transaction price of the Incyte License Agreement at inception was $154.0 million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The standalone selling price for the agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. The potential development and regulatory milestone payments are </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. In July 2024, the Company and Incyte executed Amendment No. 4 to the Incyte License Agreement pursuant to which certain development milestones were deemed to have been met. The Company evaluated the amendment as a contract modification under the provisions of ASC 606 which resulted in $100.0&#160;million of revenue being recognized during the year ended December&#160;31, 2024. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From 2018 through December&#160;31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">it became probable that a significant reversal of cumulative revenue would not occur for development milestones totaling </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$215.0 million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to clinical and regulatory activities related to the further advancement of retifanlimab. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therefore</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the associated consideration was added to the estimated transaction price and was recognized as revenue. </span></div><div style="text-indent:42pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$150.0 million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> allocated to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license when it satisfied its performance obligation and transferred the license to Incyte in 2017. The $4.0 million allocated to the clinical activities was recognized ratably as services were performed during 2017 and 2018. The Company recognized revenue of $100.6 million, $15.0 million and $30.0 million under the Incyte License Agreement during the years ended December&#160;31, 2024, 2023 and 2022, respectively. The revenue is primarily related to development milestones and includes royalties on ZYNYZ sales beginning in late 2023.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incyte Clinical Supply Agreement</span></div><div style="text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into an agreement with Incyte, under which the Company is to perform development and manufacturing services for Incyte&#8217;s clinical needs of retifanlimab (Incyte Clinical Supply Agreement). The Company evaluated the Incyte Clinical Supply Agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of retifanlimab. The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services. During the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 2023 and 2022, the Company recognized revenue of $0.2 million, $1.9 million and $0.7 million, respectively, for services performed under the Incyte Clinical Supply Agreement. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incyte Commercial Supply Agreement</span></div><div style="text-indent:42pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company entered into an agreement with Incyte pursuant to which the Company is entitled to manufacture a portion of the global commercial supply needs for retifanlimab (Incyte Commercial Supply Agreement). Unless terminated earlier, the term of the Incyte Commercial Supply Agreement will expire upon the expiration of Incyte&#8217;s obligation to pay royalties under the Incyte License Agreement. The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to manufacturing the commercial supply of retifanlimab. The transaction price is based on a fixed price per batch of bulk drug substance to be manufactured and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor costs incurred) related to the manufacturing services. During the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023, and 2022, the Company recognized revenue of $1.8 million, $4.2&#160;million and $0.3&#160;million, respectively, for services performed under the Incyte Commercial Supply Agreement. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Gilead Sciences, Inc. </span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the Company and Gilead entered into an exclusive option and collaboration agreement (Gilead Agreement) to develop and commercialize MGD024, an investigational, bispecific antibody that binds CD123 and CD3, and create bispecific cancer antibodies using the Company&#8217;s DART platform and undertake their early development under a maximum of two separate bispecific cancer target research programs. Under the agreement, the Company will continue the ongoing phase 1 trial for MGD024 accordi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ng to a development plan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, during which Gilead will have the right to exercise an option granted to Gilead to obtain an exclusive license under the Company&#8217;s intellectual property to develop and commercialize MGD024 and other </span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bispecific antibodies of MacroGenics that bind CD123 and CD3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CD123 Option). The agreement also granted Gilead the right, within its first two years, to nominate a bispecific cancer target set for up to two research programs conducted by the Company and to exercise separate options to obtain an exclusive license for the development, commercialization and exploitation of molecules created under each research program (Research Program Option). Gilead nominated the first of the two research programs in September 2023. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2024, the parties amended the Gilead Agreement to revise certain matters related to intellectual property in the performance of the research plans under the agreement. On August 30, 2024, the parties amended the agreement by entering into a second letter agreement under which Gilead will pay the Company to conduct certain research and which extends the period for Gilead to select its second research target combination.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Gilead Agreement, as amended, in October 2022 Gilead paid the Company an upfront payment of $60.0&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming Gilead exercises the CD123 Option and Research Program Option and successfully develops and commercializes MGD024, or other CD123 products developed under the agreement, and products result from the two additional research programs, the Company would be eligible to receive up to $1.7 billion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in target nomination, option fees, and development, regulatory and commercial milestones. Assuming exercise of the CD123 Option, the Company will also be eligible to receive tiered, low double-digit royalties on worldwide net sales of MGD024 (or other CD123 products developed under the agreement) and assuming exercise of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research Program Option,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a flat royalty on worldwide net sales of any products resulting from the two research programs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Gilead Agreement under the provisions of ASC 606 and identified the following material promises under the agreement: (i) a license to perform any activities allocated to Gilead under the MGD024 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development plan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; (ii) development activities regarding MGD024, including manufacturing, research and early clinical development activities, necessary to deliver an informational package of development and clinical data, information and materials specified in the Gilead Agreement during the period </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which Gilead can exercise the CD123 Option; (iii) the CD123 Option and (iv) the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research Program Option</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the license under the MGD024 developme</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nt plan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and development activities are not distinct from one another, as the license has limited value without the Company&#8217;s performance of the development activities. Therefore, the Company determined that the development term license and development activities should be combined into a single performance obligation (Development Activities). The CD123 Option is considered a material right as the value of the exclusive license exceeds the payment to be made by Gilead if they exercise their option to obtain an exclusive license to develop and commercialize MGD024 or an alternative CD123 product, and is therefore a distinct performance obligation. The Company determined that the Research Program Option does not provide a material right, as there is no discount on its standalone selling price.</span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, the Company determined that the initial transaction price under the Gilead Agreement was $60.0&#160;million, consisting of the upfront, non-refundable payment paid by Gilead. The CD123 Option and Research Program Option payments are excluded from the initial transaction price at contract inception along with any future development, regulatory, and commercial milestone payments (including royalties) following the CD123 Option and Research Program Option exercise.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company reassesses the amount of variable consideration included in the transaction price every reporting period.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:13.5pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated the $60.0&#160;million upfront payment in the transaction price to the Development Activities and the CD123 Option based on each performance obligation&#8217;s relative standalone selling price. The standalone selling price for the Development Activities was calculated using an expected cost-plus margin approach </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the pre-option development timeline.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the standalone selling price of the CD123 Option, the Company utilized an income-based approach which included the following key assumptions:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">post-option development timeline and costs, forecasted revenues, discount rates and probabilities of technical and regulatory success. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is recognizing revenue related to the Development Activities performance obligation over the estimated period to complete the Development Activities using an input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the Development Activities. The Company has deferred revenue recognition related to the CD123 Option. If Gilead exercises the CD123 Option and obtains an exclusive license, the Company will recognize revenue as it fulfills its obligations under the Gilead Agreement. If the CD123 Option is not exercised, the Company will recognize the entirety of the revenue in the period when the CD123 Option expires.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 2023, and 2022, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company recorded revenue of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.5&#160;million,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.5&#160;million, and $0.2&#160;million, respectively, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to the Gilead Agreement. As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$56.8&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in revenue was deferred under this agreement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.3&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was current and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$55.5&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was non-current. As of December&#160;31, 2023, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$58.3&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in revenue was deferred under this agreement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.2&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was current and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$56.1&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was non-current.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company and Gilead executed a Letter Agreement through which Gilead nominated the first of the two research programs contemplated in the Gilead Agreement (First Research Program), the Company granted Gilead a research license, and the parties agreed on a research plan for the First Research Program under which the Company will provide research and development services. Gilead paid the Company a $15.7&#160;million nomination fee. The Company evaluated the Letter Agreement under the terms of ASC 606, and concluded that it is a modification to the Gilead Agreement that results in a separate contract since the modification is for additional goods and services that are distinct and at standalone selling price. The Company determined that the license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that these should be combined into a single performance obligation. Gilead also has the exclusive option to pay the Company $10.0&#160;million to obtain a license to exploit the research molecule and research product with respect to the First Research Program. The Company determined that this exclusive option does not provide a material right, as there is no discount on its standalone selling price.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, the Company determined that the initial transaction price for the First Research Program agreement was $15.7&#160;million, consisting of the non-refundable payment paid by Gilead. The Company is recognizing revenue over the estimated period to complete the services using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the research and development services. In June 2024, the Company received variable consideration totaling $3.3&#160;million from Gilead upon achievement of a research plan milestone. The variable consideration was added to the transaction price and allocated to the performance obligation to determine the amount of related revenue to be recognized. A proportional amount was recognized based on the input cost to cost measurement of work completed to date.   </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023, the Company recorded revenue of $7.8&#160;million and $0.8&#160;million, respectively, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to the First Research Program. As of December&#160;31, 2024, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$11.0&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in revenue was deferred under this agreement, all of which was current</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of December&#160;31, 2023, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$14.9&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in revenue was deferred under this agreement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$11.8&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was current and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.1&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of which was non-current.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zai Lab US LLC</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the Company entered into a collaboration and license agreement with Zai Lab US LLC (Zai Lab Limited and Zai Lab US LLC, either singularly or collectively are referred to herein as Zai Lab) involving collaboration programs and license-only programs (collectively, the Programs) encompassing four separate immuno-oncology molecules (2021 Zai Lab Agreement). During 2022, the Company and Zai Lab agreed to discontinue research and development of the lead program, and in August 2023, the parties mutually agreed to terminate the 2021 Zai Lab Agreement. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the Company received $7.0&#160;million from Zai Lab in fulfillment of a milestone. This was recognized as revenue for the year ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, no revenue was recognized under the 2021 Zai Lab Agreement and during the year ended December 31, 2022, the Company recognized revenue of $16.8 million under the 2021 Zai Lab Agreement. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provention Bio, Inc.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company entered into a license agreement with Provention pursuant to which the Company granted Provention exclusive global rights for the purpose of developing and commercializing MGD010 (renamed PRV-3279), a CD32B x CD79B DART molecule being developed for the treatment of autoimmune indications (Provention License Agreement). As partial consideration for the Provention License Agreement, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of $2.50 per share. If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-3279, the Company will be eligible to receive up to $65.0 million in development and regulatory milestones and up to $225.0 million in commercial milestones. As of December&#160;31, 2024, the Company has not recognized any milestone revenue under this agreement. If commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product. The license agreement may be terminated by either party upon a material breach or bankruptcy of the other party, by Provention without cause upon prior notice to the Company, and by the Company in the event that Provention challenges the validity of any licensed patent under the agreement, but only with respect to the challenged patent.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, in 2018, the Company entered into the Provention Asset Purchase Agreement (Provention APA) pursuant to which Provention acquired the Company&#8217;s interest in teplizumab (renamed PRV-031), a monoclonal antibody being developed for the treatment of type 1 diabetes. As partial consideration for the Provention APA, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of $2.50 per share. Under the Provention APA, Provention is obligated to pay the Company contingent milestone payments totaling $170.0 million upon the achievement of certain regulatory milestones. In addition, Provention is obligated to make contingent milestone payments to the Company </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">totaling $225.0 million upon the achievement of certain commercial milestones as well as single-digit royalties on net sales of the product. The FDA approved the BLA for TZIELD in November 2022, and the Company recognized $60.0 million in revenue related to this regulatory milestone during the year ended December 31, 2022. In November 2022, the Company and Provention amended the Provention APA. Under this amendment, the milestone for first approval was split into four equal payments, all of which were received prior to June 30, 2023. Provention has also agreed to pay third-party obligations, including low single-digit royalties, of which a portion is creditable against royalties payable to the Company, aggregate milestone payments of up to approximately $1.3 million and other consideration, for certain third-party intellectual property under agreements Provention assumed pursuant to the Provention APA. Further, Provention is required to pay the Company a low double-digit percentage of certain consideration to the extent it is received in connection with a future grant of rights to PRV-031 by Provention to a third party.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Provention License Agreement and Provention APA under the provisions of ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: (i) the license of MGD010 and (ii) the title to teplizumab. The Company determined that the transaction price of the Provention agreements was $6.1 million, based on the Black-Scholes valuation of the warrants to purchase a total of 2,432,688 shares of Provention's common stock. The transaction price was allocated to each performance obligation based on the number of shares of common stock the Company is entitled to purchase under each warrant. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such were excluded from the initial transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, therefore they have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. The Company recognized revenue of $6.1 million when it satisfied its performance obligations under the agreements and transferred the MGD010 license and teplizumab assets to Provention in 2018. In 2019, the Company exercised the warrants on a cashless basis, and subsequently sold all the shares of Provention common stock acquired through the exercise. No shares of Provention stock were held subsequent to the sale of stock in 2019. During the year ended December 31, 2022, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">it became probable that a significant reversal of cumulative revenue would not occur for a regulatory milestone of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$60.0 million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">herefore</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the associated consideration was added to the estimated transaction price and was recognized as revenue. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2024, no revenue was recognized under these agreements. During the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022, the Company recognized revenue of $5.6 million and $60.0 million, respectively, under these agreements.   </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the Company sold its single-digit royalty interest in TZIELD to a wholly-owned subsidiary of DRI Healthcare Trust (DRI) and received a $100.0&#160;million payment from DRI under a Royalty Purchase Agreement. The Company retains its other economic interests related to TZIELD, including future potential regulatory and commercial milestones, as well as the right to receive a 50% share of the royalty on global net sales above a certain annual threshold. In addition, the Company received $50.0&#160;million upon the occurrence of the primary endpoint milestone event in September 2023, and remains eligible to receive an additional $50.0&#160;million if TZIELD achieves a certain level of net sales.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 27, 2023, Sanofi S.A. (Sanofi) completed its acquisition of Provention and the Company entered into a Tripartite Agreement. Also on April 27, 2023, the Company and a subsidiary of Sanofi entered into a Side Letter Agreement which specified certain post-closing covenants and also accelerated certain payments due to the Company under the Provention APA upon the closing of the merger between Sanofi and Provention. The Company evaluated the Side Letter Agreement as a contract modification under the provisions of ASC 606. As a result, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December 31, 2023</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recognized $5.5&#160;million related to other consideration under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provention APA</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Side Letter Agreement. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company recognized $0.3&#160;million in royalty revenue under the Provention APA based on sales of TZIELD. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, the Company and Sanofi executed Amendment No. 2 to the Provention APA and terminated the Royalty Purchase Agreement with DRI. As a result, the remaining $50.0&#160;million milestone under the Royalty Purchase Agreement was incorporated into the Provention APA. The Company evaluated the amendment as a contract modification under the provisions of ASC 606 which did not result in any additional revenue being recognized during the year ended December 31, 2023. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing Services Agreements</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incyte </span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company entered into a Manufacturing and Clinical Supply Agreement with Incyte (Incyte Manufacturing and Clinical Supply Agreement) to provide manufacturing services to produce certain Incyte bulk drug </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">substance over a three years period. Under the terms of the Incyte Manufacturing and Clinical Supply Agreement, the Company received an upfront payment of $10.0&#160;million and was eligible to receive annual fixed payments paid quarterly over the term of the contract totaling $14.4&#160;million. The Company will also be reimbursed for materials used to manufacture product as well as other costs incurred to provide manufacturing services. In July 2022, the Company and Incyte executed an amendment to the Incyte Manufacturing and Clinical Supply Agreement which extended the term for one year and provided for an additional annual fixed payment of $5.1&#160;million (July 2022 Incyte Amendment). In December 2024, the Company and Incyte entered into a letter agreement whereby Incyte reserved additional manufacturing services with a fixed cost of $9.1&#160;million (December 2024 Letter Agreement). </span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Incyte Manufacturing and Clinical Supply Agreement, the July 2022 Incyte Amendment and the December 2024 Letter Agreement under the provisions of ASC 606 and identified one performance obligation to provide manufacturing runs to Incyte, as and when requested by Incyte, over the term of the contract that is part of a series of goods and services. The Company determined that the transaction price consisted of the upfront payment of $10.0&#160;million and the fixed payments totaling $28.6&#160;million. The Company is recognizing revenue over time on a straight-line basis as the manufacturing services are provided to Incyte, as the Company determined that its efforts in providing the manufacturing services will be incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product for Incyte will be allocated to the related manufacturing activities and will be recognized as revenue as those activities occur. Materials purchased by the Company to manufacture the product for Incyte are considered costs to fulfill a contract and will be capitalized and expensed as the materials are used to provide the manufacturing services.  </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2024, 2023, and 2022, the Company recognized revenue of $11.0&#160;million, $9.7&#160;million and $8.7&#160;million, respectively, under the Incyte Manufacturing and Clinical Supply Agreement. As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.4&#160;million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in revenue was deferred under this agreement, all of which was current. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$7.0&#160;million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in revenue was deferred under this agreement, all of which was current.</span></div><div style="margin-bottom:9pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales, Net</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales, net reflected sales of MARGENZA until the Company sold global rights to MARGENZA to TerSera in November 2024. Prior to the sale to TerSera, product revenue was recorded net of applicable reserves for variable consideration, including discounts and other allowances. The Company entered into a limited number of arrangements with specialty distributors in the United States to distribute MARGENZA. The delivery of the product represented a single performance obligation for these transactions and the Company recorded net product revenue when control was transferred to the customer, generally upon receipt by the customer. The transaction price for net product revenue represented the amount the Company expected to receive, which was net of estimated government-mandated rebates and chargebacks, distribution fees, estimated product returns, and other deductions. Accruals were established for these deductions, and actual amounts incurred were offset against applicable accruals. The Company recognized net product sales revenue of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$16.4&#160;million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$17.9&#160;million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$16.7&#160;million</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the years ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024, 2023 and 2022, respectively.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the sale of MARGENZA, the Company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">paid an $8.0&#160;million amendment fee to Eversana Life Sciences Services, LLC (Eversana), a former partner that had previously commercialized MARGENZA, which was recorded as selling, general and administrative expense in the consolidated statement of operations. </span></div><div style="margin-bottom:6pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NIAID Contract</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a contract with the National Institute of Allergy and Infectious Diseases (NIAID), effective as of September 15, 2015,&#160;to perform product development and to advance up to two DART molecules, MGD014 and MGD020 (NIAID Contract). Under the NIAID Contract, the Company developed these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID did not receive goods or services from the Company under this contract, therefore the Company did not consider NIAID to be a customer and concluded this contract was outside the scope of ASC 606.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both the Phase 1 study of MGD014 in persons with HIV maintained on antiretroviral therapy and the Phase 1 study of MGD020 alone and combined with MGD014 have been completed and the Company is in the process of closing out the contract. The Company recognized revenue of $1.6 million, $1.6 million and $1.9 million under the NIAID contract during the years ended December&#160;31, 2024, 2023 and 2022, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text">Stock-based Compensation<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company&#8217;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended, and is not subject to the provisions of the Employee Retirement Income Security Act of 1974. The Company reserved 800,000 shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to 10% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for six months offering periods ending on May 31 and November 30 of each year. At the end of each offering period, employees are able to purchase shares at 85% of the fair market value of the Company&#8217;s common stock on the last day of the offering period. During the year ended December&#160;31, 2024, employees purchased 94,619 shares of common stock under the 2016 ESPP for net proceeds to the Company of approximately $0.3&#160;million.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Incentive Plans</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2013, the Company implemented the 2013 Equity Incentive Plan (2013 Plan).&#160;In May 2023, the 2013 Plan was terminated, and no further awards may be issued under the plan. If an option granted under the 2013 Plan expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares will become available for issuance under the 2023 Equity Incentive Plan (2023 Plan). As of December&#160;31, 2024, under the 2013 Plan, there were options to purchase an aggregate of 10,613,229 shares of common stock outstanding at a weighted average exercise price of $14.96 per share. As of December&#160;31, 2024, there were 404,449 unvested RSUs outstanding under the 2013 Plan.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Plan was effective as of stockholder approval in May 2023. The 2023 Plan provides for grants of stock options and other stock-based awards, as well as cash-based performance awards. The 2023 Plan authorized the issuance of up to an aggregate of 4,850,000 shares of common stock. In May 2024, the board and stockholders of the Company approved an amendment to the 2023 Plan to increase the number of shares of common stock available for issuance thereunder by 2,000,000 shares. Accordingly, the maximum number of shares of common stock authorized for issuance under the 2023 Plan is 6,850,000 shares. If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards. As of December&#160;31, 2024, under the 2023 Plan, there were options to purchase an aggregate of 2,326,288 shares of common stock outstanding at a weighted average exercise price of $14.06 per share. As of December&#160;31, 2024, there were 664,545 unvested RSUs outstanding under the 2023 Plan.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following stock-based compensation amounts were recognized for the periods indicated (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,759&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,439&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,373&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,438&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 25, 2024, Dr. Scott Koenig, the President and Chief Executive Officer of the Company and the Company entered into a separation and consulting agreement (the Separation Agreement), which provides for the terms of Dr. Koenig&#8217;s separation from employment, effective February 28, 2025 (the Separation Date). Under the Separation Agreement and in accordance with the terms of his employment agreement, the Company accelerated vesting of 50% of the unvested stock option awards and RSU awards granted to Dr. Koenig during his employment outstanding as of the Separation Date. Additionally, pursuant to the Separation Agreement, following Dr. Koenig&#8217;s Separation Date, Dr. Koenig will serve as an advisor to the Company. As compensation for the advisory services, all remaining unvested option awards and RSU awards as of the Separation Date will continue to vest during the advisory services period. Lastly, all outstanding, accelerated and continued vesting options during the advisory services were amended to extend the exercisability period. The Company evaluated the impacts of the Separation Agreement and the related modifications to Dr. Koenig&#8217;s option awards and RSU awards.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, the Company recognized all additional stock-based compensation expense in 2024 in accordance with ASC Topic 718, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation &#8211; Stock Compensation </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 718) in the amount of $6.1&#160;million. On February 25, 2025, Dr. Koenig and the Company amended the Separation Agreement to extend Dr. Koenig&#8217;s Separation Date to a date to be determined by the Board </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of Directors of the Company as the special executive search committee of the Board of Directors continues its process to identify the next Chief Executive Officer of the Company.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used to estimate the fair value of Dr. Koenig&#8217;s modified awards in 2024 were as follows:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.175%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108% -174%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2% - 4.3%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00 year - 5.50 years</span></div></td></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Options</span></div><div style="text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation to employees and non-employee directors in accordance with ASC 718. The Company estimates the fair value of stock option awards using the Black-Scholes option pricing model on the date of grant using the assumptions in the table below. Stock options granted to employees generally vest over four years and have a term of ten years. Stock-based compensation expense for stock options is recognized as expense over the requisite service period, which is the vesting period. As the Company has not paid dividends since inception, nor does it expect to pay any dividends for the foreseeable future, the expected dividend yield assumption is zero. The expected volatility is based on the historical stock volatility of the Company&#8217;s own common stock over a period equal to the expected term of the options. The risk-free rate of the stock options is based on the U.S. Treasury rate in effect at the time of grant for the expected term of the stock options. The Company calculates expected term based on the historical experience with similar awards, giving consideration to the contractual terms of the share-based awards, vesting schedules and expectations of future employee behavior. In addition, the Company estimates the expected forfeiture rate and only recognizes expense for those shares expected to vest. The Company estimates the forfeiture rate based on historical experience and its expectations regarding future pre-vesting termination behavior of employees. The Company reviews its estimate of the expected forfeiture rate annually, and stock-based compensation expense is adjusted accordingly.</span></div><div style="text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:56.211%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95% -116%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76% - 96%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88% - 92%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5% - 4.7%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5% - 4.8%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4% - 4.0%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.06 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.88 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95 years</span></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for 2024:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contractual Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,223,637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,986,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(333,522)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165,111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(771,669)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,939,517&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December&#160;31, 2024:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,004,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,456,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the total unrecognized compensation expense related to unvested stock options, net of related forfeiture estimates, was approximately $20.1 million, which the Company expects to recognize over a weighted-</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">average period of approximately 1.4 years. The following table summarizes additional information on stock options (in thousands, except per share amounts):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.080%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.454%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock issued with stock options exercises</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,608&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value per share of stock options granted</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intrinsic value of stock options exercised</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash received for stock options exercised</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,128&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant date fair value of stock options vested</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,573&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs are valued based on the closing price of the Company&#8217;s common stock on the date of the grant. The fair value of RSUs is recognized and amortized on a straight-line basis over the requisite service period of the award</span><span style="color:#252525;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity for 2024:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.268%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.954%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679,715&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(483,181)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,154)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,068,994&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2024, there was $6.4 million of total unrecognized compensation cost related to unvested RSUs, which the Company expects to recognize over a remaining weighted-average period of 1.4 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TeSera Transaction<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">TeSera Transaction</a></td>
<td class="text">TerSera Transaction<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2024, the Company entered into an Asset Purchase and Sale Agreement (ASA) with TerSera in which TerSera acquired global rights to MARGENZA. Pursuant to the ASA, the Company received $40.0 million and may also receive up to $35.0 million in future sales milestone payments. The transaction closed in November 2024. In connection with the ASA, the Company also entered into a Master Manufacturing &amp; Supply Agreement (MSA) with TerSera under which it will manufacture MARGENZA product for TerSera, and a Transition Services Agreement under which it will provide certain services to ensure a smooth business transition to TerSera.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the sale of MARGENZA does not qualify for reporting as a discontinued operation since it does not represent a strategic shift that has or will have a major effect on its operations and financial results. The Company determined that the agreements should be accounted for as one single combined contract with multiple elements under which the Company allocated the total consideration of $44.5 million on a relative standalone selling price basis in accordance with the applicable authoritative guidance. The Company recorded a $36.3 million gain on the sale of MARGENZA and related inventory in the &#8220;Gain on Sale of MARGENZA&#8221; line on its consolidated statements of operations and comprehensive loss for the year ended December&#160;31, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/720/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 610<br> -Publisher FASB<br> -URI https://asc.fasb.org/610/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Tax<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024, the Company is in a taxable income position due to the Tax Cuts and Jobs Act of 2017 (the Tax Act) limitation on utilization of Net Operating Losses to 80% of taxable income as well as the limitation on utilization of income tax credits, while the company remains in a full valuation allowance position. For the years ended December&#160;31, 2023, and 2022 there was no provision for income taxes due to taxable losses generated, fully offset by a valuation allowance.</span></div><div style="text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense consists of the following f</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or the year ended</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">944&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the reported estimated income tax expense to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States federal tax at statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,866)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,902)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,149)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes (net of federal benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,183)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,385)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,024&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred state blended rate adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,663)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credit, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,082)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,569)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan drug credit, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,308)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,846)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,257)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense/(benefit)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">944&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal U.S. net operating loss carryforward</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State net operating loss carryforward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credit, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan drug credit, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 174 deferred tax asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,810&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity based compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(401,297)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(365,010)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,402&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,745)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,372)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,155)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,030)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,900)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,402)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax asset/(liability)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes valuation allowances to reduce deferred tax assets to the amount that is more likely than not to be realized. In assessing the likelihood of realization, management considers (i) future reversals of existing taxable temporary </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">differences; (ii) future taxable income exclusive of reversing temporary difference and carryforwards; (iii) taxable income in prior carryback years if carryback is permitted under applicable tax law; and (iv) tax planning strategies. The Company's net deferred income tax asset is not more likely than not to be utilized due to the lack of sufficient sources of future taxable income and cumulative book losses which have resulted over the years.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activity in the valuation allowance on deferred tax assets was as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.862%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at Beginning of Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at End of Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,010&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401,297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,257)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327,592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company has U.S. federal and state net operating loss (NOL) carryforwards of approximately $554.0 million. Of these NOLs, $2.1 million will expire beginning in 2027 through 2028. $551.9 million of NOLs were generated post December 31, 2017 and carryforward indefinitely. In addition, the Company has U.S. federal tax credits of $109.0 million, which will expire in various years beginning in 2027 through 2044.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of the Company's U.S. federal NOL and tax credit carryforwards in future years are restricted due to changes in the Company's ownership and tax attributes acquired through the Company's acquisitions. As of December&#160;31, 2024, $2.1 million of the Company's U.S. Federal NOLs are limited for use over 2027 through 2028, in which a range of such amounts could be utilized on an annual basis of $0.2 million. The remaining $551.9 million of NOLs is not limited and can be offset against future taxable income, subject to certain limitations for newly enacted tax legislation. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning January 1, 2022, the Tax Act eliminated the option to deduct research and development expenditures in the current year and requires taxpayers to capitalize such expenses pursuant to Internal Revenue Code (IRC) Section 174. The capitalized expenses are amortized over a 5-year period for domestic expenses and a 15-year period for foreign expenses.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,821&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,376&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases for current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases/(decreases) for prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(369)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,334&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,821&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,376&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, of the total gross unrecognized tax benefits, approximately $9.3 million and $7.8 million would favorably impact the Company's effective income tax rate, respectively. Although, due to the Company's determination that the deferred income tax asset would not more likely than not be realized, a valuation allowance would be recorded, therefore, zero net impact would result within the Company's effective income tax rate. The Company's uncertain income tax position liability has been recorded to deferred income taxes to offset the tax attribute carryforward amounts.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2024, 2023 and 2022, the Company has not recognized any interest or penalties related to the uncertain income tax positions due to the fact such position is related to tax attribute carryforwards which have not yet been utilized. The Company does not expect its unrecognized income tax position to significantly decrease within the next twelve months.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's U.S. Federal and state income tax returns from 2007 </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forward remain open to examination due to the carryover of unused income tax credits, and from 2007 forward due to the carryover of unused net operating losses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text">Employee Benefit Plan<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2002, the Company established the MacroGenics 401(k) Plan (the Plan) for its employees under Section 401(k) of the IRC. Under this Plan, all employees at least 21 years of age are eligible to participate in the Plan, starting on the first day of employment. Employees may contribute up to 100% of their salary, subject to government maximums.</span></div>Employees are 100% vested in their contributions to the Plan. The Company's contribution to the Plan, as determined by the Board of Directors, is discretionary. For the years ended December&#160;31, 2024, 2023 and 2022, the Company's contributions to the Plan totaled $2.2 million, $2.1 million and $2.3 million, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting Disclosure</a></td>
<td class="text">Segment Reporting<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identifies its reportable segments based on information reviewed by the Company&#8217;s CODM. The Company operates as one operating and reportable segment, which is discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer. The Company has determined its reportable operating segment based on the management approach, which considers the internal organization and reporting used by the Company&#8217;s CODM to make decisions about allocating resources and assessing the Company&#8217;s performance. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance and allocating resources. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CODM uses consolidated net loss, consistent with the amounts reported in the Company&#8217;s consolidated statements of operations to evaluate performance, forecast future period financial results and allocate resources. Total consolidated assets presented in the accompanying consolidated balance sheets also represent the segment&#8217;s total assets.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the significant expenses regularly reviewed by the CODM (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue (a)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,962&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,749&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,941&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of manufacturing sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vobramitamab duocarmazine</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lorigerlimab</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,716&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGC028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical antibody-drug conjugates (ADCs)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGC026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Margetuximab</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGD024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Next-generation T-cell engagers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retifanlimab</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enoblituzumab</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other programs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,047&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,188&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,949&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segment income, net (b)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,966)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,058)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,758)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Total revenue includes collaborative and other agreements, product sales, net, contract manufacturing, and government agreements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Other segment income, net includes the gain on sale of MARGENZA, interest and other income and expense, and income tax expense.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company operates in the United States and all material long-lived assets of the Company reside in the United States For information about the Company&#8217;s revenues, see Note 8, Revenue.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (66,966)<span></span>
</td>
<td class="num">$ (9,058)<span></span>
</td>
<td class="num">$ (119,758)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=mgnx_JamesKarrelsMember', window );">James Karrels [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">James Karrels, Senior Vice President and Chief Financial Officer, adopted a new trading plan on November 21, 2024 (with the first trade possible under the new plan no sooner than April 16, 2025). The trading plan will be effective until April 15, 2026 and covers the potential sale of up to 410,000 shares of common stock.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">James Karrels<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Senior Vice President and Chief Financial Officer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">November 21, 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">April 15, 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">364 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">410,000<span></span>
</td>
<td class="nump">410,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=mgnx_JeffreyPetersMember', window );">Jeffrey Peters [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Jeffrey Peters, Senior Vice President and General Counsel, adopted a new trading plan on November 15, 2024 (with the first trade possible under the new plan no sooner than March 21, 2025). The trading plan will be effective until March 20, 2026 and covers the potential sale of up to 448,881 shares of common stock.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Jeffrey Peters<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Senior Vice President and General Counsel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">November 15, 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">March 20, 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">364 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">448,881<span></span>
</td>
<td class="nump">448,881<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=mgnx_JamesKarrelsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=mgnx_JamesKarrelsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=mgnx_JeffreyPetersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=mgnx_JeffreyPetersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Management and Strategy</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have implemented and maintain various information security processes designed to identify, assess, and manage material risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and clinical trial data (Information Systems and Data).  </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our information security function is led by our Executive Director of Information Technology and supported by the Senior Information Security Manager, our legal team, a management-level Technology Steering Committee, and the Audit Committee of the Board of Directors. This function is responsible for identifying, assessing, and managing the Company&#8217;s cybersecurity threats and risks. We employ various methods to monitor and evaluate the threat environment, including automated tools, subscriptions to cybersecurity threat reports and services, analysis of threats reported to us, evaluations of our and our industry&#8217;s risk profile, threat actor analyses, audits, vulnerability assessments, and tabletop incident response exercises.  </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the environment and system, we implement and maintain various technical, physical, and organizational measures, processes, and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data. These include: an incident response plan and procedures, incident detection and response playbook, business continuity plans, encryption of certain data, network security controls, identity management and access controls, physical security controls, 24/7 systems monitoring, vendor risk management processes, employee cybersecurity and privacy training, penetration testing, cybersecurity insurance, and dedicated cybersecurity staff. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our assessment and management of material risks from cybersecurity threats are integrated into our overall risk management processes. Specifically, (1) cybersecurity risk is addressed as a component of our enterprise risk management program and identified in our risk register; (2) the information security function works with management to prioritize our risk management processes and mitigate cybersecurity threats that are more likely to lead to a material impact to our business; (3) our Technology Steering Committee evaluates material risks from cybersecurity threats against our overall business objectives and reports to the Audit Committee of the board of directors, which evaluates our overall enterprise risk.  </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We engage third-party service providers, including professional services firms, cybersecurity consultants, cybersecurity software providers, managed cybersecurity service providers, penetration testing firms, and dark web monitoring services, to assist in identifying, assessing, and managing material risks from cybersecurity threats.   </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we use third-party service providers to perform a variety of functions throughout our business, such as application providers, hosting companies, CROs, distributors, and supply chain management resources. We have vendor management processes to manage cybersecurity risks associated with our use of certain of these providers, such as reviewing security questionnaires, reviewing the vendor&#8217;s written security program, conducting risk assessments for certain vendors, arranging security assessment calls with the vendor&#8217;s security personnel, reviewing security assessments, or imposing contractual obligations on the vendor. Depending on the nature of the services provided, the sensitivity of the Information </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Systems and Data at issue, and the identity of the provider, our vendor management process may involve different levels of assessment designed to help identify and mitigate cybersecurity risks associated with a provider. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of the risks from cybersecurity threats that may materially affect the Company and how they may do so, see our risk factors under Part 1. Item 1A. Risk Factors in this Annual Report on Form 10-K.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">Our assessment and management of material risks from cybersecurity threats are integrated into our overall risk management processes. Specifically, (1) cybersecurity risk is addressed as a component of our enterprise risk management program and identified in our risk register; (2) the information security function works with management to prioritize our risk management processes and mitigate cybersecurity threats that are more likely to lead to a material impact to our business; (3) our Technology Steering Committee evaluates material risks from cybersecurity threats against our overall business objectives and reports to the Audit Committee of the board of directors, which evaluates our overall enterprise risk.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors addresses the Company&#8217;s cybersecurity risk management as part of its general oversight function. The board of directors&#8217; Audit Committee and management&#8217;s Technology Steering Committee are responsible for overseeing the Company&#8217;s cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">The board of directors&#8217; Audit Committee and management&#8217;s Technology Steering Committee are responsible for overseeing the Company&#8217;s cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">The board of directors&#8217; Audit Committee receives periodic reports from our Vice President Information Technology concerning the Company&#8217;s significant cybersecurity threats and risk and the processes the Company has implemented to address them. The board of directors also receives regular reports, summaries or presentations related to cybersecurity threats, risk, and mitigation.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our Executive Director, Information Technology, who has fourteen years of information security experience and holds a Certified Information Systems Security Professional (CISSP) certification. Our Senior Information Security Manager holds CISSP certification, an MSc. in Information Security, and has over 20 years government and industry cybersecurity experience.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company management is responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company&#8217;s overall risk management strategy, and communicating key priorities to relevant personnel. Company management is also responsible for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports. </span></div>Our cybersecurity incident response processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances and incident severity, including our Executive Director Information Technology who works with the Company&#8217;s incident response team to help the Company mitigate and remediate cybersecurity incidents. In addition, the Company&#8217;s incident response process includes reporting to the audit and technology steering committees of the board of directors for certain cybersecurity incidents.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our Executive Director, Information Technology, who has fourteen years of information security experience and holds a Certified Information Systems Security Professional (CISSP) certification. Our Senior Information Security Manager holds CISSP certification, an MSc. in Information Security, and has over 20 years government and industry cybersecurity experience.</span></div>Company management is responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company&#8217;s overall risk management strategy, and communicating key priorities to relevant personnel. Company management is also responsible for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our Executive Director, Information Technology, who has fourteen years of information security experience and holds a Certified Information Systems Security Professional (CISSP) certification. Our Senior Information Security Manager holds CISSP certification, an MSc. in Information Security, and has over 20 years government and industry cybersecurity experience.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text">Our cybersecurity incident response processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances and incident severity, including our Executive Director Information Technology who works with the Company&#8217;s incident response team to help the Company mitigate and remediate cybersecurity incidents. In addition, the Company&#8217;s incident response process includes reporting to the audit and technology steering committees of the board of directors for certain cybersecurity incidents.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div>The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited.&#160;All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is developing and commercializing monoclonal antibody-based therapeutics. See Note 13, Segment Reporting, for the Company&#8217;s evaluation of its reportable segment and additional disclosures.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, inventory, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Although actual results could differ from these estimates, management does not believe that such differences would be material.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents and Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Marketable Securities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Classification of marketable securities between current and non-current is dependent upon the maturity date at the balance sheet date taking into consideration the Company&#8217;s ability and intent to hold the investment to maturity. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income, along with interest income and amortization of premiums and discounts.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable arise from product sales, amounts due from the Company&#8217;s collaborative partners and contract manufacturing work performed by the Company. The amount from product sales represents amounts due from specialty distributors. Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. No allowance was recorded as of December&#160;31, 2024 or 2023, as the Company has a history of collecting on all outstanding accounts.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8211; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8211; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8211; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#8211; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy. </span>There were no transfers between levels during the periods presented.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, the Company has not experienced any losses on related accounts to date.&#160;The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The counterparties are various corporations, financial institutions and government agencies of high credit standing.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company believes regulatory approval is probable and expects future economic benefit from the sales of a product candidate to be realized, the Company capitalizes manufacturing costs (whether internally produced or through third-party contract manufacturing organizations) as inventory. Prior to receiving its first approval from the FDA in December 2020, the Company expensed all costs incurred related to the manufacture of MARGENZA as research and development expense because of the inherent risks associated with the development of a product candidate, the uncertainty about the regulatory approval process and the lack of history for the Company of regulatory approval of drug candidates. Subsequent to FDA approval in December 2020, the Company began capitalizing its MARGENZA third-party contract manufacturing inventory costs. In November 2024, the Company sold global rights to MARGENZA to TerSera. As part of this transaction, the Company transferred all of its inventory to TerSera.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is composed of raw materials, work-in-process, and finished goods, which are goods that are available for sale. The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and third-party contract manufacturing costs, on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess, obsolete or unsaleable inventories to their estimated realizable value in the period in which the impairment is first identified. Such write downs, should they occur, are recorded within the cost of product sales in the statement of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Equipment and Software</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Equipment and Software</span></div>Property, equipment and software are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment </span>(ASC 360). ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue under ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s (ASC 606) when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Agreements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into licensing agreements that are within the scope of ASC 606, under which it may license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products. The Company may also enter into development and manufacturing service agreements with its collaborators.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each arrangement that results in revenues, the Company identifies all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#8217;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. The Company must develop assumptions that require judgment to determine the standalone selling price in </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">order to account for these agreements. To determine the standalone selling price, the Company&#8217;s assumptions may include (i) the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company grants a license to its intellectual property, it </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determines whether the </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nature of the intellectual property to which the customer will have rights is functional intellectual property (functional IP), which has significant standalone functionality, or symbolic intellectual property (symbolic IP) which does not have significant standalone functionality. Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to the Company&#8217;s intellectual property</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research, Development and/or Manufacturing Services. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promises under the Company&#8217;s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Options. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an arrangement contains customer options, the Company evaluates whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined using assumptions regarding estimated costs, discount rates, post-option development timeline, the probability of technical and regulatory success and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by the Company. The Company accounts for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on ASC 606. The Company accounts for other components based on a reasonable, rational and consistently applied accounting policy election.&#160;Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a complete discussion of accounting for revenue from collaborative and other agreements, see Note 8, Revenue.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product sales, net</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the sale to TerSera, the Company entered into a limited number of arrangements with specialty distributors in the United States to distribute MARGENZA. These arrangements are considered to be contracts with customers and are in the scope of ASC 606. The Company has written contracts with each of its customers that have a single performance obligation - to deliver products upon receipt of a customer order - and these obligations are satisfied when delivery occurs and the customer receives the product. The specialty distributors subsequently resell the Company&#8217;s product to healthcare providers. Product revenue is recorded net of applicable reserves for variable consideration, including discounts and other allowances. Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Variable Consideration. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration. Components of variable consideration typically include discounts, product returns, provider chargebacks and discounts and government rebates. Variable consideration is estimated following the expected value method in accordance with ASC 606 and includes such factors as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer Discounts and Service Fees. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may provide customers with discounts which are explicitly stated in the contracts. These discounts are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, these contracts may include written service arrangements whereby the Company pays fees to customers who provide services such as sales order management, data, contract administration and distribution services, at rates which the Company believes to be consistent with fair market value. The Company has determined such services received to date are not distinct from the Company&#8217;s sale of products to its customers and, therefore, these payments have been recorded as a reduction of revenue within the statement of operations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, the Company offers the specialty distributors product return rights pursuant to written contracts and/or Company returned goods policies. The Company estimates the amount of its product sales that may be returned by its customers and records an estimated liability and a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product returns using industry benchmarking as well as other information available, such as visibility into the inventory remaining in the distribution channel, since the Company does not have its own returns experience. The Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provider Chargebacks and Discounts. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks for fees and discounts to healthcare providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. In such cases, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. The reserve for chargebacks is established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer&#8217;s notification to the Company of the resale. Chargebacks consist of credits the Company expects to issue for units that remain in the distribution channel at each reporting period end that the Company expects will be sold to qualified healthcare providers and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to discount and/or rebate obligations under state Medicaid programs, Medicare and contractual agreements with and statutory obligations to certain Federal and State entities. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. The Company&#8217;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer discounts are recorded as a reduction of accounts receivable on the consolidated balance sheets. Allowance for product returns, provider chargebacks, government and other rebates and service fees are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract manufacturing revenue</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements with third parties to manufacture their drug substance at its Good Manufacturing Practice (GMP) facility. The terms of these arrangements can include an upfront payment to the Company to reserve manufacturing capacity, scheduled payments during the manufacturing process and reimbursement for materials used to manufacture product.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue over time on a straight-line basis as the manufacturing services are performed, as the Company believes that its efforts in providing the manufacturing services are incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product are allocated to the related manufacturing activities and are recognized as revenue as those activities occur.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Product Sales and Cost of Manufacturing Services</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cost of Product Sales</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the sale to TerSera, cost of product sales related to sales of MARGENZA. These costs include material, manufacturing and shipping costs, as well as royalties payable on net sales of MARGENZA and inventory reserves. All product costs incurred prior to FDA approval of MARGENZA in December 2020 were expensed as research and development expense. As a result, cost of product sales was positively impacted as the Company sold through inventory that was expensed prior to FDA approval of MARGENZA. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Manufacturing Services</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of manufacturing services consists of the costs to provide manufacturing services to produce certain bulk drug substance under manufacturing and clinical supply agreements with third parties, including salaries and benefits and related stock-based compensation, materials, overhead and other related costs.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses, Including Clinical Trial Accruals/Expenses</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense, Including Clinical Trial Accruals/Expenses</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations (CROs), investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials, including costs incurred under agreements with contract manufacturing organizations (CMOs), and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities. Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expenses are a significant component of research and development expense, and the Company outsources a significant portion of these costs to third parties. Third party clinical trial expenses include investigator fees, site and patient costs, CRO costs, costs for central laboratory testing, data management and CMO costs. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as a prepaid asset or accrued expenses. These third party agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> When evaluating the adequacy of the accrued expenses, management analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement is or contains a lease at the inception of an arrangement under ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span>. For leases where the Company is the lessee, right-of-use (ROU) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term of the lease for which the rate is estimated. Certain adjustments to the ROU asset may be required for items such as initial direct costs paid or incentives received. The lease terms used to calculate the ROU asset and related lease liabilities include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while the expense for finance leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale debt securities.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div>Basic and diluted loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. All stock options and restricted stock units (RSUs) are excluded from the per share calculations as such securities were anti-dilutive for all periods presented.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued Accounting Standards Update (ASU) No. 2024-03, Disaggregation of Income Statement Expense. The standard requires further disaggregation of relevant expense captions in a separate note to the financial statements. The standard is effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is currently assessing the impact of adopting this guidance on its consolidated financial statements.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740). The standard requires disaggregation of the effective rate reconciliation into standard categories, enhances disclosure of income taxes paid, and modifies other income tax-related disclosures. The standard is effective for fiscal years beginning after December 15, 2024. The Company is currently assessing the impact of adopting this guidance on its consolidated financial statements.</span></div><div><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which is intended to improve reportable segment disclosures, primarily through enhanced disclosures about significant segment expenses, as well as how the chief operating decision maker (CODM) uses the reported measure(s) of segment profit or loss in assessing performance. The ASU also requires all annual disclosures currently required by Topic 280 to be included in interim periods. The Company adopted the standard in the fourth quarter of 2024. The adoption did not have a material impact on its consolidated financial statements. See Note 13, Segment Reporting, for additional information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org/705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-15<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Fair Value Measurement Financial Assets</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:51.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.612%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.852%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at December&#160;31, 2024</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,428&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,886&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,542&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.108%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at December&#160;31, 2023</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprise</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,043&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,043&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,514&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,665&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,849&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:15pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Total assets measured at fair value at December&#160;31, 2024 includes approximately $83.6 million reported as cash and cash equivalents and $18.8&#160;million reported as marketable securities on the balance sheet.</span></div><div style="margin-bottom:9pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Total assets measured at fair value at December&#160;31, 2023 includes approximately $91.7 million reported as cash and cash equivalents and $128.8&#160;million reported as marketable securities on the balance sheet.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Summary of Percentage of Customer Concentration</a></td>
<td class="text">The following table includes those counterparties that represent more than 10% of total revenue earned in the periods indicated:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:68.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.620%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.620%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incyte Corporation (Incyte)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC (McKesson)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASD Healthcare and Oncology Supply (ASD)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provention Bio, Inc. (Provention)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zai Lab Limited (Zai Lab)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td></tr></table><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Amount is less than 10% for the period indicated.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes those counterparties that represent more than 10% of accounts receivable at the date indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:72.946%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incyte</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASD</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Zai Lab</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Balance is less than 10% as of the date indicated.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock', window );">Estimated Useful Lives</a></td>
<td class="text">Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:<div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and office equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of lease term or useful life</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Stock Options and RSUs Excluded from the Calculation of Net Loss Per Share</a></td>
<td class="text">The following table presents the number of stock options and RSUs that were excluded from the calculation of net loss per share:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:44.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.380%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and RSUs</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,008,511</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,129,251</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,514,013</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property plant and equipment estimated useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-16<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Available-for-sale</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:31.5pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale marketable securities as of December&#160;31, 2024 and 2023 were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:49.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,995&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,995&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,823&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,827&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:49.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,043&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,855&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,849&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current</a></td>
<td class="text">The following table sets forth the Company's inventory as of December 31, 2023, net of reserves (in thousands):<div style="margin-top:9pt;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"><tr><td style="width:1.0%"></td><td style="width:76.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.487%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.066%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,221&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ScheduleOfInventoryReservesTableTextBlock', window );">Schedule of Inventory Reserves</a></td>
<td class="text"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inventory Reserves (in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at Beginning of Year</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions Charged to Expenses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at End of Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December&#160;31, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,119)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,798)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ScheduleOfInventoryReservesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Inventory Reserves</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ScheduleOfInventoryReservesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Software (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment and software consists of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,661&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,542&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Motor vehicles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,787&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,241&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,687)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,394)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,847&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock', window );">Schedule Of Supplemental Balance Sheet Information, Operating Leases</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents supplemental balance sheet information related to operating leases:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost for the years ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2023 were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.948%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease cost</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,610&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,459&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sublease income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,145)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,109)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,579&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,666&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the maturities of the Company&#8217;s operating lease liabilities were as follows (in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.327%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,021)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,461&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Supplemental Balance Sheet Information, Operating Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following stock-based compensation amounts were recognized for the periods indicated (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,759&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,439&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,373&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,438&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ScheduleOfShareBasedPaymentAwardModifiedAwardsValuationAssumptionsTableTextBlock', window );">Schedule of Share-Based Payment Award, Modified Awards, Valuation Assumptions</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used to estimate the fair value of Dr. Koenig&#8217;s modified awards in 2024 were as follows:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.175%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108% -174%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2% - 4.3%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00 year - 5.50 years</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Employee Stock Options Award Valuation Assumptions</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:56.211%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95% -116%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76% - 96%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88% - 92%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5% - 4.7%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5% - 4.8%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4% - 4.0%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.06 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.88 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95 years</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for 2024:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contractual Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,223,637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,986,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(333,522)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165,111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(771,669)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,939,517&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December&#160;31, 2024:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,004,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,456,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of RSU Activity</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity for 2024:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.268%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.954%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679,715&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(483,181)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,154)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,068,994&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ScheduleOfShareBasedPaymentAwardModifiedAwardsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions for Dr. Scott Koening</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ScheduleOfShareBasedPaymentAwardModifiedAwardsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense consists of the following f</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or the year ended</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.747%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">944&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Reported Estimated Income Tax Benefit</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the reported estimated income tax expense to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States federal tax at statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,866)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,902)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,149)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes (net of federal benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,183)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,385)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,024&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred state blended rate adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,663)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credit, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,082)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,569)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan drug credit, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,308)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,846)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,257)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense/(benefit)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">944&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of the Company's Deferred Income Tax Assets (Liabilities)</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal U.S. net operating loss carryforward</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State net operating loss carryforward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credit, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Orphan drug credit, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 174 deferred tax asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,810&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity based compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(401,297)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(365,010)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,402&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,745)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,372)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,155)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,030)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,900)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,402)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax asset/(liability)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Summary of Valuation Allowance</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activity in the valuation allowance on deferred tax assets was as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.862%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at Beginning of Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at End of Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,010&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401,297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,257)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327,592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,821&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,376&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases for current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases/(decreases) for prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(369)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,334&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,821&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,376&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the significant expenses regularly reviewed by the CODM (in thousands):</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue (a)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,962&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,749&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,941&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of manufacturing sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vobramitamab duocarmazine</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lorigerlimab</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,716&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGC028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical antibody-drug conjugates (ADCs)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGC026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Margetuximab</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MGD024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Next-generation T-cell engagers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retifanlimab</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enoblituzumab</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other programs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,047&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,188&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,949&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segment income, net (b)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,966)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,058)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,758)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Total revenue includes collaborative and other agreements, product sales, net, contract manufacturing, and government agreements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Other segment income, net includes the gain on sale of MARGENZA, interest and other income and expense, and income tax expense.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Operations (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">53 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>productCandidate</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NumberOfProductCandidatesApprovedByTheFoodAndDrugAdministration', window );">Number of product candidates approved by the FDA</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NonDilutiveFunding', window );">Non-dilutive funding | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NumberOfProprietaryProductCandidatesAdvancingInClinicalDevelopment', window );">Number of proprietary product candidates advancing in clinical development</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonDilutiveFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-dilutive funding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonDilutiveFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfProductCandidatesApprovedByTheFoodAndDrugAdministration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Product Candidates Approved By The Food And Drug Administration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfProductCandidatesApprovedByTheFoodAndDrugAdministration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfProprietaryProductCandidatesAdvancingInClinicalDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Proprietary Product Candidates Advancing In Clinical Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfProprietaryProductCandidatesAdvancingInClinicalDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Accounts receivable, allowance for credit loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 83,600<span></span>
</td>
<td class="nump">$ 91,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">18,827<span></span>
</td>
<td class="nump">128,849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="nump">18,827<span></span>
</td>
<td class="nump">128,849<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">102,428<span></span>
</td>
<td class="nump">220,514<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">67,886<span></span>
</td>
<td class="nump">91,665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">31,179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">3,994<span></span>
</td>
<td class="nump">45,043<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">25,548<span></span>
</td>
<td class="nump">52,627<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">67,886<span></span>
</td>
<td class="nump">91,665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">67,886<span></span>
</td>
<td class="nump">91,665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1 | U.S Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1 | Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">34,542<span></span>
</td>
<td class="nump">128,849<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2 | U.S Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">31,179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2 | Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">3,994<span></span>
</td>
<td class="nump">45,043<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">$ 25,548<span></span>
</td>
<td class="nump">$ 52,627<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(h))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned and Accounts Receivable (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Sales revenue, net | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="nump">76.00%<span></span>
</td>
<td class="nump">53.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Sales revenue, net | McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Sales revenue, net | ASD Healthcare and Oncology Supply</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Sales revenue, net | Provention Bio, Inc. (Provention)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">43.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Sales revenue, net | Zai Lab Limited (Zai Lab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts receivable | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="nump">39.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts receivable | McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts receivable | Cardinal Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts receivable | ASD Healthcare and Oncology Supply</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts receivable | Zai Lab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_IncyteCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_IncyteCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_ASDHealthcareAndOncologySupplyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_ASDHealthcareAndOncologySupplyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_ProventionBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_ProventionBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_ZaiLabLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_ZaiLabLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_CardinalHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_CardinalHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=mgnx_ZaiLabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=mgnx_ZaiLabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Estimated Useful Lives (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_LaboratoryAndOfficeEquipmentMember', window );">Laboratory and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_LaboratoryAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_LaboratoryAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_StockOptionsAndRestrictedStockUnitsMember', window );">Stock options and RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive stock options</a></td>
<td class="nump">14,008,511<span></span>
</td>
<td class="nump">13,129,251<span></span>
</td>
<td class="nump">10,514,013<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_StockOptionsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgnx_StockOptionsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 18,823<span></span>
</td>
<td class="nump">$ 128,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">18,827<span></span>
</td>
<td class="nump">128,849<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,995<span></span>
</td>
<td class="nump">45,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,995<span></span>
</td>
<td class="nump">45,043<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">16,828<span></span>
</td>
<td class="nump">52,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 16,832<span></span>
</td>
<td class="nump">$ 52,627<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities - Available-For-Sale Securities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Debt Securities, Available-for-sale, Allowance for Credit Loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest Income, Other</a></td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory, Net - Schedule of Inventory (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 261,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">960,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,221,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory valuation reserves</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_InventoryValuationReserveMember', window );">SEC Schedule, 12-09, Reserve, Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at Beginning of Year</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,119<span></span>
</td>
<td class="nump">$ 4,917<span></span>
</td>
<td class="nump">$ 2,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Additions Charged to Expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Deductions</a></td>
<td class="num">(3,119)<span></span>
</td>
<td class="num">(1,798)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at End of Year</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,119<span></span>
</td>
<td class="nump">$ 4,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_InventoryValuationReserveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_InventoryValuationReserveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Software (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">$ 106,787<span></span>
</td>
<td class="nump">$ 110,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">1,216<span></span>
</td>
<td class="nump">1,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(88,687)<span></span>
</td>
<td class="num">(88,394)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment and software, net</a></td>
<td class="nump">18,100<span></span>
</td>
<td class="nump">21,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">7,500<span></span>
</td>
<td class="nump">9,600<span></span>
</td>
<td class="nump">$ 11,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">3,661<span></span>
</td>
<td class="nump">3,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">10,926<span></span>
</td>
<td class="nump">9,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_FurnitureAndOfficeEquipmentMember', window );">Furniture and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">697<span></span>
</td>
<td class="nump">706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Motor vehicles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">46,140<span></span>
</td>
<td class="nump">46,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">$ 44,097<span></span>
</td>
<td class="nump">$ 48,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease', window );">Right of use asset and lease liability increase</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average lease term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Discount rate</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease payments</a></td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="nump">$ 5,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, ROU Assets</a></td>
<td class="nump">24,509<span></span>
</td>
<td class="nump">23,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">6,610<span></span>
</td>
<td class="nump">7,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">1,114<span></span>
</td>
<td class="nump">1,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease Income</a></td>
<td class="num">(1,145)<span></span>
</td>
<td class="num">(1,109)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease, cost</a></td>
<td class="nump">6,579<span></span>
</td>
<td class="nump">7,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">5,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">5,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">6,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">7,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">6,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">39,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">70,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(33,021)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">37,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 177,194<span></span>
</td>
<td class="nump">166,583<span></span>
</td>
<td class="nump">$ 207,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_SynaffixBVMember', window );">Synaffix B.V.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 4,700<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Development and Regulatory Milestone Payments Under Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RightOfUseAssetAndLeaseLiabilityIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right of Use asset and Lease Liability Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RightOfUseAssetAndLeaseLiabilityIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_SynaffixBVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_SynaffixBVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mgnx_UndesignatedPreferredStockMember', window );">Undesignated Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Undesignated preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Undesignated preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Undesignated preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Undesignated preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember', window );">At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CommonStockMaximumAmountAvailableForIssuance', window );">Common stock maximum amount available for issuance</a></td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">95,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of common stock (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds of stock sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CommonStockMaximumAmountAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Maximum Amount Available For Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CommonStockMaximumAmountAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mgnx_UndesignatedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mgnx_UndesignatedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Incyte Corporation (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
<th class="th" colspan="1">87 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>performanceObligation</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,962<span></span>
</td>
<td class="nump">$ 58,749<span></span>
</td>
<td class="nump">$ 151,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember', window );">Incyte MGA012 Agreement | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Amounts recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 215,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NumberOfPerformanceObligations', window );">Number of performance obligations | performanceObligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount', window );">Clinical trial activities selling price amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Incyte MGA012 Agreement | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Incyte MGA012 Agreement | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 330,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte MGA012 Agreement | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,600<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte MGA012 Supply Agreement | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte MGA012 Clinical Services | Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement Transaction Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development And Regulatory Milestone Payments Under Agreement, Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Commercial Milestone Payments Under Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialCommercialMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Development and Regulatory Milestone Payments Under Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Royalties, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteClinicalSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteClinicalSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteCommercialSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteCommercialSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Gilead Sciences Inc (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 14, 2022</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,962<span></span>
</td>
<td class="nump">$ 58,749<span></span>
</td>
<td class="nump">$ 151,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_GileadMember', window );">Gilead | 2022 Gilead Collaboration And License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments', window );">Target nomination, option fees and milestone</a></td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,800<span></span>
</td>
<td class="nump">58,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,500<span></span>
</td>
<td class="nump">56,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_GileadMember', window );">Gilead | Gilead First Research Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,800<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="nump">14,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_OptionToBuy', window );">Option to buy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with Customer, Liability, Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OptionToBuy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option to buy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OptionToBuy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential target, nomination, option fees and milestone payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_GileadMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_GileadMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2022GileadCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2022GileadCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_GileadFirstResearchProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_GileadFirstResearchProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Zai Lab (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 149,962,000<span></span>
</td>
<td class="nump">$ 58,749,000<span></span>
</td>
<td class="nump">$ 151,941,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember', window );">2021 Zai Lab Agreements | Zai Lab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 16,800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_A2021ZaiLabAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_ZaiLabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_ZaiLabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Provention (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 08, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_GainOnRoyaltyMonetizationArrangement', window );">Gain on royalty monetization arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 150,930,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,962,000<span></span>
</td>
<td class="nump">58,749,000<span></span>
</td>
<td class="nump">151,941,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_ProventionBioMember', window );">Provention Bio, Inc. (Provention)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares', window );">Stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,432,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_ProventionBioMember', window );">Provention Bio, Inc. (Provention) | Revenues From License Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_ProventionBioMember', window );">Provention Bio, Inc. (Provention) | Provention PRV3279 | Provention License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare', window );">Consideration received common stock warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_ProventionBioMember', window );">Provention Bio, Inc. (Provention) | Provention PRV031 | Asset Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare', window );">Consideration received common stock warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Amounts recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement', window );">Potential milestone payment to third parties for intellectual property under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">5,600,000<span></span>
</td>
<td class="nump">$ 60,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_ProventionBioMember', window );">Provention Bio, Inc. (Provention) | Provention PRV031 | Side Letter Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_ProventionBioMember', window );">Provention Bio, Inc. (Provention) | Provention PRV031 | Provention APA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_DRIHealthcareAcquisitionsLPDRIMember', window );">DRI Healthcare Acquisitions LP (DRI)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_GainOnRoyaltyMonetizationArrangement', window );">Gain on royalty monetization arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_UpfrontPayment', window );">Upfront payment from DRI Health Trust</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties percent</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_AdditionalTZIELDMilestones', window );">Additional TZIELD Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalTZIELDMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional TZIELD Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_AdditionalTZIELDMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement Transaction Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development And Regulatory Milestone Payments Under Agreement, Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_GainOnRoyaltyMonetizationArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on royalty monetization arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_GainOnRoyaltyMonetizationArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Commercial Milestone Payments Under Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialCommercialMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Development and Regulatory Milestone Payments Under Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Royalties, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_ProventionBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_ProventionBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV3279Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV3279Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgnx_ProventionLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgnx_ProventionLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgnx_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgnx_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgnx_SideLetterAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgnx_SideLetterAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgnx_ProventionAPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgnx_ProventionAPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_DRIHealthcareAcquisitionsLPDRIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_DRIHealthcareAcquisitionsLPDRIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Manufacturing Service Agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">30 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,962<span></span>
</td>
<td class="nump">$ 58,749<span></span>
</td>
<td class="nump">$ 151,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,426<span></span>
</td>
<td class="nump">17,939<span></span>
</td>
<td class="nump">16,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember', window );">Incyte Corporation (Incyte) | RevenuesFromCMOAgreementsMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_TotalFixedPayments', window );">Total annual fixed payments</a></td>
<td class="nump">$ 14,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="nump">9,700<span></span>
</td>
<td class="nump">$ 8,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember', window );">Incyte Corporation (Incyte) | RevenuesFromCMOAmendmentAgreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_TotalFixedPayments', window );">Total annual fixed payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_AdditionalAnnualFixedPayments', window );">Additional annual fixed payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_FutureManufacturingRevenue', window );">Future Manufacturing Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember', window );">Incyte Corporation (Incyte) | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborativeArrangementTerm', window );">Collaborative arrangement, term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CollaborativeArrangementExtensionTerm', window );">Collaborative arrangement, extension term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalAnnualFixedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Annual Fixed Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_AdditionalAnnualFixedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeArrangementExtensionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Extension Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeArrangementExtensionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeArrangementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeArrangementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_FutureManufacturingRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future Manufacturing Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_FutureManufacturingRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_TotalFixedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Fixed Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_TotalFixedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromCMOAgreementsMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromCMOAgreementsMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromCMOAmendmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromCMOAmendmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - NIAID Contract (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 149,962,000<span></span>
</td>
<td class="nump">$ 58,749,000<span></span>
</td>
<td class="nump">$ 151,941,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromGrantsMember', window );">RevenuesFromGrantsMember | NIAID</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_NumberOfProductCandidates', window );">Number of product candidates to develop</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfProductCandidates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Product Candidates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfProductCandidates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Product Sales (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,962<span></span>
</td>
<td class="nump">$ 58,749<span></span>
</td>
<td class="nump">$ 151,941<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_TerSeraMember', window );">TerSera</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_AmendmentFeeToCommercializationPartner', window );">Commercialization partner payments</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AmendmentFeeToCommercializationPartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amendment Fee to Commercialization Partner</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_AmendmentFeeToCommercializationPartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_TerSeraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_TerSeraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 25, 2024</div></th>
<th class="th"><div>May 31, 2024</div></th>
<th class="th"><div>May 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>May 23, 2024</div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 18, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 616<span></span>
</td>
<td class="nump">$ 1,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,939,517<span></span>
</td>
<td class="nump">12,223,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.80<span></span>
</td>
<td class="nump">$ 15.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingPercentageOfUnvestedAwards', window );">Accelerated vesting, percentage of unvested awards</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 21 days<span></span>
</td>
<td class="text">5 years 10 months 17 days<span></span>
</td>
<td class="text">5 years 11 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost', window );">Share-Based Payment Arrangement, Accelerated Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
<td class="nump">88.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116.00%<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.70%<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_DrScottKoenigMember', window );">Dr Scott Koenig</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_DrScottKoenigMember', window );">Dr Scott Koenig | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_DrScottKoenigMember', window );">Dr Scott Koenig | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod', window );">Offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options granted, maximum term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding nonvested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,068,994<span></span>
</td>
<td class="nump">905,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember', window );">2016 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation, number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum employee contribution percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percent of fair market value to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock purchased by employees (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2023MemberMember', window );">StockIncentivePlan2023Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation, number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,850,000<span></span>
</td>
<td class="nump">4,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,326,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding nonvested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">664,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member', window );">Stock Incentive Plan 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,613,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding nonvested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">404,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingPercentageOfUnvestedAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Accelerated Vesting, Percentage Of Unvested Awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingPercentageOfUnvestedAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_DrScottKoenigMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_DrScottKoenigMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2023MemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2023MemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 29,439<span></span>
</td>
<td class="nump">$ 18,373<span></span>
</td>
<td class="nump">$ 20,438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">11,759<span></span>
</td>
<td class="nump">9,190<span></span>
</td>
<td class="nump">10,094<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 17,680<span></span>
</td>
<td class="nump">$ 9,183<span></span>
</td>
<td class="nump">$ 10,344<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Option Pricing Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 21 days<span></span>
</td>
<td class="text">5 years 10 months 17 days<span></span>
</td>
<td class="text">5 years 11 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_DrScottKoenigMember', window );">Dr Scott Koenig</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
<td class="nump">88.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Dr Scott Koenig</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">108.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">116.00%<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.70%<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Dr Scott Koenig</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">174.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_DrScottKoenigMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_DrScottKoenigMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning Balance (in shares)</a></td>
<td class="nump">12,223,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">1,986,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(333,522)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited or expired (in shares)</a></td>
<td class="num">(165,111)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(771,669)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending Balance (in shares)</a></td>
<td class="nump">12,939,517<span></span>
</td>
<td class="nump">12,223,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">9,004,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">12,456,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning Balance (in dollars per share)</a></td>
<td class="nump">$ 15.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">15.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">9.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited or expired (in dollars per share)</a></td>
<td class="nump">11.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share)</a></td>
<td class="nump">25.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending Balance (in dollars per share)</a></td>
<td class="nump">14.80<span></span>
</td>
<td class="nump">$ 15.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">16.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">$ 14.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual term, Outstanding</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual term, Exercisable</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual term, Vested and expected to vest</a></td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Outstanding</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, Exercisable</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, Vested and expected to vest</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">333,522<span></span>
</td>
<td class="nump">34,608<span></span>
</td>
<td class="nump">120,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from exercise of stock options</a></td>
<td class="nump">$ 3,128<span></span>
</td>
<td class="nump">$ 129<span></span>
</td>
<td class="nump">$ 172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of options granted (in dollars per share)</a></td>
<td class="nump">$ 12.61<span></span>
</td>
<td class="nump">$ 3.83<span></span>
</td>
<td class="nump">$ 6.84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value</a></td>
<td class="nump">$ 2,617<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">$ 634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of shares vested</a></td>
<td class="nump">17,992<span></span>
</td>
<td class="nump">$ 16,435<span></span>
</td>
<td class="nump">$ 19,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to non-vested stock-based compensation arrangements</a></td>
<td class="nump">$ 20,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period</a></td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member', window );">Stock Incentive Plan 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending Balance (in shares)</a></td>
<td class="nump">10,613,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending Balance (in dollars per share)</a></td>
<td class="nump">$ 14.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance (in shares)</a></td>
<td class="nump">404,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance (in shares)</a></td>
<td class="nump">905,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">679,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(483,181)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(33,154)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance (in shares)</a></td>
<td class="nump">1,068,994<span></span>
</td>
<td class="nump">905,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning Balance (in dollars per share)</a></td>
<td class="nump">$ 5.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">16.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Exercised (in dollars per share)</a></td>
<td class="nump">6.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited or expired (in dollars per share)</a></td>
<td class="nump">13.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending Balance (in dollars per share)</a></td>
<td class="nump">$ 11.97<span></span>
</td>
<td class="nump">$ 5.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period</a></td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards granted in period (in shares)</a></td>
<td class="nump">679,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Total unrecognized compensation cost</a></td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TeSera Transaction (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,962<span></span>
</td>
<td class="nump">$ 58,749<span></span>
</td>
<td class="nump">$ 151,941<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_TerSeraMember', window );">TerSera</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_FutureMilestone', window );">Milestone from DRI</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other Income</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_TerSeraMember', window );">TerSera | Combined Services Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_FutureMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future Milestone</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_FutureMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_TerSeraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_TerSeraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_CombinedServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_CombinedServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Provision for federal or state income taxes</a></td>
<td class="nump">$ 944,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Gross unrecognized tax benefits</a></td>
<td class="nump">9,300,000<span></span>
</td>
<td class="nump">7,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized interest or penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember', window );">U.S. Federal and State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards</a></td>
<td class="nump">554,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationAmountUtilizableOnAnnualBasis', window );">Net operating loss carryforwards, amount utilizable on annual basis</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember', window );">U.S. Federal and State | Tax Year 2025 To 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards</a></td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember', window );">U.S. Federal and State | Indefinite</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards</a></td>
<td class="nump">551,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. Federal Government | Tax Year 2027 To 2044</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">US Federal tax credits carry forward</a></td>
<td class="nump">$ 109,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationAmountUtilizableOnAnnualBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Loss Carryforwards, Subject To Expiration, Amount Utilizable On Annual Basis</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationAmountUtilizableOnAnnualBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=mgnx_TaxYear2027To2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=mgnx_TaxYear2027To2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=mgnx_IndefiniteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=mgnx_IndefiniteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=mgnx_TaxYear2027To2044Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=mgnx_TaxYear2027To2044Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred income tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal U.S. net operating loss carryforward</a></td>
<td class="nump">$ 116,341<span></span>
</td>
<td class="nump">$ 140,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforward</a></td>
<td class="nump">31,758<span></span>
</td>
<td class="nump">33,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit, net</a></td>
<td class="nump">79,108<span></span>
</td>
<td class="nump">68,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther', window );">Orphan drug credit, net</a></td>
<td class="nump">33,834<span></span>
</td>
<td class="nump">33,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">10,308<span></span>
</td>
<td class="nump">9,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">18,795<span></span>
</td>
<td class="nump">17,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_Section174DeferredTaxAsset', window );">Section 174 deferred tax asset</a></td>
<td class="nump">98,810<span></span>
</td>
<td class="nump">48,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Depreciation</a></td>
<td class="nump">16,272<span></span>
</td>
<td class="nump">16,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">4,971<span></span>
</td>
<td class="nump">6,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred income tax assets</a></td>
<td class="nump">410,197<span></span>
</td>
<td class="nump">373,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(401,297)<span></span>
</td>
<td class="num">(365,010)<span></span>
</td>
<td class="num">$ (372,267)<span></span>
</td>
<td class="num">$ (327,592)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred income tax assets</a></td>
<td class="nump">8,900<span></span>
</td>
<td class="nump">8,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred income tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets', window );">Operating lease ROU assets</a></td>
<td class="num">(6,745)<span></span>
</td>
<td class="num">(6,372)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenditures</a></td>
<td class="num">(2,155)<span></span>
</td>
<td class="num">(2,030)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred income tax liabilities</a></td>
<td class="num">(8,900)<span></span>
</td>
<td class="num">(8,402)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred income tax asset/(liability)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Operating Lease Right Of Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_Section174DeferredTaxAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Section 174 deferred tax asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_Section174DeferredTaxAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Valuation Allowance Activity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ValuationAllowanceRollForward', window );"><strong>Valuation Allowance [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance at Beginning of Year</a></td>
<td class="nump">$ 365,010<span></span>
</td>
<td class="nump">$ 372,267<span></span>
</td>
<td class="nump">$ 327,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ValuationAllowanceDeferredTaxAssetIncreaseAmount', window );">Additions</a></td>
<td class="nump">36,287<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">44,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_ValuationAllowanceDeferredTaxAssetDecreaseAmount', window );">Deductions</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,257)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance at End of Year</a></td>
<td class="nump">$ 401,297<span></span>
</td>
<td class="nump">$ 365,010<span></span>
</td>
<td class="nump">$ 372,267<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ValuationAllowanceDeferredTaxAssetDecreaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance, Deferred Tax Asset, Decrease, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ValuationAllowanceDeferredTaxAssetDecreaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ValuationAllowanceDeferredTaxAssetIncreaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance, Deferred Tax Asset, Increase, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ValuationAllowanceDeferredTaxAssetIncreaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ValuationAllowanceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ValuationAllowanceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">United States federal tax at statutory rate</a></td>
<td class="num">$ (13,866)<span></span>
</td>
<td class="num">$ (1,902)<span></span>
</td>
<td class="num">$ (25,149)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes (net of federal benefit)</a></td>
<td class="num">(4,183)<span></span>
</td>
<td class="num">(163)<span></span>
</td>
<td class="num">(7,385)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount', window );">Deferred income tax adjustments</a></td>
<td class="num">(7,299)<span></span>
</td>
<td class="nump">5,024<span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount', window );">Deferred state blended rate adjustments</a></td>
<td class="num">(2,663)<span></span>
</td>
<td class="nump">1,841<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research credit, net</a></td>
<td class="num">(12,082)<span></span>
</td>
<td class="num">(3,168)<span></span>
</td>
<td class="num">(4,569)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount', window );">Orphan drug credit, net</a></td>
<td class="num">(1,308)<span></span>
</td>
<td class="nump">2,374<span></span>
</td>
<td class="num">(10,846)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Other permanent items</a></td>
<td class="nump">388<span></span>
</td>
<td class="nump">1,301<span></span>
</td>
<td class="nump">1,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Equity-based compensation</a></td>
<td class="nump">5,594<span></span>
</td>
<td class="nump">1,950<span></span>
</td>
<td class="nump">1,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">36,287<span></span>
</td>
<td class="num">(7,257)<span></span>
</td>
<td class="nump">44,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense/(benefit)</a></td>
<td class="nump">$ 944<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Deferred State Blended Rate Adjustments, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred tax adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Tax Credit, Orphan Drug, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying statutory federal (national) tax rate to pretax income (loss) from continuing operation attributable to other reconciling item. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Unrecognized Tax Benefits [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 7,821<span></span>
</td>
<td class="nump">$ 7,376<span></span>
</td>
<td class="nump">$ 7,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases for current year tax positions</a></td>
<td class="nump">1,001<span></span>
</td>
<td class="nump">449<span></span>
</td>
<td class="nump">548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions', window );">Increases/(decreases) for prior year tax positions</a></td>
<td class="nump">512<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(369)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 9,334<span></span>
</td>
<td class="nump">$ 7,821<span></span>
</td>
<td class="nump">$ 7,376<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Increase (Decrease) Resulting From Prior Period Tax Positions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income Tax Paid Table (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Provision for federal or state income taxes</a></td>
<td class="nump">$ 944<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan', window );">Eligible age to participate in plan</a></td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Percentage of employee contribution to salary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage', window );">Percentage of employee vested contribution</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined contribution plan, employer discretionary contribution amount</a></td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage vested of employee's contributions to defined contribution plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers to minimum eligible age of employee to participate in benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>performanceObligation</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of Reportable Segments | performanceObligation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 149,962<span></span>
</td>
<td class="nump">$ 58,749<span></span>
</td>
<td class="nump">$ 151,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product sales</a></td>
<td class="nump">847<span></span>
</td>
<td class="nump">619<span></span>
</td>
<td class="nump">3,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mgnx_CostOfManufacturingServices', window );">Cost of manufacturing services</a></td>
<td class="nump">11,452<span></span>
</td>
<td class="nump">7,603<span></span>
</td>
<td class="nump">4,033<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">177,194<span></span>
</td>
<td class="nump">166,583<span></span>
</td>
<td class="nump">207,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">71,047<span></span>
</td>
<td class="nump">52,188<span></span>
</td>
<td class="nump">58,949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(66,966)<span></span>
</td>
<td class="num">(9,058)<span></span>
</td>
<td class="num">(119,758)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mgnx_MainSegmentMember', window );">Main Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Segment Reporting, Other Segment Item, Amount</a></td>
<td class="nump">43,612<span></span>
</td>
<td class="nump">159,186<span></span>
</td>
<td class="nump">1,660<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mgnx_MainSegmentMember', window );">Main Segment | Vobramitanmab duocarmazine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">39,809<span></span>
</td>
<td class="nump">39,217<span></span>
</td>
<td class="nump">55,381<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mgnx_MainSegmentMember', window );">Main Segment | Lorigerlimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">36,805<span></span>
</td>
<td class="nump">27,716<span></span>
</td>
<td class="nump">21,581<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mgnx_MainSegmentMember', window );">Main Segment | MGC028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">24,055<span></span>
</td>
<td class="nump">14,408<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mgnx_MainSegmentMember', window );">Main Segment | ADC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">18,102<span></span>
</td>
<td class="nump">11,170<span></span>
</td>
<td class="nump">12,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mgnx_MainSegmentMember', window );">Main Segment | MGC026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">14,126<span></span>
</td>
<td class="nump">13,523<span></span>
</td>
<td class="nump">5,287<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mgnx_MainSegmentMember', window );">Main Segment | Margetuximab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">10,846<span></span>
</td>
<td class="nump">16,081<span></span>
</td>
<td class="nump">26,869<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mgnx_MainSegmentMember', window );">Main Segment | MGD024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">9,734<span></span>
</td>
<td class="nump">6,974<span></span>
</td>
<td class="nump">7,857<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mgnx_MainSegmentMember', window );">Main Segment | Next-generation T-cell engagers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">8,421<span></span>
</td>
<td class="nump">10,464<span></span>
</td>
<td class="nump">13,335<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mgnx_MainSegmentMember', window );">Main Segment | Retifanlimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">2,129<span></span>
</td>
<td class="nump">3,452<span></span>
</td>
<td class="nump">2,156<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mgnx_MainSegmentMember', window );">Main Segment | Enoblituzumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,906<span></span>
</td>
<td class="nump">5,344<span></span>
</td>
<td class="nump">14,725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mgnx_MainSegmentMember', window );">Main Segment | Other programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 11,261<span></span>
</td>
<td class="nump">$ 18,234<span></span>
</td>
<td class="nump">$ 46,860<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CostOfManufacturingServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of manufacturing services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CostOfManufacturingServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mgnx_MainSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mgnx_MainSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mgnx_VobramitanmabDuocarmazineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mgnx_VobramitanmabDuocarmazineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mgnx_LorigerlimabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mgnx_LorigerlimabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mgnx_MGC028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mgnx_MGC028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mgnx_ADCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mgnx_ADCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mgnx_MGC026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mgnx_MGC026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mgnx_MargetuximabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mgnx_MargetuximabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mgnx_MGD024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mgnx_MGD024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mgnx_NextGenerationTCellEngagersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mgnx_NextGenerationTCellEngagersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mgnx_RetifanlimabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mgnx_RetifanlimabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mgnx_EnoblituzumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mgnx_EnoblituzumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mgnx_OtherProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mgnx_OtherProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>87
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( )R =%I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( )R =%K3PQIA\@   "L"   1
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( )R =%KL/6TVO0<  $@P   8
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M[G;?XC-%!]+[K?3^*Z37QQ+AC2JX(+\AMQ;J;*?NFGRP)\D/(L]>C\2_I/+
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M]'K"O9[0J&?&W0I/R3%8D8SD."EUX05?I>."Y5@8&IVT4(T_M)11IZ)<!(-
M$J9!!>%!A6KI@E9C"BRCL@?*N)RY4H*T"[NE!M>S7,>2!.EPR M#.5<ZG,]G
M4Y>H Z<#C:(^TZ( RYRF@+MFD1Z:Z05!I0,G$%JN'\B*=$ O0(XC2](!$71@
MT*$)-9J04=-'[NR!<.#T&T[8-Y#2C+#X.ZX\=9[C;$6ZIEA-?=@K)6<J!+I6
M:%NR0!-56UKC>*#1'>REB=HMRN#-^/[CU>T_8ZT46ZV_'G(5.2I,46*"M)4T
M1@2:G<AUQ@A?XU@YE2A;DYR[Y3E-M=6AYCKL0.@@*"O1H+S D\6H*%X>N_0T
MS@0:UVZ=GKI : 6YNND$75F1#N:H(TV%=>EIS (TNX7K,AG@2!2(]U6%F/#-
M2)QMQ8([W1<+\$CX1IN &O^ GTEQ#&XI?YNQG):+ 7@)CC84JDTXX?E \@JM
MPX66*Q=_'0S"T'>[RDKC/*#9>M0*&7X6%FH7BUV^5I!J$T*Y^DTT("6K)DA;
M0V,VH-EMW!(&$IY1;;]50\ 3$7J>W'4-3I<(#<R8B,9AP-"X"YB6LXLG@YOD
MM3AMV9&Z=H C(>Z]=E, C;[EK;N"7MFBOMC:AP*-LT%F9_,ERPE.XN]D 59B
M@:FB*-:9.-OQ:2L62^V00:HM@?+ZHL&<2)4[TF#<#A^*&FN#S-9FTAH@7:.^
M)O&E4>_*HUZ'XZ->WO/H8&+46ZA#3N-JD-G57.(BGE>[A#C9,IZKK)[,8%--
MAU08@S7.R;$X]>/@(Y[+!2_!.*\PY9?OM5&H?CMH=?O4DOVW#F:=RLM6I&<+
MW8X0-.X'F=W/FT+P GE#$.S7!4$#TP5!R]89A,8X(;-QJH+P5)[=<GEXQU?B
M%0'9-GWDZK@G/ Q# >B6%8R'3"S#(A35QWK]JC/RD(<@#&1?HD/"$(4PE%<!
M+=*Q;8B<CD TC@N9'5=4)_BWA$)U5%VAT" [0J%#&D/1F#5D-FOUL5YET^9B
ML#_2:J\-\"HGI+N &WG?NBCVRA;UQ=:.:6/WD/_SI\O(:!7?'+<^V:*^V-IQ
M:RPF^M&!5O<1<]VT=2P,@T!=;%4<4C=\D9:.;\0[CN10XS"1^1"K-9]6E->5
M3$RA'TVF7AUFKVQ17VSMBYK&8=K6+US5&-WIF^]J^F2+^F)KQZWQL+;9PYHF
MDZT>H$$/22>'$QW*E2=<I$.%J&,>V8UGM<V>]:ZZ:M#VWMCRS4GODRWJBZT=
MM8-KS5^YU^SW8K/?F\W?<;5I-\[8_OG+35MWZN<@>>'1P?S0EG=Y6C8?^1WS
MI;&TMMG2BA.V',\9N#F\WM+JZ?6.LU>VJ"^V=A ;,VQ[OS!]>C6\O;)%?;&U
MX]887MM\OFF</K[JM&S+E;?&&E@8V/)EEI8L#.1SP>'! SPIR5?E@U %W]YL
M,U8]\K+_M'K8ZA*>1>4S2=+G8W@V+A\]&C8TU1-<-SA?Q5D!$K+DE-:IST=N
M7CT45;UA=%,^)O1(&:-I^7)-\(+D L"_7U+*7MZ(']@_FC;Z'U!+ P04
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MM&B\"G0-;#FN4+Q XP:@:"$4&D]EI^9Q/SG?BSY9=F.+&*+.F[5VO!B4.%&
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MZ;*T6TG$@==!+VV^'Q,)Y*2PDQ6?ZG&88PL">#%0:) 5&>)%N:$-:U422@H
M('PJ72E"F%97SN9U%FA73G&()2MGB[C.V<II%<":8$\=06KT$4%EF](:N]Z+
MRLA 1.T?()?5SD$OL^\!,+0!?Y/1!1A-5T:)PN8 (F@%-\)AILXC3@F(W-5K
M(%;^IUZSOD_FBRM_PCBRB+&O5*97.FNV:%JTV^AL0RJ!?A64 I162"\6\]L[
MWGMW^V'Q]N,=3@=UUT;YDV@-?+-$$C8)V8NH'W_X>39]_M(?A8)EMF"I<@W
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MVVBOI OP-8Y]Z. ):*P]\72@EZU21DOQ# Z:39^]%+-3V".0.H"EHY2Q!]2
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M4MT^I5("[X"L29>^$2 ^D^\TM4G;F-R=L;I<F70QO3((W#KZ35/**HJ5>-_
MU1WS(%W14<#6U4;!?&1<02,*$G<EMV"U)7A? ]PL' #=*XSM-1=W +TL3OA-
MT%E#3Q90EVDFBO<4],@AC7,<DVTD7;"M&^=PI](,3O@?Q?I85F)B!QZC.IF<
M<@\HH]]#*-A8QZA4HHP7T'P0]9NAJ33)XOCM\(2F#VQ"[<!_E?6LZ.383?Q9
M[]<6M*)K_DV)B+\N0_SAI7W:_FPUC[_6=,OC;U[7&#9 \,*H%;:>3YX_&\7Q
MLOF"<9]_NUG:$&S!'^DF2#E:@/<KBW!-7^B ]L>\R_\"4$L#!!0    ( )R
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M93O'KQLP9T$H5"5,&Y)^68-UU/-C)$ R! >G)SOA^4E29'N+.*]0#F?,U\A
M^/,.1#YPB1$4YPBX\8#SAI@Z!C\I?]@AH""QS1Y@P-TF*S@I@<M+=J"6^BLC
M)=Y'V?5$ 2E(7H>A$B@#J'VY)\!_7-PLDG5S:]K:B68DNTRH,DV^]S_>[%!<
MM##ZNT#[XI-[T#O++FF65;D.5!>(8I!WI(X'/PLF0@2@QB=14"!606R JOG-
MX"06%-RN MHF'B(1 LL;Z_1>MMNUS:_")YY?!Q9)UJ*A)*@4A>30DE? ,F !
MLKGAK(1C4'3'%B!$F/S,^$P!UD6[)0,%D G(0!I&O0@T!WR-3 H?+-A+5=:&
M2PG-++.*U!0[ITA!@!2!(G>Z;AK:I>GNT!P3*XN073?UL7XF0P"4!D*2]+N&
M1:XC9"+763"2CJT<P'(SE,(3*I\UC)BH<#"P(HP#.Y5LBH"<1883"(N0?\-C
MP.5 L<#./Z EDYS-\*9J$3B28SX2,./:#-AO'Q\[RO(6F*:O0>!51%%KT$NB
M'QLTS.C$O8F)BZN WH)LWZ"/#E(+'R;>D[4#PZ-9#:VVB:%L",)*SDB-E@31
MGG]%M('$^B-Q!J+I<PPTRAV&&=V/,96&9$86M*/1WHK:3^P.C%:@,2%41VU;
M \*>'890D3K!5 -]S.,0+5)"&CS?; W8*F!FKEE6*;_*;XP)9G!'Z("M;0FJ
MAWY$VX;,AH5Z8Q8PD1L0%D@P[KO6?Y>1-")=!,*@Z,'B0HR@T206"!H5JJM&
M5)R#7P6.!!XAG!><3U>3YJ"CK,EA1I76KU 3D@6%X1@UY[U E7F9!GGE":#0
M$&1'TH[!H_/)*N138(6V7/:@]$-,!+LF33HPT9CK.F=I"W\2,U<8+B+2<*:H
M4'-D"D9"@206N%AH%9#=)!"GH@)K\GKN: #*OZ+IE]VJKYQ#&3/D'= GF5(K
MX$F!J,2]^&VAGVL8K*K\"D;#I@'")"NWTGA7B7C8-MU RGNSCS=%SRL*T'R;
M0"*R$GQ>]RBHR924X]-M@;6'3B>8>K JNTLD5-7F0J* (XI,R]#"!=RRMT,'
MLLOV?%9DS1%4' D#@DO)JKTEEP7-48S[1?NVD>6G/!>Y[B#PZF8+_*U@P9F@
M8=OQV%R,77%+5GV'+L3T"@MP H/3O<NLR%-6DP#9.T#C=@D@:-@*5X-_P6W,
M8B=J0[(OW+0L">AJB(9B(G/$\Q[5[D\DXV'4>X?5'P)U$)# '^V,R@AT2SYG
MAJ73"C>=HIO@2SA2%D)UX8P4]=J8EM#ZV'OFF2'%1TY)#.P]6]71?*YDVN]<
MF.K6B,L,2(0O\?SQN]"K69H\ZVWPG-V :#A&U9'4J+ '/.9@1&YO$4FMQAO0
M"/'?! ;3%KP-F&C63T=*\4<;A.!ND" RU.!O&_@G.7Q_=?/V:/J)ZZ;PZNSP
MZN;Z*+D\.TE#"OH8PH$0O_/1!QJ"(XY V/)?$H,*K<H4O1PXFA*$(U)TL$EG
M@A!FIOUPQ4016Y3JVTOT 4XZPZ!R&!R10-<,4OF(%&P/24O. :+WESY3*0@^
M;QD(Q;+>]4C[3>0XIF S>/V@IH13V*$U'((^LVTVOP>[5C\I,+YKMV=>FT*&
M$O-I4!*Q>&T-\E1GU@T:]2\25.1GSUZ*U7A*GT]/7_+1\UKET&9GDZBOL^)G
MD+_PW2]]@_^(+<_!&^ T'S,L-<\B8F)H\,^%7F+HSOX.Z/AH1,P#1+7;X0RP
M!1Q"3G%7-,7\IR4&O7$3& BB.7.83&//\62KP'&9.<XQ)F#,>):'4(/S $U%
M,Z'16TF(V0&:5;8)(N48N%'J#$*.K2 *(>!P9V$J]'\QUI!9;XBV+FBU+PUX
M*B"Q;A6+N!P29=.V#5F$?!X>@^J-@ZV4#<_V_%%G*QMSA];7P>PL1[L1 -&J
M/SIY;8U.!ZY64^$V;)#-P-ELO_Q9Y+Z/T3'K43P/)L_$($2LX9&!8-"-F,5Z
MD;H-L*1GEQO03)XD\8^Z>)FSWL4 84*H.-1"GJ*U35[2MB3$L@;0:M6W^SF+
MSJOU&6*2?2(4<ZI';#W54&3MX?/N?#@-$^RNHG/--,. 9C2+*S+XMXG)X%N/
M/#2=F@*W$)PZD^>]L>7),\H(-G+:W)'FQHMLQP/AZ0P$,YC2&%E!#I!!56E"
M/W:D,PC_,.8._U<WG M:H3ND<0?"";HL&DN6;=M$# ],,+T?'M>TYIL^$EH[
MLR+S0343L&!LPY;LT8L9E8XSCRW2+TT'0*C<5!E\14"]P!SN,,#V^^39M^GE
MY;/P#^*&LY<8,4N^M+3D/G2WGZ8G)R?N*?[D8V?'UL7.?.;*)N?I\^<7;A!_
MNHZ#9L$29T_3IQ>7[G'YR+N['\6'V1%LX?3D++TXNPQW=7X!<YS]'=@\_T>P
M^?PT??;L:?C'0]B$U4Z_?>XQPQ\?P&=R 6B_.'>CY.,\0I^>I<_.OO6'QA\?
MA= E(O0,C,NGIQ?AQD[/+M/+B^>$\<=,-$FP+N02!#9!A__^\GSQ+-FB*"5I
MHKDD.^_/T)>_/[U<7$Z.FXXN2J O"@(L:,O_X([.9W?T_'3Q[3^TH[-_Q9:N
M&_B P1VU::]A.V67?"[MUT!\A4XDJ>Q=@]&5DIPOIW-BF9Z'4W-"C.=N<6YU
M127_2!.)6YH^UB=5SW#H0\;:$PN7.HK5E5V U;FLPG0"P1LJ*U.(TPF_X^$O
MDK]MRLIAEN+.C2U]8(G,DV"J9M5A'<&ON8%'WO-T0# T"%WZOJ434J;%@\&:
M@VZ0WL-H AI)/E:!OL,^B(YJ7L^A"+5\-H@7_3',M\"Y5F6^E_6B1 R>J"0T
MN_V.,X%#:7)O9B6-TBH2+ _0(G%27?%XW:)AIC1#E0D\:E=E.040,30H 1NJ
M3.A"NHC(CT "J'E5A+*5H 0B!H1GUKJ(L8:T<H]_P/P,6>!\8?)(=P?(P?R:
M@J\QG2'F?;JUXH@=&(]K<.R"[)L'1\.S#0;)/EY]_OZ[O_S'%<6DX\CJ(? 4
M%B>(V81!<?C[BVEO@-+(L-$JA^3#A^OD4'XY0G+]"^R%Y!9*X:,H^&O%R;4&
M3:0$CL=S'>;.,7 [2J:YU.Z7V'L57U)$(GLS@[,@CG-Q'.#7UK#[=WKR#1G^
M)(D5@P!4[5UUM<70_4,?N7B1_#L\P65J$^J&)#3\[PSX+]]W,?,=\G='R;?/
MODF>GG^3G,&_'_,_&S#BZ^03F,+;+/E#MMV]3-Z63=6L$;.4H-5G;EP\^QHI
M[)T&M7%V.@)]\BCY-]"?W\#_KV[>)7\R,&:3DP,.T_T58\7->I_<]+L=R)]#
M>(8&G." 3VV#$4Z<$J!(<2.@L?RW^N0%;. _LC+YD"U=A=2A?('/P%-/"0".
MTH$A2C%NAWFM>V$4>PS_3QSQ5*@ZS#<'QSMSIG*<Y\_AU&!;B-73RV]HB^YT
M3@$CIW"D<#; HT!3C'=!(1X'#E&<Z0&]%44Z0E#F2M=B&#'J( 43H#%,E$KT
ME0D<A*>'R%"X18F#3D6S=*XQQ["M!JY=M'MI:K,J.Y_B87F B'0B(D=!Q#E.
MK8&@=%:L6_)L5W;T@QWD?# 7#2(&7"I)=<%QUJ0.>06@)B*0EHHFP,-JBV,\
M[OU<$JEIUUDM63![Q"$*0=,"2PM9DC$!4#@(-UZV8#HX_+C]OG]WA1+ T0*0
MP,F@)H;CQP4%VWDO0**8,_9E12(X/9CD;CJ!2QD $8(4J^-Z,Y)W,OT@G@Q+
MH#=9L^EC1]X_!Q?]+-,'QAOI:]'"&$6@:"A758VI!O[)C21=*8^4Y5]9+W'^
M85# QD'1\32HYMM^[>' VKA^:<$\DW '8MW3ZKWH7QHX;$]=>IX.MX^@%T<=
M?'Q4U!5IK7A%BUGX=07< [H""[A)R?H%G6)<@ -'64\^-(R)^ +0>$Z-!K1"
M1U+GYR$+9_5,7TH1)Y(?(CN[<W4^H- QF7I<UL=R;*E6LV"0'6T,4&>NV -S
M'_C%5("6(I?9T B6/$<(9E"( 2(;D$<)*<P.M:Z*J0A2WC3[1%6)BQMIPI$3
M3(.E7(&F<X.V*MH=USEL",T^2 M$ 2F'3T@F  )3^0M9(\AD*K22KN:D+=6D
M*LLQ'^64>O2) 2\)B^" )>PS&?A*I81(T[Q%<U<G+'OX8)LE$"46Y@*B^QK/
M2E2E/Q<6065X$,-#B$T=_"31.90WL->RW4H=#$M++75 172#H3 "CZ##\/"&
M2L]@,.PZ!X&82HI<4IU!L$P/.#8ZAQ4A<4$(2G+\U.U3*F/;N5*K&_"&[G I
M_X")'K#Z0%P=A5 LDA]WY.9TI81KA/;3"%!QUHO2.MY3F1AX2/VVEZI2M$=0
M/$L\/2K38*1L&V?Q1B7KY(]2Q0T6"5*=-/I+4K)" H#\ 5:2^29KUTSY(:8^
M&SP\K7RF,@8R-%A;(0!>B7GMM4 /TL,]JB_)6BZVZ;NX$@;8"J7B,5X7T/H7
M9(%!NLG3(:@UK&RHP.BW+XBM8,HV.+3S9 _*T?J3U2_>]VU=DCH]/9&O/JA'
MP\53S6I5PD[]7$_U.9-90P550-IHTK*#=(-96I9<E:&B0TS8(ELID"N3_."9
M 6NJFGI]_($\%@[8Q7E=D@@BR<;" &4:UO0<5S2!$-9,+A?AI)IYLL PQ'S^
M#-2AIW/P'(3&/4L<RG.2?X6_PI@YT/UX>3+BL$P"21+S#'Z_6$-B\#"E^(&)
MKEXSO\:%VFJG\C+=3,*>A2;*X;W4LWHTH<[Y/,(9ZY<8:.0$%SNCU O=P #K
MR)>W3ZQ.O$;C,;W!QF]?:ZY%E!4%>%84,0]K/99:+M#Y  7/I7EJOM, "GOE
MUV9)RZ$:)@K;;Q&4:%F_Y,!.0"M_H![#J/]*++K"M!5O-83C"BO/_%FJN4YU
MV:2-8AQVOMH*/GE=<"\>::EH?Y[1QY#&X#'U,5B1; U+JX8&QB1$;50%0-X4
M"SN8W)JJ6B3OQ59E:6"FO7A6O%QY$QY#D'A4V@Y2.XQBQTY(PJ,2^%$Y)1V!
M#]]P]3@R[)=F!X[8LY-GJ9N'U,2U"Z*0?+B6:J=$*BY@P!%7?%&,4G]MEARX
M)/.GJ43K;DNK%B$I/-/>8K:9;N-D>MU ?>M51:ZBUK?Y0E9/(9+L5*_2>5MD
M8@!MD,00=P&=^-'*8&&%Z<.).P1<#=*V.%,01>9;3%2/Z[D$Z2>L,<U!7JH$
M)<0&,#MK+M96*P3>=F8'&NJP/%+;9Z]HH*,X!&]3DJ^*\)?P]/#QX+I25-WM
MBP9I-AH*8^,L:N!"<$T /G9[Y"])33ZD'NBCET:Z/[P]\J3ISH!HZI!$W%&(
M. M3V16Y #/+C&N(A>@S3_>!S!'>GM@+W;VP;LO.OPY*L:8A& ,_\QS,KOLI
M,*41UK%2X(Q"%5<^L!HEUS&"8;G4NP* :[*-@BBL\['N)4H6 >+CL'[DV4S@
M=FK<(%5W/XVB#,/K:GS-:!0($/< O*-$ FE\5DAX&GO":PD1N^UW6(-2N6)F
M5X,IIQ%$ :C>J.5HW+#NZ(74MV'"A,OU^AT(.)A'=[LRQKZ$G9;;9=]:YPNX
MVV$HV%\&(HXJK4#,X*;=\" :DD91B0A#F/T"?87PRFXL\T+;[+-*LUYH%+A
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M>% F$GF*>A7P;M/0Z2^;;J-]=5C,E+LL:'<9EYOX(>97+D#%DM%0,/"%*S*
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MM7VTS*M>_29>O7CNR(V<'"9P1:J#_NEQ4!7+9F)5X3OW4EEZ!_AA1@\OU$Z
M]E=*V6;B#FB?<K-_ 5!+ P04    " "<@'1:IEJ?64H#  "%!P  &0   'AL
M+W=O<FMS:&5E=',O<VAE970Q,BYX;6RE55%OVS80_BL'+1@:0+!$69;LS#:0
MI"TZH 6,!NL>ACW0TLDB2HDJ2<7)?OV.E"V[:.H &R"(Y/&[[^[(N^-RK_17
M4R-:>&ID:U9!;6UW$T6FJ+'A9J(Z;&FG4KKAEI9Z%YE.(R^]4B.C)(ZSJ.&B
M#=9++]OH]5+U5HH6-QI,WS1</]^A5/M5P(*CX+/8U=8)HO6RXSM\0/M'M]&T
MBD:64C38&J%:T%BM@EMV<Y<ZO =\$;@W9W-PD6R5^NH6OY>K('8.H<3".@9.
MPR/>HY2.B-SX=N ,1I-.\7Q^9'_O8Z=8MMS@O9)_BM+6JV >0(D5[Z7]K/8?
M\!#/S/$52AK_A_V 3<EBT1NKFH,RK1O1#B-_.IS#F<(\_HE"<E!(O-^#(>_E
M6V[Y>JG5'K1#$YN;^%"]-CDG6G<I#U;3KB ]N]YHNE]MGT-X]ZT7'1VW!=Z6
M\* JN^<:EY$E*PX;%0?&NX$Q^0DC2^"3:FUMX%U;8OD]043NC3XF1Q_ODHN,
M;[&8P)2%D,1)>H%O.L8\]7S35V/>2'Z(]Q3]7[=;8S5ER]\OQ3XPIR\SNPJZ
M,1TO<!50B1C4CQBL?_V%9?%O%_Q.1[_32^S_Z:[^'R.< /@=P!P!A:+Z--:
MJL#6")625.>BW<$;T9)$]8;PYOH&Z!:QV:(>;]+]IG"OFJZW)#X9N()IF&7,
MC[,T.7G#XG"19+ (\]D"WO>Z%;8GL7-(594H\(PD6^20QQGEHE4:'K$6A40#
ML]A]'_GV#)IF(4MC-Z2S!#XB%7FM9 FBZ;1Z1(<QD*9A3)3I/,R2F+QN*4GZ
MH;-0H 3<T84;8&'",OHS*H-7#X_%69C/<V 46)(R,DT,O"CZII?<8DGMA=*H
M$'QH8*3*&Z6M^&<0O)F3,_/\VD^FB_3Z58LAM.C.E\U#%L<T25@X3W.ZFTMV
M\(F> (/4@P>OK'+Q7@Z-G@N?#\_(M0%TG>#'# B'%'"*-$E@SPU<Y9,9-3HI
MR7((5XM)=EQYW!5CD\5IG\Z\0]_8Y?/DI1*+SEIC@WKG'P!#:=NW=NB2HW1\
M8VZ'UGJ"#P_4)ZYWHC4@L2+5>)+/ M!#TQ\65G6^T6Z5I;;MIS6]DZ@=@/8K
MI>QQX0R,+^_Z7U!+ P04    " "<@'1:'WFKZ*4)  "G%P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970Q,RYX;6RM6&ESV[86_2L8U:_/GI%ED5IL)[9G;"=M
MTR9U)F[2#YWW 2(A"2U(L !H6_GU[]P+DEILI^L'6UR NYQ[[@*>W5OWFU\J
M%<1#84I_WEN&4+TX.O+94A72#VRE2KR96U?(@%NW./*54S+G384Y2H?#Z5$A
M==F[..-G[]W%F:V#T:5Z[X2OBT*ZU94R]OZ\E_3:!Q_T8AGHP='%6247ZE:%
MC]5[A[NC3DJN"U5Z;4OAU/R\=YF\N!K3>E[P2:M[OW$MR).9M;_1S9O\O#<D
M@Y1162 )$C]WZEH90X)@QN^-S%ZGDC9N7K?2OV'?X<M,>G5MS<\Z#\OSWDE/
MY&HN:Q,^V/OO5.//A.1EUGC^+^[CVDG:$UGM@RV:S;"@T&7\E0\-#AL;3H;/
M;$B;#2G;'16QE:]DD!=GSMX+1ZLAC2[85=X-XW1)0;D-#F\U]H6+:UL4.@#E
MX(4L<W%MRZ#+A2HSK?S948 *6GB4->*NHKCT&7%)*MY!PM*+UV6N\FT!1["M
M,S!M#;Q*ORCQE<H&8I3T13I,QU^0-^H<'K&\T=]Q6+S2/C/6UTZ)7RYG/CBP
MYG]/P1"5C)]60IGTPE<R4^<]I(I7[D[U+K[^*ID.7W[!A7'GPOA+TO]ZS/Z!
M./%6@?->_+14>%%4LER)I?2BM.5A)LM,&3DS2J!(.$F[A(GK42Y T[*> \#:
MX45?8*7%(NM6?6'G<YTI5G<OG5K:VBO!B E=BG<H#P;O!IMJO_[J)$V.7_I6
M@Y+9$J;<07F)/ZBSB-H<.7ZX4M+!)$I[+X)%\2A1'@;B32ENLF!GRC&;^B)L
M>"6! "C+S]2#]FMOV!E6,A<:(*T=B2:S#O40L)]WQTU!N0*WSM:+):D[)<_4
M0[:4P)9%9LH%E$V16>#H/5L[=[9HA'AO'2&@?;2-(@2T<)=EMBX#;"4I]*!1
M6=A< U=)CO<97)+DJ# =VODA82R]1Z6G5W&+T7*FC0XK<:\ GU,%'H/^N9"!
M=V_*%+D,JH]%'C6/X('QLL3_S$67K9C9L$29-$0-3X#)JG+V0:-^*K,2>Z/!
M$&7,&$B+T0W,GQEU!\&Y0C3T=54910Y+TTH3L4GI,G:BV!2,)!B@=Y> +P0*
MARHHU&WQH'\C\3/7:94?@CD.;8=<1A#6P>:X[<,S8I$_$,D0)B<)_CW:FJ-:
M4"0$5"N1I%CSG_;G%;.>(61!(K+KL544"[(,;!0;="QDKD0F_5)4<A63DVFX
MFVB &*">M*"RN+W)X+1]P.&J%#<_LQJ(2][R13.>R+D/-Q\C=7SDR9TT=>3(
M7CH>3+:UIQOV[*JGD&<0CG0BEV!*1#VS/K"#?QZP:(DD7 S8XSEH@4H)5OB#
M9QEPLPUA5+TGIOUI,L3O<7\\.16?I-/,S(TU23])QO@_2J;BMI[%-R"_+938
MQ\OQY(!_AZ<'XD=0=4?\Y/B4Q4^GTV>C$-$'O<&>H&-XGXK'#@VZ-*8M?P0+
M%$U@R*2?G$SH9HK+R?"8+H]A9CHYH<L3 B(9Q<HU[8_&4XH=\GP>R.#3_O'Q
M2/QD*4&C"1U-CX?]\4F*QN&1A;JH:DI1C7H%)@2Q/QKUAVERL+5WT_P],8+F
M:8)J?6C0)##_P4WI'-5-KH$HX]^CM:!)D'7I=AE7K(@56A1&ZE,HNJ;V(*"(
M\H#.PJDHZUZC7MVN2HF&]""N!I\&*)SBK2T_2^8I1/;%?KO@@$I-KD!E6_4W
M^EOL9%A?*)=I:?1G)>J*%J,!*'H;],SFJ\/<U0NJ][_6"RH90;H%Y53-/K9:
MNBBC<E9.JT">!I4M2VOL8K75%6.=0!&N*[0..-2$@71W;M5(-]+*XPQZD,KJ
MP 7X#??:;/DX\]FA3L!F;^RP U!Y3G;/;>WXFH0BIHU75&LPZW/TC!$>L)6=
MQVCZJ/(9];UY;= 9&E2IJ.Q"F6];=F]KDZ-C"#LS>M$V /C=0+Z7HOS,FH)$
M):41'6UV:E&;V+Q)D9=HM%2LP$W4)!C]C88/!E&O:N=K&:$D_=08FH1$2WY$
MI3YWX@A4OX4<7J!U<4"P<>U5HY?Z(SQ"G/,Z RIK$-HYP'<D>08$IWZOM5MC
MT,4,R42/G5U)PXG%90 Y8.^)8,/3ET0Z0UULH<$;&$;]=D%FE:)$_>ILY"FB
M*^.=N;M$7#%$@(^8S6-+EV8RL*,!Y[F8<J,AAHF5;ZB.- TT#VZ0%NPIJ+<B
M"Z3.M^D,B-TC#3R]9-813Q$)&B68VA3E#0: _A4'KH$#:>&MT3GSR ?\M-%J
M:BS>;SN*BE\[@G9O/#A>]SFFW58?3-:S3IS]HN(GS<__Y+C0CSVLZ8'I;GN]
M16HWG>,M?A9Q3J*"69M5(T""V?"3(NG7RS.#_LZ'9&SPM0:?89<.!E9<.QI3
M[P8H%IFSWZI29Z#CFQ(GL_UKJM\_VH%(QX?9W2%*^\GXH,]SZEP;+L3LU<?!
M[8".5\%IU*!KE(QUO^\> _5V]@<V4.K#XZ*4V1#$#Q96X%#Q;O *%?O]DG^>
MZI3O 9#..3^OEUK-Q>M8_N#]#1]"'$N5HHA /]-PKZQT.?=L)!O.$ X H$RH
M!47M3EL3F4(K-D U$OVW"2V!'XE$Z/(TY8ASW2G 2(WZ$MEQVWRTP$1"UGVH
MD:?)<'8X:>W;"#0M>-V>*RXCBLGI:,Q?*W)*9C84EX7V'<,]'9DL/6&[^0SB
MRI:#C?O_Q<'O\MWEA\OK'X Q13I%CM3YBG3<V9F3.#G*0L[@I,TDYO+/.%Q2
MR"O@P5HXVPOT,-*L,QII0TRK0XH,GE+3<I8-$WRDQ*GGIEQ3/QWV-XYK.Q2"
M_3R(XF3G"#B,Y.Q3XP>TX<!"-MB:U*A?ZQPQWU9PVN\RPR_Y-&I8E'+ZKLF3
M[7SX%DT$)T#*B.\4D4O0F<H\D0VCR7CZKV9#RY;GYL)(Z4B*O*4JWY6RV(EN
M/#J6EDJVH4]9J#F(QB.2^C_BZ/[LX!_0E%Z0[S/'1WH\GFOT%TU33UX'=&(T
M )XB"(>9"CSW/K^ZQG0%I%0)$)=-9^;O##ZHV(5=9?G$UIQHNCPABSU:N*"I
MSA,\.SY<<Y&\S.+T=--.3TEDZ"0RM )(8,I\WH1<MMV-<\:@I[&MD:C$FDTN
M)LE?)>,URB%@?ZHZ]Q_S\N1%Q\SCDW^]3C-X'9%BS+LJZ36:H70MB1ITVUS:
M<%#NXIMNXRL=!Z-%UP==U;'^DF$=L$^D_5,?WXXV/IYB.EOP)V(JB A4_([:
M/>V^0E_&CZ_KY?$3-JR%I_2%:HZMP\'QI!>_OK0WP5;\*7:&F-F"+Y<* [RC
M!7@_MS:T-Z2@^S9_\7]02P,$%     @ G(!T6C'?SO&5 @  [04  !D   !X
M;"]W;W)K<VAE971S+W-H965T,30N>&ULC51-;]LP#/TKA#>LER+^2-H576*@
M:3MLAP)%NX_#L(-BT[902W(IN6GWZT?)B9<!:="#95'B>WR41,[7AAYL@^C@
M6;7:+J+&N>X\CFW1H!)V8CK4O%,94L*Q275L.T)1!I!JXRQ)3F,EI([R>5B[
MI7QN>M=*C;<$ME=*T,L26[->1&FT7;B3=>/\0IS/.U'C/;KOW2VQ%8\LI52H
MK30:"*M%=)&>+V?>/SC\D+BV.W/PF:R,>?#&UW(1)5X0ME@XSR#X]X27V+:>
MB&4\;CBC,:0'[LZW[)]#[IS+2EB\-.U/6;IF$9U%4&(E^M;=F?47W.1SXOD*
MT]HPPGKPS3ABT5MGU ;,MI)Z^(OGS3GL ,Z25P#9!I %W4.@H/)*.)'/R:R!
MO#>S^4E(-:!9G-3^4NX=\:YDG,OOG2D>&M.62/8(KA][Z5[FL6-FOQ\7&Y;E
MP)*]PI)F<&.T:RQ<ZQ++_PEBEC3JRK:ZEME!QBLL)C!-CR%+LMD!ONF8YS3P
M35_A&S*#7Q<KZXB?PN]]20X4L_T4OCS.;2<*7$3\_BW2$T;YAW?I:?+I@,#9
M*'!VB/W-%W&09;_&?=3PK4&X-*H3^N7(@N ZXXL#H4LN->N$8Z- <K*2!1M@
M*I"Z,-09$D,Y]:XQ)/^@A30[.4Z2Q']@&\%X[UX8I=C/^N#'@7B?5\]AK:QU
M",B2*R3BV0:U,J[A@N!!0"<(GD3;!RWODTF20H<T4$U\.H2P]H,V;^0':6W/
MAB'@=L5)ZU+J&D0 \@-$M>( VT?HW?@_G<"^VXYW2E AU:'16#Z$7KNA&L?5
ML9==#"7\SWUHA#>":JDMM%@Q-)E\/(F AN8R&,YTH:#Y=+@]A&G#_1C)._!^
M98S;&C[ V.'SOU!+ P04    " "<@'1:ZS^_*9XA  !C@P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970Q-2YX;6SM/6MSVT:2?P6E]6ZD*DJ6*,EV$MM5LI5D
MO64[+CO)U>;J/@R!(3EG$& P@&3NK[]^S!L/48XW>W>U'^*()&:FIZ??W=-X
M>ELW'_5:RC;[M"DK_>Q@W;;;;QX^U/E:;H0^J;>R@E^6=;,1+7QL5@_UMI&B
MH$&;\N'\]/31PXU0U<'SI_3=N^;YT[IK2U7)=TVFN\U&-+L7LJQOGQV<'=@O
MWJO5NL4O'CY_NA4K^4&V/V_?-?#IH9NE4!M9:55762.7SPZNSKYY<8'/TP._
M*'FK@[\SW,FBKC_BAU?%LX-3!$B6,F]Q!@'_NY$O95GB1 #&;V;. [<D#@S_
MMK-_3WN'O2R$EB_K\C]4T:Z?'3PYR JY%%W9OJ]O_RK-?BYQOKPN-?V;W?*S
M%_!PWNFVWIC! ,%&5?Q_\<G@(1CPY'1DP-P,F!/<O!!!>2U:\?QI4]]F#3X-
ML^$?M%4:#<"I"@_E0]O KPK&M<_?RQM9=?+IPQ8FPZ\>YF;@"QXX'QEX-L_>
MU%6[UMEW52&+>(*' (4#96Y!>3&?G/%:YB?9^=DLFY_.+R;F.W=;.Z?YSD?F
M@X,JQ:)N!!]_562O50[D)+.K52,E4%:KL_^\6NBV =KXKR$4\ (7PPL@OWRC
MMR*7SPZ (;1L;N3!\[_\Z>S1Z;<3X%\X\"^F9I\ZF;T&9L'^;R3M_\=V+9MP
M]Z^J?-?BD\W6XLE\U4,5_  '<_9XEL$D,&*S%=4N@Q]D(XM,56T-2V3R4UYV
M&M=;E?5"E%G>.X32S"S<S+>J79MU9]GM6N7K[%;H3,"/!<V=O1$-? G+/YEE
M5]M&E4@C\UGVMZ[<F3]Q:OOQ8I:!N *9T:JE /QLQ (?@)ENI&[5BH !X#9U
M5><E_2FJ5BWJ8@>[$RT\N%8+!0AZ=WU\EAV.X>3HQ*)K#?#6BQ:$( #LD0 2
MJ2R H676H'30!!;BKX S*NLM;1\AS^O-1C:Y$J7Z!Z.J7D;P(Q9$6<+_"I73
M$YIP5<KH/& (P*#I.UHR@W,QBV6XH:W:2B283&@MX3-,"VLO5,6KTE&$ZYYD
M/\,A,-!PU!N-@.&',9S,["];H8H(-CB ;KML0&C ;SO:.LSUX.SR].041%M9
M(@"*J>PD^RD8N1%5MP0>[8#+,I$!K5H4\5I_^=.3^=GC;[4G.HM-4#;;+1!%
M@DT\-T=4\W.FZ>^OKS*QW3;U#9PA3_R5SEZHNJQ7*M=^JS"C.8/L\,7KJR,Z
MU5___O;OOV:'X2K'17G;'+DS;T%IMG;;H@"UH1G?&S@TW<*$>494FW=-@X^5
M=0Y'#H@K;D25 U!O9/-1PO9 AV4Y0*^J>B,B&L1ID&6 A.&LNT9WJEI%U#9
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MFA?BKR]>7Q%%_?3KJ^]>7R.)AR;FW$>0!TRH..L<^%61@ZCT(-[W->!Z9N^
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M'466[U50BW-GM^1D-]#D(X8:K4%.5W(HM\%A5<,N++Y"=Z?HJU.55U&H\W$
MKJR.TP[CLL68/H-Q-*4K6X7"TX<JX^PAP!B$!E;3GM7E]$7$]YR.:'9T2-/)
M=/X"WFR(<A;Q9L_@?0D%._I4I;9D4E5&'^Z0U9X]_;5<^> 0^=]/Q=VBSI]&
ME7IYZVN5\D6"@O#L-IPL7K\Z.IF<O<!Y/G">OX3^/T_F1QCN,0A4H"]IL"L(
M(NH>$K2A=[:L5;4CK@([SDA7P4(H6GJ/B^&Z<6F!U(_2W2K#M%P[9M1FH)^6
MM\N?D;2AH-Z;KFA;Z/1^0J7?&RVP:V-7RI"34O$$%U?+FX\?/O^Y'(D/WR@
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M]VRX,/\7;7)S0G$4MKA-<"464NL]@&TG=0KU@F#B18@,W,6^E_B3.HR?HX1
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M=^L4?3C[B,X09>AGP1M)6"YCK'1NPX"S+L^RS>._D,?ST0UGJI#H"\LA/R;
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MC0TJRTVJ\D2+W.SS+(36(C6'*\"%518%\'XL<'6K3HH'U%N%T_\!4$L#!!0
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MR>SU$B,S--,0.-W&"[S7SK=#G#;^_0$3$OS^06MW#$*!Z44K?P%02P,$%
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M?P%NUF37"V=3)1ULR05OR;8&*.'X'=)M1WG3PZ$96V#*#5'4!F2GR/#.HS#
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M5*.SWI7 /47.!K\,G>#1>[$])D2?1+?*HQ19H>_@$\06A"[[M8-A7X14=BS
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M*2TDF"@F[2R/O=M$2:"CP]K-S42["0+F,OF)(K+.336@!:W9Q%Y)N@;RLV8
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M^'W=P;KD TZ ]T 1>"__'U!+ P04    " "<@'1:D89J."X&  !F$   &0
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MY:VV'#B=^YOD3#NT1_^Z$#P6AA;@>Z*U6P_(0/W7PMF_4$L#!!0    ( )R
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M-+V;32.P0[<<-MZT?8?:&D_]KE_6](-!&Q3HO#+&'S?!P?C+6O\/4$L#!!0
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M40_J[K'N%E8U_H%<*4O/K9]NZ?\&M1.@\[52]FGA#/1_3//_ %!+ P04
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M<;, ?U\(H7<?1D'[!\_T'U!+ P04    " "<@'1:T,1LC:L$  !N"0  &0
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M&AR?D/BZFDO5QJJ\;.T+96E0E,LUC7+4[@*=+Y6RNXT+T/PYB'\!4$L#!!0
M   ( )R =%H477%RM@(  $P'   9    >&PO=V]R:W-H965T<R]S:&5E=#,U
M+GAM;*U576^;,!3]*Q:;IE;J"H&$3AU!RL>F]J%3U*C;P[0'!RY@U=C,=I).
MVH^?/PA+*\*F:2]@FWO//><:'R=[+AYE!:#04TV9G'J54LVU[\NL@AK+2]X
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MTF9JAY6^[D"8 /V]X%P=)J9 =X&FOP!02P,$%     @ G(!T6M/RLE1B!@
M\2X  !D   !X;"]W;W)K<VAE971S+W-H965T,S8N>&ULM5I=C]HX%/TK%ENM
M6FDZQ([#1Y=!FLZHW9$ZZFQINP^K?3#!#%9#3&W#M-+^^+5#!L<0#"GF98;
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M PNL=ES0I'"6#)(H/?[CGT4@3AR@U^* "@=TK8-;.+BYT".S7-8=%G@V8?0
MF+*6:.HBCTWN+=5$J5K&A6#R:23]Q.PK9L]$X&5,P(*L=BP2$>'@[9V\%\7\
M'1B Q\4=>/OF'7@#HA1\W](=Q^F:3VPA9U<8]JJ8Z<-Q)M0RTQU9#8$+WP/D
M($_C/K_>W:V[VU)S*1R5PE&.Y[;B+<6)Y/?@=B\5JT ,Y.88<"PC\M<7Z00^
M"Y+POW6"CS-X^AG4!KSA&5Z1J25W&"=L3ZS9[[_!D?.'3GY/8+5@N&4P7!/Z
M[#:A3$3_DC684RYT4H_^0>ZO4L-^!L-0+<3^5(/&"H6A[Y=F-79>R<XSLKMG
ME'/PF,HT%><D[V5ZTKZ!1YS1R?S>&<.F!1SIV?DE.[\;NR]R3+3T_,;DSAF]
MIL4 (3V_4<EO9.3W$4<,_,#QCN@HC9KQD.L:G-'26,EU]<9Z9D')+# R>QPN
MAN"[C!O?L5^ EWM1Q].(U'6K]016$QV6HL-7SSMAG\'H":P6C'$9C/'_S#M&
M_ZY2QXW7V(4P"/1O,72J$NKTE)_,0%WE%&CZ=%?7<M(.P+ZRF1FILQBH27TM
M:JH:#XU5\T+N,SMW%H"T;U=+CH15:8;FVGQ/]X2ELG,6 Y[1E%,F5T6.",M8
MU+8T1LC.RGI"JP>@JO[0>_6,"8T=1N> ](16#TC5<$!SQW$Y:\)F'P''8_^L
MJFNL/-_Q8,L;6S4<T-QQ=,B'S<;BO"/2F+0E[*KO@.;&HTN2"RXS;)H,6CI>
M6'4)T%AW+V6N\*KU;5JI]75;N%5%&YJK]IRRC#(LB#PORZUI;MS,6)UW7D]H
M]2-C5>F1\_J'QEY[@+[0Z@&IV@5D;A<NIR+4K.MP%*+P[%W5F/EHY+9L=71R
MRC=W -?G(M2LW^>'1XU)RT9'57E'%\K[];FH0#+E(HW) +9QK"HP,A_ S<FH
M< [J*^RB<VI-,[G"Z'R%[9-O6>I#XE?,GN2*@9ALI)\S#&318L=O<\>!H%G^
M>6M)A:!)?KDE>$V8,I#/-Y2*EX'Z8E9^(9W]!U!+ P04    " "<@'1:L'.<
MVL "  #*!P  &0   'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6RM55%OVC 0
M_BM6-DVM5)H0 DP=1 +2:4BK5A5U>YCV8)*#6'5L:AMH__W.3II"&U@UE0=B
MG^_[[NYS<C?82G6G<P!#'@HN]-#+C5E=^+Y.<RBH/I<K$'BRD*J@!K=JZ>N5
M IHY4,'], AZ?D&9\.*!LUVK>"#7AC,!UXKH=5%0]3@&+K=#K^T]&6[8,C?6
MX,>#%5W"#,SMZEKASJ]9,E: T$P*HF Q]$;MBZ1K_9W#3P9;O;,FMI*YE'=V
M,\V&7F 3 @ZIL0P4'QN8 .>6"-.XKSB].J0%[JZ?V+^ZVK&6.=4PD?P7RTP^
M]#Y[)(,%77-S([??H*K')9A*KMT_V9:^_<@CZ5H;651@S*!@HGS2ATJ''4"[
M=P 05H#P)>!0A$X%Z+P5$%6 R"E3EN)T2*BA\4#)+5'6&]GLPHGIT%@^$_;:
M9T;A*4.<B:^HN@-#YQS(#-*U8H:!)BTRVE#&K;F%\K9F=/_\)$$,X_H4/6]G
M"3GY>#KP#:9C2?VT"CTN0X<'0K=#<B6%R36Y%!ED^P0^UE$7$SX5,PZ/,B:0
MGI-.^XR$01@U)#1Y.[S3 $_>#@^/5-.IKZ;C^#H'^*9B ]K@)V;T&4E@;@@5
M&;F\7S/SN'L9OT=S;11^0'^:[J",$37'L$WE0J]H"D,/NX8&M0$O_O2AW0N^
M-.GWGF3).Y'M:1O5VD;'V&,GY[.&9SOO.[;2EL;W'6T<FR(5*1"TD8F"C!GR
M76K=I',9K^_BV5Z[B8.!O]D5[Y\>R=&<_U.1;JU(]Z@B4V$ 60V9BE066/T/
MDX-JJK3[JHYN+["_%_6^]HN"!K_DM5^[O^]7%N3O=+D"U-)-"TU2N1:F[!&U
MM1Q(8QQ(KG&_L..@&KG^[#_3E%,.N^&2"4TX+) R..]C;JJ<'.7&R)7KI7-I
ML#.[98[#%I1UP/.%E.9I8P/4XSO^"U!+ P04    " "<@'1:R;OLZ%H"  ")
M!@  &0   'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6RME5UOVC 4AO^*E4U3
M*W7D"^C*0J065+47FU!1UXMI%R8Y@%7'SFQ#VG^_8R=D5 VLE79#[/B\[SF/
ML4^22JI'O08PY*G@0H^]M3'ER/=UMH:"ZIXL0>#*4JJ"&IRJE:]+!31WHH+[
M41 ,_8(RX:6)>S=3:2(WAC,!,T7TIBBH>KX"+JNQ%WJ[%W=LM3;VA9\F)5W!
M',Q].5,X\UN7G!4@-)."*%B.O<MP-!G8>!?P@T&E]\;$DBRD?+23VWSL!;8@
MX) 9ZT#QL84)<&Z-L(S?C:?7IK3"_?'._=JQ(\N":IA(_L!RLQY[7SR2PY)N
MN+F3U0TT/*[ 3'+M?DE5QPXN/))MM)%%(\8*"B;J)WUJ]F%/$/8/"*)&$+U5
M$#>"V('6E3FL*34T392LB++1Z&8';F^<&FF8L/_BW"A<9:@SZ:W8@C!2/9^1
M[WAF/I,YGI-\PX'()6D7R<D4#&5<GV+$_7Q*3CZ>)K[!_-;%SYI<5W6NZ$"N
M*60]$H=G) JB?H=\\G9Y_%+N(W6+'K7HD?.+_X5.IDQG7.J- O+S<J&-PL/U
MJXNO-NQW&]H+-](ES6#LX8W2H+;@I9\^A,/@:Q?M?S)[P1ZW[/$Q]_0![Q9A
M@I1*9J!U%^M1@_>RUF;GSLPVEFT:#<,@"!)_VT'1;RGZ1RFNF6!X]'.RDC+O
MA#BJ?R]$;3;<@[@8!@<A!BW$X"C$W@T48+H@!J\V[V_*NK+7$6$4=>ROO]<H
M;)/^1M6*"4TX+%$9],[12-6-KYX86;K>L9 &.Y$;KO%; <H&X/I22K.;V';4
M?GW2/U!+ P04    " "<@'1:.Z1?/9H#  "=#P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970T,RYX;6S%5]MNVS@0_96!MBA:P(DNOJ>V@=C28@-LBS3>MB@6
M^\!(8XNH1+HD92=_OZ2D*+XH6J<0L"\V2<TY<].,.),=%S]DC*C@(4V8G%JQ
M4ILKVY9AC"F1EWR#3#]9<9$2I;=B;<N-0!+EH#2Q/<<9V"FAS)I-\K-;,9OP
M3"64X:T F:4I$8]S3/AN:KG6T\$=7<?*'-BSR8:L<8GJR^96Z)U=L40T128I
M9R!P-;6NW:O =0P@E_A*<2?WUF!<N>?\A]G<1%/+,19A@J$R%$3_;7&!26*8
MM!T_2U*KTFF ^^LG]M]SY[4S]T3B@B??:*3BJ36R(,(5R1)UQW=_8.E0W_"%
M/)'Y+^P*V>'8@C"3BJ<E6%N04E;\DX<R$'L =_ "P"L!WC&@]P*@6P*ZYP)Z
M):!W+J!? G+7[<+W/' ^460V$7P'PDAK-K/(HY^C=;PH,R_*4@G]E&J<FMVP
M+3+%Q6,'/NG7\IV/BM!$OH<+^++TX=V;]_ &*(._8IY)PB(YL956:\!V6*J8
M%RJ\%U2X'GSD3,42 A9A=$A@:WLKH[TGH^=>(Z./X25TW0YXCM>K,6AQ/KQ;
M _?/AWLU\.!\N-L0C&Z5P6[.UWV!;QDL8*G[1Y0EV '7NW#&'?A*DHP4E<@B
M^)R1A*X>*5O#=1CRC"D)/I5APF4F$/[^4U/"C<)4_E.7WD)_KUZ_Z617<D-"
MG%JZ54D46[1F;W]S!\Z'NM2T2>:W21:T1':0Q%Z5Q%X3^W,9PK;*7*FEMN(:
MV5Z;DH)LF).9#\MVUG4=9V)O]T/=IL:@);*#4/>K4/<;0UU;+W>%F@Y4B:B+
M>B/Q:Z/>)IG?)EG0$ME!=@95=@;_<S<;M)G$-LG\-LF"EL@.DCBLDCAL++$Y
M20@+$8B".:XI8R97? 7?D8BZE Q/&M!1]UD4$H.#%N6.CUK4*4UO[ X/A8)3
M(<_I]BNA W]'E;^C1G^OHXB:UU/"(B9BC1$H#L&#OLS+^O8].G'GV.'_E/!/
M);S1R#ORMM'N7WP+QE54QHU1\741Y]- ;0C&)^9?G*9T42/E#L>CHU"<2AT%
M*VBT]!?CX#K/=VSGW'K05^"F2BB)FDJA1J2F%FJD:HJAV>[7QL7>&T-2U'5@
MYC\)>8LN+O?5:3%CSMTK/Q_%CL[U['F=3USV,TTQN'[4Y45UG26XTI3.Y5!_
MJT0Q"Q8;Q3?YL'//E1Z=\F6LYV<41D _7W&NGC9&0361S_X%4$L#!!0    (
M )R =%H$^K4I\@0  "L@   9    >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM
M;+5:6V_;-AC]*X17#"V01B(MRW9F&TC"%BV0 $:S;@_#'AB9MH5*HDM2=KI?
M/^H271DV=NF76)?O.^(YY"<>BID=&/\FMI1*\!1'B9@/ME+NKAQ'!%L:$W')
M=C11=]:,QT2J4[YQQ(Y3LLJ3XLA!KNL[,0F3P6*67UORQ8RE,@H3NN1 I'%,
M^(\;&K'#?  'SQ>^A)NMS"XXB]F.;.@#E5]W2Z[.G IE%<8T$2%+ *?K^> :
M7F'D9PEYQ%\A/8C&,<BH/#+V+3OYO)H/W*Q%-**!S""(^MG36QI%&9)JQ_<2
M=% ],TML'C^C?\S)*S*/1-!;%OT=KN1V/I@,P(JN21K)+^SPB9:$1AE>P"*1
M_P6'(M97P4$J)(O+9-6".$R*7_)4"M%(@/X+":A,0-T$[X6$89DP?&V"5R9X
MN3(%E5P'3"19S#@[ )Y%*[3L(!<SSU;TPR3K]P?)U=U0Y<G%DJLAQ.6/"_#A
M>QKN5(]*0)(5>&!K>2"<@K>82A)&XAUX#[X^8/#VS3OP!H0)^'/+4J%"Q<R1
MJB$9G!.4#[TI'HI>>"A$X)XE<BO AV1%5VT 1S&H:*!G&C?(B(AI< F&\ (@
M%WF:!MV^/GVH2<>O3T<&-L.J4X8YWO"GG;*,2-DA=??\<Z?"P6=)8_&O3OL"
MV]-C9^^1*[$C 9T/U(M"4+ZG@\7OOT'?_4.GFTTP; FLI:E7:>J9T!N:TM9
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M([ B:[S+Y!U[_ILT%0I+O27+1/47/-=IHW $ECLA6=X$JQ+DM*C_XY\-B(,
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M!J$'X/TYY^KY0CNH2J7C[U!+ P04    " "<@'1:4LF8W=$'  "/5P  &0
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MF@-,6S$+-TT#V38?BJ::IDYL8VVJLLXLE0=NQ%.!'F5- 0\WZ(&S-0^25ON
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MPK,"\O,58^)PDE50O=\R^P]02P,$%     @ G(!T6@STN0G+ @  Z@D  !D
M  !X;"]W;W)K<VAE971S+W-H965T-#DN>&ULM59M;],P$/XK5D!H2+"\-EE'
M&FE=0$S:Q+1I(('XX";7)EIB!]MMA\2/QW;2D+9I-5#HA\9V[GE\]^3.OG!-
MV2//  1Z*@O")T8F1'5NFCS)H,3\E%9 Y)LY9246<LH6)J\8X%2#RL)T+,LW
M2YP3(PKUVBV+0KH414[@EB&^+$O,?DZAH.N)81N;A;M\D0FU8$9AA1=P#^*A
MNF5R9K8L:5X"X3DEB,%\8ES8YW&@[+7!YQS6O#-&*I(9I8]J<I5.#$LY! 4D
M0C%@^5C!)12%(I)N_&@XC79+!>R.-^P?=.PREAGF<$F++WDJLHEQ9J 4YGA9
MB#NZ_@A-/"/%E]""ZW^TKFT]:9PLN:!E Y8>E#FIG_BIT:$#L/T# *<!.+L
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M]Y^;TMJ]PAY:4]=2/_J5U,32Q##<BF%H%$.53O.VRC9&=JUL),Q#PGPD+-C
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M2**T^B1/]8WH!$B./L"N ^S= .= P* .&.P&# \$#.N X6L#1G7 Z+5#<NH
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MISC<D9<JB-;-Q&8[T\]%SNG.5HQZT:(5 ZA=6=.ZDYK@_:4GJ!$)2O-?-8,
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MG&T(5]9(4PTMIO;&\)-<;?N=Y/@U03_IW\(:\A60M^1Z-IX%9,IRR7$SR%D
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MP)4!?E\P)K<=-4%='?M_ %!+ P04    " "<@'1:0AMZ(@@#  !S#   &0
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MKBJ8Q.BK2("A\Q4#D%>#X.C'%XE!EP)R_K,M_Y4#K]V!NO+.>($CF!KR3N/
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MD:QK5K6XU4300O=P=U3(CE /$_E5 $P9R/TEI6([40Z:[PS_#U!+ P04
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M('\^3]-B^TVY@M<T^U8]G=O_ 5!+ P04    " "<@'1:=EX5JTT#   1#@
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MC$7-!E0:B/DE(7S?D0M45:#_'U!+ P04    " "<@'1:C06+8=<$  "9(
M&0   'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6S%FFUOJS88AO^*Q:1ID]:
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MJ@3\\^<\+]_?5 4<GFAS_W]02P,$%     @ G(!T6F/0R&V  P  2Q(  !D
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MR(V^OLT I\!4 _E\0:FX+Z@.FO.C\ ]02P,$%     @ G(!T6LGYSYQY!
M]1@  !D   !X;"]W;W)K<VAE971S+W-H965T-3DN>&ULM5E1;]LV$/XKA#8,
M+=!%HBS;<68;2**V"[ .0=UL&(8],-+9)BJ1+DG;:;$?/U)29"MFV#AC7BQ1
MNON.]Y%WNJ/'6RX^RR6 0G=EP>0D6"JU.@M#F2VA)/*$KX#I-W,N2J+T4"Q"
MN1) \DJI+,(XB@9A22@+IN/JV;68COE:%93!M4!R799$?+V @F\G 0[N'WRD
MBZ4R#\+I>$46, -UL[H6>A2V*#DM@4G*&1(PGP3G^"S%(Z-02?Q!82OW[I%Q
MY9;SSV9PE4^"R,P("LB4@2#ZLH%+* J#I.?QI0$-6IM&<?_^'OU=Y;QVYI9(
MN.3%GS17RTEP&J <YF1=J(]\^RLT#O4-7L8+6?VB;2T[T,+96BI>-LIZ!B5E
M]97<-43L*>#!(PIQHQ _5$@>4>@U"KVG*B2-0E(Q4[M2\9 21:9CP;=(&&F-
M9FXJ,BMM[3YE9MUG2NBW5.NIZ17+> GH$[D#B7Y&YWE.S7J0 EVQ>E>9U7F5
M@B*TD*^UR,TL1:]^?#T.E39O0,*L,751FXH?,85C]($SM93H+<LA[P*$>M[M
MY./[R5_$3L04LA/4PV]0',6)94*73U?O6=33IZO'#F]Z[5+T*KS>=Y<"O;TC
M>JUK[O_^3<NA*P6E_,=&>@V:V$%-VCB3*Y+!)-!Y08+80##]Z0<\B'ZQ$>83
M+/4$UB$S:<E,7.C3:\$WM$I.>A>C.>0@])[6MU(1!8C67"NS[6VDUN##"MRD
MSLUTE"11%(W#S3Y=AV(/)%*71,>Q?NM8W^G8>\&E1&LF(.,+1K]!;KQ M\!@
M3I75F1IPL.],+XH.O3F4&YY:Y%+G!)^YKH/6_8'3_9M]QRE3H$THLZ[Z0T@*
M1>W+.3CP[*'O@^^NI$NBX\JP=67H=N5D=H+>-3N3L!S-S-:T3=^)<VR(^P1+
M/8%U^#MM^3M]B7QYZI-,GV"I)[ .F:.6S)%S,_ZN2TQ=3 K-(5N@PN28C CQ
M56?/+1&Y-:I&!U'5[R>1+;,X;1]+DR>P#DTXVM5+T?\BZ@TB)5\SA=:*%O0;
MN2T F?J6L;4.<UVB4BN7C=5],F,;D^[9'4NE+[0NEWNU)WY&!D3_5C']%Q!A
M2JL^^L3UM3>TTN8T<&PT>T5+?:%UR8UWY,8OD1X;5%^,^D1+?:%U&=W5Y]A9
ML3XK1S:0G;C&UL#V6GK[0NLRM2N^L;OZ?C2PKW3G-Z>,VNL<-^K1>\\G6NH+
MK<OHKNK'_1>)9D^U>L.H3[34%UJ7T5TC@=V=Q+.B^;"1Z/?QR!K/3NM'<^4)
MK<O5KE/!1[0J[_D&!"M!USC=+_6P_E(GMJ.8"[>%HW>BUR[&%UJ7W5T?@U^D
MD<%>.QFO:*DOM"ZCNV8&N[N9FUF[6\WA2"8@IZJ);]0$N)72T4&3CZ.1M:5Q
MS^!HOKPV->'>>7 )8E&=JVOW35]2GZZV3^NS^PMS=F_.DQ\\/\=GY]5)=KB#
MJ?\0^$#$@C*)"IAKR.ADJ).YJ,_8ZX'BJ^K4^98KQ<OJ=@E$KXD1T._GG*O[
M@3'0_M,Q_0]02P,$%     @ G(!T6@3@[,@9!0  UAL  !D   !X;"]W;W)K
M<VAE971S+W-H965T-C N>&ULM9E=<YLX%(;_BH;M["8S=4!\D[4]TYJTVYG=
M;29INM<*R#%30%Y)CI-_OP(3,$A1S Z]2< ^Y_71(_E(KYGO"?W!-AAS\%3D
M)5L8&\ZWEZ;)D@TN$+L@6UR*=]:$%HB+6_I@LBW%**V3BMRT+<LW"Y25QG)>
MOW9-EW.RXWE6XFL*V*XH$'W^B'.R7QC0>'GA)GO8\.H%<SG?H@=\B_G=]IJ*
M.[-52;,"ERPC):!XO3 ^P,LK&%4)=<3W#._9T36HAG)/R(_JYDNZ,*RJ(ISC
MA%<22/Q[Q"N<YY62J./?1M1H/[-*/+Y^4?]4#UX,YAXQO"+Y/UG*-PLC-$"*
MUVB7\QNR_P,W _(JO83DK/X+]DVL98!DQS@IFF1109&5A__HJ0%QE #=5Q+L
M)L$^-<%I$IQ3$]PFP3TUP6L2ZJ&;A['7X&+$T7).R1[0*EJH51<U_3I;\,K*
M:J'<<BK>S40>7WXI$U)@\ T]809F8$6*+2EQR1D@:\ WN'X%E<^_,1#C-:84
MIU4P^, 8%D%G?V;H/LLSGF%V#LYBS%&6BZL9N+N-P=F[<_ .9"7XMB$[ALJ4
MS4TNBJX^VDR: C\>"K1?*3#&R05PX'M@6[:K2%^=GNXHTN/3TVU%^M7IZ;"?
M;HJ):F?+;F?+KO6<5_6:*<@.T\;%3*!Z)BY59 ]BKEJL:D&7;(L2O#!$CV&8
M/F)C^>LOT+=^5W&>4BR>4NQJ(K'>C#CMC#@Z]>4GG&**<G!W<7L!2M'810NG
MB&?E \@)8R!!E#Z+?KY'-%5-T4$]J-6KIOZXA-!W7+%8'H_A*\)<*[#\?EBL
MK74LUHG$>EC=%JNKQ7K+$<?_A^=!UC\"Y<# "P<X%5&.XUD#FMH2Q]*<2*Q'
MTVMI>EJ:-T(1T60#1 L6N^BC.!YLQ6;/02)Z2<;?5Z!5,#T)4Q!!:PA3CO)#
MVQNLX%A;X5B8$XGU8/HM3%\+\RO=;E )4KI[>(N?KUAFH>,.^*FB'&>X&+5%
MC>4WD5B/7]#R"_3\NB\T%B<\D'<G"!7#0*(#+4=:@W)49 6#H%A;UUB$$XGU
M$(8MPE"+L#T&4/%=+G=8Q2V4N85!Y VX*:("U[4'X+35C 4WD5@/7-2"B_3;
M2F-/Q" K-W& V!ZB5!@C>6&%(1Q\.5=RE!NZ]K %:FL;BW$BL1Y&:'6NP7IC
M!0K9)$,53>69WI(7EF\'@X6U4H?!8 !.7\Q8<E.I]=$=&2ZH[W_"55$E,RBO
MHB@8G@054;XO$]/6,)K81&I]8IWI@=H3_/(SK4Y^Z:O>1PG3EF%""T;!$*<<
MYP3B_#UL@?H21P/]&98%=IX%ZDW+=Y3OT.%WFCPG>U0FRBVD43EF,W,M:,L0
M%8&.[UG#/AE#V<?,G,"V_8'BE3+0#KRHFY?^V#MC ?7.XF_A*48N)=DMA)$U
MW )44:XE+:-)/<54:GV4G:N WNA?(XY.<\J?)."4/F UJ5H\J=K55&K]R>E<
M"GS#I@R.V3=?[W1K7#8A,S]PA\=%99@SW-9C?6FC0?X,MP([NP+U?N6:XBW*
M4H"?MK@4;F]'U48%RAYD9D-/0J@*LR2[IR]J-,*?X59@9U>@WJ^\OH&_8?Z@
M[$]FJMZK"E,TWTE]S%1J?::=DX%Z*Z/=Q\RS%[#/YTJND;2]2DS?#(GU%8[F
M.:FC,8\>B51/O/Y"]"$KF6B&:R%O702B.]/#0Z3##2?;^BG)/>&<%/7E!J,4
MTRI O+\FA+_<5 ]>VD=YR_\ 4$L#!!0    ( )R =%J"^N#*\0(  .\(   9
M    >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;*U676^;,!3]*Q:KIDY:"S@$
MVBY!2L*F]:%2U:]IFO;@PDU -79FFZ3]][,-8?D@61[ZDMCFG.-[KB^^#)9<
MO,@<0*'7DC(Y='*EYE>N*],<2B+/^1R8?C+EHB1*3\7,E7,!)+.DDKK8\T*W
M) 5SXH%=NQ7Q@%>*%@QN!9)561+Q-@;*ET/'=U8+=\4L5V;!C0=S,H-[4(_S
M6Z%G;JN2%24P67"&!$R'SLB_2B*#MX"G I9R;8R,DV?.7\SD.ALZG@D(**3*
M*!#]MX )4&J$=!A_&DVGW=(0U\<K]6_6N_;R3"1,./U19"H?.A<.RF!**JKN
M^/([-'[Z1B_E5-I?M*RQT:6#TDHJ7C9D'4%9L/J?O#9Y6"/XX1X";@AXFQ#L
M(?0:0N]80M 0 IN9VHK-0T(4B0>"+Y$P:*UF!C:9EJWM%\P<^[T2^FFA>2J^
M9BDO 3V05Y#H##T16A%[(".J*X*P%-#('$VAWM!I HH45'[2P,?[!)V>?$(G
MJ&#H(>>5)"R3 U?IF(RRFS;[C^O]\9[]?8QN.%.Y1%]9!MFF@*O-M([PRM$8
M'U1,(#U'/?\SPAX..@*:'$_O=="3X^GX@)M>>SX]J]?;H]=U(+_N.*5(E_V2
MB.QW5\YKS:!;T]PD5W).4A@Z^JJ0(!;@Q!\_^*'WI2M?[RF6O)/81BZ#-I?!
M(?5X3*C-'U%H#+."L8+-$)^BGT!$5Q9KM<BJF>MS$??"ON=[ W>QGI\.6(1Q
M&&W"D@X8COJ7N(5M>.JWGOH'/8VRK##ET?GJU=1PPP"^V ILLHO:<ICL(H(@
MC/K=D8=MY.'!R!/(JG1OZ.'_@IKL(LXBW-_.^B&=C;"C-NSHV"+2-]:A\HEV
M#CSP?'RYG?Y=6%>5)1VPS2JKW;AKK: $,;,M5:*45TS5=VB[6G?ML>[:MKMM
MK>MN/K)-S/TG4W\*W!"A7QZ)*$RUI'<>Z?(0=7NM)XK/;<-YYDJW+SO,]1<)
M" /0SZ><J]7$;-!^X\1_ 5!+ P04    " "<@'1:FFI".',$   I#P  &0
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M2S(9)/F3;S):D837Z_=@)@:8PPW2L/15GC_N[C23*R<*0C.+Z^QO?V>81F;
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M_8Z=$$J;5GW@);&=[_MRON/+\6@AY!]5 FCR5%=<C9U2Z^;,=55>0DW5D6B
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MIN=%%0'0706,XFQ?K^,H"4*3LWTS)*N?WNQK,8/A$&>14O_(K?X-SG[X_CY
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MF9)Z?QAN?R'XMCL>-N="\++[N&'9DM6M@?Q]Q;DX7K0W.!U)G/T+4$L#!!0
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M)>S/N,IFEM4?^]==HKA>MUY62@U@WU3?&9Z_O'?Z\L[LI]]02P,$%     @
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M(]KB!5!+ 0(4 Q0    ( )R =%I&QTU(E0   ,T    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ G(!T6M/#&F'R
M*P(  !$              ( !PP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ G(!T6IE<G",0!@  G"<  !,              ( !Y $  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    " "<@'1:[#UM-KT'  !(,   &
M            @($E"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ G(!T6K?2ST$Y @  N@4  !@              ("!&!   'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( )R =%J$D0U(N 4  "D8
M   8              " @8<2  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"% ,4    " "<@'1:<]-4?I4"  "J!@  &               @(%U&
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ G(!T6I@_9!5]
M!P  IB8  !@              ("!0!L  'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+ 0(4 Q0    ( )R =%H5-/1"H@8  .,N   8              "
M@?,B  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " "<@'1:
M6!)T8R()   '+   &               @('+*0  >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL4$L! A0#%     @ G(!T6L$QPL<O"P  V!L  !@
M     ("!(S,  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (
M )R =%KC>+K_("@  'N%   8              " @8@^  !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"% ,4    " "<@'1:D,V2V.($   /#   &0
M            @('>9@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4
M Q0    ( )R =%KSB.EX,@0  -8)   9              " @?=K  !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ G(!T6J9:GUE* P
MA0<  !D              ("!8'   'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"% ,4    " "<@'1:'WFKZ*4)  "G%P  &0              @('A
M<P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( )R =%HQ
MW\[QE0(  .T%   9              " @;U]  !X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L! A0#%     @ G(!T6NL_ORF>(0  8X,  !D
M     ("!B8   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )R =%HHWG-0?@8  ) .   9              "
M@2C$  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ G(!T
M6F96*M)> @  ?P8  !D              ("!W<H  'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6Q02P$"% ,4    " "<@'1:YW +GQ0%   V'   &0
M        @(%RS0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0
M   ( )R =%H\I3,X$0(  -T$   9              " @;W2  !X;"]W;W)K
M<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ G(!T6HXN2C#M"P  W3
M !D              ("!!=4  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q0
M2P$"% ,4    " "<@'1:M,)>15DI  #FD   &0              @($IX0
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( )R =%J1AFHX
M+@8  &80   9              " @;D* 0!X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL4$L! A0#%     @ G(!T6A9U38H: P  0@<  !D
M ("!'A$! 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " "<
M@'1:UA!%E0D#  !(!P  &0              @(%O% $ >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( )R =%KHQ^K$%@,  +X&   9
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M970S,RYX;6Q02P$"% ,4    " "<@'1:_ZOR_.<"   H"   &0
M    @(%-, $ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (
M )R =%H477%RM@(  $P'   9              " @6LS 0!X;"]W;W)K<VAE
M971S+W-H965T,S4N>&UL4$L! A0#%     @ G(!T6M/RLE1B!@  \2X  !D
M             ("!6#8! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"
M% ,4    " "<@'1:9^G^1ZD%  #C*@  &0              @('Q/ $ >&PO
M=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( )R =%I;'M-\O (
M ,H*   9              " @=%" 0!X;"]W;W)K<VAE971S+W-H965T,S@N
M>&UL4$L! A0#%     @ G(!T6MD6/3K= @  = @  !D              ("!
MQ$4! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " "<@'1:
MP_Y81B@$   M%0  &0              @('82 $ >&PO=V]R:W-H965T<R]S
M:&5E=#0P+GAM;%!+ 0(4 Q0    ( )R =%JP<YS:P (  ,H'   9
M      " @3=- 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%
M  @ G(!T6LF[[.A: @  B08  !D              ("!+E ! 'AL+W=O<FMS
M:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " "<@'1:.Z1?/9H#  "=#P
M&0              @(&_4@$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+
M 0(4 Q0    ( )R =%H$^K4I\@0  "L@   9              " @9!6 0!X
M;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ G(!T6CM_S,]-
M!@  /BH  !D              ("!N5L! 'AL+W=O<FMS:&5E=',O<VAE970T
M-2YX;6Q02P$"% ,4    " "<@'1: @+EOC0$   V%0  &0
M@($]8@$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( )R
M=%I2R9C=T0<  (]7   9              " @:AF 0!X;"]W;W)K<VAE971S
M+W-H965T-#<N>&UL4$L! A0#%     @ G(!T6GH[SC$L!@  ZS(  !D
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M=#4R+GAM;%!+ 0(4 Q0    ( )R =%I"&WHB" ,  ',,   9
M  " @5>* 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @
MG(!T6EMDMUXA#@  H;,  !D              ("!EHT! 'AL+W=O<FMS:&5E
M=',O<VAE970U-"YX;6Q02P$"% ,4    " "<@'1:=EX5JTT#   1#@  &0
M            @('NFP$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4
M Q0    ( )R =%J-!8MAUP0  )D@   9              " @7*? 0!X;"]W
M;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ G(!T6FGX'U>J"0
MW48  !D              ("!@*0! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX
M;6Q02P$"% ,4    " "<@'1:8]#(;8 #  !+$@  &0              @(%A
MK@$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( )R =%K)
M^<^<>00  /48   9              " @1BR 0!X;"]W;W)K<VAE971S+W-H
M965T-3DN>&UL4$L! A0#%     @ G(!T6@3@[,@9!0  UAL  !D
M     ("!R+8! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )R =%K!#]M3" ,  $0*   9              "
M@3C* 0!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ G(!T
M6GEFJAVB!P  GC@  !D              ("!=\T! 'AL+W=O<FMS:&5E=',O
M<VAE970V-BYX;6Q02P$"% ,4    " "<@'1:OEW1]BT#  #J$@  #0
M        @ %0U0$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( )R =%J7BKL<
MP    !,"   +              "  :C8 0!?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( )R =%HZ]<2QDP4  +<K   /              "  9'9 0!X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    " "<@'1:'M^97AP"   ])P  &@
M    @ %1WP$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" "<@'1:I7\.<>X!  "0)@  $P              @ &EX0$ 6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     2@!* #T4  #$XP$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>281</ContextCount>
  <ElementCount>382</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>95</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952151 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952152 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952153 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952154 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952155 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - Organization and Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/OrganizationandNatureofOperations</Role>
      <ShortName>Organization and Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Property, Equipment and Software</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/PropertyEquipmentandSoftware</Role>
      <ShortName>Property, Equipment and Software</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - TeSera Transaction</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/TeSeraTransaction</Role>
      <ShortName>TeSera Transaction</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://macrogenics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/MarketableSecurities</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Inventory, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/InventoryNetTables</Role>
      <ShortName>Inventory, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Property, Equipment and Software (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/PropertyEquipmentandSoftwareTables</Role>
      <ShortName>Property, Equipment and Software (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/PropertyEquipmentandSoftware</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/CommitmentsandContingencies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/StockbasedCompensation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/IncomeTaxes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/SegmentReporting</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Organization and Nature of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/OrganizationandNatureofOperationsDetails</Role>
      <ShortName>Organization and Nature of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/OrganizationandNatureofOperations</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned and Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned and Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Estimated Useful Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/MarketableSecuritiesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Marketable Securities - Available-For-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Available-For-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Inventory, Net - Schedule of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/InventoryNetScheduleofInventoryDetails</Role>
      <ShortName>Inventory, Net - Schedule of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Inventory, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/InventoryNetDetails</Role>
      <ShortName>Inventory, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/InventoryNetTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Property, Equipment and Software (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails</Role>
      <ShortName>Property, Equipment and Software (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/PropertyEquipmentandSoftwareTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/StockholdersEquity</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Revenue - Incyte Corporation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/RevenueIncyteCorporationDetails</Role>
      <ShortName>Revenue - Incyte Corporation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Revenue - Gilead Sciences Inc (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/RevenueGileadSciencesIncDetails</Role>
      <ShortName>Revenue - Gilead Sciences Inc (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Revenue - Zai Lab (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/RevenueZaiLabDetails</Role>
      <ShortName>Revenue - Zai Lab (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Revenue - Provention (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/RevenueProventionDetails</Role>
      <ShortName>Revenue - Provention (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Revenue - Manufacturing Service Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails</Role>
      <ShortName>Revenue - Manufacturing Service Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Revenue - NIAID Contract (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/RevenueNIAIDContractDetails</Role>
      <ShortName>Revenue - NIAID Contract (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Revenue - Product Sales (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/RevenueProductSalesDetails</Role>
      <ShortName>Revenue - Product Sales (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Stock-based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based Compensation - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Stock-based Compensation - Option Pricing Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails</Role>
      <ShortName>Stock-based Compensation - Option Pricing Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails</Role>
      <ShortName>Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - TeSera Transaction (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/TeSeraTransactionDetails</Role>
      <ShortName>TeSera Transaction (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/TeSeraTransaction</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - Income Taxes - Valuation Allowance Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxesValuationAllowanceActivityDetails</Role>
      <ShortName>Income Taxes - Valuation Allowance Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - Income Taxes - Income Tax Paid Table (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxesIncomeTaxPaidTableDetails</Role>
      <ShortName>Income Taxes - Income Tax Paid Table (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9955551 - Disclosure - Employee Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/EmployeeBenefitPlanDetails</Role>
      <ShortName>Employee Benefit Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="mgnx-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9955552 - Disclosure - Segment Reporting (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SegmentReportingDetails</Role>
      <ShortName>Segment Reporting (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/SegmentReportingTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="mgnx-20241231.htm">mgnx-20241231.htm</File>
    <File>mgnx-20241231.xsd</File>
    <File>mgnx-20241231_cal.xml</File>
    <File>mgnx-20241231_def.xml</File>
    <File>mgnx-20241231_lab.xml</File>
    <File>mgnx-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>mgnx-20241231_g1.jpg</File>
    <File>mgnx-20241231_g2.jpg</File>
    <File>mgnx-20241231_g3.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="773">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="20">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>94
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "mgnx-20241231.htm": {
   "nsprefix": "mgnx",
   "nsuri": "http://macrogenics.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "mgnx-20241231.htm"
     ]
    },
    "schema": {
     "local": [
      "mgnx-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "mgnx-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mgnx-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "mgnx-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mgnx-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 323,
   "keyCustom": 59,
   "axisStandard": 26,
   "axisCustom": 0,
   "memberStandard": 30,
   "memberCustom": 59,
   "hidden": {
    "total": 6,
    "http://xbrl.sec.gov/dei/2024": 4,
    "http://xbrl.sec.gov/ecd/2024": 2
   },
   "contextCount": 281,
   "entityCount": 1,
   "segmentCount": 95,
   "elementCount": 692,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 773,
    "http://xbrl.sec.gov/dei/2024": 39,
    "http://xbrl.sec.gov/ecd/2024": 20,
    "http://xbrl.sec.gov/cyd/2024": 15
   },
   "report": {
    "R1": {
     "role": "http://macrogenics.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://macrogenics.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
     "longName": "9952151 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "longName": "9952152 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "longName": "9952153 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CostsAndExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "longName": "9952154 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:SharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:SharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "9952155 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://macrogenics.com/role/OrganizationandNatureofOperations",
     "longName": "9952156 - Disclosure - Organization and Nature of Operations",
     "shortName": "Organization and Nature of Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "9952157 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://macrogenics.com/role/MarketableSecurities",
     "longName": "9952158 - Disclosure - Marketable Securities",
     "shortName": "Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://macrogenics.com/role/Inventory",
     "longName": "9952159 - Disclosure - Inventory",
     "shortName": "Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://macrogenics.com/role/PropertyEquipmentandSoftware",
     "longName": "9952160 - Disclosure - Property, Equipment and Software",
     "shortName": "Property, Equipment and Software",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://macrogenics.com/role/CommitmentsandContingencies",
     "longName": "9952161 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://macrogenics.com/role/StockholdersEquity",
     "longName": "9952162 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://macrogenics.com/role/Revenue",
     "longName": "9952163 - Disclosure - Revenue",
     "shortName": "Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://macrogenics.com/role/StockbasedCompensation",
     "longName": "9952164 - Disclosure - Stock-based Compensation",
     "shortName": "Stock-based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://macrogenics.com/role/TeSeraTransaction",
     "longName": "9952165 - Disclosure - TeSera Transaction",
     "shortName": "TeSera Transaction",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://macrogenics.com/role/IncomeTaxes",
     "longName": "9952166 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://macrogenics.com/role/EmployeeBenefitPlan",
     "longName": "9952167 - Disclosure - Employee Benefit Plan",
     "shortName": "Employee Benefit Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://macrogenics.com/role/SegmentReporting",
     "longName": "9952168 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R22": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "ecd:NonRule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "ecd:NonRule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://macrogenics.com/role/MarketableSecuritiesTables",
     "longName": "9955513 - Disclosure - Marketable Securities (Tables)",
     "shortName": "Marketable Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://macrogenics.com/role/InventoryNetTables",
     "longName": "9955514 - Disclosure - Inventory, Net (Tables)",
     "shortName": "Inventory, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://macrogenics.com/role/PropertyEquipmentandSoftwareTables",
     "longName": "9955515 - Disclosure - Property, Equipment and Software (Tables)",
     "shortName": "Property, Equipment and Software (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://macrogenics.com/role/CommitmentsandContingenciesTables",
     "longName": "9955516 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "mgnx:ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "mgnx:ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://macrogenics.com/role/StockbasedCompensationTables",
     "longName": "9955517 - Disclosure - Stock-based Compensation (Tables)",
     "shortName": "Stock-based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://macrogenics.com/role/IncomeTaxesTables",
     "longName": "9955518 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://macrogenics.com/role/SegmentReportingTables",
     "longName": "9955519 - Disclosure - Segment Reporting (Tables)",
     "shortName": "Segment Reporting (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://macrogenics.com/role/OrganizationandNatureofOperationsDetails",
     "longName": "9955520 - Disclosure - Organization and Nature of Operations (Details)",
     "shortName": "Organization and Nature of Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "mgnx:NumberOfProductCandidatesApprovedByTheFoodAndDrugAdministration",
      "unitRef": "productcandidate",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "mgnx:NumberOfProductCandidatesApprovedByTheFoodAndDrugAdministration",
      "unitRef": "productcandidate",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "longName": "9955521 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails",
     "longName": "9955522 - Disclosure - Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details)",
     "shortName": "Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails",
     "longName": "9955523 - Disclosure - Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned and Accounts Receivable (Details)",
     "shortName": "Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned and Accounts Receivable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-88",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-88",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails",
     "longName": "9955524 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives (Details)",
     "shortName": "Summary of Significant Accounting Policies - Estimated Useful Lives (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-105",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-105",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails",
     "longName": "9955525 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-109",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-109",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://macrogenics.com/role/MarketableSecuritiesDetails",
     "longName": "9955526 - Disclosure - Marketable Securities (Details)",
     "shortName": "Marketable Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails",
     "longName": "9955527 - Disclosure - Marketable Securities - Available-For-Sale Securities (Details)",
     "shortName": "Marketable Securities - Available-For-Sale Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://macrogenics.com/role/InventoryNetScheduleofInventoryDetails",
     "longName": "9955528 - Disclosure - Inventory, Net - Schedule of Inventory (Details)",
     "shortName": "Inventory, Net - Schedule of Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:InventoryWorkInProcess",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:InventoryWorkInProcess",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://macrogenics.com/role/InventoryNetDetails",
     "longName": "9955529 - Disclosure - Inventory, Net (Details)",
     "shortName": "Inventory, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:InventoryValuationReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:InventoryValuationReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
     "longName": "9955530 - Disclosure - Property, Equipment and Software (Details)",
     "shortName": "Property, Equipment and Software (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://macrogenics.com/role/CommitmentsandContingenciesDetails",
     "longName": "9955531 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-11",
      "name": "mgnx:RightOfUseAssetAndLeaseLiabilityIncrease",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-11",
      "name": "mgnx:RightOfUseAssetAndLeaseLiabilityIncrease",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://macrogenics.com/role/StockholdersEquityDetails",
     "longName": "9955532 - Disclosure - Stockholders' Equity (Details)",
     "shortName": "Stockholders' Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-139",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
     "longName": "9955533 - Disclosure - Revenue - Incyte Corporation (Details)",
     "shortName": "Revenue - Incyte Corporation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-145",
      "name": "mgnx:NonRefundableUpfrontFees",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://macrogenics.com/role/RevenueGileadSciencesIncDetails",
     "longName": "9955534 - Disclosure - Revenue - Gilead Sciences Inc (Details)",
     "shortName": "Revenue - Gilead Sciences Inc (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-164",
      "name": "mgnx:NonRefundableUpfrontFees",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://macrogenics.com/role/RevenueZaiLabDetails",
     "longName": "9955535 - Disclosure - Revenue - Zai Lab (Details)",
     "shortName": "Revenue - Zai Lab (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-177",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://macrogenics.com/role/RevenueProventionDetails",
     "longName": "9955536 - Disclosure - Revenue - Provention (Details)",
     "shortName": "Revenue - Provention (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "mgnx:GainOnRoyaltyMonetizationArrangement",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-185",
      "name": "mgnx:CollaborativeAgreementTransactionPrice",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails",
     "longName": "9955537 - Disclosure - Revenue - Manufacturing Service Agreements (Details)",
     "shortName": "Revenue - Manufacturing Service Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-197",
      "name": "mgnx:NonRefundableUpfrontFees",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://macrogenics.com/role/RevenueNIAIDContractDetails",
     "longName": "9955538 - Disclosure - Revenue - NIAID Contract (Details)",
     "shortName": "Revenue - NIAID Contract (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-207",
      "name": "mgnx:NumberOfProductCandidates",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://macrogenics.com/role/RevenueProductSalesDetails",
     "longName": "9955539 - Disclosure - Revenue - Product Sales (Details)",
     "shortName": "Revenue - Product Sales (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-206",
      "name": "mgnx:AmendmentFeeToCommercializationPartner",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails",
     "longName": "9955540 - Disclosure - Stock-based Compensation - Narrative (Details)",
     "shortName": "Stock-based Compensation - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-226",
      "name": "mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingPercentageOfUnvestedAwards",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails",
     "longName": "9955541 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense (Details)",
     "shortName": "Stock-based Compensation - Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails",
     "longName": "9955542 - Disclosure - Stock-based Compensation - Option Pricing Assumptions (Details)",
     "shortName": "Stock-based Compensation - Option Pricing Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R57": {
     "role": "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails",
     "longName": "9955543 - Disclosure - Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details)",
     "shortName": "Stock-based Compensation - Stock Option and Restricted Stock Unit Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://macrogenics.com/role/TeSeraTransactionDetails",
     "longName": "9955544 - Disclosure - TeSera Transaction (Details)",
     "shortName": "TeSera Transaction (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-240",
      "name": "mgnx:FutureMilestone",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails",
     "longName": "9955545 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails",
     "longName": "9955546 - Disclosure - Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details)",
     "shortName": "Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-11",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://macrogenics.com/role/IncomeTaxesValuationAllowanceActivityDetails",
     "longName": "9955547 - Disclosure - Income Taxes - Valuation Allowance Activity (Details)",
     "shortName": "Income Taxes - Valuation Allowance Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "mgnx:ValuationAllowanceDeferredTaxAssetIncreaseAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails",
     "longName": "9955548 - Disclosure - Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details)",
     "shortName": "Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails",
     "longName": "9955549 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)",
     "shortName": "Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-31",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://macrogenics.com/role/IncomeTaxesIncomeTaxPaidTableDetails",
     "longName": "9955550 - Disclosure - Income Taxes - Income Tax Paid Table (Details)",
     "shortName": "Income Taxes - Income Tax Paid Table (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://macrogenics.com/role/EmployeeBenefitPlanDetails",
     "longName": "9955551 - Disclosure - Employee Benefit Plan (Details)",
     "shortName": "Employee Benefit Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "mgnx:EmployeesEligibleAgeToParticipateInBenefitPlan",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "mgnx:EmployeesEligibleAgeToParticipateInBenefitPlan",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://macrogenics.com/role/SegmentReportingDetails",
     "longName": "9955552 - Disclosure - Segment Reporting (Details)",
     "shortName": "Segment Reporting (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "performanceobligation",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "performanceobligation",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mgnx-20241231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "mgnx_A2021ZaiLabAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "A2021ZaiLabAgreementsMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Zai Lab Agreements",
        "label": "2021 Zai Lab Agreements [Member]",
        "documentation": "2021 Zai Lab Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_A2022GileadCollaborationAndLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "A2022GileadCollaborationAndLicenseAgreementMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Gilead Collaboration And License Agreement",
        "label": "2022 Gilead Collaboration And License Agreement [Member]",
        "documentation": "2022 Gilead Collaboration And License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_ADCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "ADCMember",
     "presentation": [
      "http://macrogenics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ADC",
        "label": "ADC [Member]",
        "documentation": "Preclinical antibody-drug conjugates"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_ASDHealthcareAndOncologySupplyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "ASDHealthcareAndOncologySupplyMember",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASD Healthcare and Oncology Supply",
        "label": "ASD Healthcare and Oncology Supply [Member]",
        "documentation": "ASD Healthcare and Oncology Supply"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r763"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amortization of premiums and discounts on marketable securities",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r143",
      "r571"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive gain (loss)",
        "label": "AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax",
        "documentation": "Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r8",
      "r16",
      "r465",
      "r468",
      "r518",
      "r604",
      "r605",
      "r919",
      "r920",
      "r921",
      "r933",
      "r934",
      "r935",
      "r936"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "mgnx_AdditionalAnnualFixedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "AdditionalAnnualFixedPayments",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional annual fixed payments",
        "label": "Additional Annual Fixed Payments",
        "documentation": "Additional Annual Fixed Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r620",
      "r933",
      "r934",
      "r935",
      "r936",
      "r1020",
      "r1079"
     ]
    },
    "mgnx_AdditionalTZIELDMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "AdditionalTZIELDMilestones",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional TZIELD Milestones",
        "label": "Additional TZIELD Milestones",
        "documentation": "Additional TZIELD Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r382"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r808",
      "r819",
      "r829",
      "r862"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r811",
      "r822",
      "r832",
      "r865"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r812",
      "r823",
      "r833",
      "r857",
      "r866",
      "r870",
      "r878"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r416"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, allowance for credit loss",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r248",
      "r285",
      "r288",
      "r289",
      "r1046"
     ]
    },
    "mgnx_AmendmentFeeToCommercializationPartner": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "AmendmentFeeToCommercializationPartner",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/RevenueProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercialization partner payments",
        "label": "Amendment Fee to Commercialization Partner",
        "documentation": "Amendment Fee to Commercialization Partner"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anti-dilutive stock options",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails",
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "mgnx_AssetPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "AssetPurchaseAgreementMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Purchase Agreement",
        "label": "Asset Purchase Agreement [Member]",
        "documentation": "Asset Acquisition Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r117",
      "r145",
      "r175",
      "r209",
      "r217",
      "r236",
      "r240",
      "r282",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r460",
      "r462",
      "r494",
      "r566",
      "r653",
      "r723",
      "r724",
      "r763",
      "r786",
      "r973",
      "r974",
      "r1034"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r153",
      "r175",
      "r282",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r460",
      "r462",
      "r494",
      "r763",
      "r973",
      "r974",
      "r1034"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets measured at fair value",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r477",
      "r750"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets [Abstract]",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_AtTheMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "AtTheMarketOfferingMember",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At The Market Offering",
        "label": "At The Market Offering [Member]",
        "documentation": "At The Market Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://macrogenics.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r791",
      "r792",
      "r815"
     ]
    },
    "mgnx_AuditorInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "AuditorInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Information [Abstract]",
        "documentation": "Auditor Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://macrogenics.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r791",
      "r792",
      "r815"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://macrogenics.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r791",
      "r792",
      "r815"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r293",
      "r565"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      },
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Securities",
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r293",
      "r476",
      "r558",
      "r750",
      "r754",
      "r948",
      "r1024",
      "r1025",
      "r1026"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Principles of Consolidation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital Expenditures Incurred but Not yet Paid",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24"
     ]
    },
    "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis",
     "presentation": [
      "http://macrogenics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Project [Axis]",
        "label": "Project [Axis]",
        "documentation": "Information by project."
       }
      }
     },
     "auth_ref": [
      "r556",
      "r557",
      "r1043"
     ]
    },
    "mgnx_CardinalHealthIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "CardinalHealthIncMember",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cardinal Health",
        "label": "Cardinal Health, Inc [Member]",
        "documentation": "Cardinal Health, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r141",
      "r707"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1022",
      "r1023"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, Cash Equivalents and Marketable Securities",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r85",
      "r172"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r85"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r146",
      "r147",
      "r148",
      "r175",
      "r200",
      "r201",
      "r203",
      "r205",
      "r211",
      "r212",
      "r282",
      "r327",
      "r329",
      "r330",
      "r331",
      "r334",
      "r335",
      "r340",
      "r341",
      "r344",
      "r347",
      "r354",
      "r494",
      "r614",
      "r615",
      "r616",
      "r617",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r641",
      "r662",
      "r681",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r900",
      "r925",
      "r937"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r211",
      "r340",
      "r341",
      "r342",
      "r344",
      "r347",
      "r352",
      "r354",
      "r614",
      "r615",
      "r616",
      "r617",
      "r733",
      "r900",
      "r925"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "mgnx_CollaborationAndLicenseAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "CollaborationAndLicenseAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration and License Agreements [Abstract]",
        "label": "Collaboration and License Agreements [Abstract]",
        "documentation": ""
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "CollaborationAndLicenseAgreementsDisclosureTextBlock",
     "presentation": [
      "http://macrogenics.com/role/Revenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Collaboration And License Agreements Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaboration and license agreements."
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration received common stock warrant exercise price (in usd per share)",
        "label": "Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share",
        "documentation": "Collaborative Agreement Consideration Received Common Stock Warrant Exercise Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock warrants (in shares)",
        "label": "Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares",
        "documentation": "Collaborative Agreement Consideration Received Common Stock Warrants Number Of Shares"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_CollaborativeAgreementTransactionPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "CollaborativeAgreementTransactionPrice",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction price",
        "label": "Collaborative Agreement Transaction Price",
        "documentation": "Collaborative Agreement Transaction Price"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_CollaborativeArrangementExtensionTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "CollaborativeArrangementExtensionTerm",
     "presentation": [
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, extension term",
        "label": "Collaborative Arrangement, Extension Term",
        "documentation": "Collaborative Arrangement, Extension Term"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_CollaborativeArrangementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "CollaborativeArrangementTerm",
     "presentation": [
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, term",
        "label": "Collaborative Arrangement, Term",
        "documentation": "Collaborative Arrangement, Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement."
       }
      }
     },
     "auth_ref": [
      "r1019"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails",
      "http://macrogenics.com/role/RevenueNIAIDContractDetails",
      "http://macrogenics.com/role/RevenueProductSalesDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration and Other Agreements [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "mgnx_CombinedServicesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "CombinedServicesAgreementMember",
     "presentation": [
      "http://macrogenics.com/role/TeSeraTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Combined Services Agreement",
        "label": "Combined Services Agreement [Member]",
        "documentation": "Combined Services Agreement - Asset Purchase Agreement + Master Manufacturing &amp; Supply Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r321",
      "r322",
      "r701",
      "r968",
      "r970"
     ]
    },
    "mgnx_CommonStockMaximumAmountAvailableForIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "CommonStockMaximumAmountAvailableForIssuance",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock maximum amount available for issuance",
        "label": "Common Stock, Maximum Amount Available For Issuance",
        "documentation": "Common Stock, Maximum Amount Available For Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r776",
      "r777",
      "r778",
      "r780",
      "r781",
      "r782",
      "r783",
      "r933",
      "r934",
      "r936",
      "r1020",
      "r1078",
      "r1079"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r641"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r67",
      "r641",
      "r659",
      "r1079",
      "r1080"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, 0.01 par value -- 125,000,000 shares authorized, 62,819,857 and 62,070,627 shares outstanding at December\u00a031, 2024 and December\u00a031, 2023, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r567",
      "r763"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax assets:",
        "label": "Components of Deferred Tax Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax liabilities:",
        "label": "Components of Deferred Tax Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r158",
      "r160",
      "r165",
      "r559",
      "r577",
      "r578"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Loss",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r52",
      "r53",
      "r246",
      "r700"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r52",
      "r53",
      "r246",
      "r610",
      "r700"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r52",
      "r53",
      "r246",
      "r700",
      "r902"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r125"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Line Items]",
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Percentage of significant accounts receivable",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r52",
      "r53",
      "r246"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Table]",
        "label": "Concentration Risk [Table]",
        "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r30",
      "r52",
      "r107",
      "r700"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r52",
      "r53",
      "r246",
      "r700"
     ]
    },
    "us-gaap_ConstructionInProgressGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConstructionInProgressGross",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress",
        "label": "Construction in Progress, Gross",
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "mgnx_ContractManufacturingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "ContractManufacturingMember",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract Manufacturing",
        "label": "Contract Manufacturing [Member]",
        "documentation": "Contract Manufacturing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails",
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r357",
      "r359"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails",
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, current",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r357",
      "r359"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails",
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, noncurrent",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r357",
      "r359"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with Customer, Liability, Revenue Recognized",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Corporate debt securities",
        "terseLabel": "Corporate debt securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r741",
      "r743",
      "r750",
      "r764",
      "r773",
      "r1075"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of product sales",
        "label": "Cost of Goods and Services Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r78",
      "r555"
     ]
    },
    "mgnx_CostOfManufacturingServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "CostOfManufacturingServices",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of manufacturing services",
        "label": "Cost of manufacturing services",
        "documentation": "Cost of manufacturing services"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Product Sales and Cost of Manufacturing Services",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total costs and expenses",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs and expenses:",
        "label": "Costs and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails",
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails",
      "http://macrogenics.com/role/RevenueNIAIDContractDetails",
      "http://macrogenics.com/role/RevenueProductSalesDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails",
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/TeSeraTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r177",
      "r178",
      "r336",
      "r342",
      "r519",
      "r536",
      "r563",
      "r710",
      "r712"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesIncomeTaxPaidTableDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesIncomeTaxPaidTableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r903",
      "r927",
      "r1018"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesIncomeTaxPaidTableDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://macrogenics.com/role/IncomeTaxesIncomeTaxPaidTableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for federal or state income taxes",
        "totalLabel": "Provision for federal or state income taxes",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r927"
     ]
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesIncomeTaxPaidTableDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesIncomeTaxPaidTableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r903",
      "r927",
      "r1018"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r246"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r800",
      "r889"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r800",
      "r889"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r802",
      "r891"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r802",
      "r891"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r804",
      "r893"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r802",
      "r891"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r795",
      "r884"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r796",
      "r885"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r796",
      "r885"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r794",
      "r883"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r794",
      "r883"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r794",
      "r883"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r797",
      "r886"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r799",
      "r888"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r799",
      "r888"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r800",
      "r889"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r803",
      "r892"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r801",
      "r890"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r798",
      "r887"
     ]
    },
    "mgnx_DRIHealthcareAcquisitionsLPDRIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "DRIHealthcareAcquisitionsLPDRIMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DRI Healthcare Acquisitions LP (DRI)",
        "label": "DRI Healthcare Acquisitions LP (DRI) [Member]",
        "documentation": "DRI Healthcare Acquisitions LP (DRI)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss",
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r293",
      "r297",
      "r298"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available-for-sale",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Gross deferred income tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r109",
      "r438"
     ]
    },
    "us-gaap_DeferredRevenueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueCurrent",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Revenue, Current",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred revenue, net of current portion",
        "label": "Deferred Revenue, Noncurrent",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Tax Assets, Deferred Income",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross deferred income tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred income tax asset/(liability)",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred income tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "mgnx_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Deferred Tax Assets, Operating Lease Liabilities",
        "documentation": "Deferred Tax Assets, Operating Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal U.S. net operating loss carryforward",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State net operating loss carryforward",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "mgnx_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationAmountUtilizableOnAnnualBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationAmountUtilizableOnAnnualBasis",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards, amount utilizable on annual basis",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject To Expiration, Amount Utilizable On Annual Basis",
        "documentation": "Deferred Tax Assets, Operating Loss Carryforwards, Subject To Expiration, Amount Utilizable On Annual Basis"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsOther",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Orphan drug credit, net",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development credit, net",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails",
      "http://macrogenics.com/role/IncomeTaxesValuationAllowanceActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "periodStartLabel": "Balance at Beginning of Year",
        "periodEndLabel": "Balance at End of Year",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "mgnx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Operating lease ROU assets",
        "label": "Deferred Tax Liabilities, Operating Lease Right Of Use Assets",
        "documentation": "Deferred Tax Liabilities, Operating Lease Right Of Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenditures",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses."
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "DefinedContributionPlanEmployeesContributionVestedPercentage",
     "presentation": [
      "http://macrogenics.com/role/EmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of employee vested contribution",
        "label": "Defined Contribution Plan, Employees Contribution, Vested Percentage",
        "documentation": "Percentage vested of employee's contributions to defined contribution plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/EmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined contribution plan, employer discretionary contribution amount",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "presentation": [
      "http://macrogenics.com/role/EmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of employee contribution to salary",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r40"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r209",
      "r222",
      "r240",
      "r723",
      "r724"
     ]
    },
    "mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts recognized",
        "label": "Development And Regulatory Milestone Payments Under Agreement, Recognized",
        "documentation": "Development And Regulatory Milestone Payments Under Agreement, Recognized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://macrogenics.com/role/TeSeraTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://macrogenics.com/role/TeSeraTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r384",
      "r412",
      "r413",
      "r415",
      "r745"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r791",
      "r792",
      "r815"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r791",
      "r792",
      "r815",
      "r858"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Federal Government",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Federal and State",
        "label": "Domestic Tax Authority and State and Local Jurisdiction [Member] [Member]",
        "documentation": "Domestic Tax Authority and State and Local Jurisdiction [Member] [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_DrScottKoenigMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "DrScottKoenigMember",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dr Scott Koenig",
        "label": "Dr Scott Koenig [Member]",
        "documentation": "Dr Scott Koenig"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic and diluted net loss per common share, basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r198",
      "r200",
      "r203",
      "r204",
      "r205",
      "r208",
      "r455",
      "r458",
      "r473",
      "r474",
      "r560",
      "r579",
      "r716"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic and diluted net loss per common share, diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r200",
      "r203",
      "r204",
      "r205",
      "r208",
      "r455",
      "r458",
      "r473",
      "r474",
      "r560",
      "r579",
      "r716"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r207"
     ]
    },
    "mgnx_EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred state blended rate adjustments",
        "label": "Effective Income Tax Rate Reconciliation, Deferred State Blended Rate Adjustments, Amount",
        "documentation": "Effective Income Tax Rate Reconciliation, Deferred State Blended Rate Adjustments, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax adjustments",
        "label": "Effective Income Tax Rate Reconciliation, Deferred Tax Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred tax adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Orphan drug credit, net",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Orphan Drug, Amount",
        "documentation": "Effective Income Tax Rate Reconciliation, Tax Credit, Orphan Drug, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost related to non-vested stock-based compensation arrangements",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense recognition period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total unrecognized compensation cost",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Option",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum employee contribution percent",
        "label": "Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent",
        "documentation": "Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan": {
     "xbrltype": "durationItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "EmployeesEligibleAgeToParticipateInBenefitPlan",
     "presentation": [
      "http://macrogenics.com/role/EmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Eligible age to participate in plan",
        "label": "Employees Eligible Age To Participate In Benefit Plan",
        "documentation": "Refers to minimum eligible age of employee to participate in benefit plan."
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_EnoblituzumabMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "EnoblituzumabMember",
     "presentation": [
      "http://macrogenics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Enoblituzumab",
        "label": "Enoblituzumab [Member]",
        "documentation": "Enoblituzumab"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquipmentMember",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab equipment",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r135",
      "r161",
      "r162",
      "r163",
      "r184",
      "r185",
      "r186",
      "r188",
      "r193",
      "r195",
      "r197",
      "r210",
      "r283",
      "r284",
      "r314",
      "r355",
      "r445",
      "r446",
      "r452",
      "r453",
      "r454",
      "r456",
      "r457",
      "r458",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r472",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r502",
      "r503",
      "r518",
      "r575",
      "r604",
      "r605",
      "r606",
      "r620",
      "r681"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r808",
      "r819",
      "r829",
      "r862"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r805",
      "r816",
      "r826",
      "r859"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r477",
      "r488",
      "r750"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r477",
      "r488",
      "r750"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Fair Value Measurement Financial Assets",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r750",
      "r1022",
      "r1023",
      "r1028"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class [Domain]",
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r489",
      "r752"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class [Axis]",
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r489",
      "r752"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r475",
      "r477",
      "r478",
      "r479",
      "r480",
      "r487",
      "r488",
      "r490",
      "r523",
      "r524",
      "r525",
      "r731",
      "r732",
      "r741",
      "r742",
      "r743",
      "r750",
      "r754"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r477",
      "r478",
      "r480",
      "r750",
      "r1025",
      "r1029"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets, Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r364",
      "r369",
      "r477",
      "r488",
      "r523",
      "r741",
      "r742",
      "r743",
      "r750"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Other Observable Inputs, Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r364",
      "r369",
      "r477",
      "r478",
      "r488",
      "r524",
      "r731",
      "r732",
      "r741",
      "r742",
      "r743",
      "r750"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r477",
      "r478",
      "r480",
      "r750",
      "r1025",
      "r1029"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r475",
      "r477",
      "r478",
      "r479",
      "r480",
      "r487",
      "r488",
      "r490",
      "r523",
      "r524",
      "r525",
      "r731",
      "r732",
      "r741",
      "r742",
      "r743",
      "r750",
      "r754"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r750",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1029"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r286",
      "r287",
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r296",
      "r338",
      "r352",
      "r470",
      "r491",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r576",
      "r729",
      "r750",
      "r752",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r764",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r961",
      "r962",
      "r963",
      "r964",
      "r1021",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1029"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r812",
      "r823",
      "r833",
      "r866"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r812",
      "r823",
      "r833",
      "r866"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r812",
      "r823",
      "r833",
      "r866"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r812",
      "r823",
      "r833",
      "r866"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r812",
      "r823",
      "r833",
      "r866"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_FurnitureAndOfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "FurnitureAndOfficeEquipmentMember",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and office equipment",
        "label": "Furniture And Office Equipment [Member]",
        "documentation": "Furniture and office equipment are movable furniture, fixtures, or other equipment that have no permanent connection to the structure of a building or utilities. These items depreciate substantially but definitely are important costs to consider when valuing a company, especially in liquidation."
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_FutureManufacturingRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "FutureManufacturingRevenue",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future Manufacturing Revenue",
        "label": "Future Manufacturing Revenue",
        "documentation": "Future Manufacturing Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_FutureMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "FutureMilestone",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/TeSeraTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone from DRI",
        "label": "Future Milestone",
        "documentation": "Future Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnDispositionOfAssets",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "(Gain) loss on disposal of assets",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r923",
      "r966",
      "r967"
     ]
    },
    "mgnx_GainOnRoyaltyMonetizationArrangement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "GainOnRoyaltyMonetizationArrangement",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      },
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on royalty monetization arrangement",
        "negatedTerseLabel": "Gain on royalty monetization arrangement",
        "label": "Gain on royalty monetization arrangement",
        "documentation": "Gain on royalty monetization arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_GainOnSaleOfMARGENZA": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "GainOnSaleOfMARGENZA",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      },
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on sale of MARGENZA",
        "negatedTerseLabel": "Gain on sale of MARGENZA",
        "label": "Gain on sale of MARGENZA",
        "documentation": "Gain on sale of MARGENZA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r665"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "mgnx_GileadFirstResearchProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "GileadFirstResearchProgramMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gilead First Research Program",
        "label": "Gilead First Research Program [Member]",
        "documentation": "Gilead First Research Program"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_GileadMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "GileadMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gilead",
        "label": "Gilead [Member]",
        "documentation": "Gilead"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r791",
      "r792",
      "r815"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of long-lived assets",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r39",
      "r95",
      "r751"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r96"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r111",
      "r116",
      "r561",
      "r573",
      "r718",
      "r723",
      "r938",
      "r940",
      "r941",
      "r942",
      "r943"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r317",
      "r318",
      "r482",
      "r486",
      "r489",
      "r601",
      "r603",
      "r666",
      "r704",
      "r753",
      "r1048"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r318",
      "r482",
      "r486",
      "r489",
      "r601",
      "r603",
      "r666",
      "r704",
      "r753",
      "r1048"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Axis]",
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r424",
      "r425",
      "r433",
      "r442",
      "r749",
      "r1015"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Domain]",
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r424",
      "r425",
      "r433",
      "r442",
      "r749",
      "r1015"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r421",
      "r424",
      "r429",
      "r430",
      "r431",
      "r437",
      "r441",
      "r447",
      "r449",
      "r450",
      "r451",
      "r619",
      "r749"
     ]
    },
    "us-gaap_IncomeTaxExaminationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExaminationLineItems",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Examination [Line Items]",
        "label": "Income Tax Examination [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax provision",
        "totalLabel": "Income tax expense/(benefit)",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r132",
      "r196",
      "r197",
      "r209",
      "r225",
      "r240",
      "r423",
      "r424",
      "r448",
      "r581",
      "r749"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r749",
      "r1007"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States federal tax at statutory rate",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r749"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r749",
      "r1007",
      "r1009"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity-based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r749",
      "r1007",
      "r1009"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationOtherReconcilingItems",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other permanent items",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount",
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying statutory federal (national) tax rate to pretax income (loss) from continuing operation attributable to other reconciling item. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r1007",
      "r1008"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State taxes (net of federal benefit)",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r749",
      "r1007"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationofReportedEstimatedIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research credit, net",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r749",
      "r1007",
      "r1009"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes Paid",
        "label": "Income Taxes Paid",
        "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r87",
      "r924",
      "r1013",
      "r1014"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r922"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "mgnx_IncreaseDecreaseInLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "IncreaseDecreaseInLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Increase (decrease) in lease liabilities",
        "documentation": "Increase (decrease) in lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non current liabilities",
        "label": "Increase (Decrease) in Other Current Liabilities",
        "documentation": "Amount of increase (decrease) in current liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other non current assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "mgnx_IncyteClinicalSupplyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "IncyteClinicalSupplyAgreementMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incyte MGA012 Supply Agreement",
        "label": "Incyte Clinical Supply Agreement [Member]",
        "documentation": "Incyte Clinical Supply Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_IncyteCommercialSupplyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "IncyteCommercialSupplyAgreementMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incyte MGA012 Clinical Services",
        "label": "Incyte Commercial Supply Agreement [Member]",
        "documentation": "Incyte Commercial Supply Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_IncyteCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "IncyteCorporationMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incyte Corporation (Incyte)",
        "label": "Incyte Corporation [Member]",
        "documentation": "Incyte Corporation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_IncyteMGA012AgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "IncyteMGA012AgreementMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incyte MGA012 Agreement",
        "label": "Incyte MGA012 Agreement [Member]",
        "documentation": "Incyte MGA012 Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_IndefiniteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "IndefiniteMember",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite",
        "label": "Indefinite [Member]",
        "documentation": "Indefinite"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r812",
      "r823",
      "r833",
      "r857",
      "r866",
      "r870",
      "r878"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r793",
      "r882"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r793",
      "r882"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r793",
      "r882"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest and other expense",
        "label": "Interest Expense, Operating and Nonoperating",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r217",
      "r221",
      "r227",
      "r240",
      "r501",
      "r723",
      "r724"
     ]
    },
    "us-gaap_InterestIncomeOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeOther",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Income, Other",
        "label": "Interest Income, Other",
        "documentation": "Amount of interest income earned from interest bearing assets classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://macrogenics.com/role/Inventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory, Net",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Gross",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/InventoryNetScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory, net",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r708",
      "r763"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r140",
      "r150",
      "r299",
      "r300",
      "r301",
      "r554",
      "r713"
     ]
    },
    "us-gaap_InventoryValuationReserveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryValuationReserveMember",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Reserve, Inventory",
        "label": "SEC Schedule, 12-09, Reserve, Inventory [Member]",
        "documentation": "Reserve to reduce inventory to lower of cost or net realizable value."
       }
      }
     },
     "auth_ref": [
      "r928",
      "r929",
      "r930",
      "r931",
      "r932"
     ]
    },
    "us-gaap_InventoryValuationReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryValuationReserves",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory valuation reserves",
        "label": "Inventory Valuation Reserves",
        "documentation": "Amount of valuation reserve for inventory."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r917"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work in process",
        "label": "Inventory, Work in Process, Gross",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "us-gaap_Investments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Investments",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "verboseLabel": "Investments",
        "label": "Investments",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r564",
      "r772",
      "r775"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r134",
      "r249",
      "r251",
      "r492",
      "r493",
      "r1044"
     ]
    },
    "mgnx_JamesKarrelsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "JamesKarrelsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "James Karrels [Member]",
        "documentation": "James Karrels"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_JeffreyPetersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "JeffreyPetersMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Jeffrey Peters [Member]",
        "documentation": "Jeffrey Peters"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_LaboratoryAndOfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "LaboratoryAndOfficeEquipmentMember",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory and office equipment",
        "label": "Laboratory and Office Equipment [Member]",
        "documentation": "A facility that provides controlled conditions in which scientific or technological research, experiments, and measurement may be performed. and tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease, cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r509",
      "r762"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease, Cost",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r516"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r517"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r517"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate",
        "label": "Lessee, Operating Lease, Discount Rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Operating Lease, Liability, Maturity",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease renewal term (in years)",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r57",
      "r58",
      "r59",
      "r60",
      "r61",
      "r62",
      "r65",
      "r175",
      "r282",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r461",
      "r462",
      "r463",
      "r494",
      "r640",
      "r717",
      "r786",
      "r973",
      "r1034",
      "r1035"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders' equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r110",
      "r569",
      "r763",
      "r926",
      "r965",
      "r1030"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and stockholders' equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r139",
      "r175",
      "r282",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r461",
      "r462",
      "r463",
      "r494",
      "r763",
      "r973",
      "r1034",
      "r1035"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_LorigerlimabMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "LorigerlimabMember",
     "presentation": [
      "http://macrogenics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lorigerlimab",
        "label": "Lorigerlimab [Member]",
        "documentation": "Lorigerlimab"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_MGC026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "MGC026Member",
     "presentation": [
      "http://macrogenics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MGC026",
        "label": "MGC026 [Member]",
        "documentation": "MGC026"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_MGC028Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "MGC028Member",
     "presentation": [
      "http://macrogenics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MGC028",
        "label": "MGC028 [Member]",
        "documentation": "MGC028"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_MGD024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "MGD024Member",
     "presentation": [
      "http://macrogenics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MGD024",
        "label": "MGD024 [Member]",
        "documentation": "MGD024"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_MainSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "MainSegmentMember",
     "presentation": [
      "http://macrogenics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Main Segment",
        "label": "Main Segment [Member]",
        "documentation": "Reportable segment, which is discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r246",
      "r736",
      "r766",
      "r770",
      "r976",
      "r1047",
      "r1049",
      "r1050",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1076",
      "r1077"
     ]
    },
    "mgnx_MargetuximabMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "MargetuximabMember",
     "presentation": [
      "http://macrogenics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Margetuximab",
        "label": "Margetuximab [Member]",
        "documentation": "Margetuximab"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r323",
      "r324",
      "r325",
      "r326",
      "r379",
      "r417",
      "r480",
      "r552",
      "r600",
      "r602",
      "r609",
      "r632",
      "r633",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r702",
      "r703",
      "r728",
      "r733",
      "r744",
      "r754",
      "r755",
      "r759",
      "r760",
      "r767",
      "r975",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041"
     ]
    },
    "mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC",
        "label": "McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC [Member]",
        "documentation": "McKesson Plasma &amp; Biologics and McKesson Specialty Care Distribution LLC"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails",
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r323",
      "r324",
      "r325",
      "r326",
      "r379",
      "r417",
      "r480",
      "r552",
      "r600",
      "r602",
      "r609",
      "r632",
      "r633",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r702",
      "r703",
      "r728",
      "r733",
      "r744",
      "r754",
      "r755",
      "r759",
      "r767",
      "r975",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r246",
      "r736",
      "r766",
      "r770",
      "r976",
      "r1047",
      "r1049",
      "r1050",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1076",
      "r1077"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "NationalInstituteOfAllergyAndInfectiousDiseasesMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueNIAIDContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NIAID",
        "label": "National Institute of Allergy and Infectious Diseases [Member]",
        "documentation": "Represents a collaborators with which entity has an agreement related to contracts and research grants received from U.S. government agencies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86",
      "r88"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/SegmentReportingDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r88",
      "r112",
      "r137",
      "r157",
      "r159",
      "r163",
      "r175",
      "r187",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r196",
      "r197",
      "r202",
      "r282",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r455",
      "r458",
      "r474",
      "r494",
      "r574",
      "r661",
      "r679",
      "r680",
      "r784",
      "r973"
     ]
    },
    "mgnx_NetProceedsFromSaleOfFutureRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "NetProceedsFromSaleOfFutureRoyalties",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from sale of future royalties",
        "label": "Net proceeds from sale of future royalties",
        "documentation": "Net proceeds from sale of future royalties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_NextGenerationTCellEngagersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "NextGenerationTCellEngagersMember",
     "presentation": [
      "http://macrogenics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Next-generation T-cell engagers",
        "label": "Next-generation T-cell engagers [Member]",
        "documentation": "Next-generation T-cell engagers"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_NonCashInterestExpenseRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "NonCashInterestExpenseRecognized",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash interest expense",
        "label": "Non-cash interest expense recognized",
        "documentation": "Non-cash interest expense recognized"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_NonDilutiveFunding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "NonDilutiveFunding",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/OrganizationandNatureofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-dilutive funding",
        "label": "Non-dilutive funding",
        "documentation": "Non-dilutive funding"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r812",
      "r823",
      "r833",
      "r857",
      "r866"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "mgnx_NonRefundableUpfrontFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "NonRefundableUpfrontFees",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-refundable upfront payment",
        "label": "Non-refundable upfront payment",
        "documentation": "Initial fee received from collaboration or license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash operating and investing activities",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r724",
      "r939"
     ]
    },
    "mgnx_NumberOfPerformanceObligations": {
     "xbrltype": "integerItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "NumberOfPerformanceObligations",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of performance obligations",
        "label": "Number Of Performance Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_NumberOfProductCandidates": {
     "xbrltype": "integerItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "NumberOfProductCandidates",
     "presentation": [
      "http://macrogenics.com/role/RevenueNIAIDContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of product candidates to develop",
        "label": "Number Of Product Candidates",
        "documentation": "Number Of Product Candidates"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_NumberOfProductCandidatesApprovedByTheFoodAndDrugAdministration": {
     "xbrltype": "integerItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "NumberOfProductCandidatesApprovedByTheFoodAndDrugAdministration",
     "presentation": [
      "http://macrogenics.com/role/OrganizationandNatureofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of product candidates approved by the FDA",
        "label": "Number Of Product Candidates Approved By The Food And Drug Administration",
        "documentation": "Number Of Product Candidates Approved By The Food And Drug Administration"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_NumberOfProprietaryProductCandidatesAdvancingInClinicalDevelopment": {
     "xbrltype": "integerItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "NumberOfProprietaryProductCandidatesAdvancingInClinicalDevelopment",
     "presentation": [
      "http://macrogenics.com/role/OrganizationandNatureofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of proprietary product candidates advancing in clinical development",
        "label": "Number Of Proprietary Product Candidates Advancing In Clinical Development",
        "documentation": "Number Of Proprietary Product Candidates Advancing In Clinical Development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://macrogenics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Reportable Segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r719",
      "r727",
      "r939"
     ]
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r718",
      "r938",
      "r940",
      "r941",
      "r942",
      "r943"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r762"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities, net of current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "mgnx_OperatingLeaseNoncashExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "OperatingLeaseNoncashExpense",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash lease expense",
        "label": "Operating Lease, Noncash Expense",
        "documentation": "Operating Lease, Noncash Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease payments",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r513"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, ROU Assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average lease term (in years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r514",
      "r762"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "mgnx_OptionToBuy": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "OptionToBuy",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option to buy",
        "label": "Option to buy",
        "documentation": "Option to buy"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://macrogenics.com/role/OrganizationandNatureofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization and Nature of Operations",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r106",
      "r611",
      "r612"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non current assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain (loss) on investments",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r575"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss):",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncome",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/TeSeraTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Income",
        "label": "Other Income",
        "documentation": "Amount of revenue and income classified as other."
       }
      }
     },
     "auth_ref": [
      "r580",
      "r663",
      "r691",
      "r692",
      "r693"
     ]
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncomeAndExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "presentation": [
      "http://macrogenics.com/role/TeSeraTransaction"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TeSera Transaction",
        "label": "Other Income and Other Expense Disclosure [Text Block]",
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions."
       }
      }
     },
     "auth_ref": [
      "r904",
      "r1005"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non current liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other non-cash items",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest and other income",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "mgnx_OtherProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "OtherProgramsMember",
     "presentation": [
      "http://macrogenics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other programs",
        "label": "Other programs [Member]",
        "documentation": "Other programs"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r810",
      "r821",
      "r831",
      "r864"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r813",
      "r824",
      "r834",
      "r867"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r813",
      "r824",
      "r834",
      "r867"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of marketable securities",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r167",
      "r250"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property, equipment and software",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://macrogenics.com/role/EmployeeBenefitPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Benefit Plan",
        "label": "Retirement Benefits [Text Block]",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r362",
      "r363",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r743"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "mgnx_PotentialCommercialMilestonePaymentsUnderAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "PotentialCommercialMilestonePaymentsUnderAgreement",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential commercial milestone payments",
        "label": "Potential Commercial Milestone Payments Under Agreement",
        "documentation": "Potential Commercial Milestone Payments Under Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential development and regulatory milestone payments",
        "label": "Potential Development and Regulatory Milestone Payments Under Agreement",
        "documentation": "Potential Development and Regulatory Milestone Payments Under Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential milestone payment to third parties for intellectual property under agreement",
        "label": "Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement",
        "documentation": "Potential Milestone Payment To Third Parties For Intellectual Property Under Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_PotentialTargetNominationOptionFeesAndMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "PotentialTargetNominationOptionFeesAndMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Target nomination, option fees and milestone",
        "label": "Potential target nomination, option fees and milestone payments",
        "documentation": "Potential target, nomination, option fees and milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Undesignated preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r340"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Undesignated preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r641"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Undesignated preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r340"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Undesignated preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r641",
      "r659",
      "r1079",
      "r1080"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r302",
      "r303",
      "r709"
     ]
    },
    "mgnx_PrincipalPaymentsOnRoyaltyMonetizationArrangement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "PrincipalPaymentsOnRoyaltyMonetizationArrangement",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Principal payments on royalty monetization arrangement",
        "label": "Principal payments on royalty monetization arrangement",
        "documentation": "Principal payments on royalty monetization arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock, net of offering costs",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sales and maturities of marketable securities",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r168",
      "r949"
     ]
    },
    "us-gaap_ProceedsFromSaleOfMachineryAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfMachineryAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sales of equipment",
        "label": "Proceeds from Sale of Machinery and Equipment",
        "documentation": "The cash inflow from sale of machinery and equipment."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_ProceedsFromSaleOfOtherProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfOtherProductiveAssets",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of MARGENZA",
        "label": "Proceeds from Sale of Other Productive Assets",
        "documentation": "Amount of cash inflow from the sale of tangible or intangible assets used to produce goods or deliver services, classified as other."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash proceeds from exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r13"
     ]
    },
    "mgnx_ProceedsfromRoyaltiesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "ProceedsfromRoyaltiesPercent",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential proceeds from royalties percent",
        "label": "Proceeds from Royalties, Percent",
        "documentation": "Proceeds from Royalties, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "ProceedsfromStockOptionsExercisedAndESPPPurchases",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from stock option exercises and ESPP purchases",
        "label": "Proceeds from Stock Options Exercised And ESPP Purchases",
        "documentation": "Proceeds from Stock Options Exercised And ESPP Purchases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductMember",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product",
        "label": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails",
      "http://macrogenics.com/role/RevenueNIAIDContractDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/TeSeraTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r243",
      "r555",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r706",
      "r734",
      "r765",
      "r767",
      "r768",
      "r771",
      "r774",
      "r971",
      "r972",
      "r976",
      "r1047",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1076",
      "r1077"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails",
      "http://macrogenics.com/role/RevenueNIAIDContractDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/TeSeraTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r243",
      "r555",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r706",
      "r734",
      "r765",
      "r767",
      "r768",
      "r771",
      "r774",
      "r971",
      "r972",
      "r976",
      "r1047",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1076",
      "r1077"
     ]
    },
    "us-gaap_ProjectMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProjectMember",
     "presentation": [
      "http://macrogenics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Project [Domain]",
        "label": "Project [Domain]",
        "documentation": "Planned program of work."
       }
      }
     },
     "auth_ref": [
      "r556",
      "r557",
      "r1043"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r516"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftware"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Equipment and Software",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r126",
      "r130",
      "r131"
     ]
    },
    "mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Useful Lives",
        "label": "Property Plant And Equipment Estimated Useful Life Table [Table Text Block]",
        "documentation": "Property plant and equipment estimated useful life."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, equipment and software",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r142",
      "r572"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, equipment and software, net",
        "totalLabel": "Property, equipment and software, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r516",
      "r562",
      "r572",
      "r763"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Equipment and Software",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r126",
      "r130",
      "r570"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r516"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful lives",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_ProventionAPAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "ProventionAPAMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provention APA",
        "label": "Provention APA [Member]",
        "documentation": "Provention APA"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_ProventionBioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "ProventionBioMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provention Bio, Inc. (Provention)",
        "label": "Provention Bio [Member]",
        "documentation": "Provention Bio"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_ProventionLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "ProventionLicenseAgreementMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provention License Agreement",
        "label": "Provention License Agreement [Member]",
        "documentation": "Provention License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_ProventionPRV031Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "ProventionPRV031Member",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provention PRV031",
        "label": "Provention PRV031 [Member]",
        "documentation": "Provention PRV031"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_ProventionPRV3279Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "ProventionPRV3279Member",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provention PRV3279",
        "label": "Provention PRV3279 [Member]",
        "documentation": "Provention PRV3279"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails",
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r323",
      "r324",
      "r325",
      "r326",
      "r362",
      "r379",
      "r407",
      "r408",
      "r409",
      "r417",
      "r480",
      "r526",
      "r535",
      "r552",
      "r600",
      "r602",
      "r609",
      "r632",
      "r633",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r702",
      "r703",
      "r728",
      "r733",
      "r744",
      "r754",
      "r755",
      "r759",
      "r760",
      "r767",
      "r778",
      "r969",
      "r975",
      "r1025",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails",
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r323",
      "r324",
      "r325",
      "r326",
      "r362",
      "r379",
      "r407",
      "r408",
      "r409",
      "r417",
      "r480",
      "r526",
      "r535",
      "r552",
      "r600",
      "r602",
      "r609",
      "r632",
      "r633",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r702",
      "r703",
      "r728",
      "r733",
      "r744",
      "r754",
      "r755",
      "r759",
      "r760",
      "r767",
      "r778",
      "r969",
      "r975",
      "r1025",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract",
     "presentation": [
      "http://macrogenics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable",
     "presentation": [
      "http://macrogenics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized Tax Benefits [Roll Forward]",
        "label": "Unrecognized Tax Benefits [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r805",
      "r816",
      "r826",
      "r859"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails",
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails",
      "http://macrogenics.com/role/RevenueNIAIDContractDetails",
      "http://macrogenics.com/role/RevenueProductSalesDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails",
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/TeSeraTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r177",
      "r178",
      "r336",
      "r342",
      "r519",
      "r536",
      "r563",
      "r711",
      "r712"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r420",
      "r1006"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r420",
      "r1006"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails",
      "http://macrogenics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r704",
      "r723",
      "r1042"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expenses, Including Clinical Trial Accruals/Expenses",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r806",
      "r817",
      "r827",
      "r860"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r807",
      "r818",
      "r828",
      "r861"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r814",
      "r825",
      "r835",
      "r868"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r102",
      "r568",
      "r607",
      "r608",
      "r618",
      "r642",
      "r763"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r184",
      "r185",
      "r186",
      "r188",
      "r193",
      "r195",
      "r197",
      "r283",
      "r284",
      "r314",
      "r445",
      "r446",
      "r452",
      "r453",
      "r454",
      "r456",
      "r457",
      "r458",
      "r464",
      "r466",
      "r467",
      "r469",
      "r472",
      "r502",
      "r503",
      "r604",
      "r606",
      "r620",
      "r1079"
     ]
    },
    "mgnx_RetifanlimabMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "RetifanlimabMember",
     "presentation": [
      "http://macrogenics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retifanlimab",
        "label": "Retifanlimab [Member]",
        "documentation": "Retifanlimab"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_RevenueFromCollaborativeAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "RevenueFromCollaborativeAgreementsMember",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from collaborative agreements",
        "label": "Revenue From Collaborative Agreements [Member]",
        "documentation": "Revenue From Collaborative Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_RevenueFromGovernmentAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "RevenueFromGovernmentAgreementsMember",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from government agreements",
        "label": "Revenue From Government Agreements [Member]",
        "documentation": "Revenue From Government Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical trial activities selling price amount",
        "label": "Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount",
        "documentation": "Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r705",
      "r714"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, remaining performance obligation, amount",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails",
      "http://macrogenics.com/role/RevenueNIAIDContractDetails",
      "http://macrogenics.com/role/RevenueProductSalesDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails",
      "http://macrogenics.com/role/SegmentReportingDetails",
      "http://macrogenics.com/role/TeSeraTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r115",
      "r164",
      "r175",
      "r209",
      "r218",
      "r219",
      "r234",
      "r240",
      "r243",
      "r245",
      "r246",
      "r282",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r494",
      "r561",
      "r723",
      "r973"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_RevenuesFromCMOAgreementsMemberMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "RevenuesFromCMOAgreementsMemberMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RevenuesFromCMOAgreementsMember",
        "label": "RevenuesFromCMOAgreementsMember [Member]",
        "documentation": "RevenuesFromCMOAgreementsMember"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_RevenuesFromCMOAmendmentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "RevenuesFromCMOAmendmentAgreementMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RevenuesFromCMOAmendmentAgreement",
        "label": "RevenuesFromCMOAmendmentAgreement [Member]",
        "documentation": "RevenuesFromCMOAmendmentAgreement"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_RevenuesFromGrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "RevenuesFromGrantsMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueNIAIDContractDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RevenuesFromGrantsMember",
        "label": "RevenuesFromGrantsMember"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_RevenuesFromLicenseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "RevenuesFromLicenseAgreementsMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues From License Agreements",
        "label": "Revenues From License Agreements [Member]",
        "documentation": "Revenues From License Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_RightOfUseAssetAndLeaseLiabilityIncrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "RightOfUseAssetAndLeaseLiabilityIncrease",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right of use asset and lease liability increase",
        "label": "Right of Use asset and Lease Liability Increase",
        "documentation": "Right of Use asset and Lease Liability Increase"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds of stock sale",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of common stock (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of common stock (in dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales revenue, net",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r901"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Options and RSUs Excluded from the Calculation of Net Loss Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://macrogenics.com/role/RevenueGileadSciencesIncDetails",
      "http://macrogenics.com/role/RevenueIncyteCorporationDetails",
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails",
      "http://macrogenics.com/role/RevenueNIAIDContractDetails",
      "http://macrogenics.com/role/RevenueProductSalesDetails",
      "http://macrogenics.com/role/RevenueProventionDetails",
      "http://macrogenics.com/role/RevenueZaiLabDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of the Company's Deferred Income Tax Assets (Liabilities)",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Reported Estimated Income Tax Benefit",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r749",
      "r1007"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory, Current",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r73",
      "r74",
      "r75"
     ]
    },
    "mgnx_ScheduleOfInventoryReservesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "ScheduleOfInventoryReservesTableTextBlock",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory Reserves",
        "label": "Schedule of Inventory Reserves [Table Text Block]",
        "documentation": "Schedule of Inventory Reserves"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r516"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://macrogenics.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r383",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r103"
     ]
    },
    "mgnx_ScheduleOfShareBasedPaymentAwardModifiedAwardsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "ScheduleOfShareBasedPaymentAwardModifiedAwardsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Payment Award, Modified Awards, Valuation Assumptions",
        "label": "Schedule of Share-Based Payment Award, Modified Awards, Valuation Assumptions [Table Text Block]",
        "documentation": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions for Dr. Scott Koening"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Employee Stock Options Award Valuation Assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of RSU Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock, Class of Stock [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r98",
      "r100",
      "r101",
      "r102",
      "r146",
      "r147",
      "r148",
      "r211",
      "r340",
      "r341",
      "r342",
      "r344",
      "r347",
      "r352",
      "r354",
      "r614",
      "r615",
      "r616",
      "r617",
      "r733",
      "r900",
      "r925"
     ]
    },
    "mgnx_ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Supplemental Balance Sheet Information, Operating Leases",
        "label": "Schedule Of Supplemental Balance Sheet Information, Operating Leases [Table Text Block]",
        "documentation": "Schedule Of Supplemental Balance Sheet Information, Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r748"
     ]
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Percentage of Customer Concentration",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r30",
      "r52",
      "r107"
     ]
    },
    "mgnx_Section174DeferredTaxAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "Section174DeferredTaxAsset",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesComponentsoftheCompanysDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Section 174 deferred tax asset",
        "label": "Section 174 deferred tax asset",
        "documentation": "Section 174 deferred tax asset"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://macrogenics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r117",
      "r209",
      "r214",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r228",
      "r229",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241",
      "r242",
      "r246",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r319",
      "r320",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r720",
      "r723",
      "r724",
      "r730",
      "r769",
      "r1047",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1076",
      "r1077"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://macrogenics.com/role/SegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Disclosure",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r209",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r230",
      "r232",
      "r233",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r719",
      "r721",
      "r722",
      "r723",
      "r725",
      "r726",
      "r727"
     ]
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting, Other Segment Item, Amount",
        "label": "Segment Reporting, Other Segment Item, Amount",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r232",
      "r233",
      "r240",
      "r723"
     ]
    },
    "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems",
     "presentation": [
      "http://macrogenics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Accelerated Cost",
        "label": "Share-Based Payment Arrangement, Accelerated Cost",
        "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost."
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingPercentageOfUnvestedAwards": {
     "xbrltype": "percentItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingPercentageOfUnvestedAwards",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accelerated vesting, percentage of unvested awards",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Accelerated Vesting, Percentage Of Unvested Awards",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Accelerated Vesting, Percentage Of Unvested Awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited or expired (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in shares)",
        "terseLabel": "Awards granted in period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding nonvested (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)",
        "periodEndLabel": "Ending Balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r397"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance (in dollars per share)",
        "periodEndLabel": "Ending Balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r397"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r383",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation, number of shares authorized (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering period",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Expired (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited or expired (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average grant-date fair value of options granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)",
        "periodEndLabel": "Ending Balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r389"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price (in dollars per share)",
        "periodStartLabel": "Beginning Balance (in dollars per share)",
        "periodEndLabel": "Ending Balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r389"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock purchased by employees (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited or expired (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options granted, maximum term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationOptionPricingAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining contractual term, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining contractual term, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining contractual term, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of shares vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percent of fair market value to purchase shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssued",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in shares)",
        "periodEndLabel": "Balance (in shares)",
        "label": "Shares, Issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "mgnx_SideLetterAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "SideLetterAgreementMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Side Letter Agreement",
        "label": "Side Letter Agreement [Member]",
        "documentation": "Side Letter Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r173"
     ]
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software",
        "label": "Software and Software Development Costs [Member]",
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://macrogenics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r117",
      "r136",
      "r209",
      "r214",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r228",
      "r229",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241",
      "r242",
      "r246",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r316",
      "r319",
      "r320",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r720",
      "r723",
      "r724",
      "r730",
      "r769",
      "r1047",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1076",
      "r1077"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r146",
      "r147",
      "r148",
      "r175",
      "r200",
      "r201",
      "r203",
      "r205",
      "r211",
      "r212",
      "r282",
      "r327",
      "r329",
      "r330",
      "r331",
      "r334",
      "r335",
      "r340",
      "r341",
      "r344",
      "r347",
      "r354",
      "r494",
      "r614",
      "r615",
      "r616",
      "r617",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r641",
      "r662",
      "r681",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r900",
      "r925",
      "r937"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r67",
      "r70",
      "r71",
      "r135",
      "r161",
      "r162",
      "r163",
      "r184",
      "r185",
      "r186",
      "r188",
      "r193",
      "r195",
      "r197",
      "r210",
      "r283",
      "r284",
      "r314",
      "r355",
      "r445",
      "r446",
      "r452",
      "r453",
      "r454",
      "r456",
      "r457",
      "r458",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r472",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r502",
      "r503",
      "r518",
      "r575",
      "r604",
      "r605",
      "r606",
      "r620",
      "r681"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r210",
      "r503",
      "r555",
      "r613",
      "r631",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r641",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r660",
      "r664",
      "r665",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r681",
      "r779"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r210",
      "r247",
      "r503",
      "r555",
      "r613",
      "r631",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r641",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r660",
      "r664",
      "r665",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r681",
      "r779"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r809",
      "r820",
      "r830",
      "r863"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_StockIncentivePlan2013Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "StockIncentivePlan2013Member",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails",
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Incentive Plan 2013",
        "label": "Stock Incentive Plan 2013 [Member]",
        "documentation": "Stock Incentive Plan 2013 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_StockIncentivePlan2023MemberMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "StockIncentivePlan2023MemberMember",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "StockIncentivePlan2023Member",
        "label": "StockIncentivePlan2023Member [Member]",
        "documentation": "StockIncentivePlan2023Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, net of offering costs (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r66",
      "r67",
      "r102",
      "r614",
      "r681",
      "r695"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r66",
      "r67",
      "r102"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationStockOptionandRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r66",
      "r67",
      "r102",
      "r393"
     ]
    },
    "mgnx_StockIssuedDuringPeriodSharesStockPlanActivity": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesStockPlanActivity",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock plan related activity (in shares)",
        "label": "Stock Issued During Period Shares Stock Plan Activity",
        "documentation": "Number of shares issued due to stock plan related activity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, net of offering costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r66",
      "r67",
      "r102",
      "r620",
      "r681",
      "r695",
      "r785"
     ]
    },
    "mgnx_StockIssuedDuringPeriodValueStockPlanActivity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "StockIssuedDuringPeriodValueStockPlanActivity",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock plan related activity",
        "label": "Stock Issued During Period Value Stock Plan Activity",
        "documentation": "Value of shares issued due to stock plan related activity."
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_StockOptionsAndRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "StockOptionsAndRestrictedStockUnitsMember",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntidilutiveSecuritiesExcludedfromtheCalculationofDilutedLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options and RSUs",
        "label": "Stock Options And Restricted Stock Units [Member]",
        "documentation": "Stock Options And Restricted Stock Units"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r70",
      "r71",
      "r91",
      "r643",
      "r659",
      "r682",
      "r683",
      "r763",
      "r786",
      "r926",
      "r965",
      "r1030",
      "r1079"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r174",
      "r339",
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r353",
      "r355",
      "r471",
      "r684",
      "r685",
      "r699"
     ]
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Sublease Income",
        "label": "Sublease Income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r762"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Valuation Allowance",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r1012"
     ]
    },
    "mgnx_SynaffixBVMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "SynaffixBVMember",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Synaffix B.V.",
        "label": "Synaffix B.V. [Member]",
        "documentation": "Synaffix B.V."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US Federal tax credits carry forward",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Period [Axis]",
        "label": "Tax Period [Axis]",
        "documentation": "Information by period subject to enacted tax law."
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Period [Domain]",
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "mgnx_TaxYear2027To2028Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "TaxYear2027To2028Member",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Year 2025 To 2037",
        "label": "Tax Year 2027 To 2028 [Member]",
        "documentation": "Tax Year 2027 To 2028"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_TaxYear2027To2044Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "TaxYear2027To2044Member",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Year 2027 To 2044",
        "label": "Tax Year 2027 To 2044 [Member]",
        "documentation": "Tax Year 2027 To 2044"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_TerSeraMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "TerSeraMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueProductSalesDetails",
      "http://macrogenics.com/role/TeSeraTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TerSera",
        "label": "TerSera [Member]",
        "documentation": "TerSera"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Text Block [Abstract]",
        "label": "Text Block [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_TotalFixedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "TotalFixedPayments",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total annual fixed payments",
        "label": "Total Fixed Payments",
        "documentation": "Total Fixed Payments"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r945",
      "r946",
      "r947"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r338",
      "r352",
      "r470",
      "r491",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r576",
      "r750",
      "r752",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r764",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r961",
      "r962",
      "r963",
      "r964",
      "r1021",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1029"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "TwoThousandSixteenEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2016 Employee Stock Purchase Plan",
        "label": "Two Thousand Sixteen Employee Stock Purchase Plan [Member]",
        "documentation": "Two Thousand Sixteen Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://macrogenics.com/role/RevenueManufacturingServiceAgreementsDetails",
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Government-sponsored enterprises",
        "terseLabel": "Government-sponsored enterprises",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae)."
       }
      }
     },
     "auth_ref": [
      "r977",
      "r1045"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofFairValueMeasurementFinancialAssetandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "U.S Treasury securities",
        "terseLabel": "U.S. Treasury securities",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r715",
      "r741",
      "r743",
      "r750",
      "r1045"
     ]
    },
    "mgnx_UndesignatedPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "UndesignatedPreferredStockMember",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Undesignated Preferred Stock",
        "label": "Undesignated Preferred Stock [Member]",
        "documentation": "Undesignated Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrealizedGainLossOnInvestments",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Gain (Loss) on Investments",
        "label": "Unrealized Gain (Loss) on Investments",
        "documentation": "Amount of unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r434",
      "r748"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized interest or penalties",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r432",
      "r748"
     ]
    },
    "mgnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases/(decreases) for prior year tax positions",
        "label": "Unrecognized Tax Benefits, Increase (Decrease) Resulting From Prior Period Tax Positions",
        "documentation": "Unrecognized Tax Benefits, Increase (Decrease) Resulting From Prior Period Tax Positions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesReconciliationoftheBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases for current year tax positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r748"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r748"
     ]
    },
    "mgnx_UpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "UpfrontPayment",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/RevenueProventionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment from DRI Health Trust",
        "label": "Upfront Payment",
        "documentation": "Upfront Payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33",
      "r123",
      "r124",
      "r127",
      "r128"
     ]
    },
    "mgnx_ValuationAllowanceDeferredTaxAssetDecreaseAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "ValuationAllowanceDeferredTaxAssetDecreaseAmount",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesValuationAllowanceActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deductions",
        "label": "Valuation Allowance, Deferred Tax Asset, Decrease, Amount",
        "documentation": "Valuation Allowance, Deferred Tax Asset, Decrease, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_ValuationAllowanceDeferredTaxAssetIncreaseAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "ValuationAllowanceDeferredTaxAssetIncreaseAmount",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesValuationAllowanceActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase, Amount",
        "documentation": "Valuation Allowance, Deferred Tax Asset, Increase, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_ValuationAllowanceRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "ValuationAllowanceRollForward",
     "presentation": [
      "http://macrogenics.com/role/IncomeTaxesValuationAllowanceActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Allowance [Roll Forward]",
        "label": "Valuation Allowance [Roll Forward]",
        "documentation": "Valuation Allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesBalance",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance at Beginning of Year",
        "periodEndLabel": "Balance at End of Year",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "documentation": "Amount of valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r183"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "crdr": "credit",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions Charged to Expenses",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense",
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense."
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesDeductions",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deductions",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesDomain",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "documentation": "Valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r182",
      "r183"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "documentation": "Information by valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r182",
      "r183"
     ]
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r182",
      "r183"
     ]
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "presentation": [
      "http://macrogenics.com/role/InventoryNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r182",
      "r183"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease cost",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r511",
      "r762"
     ]
    },
    "us-gaap_VehiclesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VehiclesMember",
     "presentation": [
      "http://macrogenics.com/role/PropertyEquipmentandSoftwareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Motor vehicles",
        "label": "Vehicles [Member]",
        "documentation": "Equipment used primarily for road transportation."
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_VobramitanmabDuocarmazineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "VobramitanmabDuocarmazineMember",
     "presentation": [
      "http://macrogenics.com/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vobramitanmab duocarmazine [Member]",
        "label": "Vobramitanmab duocarmazine [Member]",
        "documentation": "Vobramitanmab duocarmazine"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted weighted average number of common shares outstanding (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r205"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic weighted average number of common shares outstanding (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r205"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "mgnx_ZaiLabLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "ZaiLabLimitedMember",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Zai Lab Limited (Zai Lab)",
        "label": "Zai Lab Limited [Member]",
        "documentation": "Zai Lab Limited"
       }
      }
     },
     "auth_ref": []
    },
    "mgnx_ZaiLabMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://macrogenics.com/20241231",
     "localname": "ZaiLabMember",
     "presentation": [
      "http://macrogenics.com/role/RevenueZaiLabDetails",
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesSummaryofCollaboratorsthatRepresentMoreThan10ofTotalRevenueEarnedandAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Zai Lab",
        "label": "Zai Lab [Member]",
        "documentation": "Zai Lab"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/942-320/tableOfContent"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii)(B)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479664/932-10-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477385/932-360-S50-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(h))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "610",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/610/tableOfContent"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/705/tableOfContent"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/720/tableOfContent"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-1B"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/940-320/tableOfContent"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>95
<FILENAME>0001125345-25-000042-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001125345-25-000042-xbrl.zip
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M_&7+\Y-Q(";'811*6(#_<(P7RIC_]#U/AO0G_/X9N$WLN_S^A_1:]G_9<NN
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M\2.0'\.?+WK:6,9$:8"^42_P!TQ]\X\AO_327/J<ERFJI_<A)]/?2V)C^A,
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M 4"E,^NJP+3+ +C2A8!+I^:4 4JE"P"7B?]9"D)[@0I"U8W>91A@BSS_JAO
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MWRV=?5S!RKSFHM!_MY26\7=#XUEO>:)2XB0:]?P02(Q_259[ID![MW36>3'
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MNXOQ<K3V&ZT%N5YV.XWV_G<Y3-1QHV5R#(J]DT2![SF(!V_53^A#G?JE=-;
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M!CG%'("I<I\JR0KR6@8X8=$1K@NR(A;(\)&]HLLRG/NM ZRG/O,#?)^,0,;
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M'FD*(B7?&$YOQ.GJ<"'=R7S?W)$[[3>H\<KL(0=.CY*RE=JM]'-#QYIWR <
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M+?07+?,Y:T!G? J5&Z[S3I#)@[2UIL]A[2;JN#J9/3=C29RSX@SF03!Y7-#
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MNVM)(0:E=<O<B"O.+U+$-@19GZK672-R56#B8G%*4/?B4T/UQ.9L>FLS&/W
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MDEGFGFCN;B9Z\"O,&"\K(6Z6OO@DS9+-31Q@SS,"I^;1S#";!C8(Y&<87JO
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M3#)1OH0)#S\ 5H;A=+TYNSN)B#&$I5QBP60T'G(U,3D"Z2D]M 9@'0@A9K,
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M5A(R3WZAA$:[@4:LT OM[UN5Z(@E=Y0#CBV]T)&O>@SJQ^%-H+)'=2LUC?V
M0L4#%4J1%IWC&;9DT#M2S8Y!7.4]#)G]-YP/Y$($TT'5INBT-/0-T)$F*')3
MBT)H@A-F[F,O K-9P]E1\.#*4"":1GJ43LVO)"M8COTT0AMDVV]([%"B-Z<-
MF'R)(/.P#ZE*<-+GLF,7V"1BE#?'XZ,%;28()%@$//>6AN:B,Q.+2_-%YQDT
M7#P)@DC1=EZPH;)3K1PG*[V)/1@^]D-!VB0G2D)3951]YMU4?CV_AUK$8CZ3
MS^LK>EQ9WA'$8.=)81+&+.O"'A8H)[F<GF<7*39.IEA^$+W)U #-L24&7.Q
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M/N4!^N!,?G'WFW[$BTY.V2-M5-P$OU?4S?0C4MD)^VGYF$1^]Y16<@^^+LB
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M!I/DWT LSIWIUK? RW?*B20"]I9IJ.D\7C2[@C-TM%V-X/4<]3^T6=]OHH:
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M;&1G*=R$7J-&Q&F NN#&-;;UW&*)6!2/,,D<+LRAQ<SHR8(:X6 %(QA3S=J
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M<?O >Z,+O(AVD699/.=K N;7"A3!=N'QD:>,2^?(P1!9Y$Y;>W=%K%_/_E1
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METQ;XOG_GO*@8GX,94&W_>MN=17Z0N5RH*@D.7O+EJ$\ +8N?U#8GA<.E3Q
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M#2IOKLM1<@^N=S+/$@V1@^I?(T&AQ, <E+>C&$J+CR1E>^05H^]&U<N$F#N
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M^.W8G/UIF3TN*),&ACT[="FNI3+/^'3HJ J-<+W@>';<#)&-BIW<,WX=919
M"RL\:#3XY *@.YM1!ZE>HDP(QWXH7W034 B/F4PEUG*443?HLJ*:!7C X4?&
MRFZ@RH8!8C/09@ F,O_8V?OW8?PRIJ_!45KPBJ/P)?WJ<F_')Q4<N:5?@R*Z
M4[5.']9#?.PWZJUNHC_'W:.7%@PHP@]A5&=K\5S1$Q*ZE4F'\_"T#/.7G$[?
M9;/T$(BOSR,,9[6;A?Q*NNN T1F*^@U^G)TNYDA"HTYADSQ!R^U:YCC]X9L"
MQ+\B6OK=C=B;+M$]S%%6'?M>?F59-P:NCQS!TA+'G"*-FVI,Z9QC8=3&QT'<
M\J K%E-X%S<DDJ!9=K*R;;!T;^)_Q)\9]KV2GNC50-K'CET$\>Z)*_=:TY<N
MX-A7UN*D%V=V:Q7&8QR6?@9FR]KJ:B$-'3\61RV2?@DB$;79SPB,)M60>_;&
M('@1S-L/TVE +OC8%>DL50F(*9:3&J&(7IHFJ%AP"1.-=)H5V>OVWB*;3_96
M8>O4DOGURXNS_/G4/4]-(%0@6Z8\BF>-E$9GIPT@ZZPY(RQL0W1!0LC%/8K;
M:/>0RCDPA=.3EN<Y_D&@K>NP ??6**^A61<IN,5GE3MM]HX,'6Z>O]4@390.
MI0/3/)TPFB1NT431,!FP@G7,+^O3&@7'D*@CD1UC"=:)AW#;RYXXRR^.W:O\
M.JUI4TB)FWHCXJMPISQX62LBMKUM6,SSP+B@H@0'M.S9M1**](EO9\\X]T0#
M6,8 QIW7]>[")&UUQDD@+=;DEU3E5=T0PRT4SG@' .F"XV>:9>B.I6Y2]A>+
M9_*NND1\-4_8@.ZQ'XQSXX=21YCM+\UA*L,?6I]"C$@T1(>4A1FJH_P'M /V
MH7>\^8Y48&[(#AS]T#J::;S+$T6:H1AX!%/C->/J:]#740L7%T*G*HJ_'^+%
M5UEA+QX%.F[4)[RK))^5Y2,O6VXD4W;0G:6UIRE6914Q#:U/#NG-!A4,O]3U
M7#M,MSA+AGG<WIHJV98$*:#53S:MZMXY&OZI"<L2IJE^.XB9"Q66R7Y_*5SN
MHM9X4,J !*1:@>!5CH#/U$7=PRTW9;4U6SR]@L;&CX(CN!)5'/V^$T:]1(\]
M(I#31RBR2,4XXXS>3?2I"H.^,"P2*0/F[SN<9F=:##GML\U!( N.290C7MZ1
M+LC=01B*AVV+\\4;&+6-^#$]!(WB7J@0+X&&%BW_NY[0JL7TB!OLXB\?N!]N
M*&2LK\XV81W7ZI=@@O)[Y.S9GS_:)@'J_4\?D7GJ>38ZSSZGT?FW_UP%!JRO
M7!GN8)_Z\PEC-3G^SS[C.YPF[E>9.)*L;_=ZT+?A9L?@I]/\/([Y26SZZ \:
M,*6ZT^(T88]CPGQI83QC+&;&=)45>N6$E@?];*<Y?!QSJ.U7&:F+=EZ>)NEQ
M3)*/B\E]O!*J1DILG^;HD<R1\_.M=[2\0\,7]WV*5DH7^GZC"3HJX2A9:1(0
M(@?_=- ]GKG5(%D$?EB/)K7[,.I9L^&<]>+L.K"/RB4?C>QI0A_'A$*=#?ER
M5!M/T_(XIB6.'G5#LCNYS5O''- D\?4BU9VS^%M'R'-\[00.R\!AGSTV<-AI
MFWV$N WGU4/PX'G*_<AS[@->BYGL-\JQG%ME_KE,C\,KCY8;J^Q1=J*.IDL;
M[3(N8X/I2L6O4!%1QMF3@6.:A^M]1T15M1!7"@$, 8INK$EOIR5;2O^O@]3&
ME0=R2E.0 3Q4BQYHDH258R%V; A& \M@J'A==QT@*F<OYG+KP\:(H<1]XH<6
M^6UV?8WA^B8IP@.WA2[:+LY]K\J4<1S+=KO>;1@;J26*OT8GS15 =)"7@4>9
MT8X$0DL#RTR$VFAEKTWW:Y;,S0)7/<Z?2L6(EDS6FZ4L1:"I9^0F/Y0N"SQ6
MN]A6W52%Y@,'BN=E3LXEETA+"BX$T:A4,O;W1@*@Z,;X/LK0\7_^U[,_??+\
MLV=%4ERX;N*X_7^??G+^29R1S4;Z>\?EMVDV/B9IN:+2=!\$A%HN6)!WR?2"
M7.*,#Y'=Q) WKCG$]96PYF*YR8NH7CX!=:41YB;3_)EX9/!SW 5F\1-XP$3M
M=<KPOYH8@(YI5+C+TV&T#/(SP"E/"B,J?[@A;7VO8GH'@IOXWF7 <QB#3)RP
ML(E2BQ/=1]>=^WXZ1_&I7=5O8C$@-N=R8BLZI5*/&Y<^!X01T3[^<[>Z8@QG
M^&D9!#\Q-5G!6D +>0\M.W%YM.RN![(5DXI328AP:N?/\7\<K:R30I'N@L%'
M\[+SO-J6%TO"]Z1/76D>YXI[Q?S-I.=QR^O:CM>DLJ&*=9X.)AX]5ZXMWNAA
M/* ZQAW]F;DE7E6T\"O?:1R[_*'#"(L>F*#KIF&^*)-/O=[_/=Q0^-#Q._93
MYL>YV1\X5>-9'TZUTM%DF7CA#X0WX<!*$QP/DR(LAL V:.K$TB\6J7DV/839
MR5MN'*?V#;Z $[&%HTJK,<EKT%*H>EF-(N^1#KSI->D7HAR:IV7WD&779P+Q
MP,&LWVL<V*TFGUZQ67"VA]C$8J1C^<UWKSV'ASHU"B+.5@EG5)@53",52#HU
MFRQZ20T\90?Y(;1SPU-I:6$W3)22M9^O@?175K55L]R!MY2/,<.]3NV7+5'P
MR8 (I')6Y/F2.C0"IW-%?64G'()N^&>ACC)57?#7'!B(B<,@.@8WS-DQE%&?
M>A^]EL=_FY)*!0BTXQ>=6CW6K.F>DM'<9!-PU, :H2LF/5MV-!%N;%4MR<LS
M/L/L/7ZX9IV6N$#0H$8=!='2[(4*5IG?E'@KOD$T>"JJX)>VA$OS![.CP?*V
MC,/HV@NI@% 6\7,,D5H\V7)?"/30W1[0XC0V#/9]CV?"G+L17Q4#HYB)OF9L
MI@ZR-[@93/?\*% 33"-3IN.1(RT0R6@0K\O70,1\>U.ZG-LBQ92I/O#A5EAZ
M4EO.#:/M6<FU@@XL:; /+<_T*9@[01@24O^F[U7B6N<ND=]!258BTYCJN -Q
M=_2'Q=<B93\_DM"MG*(GS.PX$.-B9;@+U/.+@4W,R-;9@P31:GSTD:'XRX<.
MZ2G=^_X0CWBLZF'Y-34:TFQ__N?/*/O Q++MXL>21:+^'OH^M)UCS4K)KHE#
MYU0X>R13O-5:%$WRFF)^MY^9T-IXK$^3]C@F;=F"LA%9I@Z$C*A:GB;G,4P.
M@87MV.IV';*:\,K0H]PHU@,!R#B;=)K&QS&-:>9,J57BK$&'R6G"'L>$]4W/
M=-I(G5.9-9O!+*(XS=GCF+/4 C\J*?TJ4_2'1.Y\?A3(G=.&><B&:<-ZUT7;
MYJ(L"J8E%VFTWAR?]^IV(#$23*W/<CW9YV)\OJUZ@0KL3L?:XYIQILZ"CHVR
MHS9"8="TS%_ 6/'PD_S"\G 9H]AI6A_+M.;YVFD^<@'^Y\J&PUK:?7#5T[1^
M5+Q_%ZI_,:_R<>>"J?QBQ"J2_)_-_J9:F>-^R=/DCLW74_HK9Y(H[CE4PDW+
M%>6F9>JDJ?#Y$.LVE6BXK&?5$H[)<94P $=0;O]6&N['ZC]]IHQ<+.J2RWBM
M,K-2S"BUH\D736C1DD0@V%I++<:K!5"I)D^5<]'!:S]/B"L2UTG;E"NE):#R
M$9A0AP J-X:IYG& \,9(GYBQ3CR&:03,O36M@5SIX@[S3$BNT!XME(@+[/\^
M&C[0: K:5_!WA-<38%%:P.T$."$A/7<],5#I_AN0A7(EG4?1H2$2["'Z][@F
M<T80.X7.FVD3'CDC_ZM:E6EL26;DZO<,H,/D.!Q$$FZ<FTY"!"1:>@;EI'I9
M3;!A5;"X+=O]H%R?U<K(@@E0=U?W@ HF%B.'W Z$=RR7^_/%BSPAI21JPHE2
M![G2/@..0K* G?UIF0%\.7\0E1(=F]W!C8QY>1M*(ZD??TO!(IXL%9DV=]OX
M?A>9+,H*C*"W:)*$]&@:)R4,4L)9=]I035>'20GDFA%;#)M;^]+ \@J(@9$*
M YK+:7@2YS<*4/02FM-HC;A&S+Q@ X0&T-:I[CH//-31\K/+!V.\++-N*1Y?
M4>8"#%!RWG73SLYF/O,.$1,$*CG%N"V=#]WTT7QPZS%:)YTUMEAS:^C9EQ_T
M(2/C(VIB/@RGP %SNY$4G2AY4ZLR(QL5K)0T.[SP[$@5KBK+Z?.D]L1CV:M5
M2D I$F=83;&6.FL];:M'C0!Z46IO('&5(SU"7R6]A/6.4QIQN)T?%03KO=Q[
MW45C:LO=4B\;H6ZI;EHOXQ;-=[PLW^NZ EF^_,7-R775*BL>)OM=V)-.,#%)
MD3ISNFNT$ATI)VT*<UQS20#J3%3)8WA_EX%NGACRAIX FT=P)T)$(%Z\M1K[
M706Q6;X1 V3L9;FC)+1$X4FWJ(E?>Y/<KK76J\@^6/MQ"DEUF=D7V,9N]O<Q
M_>;X^(\7J_W;?QZW4T.AEZY!%WG!1!BN3I. V2H3R*$7 "JAIQ7X4BS*FN4<
MW':Y%-%%W81"*LV[A#5WBOLVA^T#?DBX'6R@1;L'K6FD>AC4P6#QN(:H9@=Z
MIKGB8_0,I.M!Q=(QZ$)M*GL7!^%Z$T=C5XI+)*J;T&EF<ELYO=5_L(\/2/4'
M'*'9L>V&[<!P)>]NRBK9]LL5ZMQ^&TK5P;6B^\W24[M %D29N78Q#:A2>L,G
M,#AN9_R"&PQ(Q4?4KI80F"+)8T]IO*RZ=B<=DK)J\J,C2V, [-R1&@H4[4CZ
M.''_JN2+S\WRJN2SG>)!BX O/6OPQ$+(([F#_3GG!,Q*"C5H >/=U4$LKEP%
MIRGI[G4=%WYWO>O!]\XX5G*#>0>1ARH*4Q-)':>8I>JPV&77)3(!ZUV[@5KX
MLI6UA8],'L@A/G:S#ZJT54J?8]<3H:Y^W:=B7HGC20*8(1,XII?!NS3+&+N9
M4%,&1)NZLW7>2F6/L;:JBLKGL A_WY9D""!VQT?>P#PD.<=I:RU'MS/:ZHDS
MDC71*%$MINL\/O[#>M*.U %\(7*7<?UAW?;E3]!V3>J&#QV"]^M?4\&5=/O<
M^8^1X$I4/<TPW_\\LRV3T*EK6FUV^658A!^9C75326RT_ACWW1UQAL-]ZI4_
M8UZ)-!6'/JTD5LV85MSAV_,UV%OP\;R388W'H,D.VQIM=QMC';>4MHI,ZY?I
M)6-0?76%9HH/><_?IP []UYGO.O&[YUQ'1<DQ1=6;FO%L^^GM"UC(-9);F@\
MO]J^DK)&E7I==ZH/G70(G**[=$B:QT19G7B$D%+1DLV&F0G"9*(K1-QKN.$4
M)4)W>=-<.E/BRH GV(J'K7SQV& K'V<<!N<1+YM,X( K_ED1+167#OF.[)(Y
MT_'#Y&X99J-A(;5%0T,F;?\$H0#^!G=X8I5//[*XD!MRC5:4*JO6:]FL.!F(
M?T,\TJL&V=?4>SP,TJ3=72\"$4]4PZ)GUY9PRG"-\\7W\'KC5G[HB9^[OCEX
MOFG3O6FF]/;J?/*E+N,S<(\2/[SZ#9O]H!G?Y5!$5LD[EBAOO OW:0UK.Z]\
M(#O+=M'+WE+U8C[1;[JQ+*!4S>BGW,.O?\\1\UO[HH?5MN/YTD5GP>CR20#W
M96*"B5,-N9W%:T*9A@FC_:#3=ENV5]$HB7W^\M<\;M_3]:;W-<>&5D5Y XVG
MO/0E&DL 'Y6UL2(EKP7TYESX'7S10NG+P05VG:]63Y!]R$+F?MC\JDZ6=_0W
M*WXG>HXBMX,'B([./VK6\KWWTD?H)F>[+1K)R_(F4<]03@0:?5DZJE[I5XC-
M%+11C1K=3;K WI31(7ANG:QM8C52 2E<#KZ*XN &"\#)OB7V(R7&N8RA?GP^
M^&BF30E1!O<N/O.&*@U)V'*%B"X^T G^IH*S]Q8E"OKRJUI<Q/B/?1\6+YKV
MIE'*%(D.I-X\7+NT4_""\FPK:J!D3BG;/)IP5#T!/]Y*FRT2'LOK.BZ-JSUY
MNCV'02 8"Z!2X,2@\9>E2JC>@36$)W?9(#GZ0#M2#(D&AE,G,XMYY:9G.!<E
M%=4OJ0"R1DS0Y;G1(,+%W##ZBW2,GM!O]_>E95@AK-JL&EYUT3WJA2Y+!69U
MPF+\&Y>SA;9"4-2+4MF>:YN$6-Y+\GJT!!^,;?WRPQ"0IQ7PGBM J_-2>Q38
M449?TXG=>0^&X]/L_<:SMVN[&-@-#_')C*:G#AI28Y;+:QRTD]@0AG*$#1U!
M=-/$'B)JSRBNN$<85,=-IIH/.TL0#:0E)&>6!7Q#Y$GW?Q<L*7D53ZMULQ0M
MLZ3'R&=AH6A/^"U62-7XD#)[R__959W4!S$$*Z(I[IUYH[>($6-O$58-16.!
M8)VVQ"/<$@RQ&LN,B>M(G'S&1.@=LW(D3,.+M>!JU^C/P/#&+83TQ6A/46G\
M)I2R#SA925MD M!F:#A\0'1<;<-.H+C6&3".5=].2_&1+46.66FTA IX8U*D
M!4/D6994Z(<H97'#*8O"2?XQNI[%L5=QD2Q%OIY$">2GH6CIC+"B1-]#M3X)
MKMR-*F8(SHB-B"(+</J]E,X'^GD>$L6(E@$R2N*20/$,'S9Z694-Y@Q;'PT[
MDP7%3Z'2<C*R'W]E3ZPF9??B&EP.N\:*W%FKB( LB.!XS*789:M.N;C("[VK
MIU9Q6MN=I]ME8NC\VN2B<**9A*AO&^!?+6YIYLN^TYG3TSK\Z.NPS!'(6"TI
M]01@E<L]+5JZ'&OTU$S/30;G0"[^/B_8HYFKWE,:CQ;6@<<B8 $YH0XF_=Z"
MDJ<U]NLIE72#Y.%0&SGEL?+/ MO%\N"L$<7KKV!&3*H5(8MZ0^!+[1UC)'Q8
MAY8LZ1(2M+1 7"152%,7F[C$R"#X3#@3=5.?I9_7B[;9,R,4?7D3/<2F#J[2
MM6V086WNB*=0KMCP\>Q4_^C9%+58W!_;35*,Z\-K<=VE+)GWLZNR=/1NS'8[
MTRK(UTUM'4X]#9H"EU7/QU&A=0F/V;MD@. 9:P;H-C6*\],^_.C[<";7T5(]
M'/#ZQ#"?])NQPS:4I-AQ !<_W.M&U"3&KK.F/=NJ54UQ5ZFY3TX2+.ZH%-8Q
M!_]MU0>_R%SCZS]#<T/]7_\*[)K'HX(#M?DG:N9O+QP!71 FQM1-DNY^6I^/
M<'W&2:3>_R"J<8<6XGH8\25/-IM[M][R/D>3+7@O<H$'KX8_)*#I3X\-T'3:
MFS][;WK* G5OPLH:T>+Q?QOJ*@B'ZJC',>ZM HD3^RIZD V/8*V$5)4MJ<7+
M\PR7-X3J@ WG%+W2&SS$EP*8*/'X3B%YLLZ"4%)?RGJBJ9VY]Y?,PY_<U>E1
M\2,"5:6$X$PI2?+-JC4!P9AH5EINCUY([-7$\'6+50/7([F:D.A*4C(/*KSX
MY%Q<4 A(AW=#TD*GHP.SN\V7)E5,;X<?28  J3QO;4:N,=-" &2;$1KL-7SH
M$F0@?^_SQ<7&2,11P<_PX+H>LT!E*F:>'I%5Z)8Q(.;L43P+N\5%#2+Z-Y"C
MH,H0"(V??7+V7XRQ\)5EWS.5PGE*UN>C^?L"6[O6,%H:&E72J/F2+9!:Q<%%
M!L#V;;.YU9Y5A[3:7DH(.-7RC9AK%<["]N:Z[,3AM26++SS$MDU6(=5&L>95
MSRQGS$[_LS?+NB*6_)X30-;LCX"4,\Y<F_D]K9T?55+,H7ZHX8QJ8!D"2[*N
M[N"ZH?;T<@DXD.S@RZIQV*0$TEHW[<C^>3:.P>1C66J;73$+4?T18@PY.,72
MQ!*AA?!.J/001W&)-IN_[T?=^@CJ8K2(GO1;=QIJ 7"0QMYL1&2PD'8% 0I?
MQSM#@$&:04B]L.NT6W:X;4Q\(Y?UHF1#]/X[Z?_CVHC(!6D;B5R-7A%H[O'!
M/O-G=]<0K?#.U1,3+DMJXHIPTV8(4:*#V@OO:)J'@9K@J+Z:,R[A5GH$Y)3S
MJH(XPVJB+!0S%!1I<0G9@KIR:ATG*K$\(5VOPXMV%#L]<N(V[L[=$ X ?"X^
M49M,E9.E'#X6C8V#"FBI @@J@MNIKTD"*L#+]_M1R@OMQ7>U<!;0(K"]9^V&
MT:+@>E+7XS8<:)?'L!-1:,-/GRY$MXG#*W0UEJDF@11;:NG[+"RRVG6]-'?+
M@+OE>15JX//WW)HPH@?!P4TIM@ID#1L![KOR8C%3X[$75B.CJ\:KL5L7!2&#
M#?XQ,&ZR3^ZN _:N9';RC63^/,Z'81$27 MUL+*6HCA'3W[L1\:+,2Q;>[=@
M:O*$*>O)-CU,KY=HFD:)B_D=I-:[7=6+\F.FYN>(-"ZCHT$IWUK("?B"9"U9
M/;9?H$/$"2MB">QH<VW&+LD\_YRT4QA]W431J!F%;XIHDCSZ?%%Q"L@!DVH]
M'-VRN0GJ'DG?2.L+2>;T%EDO2P,D+[AE>W O,0_ BLS+NP<X9,Z9+GNU/:K<
MII/)R"]TC]>KGW$'.3'C'5(D(SJGRM63RQCBB!Q)^'!H/26XZNW KIM:-FG5
M# F'$I)Y!//&^L9-&#:;8X@ZR=K*T]*M;71H:A.;P/W!HI]F%^O1N\EK#=((
M<^5,ZHMO!;V[]12 ;=8-YJ\RBS\?T<N0L9SKC++>C".WA^)":S.,=LD9G&7@
MC273!D(?+*8**KIYX<N7#%/7'"]-&,4I.COX:=^1/*Z8HH?T -$T8TOY#C_=
M@O&0+Z_X^?P&-72.=ZI&7JW!/+(\-I_4EAP2(C9\.\[+^Z>''DO/%332I8;+
M[23:5IF'5X,/C<>&CM-XK-3)W\J]SP.GTZ"_):Z/RV:UY_Z=>-]_[JX0 OGT
MH)#4:;7AC)YD;P\I$)D,R34/!%=ZB_C' 0N:V8\#Q)C3D+2/V;IUY*P-/UI#
MTD9\'M [DG;GI#3??K$A81O.][QIEN]N8W ;0Z/OXIFT84]_X33UDA(H5L@-
M<G*ZR#7RRX\OG5^'H3*J3F_%C,YE.N[WHIM8VZ0HV>.A-DTO-$!5E]Y+V\2H
MJIL#8P5@^^'/@@2 /RJ)XXE9#88;^[)J=!.B.*P)TK"X>/F"CU#ZV)JN2.D'
M(B%UYWPM9,&&4L"C'IA-"O_2 H@>3IR'AF.08U_7XV[!,1Y'S.S >+9792U>
ME#4.@&=)%C%++/#8&M?H#GEEW@*NQW')LK6(8U:W6']3F%H^2F^JFT#O,J <
MRPX'<^9VH 4;+J#\+ A#]IG\X)AQ^*9PX9E8ZO2A03U^295WG=GQZ6<ZC*#3
MJH2+7'PQP!P,\,\ZR53.^ *EE!*^^<F5>4/BGET>B#(EM9GW)8\63Q V*LH[
MTP:HUGOI<L/%VI9:4<QAZ^("ZSA7MO=>F_:O3E]^H"?L>OZGC,^(9<6+TT*?
MF(@"Z_WT[69N=JKV^VK_?SRV:O_'&8>9C0S"[,M1$%#FJS_)/SL=[0.B R[-
MJVR8Y>*O?[\8Y#GX8Q(.JW$<9T\RVP&_@+@6Y81,!SAG\(6,2&VO6)3\ #&Z
M<'75O3<D;^:2^8Z%>,:"@RH:IWTF4#\27 Y,091S(&SVV>6,OTR 9S4'YY(M
MEJ!KZ=(5#YT*=8)$^-VK+<\L#@RKYB24,[%IN;BSB;MEM7=%'K'1KGHIXAO'
MGAYX$V1]J$<X6E0TKX%"\.B'<@D]OKUQ63$25<91AZ=:LY_@EO8]?3W #&]N
MLQCQ%Q)A/D&-[E<U1/&G$QCSGHWD9:MHG'&([YQ9J8OESN!E8*!WJL_%7^T;
M"U_B>=]L3OC/QSCQ&7X>H'RT19<&H[E_[G&(2NU$?5IQ0*5&_3^[Z#TAO=:&
MFTVY9#]WSO[\.O#0TV+YF8M%DQ83R7UP$S)AJ?/HFW9@1BQ&G>"<+]G=F0A4
M*J^^$D0.*+\P56.._FB^\!&?D3P.V)H='? #*X1<XGN@EA6;\9VT#\1)75S'
M)PS"%L>'.<L![*1BX-.GFNB]Y_#W[J)I@%#%$L[8=#!JY2[!.4BCCR!9HWVI
M>P-'#+W7<666:S]>X0,,RF77U )<K99*6#<J"@.7Y>NLWJ8-_>,;?"MA*5%T
MZ2DFX11AS_>F%XFSPUQ-75]P/\?,)VYCM*J,VK"L(MXS48 VCTT:H;.\ S83
M,Z6("ZXH 4O(^#6&39:SB$O-.<^MAY](/3XXW$H?1AG.5PR"0+%1><*9.Y^N
MX$2/,@0&0Y&X&1$IL%E8@X03C3+_[AE$08@YN8@G3G=(GR05U(9-N"WK?B8$
M.5H>[*^3#M!41_RHPAL4.D<0V*J\JN,"K9;=L)26%VFX+RZ,&OW]#,V79^9K
M,H=)(8_)W/^8B($]Q0(JG$,?RW]F>C(.;(0[ *T<YO!\<8'FQHZEI2@[NBP[
M!:MI^/VAD#<3RPI=[YE"AD>6([0>BBV6DR_)JAJ)E]M$AW'L/*19&OD5CX@
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M!PG5U9N8D]C]@!BZ2*%QHA)D'@PM%X2<]B;>/+ZAT+1P_<N%63QNU4$58K8
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M:[]X(NE/#CR5!2K[/#OUI8/<QQ-I^2[.[/*:6[@+3FFQ:(?ZN\0RJ94,'F,
M)]E9DWB-'-A1,^( *3HN+ZTJ:5C/57<L\4==3'I )G@TJMF(>SK5'Z&T;_Q^
M+RU;638MZ^\=4_>JE)>K5$IBQY*+$^X\T;_C5,]R(%P6MRDAAPH<:9D4"JBN
MO! D(SQ!PX**2)R43NIWQ#(N'?3:O) =&1YZ2D.3ME-6E1=6;F9 U,V2W.!B
MJG:"9Y%*!J.O% _*.Y?H-;BN:D40,)!"H;7=L?KE;I+6\J&J+)+V^ 68+!_9
MYA:*+@K&<5D02S\A#:#@RFW:ZT1_#:NGP*#NP*H/P-Q@-3<IJ7\X1>])YU4V
MV5VW&&A/ [1RN(K#D>68&WM8&,S70AVN2JE=*+OI='5.Z6&5M?Z>IZ$G*90.
M=FXT"P9:KEKA$?:/[54!'E;S,.Y#Q-<93L65_@YS,/W%@S(F-JQF>?/SS_ L
M#NH"CEO<C0'Q=C1*YN;IP6KKF:@"/JSHZD[MU*0UC'0@ADD;G;; <\LSN(@[
M\X&?,]2ZX\[8:'@;9"IHN,CD##Z+PV(;YZA3E:JU)#WVB5CZR.W%J]K13A14
M,*P(=+_NLC)4=F(C<U<:1?,EG;*<AL=B/E.?0MO!A;!P4HW45^$/K@<!81LY
MH'X%("1EAY%$+J \HP0N\TT0"T9"JX&. BNX(-CX+7H-"H*@M-P;DU*O=(^#
M">)"9!^1YN&S^#;&*OS05GP&OLJ2?"F-S0YM$AZ]%;6@AQ]M"6=0>'J^=HJ2
M[SY[,0%"@->4  \4PC0W-QC8JIZSK\X$C'#,3^F:+B\P7;!G@11'I*Y9_,P1
M>VY/[RYH$LDYRC%DX,;GS#(:AT58%"&>*-Z!4,DYD=5Z+YP(8#,B6[1_/O9E
MD!/,^#')"4Y<I4G7J5F)5*+/53V6 NO[JJ1F>0XZN4-]1:2I5(\F=6@I)VO/
M+)E6>N\,QI[692X=J!VXQK1B_K(K8*4$6,6E"P SXL4>#3WYA]6LA;48=,#L
M;_2.@UG'7,A4;'S3F$>_+(W_Y=[-$AL8;4;F!GD^<P61-7(&G7:2IA<37RX1
M-O,^3<%#8HIT-/LF43NX^AQ@>.'88DKE.YSCI[8.T4F4"TH3,,?RM!NAW[7.
MN&$,9? 58(V1.O=GYK!5!$^4 @W/^"4QFG\GBP '"#\13+J=?LN,YNJF9<%*
M#$_AYKU8:)<P $.;]=E**"@<I(R>]#8L'#K^*UU0;M<*)A;-3T*[!4X@W<.2
MBLG&&80BOA2J@*Y1)=0[[RG0S(B5O.@![2^PY):4#FT&QU_2M54:XQ+-O*Z7
MM\"I5_6L2T$]<I1V4U$FYI?F[D/VS5>A3S+C(1MA/=3C),2X54 V\0J@WVKP
M35$!TFE"NDI6U=Z8J2Y#KGPA]"=2N")^BYJI4IC6;87MS]F"ALM&[<+)&=*W
MI"4CB]?'.,G42B2_T#07%<ZV6T<O- /2[.?9FE\Y!3"] R]Z(1[R?-96(:9/
MT)#,J95C'1&7/T(Q$&,KE37C!PJ!(N?:)N)&99"J&>V+G,04V)1*VQO\]XW1
M>B#-\7N3\C*+H!)>-%/?0N'B10ENB/@7U7D_2GTO<EXD1R?+SJNX#TI8<1!:
MH>01X:!WP7B:;B7=E3Y7Z*<0X#0]UXJ90Y"8ORPC<H@>]I'$B^**7,=?Q?W/
M0X306+65I^4WG/>?G8Y>H8,<\;B3Y8A0(!@CJVULA7C9=[;RX*M+DTL8" :M
M%Q0+G:OX(*<_J/?6$;Q,WZ@PJ=9XLRWL->E50;-":G'NFKC0#F@8D#K%L6<T
MDX94Z$-52HWYMS.;DKV<^FO;FR!H$J)HB6.HZ8G&2: 4^02DOF!U 'Q4I$?V
M/_D$RLY9D9L=[H)DGC>^4)P%..CD"5?[8Z_A1I?O^V7?4-C^Z2>??BY(]+K9
M@1B6YS3ZA-8#1X/P6B%63)L1YVF]^,IFF@G-H_OXLCU?O%U&B[CXKR;4U95Y
M%.7-31.7;))T!PX/NDYZ$=EL2EEE75M_;82I*'DQZ/J>>0CFEA"005RV^1YB
M5Q. [?*6/(<@%3<J&_"Q:)[+QB@HC+YAZ0C4#CU#E3NUIVJRKR9_>:HFT\-Q
MMRFMKLO0)3*IU'/&R5GMPNOZ9OGNNMEP'SVPBFD-T[[C'6>P(K>'=15?5]HR
M>'#UBFQ4JEFJA"W*"FFCB+ZMJ*@ ]&FQ?)<%\RLH$[ .D.-OH@ L14B].UC4
MI^;PG2):JHCCR#5VO.Q2AW0]CCRK_28LVUUEP3B[7_13<KJZ927V*?DF4X>D
M!]92T0HLQYB&2V8,YD"6@U Y$@>(2_-#R,&I HX,FV>B0^>*F:L[&V,%M!_B
M_2_B05U!!1E43'N+E6@F*52L:I9%2O<8WV+0WV'8JZ$BX$S)-)WE-$O7 (PK
MZ8@/BN+'>+ YK5Y'EY?2_R50^XB+LT]3OO4R4,,B4VR+1[,@OT+3M B5^;YY
MAI$C9]0H(#\EGPZRV1F6D W6I9>RII=P7GRW0U6'9H!S]-A8:<TX%/N@ :(-
MQ"-#+SWCJ>9NG#P(@10HB]1+Z6//PZ,:XRN.#<A@:&+Z,DAQG,]YS7JGBH('
MVDM>WC),;E6%<L5JX-V[N)Z3W)8L'9G6U<C-$X^R8'54EZ Q!6V@9U>#C'N2
MN_,R]3H!(M-%PN"J>]\T&W,(E&5U;@(+7G$691%T48,LSDW0X+NR,R3FPDW/
M%XE3V"VN*F(.XBQ5>D"&?%ASRX"K H%,U63 (\]>H6AV%][]*-)S;JC]_;2.
ME0Z=9*5X5#6(2F^#P=O5%8J@)MID<9@[%;H! S6TURGY63.X9Y-((:,EJ#KP
M2SK"H9E'29]%AR"9, J JEJE"%)R9DZ;<3H82?:&\:_3CZAK0C;7RN6W:?LR
M.R=)S>\ZVV6.YY7#/T:&RRU4?()OL$\T!A(E,CA964_,BC+8E0-"X2Y-F%=#
M&E#PG):OM]R:5$@'%J)L-C^]6\!%6M[AISC:L#IJ6@I&[BK9' :N)4P^\7W'
MEV.I2^(RWE^VK'?1AG@]03@,!4WEQ-A6*_:RZ(EH0.W0&L2$D+_E"MM5V]R!
M;8QGT>0!9(\?>T280]+B./TMN@[4^1#CP\^<PM1LW]V3KW]X\91KAN"U0&,$
M%WBH/5_@V(CW)]2TXP?[,Y=WJ)OZC$T):N-$9 C8CW17R&^XOXVL5(LER"<]
M\#\N&:*Z)&D;B3=<M5F>!:?CQ>Z*$%F??E)(9(QBSP\O5.)3\"9LW_%BU"ND
M/JQP&,:CE)$9ZJ#&-4EIX8PPXN8FD(3GJ[6[UE43A 2.7X5E9K#3%#:D(H[D
MZ HJQS'42%,M6ISEP ,1#5%<CXA ')CH/;*!WNEVH-2'0M5,8H\[%8%8RUNX
M)Y3VCJMR+* U6&%X0-:;G1.W3!>*C8*315IYN<6YW"E B1DY!\4E3]\P+,MG
MA)B.:=VR8)/(P1FLA=4"/DI)^:AM[-=P#,GOI2)R_+_Q/,TME4IH_#]LH7#0
MD(53HF7#+@=++S @)3Z.8DD(2<ZQHFU47;4X;#?T2D !)9]GC)JQ@Y([)^NK
M,W)-W35!YC (+>-%S !_^ND@+5FFEUN(BB^_\Z7XZS]56S:,S[[XWU.D$Y+1
M'U,GV4.C^EQ!(/)?HAW=+'=6,P%1"U7H>D59.>-?<'(1*.E5ZKK.[K>,6^XJ
MG\44UDH6/CYNPISQYQE--6<\K--IN))\=)Q;ZSN2!CIK"!=GA^HO\J13PXX4
MUN&U:EJ\=,2V 5$65@.B9BD%EVW/QS&AD, Y!ET=U7#H2N(,Z@SFV-R&;&5.
MK6:N!(_&5H'#HLV\HS,_.ONA3B$N4Z7%E]]W7,?FV!S4 -R0..$?RYOA)>SS
M9G$I%2X!NQ$382_JFTT_;3%KPN?.U86)B0^39N3'9HD E+MY)X.!U(\2;> 4
M^O/Q<VOM;AX"ENUQNN34&I"GVE=$I!_'S$URC@U6WA1R5/A]+L.^(41"?" "
M:'1]?)O,$FIR<I5-H*Z,5;D_ZYNS^+\A!1BNX=-;<53*3>#]F/(?P%RXUGR>
M(V>K^%UIK.(J>A>#9ACY/KA2VQQJ9-?A.]+!SJX9*4T0(&C*$=O5.@P.<2S2
MX[12[=#/<U$7AV=%R/W'5;.),"\EF+961"]F$I0<POHDI4M-"M'#,"N9DKKT
MT [%,?9<)XK2\D**7E%4R51:2 -]90R.(<"J6J'%_V=U\S\R/U4%:"C"-:4B
M#0Q\5W:6MW(YG^&>PK1SM0"-Y0B<W84=-Q-/AEB/D=WXA6 GS^4W?7/SE\_B
MCX_$'>2 \V580@N$H9&?/2M21?8Z>AN???X,A^ 9_$87KKX:JU=SU<4?M3A^
M)TP1'!?HK[,8:%<\(($%ATV@C'PBQ+$ 5U]R9)?7#=J:D!.$#SE83V9)2301
M&4+1]:S('+BS<%"\*-Q!ENH8!FJF8PLG>EIM69ND+3Q)00@_3]Z  H(2QP"R
MHHPUD9)0)0,FKV+<O:BW"*.\F;@<9I6P]KK!M'H-'04JZ"0=!9<$TYX^[J'V
M1MQC0KJ&S_UT_VPOKRB!2K)[<6LA#]/B(G3!+:F[2;Z@8@&VFKV%NU+DJ >'
MHG,U)=5)";8R@X2[RTJ 8U8@5,Q^.V4'W+4S'Y!\$W&:?#&>WW9(UCEU#)[J
M[<[2?/')8ZNW/]16?Z0!NXN#(,115G5:MZ4%#@4J+&1P0^KGD%W:MJ@>:!W;
MM9'0+MS5$L?KWW,J!74XO7,F=1O.(6;9\2, V'W#NUZ]VG%Y=2F 2]>WDBH;
M8L:2Z4]=+&RHA+ZA ;-,"@W (>$.-!IGK2UPM<6LZMBY0^PVL*U5Y\*X"8N$
M&[.%*P0#!X];B0@%&['ELC JHAS^C4H.P@L0M!T07IDRJUK@INO$.60#LWDO
M@LU!1-/X"BD'>E04=C+1@S0NB<[XR?)!Y/']L*72TU1=-YZ_#,4L4N _AJU.
M3(.ALWDJ?C$/\K$ EVG.7K B^5L" QTC-%F[&2 LKQL]3U8-5,NYDYC<#]^)
MSZ=^W)B\U8"2L)Y[,1QN!SL_IYXI@MS/T/-H6J@(@LL=.A!R<33E6!Q BL5A
M[O)1]JG@2_1SQK&D=,:+)$]#N<01O$<^R50-7$(=W)R=R>SVK"L;1WUF,KE9
M5OS -+/CE/#?=IN]1$7E@MMB !:=OE('QQH%[4U\]!<$IEC<GB^^*Y=M\TVH
MJV4\*%[5R_/%DQ=DD__1G"\^_?QL>7OVR:?/_OPY:>G&<2/I':L7H_+YLN*$
M?!PLJN\IN,%^'0?AN[+=;["\I MDB.+SP-AB\=WYR_-B\?H:_\L@ML4LK!17
MEP!$)YWAL11+5D0Z!_>CW) N43SN'+4D 3#<7H)>!2==:'#CB5!;-#HH@ [>
M'55&.GP6WT/J*P89* -+Y,/4<RI,<=.&?\:H:!F767R_6T9@PYZ_#3<]W^W9
M9X4H[I6S\XH>'0J7W/P,NVT&,'L/6?IW*&;)^'SHQ&*,TF-_^B4&Z=G/&Z0T
M0L);6]/]HFW[%%?_C$O0=,WKQ8NJ7<;U3=G&JMT*5CN_L<$_Y8;E9!_&,=7-
M7K+%0GV[)L)GRML9-E623DPR@Z[KL&+U#"I^<=7>]4;&P:8V:P:X;GJ4C.)B
MZ9?2CV\NA+L49QHGSR'/>*BTB<JXT;2S3!72,#K*]F9=UL:8NF(XE&G8R9EF
M,YV?;>8C%S,"()-''KVA5N[1'Z@E'B[YV?NZ?'!.?^Z=>B5VK8Y?G6CNI.4S
M#H0N&PH*:>)WM:RNZ(3ON>43R2,LW[5(5^YJQU*5%Z:<]\U=-GH3W)Z.<Q+@
MK/O-/CN=_<BGD[IP7;V;,<-NCOXK<NB?)]#>5.O V?NE,/IR42@^F3 ;.^]@
MI)OX@1<6Q\%$TGG(U I,CIA"8!)JT>A"DS@LKIZ1;]B\&/*-(:E33L[(PZ)I
MM=F7MO._?.B"OZ&HM+XZVX1U7(Q?#!+59\_^_-'V *B\__3\XR$_GF=C\^SS
M\R]H+#Q\B/ +J: _I3$X_)UKLB# :I.HX!*9QGQ\E3U0"J].4_S+3K%6]UCN
M5.*7H30;TM4NVZ/"8Z?Y^^CSET0^\BKO3+JHL904 _!3)O0TF1]_,EU_1 ;]
MHG#=.;=3BBZ"I6(5KR65BEKCI/.T_[/+XF2J'_OJR#H_*#EO&?>DO-FBZ=!^
M-I<K+ISV*IPF\:-/XG!?4_EXUX=,-H8P6?)GJ[^8M!@SEIQF\J//9$5\.XK[
MH%#'V-&7X,VIF]N$\Z9=F>HY:8->_C_VOH2I<2Q;\Z\HF'K3$&%<V.R9W17A
M C*+KF09H*I>]<3$"]F2096RY-8"Z?[U<[:[2):,S68[\>MXW0G8TEW.OGP'
M0:DKQ._J?N=^OZHN6GI<1A0#'9]4.GYW9= ?"T89,ZBZV%.-4KL+AO#[OQ"[
MP<&2.>[A-F]1-*02N58CVHI,YDXF"JH1Q\*D'.T47"OB]\B3"^P6XILXS79$
M>/(!>UD\4:H<_UC=[]SO5X6?!$6/<5JIR4/DO@F'&83GKAH.$#-V<->WN^BH
MP7-UM7._6L9?59:7HSFPVD%"+GV*[_PNZ^%:BUH/MV*M-V&M[(ZFG6&71*PG
M>)LDUTKXS?V&1)218#.-0(1-6Y6)6=W8W&\LO:,Q$I0KPVB?H,47#!1JV>KF
MF2Y2M*?3"+BU^B+/V=3I5GSZRBJ9_S6KTED.#VE4+[RG B[-ZJKF?E66[\>Y
M;]7VBL@G%F;WT&70C72$$,G5(]D=-9G$=U=<./^KU7G10A)TW#-@!U[\ 88T
M$CPR*]PGO8^K:YW[M3(<GD!2J;&Q @BAZE1TV-T+4C?-!%VWA[THJRN<_Q4R
MPAVVS@G673E"8]HNBTWYM2/<RHV%IM0%J\&"8::D .P08SJ1;Z5F6+0;2+ Q
MB&2LP^IA_3RVQFC0I!4AS9V0!"5+%:%I0E'=4>7?8MUR-XA+J'Y<3L?#OU8W
M.M\;1?O)#<,QB4!5Z-@:1_,S\%Z7';"V ,PHYN00E!56)/O5#21NN6E%=:<T
M'($\YH)--],?Q":0>.#S9$AK!L?C/2:Z<< 4C([XV5*U;]6*EK%O=0DNMN>C
ML*5J\=IW\O01729N.A8$ML?%3@P<QX)N;Y2Y28  %%RZ;^I6S2 [:MW'6KB<
M!P\SNAN50#[$>@ N#QN"4\.*=#5UAZ:@T%MYX&/$LZ3^4'V%!%Y448)N1I4P
M_JA" E7/;-A=\X5:=5%7!F\JLA'E[=YYLF(3;%O!O]IUZQ6H_4\>I;XH/7"7
M.&$J54TY%,R"S64(&-@=\5!=&MZYB>[UR 8SQ(,\ADM^<'G\+I7/# 1FUTKE
MXG,Y=>_*N#9E>]B( =B.JM$[C,R9A\A8;H%W)(U'P[&+1<PD!C'":2 T/T!&
M2RDD4]V3.&",9#$$^5M,#@8G!<$E740^)^PIPH=44#;8%I;<(@T5)B,;U$Q-
M!C*,R9*F2L1*ER!/F^N[]W'"(R0M"Q31W]4D(H02(U8=Q3F8GX0+IY$&R3JE
M&46PPD&0#\A$&9EH'G4/I+Y]:-17PIO5 +2B(U@\Z[0EOZWK4[LP+0QGKI<[
M20FXF%Y6%36FOJW$[]+DE\0WS5F/%?XWN?U6G1HB%<&6[W@-B8I7RUI2OWAH
MJEF;%!BW,RAD &ZRCD&ME7"X8&4];K+NJF8_JYDM-2@E(>]9AFWH_1C DI((
MR'QWH$:06_=0!$G"LEP<5,U]Z0P;2"4#Y:D$,JPNQ.&^ L5[[Y=?V26!A4L+
MRB*([ZOF@:5-C!_$.#VM>C'>+"Q,DVL)G<_,&C0X[H98I=R 9!':3Z#7NP3<
M@JECRS@8O]Z53SKW6T:M1 #/:%6@F<O@:N-WU9 AFBR W$S&$H8V$Q-T_[@T
M0_#SD*'TW(P,;+0@5Y<_]\O7C%VGAS"AA^Z3;OVV)+F9J- -W>@K"  ??+BA
M!JJ6?CH@%0I9LQO6$#VDYB43VNH::+84X<A [Z\QUA46G1B7S8D?I&Z1_4H#
MQ'4'[DR D-T]PJ%)[&FC)?-9G$&F6U5/(QIO)9H6D#H5ME#9IM53,P<(*ZS'
MDK)T<1T/L25ZB);@%;XU\,WP6XU2/_Y8) D$T\5F54(IC;(5+<R=%BPUY=U3
M;S"P<6 &P; K7;(U'<R\1&X10GU<R,7)V!=YT 'VE#(TNQL1$!.C^T9.B1Z%
MLE8R8_YTPBXF>F_<]QV&-3>%4F!U6PLCX?W"?"8:,61"Q/N[_Z5^"S8(AC)Y
MWD\Q"B#-"FPP:+ @8'O"MJ2Q2QX;"!26T<@RSPGPE((Z36=5EELLRVTO6EGN
M,H4@"_$BB8(!$8-*HZ%/:EA]<19+OSR2 C,<DEW@*6I(#SR2IMCRTY"\L6^/
M+B[$N:BY]][EV?84SE;(.'8\4?+4Q:RE:5J8,)6LZ?R!R21<L.\/,)A$4F&8
M(/BQX"J61B)3JJ:P%(7/B,@=#@D+=!%"B\]55*GRCPTG]2FK9[(6@HBO4=_U
M$6-- $_]R$9#W*8] (DAAV1-#/1/3HIJEK?R2Q3?*TW2LX?RF"CQQ*=:>&@.
MND#H=GDQB<I84)*[OLQ7H%(%-132"L\M.[A/(4^IAA'*V 8COQD(3F5=&NH#
MC.UDY>@*JN&:1V"@+MT^_-C>VE9*26=O/DN"_\A2$U_<!^LJ&TX>A8C:J;0/
M0N$C5#:]?^!G#4- (<[?*%R.!L]D#"!X.4)>@W.,=XPC4FBR8**E@JTM00L2
M)7"4G"@'DPL!SY(#%NPR%*V:#RXT"1H.EM@=&_2(/!2DYH3$K]<1<#4JJL]I
M#7F-N.;DAJGL!74T4?:"<LDD/+"!%=ST@!QVST]IU&.7\HF/DF^%!@Z\?ZP%
MW<.M@\-==Q\LH9V= Z]_Z.^ZK?W#ULYVS]_9/VS_3[N]-BN><:N-FMPV;9#T
MBV;?FS!#=5+R].;DS&G]W*S#G/SM_.KD^N++[R?'SO5-Y],GY^CB[.SD_.9Z
M!B3^!>'[\SCRF\]?=IV0FY*"=JLHR#+&_LI3A(N?*SD<-9V_!]\^1'%TGM/0
M7F(_6..5WX>U;+;6G @L9/CGR/MP-,+8+FNJ$8+7GNEA8QV)NEPD5[Z;QHBE
M//H2?/7#T4U<_M25?XN(AFZ4?0K=VS4:O.EF<*3?L@_]X)OOP8;#U%^C<^YO
M;N^O_73TY\\G5]<G1[]=G=[\^?<?"RLN7=!S=J-R6)>(#8CPX)_BI(/_BYG#
M4X'WAW]V(N],X.]OJ-4HO8&7_!R"Z-&K/EC3>*Q>)^-?X0) A+I#)(0D]]>J
MZ!)%B2;*1: 4/!OGS(+:1:13P9E^C,D*FYF_8%#@Q!H]6_+Q>@2ILF>#B*F2
M$&>%1A@RDE#C40O=1N6Q#RZ1BIYZ@Q::GIK(PSM(T_9LPG.X5TV'I/0T'+2#
M<S3.(S_#R3VJ9L3AFA&,=5,M5'(?]+AC?S#($0&-K7,I]F]@58U']@A-]HC[
M&1LY"OU;O\]S,]<VW'%&18B)FIP1(T#C(^@@T'2?=TPP$^:45$3=0@NQX09B
M U* 10-PU)'+4/OCX&VT%F?]U'KZM?0N4'T,_'5C$C;^8M+>!8\9&">K?A[)
M^);4"4T:PH #*]Q?M([L0[DQ7A-=+H^-,A;K-5C_\*W".:J7,C_+2%P&5^5:
M =?*Y6]2DY;]GNO,]\F]H-&P&?S44.-6G0X03F;^H SB<?AB,1?M?9<+' (C
M;!5?\3\5:ZG2!X:V'FFLU&KFHO ,<B"5P_& !<WK8&C?Q1YQX"".$$2#76,U
M3)&JW.A!]L#APJC&'"P)P?R,0QI4T$5+V0SLK%H65C[0'#JZ/,W(#,X02 Z5
MU\^?9'F#0""^Q@#0<2K%T IG7Y\([ANYLD_%EO)J:C:05]%+\>[@?^_S$+T6
M0>'G@R<'6ZX9RX6 KW#O=$4& M7_AI7GZ>2I%8O)F<>^%$LZ,<=5RG.E69CR
M!$@]=Z%2;U @@X%1AW=PBWH*FCUH"ZN^P4IBI!6M5/ASPS@,"#K85C%Z_ &\
MD8M<GZ!9)HE3%031&*=N5''%-!%0,F8]W^/UZX\AJG#/#H;J+XVZ<0QNIAY2
M(781J50<.H5P[KUD--28%N(.LTH2_6?DI3B(^&Z2$MG(+C^B4CMJ>+(^J.ZB
MZB'MG1_W=6^<" "2->"<>ECEA/QCO<"Z,#WMJGCP?$3!O=L;8<B,7.D&%N3Z
MF<0!,I^@TQJE+P81$ 4FM!HRB<FC<+-7^A@-0*PH(5]L+GM9R_Q4C=#RQDSO
MG:TQ*_N57EWGO]!;E2-PR*K?R%++/E33:Z9G9@Y=J05PY):B.])\4$NMS;+;
MY%P/_1XE-&@F_'IKH_1*>E20JCGD:"JG-/]\ )PM"Z=9.!A#'M*PI(JW(U0K
M#SUCE1YPN(U2*_CIA+Q!/_GHK+<W! 1^DI%$MC 'INPZQ\)D7_WPJH,HBM$:
MD:FJZ"F %I(CB^^@"<&8-#(W)FCKI>&5L)OM#?K-1.-)&QGI+"1@39]0UV[&
M4!%F.PYR%S',)H8@:]>8:%4%7ARE-.NSWU:Z\7'2>I>RZ0;=LTOTSDZB6_C=
M5.)AIT5>J4_?*'0%B$4HE782\%46)]IS:!.3,:%L1P>'1J1EI8)U*WF(+1]C
M?U+NH/T.9IDQE3.^F I]IA9 RLL%G?W@=RV5:AFYR$,I(D.@+)C*V)^:/RJH
M<=G(L9"W *.3 >LGD ;)/\;*!]F$QJC/:/U*;*)(HQ8EK-LKY@CUO.7A,)3P
M@7W-5%1'TXDE+]=PCJXN<*(HC27IYC*01AQ0++>Z<]646!:]UAC/9S":8:\+
M:D&"X^I$GD3E9.$F<#<-Z[7'0G0[[<V6B1*) 5BI1(Q5/JXTQX>TXHGGG*"U
M9MA89?E\UNHJ<(Z._\ <(\_]=XXL%D>1&Y#9;3Y"D'"T4NWRJ9(U.W*%>IC"
M-P0:B@,'44%:'A[YW6IU_$"\UP0,TMO"4BQ+!FT'4<85RS"O5Z@AC:JM%;Q,
M]/UQ>&M@#<3&"%3<#:6Y+U5>&K^MZ8RY;QQ94LI-2T<Y:*\AOXZP@.)>QEK@
MKVP/:7*0N?S']U[9L;U0E1UP.851 BHBC[Q=+_SG:'I4K)8E4=E/=U0+JXFZ
M:1]8B%B)$X[LU8HP*8R@\<[4H,-SEPPJD\7E=BCBS@^'6F%/,J7KIE6K];&:
MMG=>T2.XV&KZ$V7%/5^'^M0=/!Z24<CH YT;PYE?O@RN.K)FRMUQW\V(:S^P
M=PR+4BP?QPP>PHHV5)!.J^F< MTXK4[3H>S-)]>:BP8N72>*4*A>D7> 8O,3
M6@ZMK<U?F^."KG!'<^2?ZNS49RK3P*#)2^4!*6!]T=?A:FUNC$<:MF?-Y\V?
M:"^JZYZ5DY].$54ON]9@L:!=2E610-P*V2)6YZ:MT&?9?W0MVG6]2*[S;D_]
M=&72!T#)$RYLIWQA-Y7NKYH_4?:7BY$;?3R3?7QTL,KY#<;:\J?+8DR(0%J%
M=OJT+:$L,FEFEVFRM?/T.[R*0_^B;[G,8Q>T.VZ3[U:DS5\DH"=V5GJ1Z,M*
M+4H:7]S^^.+V7VEQ)S@ +@O2PG%-7-S><LJB"E*O#Y5:0;RD/HO/&= WH9&I
M_,R#M9^47Z4TN]E3F;L*/%V9!F[4)($;U.J  "M]'!2*("LCW^6J^<J8JADR
M*)9&Z&& ]X@+W>$4JU)&.H-\:8>@UH].KZ\O-ZPB>1+W>,%39*'EU?2,XB/0
MSG7.KGM--%VJ'L&&,&Z: +3;6[)G:S(G!9_5]/$BN9D3J+!["O*PWN%;3-:J
M<RM07OTT3H55.?@[+B2VJJYM1QX= <%ET/F(*F96<!,:#TE"T6655Y? 4!/M
M&WHJO52YP+L)D53"_KZ "8 '@V,O]$J;%3Q'60V$HJC 54#W!![=S;U;'P,2
M:I_#!,%0^6/EK!UG0#%:HK]?_$@IR3LY"&(5W*L_;RK@'XGG/^X\+27!/E%<
M2]0/+#^6$'"P1H)/K=P/J_1X%0NA/5*ANBKRY05M97O1^"*:>*HKOZLIBL*,
MIJ7>HF"O'/3JX>CH 59X]R3WHQ=$/0PD*Q]3+77E182 8A)O5?P[OGVL)](A
M ]NMU1$#YH6![P7CPD.? ?BR=CA\NG>K*(<4-*@*&A%8C&.!ICU%4<P^4V6]
M:\]B$I2!'3"M6WR%!UU.3TQ9J+Q7K#;_;EGW)?R\W;$2 /3SWL0BY)C*34S;
MF,8\W 5I0L0U1AC3>*2"PI1*1P9L2Z5\R=U#-O\=4T67P!K,(S4L;DV JV(Q
M>Z34Y!H['9FTDB46\Z.I9AONF GDV -^;, CIZL"%*RO9;<\JS)1F\74R6#@
M)C*67>9"B\EAS>.N7'F#EMTH^<WC:<07Y]-G]A<<S-RA<KCX#2KMVOZ4RZN+
MRY.KF].3)6Q(^0/G';@I@J5E<<;MA&0K?J.17>'(:1UN-6 -3OKOG*Q,WY?"
M(&NL;@-^ RSH-QP] 8YCQ)C#OXLQP0B;ZU%U]9F;C$+X&_M@=[[KX8,)3KJ;
M!Z&4>,/>>E_O@Q K0]4W'.".1" P\9FI]3:U N67VR-_-: Q,IK4(IO";F6\
M"R8Y+ :S%JH%%,TAU44&<MQ59<%QKY</T1/EX+8KITCA<_#=,!6*NVAO;>_R
M1NGOJ>.[O3O.X0I<,M7Q]$%T;*)["(O5*X6M^@]4%MSU0X).IZ<+WCH%8<2
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MM?O1:5.'5X@SOBQ!L$G-3T[O\]FEH;6BY)">GI'29[JNK=#79;5=T1Y5ZY6
M/PKW8ANE7 LE:ZB[R--8BX7=CW=Y:3!%-:ZD<)#6I,#"$+Y^;&^X./%#SI*?
MV.^CI8@SO1,;3TWL%.K+3C-IR<8)$G(N2UY;.294F1I9IJ)TL"5UA2BABETY
M3NOZ/CBP_.#63\ >=[M8K-D-M PE$:G$(KL!&8Z8PRI@G-T^C ,J':/I<WBW
ME\>;+;JYHYLOG<V=C\[9YZ.M]AZ5-8&D+C[BY_W-7[8%PSX,[JE\'=@<AXF
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M.%U5L)33RW;"R,RKL7:(5HE+[IPG,R%X."VPI<D?\= M''Z#@LJ(1%,+(QA
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MK<_&S&Z2=-W>5_ T89N;(@?Z]'\?)TB%=V:K<'IOGI*3"M8N>EG,**-8I?W
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MPEX2I&Q!8'Q#HQZ)%8B0B>G$^6UD,L _MIUU#X,C7"TD<TC3C0_,/#8'961
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MJ[L^C@'6^%\N+3-"Q$;7 D(SX.O6R$A%NP5P>&>]V#,^"T#!V[:3@RYK;C%
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MSJG72]"#2D&<)Y@"*=@@^%8?7&3^GGN;^#ZM5PO-H[O [P/Q^KV<SOFBWP]
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M6N#CBJY:0X'%Q0F&FT+P[4JWP&@[/A\ETX/QB(8A,-6T_(S1E$5AZ XZR-T
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M9)I28^NE)$B_RL-Q:TIL66L?QF *C63=_'L\@0@E$SK*L'+/I_QD*F#UFOV
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MG$L]+>=^=*#>>JPD*1?=AY7RF89C\CBQPW&!(C@]0R5GH7CL(#='V"-/>+Q
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M/S)$HSCBTR)<@!5L22+T%[(DS@F $KG_B4#NC&R<HE"H\$J?>N[:%D%_;R;
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M2J.091"^?;M*;A%7)+?!R+@6BV\U3&'F/#O>$ -L2 BF[6+9 PK? ]'$7F@
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MQY'S\\44#?!%P2;$9$,-!E$X]GQ8<6L]?9294GL)A1<,KP1Q-QX>GNFHM17
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M#G90^.+YC\!%C\F1] /KWQ$_'ON.AO>C)^-7$:.USB[E[II#P=>'S:1V !.
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M=IU"9#T1WE\HPK,61('ZP@8S,5 RP+P@L##V,_4=F-@09 6(VD2G,WT=ZVC
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M0^P(QU";6[]89)41E&O[1YM6DK;7JB3-ALQ:>RLLU<H6ECZF+#+@VQ4!33\
MXJ P@WRY:*^@5+.GYLM%'Z/)!//Q@(;,&TCZ"A*_XUTUH_R5!0/1D@T9:\X?
M#!$[N!_-S?V-_ULP?ZW@M5I^_GLJ.BX93F63QS7*EA SUA1',CO<+)^I.,ZS
M:';U#B& L1!5N)"7O!PSGC#-BJD@*:E. J>L<BS>YSL7"8P+ %[''D;9P!H6
MD3=PH0V?R=U,-3'Y_6_D&ZAQ?"4KY\A\)3YO\)JX <AGIIOB>N!D *S8$!R7
M@"?)17AL2$&1) X!*TDVLRLZZURG@>>D$@UN6%A"$-!G7L2S7N5 <M*7*!ZX
MCZWP1_Z<8'E9@*@>;*8,V3J[! ^GH+ S,>_%"!OD?OZCN"0#5AB)SF)-X)M2
ML9: 3&853WTL!32&7A2*4HR 3@VFO3%UXU.,\+E\V Q.V9!)7#YMCFTZRHP*
MJ1/@U1/C)Z;"T5_*?(278&9OBG8*^X99*F-PA##HZX!4PO?/NHG<CV0N#?=5
ML49Q=G5YE&<N"B=J],"X#F:U=)T77E^P\&)<"DF*L3,U-T5U\ 6U# 5U\ V"
M.\CNP%HE:DLA8M3"[V/YD'BEY]U983Z)6D2DK\]NXL$/\1P>+T^LP$Q#P$;>
M#"(DIR77UWB_!_1^=!/PI$*0TK-]F#KL=UZEFTSH\.+IR)Y3GTN43,'J K4C
M\@VL^I@7BO.,B\/4 )TR]9&:6=-4D7_X.AC\^!@'D69"O2R6"G*(T)B,#)#_
MCJSGY+UQK9EI^V8TP>P1J^'%0(C!DRK,,6'0QC%,$IV(8@D=+L?F#I ((K$H
MK,@N94-'B;.2,@&+#3(.>&;,PA[(KLT\D]54<T**#2#!&II<$9*/<2&F+":&
MQ2-60W3]%A$$!R0($L\TV_ICT0(JY-E^8>(_XF,#AU0L.UL"T#8HE[ <^1XM
M,?";GCT654=3;=9/B]TR+K.3@68=VW#L!33K_,6Q;Q^<1##+A<]KV#[!A]&9
MY<*&0"ZF=I5<4OAM+B7LLY)LT=HD4\*=K)G)UB>3>4 !.S=P]!''=@!O9 ]E
M1?BLK(2%4UT8H6][41#'X(,@FDRY_N*I[# -!L),6;C4"#P>X.4Q6Z:'L_!M
MD($#-(J>QQ@GCGC<-7)8UBER$(&894IB?P'-DCF#&\N#E[I>,@(^(N;:\T>P
MZACRRAX*(XL7NL#?S1K3I>2ZZ!\\?P+8(D>F<YCB'J>G$-:.]"9[=@4SF#$$
MPI;[D8(5.]O!ZJ#406*+"PG!=G")#EV)0![#32#U>4XN(VTR&1*N(0S$&]*#
M^>/])K&,-Q;:=U@D)DS#VKA7#\S)L<'3]$.:.R6D018?("($8# _4#"P:!(^
MQ/B6&%>F/F1HN#_G@T(X#SN,&(LK&#H42\H#A=;,AJQGW-;D)I842\,+L:.0
MK^F7CU/4!YA"N<E8]L\L$\G22][0L9\S9G&RDS/WM:#$S DJOMCH:2%502^
M9?@'VQB#:8NI \*+"4FF(WAL,3936?7,+R$(4X%<?7F UL;_[@J_AH]^KEA[
M8? FZV@Z(,3MD<U]K\1E.@=#^IQ5   14U(05KX"5)LP;VV(FSW8-B+6D9A5
MU:#:@#\"$0S/O$J ?&@XS' *QI@X1L@W]IHTO1(4,!/+KYA20QJ^HA.?S5;C
M=KCX[YF:(Y9>Q=DF7,]X>R$)2,C=39;[G+-)BJH!AFGP'U',,PIC5M>*8>"$
M]X5%PX:PE,Q;A^3W8OCA5 ,6L?Z&'B+1%@C1V)X#*)YS*((O[V/B]&W6N4:K
M"OQ5L#; ]' 8ZS^#A2@L55'(Q'9ZQW$&?'EL*DW RAJ+*CR\F G)[/;QQ/*<
M<]T+;N71 'A3$JF8>66VSNG/(K_3 %]V9M"H(/B8L^GZE#NS[,7"* EO1H$P
MP$E28BO*WF*D3RB873S.-9.1CS6(2S&+NXB&0!1.--Z('+P&<-]%F722M!%-
MRADEN"1.F RH-;$CL7V:[:"/LA5!%1AC3SYX$6"-W>,P17 Y>&"[BY&(W"I+
MC;'N81IC\<1(.K/#L[>22?C)) #/:!<PLS^NE4#(HW\JG#TK+B J$I&9NJ$7
MFMG_Y6;VR,[NB<5RISAHEYHVXKE<R/ W%PP*?6X>OP_RPV,,:#BH!+ 2TQY&
MF UND*)9,Z=ESAOF(CU,0E1I!A,GB5X_\G[B]0MQ->-USV@<IHIQSW!H\#RQ
M&+$BC%&7]RI@-XQ8#4DT#$>1D\2X9R7N*P@@YK6.,-_(1V3C7-)I8?Q=)%(=
M^R?X9V/<O,\""OQR'K$%D>"%6["W=NHOI"$!O@IL@IGDO%&PZBC<XT) 'F80
M>(O702$VQL*QNC4@/##*3(S8'X\K#+)AAVST(TE#,P1-C3<.+N;ILU&9$?P*
M8I6%?UB# H/5MV.L>G:A@IFH0*P%9M(?2?8['A860[&,/[O7%($0$;(2I5O%
M;V@L#GZO/(:K(/(]B GZQ?.O!:SSJF&];9&]30[KV_+8^MAB.A>7SP?J4T;'
M0BEN.W%7@+7),2DF"GC&JZ4J1&MJ.BXF_&RQ"I+Y6F-C!E-B17&?K<L+W+-"
MQUQ+Y<M"K8)"K=XA%&JQ4H"B H%6V0*!+V#U_QV-_DQKK=O4.9BSY/K-_%O[
MS4.M#\"Y$S9Y9*ED^B0S_X..3_PY6.#Q95Q#<U&X2RGVU94B):OD>X&+K2,L
M&!2G/[94/;[F=M9]>NBLZ,+P_;?4)%Q@KZQ)2F:6IJFQ.*S!E3_+#4R3FI<7
M*G)N@';X$(T$UF(HDQ894M.(@LQUP1@,WG/T>$5%7&.VT^J^+<&$2&A$^XC.
MI \<!H[23S(!M@DU,-FV,-/(FBLD_)*IY7I$O6I@Y..S!S_(AR^#Q\\?BZ^X
M\JPT#/!A\'CUD?2TIK+M,%S);K$9R?<]2Q76\RM_6-]^MI\#\9!V'\&;X[^)
M4I9L %G!C!5PB0W>%YI(F>5.@EB\]+TPIQICPIJ-Q<9Y6I%)!J8SV.ZN3-F"
MJ)=9 "_N8L3#3D?BLSP  NT_D1%[+6!1V1DGQG:G$8I?;R8)J!#6$M&.=WWS
M8%02\LG&D;-#7S!M'KB>FW6<$LF$K=UDSOS=GDN3_+V']BUWAWR*XBVDSQZ&
MPR]**$W1B?D<>WI?M/4Y-7JN]O;F=V*T0^OL4>#-TD;5&VRG.@_EJDG_O2_I
M\MGS"00>IXQ<P\)=QO#9?R*V.U8D%GAM Q8[)]5<3"HR[1"7G,]F'Q94)L@%
MW_:":R46G N0I,L<3",&S8+UMT!4F*PB$D/.Z5]#;&6'N,#2$_9,TW"3TM#9
MAXTRB:D%0B</+K@G_Y15:&.]_MS9)V%PWQ'%G\E 6:>1M) 52T5B&9HI68LW
M/>((>+F<11U,R+*-"T'1+HDWFSH6)JM>8BKBZU!T>K[O#45GW&&6@G%ZV#)"
M0[++UMFEM1:["*PD?!"YF07CIF286]/L0I+?$YN9M2-CC[/=%\]!9,QTKG!9
M:?2_A>V=%EIQG<N*LN#AA@@UL_V&P 5@$<03H8WGAI),@!N[/*T.R&4)4";E
MX\RDD21^1*20\Y:3;G$&[O),FTU+E%$\LRTYPM=[6Q$\*NL++XAD\.A!04Q!
MJU6\.?6C%P@EL;AL"^8"ET-$HF//A,6B^597 4I>;9]94H>!V8C+LC$KP8TS
MEC^9$&JP_A(Q8C"PZ[&VAAFH<VHOK8HL!*81Q#OI4AR;-#50$UF:A>2<&?H*
M@E5L 1,W.3;-YGUS%G*F]T\N.+D/QWT);#6&%9C?*_[C>GQGP@@S87$] UL_
MS%;%%9MBB7"+,O/.V=[97/GS!M7/23AOP& Z<*UO*4B%JV?=NP\Q"N&".\]-
M0,EVS#RA_,N7U/7+1?GJDC_Z,L^YQ2Y?,7>RI<5MSLS9"<@'AELO@@%9P<?$
MT1%!LCC^S<Y89TG2:4 OXE\^Q6<(VBX;);OITRS="EK",3+RKT7TN-]OM#LJ
M@E,<0"A>+&++#9CU;_G/VVJCHW8*OVHVU,+/%ST*=&U'U4H]:O$K5*WL'0L&
MU6JT>WI%@]+5=C6#TAJ]]G)*K3A)<NDQG6H[=UW9\[+J=99,<W%P"MFU.&LV
M9Z?@&5";$#5SK!GG9-SRBJ=$L90_P?DO.\:3DVY/9W@5$_3)"PUGG;-N5\[W
M1 @F_&5)LK(DTV9(MJ.CIO=Z/AZWLR[6@<JBZ2Z$0!D8;>N8YR,:7$5G-K/3
M KLUA^7WW)X$>2+SJ1S#V>ZM.H:S:"=5XCFF^;_UCKI)#^GL@TO<Z2J]7J<F
MYW3*TVHEFRQFD_Z^V*0EV42RR:&P2:>Y%389V;^H=?X'];TB#M%Y?DG5/M6$
M12IR90["=OR]\4B>?!9Y><M4_BUT<;1R9"AD_P/G$74YCPSB HLOGO\(6$_W
M;U_389C^55J3M,\NVWAVWJ9<L@2MVU DZ[A_$E4=;1NH6BYX.Y4)7@FI.D*J
MM2=!U:V7H#JE4%#:'N(\2-I#I(W?WJ?7US7K#YQ=]#VQ2^_LLJ7T^XM.#3Y
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M=HJN>#T3VJZ!EP0=?/D:X!C-=F29?6/@.19Y=H![',*:I+(&,ND+DZ8O#3(
M-H,W\T4#GH.WNP%72K//9%^,* ,-X@ANB-LH\9%EGEJB?*.>HBH1L2B&3*"
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M("@Q=WIBQHV:;%'IR/?*OC>\%M7;SUCC[M0WZLS1)*(T'WI+)8.-2/H; %S
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MBBUJEL>;5'T,^?2'VYI/N8T[VX4-?^31(X\^M__S>"8=8 QI,-B6W[,3)MT
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M-O_T0=]T&ZU.?KCGYN571U537]48J;U'BJACF<=SG,L>2Y=M"I<2L5);? Q
M? P;O<&39P-O\0Z?H^JC$L&IJBQC;^:$O _.X8->$&-Y@1M%.*< K:[#FU?U
M/G#^GQND;K2BF5'VG =J'6?S(W1<FN7A?9\LTAB<,8</P'/<V\CS>.""G\R=
MJU7@SF;^=^>WYI_-!GSK0QC\[1*@"#RRX9S*#YPA'OS4N_<6X;)AS #A:1_P
M>:"6B0\7\K?GI$O\<()A<_AMXM^$T]7Y-$IOD5/_G=ZZ"2+41[<(GY/2I<BW
MJ'(0G+,5^5Z".TV\R3R  [Y=69-#&"(*[B!=SB(X.>G"X+O5MM)E2&,H$N1-
MQ_ON35)D49J8\=&-)G,)>V7.RX -J0>8PS/4V<%!$<^!R$@C^CL^%!2<V!5B
M*L7I'9';8N'$<&R!VC%."8O3"1HNLW2Q6,E31?R@[%%.[94]A.EBZMQX3G@#
M3*QFDKDK<>3UD'VZ)8!3-'3A2YC 1F$5;WAU-#8@F'[U;G%&;QBM/OH+,''#
M0"%1@5WF19?RB#83IV,M3A$7J  6B&7IC8 O0CR;J5X08@7)]? 8-GAJC$A"
MO#2XB'<^W,L"*'F91G'J,GG@F2(&M:A&\N,\>S1H_ A??D.2$=Q,,&'N@2_J
MFQ+OQ:$@<$M N]-T C>M+U8./XD5X9=<;(1CY2)]KXH.P5K"'T?AREU04135
M0 %?AP_(-*WQK\A("T2UO?6!%V!A>&.WN*P 1^GJ-=+H%(6QI):;9:X5'1$<
M'W(KS6I1HL--:*,)B#86(]V6,W57L6!?$#T)S@$R&!$X@HQTX&S7G]HLBG23
M>P.-;)F@TIOB3> ,"V)7O&6# M2,/G$<0.*D&HDWX@3^(V]+%)C![^V-^L$D
MC?!H:S+/FO%R7\6"+X.IP4%O>;6;,8<&S1J.3BYZS;+$^N,&]K6[PY?<P;B*
MO1^/3M8=/6D3N76.$ :]8H(.CSIBDBLDW&D=S,?,",@L,-\!FEI7H&!%H><'
M^,\M<=QAVEGI8B4NR07ED1 B+*ARM;_)PHUQ9!41:9SZH#)08R8+N.[7$8Z_
MNF^"C3&)PM^]P)^ Q'\?3)K.Z6OT@3^%3:?3.Y_<G[<Z[5'OK$'SKV;^@NPW
M(I\_FE=-YXT?)V"%)R"NTDCCN:D?@V"38]6 ".&E<9*W929POLY_A["*VX;S
ML?D&#+TO<_I/427N%R!"?THJ\/7<]V;.6[::8/>?:;Y;Q)-2G3M&FRHIZ/TM
M=*,I 4N"/IN AH8# $WLW2)[W/OA@H4Q?L(XU(7[$$L>PL-G68VG2WB+$8IU
M-5ULX?J@PID-KSR^B':+5O<U!578;MV<]^7Z#,K$#[R5\\HN^13;XV[/N8&K
MF:*^I(7"7^_\6"F1&*?1A?@36C?--HL"R>QB^_^(G>O+CY=?+U__-YPQWG0'
M:#>=KO =]^%-!-2:N'?N#6PRG+@@0O\&XL,K7\)YT%M(H=Z!Z8MOQCI[^ MK
MKG.\&?@IVKI12 MS:%I?U'0^!TK&P,$UC#%P&1*"]1-49>!\1H\24?!I3V(?
M\#:O06L(4WR-]^]T"G?>/#P>-D]DW%"L',]I,N&"]@Y/OA>,;3/P[V!8AI&+
M+/Q?'G*#@\/E%@7LV^WW!EME7TG>987RS(-,Q5/)6_0O4'T9<N09>D&(9MP"
MMCL#;03DD^.J>!U3G=Z</8&O\!>X=T23!AL.?CSSP>;TT;N;ICA-&8Q"\I;P
M'&Z\A!H!RC^=@A<))^4%<(AS8:W3S,DX\=@RCY8XR-"3(*V*L7'%,5@(#GJO
M,1Y/9@^O2:I?3MA+_"R]Q#:S5)]9:@F'!)0RFXDK=Z7%2TR^ #N7ULJ<A51S
M!"5?#TH^RAS2;D')*S]2CEC>*SC@_1*%[79=6?@:" NXOLB::>3%XNB5$HS#
MT=;M&N)=)<=8Y"BK(O;A[-Q(RC#!W%*4&QMTL^S=L=G;C4@62.:.$W^9LKV"
M"U-\O59-5C)Z"6V415DW'!Z.*!0UAX=W=S8[?%AW=OA5$DZ^,<'&;_\",EU]
M"A.O:FSXJ&" ]ZB=G_1I/OD?#C^[=%Y2E1#@AQ>\LG,@78S7EC4KXY_(:)C3
M=J4%SK-S>71P(!4N.?$I,$4$+XR=4E>>!$]<G;EY_^E=T>CX,*"KNJ(G7,IW
M33<+2+0T7=#XH7X#SA+_EW?X>8DRSH<N'KZ6#8VZ^^J.UVP,?*Z9AU&H[>RM
MBYT8&^P,K;P8M#]=ZE*N0>Z4)AZ3-^*B2&20^[4#%[YX$:W_J8?PQ8T^1U=$
M;W_BB_5S\_OM56<(2Y?4:SW;DOHG%SAE-7?Z^>M8@O*E*VER<(C*%;GG]47H
M['.:H$^)]K=-:#/_NS<]_]N+PJ(-#BK.?)O+>T_^:IV5#>NOK"8A/.G@1B^T
MO/H'-SZY",+U%+L!36\F8F0L N,J^BS1;BN?1Q+2A/MN+9?JT1."GEW75A@1
M'8I"EN4H,[E>SNUD<KNP'?"6..,5>XM%0Z2A,&N#23#X;\.X*1^C (:J<^;N
M/?OD\!AX,J5M^47+2#B[CTD[]DJ&GE#:T=#P']WO_EUZQWFCRWL73/N;A?<N
MC)"P,>I5-P<QIA&GK=+Q;3+$G\RC,+VE\\.H2Z?UJYL(%(/HFX>^"1 QG S]
MLOVK<WIY_1%#H_3#,R1?<%#@JLGCH8!)K]U7V0(KVJ"#)%TSX0C^D9U&R&01
M',$.&:( ;[^^;=+KK)$M5W",GV=T)9]HT![\PQ P[X/K"#B WU;74AFW3R[&
M_3H&&.4>'68J-$O%+$^F2*5*'V^E]+KF<>2&LQJ'\05?66$"C+'/HSG([XS2
M/.F"8EP^YV:743CQO"FGD)?P+R!]8+?%JBYOK9G68RS_=1A@F)^-]J] 6. 8
M3S_7OTR#O[IH\Y2UM:@L9>!Q/E8PC$RGQ<WZI-M[+M*E,;JPXX<PFL9>H+<(
MEN:GO(J4M$I&&W&AYG84#FJOTXW8NM?,Z[."9."F$8'! 44$1IM&!(2V6(!2
M$([G93#]P%4<J@@EKHH,C/MY-WW<ST<&OF+U3NH]*AC SRMXR]I@P%[<AG&^
M]USH]1E(-W+T 1]BCOI],%DEJ#55S&*O-U&6H:9-"(K7-[+A5@;[8P.#E=MI
MM8=5]BW67,A"QMM%>.,NG(G)^D2:)16.?% -YV'N@R7]H(TLU+W2O&Z/&LXE
MV! +48<AD_\=CO<8M0 8J8Z\Q)^YP0(4SPU^ )YT[\6RV@$6!]9*"'('_RKK
M'V%W8+GXP=R_04/[RYOSMG-:=HEG3;%LL,'!)KC!S!PL6!\"Z*7%] '4MT/%
MO;$*H)NE4=EJ0A7 -M>/IX UBD '&,_#U#:=U<*S[@.^@D%XKAW#5QKEH.0Y
M+/VEAW<K,VX^U<O=8/D8OI6NPGQOT_E#J4BC%,]SRLZD(7_#!616C4.N!+3V
M5-!>52WD)S209J#2T0'Y@U_USO.*9F^.0=FV^T4^AEE!A/2>+;=3!;68L07!
M)"^+=ZW2OXK\=>UANEPN5ME[+:QP???FDLU+,/7$@_\1.[_Y6%SK3V)]Z/!$
M00W.Z6\?+L^(OO[UST___)=S:K[E?+IXB,X4]261YR;R MPIV+CY<@;B'RJY
M@X^!0L;J3/CL/7IT4^>C!RX6; _<56<"J_<#$# 6-X@0M(^5#%S428:50?<%
M%+Z4U:P+).5;7U54> '<*>6.DG0*'ED#@]F+="IL<[LH(_XK=<$;C3/+DY3K
M(K]/\,^&\_'J_?D<^ 0MO!!V'_G\.UD]@\79\1TR'CUKD<+[9"F'V"R6E2WB
M<.,]YMCM#GV,Y4)5>.(+IE0:&7,DP.3;IE.NRO=$4=06&&8%K_C4@[^@-J2I
M9*2*0VTZ[T39+A*%MY0<6?52%3PXHD#F42"EL)M30>\DO TPNU%74I<4WI*D
M-FH\+VL4JW]5BRD2Z5B9WNY7B724?[* )JN!C0IU79=N^(?EY*LE4<T36EO8
M2PY-H?H:H?JJVFHD(@4"C%-ZLUJS $\!C["NJ%_/VUM;SRO77C,V,=XL]J>V
M!S=YF=YBE1&%G:D!@(Q2U@QLE9)TD3TGE6+![#Y@2[2(7@P"H5#"%+]-U?)S
M%ZR^&\\+4)4:[26ZD60#T^]FI71+H+6#9?F9; H*"%3#K8\]:+ $<30BYHN[
MUWTO-2]Y_*R-)]G+'[1:R,'KC+*-&)?]@4>%O3?:]&MU:8_89AL;FM=MT[ <
MS3Z9:_OBR?(HNOU<'PHB'I>=0T!!M]Q1]%N%,58^"1$)10/EJWS)%^YF47L^
M[^A-8QX_#[_Y'[CFVNMJ;W%=71S%7K N6(<P/513CGWZ6W>U&J8C;(D%E""6
M&8G$;8J [(=]JIF$MY[&9Z"@N-\)9-!<6]CF6KC937H<Y))(H=%8[UY:38:F
M2T2%"=RB")?PCW*?*) Q=?LXXO3FW]Y$">W86[I4+)I_@(HEE-<_[]XX;G=P
MCODC"[1[G7TH-'(\+"[AAL8J-:K-)B0I/Y8=!)=7KYU!:^!0B$6:ZDC,U,C@
MSWSQ8&VTE,J&I1>1:0&/$5V6E!S(BHJRK!D'#$2RX8M^UF?UK+@ZTY#-(PU:
MO9.+Y*$@Z6"LU-%+-6U+1;ZOG%/_C/L%Q9EF'4@\K%-??,AZ\LRH#?<#;"&G
M^LE[SF"J9*ES$V&SB&[6=1),KLQ@*? X/YS:4F[J<7<A78S(KZH('EHO!>^B
MSEG)K&6[O_$F;AI3]&I%WYBX2P*#1\'AD1\-[C]0B2@:QX_(GQA=A'C9TMF3
M_<.\ [E*$8P(INX"5*@S2X,)6T-^0G7W'*$ 6<-?P#4TK$"&#RX'%M$%":]1
MPMUCW($WAZM5!T$Q!&& Z!"!L3OC2]QJ:AR=K%2U6U7\X#Y<W!.%_&K)8_$H
MV?>LGV,DL#+7RZT&0-8)]P3!H8&I[F/#[/J;3W0>3A<75$H"B],QJEO/&NMW
M*XL0C+2'>J61*Z34;Y$%UD=CI%=A@36H0Y7([=8@+YV)U0Z"U1_LQKH>FUH0
M19>%C+R9K(/A<GC!G:C.S+^"W-4B7@ZQ!5G=/5];_FHHAK[ T)UH0*<VC6)^
MM#HO? S]+42-N>8<K$W!XZ"GB]:4DM_*_1S[*=;W4XSWJI^B/$':*4R0=M<D
M2'=TLI+/'JC*1PFR5/7/N5-L3<+602X60FLYCEEDH1V,K"*YT>I96)_/BM?P
MAI0%](7I.6,6K&?S\KU@9<:$ZKW#V%B^8FFY=@-2)<X%^LCW""EM+/HJ>!O:
M8=C$\5;XA*2O=QE<9<P.O,(DXK1<"MM89-PF"MV1>83U2I.Y[]TK) (J)5,;
M\PGLY(:4.+M?\ T1'=4).XIZL?1DF6L_A,+:09B(RB)*ZED&!CXAPI85_(U
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M"05J?%%UHM/WR2Y2>BL+./_F\NLU(IXG9)Y0^QM2>N)^\T11+UIW*RO\P[R
MY>"$X4;6WD.HB_?S2^&Q2'K.#U@*MY%[%YLX$<9P)JLX&@U$64)*OPF#VY"*
MF&@"0YM+YXEO^6 ==X*CA?Q=:AL\;83N,X\-3KDP3;=SYFC(8#V[&X*:Z>"I
M7,KJV_*^(R&3029YPZAQ$]^%OS&NB<U+,J.FA6F6''&X[@)MJ12N%,?$ 2FN
M-N$F^@47J!W+Q]>6CW=:!U(^WBTL'^^9C]T;-LJ+;M%!:P#K:UENB_)=RBKG
ME)?RF;A99"6,86U8FBI97/*WE C<?>H'E%N?^1$"^8,J($>D@7S+TTG0P2M7
M"^CVH?@6DR4?PKRB0"K &#\L(>-(DE]HB"6EA5@XQ>MD40&V4J.@NQY?XWU?
M+D(_48&)NQ D58KY0];!TDH4Q;;V%IQ3.:W,^2)^H@Y<G*H\*]'-2*<I(BG%
MAP)[NO*6B9P+9 +G[A5GV(-->_8<!G,&9]:0XBKK>[Q76>;+/6A6 *58:8AN
MOTRW(]=YRX,$C5S844G#(P1"1->:MU2T:LTK-ZLLC 2.OPK1Q?>H=2X;8<IK
M7 QHF?2-]75,^^H(K'&)_ 30+1[:AV+'6-R-A*W5<>SA 1&;BA6IIP@N-#J[
MUR:^A;>R#F1NYX17 BJ4)3,;3 A.^/,D"05/=>2GGP69;%!2$[8&F:RF'SP^
MN1BL+?;>I0K:4[FE@%BDERB4C.B#,K0FC\\J%O \N[9@)G"<MV9CY1RJ?@M^
M3<'8V0*YQ1ZA^JSH%]*=)*!%#%R7G$(I&5M;CA-3D]@W&DE\3>+H4Z@JW>@0
MD>XO@VFNH#H_;'C0H2F?!2FWF]T3^G[2N2_G5TL3A.)BPKN;>1(8IVHV<PGP
MC.(@99_)P7<&\Q0X_*(?J@*DIH'#D9UIF,)OSWDLLE7>I4$TK?'(PEL\?11[
M\90\MVQ/NR2L$MG3V$MZP]S4PI47MJJX+FOBM@96MR1:/JKT/!?1V6QO:X._
MAV(\E1>GY<STM<@M56 MV+- (3SX[AUIUU*,$]<LRI8Y5;+%#!P1LZ)9K%0_
M4/#_+EGU(&*"OS)>C%7U9[;SW+H1932EN:)SG%:>LF$[*QQ+5E6"Q4_'(0)H
M*Z&[2)$_JH;G:#D;OFR^+.&,<#H$#NW+HN.I-[B)VS"_)RH(F>+ %^*(A)Y?
MF"-MHXY9.%:[I!U_/ZG%]F,G%&@1NC&K[(FP!!)1SH(^]>_/]E65[N7!/[Y$
M_:#4CX1<*("3RHEV)0MVFO_98]&>M>6S(%Q8E:,PL\C2PH(G-R![6=7VF$!9
M"__.1X7+,P0+T*A4?J<@&E>\$HI"2X@$JW"H &#*? 35GYF 224[C>?2O>7
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M? V>/?+;'NVE>W+1;_:+]Q*7L=O&F?;*@3G/&HPH#?IOA($MX(V>.+3MV=,
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M8M2E]!G/I:J2I13]8 KY>@U(KTP#XGQ5QUCC/1EKG6J]!6H9K8XI*CJO8-0
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MOC>\&@,GPO4P)%&(9(\R[P.BNWU2_+8//JX"@QH$,F#K.,H^35NLF&_#5 J
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M15F.7*VKLCG6(*/JVU]M=2W P5KG<3'6"1XIZ4)O<4\X$N;CX7KQ>#/-S#6
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M"?-+\C"N!MKJC(QHA,$%+$0NNHN178K7;K;/R@3E92A-\/ L.5MGU76+:8P
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MLC.DR]0ZKS?D4(XFBY62U4 'OH@2@K40O:R;0K.'D%T&$F)"4:Q'T7XU]AY
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M=R!#,-Y(9^7U(R;OF%X>OM=:B3[V \TPC<7?T6Y?&IZQ-B/DVG%9,6,ANEQ
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M3_2R&(Z)6<6:6]"UT7T/>_LZ)U@;W;7KMT,RJ/\JC*_$]T4<-IM/AVF.N7Y
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MK^%YN@J[(QS]<O[>JG'#Y69D!/8UCK$,Y[/;NY75G.W %(_.&P5"5COJ#:=
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M*-XY90(/I7G%<1/@?2JPVR+_.M1NU\3<733F?#=>9[W:Q>P9^89U?Y@#Q9*
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M"#*#J@T(53U./&W^(+T33B1I';;N3ONP^-S=_G\(=%Y'W3W0N+9@/_\M3/[
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M..D3$H X3U(LM;A+YP@.T:HZ/4W$V$F!2S[\P2MP6X&UG@MT@6<!I#)%ERS
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M&P=NWB\WT$4/+B*M<C0MM=G *+_'R9=!HC4?ER5HI_7&=;K\1Y?]33NLI:<
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MHE"HLW:=($M9A'+1]34$QH$QXYGF(DG5.@7U(?=W[YLYZZACA_W=N1'*R)R
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MZ^UX1CO>( RO-0,,M>O^Q]J%83PY_VTPQ.EL/+JZ.R<^X^2JIN*$T<F*7&C
M5.:M@PI$'1U(45+)CGGI;^2SK$B3VQ;)XR#+[I6RA%);!\3KT ;ZQ$]'HWQM
M"9>#5%(A\YX% 9X(#LH0L,C)#;!U\#,31;+0NNW!G8 >!W/:RWY)>AQKWQ;A
M_6R<_JA]R7 RK?T@9N=;=$-8_6';-T'H"+11[X-GPS"='I?Y0[\1(_C$#7<(
M@H=*#$[6@V<2<B0/QVHTHEN%YAJOSE(@[>9HS#_WE_/Y4Q:S<Z,7U<H&+E,
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MRMH:YB(JD1($G2PHIC6]&JBA%"8"6NF<;C'I[I'7-6YBY3512>..Z=UK=[J
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M3\9:X;H=[(]TNOO&5&@B\=;&WH?Q+ Q?#KYBOBS@/5&>&21KHY:*DR4298"
MM1%](/TZS#ZS;OO![<]^JJK?4LJ[.@Y>U*32Z@+-=R<G')FC@;R:7/LR11_
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MQY(X%2TDLA&PD"6J<B<V/^V\MK6H<%]>VSHJV5EF4Q=03RBO;2T==4IQVD3
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MXMF\3N0M3B[_%7U94QM.;%:\L&!!*TORE'X^OD1"R(9>;B5*3#>:^ZYPYYK
M>3*4W),&FR<8;2J]XU*PCA^@10S&]!X)J;EBC'A%OK7*IL;HE00NE3 663(W
M6]"ORD5J ^AI\7 ?6NPK^>56B=7M9<2;R[AZ]2:#-&_K<'HZ'EV\E)?O&&WS
M&(0")00'Y>N\,*LXA.A\XBF7]BE6_:WFR9#[P(C1\*)G:\%>6#*OIM,SS*]&
MB_>73A&?8G8@DJU#IXH%KR79^M'$DI0F!ZQ34' 71NVR!3Q-8N]%_3W,QGP[
M&2?$/.^879&%T8UW[D0J5G)@&K2N6;<"#?CB-=B,R;A8R/QN7IAV'Z@GQ[FV
M:NIAN.;FULSGN8E]?#:;SFH#S-''"[_O1&A78E$1M,_T8O 2P<6@H0AD2A?'
M1.C4O'@7^^*J13PYGNZ7!CV,^VRXH'_@X..G&>:C+S@)'_'%U]H-9&'FG'C'
M0PQ20=;"D.0S'0,YU+*WG&B16A<\F%K_]9;VXQTX ,KT,*UTXV6^^.^SP>R\
MML:>G,VO@(]GGW#RX5,8+03P9CSZ@E-:]F(+8&A"P%3;<(=8E<' >Y&AZB(0
MJS,OK1O3[&QQ/]Z.@Z!-ZTFK&Z_R*"4<TLM.R_@[+>8BS%.=7GK]C\OOBQ7.
M?W5**XR(R I@G5),!J &Y[('Y-+J8&-2]D: I'4 ;QVX3X;J!\J E0-D]W &
MS/_XMCQRA/F)C"$4+CSHX@-YPHX\&$F>L"4GV(9L4)>#N=U;@O_)T'OORE]R
MG[)UD<C&T<H77S\/)A?]_"X".E$%C&22@4B\UCZ3U^*"2L!YDE%H$U U;SO5
M"OS3Y/#.U;Z$P/O+MG@9!I._A^$9'DVG9Z<7IA2M#FO]S?/!ET'&47Y'I]$)
M%YF%( N$1,M4T0@Z:Q)YXM%Q7U))@?=R'=/GHIXFX0^&)DM>A/ZK\>_+-SG*
M><Z!,+R5>6(TIJ#00L@U)=U*#UZ1RQVM%X4G=.QFX]S])R"M7LX/\N^)&DMH
MO[]+R;M>[+^/A_0Q0_*[YZ^VC]S[.C0/-=*K+6*$H'* 8J7ER@;R1%I?!>U@
M63]>@SU39<GKL/6]9M,UOAM,_W@Y07Q5RY3(;YFOL,[?*C$B,%06E"P2HC,)
M$F=>&'KWK3F8B'W71?UX%?9*DR4O0IN+V4T\G+M>]@\X.26?W;*<)4J0C,P]
ME<C;";).8_:)Z90\2M&ZZ49_JWF:U-\_,99P?G^7MM=BK]?_Y;/Q='82@HA&
M!@?>HR*!6P1Z<@)IK9,E^:QB.93]_HYU/$V>[Y,,2QAN=S6M8?[=6XNO;^MH
MVGZ"0Z>G]3758?VE'LZD!Q:*5]%',A*T 65L;6=3''$J">&T,<D>S WWZ\.;
M]$ GC$R>>\A,9%",=@8O? &GR?56.@MT/R8][):E_4UZ6$?9AS+IX=6(-B]\
M/Z.SI'[<Z_H/ZJ+G[?V*XEX6!08Y!X5)0BA*@N=*:*E+0MVZY_L=<!Y^RXBU
M^#'N1T\]5-.N@';92;0#N)ZZQ=X);#]M7YNIL1L]MM#!SHG"H[)6ZMH^FY#2
MNY+!JVQ 9^6+=SH(U]J+V0-![NFONA]^K"/Z'GCQ#J=('_CI:)2?XQ<<CC]7
MC O[>-$Q@)R::+,+X&6TM/C:)<F4!,XX%:7SM<ZU,3LZP-J]R]I0D;=[6S;5
M0@_]4G_%$7F]0T)XE$])U-/9Q;2\[T':S,@'Y@&4K9EGMM3.3+7+9]0E)"Y-
M<:VS 3H!>TQD::^)'O:5H^'\=S O-]P66$]\[=5G5:*%)Y*#(GI'%Q0DJ:W(
M44J6=&.^=$/V( -BV[AB/2ALY2[4?X3K(OF[5D0,1A^O1:2;![?N>U!?<:VU
M%G@X(:TBE9X7LBJ1$^U*&L%QSX 9S$R'$$VW7H=/-*1%9T9 [1TY._/^V9[$
MIS0#R5G07BA+/NZ/D-9.6=I?2&L=9>\[I/5]@\ HHREU2K6W28-R:M[FG8/1
M-L52CXG4*7CU=#J:KJ7KI1U-UY%YCXTPN\!X?!U-UQ+^BHZ8FTBN1T7J4J?(
M* 8QFDSN)BOD.D0)-G@C4Q$66:<TCGTKL%-'TQ;Z6T=@O78T)=_2:/3_K[UK
M:VXK1\[O^16IO&,']TLJ2977]DQY,S.>\GAV:Y]8#: A,Z%(AZ1<]OSZ-"CJ
M+DJ\X)"',E]LFI+/Z<O70#?0E\!R0B*D<%%W+\.(.!>R]>#B6BEHQ]'1=".Q
MK^QHNHG,.NUH:JRP8 B)6B3R/U Y%I.-#$QR-J)V*'0+Y?6CH^G6RMM:9ON8
M_6)*$B81>J01Q)5TP+RSP(H*0+0J$9L8X,N<_;*M)[2S)AIVP=MLHL$Z1'['
MLU\VTN%68SVV4<#!9K]PA:6./&?"6UG/^.KB62\$O/9D,;1_I29^V7'-?ND>
M))O(?1^S7X"[;&5&YK!NG<(H%I+RC'N3K0G91;Y>EX<CFOVRD0Z>F_VRB0 [
MN$_;0\FE," "2):L)P8A)Q8-]PP-%S[D$&1J/</P5)G;_#BQ5S Y%CNX5W;F
M1%8NU8$E*1<R]4B!?@S ."3G? WN<:V@ZM"6\ (J%'MG"SM I4_3,=:N/!-%
M4[ L!8M06ZH8"JTB-Z0*B\FXJ,&*WMS O>@"Q=Y8PLXPZ5/_^#7*T'1"$6FK
MDUG4 8)9L8C!,DS2!M J<]TZF^U4G]@6^8<'QLK^\7LJWKI,_P!RX1Y.Q7Z5
MYN3?S;]U4\BUR9L[+>K:6@3]R8:1T7/A(+ H,1#B@J9X5@1&'K?-WN5 46U?
M]N*?^Y<-8W6R,8-@)BC'=$;%(&3/R%J=RR(4)9N[]=]A-LPF*.TN&V8391\Z
M&^8ZIW)!/OWRXHPR!(@N<,>"A5J"E.A3=(;E3(Z645[YU#HW^@X!QW\WM!$&
M[N>W;JV+0X1Y*P5QP\8XU_%DMTY'U^&IHVJO+O@Y3)'8#C#9-$;;EXZ/!;]6
M@JP^.!.JCBSSJ;"H5&$AD'T#JLC;;^='@]MG:M=Z#MM-5-M-D=O]"&'VX?<_
MEA=!J%S)]4()?!)$G#1LT:F26V<4#YF3B].^O&TU03V,Z3O7^<-ZN$8*Z^#&
MXHK/RXOG -QR)YE#CK60RQ*#1;(LHQ4Q9X[WKV%WGX-UZ_W?MT^WM28Z.+&\
MA_YUJ.G(&>N#&[6]9E:H> >Q=K"AW*/*^1BXH*U61K!,"VN85YPS*%SX8E10
MV-4B<$"?HRL=;R+-YD.4ZW;S;EP':PR_+.8_2R[459XI$08H%;,<B4>;.(O2
M%J8C2!L%6J/6G(S\Q%OVO_OO(OY)%[+K4Y;!P^E;'R:CT8^3:?WA((4@(=4.
MGH+79%5./HXQD3G-@P.>4PZ]Z?[W)"<]]#D[/I@\/"#Z#?/EN"P32\KUXM=;
M7ML(0 TJN68F6VUXA&QD;YI[OX!YFPW1U?D,SDV@T:=4F25#/]$OSF?7$Y<I
MW. 1B9'L"LE6%\6"-.3%)&<P"Z.RZ$VVY*,<G%!^6%!TD06S\*@6D\'?7$RO
MYV(M.)C=N@2?78T S0,.5O&2ZL!GLL=:^L1\=H&1V^8%;99)M)\;OS&5)ZAV
MK]R5&2J'6W%):@6'\XLZ[OYZT+U(+FMM*-J(% U(Y5AMC,]\,$)@""!,)]E8
M;=DX ;H'\'B(^,/-"[DVW:MY<#<L)9.-\E(P7B1%+:'4 ;3)DR4;9ZV(2D'K
MSJX=L'%"? _@\1#Q;0:#- T38E9&*Z%92;75G:5/T<7,LM229[#HL#?3T=:+
M( ^QCBQ<@'IALI0J<L.-<:Y.T8L$$\492*<8N0@BAQRXA=:-\YHS<5I##@Z-
MARN(.S36_WXYR7J<K[.S)_6KAPL+* -@/?D&3I@J=46^0<[,.FY+EAB,Z]O1
MU+J\G2RCKT!Z:##^T 9SRV^^9/:^3_$/')Y]JJ+X@E,XPZMXLC:/Q%>QMH]-
M\X'S*LDH.1.8Z\QX75A(UK%<A$@I"<Y%W]S2)HP?D:GUX^9C_W#KX>'QK47D
M*78'V09ED'.*7Y'8Q  L<(^L[M'<@)9"V9Y9U9JL'9'=' ZXW=W!-$-=K[*#
M'SV%?Y)54Y)%6Y"1DV'J7'%!SJY*3"03?-#!<>ADVN1^V#L960=&=B#T=54E
MO0NK5]RLQZT&I[TVDOD0%-/)*A8AD1.2C56D&,NA=9K;?CD\F=L!S*T[#![B
M"NPY;A^YY'B27[0.E:GG.+(6S*/SK [*9=$A=\9GD>7>2X0;\WBRN@-879<X
M/,1%W/.KS$9*&BAMO"I:,F5K&U*=@4%0M,YHT$8A6!OVG@[4F,>3W1UDM^L.
MA_V^#GR23>>RA9)()]8N6C@+YLMB/%:,F(R.F'M\2;B^E1WTZO!I#7COT03!
MN),$-*N1>2R6H43AK$^QB+T'TFU8.ZUS^S^IZ@)U1WE7^23W47$!GAC/M>V4
MYM*P4$\3ZB+HB@JT\O=MU=N-XY,I[M\4]XC1'EZ.OLIY@3 8O1G.:N^?A2:O
M](+&: 1B25J NOSD.FS ,U54YK8HR87LF0$^R= 1V5<_+C/;P:-/33"?]5 _
M8%4N??]Z,EZP>@&CV@11#J)7Z%,*K( E960965!@6<J +D)MK]!)7ME^V3PB
M.VD/U%8=-?>$LJXN*'=@>;5WNXIE,> I1.U59 D\>;K*!0;9T3]UHAB^1%U\
M)Z7"^V7S9%C'@[(>[E@;^ZJK)>')Y58:,BM965IBC&+@8^T4E&A]<5R[T$DW
ML5YP?S+#H\=D#^OW;K'\CC@;CF?#M&BI/0A9)G04U3H;-=/! @N @ESXD(.P
M,M+JT[,X:B4S)]OI&V*ZND]LLS??94P,K.$2#!1F92W@BERS($I@(G,LHD@1
M8R<#-CKAYF0,O<-,#V_YGM\B7YV=3?$,YO<X'T@3@Q+UV$<HP;01EL5@)%.U
M5:30RBK3MUNGK9D]V=*Q(>ZAJ=F#F=K;_[L8SK^]&Y/P+Q:)!N_GGW#Z\1.,
MER+Y=3+^LI#*[?HKFWS [#2SUB+%@YQTI*QE?C%F%P&YZ<WDLZTX/"*C.O")
M=_< ZE/(LCZWRR) R8NQOG:_E9ET8D)D$="PF'+2&;W&L/?DYE;,'9&1[ &E
M^S>H+2#6IYJW9QF]US6K</(#@DQ,Z3I(RU. %Y3BS&+R7IH$+O=FQ."&O)TL
MZ2"6M / #E%VLXI/DO@E0P\8OM7CRRI9NQLQX%&1 HQC/OK(,C$GG RNE-X<
MI:W!S\E@NC"8UD Z*L]MF9*%^7H],"6HZ, S)WVA]<#4[&%2A"(V10"0 *TG
M>.R1O9,)'63/V0UF?6I&M[&CZI4#(T)A@!&8%C4] ]"RK-!+'@,GK1R-/3T9
M"_52"_?N$Q?.SQN8X_4(V]O&PX,$28;";/%D/#Q[%@*W3$#FM/I[1-Z;+DC=
MB."(UL>C.0+J#(+'N2X^*XY!L#9GQ2.3,F:F@W L9$\;!*"&$%WP "_0#(_(
M]OH _AX:\D;(/>)3J><%01Y/ EN@^IV":2PD@^@DD\7[A,(GK7LS : U\R<[
M[J<==XGA/IV,/2N(RPO?]06ABM798&1"AES/VI'5YOD,G$W)<-2Z',]^O"'S
M)V/NIS%WB>%C/,&KV23/2P&]U%)XS7@0I$N!A45:R1AJE6/P-A'E1V/)FW!^
M,N-^FG%GZ'VIL;'#Z%!Y7^\?ZA /<DK Q,2D06\Q:.?3\=P';QL;;Z&[)P<$
M/<K@@$N XDM@P;O(=$3'8I*<%>YY\&@3]\UCF,W)/**5K=&)7<>J[" G^+?I
M)"'FV8\DR\>G4<EHC)"1,PQ8,RF=91"@,$5$)YXE%FA=T?@L4=\=LMJJJ4\)
MKUM&P-[;7*-=QJ,FIUF#99Z<"!8P&F>$X^1!]&6S>?%G-0>^[]@#A'K8E.A!
M0]6/DSF,[J7!@PW6!*%8,5(R#4!A)7+)T'D$QT'YM/>^H@WX.MG&H<'250^@
M'0JO[IZ[7-NY&'A++I;0BCE0COBRB8'6A0FR^2(Q>ATZR1OJ@)?O$_B'!L5#
ML(==P?[V_/-H\@WQ=YQ^&29\7,K70>B"H]G"9F___/5D-O]U,O\GSC]@FIR-
MAW^2(Y@P!D/Q-D,D'U#7.;(09&$2ZURF$"#JUFCOC)GO#N[]@,4C][^\MX!?
M6O9DNORJ_IX8J.*-SQHHF Y SIVD<(A;8"BS2C[RY%SKJ'6_')Y,HS\ >L1>
MCB9A8B"$]T49Q7B*==JX\2R6+)EWI60EK'7R>&I'GRKCZ=&:=?.DR_]TGPTR
M%.>+SIRI8@6ACP<&/B%]LB7HE*/DK0]X#\;L:27K):P>6=1VOFO>\QIN4#I,
MA3/4D=/2YC.+SI++CUFF@#X;W7II.X03\!\_W+,<@NG_+GZP^+Y:Q@<L_UK_
M_N/#NVLK.@<RFC,<#]/L+VER_L/"@CY6RN$C6<(,4GW6&YS#<#2[BXK9D-B\
M=QU_?C;^NI"'D$HL9++R63_<$'>7Z.4#[QC[#F3BUSF.,X41NZ'VS7 &RS83
M]*;WY0-^P?$%WBP&T6B>4&GFZU0PK6D?C=$XECP6Z5U2W+8^C'Z.IETM=<7S
M/]:V-@/N-$+@D4%64/O88.USK2B MMIGZU0)K;.NGJ*GX08"H]'J;:,I#NYO
M"LT$_ECR[K]6AO/\WVMS%\S_^6_D/N'-EY/QG"SE[6BQ]9%QXUG]L"V"9M/Y
MX/7D@IXY_0S3^;=?X1Q??1W.!L&5%+D-C';(4&<+619L\LP:A8K[8O5Z,Z[H
M!;<00_^Z0<NJ=S=$R"=B?YHN:GG_D,0TJ_?<FR)F"Z5.&@JW87IWI><#?KZ8
MID^TR;TB5A<@ND_BFX5?MA:1 ](.7(SF#9"P-F$M/= K4+![?-R HXT.)_M2
MP,'0(HH"'6LR6%3DO7%36.2",V]U,A"4R>L%IOU&R>6C^P223>3>$!S5?QQ\
MQ&EU['Y9!' #)U.D^,0SE:!V\M)0DV(U[:<JQ^*$,/)9)_3A8_<7;W8H]TD3
MH3U4W];GO)77WZ:3?)'F[Z?+Z&<!6 [>! R%$32)GI!HPQ,@60[@N0M62=UB
MVW_LW2]JV]]9N T+06[1,WLUSDN*9DL@KT-4PVU^)2'[W]9WU]%#A3<2<.-M
M?#5Q*G, J243!2D("E[3@@:E)A4D:8J(3JU5J=XOK3^Q3>])Z9O(M?6V_'IR
M'BG*O2;I>BN[VG.*25S(PCA7N:YIDA&;@8$,"0QM1H+;M3;J9UZTWZV[D2XF
M'0FRX>9]M7$M-ZK9@'Q+HR!GE@RY#EKK6FJ8!#,(SIM4%);6>6-7[][_=4"G
MYSI;B;2A:A>P^_&BUK'\,ASA;#X9XX#8,;'V]#5>&:9SH-6I&,-<\MK18A6*
M@+7L]=Z#7XCN=I99!P7TB[N<=^,T.2<74MBH9=U7+"JF)0<6)?%D!+C"LP'7
MO!'6K=>_$"7O*MB5[G3+ZYA+NC["5[S5I?O=N$RFY[#C[<RZC][]LF8K)AK=
MW5R_^^U7.!^.84G\$C?H$Y=!&R9TG4<M+#*?*,8SP1>IT-3(N[$A/4G0SHL$
M!:GTQ/'9SY/9[#5,I]_*98WE[#+V=#7+RV1@V8&H%Z*>!1,<XY*^X* X^1FM
M%XZG2=K7W4T['#Q8/QK*_-!W-P^D]>IB_FDR'<Z_+8(: 8'S$@PK0DFFZZ>H
M."<'6*?$2XG2M;[G?)R20QWL--7UI+G,.W ['E)U=5JY!EV;'/+LA(E#G/>T
MU-NS4-A!Z/L$A>*%.RMJ1TF@\+5VL?"+*=@!B@_.6Y5:[R_[!<.*8Z!#8&$3
M6;<^#R(2*"H:IMMDP3C_/H<YTM\_T_\>_>UB.ISEX2([Y_)TX^J, S.YY=HS
M&U)-0@O 0@;%G"'W&SD'P_ESSNO.5.P_B&FCR,DAM-#!2=,5[8N[L.FW)5%@
MP03PBJ&A0%N;()AW4C/%G4E>.?2B]72.1PDY<G2T$W('FP?Q>)G+N%@:R6/B
MPF%B(.N(Z,6 0/21&2.$\Y@CB-18XW<(>(F>Y/82[J!7W#4Q2SRO0TY'?N,]
M4@[C+NZ@G%5JWD&R7=KW%5FHH["UAH9C76X$L.@2,&Z\P90D#Z%U8Z^]*/H9
M5[!#/6\@T.;Y.?#UGPA3DKC[.*$__<V>0OP58"I?$H;,&_(F>(ZHK)-<\["6
M3[?B!?O?D'>2^J2QR%K?![T;+T6(2V*2\5*K.@H@A\2TM(;YR,G+B(8\0W":
MJ%I+?_>??,2*VTE('1N>UDN:K+$I2T\!90A^>:NHR5E(*N2,:".8O(WA7;W@
MB/770F2-<Z8^U *SQ89@?"&>G&4VZ3IDI!"J3*F7BTC?"*Z)QQ;)K5<O?$E^
M[O:2;-@^]9J():K6(:-E;OO-J_>?YK:E\.^K;P?)M4Y*OT6.%DE[C)EQY);I
M.A_'A^Q9%)[36D0A\GI3<0ZMP"<RUMKJ;Q.!-=;;+R2I\XOSJR,M*%#7$R:B
MKYG/M&=$(J*>NEH(06B,:]WF/J.Y.R_=<S+YMF*?M)!9XVSQ7^#K+4*4U+ED
MVI4]TA\ZDB<,'"-3$+),/MF<UVK8\9SR;K_T")6WM<PZB/1?7TRG.)[?NEJO
M%<SX5QR3).<#;K(5/B-+%.D0=9$\92\M*\Y::[1*JOF@C:<I.N"I;O.L@X:R
M[^)T'PL2?;F>9\]F.)^M=@-_OXC_@VG^<4(<#*?+GKC6I)R%8X8G$HRI;18R
MDH?.HPH^:RY%ZR.CW2A^2<C:H^Z:7TON1/JK\WI-\L=\.!K^66.3]^-7X_$%
MC/X*,_*4, 1G'06,SAA:L;42S!NM&>V21O#L1>%RO5O+[HA\"3#LE2*[N0]Y
M39P-Y[>YN*1XH %TK#V<"Z1Z2FPTD28DLQF3#UYHSUNG(SY!SDM 4VNI=S!_
MY8_Q]+K)"Y&YW,%G'S_!_!^3BU%^=_X9TOQM*83RX9<JG0\PQT'6Q93:K%67
MFJ]<E&)!:ZQS%T(R4F9M6WM7VU'ZDF"T!UUU,!UD!=778OH-QS":#[$6.KVK
ME<DXFR_]R8'6I3BN%9,I"J8YC\SG6O5 >WPR/( 2K0N!=B#W.\!:<ZVM'"K1
MLH[A]\N\Y _X>3*MV_@.=0NK'K5[G<):1#:J2[C_KMK5:YS(8QF?5>C\.)E>
MNSR_32>D^.KX+*8_7/['CY/7D_%L,AIF6F!N]:7+T7$#F%B)&&M[",Z@)-K;
MDDA"B)!!^,;VVA$KN]<R+LE8%@T]3<3L+A67EQ/*8Y992A8,0IU83YY!+?[*
MTF0',@7E6@_=WIWJ?554] '!#XLM]ZKSOI1K+#(^%WTK+V8DQ]GLBL'%&;]V
MP>EZ@0I8YUPD68N5?9VV9B'Z@%F)Y@U>GR+H4%>1^P;'@^%0K934Q7CF2UJ6
M5^[K$--1CMX=0@Z3H==04?<AL+.4.U>]YYGHJLUA T\U.;A0J!(E2]Y$:2+H
MU'ZR7/<J?R97;U\:WT2XK<]&?R$"EM0L;X]B\C):F9C*HM3,\L*\0:PSZ 1$
MX\'(\IPS_OBC#]#1>7LY3YH)J8.+E-?P>3B'48T!:U/@V?ORQ_CS=/(%,VU:
MM'_5^._MUS2ZH(BD;EZOSJLS]N=BA_OKM^7O?'L_I4_UE'2!9X0D0,O,BC3U
M2*+VGG(>F!'"<Y63%D:TOI=KS\9WZD4<&A =G(@O25D:W#K$=.1[W"'D,+['
MP=7[<.[DCKKIP&.Y2Q0O"7W.R! $IQ7:UD[\M.++A"[Z@AYTZ^5L#T!YQF/I
M-TXV44EK/^?ODSB%<Q+.^!SBFPOZY>DY_$E>W57FC>2Z&"E8@F3(07"61;#
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MX2EXD]S25[&NHFD^4*J8 %@8]\HR'7*=$"T<BP9U*%)XD5MW3VE"^ F0A\'
MRHN!+0N %UJ98?K+V>3+#YCRU1"P//PRS!<PFKT?C[[=??ECE;]W0'G[<9=X
M3/D&AO>?O5$I\!;D[E@#3"\9O!J-;KWBESM W9C_E0_<)93_&YSC[+]A.L6K
MQPW0!9%24(Q<^TS>/BV/43G#N)21@Y=>^WM;UHH(_N&S]V?\STG_3C"]HQ!:
M'Z_\#4N9XK??<'YS<VMLU,"38#R6VKY$>19!:>8H+%/"@S;ZV9KZ50_OJU9V
M%,/*HXT5*][RZ_I'A!G^U[_\/U!+ P04    " "=@'1:A5#]TF>A  "1[P
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M..<P?HOD[NL=XE\PH$F1W:ZIKMXO]_SPXJ45N!?MVL:BSA]3.Q6RHGV9/0M
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MBAO^3)K!L%&EM6M%#'M86=++6B@- 63I.R!GC@0V5\DV%M8'F [P$ +XCSL
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M^M8)X*->MSHGC((4SN_[[)RGJFF8ZG3C[=IF'Z[)959Z6$Z_%[W_=KG@"5C
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MM#&AGE5L602.6VA@=V B^;[=,_.#LU>!:>3AS1+[%I3GDB9?SZL8 $8%[+F
M-+HD1FQ=A'46024[RCU<@Q^IH@KIUQEU!6NYT0C8F']B3\](?6U?P*K3,B7S
MB7!?K2R;@>]]_Y0]7T _4G69UO*TG>^>.^YRY(OMPT_1F+M9)V5!K43I>U<T
M!B2C1!LWWV\P(+5X/R,*E-?SKYW\49;%2&O*RW0M1X'#LS0E+L0=E4%]RO;;
M)=\@0NC//Y6[R%F3"NP>] TD6O4SZE(FBONE9VO2U BZK#;^L$H2*!$@.=-4
M<%F!+[D;.XJW6UJHJT1^0U>7(R8NQX3;+9F7FI1MECN9<2]UK"F69'=4V=!2
MV\V3H%\@=0"\[G.&+$2JH>-)HB,_?X-$^),L"%9DE;I2$U<$U$AZSB3[62_-
M$I6!4DOJT*QNP0BSG*^,8UICHID2;'P+^"[A43AY"WBK.]OH&A[&U&WJPERB
MMD."ON#4I7B.)Y!_DU_DKH/Q9F_G$)C!W/!%;B1;H5<:Q/?DY4%#>B'IV!!*
MF;J/A'+52-5Y>353<BGH[<O#?J8':F1YJ0?7Y 8'$\$4D .\%.N2'F9(X5./
MT[#",)?D7"EE2%HMA2C'.>1)\E(3;\<-25C'.^(DN<2-4M*\2"T+28R5/N(@
MB:K]-L?P]V/*]RQ%.(<:Y1RXFR,\S5-QGQPT8K^:EOWVEE1*NK:[M/=(0:FK
M_BR(:]:SR[#BJX^;P@BY2E5]%3-HUQCC2^7S\US&=NPZBLC @@8%D^^:S<3-
M9 Q-4'"URR.;LIW=QDJ<''7Z'\&,_FDRL[XRL"<^ELB%7P]\ JY49-'Q/\A^
M4B@(UTV<9I;?_-'AB,L9A.XP#:UR*=7 0!-O&2_'DX)40&*7U,/O=:C(/47J
MXL-=K2?+=C.QSI>VL-_/GXAP>62!%C4GO:I7,[J3@+)?<NVJH-EN^/A*?2FM
M'&M6EYSUYM'QY%4%B$2ELF-%(*''%:W/@N)+E[PR2LG,YFFB)^5X6:K,C@8E
M$Q:QX .^&]S[<8-OK5$4X>F+"KIO%$25QEAIZSTTV-@N119=Z]8)DK\99!V%
MKCMGGM^; D\T@B\>E7/^K_:^,RJJ9DN[D= B&1')"#1!29)SEBQ18@.-DC.2
M<Q DAZ910$!:0))"DW/." A(:B1G$+"AFZQ ,[[OM[Z9>>]=:^;>-6O=^\<?
M]>/4\U2MBJ?V.7O7WL@3HD5^U?/2L")S=7<_5V%/9<&0#58DGTI("2Z2JUS5
M>+H\'W,0688XH'W:GHS:CE/K[;+2+[@BO'*.2KX&]-U?L2#KA9U_/$+-9%5_
MI;%)%FLX+&QR4'GBIEG"$FE?TB\@SS2N'&#T88W1OG,&SEL#?=*$9*L>?S:%
M8M:;&R%./E3I3"-Z38]K74_*K;++:]DM61R]G]%W=VYHMP$S:S&_%& GH?1>
M+)/<$%\T;12'S<UK3YXI3CD@.A'.-]W*7N$T9]<@_;-ZR7)N!SE1S7/S@^=0
M$W[ <ZHHT(H'#-EPB5.BY$']WF:F>2'C-)5S#B%2'>UL-9S6)7\'5JEV#];U
M4Q?X[!_]66<"9\%$)ZSJ4<RXV3:8&F::\MJ^!K2I<Q7P0\X1S?T8Z&5L\]E5
MI)O<\1-=?"VY-;)H$1G! [V&J5-3T_YJ'0\OO'3,QX9%E@)#H.PL:O?^G!@T
M6*ABE[7G\?2=_5G- >(J=2*U]Q_D=\6@/B,>S=!4I.6M2:.!4TUIR/-75Z:-
M%RP7L@?G3![P<\2[!%:VU2O^P<Y?0FL]SS6@^O3J&B V:C$?M#Y\)(1Z^X4@
M[=?!64'H&(@8S2EQ6GIT6GUSG\A,<[.[]P:N>H,56F'C#!%BV0N6C2PNW*\H
MF9\S^V1H'< 0BFZ0?U]Z&SY;(50OR]:&Q+(XS!$D.?J08(N>I?X\_ YZ?K<V
M2MOJEBE:8IUVQSB4]5Q':T*6G,N?M;EMP@7%D]N6_M#F9LTC4C+T-L-:N QU
MB#9]"'A2QW^?SJP.!IN@=ICB$&KJ[(;[CT$\C I@K$D%L(C\&Y][T8 #<V15
MB447AKG'Z.&")'C1#%*+AK:P*%!/A&9#MTW?W15QY)6F$\X&-:4>6>2XL"5/
MR FZ\U;;V>I-Q?[J+(,N4.^]?XP&AB"*J>8]I'#IW3T[]2_D-_65GJOXWSLM
MHY>+7[K5[H\'GNMOP.,17# ;)O:\/4DIB2_Q<X9W)4F;1*Z7B1-]4I\15N!X
MEK[]9-*U I5(W'$OV4<W,+R+'DO@K-.C55C\?;N8F?R'W&S'5\U3J!R]QH_0
MJRNI;9I<TDDS#.FKU6$*OW++'GLB\4>"3!9094.&JE- %E0!H_)JS6$[A&Y-
M/:H%/T7='<2N3LL@^:%"#$WL!:4YMV*^XW;AS43>X(S7N,O.]VC#'@O&I\!=
MICVK@(R)'_PK0AD%&O]%*3>$)0T;V$)< \S7L*Z0#Y8R25BI'Z&JA4KG#ESY
M\>NB_U*#NZ,$LMO9)%(#LL+3Y2#_VHLF%"\B,68X6<JCE@N2#5?LA;>6H"!0
M<[9@*;-AA+7V5"%_KJ43;(^BC^J-EZA"ZGT<?6+;*3D\AE0I72 [.JCW,,E,
M'XW-6S,YV4L8OGD2NZ69)P;C)JGI2M&^43\!S"M#,#]NJ3DG D)=@M7+YO?2
MD>[^8Z)YH"_:>F.?,!(/%' 9< 8K(&UH"-2OPA'<K>C*=US#_QJ99TW)DU '
MZY>U[2>KNC/FV $4YJ:7TB3*T0%/U9:*D9%F!OG3S:JY]G!];*D,Z+'1!;)@
MGO0++6L6[*2'LD![&M)_/G%.=6\F_S$)D,YV4QO=6DX[OE&$^?5)*V)Y>P>"
M-]U*'^3AZA' V)_'\'!(/G/MI>9&(W +[X,YW7&+',$.==9I:9DZ84OK-$0T
MLSRB,9$59:  39-'[3HEOT*O*X^["3>Y%+82%5I86( ?3=R 98<K%8E>=:7*
MH^!%X=+; UCA9LRC):8F='N>3'FV(T=.D/\7#8-/9T\>#!!9C^.]A'KH!2NU
M8PB22OR+C=NN 2_3N8?OJA]+)7 ^*R[ ,6:5)^W6="-FH/04@,2XHTM[?+-X
M^S,<,LCG%YQ*/[8/$AR(F N6B%]$.@ "_0Z,3L( 7YWGQN9%7#4-FVH%0<4:
M017'HM[]$];]:I^ ;AYP#WFJ6JF]4IVXF6;SU*'3YJ(TZK*43YOM(UQA?(;F
MQT]>BW\C/0"C2M].>M-7K;<9]P9F]V7RKE=5QHMR#K]0][439Q:2\F:\4<'1
M+/D7RX\':?LPZY*EKQ9+\J!W.FE%=2&] 6ZZ>=),H49L[\ MR@ [,E)'G!-[
M,YKIDQ3\"SZ%MRZS8W*+ZXF&4@>XYT'Z=9.(_=IK0(9FK)+=N [(G<J?J%*R
MTJH <!,4F>P<&@_HK4/[OK!V='9V+%8EIO:+_GES_ V/%^/L4R'LI,<D_/4P
M%.\\=/?L24M6C^#N%Y&V;Z8%ACFTBF]S75OBP\5P6G 1[GKR##)GX:@Z:.SM
MI5U?Y=J-B:?U]5G<Z?&/?%(5AVAIQ.E-O49)O!_Z&S^JJY] H;R_Y<6HI0S;
M,@3H$:79<@(.U7SWX$U[X&-=H*0T[FHA,MM 2\QV6.<TW0"N'%<X&MQ#[AI5
M,XIJ&G'< W.\6V,4.+ZR^FH^U\)-M3"D +P744"NP*A0>JQ+P 1=&<%5T,PK
M=MQKQDBWQ/&! I8,MC?M4ZJX!]?%M_(FI/%7VXATD\\>3P8WK>I7WH6K4R\P
MY8OXLCY49>9B\+"X0X4#8X[R=DC'84PM:6A_I9>P[9Z^.DP=VG;6P"BQ8SH7
MT^-.N)MAW'"W6?&3^Z';^]MJ54.]3YL2'UI< U#6?L$SOUY1@ERI-_6YHJ>2
M%$N.<5\89"A,WJEC.Q6?OS#8.K'DJ;E\(0%,= 58U7+EDGJIHX'1M9I[9B-B
MV@(+IC%F 9 U=3KV9[7Y^]91 \K?I&[52W/FD]#-:%!SGW)+135'\ NTJQOI
M")A)#/8<1?:YZ,G3'CJ ;9H1H^]Y\]5]?)QXMOV&"5GP8Q6+$VWG&P)'QR^!
MJVT$6*E%(>W#[2@->1NX^J-;@;'37V.[=J)PD[GS\L,%5:.%7^2;.Q(ZZ0]M
MF7*D"Z=-9?@)"A$ G[/'25,D3Z'(>@*-8U@SA1.L*1J?'FF"*GA24QX22:6.
MO.@<7*O[)VS@\UIK([#]05*U1[S[; Z%CV%-)D^399*TE 'VYOYA&JWH\R\'
M/,\:)_&X;]:G^97W ;BV)W'AK4:^22O\)-\DXY=WYGSYQC5497H/M3'W=\D_
MC=2&"/PQ:1H#:E63;A7E/+D4FB4ZIPGI"SJ9'--:"W!90[V!0KIVF'7YCN?.
M7.V-M0FKPG4>8U\DL00>4R[=KPUD\$ZCIFG:5>3^*HF?72J(<E_N7K [S2BI
M;W+[Z^$DNNX]<,UT.6]O1OU]D.]$NEPSY5-9 H]4*N)UD<!XP%C[EV.4IGY-
M1UL]I85)''YK2RP7R*)<7#I"BN$86%+&*+=J'UD[Z[JTK':$_X'$G7%D:G*
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M!ET@0L_4+_1>7<V,< Z?R::04_<37"YZXV'YD1:XN+2UR'!Q7QO#UWDGRIW
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M;\9OQK^386A21LFE+Y*U&<&E"_&U$S\!;;P+Y,*]GOT/4$L#!!0    ( )V
M=%J@2+O4\.D  "MM 0 4    ;6=N>"TR,#(T,3(S,5]G,BYJ<&?LO 585.V^
M/KP(000IZ980E)+N$FEIZ1)I<&AD:$&E0T! 26F0&.D:ND5Z *6[8P:)D9CY
MYCUG[W/>?<Y^W_/_?]]UOA/77K"&-<^SUO/\[OO7<\T%^CMZ&2!55U93!K"P
ML(!GF!\ O8*=IP1VL@< 34W@ 0  -P%<+"D &W-%"@!8ZA%. "[F&@OS:YJ9
M]=M?@ 4 L/UW&0!\S!@1YKTLY@08=O_YKG\< /#4T0UD[<7#HN'DY^;CZH#A
MY5_9PGKQVQW_8.OWQU/ $7 #0( UX 7P8,Q+ W "_# C/H K@&$/8Z,XCH[>
MWNZ2_/RN7GS6MF[/[?ALW$#\8&MW?@&^A_R M!S8W=K&Q<Z;Y;F=@Y.K#.=1
M2SLGBY.M#*>1B.9#37=%.T<G57]/.WU_K:<V_BXV$K:<<K*W;TF#)<$@=Y"=
MMS4+&/3"U4L2+,/Z3ZM+8JY_&^9GE97VM+67U'NL_)<[,.]D6/\BBZ^O+Y^O
M$)^;IP._@(2$!/]#07Y!05[,';Q>?J[>UF!>5R^VORSPV,[+QM/)W=O)S97E
MM_?6S]U\O&58?7R<;"7MK>U%GMO:BO ^MQ:RY140L+7FM;85$N"U%1*R%1,1
M$!>T%WC.^I?M;6W^97=W'\\7_[2WK0V_W0L[D)VKMQ>&#0%^5O[_@CUEI6UM
M)&T\[:R]W3S_>7M].X__;YR]<)+]-XXDS?^7\7^^P.R 42(! 8$T_^\WY_\W
MX/\R@M$AYNI?-(YYDN7_A^._\R;_ZC5VKAA7\<7X!'H.4 3P;]S NX&+CW<#
M[R8^_LU;9(08CF]1DI 2D=%0TM'24-)0TS-QWJ5GY&"DIF'E8^7@NL_-PTW'
MPB_$_T"0\P'W@]\6P<*_>?,6P2T*0D**!PPT# _^KP]T!T!V$ZL*=P$'BQ7
M)L/"(<-"]P#,F*AY ^N?CK\&#RQL'-P;>/@W"6X18FZH(P6PL7!PL'%Q;MS
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M]NNP!-0;;HE CU\1B@/MM:<D%S<70Y8Q*HUCGO6/N,9UDX-SH(&^,EW3_T"
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M&7P?R^4_)P3_I\XRS<$E#W?=\ ,5G"HK.6PG0Q79RWNUT\2>8( GZ\.(7-#
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M&U>B++E!@4F$OW+!1_)5#?!['P,^F[;E>.1J%NWN;,::'1IPMU]"P^3N:)2
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M0?_[HH*O [>BAQOK$$7,%*V6PE7O"W!^KQ<RHY=_%<N%Z6,0ESZWR4"W=[3
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MAI+$NGD?4/4>\8A(<7MMQ,6!)\J!FH;SB'1YV5=/^WL613&YOCJ$Z+:4TF6
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MPS/GOCBN(-E^T2L9UY&S&9V&G_NN;(TQ ?>0'Q[.%Y01Q2^'D326[@U(2T'
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M0U4G-U)!]CEM)_]^EQ-*)G!,A"K.2>CN:N$RU.!;V!T]EE<-WY[M0.B(KPH
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M//DF9 - ] %VX"'T.+NU7A8'QH_T4N+I#:1I75>=JNITK:&V?.X<=3!1\19
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M1/A%./OPXI&X9!Z(Z;ID+ASZ/:@/LYG:M>6>J]=A>G,5__VB:*IKK_X%GN;
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M $W1,$!P^M:86^#XFO,-_O;?G_P-- _72)L_</Z!\P^<?^#\.YS1/[-$O;,
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M]^EW,MB,Y!Y2XV+9H%VW":"$J6NS'^<7DTAZ'.@,0K\ S33*M'0W[]7-$2>
M:\.=C%T^A6!X;".$ $ZB[! ZZ<)V;?W6R$HVF_6Q\1:IB(D1<QT 9>OOL)]/
MOC4K-LUV)I48CZ+QDQUU-W5@B:3B RVP"S&+N2CSY] <#_&6YSJG*\1I'*P5
MFYC5#02-VI_+7KSESA?)&ZB5I./]&LN<C%\J05&)OUKQI>'+K!2-7-)@!%J1
MT,IIJKXNP3OTH.!@)UG$R'=&@F)^^(L$=KJ82IW@#56S'5-^O[6HR2=59H7
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M)O/9Q9BWGS@AX##*P894,T^> Z6WE=8/-F)=94&&)P[YQ*;Q*DXXGV6FWS,
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M3K:?71Y'RX-=7/ <M]:,WMS/D@T'D*/CM"="E$I2,2T8TKS1_DV[GQ:+\8*
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MT>%05!AHSL-N4O#'<6,%,6@'.2B=@7+OSLKZ$2]Y492)J7@2Z(%,*_$1$0S
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MXFC]$<8N[+_C2G211N3S4%4<VEE=N"M]3[H3429N_ EV#YQ:B'$XEO=Y5V"
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MXE.73:59=%[C,_^+O;>,JF-9UT:;0" )EB#!)4&#NP2-8,$)KL'=W2$LW$F
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M9WU][N;?._QJRZ'U>@?2XQ5\4[N<153S1=F)[)0*%#Z4(2)(6-^ 5>*/"#C
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MH8K9PG'RT(2B)ZLKN7VB+H7.ZH))GN[FKNZY,W-::I4[KMG^:LN"!6V&WH\
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MX[4W8I^H63FBA,J,W7",MA([4R/:)\1^C%/ !#Y5/!F=J1><F4#E$R^R)(]
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M$S2E8[[*J#+A%'I\H=%!*!,-(9%A-)>92!2W+.XO:^; SL";61945E:R>(R
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MRMR32:)R8BTN(F@S?XIF+?+XLT *?Q]XS\^#>CS;NO;2]YO/*!V\I5V@?U;
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M5':GYO9MT:#6\I'EE>X_9OZFTI];VKS]4JKS.)UKJ#/L_9C!$<E_"@YF!61
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ML^9]XO(WFM0SXZ+WK\Z\SU:UDS7[:G-59-P'4,,RI3OAH+B)85@I-A\*!9S
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M7! >90AV;D7+,_YEL_[JE>&AE6)O?K3Y'BF0(_I<Q'2?P)T KR&#1XQ!F<>
M!88>DZN@#R87T\G7&*L2#?8%7BCSOG/!X64C;2'^66>\90N5/FP=>>",\Q_@
MV$Y=5V?<QG2?PX?N0H 3CDLYZ0G42?)F<SW*D&I91];"<'LSK=Y.MB!$0E^&
M%PE&&38,AS8/)=SX.2@7E\^'6C3)]L]1H=NE8$BM,-%&/*G=(Y<IUMM';);.
M#:-/1R]Z(/^.#$Q\:+9F9;/J]JW9OCJ5]7Y$X:Z*P'R:#F2L!TMU\DE#*[/N
M8TC?MPAC9UB/#TX9:%L/GE_+))5K_WI3_6:FNFMZ/7+#>=K .5#_G;P-HD-*
MJ>2!JN@6P8X"VM\/%-O<982>SJJ-'2>+< .IW>F'"BE.SHM6$=<5>I:[;[ZJ
M6RA[ZJ',\>>]4C_D]ASHI4^@KZ>0:_2?K+>X$^P>94-624PC;QB&1V.J03=V
MP7@@/^Q\F*N11\7DEX,6#X3RFCG)Z1JR/.&#3%XP#Y69\;2M#01MD"Y'S65*
MH%?Z?<1Q4CI-$>0%A6ZTF;$CQ6S4\I?G\(?MN9-'-^Y9+>OK!1]531;[6LCQ
MIXHM/ ZTDAK%,-W=/FWH-[&80]G&F;\Q4CXAI;"T2B/CGX=I6E?,G2*,U!RJ
MLHKR#QK;M;9SM%!\ !7>/FRR:3M3<93A%T[W-ONTXB,V2GG=I8TL?6 3>W)1
MK36OZ'.['ZHZ@7WVV\7K[^4>B]2!Q!L*Z#9NA#) 1FG(ED O$%M$F!)I(:4K
MN5WPV,?(5#(Q#>4>6QTF;S&L,-C^T,XP"5]L(!UQ:([3-#X-<CWN(OH0*.DN
M!&H)04_#FE=Z<PG'Z:)MU.)>#$&>T-UEV+ +Z;E1?&OT?D<^W^D=H_'>;WU/
M=XXU6[_%#E^?OW>WPD<;S.@Y\XODIYBK\&0<?UF?M./S*\RK*7^)9\(+9<0]
M[6K"](;T!\L'#./]G&??Z6MJJ+E^P%.]1;*A?*U;V6!\+""L@?+'B^X_E&7'
M8Y5<EF=<4DXWMX0WJ%[[^:I)K.+GH3]E7#MPUN0=D>^4C(P>]N#EIM1+$UM^
M;]K>I >VOVZ_;WYCX)U4K&_O86Y1.V[YHCL"FI7_!XP7T92X?F(*9I^!IX@H
M\R*M)B<UL&[M+SJ]]HO/2,N5,)D9/0)AOO'&3Z<CFNOZ#CV))WGM_KMG\WM#
MRM/C<T.,TJ$5#US&JGV$2FB@H];AR*# "_GBFI>K\]Y*239]YW@L:. Z"A/>
M>\9%I#K!,V'*#9A (A=Z6EYIL$]KU"-"!\JWZ.8]MYCY/:E$NUSG %SGLE['
M Y31M_GL6:E?=AGF<#*8-4#P!5IQ9FR:P8:6?5/ISL4IG6I^J=8N>V\'KUR;
M2\Y]=,@GGE6MY5W(W A;8 6<L,%J1*$L9=@?H"W9M3FM9/$1(RP(?ZNNAPCB
M:]!R,^VVV8/[5X5>2=D<U>_!W?]OGJH?*4XW=R2/[0/0._V/=&?66QJTG%H3
MRNTN3KW(%TQPN^!H_LK^ZY&#=QR"#D#T0S@WI+9E4O"D)A@5CE?JQ]2AC@/U
M%(SL#WFOD>XZ9%4WE+_+J>%[T4=\ KK6M]8IZ'&<O]$GD]%;F'?0>3OZ.=:S
M5D>6 CV<56&NM53WJ^'(V(7/O,FM(5O.'Q=7'=-(V]X'78R#6_^)/WLZ\UOY
M\!LYR*_5?[FP40%H__=."V[VI+( *P>GS;PU$0-/]Q&EN)M#R>%/@T,1G[\B
MJPZ=SNH7*5%#*/JY6FM5'8F\:@-)4)>\<))G;TCU,6^S*M%BZ)%=B$@D^R@J
MBB8UG4U^:WJH^.)TU;BNKO:ZWX6B(G)#1<'[K+A\I_JM*[KK8'O,H\+*Q$0P
MUN:A<\9+SL@?,3/\==[?2_<_GBZ*O-11/:,;^;)O_=F9^M?:.1R/1:[_QX:6
MY\(*9+L>XGYD"EP&F4!^<=>W_BQ?\<57XX\SR-O_+-N<'S2Q@-\B@@I^^,24
M(6T)>2^L>LM3'Y6 @3F$8U,&>DYX?WMU[H<<1.>&P]#818<7P$@O3OG3;X0H
MT;MK^J_BN;_5MV*?%T=WMZD_J"W@['K.]M3B^^QX?^W.C>/+/J]@&PR&$GM1
M_N:;>O1[O-(OK.(\,A*I,J,^45EN4_9!J=)EVQ_>I7I##]L1PC4;4ID!<9"M
M//X\,(T[^4H ([H??1J$/ RI;!?2KOMN"]#Q&23.-R^UK]=JXWNA6=/RF^5/
M4FFVZ?%1P4K+#?ZQ$HN>ZDM!L".?>Y\'.<O=X1AP0G=X7;$+CE#_4J]B7Z73
MHUDR>T?_^C-!O5\0\02!/[W=/E17$%0.S>2R8?/HX;^\&^Z5-C3I+1<P3WA7
MZ3*EMZFX\]%AXPM6T&*C2T^S7_:_?"Q]0%2DLN6V@AV57K(_\W&HR[31S:%7
MBQ,?>3(TB\<OGQ2PN%-K4Q-ZWW,T=%\9I\WUS>V^^T_=Y=@TWRSQZ"&+A!DL
M>V(7TMKX3F1VNUN0IDO/I74MRE-_/+ S>JN3FA =?*U_7!)NV*6O_B8N3\J\
MIW.6?,.*JYD*SXJ!IUE*O:)A4Z8!M[!C?]KP!(_+_5G]^B>U>3Y$#9<,V'Z3
MXQ:[;W5 WHA.I]_\$1K*:2-I+WUBZ?RSC'T0R'7(K]IQ&XA4"8*$Y_4(UT/F
MS/3<"O#(?ONX-9%MQC<=0E+D*WSW18)U/VK#(Y:,AH'(683N@PG@0X45Z*>!
M$AIA_B201]%BA,-$ %?7\<:&E:FOKQ_V<K0'W[$S0&AJOJJ2'=$2)AY^Q]NR
M5KHOF7);QTNDKT/[247@"<X$L[7 TL,0$X6\;M[[(@>Q-:&FWLFUUE7?2R/>
MEM=T<+>WMB;[YZ@K2>T9,-GMWY7SPS@*C$KA59E;[:DHC2=N7F$B./;R<,^)
MZC?7"CILSPO^DW\C>KIE;06:@:&Z$ &-]A[=K&CTF.G.AJ!RZU*]<P^CQY*3
M.E!'N6T[].#.B+F\1</D_*M\_5<\JJH'@NY8YE1VA9/MF)(:]*, ><G)F%S<
MLT70ZOU;F_';,9V4VDUQ5YF.6%2X^;IXPQ3UK-W(U\^YOS9'K\CFX\KYVR"\
MO)M$2Z*TQ[O.L W&V0HATJ5];[8-PR/D^39]3#X&7MZ/WH[;O!V.SH <R;E+
MQ@H#SD,M1$$D>M"I+;[4M7UR0UPR5&'+Y!)$VF+LHNO3_UP2GZZQY:C$C/7B
M<S1XZGJL5DQ)H+VAX.D2:1O&"ZENCE3_J<NK8'IW(<"F9X] &@&\# = E7X2
MZ*:M.7S"J:%L;1#[ .]5.8+72?,&H?@\U9"*;76[')CAY&B,9ME#,>^W<4_=
MW&1=_OZ5=>KKT>2>2-Y6.W _\]'SD^;[D0:0E[-N\U=&$Q"!DM%7I(S%JZ\:
MU-CNHYA<V[_OEL#1]6LMWWE>8(,EQ?8=54TY5I_OH,'U1JU@,\Q#DU-!VPP^
M>6%I\KGOW8#"FCS?-,U@_R+_G.I'M75U]2FLQ_A0D23\J['>M<:,78A2EV-L
M)3*LQZC >7K&NJNSK2D[JD1'F2#'S?]>X2OAS8G1*)]7M4S)<+H^Z[6.KB^K
M '=<(\=O,D!LU2,E\_'JOH\3IVKZ;GQYV]&K4"C']U&ND^ND\D21RX7%H:<U
MU8Y11QT4F]/>Q9T^>MDQ]H#,#=Z37DU3$V&F-['ULTXUJ].B"QY?;/U?M[U.
M,[]1(7MD>$Z(;STL3)/S23*9Q=OS]XH'-"7&T<ET6.B/T4VC$:$+7[]NG(8(
MY<.YWGHVFK">@'P+!O)+NC%P"WV4/8$S1P@"?B9%6N7H)?O.URVM-P-/2XP@
M)#,AP;$V^E)"'Z1N(!LP=W8ARCA1]B2>/P:10^1 Q892?/B Q,/JXZTC4E%2
M$W9:/=^LG[6+VZZ]5ZQ[O!\'1H/0J&LW>O],;"9,+!PM,:EK*&R^W/-WM<?D
M4)O)V.;"W8"51WP-^ARR!S,T.06]M,XVO92_G%/&;51Q)C.DXG(6UU0$EZP)
MK-RP)4)E775B_DR;T<N-GPU9@M^>3 B0H^XF[K/0<PG9@V%<0]U\2,?ECTWQ
M2KV]H9';9XJ*\J^<&7[F=B]#/3COY8G3SA^N0]3NGI36;!1GE6)(53Y-\(TD
MFD0?C!\6+))[*RZ]"TX^40H7_WY^=L'SRX^*H)]N9XO%;"\4^=RO^Y/$R2?;
M&/&8.]#5.>=QXC$KI7!8+UJ4BDV*4)MDJI!OFYU)=#_[JOO)G!VGV:/GIR#\
MI.B9C-L[Z0;A@DJVK!>EI%"]9F*WK^"7,6E5\?6??L*J)J>>-STKBAAI4<SZ
M8[Q> 4*D("L+'^GDV'?+>+V*MG6&5DZ\Y_2:IMV&140I_%B^6>@GSE]U2E!6
M75;N0,5'3:Y9SW.3BW]B[9KN?:D.,GBM)Z)W_I]"X2DA^K._M2DHXQ<^[F&W
M9E+7$3HQ/\YVW.[_7&E/?Q%5G/U0//O=M^O(^BF0DJF*/G-;N3L;A M[!1;+
M'K S,]S$67JB1^+PK2ZY-<S3G=.J$W[4U#2#D0VC/XCJP>)(VD(WM%BUZ/PS
MX*C[R2'?^R(U3U_PTK-8M6P^]A!&) AH8E@!'1@19- ,&]8Z6;GHY3$G=$>>
MXA@2(+WJ>"2E("S_)/<CK0H@G ;MP<J8B]4R;:@&.\VA\M66L?=V_MJ,9A78
M/5*TB5:\P>,[W'1>SCY03=1^W\:_"(AK,C/HWU6]&3]H ?(@8 FLZCV+1C2E
MA=;VU!:+8%O<O=7\*_9-UO30L\J75B>.Y=XR.?_'V<H%PK7P7[9]O3!>:A_<
M2L8TPWM'B)DP></YMQJ]I0&Z1G7/K2N]O:U]!0['E4:'2Z;P%5II:VU8+22C
M_M1@NF,QI()28G(D*KZ:/>>A]E>X?&+>>ZVN*LS'MZWDY>D;5VZ7C62G!9(?
M0A_>^L0[W>*J0@VFWP$4&#8HXW:@EPJEK*2B?,CAY>QS>/*"MU:GU]#.U)""
MZ'-\7T.*-\E5@0%%$_%-*QL[C\/9FJS[EJ:A:.,F*NY%S.C-",M%BD1X5.*E
MB$<GYI:N\CM<DOVB=2VH^QWORW$;H]"*]N1-'76WI6Q'L\ZKFHKY#M\U.:8N
MW6QW:9]N6IR[,FAPW%99KO+Z\*JM->>) SE64NH0R0O>K@Q7]+S/JYUU$[(2
M;! $=41_B+E<15CQP/"8^Y3!?%V$T\>%'NDBV7+_F^?[+P\7\WV+;GK)L?K
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MHCV0/U=+'AD7VXYXX>+@5TI !GRIM&I7MZX2O9S[;8PICZ&NT#-9S[I4&*>
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M]-K@_LPT79UFA!9A\_@Q[^;&B9E^4O:\E)EMGHE39$@C)''X_ Y$@3T!O+
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MP6T0/7OXV"4_FX23]Y71X=?ENEQ0Z?@@8? 0BL*&?7O8GGBL*NLCO(EPGPW
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MB!Z70,'&./&-^H=IE0R'<_#-KZU7.OUN&98'7S]TXD#+S=/6""=KR(VOBD)
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M<_R1X_'7J(-^:=*9-WN1ZCGON(YN6-TV=KHR5&'M)S:F_VK$=(#KM2>%>_O
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M.F4D&KGZA&Y;>/W;(]1=3.>],M$J!F[(]O (N).CIW[-K$,5_L^KD7OMQ&]
M,ND!3.#@#9P79GR I VT]+!;87!E&<<O-)^6VDRV9S/6M-(5>S/5<-#C36/M
M4\5I<:\0P7CU>YF*>NIEN85OV%L@8500WA 1#<;3<-QX)DYM3:: TE-#!;$U
M7,1#B6$TVNXE#+M,D!MK*@R. W.HLNH9]=VK#G.5"@R[G2R982_B\W*14^49
MZU04F8<*.JS[&J^M L=:&[4:C8$IQY=FNC:BH$P?G<$L. (ZCJSI)SJ=A^E"
M<*A6N/6MUHZA-!$J?&%2SLPBY=H0!^DW[+U)HPXXQL-G$;L/#CMZ:E!!8>,/
MSN?P#Z).NT+P,3^U!? [ZTC5]Z_R0V.]QY\==_+S$9K4VDTTT-Q[-G[MV+'D
MD;9^&K21IM'&=^<036!NRC%G;,5:Q\@[X)MGZNS8T,.HB*@H^*07NK)FCPIR
MVU)+!8]I):FAE+OA/TTN@3.1>$LH<!+>2, 0_P!X\1CBN9HJ-*%W%26O%Z:R
M9K&H:3(K+/VV)G%Y+-^72S@FIW_ZWOH5+UT+6?"C7@B9>VE.BLS#2&'.Q$$
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MX78HCS:AFYLE*X_ME,=<WR>;Q*I(Y*_)KBAU==#P-S1+]/)_6"L<@]O;*?1
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MVB$51O$PR1FE^$<7*?F(W$J+0.\;K0NAG8'Q97;2=#__NF5P%]'<*PA8400
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M<K,GI<LGB6+7;XFAJ1P\!U^_PN\QF?]C:;YEAL+8+=:+:#@(?(?FA#/0_D,
M^L\4,"/A\<,J;.9E3ZW1,2K?DC(]9J-G8R_>;BY@N%-@1K0U 7W]Y@1+L;;0
MLAQ!"")P\TG Z0V,%PL@UT(Y3LC)G=,A6.0E+V=<4(UK#9A9N70I:W99)OVZ
MH\31&%]'#*_D):F6[S"9N9MBLME:Y\$K*LO0E'S^-9ENB:G!C'&IO%)XIJ)Z
M)U?"1(6MV!)VVU(.QYX(/JXM&RQW$TC K\PRO/KP\U%WEJWKH^QXTFQM3.15
MF8-C6F''3G#H//S= 2T%R SFFS2[%DDYYR2HUKGGZIFZYOYM[8!_-QQ\M)D=
M:5)ZAA5M.$MA!QIQK&K0@0G-4^@:EA^?!11$PMFY$97/P(]&_NU'OS>)G^N2
M]'>RBV Q%S0MY97NTLTR5!TKR(5H05PW@).POH/<5G!Y9D)-(I3"Z<5E&+Y2
M+?SF3.@?G8P-Z5MZ3R /C"9R*<=[YSAQ)07#*M+OGC?D\!!4*PP+)C^&/!C,
MKJ?AW(SG9WIW$^ #OWT "\86*#N,$ZB?&<%GMK(RZHQLCWBT]9I76B7;5"CB
M C^M8N@?C<1%=\ALD6ZJ9&N$>%!!=/L_R'$7\%%*P65E^(.0>P1F\TZL^&9Y
M4 +Y5=+N=;0+>S1*!:C'G\. N5$G@+-*[,MUZ^FB"VVIK%TW/I7,M_EVYGDF
M.:R)RZ%=)>)SQLOG"%X1)Q/NQUG6W#8_8AX,8GO"%/2;HWAL?.N,?CWJH'<8
M7UG\ W,E6_]+IXR4E.-\_U!EI6&C_X_^=R@[!" 7M/HVCQPR@F($VN\T]#OT
M[;!_OCP;<G++G_3R]I%3*2^#JSN^J/%*!_+)'RE[JV(4@V6'&>9?_@CXM5F'
M'B0,VJ^5R7^TN)-O1KZQ\APS*=23<2HB<$A#RJ.'I>9B1T7,8"13@]N-5SXI
M1K<'*NJF1\96]\][]OT-P+1H__!?!>C^2^J?I-IA5P_>P)E@IW^\:L%RP4__
M$E)(6>*&3M%O':/P0!O6*)UAH27?#UN4 S+\JU.DFS#38;@ [/S@#ONY&P.M
MDT*)N:[S.H6G#Q+M+33Q];F0"T6:O2+<=[HXK_#R:NC+7,PTZVI9"M'E%C4Z
M:MW@8)U;>6_^2T[F!")G2NTBL2&)V'M0ZF\T.C)S"G9[!,98[/Y+^TW&>>*^
MW[M3-W^NOW<52!42?>;)1'ZNW/W(\K>W\D6(:+'C@X@1 +08=A)(?53Q<[_N
MU&1<2/7U" DKSKY/@9^<3-ED1LR==&^D5I86%(4T:G5^M+06A W*U:)TA_K3
M*^N"^BE&?<CTPPR8(G1UT-K%8EK4Y<7)D9)8[V"_W:_Z >-GB5Q?NLA9<+=;
MG//YE8=F!^,3!SE4$"X!4@5N<YTC2+5VO8 QYT^JO91;QDVZG0WSO5YC(:R_
MI.V>2]?#"D\CLP-@D@*E1\B2:-E4=O1!G?(#HE&HB+/!E_8#E1S#?O5>=86G
MHTP;Z-_0?FM!2EW_4MMMO] ZA%T&1/PKH&.ITO+!A=?!);:('%-U="%4M.'=
MFV"CU5]4$'WC00K"Q4O<O!PO33C_A4V8Y-5ZTC/[;E"B_+%W33^O>(&G+[K_
M? (2H /Y__%W +W,+8%)/7AS(-;@VX&77,=F0R;+)X!).9^M3Q_:O>/5/97U
MMV4_BG[]3\*8?XG];Q$SKB;H16U(V=C86D@E]W#R;!I"_[F*-LKGH%Q; CX.
M9H \ $= >2 N5-#8B@V-K4TKR+5<\&I-8@5<;#[5#)8*!0U(# 0(/U#R/&%0
M$STQK>O )B#9E=PC]W-9FH[ CD.3N:&SC&0>!#$?8"7=<*6"*DJI($P9.XS_
MX U*(OA5&Y8#=H/H[29VJKV%]:K)P/8=A3=9^E-OTB7TG5[HB3B'/#,\21?T
MA0:J>JF@SXBU1AJA$SK(TA(DG8>W0\MS*F;KN]EG);1/#@;\@IF]=26>.K:]
M4JA527)^R_-]8?WKX@F(_R2N"%*D8LSX'<+R$>U1%H7&&QB*8]#'$2YRH>)S
MB' X[Z]QNRC<1K10=WRU6E95?KSRV9?;*QWB#ZSZFODR3K5[SG%(1L7 M #2
MX7;200/$(4F4TH&MVB!S59@"B#DL?["E,7Z!"HKQ;+CZ'A*>KHA+F2J[*]RA
M%/;&MWE:X*,!C\G2"8]?^_PZ(+@%[5UN(W!AUKTM6$ *^A41COP<E%P,;!#O
MI8Q[,8Z[JYF,(YH-O*JY$<PW6O3HM[J]6)LK. 4<'26O>MK2OB ."1&$X-Y
M\'?11VC/,D:=(;./P$5@&H &?K/])IX8-:?_L*VDS#VY&^&=>*(JQYZUL2&3
MU-#N;6?@?^QC_'=T0=J?V]Y'%5PP.6($$7W&:']AN>V$&MW,ZB+IJ\MT=.%V
MFJ2',&T\6R9))GC)>$"+,W=B4N=MO8Z6D./UGT%*)\/FA8C[?VVH40G8OO^%
MF<F, GUZ=N2M%2[D*B6XH,KS]UH4R7_ML/$'^!\E6Y+^<?O^W9.3E)X!*FBI
M#4S:EO['K:R;]/^B2,-CXO1!%<1%:901E[[4ADUZU,!'7*E3$-:M2A#:M:J?
M2*^NCI_S$\M/Y.5?O _JMC_,G$#@\B @-.X5FD$">$GP,^6OZ][L $=H@5TN
MQ$VY+5S:L]38G#&]W:%\U)@3HWE*;2%H-83$0AF&X.VHH'$!^!06;ZQ@3=('
M#%U].V8.F(9RIE0%.+>(K!>/?S__)-X@8'?^7I,5TJ]U7^^8MX6P:%C&XYQ!
M_[/+7E:A=?U4$-(_TX+H.^8^-I'1&"3X^(+;)B+JU5D* Z474JU&%@DAW:09
ME1Z\;U<-S@1PS]3OAM_\/!!SQ^($)B 1^<5'%7/O^(;@=5/EI/23T EL.)9.
MFY,, MSS8"< 33P59/A#2^/M.'/HN9N?:XZ(FW1(O*ZHY[+*CG%QEF]),70#
MN+_FL #VN*ES,TL8-//HSSJ^!.>,+(O4]Q,?C*V;PYFB8\^ >$OM$((^U>*Q
M4D;,4>\+[Q7^THV'"Y0M9FX9[J2NK]5[%AK?-O.8-@K\V_(2F.S_0C5R+&,1
M3=<HDD 7SG+5;XX]%LU4)>U?BKA!Z24=I8)&3R [MP*8'T#G7XH**W];Z7SM
M(DY/9PH+IH+"HN'?L!7MV4YST#B+H+H\#<:K^#U2P/0,F45<\K[7_L\.*(@R
M207A+0VPXW$SB9_Q<E^AQW/[M31*&L#N@P&/*Q162UA;@HY7B;=X9Q.D3[Q4
M[SDF)=[Y_9R( A-W&!(U<&-B>MSC\UZ!J,\&F^.>HA*SR/T[+\U>WWLS\=IY
M=M!V#J^RNC[N[A^")E]\3-RCF=D2.X5S7X\*.F5YF JC2?,=T"IT.W1"N(D*
M8D+)DDVCS'^H0M?8:T81S:KOFQ;WK$._=VQA/!-K4U0\!5P$-.AC 454$NW=
MKB,ZKVB#J:!)&YK2J*5OOI#W/!O<Z9.NKS)?AUKY3G&94528_6#$>T]ZN'TX
M3=(ZQ76H<.!6GIFAAM7[2M>??22CW[[PO-2:.,V?"A\T[$#CQ$X J@5 [,CE
MVOZJKE+E[8UC#Z13ON$[^\B)L_J;@?,>/J]'5EF=7<68\4%1.P;=?I?Q.2\=
M'A=V.@TJR:^*Q]H47+33,V;^O".111()Y*I65$ZXD"BZ-K()^:#>%5GA*8GI
MSPUK[V5ZA]6,V) 8'K^AJ3H]WB@(M,Z@1R&'96)NN9D X2T0-K*9K]/\\K3&
MH/5D,7*6"C+P$:>C=&;M]D8@\9?9A:?W@A!"\ N_LGSQCI_QTSF[-S$#/:^Z
MF$*)9R@!^ZXZ/OW?SA@'%85 U"AZ'4[33-Z10O 1H>7[IW?]4O71U\<.-EVZ
MD,P07!+T,QCCI;AD@;^5.UM?B]=ICPG0"^@]\'VFQRGVO11Z&5":@31O1.XC
MB$88;)007Y3'$Q8AW536NM>/H@=="!_#8G>D9[RW(5'TAXM0EI@Q/@/A>V=^
MY"\)Y%$\1Q#G_T[]+9;*_]]6H^I_2H0QD3*%..*E#:%T:JL"KKB-B)QC!$AT
MF;\&%30C-* 5]/[#.&*B.EFX1E!/4%.$LXJ8<JD;<1K,21$!-F;XDU2](B'<
M#3*/WP+A5QL?&]KH#]Y3[O8X*\+K!'DA'G;LQ//+9:MM*)I5A472C$H0X;@!
M2/<FDI4)FK,!C>M1LZQL1-ZA*@^0A)][EIO(*^$PA,0+&"'LJR,'X[HV&Y ;
MCK.N^F05+XP9@DWVU:<Y9F39]2AYR ^,F-<@$YL-.-)RZR GT3BL%R K3O,H
MHMS$4!HG4QC]!3G6<#.E]L)!?1=#:K'(L;Q8&O@3*Q+WD5-;KV69N*X$[5/,
MIH*.43X7-)6X0ASJJNHBG*N_5(\2NH7_#_;>.ZJI+GP7C!41%9$.0I0J79I4
MR6<!!(1(#46(!42:B'0)B0("4@4$!(0HO8<>>J0+J$AO DF0WA*0<""%B=]=
M:^;>6?<W=\J=N3-KS1]A965EDW/.?LOS[+W?YP59CJ9>?A]R2C3D+ )#96;@
M-E[<(X5I,!Z93(KR#*<XL+62ZA+KA%G):F_6$V4R1;A8'&6;V3XH&3S-E13/
M3$Z8:$$^I6G3LU'X/&8$>Q;1286&'()J(L(WD2((MA&%F)>JWYLW*2%*1KS#
MY1>?##U7^NXLSQ'YZ-.SG1)LY-6/D/ES2OF/W]7>NHIMB4!+4WH=A@M4'5=5
MR;IK^2OR+M+/\D]+JZK&(V<+-I?^ W4KA\?4RXPI5'7JQG=2,7LTKCJB4R;8
M#:IE?J_*<V9VQ3L!+;)ZU/_6I:5RRU>_8OIN@2TP[94?M!W@;[,$.5E.O_-[
M[YC^M^ [_J:2&<SN/Q?*XD+]+SA%E?N;TO\UF!&:O_+[O/O#I2%%<]-_P$<8
M(SC2K;F30&,0C@_Y+4LUZ?:(A%\R#4)D_9TU!),4T_?:,>)!3>\H02VYR=]X
M#T%8"(W3LP?B5(\=HUUQ^ICDZ2OP:\4V2S,A\^==+YJA?^%UB_%-;N> ZC8&
M)WGQM1<!*@BX=L"&Y8<]QM!%MF*DONO\%\^CI,E>&N*L U/WGGULKCL$O=Z&
MB XTB_22 ^(QCJ/BH9URYJ$([-_]X![&C O*%WV6\0U"LF,/95RC0L)1+J@3
MN@1CW8H(^Z&-J6!-JUV?MI1SJ+5/FS:ZP4T$\'F K8<!QI+AKVLS9:R9/^U;
M]SG?^"*I#S+I(R8 E/R5\P^YA) A]TQI&U-5 Y*;)8NNW7_Z,JGYP*=L&?.M
MPOL09,_[Z71VJSSN)X0)% $)=!SR5XX#*35#G2W0O7W>8(3\DW/GAF*/EK7G
MO9=2Y4[QWZHV%)\OQN\HK.U4XGMBU:FOQ8J\KO&N\?D68 M:FO\8[$M=49M!
M8\'_U8B!8*4RK:CM13,O4:$:>$S)(P7^+/]Q'DB]^7:QVIN^\F _+WHU_&[2
MH&[P(%XA,NL8D$<HU'Y,FN\6\&O(^Q7_:V[%WT7%<<_,XN/5S8+C/I=@U>'=
MA,J$%BEX/^87LJSCEWW'+W/]*:?1D3GK#=4U7LR \V U]#^0NRG/6?G_A!+/
M__-#$M(LC11!1Q*AKJ#H_[KHV?M#T%,<( M=+R/9#0PB6%!J\;Z%5=EG3_Y3
M=V>^>J9"6K_YIB$ GX?3N-8H8_3BW7C@1C-GX<RRU<O0#V4(#;Q;H.[WKY O
M0^7.[Q/:3EM"]]QZNYS59947H.GV*;BXGD6$+K&'U5')QV7DH,OCO530%.4%
M8-7"Z>$',88\14T'4:#T#SDIXT3/^!K*Z&/S>'87Q;)1JO"73O1J]<174V@9
M0I"JRS0VCU8I8'S@)\H9=<0ZX&9;54G)ZM4>_T)UQG:1\%UMO\XPOX?6Z.H>
M&D<0Y0/0(.8@ O2@//'V\GX[8G9D2J;AO<"OKZV/2W[<CRME)Z53!R@^3*]Z
M@NQ%54<D%#_-.F*,NA]Q1G6+<Z,I[3Z*ZZF%+BN+^I77+=;CX&N^'Q RD[?(
MAR#(UWT%3^*X$.JTC'R'3CEC$$.79T2E!P]\.P2]05<J; Q2O=S6YK]##4;S
MZUK:/'F L>T[GQROGWGRCV/R]>-W^C2]X,&,+@C)8" "4H6.+FV5#8@FGLPC
M*G!/W1*Y_5-ATOWR!;VO:PM';1WX8IH>?YXXQ7<P%K76[CAQ7V74P,%L=@M7
ML/_KH%R E!.^?>:N5^W'2K[W^PV+E,2Q51FC.;O>WH*1_\A*,/?IVO\OM=/_
M?\C_\2%O9=US'I G.TLUN6..2MO^[^CJ]G]#,T],,@Y?!"%9XE[/D>[.O4%-
M94DDROGWI'=5HT\!(K-X6:QQ'SW[A=*#.BL^>3WKD$)6%D]))EOQ8_K>5YH$
M\Z]; $>S.&&N$D@EME8^@7<PN)46M;C<W[2T3MVX<X-:&2)L=K7)0N4M>8]V
M89IQ:HT<2AD B@Y![#+,P9COP>7V;EBIH@#_MI<'CXR-/D<1*2*@\$'8TZAO
M(/Z;FY8QQY-VA;GQOYK84^1%B7XK^*2]2S5%D8G4J[:J[(M9Z>YC5?>32WH'
M)LW&[(-$,YC_,P#5IL ,BAA !M4]R+Q4<>9GN:ZP'0!Z+UE>6YE@T#&=Z3IC
M76/:P^/MEB^/M.0+W+93?RS*F'B:+A%+*!,8[F@5&O(H5:&R.6(K*ZM>/PJ?
MY;I7)"#RJK#X$^@3" 2RC'P8/L6%Q;YY'*?*=O'I)^E"/M"1G^8E2P&XF&IA
MA>YN7[."F^D+>7J:-S]JBM6,C367^?].-++E$M73=)W=JC?5Y=X^V?9?%%XX
M!0ST(%D![\]&1%2DL,*PBK$F>!<[5?O'CZQ0Z7_)>:I\^: UC7A68MQA4('8
M6-529Q1M5'A1R9BST-%7M%#Z!LO/H<78C>"[H[8F)?FY#8DMF+*FZ<I']9XQ
MZ!KL%_CD'I0Q"/208?H_JS+F:QL;SWHK'?0<?98"!4ZG;[KM#%#&F(_)$&%#
MSX:XS4")T ZYQ[I#" TBFU90"^S>R*;=58<3VWEW"+JROR.'[F86WPU[QE=^
MU\/=6$#M\SD7ASD2J@2LW+5?<-Y)P[8DB8"LM#4S7?!83D?N&(X;Y*);!!WV
M9/]=%]@"P/H[-?&3PP3[L6KUOOQJ(NS:V!>*4XB28P)J]FE\+2)SGGTJ@W'Z
M&-5W+1'0,AJC&97=@K 3<"P3S=<B(VI*0/M)F._*UZX'8)IUCC$3"]<AR D7
M[F!20M;;,B//Y@FSR5$S[,YWU(=(_$+&BX:NP*T!2)OP&2#H<Q<A_D@ U'C0
M9P(R,N%BI3C=CKX=<^0 EK1[9EBP7 (CO8XK03HOHE:AD33[+:^3#]>EKJ^8
M;4QN3T'4I",6<%]0P&5<SY9@H":V!\SGTGJFREUYPBX!A=#_?*I=; #SH=/?
M]F"/P#3U8Y2+)-B;?-)B$VEUIW/X5W;9CZ*R-<ZRMHZ3^V>;;E>^T/QTYH:T
MP?'0/W3NN8B^JWR^N?+4%A0>R3+EF,7[W$3?Y&=[<57MQ^(I#UKZ OQ*SA([
MX!-!XYQCQ%(/0?(M=H>@Q))<@$F\CJ_3XY G$#>'&=(T:> Z/1FSXN YP70!
MPJ41R>WFB2S>?8EZ'_<>48RTU\>8\V>#[+E'+_*<NV 6JY[?G+H/UM4/JX>=
MM54MQ%_I]G+)+S(W5ME,=U4SOFYNF\]EJNN#_N?_E++  ,("@)*&Y^-?J2J\
M0?/2V/.!^([&KH8(LR%5-\MT_M3"K]?Y+G(_#+<"A9PZV2@@O6)9I)==9&*B
M9+)2\"1],K_NJ8"Q#?HMJG:)QH&C=#--QX9FB:9,,]_H 6L.K3_7L<8E 9H\
M:IIO8NO\M>58OX[* M28,[UOU%_DF^X.T"Y@&6R#)';*;EP/@;UKM(K$TA5^
M]'+V_5_<%6._+_)4IMS*_+U#<=9Y\(.K[]A5ZB9.&X4OAI/^@8>@ZKZES@DR
M.=';TE9AFK7L,['F$%'AM/)O.NXS^GS?S'F6-A1C)\4:OSZ'4<Z ^1RU/=^$
MVW<+;S@VN,R+M  4RT2&F#9#?/57'._-?.'[(]?6P-OKR A3>-1<902-9YC"
MC'\A/C2S>,HEYILV0-3A6J/+'95#T$7[F\XC[I]^C*3 [L::_)R/CNPWO/KK
M&]*2'@_XDP6_P'FU.?-I=YAX3D@+_E,UZ*%7OIN \=2 IS<_0\Q73/C%J=53
ME_ A,L1Z3$AU.0<&7)JGJ:I:8,N>GJG;Z)4X1%G>7:O-6,YQR'3*7_,=%;0P
MU46\K?@OBO:NHSJF6*+^N,4SR?GMZI$::OTW?RLU2K^*\N75\KC3%121<M-;
M!B5*3GP_Y)5@=X'X?]F-!.T"D$J)O\ 8F.H/D(0A<!3'SP7#$I[_Y.Z_<]R[
MV<=R9[6 =@%-.0),4N5IQN2(6(;J9J64>_JS6.>"U5:G\D]\$8G+8:+/[W'?
MTPQAZTT^?IJ:%;63 @N-$X?%N(][M&YMZP@+7WR>>>Y2WL>'RT&:-=-^H36"
M+B7UZV5!Y0[V_LRHBG!BAOLW]!S44_CK6192+>9+O2I=6DI5-*@L &M<^_A$
M1?Q"U.C<"451Q2<P0IBKQO&HE:Y'HF\^2U?!C"K_7-3->ECO*5'R83PF3\#E
M6G;YS)1M\ $VV[9Z?4IFQYOR\&^%@/TM"HJ-,=K*NI,:=@@**^AX]VHV([]6
MDF6DYG:0GML6.@PER+B ""#U 3@"2^=9-7B%^HY81?T)PB,E'NL?PLR4Z=2.
M=AU@BV^?Y]U<P#S#>2T]GQ-\/L<]W JWU]@-W7O2\F@/Z^N[Z&OQWY#Y<%"F
MWD;.X:H&UKNK;1"W@61/KY)V=IIYHX3\5C3*-\%D DKW=13>S32L*>Q)SS$(
M_&@3[I2Z8.T<V6T9JRY?Y:+0@TE9JH9=)[,0!SK 892KKA!.;53NTWLS)A53
MUXJ0[])^BX$B^4*6Q)XKKPWA%/^E&O+L3%<4#CQ@7V=&F"#X29>!9'NS=;G%
M[+55-7;IBW%M]^,&'.Q))11.>B/* W<^'KPV]:2$$D04@/,&K%*LAVYKAX+3
M&FU@Y=JUTIJ.L&B85LS2.JG"&Q6QS]#_G18?HXZPDEF]KQ:6I83Q20_9F4[#
M7,MN_$4OSJ[0X0[P[G)@!UP^ >8]PI+&;M;#*M%!]OJPN&/GFU/4VVN:C!1/
M1/8N)1K,JPON;G9AN:8JJ>+\?7E7?C"3D<1P[7A277K@4X1"(#-LW@#LB9AX
MI!@0/0^.Q+X#8&9C8BU#-,5LNU(SO2JP8D[@W',+F/QG4^\*A6_LT!+&:>1W
M^%&4LSV8RHL?Z)!3N*7W3]*OZ8[613S[_IK6H@$$?]=KJBE=)B6<A34B*5E=
M;,Y\J0K)3O@8P:$)R,H^-#/&RCC8-M5D-$5M6SG<T.6"V?SY_#]"0N^_=^$O
M;&F+QF/$8//$HR<$==%XR)= 69H1.<,"RW8BZK4J+N+"C6VH3\[6MQLGM9 %
ME^=.61A\_:O)A\/7DY#?]G88/?!*+<S;5L75JK(W&XQ,3TH]34,V5Z0]H="S
M!I[X159=1.G&<SN.=#A);PZXW'D(.KI;"/% 3_<*=N)X:^U"BU8:]<J\*+4_
M)=]MJ:F=ZVH=1!K(WD\4>628@LI$V1)FN?H"@J0C+GA9H'SEGCZD9/H/]N^[
MR EZ$AV,I<BC99I)% O_52JJ30,,B$%I'.#N61'R%/,2;QV"\ 6#LP'1/5,S
M^-$:R"G@75IN75I%;U!A"7VEYZ36HVOM1S<%O]S!V2YGM\I$U6.N$6G?YQ6'
M!F5N<@QQ$>MB1 <56C:_+P^^.?6BAW'Q2G;4?LZ]_P2^=U!3[)0Z.AKG-*,I
MN!4+.;]1TU!.=)'U^1V[V-AX^KFA+I]<#+F><&-5]_;JS??W\]>;JC/X8]L6
M@,!'BI:B)ARS9JY2+[&?5[CZHZ.#M/R;FC)%HL3DQ!*O6NH>$TL, +T<7]SK
MB0<4Q-=G_1*H:@A1:UARO!W9/2-#2*GN9]V133;#X/%:1'\P<0NXHD_C4K )
MOJ:%Y@WH^_4]HKHR?OW LMIOEM.IQM%K1X>] 2-<%Q0>TW"E0"/0@_Y2=#MF
MNMM!^+/=ZJ2QU+S,]0LAKG('-<S<C'TLOHC\0/N+](J0/>"CS1LZT,C0+LU2
M&_ D\H)NLU:+@$<[=QL^EAH!D5J!\_S[32+C)U)CIP8=HL,UK,W]:-^BY0,;
M=5O3425*Y&[<K!W'9/UW']01YER$P<^KXB1A].S6*U-/GU]47IZ]>,/71]_7
MY>.I'$]?&]W@@K_]&S:H8HP?L\9;KY$7)NU=W^%CO>W!'DV_(+&V=TOU&0W%
M[*X=J=H]ST:O,"!+^\+0"G)$#"Y:?6$$K$LS0F1D,GSH[/WPD\C>.=(]\'2&
M?73WR[HW1&,'F3CSSE;EUD1!BYB]MP4:CH>@)]P/KJMCQC"3[ 1()_MK5'7!
M&P8'PIBLFU)9O,PC,8BIV?7B>&/?7-CVG"\LIO0!WO$2'I8[: ]<K$HY^<S5
MQ"P(2T>E43X*$F;MV_G2B/,.>:Z[W'E2+<)%-)T2O]^TW=-7LEN4_US*CHHZ
M..BY6Y-T;P0C@@T1GY'=^<IQ_F5BP-'8\*2D*O'L9AC1D\8%IUP"=!?UYR%3
M=ATGGU:)U0PIG,M10F]^V#@>4S#Q&JY%,SX$A;YBIB#4F?V4N3,,H8#J+LY\
M/V,516L[2+[0Y&]PC.7B(^_2 E::[2"T=I.QX!=<9TS @)TI 1?K:K(I2:%A
M*)+&=@]99Y8,B=66Q \PTP!@2+OA5G (<G--<)GRG,ICHV0T>"^TIZUNU.#]
MNUQA!/V-[\S,?!O 4I^Z,?B;ZTCK#F>'$>)(W[,B/<8C68'(Z62IY]O)__QX
M_?R#[G3#(:BE9^T0M*Y+O;OR5_IZF("+H4 OS-G;TC/@M=%Y=9]Y>'QZ'M@M
MW4.%W+Z^%BU#O"CL%EMT,V70H "KM):S/I WCV$!(E[5.[.D/V&;+9'2RS4W
ML\AKYE6Q@Z9+U0U7N8Y??Q3UNU4G8-@:\"3)=./.T[0?"82'$N2,3"N5>QJT
ME^4<D]7D]?06^/E_PWY;XFB\J925<.-M77R1GLYZEO [=IK? S?W89TOOW=B
M%'F;:ZU@=*C::X0T$<UQM;9D06<@)<DT5?NC_50CMG%@2EJ&',\ SU&]4#\E
MOZ"!2VAF;)6I^%OU?^(+O9(ABO D^7>@. #4EX''1##WRI3'[W?+J:S2MZY_
M\]*X1?EX<FKI>,B1GI/-JPBG)(OTD,6F84] <O)1:RQ#[ &I&J.JG\+:.Y5?
M9[BUCBY[;ZH;; /PF<*3#T$UXS1>=DHYP(0*P#Q!\@T2C-"N'T:H$C,VE+J#
M;QFT!OZ.XI]5=>%7L#0ZGR-VA7]=YAT44(=2ZDX?HXD!/G87$QXBCT  7KB"
M>8R2K:4XJR',9(YM&;D4=J %),>U#7<.YAEWYUJD;EWP2S2&_QX8/Y#9/H'"
M$Z!3G5<52!&$R?O;)Y(!,13>'IF+_([C]$7%@JNW0EKEUPZ":_/VWC8K.!7-
M3-ML;F<G!ECI6?PRF&)[X)CD$&Z3M;!?:W#KW+2+_8SUOK JJ3JZ_ABK$6?&
M<,Q#,Q/%A?24(GA!PC03]3$YT F5OR2?9DP/1RH]19VA<9#&;XR5[4+/Y!?(
M=9>H]"UO>&G;L:1\><QQ;"W1K1H<W^%4[^_05&.5 ?=>"H"]42Y7_CZ?XO3<
MK$QLRL10>A#VLDETHT]F^\DTX]QE8#F,7DT))GT,!1!-U-R>11-7.!"9-*]&
M%RP(AY#<O!C<A$-0.3\[C88"V Y!HG^6_OB0+2%[=U#X*10MX:!#%_'W.-H(
MO99F2O5!7!QKE0C ?*$(G#F O84;Q4U#&P+-=.T"Q&>-ML\YB0J/_K$//LG+
MJ<\?$?O2A)Q22$NZWJLL+/A]S>D#L#V6NR&6[J(%]_796^:"A:':;J'<@_4I
M0@"O"SG"B'116"1EK=/O #XAKWK,O5@L/%!MZQ0M7I*OA^Q+;)4"D[Q0,=4#
MZR7YCW$TRT34MFK@Q.:EOJHI1@^'EN'X9 N=@W)?@: @[)5B47VQX'2QZ:(7
MKJ9 R&IU*#$X"%Q4 UN8H]UV*4,-YC#3(^'9'"W"88EY:_M_]257X5C)'D%<
M*!9^]#)IR!;P"S:GWH1<$*SJUO@4WS_A,=^-6%_2]E@9X']8GR'>-1XK8.DI
MI27>KS JU- 3DB7^F]_^?H]0R+T< PU#A['H*GL/@5A<HCM5+TH&#53/=P(V
M)$SG'&?>\-E5P+MCKS''YFUSM3KV]<+V'GYCIIJ_K=L[U.'W I]NGYWH]@&7
M--&M.U8UT" WU6\FD?HC)(K&1#B1L2KP Y4@#$UN_!#T;M4-!:CWM'_+G6'T
M"81<"^  VO@>DVNY=PY!:W!VW'XPTTW[#T$)$#ODT8":5%HTG''V\R&HGWVH
M6&9GGJ!/XQUHAW.U2@6X$6*QZP.%D[W$Z\@!H[@-&E0P4H#H$ZEA^DSMQ-Q'
M1V<AMS_"+=KGG%]_FY=Z6/ MY4!U/Q<!Y2)!N9Y;OO3Q+M7*D7Y;7W#%<$5+
M;=/0:IQ)9I!_%2?O,'->^>RU88;B) T,R!"H,^=0X7/G?V?<;ZEO/J'Z5C9/
M,5?0/.$8^FIC96_?GQZ-Q;1RWBL=5-N!X NKAZ"R'ZTG\+)[G1=G\"\F,+X:
MAL9Y?&7NL]C1*>GQ40K$O! 3AI \!+$<8WQMK/'J(>(B=+2')!YHMZ?P8*\6
M;>W(?6'B1 0L-P#.8--@3C.9+#%2#XQ[YQG.B(QJJR)P&6*RH637'RG!29:
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MB_\NYQJM: _GP:<1UTGE.?-HH8"X?OW!F@P-^=WKYJ8-U@]J7W-5]XI6'K$
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MQES J2-0F\<@H_F)<J:4&,Z_U\6^@*]^QBB5X:"5_V?UY7<D@FDE+K2'5#<
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MU5!.)2PN88YXD_O:P"ZD$HBO^^%:1_))2Y<;X\P+V!$H\F#:XY\\=<\=EK\
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M(O0YU%^F'!R36K& '&P]F*("[$-CF"X0>:S_+3S9KM]+68JD5J!Q_QU(4R7
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M,.&ZBC1U$\4(<7Z(,;^SA([K.[K'F]L*2K/!&<6ZTG^+N+^9@Z2(Y I5MX&
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ME,N4.M2-SL$:JN(_]ED].1Y_-&QBU58Y9F\6S%)!'>?M<88NS_B&8HBWQF_
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MF_0JVPGZ86WT@VFGG<[_D\M[LW9#:VVH1U/)/+0ZW4E\%OH@ ]3.NF"2,\0
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MU-4':R_>@.9LG^WULBV=]S__G'?OS]K!+:9' B.":,FZ6AY8X@"2>[S)C\@
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MY)V2W5>4</E!1Z:\9>M+B!6YC*!N)<:; ]''<VU&G2<"8PRR-J$R Y5&P?5
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M4C2!)!Y=.*8=G,Y\%!<+5[?2#L*K UQ&*V\[@>E.>?XV['D03[V6\6-TUK_
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M8+MG5_^@7>M0<&JX'O7JUSK(ROHYLC2>,.BW_+.,#0@]C(R8+F?U ?=O\B2
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M: >V)>\= _,#6&?%C2!-+)PIN2<_^+YF2K\ *;2%8^-?*/0"EN'I#&@B^Y'
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MW#GQ[,KZRZ-U]3TGLI_G^-M_0G6_."T#^6G^?PL>.%/NTPU(2/$,FV4 7-F
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M<Y0M+X?-??8N&+YZ:'(^,F==XO[49#7.O5<Q>E<MJG:]6=F!79>Q4E@ 'L&
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M\;C[CCQ9/1;+Q7$];F..N$?1G>WBD+>I#1WWL!ZPBD8@8G,U__GZ?\AC6OU
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M&'DA1"F+(!(Q@IA3 2/.213PV!>!UGV3%?61E>:7=U= =19G2U79V ^@EUV
M%9--XN::3=#SN6$8@#\5JZ#A53/ UVX6AI7LZ-@:^DRG@=6H980U/&<TEC"G
M.5G["6LX-IM4V ]BUR.,EV63KW#9%#,^G(6EMMV4B<2/Y($:I5D,4>()2%)!
M($D2BG# <1)HU78UI#NRLEJG'9YS/VP HX9A-PXX9MJFYZ%)/6BYV,O1!!_&
M!LNL3=<(H%F6*7,%GG'K+4,(3C7:TAUNTK9:AC+N-M$R?=WFK-Q\+GA^O:CJ
MO%[6TMB\G,]Y>?\B=?KUHDD *Y9*ERNB?<1:G%+J2PT+ TQ\53P[A1A%JI=0
M++D._#35ZZYES\+8I^GKR^NW)J=!*QAU3LYC@V-XE.[8 2M^U-FPXZ@Q[-8\
M@9XIFZ*0=H":G+?'!M9.'W_F3_*W35("!K282WZ+4FG2"GS+ZP?P[2&G#T#^
M7M45>,"JU0/ ]R5OKPQ*WO9EJ8NV:2*F==L,0HTI%<,#N"^Q&KODE.?/\LGF
MC/_UUR^_@GM5!F_1#(/O^8)*Q?*KJT/^.5@/G_JM1I[0#7".Y-M^@;-&,K_7
MN,4O?ZC"+:(H'[$4U/Q0JCG*>,I*$@?/%=@@/]X1TU!8*_^^SOB3.?H-A-WT
M^)N\9O'1<E[^7A;+ISM5@*V)GGDHYO+=S_7B\K'6O9$[,<S(MH>B#AKRH*$/
M-A@ GWF]+!>G C6,@=%8R>XP,5S%Y\-AMHKU!+5;P2?&GF[UZ@FYM7(U7SFS
M.,2[[_@Q7S2;W7JC$2%'(?<(Q'Z80123"&98=2P588HS*N(H\*PJ1!RB-O+R
MWJB3L$'=PI&L!]WPRG8.B-G:/@<+^[(10S*ZKAUQD-;K%) 8$OMH%8G!EUQU
MZ.L]QI^;4TD3+I)&PN<T#"&C*(2(<PYQEJ20!%X6)AFA4AWT7?KNC!;^2=I:
MG_MVN[X[B^";_M:C7!$^MSO? 1BU5[\;5%QVZ5L!]/DT0 XZ]1V7>+1N?0=(
MOG+'ON,@G.[:-_"NV]N>HJHV V6K+TOR=WGZO2O>?7_*R_8^JK$'O];Y//^7
MXN1F<;E8+/'\#:[R:H;]S"<1PY!AGT/D)2%, \&A%Z7$E].F8MQ=7 ^=R^@$
M$4/%^DY)E=*CF^Q> -QP!Y8K]D!S>ZL8!$1QZ.8JY>P)/>^B:LII<GNSI:;L
M:GO*.N;E40FLV>\#^\%: G C-6P[DV]^H)ET<XLVY8R.<^TVQ<PZN[%S!;?M
M%=_9]'^(.T%7*.I>(CJC9W<*>(?+A61#^0(;7\)M,<_IR[HN34@S[H=1" 65
MMC\B3=@9"6#J)W+')G&0!D:]/$_0FV"O;1:U)-\ZL,R,_5-HZ=GY#C$PV\AZ
MPFOQ+T!+'/S9_7>4XMB: CNR\$]1F]2XUQ1]UZ[7?<UNT=^4]W@A=8E2+E?%
MHI*#LSZ [+:]]VS^>2/>YPN\H'G;T;*M&+:^*MCHXIW%&<.<PL2+$H@XYC 3
M,8>,,>$GU,>,^29:PC6#8X>$;;#;W/-^PDV4=B%Z8T+*8*9IG$^1GFIZ3>#-
M=-DFIZHC^0:OS11L<JLF8L4O6#.\=0\YBN8;"T]'JM(Y>Y/JUK' W57&H]&Q
M==P^RX&+\F77^N L$UF8"AB&F0<1C0@D./ AB007B4=%D!CV73],:/2;F8ZL
MJ2/V""RZSM?SA35UN'84IS'"3@GHS+]ZA,S$/M5A8??]J">>MZJ7>&;N__$1
MQCXF%0OHK 3   [#*],=!&;K4D-ZI\4 3LMH6Z3QU4L"G!9MIWRCV\( _>K>
MRN2KY;*^>6I,\G??>4GSBK-91N-(/H+EB25.(?*R$.(T3&%,@X0'!"4L,"I:
M=I+BR"NX:6ZXG4'*.]+*&*X42Z!XLCB8G,92;[]UBI#9 K_=PJ4A#CKJ8$7>
MW<:K+:FC'?@TO4FW8FWQ=_=D_1<M+C;EX/)D7K_<RB^CEG:\:I/XI%3\NZK.
M'U4PP=>*B^7\0RYXVTALNV^>+W5"3%3[#2XRB'@4J,X;,60APH0$S(NY?OG7
M,YD969>LF  M%^!#_FR4OG4NUAKWBA,B:*QK&L9 PQF0K($5;^  LD*%8:GK
M(X-FA>X1-[C_FQ!YNSN^U0P\-3.@?$-\-0-\-0/+=@;FDDU7^1:.H!F\CSN7
MQG1W;H[0V+I7<S6F9;VIN\=[Y=[Y8)")<?"]\=1/6_/T+G]4U]E;A90^N$Z[
M&)3,OI#2WHC3UE Z)M!>^:2C#]ID@Q:+M_E\J7K^O5\N5,N6F9?ZF9]F/DR(
M"I8*$G4/ZQ$8IX&?!3[%<8#T4SWWQI_ H< ZBD"T)$VR$/?QT+ )SI/2W&?@
M5D"3',JS!+6L4&0BL&&:XE%QAG,0]U^;,,'P*,_;V8/''S/?@F[J!UZJ'*Z/
M'"NE;I!9=>#5L:](%<6M',".],EJMUIRG]YXSQ393!W82VNTY0[(9+7A'AIO
MLNUV0)C-S7;H,3OOX%7Q^%@L&@]#$VM1W2SKJL;=OIMD41(%,0R#R(/(YPE,
M0U6 *R0!"3W&:12:. :'B(WM$VQ(M[Z_"U UU$&Q)@]^SA?=CW\Q\PD.(JCG
M#G2%B]DZ[2#YTD+2$KX &Z3=>0%U!'3D !PD-:GO3T?H7;>?UCOFW7/?=F9.
MI7*JRB=5S8&S-R^?560FE\*LG1\>0U&:1"G$OL"JLY. 1%4H33/L9<P7,19"
MM[.N-M61U_Z*#[#)B&J8L6)%OQ6O/I3#:W\T@,R4@ 8VCJ.#K 2W:@"L3V6R
MYL#&@F\V#C9_V3)"<JO(TU51U3-&D9?&2%H"S16A+T_@&8EBR!CR!5>_)%H>
M_^,DQC;!=PK744G2,"AQ'Q6]W?T\60UM[^VJ:2HV<$!.\XB^HZ*XBLG;)S!M
M5-U1 ??BXHX_:>'T^DC_'UY5Q>)VCJM'_"8OYL5]3JO+!>M_\^6)J]BZ^N5*
MF@5O\ZHN<[)L4J(_7'65I\*$(R:R"*:>3R 2B8 9IQQ2WV=QDJ8L\?0KHKG@
M:.0UW3,"6A[!_XT?G_X;6+':W':LGEEQJW*:FB(\*WZ!9-C 7^5DKC1<>%//
M@)FF<0F^37$V)[-@X&><>C;L/).3+ DSCZ9+X 9]H$X(3><U=8G+EI_5Z< N
M+,B^3.C+)PG+LI2V:CVC I,P"2+H4R0-RB@((8XR55P'$1()#VE>Z6A3''DO
MVNLA? $6*K==@(X^D/:Z@O@<H_,0D#8VZ)GPG&F2KJA?@#7]L6S4 5%',5D/
MT7M%"W9 _&&#=NA%.YWP.\X7*OWT9B$USE-1Y6W62)L2/ O2A,4B(E#$3-JN
M/B:0A'X&TY1',6<DY32RJ+4S2%3KFS^[R,[/BH=?VMH6<F-E#1]XKE0#;M@P
MTPC#,.II@_-1L=($BBSX61'^12&Q05N!L1,LMHIFN0#OOM/YLG'2W^3SQH3Y
M'5?KY]4/[G*U:ZU^YDZ;:$'E2),,TYI4BVB)O:M!]%ZRTQZ?>*W"NN4$/^=,
M>;V^5IQ=+[J<,]7PH<Z?FXWWJEA(+;:4/UNGGUZ2JBE$/*,\9'XJ!!0$JRPQ
M$4&2( $#AG& HPA'OE97!K=LC7WWI>+AQ;SXU@5]BYX[@%?LF2DA1[.AIZVF
MQ]A,K:FZ"@W$/8?*>_ZS8A(HQ;_B$ZP9;7)V.U8WLJ3!GSVW#E/?W,+G2-4Y
M8FI2G>@6R%WEZ7ATVVB OMA[_LPW4K_4X5$9@D=^?2?_5BE=(CGYL(H']1'W
M1200]#U5,-5##&:Q'TM=&V0\2<-$GOS,H@?<,3=ZM,&*ERXCOPV*N>RKY&O&
MH(X_27HJ^+6@-U/$6UQN92ZJ&=C\=SL;]0->@.V7QJGZ.@9\SL(E'+(V<7B%
M>U#WPS%&H&&KFMM>&G_-ZX>K9547C[Q<'=*O.F<0P0&),)5&+4L01%&<PHR@
M"%(O%A[-1.Q[1M>T.D3'#M[HJ]25_)DOEOP"G/(8V<.GJPS=@F*JY%KJ;2N6
MGOZ65^W*M4O-1&)G>DF#Y,3Z1A^$?3UB\*Z=?ECW09S+DYX*NU5*ZC.O>/G,
MJSLYZ.5W57<V$0$)<0KE'](H2\($IH$\ +.$>1%&"*6(F&@(/;(CZX@3O3[7
MK#6&0,\<4-S)(Y?DS] "T\1:3YVX1]!,H8P(GK&B,</"D:K1)#JILC$#8E?=
M&+YM65="?D6?\"-_6SSB?#'C4J&0($IA&$J=@H),*A:/2OLC\RCU$DR3S.A"
M;WOXD16((@84-?!G2\]0(>Q@H;?P[24T6^ &PIF7=S@H@ZM:#MN#3UNXX:!@
M>U4:#C]EMZ#:-NM-[/=MF5/>E[^<<9$$0>IY$ FU9[-(+JT41]"+Y:+"6180
M9-1YYABAL7=I/&_JK]"-5(PF[8*I8U19@2=Y)F]2, PS,(X"I[<.7<!AN.5V
M2'2I%PU5C:J\QJOSE&2.UNE1,I.NV%/"[J[=D\];AKXHUU)[Y;41I8&I)TCF
M"Y@E/(!(GL,A]N5BEH?S#"4QYEX2&86['*(R\OIMG68+N73[D!:;^^O#^.BM
MU+.E-ENFG<^VJXP_2JS*D$"NXE,.TI@V)F5(S+TXE,&'S7.?WC5]:N_P]VNF
M6M:*G#:F\:=E$P$J,FFSIHA")O=1B%+5WLGW?;G+^CY'S L1USH/GZ0T\N)L
M:3>M'+:I@Y:\?H+3,%[#"]4I"F:+U1H H\0E+>&LDI6&1YXL04E+P,VD)+T7
M+%(BCOG>[WCY. MBDF1A$$,B(@21%W@P57>+GN=G-. H0%FBG>HP1&FZB\)G
M#O":]@60HST:Q,,/PC6\:IV"8.K-/G)E=P'N',IO$.?O"@>[^'U;/,Q"\G5D
M' RU'QQ@NA!Z'3FV0N.U7K"S^R^E\NMKPGSATFQI8C4VG$*"L<S/LA"B,.+R
M*)\RF&6)@")C D5A@D5JY'D_17!DS;5)'JSI7YSC1CN)H=XQP24R9NKL3%",
MSP^ZDCHZ2IPD-^FI0E?XW0.&]GL61LNEU"9,:93WG-\5JIJ#*M>*YUT#A5M<
MU@MUZJ"9SX3 ,, L@0B'F31D @)I%I,4QV&0)ES;?-&C.;HALT,6/+5TY7]?
MFI )@[U<$T4-J\8]-H8*H:</) .@+L ^3AT/[N$Q,'K<PV1G_CB R\P2,A-\
MT";2'&HZZ\A,MBT[R?#5\TYW32N9#SGEBXJO R0/M7'*8DZE:D0PIB*&*.5$
M1>^'T"/R/)CZ'DVQ?M-<&PY&5J*?VQ GNU.//HQFI\%1P+$^):J(A 4#'3^;
M ;6F[:P<@6EWM!P%5#N=>_? @?+<2-S8&D)1E(!NP:ZB/^8=['C%LJMRT>=@
MHWM4U1_X58ZPQG(?.]J:#V1WY-UK["K_<B7_G==;35U5W(D<^V&& QH'"4+0
M"U7R59C%,/-1!",O"4(JL@B'6DX[2_JC*^^63+-0F-3D\Z(MLTX;EII\<+/C
ML"F^>J?C$5$ST^H'^T^KO[?<[/:>[AER=WJV1,+18=J4^J1G:TMH=H_:ML/8
MZ:./Q8*_?,3E/WBM"@Q7?5FDU \$CCF,112IG$\&<4@#&*<D0(A&'HMB$[5S
MF,S(VJ4A"AX;JDW):<-K]R/8Z*F,\R4VTPRML"U!T% \72'(>/4/"^5HD1\A
M,NE:'A9T=\F>>-II]O:JY,0ZN7$69R3R8^9!GL0(HIB'D,24R77KT3! <9(%
MT:PN:CS76ZWZI(U6\(H![8]:I0E3E2:\;#.#0;$JC.(X#?L0K'H+?1RPS!;_
MB73J=3F9R].HN4J6'@!@W(3H0X1_A*3G 4 T$YN'1K#P)W6NDZ9?VM7'F_6Q
MI]5?W7:7Q,0+D:J+2/P0(L(22#QU A&(2,. 8!IIW<'IDYS&8W2,!P/GAQZ
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M8+^76*J'M^JOZ\Y135W:?RY5WD?KB6S1=)]M9P+R\$XX(KYF>]ZXT#I.I;-
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MD+)$A!2%PD_3;D[>+=@/.2,]7V[F@RL'_FO,A*:BGPI;P[U $KH #; ;]"[
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MMB3$ODA[51X./&(1T?:9/_/%DK=IR*LR[<_KXNQ]+$%($Y$E'H<^B^3NR82
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MKS<\\_2ID3_]6[#5[8^R7:0XB_PL2%'B)QSA@D4H4Q=[G+&<!H+@/ -UP'2
MHV/M-4#R?E>P@*%6%SNB:;P\+Y]AVDZ3Q7#[QAT3;%E%#C"<UY9RQ^(C"\PA
M*#.%^V[=5.5JW:A<L7?E#_739N1=$84)R81 4>Y3A''*559$AO*<DT!JS2(*
M0(T6SH-RK/ZV@(&SQ,^S1D^!V2$8IH>V,+O[H U4B^%<?>)L#=\^#VC>(=H7
M"3X:AGWY#<,LS&I5\G+930?=I5N-%8>Z<5_W<;9/Q5O2J QFU3VIOW!_.KU
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M1"$B49&C. ]$&I"BX!A4;S\-SK$@O:_D2Z+M>T?6W85W:7J#?YYE>@>:/4;
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M$TL0#WP:AA%-BT*K&<7IY1VK'P5O,P,'X.D?<T$C&'(5;3"-,";+)+GJF#Y
MJ.(J.LUB$9_%8]ULVE/>]S;OG]]*]LTK6X^K3@W?12.MW1N/B^]B63]V/S^0
M:EU(T5BK/W7W_=+U>5!SHU6H4OVNK*KZNT3ENY!_7I6TYD^(=F:VL@W(HUBO
M2M9Z1=UTXWM7TG->;=)JF/*N&TO!CK,\G8QF'+\U7[CB+,9[\8CS3QD4:W96
MV^MEW8JO]2_58ZGJ+@X&&4,FL$\OY5@Q]1AX'0JJ*?O7\J$;Q/'+Q[OWH_*>
M]L;KT +.;;_ I6EEYH!!,.VFRQLG5@Z0>O/I\!?6GW=DO!ZQ1W/D-5^[LDQO
MOX!<NGZ\O_^0L(9D],Z56S#&HBCU&8I\YDM+)<@144GD) V9'Z8T)CB M5^&
M(> ZFZ4H!.O.JE$EH&I/Y.WCUX6#=AAN!G3=]&,A8/<>QGNAYV:YY#!,Y\S$
M7/-23""';-=GZH)_GJ)-('/.5G)"US%PL+H%[IKZOB$/FTX,44S\A!7RE(C"
M#.&01B@/4H[RA/,X)Z' @5:ZSSD CA537\3U.( $N"&G>*'A:%U)(4PQ[!-G
MXFR=HA+@;EU)K9G#I;FE,"=G@I))-^?4>_,Y.A-8[[DZ4\\9YA*J^]IV.T;F
M1+>"+$N+.$T35&1!@K!(<D1IFJ.4^E$1^XG/85GZ%R&Z]HHZ^#K%*88,TS-+
MK+(!Z/MTH&]& [A<-WO0)M96HMU%>/,FT>F2?Y0@I_TB/-3Q3JUYVWXJ[IKF
M7\W;BG\JWO[WZNGV3^ER_=Q4*_Z^ZO[2OEORW]I5=?]:FBKMFT;^\+WA_VI@
M/7KL0'.L&NZ:LFZ\?PG2>!+#L7S4Q::H;0@<;&8FEI5W6SUYHS=7W\A*O;KL
MP@E"K+S;Q\=ER;HPPF]J-E!UKVY8>-G="'IO^M#A:Q5>E NJ-?0C,98V\7*P
M9O[]@^FTE[)UEILLV66[42#)$@JSQ9KLLFP<CK*\LIG!]IJTWVXKKOY'?=;?
MR5)UXC]Q1"SBB)$BB06*?1P@G.($Y9SXJ/#C /M^'.4A*%2E#=FQEE8(]#<M
MZ@>Q0P5FR.DS4L^@<\(>F!+<<J;[883%&5O/GH$')MZ2H:</=U:##\R.0\,/
MOH!!F$B*7=VHC7VZ5;JL*)G85GIN+N9]&@@<811G7"#LAYFJS(P0*^(BS;)"
M$*ZE0S3A.=8<.P3Z?D@="IT&>01>WFNP3B/(9)<A,%UQP(L>^JY8W20(I<$4
M0$S*+G/,0E2W7D%4J%8:CYUM^-C4WTLN6D_J@95<=]FE.F_M06E1]AD#+2LE
MK%+B[*EK?<&^5?6ROI>6Y-*3X*2=R+[=>.+'HVC*AUY!JTUX$$3)=,?_!_+D
M4:'FL!=U\R#XW[LG5INR>?G[MJ[D<H]#K;:W;GN;EE2;#UOZCLIB_;NG6AL_
MJMRNLE(IN^+&H^N51Z2S7]4K;UD^E,H>7M4W7=[V>M6-G6/U8RE_Z, 6Y(=$
MB'TK*_%W2X$Z_>V=C-MI+#-?&$^?IKVH'N U@XR&^_O5VZ91B:NW#ROMY(6]
MMUQ'Y.[OFZY.S9,@ZTK4Z_9@4#W@-O$$S9>]6W-R@9&W*RF%91B<),HLF6!_
MJ?GR!DZ2L)<B</H)>%>*#Y*7R[MO<E,^KKNC*DXRPB(6H RKT7-ID2/"LE":
M/O+'S(](0+1ZIYY:W+6=H\!Y'3RO!ZC?DN*(#]/2<RUU0*-%GS!0/XIS%!BU
MHSA:;+9N%.?(&#>C./N,63CBL/2O/:X.7&0X\UDF&.(TX AG18!R&B8H2<,"
MQVE*DSC=%$WKA2(TH&I]A/M5TC AV]6ND@U,6 !"AW6<^GD62%X1+B3K@I3*
MGPA!.&8Y%93[><H7RHJL^9<5:5;SLF^0X4/XVBQ\198*EB<MZU?BOJS4( X5
MK]6/@4-XF>34)X1)#A:Q]&53*GW9/" H+ 3.$I%SR="!EV^KF3_$/4YNH)OP
M\6WGUSKBH%X@S#)/8"?$<?&X=&5.E)G;"WT!R+44]-*!.&NX"\""PT 7Y-6K
MG)^^4N^-D.94/^8'G,^ML=9S.TJJ]E9BYNU0,W*:SO,*Y$I989-E!^N80PZF
M*T)X<*T_=A[ <WAI%\D]X[M=?L_,/-WO&?2A;MM/U?NNK+<+NRT"0I*,!0G*
M"%>%9ZK% ^$%$E&41GDF@D 0R!W9!7B.]<-!8RWO)X7 WSSYV8]P@)D%EQBH
M9Q)89 M,'US'$; MH$FG)3O@$K19;0!-T@_/?]W7#.OE3Q;VC]I:O'K:/3)T
MO>BR1+8W;=(H63_TM?LJ.YM)-_&W>BF749<"W71P'!=QP5F&TCB1*B3)!,HH
M+E H@HS$410G">B:?0:<':NA#5#O^Q8JL.9^AFW34UPO;#-@RF_<TF4_RCR:
M+4V?O).M7_H>+Z.T@1$A-]YVBW>T6!XR/R/G;74,F 'C>3L,S+<%1QT)9@0]
M\]$R=(*YY?VM,5F.JDVW.>2D*!B.!$9!P'/5$3M'>1()Q(.$AE& &65:$VIF
MP=;Q<=*K)ZJIQN@I-?9IH[=V=.P7^1H6 [C]"!P?4;:W=O;#R<*NSG<L0;C]
MW >2%JY_C:,(PG9KAQ (J''A>M=B<]-J\WW5U89]VLQ1ZX.I"Y&H9I4B1&G
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M^3I?Y'G2.86J^4CG)_XHVT66"YHQ)E!"U5V_B#G*&$VE8Q;%+!8B#S!(-4S
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MAY,;^X[A*]1C#6E^9@J^AC[;Q"&8HX]A'XA=]AWFBZ0,%/76\=00BW^-J,I
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M*28L)3A-0P_+W),B\V@:4]@<CF%Z4P<ZAX'\%6H80)N_T)S JF5,%6EWMKE
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MF0M, AK@+,E3]9\B]&(>97GH0_S(22H3NXTNJ[0E:HGE>UI!9@[@8K&M\F@
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MLDS%U$S%U!D)<)9G 14RB&F>P3 ^A@E.7J_2(X\T?;0E;S5?8U2!9D&"2[4
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M(/X#5/W6\/TFK/XUL/@!2G<&K ^A:9O-4O&0.FNU('A-6\2"TU!2GX4XC/T
M$U\2G/$DP+Y,XS!)@L3/0+.#3]"8.&#;4$0MR:NV2PB:1#K6C&G^YR)YH:D;
MD*@6>9:SPCA+D1Q3F#F[<5;$X\3$^4?A,,W7RI2Y-N</2_JPR"2-(C^.,*4\
MPR3.$YQ&D8>IGP@O347&B!$HY-'*$QO;EA;2Q,PQE_>E'S:MBV0"WM*8B0,"
M4#[)NA5@\OY*LP$DGQ2@#XA\^@&+-%L[E/E6WE4K_LS6-[3DNE98U-=/NGQ
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M9JDZ"D5AYF&2>C[.@S#%<>;S,(O3B,#P:=RP-;$9[ZK!'1?(0K5OEO287Z?
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MEB>8N-O/&XS>FW2CP_DF;Q>B5/(D!I#89XQC(D(?LU32>F._RB48!%)?,&3
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M4=G7YXC:"XH,OECK%A&0IZR$M<GO!GU:X!(ZZ&\7R+AK[4[,[3WDN&C(U#Y
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MB!!R'>0B5&WM*CAX%9+,41CDNXW-V66U+B-)3P:ZYO+HX [?G:<39A3I[Q@
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M=\)Y[YSTH7UMQ9WDC-N*=*@[LA'[.T#2>9GI]1O>\NQ+UA9LM+:^?M,^C&'
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M?PB>'57/96*B"QZ]@TW?*V44@^@,AV2UH?^Y(F/K 91-".]19P^-N;; WP,
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M-=(]Y45KDW(?.L>-,'4$UH%%W &,S[JQX:V;4:Q6NBLRT76L^=O6@-<60::
MVB6KBVX_,^,>@L9-?.X&F.V$U@$"+P64[YQ?>!$VXR8Z.D0*I$MD)W$Z:%%;
M!<0O%$$G877KJ.6C".PE./]4#M)PTNL FM>W=/6X/3M:+-?3_\9<*UXV\_ F
M*JD84ZJOO I!2<X@>A^ :1:29;GHW/Q5Z9$T]N+!-X?+ \-0F\JN@SF6#^PO
MI>.CFI&)^2_+Q6KU^YS,[EG=\%_H\GF.I8ZV"S\F@7F96 J0?5"T:=IY",5
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MZ9XXK[R+:*5@OG6VZ-T=M!NVM:;C#]]>7X3E<C-L.WI1/1#@LDZ*<HG1N5R
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M",+XS6AI=!&TYMPZS#'PUAEF=S8P+DH.:1OM3N>>0+*1&HLJ<E-+7AA6C/,
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M@TJN]3O%G0V,K,K:,?8^9':F\MA.ZZ^TX<WN?\4O$1>3F)R(1B20F1>H[83
M:41ROI&'J%W08E@X[\%'=W&1[<*C>3."=: 17H>OTU6XJ*DBM6AU65-9OB[F
M?Y"GNYB3IJW3 ZZR6#!7-4M^ _WLWVL^_?!M\S??WB[HN__&M%K+#H;$@Q(9
MBM!D"Q0C(5CW?]J[MN:V=1S\OO]%NY*LB_6R,VYNV]TV]B0^F>E3AB(I1WMD
M*4>2T^3\^B4=V_%%%TJ""Y[9O'0Z30H"WP>") B!Q' M:VR.&'6LXY[%PY/A
M\&;H50/ZBU<];+?08&9L5-],:S.B?,P8-SBQS/5WAT88BC!A4^Z'XXB/B0/M
MTP<*(-]O8+M#!L4-]@K[D(4Y60HPTR4)+U?BE_,E^5/L/S:V.+;I1/+#1TID
MQ][ ]XR0>,0(/6)[44#XZ+C LJXM=_- N/XT@+_L3&!B.\:W+(\7/$]B8<I&
M?<\RQZ.0F,98EL>+&1*( $X=@U,WBGQNA:ZO]A;AJ6S<Q0V(_H&083/^_>;"
MM,>[;6,DE WD.NW*EY_"R A]XLD/ED,1"YV 1&KS?E\J[@T.$,N]8<+F=W)Y
ML=&:V&/AER8W;#:66?8Q%WLRH;7M4L_GODW&Q^^[UY"[$XE[N0'$;#^ L&E=
M^Z.W43P0&^J1&3+#<FQQVC,Y-4+3-PV7\;%% Q&,6(=IZW4@]VQ-$"&G;1^8
MT/DE^8*7J]>]586(HQ*WJ(@Z)F'R3!^*@,,=L5]U(]^CEFE;(S663V3CMA^$
MXGH89.B,WUP*IC:*4XLYCCOR#!%XA*L2/S0(-3TCL$/N!K[I6+YBPFM/*FY;
M/[ 9W1,F;'YO^6MYP]-U B5+YQ<\2:[2!1%;QV)C310Z#K5<6<4A>PXR,C;&
MLE_;>!P%'AV%WIBH3?#6H7 ;Y@%Y BR@V.XA:S,BDNX?(XA'74^^^SQR7+$?
M\6S?$)M.R^".&[EL'(0C3I7\X50V;KLY( <8"!DVXU=I%B9QN?IS]:$_=VS/
M&?' <-U0Z._(IY*X([ (3)>((Z4?V&J45PA';N,&1/I0U+!97[>2$U@L<K+<
MQBE?1"8:4>&UMCA].+Y%C+%';8.;IN5X+B-6I!;X*X0C]U@#8GTH:AID\H^+
M5HY:#E]G>?/MRN'ERK<XY>^=BEGH"R\79YDHY*'A<'&@(1$UC8A:U+*L0. P
M/G0>\&HJ(%/TZ@#QJRL\-' /#6;)[4K.[>GF23F)ZA;P1TXC=Q0&@>$[KFTX
M5%;@<^(9O@@I8J%W[>AX;1SLZ/7::%$W@.LLV5F8T\ '[_@+3U>\>+38R'7X
M6&P?/=<2R]78-$+J.@;C8],?\R@,.'2;_NW8N%<C.OI7+U8T\"9Y53V-;K*,
M%9.4W?/\)::\N,\2]N@'U+:(SXVQ*]L66EYH$,8BPPL],W0#<4QUH)?N>FUP
M5U\=/0Z(.>P3Q[L9WTFZB@@M5[F <&O+(_<<3B(!C^W+AZ!E5RAB._)E-(N.
M35?\V%+[Q*MA$-Q;(IT<"Y0.#4+;]L$H,3LN171.LF>)V*8_@3B5,^I:(U,^
MG$(-AP6>$1#J&:-(S)[ =&S?A/^PH4$AW LMG?P0GC\-G/$]%9P(6R9L&:>Q
M_"1$/C^U-8=Y\N4>,:-L?R3F%K6$.5'@&E[ ;,Z#R/+!FR.TJ(1[ZZ:C0T)R
MJ(%+'D.\SF))E#;?/5IB4G$_] W7C$8BW)N6$?BV:T1N:)J^Z[ON"/P3FV:5
M<*\(=71)2 XU<,E;OFDD)*%[M&E@.22TC!&7O8.\D66,/4><TZ/('@74).)T
M#IU2V5< ]QY21W?KSX\&SC4HA;K[B',TBMR \$B^M><93L!$D/<LWPA=[@21
M;8TMQL'WC0"*X]ZIZNC,O]X?\+L#K&47G/Y]D;W\@U/V+GXBV^G.XZ7\Y'[7
M>N%0Z:KF  >.O2_TW:<I^W#EZA$Z]@SHK?S E@%BJ,?W49;K(3ZNA/K"42^Q
M9XS;%_@]?8ZET+DP^XOXX>\@:IY*1;EC:.5B.\N5$$%<E0[TX^53QH#Y.I*)
MDK'OQU8U&IIP-1/#EODR9=<)68 P=2@1)<_=BZ=*)#1A2<[XB[1@.1Q-1R)1
MTL:]H]\I%IH0]:_LYX=^L!&P1C1*GK47<<W8(!.X6U/C)6=B_RZ;>3V09/!T
M:Y*+DI'L1)T"*CI,O.)";)/Y/-NI*PLB &=?BWR4-%[W*:B&DK9\GHE&G*P8
M$'N:D/8U9?%+S%8D67?1&$+4D2C<0UDSYED; -A3*4D^]-H6* ^:1%4"T1BJ
MP3Q3 T"#!.[[_!>_W#)I^N18#V7C'I:59E$C*!J0=?\DC/U""MD-9:_-:YZ3
M=+%N*59\>?OXG1EYD_^V-N;#HI3)/JVW9,DWS=" ;QO/H2)JY6VU,QS?&9Z1
M&0T<;]N8^KX4F[3IL[2M-93W\9[Z<7"+K\_);M81:@W<8:W;Y%D,3]\O>N[B
MQ5-9W$_N[L_B%NWCX=9._T+W4(8>>]]7M>B*C9"T$/X0M16,<A\[_!AUA(L.
MU/V6LCQY6]QSNLICV69MLBR'\U8I%><CU>ZL-4&B V57KSF=Y3$%F%\?HG"^
M)>U.SHGQ.C!R(U: \I*4_)K$^0-)5@#45,A4XDB#>\AZ.)#).IS9;]]_+]>N
M=/&4+F9T6-AK$:U$'>[5I!HXNI;A7.7K^X(SE>"<2@<IOVE1&J#T1M9IO?#\
M;1J=C'7B#+W\7FF  5-V(W4[S/#D?*5 M+QB%W[V)VL3+,A!]HX7V\[W<@T8
MG*2ODH?&5R/NF1((_]?7)V?9G:B2\GEQ\GEQTHF;VRR]Y1D$*8>2\"X:F[#.
M6@S7:%WA0N0R3M>8R?@*ML"<"$8+:GUW!BHP88>\Q:+<&#4XVW0H"JT M"];
MU5 @\[-5*"7)6Q$7,+5-M4+1BD$'[KUKX4%F[[[\?9;3:3XO\JNBC)?D_6H)
MKDI>:0"T2M&^K':!#9GAZ:H4,5ZLX^D",)362T4K'>W+92M ^BR MUGY@^]6
M:@Y5QJTR %HE*<!BV0H;,L/70FB6\JVE$!>B-2+1*DK[LM@,C5Z\7:[X/-NT
MJ!!VIE&6T_76>FBP[3(.VF4W$,,J(&I(^T.<)9NOF_^5+?F%[ F1OWTC/\_!
M?>-@>!?GD!Z@@J>&;B L_F-%DCB*Z4;[.7G]PE,>Q>7@8HE> ^)=U4.Z@RJN
M>KF$"&,)23<*?UT^RS8&PH P3N+R#6;OUF]$O-H (*?HAJP^)S#(+5Z#6+P"
M H!#F)Y[O0H%@<_1QV*52-0JU]6.D4:W ADOQ+GPCO^QBO-=7($)RAV&42)9
MJ]17=PQUK0*:O9RK NA0,DCU3X.R )4_,_+V4,QX+DY;2Y)2#EWXHR)_P+P6
MX RO]=D)0;MP[<#"_HP\MA[[0NB5TY7LUGDAPL0BR]\&EXY42\2CZ1CO3-%X
M[$1RDARK%W.@(I)ZP7C55XU49-UP0:9NQC, GCZD8-:4M&.=-1B.7^0C5+H%
MH>-8%MZWT!U)J0'ALU;Q5ZXTG_6)G_6)W;AA_Y6=5<5Y?.CT.)2$5D;5-#LJ
MC<4F($EV:L%,C6-Q>,MZ)=R9BNW8I"P6Y?JKI;1('XB8O/>KY?(];U64Z3Q,
MKK-\\IR$R8\<@K/.HV'NU.H8RP#@TX!VJ;,PL;A_H1=%"<1NI5#,G9TBB4U@
M8!]^H'GJS=%Y)EH;^ID:%)JP-,MS<**.9>+-IQY<U0""G:7[HWR;_,Q9(54$
MH*I*'EZ'9:6PUP"!+N2<>3O291R\/%X#355L_F7V( >&7;W29"%V4'?/><E.
M38">H6K#X7VDV9'SS@@B4_\COTK9M6QW,8UV1MSDJ53\XB5G/W)YE\[2Q21E
MOZ4O1<D '*#WH'I,_6[\9G!@(_N*/%Y]33?Z'VMZ;(_8;/S((=;S_J/J$31Z
M>\M@N)'=Y4$8N+@L*_U=V"%^O'-[ #?I/AK:IA#&/7K#JT\4F133:&/&-%I[
M\,X,8._H/2C:9Y[@,:07V-AES%O%W_5-V>FZ^1[XKA.VMNTB2UEQF8N_0'D.
MD IH'Y;"^!$L$<A>=?G"6#'-I^53?B4T+&9LFNZLN2WEO_\L[J*$2K/F92(!
MD@][0+D4Q/AH'[?"^!,@!=B/XG BZ^(&7V7NRT%;=)HN,BL,Q4[T;K2%J94^
ME897;3&L_%*WSTXNLGN><%IRMO&AP5^<5$O$N__OQU<C+MCE94(5MJO%FD91
M3(7<ZQ1FKK5+QPN!_;A4Q@L[9G*>W^39ZOEK4:P &6V2B[;W[1M'VS'"CJA/
MLG<_VRD*Q6*37+0=9]_HVHX1^ES,YEE)$HC/]XYEH75)Z3WG*K' 9VA"RQ5)
MDK<9B1D0454BT?JA].>K 1GLFBIYY2XT7)\:@4)CG4RT-B<]B6O!!GO;N2WH
MG[PLP&)CK5"\#B5]=YDM\&C$WEJSO0@!26*5;+SV(@!<-H"E0RC=J0H>4&LE
MXS4&&1)7VX!"K_-9Q>6;?-KD'4IQO%FNGW"[C".A#!?60K';<2B\/B$]Z>X'
M)?:Q\2C,/!3K163]^-M3E@B4[TJHDV2WH?!:C/3.W?6!4CO^;WGY-:79$BB'
MKC0 7J<1,*[K8=..X9,D\[F8;AA(B7&M<D<]8$1FOB+\2,LWR2\8TE7'4.);
MI^Q31_"TF^33\HGG9Y[?U6,H4:U3XJHC>-BSFH2KA.3?XJ($O.JNEZI$IT[I
MK%: L D\C2Q#,R$U(I6J%71*9C5#@Y[YWP9_> +;9"LQJ5,J2Q$L1$JW[Y/O
M-N[?LJ*I7JO/,_"'LI5(U"6!U0@/^F[G:.<]=/I5"E2B2Z<$5!,LV!UJY89*
M6@1$6)4\);YT2A@U@*)#BA_D5;-]04H$Z93EJ8(!?1.2#2Z5W,I0XD.G',R1
M\7J4>0^FHVN]JJU3FD3#,M4LO1$;EXUBE[R@>;R^A@&J4VT7KT2B3@D0=<C0
MUR462[U(XICVRX=U4-?/;=*5F-4I%Z(,&/:REA;IES0JY2=$8/7'-3*5O@G0
M*2O2 @YZ!<''UU]PI0+5,I6HTRD-T@*.KJ\/?$V+6( YS\GZY<D\EW73\E6%
MHPS P*<(&H8!>9= U0R 1PI.ACIQBY[-?FO%#LE [\1]D2_9#'^>H%(@8B?<
M-BX.<LX-8&#?%.Q4&_PMZ9$H-&X:T:YD1:.O2R=)4A%+8-KEU@O6@*N&SKFM
M@'QV7L>:0Y]=V#^[L"MSLURDKX__)DM>_(>(8:NID;^T1M^R1]::@;K_AMD:
MNA[>3,G6WBPDPPG@493SMYE\#KP3 Q7_#[.QLR(%]=;B<+#.:)9Y,N?YLIA&
M\YR)( MSI&T0BT94MXUR.S#HVV6I%<3SI8>2T)I(=#W(5)BO"R7SN!Q\QCP0
MA=8-HB<I!P @LW*W2KAEAJXEM_8L>RXYNT[(8A ]=3+1.CUTXZD%$OP[K7-P
MUB 6K;5#-]K:@=$B *[UDE^"D1(B"!Z(0VOKT"<05@&A43"<Y\NTA(V%>R+1
M&CKT#X6G@.@5"8$(JY>*ULMA4!S4CK;M@2%?QBD!C(3'$O':-_2)AC5X:,'5
MU>MSG$-2=200KSE#'Z:JT=""J,O5NV( %.U$X;5:Z$/.,0):T'+/Z2J/RY@7
MD\5B\D+B9/!'/@UR\9HE]"&L$9N_1DW$+$MB*@R8Y1D]8TW$P3!GJ(FH-P.\
M)F)_J!,? 2B.J)8_Z.9P(Y[MBX8Z>[=+UZ1^HI&WP^M&1;S0;X2K]+S-RHVJ
M,/E^]5$T2?\/Y+D!O_-'],T/Y!\A*?@___8_4$L#!!0    ( )V =%J:*+-;
MQBP  &_V   >    ;6=N>&5X,3 S,W-E<&%R871I;VYA;F1C;VXN:'1M[7U9
M<]O&FO;]]ROPY<R<D:H@'2W>G4D5(\N)ZMB22Y)/)E=33:!)=@P"#!J0POGU
M\VZ]  1EQ4E,>N1<Q))(-'I]U^=]^MM9,R^^^W:F5?[=__OV_^_M):^JK)WK
MLDFR6JM&YTEK33E-?LJU_9#L[<FW3JK%LC;369,<'1P]3GZJZ@_F1O'GC6D*
M_9UKY]M_\._?_H->\NVXRI???9N;F\3D__F-.3A\?#S6F3I\,AX_4L\/GC_/
MGST[?/XL>W)P]$Q/#O[[^,DW\"Q\GQ^RS;+0__G-W)1[,XT=>/'T:-&\O#5Y
M,WMQ>'#P[]]TOM?HWYH]59AI^8*Z"Y].*AB<?)Q5156_^-L!_?<2/]F;J+DI
MEB_^X]K,M4W.]6UR6<U5^1^I5:7=L[HV$_ZB-?^CX8WP<OKUEGOS"-HI3*E=
M[PZ/L$M)<OK;S(Q-LW]XL']\_.T_\!$W+#^X/[MO1Q_IV_'A,?3M(FNJL:Z3
MH\<I+N:CY"JKFB;Y9Z5+,^WV= -]/#P\@CX^/3QXGKR%=1RWL/5N].:[]>P)
M=&O4VL:4:7+]7\G39T^/#Y)76M4\?W__V^-G+S??39J]ZYFQ2:&;!E;9ZL8F
MDZIN9DDSTXEMQ[919::3:L)_T M5J\949:*FM=8D"G;PD[__[=G1T8$?TU\[
MD*># QFY'GV>3@S/)LW#X<M=F"[5P*;,ZNH'."J939.S,MO?FLDZJ>8+52ZW
M8JI@_U63"30"FJ2IDF75XC_*Y(DI\;<ZT?-%42UIMS4UO-+@%MQ?.4 =N6[*
M'+[_XOG"B770+O5W=S_#NN 7/+B3Y<NXF<-GBS]?/1S>:YX.]S>W45XN5)[#
MNNP5>@)SN?_T,4[#U5_2H>?[C^^U=4_?C2Y'UV<7YYO<O/O)S[@Q"V6;)%=+
M%)"W8.8DMT9DIQRP1)7YZA[6-9@H+$=S,*/@J:)(QCIYK<=UJ^IE<O0L9=MI
M6^3%59#\KZ#'VR W]I-3F&S06B@PJKHSZW-8$EWHK$F3=@%]MOI&E\G.TUU<
M+(LM'#Y]F9158T"Y@;#!9RMJ#(;9+%/\6S93Y5331[W1DWCBE2,Q#P(,5'MA
M-'9"E:O+N _"/\&3A$VD@TUBCV$'@,C1('%RZ ?LK-7]X/?7O&U:521955K<
M4K#_QC  F@O<<M%DR&AM\GVEZAR_^<K4,#55;6D7\^ZK]5R!N-4@ <VXT&@%
M\+Z=M/!I6=5S>!M9@*HL\<WCJFPM/#:%1@MM+1V!F78K4J^,L,JRMK8P2&A:
MXX*I"=H<*V-,:0"?W#".G)8&/KZ=F8RG:[7GL&@+T#&PBT#W9(VYT8FRSM#I
MO2*E>84.Z/$RN:F*MFQ4#3L;>FE!8W"W%A7K)7SQ_:;?C93:F-35/'$20\&<
M\WX$S0A[M,;YD@TJK['4)]PVLZK(5P1/FIAF_3OI/=!R8<B+@\9K7="/&3UN
M-!R2Q\]?)HNZNC&X'W&CRV'"M]S6!BS&$A[[M=6V<?-F2G@>]?C)S.@)^#4Z
M:VEJ+]PP)MU.\@JY5NQ,L2"<JUS#NPT>ZVK]BN#H:WU3?="\!#R5_"V:3WQR
M:-OOO!:!H6XJDSL3-Z_:,0S2MM0EWY1-%.PK[;<)30++=!X?KCF."[:4-T+O
MVL7P;A ]- +I??=9W(A@BHLE/M9%=;N_2T>U!=E0HTV>\S+B$RR#Z.!#-[%A
MU3:SJ@:1FN/LT?; [EI=3)*JI>;'&E>)=1)O@&@[K"@Q$ SXSRU,]Z0JH#MD
MJ@VM"FR HD6+ 5^BDKF>C\.J#ZS$I]ICQT^^>+ON:.OLNM<;M>O.SD=ODDW:
M..\V.OS1SYNU9R]8L)=P.%!LM058-,O$9C.=MP49)$O6JQ^1 +'<(,L"'R3I
M!#^K+*M;:,RJ E6^4W7NS_A["\H9?KQ1&;?:P##1O"I)"=55.YT-O]BVXU]
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MYJM=3B!NF_8U.]K4*W',I#8#VM6PUCO/#YACB94B:KB=8P<VHZT9#LG]QDA
MC>96%[#C=PZ//'#M7L^:X3_#$ZC6M#<:N9037O0*QPFJMUGN4L#*EYJ #C:U
MQ_ET-B N)NTB5%IK)E0L@JQKE4;\+8S9B@[L:C!XX64#X;!0.QOB8H7V04;4
M'SGH#UL-YMND!@^.<"+.2H^( E%1-K5"<S*Y:E33VBV(,M=1#F=5J-TA*UWH
MA#8V8=X2$XTU\V--'8!@Y@5[)X!HT+B50$Y3T8&T,P)VL>RU#=&&X$=,2(R0
M5U4WI:ZQT]#\%%P^D/F_5-!.@M7;+7./1>*Z,\P@55:BYWU#.J8+P0D1L1"J
MOCU0(4;5D6/4\8?PN[[J*LX6HVF [RK,W#0RS&E=@7<TTZI@>568"4(\;4OI
M*;(7X.5[B)W )LA!;L#<ET)M[IK7@7<)I.4?WP(R49%Y@U]]K<!3>J/&O-6I
M2@[6/&L"Q5FA;@4/@74JK)"F:!"4@;1J9>D&Y-L7+K+T-HDLLMS?X$Z4!8%S
M,6*>L6:Y<6'%^XVLXK(BM!#J1%+DZ ^BQ>WZVDO)]N)-O &I4(O HF)]4WE!
M) +<FT*K: ^:+H6 $PQ.WB'W8$3AD7H^."'30_F&7ZD1,@RV57"O^R?/>[Q@
ME=28WW!T?([YC=X01R$HX4<./WQ?O!8R2>O>WP>";[! )?82I(*M--GE/#"0
MUE3A6L/X)=$24<]UG?0T"KVG/MO^L&V2R?8<\$?[!\<X$>_J:E$;W6 6[:S$
MF)+RH,&S$A4H6[.;/N]!4:5WJ2$A]0#; /5Z%.S#\]!R!!F+.(J*@FMT5B<&
M-X;AD[B(YL-$\P$?P4_P$E787M5(AP3Q=S3I*Y^DG.9KSO)+S5GBI@(Y650+
M%ZS(*!).P=Y.I'; 2UN)15&%<06V4$6B,\Y^'CY+WN]?[9_L^X#5X;-CK%-)
M>_$BL,)FNL#8L<$L*H9HH9.9N3'X8V'$MZ=B%-BRKS6ZD[1;T1O1R+J.)1 :
MK.P&S;-0)LR'AZSJ"3(/Q5_$'4WL+N"X$\T[E4[#E+@CD0F5LKPOY;>1G5]4
M&72 K3X.LY&_BU_23/OL _44@'._T<.DGY"6IZI++2$?#(D52]]QB<=@KSD*
M+N:R(: GZ6@\OV"\$O(8&0GC0A^8 RY;PQC!46=PBHF[E"DCDS9W%Z=,3,$8
M3D5F;FNB+U'(FNJ0"&@AY=Y4W^W:YS6R8/_O)Z.(+)C(QQU=!JZ]^$._>_]%
MSIOF,"*GST"B68QCHO32J/"[0H]M#6%(5I;IT+JF%7:3CC2H?W2<4BGE 8F!
MH4:<$OB&\4H&OJ:S66DPDY#RW%B+/WK!RRWPW&$[Q(.&5I;OI!Q#G7_"07S0
MILET>TP3%RZYCDC-8/VV"I7WDY"JW2J&@@=7@G:\>+.(67,!]Q[=&,<&B-,=
MA)3/'(8://RNSY9W0Q8-&^.N.(YY:Y:29=M/WA,^KCMY@[%D/'Z2MV#8%3(\
MN/#ZPSX.L^T[#A>TO?!N+0R>P+8C3Y=P#&!"E'N47&OXII0-4SP1:2\>C[4I
M#+ 6E$AHOC@,L^:,HL8$A(_XI!3U:POV(KWB).W7"0:1.A$: A_EIZ\Y \ K
MKC.TYG/V:D%Q-!2JFG5M'@_5#I:\Y)B'O8.>0["\M\?2<U%$205XS 2#IB'C
M>$L1Q1+F"?ZZP!2 YF!GRE&'BFPX#I:6;,8PC$V5/N:8<J45LE'!).QT(R"J
M\R&9>(MV7)@, 1(X0>[& ,R7Y(*(2*5/^ ,1P/ME4Y2?Q"'C'_DF!:UY2!*X
MI3 G^TU1W1EO!E[69(RWSF&TP646,7:AZFPF-IQH?:KGAM[/5:9; M\Z"\GB
MWL# B9/58[#MJBE]17C#7--D!DD L[NL/@B3U^W4O9-L/#W!Q$T'.!%RC5'X
M\F[^,2ETYC R9ZG:QJ$;7.#)"&1&JI-=W 9F%FPUVN^5!'' E,O:0LND(;D7
M1L_!7JJ=.S!IRXQI.^!WWN<9.P$6O 8D#.(3XK=\:#/866-JBLW4>$YZ.) _
M,C5=K!$ES_!RET.7>?3/$AJ^=&L<=N>GR!,*P:F2/\_B@^T.JY%BD1]T2<[3
M2=665A=]3HD0!DMV>&WEZI<;HQ),N!8#=4H/2=>:[=&UC_:?$.?HI0N/JBT)
M?X5X+9$)JKJFB$!\$0@"[_;\!1^D+^(L'%+D6(1:&(O,M23+4[I*9Z'XEB)4
M'")H4: ;HJUFCXLUS9 DEAL"'4U#2/IYDL*^] SO6+VH1,X_:QSB&.D,@/+E
MC9N%09!A!,GQ.C229FL0,13>YS <UW\Z>"@B\3B3)4&ZK#"$P<-H"IRC:JX1
M#QA4:!\&<CN#:?!2HZ_>4^&&C#X:LEG"0D?WP1B[)O_U.??G8XQ^M8UU^,[6
M\B55SNF^:P,@#6:O\(.2I1%:D/8YX_,MFXCT9[DQT$W96ELO<4Q!#8U7%"S]
M1;DLAV/6,4VPPBA&,=&U8(=Y>54PNF,MS6@<LE:^G'+3^PF>Q]M3;AH<H!A#
MB*?P>\EQ;UY&?P3LXW$"=/=E8%V06P%<^2G6IRQ=#$[KO'M%F""1HGL!.L53
M@0-GIG)F+V.NG0%N>0[+EA)'#I<.#!/-A^1E'(]>BY&,*.)7(A\2KI!3%5'"
M"5:24+W@IWV_=/=MD>'8Q3P&#XOF)IIZ/^$K\.9XUH+&X"Z&.1Z8JIV0X'%L
M^H7/C$=%OD-3L9MV85[>Y@S@C*X'MHH#^YH8^E(30S%(M]8N7 Z]@ZW4DB'&
MKLVDK47'=/=QC+>7U#^1K0E*805 )?<6,EBA<;<H>1L#_^8J/OOV&9^!0.38
MV;31 8AHMU,FVTXCU'/\%%F4'%]$KFQWK-C0=$>K?SOD@/N7!C@$ST;$K";P
M8HXA^?L1<?SA5#K,!)?@4TC#P2=.+\^N1GN_@LUB)H;8=P-;8[*C]Z?[:?+H
MX'#GPR[1R+58!RWB:X@>9.,L81LT%IYLE[%P^AON0YU<=@C>ML!(B**"4H*/
MJ!I$4A^[>,8=)\%[$K8=@P*2&UL)E>PRCIJ+WW#P'78[&"TT(3"ZB6.U))"[
M<^KD.;YI% YURW6P=UW"9N@<IN+K.)O88MU6Y^U=8U\58';35%A&(\DW/2LF
M5X3]V^%!"DOB"P%CSP!D6C3B0D]A"B::C'/I]X"!4^IIU1A)]48MK%H8_M94
M=T^J-U2&_);5 7!5EI_0V&ABGDMFY/93OT# &%9&/6 1\G2[1,@E4Y[C[CLI
ME)G_WP.<;A'UB@!.72QU9>XW6RYVAD4Q<C]X(-R-JS "GW45 C5]F>+9[$B,
MD[.&)EGGHC"',N]<03WE:1''D. FFKA0A):_FWVB. ?1T[D;?E,GQO"*D-J)
M-Z3V-;E1Q(/04&@C>IB]-E/[FT(DUSSW4!RZ75KNJ[9IC&F/<D@V]0A]AN<3
M'%V0.H3ST+E&I >U9MO,_TPH=W[,#<3=9DUX$[MZA79&>R4E@)-@@9$(%W9
M#C]D> ,:6X 9&Z@4W(P1NG2G.MK@I;# T<]HO1OKKU[IIN.<@L#PU(T,+\/_
M(]%3BS?2H\LW-U98AO'R<LJ%Q'E\G\+@&)4SM@EQA=%5SYG3(VKY5*GS^-$6
MT]+>4WIM$06#R]%?914SG8O\VJS4HEN&1'1X2<&;"\\%EIM(E6:H.!'XGMF-
MSM,]=W\_>K12/E(%*K0.-$4UT6.,LJ,RO*@'_=?T0RK>G^R[M1TVQMAKU71"
MY^Y<IN$"XH5:IL,FM(W<6/[:!$^RCF(YY ^F7;<P[8:\0*"X<B4M):J,$I:P
M'./C[,IM S(OW8E!;801%U J1$;/E0?@6]15.9VT13>&A](E?!M;E\H#(KHN
M%<$NDRDR[D\4)T#I)RJ81%RBZ\4-=Z+!<@(G=,-$1WV;U*K-40;#'I=.Z'DE
M,8;<V*:F5! 9X\;RY0<X\@[X4O)!'!CD+A"EO/1BXM"DMO%T\PPGQ3^T#>9Z
M[NPDOIF!LMQ#Z 6H& ZH(%(%=0_/G]-;$E0DCR/*(_?.2XA!2!>3$T3@)I>,
M$1LQQ.#P^9-'= >0FE/EFU![ND=&H'!-IDI)2?N"54Q$^!:>'_!#(YB]5YW1
M)+U;/.&);;C?:_3J=+0--"9I*%&+9NF=>&-N@M^"W"A@6_&WW6_P6 $B@@U4
M_&KOXW=D:L$2OM$8D:(ON&"X_]*/5-JW)& 7[IG7.%I9VP>MWK>0QP+V['9H
M]GZZJ0,$P#]#W\598,P52"2\6=JC57.Q!QQ61E"K:R*H.'"W=7WI>NS]3/&V
M,.\9X6NHL,"]12)*U"I_=4WI;P?"!_WB.F$X@#>JX.K]R'_"_*PJ0)OE2^\U
MW1U.#[V@*R(8EY:GC@3*1-=J\)"C@@90NYQG7AE<DE>:S2@$'_@JP  $[FF%
M$-Z[R[2/[" N[2!W4=!+#IWD%5)P(+"I@7#6CG*TN&Z-LUF%]1#Q_I"B0:K4
MVXT-#C]O7U-17VHJ2NZ#PML(=XX.)=(,B^T.\B=M&-EO")ZP%31=[T8&HM\T
M:#.7R<Y3>6GWUJF[S@#'AHD]MM\[PH6Z- Y^)W,L&BL\I+M=B['74J?"WU^E
M$&A/J'_$8A7J^Z/W"9AQQ@DZE""I?#&NJZ&%F/6X5X<&O'HMFI#W!A+=;6&E
MZ]X[L0VVW(,VE[:0[^0G5I6@OM]S'&TK8KD_7[Q/WI^_.KV\NAZ=OTJN?QQ=
MP__.KI+1#Y>GIV]/SZ^3L_.3-^]?G<*?DLO3-Z>CJ]/DXG4R>O,F^>?YQ4_G
M"3[W_IQ_/GDS.GM[E2:G_SH]AW8NX+O=C^@-:7+V6A[^_F?L0IK\=/'^S:MD
M]/KUZ<DU_N4R>75Z<G9U=@'-7"2CDY/3=_V.42!:+I]@.236U2IF)(($L#B2
MN(\S1CI(9 ES^IN\4 X1VK03A X !+*!G EDRE\1RA#*_3AV[",RH<H4ZT@E
M;_]+"\90;J+47/<VL=H;5_* ZR)AS4.-IHR&,50/^OQO'WG(J0-K;/C ?Z2^
MVKE-K&6=4Q3'+67_8V@Q"H]B/*]SG01N@GF)50'89!\F-T(Z^$)0J-\OF?*F
M5S9$N!+87KF@ (5R/_=-&[$Z5&2^K)#;#EPN&/[D,S><^Y#DC4^8+&-NH;N8
MB3AUH4P1[@ETD/#H;?@]MA'6O+</$0ZQW]+%[+C=3)5BI)'P(3_-UV1+5+3K
MQY+IB;2RIM#"?F);Q+!3LPQ8J.H/T L7S.L'E=LRBF;[>0EEX!0%#?WLAF+O
MFZAY"!4>V\E[TK *X6#LYI%!$;1?[J1?QY)&I]#*Y0AR;-U&5W*!,,4=/"V!
MEQ*GB'6+(YT7"^1"P'O'B)Y5TB$<R'R%8)]&R!B8P8L_.%<2P&=6+W_W#W,E
M\W<N?&4)?.]*39 L,L0[DU&.?)BVJ26RSN"BK)42-_SFJ<NXAWYU$RG=N/\0
MB026;1(CG$R':V8;(N _!*J+$?;1;!.OMXN@=39E9Q/ZH!?MQI7-B),-NRK#
MA9%@U3(9&++/G1#^H7?9MM0V.GX.7O] FL'G1&Q8R;:S9AAZ62<5&)BG'00L
M]"2N[$T]X)N)JWNA!>2QQE-WC[GQ9<X.@(O1.^((GE2=5W:@)/<[%FF_-JA;
M?I R0?MO9M[.W<W2"TP+-HU7I,$."JL1DQLXA,50H)AM'_ANWG*BV>@)X81S
M5XP::W*OF\7"SP/4KJ>\@Z8?#FKN)Z]YF\[!FDOO$)C4D/U(H-LQZCQU1LE:
M*4<YM![)8>2NR&"#3\;>R1=T&]W]),:S+8/KG5Z_OSQ'1_WDXNV[T?G/R;O+
MBW>GE]<_;T&N)I0".="OJV#V"-![0W_=W4NK;#N^V-K+M!V/C*H6AFK!82]6
MD]V(2,<]Y#ETC%S(M:B0?L>I7:$7B(1H.DA8ZHL?02Y:.I2$P:H51GPMYM/Q
M.G:;NEO(T1/+E&WH([1%"$31Y@)&4\72"AT0](<Y@#P2E]J=X+\(@2XS1]/
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M: M[D4#\L?'+PXRBO1\WS&X]'B64WOR60:E$K13XG(Y3='05LP+7.J.+G.#
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MDIV(<G%0H%-@F-U(U D$-3>WJ$%(W'8CQ B@G@.4,4A<8(%:!<9@G5,Q1(R
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M]Y$?^BBW?A?GH>_X<]C_!5!+ P04    " "=@'1:*\T1AW0-   K4@  '@
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MG7J-U*"?HG0:N\R-WJRQXD!U 3) K(*\=K"2B&UVD4W.E(7!#$((T_>* @A
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M1>=()"+$RF-5.)!TN.;(Z]=:*Z>Y?Y>H>22"L=C,E7AY[>Q2N#R<@Z?#6+Y
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MR)09*B6KA/(87_NS3#+QL2>^J(">.A83%9F[KGSY[1SV3\[.[PJZ &8R I@
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M]2SJ<GE/]&E5333LG(OKUW"5O0PD39"3)5PHD[;K\2%P#]R$/Y6J)C76DZ4
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MM"WVU6OIF07?S;6:BK\4L,3BA\9A8Q9J*L+<;\#483;;K:6JA=G2.7PC#SS
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M):O+W@-E6P-E&*@+X)N AH3- KXHSPJC5P>$4GXX*#WO#\ZL':[)8$L A[G
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M:'1MW5IM<]LV$OY^OP)GSZ7.C"2+DF7)LN.9M$E;7Z=WG333WK<;D%A*.(,
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ME0^\X-1\QM>M3L-K7O\'4$L#!!0    ( )V =%IH%143G@,  $4,   ;
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M^G\+1^Y?RA]02P$"% ,4    " "=@'1:P@$^^%P  P"?71L $0
M    @ $     ;6=N>"TR,#(T,3(S,2YH=&U02P$"% ,4    " "=@'1:VJ6U
M'),5  ! Z   $0              @ &+  , ;6=N>"TR,#(T,3(S,2YX<V10
M2P$"% ,4    " "=@'1:YJ-W9E\<   H#@$ %0              @ %-%@,
M;6=N>"TR,#(T,3(S,5]C86PN>&UL4$L! A0#%     @ G8!T6I3I@6_*:0
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M,#(T,3(S,5]P<F4N>&UL4$L! A0#%     @ G8!T6IHHLUO&+   ;_8  !X
M             ( !WKL( &UG;GAE>#$P,S-S97!A<F%T:6]N86YD8V]N+FAT
M;5!+ 0(4 Q0    ( )V =%I 9,=\"@<  &!]   >              "  >#H
M" !M9VYX97@Q,#,T86UE;F1M96YT,6IK96UP;"YH=&U02P$"% ,4    " "=
M@'1:K[WY-@@'  ".?0  '@              @ $F\ @ ;6=N>&5X,3 S-6%M
M96YD;65N=#%S96-K96TN:'1M4$L! A0#%     @ G8!T6BO-$8=T#0  *U(
M !X              ( !:O<( &UG;GAE>#$P,S9A;65N9&UE;G1?=&]X:V]E
M+FAT;5!+ 0(4 Q0    ( )V =%I?GD+N AX  ,_#   >              "
M 1H%"0!M9VYX97@Q.6EN<VED97)T<F%D:6YG<&]L:2YH=&U02P$"% ,4
M" "=@'1:</D(_R<$  #+(@  &P              @ %8(PD ;6=N>&5X:&EB
M:70R,RTQ,C R-#$P>&LN:'1M4$L! A0#%     @ G8!T6@2Y'QN@!P  ;R4
M !L              ( !N"<) &UG;GAE>&AI8FET,S$M,3(P,C0Q,'AK+FAT
M;5!+ 0(4 Q0    ( )V =%JDN>5CFP<  .TE   ;              "  9$O
M"0!M9VYX97AH:6)I=#,Q+3(R,#(T,3!X:RYH=&U02P$"% ,4    " "=@'1:
M:!45$YX#  !%#   &P              @ %E-PD ;6=N>&5X:&EB:70S,BTQ
M,C R-#$P>&LN:'1M4$L! A0#%     @ G8!T6EE(0">E P  K P  !L
M         ( !/#L) &UG;GAE>&AI8FET,S(M,C(P,C0Q,'AK+FAT;5!+!08
1    $P 3 #D%   :/PD    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>mgnx-20241231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mgnx="http://macrogenics.com/20241231"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mgnx-20241231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2025-03-14</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">mgnx:JamesKarrelsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">mgnx:JamesKarrelsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">mgnx:JamesKarrelsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">mgnx:JeffreyPetersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">mgnx:JeffreyPetersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">mgnx:JeffreyPetersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:ContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:ContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:ContractManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2020-08-14</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ASDHealthcareAndOncologySupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ZaiLabLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ASDHealthcareAndOncologySupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ASDHealthcareAndOncologySupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:LaboratoryAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:SynaffixBVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:SynaffixBVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:SynaffixBVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:SynaffixBVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:UndesignatedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:UndesignatedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteCommercialSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteCommercialSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteCommercialSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-14</startDate>
            <endDate>2022-10-14</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2022GileadCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:GileadFirstResearchProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:GileadFirstResearchProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:GileadFirstResearchProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:GileadFirstResearchProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:GileadFirstResearchProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:GileadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:GileadFirstResearchProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:A2021ZaiLabAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:DRIHealthcareAcquisitionsLPDRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-08</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:DRIHealthcareAcquisitionsLPDRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-08</startDate>
            <endDate>2023-03-08</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:DRIHealthcareAcquisitionsLPDRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:DRIHealthcareAcquisitionsLPDRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:SideLetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionAPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAmendmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAmendmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAmendmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromCMOAgreementsMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:TerSeraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-18</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2023MemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2023MemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2023MemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-23</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2023MemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2024-10-25</startDate>
            <endDate>2024-10-25</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:DrScottKoenigMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:DrScottKoenigMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:DrScottKoenigMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:TerSeraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:TerSeraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:CombinedServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mgnx:TaxYear2027To2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mgnx:IndefiniteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">mgnx:TaxYear2027To2044Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:VobramitanmabDuocarmazineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:VobramitanmabDuocarmazineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:VobramitanmabDuocarmazineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:LorigerlimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:LorigerlimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:LorigerlimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:MGC028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:MGC028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:MGC028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:ADCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:ADCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:ADCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:MGC026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:MGC026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:MGC026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:MargetuximabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:MargetuximabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:MargetuximabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:MGD024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:MGD024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:MGD024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:NextGenerationTCellEngagersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:NextGenerationTCellEngagersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:NextGenerationTCellEngagersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:RetifanlimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:RetifanlimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:RetifanlimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:EnoblituzumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:EnoblituzumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:EnoblituzumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:OtherProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:OtherProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">mgnx:OtherProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mgnx:MainSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="productcandidate">
        <measure>mgnx:productCandidate</measure>
    </unit>
    <unit id="segment">
        <measure>mgnx:Segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="performanceobligation">
        <measure>mgnx:performanceObligation</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-33">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-34">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-35">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-36">0001125345</dei:EntityCentralIndexKey>
    <ecd:TrdArrDuration contextRef="c-6" id="f-69">P364D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-8" id="f-70">P364D</ecd:TrdArrDuration>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-4">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-3">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-36112</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">MACROGENICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">06-1591613</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">9704 Medical Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Rockville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">251-5172</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">MGNX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-19">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-20">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-23">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-24">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-25">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-26">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-27">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-28">false</dei:EntityShellCompany>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-29">2024</dei:DocumentFiscalYearFocus>
    <dei:EntityPublicFloat contextRef="c-2" decimals="-5" id="f-30" unitRef="usd">259400000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-31" unitRef="shares">63090323</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-32">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Portions of MacroGenics, Inc.'s definitive proxy statement for the 2025 annual meeting of stockholders are incorporated by reference into Part III of this Annual Report.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c-1" id="f-37">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c-1" id="f-38">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Risk Management and Strategy&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have implemented and maintain various information security processes designed to identify, assess, and manage material risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and clinical trial data (Information Systems and Data).  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our information security function is led by our Executive Director of Information Technology and supported by the Senior Information Security Manager, our legal team, a management-level Technology Steering Committee, and the Audit Committee of the Board of Directors. This function is responsible for identifying, assessing, and managing the Company&#x2019;s cybersecurity threats and risks. We employ various methods to monitor and evaluate the threat environment, including automated tools, subscriptions to cybersecurity threat reports and services, analysis of threats reported to us, evaluations of our and our industry&#x2019;s risk profile, threat actor analyses, audits, vulnerability assessments, and tabletop incident response exercises.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depending on the environment and system, we implement and maintain various technical, physical, and organizational measures, processes, and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data. These include: an incident response plan and procedures, incident detection and response playbook, business continuity plans, encryption of certain data, network security controls, identity management and access controls, physical security controls, 24/7 systems monitoring, vendor risk management processes, employee cybersecurity and privacy training, penetration testing, cybersecurity insurance, and dedicated cybersecurity staff. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our assessment and management of material risks from cybersecurity threats are integrated into our overall risk management processes. Specifically, (1) cybersecurity risk is addressed as a component of our enterprise risk management program and identified in our risk register; (2) the information security function works with management to prioritize our risk management processes and mitigate cybersecurity threats that are more likely to lead to a material impact to our business; (3) our Technology Steering Committee evaluates material risks from cybersecurity threats against our overall business objectives and reports to the Audit Committee of the board of directors, which evaluates our overall enterprise risk.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We engage third-party service providers, including professional services firms, cybersecurity consultants, cybersecurity software providers, managed cybersecurity service providers, penetration testing firms, and dark web monitoring services, to assist in identifying, assessing, and managing material risks from cybersecurity threats.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we use third-party service providers to perform a variety of functions throughout our business, such as application providers, hosting companies, CROs, distributors, and supply chain management resources. We have vendor management processes to manage cybersecurity risks associated with our use of certain of these providers, such as reviewing security questionnaires, reviewing the vendor&#x2019;s written security program, conducting risk assessments for certain vendors, arranging security assessment calls with the vendor&#x2019;s security personnel, reviewing security assessments, or imposing contractual obligations on the vendor. Depending on the nature of the services provided, the sensitivity of the Information &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Systems and Data at issue, and the identity of the provider, our vendor management process may involve different levels of assessment designed to help identify and mitigate cybersecurity risks associated with a provider. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For a description of the risks from cybersecurity threats that may materially affect the Company and how they may do so, see our risk factors under Part 1. Item 1A. Risk Factors in this Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="c-1" id="f-40">Our assessment and management of material risks from cybersecurity threats are integrated into our overall risk management processes. Specifically, (1) cybersecurity risk is addressed as a component of our enterprise risk management program and identified in our risk register; (2) the information security function works with management to prioritize our risk management processes and mitigate cybersecurity threats that are more likely to lead to a material impact to our business; (3) our Technology Steering Committee evaluates material risks from cybersecurity threats against our overall business objectives and reports to the Audit Committee of the board of directors, which evaluates our overall enterprise risk.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="c-1" id="f-39">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="c-1" id="f-41">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="c-1" id="f-42">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c-1" id="f-43">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our board of directors addresses the Company&#x2019;s cybersecurity risk management as part of its general oversight function. The board of directors&#x2019; Audit Committee and management&#x2019;s Technology Steering Committee are responsible for overseeing the Company&#x2019;s cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-44">The board of directors&#x2019; Audit Committee and management&#x2019;s Technology Steering Committee are responsible for overseeing the Company&#x2019;s cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="c-1" id="f-45">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our Executive Director, Information Technology, who has fourteen years of information security experience and holds a Certified Information Systems Security Professional (CISSP) certification. Our Senior Information Security Manager holds CISSP certification, an MSc. in Information Security, and has over 20 years government and industry cybersecurity experience.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company management is responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company&#x2019;s overall risk management strategy, and communicating key priorities to relevant personnel. Company management is also responsible for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports. &lt;/span&gt;&lt;/div&gt;Our cybersecurity incident response processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances and incident severity, including our Executive Director Information Technology who works with the Company&#x2019;s incident response team to help the Company mitigate and remediate cybersecurity incidents. In addition, the Company&#x2019;s incident response process includes reporting to the audit and technology steering committees of the board of directors for certain cybersecurity incidents.</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-47">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our Executive Director, Information Technology, who has fourteen years of information security experience and holds a Certified Information Systems Security Professional (CISSP) certification. Our Senior Information Security Manager holds CISSP certification, an MSc. in Information Security, and has over 20 years government and industry cybersecurity experience.&lt;/span&gt;&lt;/div&gt;Company management is responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company&#x2019;s overall risk management strategy, and communicating key priorities to relevant personnel. Company management is also responsible for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="c-1" id="f-46">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our Executive Director, Information Technology, who has fourteen years of information security experience and holds a Certified Information Systems Security Professional (CISSP) certification. Our Senior Information Security Manager holds CISSP certification, an MSc. in Information Security, and has over 20 years government and industry cybersecurity experience.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="c-1" id="f-48">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-49">Our cybersecurity incident response processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances and incident severity, including our Executive Director Information Technology who works with the Company&#x2019;s incident response team to help the Company mitigate and remediate cybersecurity incidents. In addition, the Company&#x2019;s incident response process includes reporting to the audit and technology steering committees of the board of directors for certain cybersecurity incidents.</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-50">The board of directors&#x2019; Audit Committee receives periodic reports from our Vice President Information Technology concerning the Company&#x2019;s significant cybersecurity threats and risk and the processes the Company has implemented to address them. The board of directors also receives regular reports, summaries or presentations related to cybersecurity threats, risk, and mitigation.</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="c-1" id="f-51">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-4" id="f-52">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-4" id="f-53">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-4" id="f-54">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-5" id="f-55">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;James Karrels, Senior Vice President and Chief Financial Officer, adopted a new trading plan on November 21, 2024 (with the first trade possible under the new plan no sooner than April 16, 2025). The trading plan will be effective until April 15, 2026 and covers the potential sale of up to 410,000 shares of common stock.&lt;/span&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrIndName contextRef="c-6" id="f-56">James Karrels</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-6" id="f-57">Senior Vice President and Chief Financial Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-6" id="f-58">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-6" id="f-59">November 21, 2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrExpirationDate contextRef="c-6" id="f-60">April 15, 2026</ecd:TrdArrExpirationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-7" decimals="INF" id="f-61" unitRef="shares">410000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-9" id="f-63">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Jeffrey Peters, Senior Vice President and General Counsel, adopted a new trading plan on November 15, 2024 (with the first trade possible under the new plan no sooner than March 21, 2025). The trading plan will be effective until March 20, 2026 and covers the potential sale of up to 448,881 shares of common stock.&lt;/span&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrIndName contextRef="c-8" id="f-62">Jeffrey Peters</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-8" id="f-64">Senior Vice President and General Counsel</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-8" id="f-65">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-8" id="f-66">November 15, 2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrExpirationDate contextRef="c-8" id="f-67">March 20, 2026</ecd:TrdArrExpirationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-10" decimals="INF" id="f-68" unitRef="shares">448881</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c-1" id="f-71">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <dei:AuditorFirmId contextRef="c-1" id="f-72">42</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-73">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-74">Tysons, Virginia</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-11" decimals="-3" id="f-75" unitRef="usd">182840000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-12" decimals="-3" id="f-76" unitRef="usd">100956000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:Investments contextRef="c-11" decimals="-3" id="f-77" unitRef="usd">18827000</us-gaap:Investments>
    <us-gaap:Investments contextRef="c-12" decimals="-3" id="f-78" unitRef="usd">128849000</us-gaap:Investments>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-11" decimals="-3" id="f-79" unitRef="usd">4309000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-12" decimals="-3" id="f-80" unitRef="usd">10367000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-11" decimals="-3" id="f-81" unitRef="usd">0</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-12" decimals="-3" id="f-82" unitRef="usd">1221000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-11" decimals="-3" id="f-83" unitRef="usd">11514000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-12" decimals="-3" id="f-84" unitRef="usd">9946000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent contextRef="c-11" decimals="-3" id="f-85" unitRef="usd">217490000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-12" decimals="-3" id="f-86" unitRef="usd">251339000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-11" decimals="-3" id="f-87" unitRef="usd">18100000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-12" decimals="-3" id="f-88" unitRef="usd">21847000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-11" decimals="-3" id="f-89" unitRef="usd">24509000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-12" decimals="-3" id="f-90" unitRef="usd">23846000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-11" decimals="-3" id="f-91" unitRef="usd">1556000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-12" decimals="-3" id="f-92" unitRef="usd">1386000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-11" decimals="-3" id="f-93" unitRef="usd">261655000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-12" decimals="-3" id="f-94" unitRef="usd">298418000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-11" decimals="-3" id="f-95" unitRef="usd">5013000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-12" decimals="-3" id="f-96" unitRef="usd">6443000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-11" decimals="-3" id="f-97" unitRef="usd">29334000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-12" decimals="-3" id="f-98" unitRef="usd">24239000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="c-11" decimals="-3" id="f-99" unitRef="usd">16319000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="c-12" decimals="-3" id="f-100" unitRef="usd">21651000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-11" decimals="-3" id="f-101" unitRef="usd">4864000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-12" decimals="-3" id="f-102" unitRef="usd">3775000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-11" decimals="-3" id="f-103" unitRef="usd">55530000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-12" decimals="-3" id="f-104" unitRef="usd">56108000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="c-11" decimals="-3" id="f-105" unitRef="usd">55503000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="c-12" decimals="-3" id="f-106" unitRef="usd">59243000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-11" decimals="-3" id="f-107" unitRef="usd">32597000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-12" decimals="-3" id="f-108" unitRef="usd">30196000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-11" decimals="-3" id="f-109" unitRef="usd">1968000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-12" decimals="-3" id="f-110" unitRef="usd">258000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-11" decimals="-3" id="f-111" unitRef="usd">145598000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-12" decimals="-3" id="f-112" unitRef="usd">145805000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-11"
      decimals="INF"
      id="f-113"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-12"
      decimals="INF"
      id="f-114"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-11"
      decimals="INF"
      id="f-115"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-12"
      decimals="INF"
      id="f-116"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-11"
      decimals="INF"
      id="f-117"
      unitRef="shares">62819857</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-12"
      decimals="INF"
      id="f-118"
      unitRef="shares">62070627</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-11" decimals="-3" id="f-119" unitRef="usd">628000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-12" decimals="-3" id="f-120" unitRef="usd">621000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-11" decimals="-3" id="f-121" unitRef="usd">1285143000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-12" decimals="-3" id="f-122" unitRef="usd">1254750000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-11" decimals="-3" id="f-123" unitRef="usd">4000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-12" decimals="-3" id="f-124" unitRef="usd">-6000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-11" decimals="-3" id="f-125" unitRef="usd">-1169718000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-12" decimals="-3" id="f-126" unitRef="usd">-1102752000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-127" unitRef="usd">116057000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-12" decimals="-3" id="f-128" unitRef="usd">152613000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-11" decimals="-3" id="f-129" unitRef="usd">261655000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-12" decimals="-3" id="f-130" unitRef="usd">298418000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c-13" decimals="-3" id="f-131" unitRef="usd">118856000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-14" decimals="-3" id="f-132" unitRef="usd">29421000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-15" decimals="-3" id="f-133" unitRef="usd">119303000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-16" decimals="-3" id="f-134" unitRef="usd">16426000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-17" decimals="-3" id="f-135" unitRef="usd">17939000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-18" decimals="-3" id="f-136" unitRef="usd">16727000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-19" decimals="-3" id="f-137" unitRef="usd">13057000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-20" decimals="-3" id="f-138" unitRef="usd">9833000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-21" decimals="-3" id="f-139" unitRef="usd">13988000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-22" decimals="-3" id="f-140" unitRef="usd">1623000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-23" decimals="-3" id="f-141" unitRef="usd">1556000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-24" decimals="-3" id="f-142" unitRef="usd">1923000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-1" decimals="-3" id="f-143" unitRef="usd">149962000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-25" decimals="-3" id="f-144" unitRef="usd">58749000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-26" decimals="-3" id="f-145" unitRef="usd">151941000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-3" id="f-146" unitRef="usd">847000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-25" decimals="-3" id="f-147" unitRef="usd">619000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-26" decimals="-3" id="f-148" unitRef="usd">3351000</us-gaap:CostOfGoodsAndServicesSold>
    <mgnx:CostOfManufacturingServices contextRef="c-1" decimals="-3" id="f-149" unitRef="usd">11452000</mgnx:CostOfManufacturingServices>
    <mgnx:CostOfManufacturingServices contextRef="c-25" decimals="-3" id="f-150" unitRef="usd">7603000</mgnx:CostOfManufacturingServices>
    <mgnx:CostOfManufacturingServices contextRef="c-26" decimals="-3" id="f-151" unitRef="usd">4033000</mgnx:CostOfManufacturingServices>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-152" unitRef="usd">177194000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-25" decimals="-3" id="f-153" unitRef="usd">166583000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-26" decimals="-3" id="f-154" unitRef="usd">207026000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-155" unitRef="usd">71047000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-25" decimals="-3" id="f-156" unitRef="usd">52188000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-26" decimals="-3" id="f-157" unitRef="usd">58949000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses contextRef="c-1" decimals="-3" id="f-158" unitRef="usd">260540000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-25" decimals="-3" id="f-159" unitRef="usd">226993000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-26" decimals="-3" id="f-160" unitRef="usd">273359000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-161" unitRef="usd">-110578000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-25" decimals="-3" id="f-162" unitRef="usd">-168244000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-26" decimals="-3" id="f-163" unitRef="usd">-121418000</us-gaap:OperatingIncomeLoss>
    <mgnx:GainOnRoyaltyMonetizationArrangement contextRef="c-1" decimals="-3" id="f-164" unitRef="usd">0</mgnx:GainOnRoyaltyMonetizationArrangement>
    <mgnx:GainOnRoyaltyMonetizationArrangement contextRef="c-25" decimals="-3" id="f-165" unitRef="usd">150930000</mgnx:GainOnRoyaltyMonetizationArrangement>
    <mgnx:GainOnRoyaltyMonetizationArrangement contextRef="c-26" decimals="-3" id="f-166" unitRef="usd">0</mgnx:GainOnRoyaltyMonetizationArrangement>
    <mgnx:GainOnSaleOfMARGENZA contextRef="c-1" decimals="-3" id="f-167" unitRef="usd">36250000</mgnx:GainOnSaleOfMARGENZA>
    <mgnx:GainOnSaleOfMARGENZA contextRef="c-25" decimals="-3" id="f-168" unitRef="usd">0</mgnx:GainOnSaleOfMARGENZA>
    <mgnx:GainOnSaleOfMARGENZA contextRef="c-26" decimals="-3" id="f-169" unitRef="usd">0</mgnx:GainOnSaleOfMARGENZA>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-170" unitRef="usd">9421000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-25" decimals="-3" id="f-171" unitRef="usd">9686000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-26" decimals="-3" id="f-172" unitRef="usd">1660000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-3" id="f-173" unitRef="usd">1115000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-25" decimals="-3" id="f-174" unitRef="usd">1430000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-26" decimals="-3" id="f-175" unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-176" unitRef="usd">-66022000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-25" decimals="-3" id="f-177" unitRef="usd">-9058000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-26" decimals="-3" id="f-178" unitRef="usd">-119758000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-179" unitRef="usd">944000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-25" decimals="-3" id="f-180" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-26" decimals="-3" id="f-181" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-182" unitRef="usd">-66966000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-25" decimals="-3" id="f-183" unitRef="usd">-9058000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-26" decimals="-3" id="f-184" unitRef="usd">-119758000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-185" unitRef="usd">10000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-25" decimals="-3" id="f-186" unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-26" decimals="-3" id="f-187" unitRef="usd">56000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-188" unitRef="usd">-66956000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-25" decimals="-3" id="f-189" unitRef="usd">-9059000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-26" decimals="-3" id="f-190" unitRef="usd">-119702000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-191"
      unitRef="usdPerShare">-1.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-192"
      unitRef="usdPerShare">-1.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-25"
      decimals="2"
      id="f-193"
      unitRef="usdPerShare">-0.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-25"
      decimals="2"
      id="f-194"
      unitRef="usdPerShare">-0.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-26"
      decimals="2"
      id="f-195"
      unitRef="usdPerShare">-1.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-26"
      decimals="2"
      id="f-196"
      unitRef="usdPerShare">-1.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-197" unitRef="shares">62621185</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-198" unitRef="shares">62621185</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-25" decimals="0" id="f-199" unitRef="shares">61929198</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-25" decimals="0" id="f-200" unitRef="shares">61929198</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-26" decimals="0" id="f-201" unitRef="shares">61433124</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-26" decimals="0" id="f-202" unitRef="shares">61433124</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesIssued
      contextRef="c-27"
      decimals="INF"
      id="f-203"
      unitRef="shares">61307428</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-204" unitRef="usd">613000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-205" unitRef="usd">1213002000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-3" id="f-206" unitRef="usd">-973936000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-3" id="f-207" unitRef="usd">-61000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-208" unitRef="usd">239618000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-32" decimals="-3" id="f-209" unitRef="usd">20438000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-26" decimals="-3" id="f-210" unitRef="usd">20438000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-33"
      decimals="INF"
      id="f-211"
      unitRef="shares">160480</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-33" decimals="-3" id="f-212" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-32" decimals="-3" id="f-213" unitRef="usd">1083000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-26" decimals="-3" id="f-214" unitRef="usd">1085000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <mgnx:StockIssuedDuringPeriodSharesStockPlanActivity
      contextRef="c-33"
      decimals="INF"
      id="f-215"
      unitRef="shares">233559</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="c-33" decimals="-3" id="f-216" unitRef="usd">2000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="c-32" decimals="-3" id="f-217" unitRef="usd">572000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="c-26" decimals="-3" id="f-218" unitRef="usd">574000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-34" decimals="-3" id="f-219" unitRef="usd">56000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-26" decimals="-3" id="f-220" unitRef="usd">56000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss contextRef="c-35" decimals="-3" id="f-221" unitRef="usd">-119758000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-26" decimals="-3" id="f-222" unitRef="usd">-119758000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="c-36"
      decimals="INF"
      id="f-223"
      unitRef="shares">61701467</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-36" decimals="-3" id="f-224" unitRef="usd">617000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="-3" id="f-225" unitRef="usd">1235095000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-38" decimals="-3" id="f-226" unitRef="usd">-1093694000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-39" decimals="-3" id="f-227" unitRef="usd">-5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-40" decimals="-3" id="f-228" unitRef="usd">142013000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-41" decimals="-3" id="f-229" unitRef="usd">18373000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-25" decimals="-3" id="f-230" unitRef="usd">18373000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-42"
      decimals="INF"
      id="f-231"
      unitRef="shares">167270</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-42" decimals="-3" id="f-232" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-41" decimals="-3" id="f-233" unitRef="usd">1037000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-25" decimals="-3" id="f-234" unitRef="usd">1039000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <mgnx:StockIssuedDuringPeriodSharesStockPlanActivity
      contextRef="c-42"
      decimals="INF"
      id="f-235"
      unitRef="shares">201890</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="c-42" decimals="-3" id="f-236" unitRef="usd">2000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="c-41" decimals="-3" id="f-237" unitRef="usd">245000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="c-25" decimals="-3" id="f-238" unitRef="usd">247000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-43" decimals="-3" id="f-239" unitRef="usd">-1000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-25" decimals="-3" id="f-240" unitRef="usd">-1000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss contextRef="c-44" decimals="-3" id="f-241" unitRef="usd">-9058000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-25" decimals="-3" id="f-242" unitRef="usd">-9058000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="c-45"
      decimals="INF"
      id="f-243"
      unitRef="shares">62070627</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-45" decimals="-3" id="f-244" unitRef="usd">621000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-46" decimals="-3" id="f-245" unitRef="usd">1254750000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-47" decimals="-3" id="f-246" unitRef="usd">-1102752000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-48" decimals="-3" id="f-247" unitRef="usd">-6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-12" decimals="-3" id="f-248" unitRef="usd">152613000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-49" decimals="-3" id="f-249" unitRef="usd">29439000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-250" unitRef="usd">29439000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <mgnx:StockIssuedDuringPeriodSharesStockPlanActivity
      contextRef="c-50"
      decimals="INF"
      id="f-251"
      unitRef="shares">749230</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="c-50" decimals="-3" id="f-252" unitRef="usd">7000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="c-49" decimals="-3" id="f-253" unitRef="usd">954000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="c-1" decimals="-3" id="f-254" unitRef="usd">961000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-51" decimals="-3" id="f-255" unitRef="usd">10000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-1" decimals="-3" id="f-256" unitRef="usd">10000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss contextRef="c-52" decimals="-3" id="f-257" unitRef="usd">-66966000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-258" unitRef="usd">-66966000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="c-53"
      decimals="INF"
      id="f-259"
      unitRef="shares">62819857</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-53" decimals="-3" id="f-260" unitRef="usd">628000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-54" decimals="-3" id="f-261" unitRef="usd">1285143000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-55" decimals="-3" id="f-262" unitRef="usd">-1169718000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-56" decimals="-3" id="f-263" unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-264" unitRef="usd">116057000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-265" unitRef="usd">-66966000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-25" decimals="-3" id="f-266" unitRef="usd">-9058000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-26" decimals="-3" id="f-267" unitRef="usd">-119758000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-268" unitRef="usd">7540000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-25" decimals="-3" id="f-269" unitRef="usd">9645000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-26" decimals="-3" id="f-270" unitRef="usd">11865000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-1" decimals="-3" id="f-271" unitRef="usd">2810000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-25" decimals="-3" id="f-272" unitRef="usd">5004000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-26" decimals="-3" id="f-273" unitRef="usd">-403000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-274" unitRef="usd">29439000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-25" decimals="-3" id="f-275" unitRef="usd">18373000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-26" decimals="-3" id="f-276" unitRef="usd">20438000</us-gaap:ShareBasedCompensation>
    <mgnx:GainOnRoyaltyMonetizationArrangement contextRef="c-1" decimals="-3" id="f-277" unitRef="usd">0</mgnx:GainOnRoyaltyMonetizationArrangement>
    <mgnx:GainOnRoyaltyMonetizationArrangement contextRef="c-25" decimals="-3" id="f-278" unitRef="usd">150930000</mgnx:GainOnRoyaltyMonetizationArrangement>
    <mgnx:GainOnRoyaltyMonetizationArrangement contextRef="c-26" decimals="-3" id="f-279" unitRef="usd">0</mgnx:GainOnRoyaltyMonetizationArrangement>
    <mgnx:GainOnSaleOfMARGENZA contextRef="c-1" decimals="-3" id="f-280" unitRef="usd">36250000</mgnx:GainOnSaleOfMARGENZA>
    <mgnx:GainOnSaleOfMARGENZA contextRef="c-25" decimals="-3" id="f-281" unitRef="usd">0</mgnx:GainOnSaleOfMARGENZA>
    <mgnx:GainOnSaleOfMARGENZA contextRef="c-26" decimals="-3" id="f-282" unitRef="usd">0</mgnx:GainOnSaleOfMARGENZA>
    <mgnx:NonCashInterestExpenseRecognized contextRef="c-1" decimals="-3" id="f-283" unitRef="usd">0</mgnx:NonCashInterestExpenseRecognized>
    <mgnx:NonCashInterestExpenseRecognized contextRef="c-25" decimals="-3" id="f-284" unitRef="usd">1430000</mgnx:NonCashInterestExpenseRecognized>
    <mgnx:NonCashInterestExpenseRecognized contextRef="c-26" decimals="-3" id="f-285" unitRef="usd">0</mgnx:NonCashInterestExpenseRecognized>
    <mgnx:OperatingLeaseNoncashExpense contextRef="c-1" decimals="-3" id="f-286" unitRef="usd">-663000</mgnx:OperatingLeaseNoncashExpense>
    <mgnx:OperatingLeaseNoncashExpense contextRef="c-25" decimals="-3" id="f-287" unitRef="usd">3489000</mgnx:OperatingLeaseNoncashExpense>
    <mgnx:OperatingLeaseNoncashExpense contextRef="c-26" decimals="-3" id="f-288" unitRef="usd">3341000</mgnx:OperatingLeaseNoncashExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-1" decimals="-3" id="f-289" unitRef="usd">-2000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-25" decimals="-3" id="f-290" unitRef="usd">-423000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-26" decimals="-3" id="f-291" unitRef="usd">-2882000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="c-1" decimals="-3" id="f-292" unitRef="usd">57000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="c-25" decimals="-3" id="f-293" unitRef="usd">-111000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="c-26" decimals="-3" id="f-294" unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-295" unitRef="usd">-6058000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-25" decimals="-3" id="f-296" unitRef="usd">-45855000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-26" decimals="-3" id="f-297" unitRef="usd">45836000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-3" id="f-298" unitRef="usd">2188000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-25" decimals="-3" id="f-299" unitRef="usd">-230000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-26" decimals="-3" id="f-300" unitRef="usd">-55000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-1" decimals="-3" id="f-301" unitRef="usd">1567000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-25" decimals="-3" id="f-302" unitRef="usd">-215000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-26" decimals="-3" id="f-303" unitRef="usd">-11009000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-1" decimals="-3" id="f-304" unitRef="usd">170000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-25" decimals="-3" id="f-305" unitRef="usd">7000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-26" decimals="-3" id="f-306" unitRef="usd">14045000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-307" unitRef="usd">-1530000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-25" decimals="-3" id="f-308" unitRef="usd">1281000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-26" decimals="-3" id="f-309" unitRef="usd">-10860000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-310" unitRef="usd">5003000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-25" decimals="-3" id="f-311" unitRef="usd">-4823000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-26" decimals="-3" id="f-312" unitRef="usd">-4638000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <mgnx:IncreaseDecreaseInLeaseLiabilities contextRef="c-1" decimals="-3" id="f-313" unitRef="usd">3490000</mgnx:IncreaseDecreaseInLeaseLiabilities>
    <mgnx:IncreaseDecreaseInLeaseLiabilities contextRef="c-25" decimals="-3" id="f-314" unitRef="usd">-861000</mgnx:IncreaseDecreaseInLeaseLiabilities>
    <mgnx:IncreaseDecreaseInLeaseLiabilities contextRef="c-26" decimals="-3" id="f-315" unitRef="usd">9364000</mgnx:IncreaseDecreaseInLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-316" unitRef="usd">-9414000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-25" decimals="-3" id="f-317" unitRef="usd">11426000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-26" decimals="-3" id="f-318" unitRef="usd">48821000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="c-1" decimals="-3" id="f-319" unitRef="usd">1710000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="c-25" decimals="-3" id="f-320" unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="c-26" decimals="-3" id="f-321" unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-322" unitRef="usd">-68373000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-25" decimals="-3" id="f-323" unitRef="usd">-78205000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-26" decimals="-3" id="f-324" unitRef="usd">-86959000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="-3" id="f-325" unitRef="usd">77182000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-25" decimals="-3" id="f-326" unitRef="usd">239683000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-26" decimals="-3" id="f-327" unitRef="usd">120602000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-1" decimals="-3" id="f-328" unitRef="usd">190025000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-25" decimals="-3" id="f-329" unitRef="usd">161299000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-26" decimals="-3" id="f-330" unitRef="usd">194940000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-331" unitRef="usd">3706000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-25" decimals="-3" id="f-332" unitRef="usd">1764000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-26" decimals="-3" id="f-333" unitRef="usd">3623000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfOtherProductiveAssets contextRef="c-1" decimals="-3" id="f-334" unitRef="usd">40000000</us-gaap:ProceedsFromSaleOfOtherProductiveAssets>
    <us-gaap:ProceedsFromSaleOfOtherProductiveAssets contextRef="c-25" decimals="-3" id="f-335" unitRef="usd">0</us-gaap:ProceedsFromSaleOfOtherProductiveAssets>
    <us-gaap:ProceedsFromSaleOfOtherProductiveAssets contextRef="c-26" decimals="-3" id="f-336" unitRef="usd">0</us-gaap:ProceedsFromSaleOfOtherProductiveAssets>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment contextRef="c-1" decimals="-3" id="f-337" unitRef="usd">160000</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment contextRef="c-25" decimals="-3" id="f-338" unitRef="usd">64000</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment contextRef="c-26" decimals="-3" id="f-339" unitRef="usd">0</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-340" unitRef="usd">149297000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-25" decimals="-3" id="f-341" unitRef="usd">-80084000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-26" decimals="-3" id="f-342" unitRef="usd">70715000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-343" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-25" decimals="-3" id="f-344" unitRef="usd">616000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-26" decimals="-3" id="f-345" unitRef="usd">1085000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases contextRef="c-1" decimals="-3" id="f-346" unitRef="usd">3435000</mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases>
    <mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases contextRef="c-25" decimals="-3" id="f-347" unitRef="usd">553000</mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases>
    <mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases contextRef="c-26" decimals="-3" id="f-348" unitRef="usd">574000</mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-349" unitRef="usd">2475000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-25" decimals="-3" id="f-350" unitRef="usd">306000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-26" decimals="-3" id="f-351" unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <mgnx:PrincipalPaymentsOnRoyaltyMonetizationArrangement contextRef="c-1" decimals="-3" id="f-352" unitRef="usd">0</mgnx:PrincipalPaymentsOnRoyaltyMonetizationArrangement>
    <mgnx:PrincipalPaymentsOnRoyaltyMonetizationArrangement contextRef="c-25" decimals="-3" id="f-353" unitRef="usd">157000</mgnx:PrincipalPaymentsOnRoyaltyMonetizationArrangement>
    <mgnx:PrincipalPaymentsOnRoyaltyMonetizationArrangement contextRef="c-26" decimals="-3" id="f-354" unitRef="usd">0</mgnx:PrincipalPaymentsOnRoyaltyMonetizationArrangement>
    <mgnx:NetProceedsFromSaleOfFutureRoyalties contextRef="c-1" decimals="-3" id="f-355" unitRef="usd">0</mgnx:NetProceedsFromSaleOfFutureRoyalties>
    <mgnx:NetProceedsFromSaleOfFutureRoyalties contextRef="c-25" decimals="-3" id="f-356" unitRef="usd">149655000</mgnx:NetProceedsFromSaleOfFutureRoyalties>
    <mgnx:NetProceedsFromSaleOfFutureRoyalties contextRef="c-26" decimals="-3" id="f-357" unitRef="usd">0</mgnx:NetProceedsFromSaleOfFutureRoyalties>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-358" unitRef="usd">960000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-25" decimals="-3" id="f-359" unitRef="usd">150361000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-26" decimals="-3" id="f-360" unitRef="usd">1659000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-361" unitRef="usd">81884000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-25" decimals="-3" id="f-362" unitRef="usd">-7928000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-26" decimals="-3" id="f-363" unitRef="usd">-14585000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-12" decimals="-3" id="f-364" unitRef="usd">100956000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-40" decimals="-3" id="f-365" unitRef="usd">108884000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-31" decimals="-3" id="f-366" unitRef="usd">123469000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-11" decimals="-3" id="f-367" unitRef="usd">182840000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-12" decimals="-3" id="f-368" unitRef="usd">100956000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-40" decimals="-3" id="f-369" unitRef="usd">108884000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid contextRef="c-1" decimals="-3" id="f-370" unitRef="usd">944000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-25" decimals="-5" id="f-371" unitRef="usd">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-26" decimals="-5" id="f-372" unitRef="usd">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-373" unitRef="usd">100000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-25" decimals="-3" id="f-374" unitRef="usd">505000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-26" decimals="-3" id="f-375" unitRef="usd">118000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-376">Organization and Nature of Operations&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MacroGenics, Inc. (the Company) is incorporated in the state of Delaware. The Company is a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates from its proprietary suite of antibody technology platforms. The Company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which is referred to as DART and TRIDENT molecules). The combination of the Company&#x2019;s technology platforms and antibody engineering expertise has allowed the Company to generate promising product candidates &#x2013; three of which have received marketing approval by the U.S. Food and Drug Administration (FDA) &#x2013; and to enter into several strategic collaborations with global biopharmaceutical companies. These collaborations have provided the Company with over $1.4&#160;billion of non-dilutive funding since its inception in 2000, and have enabled the Company to leverage the additional expertise of its collaborators to advance the development of multiple partnered product candidates. In addition, the Company operates a 5 &#xd7; 2,000 liter commercial-scale cGMP antibody manufacturing facility in its Maryland headquarters to support its clinical programs. The Company also provides outsourced contract development and manufacturing services to its collaborators and other third parties for commercial and clinical products to offset a portion of the operating costs of this facility. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is currently advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. The Company is also actively developing multiple preclinical-stage ADC and next generation T-cell engager programs. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and its partners are developing or commercializing product candidates for which the Company retain certain economic rights. These include three products approved by the FDA: MARGENZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (margetuximab-cmkb), an anti-HER2 monoclonal antibody (mAb) that the Company recently sold to a partner, ZYNYZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (retifanlimab-dlwr), an anti-PD-1 mAb that the Company out-licensed; and TZIELD&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (teplizumab-mzwv), an anti-CD3 mAb that the Company sold to a partner. The Company is also collaborating with &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gilead Sciences, Inc. (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gilead) on the development of MGD024, a bispecific DART antibody targeting CD123 and CD3 that utilizes its next-generation T-cell engager technology, as well as two additional undisclosed pre-clinical DART development programs. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s multiple product candidates currently under development will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The future success of the Company is dependent on its ability to identify and develop its product candidates, and ultimately upon its ability to attain profitable operations. The Company has devoted substantially all of its financial resources and efforts to research and development and general and administrative expense to support such research and development. Net losses and negative cash flows have had, and will continue to have, an adverse effect on the Company&#x2019;s stockholders&#x2019; equity and working capital, and accordingly, its ability to execute its future operating plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a biotechnology company, the Company has primarily funded its operations with proceeds from the sale of its common stock in equity offerings and revenue from its multiple collaboration agreements.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management regularly reviews the Company&#x2019;s available liquidity relative to its operating budget and forecast to monitor the sufficiency of the Company&#x2019;s working capital. The Company plans to meet its future operating requirements by generating revenue from current and future strategic collaborations or other arrangements and royalties.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company anticipates continuing to draw upon available sources of capital, including equity and debt instruments, to support its product development activities. If the Company is unable to enter into new arrangements or to perform under current or future agreements or obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of, or eliminate one or more of its product research and development programs or clinical studies, reduce other operating expenses, and/or downsize its organization. Based on the Company&#x2019;s most recent cash flow forecast, the Company believes its current resources are sufficient to fund its operating plans for a minimum of twelve months from the date that this Annual Report on Form 10-K was filed.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Similar to the other risk factors pertinent to the Company's business, including significant equity market volatility and availability of funding in the biotechnology sector, as well as potential issues in the global economy, credit markets and financial markets as a result of significant worldwide events, including inflation, fluctuating interest rates and geopolitical upheaval, might unfavorably impact the Company's ability to generate such additional funding. Given the uncertainty in the rapidly changing market and economic conditions related to these uncertainties, the Company will continue to evaluate the nature and extent of the impact of these uncertainties on its business and financial position.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <mgnx:NumberOfProductCandidatesApprovedByTheFoodAndDrugAdministration
      contextRef="c-1"
      decimals="INF"
      id="f-377"
      unitRef="productcandidate">3</mgnx:NumberOfProductCandidatesApprovedByTheFoodAndDrugAdministration>
    <mgnx:NonDilutiveFunding contextRef="c-57" decimals="-5" id="f-378" unitRef="usd">1400000000</mgnx:NonDilutiveFunding>
    <mgnx:NumberOfProprietaryProductCandidatesAdvancingInClinicalDevelopment
      contextRef="c-1"
      decimals="INF"
      id="f-379"
      unitRef="productcandidate">3</mgnx:NumberOfProprietaryProductCandidatesAdvancingInClinicalDevelopment>
    <mgnx:NumberOfProductCandidatesApprovedByTheFoodAndDrugAdministration
      contextRef="c-1"
      decimals="INF"
      id="f-380"
      unitRef="productcandidate">3</mgnx:NumberOfProductCandidatesApprovedByTheFoodAndDrugAdministration>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-381">Summary of Significant Accounting Policies&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited.&#160;All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is developing and commercializing monoclonal antibody-based therapeutics. See Note 13, Segment Reporting, for the Company&#x2019;s evaluation of its reportable segment and additional disclosures.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, inventory, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Although actual results could differ from these estimates, management does not believe that such differences would be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Classification of marketable securities between current and non-current is dependent upon the maturity date at the balance sheet date taking into consideration the Company&#x2019;s ability and intent to hold the investment to maturity. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income, along with interest income and amortization of premiums and discounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable arise from product sales, amounts due from the Company&#x2019;s collaborative partners and contract manufacturing work performed by the Company. The amount from product sales represents amounts due from specialty distributors. Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. No allowance was recorded as of December&#160;31, 2024 or 2023, as the Company has a history of collecting on all outstanding accounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 &#x2013; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 &#x2013; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 &#x2013; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#x2013; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers between levels during the periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets measured at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.616%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.612%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.852%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.108%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:15pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Total assets measured at fair value at December&#160;31, 2024 includes approximately $83.6 million reported as cash and cash equivalents and $18.8&#160;million reported as marketable securities on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b) Total assets measured at fair value at December&#160;31, 2023 includes approximately $91.7 million reported as cash and cash equivalents and $128.8&#160;million reported as marketable securities on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains its cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, the Company has not experienced any losses on related accounts to date.&#160;The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The counterparties are various corporations, financial institutions and government agencies of high credit standing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's revenue relates to agreements with various collaborators, MARGENZA net product sales (prior to the sale to TerSera Therapeutics LLC (TerSera) in November 2024) and&#160;contracts and research grants received from U.S. government agencies.&#160;The following table includes those counterparties that represent more than 10% of total revenue earned in the periods indicated:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.119%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.683%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incyte Corporation (Incyte)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Plasma &amp;amp; Biologics and McKesson Specialty Care Distribution LLC (McKesson)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ASD Healthcare and Oncology Supply (ASD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provention Bio, Inc. (Provention)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Zai Lab Limited (Zai Lab)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Amount is less than 10% for the period indicated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes those counterparties that represent more than 10% of accounts receivable at the date indicated:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.946%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.363%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.559%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.632%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incyte&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ASD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Zai Lab&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Balance is less than 10% as of the date indicated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When the Company believes regulatory approval is probable and expects future economic benefit from the sales of a product candidate to be realized, the Company capitalizes manufacturing costs (whether internally produced or through third-party contract manufacturing organizations) as inventory. Prior to receiving its first approval from the FDA in December 2020, the Company expensed all costs incurred related to the manufacture of MARGENZA as research and development expense because of the inherent risks associated with the development of a product candidate, the uncertainty about the regulatory approval process and the lack of history for the Company of regulatory approval of drug candidates. Subsequent to FDA approval in December 2020, the Company began capitalizing its MARGENZA third-party contract manufacturing inventory costs. In November 2024, the Company sold global rights to MARGENZA to TerSera. As part of this transaction, the Company transferred all of its inventory to TerSera.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is composed of raw materials, work-in-process, and finished goods, which are goods that are available for sale. The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and third-party contract manufacturing costs, on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess, obsolete or unsaleable inventories to their estimated realizable value in the period in which the impairment is first identified. Such write downs, should they occur, are recorded within the cost of product sales in the statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property, Equipment and Software&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, equipment and software are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred. Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.046%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.754%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of lease term or useful life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, Plant and Equipment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 360). ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. For the years ended December&#160;31, 2024, and 2023, the Company determined that there were no impaired assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue under ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customer&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s (ASC 606) when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative and Other Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into licensing agreements that are within the scope of ASC 606, under which it may license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products. The Company may also enter into development and manufacturing service agreements with its collaborators.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each arrangement that results in revenues, the Company identifies all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#x2019;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. The Company must develop assumptions that require judgment to determine the standalone selling price in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;order to account for these agreements. To determine the standalone selling price, the Company&#x2019;s assumptions may include (i) the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When the Company grants a license to its intellectual property, it &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;determines whether the &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nature of the intellectual property to which the customer will have rights is functional intellectual property (functional IP), which has significant standalone functionality, or symbolic intellectual property (symbolic IP) which does not have significant standalone functionality. Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to the Company&#x2019;s intellectual property&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research, Development and/or Manufacturing Services. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The promises under the Company&#x2019;s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Customer Options. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If an arrangement contains customer options, the Company evaluates whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined using assumptions regarding estimated costs, discount rates, post-option development timeline, the probability of technical and regulatory success and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by the Company. The Company accounts for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on ASC 606. The Company accounts for other components based on a reasonable, rational and consistently applied accounting policy election.&#160;Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For a complete discussion of accounting for revenue from collaborative and other agreements, see Note 8, Revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product sales, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the sale to TerSera, the Company entered into a limited number of arrangements with specialty distributors in the United States to distribute MARGENZA. These arrangements are considered to be contracts with customers and are in the scope of ASC 606. The Company has written contracts with each of its customers that have a single performance obligation - to deliver products upon receipt of a customer order - and these obligations are satisfied when delivery occurs and the customer receives the product. The specialty distributors subsequently resell the Company&#x2019;s product to healthcare providers. Product revenue is recorded net of applicable reserves for variable consideration, including discounts and other allowances. Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reserves for Variable Consideration. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration. Components of variable consideration typically include discounts, product returns, provider chargebacks and discounts and government rebates. Variable consideration is estimated following the expected value method in accordance with ASC 606 and includes such factors as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Customer Discounts and Service Fees. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may provide customers with discounts which are explicitly stated in the contracts. These discounts are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, these contracts may include written service arrangements whereby the Company pays fees to customers who provide services such as sales order management, data, contract administration and distribution services, at rates which the Company believes to be consistent with fair market value. The Company has determined such services received to date are not distinct from the Company&#x2019;s sale of products to its customers and, therefore, these payments have been recorded as a reduction of revenue within the statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Returns. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with industry practice, the Company offers the specialty distributors product return rights pursuant to written contracts and/or Company returned goods policies. The Company estimates the amount of its product sales that may be returned by its customers and records an estimated liability and a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product returns using industry benchmarking as well as other information available, such as visibility into the inventory remaining in the distribution channel, since the Company does not have its own returns experience. The Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provider Chargebacks and Discounts. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks for fees and discounts to healthcare providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. In such cases, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. The reserve for chargebacks is established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer&#x2019;s notification to the Company of the resale. Chargebacks consist of credits the Company expects to issue for units that remain in the distribution channel at each reporting period end that the Company expects will be sold to qualified healthcare providers and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Rebates. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to discount and/or rebate obligations under state Medicaid programs, Medicare and contractual agreements with and statutory obligations to certain Federal and State entities. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. The Company&#x2019;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer discounts are recorded as a reduction of accounts receivable on the consolidated balance sheets. Allowance for product returns, provider chargebacks, government and other rebates and service fees are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract manufacturing revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into agreements with third parties to manufacture their drug substance at its Good Manufacturing Practice (GMP) facility. The terms of these arrangements can include an upfront payment to the Company to reserve manufacturing capacity, scheduled payments during the manufacturing process and reimbursement for materials used to manufacture product.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue over time on a straight-line basis as the manufacturing services are performed, as the Company believes that its efforts in providing the manufacturing services are incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product are allocated to the related manufacturing activities and are recognized as revenue as those activities occur.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Cost of Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the sale to TerSera, cost of product sales related to sales of MARGENZA. These costs include material, manufacturing and shipping costs, as well as royalties payable on net sales of MARGENZA and inventory reserves. All product costs incurred prior to FDA approval of MARGENZA in December 2020 were expensed as research and development expense. As a result, cost of product sales was positively impacted as the Company sold through inventory that was expensed prior to FDA approval of MARGENZA. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Manufacturing Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of manufacturing services consists of the costs to provide manufacturing services to produce certain bulk drug substance under manufacturing and clinical supply agreements with third parties, including salaries and benefits and related stock-based compensation, materials, overhead and other related costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expense, Including Clinical Trial Accruals/Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations (CROs), investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials, including costs incurred under agreements with contract manufacturing organizations (CMOs), and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities. Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Clinical trial expenses are a significant component of research and development expense, and the Company outsources a significant portion of these costs to third parties. Third party clinical trial expenses include investigator fees, site and patient costs, CRO costs, costs for central laboratory testing, data management and CMO costs. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as a prepaid asset or accrued expenses. These third party agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; When evaluating the adequacy of the accrued expenses, management analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether an arrangement is or contains a lease at the inception of an arrangement under ASC 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. For leases where the Company is the lessee, right-of-use (ROU) assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term of the lease for which the rate is estimated. Certain adjustments to the ROU asset may be required for items such as initial direct costs paid or incentives received. The lease terms used to calculate the ROU asset and related lease liabilities include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while the expense for finance leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. All stock options and restricted stock units (RSUs) are excluded from the per share calculations as such securities were anti-dilutive for all periods presented. The following table presents the number of stock options and RSUs that were excluded from the calculation of net loss per share:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.036%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.015%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.015%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.380%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options and RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,008,511&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,129,251&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,514,013&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued Accounting Standards Update (ASU) No. 2024-03, Disaggregation of Income Statement Expense. The standard requires further disaggregation of relevant expense captions in a separate note to the financial statements. The standard is effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is currently assessing the impact of adopting this guidance on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740). The standard requires disaggregation of the effective rate reconciliation into standard categories, enhances disclosure of income taxes paid, and modifies other income tax-related disclosures. The standard is effective for fiscal years beginning after December 15, 2024. The Company is currently assessing the impact of adopting this guidance on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which is intended to improve reportable segment disclosures, primarily through enhanced disclosures about significant segment expenses, as well as how the chief operating decision maker (CODM) uses the reported measure(s) of segment profit or loss in assessing performance. The ASU also requires all annual disclosures currently required by Topic 280 to be included in interim periods. The Company adopted the standard in the fourth quarter of 2024. The adoption did not have a material impact on its consolidated financial statements. See Note 13, Segment Reporting, for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-382">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited.&#160;All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is developing and commercializing monoclonal antibody-based therapeutics. See Note 13, Segment Reporting, for the Company&#x2019;s evaluation of its reportable segment and additional disclosures.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-383"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-384"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-385">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, inventory, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Although actual results could differ from these estimates, management does not believe that such differences would be material.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-386">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Classification of marketable securities between current and non-current is dependent upon the maturity date at the balance sheet date taking into consideration the Company&#x2019;s ability and intent to hold the investment to maturity. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income, along with interest income and amortization of premiums and discounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c-1" id="f-387">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable arise from product sales, amounts due from the Company&#x2019;s collaborative partners and contract manufacturing work performed by the Company. The amount from product sales represents amounts due from specialty distributors. Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. No allowance was recorded as of December&#160;31, 2024 or 2023, as the Company has a history of collecting on all outstanding accounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-12" decimals="INF" id="f-388" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-11" decimals="INF" id="f-389" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c-1" id="f-390">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 &#x2013; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 &#x2013; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 &#x2013; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#x2013; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy. &lt;/span&gt;There were no transfers between levels during the periods presented.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="c-1" id="f-391">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets measured at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.616%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.612%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.852%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.108%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:15pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Total assets measured at fair value at December&#160;31, 2024 includes approximately $83.6 million reported as cash and cash equivalents and $18.8&#160;million reported as marketable securities on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b) Total assets measured at fair value at December&#160;31, 2023 includes approximately $91.7 million reported as cash and cash equivalents and $128.8&#160;million reported as marketable securities on the balance sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-58" decimals="-3" id="f-392" unitRef="usd">67886000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-59" decimals="-3" id="f-393" unitRef="usd">67886000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-60" decimals="-3" id="f-394" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-61" decimals="-3" id="f-395" unitRef="usd">5000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-62" decimals="-3" id="f-396" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-63" decimals="-3" id="f-397" unitRef="usd">5000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-64" decimals="-3" id="f-398" unitRef="usd">3994000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-65" decimals="-3" id="f-399" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-66" decimals="-3" id="f-400" unitRef="usd">3994000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-67" decimals="-3" id="f-401" unitRef="usd">25548000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-68" decimals="-3" id="f-402" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-69" decimals="-3" id="f-403" unitRef="usd">25548000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-70" decimals="-3" id="f-404" unitRef="usd">102428000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-71" decimals="-3" id="f-405" unitRef="usd">67886000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-72" decimals="-3" id="f-406" unitRef="usd">34542000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-73" decimals="-3" id="f-407" unitRef="usd">91665000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-74" decimals="-3" id="f-408" unitRef="usd">91665000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-75" decimals="-3" id="f-409" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-76" decimals="-3" id="f-410" unitRef="usd">31179000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-77" decimals="-3" id="f-411" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-78" decimals="-3" id="f-412" unitRef="usd">31179000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-79" decimals="-3" id="f-413" unitRef="usd">45043000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-80" decimals="-3" id="f-414" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-81" decimals="-3" id="f-415" unitRef="usd">45043000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-82" decimals="-3" id="f-416" unitRef="usd">52627000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-83" decimals="-3" id="f-417" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-84" decimals="-3" id="f-418" unitRef="usd">52627000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-85" decimals="-3" id="f-419" unitRef="usd">220514000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-86" decimals="-3" id="f-420" unitRef="usd">91665000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-87" decimals="-3" id="f-421" unitRef="usd">128849000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-11" decimals="-5" id="f-422" unitRef="usd">83600000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:Investments contextRef="c-11" decimals="-5" id="f-423" unitRef="usd">18800000</us-gaap:Investments>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-12" decimals="-5" id="f-424" unitRef="usd">91700000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:Investments contextRef="c-12" decimals="-5" id="f-425" unitRef="usd">128800000</us-gaap:Investments>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-426">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains its cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, the Company has not experienced any losses on related accounts to date.&#160;The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The counterparties are various corporations, financial institutions and government agencies of high credit standing.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="c-1" id="f-427">The following table includes those counterparties that represent more than 10% of total revenue earned in the periods indicated:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.119%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.683%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incyte Corporation (Incyte)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Plasma &amp;amp; Biologics and McKesson Specialty Care Distribution LLC (McKesson)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ASD Healthcare and Oncology Supply (ASD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provention Bio, Inc. (Provention)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Zai Lab Limited (Zai Lab)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Amount is less than 10% for the period indicated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes those counterparties that represent more than 10% of accounts receivable at the date indicated:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.946%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.363%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.559%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.632%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incyte&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ASD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Zai Lab&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Balance is less than 10% as of the date indicated.&lt;/span&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-88" decimals="2" id="f-428" unitRef="number">0.76</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-89" decimals="2" id="f-429" unitRef="number">0.53</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-90" decimals="2" id="f-430" unitRef="number">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-91" decimals="2" id="f-431" unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-92" decimals="2" id="f-432" unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-93" decimals="2" id="f-433" unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-94" decimals="2" id="f-434" unitRef="number">0.43</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-95" decimals="2" id="f-435" unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-96" decimals="2" id="f-436" unitRef="number">0.39</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-97" decimals="2" id="f-437" unitRef="number">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-98" decimals="2" id="f-438" unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-99" decimals="2" id="f-439" unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-100" decimals="2" id="f-440" unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-101" decimals="2" id="f-441" unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-102" decimals="2" id="f-442" unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-103" decimals="2" id="f-443" unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-104" decimals="2" id="f-444" unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:InventoryPolicyTextBlock contextRef="c-1" id="f-445">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When the Company believes regulatory approval is probable and expects future economic benefit from the sales of a product candidate to be realized, the Company capitalizes manufacturing costs (whether internally produced or through third-party contract manufacturing organizations) as inventory. Prior to receiving its first approval from the FDA in December 2020, the Company expensed all costs incurred related to the manufacture of MARGENZA as research and development expense because of the inherent risks associated with the development of a product candidate, the uncertainty about the regulatory approval process and the lack of history for the Company of regulatory approval of drug candidates. Subsequent to FDA approval in December 2020, the Company began capitalizing its MARGENZA third-party contract manufacturing inventory costs. In November 2024, the Company sold global rights to MARGENZA to TerSera. As part of this transaction, the Company transferred all of its inventory to TerSera.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is composed of raw materials, work-in-process, and finished goods, which are goods that are available for sale. The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and third-party contract manufacturing costs, on a first-in, first-out basis. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess, obsolete or unsaleable inventories to their estimated realizable value in the period in which the impairment is first identified. Such write downs, should they occur, are recorded within the cost of product sales in the statement of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-446">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property, Equipment and Software&lt;/span&gt;&lt;/div&gt;Property, equipment and software are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <mgnx:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock contextRef="c-1" id="f-447">Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.046%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.754%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of lease term or useful life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mgnx:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-105" id="f-448">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-106" id="f-449">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-107" id="f-450">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-108" id="f-451">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c-1" id="f-452">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, Plant and Equipment &lt;/span&gt;(ASC 360). ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-25" decimals="INF" id="f-453" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-1" decimals="INF" id="f-454" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c-1" id="f-455">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue under ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customer&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s (ASC 606) when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative and Other Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into licensing agreements that are within the scope of ASC 606, under which it may license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products. The Company may also enter into development and manufacturing service agreements with its collaborators.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each arrangement that results in revenues, the Company identifies all performance obligations, which may include a license to intellectual property and know-how, research and development activities, transition activities and/or manufacturing services. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company&#x2019;s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is generally allocated to each separate performance obligation on a relative standalone selling price basis. The Company must develop assumptions that require judgment to determine the standalone selling price in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;order to account for these agreements. To determine the standalone selling price, the Company&#x2019;s assumptions may include (i) the probability of obtaining marketing approval for the product candidate, (ii) estimates regarding the timing and the expected costs to develop and commercialize the product candidate, and (iii) estimates of future cash flows from potential product sales with respect to the product candidate. Standalone selling prices used to perform the initial allocation are not updated after contract inception. The Company does not include a financing component to its estimated transaction price at contract inception unless it estimates that certain performance obligations will not be satisfied within one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#160;months following the balance sheet date are classified as deferred revenue, net of current portion. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When the Company grants a license to its intellectual property, it &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;determines whether the &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nature of the intellectual property to which the customer will have rights is functional intellectual property (functional IP), which has significant standalone functionality, or symbolic intellectual property (symbolic IP) which does not have significant standalone functionality. Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to the Company&#x2019;s intellectual property&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and when (or as) the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the licensee and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the licensee can benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount of revenue the Company records in future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research, Development and/or Manufacturing Services. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The promises under the Company&#x2019;s agreements may include research and development or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Customer Options. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If an arrangement contains customer options, the Company evaluates whether the options are material rights because they allow the customer to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined using assumptions regarding estimated costs, discount rates, post-option development timeline, the probability of technical and regulatory success and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If the options are deemed not to be a material right, they are excluded as performance obligations at the outset of the arrangement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties who are both active participants in the activities and are both exposed to significant risks and rewards dependent on the commercial success of such activities. Such arrangements generally are within the scope of ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 808). While ASC 808 defines collaborative arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and measurement matters, such as (1)&#160;determining the appropriate unit of accounting or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by the Company. The Company accounts for certain components of the collaboration agreement that are reflective of a vendor-customer relationship (e.g., licensing arrangement) based on ASC 606. The Company accounts for other components based on a reasonable, rational and consistently applied accounting policy election.&#160;Reimbursements from the counter-party that are the result of a collaborative relationship with the counter-party, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense as the services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For a complete discussion of accounting for revenue from collaborative and other agreements, see Note 8, Revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product sales, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the sale to TerSera, the Company entered into a limited number of arrangements with specialty distributors in the United States to distribute MARGENZA. These arrangements are considered to be contracts with customers and are in the scope of ASC 606. The Company has written contracts with each of its customers that have a single performance obligation - to deliver products upon receipt of a customer order - and these obligations are satisfied when delivery occurs and the customer receives the product. The specialty distributors subsequently resell the Company&#x2019;s product to healthcare providers. Product revenue is recorded net of applicable reserves for variable consideration, including discounts and other allowances. Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reserves for Variable Consideration. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration. Components of variable consideration typically include discounts, product returns, provider chargebacks and discounts and government rebates. Variable consideration is estimated following the expected value method in accordance with ASC 606 and includes such factors as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Customer Discounts and Service Fees. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may provide customers with discounts which are explicitly stated in the contracts. These discounts are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, these contracts may include written service arrangements whereby the Company pays fees to customers who provide services such as sales order management, data, contract administration and distribution services, at rates which the Company believes to be consistent with fair market value. The Company has determined such services received to date are not distinct from the Company&#x2019;s sale of products to its customers and, therefore, these payments have been recorded as a reduction of revenue within the statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Returns. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with industry practice, the Company offers the specialty distributors product return rights pursuant to written contracts and/or Company returned goods policies. The Company estimates the amount of its product sales that may be returned by its customers and records an estimated liability and a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product returns using industry benchmarking as well as other information available, such as visibility into the inventory remaining in the distribution channel, since the Company does not have its own returns experience. The Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provider Chargebacks and Discounts. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks for fees and discounts to healthcare providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. In such cases, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. The reserve for chargebacks is established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer&#x2019;s notification to the Company of the resale. Chargebacks consist of credits the Company expects to issue for units that remain in the distribution channel at each reporting period end that the Company expects will be sold to qualified healthcare providers and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Rebates. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to discount and/or rebate obligations under state Medicaid programs, Medicare and contractual agreements with and statutory obligations to certain Federal and State entities. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. The Company&#x2019;s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer discounts are recorded as a reduction of accounts receivable on the consolidated balance sheets. Allowance for product returns, provider chargebacks, government and other rebates and service fees are recorded as a component of accrued expenses and other current liabilities on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract manufacturing revenue&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into agreements with third parties to manufacture their drug substance at its Good Manufacturing Practice (GMP) facility. The terms of these arrangements can include an upfront payment to the Company to reserve manufacturing capacity, scheduled payments during the manufacturing process and reimbursement for materials used to manufacture product.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue over time on a straight-line basis as the manufacturing services are performed, as the Company believes that its efforts in providing the manufacturing services are incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product are allocated to the related manufacturing activities and are recognized as revenue as those activities occur.&lt;/span&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="c-1" id="f-456">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Cost of Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the sale to TerSera, cost of product sales related to sales of MARGENZA. These costs include material, manufacturing and shipping costs, as well as royalties payable on net sales of MARGENZA and inventory reserves. All product costs incurred prior to FDA approval of MARGENZA in December 2020 were expensed as research and development expense. As a result, cost of product sales was positively impacted as the Company sold through inventory that was expensed prior to FDA approval of MARGENZA. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Manufacturing Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of manufacturing services consists of the costs to provide manufacturing services to produce certain bulk drug substance under manufacturing and clinical supply agreements with third parties, including salaries and benefits and related stock-based compensation, materials, overhead and other related costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-457">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expense, Including Clinical Trial Accruals/Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations (CROs), investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials, including costs incurred under agreements with contract manufacturing organizations (CMOs), and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities. Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Clinical trial expenses are a significant component of research and development expense, and the Company outsources a significant portion of these costs to third parties. Third party clinical trial expenses include investigator fees, site and patient costs, CRO costs, costs for central laboratory testing, data management and CMO costs. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as a prepaid asset or accrued expenses. These third party agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; When evaluating the adequacy of the accrued expenses, management analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-458">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether an arrangement is or contains a lease at the inception of an arrangement under ASC 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;. For leases where the Company is the lessee, right-of-use (ROU) assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term of the lease for which the rate is estimated. Certain adjustments to the ROU asset may be required for items such as initial direct costs paid or incentives received. The lease terms used to calculate the ROU asset and related lease liabilities include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while the expense for finance leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c-1" id="f-459">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-460">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;Basic and diluted loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. All stock options and restricted stock units (RSUs) are excluded from the per share calculations as such securities were anti-dilutive for all periods presented.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-461">The following table presents the number of stock options and RSUs that were excluded from the calculation of net loss per share:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.036%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.015%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.015%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.380%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options and RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,008,511&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,129,251&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,514,013&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-109" decimals="0" id="f-462" unitRef="shares">14008511</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-110" decimals="0" id="f-463" unitRef="shares">13129251</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-111" decimals="0" id="f-464" unitRef="shares">10514013</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-465">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued Accounting Standards Update (ASU) No. 2024-03, Disaggregation of Income Statement Expense. The standard requires further disaggregation of relevant expense captions in a separate note to the financial statements. The standard is effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is currently assessing the impact of adopting this guidance on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740). The standard requires disaggregation of the effective rate reconciliation into standard categories, enhances disclosure of income taxes paid, and modifies other income tax-related disclosures. The standard is effective for fiscal years beginning after December 15, 2024. The Company is currently assessing the impact of adopting this guidance on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which is intended to improve reportable segment disclosures, primarily through enhanced disclosures about significant segment expenses, as well as how the chief operating decision maker (CODM) uses the reported measure(s) of segment profit or loss in assessing performance. The ASU also requires all annual disclosures currently required by Topic 280 to be included in interim periods. The Company adopted the standard in the fourth quarter of 2024. The adoption did not have a material impact on its consolidated financial statements. See Note 13, Segment Reporting, for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="c-1" id="f-466">Marketable Securities&lt;div style="margin-bottom:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale marketable securities as of December&#160;31, 2024 and 2023 were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company's available-for-sale securities held at December&#160;31, 2024 and 2023 had contractual maturities of less than one year. All of the Company&#x2019;s available-for-sale marketable debt securities in an unrealized loss position as of December&#160;31, 2023 were in a loss position for less than twelve months.&#160;Unrealized losses on available-for-sale debt securities as of December&#160;31, 2023 &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;were not &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities. Accordingly, no allowance for credit losses related to the Company's available-for-sale debt securities was recorded for the years ended &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2024 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023. The Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded interest income of $5.6 million, $4.0 million and $1.7 million during the years ended December&#160;31, 2024, 2023 and 2022, respectively, which is included in interest and other income on the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="c-1" id="f-467">&lt;div style="margin-bottom:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available-for-sale marketable securities as of December&#160;31, 2024 and 2023 were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-112" decimals="-3" id="f-468" unitRef="usd">1995000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-112" decimals="-3" id="f-469" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-112" decimals="-3" id="f-470" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-112" decimals="-3" id="f-471" unitRef="usd">1995000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-113" decimals="-3" id="f-472" unitRef="usd">16828000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-113" decimals="-3" id="f-473" unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-113" decimals="-3" id="f-474" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-113" decimals="-3" id="f-475" unitRef="usd">16832000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-11" decimals="-3" id="f-476" unitRef="usd">18823000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-11" decimals="-3" id="f-477" unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-11" decimals="-3" id="f-478" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-11" decimals="-3" id="f-479" unitRef="usd">18827000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-114" decimals="-3" id="f-480" unitRef="usd">31177000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-114" decimals="-3" id="f-481" unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-114" decimals="-3" id="f-482" unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-114" decimals="-3" id="f-483" unitRef="usd">31179000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-115" decimals="-3" id="f-484" unitRef="usd">45041000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-115" decimals="-3" id="f-485" unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-115" decimals="-3" id="f-486" unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-115" decimals="-3" id="f-487" unitRef="usd">45043000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-116" decimals="-3" id="f-488" unitRef="usd">52637000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-116" decimals="-3" id="f-489" unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-116" decimals="-3" id="f-490" unitRef="usd">15000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-116" decimals="-3" id="f-491" unitRef="usd">52627000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-12" decimals="-3" id="f-492" unitRef="usd">128855000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-12" decimals="-3" id="f-493" unitRef="usd">16000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-12" decimals="-3" id="f-494" unitRef="usd">22000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-12" decimals="-3" id="f-495" unitRef="usd">128849000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss contextRef="c-12" decimals="INF" id="f-496" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss contextRef="c-11" decimals="INF" id="f-497" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:InterestIncomeOther contextRef="c-1" decimals="-5" id="f-498" unitRef="usd">5600000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther contextRef="c-25" decimals="-5" id="f-499" unitRef="usd">4000000.0</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther contextRef="c-26" decimals="-5" id="f-500" unitRef="usd">1700000</us-gaap:InterestIncomeOther>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c-1" id="f-501">Inventory, Net&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company's inventory relates to the manufacturing of MARGENZA. In November 2024, the Company sold global rights to MARGENZA to TerSera. As part of this transaction, the Company transferred all its inventory to TerSera, resulting in no inventory balance on the Company&#x2019;s consolidated balance sheet as of December 31, 2024. The following table sets forth the Company's inventory as of December 31, 2023, net of reserves (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.487%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to FDA approval of MARGENZA in December 2020, the cost of materials and expenses associated with the manufacturing of MARGENZA were recorded as research and development expense. Subsequent to FDA approval, the Company began capitalizing inventory costs related to the manufacture of MARGENZA. The inventory balance as of December&#160;31, 2023 is net of a reserve of $3.1 million, for unsaleable inventory. These reserves are reflected in cost of product sales during the period they are recorded.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.952%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inventory Reserves (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at Beginning of Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Additions Charged to Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at End of Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December&#160;31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,798)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:InventoryNet contextRef="c-11" decimals="INF" id="f-502" unitRef="usd">0</us-gaap:InventoryNet>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-503">The following table sets forth the Company's inventory as of December 31, 2023, net of reserves (in thousands):&lt;div style="margin-top:9pt;text-indent:31.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.487%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryWorkInProcess contextRef="c-12" decimals="-3" id="f-504" unitRef="usd">261000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods contextRef="c-12" decimals="-3" id="f-505" unitRef="usd">960000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet contextRef="c-12" decimals="-3" id="f-506" unitRef="usd">1221000</us-gaap:InventoryNet>
    <us-gaap:InventoryValuationReserves contextRef="c-12" decimals="-5" id="f-507" unitRef="usd">3100000</us-gaap:InventoryValuationReserves>
    <mgnx:ScheduleOfInventoryReservesTableTextBlock contextRef="c-1" id="f-508">&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.952%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Inventory Reserves (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at Beginning of Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Additions Charged to Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at End of Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December&#160;31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,798)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mgnx:ScheduleOfInventoryReservesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-117" decimals="-3" id="f-509" unitRef="usd">3119000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-118" decimals="-3" id="f-510" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-118" decimals="-3" id="f-511" unitRef="usd">3119000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-119" decimals="-3" id="f-512" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-120" decimals="-3" id="f-513" unitRef="usd">4917000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-121" decimals="-3" id="f-514" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-121" decimals="-3" id="f-515" unitRef="usd">1798000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-117" decimals="-3" id="f-516" unitRef="usd">3119000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-122" decimals="-3" id="f-517" unitRef="usd">2035000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-123" decimals="-3" id="f-518" unitRef="usd">2882000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-123" decimals="-3" id="f-519" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-120" decimals="-3" id="f-520" unitRef="usd">4917000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-521">Property, Equipment and Software&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, equipment and software consists of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.706%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Motor vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88,687)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88,394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, equipment and software, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense related to property, equipment and software for the years ended December&#160;31, 2024, 2023 and 2022 was $7.5 million, $9.6 million and $11.9 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-522">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, equipment and software consists of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.706%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Motor vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88,687)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88,394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, equipment and software, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-105" decimals="-3" id="f-523" unitRef="usd">3661000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-124" decimals="-3" id="f-524" unitRef="usd">3542000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-106" decimals="-3" id="f-525" unitRef="usd">10926000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-125" decimals="-3" id="f-526" unitRef="usd">9759000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-126" decimals="-3" id="f-527" unitRef="usd">697000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-127" decimals="-3" id="f-528" unitRef="usd">706000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-128" decimals="-3" id="f-529" unitRef="usd">50000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-129" decimals="-3" id="f-530" unitRef="usd">50000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-130" decimals="-3" id="f-531" unitRef="usd">46140000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-131" decimals="-3" id="f-532" unitRef="usd">46452000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-132" decimals="-3" id="f-533" unitRef="usd">44097000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-133" decimals="-3" id="f-534" unitRef="usd">48620000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:ConstructionInProgressGross contextRef="c-11" decimals="-3" id="f-535" unitRef="usd">1216000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross contextRef="c-12" decimals="-3" id="f-536" unitRef="usd">1112000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-11" decimals="-3" id="f-537" unitRef="usd">106787000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-12" decimals="-3" id="f-538" unitRef="usd">110241000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-11" decimals="-3" id="f-539" unitRef="usd">88687000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-12" decimals="-3" id="f-540" unitRef="usd">88394000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-11" decimals="-3" id="f-541" unitRef="usd">18100000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-12" decimals="-3" id="f-542" unitRef="usd">21847000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c-1" decimals="-5" id="f-543" unitRef="usd">7500000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-25" decimals="-5" id="f-544" unitRef="usd">9600000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-26" decimals="-5" id="f-545" unitRef="usd">11900000</us-gaap:Depreciation>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-546">Commitments and Contingencies&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has non-cancelable operating leases for manufacturing, laboratory, office and warehouse space in Maryland. The Company&#x2019;s leases each have one or more five-year options to renew&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In October 2024, the Company amended the existing lease for one of its laboratory spaces to extend the lease term through 2029 in exchange for certain concessions from the lessor. This amendment was accounted for as a lease modification, and the right-of-use asset and lease liability were remeasured at the modification date, resulting in an increase to both balances of approximately $3.0 million.&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents supplemental balance sheet information related to operating leases:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.092%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.013%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2024 and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 2023, t&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he Company made cash payments for operating leases of $3.8 million and $5.9 million, respectively. As of December&#160;31, 2024 and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 2023,&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the Company&#x2019;s ROU assets were valued at $24.5 million and $23.8 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease cost for the years ended &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 2023 were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.225%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.946%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.948%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Sublease income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,145)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the maturities of the Company&#x2019;s operating lease liabilities were as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.473%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.327%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,021)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;In-licensing arrangement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, the Company entered into a non-exclusive license agreement with Synaffix B.V., a Lonza company, (Synaffix) to develop, manufacture and commercialize up to three antibody-drug conjugate targets using Synaffix&#x2019;s proprietary technology. The Company made an upfront payment to Synaffix upon contract execution. In March 2023, the Company and Synaffix amended the agreement, adding four additional targets. Assuming all seven targets are successfully developed and commercialized, the Company would be obligated to pay up to $2.8&#160;billion for development, regulatory and sales milestones. Finally, pursuant to the terms of this license agreement, as amended, upon commencement of commercial sales of any products developed from these targets, the Company would be required to pay Synaffix tiered royalties in the low&#x2011;single digit percentages on net sales of the respective products. The Company may terminate this agreement at any time with 30 days&#x2019; notice to Synaffix. Amounts paid to Synaffix under this agreement are recorded as research and development expense in the consolidated statement of operations. The Company incurred $4.7&#160;million, $2.8&#160;million and $1.0 million in expense under this agreement during the years ended December&#160;31, 2024, 2023 and 2022, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2024, a putative securities class action suit, entitled Crain v. MacroGenics, Inc. (Case No. 24-cv-02184), was filed in the U.S. District Court for the District of Maryland against the Company and Scott Koenig, M.D., Ph.D., the Company&#x2019;s President, Chief Executive Officer and a member of the Company&#x2019;s Board of Directors, alleging violations of securities laws during 2024. The suit asserted certain claims under Section 10 and Rule 10b-5 of the Securities and Exchange Act of 1934 based on alleged misstatements or omissions concerning the Company's TAMARACK Phase 2 study of vobramitamab duocarmazine in patients with metastatic castration-resistant prostate cancer. On December 20, 2024, the District Court issued an Order dismissing the case, without prejudice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 9, 2024, a shareholder derivative suit, entitled Gregora v. Heiden et al. (Case No. 24-cv-03546), was filed in the U.S. District Court for the District of Maryland against certain of the Company&#x2019;s officers and directors and naming the Company as a nominal defendant. The suit asserts certain claims under Section 10(b) and Rule 10b-5 of the Securities and Exchange Act of 1934 and for breach of fiduciary duty, aiding and abetting breach of fiduciary duty, unjust enrichment, and waste of corporate assets based on the same facts as the Securities Class Action. On March 10, 2025, the plaintiff filed a notice of voluntary dismissal. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 11, 2024, a shareholder derivative suit, entitled Cottle v. MacroGenics, Inc., et al. (Case No. 8:24-cv-03578), was filed in the U.S. District Court for the District of Maryland against the same defendants and alleging similar claims as the Gregora derivative action. On March 20, 2025, the parties filed a stipulation of dismissal without prejudice.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-134" id="f-547">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <mgnx:RightOfUseAssetAndLeaseLiabilityIncrease contextRef="c-11" decimals="-5" id="f-548" unitRef="usd">3000000.0</mgnx:RightOfUseAssetAndLeaseLiabilityIncrease>
    <mgnx:ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock contextRef="c-1" id="f-549">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents supplemental balance sheet information related to operating leases:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.092%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.013%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mgnx:ScheduleOfSupplementalBalanceSheetInformationOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-11" id="f-550">P10Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-12" id="f-551">P11Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseDiscountRate contextRef="c-11" decimals="3" id="f-552" unitRef="number">0.120</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseDiscountRate contextRef="c-12" decimals="3" id="f-553" unitRef="number">0.120</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-5" id="f-554" unitRef="usd">3800000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-25" decimals="-5" id="f-555" unitRef="usd">5900000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-11" decimals="-5" id="f-556" unitRef="usd">24500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-12" decimals="-5" id="f-557" unitRef="usd">23800000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-558">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease cost for the years ended &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 2023 were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.225%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.946%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.948%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Sublease income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,145)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-3" id="f-559" unitRef="usd">6610000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-25" decimals="-3" id="f-560" unitRef="usd">7459000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-1" decimals="-3" id="f-561" unitRef="usd">1114000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-25" decimals="-3" id="f-562" unitRef="usd">1316000</us-gaap:VariableLeaseCost>
    <us-gaap:SubleaseIncome contextRef="c-1" decimals="-3" id="f-563" unitRef="usd">1145000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-25" decimals="-3" id="f-564" unitRef="usd">1109000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-3" id="f-565" unitRef="usd">6579000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-25" decimals="-3" id="f-566" unitRef="usd">7666000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-567">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the maturities of the Company&#x2019;s operating lease liabilities were as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.473%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.327%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,021)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-11" decimals="-3" id="f-568" unitRef="usd">5185000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-11" decimals="-3" id="f-569" unitRef="usd">5507000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-11" decimals="-3" id="f-570" unitRef="usd">6258000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-11" decimals="-3" id="f-571" unitRef="usd">7413000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-11" decimals="-3" id="f-572" unitRef="usd">6346000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-11" decimals="-3" id="f-573" unitRef="usd">39773000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-11" decimals="-3" id="f-574" unitRef="usd">70482000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-11" decimals="-3" id="f-575" unitRef="usd">33021000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-11" decimals="-3" id="f-576" unitRef="usd">37461000</us-gaap:OperatingLeaseLiability>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement contextRef="c-135" decimals="-5" id="f-577" unitRef="usd">2800000000</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-136" decimals="-5" id="f-578" unitRef="usd">4700000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-137" decimals="-5" id="f-579" unitRef="usd">2800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-138" decimals="-5" id="f-580" unitRef="usd">1000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-581">Stockholders' Equity&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's amended and restated certificate of incorporation authorizes 125,000,000 shares of common stock, and 5,000,000 shares of undesignated preferred stock, both with a par value of $0.01 per share.&#160;There were no shares of undesignated preferred stock issued or outstanding as of December&#160;31, 2024 or 2023. &lt;/span&gt;&lt;/div&gt;In March 2023, the Company entered into a sales agreement with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to $100.0&#160;million through an &#x201c;at the market offering&#x201d; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended. During the year ended December 31, 2023, the Company sold 95,000 shares of common stock at a weighted average price per share of $6.60, resulting in net proceeds of approximately $0.6&#160;million, net of offering expenses. No shares were sold under the ATM offering during the year ended December 31, 2024.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-11"
      decimals="INF"
      id="f-582"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-139"
      decimals="INF"
      id="f-583"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-139"
      decimals="INF"
      id="f-584"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-140"
      decimals="INF"
      id="f-585"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-139"
      decimals="INF"
      id="f-586"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-139"
      decimals="INF"
      id="f-587"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-140"
      decimals="INF"
      id="f-588"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-140"
      decimals="INF"
      id="f-589"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <mgnx:CommonStockMaximumAmountAvailableForIssuance contextRef="c-141" decimals="-5" id="f-590" unitRef="usd">100000000</mgnx:CommonStockMaximumAmountAvailableForIssuance>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-142"
      decimals="INF"
      id="f-591"
      unitRef="shares">95000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-143"
      decimals="2"
      id="f-592"
      unitRef="usdPerShare">6.60</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-142" decimals="-5" id="f-593" unitRef="usd">600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-144"
      decimals="INF"
      id="f-594"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock contextRef="c-1" id="f-595">Revenue&lt;div style="margin-bottom:9pt;margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Collaborative and Other Agreements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Incyte Corporation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Incyte License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte, which was amended in March 2018, April 2022, July 2022, and July 2024, for retifanlimab, an investigational monoclonal antibody that inhibits PD-1 (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while the Company retains the right to develop its pipeline assets in combination with retifanlimab. Under the terms of the Incyte License Agreement, Incyte paid the Company an upfront payment of $150.0 million in 2017. The Company manufactures a portion of Incyte&#x2019;s global commercial supply of retifanlimab. In March 2023, the FDA approved Incyte's Biologics License Application (BLA) for ZYNYZ (retifanlimab-dlwr) for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma. Incyte has stated it is pursuing development of retifanlimab in potentially registration-enabling studies, including in patients with squamous cell carcinoma of the anal canal, MSI-high endometrial cancer and non-small cell lung cancer. Incyte is also pursuing development of retifanlimab in combination with multiple product candidates from its pipeline.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Incyte License Agreement, as amended, Incyte will lead global development of retifanlimab. From the inception of the Incyte License Agreement through &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company has recognized $215.0 million for certain development and regulatory milestones under the Incyte License Agreement, including $15.0 million received following the FDA approval of ZYNYZ and $100.0&#160;million received in August 2024 upon entering into an amendment to the Incyte License Agreement pursuant to which certain development milestones were deemed to have been met. Assuming successful development and commercialization by Incyte in multiple indications, the Company is eligible to receive up to an additional $210.0 million in development and regulatory milestones, and up to $330.0 million in commercial milestones. The Company is also eligible to receive tiered royalties of 15% to 24% on global net sales. The Company retains the right to develop its pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of retifanlimab, subject to the separate commercial supply agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:42pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Incyte License Agreement under the provisions of ASC 606 at inception and identified the following two performance obligations under the agreement: (i) the license of retifanlimab and (ii) the performance of certain clinical activities through a brief technology transfer period. The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company performed the activities during the transfer period as a matter of convenience. The Company determined that the transaction price of the Incyte License Agreement at inception was $154.0 million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed. The transaction price was allocated to each performance obligation based on their relative standalone selling price. The standalone selling price of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;license was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The standalone selling price for the agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties. The potential development and regulatory milestone payments are &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. In July 2024, the Company and Incyte executed Amendment No. 4 to the Incyte License Agreement pursuant to which certain development milestones were deemed to have been met. The Company evaluated the amendment as a contract modification under the provisions of ASC 606 which resulted in $100.0&#160;million of revenue being recognized during the year ended December&#160;31, 2024. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From 2018 through December&#160;31, 2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;it became probable that a significant reversal of cumulative revenue would not occur for development milestones totaling &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$215.0 million&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; related to clinical and regulatory activities related to the further advancement of retifanlimab. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Therefore&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the associated consideration was added to the estimated transaction price and was recognized as revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:42pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$150.0 million&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; allocated to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;license when it satisfied its performance obligation and transferred the license to Incyte in 2017. The $4.0 million allocated to the clinical activities was recognized ratably as services were performed during 2017 and 2018. The Company recognized revenue of $100.6 million, $15.0 million and $30.0 million under the Incyte License Agreement during the years ended December&#160;31, 2024, 2023 and 2022, respectively. The revenue is primarily related to development milestones and includes royalties on ZYNYZ sales beginning in late 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Incyte Clinical Supply Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:42pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, the Company entered into an agreement with Incyte, under which the Company is to perform development and manufacturing services for Incyte&#x2019;s clinical needs of retifanlimab (Incyte Clinical Supply Agreement). The Company evaluated the Incyte Clinical Supply Agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of retifanlimab. The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the manufacturing services. During the years ended &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, 2023 and 2022, the Company recognized revenue of $0.2 million, $1.9 million and $0.7 million, respectively, for services performed under the Incyte Clinical Supply Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Incyte Commercial Supply Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:42pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, the Company entered into an agreement with Incyte pursuant to which the Company is entitled to manufacture a portion of the global commercial supply needs for retifanlimab (Incyte Commercial Supply Agreement). Unless terminated earlier, the term of the Incyte Commercial Supply Agreement will expire upon the expiration of Incyte&#x2019;s obligation to pay royalties under the Incyte License Agreement. The Company evaluated this agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to manufacturing the commercial supply of retifanlimab. The transaction price is based on a fixed price per batch of bulk drug substance to be manufactured and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. The transaction price is being recognized using the input method reflecting the costs incurred (including resources consumed and labor costs incurred) related to the manufacturing services. During the years ended &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2024, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023, and 2022, the Company recognized revenue of $1.8 million, $4.2&#160;million and $0.3&#160;million, respectively, for services performed under the Incyte Commercial Supply Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%"&gt;Gilead Sciences, Inc. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2022, the Company and Gilead entered into an exclusive option and collaboration agreement (Gilead Agreement) to develop and commercialize MGD024, an investigational, bispecific antibody that binds CD123 and CD3, and create bispecific cancer antibodies using the Company&#x2019;s DART platform and undertake their early development under a maximum of two separate bispecific cancer target research programs. Under the agreement, the Company will continue the ongoing phase 1 trial for MGD024 accordi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ng to a development plan&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, during which Gilead will have the right to exercise an option granted to Gilead to obtain an exclusive license under the Company&#x2019;s intellectual property to develop and commercialize MGD024 and other &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;bispecific antibodies of MacroGenics that bind CD123 and CD3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (CD123 Option). The agreement also granted Gilead the right, within its first two years, to nominate a bispecific cancer target set for up to two research programs conducted by the Company and to exercise separate options to obtain an exclusive license for the development, commercialization and exploitation of molecules created under each research program (Research Program Option). Gilead nominated the first of the two research programs in September 2023. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2024, the parties amended the Gilead Agreement to revise certain matters related to intellectual property in the performance of the research plans under the agreement. On August 30, 2024, the parties amended the agreement by entering into a second letter agreement under which Gilead will pay the Company to conduct certain research and which extends the period for Gilead to select its second research target combination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Gilead Agreement, as amended, in October 2022 Gilead paid the Company an upfront payment of $60.0&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assuming Gilead exercises the CD123 Option and Research Program Option and successfully develops and commercializes MGD024, or other CD123 products developed under the agreement, and products result from the two additional research programs, the Company would be eligible to receive up to $1.7 billion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in target nomination, option fees, and development, regulatory and commercial milestones. Assuming exercise of the CD123 Option, the Company will also be eligible to receive tiered, low double-digit royalties on worldwide net sales of MGD024 (or other CD123 products developed under the agreement) and assuming exercise of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research Program Option,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; a flat royalty on worldwide net sales of any products resulting from the two research programs.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Gilead Agreement under the provisions of ASC 606 and identified the following material promises under the agreement: (i) a license to perform any activities allocated to Gilead under the MGD024 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;development plan&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;; (ii) development activities regarding MGD024, including manufacturing, research and early clinical development activities, necessary to deliver an informational package of development and clinical data, information and materials specified in the Gilead Agreement during the period &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; which Gilead can exercise the CD123 Option; (iii) the CD123 Option and (iv) the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research Program Option&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company concluded that the license under the MGD024 developme&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nt plan&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and development activities are not distinct from one another, as the license has limited value without the Company&#x2019;s performance of the development activities. Therefore, the Company determined that the development term license and development activities should be combined into a single performance obligation (Development Activities). The CD123 Option is considered a material right as the value of the exclusive license exceeds the payment to be made by Gilead if they exercise their option to obtain an exclusive license to develop and commercialize MGD024 or an alternative CD123 product, and is therefore a distinct performance obligation. The Company determined that the Research Program Option does not provide a material right, as there is no discount on its standalone selling price.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 606, the Company determined that the initial transaction price under the Gilead Agreement was $60.0&#160;million, consisting of the upfront, non-refundable payment paid by Gilead. The CD123 Option and Research Program Option payments are excluded from the initial transaction price at contract inception along with any future development, regulatory, and commercial milestone payments (including royalties) following the CD123 Option and Research Program Option exercise.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company reassesses the amount of variable consideration included in the transaction price every reporting period.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:13.5pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocated the $60.0&#160;million upfront payment in the transaction price to the Development Activities and the CD123 Option based on each performance obligation&#x2019;s relative standalone selling price. The standalone selling price for the Development Activities was calculated using an expected cost-plus margin approach &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the pre-option development timeline.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the standalone selling price of the CD123 Option, the Company utilized an income-based approach which included the following key assumptions:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;post-option development timeline and costs, forecasted revenues, discount rates and probabilities of technical and regulatory success. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is recognizing revenue related to the Development Activities performance obligation over the estimated period to complete the Development Activities using an input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the Development Activities. The Company has deferred revenue recognition related to the CD123 Option. If Gilead exercises the CD123 Option and obtains an exclusive license, the Company will recognize revenue as it fulfills its obligations under the Gilead Agreement. If the CD123 Option is not exercised, the Company will recognize the entirety of the revenue in the period when the CD123 Option expires.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, 2023, and 2022, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Company recorded revenue of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.5&#160;million,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.5&#160;million, and $0.2&#160;million, respectively, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;related to the Gilead Agreement. As of &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$56.8&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in revenue was deferred under this agreement, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.3&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of which was current and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$55.5&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of which was non-current. As of December&#160;31, 2023, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$58.3&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in revenue was deferred under this agreement, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$2.2&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of which was current and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$56.1&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of which was non-current.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2023, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Company and Gilead executed a Letter Agreement through which Gilead nominated the first of the two research programs contemplated in the Gilead Agreement (First Research Program), the Company granted Gilead a research license, and the parties agreed on a research plan for the First Research Program under which the Company will provide research and development services. Gilead paid the Company a $15.7&#160;million nomination fee. The Company evaluated the Letter Agreement under the terms of ASC 606, and concluded that it is a modification to the Gilead Agreement that results in a separate contract since the modification is for additional goods and services that are distinct and at standalone selling price. The Company determined that the license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that these should be combined into a single performance obligation. Gilead also has the exclusive option to pay the Company $10.0&#160;million to obtain a license to exploit the research molecule and research product with respect to the First Research Program. The Company determined that this exclusive option does not provide a material right, as there is no discount on its standalone selling price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 606, the Company determined that the initial transaction price for the First Research Program agreement was $15.7&#160;million, consisting of the non-refundable payment paid by Gilead. The Company is recognizing revenue over the estimated period to complete the services using the input method reflecting the costs incurred (including resources consumed and labor hours expended) related to the research and development services. In June 2024, the Company received variable consideration totaling $3.3&#160;million from Gilead upon achievement of a research plan milestone. The variable consideration was added to the transaction price and allocated to the performance obligation to determine the amount of related revenue to be recognized. A proportional amount was recognized based on the input cost to cost measurement of work completed to date.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2024, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023, the Company recorded revenue of $7.8&#160;million and $0.8&#160;million, respectively, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;related to the First Research Program. As of December&#160;31, 2024, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$11.0&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in revenue was deferred under this agreement, all of which was current&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As of December&#160;31, 2023, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$14.9&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in revenue was deferred under this agreement, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$11.8&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of which was current and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$3.1&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of which was non-current.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Zai Lab US LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021, the Company entered into a collaboration and license agreement with Zai Lab US LLC (Zai Lab Limited and Zai Lab US LLC, either singularly or collectively are referred to herein as Zai Lab) involving collaboration programs and license-only programs (collectively, the Programs) encompassing four separate immuno-oncology molecules (2021 Zai Lab Agreement). During 2022, the Company and Zai Lab agreed to discontinue research and development of the lead program, and in August 2023, the parties mutually agreed to terminate the 2021 Zai Lab Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the Company received $7.0&#160;million from Zai Lab in fulfillment of a milestone. This was recognized as revenue for the year ended &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2024. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2023, no revenue was recognized under the 2021 Zai Lab Agreement and during the year ended December 31, 2022, the Company recognized revenue of $16.8 million under the 2021 Zai Lab Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Provention Bio, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, the Company entered into a license agreement with Provention pursuant to which the Company granted Provention exclusive global rights for the purpose of developing and commercializing MGD010 (renamed PRV-3279), a CD32B x CD79B DART molecule being developed for the treatment of autoimmune indications (Provention License Agreement). As partial consideration for the Provention License Agreement, Provention granted the Company a warrant to purchase shares of Provention&#x2019;s common stock at an exercise price of $2.50 per share. If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-3279, the Company will be eligible to receive up to $65.0 million in development and regulatory milestones and up to $225.0 million in commercial milestones. As of December&#160;31, 2024, the Company has not recognized any milestone revenue under this agreement. If commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product. The license agreement may be terminated by either party upon a material breach or bankruptcy of the other party, by Provention without cause upon prior notice to the Company, and by the Company in the event that Provention challenges the validity of any licensed patent under the agreement, but only with respect to the challenged patent.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also, in 2018, the Company entered into the Provention Asset Purchase Agreement (Provention APA) pursuant to which Provention acquired the Company&#x2019;s interest in teplizumab (renamed PRV-031), a monoclonal antibody being developed for the treatment of type 1 diabetes. As partial consideration for the Provention APA, Provention granted the Company a warrant to purchase shares of Provention&#x2019;s common stock at an exercise price of $2.50 per share. Under the Provention APA, Provention is obligated to pay the Company contingent milestone payments totaling $170.0 million upon the achievement of certain regulatory milestones. In addition, Provention is obligated to make contingent milestone payments to the Company &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;totaling $225.0 million upon the achievement of certain commercial milestones as well as single-digit royalties on net sales of the product. The FDA approved the BLA for TZIELD in November 2022, and the Company recognized $60.0 million in revenue related to this regulatory milestone during the year ended December 31, 2022. In November 2022, the Company and Provention amended the Provention APA. Under this amendment, the milestone for first approval was split into four equal payments, all of which were received prior to June 30, 2023. Provention has also agreed to pay third-party obligations, including low single-digit royalties, of which a portion is creditable against royalties payable to the Company, aggregate milestone payments of up to approximately $1.3 million and other consideration, for certain third-party intellectual property under agreements Provention assumed pursuant to the Provention APA. Further, Provention is required to pay the Company a low double-digit percentage of certain consideration to the extent it is received in connection with a future grant of rights to PRV-031 by Provention to a third party.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Provention License Agreement and Provention APA under the provisions of ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: (i) the license of MGD010 and (ii) the title to teplizumab. The Company determined that the transaction price of the Provention agreements was $6.1 million, based on the Black-Scholes valuation of the warrants to purchase a total of 2,432,688 shares of Provention's common stock. The transaction price was allocated to each performance obligation based on the number of shares of common stock the Company is entitled to purchase under each warrant. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such were excluded from the initial transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, therefore they have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. The Company recognized revenue of $6.1 million when it satisfied its performance obligations under the agreements and transferred the MGD010 license and teplizumab assets to Provention in 2018. In 2019, the Company exercised the warrants on a cashless basis, and subsequently sold all the shares of Provention common stock acquired through the exercise. No shares of Provention stock were held subsequent to the sale of stock in 2019. During the year ended December 31, 2022, &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;it became probable that a significant reversal of cumulative revenue would not occur for a regulatory milestone of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$60.0 million&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;herefore&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the associated consideration was added to the estimated transaction price and was recognized as revenue. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2024, no revenue was recognized under these agreements. During the years ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2023 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022, the Company recognized revenue of $5.6 million and $60.0 million, respectively, under these agreements.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023, the Company sold its single-digit royalty interest in TZIELD to a wholly-owned subsidiary of DRI Healthcare Trust (DRI) and received a $100.0&#160;million payment from DRI under a Royalty Purchase Agreement. The Company retains its other economic interests related to TZIELD, including future potential regulatory and commercial milestones, as well as the right to receive a 50% share of the royalty on global net sales above a certain annual threshold. In addition, the Company received $50.0&#160;million upon the occurrence of the primary endpoint milestone event in September 2023, and remains eligible to receive an additional $50.0&#160;million if TZIELD achieves a certain level of net sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 27, 2023, Sanofi S.A. (Sanofi) completed its acquisition of Provention and the Company entered into a Tripartite Agreement. Also on April 27, 2023, the Company and a subsidiary of Sanofi entered into a Side Letter Agreement which specified certain post-closing covenants and also accelerated certain payments due to the Company under the Provention APA upon the closing of the merger between Sanofi and Provention. The Company evaluated the Side Letter Agreement as a contract modification under the provisions of ASC 606. As a result, &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;during the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;year ended December 31, 2023&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company recognized $5.5&#160;million related to other consideration under the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provention APA&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Side Letter Agreement. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2023, the Company recognized $0.3&#160;million in royalty revenue under the Provention APA based on sales of TZIELD. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2023, the Company and Sanofi executed Amendment No. 2 to the Provention APA and terminated the Royalty Purchase Agreement with DRI. As a result, the remaining $50.0&#160;million milestone under the Royalty Purchase Agreement was incorporated into the Provention APA. The Company evaluated the amendment as a contract modification under the provisions of ASC 606 which did not result in any additional revenue being recognized during the year ended December 31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Manufacturing Services Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Incyte &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, the Company entered into a Manufacturing and Clinical Supply Agreement with Incyte (Incyte Manufacturing and Clinical Supply Agreement) to provide manufacturing services to produce certain Incyte bulk drug &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;substance over a three years period. Under the terms of the Incyte Manufacturing and Clinical Supply Agreement, the Company received an upfront payment of $10.0&#160;million and was eligible to receive annual fixed payments paid quarterly over the term of the contract totaling $14.4&#160;million. The Company will also be reimbursed for materials used to manufacture product as well as other costs incurred to provide manufacturing services. In July 2022, the Company and Incyte executed an amendment to the Incyte Manufacturing and Clinical Supply Agreement which extended the term for one year and provided for an additional annual fixed payment of $5.1&#160;million (July 2022 Incyte Amendment). In December 2024, the Company and Incyte entered into a letter agreement whereby Incyte reserved additional manufacturing services with a fixed cost of $9.1&#160;million (December 2024 Letter Agreement). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Incyte Manufacturing and Clinical Supply Agreement, the July 2022 Incyte Amendment and the December 2024 Letter Agreement under the provisions of ASC 606 and identified one performance obligation to provide manufacturing runs to Incyte, as and when requested by Incyte, over the term of the contract that is part of a series of goods and services. The Company determined that the transaction price consisted of the upfront payment of $10.0&#160;million and the fixed payments totaling $28.6&#160;million. The Company is recognizing revenue over time on a straight-line basis as the manufacturing services are provided to Incyte, as the Company determined that its efforts in providing the manufacturing services will be incurred evenly throughout the performance period and therefore straight-line revenue recognition closely approximates the level of effort for the manufacturing services. Variable consideration relating to the reimbursed materials and other reimbursed costs incurred to manufacture product for Incyte will be allocated to the related manufacturing activities and will be recognized as revenue as those activities occur. Materials purchased by the Company to manufacture the product for Incyte are considered costs to fulfill a contract and will be capitalized and expensed as the materials are used to provide the manufacturing services.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2024, 2023, and 2022, the Company recognized revenue of $11.0&#160;million, $9.7&#160;million and $8.7&#160;million, respectively, under the Incyte Manufacturing and Clinical Supply Agreement. As of &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2024, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$3.4&#160;million&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in revenue was deferred under this agreement, all of which was current. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$7.0&#160;million&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in revenue was deferred under this agreement, all of which was current.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Sales, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales, net reflected sales of MARGENZA until the Company sold global rights to MARGENZA to TerSera in November 2024. Prior to the sale to TerSera, product revenue was recorded net of applicable reserves for variable consideration, including discounts and other allowances. The Company entered into a limited number of arrangements with specialty distributors in the United States to distribute MARGENZA. The delivery of the product represented a single performance obligation for these transactions and the Company recorded net product revenue when control was transferred to the customer, generally upon receipt by the customer. The transaction price for net product revenue represented the amount the Company expected to receive, which was net of estimated government-mandated rebates and chargebacks, distribution fees, estimated product returns, and other deductions. Accruals were established for these deductions, and actual amounts incurred were offset against applicable accruals. The Company recognized net product sales revenue of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$16.4&#160;million&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$17.9&#160;million&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$16.7&#160;million&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; during the years ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the sale of MARGENZA, the Company &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;paid an $8.0&#160;million amendment fee to Eversana Life Sciences Services, LLC (Eversana), a former partner that had previously commercialized MARGENZA, which was recorded as selling, general and administrative expense in the consolidated statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Government Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;NIAID Contract&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered into a contract with the National Institute of Allergy and Infectious Diseases (NIAID), effective as of September 15, 2015,&#160;to perform product development and to advance up to two DART molecules, MGD014 and MGD020 (NIAID Contract). Under the NIAID Contract, the Company developed these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID did not receive goods or services from the Company under this contract, therefore the Company did not consider NIAID to be a customer and concluded this contract was outside the scope of ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Both the Phase 1 study of MGD014 in persons with HIV maintained on antiretroviral therapy and the Phase 1 study of MGD020 alone and combined with MGD014 have been completed and the Company is in the process of closing out the contract. The Company recognized revenue of $1.6 million, $1.6 million and $1.9 million under the NIAID contract during the years ended December&#160;31, 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock>
    <mgnx:NonRefundableUpfrontFees contextRef="c-145" decimals="-5" id="f-596" unitRef="usd">150000000.0</mgnx:NonRefundableUpfrontFees>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized contextRef="c-146" decimals="-5" id="f-597" unitRef="usd">215000000.0</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <us-gaap:Revenues contextRef="c-147" decimals="-5" id="f-598" unitRef="usd">15000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-148" decimals="-5" id="f-599" unitRef="usd">100000000</us-gaap:Revenues>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement contextRef="c-149" decimals="-5" id="f-600" unitRef="usd">210000000.0</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement contextRef="c-149" decimals="-5" id="f-601" unitRef="usd">330000000.0</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:ProceedsfromRoyaltiesPercent contextRef="c-150" decimals="2" id="f-602" unitRef="number">0.15</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:ProceedsfromRoyaltiesPercent contextRef="c-151" decimals="2" id="f-603" unitRef="number">0.24</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:NumberOfPerformanceObligations
      contextRef="c-152"
      decimals="INF"
      id="f-604"
      unitRef="performanceobligation">2</mgnx:NumberOfPerformanceObligations>
    <mgnx:CollaborativeAgreementTransactionPrice contextRef="c-153" decimals="-5" id="f-605" unitRef="usd">154000000.0</mgnx:CollaborativeAgreementTransactionPrice>
    <us-gaap:Revenues contextRef="c-148" decimals="-5" id="f-606" unitRef="usd">100000000</us-gaap:Revenues>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized contextRef="c-146" decimals="-5" id="f-607" unitRef="usd">215000000.0</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <us-gaap:Revenues contextRef="c-154" decimals="-5" id="f-608" unitRef="usd">150000000.0</us-gaap:Revenues>
    <mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount contextRef="c-155" decimals="-5" id="f-609" unitRef="usd">4000000.0</mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount>
    <us-gaap:Revenues contextRef="c-156" decimals="-5" id="f-610" unitRef="usd">100600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-147" decimals="-5" id="f-611" unitRef="usd">15000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-157" decimals="-5" id="f-612" unitRef="usd">30000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-158" decimals="-5" id="f-613" unitRef="usd">200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-159" decimals="-5" id="f-614" unitRef="usd">1900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-160" decimals="-5" id="f-615" unitRef="usd">700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-161" decimals="-5" id="f-616" unitRef="usd">1800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-162" decimals="-5" id="f-617" unitRef="usd">4200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-163" decimals="-5" id="f-618" unitRef="usd">300000</us-gaap:Revenues>
    <mgnx:NonRefundableUpfrontFees contextRef="c-164" decimals="-5" id="f-619" unitRef="usd">60000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:PotentialTargetNominationOptionFeesAndMilestonePayments contextRef="c-165" decimals="-5" id="f-620" unitRef="usd">1700000000</mgnx:PotentialTargetNominationOptionFeesAndMilestonePayments>
    <mgnx:NonRefundableUpfrontFees contextRef="c-164" decimals="-5" id="f-621" unitRef="usd">60000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:NonRefundableUpfrontFees contextRef="c-164" decimals="-5" id="f-622" unitRef="usd">60000000</mgnx:NonRefundableUpfrontFees>
    <us-gaap:Revenues contextRef="c-166" decimals="-5" id="f-623" unitRef="usd">1500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-167" decimals="-5" id="f-624" unitRef="usd">1500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-168" decimals="-5" id="f-625" unitRef="usd">200000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiability contextRef="c-169" decimals="-5" id="f-626" unitRef="usd">56800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-169" decimals="-5" id="f-627" unitRef="usd">1300000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-169" decimals="-5" id="f-628" unitRef="usd">55500000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability contextRef="c-170" decimals="-5" id="f-629" unitRef="usd">58300000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-170" decimals="-5" id="f-630" unitRef="usd">2200000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-170" decimals="-5" id="f-631" unitRef="usd">56100000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-171" decimals="-5" id="f-632" unitRef="usd">15700000</us-gaap:RevenueRemainingPerformanceObligation>
    <mgnx:OptionToBuy contextRef="c-171" decimals="-5" id="f-633" unitRef="usd">10000000</mgnx:OptionToBuy>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-171" decimals="-5" id="f-634" unitRef="usd">15700000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-172" decimals="-5" id="f-635" unitRef="usd">3300000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:Revenues contextRef="c-173" decimals="-5" id="f-636" unitRef="usd">7800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-174" decimals="-5" id="f-637" unitRef="usd">800000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiability contextRef="c-175" decimals="-5" id="f-638" unitRef="usd">11000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-176" decimals="-5" id="f-639" unitRef="usd">14900000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-176" decimals="-5" id="f-640" unitRef="usd">11800000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-176" decimals="-5" id="f-641" unitRef="usd">3100000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:Revenues contextRef="c-177" decimals="-5" id="f-642" unitRef="usd">7000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-178" decimals="INF" id="f-643" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-179" decimals="-5" id="f-644" unitRef="usd">16800000</us-gaap:Revenues>
    <mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare
      contextRef="c-180"
      decimals="INF"
      id="f-645"
      unitRef="usdPerShare">2.50</mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement contextRef="c-181" decimals="-5" id="f-646" unitRef="usd">65000000.0</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement contextRef="c-181" decimals="-5" id="f-647" unitRef="usd">225000000.0</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare
      contextRef="c-182"
      decimals="INF"
      id="f-648"
      unitRef="usdPerShare">2.50</mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement contextRef="c-183" decimals="-5" id="f-649" unitRef="usd">170000000.0</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement contextRef="c-183" decimals="-5" id="f-650" unitRef="usd">225000000.0</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized contextRef="c-184" decimals="-5" id="f-651" unitRef="usd">60000000.0</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement contextRef="c-183" decimals="-5" id="f-652" unitRef="usd">1300000</mgnx:PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement>
    <mgnx:CollaborativeAgreementTransactionPrice contextRef="c-185" decimals="-5" id="f-653" unitRef="usd">6100000</mgnx:CollaborativeAgreementTransactionPrice>
    <mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares
      contextRef="c-185"
      decimals="INF"
      id="f-654"
      unitRef="shares">2432688</mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares>
    <us-gaap:Revenues contextRef="c-186" decimals="-5" id="f-655" unitRef="usd">6100000</us-gaap:Revenues>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized contextRef="c-184" decimals="-5" id="f-656" unitRef="usd">60000000.0</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <us-gaap:Revenues contextRef="c-187" decimals="INF" id="f-657" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-188" decimals="-5" id="f-658" unitRef="usd">5600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-189" decimals="-5" id="f-659" unitRef="usd">60000000.0</us-gaap:Revenues>
    <mgnx:UpfrontPayment contextRef="c-190" decimals="-5" id="f-660" unitRef="usd">100000000</mgnx:UpfrontPayment>
    <mgnx:ProceedsfromRoyaltiesPercent contextRef="c-191" decimals="3" id="f-661" unitRef="number">0.50</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:GainOnRoyaltyMonetizationArrangement contextRef="c-192" decimals="-5" id="f-662" unitRef="usd">50000000</mgnx:GainOnRoyaltyMonetizationArrangement>
    <mgnx:AdditionalTZIELDMilestones contextRef="c-193" decimals="-5" id="f-663" unitRef="usd">50000000</mgnx:AdditionalTZIELDMilestones>
    <us-gaap:Revenues contextRef="c-194" decimals="-5" id="f-664" unitRef="usd">5500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-195" decimals="-5" id="f-665" unitRef="usd">300000</us-gaap:Revenues>
    <mgnx:AdditionalTZIELDMilestones contextRef="c-193" decimals="-5" id="f-666" unitRef="usd">50000000</mgnx:AdditionalTZIELDMilestones>
    <mgnx:CollaborativeArrangementTerm contextRef="c-196" id="f-667">P3Y</mgnx:CollaborativeArrangementTerm>
    <mgnx:NonRefundableUpfrontFees contextRef="c-197" decimals="-5" id="f-668" unitRef="usd">10000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:TotalFixedPayments contextRef="c-197" decimals="-5" id="f-669" unitRef="usd">14400000</mgnx:TotalFixedPayments>
    <mgnx:CollaborativeArrangementExtensionTerm contextRef="c-196" id="f-670">P1Y</mgnx:CollaborativeArrangementExtensionTerm>
    <mgnx:AdditionalAnnualFixedPayments contextRef="c-198" decimals="-5" id="f-671" unitRef="usd">5100000</mgnx:AdditionalAnnualFixedPayments>
    <mgnx:FutureManufacturingRevenue contextRef="c-199" decimals="-5" id="f-672" unitRef="usd">9100000</mgnx:FutureManufacturingRevenue>
    <mgnx:NonRefundableUpfrontFees contextRef="c-197" decimals="-5" id="f-673" unitRef="usd">10000000</mgnx:NonRefundableUpfrontFees>
    <mgnx:TotalFixedPayments contextRef="c-200" decimals="-5" id="f-674" unitRef="usd">28600000</mgnx:TotalFixedPayments>
    <us-gaap:Revenues contextRef="c-201" decimals="-5" id="f-675" unitRef="usd">11000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-202" decimals="-5" id="f-676" unitRef="usd">9700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-203" decimals="-5" id="f-677" unitRef="usd">8700000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-204" decimals="-5" id="f-678" unitRef="usd">3400000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-205" decimals="-5" id="f-679" unitRef="usd">7000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:Revenues contextRef="c-16" decimals="-5" id="f-680" unitRef="usd">16400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-17" decimals="-5" id="f-681" unitRef="usd">17900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-18" decimals="-5" id="f-682" unitRef="usd">16700000</us-gaap:Revenues>
    <mgnx:AmendmentFeeToCommercializationPartner contextRef="c-206" decimals="-5" id="f-683" unitRef="usd">8000000</mgnx:AmendmentFeeToCommercializationPartner>
    <mgnx:NumberOfProductCandidates contextRef="c-207" decimals="INF" id="f-684" unitRef="usd">2</mgnx:NumberOfProductCandidates>
    <us-gaap:Revenues contextRef="c-208" decimals="-5" id="f-685" unitRef="usd">1600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-209" decimals="-5" id="f-686" unitRef="usd">1600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-210" decimals="-5" id="f-687" unitRef="usd">1900000</us-gaap:Revenues>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-688">Stock-based Compensation&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2017, the Company&#x2019;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended, and is not subject to the provisions of the Employee Retirement Income Security Act of 1974. The Company reserved 800,000 shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions of up to 10% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for six months offering periods ending on May 31 and November 30 of each year. At the end of each offering period, employees are able to purchase shares at 85% of the fair market value of the Company&#x2019;s common stock on the last day of the offering period. During the year ended December&#160;31, 2024, employees purchased 94,619 shares of common stock under the 2016 ESPP for net proceeds to the Company of approximately $0.3&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Incentive Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2013, the Company implemented the 2013 Equity Incentive Plan (2013 Plan).&#160;In May 2023, the 2013 Plan was terminated, and no further awards may be issued under the plan. If an option granted under the 2013 Plan expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares will become available for issuance under the 2023 Equity Incentive Plan (2023 Plan). As of December&#160;31, 2024, under the 2013 Plan, there were options to purchase an aggregate of 10,613,229 shares of common stock outstanding at a weighted average exercise price of $14.96 per share. As of December&#160;31, 2024, there were 404,449 unvested RSUs outstanding under the 2013 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2023 Plan was effective as of stockholder approval in May 2023. The 2023 Plan provides for grants of stock options and other stock-based awards, as well as cash-based performance awards. The 2023 Plan authorized the issuance of up to an aggregate of 4,850,000 shares of common stock. In May 2024, the board and stockholders of the Company approved an amendment to the 2023 Plan to increase the number of shares of common stock available for issuance thereunder by 2,000,000 shares. Accordingly, the maximum number of shares of common stock authorized for issuance under the 2023 Plan is 6,850,000 shares. If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards. As of December&#160;31, 2024, under the 2023 Plan, there were options to purchase an aggregate of 2,326,288 shares of common stock outstanding at a weighted average exercise price of $14.06 per share. As of December&#160;31, 2024, there were 664,545 unvested RSUs outstanding under the 2023 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following stock-based compensation amounts were recognized for the periods indicated (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 25, 2024, Dr. Scott Koenig, the President and Chief Executive Officer of the Company and the Company entered into a separation and consulting agreement (the Separation Agreement), which provides for the terms of Dr. Koenig&#x2019;s separation from employment, effective February 28, 2025 (the Separation Date). Under the Separation Agreement and in accordance with the terms of his employment agreement, the Company accelerated vesting of 50% of the unvested stock option awards and RSU awards granted to Dr. Koenig during his employment outstanding as of the Separation Date. Additionally, pursuant to the Separation Agreement, following Dr. Koenig&#x2019;s Separation Date, Dr. Koenig will serve as an advisor to the Company. As compensation for the advisory services, all remaining unvested option awards and RSU awards as of the Separation Date will continue to vest during the advisory services period. Lastly, all outstanding, accelerated and continued vesting options during the advisory services were amended to extend the exercisability period. The Company evaluated the impacts of the Separation Agreement and the related modifications to Dr. Koenig&#x2019;s option awards and RSU awards.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result, the Company recognized all additional stock-based compensation expense in 2024 in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation &#x2013; Stock Compensation &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 718) in the amount of $6.1&#160;million. On February 25, 2025, Dr. Koenig and the Company amended the Separation Agreement to extend Dr. Koenig&#x2019;s Separation Date to a date to be determined by the Board &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of Directors of the Company as the special executive search committee of the Board of Directors continues its process to identify the next Chief Executive Officer of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumptions used to estimate the fair value of Dr. Koenig&#x2019;s modified awards in 2024 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.625%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.175%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108% -174%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2% - 4.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00 year - 5.50 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for stock-based compensation to employees and non-employee directors in accordance with ASC 718. The Company estimates the fair value of stock option awards using the Black-Scholes option pricing model on the date of grant using the assumptions in the table below. Stock options granted to employees generally vest over four years and have a term of ten years. Stock-based compensation expense for stock options is recognized as expense over the requisite service period, which is the vesting period. As the Company has not paid dividends since inception, nor does it expect to pay any dividends for the foreseeable future, the expected dividend yield assumption is zero. The expected volatility is based on the historical stock volatility of the Company&#x2019;s own common stock over a period equal to the expected term of the options. The risk-free rate of the stock options is based on the U.S. Treasury rate in effect at the time of grant for the expected term of the stock options. The Company calculates expected term based on the historical experience with similar awards, giving consideration to the contractual terms of the share-based awards, vesting schedules and expectations of future employee behavior. In addition, the Company estimates the expected forfeiture rate and only recognizes expense for those shares expected to vest. The Company estimates the forfeiture rate based on historical experience and its expectations regarding future pre-vesting termination behavior of employees. The Company reviews its estimate of the expected forfeiture rate annually, and stock-based compensation expense is adjusted accordingly.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.211%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.639%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95% -116%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76% - 96%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88% - 92%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5% - 4.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5% - 4.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4% - 4.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.06 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.88 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for 2024:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contractual Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,223,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,986,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(333,522)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(165,111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(771,669)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,939,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As of December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,004,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,456,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the total unrecognized compensation expense related to unvested stock options, net of related forfeiture estimates, was approximately $20.1 million, which the Company expects to recognize over a weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;average period of approximately 1.4 years. The following table summarizes additional information on stock options (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.080%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.452%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.452%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.454%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares of common stock issued with stock options exercises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average fair value per share of stock options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intrinsic value of stock options exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash received for stock options exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total grant date fair value of stock options vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs are valued based on the closing price of the Company&#x2019;s common stock on the date of the grant. The fair value of RSUs is recognized and amortized on a straight-line basis over the requisite service period of the award&lt;/span&gt;&lt;span style="color:#252525;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity for 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.268%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;905,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;679,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(483,181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,154)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,068,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2024, there was $6.4 million of total unrecognized compensation cost related to unvested RSUs, which the Company expects to recognize over a remaining weighted-average period of 1.4 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-211"
      decimals="INF"
      id="f-689"
      unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="c-212"
      decimals="INF"
      id="f-690"
      unitRef="number">0.10</mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent>
    <mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod contextRef="c-213" id="f-691">P6M</mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c-212"
      decimals="INF"
      id="f-692"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="c-214" decimals="0" id="f-693" unitRef="shares">94619</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-214" decimals="-5" id="f-694" unitRef="usd">300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-215"
      decimals="INF"
      id="f-695"
      unitRef="shares">10613229</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-215"
      decimals="2"
      id="f-696"
      unitRef="usdPerShare">14.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-215"
      decimals="INF"
      id="f-697"
      unitRef="shares">404449</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-216"
      decimals="INF"
      id="f-698"
      unitRef="shares">4850000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-217"
      decimals="INF"
      id="f-699"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-218"
      decimals="INF"
      id="f-700"
      unitRef="shares">6850000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-219"
      decimals="INF"
      id="f-701"
      unitRef="shares">2326288</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-219"
      decimals="2"
      id="f-702"
      unitRef="usdPerShare">14.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-219"
      decimals="INF"
      id="f-703"
      unitRef="shares">664545</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-704">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following stock-based compensation amounts were recognized for the periods indicated (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-220" decimals="-3" id="f-705" unitRef="usd">11759000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-221" decimals="-3" id="f-706" unitRef="usd">9190000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-222" decimals="-3" id="f-707" unitRef="usd">10094000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-223" decimals="-3" id="f-708" unitRef="usd">17680000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-224" decimals="-3" id="f-709" unitRef="usd">9183000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-225" decimals="-3" id="f-710" unitRef="usd">10344000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-711" unitRef="usd">29439000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-25" decimals="-3" id="f-712" unitRef="usd">18373000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-26" decimals="-3" id="f-713" unitRef="usd">20438000</us-gaap:AllocatedShareBasedCompensationExpense>
    <mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingPercentageOfUnvestedAwards
      contextRef="c-226"
      decimals="INF"
      id="f-714"
      unitRef="number">0.50</mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingPercentageOfUnvestedAwards>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost contextRef="c-1" decimals="-5" id="f-715" unitRef="usd">6100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost>
    <mgnx:ScheduleOfShareBasedPaymentAwardModifiedAwardsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-716">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumptions used to estimate the fair value of Dr. Koenig&#x2019;s modified awards in 2024 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.625%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.175%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108% -174%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2% - 4.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00 year - 5.50 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mgnx:ScheduleOfShareBasedPaymentAwardModifiedAwardsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-227"
      decimals="INF"
      id="f-717"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-228" decimals="3" id="f-718" unitRef="number">1.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-229" decimals="3" id="f-719" unitRef="number">1.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-228" decimals="4" id="f-720" unitRef="number">0.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-229" decimals="4" id="f-721" unitRef="number">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-228" id="f-722">P1Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-229" id="f-723">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-230" id="f-724">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-230" id="f-725">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-1" decimals="INF" id="f-726" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-727">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.211%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.639%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95% -116%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76% - 96%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88% - 92%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5% - 4.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5% - 4.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4% - 4.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.06 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.88 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-1" decimals="INF" id="f-728" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-25"
      decimals="INF"
      id="f-729"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-26"
      decimals="INF"
      id="f-730"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-231" decimals="3" id="f-731" unitRef="number">0.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-232" decimals="3" id="f-732" unitRef="number">1.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-233" decimals="3" id="f-733" unitRef="number">0.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-234" decimals="2" id="f-734" unitRef="number">0.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-235" decimals="2" id="f-735" unitRef="number">0.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-236" decimals="2" id="f-736" unitRef="number">0.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-231" decimals="4" id="f-737" unitRef="number">0.035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-232" decimals="4" id="f-738" unitRef="number">0.047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-233" decimals="4" id="f-739" unitRef="number">0.035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-234" decimals="4" id="f-740" unitRef="number">0.048</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-235" decimals="4" id="f-741" unitRef="number">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-236" decimals="4" id="f-742" unitRef="number">0.040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-1" id="f-743">P6Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-25" id="f-744">P5Y10M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-26" id="f-745">P5Y11M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-746">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for 2024:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contractual Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,223,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,986,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(333,522)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(165,111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(771,669)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,939,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As of December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,004,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,456,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-12"
      decimals="INF"
      id="f-747"
      unitRef="shares">12223637</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-12"
      decimals="2"
      id="f-748"
      unitRef="usdPerShare">15.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-25" id="f-749">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="c-1" decimals="INF" id="f-750" unitRef="shares">1986182</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-751"
      unitRef="usdPerShare">15.95</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-752" unitRef="shares">333522</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-753"
      unitRef="usdPerShare">9.38</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="INF" id="f-754" unitRef="shares">165111</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-755"
      unitRef="usdPerShare">11.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="c-1" decimals="INF" id="f-756" unitRef="shares">771669</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-757"
      unitRef="usdPerShare">25.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-11"
      decimals="INF"
      id="f-758"
      unitRef="shares">12939517</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-11"
      decimals="2"
      id="f-759"
      unitRef="usdPerShare">14.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-760">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-11" decimals="-3" id="f-761" unitRef="usd">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-11"
      decimals="INF"
      id="f-762"
      unitRef="shares">9004928</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-11"
      decimals="2"
      id="f-763"
      unitRef="usdPerShare">16.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-764">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-11" decimals="-3" id="f-765" unitRef="usd">9000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c-11"
      decimals="INF"
      id="f-766"
      unitRef="shares">12456248</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-11"
      decimals="2"
      id="f-767"
      unitRef="usdPerShare">14.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-768">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-11" decimals="-3" id="f-769" unitRef="usd">14000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-11" decimals="-5" id="f-770" unitRef="usd">20100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-1" id="f-771">P1Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-1" decimals="INF" id="f-772" unitRef="shares">333522</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-25"
      decimals="INF"
      id="f-773"
      unitRef="shares">34608</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c-26"
      decimals="INF"
      id="f-774"
      unitRef="shares">120900</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-775"
      unitRef="usdPerShare">12.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-25"
      decimals="2"
      id="f-776"
      unitRef="usdPerShare">3.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-26"
      decimals="2"
      id="f-777"
      unitRef="usdPerShare">6.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-3" id="f-778" unitRef="usd">2617000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-25" decimals="-3" id="f-779" unitRef="usd">93000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-26" decimals="-3" id="f-780" unitRef="usd">634000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-781" unitRef="usd">3128000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-25" decimals="-3" id="f-782" unitRef="usd">129000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-26" decimals="-3" id="f-783" unitRef="usd">172000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-1" decimals="-3" id="f-784" unitRef="usd">17992000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-25" decimals="-3" id="f-785" unitRef="usd">16435000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-26" decimals="-3" id="f-786" unitRef="usd">19573000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="c-1" id="f-787">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity for 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.268%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;905,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;679,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(483,181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,154)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,068,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-237"
      decimals="INF"
      id="f-788"
      unitRef="shares">905614</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-237"
      decimals="2"
      id="f-789"
      unitRef="usdPerShare">5.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-238"
      decimals="INF"
      id="f-790"
      unitRef="shares">679715</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-238"
      decimals="2"
      id="f-791"
      unitRef="usdPerShare">16.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="c-238"
      decimals="INF"
      id="f-792"
      unitRef="shares">483181</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-238"
      decimals="2"
      id="f-793"
      unitRef="usdPerShare">6.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-238"
      decimals="INF"
      id="f-794"
      unitRef="shares">33154</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-238"
      decimals="2"
      id="f-795"
      unitRef="usdPerShare">13.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-239"
      decimals="INF"
      id="f-796"
      unitRef="shares">1068994</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-239"
      decimals="2"
      id="f-797"
      unitRef="usdPerShare">11.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-239" decimals="-5" id="f-798" unitRef="usd">6400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-238" id="f-799">P1Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock contextRef="c-1" id="f-800">TerSera Transaction&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2024, the Company entered into an Asset Purchase and Sale Agreement (ASA) with TerSera in which TerSera acquired global rights to MARGENZA. Pursuant to the ASA, the Company received $40.0 million and may also receive up to $35.0 million in future sales milestone payments. The transaction closed in November 2024. In connection with the ASA, the Company also entered into a Master Manufacturing &amp;amp; Supply Agreement (MSA) with TerSera under which it will manufacture MARGENZA product for TerSera, and a Transition Services Agreement under which it will provide certain services to ensure a smooth business transition to TerSera.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the sale of MARGENZA does not qualify for reporting as a discontinued operation since it does not represent a strategic shift that has or will have a major effect on its operations and financial results. The Company determined that the agreements should be accounted for as one single combined contract with multiple elements under which the Company allocated the total consideration of $44.5 million on a relative standalone selling price basis in accordance with the applicable authoritative guidance. The Company recorded a $36.3 million gain on the sale of MARGENZA and related inventory in the &#x201c;Gain on Sale of MARGENZA&#x201d; line on its consolidated statements of operations and comprehensive loss for the year ended December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:OtherIncome contextRef="c-240" decimals="-5" id="f-801" unitRef="usd">40000000.0</us-gaap:OtherIncome>
    <mgnx:FutureMilestone contextRef="c-240" decimals="-5" id="f-802" unitRef="usd">35000000.0</mgnx:FutureMilestone>
    <us-gaap:OtherIncome contextRef="c-241" decimals="-5" id="f-803" unitRef="usd">44500000</us-gaap:OtherIncome>
    <mgnx:GainOnSaleOfMARGENZA contextRef="c-1" decimals="-5" id="f-804" unitRef="usd">36300000</mgnx:GainOnSaleOfMARGENZA>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-805">Income Tax&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2024, the Company is in a taxable income position due to the Tax Cuts and Jobs Act of 2017 (the Tax Act) limitation on utilization of Net Operating Losses to 80% of taxable income as well as the limitation on utilization of income tax credits, while the company remains in a full valuation allowance position. For the years ended December&#160;31, 2023, and 2022 there was no provision for income taxes due to taxable losses generated, fully offset by a valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax expense consists of the following f&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or the year ended&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.747%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of the reported estimated income tax expense to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States federal tax at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,866)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,902)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes (net of federal benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,385)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred state blended rate adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,663)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,082)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Orphan drug credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,308)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,846)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense/(benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.706%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal U.S. net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Orphan drug credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 174 deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(401,297)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(365,010)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,745)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,372)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenditures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,030)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax asset/(liability)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes valuation allowances to reduce deferred tax assets to the amount that is more likely than not to be realized. In assessing the likelihood of realization, management considers (i) future reversals of existing taxable temporary &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;differences; (ii) future taxable income exclusive of reversing temporary difference and carryforwards; (iii) taxable income in prior carryback years if carryback is permitted under applicable tax law; and (iv) tax planning strategies. The Company's net deferred income tax asset is not more likely than not to be utilized due to the lack of sufficient sources of future taxable income and cumulative book losses which have resulted over the years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The activity in the valuation allowance on deferred tax assets was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.309%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.862%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at Beginning of Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at End of Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the Company has U.S. federal and state net operating loss (NOL) carryforwards of approximately $554.0 million. Of these NOLs, $2.1 million will expire beginning in 2027 through 2028. $551.9 million of NOLs were generated post December 31, 2017 and carryforward indefinitely. In addition, the Company has U.S. federal tax credits of $109.0 million, which will expire in various years beginning in 2027 through 2044.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The use of the Company's U.S. federal NOL and tax credit carryforwards in future years are restricted due to changes in the Company's ownership and tax attributes acquired through the Company's acquisitions. As of December&#160;31, 2024, $2.1 million of the Company's U.S. Federal NOLs are limited for use over 2027 through 2028, in which a range of such amounts could be utilized on an annual basis of $0.2 million. The remaining $551.9 million of NOLs is not limited and can be offset against future taxable income, subject to certain limitations for newly enacted tax legislation. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning January 1, 2022, the Tax Act eliminated the option to deduct research and development expenditures in the current year and requires taxpayers to capitalize such expenses pursuant to Internal Revenue Code (IRC) Section 174. The capitalized expenses are amortized over a 5-year period for domestic expenses and a 15-year period for foreign expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases for current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases/(decreases) for prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(369)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024 and 2023, of the total gross unrecognized tax benefits, approximately $9.3 million and $7.8 million would favorably impact the Company's effective income tax rate, respectively. Although, due to the Company's determination that the deferred income tax asset would not more likely than not be realized, a valuation allowance would be recorded, therefore, zero net impact would result within the Company's effective income tax rate. The Company's uncertain income tax position liability has been recorded to deferred income taxes to offset the tax attribute carryforward amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2024, 2023 and 2022, the Company has not recognized any interest or penalties related to the uncertain income tax positions due to the fact such position is related to tax attribute carryforwards which have not yet been utilized. The Company does not expect its unrecognized income tax position to significantly decrease within the next twelve months.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's U.S. Federal and state income tax returns from 2007 &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;forward remain open to examination due to the carryover of unused income tax credits, and from 2007 forward due to the carryover of unused net operating losses.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-25" decimals="-5" id="f-806" unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-26" decimals="-5" id="f-807" unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-808">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax expense consists of the following f&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or the year ended&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.747%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-809" unitRef="usd">707000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-810" unitRef="usd">237000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-811" unitRef="usd">944000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-812">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of the reported estimated income tax expense to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States federal tax at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,866)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,902)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes (net of federal benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,385)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred state blended rate adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,663)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,082)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Orphan drug credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,308)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,846)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense/(benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="-3" id="f-813" unitRef="usd">-13866000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-25" decimals="-3" id="f-814" unitRef="usd">-1902000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-26" decimals="-3" id="f-815" unitRef="usd">-25149000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="-3" id="f-816" unitRef="usd">-4183000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-25" decimals="-3" id="f-817" unitRef="usd">-163000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-26" decimals="-3" id="f-818" unitRef="usd">-7385000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount contextRef="c-1" decimals="-3" id="f-819" unitRef="usd">-7299000</mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount>
    <mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount contextRef="c-25" decimals="-3" id="f-820" unitRef="usd">5024000</mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount>
    <mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount contextRef="c-26" decimals="-3" id="f-821" unitRef="usd">308000</mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount>
    <mgnx:EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount contextRef="c-1" decimals="-3" id="f-822" unitRef="usd">-2663000</mgnx:EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount>
    <mgnx:EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount contextRef="c-25" decimals="-3" id="f-823" unitRef="usd">1841000</mgnx:EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount>
    <mgnx:EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount contextRef="c-26" decimals="-3" id="f-824" unitRef="usd">0</mgnx:EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="c-1" decimals="-3" id="f-825" unitRef="usd">12082000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="c-25" decimals="-3" id="f-826" unitRef="usd">3168000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="c-26" decimals="-3" id="f-827" unitRef="usd">4569000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <mgnx:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount contextRef="c-1" decimals="-3" id="f-828" unitRef="usd">1308000</mgnx:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount>
    <mgnx:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount contextRef="c-25" decimals="-3" id="f-829" unitRef="usd">-2374000</mgnx:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount>
    <mgnx:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount contextRef="c-26" decimals="-3" id="f-830" unitRef="usd">10846000</mgnx:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="c-1" decimals="-3" id="f-831" unitRef="usd">388000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="c-25" decimals="-3" id="f-832" unitRef="usd">1301000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="c-26" decimals="-3" id="f-833" unitRef="usd">1362000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="-3" id="f-834" unitRef="usd">5594000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-25" decimals="-3" id="f-835" unitRef="usd">1950000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-26" decimals="-3" id="f-836" unitRef="usd">1604000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="-3" id="f-837" unitRef="usd">36287000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-25" decimals="-3" id="f-838" unitRef="usd">-7257000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-26" decimals="-3" id="f-839" unitRef="usd">44675000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther contextRef="c-1" decimals="-3" id="f-840" unitRef="usd">76000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther contextRef="c-25" decimals="-3" id="f-841" unitRef="usd">0</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther contextRef="c-26" decimals="-3" id="f-842" unitRef="usd">0</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-843" unitRef="usd">944000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-25" decimals="-3" id="f-844" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-26" decimals="-3" id="f-845" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-846">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.706%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal U.S. net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Orphan drug credit, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 174 deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(401,297)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(365,010)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,745)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,372)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenditures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,030)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax asset/(liability)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="c-11" decimals="-3" id="f-847" unitRef="usd">116341000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="c-12" decimals="-3" id="f-848" unitRef="usd">140706000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="c-11" decimals="-3" id="f-849" unitRef="usd">31758000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="c-12" decimals="-3" id="f-850" unitRef="usd">33350000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-11" decimals="-3" id="f-851" unitRef="usd">79108000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-12" decimals="-3" id="f-852" unitRef="usd">68251000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther contextRef="c-11" decimals="-3" id="f-853" unitRef="usd">33834000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther contextRef="c-12" decimals="-3" id="f-854" unitRef="usd">33330000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther>
    <mgnx:DeferredTaxAssetsOperatingLeaseLiabilities contextRef="c-11" decimals="-3" id="f-855" unitRef="usd">10308000</mgnx:DeferredTaxAssetsOperatingLeaseLiabilities>
    <mgnx:DeferredTaxAssetsOperatingLeaseLiabilities contextRef="c-12" decimals="-3" id="f-856" unitRef="usd">9078000</mgnx:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-11" decimals="-3" id="f-857" unitRef="usd">18795000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-12" decimals="-3" id="f-858" unitRef="usd">17442000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <mgnx:Section174DeferredTaxAsset contextRef="c-11" decimals="-3" id="f-859" unitRef="usd">98810000</mgnx:Section174DeferredTaxAsset>
    <mgnx:Section174DeferredTaxAsset contextRef="c-12" decimals="-3" id="f-860" unitRef="usd">48421000</mgnx:Section174DeferredTaxAsset>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-11" decimals="-3" id="f-861" unitRef="usd">16272000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-12" decimals="-3" id="f-862" unitRef="usd">16217000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-11" decimals="-3" id="f-863" unitRef="usd">4971000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-12" decimals="-3" id="f-864" unitRef="usd">6617000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-11" decimals="-3" id="f-865" unitRef="usd">410197000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-12" decimals="-3" id="f-866" unitRef="usd">373412000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-11" decimals="-3" id="f-867" unitRef="usd">401297000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-12" decimals="-3" id="f-868" unitRef="usd">365010000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-11" decimals="-3" id="f-869" unitRef="usd">8900000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-12" decimals="-3" id="f-870" unitRef="usd">8402000</us-gaap:DeferredTaxAssetsNet>
    <mgnx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets contextRef="c-11" decimals="-3" id="f-871" unitRef="usd">6745000</mgnx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets>
    <mgnx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets contextRef="c-12" decimals="-3" id="f-872" unitRef="usd">6372000</mgnx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses contextRef="c-11" decimals="-3" id="f-873" unitRef="usd">2155000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses contextRef="c-12" decimals="-3" id="f-874" unitRef="usd">2030000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-11" decimals="-3" id="f-875" unitRef="usd">8900000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-12" decimals="-3" id="f-876" unitRef="usd">8402000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-11" decimals="-3" id="f-877" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-12" decimals="-3" id="f-878" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:SummaryOfValuationAllowanceTextBlock contextRef="c-1" id="f-879">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The activity in the valuation allowance on deferred tax assets was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.309%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.862%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at Beginning of Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at End of Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-12" decimals="-3" id="f-880" unitRef="usd">365010000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <mgnx:ValuationAllowanceDeferredTaxAssetIncreaseAmount contextRef="c-1" decimals="-3" id="f-881" unitRef="usd">36287000</mgnx:ValuationAllowanceDeferredTaxAssetIncreaseAmount>
    <mgnx:ValuationAllowanceDeferredTaxAssetDecreaseAmount contextRef="c-1" decimals="-3" id="f-882" unitRef="usd">0</mgnx:ValuationAllowanceDeferredTaxAssetDecreaseAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-11" decimals="-3" id="f-883" unitRef="usd">401297000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-40" decimals="-3" id="f-884" unitRef="usd">372267000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <mgnx:ValuationAllowanceDeferredTaxAssetIncreaseAmount contextRef="c-25" decimals="-3" id="f-885" unitRef="usd">0</mgnx:ValuationAllowanceDeferredTaxAssetIncreaseAmount>
    <mgnx:ValuationAllowanceDeferredTaxAssetDecreaseAmount contextRef="c-25" decimals="-3" id="f-886" unitRef="usd">7257000</mgnx:ValuationAllowanceDeferredTaxAssetDecreaseAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-12" decimals="-3" id="f-887" unitRef="usd">365010000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-31" decimals="-3" id="f-888" unitRef="usd">327592000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <mgnx:ValuationAllowanceDeferredTaxAssetIncreaseAmount contextRef="c-26" decimals="-3" id="f-889" unitRef="usd">44675000</mgnx:ValuationAllowanceDeferredTaxAssetIncreaseAmount>
    <mgnx:ValuationAllowanceDeferredTaxAssetDecreaseAmount contextRef="c-26" decimals="-3" id="f-890" unitRef="usd">0</mgnx:ValuationAllowanceDeferredTaxAssetDecreaseAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-40" decimals="-3" id="f-891" unitRef="usd">372267000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c-242" decimals="-5" id="f-892" unitRef="usd">554000000.0</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c-243" decimals="-5" id="f-893" unitRef="usd">2100000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c-244" decimals="-5" id="f-894" unitRef="usd">551900000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-245" decimals="-5" id="f-895" unitRef="usd">109000000.0</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c-243" decimals="-5" id="f-896" unitRef="usd">2100000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <mgnx:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationAmountUtilizableOnAnnualBasis contextRef="c-242" decimals="-5" id="f-897" unitRef="usd">200000</mgnx:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationAmountUtilizableOnAnnualBasis>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c-244" decimals="-5" id="f-898" unitRef="usd">551900000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="c-1" id="f-899">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.631%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases for current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases/(decreases) for prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(369)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-12" decimals="-3" id="f-900" unitRef="usd">7821000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-40" decimals="-3" id="f-901" unitRef="usd">7376000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-31" decimals="-3" id="f-902" unitRef="usd">7197000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-903" unitRef="usd">1001000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-25" decimals="-3" id="f-904" unitRef="usd">449000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-26" decimals="-3" id="f-905" unitRef="usd">548000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <mgnx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-906" unitRef="usd">512000</mgnx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions>
    <mgnx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions contextRef="c-25" decimals="-3" id="f-907" unitRef="usd">-4000</mgnx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions>
    <mgnx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions contextRef="c-26" decimals="-3" id="f-908" unitRef="usd">-369000</mgnx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-11" decimals="-3" id="f-909" unitRef="usd">9334000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-12" decimals="-3" id="f-910" unitRef="usd">7821000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-40" decimals="-3" id="f-911" unitRef="usd">7376000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="c-11" decimals="-5" id="f-912" unitRef="usd">9300000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="c-12" decimals="-5" id="f-913" unitRef="usd">7800000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="c-25" decimals="INF" id="f-914" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="c-1" decimals="INF" id="f-915" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="c-26" decimals="INF" id="f-916" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="c-1" id="f-917">Employee Benefit Plan&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2002, the Company established the MacroGenics 401(k) Plan (the Plan) for its employees under Section 401(k) of the IRC. Under this Plan, all employees at least 21 years of age are eligible to participate in the Plan, starting on the first day of employment. Employees may contribute up to 100% of their salary, subject to government maximums.&lt;/span&gt;&lt;/div&gt;Employees are 100% vested in their contributions to the Plan. The Company's contribution to the Plan, as determined by the Board of Directors, is discretionary. For the years ended December&#160;31, 2024, 2023 and 2022, the Company's contributions to the Plan totaled $2.2 million, $2.1 million and $2.3 million, respectively.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <mgnx:EmployeesEligibleAgeToParticipateInBenefitPlan contextRef="c-1" id="f-918">P21Y</mgnx:EmployeesEligibleAgeToParticipateInBenefitPlan>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent contextRef="c-1" decimals="INF" id="f-919" unitRef="number">1</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <mgnx:DefinedContributionPlanEmployeesContributionVestedPercentage contextRef="c-1" decimals="INF" id="f-920" unitRef="number">1</mgnx:DefinedContributionPlanEmployeesContributionVestedPercentage>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="c-1" decimals="-5" id="f-921" unitRef="usd">2200000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="c-25" decimals="-5" id="f-922" unitRef="usd">2100000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="c-26" decimals="-5" id="f-923" unitRef="usd">2300000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-924">Segment Reporting&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company identifies its reportable segments based on information reviewed by the Company&#x2019;s CODM. The Company operates as one operating and reportable segment, which is discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer. The Company has determined its reportable operating segment based on the management approach, which considers the internal organization and reporting used by the Company&#x2019;s CODM to make decisions about allocating resources and assessing the Company&#x2019;s performance. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance and allocating resources. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CODM uses consolidated net loss, consistent with the amounts reported in the Company&#x2019;s consolidated statements of operations to evaluate performance, forecast future period financial results and allocate resources. Total consolidated assets presented in the accompanying consolidated balance sheets also represent the segment&#x2019;s total assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the significant expenses regularly reviewed by the CODM (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.794%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.062%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue (a)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of manufacturing sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vobramitamab duocarmazine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lorigerlimab&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MGC028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Preclinical antibody-drug conjugates (ADCs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MGC026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Margetuximab&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MGD024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Next-generation T-cell engagers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retifanlimab&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Enoblituzumab&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other segment income, net (b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66,966)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119,758)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Total revenue includes collaborative and other agreements, product sales, net, contract manufacturing, and government agreements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b) Other segment income, net includes the gain on sale of MARGENZA, interest and other income and expense, and income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company operates in the United States and all material long-lived assets of the Company reside in the United States For information about the Company&#x2019;s revenues, see Note 8, Revenue.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-925"
      unitRef="performanceobligation">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-926">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the significant expenses regularly reviewed by the CODM (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.794%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.062%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue (a)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of manufacturing sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vobramitamab duocarmazine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lorigerlimab&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MGC028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Preclinical antibody-drug conjugates (ADCs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MGC026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Margetuximab&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MGD024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Next-generation T-cell engagers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retifanlimab&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Enoblituzumab&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other segment income, net (b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66,966)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119,758)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Total revenue includes collaborative and other agreements, product sales, net, contract manufacturing, and government agreements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b) Other segment income, net includes the gain on sale of MARGENZA, interest and other income and expense, and income tax expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues contextRef="c-1" decimals="-3" id="f-927" unitRef="usd">149962000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-25" decimals="-3" id="f-928" unitRef="usd">58749000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-26" decimals="-3" id="f-929" unitRef="usd">151941000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-3" id="f-930" unitRef="usd">847000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-25" decimals="-3" id="f-931" unitRef="usd">619000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-26" decimals="-3" id="f-932" unitRef="usd">3351000</us-gaap:CostOfGoodsAndServicesSold>
    <mgnx:CostOfManufacturingServices contextRef="c-1" decimals="-3" id="f-933" unitRef="usd">11452000</mgnx:CostOfManufacturingServices>
    <mgnx:CostOfManufacturingServices contextRef="c-25" decimals="-3" id="f-934" unitRef="usd">7603000</mgnx:CostOfManufacturingServices>
    <mgnx:CostOfManufacturingServices contextRef="c-26" decimals="-3" id="f-935" unitRef="usd">4033000</mgnx:CostOfManufacturingServices>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-246" decimals="-3" id="f-936" unitRef="usd">39809000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-247" decimals="-3" id="f-937" unitRef="usd">39217000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-248" decimals="-3" id="f-938" unitRef="usd">55381000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-249" decimals="-3" id="f-939" unitRef="usd">36805000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-250" decimals="-3" id="f-940" unitRef="usd">27716000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-251" decimals="-3" id="f-941" unitRef="usd">21581000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-252" decimals="-3" id="f-942" unitRef="usd">24055000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-253" decimals="-3" id="f-943" unitRef="usd">14408000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-254" decimals="-3" id="f-944" unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-255" decimals="-3" id="f-945" unitRef="usd">18102000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-256" decimals="-3" id="f-946" unitRef="usd">11170000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-257" decimals="-3" id="f-947" unitRef="usd">12975000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-258" decimals="-3" id="f-948" unitRef="usd">14126000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-259" decimals="-3" id="f-949" unitRef="usd">13523000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-260" decimals="-3" id="f-950" unitRef="usd">5287000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-261" decimals="-3" id="f-951" unitRef="usd">10846000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-262" decimals="-3" id="f-952" unitRef="usd">16081000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-263" decimals="-3" id="f-953" unitRef="usd">26869000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-264" decimals="-3" id="f-954" unitRef="usd">9734000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-265" decimals="-3" id="f-955" unitRef="usd">6974000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-266" decimals="-3" id="f-956" unitRef="usd">7857000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-267" decimals="-3" id="f-957" unitRef="usd">8421000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-268" decimals="-3" id="f-958" unitRef="usd">10464000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-269" decimals="-3" id="f-959" unitRef="usd">13335000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-270" decimals="-3" id="f-960" unitRef="usd">2129000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-271" decimals="-3" id="f-961" unitRef="usd">3452000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-272" decimals="-3" id="f-962" unitRef="usd">2156000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-273" decimals="-3" id="f-963" unitRef="usd">1906000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-274" decimals="-3" id="f-964" unitRef="usd">5344000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-275" decimals="-3" id="f-965" unitRef="usd">14725000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-276" decimals="-3" id="f-966" unitRef="usd">11261000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-277" decimals="-3" id="f-967" unitRef="usd">18234000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-278" decimals="-3" id="f-968" unitRef="usd">46860000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-969" unitRef="usd">177194000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-25" decimals="-3" id="f-970" unitRef="usd">166583000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-26" decimals="-3" id="f-971" unitRef="usd">207026000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-972" unitRef="usd">71047000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-25" decimals="-3" id="f-973" unitRef="usd">52188000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-26" decimals="-3" id="f-974" unitRef="usd">58949000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-279" decimals="-3" id="f-975" unitRef="usd">43612000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-280" decimals="-3" id="f-976" unitRef="usd">159186000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-281" decimals="-3" id="f-977" unitRef="usd">1660000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-978" unitRef="usd">-66966000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-25" decimals="-3" id="f-979" unitRef="usd">-9058000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-26" decimals="-3" id="f-980" unitRef="usd">-119758000</us-gaap:NetIncomeLoss>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
